Neuroﬁbromatosis:AReviewofNF1,NF2,andSchwannomatosisJesseLeeKresak1MeggenWalsh11DepartmentofPathology,Immunology,andLaboratoryMedicine,UniversityofFlorida,Gainesville,Florida,UnitedStatesJPediatrGenet2016;5:98–104.AddressforcorrespondenceJesseLeeKresak,MD,DepartmentofPathology,UniversityofFlorida,1600SWArcherRoad,POBox100275,Gainesville,FL32610,UnitedStates(e-mail:jkresak@uﬂ.edu).NeuroﬁbromatosisNeuroﬁbromatosisisaheterogeneousgroupofhereditarycancersyndromesthatleadtotumorsofthecentralandperipheralnervoussystems.Byfarthemostcommonformisneuroﬁbromatosistype1(NF1,96%),followedbyneuroﬁbro-matosistype2(NF2,3%),andalesserknownform,schwanno-matosis.Neuroﬁbromatosishasnogenderorracialpredilection.NeuroﬁbromatosisType1IntroductionNF1,alsoknownasvonRecklinghausendiseaseorperipheralneuroﬁbromatosis,isanautosomaldominanttumorpredispo-sitionsyndromemostreadilycharacterizedbythedevelopmentofmultipleneuroﬁbromasoftheperipheralnerves.Theinci-denceofNF1isapproximately1inevery2,500to3,000births.1Lifeexpectancyisshortenedtoanaverageof54years,oftenonaccountofmalignancy.2MalignanciesassociatedwithNF1includemalignantperipheralnervesheathtumors,gliomas,leukemia,pheochromocytomas,gastrointestinal(GI)stromaltumors,andothers.NF1iscausedbyamutationintheneuro-ﬁbromintumorsuppressorgenelocatedonchromosome17.IthasahighrateofpenetranceandthemutationrateoftheNFgeneishighwith80%beingofpaternalorigin.3Theearliestknowndepictionofpresumedneuroﬁbromatosisdatesbacktothe13thcenturywithsketchesbyaCistercianmonk.4In1862,Virchowmadereferencetothehereditarycomponentwhenhedescribedamaninwhichthe“bodywasquitecoveredwithlumpsfrompinhead-sizedtopigeonegg-sized”andhenotedthatthe“peculiaritieshaveexistedinaninheritedmanneralreadyoverthreegenerations.”However,itwasVirchowstudent,FriedrichvonRecklinghausen,in1882thatgavethemostthoroughclinicalandhistologicalaccountofthediseaseandwhocoinedtheterm“neuroﬁbroma.”DiagnosticCriteriaThesymptomsofNF1canvarysigniﬁcantlyamongaffectedpatientsandthusatimelyandspeciﬁcdiagnosiscanbedifﬁculttoascertain.Thoughtheclinicaldiagnosismaybesuspectedveryearlyinchildhoodorinfancy,thecardinalfeaturesmaynotbeentirelypresentuntilanolderage.Approximately30%ofNF1patientswillmeetoneofthebelowcriterionbytheageof1year,97%ofpatientswillmeettwocriteriabytheageof8yearsand,inaretrospectivereviewofNF1patients,allpatientsmetthecriteriabytheageof20years.1In1987,theNationalInstitutesofHealth(NIH)developedaconsensusfordiagnosisduetoclinicalvariation.Theclinicaldiagnosiscanbeestablishedifthecriterialistedin►Table1aremetwithoutcausebyanalternatediagnosis.5Keywords►neuroﬁbromatosis►NF1►vonRecklinghausendisease►NF2►schwannomatosisAbstractTheneuroﬁbromatosesareaheterogeneousgroupofhereditarycancersyndromesthatleadtotumorsofthecentralandperipheralnervoussystems,aswellasotherorgansystems.Byfarthemostcommonformisneuroﬁbromatosis1(96%),followedbyneuroﬁbromatosis2(3%),andamorerecentlyrecognized,lesserknownform,schwannomatosis.Thediagnosticcriteria,pathogenesis,molecularconsiderations,andclinicalmanifestationsarediscussedinthisreviewarticle.receivedJuly10,2015acceptedafterrevisionAugust10,2015publishedonlineMarch9,2016IssueThemeHereditaryCancerSyndromesinChildren;GuestEditors:NicoleD.Riddle,MD,andRaulS.Gonzalez,MDCopyright©2016byGeorgThiemeVerlagKG,Stuttgart·NewYorkDOIhttp://dx.doi.org/10.1055/s-0036-1579766.ISSN2146-4596.ReviewArticle98This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.PathogenesisandGeneticConsiderationsThecausativegeneforNF1,wasidentiﬁedin1990anditwasfoundtobeoneofthelargestgenesinthehumangenomeencompassing280kbpofDNA.6TheNF1geneislocatedonchromosome17q11.2,whichencodesforaproteinknownasneuroﬁbromin.7NeuroﬁbrominbelongstotheGTPase-acti-vatingfamilyoftumorsuppressorproteinsthatregulatethefunctionoftheRAS/MAPKsignalingandmechanistictargetofrapamycin(mTOR)pathways.Approximately50%ofmuta-tionsaredenovo,occurringinpatientswithnofamilyhistory.Forfamilieswithaninheritedmutation,thereiscompletepenetrance;however,clinicalmanifestationsamongfamilymemberscanvarygreatly.Thevariabilityinphenotypicexpressionislikelyaresultofepigeneticmodiﬁcation.8Studiesaddressingthegenotype–phenotypecorrelationhavefoundthatdeletionoftheentiregene,knownas17q11.2microdeletion,isassociatedwithamoresevereformofthedisease,whilemosaicismcanleadtoamildorevensegmentalpresentation.6,7Nearly1,500differentmutationsoftheNF1genehavebeenidentiﬁedandthesemutationshavebeenfoundthroughouttheentirelengthofthelargegenelocus.6Non-sense,frameshift,andpointmutationshaveallbeenidenti-ﬁedwiththemajorityofthemutationsleadingtoatruncatedformoftheprotein.Genetictestingisoftenreservedforfamilymembersofapatientwhosepathologicalmutationhasbeenidentiﬁed,andthustheexactmutationcanbescreenedforintheirrelatives.Otherwise,giventheremarkablyhighdegreeofmutationsusceptibilityandthelackof“hotspots”onthegene,NF1doesnotlenditselftomutationalanalysisasapracticaldiagnostictool.6ThediagnosisofNF1ismostoftenmadeontheclinicalgroundsdiscussedabove.ClinicalManifestationsNeuroﬁbromasNeuroﬁbromas,thenamesakeofthedisease,arethemostcommontumorofNF1,occurringinapproximately60%ofthepatients.Histologically,neuroﬁbromasofNF1areindistin-guishablefromsporadictumors,albeittheformerareoftenlarger.Neuroﬁbromasmaybecutaneousorinternal,involv-ingdeepsofttissues.Thecutaneousformsmaybepeduncu-lated,nodular,orplaque-likedevelopinginlatechildhoodandincreasinginnumbersintoadulthood.2Theinternalordeepneuroﬁbromascanoccurthroughoutthebodyincludingperiorbital,retroperitoneal,GItract,andmediastinalloca-tions.9PathognomonicofNF-1,plexiformneuroﬁbromasareinternalneuroﬁbromasthat,ratherthangrowingintraneur-allywithinasinglenerve,growtoinvolvemultiplefasciclesorbranchesofanerveorplexus.Thisgrowthpatternlendsitselftothecharacteristic“bagofworms”descriptiongivenonpalpationorsurgicalexaminationofthesetumors.Plexiformneuroﬁbromasoftendevelopinchildhoodandgrowrapidly,exertingmasseffectonadjacentstructures.Unlikethecuta-neousform,plexiformneuroﬁbromashaveanincreasedriskoftransformationintomalignantperipheralnervesheathtumors(MPNST).MPNSTsarerareaggressivespindle-cellsarcomas,accountingforonlyapproximately5%ofallsofttissuesarcomas.About50%ofMPNSTsoccurinthesettingofNF1asthesepatientshavean8to13%riskofdevelopingoneintheirlifetime.3Suddenchangeorgrowthofaplexiformneuroﬁbromaonimagingsurveillance,aswellasincreaseduptakeonﬂuorodeoxyglucose-positronemissiontomogra-phy(PETscan),shouldraisesuspicionformalignanttransfor-mation.Treatmentforneuroﬁbromasincludessurgicalresectionandlasertherapy,whilethegoalofplexiformneuroﬁbromasurgeryisoftenfordebulking.Recentclinicaltrialsinvolvingtyrosinekinaseinhibitorimatinibhaveshownadecreaseintumorvolumebygreaterthan20%inasubsetofpatients.10Furtherstudiesaddressingthistherapy,aswellasmTORinhibitors,areunderway.10MPNSTsareasigniﬁcantcauseofmortalityinNF1patientsanddespiteradicalexcisionwithwidesurgicalmargins,followedbychemoradiation,5-yearsurvivalratesarepoorduetofrequentlungandbonemetastasesaswellaslocalrecurrence.2PigmentaryAbnormalitiesCafé-au-laitspotsarebenigntan-brownpigmentedmaculesthatcanoccuranywhereonthebody,andareoftenthepresentingsignofNF1.Bytheageof1year,99%ofthepatientswiththediagnosisofNF1willhavesixormorecafé-au-laitmaculesgreaterthan5mm(prepubertalcriteriaasperNIH).1,9ThoughacommonfeatureofNF1,café-au-laitspotsareanonspeciﬁcﬁndingastheycanbeseseeninapproximately10%ofthegeneralpopulationaswellasinothergeneticsyndromes—SilverRusselldwarﬁsm,MENIIb,Legiussyndrome,andMcCuneAlbrightsyndrome.ThenumericcutoffusedinthediagnosticcriteriaisbasedonastudybyCroweetalin1956inwhich78%ofthe203NF1patientsanalyzedhadatleastsixcafé-au-laitspotsgreaterthan15mm.11Thisquantityisgreaterthanthosereportedforthegeneralpopulation.Inaretrospectivereviewofinfantswithbirthmarks,Mihmetalshowedthat1.8%ofAfricanAmericaninfantswillhavethreeormorecafé-au-laitspots,whilenonsyndromicCaucasianinfantsrarelyhavetwoormore.12Histologically,theselesionsshowhyperpigmenta-tionofthebasalepidermiswithmacromelanosomespresent.9AlthoughthereisnopotentialformalignantTable1Clinicaldiagnosticcriteriaforneuroﬁbromatosistype1DiagnosticcriteriaofNF1Twoormoreofthefollowing:(cid:129)Atleastsixcafé-au-laitmacules(>5mmdiameterinprepubertalindividualsand>15mminpostpubertalindividuals)(cid:129)Frecklinginaxillaryoringuinalregions(cid:129)Opticglioma(cid:129)AtleasttwoLischnodules(irishamartomas)(cid:129)Atleasttwoneuroﬁbromasofanytype,oroneplexiformneuroﬁbroma(cid:129)Adistinctiveosseouslesion(sphenoiddysplasiaortibialpseudarthrosis)(cid:129)AﬁrstdegreerelativewithNF1JournalofPediatricGeneticsVol.5No.2/2016Neurofibromatosis:AReviewofNF1,NF2,andSchwannomatosisKresak,Walsh99This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.transformation,cosmetictreatmentissometimessought.Casereportsshowthatsomepatientsmayhaveagoodresponsewithdermatologiclasertherapyfordepigmenta-tion;however,itmaytakeseveraltreatmentsforaresponseandasubsetofpatientswillhaverepigmentationofthelesionwithin6months.13FrecklingintheaxillaandgroinareanotherdeﬁningsymptomofNF1.Onlyapproximately40%ofpatientswillbenotedtohavefrecklingininfancyand90%ofNF1patientswillhavefrecklingbytheageof7years.1MelanocyticnodulescanalsooccurintheirisesofNF1patients.Thesesmall,oftenmultiple,hamartomatouslesions,knownasLischnodules,arefoundin93%ofadultswithNF1.Theyareasymptomatic.14GliomasPatientswithNF1areatanincreasedriskofdevelopinglow-andhigh-gradegliomas.ThemostcommonlyencounteredgliomainthesettingofNF1isalow-gradegliomaoftheopticnerve.Theseopticnervegliomasoccurinabout15%ofNF1patientsandusuallypresentbytheageof7years.2Generally,thesetumorsarepilocyticastrocytomas,WorldHealthOrganizationgradeI,andarehistologicallyequivalenttopilocyticastrocytomasofthegeneralpopulationwithabiphasicgrowthpattern,hair-likeprocesses,andRosenthalﬁbers.Giventheindolentnatureofthesetumors,managementusuallyconsistsofimagingsurveil-lance.Whenvisualacuitydeclines,chemotherapymaybeemployed.2ThelocationofthesetumorsdoesnotallowforsurgicalinterventionandradiationtherapyisavoidedinNF1patientsduetoincreasedriskofdevelopingradiation-inducedmalignancies.15BrainstemgliomasarethesecondmostfrequentgliomaofNF1andagain,thesetumorsareusuallypilocyticastrocytomas.Forthesamereasonsasopticgliomas,chemo-therapyistheonlytreatmentavailablewithagoalofsymptom-aticreliefandprolongedsurvival.Finally,NF1patientshaveaﬁvefoldriskofdevelopingmalignantgliomas,particularlyglio-blastomas,overthegeneralpopulationwithanaveragesurvivalofabout1year.MusculoskeletalManifestationsChildrenwithNF1haveasigniﬁcantlyincreasedriskfordevelopingrhabdomyosarcomaswithanapproximately20-foldincreaseoverthegeneralpopulation.2Theserhab-domyosarcomasmayarisefromanysite;however,alargereviewfoundapredominanceofbladderandprostatesitesoforigin.16Thetreatmentprotocolsfollowedfornonsyn-dromicrhabdomyosarcomasmayalsobeappliedtoNF1patients.VariableskeletalabnormalitiesarefrequentlynotedinNF1patients,includingosteopenia,scoliosis,andsphenoidwingorcongenitaltibiadysplasia.Inaddition,manypatientswithNF1willbeofshortstature;thoughtheirbodyproportionsremainnormal.17ThemechanisticassociationofNF1andskeletaldeformitiesislargelyunknown;however,NF1patientshavebeenreportedtohavelow-bonemineraldensitiesandlowconcentrationsofvitaminD.2StudieshaveindicatedathreefoldincreasefractureriskinNF1-affectedchildrenincreasingtoaﬁvefoldincreasedriskinadults.17,18Repeatfracturesinthesepatientsmayleadtopseudoarthrosis.GastrointestinalManifestationsTheGItractcanbeinvolvedbyneuroﬁbromasandmalignantperipheralnervesheathtumorssimilartoothersitesofthebody;however,alsotherearevariousotherGImalignanciesassociatedwithneuroﬁbromatosis.Asforneuroﬁbromas,theGItractcanbeinvolvedbyfocalneuroﬁbromasordiffuselybyaneuroﬁbromatousproliferationexpandingthelaminaprop-ria.Inbothinstances,ganglioncellsmaybeintermixedwithoutclinicalsigniﬁcance.GIstromaltumors(GIST)arenotuncommonoccurrencesinNF1patientsandhavebeenreportedinupto25%ofpatients.19IncontrasttoGISTsinthegeneralpopulation,NF1-associatedGISTsrarelyharbormutationsinKITorPDGFRA.Inamajorityofcases,theGISTissmall,asymptomatic,andfollowsabenigncourse.Histologically,theGISTsaresimilartononsyndromictumorscomposedofspindlecellandskeinoidﬁbers.EndocrinetumorsoftheGItractarealsoseeninNF1patientsandthesehaveapredilectionfortheperiampullaryregion.Themostcommonendocrinetumorreportedisasomatostatinoma;however,gastrinoma,insulinoma,carcinoids,andparagan-gliomashavealsobeendescribedinthissetting.19OtherMalignanciesPatientswithNF1alsohaveasigniﬁcantpredispositiontomalignanciesoutsideofthenervoussystem.ChildrenwithNF1haveasevenfoldincreasedriskofhematopoieticmalignancies,especiallymyeloidleukemia,comparedwiththeirage-matchedcounterparts.Thetreatmentandprognosisaresimilarforthesyndromicandgeneralpop-ulations.NF1patientsarealsoatanincreasedriskforthedevelopmentofbreastcancer,particularlyinwomenundertheageof50years.Again,thetreatmentisthesameforboththegroupsofpatients.Finally,althougharareoccur-rence,pheochromocytomasoftheadrenalglandareseenmorefrequentlyinNF1patientsthaninthegeneralpopu-lationwithareportedincidenceupto5%comparedwithlessthan1%.2Thepresentationforpheochromocytomasofteninvolvesﬂushing,palpitations,andhypertensionandsurgeryisoftencurative.Neuroﬁbromatosis2IntroductionNF2,alsoknownbilateralacousticneuroﬁbromatosisorcentralneuroﬁbromatosis,isahereditarytumorsyndromecharacterizedpredominantlybythedevelopmentofschwan-nomas,alongwithmeningiomas,ependymomas,andocularabnormalities.Despitethename,neuroﬁbromasarerela-tivelyinfrequent.NF2isinheritedinanautosomaldominantpatternwithanestimatedincidenceof1in25,000,preva-lenceof1in60,000,andapenetranceofapproximately0.95.20Patientsusuallypresentaroundage20andprognosticconsiderationsincludeageatdiagnosis,meningiomastatus,andaccesstospecialtymedicalcenters.21ThediseaseiscausedbyamutationintheNF2geneonchromosome22,whichencodesforaprotein,merlin.Overhalfofthecasesarecausedbydenovogenemutationsinpatientswithnofamilyhistoryofthedisease.JournalofPediatricGeneticsVol.5No.2/2016Neurofibromatosis:AReviewofNF1,NF2,andSchwannomatosisKresak,Walsh100This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.DiagnosticCriteriaBilateralschwannomasofthesuperiorvestibularbranchoftheeighthcranialnerve(vestibularschwannomaoracousticneuroma)arepathognomonicforNF2.However,since41%ofpatientseventuallyproventohaveNF2donothavebilateralvestibularschwannomasattheinitialtimeofpresentation,therehavebeenseveraldiagnosticstandardscreatedforNF2.TheseincludethewidelyrecognizedManchestercriteriaaswellasadditionalNIHcriteriashownin►Table2.BaseretalrecentlyproposedascoringsystemtoreplacetheManchestercriteriawithreportedlyincreasedsensitivitywhilemaintain-ing100%speciﬁcity.21,22PathogenesisandGeneticConsiderationsNF2wasproventobegeneticallydistinctentityfromNF1whenlinkagestudiesdiscoveredanovelprovenin1993.23,24Thesestudiesfoundthediseasetobecausedbyabnormalitiesofagenelocatedontheq12bandofchromosome22.ThisNF2genecodesfortheproteinmerlin(alsoknownasschwanno-min),whichisatumorsuppressorproteinimpactingPI3kinase/Akt,Raf/MEK/ERK,andmTORsignalingpathways.Merlinisnamedforitsrelationshiptothemoesin(membraneorganizingextensionspikeprotein)—erzin(cytovillin)—radixinfamilyofcytoskeleton-associatedproteins,23whichsuggeststhatitmaybeinﬂuentialincommunicationbetweensurfacesignalingandthecytoskeletonmatrix.Mutationsinmerlincanbefoundinapproximately93%ofpatientswithclinicalevidenceofNF2andapositivefamilyhistory.25Amoleculardiagnosisismoreelusivetoﬁndinpatientswithdenovomutations,59%,duetosomaticmosaicism,26whichispresentin30to60%ofdenovocases.Inmosaiccases,themutationisharboredwithinthetumoritselfandonlyasubsetofcirculatinglymphocytespickeduponaroutinebloodtest.Recentstudieshavefoundthat,whilepenetrancelevelswillbedifferentfortheoffspringofamosaicpatientthanforafullypenetrantfamilialpatient,thereisstillariskoftrans-missionofthediseaseinthesettingofanondetectablemutationintheblood.Ithasbeenestimatedthattheriskoftransmissiondropsfromtheautosomaldominant50%toaround8to12%dependingoninitialclinicalpresentation.ThephenotypeofNF2canhavevaryingdegreesofseverity.Withinanaffectedfamily,thenaturalhistoryandphenotypicexpressionofNF2isusuallysimilarbetweenitsmembers.However,interfamilyvariationscanbestriking.Thedifferencescanbeattributedtodifferingabnormalitieswith-intheNF2gene.Forinstance,themostsevereclinicalmanifestationshavebeenassociatedwithframeshiftornon-sensemutations,whichalsohappentobethemostcommonmutationtypes,inwhichthemutationcausestruncatedproteinexpression.Ananalysisof268NF2patientsbySelvanathanetalfoundthatpatientswhoharboredmuta-tionsleadingtotruncatedproteinexpressionwerediagnosedatayoungerageandhadahigherprevalenceofmeningiomas,spinaltumors,andcutaneoustumors.27Theyoungerageofdiagnosiswasfoundattributabletoearliersymptomaticpresentations,especiallytinnitus,wasting,andweakness.Incontrast,mutationsresultinginlargedeletionsormissensemutationsleadtoamilderdiseasepresentation.Smithetalreportedthat,inadditiontomutationtype,thepositionofthemutationwithinthegenealsohadphenotypicimplications.Mutationstowardthe5′endofthegeneareassociatedwithahigherprevalenceofintracranialmeningiomas,whereasmutationsinexons14and15conferalowerrisk.28Itwasalsonotedinthisstudythat,whilethereisafemalepredomi-nanceofdevelopingmeningiomasinthegeneralpopulation,thereisnogenderpredilectionformeningiomaswithinNF2patients.ClinicalManifestationsNF2predisposespatientstothedevelopmentofnervoussystemtumors,includingpredominantlyschwannomasfollowedbymeningiomas,andependymomas.Inaddition,patientsarealsoaffectedbyocularmanifestations.ThehallmarkandpathognomonicﬁndingofNF2isbilateralvestibularschwannomas,whichcanbefoundin90to95%ofNF2patients.VestibularSchwannomasVestibularschwannomas,alsoknownasacousticneuromas,presentwithtinnitus,gradualhearingloss,andbalancedysfunction.Usuallypresentbytheageof30years,thesetumorsarisefromthesuperiordivisionoftheeighthcranialnervewithintheinternalauditorymeatus.Histologically,vestibularschwannomasinNF2aresimilartosporadicschwannomasbydisplayingcharacteristicalternatingAntoniAandBregions,Verocaybodies,andhyalinizedvessels.Incontrasttosporadicschwannomas,vestibularschwannomasofNF2areoftenmultifocal,asevidencedbyradiographicstudies29andappearmultilobulatedorbotryoidatthetimeofsurgery.Infact,arecentstudyhasfoundthateachofthesetumorsor“lobules”harborsadmixedcellpopulationswithvarioussomaticNF2mutations,supportingpolyclonalityTable2Clinicaldiagnosticcriteriaforneuroﬁbromatosistype2MaincriteriaAdditionalcriteriaBilateralvestibularschwannomasorUnilateralvestibularschwannomaplusanytwoofthefollowing:meningioma,glioma,schwannoma,orjuvenileposteriorlenticularopacitiesorFirst-degreerelativewithneuroﬁbromatosistype2plus1.Unilateralvestibularschwannomasor2.Anytwoofthefollowing:Meningioma,glioma,schwannoma,orjuvenileposteriorlenticularopacitiesAtleasttwomeningiomasplus1.Unilateralvestibularschwannomaor2.Anytwoof:glioma,neuroﬁbroma,schwannoma,andcataractJournalofPediatricGeneticsVol.5No.2/2016Neurofibromatosis:AReviewofNF1,NF2,andSchwannomatosisKresak,Walsh101This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.withmultipledistincttumorclones.30Thisﬁndingmayexplainthedisparitiesobservedintreatmentoutcomeswhencomparingwithsporadiccases.Treatmentisusuallyreservedforcaseswithsigniﬁcantimpactonqualityoflife,particularlyhearingpreservation,orforinstanceswhenthetumorgrowsmediallyandcausesbrainstemcompression.Forsporadictumors,surgeryandradiosurgeryhavebeenthemainstaysoftherapeuticintervention;however,bothoptionsaremorecomplexinthesettingofNF2.Surgeryhasasimilarhearingpreservationrateofapproximately50%betweenbothsporadicandNF2tumors,however,recurrenceratesforNF2vestibularschwannomasareabout44%comparedwith1.3%fortheirsporadiccounterparts.31Thisdiscrepancyisattrib-utabletothemultifocalgrowthpatternaswellastheten-dencyofthetumortoinvolvethefacialnerve.Thus,thereisalsoincreasedriskoffacialnerveinjuryandconsequentialeyelidandlacrimalglanddysfunction.Ifsurgicalresectionyieldsanintactcochlearnerve,cochlearimplantationcanbeutilizedforfurtherimprovementinhearingoutcomes.32StereotacticradiationhasasigniﬁcantlypoorerhearingpreservationrateforNF2tumorscomparedwithsporadic,andthismaybeinpartduetohistologicaltendencyofNF2schwannomastoinvadenerveﬁbers,ratherthandisplacethemassporadictumorsdo,whichleadstoinevitablenervedamagewhentargetingwithradiationorsurgery.33Also,thereappearstobeagreaterriskofmalignanttransformationfollowingradiationinvestibularschwannomasofNF2patients.31Finally,chemotherapywithbevacizumab,avascularendothelialgrowthfactorinhibitor,hasrecentlybeenutilizedwithpromisingsuccessshowingaclinicalresponseofhearingimprovementin57%ofcasesandtumorshrinkagein53%;however,toxicitiesincludinghypertensionandproteinuriaarenotuncommon.34,35PeripheralSchwannomasSchwannomasofothercranialandperipheralnerves,especiallyparaspinalandcutaneousnerves,areencounteredinupto70%ofpatientswithNF2.36Symptomsattributabletoperipheralschwannomasaremostoftenpain,sensoryloss,andweakness.Aswiththevestibularschwannomas,thehistologyofperipheralschwannomasofNF2andsporadicschwannomasaresimilarwiththeexceptionofthetendencyofNF2schwannomastoinﬁltratetheassociatednerve.Also,immunohistochemicalstudyforINI1(SMARCB1)displaysamosaicpatternofexpressioninsyndromictumorsasopposedtointactpositivityinsporadiccases.36TheﬁndingofSMARCB1alterationsintheseschwannomasraisesthepos-sibilityofadiagnosisofschwannomatosisratherthanNF2(see“Schwannomatosis”discussionbelow),howeverinmostcases,theotherclinicalormolecularcriteriaofNF2arepresent.MinuteSchwanncellneoplasms,calledtumorlets,arenotuncommoninNF2patientsandareoftenfoundstuddedalongtheparaspinalnerveroots.Thesetumorletsarebelievedtobeschwannomaprecursorsinthesepatients.37SimilartoplexiformneuroﬁbromasofNF1,plexiformschwannomasinvolvingmorethanonenervefasciclearemorecommonlyseeninNF2patientsandtheﬁndingofaplexiformschwannomaconfersa10to50%chancethatthepatientinfacthasNF2.38,39Plexiformschwannomasaremostoftencutaneousorsubcutaneouswithapredilectionfortheheadandneckregion.IncontrasttotheneuroﬁbromasofNF1,schwannomasofNF2rarelyundergomalignanttrans-formation.Excisionisthetreatmentofchoiceforperipheralschwannomasandsurgicaloutcomesarereportedlyvaried.SomeauthorsreportaworsepostsurgicaloutcomeforNF2-associatedschwannomasincomparisontosporadicschwan-nomas,asmaybeexpectedduetotheirinﬁltrativenatureandplexiformsubtypes,whileothersreportgreatimprovementinneurologicdeﬁcitsamongboththepatientgroups.40MeningiomasMeningiomasoccurinabout50%ofNF2patientsandareassociatedwithsigniﬁcantmorbidityandmortalityinthispopulation.Mostareintracranialmeningiomasandfre-quentlymultiple,thoughspinalmeningiomasalsooccur.Symptomsfromanintracranialmeningioma,suchashead-acheorseizure,arethepresentingsymptominupto30%ofpatientseventuallyfoundtohaveNF2.20MeningiomasoccuratayoungerageinNF2patientsthaninthegeneralpopula-tion,andinfact,approximately20%ofpediatricpatientsdiagnosedwithameningiomawillbefoundtohaveNF2.41EpendymomasGlialneoplasmsarerelativelyuncommoninNF2withtheexceptionofintramedullaryspinalependymomas.SpinalependymomasinNF2haveapredilectionforthecervicalandcervicomeduallryjunction,withabout85%occurringinthisregion,42andcommonlypresentasmultipletumorswitha“stringofpearl”appearanceinthecord.Histologically,thetumorsareoftenlow-gradeclassicortanycyticependymo-mas.EpendymomasofNF2patientsareoftenasymptomaticandareonlyidentiﬁedbyroutineimagingsurveillanceandthusthemainstayoftherapyismonitoring.OcularManifestationsOphthalmiccomplicationsarefoundinamajorityofpatientswithNF2.Themostcommonocularmanifestationisacataractcausedbyposteriorsubcapsularlenticularopacitieswhichispresentinupto80%ofNF2patients.43Additionalocularﬁndingsincludeepiretinalmembranes,retinalhamar-tomas,opticnervegliomas,andmeningiomas,andintraocu-larschwannomas.SchwannomatosisIntroductionSchwannomatosis,asthenameimplies,isasyndromecharacterizedbythedevelopmentofmultipleperipheralnerveschwannomas,withoutconcomitantinvolvementofthevestibularnerve.Sincetheschwannomaisthepredomi-nanttumorinbothNF2andschwannomatosis,therecanbeconsiderableoverlapinthephenotypesofthesesyndromesandassuchschwannomatosisisoftencategorizedasthethirdformofneuroﬁbromatosis.However,geneticallytheyaretwodistinctentities.TheprevalenceofschwannomatosisisJournalofPediatricGeneticsVol.5No.2/2016Neurofibromatosis:AReviewofNF1,NF2,andSchwannomatosisKresak,Walsh102This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.difﬁculttoassessgiventheclinicalsimilaritiestoNF2andlackofareliablegenetictestinallcases,thoughitisspeculatedtobeaboutascommonasNF2.36PathogenesisandGeneticConsiderationsSchwannomatosisiscausedbyamutationintheSMARCB1gene,alsoknownastheINI1,BAF47,orhSNF5gene,locatedonchromosome22q11.2,centromerictotheNF2gene.Themajor-ityofthecasesofschwannomatosisarecausedbydenovomutations,thoughfamilialcasesexistwithanautosomaldomi-nantinheritancepattern.44Eveninthefamilialforms,agermlineSMARCB1mutationisonlyidentiﬁedin40to50%ofcases,26suggestinginvolvementofothergeneticlociyettobeidentiﬁed.GenetictestingiscomplicatedbythepresenceofsomaticNF2mutationsfoundinmanytumorsofpatientswithschwanno-matosis.Therefore,molecularstudiesperformedonseveraltumorsmayberequiredbeforeadeﬁnitivediagnosiscanbemade.SMARCB1mutationsarealsoresponsiblefortherhabdoidtumorsofrhabdoidpredispositionsyndrome,however,rarelydothesetwosyndromesoverlapclinically.Thedifferencesintumorigenesis,outcome,andpresentationforthesetwosyndromeswithasharedmutationisnotcompletelyunder-stood,thoughmaybearesultoftruncatedversusnontruncatedproteinsorepigeneticfactors.26DiagnosticCriteriaDiagnosticcriteriaforschwannomatosisarenotyetasstandard-izedastheyarefortheothertwoneuroﬁbromatoses.Currently,thediagnosiscanbemadeonamolecularorclinicalbasis.Clinically,apatientcanbediagnosedwithschwannomatosiswiththefollowingstipulations:(1)atleasttwonondermalbiopsy-provenschwannomaswithnoradiographicevidenceofbilateralvestibularschwannomasonhigh-qualitymagneticresonanceimagingor(2)onebiopsy-provennondermalschwannomaorintracranialmeningiomaandaﬁrst-degreerelativewithschwannomatosis.Ithasalsobeenproposedthatapatientwithtwoormorenondermaltumorsthataresuspi-ciousforschwannomas,butwithouthistologicalconﬁrmation,beconsidered“possible”foradiagnosisofschwannomatosis.26Finally,asbilateralvestibularschwannomasofNF2mayoccurinthethirddecadeoflife,anagecutoffofatleast30yearsmaybeemployedtoensureanaccuratediagnosisofschwannomato-sis.26Molecularly,thediagnosiscanbemadeifapatient(1)hasabiopsy-provenschwannomaormeningiomaandagermlineSMARCB1mutation,or(2)hasatleasttwobiopsy-provenschwannomasormeningiomaswithasharedSMARB1mutationanddifferingNF2mutations,asoutlinedin►Table3.ClinicalManifestationsSchwannomasThoughschwannomasarecommontobothschwannomatosisandNF2,thereareclinicaldifferences.Theageatpresentationforschwannomatosispeaksinadulthood,usuallybetweentheagesof30and60years,44andoftenwithchronicdebilitatingpain.Incontrast,NF2canbereliablydiagnosedinearlychildhoodandmorecommonlypresentswithneurologicaldeﬁcits.Histologically,sporadicschwannomasandsyndromicschwannomasareindistinguishable;how-ever,similartoNF2,theschwannomasofschwannomatosistendtohaveanintraneuralgrowthpattern,peritumoraledema,myxoidchange,andamosaicINI1stainingpatternbyimmunohistochemistry.26,45Managementisclinicalobservationforasymptomaticpatients.Incasesofspinalcordcompressionorbothersomesymptoms,surgeryisper-formedtoimprovequalityoflife.References1DeBellaK,SzudekJ,FriedmanJM.Useofthenationalinstitutesofhealthcriteriafordiagnosisofneuroﬁbromatosis1inchildren.Pediatrics2000;105(3Pt1):608–6142HirbeAC,GutmannDH.Neuroﬁbromatosistype1:amultidisci-plinaryapproachtocare.LancetNeurol2014;13(8):834–8433WeissS,etal.EnzingerandWeiss’sSoftTissueTumors.Philadel-phia,PA.ElsevierSaunders;20144BrosiusS.AhistoryofvonRecklinghausen’sNF1.JHistNeurosci2010;19(4):333–3485WilliamsVC,LucasJ,BabcockMA,GutmannDH,KorfB,MariaBL.Neuroﬁbromatosistype1revisited.Pediatrics2009;123(1):124–1336AbramowiczA,GosM.Neuroﬁbromininneuroﬁbromatosistype1-mutationsinNF1geneasacauseofdisease.DevPeriodMed2014;18(3):297–3067BoydKP,KorfBR,TheosA.Neuroﬁbromatosistype1.JAmAcadDermatol2009;61(1):1–14,quiz15–168FernerRE.Neuroﬁbromatosis1.EurJHumGenet2007;15(2):131–1389RosaiJ,etal.RosaiandAckerman’sSurgicalPathology.10thed.Philadelphia,PA:ElsevierSaunders;201110RobertsonKA,NalepaG,YangFC,etal.Imatinibmesylateforplexiformneuroﬁbromasinpatientswithneuroﬁbromatosistype1:aphase2trial.LancetOncol2012;13(12):1218–1224Table3DiagnosticcriteriaforschwannomatosisClinicalcriteriaMolecularcriteria(cid:129)Atleasttwonondermalbiopsy-provenschwannomasplusnoradiographicevidenceofbilateralvestibularschwannomasonhigh-qualityMRIor(cid:129)Biopsy-provenschwannomaormeningiomaplusagermlineSMARCB1mutationor(cid:129)Onebiopsy-provennondermalschwannomaorintracranialmeningiomaplusaﬁrst-degreerelativewithschwannomatosis(cid:129)Atleasttwobiopsy-provenschwannomasormeningiomasharboringasharedSMARCB1mutationanddifferingNF2mutationsAbbreviations:NF2,neuroﬁbromatosistype2;MRI,magneticresonanceimaging.JournalofPediatricGeneticsVol.5No.2/2016Neurofibromatosis:AReviewofNF1,NF2,andSchwannomatosisKresak,Walsh103This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.11CroweFW,etal.AClinical,PathologicalandGeneticStudyofMultipleNeuroﬁbromatosis.Springﬁeld,IL:CharlesCThomas;195612AlperJ,HolmesLB,MihmMCJr.Birthmarkswithseriousmedicalsigniﬁcance:nevocullularnevi,sebaceousnevi,andmultiplecaféaulaitspots.JPediatr1979;95(5Pt1):696–70013ShimbashiT,KamideR,HashimotoT.Long-termfollow-upintreatmentofsolarlentigoandcafé-au-laitmaculeswithQ-switchedrubylaser.AestheticPlastSurg1997;21(6):445–44814YanoffM,SassaniJ.OcularPathology.Philadelphia,PA:ElsevierSaunders;200915SharifS,FernerR,BirchJM,etal.Secondprimarytumorsinneuroﬁbromatosis1patientstreatedforopticglioma:substantialrisksafterradiotherapy.JClinOncol2006;24(16):2570–257516SungL,AndersonJR,ArndtC,RaneyRB,MeyerWH,PappoAS.NeuroﬁbromatosisinchildrenwithRhabdomyosarcoma:areportfromtheIntergroupRhabdomyosarcomastudyIV.JPediatr2004;144(5):666–66817TuckerT,SchnabelC,HartmannM,etal.Bonehealthandfracturerateinindividualswithneuroﬁbromatosis1(NF1).JMedGenet2009;46(4):259–26518HeerväE,KoffertA,JokinenE,etal.Acontrolledregister-basedstudyof460neuroﬁbromatosis1patients:increasedfractureriskinchildrenandadultsover41yearsofage.JBoneMinerRes2012;27(11):2333–233719AgaimyA,VassosN,CronerRS.Gastrointestinalmanifestationsofneuroﬁbromatosistype1(Recklinghausen’sdisease):clinico-pathologicalspectrumwithpathogeneticconsiderations.IntJClinExpPathol2012;5(9):852–86220EvansDG,HusonSM,DonnaiD,etal.Aclinicalstudyoftype2neuroﬁbromatosis.QJMed1992;84(304):603–61821BaserME,FriedmanJM,AeschlimanD,etal.Predictorsoftheriskofmortalityinneuroﬁbromatosis2.AmJHumGenet2002;71(4):715–72322BaserME,FriedmanJM,WallaceAJ,RamsdenRT,JoeH,EvansDG.Evaluationofclinicaldiagnosticcriteriaforneuroﬁbromatosis2.Neurology2002;59(11):1759–176523TrofatterJA,MacCollinMM,RutterJL,etal.Anovelmoesin-,ezrin-,radixin-likegeneisacandidatefortheneuroﬁbromatosis2tumorsuppressor.Cell1993;72(5):791–80024RouleauGA,MerelP,LutchmanM,etal.Alterationinanewgeneencodingaputativemembrane-organizingproteincausesneuro-ﬁbromatosistype2.Nature1993;363(6429):515–52125EvansDG,RamsdenRT,ShentonA,etal.Mosaicisminneuroﬁbro-matosistype2:anupdateofriskbasedonuni/bilateralityofvestibularschwannomaatpresentationandsensitivemutationanalysisincludingmultipleligation-dependentprobeampliﬁca-tion.JMedGenet2007;44(7):424–42826LoveS,PerryA,IronsideJ,BudkaH.Greenﬁeld’sNeuropathology.9thed.BocaRaton,FL:CRCPress;201527SelvanathanSK,ShentonA,FernerR,etal.Furthergenotype—phenotypecorrelationsinneuroﬁbromatosis2.ClinGenet2010;77(2):163–17028SmithMJ,HiggsJE,BowersNL,etal.Cranialmeningiomasin411neuroﬁbromatosistype2(NF2)patientswithprovengenemuta-tions:clearpositionaleffectofmutations,butabsenceoffemaleseverityeffectonageatonset.JMedGenet2011;48(4):261–26529StivarosSM,Stemmer-RachamimovAO,AlstonR,etal.Multiplesynchronoussitesoforiginofvestibularschwannomasinneuro-ﬁbromatosisType2.JMedGenet2015;52(8):557–56230DewanR,PemovA,KimHJ,etal.Evidenceofpolyclonalityinneuroﬁbromatosistype2-associatedmultilobulatedvestibularschwannomas.Neuro-oncol2015;17(4):566–57331ManiakasA,SalibaI.Neuroﬁbromatosistype2vestibularschwan-nomatreatment:areviewoftheliterature,trends,andoutcomes.OtolNeurotol2014;35(5):889–89432NeffBA,WietRM,LasakJM,etal.Cochlearimplantationintheneuroﬁbromatosistype2patient:long-termfollow-up.Laryngo-scope2007;117(6):1069–107233HamadaY,IwakiT,FukuiM,TateishiJ.AcomparativestudyofembeddednervetissueinsixNF2-associatedschwannomasand17nonassociatedNF2schwannomas.SurgNeurol1997;48(4):395–40034PlotkinSR,MerkerVL,HalpinC,etal.Bevacizumabforprogressivevestibularschwannomainneuroﬁbromatosistype2:aretrospec-tivereviewof31patients.OtolNeurotol2012;33(6):1046–105235SlusarzKM,MerkerVL,MuzikanskyA,FrancisSA,PlotkinSR.Long-termtoxicityofbevacizumabtherapyinneuroﬁbromatosis2patients.CancerChemotherPharmacol2014;73(6):1197–120436HiltonDA,HanemannCO.Schwannomasandtheirpathogenesis.BrainPathol2014;24(3):205–22037Stemmer-RachamimovAO,InoY,LimZY,etal.LossoftheNF2geneandmerlinoccurbythetumorletstageofschwannomadevelopmentinneuroﬁbromatosis2.JNeuropatholExpNeurol1998;57(12):1164–116738BergJC,ScheithauerBW,SpinnerRJ,AllenCM,KoutlasIG.Plexi-formschwannoma:aclinicopathologicoverviewwithemphasisontheheadandneckregion.HumPathol2008;39(5):633–64039Hébert-BlouinMN,AmramiKK,ScheithauerBW,SpinnerRJ.Multinodular/plexiform(multifascicular)schwannomasofmajorperipheralnerves:anunderrecognizedpartofthespectrumofschwannomas.JNeurosurg2010;112(2):372–38240BendonCL,FurnissD,GieleHP.Comparisonofoutcomesofperiph-eralnerveschwannomaexcisioninneuroﬁbromatosistype2patientsandnon-neuroﬁbromatosistype2patients:Acasecontrolstudy.JPlastReconstrAesthetSurg2015;68(9):1199–120341EvansDG,BirchJM,RamsdenRT.Paediatricpresentationoftype2neuroﬁbromatosis.ArchDisChild1999;81(6):496–49942PlotkinSR,O’DonnellCC,CurryWT,BoveCM,MacCollinM,NunesFP.SpinalependymomasinneuroﬁbromatosisType2:aretro-spectiveanalysisof55patients.JNeurosurgSpine2011;14(4):543–54743McLaughlinME,PepinSM,MaccollinM,ChoopongP,LessellS.Ocularpathologicﬁndingsofneuroﬁbromatosistype2.ArchOphthalmol2007;125(3):389–39444KoontzNA,WiensAL,AgarwalA,HingtgenCM,EmersonRE,MosierKM.Schwannomatosis:theoverlookedneuroﬁbromato-sis?AJRAmJRoentgenol2013;200(6):W646-5345MacCollinM,ChioccaEA,EvansDG,etal.Diagnosticcriteriaforschwannomatosis.Neurology2005;64(11):1838–1845JournalofPediatricGeneticsVol.5No.2/2016Neurofibromatosis:AReviewofNF1,NF2,andSchwannomatosisKresak,Walsh104This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.Biochem.J.(2002)365,783–789(PrintedinGreatBritain)783The4.1/ezrin/radixin/moesindomainoftheDAL-1/Protein4.1Btumoursuppressorinteractswith14-3-3proteinsTingxiYU*1,VictoriaA.ROBB(cid:139)1,VinitaSINGH*,DavidH.GUTMANN(cid:139)andIreneF.NEWSHAM*2*DavidandDoreenHermelinLaboratoryofMolecularOncogenetics,DepartmentofNeurosurgeryandHermelinBrainTumorCenter,HenryFordHospital,E&RBldg.Rm.3096,2799W.GrandBlvd.Detroit,MI48202,U.S.A.,and(cid:139)DepartmentofNeurology,WashingtonUniversitySchoolofMedicine,St.Louis,MO,U.S.A.TheProtein4.1familycontainsatleasttwomembersthatfunctionastumoursuppressors,theneuroﬁbromatosis2geneproductmerlinandtherecentlyidentiﬁeddiﬀerentiallyexpressedinadenocarcinomaofthelung(DAL-1)}Protein4.1Bmolecule.DAL-1}Protein4.1Blossisobservedinavarietyoftumours,includingbreastandlungcancersaswellasmeningiomas.WehavepreviouslydemonstratedthatDAL-1}Protein4.1Binteractswithsomebutnotallmerlin-bindingproteins,raisingthepossibilitythatDAL-1}Protein4.1Bassociateswithadditionaluniqueproteinsspeciﬁctoitsfunctionasanegativegrowthregulator.Usingyeasttwo-hybridinteractioncloning,weidenti-ﬁedthree14-3-3isoforms,b,candg,tobeDAL-1}Protein4.1B-INTRODUCTIONDiﬀerentiallyexpressedinadenocarcinomaofthelung(DAL-1)}Protein4.1BisatumoursuppressorgenebelongingtotheProtein4.1superfamilyofproteins,originallyisolatedusingdiﬀerentialdisplayPCRonprimarylungtumours[1].DAL-1}Protein4.1BrepresentsthesecondmemberoftheProtein4.1familythatfunctionsasatumoursuppressor.Merlinorschwannomin,theﬁrstidentiﬁedProtein4.1tumoursuppressor,isaproductoftheneuroﬁbromatosis2gene[2,3].MembersoftheProtein4.1familycontainseveralregionsofsequencesimilarityincludinga4.1}ezrin}radixin}moesin(FERM)domainconsistingofapprox.300aminoacids,andspectrin}actinbindingsequences[4].TheFERMdomainofthefoundingfamilymem-berProtein4.1Rhasbeenfoundtoassociatewithseveralmembraneproteins,includingerythrocyteband3,calmodulin,glycophorinC,p55andthechloride-ionchannelpICln[5,6].Similarly,merlinassociateswithseveraltransmembraneproteinsviaresiduesintheN-terminalFERMdomain[7,8].Theinter-actionofmerlinwithoneofthesemembraneproteins,CD44,hasbeenshowntobecriticalformerlingrowthsuppression[7,9].Similartomerlin,DAL-1}Protein4.1Blocalizestothecellmembrane[1]andcanfunctionasanegativegrowthregulator.WhenDAL-1}Protein4.1BisreintroducedintoDAL-1-deﬁcientlungcancer[1],breastcancer[10]andmeningioma[11]celllines,cellgrowthissigniﬁcantlyattenuated.Lossofheterozygosityatchromosome18p11.3,thechromosomallocationofDAL-1}Pro-tein4.1B,isfrequentinlung,breastandbraintumours[12].Detailedanalysisofbreastcancertissuesamplesrepresentingmultiplediseasestagesrevealedthat18p11.3allelicdeletionsAbbreviationsused:DAL-1,diﬀerentiallyexpressedinadenocarcinomaofthelung;FERM,4.1/ezrin/radixin/moesin;GST,glutathioneS-transferase;NP40,NonidetP40;TnT,transcriptionandtranslation.1Thesetwoauthorscontributedequallytothepresentstudy.2Towhomcorrespondenceshouldbeaddressed(e-mailirene!bogler.net).bindingproteins.TheseinteractionswereveriﬁedbyusingglutathioneS-transferaseaﬃnitychromatographyin(cid:138)itroandco-immunoprecipitationin(cid:138)i(cid:138)o.Theinteractionof14-3-3withDAL-1}Protein4.1Bwasspeciﬁc,as14-3-3didnotbindtotherelatedProtein4.1familymembersmerlin,ezrinorradixin.TheDAL-1}Protein4.1Bdomainthatmediates14-3-3bindingwasmappedtoresiduesPro#%%andLeu#)!withinthe4.1}ezrin}radixin}moesindomain.TheidentiﬁcationofthisnovelDAL-1}Protein4.1B-interactingproteinrepresentstheﬁrststeptowardselucidatingitspotentiallyuniquemechanismofaction.Keywords:membrane,neuroﬁbromatosis2.occurinatleast55%ofductalcarcinomainsitutumours,suggestingthatlossofDAL-1}Protein4.1Bexpressionoccursearlyintheprogressionofthisdisease[13].Similarly,thelossofDAL-1}Protein4.1Bexpressionisdetectedearlyinmeningiomapathogenesis[14,15].AlthoughmerlinandDAL-1}Protein4.1Bsharestructuralsimilarities,thereareanumberofobservationsthatsuggestthatthesetwoProtein4.1tumoursuppressorshaveuniquemechanismsofaction.First,incelltypeswherebothDAL-1andmerlinareexpressed,sometumoursexhibitonlyNF2loss,whereasothersexhibitonlyDAL-1}Protein4.1Binactivation[14].Secondly,overexpressionofmerlinandDAL-1}Protein4.1Bresultsinthesuppressionofmeningiomacelllinegrowth,butonlymerlinoverexpressioncansuppressschwannomacellgrowthin(cid:138)itro[11].Thirdly,DAL-1}Protein4.1Binteractsonlywithasubsetofmerlin-bindingproteins[11].Andﬁnally,thecombinedlossofbothDAL-1}Protein4.1Bandmerlinismorefrequentlyassociatedwithhigh-grademeningiomas[15].InaneﬀorttoidentifyuniquebindingpartnersforDAL-1}Protein4.1Bthatmayunderlieitsmechanismofactionasanegativegrowthregulator,weperformedyeasttwo-hybridanalysisusingthe336residueDAL-1}Protein4.1BFERMdomain.Over1.5millionco-transfectantsfromafoetalbraincDNAlibrarywerescreenedtoidentifyseveralstronglyas-sociatingproteins,threeofwhichrepresentedthe14-3-3proteinisoformsb,candg.Thesehighlyconservedandubiquitouslyexpressedproteinsareinvolvedintheregulationofenzymeactivity,actaslocalizationanchorsforotherproteins,andfunctionasadaptormoleculestostimulateprotein–proteininter-actions[16].Thebindingofamembrane-associatedproteinsuchasDAL-1}Protein4.1Brepresentsanovelpartnerfor14-3-3.#2002BiochemicalSociety784T.YuandothersInthepresentstudy,wedemonstratethedirectassociationof14-3-3withthetumoursuppressorproteinDAL-1}Protein4.1Bbyco-immunoprecipitationin(cid:138)i(cid:138)oandaﬃnitychromatographyassaysin(cid:138)itro.Wefurthershowthatthe14-3-3interactionwasspeciﬁctoDAL-1}Protein4.1BandnototherProtein4.1familymembers.Lastly,welocalizedtheDAL-1}Protein4.1B–14-3-3interactiondomaintotheaminoacidresiduesPro#%%andLeu#)!withintheFERMdomain.MATERIALSANDMETHODSYeasttwo-hybridanalysistoidentifyproteinsthatinteractwiththeFERMdomainofDAL-1/Protein4.1BYeasttwo-hybridanalysis,utilizedtoidentifytheproteinsinteractingwiththeFERMdomainofDAL-1}Protein4.1B,wasperformedusingtheProQuestTMTwo-Hybridsystem(Invitrogen,Carlsbad,CA,U.S.A.).TheFERMdomainofDAL-1}Protein4.1B,representingtheﬁrst336aminoacidsoftheDAL-1}Protein4.1BcDNAclone2A3(1),wasampliﬁedusingprimers5«-ACGTGTCGACCATGCAGTGCAAAGTG-ATAC-3«and5«-ACGTGCGGCCGCCTCTCCATCCAAGC-TGCG-3«containingSalIandNotIrestrictionenzymesitelinkersrespectively.Theresulting1015bpfragmentwasclonedintothepDBleu‘bait’vector,creatingafusionproteinwithaGAL-4transcriptionfactorDNA-bindingdomain.AfoetalbraincDNAlibrary(Invitrogen)encodingexpressedcDNAsfusedwiththeGAL-4transcriptionfactoractivationdomainwasusedforscreening.Initially,thelibrarywasexpandedinTerriﬁcBrothmedium(1litre;12gofbacto-tryptone,24gofbacto-yeastextract,4mlofglycerol)for16hat30(cid:176)C,andplasmidDNAwasisolatedusingaBio-Radmidiprepkit.MaV200competentcells(Invitrogen)wereco-transformedwith10lgofbaitplasmid(pDBLeu-FERM)and10lgoflibraryplasmidDNA(pPC86-cDNA).Morethan1.5millioncDNAcloneswerescreened,and14positivelyinteractingcolonieswereidentiﬁedonthebasisofgrowthonleucine-,tryptophan-,uracil-andhistidine-lackingplatesaswellastheabilitytoprocessthelacZsubstrate.Toconﬁrmtheprimaryyeasttwo-hybridinteraction,pPC86-cDNAconstructswereisolatedfromthepositiveyeastcoloniesusingtheYeastDNAIsolationSystem(Stratagene,LaJolla,CA,U.S.A.),andinsertsweresequencedandanalysedwitheitherThermosequenaseCy5orCy5.5terminatorsequencingkits(APBiotech)ontheLong-ReadTMSystemsequencer(VisibleGenetics).HomologysearcheswereperformedusingtheBLASTalgorithmfromtheNationalCenterforBiotechnologyInfor-mationwebsite(www.nbti.nlm.nih.gov)[17].CellcultureandWestern-blotanalysisThelungtumourcelllineNCI-H460andbreastcarcinomacelllineT47DwereobtainedfromA.T.C.C.(Manassas,VA,U.S.A.)andmaintainedinRPMI1640}10%foetalcalfserumeitherwithinsulin(T47D)orwithoutinsulin(NCI-H460).TheMCF-7Clone27celllineisaDAL-1}Protein4.1B-induciblecelllinegeneratedfromtheparentalMCF-7celllineusingtheEcdysonemuristerone-inducibleexpressionkit(Invitrogen)[10].ThiscelllineaswellasparentalMCF-7weregrowninMEMwith10%foetalcalfserum,sodiumpyruvate,non-essentialaminoacidsandinsulin.DAL-1}Protein4.1Bexpressionisinducedbytheadditionof1lMofmuristeronetotheculturemediumfor48h.ForWestern-blotanalysisontotalcellularprotein,lysateswerepreparedinRIPAbuﬀer[50mMTris}150mMNaCl}0.1%SDS}0.5%sodiumdeoxycholate}1%NonidetP40(NP40)]withproteaseinhibitors(BoehringerMannheim,Indianapolis,IN,U.S.A.).ElectrophoresiswasperformedonSDS}PAGE(10%or12%gel)ReadyGels(Bio-Rad)andtransferredontoPVDFPlusmembrane(MSIInc.)usingtheBio-RadMiniProteanIItransfersystemasdescribedpreviously[1].Forspeciﬁcextractionofcytoplasmicandmembraneproteinfractions,cellswereresuspendedin20mMHepes,40mMb-glycerophosphate,2mMMgCl#,1mMorthovanadateandproteaseinhibitors(BoehringerMannheim),andlysedfor10minat4(cid:176)C.Sampleswerecentri-fugedfor30minat17000rev.}min.Thesupernatant,repre-sentingthecytosolicfraction,wasseparatedfromthepellet,and2%NP40wasadded.Freshlysisbuﬀerincluding2%NP40wasaddedtothepelletsrepresentingthecellularmembranefraction.Followingincubationfor10minat4(cid:176)C,sampleswerecentri-fugedandthemembranefractionsupernatantcollected.InvitrobindingassayspcDNA414-3-3b,14-3-3cand14-3-3gcDNAexpressioncon-structsweregeneratedbyPCRampliﬁcationofthecodingregionsofthe14-3-3proteinspresentintheyeasttwo-hybridpPC86-cDNAconstructs.Ampliﬁcationprimers,containingrestrictionenzymelinkersequencesforEcoRIandXbaI(underlined),werethefollowing.14-3-3bforwardprimer5«-GGAATTCCCCACGGGAATGACAATGGAT-3«and14-3-3breverseprimer5«-GCTCTAGAGCATTAGTTCTCTCC-CTCCCCA-3«;14-3-3cforwardprimer5«-GGAATTCCGAG-CCGCGAGCGACATG-3«and14-3-3creverseprimer5«-GCTCTAGAGCGGCTAATTCTTTCTAATC-3«;and14-3-3gforwardprimer5«-GGAATTCCCGAAGATGGTGGACCG-CGAGC-3«and14-3-3greverseprimer5«-GCTCTAGAGCC-TGGGGCCTTAATTGTTGC-3«.GeneratedpcDNA4-14-3-3constructswereveriﬁedbysequencing.GlutathioneS-transferase(GST)–DAL-1}Protein4.1BfusionproteinwasexpressedinBL-21cells(Novagen)followingin-ductionwith0.4mMisopropylb-d-thiogalactosideandisolatedusingtheBugBusterTMGST-BindTMpuriﬁcationkit(Novagen).[$H]Leucine-labelled14-3-3b,14-3-3cand14-3-3gproteinsweregeneratedbyacoupledin(cid:138)itrotranscriptionandtranslation(TnT)kit(Promega,Madison,WI,U.S.A.).Forin(cid:138)itrobindingassays,individuallylabelledproteinswereconfrontedwith2lgofGST–DAL-1fusionproteinusingBugBusterbinding}washbuﬀer(4.3mMNa#HPO%}1.47mMKH#PO%}137mMNaCl}2.7mMKCl,pH7.3).ComplexeswerecollectedonGST-Bindresin(Novagen),washedthreetimeswithTris-buﬀeredsaline}0.3%(v}v)Tween20,andseparatedonSDS}PAGE(10%gel)ReadyGels(Bio-Rad).Gelswereﬁxedinapropan-2-ol}water}aceticacid(25:65:10)solution,andﬂuoro-graphicsignalswereenhancedusingAmplifyTM(Amersham).Vacuum-driedgelswereexposedtoautoradiographicﬁlmfor1–2days.Co-immunoprecipitationProteinlysateswerepreparedasdescribedabovefromthecelllinesNCI-H460,T47DandMCF-7andfromMCF-7Clone27beforeandaftera48hinductionofDAL-1(residues1–503)expressionwith1lMofmuristerone.Immunoprecipitatesweregeneratedfrom1–2mgoflysateusingeitherpolyclonalpananti-14-3-3(H8;SantaCruzBiotechnology,NewYork,NY,U.S.A.),anti-14-3-3b(C-20;SantaCruzBiotechnology),anti-14-3-3c(C-16;SantaCruzBiotechnology)orthepolyclonalanti-DAL-1}Protein4.1Bantibody3A-1.Antibodiesweremixedwithcelllysatesandincubatedat4(cid:176)Covernightwithrotation.Immuno-precipitateswerecollectedonProteinA–agarosebeads(RocheMolecularBiochemicals,Laval,Quebec,Canada),elutedin2‹#2002BiochemicalSociety785DAL-1interactswith14-3-3proteinsLaemmlisamplebuﬀer,andelectrophoresedonSDS}PAGE(10%or12%gel)ReadyGels(Bio-Rad).BoundproteinswerethenidentiﬁedbyWestern-blotanalysisusingeitheranti-14-3-3antibodies(1:1000)ortheanti-DAL-1}Protein4.1Bantibody(1:2000)detectedwiththemouseIgGorrabbitIgGImmunStarChemiluminescencekits(Bio-Rad).GSTafﬁnitychromatographyGSTfusionproteinsweregeneratedasdescribedpreviously[11].Brieﬂy,GST–14-3-3gfromtheoriginalpPC86yeasttwo-hybridvector(Invitrogen)wasclonedintothepGEX.4T-2vector(Pharmacia),veriﬁedbysequencingandtransformedintoDE3(BL-21)-competentcellsforfusionproteinproduction.Bacterialcultureswereinducedovernightwith0.5mMisopropylb-d-thiogalactosideatroomtemperature,lysedinNP40lysisbuﬀerandtheGSTfusionproteinsisolatedonglutathione–agarosebeads(Sigma)fortheinteractionexperiments.EachfusionproteinwasnewlyisolatedforeachexperimentandveriﬁedbySDS}PAGEwithCoomassieBluevisualization.DAL-1}Protein4.1B,merlin,ezrin(N-ezrin,C-ezrin)andradixin(mer-radandrad-mer)weregeneratedbyreversetrans-criptasePCRasdescribedpreviously[18].Rad-merisahybridproteincomprisedoftheN-terminalradixinsequences(1–323)joinedinframewithC-terminalmerlinsequences(341–583),whereasmer-radiscomposedofN-terminalmerlin(1–341)andC-terminalradixinsequences(324–583).DAL-1}Protein4.1Bconstructs,schematicallyshowninFigure5(A),werecreatedusingfull-lengthDAL-1}Protein4.1BasatemplateandtheTAcloningkit(Invitrogen)accordingtothemanufacturer’sinstructions.ConstructMet"wasgeneratedbyPCRusingprimersthatamplifytheFERMdomainalone(FermF:5«-GCA-CTA-GTC-AAG-GAC-TCA-GAA-GGG-GTA-G-3«andFermR:5«-TCA-TGC-AGC-AGA-CAT-AGA-ATC-CTT-C-3«).Con-structsLys"*&,Pro#%%andLeu#)!weregeneratedbyPCRusingthereverseprimerU2R(5«-TCA-CTC-AGT-GGC-GGT-GGT-CTC-3«)anduniqueforwardprimers(K195F:5«-CAC-TAG-TCC-CGG-GAG-AGT-TTG-AAC-AAT-TTG-3«,P244F:5«-GCA-CTA-GTC-CTG-TTA-CCA-GAA-GCA-CCT-CCC-3«andL280F:5«-TCA-CTT-GGG-AGG-TGC-TTC-TGG-TAA-CAG-3«).ConstructsMet"–#%%andMet"–#)!,encompassingtheﬁrst244and280aminoacidsrespectivelyoftheFERMdomainofDAL-1,weregeneratedbyPCRusingtheforwardprimerFermFanduniquereverseprimers(P244R:5«-TCA-CGG-CCG-GAT-CTT-AAT-GTA-AAA-GTT-3«andL280R:5«-TCA-CAG-TAG-TCT-GAA-AAA-TGT-ATG-ATG-3«).Thecon-structswereveriﬁedbysequencing,andthensubclonedintothepcDNA3vector(Invitrogen).Proteinsweresynthesizedbythein(cid:138)itrocoupledTnTmethod(Promega;catalogno.L4610)inthepresenceof[$&S]methionineaccordingtothemanufacturer’sprotocolandconﬁrmedbySDS}PAGEandautoradiography.Interactionexperimentswereperformedbyincubating5lloftheTnTreactioncontainingtheradiolabelledproteinswithequi-molaramountsofGSTfusionproteinsimmobilizedongluta-thionebeadsinatotalvolumeof1mlofTENbuﬀer[10mMTris(pH7.5)}150mMNaCl}5mMEDTA}1%(v}v)TritonX-100]for4hat4(cid:176)C.TheboundagarosebeadswerethenwashedfourtimesinTENbuﬀer.ForassaysusingproteinfragmentsMet"−#%%andMet"–#)!,radiolabelledproteinsin5llofTnTreactionbuﬀerwereincubatedwithequimolaramountsofGSTfusionproteinsimmobilizedonglutathionebeadsinatotalvolumeof1mlofNETbuﬀer[25mMTris(pH7.5)}100mMNaCl}3mMEDTA]containing1%BSAfor4hat4(cid:176)C.BeadswerewashedtwicewithNETbuﬀerplus0.1%(v}v)TritonX-100andtwicewithNETbuﬀerplus0.05%(v}v)TritonX-100.Analiquotoftheunboundfractionwassavedforalltheassays.TheunboundandboundfractionswereelutedinLaemmlibuﬀer,boiledfor5min,separatedbySDS}PAGEandanalysedbyautoradiography.IdenticalresultswereobtainedwitheitherNETorTENbuﬀers.Inallexperiments,signiﬁcantbindingtoimmobilizedGSTalonewasnotobserved.Eachinteractionexperimenthasbeenrepeatedatleastthreetimes.RESULTSDAL-1/Protein4.1Binteractswithmembersofthe14-3-3familyYeasttwo-hybridinteractioncloningwasperformedtoisolatepotentialbindingpartnersofthetumoursuppressorproteinDAL-1}Protein4.1B.TheFERMdomainofDAL-1}Protein4.1B(Met"-Gly$$’)wasfusedinframewiththeDNA-bindingdomainofGAL4inthepDBleubaitvectorandusedtoscreenahumanfoetalbraincDNAlibrary.ThehighexpressionofDAL-1}Protein4.1Binthebrain[1]suggeststhatphysio-logicallyrelevantbindingpartnerswouldberepresentedinthislibrary.Analysisofmorethan1.5millionco-transfectantsledtotheisolationofatotalof14positiveclonesaftertworoundsofscreening.Threeofthesecolonies(g4,g14andg41inFigure1)containedcDNAsencodingthe14-3-3b,14-3-3cand14-3-3gisoforms.ThecDNAinsertsizesrangedfrom1.6to4.0kbandsequenceanalysisconﬁrmedrepresentationoftheentirecodingregionofthese14-3-3proteinsinthecDNAisolates.ToconﬁrmtheinteractionbetweenDAL-1}Protein4.1Band14-3-3inmammaliancellextracts,co-immunoprecipitationexperimentswereperformedusingproteinlysatesfromtheendogenouslyexpressingnon-smallcelllungcancercellline(NCI-H460),DAL-1}Protein4.1B-nullbreastcancercellline(MCF-7)andFigure114-3-3interactswiththeFERMdomainofDAL-1/Protein4.1BAfoetalbraincDNAlibrarywasscreenedwiththeFERMdomainofDAL-1/Protein4.1Basbait.Theresultingco-transfectantsexhibitinginteractionwereselectedinpartfortheirabilitytoinducetranscriptionofthelacZgeneresultinginabluecolourwhenassayedwith5-bromo-4-chloroindol-3-ylb-D-galactopyranoside.Co-transfectantsg4,g14andg41werepositiveforlacZexpression,whereasg36wasnegative.Controlsrepresentingknownproteininteractionsofvaryingstrengthwereplatedforcomparison.(A)NocDNAinsertcontrol;(B)RB/E2F,weakinteraction;(C)DrosophilaDP/E2F,moderateinteraction;(D)Fos/Jun,stronginteraction;(E)GAL4-bindingdomain/GAL4-activationdomain,verystronginteraction.#2002BiochemicalSociety786T.YuandothersFigure2DAL-1/Protein4.1Binteractsdirectlywith14-3-3b,14-3-3gand14-3-3cinmammaliancellextracts(A)DAL-1/Protein4.1Band14-3-3proteinsfromNCI-H460,MCF-7andtheDAL-1-induciblecelllineClone27weretestedfortheirabilitytoco-immunoprecipitate.Productsimmuno-precipitatedwiththepolyclonalanti-DAL-1/Protein4.1Bantibody3A-1wereanalysedbyWestern-blotanalysiswitheithertheDAL-1/Protein4.1BantibodyorthepolyclonalH8anti-14-3-3antibody.AnalysisshowedthatendogenousDAL-1/Protein4.1Bprotein(fromNCI-H460)andDAL-1proteininducedaftera48hexposureto1lMofmuristerone(Cl.27›)wasabletoco-immunoprecipitatewith14-3-3proteins.CelllinesnegativeforDAL-1/Protein4.1Bexpression(MCF-7andCl.27ﬁ)didnotshowinteractionwith14-3-3.Theendogenouslevelof14-3-3proteinsinthesecelllinesisshowninthelowerpanel.(B)EndogenouslyexpressedDAL-1/Protein4.1Bwasexaminedforitsabilitytointeractspeciﬁcallywiththeendogenousbandcisoformsof14-3-3inNCI-H460andT47D.Western-blotanalysiswith14-3-3bor14-3-3c-speciﬁcantibodiesfollowingimmunoprecipitationwithDAL-1/Protein4.1Bantibody3A-1revealedastrongbandforeachisoform,indicatingthatDAL-1/Protein4.1Band14-3-3proteinscaninteract.(C)GST–DAL-1fusionprotein(2lg)wasgeneratedandinteractedinvitrowithradiolabelled14-3-3b,14-3-3cand14-3-3g.AliquotsofeachradiolabelledproteinfromtheinvitroTnTreactionswererunasareference(TnTrxn).EquivalentamountsofproteincollectedonGSTbeadsandremaininginthesupernatantwereanalysedbyelectrophoresisandautoradiography.Allthree14-3-3isoformstesteddirectlyinteractedwiththeGST–DAL-1fusionprotein.IP,immunoprecipitation;Ab,antibody.aDAL-1inducibleMCF-7-derivedcellline(Clone27),inwhichexpressionofDAL-1(residues1–503)isinducedaftertreatmentwith1lMmuristeroneinculture[10].AsshowninFigure2(A),allcelllinesexpressedabundantlevelsof14-3-3proteins,whereasonlyNCI-H460andtheDAL-1-inducibleMCF-7Clone27(Cl.27›)showedadetectableDAL-1}Protein4.1Bprotein.Immunoprecipitationusingthepolyclonalanti-DAL-1}Protein4.1Bantibody3A-1followedbyWestern-blotanalysisof14-3-3proteinsusingthemonoclonalpan-14-3-3(H8)antibodydemonstratedaninteractioninmammaliancellextractsonlywhentheProtein4.1B}DAL-1proteinwasconcurrentlyex-pressed(Figure2A).Speciﬁcisoformbindingwasexaminedbyusingavailablemonoclonalantibodiesagainst14-3-3c(C-16)and14-3-3b(C-20).AsshowninFigure2(B),14-3-3band14-3-3cwereequallyexpressedinNCI-H460andtheendogenousDAL-1}Protein4.1B-expressingbreastcancercelllineT47D.Inbothcases,14-3-3cand14-3-3bco-immunoprecipitatedwithDAL-1}Protein4.1B,indicatingthistumoursuppressorproteinhasageneralizedcapabilitytointeractwithvarious14-3-3isoforms.boundsupernatantMerlinEzrinDAL-1GSTGSTGST·14-3-3GST·14-3-3RadixinFigure314-3-3bindsspeciﬁcallytoDAL-1/Protein4.1BBindingof14-3-3toDAL-1/Protein4.1B,merlin,ezrinandradixinwasinvestigatedbyGSTaﬃnityinteractionsusingGSTaloneorGST–14-3-3gasdescribedintheMaterialsandmethodssection.Theboundandsupernatantfractionsareshownforeachrepresentativeinteraction.DAL-1/Protein4.1Bexhibitedsigniﬁcantbindingto14-3-3.Bindingtomerlin,ezrinorradixin(rad-mer,resultsshown;mer-rad,resultsnotshown)wasnotobserved.Figure414-3-3complexeswithDAL-1/Protein4.1BattheplasmamembraneProteinlysateswereisolatedfromtheDAL-1/Protein4.1B-induciblecelllineClone27,beforeandafter48hexposuretotheexpression-inducingagentmuristerone.Totalcelllysate(TCL)orproteinisolatedfromfractionsrepresentingplasmamembrane(Mem)orcytoplasmic(Cyt)componentswereimmunoprecipitatedusingthe14-3-3cantibody,followedbyWestern-blotanalysiswiththepolyclonalDAL-1/Protein4.1Bantibody3A-1.ResultsshowthatDAL-1proteinexpressionissigniﬁcantlyinduceduponexposuretomuristerone.ThemajorityofDAL-1proteinproducedcanbeimmunoprecipitatedfromthemembranecomponentbythe14-3-3antibody,indicatingthat14-3-3proteinsarefoundcomplexedwithDAL-1proteinsattheplasmamembrane.IgG,immunoglobulinheavychain;kD,kilodalton;ﬁ,withoutinductionofDAL-1proteinexpression;›,withinductionofDAL-1proteinexpression.In(cid:138)itrobindingassayswerealsoperformedtorevealwhethertheseproteinsinteractedinadirectmannerorrequiredthepresenceofothercellularproteins.BacteriallygeneratedGST–DAL-1fusionprotein(residues1–503)wasincubatedwitheitherradiolabelled14-3-3b,14-3-3cor14-3-3gproducedbyin(cid:138)itrocoupledTnT(Figure2C).ComplexedproteinswereretrievedonGSTaﬃnitybeads,afterwhichthepresenceofradiolabelled14-3-3proteinwasanalysedbySDS}PAGEseparationandauto-radiography.AsshowninFigure2(C),signiﬁcantbindingof[$H]-14-3-3b,[$H]-14-3-3cand[$H]-14-3-3gtotheGST–DAL-1fusionproteinwasobserved,suggestingthatDAL-1}Protein4.1Bdirectlyinteractswith14-3-3proteins.NosigniﬁcantbindingtoGSTproteinalonewasfound(resultsnotshown).14-3-3bindingisspeciﬁctoDAL-1/Protein4.1BTodeterminewhetherthe14-3-3interactionwasuniquetoDAL-1}Protein4.1Borwasobservedwithothermembersofthe#2002BiochemicalSociety787DAL-1interactswith14-3-3proteinsFigure5Deﬁnitionofthe14-3-3-bindingdomain(A)Schematicofthedomainspresentinfull-lengthDAL-1/Protein4.1Bandconstructsdesignedtodeterminetheminimum14-3-3-bindingdomain.LettersandnumberscorrespondtotheﬁrstaminoacidresidueofDAL-1/Protein4.1Bandtheconstructs(e.g.Met1correspondstotheinitiatingmethionineofDAL-1/Protein4.1B).Met1–244andMet1–280representN-terminalproteinfragmentsoftheFERMdomainalone.(B)14-3-3bindingtoDAL-1,Met1,Lys195,Pro244,Leu80,Met1–244andMet1–280.GSTaﬃnityinteractionswereperformedusingGSTaloneorGST–14-3-3g.Theboundandsupernatantfractionsareshownforeachrepresentativeinteraction.DAL-1/Protein4.1B,Met1,Lys195,Pro4andMet1–280exhibitedconsiderablebindingto14-3-3.SigniﬁcantbindingtoGSTalone,Leu280orMet1–244wasnotobserved.The37-amino-acidsequenceofDAL-1/Protein4.1B,hypothesizedtocomprisetheputative14-3-3-bindingsequence,isshownatthebottomright.Protein4.1family,in(cid:138)itrointeractionexperimentswerenextperformedusingbacterialGST–14-3-3gandradiolabelledPro-tein4.1familymembers.Consistentwiththeresultsobtainedfromtheyeasttwo-hybridandco-immunoprecipitationassays,14-3-3interactsspeciﬁcallywithDAL-1}Protein4.1B(Figure3),butnottotheProtein4.1familymembersmerlin,ezrinorradixin.Theselectivityofthe14-3-3interactionsuggeststhatsuchspeciﬁcpartnershipsmayberesponsiblefordeﬁningpo-tentialuniquegrowth-regulatoryfunctionsforDAL-1}Protein4.1B.14-3-3iscomplexedwithDAL-1/Protein4.1BattheplasmamembraneAs14-3-3proteinsareabundantlyexpressedcytoplasmicproteinswithanaﬃnityforavarietyofcellularproteins,weaskedwhether14-3-3wasboundtoDAL-1}Protein4.1Battheplasmamembrane.Toaddressthisquestion,celllysatesweregeneratedfromtheMCF-7Clone27induciblecelllinebeforeandafterinductionofDAL-1proteinexpression.Lysateswereimmuno-precipitatedwiththe14-3-3cantibodyandanalysedbyWesternblottingusingtheDAL-1}Protein4.1Bantibody.AsshowninFigure4,DAL-1}Protein4.1BproteinexpressionwasinducedintheMCF-7Clone27celllineafterincubationwith1lMofmuristerone.Isolationofplasmamembraneproteinsfollowedbyimmunoprecipitationrevealedthat14-3-3cwascomplexedwiththeDAL-1proteinattheplasmamembrane.Thisco-localizationsuggeststhatasigniﬁcantproportionof14-3-3proteinisboundtoDAL-1attheplasmamembrane.Reciprocalimmuno-precipitationexperimentswiththeDAL-1}Protein4.1BantibodyfollowedbyWestern-blotanalysiswith14-3-3cor14-3-3bwerealsoattempted;however,buﬀerconditionsusedforcellularfractionationprecludedtheabilityoftheDAL-1}Protein4.1Bantibodytofunctioneﬀectivelyintheimmunoprecipitationreactions.14-3-3interactionrequiresspeciﬁcFERMdomainsequencesTheuseoftheisolatedFERMdomain(Met"-Gly$$’)ofDAL-1}Protein4.1Bintheinitialyeasttwo-hybridscreensuggestedthatthisregioncontainsa14-3-3-bindingsequence.TodeﬁnetheDAL-1}Protein4.1Bsequencethatmediatestheassociationwith14-3-3,wegeneratedaseriesofdeletionconstructsthatremovespeciﬁcregionsoftheFERMdomainofDAL-1}Protein4.1B.#2002BiochemicalSociety788T.YuandothersTheseconstructs,clonedintopcDNA3andusedtogeneratemoleculesforin(cid:138)itroTnT,includetheentireFERMdomain(Met")aswellassequentialN-terminalFERMdomaindeletions,designatedLys"*&,Pro#%%andLeu#)!(Figure5A).Radio-labelledDAL-1}Protein4.1Bproteinfragmentsandthe503resi-dueDAL-1moleculewereincubatedwithGSTorGST–14-3-3gandassayedfortheirabilitytointeractin(cid:138)itro(Figure5B).Intheseexperiments,DAL-1andconstructswithadeletionoftheﬁrst195or244aminoacidsmaintainedtheabilitytocomplexwithGST–14-3-3g.However,deletionoftheaminoacidsbetweenPro#%%andLeu#)!abolished14-3-3gbinding,suggestingthatthis37-amino-acidregion(Pro#%%-Leu#)!)containsresiduescriticalfor14-3-3binding.Todeterminethispossibilityandtoexcludethepossibilitythatcarboxyl-terminalsequencesintheU2regionalsoparticipatein14-3-3binding,wegeneratedtwoadditionalconstructsthatincludeonlyFERMdomainsequences(Met"−#%%andMet"–#)!;Figure5A)andanalysedtheirabilitytointeractwith14-3-3gin(cid:138)itro.OnlytheMet"–#)!FERMfragmentretainedtheabilitytocomplexwith14-3-3(Figure5B).Collectively,theseresultssuggestthattheFERMdomainresiduesPro#%%-Leu#)!aresuﬃcienttomediatethebindingofDAL-1}Protein4.1Bto14-3-3.ThesequenceofthisputativebindingdomainisshowninFigure5(B).Aconventional14-3-3-bindingsite,representedbyconsensussequenceofRSXpSXP[19],isnotfoundwithinthis37-amino-acidstretch.Aminoacidanalysisalsofailedtoidentifyhomologytoanyoftheotherpreviouslyreported14-3-3-bindingmotifs[20],suggestingthatthisinteractioninvolvesanovelinteractionsequence.DISCUSSIONPreviousstudieshavedemonstratedthetumoursuppressorpropertiesoftheDAL-1}Protein4.1Bmolecule[1,10,11].InaneﬀorttoidentifyuniquebindingpartnersforDAL-1}Protein4.1Bthatmaytransduceitsnegativecell-growth-regulatorysignal,weutilizedayeasttwo-hybridinteractionassaywiththeDAL-1}Protein4.1BFERMdomainasbait.Thisscreenidenti-ﬁedthe14-3-3adaptorproteinasaDAL-1}Protein4.1B-interactingmolecule.Wedemonstratedthat14-3-3doesnotassociatewithotherProtein4.1familymembersincludingmerlin,ezrinandradixin.TheDAL-1}Protein4.1B–14-3-3interactionwasconﬁrmedbothin(cid:138)itroandin(cid:138)i(cid:138)o,andappearedtobeadirectassociationthatdoesnotrequireadditionalproteinpartners.Theregionof14-3-3bindingwithintheDAL-1}Protein4.1BFERMdomainlocalizedtoaspeciﬁc37-amino-acidsequencethatdoesnotcontaintraditional14-3-3-bindingmotifs.14-3-3proteinsconsistofsevenprimaryisoforms(b,c,e,f,g,sandh)withadditionalisoformsaanddrepresentingphosphoryl-atedformsofbandfrespectively[21].Theseproteinsexistasdimers,formingtwointernalpocketswithwhichotherproteinscaninteract[22].Inourstudies,wefoundthatall14-3-3moleculesexaminedwereabletobindtoDAL-1}Protein4.1B.TheassociationbetweenDAL-1}Protein4.1Band14-3-3appearstobedirect,basedonin(cid:138)itroaﬃnitychromatographybindingexperiments,althoughotherproteinsmaysubtlyfacilitateorregulatethisinteractionin(cid:138)i(cid:138)o.14-3-3moleculestypicallybindtoproteinsthatcontaintra-ditionalconsensusbindingmotifs,suchasRSXpSXP,althoughotherbindingmotifshavebeenreported.Forexample,proteinphosphatasePTPH1,arelatedProtein4.1familymember,hasbeenshowntobind14-3-3bviatwoC-terminalmotifs,RSLS$&*VEandRVDS)&$EP[23].UsingaseriesofFERMdeletionconstructs,wenarrowedtheDAL-1}Protein4.1B–14-3-3-bindingsitetoa37-amino-aciddomainthatlackspreviouslyreported14-3-3-bindingmotifs.BLASTsearchesfailedtoidentifyotherproteinswiththis37aminoaciddomain,asidefromotherknownFERM-containingmolecules.Inthisregard,theDAL-1}Protein4.1BFERMinteractionsequenceisunique[16,19,20].Phosphorylationhasbeendemonstratedtobeanimportantmodiﬁcationforproteinsinteractingwith14-3-3isoforms.Forexample,theassociationbetween14-3-3andPTPH1isdependentonserinephosphorylation[23].Likewise,theactivationoftheNa+}H+exchanger-1protein,whichinteractswith14-3-3usingthemotifRIGSDP,isalsodependentonthephosphorylationoftheserinewithinthismotif[24].However,phosphorylation-independentpeptidebindingof14-3-3alsooccurs.14-3-3ebindstocalmodulin,aknowninteractorofseveralDAL-1}Protein4.1B-relatedProtein4.1familymolecules,inanon-phosphoryl-ation-dependentmanner[25].ThereforemoleculeslikeDAL-1}Protein4.1Bmightusenon-traditionalandphosphorylation-independentinteractionmechanismstointeractwith14-3-3.Studiesareunderwaytodeterminewhether14-3-3bindingisinﬂuencedbyDAL-1}Protein4.1Bphosphorylationin(cid:138)i(cid:138)o.TheinteractionofDAL-1}Protein4.1Bwith14-3-3isnotaubiquitouscharacteristicofallmembersoftheProtein4.1family.OurstudiesdemonstratedthattheFERMdomainsofmerlin,ezrinandradixinwerenotcapableofassociatingwith14-3-3.Theseresultsstronglysuggestthat14-3-3mayrepresentauniqueinteractorspeciﬁctotheDAL-1}Protein4.1Btumoursuppressor.PreviousstudiesfromourlaboratorieshavedemonstratedthatalthoughmerlinandDAL-1}Protein4.1Barestructurallysimilarmolecules,theydiﬀerintheirabilitytointeractwithspeciﬁcproteins[11].Merlinhasbeenshowntobindtoseveralproteinsthatresideatthecellmembrane,includingCD44andb1-integrin[7,8].TheassociationofmerlinwithCD44isrequiredformerlingrowthsuppression[7,9].Inaddition,merlinassociateswiththehepatocytegrowth-factor-regulatedtyrosinekinasesubstrate[26],Na+}H+exchangerregulatoryfactor[27],syntenin[28]andschwannomin-interactingprotein1[29].Todate,wehaveshownthatDAL-1}Protein4.1Bdoesnotinteractin(cid:138)itrowitheitherthehepatocytegrowth-factor-regu-latedtyrosinekinasesubstrateorschwannomin-interactingpro-tein1andlacksthebindingdomainrequiredforsynteninbinding([11];V.A.RobbandD.H.Gutmann,unpublishedwork).Collectively,theseresultssuggestthatmerlinandDAL-1}Protein4.1Bareuniquemoleculesimportantforgrowthregulation.Although14-3-3isdescribedasacytoplasmicprotein,wehaveshownherethat14-3-3isoformsassociatewithDAL-1}Protein4.1Batthecellmembrane.ItispossiblethatDAL-1}Protein4.1Brecruits14-3-3tothecellmembrane,allowingittointeractwithspeciﬁceﬀectorproteinstotransduceagrowthsuppressorsignal.Asimilarmechanismhasbeenproposedfor14-3-3bindingtoRAF[30–32].Alternatively,14-3-3proteinsmaybeguidingDAL-1}Protein4.1Btotheplasmamembrane,ashasbeensuggestedforother14-3-3-interactingproteins[16,19].Ineithercase,understandingtherelationshipbetweenDAL-1}Protein4.1Band14-3-3islikelytoyieldimportantinsightsintothemechanismsthatregulateDAL-1}Protein4.1Bfunction.Severalotherfunctionshavebeenattributedto14-3-3molecules,includingregulationofsignaltransductionthroughc-Cbl[33]andphosphoinositide3-kinase[34].Oneintriguing14-3-3-bindingpartneristhepro-apoptoticprotein,Bcl-2}Bcl-XL-antagonist,causingcelldeath(BAD)[35].14-3-3bindstophosphorylatedBADandpreventsitfromtranslocatingtothemitochondriatoinitiateprogrammedcelldeathorapoptosis[36,37].Recentwork[10]fromourlaboratorieshasshownthatDAL-1}Protein4.1Boverexpressionresultsinapoptosisinbreastcancercelllines.Atpresent,therelationshipbetweenDAL-1}Protein4.1B,programmedcelldeathand14-3-3bindingis#2002BiochemicalSociety789DAL-1interactswith14-3-3proteinsactivelybeinginvestigated.TheseanalyseswillrequireabetterunderstandingofthespeciﬁcresiduesinDAL-1}Protein4.1Bthatareneededformediating14-3-3binding.Experimentsinourlaboratorydemonstratethatthe37-amino-acidregionnecessaryfor14-3-3bindingoverlapswithregionsthatnotonlymediateothercriticalDAL-1}Protein4.1BassociationsbutalsospecifythecorrectsubcellularlocalizationofDAL-1}Protein4.1Btotheplasmamembrane(D.H.GutmannandI.F.Newsham,unpublishedwork).ExperimentsareunderwaytoidentifyspeciﬁcresidueswithintheFERMdomainwhosealterationselectivelyimpairsDAL-}Protein4.1Bbindingto14-3-3withoutaﬀectingotherbindingproteins.Thesemutantswillbecriticaltodecipheringthefunctionalsigniﬁcanceofthe14-3-3associ-ationtoDAL-1}Protein4.1Bregulationofcellgrowth.WethankDrOliverBo$glerforhelpwiththeyeasttwo-hybridanalysisandW.LiandA.C.Hirbeforexperttechnicalassistance.ThisworkwassupportedbygrantsNS/CA41520andNCI/CA77730toD.H.G.andI.F.N.respectivelyandbythegenerosityoftheHermelinBrainTumorCenterdonors.REFERENCES1Tran,Y.K.,Bo$gler,O.,Gorse,K.M.,Wieland,I.,Green,M.R.andNewsham,I.F.(1999)AnovelmemberoftheNF2/ERM/4.1superfamilywithgrowthsuppressingpropertiesinlungcancer.CancerRes.59,35–452Trofatter,J.A.,MacCollin,M.M.,Rutter,J.L.,Murrell,J.R.,Duyao,M.P.,Parry,D.M.,Eldridge,R.,Kley,N.,Menon,A.G.,Pulaski,K.etal.(1993)Anovelmoesin-,ezrin-,radixin-likegeneisacandidatefortheneuroﬁbromatosis2tumorsuppressor.Cell(Cambridge,Mass.)72,791–8003Rouleau,G.A.,Merel,P.,Lutchman,M.,Sanson,M.,Zucman,J.,Marineau,C.,Hoang-Xuan,K.,Demczuk,S.,Desmaze,C.,Plougastel,B.etal.(1993)Alterationinanewgeneencodingaputativemembrane-organizingproteincausesneuroﬁbromatosistype2.Nature(London)363,515–5214Chishti,A.H.,Kim,A.C.,Marfatia,S.M.,Lutchman,M.,Hanspal,M.,Jindal,H.,Liu,S.-C.,Low,P.S.,Rouleau,G.A.,Mohandas,N.etal.(1998)TheFERMdomain:auniquemoduleinvolvedinthelinkageofcytoplasmicproteinstothemembrane.TrendsBiochem.Sci.23,281–2825Marfatia,S.M.,Lue,R.A.,Branton,D.andChishti,A.H.(1994)Invitrobindingstudiessuggestamembrane-associatedcomplexbetweenerythroidp55,Protein4.1,andglycophorinC.J.Biol.Chem.269,8631–86346Tang,C.-J.andTang,T.K.(1998)The30-kDadomainofProtein4.1mediatesitsbindingtothecarboxylterminusofpICln,aproteininvolvedincellularvolumeregulation.Blood92,1442–14477Morrison,H.,Sherman,L.S.,Legg,J.,Banine,F.,Isacke,C.,Haipek,C.A.,Gutmann,D.H.,Ponta,H.andHerrlich,P.(2001)TheNF2tumorsuppressorgeneproduct,merlin,mediatescontactinhibitionofgrowththroughinteractionswithCD44.GenesDev.15,968–9808Obremski,V.J.,Hall,A.M.andFernandez-Valle,C.(1998)Merlin,theneuroﬁbromatosistype2geneproduct,andb1integrinassociateinisolatedanddiﬀerentiatingSchwanncells.J.Neurobiol.37,487–5019Sherman,L.S.andGutmann,D.H.(2001)Merlin:hangingtumorsuppressionontheRac.TrendsCellBiol.11,442–44510Charboneau,A.L.,Singh,V.,Yu,T.andNewsham,I.F.(2002)ThetumorsuppressorDAL-1suppressesgrowthinMCF-7cells.Int.J.Cancer,inthepress11Gutmann,D.H.,Hirbe,A.C.,Huang,Z.-Y.andHaipek,C.A.(2001)TheProtein4.1tumorsuppressor,DAL-1,impairscellmotility,butregulatesproliferationinacell-type-speciﬁcfashion.Neurobiol.Dis.8,266–27812Tran,Y.,Benbatoul,K.,Gorse,K.,Rempel,S.,Futreal,A.,Green,M.andNewsham,I.(1998)Novelregionsofallelicdeletiononchromosome18pintumorsofthelung,brainandbreast.Oncogene17,3499–350513Kittiniyom,K.,Gorse,K.M.,Dalbegue,F.,Lichy,J.H.,Taubenberger,J.K.andNewsham,I.F.(2001)Alleliclossonchromosomeband18p11.3occursearlyandrevealsheterogeneityinbreastcancerprogression.BreastCancerRes.3,192–198Received9January2002/15April2002;accepted25April2002PublishedasBJImmediatePublication25April2002,DOI10.1042/BJ2002006014Gutmann,D.H.,Donahoe,J.,Perry,A.,Lemke,N.,Kittinyom,K.,Rempel,S.A.,Gutierrez,J.A.andNewsham,I.F.(2000)LossofDAL-1,aProtein4.1-relatedtumorsuppressor,isanimportantearlyeventinthepathogenesisofmeningiomas.Hum.Mol.Genet.9,1495–150015Perry,A.,Dan,X.C.,Scheithauer,B.W.,Swanson,P.E.,Lohse,C.M.,Newsham,I.F.,Weaver,A.andGutmann,D.H.(2000)Merlin,DAL-1,andprogesteronereceptorexpressioninclinicopathologicsubsetsofmeningioma:acorrelativeimmunohistochemicalstudyof175cases.J.Neuropathol.Exp.Neurol.59,872–87916vanHemert,M.J.,Steensma,H.Y.andvanHeusden,G.P.H.(2001)14-3-3proteins:keyregulatorsofcelldivision,signallingandapoptosis.BioEssays23,936–94617Altschul,S.F.,Gish,W.,Miller,W.,Myers,E.W.andLipman,D.J.(1990)Basiclocalalignmentsearchtool.J.Mol.Biol.215,403–41018Xu,H.-M.andGutmann,D.H.(1998)Merlindiﬀerentiallyassociateswiththemicrotubuleandactincytoskeleton.J.Neurosci.Res.51,403–41519Muslin,A.J.,Tanner,J.W.,Allen,P.M.andShaw,A.S.(1996)Interactionof14-3-3withsignalingproteinsismediatedbytherecognitionofphosphoserine.Cell(Cambridge,Mass.)84,889–89720Fu,H.,Subramanian,R.R.andMasters,S.C.(2000)14-3-3proteins:structure,function,andregulation.Annu.Rev.Pharmacol.Toxicol.40,617–64721Baldin,V.(2000)14-3-3proteinsandgrowthcontrol.Prog.CellCycleRes.4,49–6022Skoulakism,E.M.C.andDavis,R.L.(1998)14-3-3proteinsinneuronaldevelopmentandfunction.Neurobiology16,269–28423Zhang,S.-H.,Kobayashi,R.,Graves,P.R.,Piwnica-Worms,H.andTonks,N.K.(1997)Serinephosphorylation-dependentassociationoftheband4.1-relatedprotein–tyrosinephosphatasePTPH1with14-3-3bprotein.Proc.Natl.Acad.Sci.U.S.A.272,27281–2728724Lehoux,S.,Abe,J.-I.,Forian,J.A.andBerk,B.C.(2001)14-3-3bindingtoNa+/H+exchangerisoform-1isassociatedwithserum-dependentactivationofNa+/H+exchange.J.Biol.Chem.276,15794–1580025Luk,S.C.,Ngai,S.M.,Tsui,S.K.,Fung,K.P.,Lee,C.Y.andWaye,M.M.(1999)Invivoandinvitroassociationof14-3-3eisoformwithcalmodulin:implicationforsignaltransductionandcellproliferation.J.Cell.Biochem.73,31–3526Gutmann,D.H.,Haipek,C.A.,Burke,S.P.,Sun,C.X.,Scoles,D.R.andPulst,S.M.(2001)TheNF2interactor,hepatocytegrowthfactor-regulatedtyrosinekinasesubstrate(HRS),associateswithmerlininthe‘open’conformationandsuppressescellgrowthandmotility.Hum.Mol.Genet.10,825–83427Murthy,A.,Gonzalez-Agosti,C.,Corder,D.,Pinney,D.,Candia,C.,Soloman,F.,Gusella,J.andRamesh,V.(1998)NHE-RF,aregulatorycofactorforNa+–H+exchange,isacommoninteractorformerlinandERM(MERM)proteins.J.Biol.Chem.273,1273–127628Jannatipour,M.,Dion,P.,Khan,S.,Jindal,H.,Fan,X.,Laganiere,J.,Chishti,A.H.andRouleau,G.A.(2001)Schwannominisoform-1interactswithsynteninviaPDZdomains.J.Biol.Chem.276,33093–3310029Goutebroze,L.,Brault,D.,Murchardt,C.,Camonis,J.andThomas,G.(2000)CloningandcharacterizationofSCHIP-1,anovelproteininteractingspeciﬁcallywithsplicedisoformsandnaturallyoccurringmutantNF2proteins.Mol.CellBiol.20,1699–171230Fantl,W.J.,Muslin,A.J.,Kikuchi,A.,Martin,J.A.,MacNichol,A.M.,Gross,R.W.andWilliams,L.T.(1994)ActivationofRaf-1by14-3-3proteins.Nature(London)371,612–61431Fu,H.,Xia,K.,Pallas,D.C.,Cui,C.,Conroy,K.,Narsimhan,R.P.,Mamon,H.,Collier,R.J.andRoberts,T.M.(1994)InteractionoftheproteinkinaseRaf-1with14-3-3proteins.Science266,126–12932Muslin,A.J.andXing,H.(2000)14-3-3proteins:regulationofsubcellularlocalizationbymolecularinterference.CellSignal.12,703–70933Robertson,H.,Langdon,W.Y.,Thien,C.B.F.andBowtell,D.D.L.(1997)Ac-Cblyeasttwo-hybridscreenrevealsinteractionswith14-3-3isoformsandcytoskeletalcomponents.Biochem.Biophys.Res.Commun.240,46–5034Bonnefoy-Berard,H.,Lio,Y.-C.,vonWillegrand,M.,Sung,A.,Elly,C.,Mustelin,R.,Yoshida,H.,Ishizaka,K.andAltman,A.(1995)Inhibitionofphosphatidylinositol3-kinaseactivitybyassociationwith14-3-3proteinsinTcells.Proc.Natl.Acad.Sci.U.S.A.92,10142–1014635Masters,S.C.andFu,H.(2001)14-3-3proteinsmediateanessentialanti-apoptoticsignal.J.Biol.Chem.276,45193–4520036Zha,J.,Harada,H.,Yang,E.,Jockel,J.andKorsmeyer,S.J.(1996)SerinephosphorylationofdeathagonistBADinresponsetosurvivalfactorresultsinbindingto14-3-3notBCL-X(L).Cell(Cambridge,Mass.)87,619–62837Masters,S.C.,Yang,H.,Datta,S.R.,Greenberg,M.E.andFu,H.(2001)14-3-3inhibitsBAD-inducedcelldeaththroughinteractionwithserine-136.Mol.Pharmacol.60,1325–1331#2002BiochemicalSocietySYMPOSIUM:MOLECULARGENETICSINSARCOMAOsteosarcomaDevelopmentandStemCellDifferentiationNiTangMD,PhD,Wen-XinSongMD,JinyongLuoMD,RexC.HaydonMD,PhD,Tong-ChuanHeMD,PhDPublishedonline:18June2008ÓTheAssociationofBoneandJointSurgeons2008AbstractOsteosarcomaisthemostcommonnonhema-tologicmalignancyofboneinchildrenandadults.Thepeakincidenceoccursintheseconddecadeoflife,withasmallerpeakafterage50.Osteosarcomatypicallyarisesaroundthegrowthplateoflongbones.Mostosteosarcomatumorsareofhighgradeandtendtodeveloppulmonarymetastases.Despiteclinicalimprovements,patientswithmetastaticorrecurrentdiseaseshaveapoorprognosis.Here,wereviewedthecurrentunderstandingofhumanosteosarcoma,withanemphasisonpotentiallinksbetweendefectiveosteogenicdifferentiationandbonetumorigene-sis.Existingdataindicateosteosarcomatumorsdisplayabroadrangeofgeneticandmolecularalterations,includingthegains,losses,orarrangementsofchromosomalregions,inactivationoftumorsuppressorgenes,andthederegula-tionofmajorsignalingpathways.However,exceptforp53and/orRBmutations,mostalterationsarenotconstantlydetectedinthemajorityofosteosarcomatumors.Witharapidexpansionofourknowledgeaboutstemcellbiology,emergingevidencesuggestsosteosarcomashouldberegardedasadifferentiationdiseasecausedbygeneticandepigeneticchangesthatinterruptosteoblastdifferentiationfrommesenchymalstemcells.Understandingthemolec-ularpathogenesisofhumanosteosarcomacouldultimatelyleadtothedevelopmentofdiagnosticandprognosticmarkers,aswellastargetedtherapeuticsforosteosarcomapatients.IntroductionOsteosarcoma(OS)isthemostfrequentprimarybonesarcoma,comprisingapproximately20%ofallbonetumorsandabout5%ofpediatrictumorsoverall[34,67,73,75,77,94,127,136,146,210,252,259].Infact,OSistheﬁfthmostcommonmalignancyamongindividualsaged15to19years,andthesecondmostcommoninadoles-cenceafterlymphoma.OShasabimodalagedistribution,withtheﬁrstpeakintheseconddecadeoflifeandasecondpeakinelderlyadults[146,210].HigherincidencesinboysandinAfrican-Americanchildrenhavebeenreported[146,210].Themostcommonlocationsinyoungadultsareareaswithrapidbonegrowth,includingdistalfemur,proximaltibia,andproximalhumerus.Nevertheless,OSisrelativelyrare,andlessthan1000newcasesarediagnosedeachyearintheUnitedStates,accountingforlessthan2%ofallnewcancercasesintheU.S.[146,210].AlthoughOSdevelopmentisassociatedwithseveralgeneticpredispositionconditions,mostOStumorsaresporadicwithoutfamilialpatterns[67,73,77,94,146,210,252,259].OurcurrentunderstandingofOSetiologyisratherlimited.Exposuretochemicalberylliumoxide[51],orthopaedicprostheses[101],andtheFBJvirus[51]causesOSinanimalmodels,buttheirroleinhumanOSisunknown.SV40viralDNAhasbeendetectedinupto50%ofOStumors[24,125,161],whileitisunclearwhetherOneormoreoftheauthorshavereceivedfundingfromtheAmericanCancerSociety(TCH),TheBrinsonFoundation(RCH,TCH),theOrthopaedicResearchandEducationFoundation(RCH),andtheNationalInstitutesofHealth(RCH,TCH).N.Tang,J.Luo,T.-C.HeTheSecondAfﬁliatedHospitalandtheKeyLaboratoryofDiagnosticMedicinedesignatedbyChineseMinistryofEducation,ChongqingMedicalUniversity,Chongqing,ChinaN.Tang,W.-X.Song,J.Luo,R.C.Haydon,T.-C.He(&)MolecularOncologyLaboratory,DepartmentofSurgery,TheUniversityofChicagoMedicalCenter,5841SouthMarylandAvenue,MC3079,Chicago,IL60637,USAe-mail:tche@surgery.bsd.uchicago.edu123ClinOrthopRelatRes(2008)466:2114–2130DOI10.1007/s11999-008-0335-zSV40playsanyroleinOStumorigenesis[51,62].Radi-ationexposureisawell-documentedriskfactorforOS[51,88,147,239,256],buttheintervalbetweenradiationexposureandtumorappearanceislong,andhenceitislikelyirrelevanttothedevelopmentofmostconventionalOStumors.Nevertheless,radiationcouldberesponsibleforthedevelopmentofsecondaryOSpostradiationtherapyofcertainprimarytumors.DespitetherelativelowincidenceofOS,morethan20,000articlesdescribingthepathogenicandclinicalaspectsofOShavebeenpublishedthusfar.Assummarizedinthissurvey,OSdisplaysabroadrangeofgeneticandepigeneticalterations,andyetnoconsensuschangeshavebeenidentiﬁedinallOStumors[34,67,73,75,77,94,127,136,146,210,252,259].Withtherapidexpansionofourknowledgeaboutstemcellbiologyandcancerstemcells[204,217,260,278],increasingevidencesuggestsOSmaybeconsideredadifferentiationdisease[75,231].Terminaldifferentiationofosteoblasts,whicharederivedfrommultipotentmesenchymalstemcells,isawell-orchestratedprocessandcontrolledbyacascadeofregu-latorysignaling[36,38,39,75,82,96,114,129,136,171,173,187,270].PathologicandmolecularfeaturesofmostifnotallOStumorsstronglysuggestOSmaybecausedbygeneticandepigeneticdisruptionsofosteoblastdifferenti-ationpathway[75,231].Promotingdifferentiationand/orcircumventingdifferentiationdefectsmaybeexploitedasanefﬁcaciousadjuvanttherapyforOSsincecurrentchemotherapiesmostlytargettheproliferativeaspectsofOStumors[75,76,188].Inthissurvey,webrieﬂyreviewcurrentlyidentiﬁedgeneticalterationsthatmaybeassociatedwithosteosar-comapathogenesis,andthenfocusonrecentﬁndingsthatsuggestpotentiallinksbetweendefectiveosteogenicdif-ferentiationofmesenchymalstemcellsandosteosarcomadevelopment.Webelievethislineofinvestigationwillprovideinsightintothepathogenesisofosteosarcoma.SearchStrategiesandCriteriaWeperformedPubMedsearchesoftheliteraturerelevanttothesubjectwiththefollowingkeywordsutilizedindividu-allyorincombination:osteosarcoma(20,168references),osteosarcomapathogenesis(8232references),osteosar-comagenetics(3587references),osteosarcomamutation(1232references),osteosarcomabiology(238references),osteosarcomastemcell(669references),osteosarcomastemcelldifferentiation(99references),andosteosarcomalungmetastasis(894references),asofMarch2008.Publi-cationsinlanguagesotherthanEnglish,pertinentreviewarticles,andbookchapterswerenotexcludedinoursear-ches.However,wemostlyreviewedtheEnglishabstractsofthearticlespublishedinotherlanguagesandonlyutilizedthearticlesthataddedanyinformationtothisreview.Wheneverinformationoverlapped,wereferencedthemostrecentarticlesbuiltonconclusionsorreportsofpreviousarticles.OursearchesofarticlespublishedintheEnglishlanguagerevealedconsiderableoverlapinarticlesidentiﬁedunderthedifferentsearchterms,andwecarefullyreviewedthearticlesforpertinencetoourreviewarticle.Inthisreview,weprimarilyfocusedonrelevantpublicationswithinthepast10years,whilenotexcludingolderbutcommonlyreferencedandhighlyregardedpriorpublica-tions.Wesuspectmanyoftheosteosarcomacasesdescribedintheliteraturerepresenthigh-gradeosteosarcomas.ClinicalAspectsofHumanOSMostOSpatientspresentwithpainandswellingintheaffectedregionsaftertraumaorvigorousphysicalactivities[146].ThediagnosisofOSisusuallymadebyradiographicappearanceandlocationoftumorlesionsandabiopsyforpathologicconﬁrmation[146].OScanpresentradio-graphicallyasalytic,sclerotic,ormixedlytic-scleroticlesion[146].Upto20%ofOSpatientspresentwithradiographicallydetectablelungmetastases,whereas80%ofpatientswithlocalizedOSdevelopmetastasesaftersurgicalresectionalone[146].DeathfromOSisusuallytheresultofprogressivepulmonarymetastasiswithrespi-ratoryfailure[146].OShasabroadspectrumofhistologicappearanceswithcommoncharacteristicscontaininghighlyproliferativemalignantmesenchymalstemcellsandtheproductionofosteoidand/orbonebytumorcells[62,146].Histologically,OScanbedividedintoseveralsubtypes.ConventionalosteoblasticOSmakesupabout70%,whereaschondrob-lasticandﬁbroblasticOStumorsarethenextmostcommonat10%each[62,73,102,231].OtherOStypesincludeanaplastic,telangiectatic,giantcell-rich,andsmallcellOS[102].ConventionalOSisaprimaryintramedullaryhigh-gradesarcoma.CurrentclinicalmanagementofOSincludespre-andpostoperativechemotherapyandsurgicalresection[62].Onlyabout20%ofOSpatientscanbecuredwithoutchemotherapy[62,102,146].Chemotherapyagentsincludedoxorubicin,cisplatin,ifosfamide,andmethotrexate[62,102,127,146].Surgicalremovaloftheprimarytumorrequiresawide-marginresection,followedbylimbsalvagereconstruction[62,102,127,146].OSprognosticindicatorsincludeextentofdiseaseatdiagnosis,sizeandlocationofthetumor,responsetochemotherapy,andsurgicalremission[62,102,127,146].ForthoseOSpatientswhopresentwithoutdetectablemetastases,approximately70%ofthemcanachievelong-termsurvival[62,102,127,146].Theremaining30%willVolume466,Number9,September2008MolecularPathogenesisofOsteosarcoma2115123relapse,mostlywithin5years[62,102,127,146].Pul-monarymetastasisisthemostcommonformofdistantspread.Theaveragesurvivalafterarecurrenceislessthan1year[62,102,127,146].Removalofasurgicallyresectablerecurrenceorpulmonarymetastasisimprovessurvival[62,102,127,146].Thus,amajorchallengeinclinicalmanagementofOSistoidentifypoorresponderstochemotherapyand/ortodetectearlymetastaticlesions.ChromosomalAbnormalitiesinHumanOSUnlikeothersarcomas,suchassynovialsarcoma,alveolarrhabdomyosarcoma,andEwing’ssarcoma,nospeciﬁctranslocationsorgeneticabnormalitieshavebeenidentiﬁedinOS[34,67,73,75,77,94,127,136,146,210,252,259].Nevertheless,nearly70%ofOStumorsdisplayamultitudeofcytogeneticabnormalities[146,210].Theploidynum-berinOShasrangedfromhaploidytonear-hexaploidy.Chromosomalregionsof1p11–p13,1q11–q12,1q21–q22,11p14–p15,14p11–p13,15p11–p13,17p,and19q13aremostcommonlyinvolvedinstructuralabnormalities[146,210].Gainofchromosome1andlossofchromosomes9,10,13,and17aremostcommonoverall.Lessfrequentlyinvolvedchromosomalregionswere13q14(locusofRB1),12p12–pter(locusofKRAS),6q11–q4,and8p23[146,210].Acombinationofseveraldetectionmodalitieshaspro-videdamoreaccurateassessmentofthecomplexcytogeneticaberrationsinOS[146,210].Themostfre-quentlydetectedampliﬁcationsincludechromosomalregions6p12–p21(28%),17p11.2(32%),and12q13–q14(8%)[210].Severalotherrecurrentchromosomallosses(2q,3p,9,10p,12q,13q,14q,15q,16,17p,and18q)andchromosomalgains(Xp,Xq,5q,6p,8q,17p,and20q)werealsoidentiﬁed,aswellasseveralrecurrentbreakpointclustersandnonrecurrentreciprocaltranslocations[210].TheseﬁndingsfurtherhighlightthecomplexityandtheinstabilityofthegeneticmakeupofOStumors.GeneticAlterationsofTumorSuppressionGenesinHumanOSRetinoblastomaTumorSuppressorIndividualsaffectedbyhereditaryretinoblastoma(RB)heterozygousforagermlineinactivationofRB1haveanapproximately1000timeshigherincidenceofOS.RB1mapsto13q14[1,111].GeneticalterationsofRB1havebeenfoundinupto70%ofsporadicOScases[2,4,12,13,164,215,235,248,267].Lossofheterozygosity(LOH)ofRB1locusispresentin60%to70%ofOStumors[12,48,271],whereasstructuralrearrangementsandpointmuta-tionsoccurlesscommonly(30%and10%,respectively)[2,4,12,13,164,215,235,248,267].Furthermore,LOHattheRB1locushasbeenproposedasapoorprognosticfactorinOS[146,210].RBisanimportantregulatorofG1/Scellcyclepro-gression[178].DuringG1/Stransition,RBbecomesphosphorylated,resultingintheactivationofE2FfactorsthatbindtothedephosphorylatedRBproteinandpromoteDNAsynthesisandG1toStransition[178].CDK4incomplexwithcyclinD1phosphorylatesRB.Thus,ampli-ﬁcationoroverexpressionofthesegenesresultsinfunctionalinactivationoftheRBpathway.TheCDKsareregulatedbyaseriesofinhibitoryproteins,includingp16INK4a,asanegativeregulatorofcellcycleprogression(seebelow).Lossofp16INK4aexpressionoccursinosteo-genicsarcomaslackingRB1alterations[179].p53TumorSuppressorThetumorsuppressorgeneTP53islocatedat17p13,aregionfrequentlyidentiﬁedasabnormalinOS[29,210].TP53encodesatranscriptionfactorandregulatesgenesinvolvedincellcycle,DNAdamageresponse,andapop-tosis[40,69,87,126].AlterationsinTP53observedinOStumorsconsistedofpointmutations(20%–30%,mostlymissensemutations),grossgenerearrangements(10%–20%),andallelicloss(75%–80%)[3,20,28,119,152,162,163,169,170,184,186,199,206,214,221,227,236,237,241,249,271].TheassociationofTP53withOSisfurthersupportedbythehighriskofOSinpatientswiththeLi-Fraumenisyndrome,anautosomaldominantdisordercharacterizedbyagermlinemutationofTP53[128,144,145,194,223].GermlinemutationsofTP53havebeenidentiﬁedinasmallpercentage(3%)ofsporadicOScases[112,156,236,237].However,TP53mutationstatusisseeminglynotassociatedwiththestagesofOStumorand/ormetastasis[60].Nevertheless,themutationstatusofTP53,andtoalesserextentofRB1,couldserveasavaluableindicatorforpredictingchemoresistanceofOS[64].p16INK4aandp14ARFCDKInhibitorsINK4A(alsoknownasCDKN2A),localizedto9p21,encodesp16INK4a,atumorsuppressorthatfunctionsinpartthroughtheinhibitionofCDK4(seebelow)[198].Thep16INK4aproteincanimposeasustainedG1arrest[123,198].In87OSspecimensfrom79patients,INK4Achangeswereobservedinﬁveof55casesexamined(fourdeletionsandonerearrangement),whereasnoINK4Aexon2-pointmutationsormethylationweredetected[94,140,2116Tangetal.ClinicalOrthopaedicsandRelatedResearch123162,210,257].CDK4geneampliﬁcationoccurredinsixof67tumors,butnoneofthosewithINK4Aalterations[94,210].Theabsenceofexpressionofp16INK4acorrelatedwithdecreasedsurvivalinpediatricOSpatients[94,210].INK4Aalsoencodesp14ARFthroughbicistronictran-scriptioninvolvingtheuseofanalternativereadingframe[198].Thep14proteinisstructurallyandfunctionallyunrelatedtop16INK4a[66,123].Whereasp16INK4aindi-rectlyregulatesRB1function,p14regulatesTP53functionbybindingMDM2(seebelow)andsequesteringitinthenucleolus,therebypreventingitfromshuttlingp53tothecytoplasmfordegradation[192,279].INK4Aisdeletedinapproximately10%ofOS,andalmostalldeletionswouldbeexpectedtoknockoutexpressionofp14ARFaswell[133].Becauselossofp14ARFshouldreleaseMDM2fromthisnegativeregulatorymechanism,deletionofINK4ArepresentsanothermechanismoffunctionalTP53inacti-vation.AsthealternativeproductsofINK4A,p14ARFandp16INK4a,interactnegativelywithMDM2andCDK4,deletionsoftheINK4Agenewouldbefunctionallyequivalentto12q13ampliﬁcationofbothMDM2andCDK4[94,146,210,252].Asaresult,eitheroftwosin-gulargeneticevents(ie,INK4Adeletionor12q13ampliﬁcation)caninactivatetwoseparatecriticalpathwaysofcellcyclecontrol[94,146,210,252].ActivationofOncogenesinHumanOSThec-MYCproductisinvolvedinregulatingcellgrowthandDNAreplication[32,177].Sevento12percentofOStumorshaveMYCampliﬁcation[9,10,120,193].ThisgeneticalterationmaybemorecommoninPageticOS(seebelow)[210].Attheexpressionlevel,MYCexpressioninOSwaselevatedinnineof21(42%)patientswhorelapsedandinfourof17(23%)patientswhoremaineddisease-free[53].FOSformsheterodimerictranscriptioncomplexeswithspeciﬁcJUNproteinsthatregulatetargetgenesinvolvedincellgrowth,differentiation,transformation,andbonemetabolism[208,255].Whentheviralhomologv-FOSisinjectedintorodents,OSformationisinduced[208,255].TransgenicmiceoverexpressingFOSinbonedevelopOS[208,255].Inonereport[266],61%ofOStumorsexpressedhighlevelsofFOS.ThehighestlevelsofFOS(andofJUN)expressionhavebeenreportedinconven-tionalOS[50].FOSwasexpressedinnineof21(42%)patientswhosubsequentlydevelopedmetastases[50,53,193].Further,FOSwasmorefrequentlyexpressedinhigh-gradethaninlow-gradelesions[210].MDM2,locatedat12q13,encodesaproteinthatnega-tivelymodulatesTP53functionbybindingthep53proteinandphysicallyblockingtheregionofp53responsiblefortranscriptionalactivationofspeciﬁcgenesandtargetsp53fordegradation[29,69,87,126,247].AmpliﬁcationleadingtoMDM2overexpressionfunctionallysuppressesp53eveninthepresenceofwild-typep53protein[30,124,184,185].The12q13region,containingMDM2andCDK4,isampliﬁedin5%to10%ofOS[132,167,184,185].How-ever,someampliconsinthisregion(12q13–q14)donotincludeMDM2[49].AlthoughMDM2ampliﬁcationhasbeenrelatedtoprogressionandmetastasesinOS[119,174],MDM2ampliﬁcationandTP53mutationshavenotcorre-latedwithresponsetochemotherapyorsurvival[274].AlthoughCDK4geneampliﬁcationhasbeendetectedinalowpercentageofOScases[93,141],CDK4proteinsarehighlyexpressedin65%oflow-gradeOS[200].CDK4formsacomplexwithcyclinD1andphosphorylatesRB,thusreleasingtheE2Ftranscriptionfactorfromitsinter-actionwithRB[33,179].IthasbeensuggestedhigherCDK4levelssecondarytoampliﬁcationmaystoichiomet-ricallyfavorRBphosphorylation,therebyimpairingcellcyclecontrol[43,107,140,213].HighlevelsofCDK4mayalsodrive12q13–q15ampliﬁcationindependentlyofMDM2becausediscontinuityofthe12q13ampliconshasbeenidentiﬁed[15,43,93,257].HighlevelsofcyclinD1(CCND1)havebeendetectedin22%ofOS,andCCND1ampliﬁcationhasbeenreportedin4%ofOS[140,257].Furthermore,theabsenceofcyclinD1expressionisapowerfulprognosticfactorbecauseitisassociatedwithametastaticphenotype[166].ERBB2(alsoknownasHER2/neuandc-erbB-2)encodesaproteinstructurallyhomologoustotheEGFreceptorwithoutaknownligand.Atthetimeofinitialbiopsy,20of47OS(42.6%)displayedhighlevelsofERBB2expression,relativetoadjacentnormaltissues[63].However,theactualroleofERBB2expressioninOSdevelopmentremainsunclear.Onestudy[281]found,inpatientswithhigh-gradeOSwithoutmetastaticdiseaseatpresentation,increasedexpressionofERBB2intumorcellswasassociatedwithanincreasedprobabilityofevent-freeandoverallsurvival[281],whileotherstudiesdemon-stratedcytoplasmicstainingofERBB2inpretreatmentOScorrelatedwithanincreasedriskofpulmonarymetastasesandOScellspositiveforERBB2mayrepresentachemoresistantaggressivesubpopulationofOS[281].DeregulationofMajorSignalingPathwaysinHumanOSWntsareafamilyofhighlyconserved,secretedproteinsthatplayanimportantroleindevelopmentandtumori-genesis[8,22,56,58,61,110,131,134,176,182,183,197,203,246,262,264].ManyWntsandtheirreceptorsareexpressedinearlyboneprogenitors[58,61,110,134,Volume466,Number9,September2008MolecularPathogenesisofOsteosarcoma2117123183].AberrantactivationofWntsignalingisassociatedwithmanycommonhumancancers[8,56,134,137,203,246].Elevatedcytoplasmicand/ornuclearlocalizationofb-catenin,acriticalmediatorofthecanonicalWntpath-way,hasbeendetectedinthemajorityofOStumorsandmaycorrelatewithOSmetastasis[74,90].Sporadicmutationsofb-cateninhavealsobeenidentiﬁed[89].OSexpressinghighlevelsofWntcoreceptorLRP5islessdifferentiatedandisassociatedwithdecreasedpatientsurvival[80].Inaddition,ectopicexpressionoftheWntagonistDKK3suppressedinvasionandmotilityofOSlineSAOS2[81].TGFb/BMPfamilymembersplayimportantrolesinregulatingcellgrowthanddevelopment[135,149–151,282].InOStumors,expressionofTGFb1andTGFb3ishigherthanthatofTGFb2[113].TGFb3expressionstronglyrelatedtodiseaseprogression[113].Also,althoughincreasedexpressionofTGFb2andb3andVEGFwascorrelatedwithOSgrade,onlyVEGFexpressionwascorrelatedwithsurvival[92].BMPsandtheirreceptors(BMPRs)regulateboneandskeletaldevelopment[135,282].MutationsinBMPsorBMPRsleadtoskeletaldefects,familialprimarypulmonaryhypertension,andneoplasias[280].NumerousBMPsand/orBMPRsarehighlyexpressedinOStumors[91,143,258].Overex-pressionoftheBMPR-IImayberelatedtopoorprognosisinmalignantandmetastaticOStumors[59,275].METencodesthereceptorforhepatocytegrowthfactor(HGF/scatterfactor),acytokinethatstimulatescellpro-liferationandmotility[46,172,207,216].MET/HGFisthereforebelievedtoplayaroleinstromal-epithelialinteraction.Approximately60%ofOStumorsexpressedMETreceptorathighlevels[46,216],whilesomeOSsamplesdemonstratedbothHGFandMETexpression[46].Thus,theactivationofMET/HGFpathwaymaycontributetotheaggressivebehaviorofOStumors[14,21,46,207].GLI,originallyidentiﬁedasanoncogeneampliﬁedinmalignantglioma,playsaroleintransducingthesonichedgehog(Shh)signal[168].Shhisinvolvedinanterior-posteriorpatterningofthelimbs,andalterationsinGLI1expressionmayplayaroleinOSdevelopment[94].GLI1islocatedat12q13.3–q14.1andisazincﬁngertranscrip-tionfactor.GLIwascoampliﬁedwithCDK4intwoofsixOSsamples[257].AnincreasedexpressionofGLIwasdetectedinmanysarcomasincludingsevenofeightOStumors,especiallyinundifferentiatedtumors[205,224].FGFR2playsanimportantroleinboneandskeletaldevelopment,andinheritedmutationsofFGFR2underlieskeletaldysplasias[261].LOHofFGFR2at10q26hasbeendetectedinhigh-gradeOS,whilemutationswerenotfoundinFGFR2[160].IGFsareproducedbyosteoblastsandactthroughtheirreceptorstoactivateproliferationanddifferentiation.OScellsoverexpressIGF1R.Additionalinvestigationsareneededtodeterminewhetherthesepath-wayscontributetothemalignantphenotypeofOS[139].OtherGeneticand/orMolecularChangesinHumanOSPagetDiseaseofBonePagetdiseaseofboneisaheritablebonedisordercharac-terizedbyrapidboneremodelingleadingtoabnormalboneformation.Approximately1%ofpatientswithPagetdis-easeofbonedevelopOS[157].PatientswithPagetdiseaseofboneaccountforasubstantialfractionofOSoccurringaftertheageof60years.GeneticlinkageofPagetdiseasehasbeendemonstratedtoinvolve18q21.1–q22[86,269].OfinterestisthedemonstrationofapossibleroleoftheFOSgeneinthepathogenesisofPagetdisease[11],aswellasRANK(alsoknownasTNFRSF11A)andOPG(alsoknownasTNFRSF11B)[68,157,222],althoughthebonaﬁdePagetdiseasegene(s)remaintobeidentiﬁed.MutationsofRECQHelicasesRECQhelicasesareconservedproteinsthatshareahighlyhomologousDNAhelicasedomain,andmutationsinthreeoftheﬁveRECQhelicasesareassociatedwithcancerpredispositionsyndromes,namelyRothmund-Thomsonsyndrome,Bloomsyndrome,andWernersyndrome[252].Rothmund-ThomsonsyndromeisanautosomalrecessivedisorderwithanincreasedriskforOS.Inonecohortof41patientswithRothmund-Thomsonsyndrome,13(32%)developedOS,tendingtodevelopatayoungerage(medianage,9years)[254].ThepresenceofRECQL4mutationsiscorrelatedwiththeriskfordevelopingOS[253].BloomsyndromeandWernersyndromehavesomeoverlappingclinicalfeatures,andbothexhibitpredisposi-tionstodevelopingcancers[78].PatientswithBloomsyndromehavemutationsintheBLMgeneandarepre-disposedtoallthetypesofcancersatamuchyoungerageandatahigherfrequency[54].PatientswithWernersyn-dromehavemutationsintheWRNgeneandarepredisposedtodevelopingOSandothertumors[65].OfthethreeOSpredispositionsyndromes,Rothmund-Thom-sonsyndromeappearstohavethehighestandmostspeciﬁcriskforOStumor[252].Thus,inactivationofthehelicasepathwaysmaycontributetoOSdevelopment.TelomeraseandTelomeresinOSTelomerase(TERT)activityisundetectableinnormalcells,benignlesions,andlow-gradesarcomas[272]andis2118Tangetal.ClinicalOrthopaedicsandRelatedResearch123presentinonlyaportionofOS[5,212,242].TERTactivityinOStumorsexhibitedaninversecorrelationwithoccurrenceofpulmonarymetastasesinpatientstreatedwithchemotherapy[211].Alternativelengtheningoftelo-meresinOSmaybeequivalenttoTERTactivity[5].Of62OSpatients,asubsetofcaseslackedbothTERTactivityandevidenceofalternativelengtheningoftelomeres,whichwasassociatedwithafavorableprognosis[242].ActivationofMatrixMetalloproteinases(MMPs)MMPsarezinc-dependentendopeptidasesthatdegradeextracellularmatrixproteins.MMPsarecontrolledbybothproenzymesandinhibitionoftissueinhibitorofMMPs(TIMPs).MMP2andMMP9wereoverexpressedinOScellsandassociatedwiththeabilityofthecellstometas-tasize[18].Increasedexpressionofmembrane-typeMMP1hasbeencorrelatedwithpoorprognosisinOSpatients[240].UpregulationofTIMP1isassociatedwithpoorclinicaloutcomeforOS.BindingofTIMP-1toanunknownreceptorsystemreportedlytriggersRas/Raf1/FAKsignalinginOS.Thus,TIMP1mayhaveadualeffectontumorprogression[47,84].Neuroﬁbromatosis-2(NF2)/MerlinNF2encodesMerlin,anezrin-radixin-moesin(ERM)-relatedproteinthatfunctionsasatumorsuppressor[153,154].NF2nullmicedieinearlyembryogenesis,whereasNF2heterozygousmiceareviablebutdevelopavarietyofhighlymetastatictumors,includingOSandhepatocellularcarcinoma,withlonglatencies[155].Merlinmediatescontactinhibitionofgrowththroughsignalsfromtheextracellularmatrix.Athighcelldensity,Merlinbecomeshypophosphorylatedandinhibitscellgrowthinresponsetohyaluronatethroughspeciﬁcinteractionwiththecyto-plasmictailofCD44[55,109,118,218].Well-dedifferentiatedOStumorshaveahigherlevelofCD44[94].Merlinmaycontrolthestabilityoftheadherensjunctionbyitsinteractionwiththeactincytoskeleton.Lossofthisfunctionmayleadtotumorigenesisandmetastasis[106,121].TheN-terminalregionofMerlinincreasesp53stabilitybyinhibitingtheMDM2-mediatedp53degrada-tion.Thus,lossofMerlinmayalsodestabilizep53[108].AdditionalGeneticChangesThebuddinguninhibitedbybenzimidazole3(BUB3)wasidentiﬁedinaregionofLOHat10q26in20high-gradeOStumors,althoughnomutationsofBUB3wereobservedinOS.BUB3playsaroleinchromosomehomeostasisandisacomponentofthespindleassemblycheckpointcomplex[23],alterationsofwhichcouldunderlietheaneuploidythatischaracteristicofOS[160].Interestingly,BUB3isatargetofE2F[6].Primasepolypeptide1(PRIM1),locatedat12q13,isampliﬁedinnineof22OStumors[276].MDM2andCDK4areconsideredthemostimportantampliﬁcationtargetsin12q13–q15[202],buttheregionalsocontainsnumerousgenes,includingCHOP(ie,DDIT3),SAS(sarcomaampliﬁedsequence)[159],OS-4[226],OS-9[225],PRIM1[276],andotherasyetpoorlycharacterizedgenes[44].AmpliﬁcationofSASwasreportedin36%ofOS[180]andwaslinkedwithincreasedCDK4expression[268].OthersuspectedoncogenesincludeMAPK7andperipheralmyelinprotein(PMP22/GAS3),bothlocatedat17p11.2.MAPK7wasampliﬁedin10of19OSsamples[243].FrequentampliﬁcationofPMP22isobservedinhigh-gradeOS[244].HMGICgene(alsoknownasHMGA2,localizedto12q14–q15)wasrearrangedbyfusingwiththekeratinsulfateproteoglycanlumicangeneLUMinanOSline[115].HMGICgenewasalsoampliﬁedandrearrangedintwoprimaryOS[16].Alleliclossat4q32–q34wasidentiﬁedin63%ofOS[220].Highfrequenciesofalleliclosshavebeendetectedat3q26[79,117],13q,17p,and18q,suggestingothertumorsuppressorgenesmayexistat3qand18q[271].ExpressionofDCC(deletedincoloncancer),locatedon18q21,decreasesinOS[85].TwopotentialOSsuppressorgenelociweredemonstratedat6q14(imbalancein77%ofcases)and15q21(58%ofcases)[175].Genome-wideApproachestoIdentiﬁcationsofOS-associatedGenesMicroarray-basedexpressionproﬁlinganalysishasbecomeanincreasinglycommonpracticetoidentifygenesassoci-atedwithOSpathogenesis[103].Onesuchstudyhasshown,amongthe100mostup-anddownregulatedgenes,35areaffectedinallthreeOSlines,witheightgenesshowinganincreaseand27genesareductionintheexpressionlevelcomparedwithnormalhumanosteoblasts[265].Theseﬁndingshaveprovidedaproof-of-principleofgenome-wideapproachestounravelingthepathogenesisofOS.OSMetastasis-associatedGenesEzrin,amemberoftheERMproteins,hasbeenidentiﬁedasametastasis-relatedgenethatisdifferentiallyexpressedinmurineOSlineswithdifferentialmetastaticpotential[104–106].Ezrinisinvolvedinintracellularsignaltrans-ductionregulatingcellmigrationandmetastasis[251]andVolume466,Number9,September2008MolecularPathogenesisofOsteosarcoma2119123isexpressedinavarietyofcancers,someofwhichareassociatedwithpooroutcome[142,148].Inastudyof19patientswithOS,thedisease-freeintervalofOSpatientswithhighezrinexpressionwassubstantiallyshorterthanthatinpatientswithlowezrinexpression,andtheriskofmetastaticrelapsewas80%greaterintheformergroup[106].ExpressionofS100A6wasreportedin84%ofanalyzedOSspecimens[138].ThereisatrendtowarddecreasedclinicallyevidentmetastasiswithincreasedS100A6staining.OverexpressionofS100A6inOScellsdecreasescellmotilityandanchorage-independentgrowth[138].Theseﬁndingssuggest,whileS100A6iscommonlyover-expressedinOS,lossofitsexpressionmaycorrelatewithametastaticphenotype.Aclusterof16typesofS100genesislocatedon1q21,whichisfrequentlyampliﬁedorrear-ranged[25,35,37,71,158,190,209].S100proteinsconstituteagroupofnearly20proteinsthatcontainwell-conservedEF-handcalcium-bindingdomains[209].Sev-eralS100proteinshavebeenassociatedwithhumancancers[25,35,37,71,158,190,209].Annexin2(AnxA2)wasdownregulatedinmetastaticsamples[57].AnxA2belongstoalargefamilyofdiverseproteinscharacterizedbyconservedannexinrepeatdomainsandtheabilitytobindnegativelychargedphos-pholipidsinacalcium-dependentmanner[7].AnxA2wasdownregulatedinasubsetofhumanOSmetastasesandmetastaticlines[45,165].TheactualroleofAnxA2insuppressingOSmetastasisremainstobeelucidated.Chemokinestromalcell-derivedfactor1(SDF-1)belongstocytokinelikeproteinsthat,throughbindingtotheirCXCRreceptors,playaroleincytoskeletonrear-rangement,adhesiontoendothelialcells,anddirectionalmigration[19].CXCR4/SDF-1isimportantintumorpro-gression[130,228].MigrationandadhesionofOScellswerepromotedbySDF-1treatment,whereasthedevelop-mentofpulmonarymetastasisafterinjectionofOScellsinamousemodelcouldbepreventedbytheadministrationofT134peptide,aninhibitorofCXCR4[191].PossibleLinksBetweenDefectiveOsteogenicDifferentiationandBoneTumorigenesisHumanOStumorsexhibitosteoblast-likefeatures,althoughthedifferentiationstatusofOStumorscanbeobservedwithinabroadrange,fromhighlydifferentiatedtopoorlydifferentiatedorundifferentiatedphenotypes[75].However,potentialcancerstemcellsresponsibleforOSdevelopmenthaveyettobeidentiﬁed.Understandingthemolecularmechanismunderlyingosteogenicdifferen-tiationwouldhelptounravelthemolecularpathogenesisofhumanOS.Osteogenesisresultsfromawell-coordinatedsequenceofeventsinvolvingepithelialmesenchymalinteraction,condensation,anddifferentiation(Fig.1A).Severalmajorsignalingpathways,suchWnt,BMP,FGF,andhedgehogsignaling,playanimportantroleinregu-latingosteogenicdifferentiation[58,134–136,203,204].Atthetranscriptionlevel,severaltranscriptionalfactorshavebeenidentiﬁedasimportantregulatorsofosteogeniclineagecommitmentandterminaldifferentiation.ThesetranscriptionalfactorsincludeRunx2,Osterix,ATF4,andTAZ[17,31,36,41,95,97–100,189,229,230,250,263,273].Amongthesefactors,Runx2playsanimportantroleandservesasahubtodirectprogenitorstoosteogeniclineage[38,39,82,96,114,129,171,173,187,270].Runx2isamemberoftheRunxclassoftranscriptionfactorsthatcontainahighlyconserved128aminoacidmotifconferringDNAbinding,protein-proteininteractions,andATPbindingactivities[38,39,82,96,114,129,171,173,187,270].Runx2-/-dieshortlyafterbirthanddem-onstratedacartilaginousskeletonwithcompleteabsenceofossiﬁcation.DespitethecartilaginousphenotypeintheRunx2-nullmice,histologicanalysisdemonstrateddelayedchondrocytematurationsuggestingtheimportanceofRunx2inchondrogenesisandosteogenesis.Additionally,whenRunx2isoverexpressedinchondrocytesviathechondrocyte-speciﬁctypeIIcollagenpromoter,itresultsinectopicchondrocytehypertrophyandendochondralossiﬁ-cation,therebydemonstratingtheimportanceofRunx2incontrollingdifferentiationofbothchondrocytesandosteoblasts[38,39,82,96,114,129,171,173,187,270].Runx2transcriptionalactivityisregulatedbynumeroustranscriptionalco-activatorsandcorepressors,includingitsinteractionwithRbprotein(seebelow).OScanberegardedasadifferentiationdiseasethatiscausedbygeneticandepigeneticdisruptionsofosteoblastterminaldifferentiation(Fig.1B).Thismodelissupportedbythefollowingfacts:First,OStumorsexhibitthechar-acteristicsofundifferentiatedosteoblasts[26,75,83,181,195,196,219,233,277].Second,differentiation-promotingagents(eg,PPARcagonistsand9-cis-retinoicacid)induceosteoblastdifferentiation[75,76].Third,RBcoactivatesRunx2throughdirectphysicalinteractionsatsitesofactivetranscription,andlossoffunctionofRBattenuatesterminalosteoblastdifferentiationinvitro[232].RBplaysessentialrolesinmanycellularprocessesincludingmesenchymaldifferentiation[70,72,116,245].Fourth,Runx2coordi-natesterminalcellcycleexitthroughinductionofp27KIP[1],whichinturnisrequiredfornormalbonedevelopmentandislostindedifferentiatedhumanOS[233].Lastly,osteogenicstimuli,suchasosteogenicBMPs,failedtopromotetheterminaldifferentiationofmostOScellsandratherenhancedOStumorgrowth,furtherhighlightingtheexistenceofpossibledifferentiationdefectsinOScells[75].Furthermore,inEwing’ssarcoma(ESW),EWS/ETS2120Tangetal.ClinicalOrthopaedicsandRelatedResearch123fusionproteinsblockdifferentiationalongosteogenicandadipogeniclineagesofmarrowstromalcells[238].Infact,expressionoftheEWS/FLI-1oncogeneinmurineprimarybone-derivedcellsresultsinEWS/FLI-1-dependent,Ewing’ssarcoma-liketumors[27].Conversely,uponEWS-FLI1silencing,someoftheESWcelllinescandifferentiatealongtheadipogenicorosteogeniclineageswhenstimu-latedwithappropriatedifferentiationcocktails[234].Takentogether,theseemergingdatastronglysuggestosteosar-comogenesismayberesultedfromdefectsinosteoblastdifferentiationpathway.DiscussionOsteosarcomasareaclinicallyandmolecularlyheteroge-neousgroupofmalignanciescharacterizedbyvaryingdegreesofmesenchymaldifferentiation.Thegeneticandepigeneticalterationsdescribedabovemayrepresentacross-sectionalendpointviewofOS.However,deﬁningtheirrolesinOSdevelopmenthasbeenhamperedbythecomplexityofthegeneticchangesandtherarityofOSsamples.Althoughosteosarcomatumorsdisplayabroadrangeofgeneticandmolecularalterations,mostalterationsFig.1A–B(A)Osteogenicdif-ferentiationisawell-coordinatedprocess.Mesenchymalstemcells(MSCs)cangiverisetoseverallineages,suchasmyocytes,adi-pocytes,chondrocytes,andosteocytes,withappropriatestimuli,presumablybyactivat-ingproperlineage-speciﬁcregulators,eg,MyoD,PPARc,Sox9,orRunx2/Osterix.Osteo-genicdifferentiationisatightlycontrolledprocess,whichcanbemonitoredbyusingalkalinephosphataseasanearlymarkerandosteocalcinandosteopontinaslatemarkers.(B)DisruptionofosteogenicdifferentiationmayleadtoOSdevelopment.Thedefectscausedbygenetic(eg,activationofoncogenesorinac-tivationofp53andRBtumorsuppressorgenes)andepigeneticalterationsmayoccuratdifferentstagesofosteogenicdifferentia-tion.ItisconceivabledefectsattheearlystagesmayleadtothedevelopmentofmoreaggressiveandundifferentiatedOS,orviceversa.Thecellsﬁlledwithblackcolorindicatecancer-initiatingcells.Volume466,Number9,September2008MolecularPathogenesisofOsteosarcoma2121123arenotfrequentlydetectedinthemajorityofosteosarcomatumors.Witharapidexpansionofourknowledgeaboutstemcellbiology,emergingevidencesuggestsosteosar-comamayberegardedasadifferentiationdiseasecausedbygeneticandepigeneticchangesthatinterruptosteoblastdifferentiationfrommesenchymalstemcells.Inthissurvey,weﬁrstreviewedthecurrentgeneticalterationsandmolecularbiologyofOS,andthenfocusedonthepossiblerelationshipbetweenosteogenicdifferen-tiationandbonetumorigenesis.BysearchingPubMedwithvariouskeywords,wefoundover20,000publicationsrel-evanttothetopic.Althoughweonlyconductedthesearchusingasingledatabase,PubMedrepresentsoneofthemostextensivedatabasesforbiomedicalsciences.WebelievemostoftherelevantandimportantﬁndingsrelatedtoOShavebeenincludedinthissingledatabasebutcannotexcludeotherinformationthatmightbefoundinotherdatabases(e.g.,EMBASE).Itisconceivablethat,atleastforasubsetofosteosar-comas,cancer-initiatingcellsmaysharefeaturesofacommittedosteoprogenitor.Tumorigenesismayinvolvedisruptionofmechanisms,appropriatelyconstraintheini-tiationofproliferationbytumorstemcells,orallowpersistentexpressionofstemcell-likefeaturesinapparentlypartiallycommittedcells.Thesimilaritiesbetweenstemcellpropertiesandthoseoftransformedcellsarestrikingasbothcelltypespossessunlimitedself-renewal,expresstel-omerase,andareundifferentiatedasdeﬁnedbytheabsenceoflineage-restrictedmarkers.Infact,asmallsubpopulationofself-renewingOScellsarecapableofformingsuspendedsphericalcellsandcolonies[55].TheseOScellsaswellastissuespecimensexpressactivatedSTAT3andthemarkergenesofpluripotentembryonicstem(ES)cells,Oct3/4andNanog[55].Insupportofthisnotion,OSisfrequentlyobservedinadolescence,astageofintensiveskeletalgrowthentailingincreasedosteoblastactivity.Stemcellsaremoreresistanttomutageniceventsthansomaticcells,inpartduetoenhancedapoptoticresponsestogenotoxicstressandDNAdamage.Theefﬁciencyofsuchprocessesappearsinverselyrelatedtothedegreeofterminaldifferentiation[231].Thus,futureinvestigationsshouldbedevotedtoidentifyingthekeydefectsintheosteoblastdifferentiationpathway,whichisalsoresponsibleforthedevelopmentofprimarybonetumors.Asoneofthemostimportantfactorsregulateosteoblastlineagecommitmentandexpansion,Runx2maybede-regulatedandplaysanimportantroleinOSdevelopment.Runx2levelsandfunctionarebiologicallylinkedtoacellgrowth-relatedG(1)transitioninosteoblasticcells[52].Runx2andhistonedeacetylase3-mediatedrepressionisbelievedtoallowhighexpressionofbonesialoprotein-abonematrixglycoproteinwhoseexpressioncoincideswithterminalosteoblasticdifferentiationandtheonsetofmineralization-indifferentiatinghumanosteoblastcells[122].Runx2ishyperphosphorylatedbyCDK1/cyclinBduringmitosis,anddynamicallyconvertedintoahypophosphorylatedformbyPP1/PP2A-dependentdephosphorylationaftermitosistosupportthepostmitoticregulationofRunx2targetgenes[201].AmorerecentstudyindicatesRunx2-mediatedactivationoftheBaxgeneincreasesosteosarcomacellsensitivitytoapoptosisandBaxasadirecttargetofRunx2,suggestingRunx2mayactasaproapoptoticfactorinosteosarcomacells[42].AnotherimportantfactorthatmayplayanimportantroleinosteogenicdifferentiationandbonetumorigenesisispRb.ThecellcycleregulatorypathwayregulatedbypRbisinactivatedinalmostallhumancancers,butindividualtumortypesseemtotargetspeciﬁccomponentstoachievethiseffect.AsdescribedinResults,pRbitselfisfrequentlyinactivatedinOS,andinheritedheterozygouslossoftheRBgeneconfersapproximatelya1000-foldgreaterinci-denceofOSthanthegeneralpopulation.SeverallinesofevidenceimplicatepRbinosteogenesisaspRbcoactivatesRunx2throughdirectphysicalinteractionsatsitesofactivetranscription,andlossoffunctionofpRbattenuatester-minalosteoblastdifferentiationinvitro[231].Runx2coordinatesterminalcellcycleexitthroughinductionoftheCDK2inhibitorp27KIP1,whichinturnisrequiredfornormalbonedevelopmentinvitroandinvivo,andislostindedifferentiatedhumanosteosarcomas[231].ItisalsopossiblepRbinﬂuencesosteoblastdifferentiationthroughothermechanismsinvolvingchromatinstructure.Thus,itwouldbeimportanttoinvestigatehowthederegulationofpRband/orRunx2functionsmayleadtothedevelopmentofbonesarcomas.Understandingthemolecularpathogenesisofhumanosteosarcomacouldultimatelyleadtothedevelopmentofdiagnosticandprognosticmarkers,aswellastargetedtherapeuticsforosteosarcomapatients.Dissectingthemolecularmechanismsthatcontrolosteoblastdifferentia-tionisimportantnotonlytounderstandnormalskeletogenesisandtopinpointpotentialdefectsresponsibleforOSdevelopmentbutalsotoimprovetheclinicalmanagementofhumanOS.Althoughpre-andpostopera-tivechemotherapieshaveimprovedthe5-yearsurvivalrateofOSpatients,recurrentand/ormetastaticOStumorsaremoreaggressiveandusuallyresistanttoconventionalcancertherapies.Inabroadersense,mostcurrentchemo-therapiesand/orradiationtherapiestargettherapidlyproliferativetumorcells,withlittleconsiderationofpromotingtumorcelldifferentiation.Itisconceivableacombinedtherapeuticapproachtargetingbothproliferationanddifferentiationphasesoftumorcellswouldbemoreefﬁcaciousandlesspronetoinducingchemoresistance[75,76,217,278].Thus,identiﬁcationofthecriticaldif-ferentiationdefectsinOStumorsmayleadtoarational2122Tangetal.ClinicalOrthopaedicsandRelatedResearch123designoftherapeuticstrategiesthatinduceterminaldif-ferentiationofOScellsthroughalternativedifferentiationpathwaysand/orbypassingthedifferentiationdefects.Thepotentiallyimportantroleofgeneticandepigeneticeventsinbothosteogenesisandbonetumorigenesisisnowrecognized.Ourcurrentknowledgeoftranscriptionalreg-ulationofosteoblastdifferentiationwillprovideimportantinsightsintothepotentialdefectsinosteogenicdifferenti-ationofOScells.FutureresearchshouldbedirectedtowardsidentifyingthesedifferentiationdefectsinOScells.ThisknowledgemayhelpusdevelopefﬁcaciousdifferentiationtherapiesforOSbyexploitingnoncellautonomoussignalstopromotedifferentiationstate.AcknowledgmentsWeapologizetotheinvestigatorswhoseorigi-nalworkcouldnotbecitedduetospaceconstraints.References1.AbramsonDH,EllsworthRM,KitchinFD,TungG.Secondnonoculartumorsinretinoblastomasurvivors.Aretheyradia-tion-induced?Ophthalmology.1984;91:1351–1355.2.AlonsoJ,Garcia-MiguelP,AbelairasJ,MendiolaM,PestanaA.AmicrosatelliteﬂuorescentmethodforlinkageanalysisinfamilialretinoblastomaanddeletiondetectionattheRB1locusinretinoblastomaandosteosarcoma.DiagnMolPathol.2001;10:9–14.3.AndreassenA,OyjordT,HovigE,HolmR,FlorenesVA,NeslandJM,MyklebostO,HoieJ,BrulandOS,BorresenAL,etal.p53abnormalitiesindifferentsubtypesofhumansarco-mas.CancerRes.1993;53:468–471.4.ArakiN,UchidaA,KimuraT,YoshikawaH,AokiY,UedaT,TakaiS,MikiT,OnoK.Involvementoftheretinoblastomageneinprimaryosteosarcomasandotherboneandsoft-tissuetumors.ClinOrthopRelatRes.1991;270:271–277.5.AueG,MuralidharB,SchwartzHS,ButlerMG.Telomeraseactivityinskeletalsarcomas.AnnSurgOncol.1998;5:627–634.6.BaekWK,ParkJW,LimJH,SuhSI,SuhMH,GabrielsonE,KwonTK.Molecularcloningandcharacterizationofthehumanbuddinguninhibitedbybenomyl(BUB3)promoter.Gene.2002;295:117–123.7.BalchC,DedmanJR.AnnexinsIIandVinhibitcellmigration.ExpCellRes.1997;237:259–263.8.BarkerN,CleversH.Catenins,Wntsignalingandcancer.Bioessays.2000;22:961–965.9.BarriosC,CastresanaJS,KreicbergsA.Clinicopathologiccor-relationsandshort-termprognosisinmusculoskeletalsarcomawithc-myconcogeneampliﬁcation.AmJClinOncol.1994;17:273–276.10.BarriosC,CastresanaJS,RuizJ,KreicbergsA.Ampliﬁcationofc-myconcogeneandabsenceofc-Ha-raspointmutationinhumanbonesarcoma.JOrthopRes.1993;11:556–563.11.BeedlesKE,SharpePT,WagnerEF,GrigoriadisAE.Aputativeroleforc-FosinthepathophysiologyofPaget’sdisease.JBoneMinerRes.1999;14Suppl2:21–28.12.BelchisDA,MeeceCA,BenkoFA,RoganPK,WilliamsRA,GockeCD.Lossofheterozygosityandmicrosatelliteinstabilityattheretinoblastomalocusinosteosarcomas.DiagnMolPathol.1996;5:214–219.13.BenassiMS,MolendiniL,GamberiG,RagazziniP,SollazzoMR,MerliM,AspJ,MagagnoliG,BalladelliA,BertoniF,PicciP.AlterationofpRb/p16/cdk4regulationinhumanoste-osarcoma.IntJCancer.1999;84:489–493.14.BeniniS,BaldiniN,ManaraMC,ChanoT,SerraM,RizziS,LolliniPL,PicciP,ScotlandiK.Redundancyofautocrineloopsinhumanosteosarcomacells.IntJCancer.1999;80:581–588.15.BernerJM,ForusA,ElkahlounA,MeltzerPS,FodstadO,MyklebostO.SeparateampliﬁedregionsencompassingCDK4andMDM2inhumansarcomas.GenesChromosomesCancer.1996;17:254–259.16.BernerJM,Meza-ZepedaLA,KoolsPF,ForusA,SchoenmakersEF,VandeVenWJ,FodstadO,MyklebostO.HMGIC,thegeneforanarchitecturaltranscriptionfactor,isampliﬁedandrearrangedinasubsetofhumansarcomas.Oncogene.1997;14:2935–2941.17.BialekP,KernB,YangX,SchrockM,SosicD,HongN,WuH,YuK,OrnitzDM,OlsonEN,JusticeMJ,KarsentyG.Atwistcodedeterminestheonsetofosteoblastdifferentiation.DevCell.2004;6:423–435.18.BjornlandK,FlatmarkK,PettersenS,AaasenAO,FodstadO,MaelandsmoGM.Matrixmetalloproteinasesparticipateinosteosarcomainvasion.JSurgRes.2005;127:151–156.19.BleulCC,FuhlbriggeRC,CasasnovasJM,AiutiA,SpringerTA.Ahighlyefﬁcaciouslymphocytechemoattractant,stromalcell-derivedfactor1(SDF-1).JExpMed.1996;184:1101–1109.20.BodeyB,GrogerAM,BodeyBJr.,SiegelSE,KaiserHE.Immunohistochemicaldetectionofp53proteinoverexpressioninprimaryhumanosteosarcomas.AnticancerRes.1997;17:493–498.21.BurrowS,AndrulisIL,PollakM,BellRS.Expressionofinsulin-likegrowthfactorreceptor,IGF-1,andIGF-2inprimaryandmetastaticosteosarcoma.JSurgOncol.1998;69:21–27.22.CadiganKM,NusseR.Wntsignaling:acommonthemeinanimaldevelopment.GenesDev.1997;11:3286–3305.23.CahillDP,KinzlerKW,VogelsteinB,LengauerC.Geneticinstabilityanddarwinianselectionintumours.TrendsCellBiol.1999;9:M57–60.24.CarboneM,RizzoP,ProcopioA,GiulianoM,PassHI,GebhardtMC,ManghamC,HansenM,MalkinDF,BushartG,PompettiF,PicciP,LevineAS,BergsagelJD,GarceaRL.SV40-likesequencesinhumanbonetumors.Oncogene.1996;13:527–535.25.CarlssonH,PeterssonS,EnerbackC.ClusteranalysisofS100geneexpressionandgenescorrelatingtopsoriasin(S100A7)expressionatdifferentstagesofbreastcancerdevelopment.IntJOncol.2005;27:1473–1481.26.CarpioL,GladuJ,GoltzmanD,RabbaniSA.InductionofosteoblastdifferentiationindexesbyPTHrPinMG-63cellsinvolvesmultiplesignalingpathways.AmJPhysiolEndocrinolMetab.2001;281:E489–499.27.Castillero-TrejoY,EliazerS,XiangL,RichardsonJA,IlariaRLJr.ExpressionoftheEWS/FLI-1oncogeneinmurineprimarybone-derivedcellsResultsinEWS/FLI-1-dependent,ewingsarcoma-liketumors.CancerRes.2005;65:8698–8705.28.CastresanaJS,RubioMP,GomezL,KreicbergsA,ZetterbergA,BarriosC.DetectionofTP53genemutationsinhumansar-comas.EurJCancer.1995;31A:735–738.29.ChandarN,BilligB,McMasterJ,NovakJ.Inactivationofp53geneinhumanandmurineosteosarcomacells.BrJCancer.1992;65:208–214.30.ChenCY,OlinerJD,ZhanQ,FornaceAJJr.,VogelsteinB,KastanMB.Interactionsbetweenp53andMDM2inamam-maliancellcyclecheckpointpathway.ProcNatlAcadSciUSA.1994;91:2684–2688.31.ChienKR,KarsentyG.Longevityandlineages:towardtheintegrativebiologyofdegenerativediseasesinheart,muscle,andbone.Cell.2005;120:533–544.Volume466,Number9,September2008MolecularPathogenesisofOsteosarcoma212312332.ColeMD,McMahonSB.TheMyconcoprotein:acriticalevaluationoftransactivationandtargetgeneregulation.Onco-gene.1999;18:2916–2924.33.Cordon-CardoC.Mutationsofcellcycleregulators.Biologicalandclinicalimplicationsforhumanneoplasia.AmJPathol.1995;147:545–560.34.CormierJN,PollockRE.Softtissuesarcomas.CACancerJClin.2004;54:94–109.35.DeichmannM,BennerA,BockM,JackelA,UhlK,WaldmannV,NaherH.S100-Beta,melanoma-inhibitingactivity,andlactatedehydrogenasediscriminateprogressivefromnonprogressiveAmericanJointCommitteeonCancerstageIVmelanoma.JClinOncol.1999;17:1891–1896.36.DengZL,SharffKA,TangN,SongWX,LuoJXL,ChenJ,BennettE,ReidR.ManningD,XueA,MontagAG,LuuHH,HaydonRC,HeT-C.Regulationofosteogenicdifferentiationduringskeletaldevelopment.FrontiersinBiosci.2008;13:2001–2021.37.DiederichsS,BulkE,SteffenB,JiP,TickenbrockL,LangK,ZankerKS,MetzgerR,SchneiderPM,GerkeV,ThomasM,BerdelWE,ServeH,Muller-TidowC.S100familymembersandtrypsinogensarepredictorsofdistantmetastasisandsur-vivalinearly-stagenon-smallcelllungcancer.CancerRes.2004;64:5564–5569.38.DucyP,StarbuckM,PriemelM,ShenJ,PineroG,GeoffroyV,AmlingM,KarsentyG.ACbfa1-dependentgeneticpathwaycontrolsboneformationbeyondembryonicdevelopment.GenesDev.1999;13:1025–1036.39.DucyP,ZhangR,GeoffroyV,RidallAL,KarsentyG.Osf2/Cbfa1:atranscriptionalactivatorofosteoblastdifferentiation.Cell.1997;89:747–754.40.el-DeiryWS.Regulationofp53downstreamgenes.SeminCancerBiol.1998;8:345–357.41.ElefteriouF,BensonMD,SowaH,StarbuckM,LiuX,RonD,ParadaLF,KarsentyG.ATF4mediationofNF1functionsinosteoblastrevealsanutritionalbasisforcongenitalskeletaldysplasiae.CellMetab.2006;4:441–451.42.EliseevRA,DongYF,SampsonE,ZuscikMJ,SchwarzEM,O’KeefeRJ,RosierRN,DrissiMH.Runx2-mediatedactivationoftheBaxgeneincreasesosteosarcomacellsensitivitytoapoptosis.Oncogene.[Epubaheadofprint].Jan282008.43.ElkahlounAG,BittnerM,HoskinsK,GemmillR,MeltzerPS.Molecularcytogeneticcharacterizationandphysicalmappingof12q13–15ampliﬁcationinhumancancers.GenesChromosomesCancer.1996;17:205–214.44.ElkahlounAG,KrizmanDB,WangZ,HofmannTA,RoeB,MeltzerPS.Transcriptmappingina46-kbsequencedregionatthecoreof12q13.3ampliﬁcationinhumancancers.Genomics.1997;42:295–301.45.EmotoK,SawadaH,YamadaY,FujimotoH,TakahamaY,UenoM,TakayamaT,UchidaH,KamadaK,NaitoA,HiraoS,NakajimaY.AnnexinIIoverexpressioniscorrelatedwithpoorprognosisinhumangastriccarcinoma.AnticancerRes.2001;21:1339–1345.46.FerraciniR,DiRenzoMF,ScotlandiK,BaldiniN,OliveroM,LolliniP,CremonaO,CampanacciM,ComoglioPM.TheMet/HGFreceptorisover-expressedinhumanosteosarcomasandisactivatedbyeitheraparacrineoranautocrinecircuit.Oncogene.1995;10:739–749.47.FerrariC,BenassiS,PonticelliF,GamberiG,RagazziniP,PazzagliaL,BalladelliA,BertoniF,PicciP.RoleofMMP-9anditstissueinhibitorTIMP-1inhumanosteosarcoma:ﬁndingsin42patientsfollowedfor1–16years.ActaOrthopScand.2004;75:487–491.48.FeugeasO,GuriecN,Babin-BoilletotA,MarcellinL,SimonP,BabinS,ThyssA,HofmanP,TerrierP,KalifaC,Brunat-MentignyM,PatricotLM,OberlingF.LossofheterozygosityoftheRBgeneisapoorprognosticfactorinpatientswithosteo-sarcoma.JClinOncol.1996;14:467–472.49.ForusA,FlorenesVA,MaelandsmoGM,MeltzerPS,FodstadO,MyklebostO.Mappingofampliﬁcationunitsintheq13–14regionofchromosome12inhumansarcomas:someamplicadonotincludeMDM2.CellGrowthDiffer.1993;4:1065–1070.50.FranchiA,CalzolariA,ZampiG.Immunohistochemicaldetectionofc-fosandc-junexpressioninosseousandcarti-laginoustumoursoftheskeleton.VirchowsArch.1998;432:515–519.51.FuchsB,PritchardDJ.Etiologyofosteosarcoma.ClinOrthopRelatRes.2002;397:40–52.52.GalindoM,PratapJ,YoungDW,HovhannisyanH,ImHJ,ChoiJY,LianJB,SteinJL,SteinGS,vanWijnenAJ.Thebone-speciﬁcexpressionofRunx2oscillatesduringthecellcycletosupportaG1-relatedantiproliferativefunctioninosteoblasts.JBiolChem.2005;280:20274–20285.53.GamberiG,BenassiMS,BohlingT,RagazziniP,MolendiniL,SollazzoMR,PompettiF,MerliM,MagagnoliG,BalladelliA,PicciP.C-mycandc-fosinhumanosteosarcoma:prognosticvalueofmRNAandproteinexpression.Oncology.1998;55:556–563.54.GermanJ.Bloomsyndrome:amendelianprototypeofsomaticmutationaldisease.Medicine(Baltimore).1993;72:393–406.55.GibbsCP,KukekovVG,ReithJD,TchigrinovaO,SuslovON,ScottEW,GhivizzaniSC,IgnatovaTN,SteindlerDA.Stem-likecellsinbonesarcomas:implicationsfortumorigenesis.Neo-plasia.2005;7:967–976.56.GilesRH,vanEsJH,CleversH.CaughtupinaWntstorm:Wntsignalingincancer.BiochimBiophysActa.2003;1653:1–24.57.GilletteJM,ChanDC,Nielsen-PreissSM.Annexin2expressionisreducedinhumanosteosarcomametastases.JCellBiochem.2004;92:820–832.58.GlassDA2nd,KarsentyG.InvivoanalysisofWntsignalinginbone.Endocrinology.2007;148:2630–2634.59.GobbiG,SangiorgiL,LenziL,CasadeiR,CanaiderS,StrippoliP,LucarelliE,GhediniI,DonatiD,FabbriN,WarzechaJ,YeoungC,HelmanLJ,PicciP,CarinciP.SevenBMPsandalltheirreceptorsaresimultaneouslyexpressedinosteosarcomacells.IntJOncol.2002;20:143–147.60.GokgozN,WunderJS,MoussesS,EskandarianS,BellRS,AndrulisIL.Comparisonofp53mutationsinpatientswithlocalizedosteosarcomaandmetastaticosteosarcoma.Cancer.2001;92:2181–2189.61.GordonMD,NusseR.Wntsignaling:multiplepathways,multiplereceptors,andmultipletranscriptionfactors.JBiolChem.2006;281:22429–22433.62.GorlickR,AndersonP,AndrulisI,ArndtC,BeardsleyGP,BernsteinM,BridgeJ,CheungNK,DomeJS,EbbD,GardnerT,GebhardtM,GrierH,HansenM,HealeyJ,HelmanL,HockJ,HoughtonJ,HoughtonP,HuvosA,KhannaC,KieranM,KleinermanE,LadanyiM,LauC,MalkinD,MarinaN,MeltzerP,MeyersP,SchoﬁeldD,SchwartzC,SmithMA,ToretskyJ,TsokosM,WexlerL,WiggintonJ,WithrowS,SchoenfeldtM,AndersonB.Biologyofchildhoodosteogenicsarcomaandpotentialtargetsfortherapeuticdevelopment:meetingsummary.ClinCancerRes.2003;9:5442–5453.63.GorlickR,HuvosAG,HellerG,AledoA,BeardsleyGP,HealeyJH,MeyersPA.ExpressionofHER2/erbB-2correlateswithsurvivalinosteosarcoma.JClinOncol.1999;17:2781–2788.64.GotoA,KandaH,IshikawaY,MatsumotoS,KawaguchiN,MachinamiR,KatoY,KitagawaT.Associationoflossofheterozygosityatthep53locuswithchemoresistanceinosteo-sarcomas.JpnJCancerRes.1998;89:539–547.2124Tangetal.ClinicalOrthopaedicsandRelatedResearch12365.GotoM,MillerRW,IshikawaY,SuganoH.ExcessofrarecancersinWernersyndrome(adultprogeria).CancerEpidemiolBiomarkersPrev.1996;5:239–246.66.HaberDA.Splicingintosenescence:thecuriouscaseofp16andp19ARF.Cell.1997;91:555–558.67.HansenMF.Geneticandmolecularaspectsofosteosarcoma.JMusculoskeletNeuronalInteract.2002;2:554–560.68.HansenMF,CaveneeWK.Geneticsofcancerpredisposition.CancerRes.1987;47:5518–5527.69.HansenR,OrenM.p53;frominductivesignaltocellulareffect.CurrOpinGenetDev.1997;7:46–51.70.HarbourJW,DeanDC.TheRb/E2Fpathway:expandingrolesandemergingparadigms.GenesDev.2000;14:2393–2409.71.HarpioR,EinarssonR.S100proteinsascancerbiomarkerswithfocusonS100Binmalignantmelanoma.ClinBiochem.2004;37:512–518.72.HatakeyamaM,WeinbergRA.TheroleofRBincellcyclecontrol.ProgCellCycleRes.1995;1:9–19.73.HaydenJB,HoangBH.Osteosarcoma:basicscienceandclini-calimplications.OrthopClinNorthAm.2006;37:1–7.74.HaydonRC,DeyrupA,IshikawaA,HeckR,JiangW,ZhouL,FengT,KingD,ChengH,BreyerB,PeabodyT,SimonMA,MontagAG,HeTC.Cytoplasmicand/ornuclearaccumulationofthebeta-cateninproteinisafrequenteventinhumanosteo-sarcoma.IntJCancer.2002;102:338–342.75.HaydonRC,LuuHH,HeTC.Osteosarcomaandosteoblasticdifferentiation:anewperspectiveononcogenesis.ClinOrthopRelatRes.2007;454:237–246.76.HaydonRC,ZhouL,FengT,BreyerB,ChengH,JiangW,IshikawaA,PeabodyT,MontagA,SimonMA,HeTC.Nuclearreceptoragonistsaspotentialdifferentiationtherapyagentsforhumanosteosarcoma.ClinCancerRes.2002;8:1288–1294.77.HelmanLJ,MeltzerP.Mechanismsofsarcomadevelopment.NatRevCancer.2003;3:685–694.78.HicksonID.RecQhelicases:caretakersofthegenome.NatRevCancer.2003;3:169–178.79.HimelsteinBP.Osteosarcomaandotherbonecancers.CurrOpinOncol.1998;10:326–333.80.HoangBH,KuboT,HealeyJH,SowersR,MazzaB,YangR,HuvosAG,MeyersPA,GorlickR.ExpressionofLDLreceptor-relatedprotein5(LRP5)asanovelmarkerfordiseasepro-gressioninhigh-gradeosteosarcoma.IntJCancer.2004;109:106–111.81.HoangBH,KuboT,HealeyJH,YangR,NathanSS,KolbEA,MazzaB,MeyersPA,GorlickR.Dickkopf3inhibitsinvasionandmotilityofSaos-2osteosarcomacellsbymodulatingtheWnt-beta-cateninpathway.CancerRes.2004;64:2734–2739.82.HongJH,HwangES,McManusMT,AmsterdamA,TianY,KalmukovaR,MuellerE,BenjaminT,SpiegelmanBM,SharpPA,HopkinsN,YaffeMB.TAZ,atranscriptionalmodulatorofmesenchymalstemcelldifferentiation.Science.2005;309:1074–1078.83.HongSH,KadosawaT,NozakiK,MochizukiM,MatsunagaS,NishimuraR,SasakiN.Invitroretinoid-inducedgrowthinhi-bitionandmorphologicdifferentiationofcanineosteosarcomacells.AmJVetRes.2000;61:69–73.84.HornebeckW,LambertE,PetitfrereE,BernardP.Beneﬁcialanddetrimentalinﬂuencesoftissueinhibitorofmetallopro-teinase-1(TIMP-1)intumorprogression.Biochimie.2005;87:377–383.85.HorstmannMA,PoslM,ScholzRB,AndereggB,SimonP,BaumgaertlK,DellingG,KabischH.FrequentreductionorlossofDCCgeneexpressioninhumanosteosarcoma.BrJCancer.1997;75:1309–1317.86.HughesAE,RalstonSH,MarkenJ,BellC,MacPhersonH,WallaceRG,vanHulW,WhyteMP,NakatsukaK,HovyL,AndersonDM.MutationsinTNFRSF11A,affectingthesignalpeptideofRANK,causefamilialexpansileosteolysis.NatGenet.2000;24:45–48.87.HungJ,AndersonR.p53:functions,mutationsandsarcomas.ActaOrthopScandSuppl.1997;273:68–73.88.HuvosAG,WoodardHQ,CahanWG,HiginbothamNL,StewartFW,ButlerA,BretskySS.Postradiationosteogenicsarcomaofboneandsofttissues.Aclinicopathologicstudyof66patients.Cancer.1985;55:1244–1255.89.IwaoK,MiyoshiY,NawaG,YoshikawaH,OchiT,NakamuraY.Frequentbeta-cateninabnormalitiesinboneandsoft-tissuetumors.JpnJCancerRes.1999;90:205–209.90.IwayaK,OgawaH,KurodaM,IzumiM,IshidaT,MukaiK.Cytoplasmicand/ornuclearstainingofbeta-cateninisassociatedwithlungmetastasis.ClinExpMetastasis.2003;20:525–529.91.JinY,YangLJ.Immunohistochemicalanalysisofbonemor-phogeneticprotein(BMP)inosteosarcoma.JOralPatholMed.1990;19:152–154.92.JungST,MoonES,SeoHY,KimJS,KimGJ,KimYK.ExpressionandsigniﬁcanceofTGF-betaisoformandVEGFinosteosarcoma.Orthopedics.2005;28:755–760.93.KanoeH,NakayamaT,MurakamiH,HosakaT,YamamotoH,NakashimaY,TsuboyamaT,NakamuraT,SasakiMS,ToguchidaJ.AmpliﬁcationoftheCDK4geneinsarcomas:tumorspeciﬁcityandrelationshipwiththeRBgenemutation.AnticancerRes.1998;18:2317–2321.94.KansaraM,ThomasDM.Molecularpathogenesisofosteosar-coma.DNACellBiol.2007;26:1–18.95.KarsentyG.Boneformationandfactorsaffectingthisprocess.MatrixBiol.2000;19:85–89.96.KarsentyG.RoleofCbfa1inosteoblastdifferentiationandfunction.SeminCellDevBiol.2000;11:343–346.97.KarsentyG.Centralcontrolofboneformation.AdvNephrolNeckerHosp.2001;31:119–133.98.KarsentyG.Geneticcontrolofskeletaldevelopment.NovartisFoundSymp.2001;232:6–17;discussion17–22.99.KarsentyG.Thecomplexitiesofskeletalbiology.Nature.2003;423:316–318.100.KarsentyG,WagnerEF.Reachingageneticandmolecularunderstandingofskeletaldevelopment.DevCell.2002;2:389–406.101.KeelSB,JaffeKA,PeturNielsenG,RosenbergAE.Ortho-paedicimplant-relatedsarcoma:astudyoftwelvecases.ModPathol.2001;14:969–977.102.Kempf-BielackB,BielackSS,JurgensH,BranscheidD,BerdelWE,ExnerGU,GobelU,HelmkeK,JundtG,KabischH,KevricM,KlingebielT,KotzR,MaasR,SchwarzR,SemikM,TreunerJ,ZoubekA,WinklerK.Osteosarcomarelapseaftercombinedmodalitytherapy:ananalysisofunselectedpatientsintheCooperativeOsteosarcomaStudyGroup(COSS).JClinOncol.2005;23:559–568.103.KhanJ,WeiJS,RingnerM,SaalLH,LadanyiM,WestermannF,BertholdF,SchwabM,AntonescuCR,PetersonC,MeltzerPS.Classiﬁcationanddiagnosticpredictionofcancersusinggeneexpressionproﬁlingandartiﬁcialneuralnetworks.NatMed.2001;7:673–679.104.KhannaC,KhanJ,NguyenP,PrehnJ,CaylorJ,YeungC,TrepelJ,MeltzerP,HelmanL.Metastasis-associateddiffer-encesingeneexpressioninamurinemodelofosteosarcoma.CancerRes.2001;61:3750–3759.105.KhannaC,PrehnJ,YeungC,CaylorJ,TsokosM,HelmanL.Anorthotopicmodelofmurineosteosarcomawithclonallyrelatedvariantsdifferinginpulmonarymetastaticpotential.ClinExpMetastasis.2000;18:261–271.106.KhannaC,WanX,BoseS,CassadayR,OlomuO,MendozaA,YeungC,GorlickR,HewittSM,HelmanLJ.Themembrane-Volume466,Number9,September2008MolecularPathogenesisofOsteosarcoma2125123cytoskeletonlinkerezrinisnecessaryforosteosarcomametas-tasis.NatMed.2004;10:182–186.107.KhatibZA,MatsushimeH,ValentineM,ShapiroDN,SherrCJ,LookAT.CoampliﬁcationoftheCDK4genewithMDM2andGLIinhumansarcomas.CancerRes.1993;53:5535–5541.108.KimH,KwakNJ,LeeJY,ChoiBH,LimY,KoYJ,KimYH,HuhPW,LeeKH,RhaHK,WangYP.MerlinneutralizestheinhibitoryeffectofMdm2onp53.JBiolChem.2004;279:7812–7818.109.KimHS,ParkYB,OhJH,JeongJ,KimCJ,LeeSH.ExpressionofCD44isoformscorrelateswiththemetastaticpotentialofosteosarcoma.ClinOrthopRelatRes.2002;396:184–190.110.KimJB,LeuchtP,LamK,LuppenC,TenBergeD,NusseR,HelmsJA.Boneregenerationisregulatedbywntsignaling.JBoneMinerRes.2007;22:1913–1923.111.KitchinFD,EllsworthRM.Pleiotropiceffectsofthegeneforretinoblastoma.JMedGenet.1974;11:244–246.112.KleihuesP,SchaubleB,zurHausenA,EsteveJ,OhgakiH.Tumorsassociatedwithp53germlinemutations:asynopsisof91families.AmJPathol.1997;150:1–13.113.KloenP,GebhardtMC,Perez-AtaydeA,RosenbergAE,SpringﬁeldDS,GoldLI,MankinHJ.Expressionoftransform-inggrowthfactor-beta(TGF-beta)isoformsinosteosarcomas:TGF-beta3isrelatedtodiseaseprogression.Cancer.1997;80:2230–2239.114.KomoriT,YagiH,NomuraS,YamaguchiA,SasakiK,DeguchiK,ShimizuY,BronsonRT,GaoYH,InadaM,SatoM,OkamotoR,KitamuraY,YoshikiS,KishimotoT.TargeteddisruptionofCbfa1resultsinacompletelackofboneformationowingtomaturationalarrestofosteoblasts.Cell.1997;89:755–764.115.KoolsPF,VandeVenWJ.Ampliﬁcationofarearrangedformofthehigh-mobilitygroupproteingeneHMGICinOsA-CIosteosarcomacells.CancerGenetCytogenet.1996;91:1–7.116.KorenjakM,BrehmA.E2F-Rbcomplexesregulatingtran-scriptionofgenesimportantfordifferentiationanddevelopment.CurrOpinGenetDev.2005;15:520–527.117.KruzelockRP,MurphyEC,StrongLC,NaylorSL,HansenMF.Localizationofanoveltumorsuppressorlocusonhumanchromosome3qimportantinosteosarcomatumorigenesis.CancerRes.1997;57:106–109.118.KuryuM,OzakiT,NishidaK,ShibaharaM,KawaiA,InoueH.ExpressionofCD44variantsinosteosarcoma.JCancerResClinOncol.1999;125:646–652.119.LadanyiM,ChaC,LewisR,JhanwarSC,HuvosAG,HealeyJH.MDM2geneampliﬁcationinmetastaticosteosarcoma.CancerRes.1993;53:16–18.120.LadanyiM,ParkCK,LewisR,JhanwarSC,HealeyJH,HuvosAG.SporadicampliﬁcationoftheMYCgeneinhumanosteo-sarcomas.DiagnMolPathol.1993;2:163–167.121.LallemandD,CurtoM,SaotomeI,GiovanniniM,McClatcheyAI.NF2deﬁciencypromotestumorigenesisandmetastasisbydestabilizingadherensjunctions.GenesDev.2003;17:1090–1100.122.LamourV,DetryC,SanchezC,HenrotinY,CastronovoV,BellahceneA.Runx2-andhistonedeacetylase3-mediatedrepressionisrelievedindifferentiatinghumanosteoblastcellstoallowhighbonesialoproteinexpression.JBiolChem.2007;282:36240–36249.123.LarsenCJ.p16INK4a:agenewithadualcapacitytoencodeunrelatedproteinsthatinhibitcellcycleprogression.Oncogene.1996;12:2041–2044.124.LeachFS,TokinoT,MeltzerP,BurrellM,OlinerJD,SmithS,HillDE,SidranskyD,KinzlerKW,VogelsteinB.p53MutationandMDM2ampliﬁcationinhumansofttissuesarcomas.CancerRes.1993;53(10Suppl):2231–2234.125.LednickyJA,StewartAR,JenkinsJJ3rd,FinegoldMJ,ButelJS.SV40DNAinhumanosteosarcomasshowssequencevari-ationamongT-antigengenes.IntJCancer.1997;72:791–800.126.LevineAJ.p53,thecellulargatekeeperforgrowthanddivision.Cell.1997;88:323–331.127.LewisVO.What’snewinmusculoskeletaloncology.JBoneJointSurgAm.2007;89:1399–1407.128.LiFP,FraumeniJFJr,MulvihillJJ,BlattnerWA,DreyfusMG,TuckerMA,MillerRW.Acancerfamilysyndromeintwenty-fourkindreds.CancerRes.1988;48:5358–5362.129.LianJB,SteinGS,JavedA,vanWijnenAJ,SteinJL,MontecinoM,HassanMQ,GaurT,LengnerCJ,YoungDW.Networksandhubsforthetranscriptionalcontrolofosteoblas-togenesis.RevEndocrMetabDisord.2006;7:1–16.130.LiburaJ,DrukalaJ,MajkaM,TomescuO,NavenotJM,KuciaM,MarquezL,PeiperSC,BarrFG,Janowska-WieczorekA,RatajczakMZ.CXCR4-SDF-1signalingisactiveinrhabdo-myosarcomacellsandregulateslocomotion,chemotaxis,andadhesion.Blood.2002;100:2597–2606.131.LoganCY,NusseR.TheWntsignalingpathwayindevelop-mentanddisease.AnnuRevCellDevBiol.2004;20:781–810.132.LonardoF,UedaT,HuvosAG,HealeyJ,LadanyiM.p53andMDM2alterationsinosteosarcomas:correlationwithclinico-pathologicfeaturesandproliferativerate.Cancer.1997;79:1541–1547.133.Lopez-GuerreroJA,Lopez-GinesC,PellinA,CardaC,Llombart-BoschA.DeregulationoftheG1toS-phasecellcyclecheckpointisinvolvedinthepathogenesisofhumanosteosar-coma.DiagnMolPathol.2004;13:81–91.134.LuoJ,ChenJ,DengZL,LuoX,SongWX,SharffKA,TangN,HaydonRC,LuuHH,HeTC.Wntsignalingandhumandis-eases:whatarethetherapeuticimplications?LabInvest.2007;87:97–103.135.LuoJ,SunMH,KangQ,PengY,JiangW,LuuHH,LuoQ,ParkJY,LiY,HaydonRC,HeTC.Genetherapyforboneregeneration.CurrGeneTher.2005;5:167–179.136.LuuHH,SongWX,LuoX,ManningD,LuoJ,DengZL,SharffKA,MontagAG,HaydonRC,HeTC.Distinctrolesofbonemorphogeneticproteinsinosteogenicdifferentiationofmesen-chymalstemcells.JOrthopRes.2007;25:665–677.137.LuuHH,ZhangR,HaydonRC,RayburnE,KangQ,SiW,ParkJK,WangH,PengY,JiangW,HeTC.Wnt/beta-cateninsig-nalingpathwayasanovelcancerdrugtarget.CurrCancerDrugTargets.2004;4:653–671.138.LuuHH,ZhouL,HaydonRC,DeyrupAT,MontagAG,HuoD,HeckR,HeizmannCW,PeabodyTD,SimonMA,HeTC.IncreasedexpressionofS100A6isassociatedwithdecreasedmetastasisandinhibitionofcellmigrationandanchorageindependentgrowthinhumanosteosarcoma.CancerLett.2005;229:135–148.139.MacEwenEG,PastorJ,KutzkeJ,TsanR,KurzmanID,ThammDH,WilsonM,RadinskyR.IGF-1receptorcontributestothemalignantphenotypeinhumanandcanineosteosarcoma.JCellBiochem.2004;92:77–91.140.MaelandsmoGM,BernerJM,FlorenesVA,ForusA,HovigE,FodstadO,MyklebostO.HomozygousdeletionfrequencyandexpressionlevelsoftheCDKN2geneinhumansarcomas–relationshiptoampliﬁcationandmRNAlevelsofCDK4andCCND1.BrJCancer.1995;72:393–398.141.MaitraA,RobertsH,WeinbergAG,GeradtsJ.Lossofp16(INK4a)expressioncorrelateswithdecreasedsurvivalinpediatricosteosarcomas.IntJCancer.2001;95:34–38.142.MakitieT,CarpenO,VaheriA,KivelaT.Ezrinasaprognosticindicatoranditsrelationshiptotumorcharacteristicsinuvealmalignantmelanoma.InvestOphthalmolVisSci.2001;42:2442–2449.2126Tangetal.ClinicalOrthopaedicsandRelatedResearch123143.MaliakalJC,AsahinaI,HauschkaPV,SampathTK.Osteogenicprotein-1(BMP-7)inhibitscellproliferationandstimulatestheexpressionofmarkerscharacteristicofosteoblastphenotypeinratosteosarcoma(17/2.8)cells.GrowthFactors.1994;11:227–234.144.MalkinD,JollyKW,BarbierN,LookAT,FriendSH,GebhardtMC,AndersenTI,BorresenAL,LiFP,GarberJ,etal.Germlinemutationsofthep53tumor-suppressorgeneinchildrenandyoungadultswithsecondmalignantneoplasms.NEnglJMed.1992;326:1309–1315.145.MalkinD,LiFP,StrongLC,FraumeniJFJr,NelsonCE,KimDH,KasselJ,GrykaMA,BischoffFZ,TainskyMA,etal.Germlinep53mutationsinafamilialsyndromeofbreastcan-cer,sarcomas,andotherneoplasms.Science.1990;250:1233–1238.146.MarinaN,GebhardtM,TeotL,GorlickR.Biologyandthera-peuticadvancesforpediatricosteosarcoma.Oncologist.2004;9:422–441.147.MarkRJ,PoenJ,TranLM,FuYS,SelchMT,ParkerRG.Postirradiationsarcomas.Asingle-institutionstudyandreviewoftheliterature.Cancer.1994;73:2653–2662.148.MartinTA,HarrisonG,ManselRE,JiangWG.TheroleoftheCD44/ezrincomplexincancermetastasis.CritRevOncolHematol.2003;46:165–186.149.MassagueJ.TGF-betasignaltransduction.AnnuRevBiochem.1998;67:753–791.150.MassagueJ,ChenYG.ControllingTGF-betasignaling.GenesDev.2000;14:627–644.151.MassagueJ,WottonD.TranscriptionalcontrolbytheTGF-beta/Smadsignalingsystem.EmboJ.2000;19:1745–1754.152.MasudaH,MillerC,KoefﬂerHP,BattiforaH,ClineMJ.Rearrangementofthep53geneinhumanosteogenicsarcomas.ProcNatlAcadSciUSA.1987;84:7716–7719.153.McClatcheyAI.NeuroﬁbromatosistypeII:mousemodelsrevealbroadrolesintumorigenesisandmetastasis.MolMedToday.2000;6:252–253.154.McClatcheyAI,GiovanniniM.Membraneorganizationandtumorigenesis–theNF2tumorsuppressor,Merlin.GenesDev.2005;19:2265–2277.155.McClatcheyAI,SaotomeI,MercerK,CrowleyD,GusellaJF,BronsonRT,JacksT.MiceheterozygousforamutationattheNf2tumorsuppressorlocusdeveloparangeofhighlymetastatictumors.GenesDev.1998;12:1121–1133.156.McIntyreJF,Smith-SorensenB,FriendSH,KassellJ,BorresenAL,YanYX,RussoC,SatoJ,BarbierN,MiserJ,etal.Germlinemutationsofthep53tumorsuppressorgeneinchil-drenwithosteosarcoma.JClinOncol.1994;12:925–930.157.McNairnJD,DamronTA,LandasSK,AmbroseJL,ShrimptonAE.InheritanceofosteosarcomaandPaget’sdiseaseofbone:afamiliallossofheterozygositystudy.JMolDiagn.2001;3:171–177.158.Melo-JuniorMR,FilhoJL,CavalcantiCL,PatuVJ,BeltraoEI,CarvalhoLB.DetectionofS100proteinfromprostaticcancerpatientsusinganti-S100proteinantibodyimmobilizedonPOS-PVAdiscs.BiotechnolBioeng.2007;97:182–187.159.MeltzerPS,JankowskiSA,DalCinP,SandbergAA,PazIB,CocciaMA.IdentiﬁcationandcloningofanovelampliﬁedDNAsequenceinhumanmalignantﬁbroushistiocytomaderivedfromaregionofchromosome12frequentlyrearrangedinsofttissuetumors.CellGrowthDiffer.1991;2:495–501.160.MendozaS,DavidH,GaylordGM,MillerCW.Alleliclossat10q26inosteosarcomaintheregionoftheBUB3andFGFR2genes.CancerGenetCytogenet.2005;158:142–147.161.MendozaSM,KonishiT,MillerCW.IntegrationofSV40inhumanosteosarcomaDNA.Oncogene.1998;17:2457–2462.162.MillerCW,AsloA,CampbellMJ,KawamataN,LampkinBC,KoefﬂerHP.Alterationsofthep15,p16,andp18genesinosteosarcoma.CancerGenetCytogenet.1996;86:136–142.163.MillerCW,AsloA,TsayC,SlamonD,IshizakiK,ToguchidaJ,YamamuroT,LampkinB,KoefﬂerHP.Frequencyandstructureofp53rearrangementsinhumanosteosarcoma.CancerRes.1990;50:7950–7954.164.MillerCW,AsloA,WonA,TanM,LampkinB,KoefﬂerHP.Alterationsofthep53,RbandMDM2genesinosteosarcoma.JCancerResClinOncol.1996;122:559–565.165.MintzMB,SowersR,BrownKM,HilmerSC,MazzaB,HuvosAG,MeyersPA,LaﬂeurB,McDonoughWS,HenryMM,RamseyKE,AntonescuCR,ChenW,HealeyJH,DaluskiA,BerensME,MacdonaldTJ,GorlickR,StephanDA.Anexpressionsignatureclassiﬁeschemotherapy-resistantpediatricosteosarcoma.CancerRes.2005;65:1748–1754.166.MolendiniL,BenassiMS,MagagnoliG,MerliM,SollazzoMR,RagazziniP,GamberiG,FerrariC,BalladelliA,BacchiniP,PicciP.Prognosticsigniﬁcanceofcyclinexpressioninhumanosteosarcoma.IntJOncol.1998;12:1007–1011.167.MomandJ,JungD,WilczynskiS,NilandJ.TheMDM2geneampliﬁcationdatabase.NucleicAcidsRes.1998;26:3453–3459.168.MotoyamaJ,LiuJ,MoR,DingQ,PostM,HuiCC.EssentialfunctionofGli2andGli3intheformationoflung,tracheaandoesophagus.NatGenet.1998;20:54–57.169.MoussesS,McAuleyL,BellRS,KandelR,AndrulisIL.Molecularandimmunohistochemicalidentiﬁcationofp53alterationsinboneandsofttissuesarcomas.ModPathol.1996;9:1–6.170.MulliganLM,MatlashewskiGJ,ScrableHJ,CaveneeWK.Mechanismsofp53lossinhumansarcomas.ProcNatlAcadSciUSA.1990;87:5863–5867.171.MundlosS,OttoF,MundlosC,MullikenJB,AylsworthAS,AlbrightS,LindhoutD,ColeWG,HennW,KnollJH,OwenMJ,MertelsmannR,ZabelBU,OlsenBR.MutationsinvolvingthetranscriptionfactorCBFA1causecleidocranialdysplasia.Cell.1997;89:773–779.172.NakaT,IwamotoY,ShinoharaN,UshijimaM,ChumanH,TsuneyoshiM.Expressionofc-metproto-oncogeneproduct(c-MET)inbenignandmalignantbonetumors.ModPathol.1997;10:832–838.173.NakashimaK,ZhouX,KunkelG,ZhangZ,DengJM,BehringerRR,deCrombruggheB.Thenovelzincﬁnger-containingtranscriptionfactorosterixisrequiredforosteoblastdifferenti-ationandboneformation.Cell.2002;108:17–29.174.NakayamaT,ToguchidaJ,WadayamaB,KanoeH,KotouraY,SasakiMS.MDM2geneampliﬁcationinboneandsoft-tissuetumors:associationwithtumorprogressionindifferentiatedadipose-tissuetumors.IntJCancer.1995;64:342–346.175.NathrathMH,KuosaiteV,RosemannM,KremerM,PorembaC,WakanaS,YanagiM,NathrathWB,HoﬂerH,ImaiK,AtkinsonMJ.Twonoveltumorsuppressorgenelocionchro-mosome6qand15qinhumanosteosarcomaidentiﬁedthroughcomparativestudyofallelicimbalancesinmouseandman.Oncogene.2002;21:5975–5980.176.NelsonWJ,NusseR.ConvergenceofWnt,beta-catenin,andcadherinpathways.Science.2004;303:1483–1487.177.NesbitCE,TersakJM,ProchownikEV.MYConcogenesandhumanneoplasticdisease.Oncogene.1999;18:3004–3016.178.NevinsJR,LeoneG,DeGregoriJ,JakoiL.RoleoftheRb/E2Fpathwayincellgrowthcontrol.JCellPhysiol.1997;173:233–236.179.NielsenGP,BurnsKL,RosenbergAE,LouisDN.CDKN2Agenedeletionsandlossofp16expressionoccurinosteosarco-masthatlackRBalterations.AmJPathol.1998;153:159–163.Volume466,Number9,September2008MolecularPathogenesisofOsteosarcoma2127123180.Noble-TophamSE,BurrowSR,EppertK,KandelRA,MeltzerPS,BellRS,AndrulisIL.SASisampliﬁedpredominantlyinsurfaceosteosarcoma.JOrthopRes.1996;14:700–705.181.NozakiK,KadosawaT,NishimuraR,MochizukiM,TakahashiK,SasakiN.1,25-DihydroxyvitaminD3,recombinanthumantransforminggrowthfactor-beta1,andrecombinanthumanbonemorphogeneticprotein-2induceinvitrodifferentiationofcanineosteosarcomacells.JVetMedSci.1999;61:649–656.182.NusseR.TheWntgenefamilyintumorigenesisandinnormaldevelopment.JSteroidBiochemMolBiol.1992;43:9–12.183.NusseR.Wntsignalingindiseaseandindevelopment.CellRes.2005;15:28–32.184.OlinerJD,KinzlerKW,MeltzerPS,GeorgeDL,VogelsteinB.Ampliﬁcationofageneencodingap53-associatedproteininhumansarcomas.Nature.1992;358:80–83.185.OlinerJD,PietenpolJA,ThiagalingamS,GyurisJ,KinzlerKW,VogelsteinB.OncoproteinMDM2concealstheactivationdomainoftumoursuppressorp53.Nature.1993;362:857–860.186.OliveiraP,NogueiraM,PintoA,AlmeidaMO.Analysisofp53expressioninosteosarcomaofthejaw:correlationwithclini-copathologicandDNAploidyﬁndings.HumPathol.1997;28:1361–1365.187.OttoF,ThornellAP,CromptonT,DenzelA,GilmourKC,RosewellIR,StampGW,BeddingtonRS,MundlosS,OlsenBR,SelbyPB,OwenMJ.Cbfa1,acandidategeneforcleido-cranialdysplasiasyndrome,isessentialforosteoblastdifferentiationandbonedevelopment.Cell.1997;89:765–771.188.ParkBH,BreyerB,HeTC.Peroxisomeproliferator-activatedreceptors:rolesintumorigenesisandchemopreventioninhumancancer.CurrOpinOncol.2001;13:78–83.189.PatelMS,KarsentyG.RegulationofboneformationandvisionbyLRP5.NEnglJMed.2002;346:1572–1574.190.PedrocchiM,SchaferBW,MuellerH,EppenbergerU,Heiz-mannCW.ExpressionofCa(2+)-bindingproteinsoftheS100familyinmalignanthumanbreast-cancercelllinesandbiopsysamples.IntJCancer.1994;57:684–690.191.PerissinottoE,CavalloniG,LeoneF,FonsatoV,MitolaS,GrignaniG,SurrentiN,SangioloD,BussolinoF,PiacibelloW,AgliettaM.Involvementofchemokinereceptor4/stromalcell-derivedfactor1systemduringosteosarcomatumorprogression.ClinCancerRes.2005;11(2Pt1):490–497.192.PomerantzJ,Schreiber-AgusN,LiegeoisNJ,SilvermanA,AllandL,ChinL,PotesJ,ChenK,OrlowI,LeeHW,Cordon-CardoC,DePinhoRA.TheInk4atumorsuppressorgeneproduct,p19Arf,interactswithMDM2andneutralizesMDM2’sinhibitionofp53.Cell.1998;92:713–723.193.PompettiF,RizzoP,SimonRM,FreidlinB,MewDJ,PassHI,PicciP,LevineAS,CarboneM.Oncogenealterationsinpri-mary,recurrent,andmetastatichumanbonetumors.JCellBiochem.1996;63:37–50.194.PorterDE,HoldenST,SteelCM,CohenBB,WallaceMR,ReidR.AsigniﬁcantproportionofpatientswithosteosarcomamaybelongtoLi-Fraumenicancerfamilies.JBoneJointSurgBr.1992;74:883–886.195.PostiglioneL,DiDomenicoG,Giordano-LanzaG,LadoganaP,TuranoM,CastaldoC,DiMeglioF,CocozzaS,MontagnaniS.Effectofhumangranulocytemacrophage-colonystimulatingfactorondifferentiationandapoptosisofthehumanosteosar-comacelllineSaOS-2.EurJHistochem.2003;47:309–316.196.PostiglioneL,DomenicoGD,MontagnaniS,SpignaGD,SalzanoS,CastaldoC,RamagliaL,SbordoneL,RossiG.Granulocyte-macrophagecolony-stimulatingfactor(GM-CSF)inducestheosteoblasticdifferentiationofthehumanosteosar-comacelllineSaOS-2.CalcifTissueInt.2003;72:85–97.197.PovelonesM,NusseR.Wntsignallingseesspots.NatCellBiol.2002;4:E249–250.198.QuelleDE,ZindyF,AshmunRA,SherrCJ.AlternativereadingframesoftheINK4atumorsuppressorgeneencodetwounre-latedproteinscapableofinducingcellcyclearrest.Cell.1995;83:993–1000.199.RadigK,Schneider-StockR,HaeckelC,NeumannW,RoessnerA.p53genemutationsinosteosarcomasoflow-grademalig-nancy.HumPathol.1998;29:1310–1316.200.RagazziniP,GamberiG,BenassiMS,OrlandoC,SestiniR,FerrariC,MolendiniL,SollazzoMR,MerliM,MagagnoliG,BertoniF,BohlingT,PazzagliM,PicciP.AnalysisofSASgeneandCDK4andMDM2proteinsinlow-gradeosteosarcoma.CancerDetectPrev.1999;23:129–136.201.RajgopalA,YoungDW,MujeebKA,SteinJL,LianJB,vanWijnenAJ,SteinGS.MitoticcontrolofRUNX2phosphoryla-tionbybothCDK1/cyclinBkinaseandPP1/PP2Aphosphataseinosteoblasticcells.JCellBiochem.2007;100:1509–1517.202.ReifenbergerG,ReifenbergerJ,IchimuraK,MeltzerPS,CollinsVP.Ampliﬁcationofmultiplegenesfromchromosomalregion12q13–14inhumanmalignantgliomas:preliminarymappingoftheampliconsshowspreferentialinvolvementofCDK4,SAS,andMDM2.CancerRes.1994;54:4299–4303.203.ReyaT,CleversH.Wntsignallinginstemcellsandcancer.Nature.2005;434:843–850.204.ReyaT,MorrisonSJ,ClarkeMF,WeissmanIL.Stemcells,cancer,andcancerstemcells.Nature.2001;414:105–111.205.RobertsWM,DouglassEC,PeiperSC,HoughtonPJ,LookAT.Ampliﬁcationofthegligeneinchildhoodsarcomas.CancerRes.1989;49:5407–5413.206.RomanoJW,EhrhartJC,DuthuA,KimCM,AppellaE,MayP.Identiﬁcationandcharacterizationofap53genemutationinahumanosteosarcomacellline.Oncogene.1989;4:1483–1488.207.RongS,JeffersM,ResauJH,TsarfatyI,OskarssonM,VandeWoudeGF.Metexpressionandsarcomatumorigenicity.CancerRes.1993;53:5355–5360.208.RutherU,KomitowskiD,SchubertFR,WagnerEF.c-fosexpressioninducesbonetumorsintransgenicmice.Oncogene.1989;4:861–865.209.SalamaI,MalonePS,MihaimeedF,JonesJL.AreviewoftheS100proteinsincancer.EurJSurgOncol.[EpubJun132007].2008;34:357–364.210.SandbergAA,BridgeJA.Updatesonthecytogeneticsandmoleculargeneticsofboneandsofttissuetumors:osteosarcomaandrelatedtumors.CancerGenetCytogenet.2003;145:1–30.211.SangiorgiL,GobbiGA,LucarelliE,SartorioSM,MordentiM,GhediniI,MainiV,ScrimieriF,ReggianiM,BertojaAZ,BenassiMS,PicciP.Presenceoftelomeraseactivityindifferentmusculoskeletaltumorhistotypesandcorrelationwithaggres-siveness.IntJCancer.202001;95:156–161.212.ScheelC,SchaeferKL,JauchA,KellerM,WaiD,BrinkschmidtC,vanValenF,BoeckerW,Dockhorn-DworniczakB,PorembaC.Alternativelengtheningoftelomeresisassociatedwithchro-mosomalinstabilityinosteosarcomas.Oncogene.2001;20:3835–3844.213.SchmidtEE,IchimuraK,ReifenbergerG,CollinsVP.CDKN2(p16/MTS1)genedeletionorCDK4ampliﬁcationoccursinthemajorityofglioblastomas.CancerRes.1994;54:6321–6324.214.Schneider-StockR,RadigK,OdaY,MellinW,RysJ,NiezabitowskiA,RoessnerA.p53genemutationsinsoft-tissuesarcomas–correlationswithp53immunohistochemistryandDNAploidy.JCancerResClinOncol.1997;123:211–218.215.ScholzRB,KabischH,WeberB,RoserK,DellingG,WinklerK.StudiesoftheRB1geneandthep53geneinhumanosteo-sarcomas.PediatrHematolOncol.1992;9:125–137.216.ScotlandiK,BaldiniN,OlivieroM,DiRenzoMF,MartanoM,SerraM,ManaraMC,ComoglioPM,FerraciniR.ExpressionofMet/hepatocytegrowthfactorreceptorgeneandmalignant2128Tangetal.ClinicalOrthopaedicsandRelatedResearch123behaviorofmusculoskeletaltumors.AmJPathol.1996;149:1209–1219.217.SellS.Stemcelloriginofcanceranddifferentiationtherapy.CritRevOncolHematol.2004;51:1–28.218.ShiratoriH,KoshinoT,UesugiM,NittoH,SaitoT.Accelera-tionoflungmetastasisbyup-regulationofCD44expressioninosteosarcoma-derivedcelltransplantedmice.CancerLett.2001;170:177–182.219.SiggelkowH,SchenckM,RohdeM,ViereckV,TauberS,AtkinsonMJ,HufnerM.ProlongedcultureofHOS58humanosteosarcomacellswith1,25-(OH)2-D3,TGF-beta,anddexa-methasonerevealsphysiologicalregulationofalkalinephosphatase,dissociatedosteocalcingeneexpression,andpro-teinsynthesisandlackofmineralization.JCellBiochem.2002;85:279–294.220.SimonsA,SchepensM,ForusA,GodagerL,vanAsseldonkM,MyklebostO,vanKesselAG.Anovelchromosomalregionofallelicloss,4q32-q34,inhumanosteosarcomasrevealedbyrepresentationaldifferenceanalysis.GenesChromosomesCan-cer.1999;26:115–124.221.Smith-SorensenB,GebhardtMC,KloenP,McIntyreJ,AguilarF,CeruttiP,BorresenAL.ScreeningforTP53mutationsinosteosarcomasusingconstantdenaturantgelelectrophoresis(CDGE).HumMutat.1993;2:274–285.222.SparksAB,PetersonSN,BellC,LoftusBJ,HockingL,CahillDP,FrassicaFJ,StreetenEA,LevineMA,FraserCM,AdamsMD,BroderS,VenterJC,KinzlerKW,VogelsteinB,RalstonSH.MutationscreeningoftheTNFRSF11AgeneencodingreceptoractivatorofNFkappaB(RANK)infamilialandspo-radicPaget’sdiseaseofboneandosteosarcoma.CalcifTissueInt.2001;68:151–155.223.SrivastavaS,ZouZQ,PirolloK,BlattnerW,ChangEH.Germ-linetransmissionofamutatedp53geneinacancer-pronefamilywithLi-Fraumenisyndrome.Nature.1990;348:747–749.224.SteinU,EderC,KarstenU,HaenschW,WaltherW,SchlagPM.GLIgeneexpressioninboneandsofttissuesarcomasofadultpatientscorrelateswithtumorgrade.CancerRes.1999;59:1890–1895.225.SuYA,HutterCM,TrentJM,MeltzerPS.Completesequenceanalysisofagene(OS-9)ubiquitouslyexpressedinhumantis-suesandampliﬁedinsarcomas.MolCarcinog.1996;15:270–275.226.SuYA,LeeMM,HutterCM,MeltzerPS.Characterizationofahighlyconservedgene(OS4)ampliﬁedwithCDK4inhumansarcomas.Oncogene.1997;15:1289–1294.227.SztanM,PapaiZ,SzendroiM,LooijM,OlahE.Alleliclossesfromchromosome17inhumanosteosarcomas.PatholOncolRes.1997;3:115–120.228.TaichmanRS,CooperC,KellerET,PientaKJ,TaichmanNS,McCauleyLK.Useofthestromalcell-derivedfactor-1/CXCR4pathwayinprostatecancermetastasistobone.CancerRes.2002;62:1832–1837.229.TakedaS,ElefteriouF,KarsentyG.Commonendocrinecontrolofbodyweight,reproduction,andbonemass.AnnuRevNutr.2003;23:403–411.230.TakedaS,KarsentyG.Centralcontrolofboneformation.JBoneMinerMetab.2001;19:195–198.231.ThomasD,KansaraM.Epigeneticmodiﬁcationsinosteogenicdifferentiationandtransformation.JCellBiochem.2006;98:757–769.232.ThomasDM,CartySA,PiscopoDM,LeeJS,WangWF,ForresterWC,HindsPW.Theretinoblastomaproteinactsasatranscriptionalcoactivatorrequiredforosteogenicdifferentia-tion.MolCell.2001;8:303–316.233.ThomasDM,JohnsonSA,SimsNA,TrivettMK,SlavinJL,RubinBP,WaringP,McArthurGA,WalkleyCR,HollowayAJ,DiyagamaD,GrimJE,ClurmanBE,BowtellDD,LeeJS,GutierrezGM,PiscopoDM,CartySA,HindsPW.Terminalosteoblastdifferentiation,mediatedbyrunx2andp27KIP1,isdisruptedinosteosarcoma.JCellBiol.2004;167:925–934.234.TirodeF,Laud-DuvalK,PrieurA,DelormeB,CharbordP,DelattreO.MesenchymalstemcellfeaturesofEwingtumors.CancerCell.2007;11:421–429.235.ToguchidaJ,IshizakiK,SasakiMS,IkenagaM,SugimotoM,KotouraY,YamamuroT.Chromosomalreorganizationfortheexpressionofrecessivemutationofretinoblastomasusceptibilitygeneinthedevelopmentofosteosarcoma.CancerRes.1988;48:3939–3943.236.ToguchidaJ,YamaguchiT,DaytonSH,BeauchampRL,HerreraGE,IshizakiK,YamamuroT,MeyersPA,LittleJB,SasakiMS,etal.Prevalenceandspectrumofgermlinemuta-tionsofthep53geneamongpatientswithsarcoma.NEnglJMed.1992;326:1301–1308.237.ToguchidaJ,YamaguchiT,RitchieB,BeauchampRL,DaytonSH,HerreraGE,YamamuroT,KotouraY,SasakiMS,LittleJB,etal.Mutationspectrumofthep53geneinboneandsofttissuesarcomas.CancerRes.1992;52:6194–6199.238.TorchiaEC,JaishankarS,BakerSJ.Ewingtumorfusionpro-teinsblockthedifferentiationofpluripotentmarrowstromalcells.CancerRes.2003;63:3464–3468.239.TuckerMA,D’AngioGJ,BoiceJDJr,StrongLC,LiFP,StovallM,StoneBJ,GreenDM,LombardiF,NewtonW,etal.Bonesarcomaslinkedtoradiotherapyandchemotherapyinchildren.NEnglJMed.1987;317:588–593.240.UchiboriM,NishidaY,NagasakaT,YamadaY,NakanishiK,IshiguroN.Increasedexpressionofmembrane-typematrixmetalloproteinase-1iscorrelatedwithpoorprognosisinpatientswithosteosarcoma.IntJOncol.2006;28:33–42.241.UedaY,Dockhorn-DworniczakB,BlasiusS,MellinW,WuismanP,BockerW,RoessnerA.AnalysisofmutantP53proteininosteosarcomasandothermalignantandbenignlesionsofbone.JCancerResClinOncol.1993;119:172–178.242.UlanerGA,HuangHY,OteroJ,ZhaoZ,Ben-PoratL,Satago-panJM,GorlickR,MeyersP,HealeyJH,HuvosAG,HoffmanAR,LadanyiM.Absenceofatelomeremaintenancemechanismasafavorableprognosticfactorinpatientswithosteosarcoma.CancerRes.2003;63:1759–1763.243.vanDartelM,CornelissenPW,RedekerS,TarkkanenM,KnuutilaS,HogendoornPC,WesterveldA,GomesI,BrasJ,HulsebosTJ.Ampliﬁcationof17p11.2approximatelyp12,includingPMP22,TOP3A,andMAPK7,inhigh-gradeosteo-sarcoma.CancerGenetCytogenet.2002;139:91–96.244.vanDartelM,HulsebosTJ.CharacterizationofPMP22expressioninosteosarcoma.CancerGenetCytogenet.2004;152:113–118.245.vanDeursenJM.Rblosscausescancerbydrivingmitosismad.CancerCell.2007;11:1–3.246.vanEsJH,BarkerN,CleversH.YouWntsome,youlosesome:oncogenesintheWntsignalingpathway.CurrOpinGenetDev.2003;13:28–33.247.VogelsteinB,LaneD,LevineAJ.Surﬁngthep53network.Nature.2000;408:307–310.248.WadayamaB,ToguchidaJ,ShimizuT,IshizakiK,SasakiMS,KotouraY,YamamuroT.Mutationspectrumoftheretino-blastomageneinosteosarcomas.CancerRes.1994;54:3042–3048.249.WadayamaB,ToguchidaJ,YamaguchiT,SasakiMS,YamamuroT.p53expressionanditsrelationshiptoDNAalterationsinboneandsofttissuesarcomas.BrJCancer.1993;68:1134–1139.250.WagnerEF,KarsentyG.Geneticcontrolofskeletaldevelop-ment.CurrOpinGenetDev.2001;11:527–532.Volume466,Number9,September2008MolecularPathogenesisofOsteosarcoma2129123251.WanX,MendozaA,KhannaC,HelmanLJ.Rapamycininhibitsezrin-mediatedmetastaticbehaviorinamurinemodelofoste-osarcoma.CancerRes.2005;65:2406–2411.252.WangLL.Biologyofosteogenicsarcoma.CancerJ.2005;11:294–305.253.WangLL,GannavarapuA,KozinetzCA,LevyML,LewisRA,ChintagumpalaMM,Ruiz-MaldanadoR,Contreras-RuizJ,CunniffC,EricksonRP,LevD,RogersM,ZackaiEH,PlonSE.AssociationbetweenosteosarcomaanddeleteriousmutationsintheRECQL4geneinRothmund-Thomsonsyndrome.JNatlCancerInst.2003;95:669–674.254.WangLL,LevyML,LewisRA,ChintagumpalaMM,LevD,RogersM,PlonSE.Clinicalmanifestationsinacohortof41Rothmund-Thomsonsyndromepatients.AmJMedGenet.2001;102:11–17.255.WangZQ,LiangJ,SchellanderK,WagnerEF,GrigoriadisAE.c-fos-inducedosteosarcomaformationintransgenicmice:cooperativitywithc-junandtheroleofendogenousc-fos.CancerRes.1995;55:6244–6251.256.WeatherbyRP,DahlinDC,IvinsJC.Postradiationsarcomaofbone:reviewof78MayoCliniccases.MayoClinProc.1981;56:294–306.257.WeiG,LonardoF,UedaT,KimT,HuvosAG,HealeyJH,LadanyiM.CDK4geneampliﬁcationinosteosarcoma:reci-procalrelationshipwithINK4Agenealterationsandmappingof12q13amplicons.IntJCancer.1999;80:199–204.258.WeissKR,CooperGM,JadlowiecJA,McGoughRL3rd,HuardJ.VEGFandBMPexpressioninmouseosteosarcomacells.ClinOrthopRelatRes.2006;450:111–117.259.WhelanJS.Osteosarcoma.EurJCancer.1997;33:1611–1618;discussion1618–1619.260.WichaMS,LiuS,DontuG.Cancerstemcells:anoldidea—aparadigmshift.CancerRes.2006;66:1883–1890;discussion1895–1886.261.WilkieAO,PateySJ,KanSH,vandenOuwelandAM,HamelBC.FGFs,theirreceptors,andhumanlimbmalformations:clinicalandmolecularcorrelations.AmJMedGenet.2002;112:266–278.262.WillertK,NusseR.Beta-catenin:akeymediatorofWntsig-naling.CurrOpinGenetDev.1998;8:95–102.263.WinslowMM,PanM,StarbuckM,GalloEM,DengL,KarsentyG,CrabtreeGR.Calcineurin/NFATsignalinginosteoblastsregulatesbonemass.DevCell.2006;10:771–782.264.WodarzA,NusseR.MechanismsofWntsignalingindevel-opment.AnnuRevCellDevBiol.1998;14:59–88.265.WolfM,El-RifaiW,TarkkanenM,KononenJ,SerraM,EriksenEF,ElomaaI,KallioniemiA,KallioniemiOP,KnuutilaS.Novelﬁndingsingeneexpressiondetectedinhumanosteo-sarcomabycDNAmicroarray.CancerGenetCytogenet.2000;123:128–132.266.WuJX,CarpenterPM,GresensC,KehR,NimanH,MorrisJW,MercolaD.Theproto-oncogenec-fosisover-expressedinthemajorityofhumanosteosarcomas.Oncogene.1990;5:989–1000.267.WunderJS,CzitromAA,KandelR,AndrulisIL.Analysisofalterationsintheretinoblastomageneandtumorgradeinboneandsoft-tissuesarcomas.JNatlCancerInst.1991;83:194–200.268.WunderJS,EppertK,BurrowSR,GokgozN,BellRS,AndrulisIL.Co-ampliﬁcationandoverexpressionofCDK4,SASandMDM2occursfrequentlyinhumanparostealosteosarcomas.Oncogene.1999;18:783–788.269.WuytsW,VanWesenbeeckL,Morales-PigaA,RalstonS,HockingL,VanhoenackerF,WesthovensR,VerbruggenL,AndersonD,HughesA,VanHulW.EvaluationoftheroleofRANKandOPGgenesinPaget’sdiseaseofbone.Bone.2001;28:104–107.270.YamaguchiA,KomoriT,SudaT.Regulationofosteoblastdifferentiationmediatedbybonemorphogeneticproteins,hedgehogs,andCbfa1.EndocrRev.2000;21:393–411.271.YamaguchiT,ToguchidaJ,YamamuroT,KotouraY,TakadaN,KawaguchiN,KanekoY,NakamuraY,SasakiMS,IshizakiK.Allelotypeanalysisinosteosarcomas:frequentallelelosson3q,13q,17p,and18q.CancerRes.1992;52:2419–2423.272.YanP,CoindreJM,BenhattarJ,BosmanFT,GuillouL.Telo-meraseactivityandhumantelomerasereversetranscriptasemRNAexpressioninsofttissuetumors:correlationwithgrade,histology,andproliferativeactivity.CancerRes.1999;59:3166–3170.273.YangX,KarsentyG.ATF4,theosteoblastaccumulationofwhichisdeterminedpost-translationally,caninduceosteoblast-speciﬁcgeneexpressioninnon-osteoblasticcells.JBiolChem.2004;279:47109–47114.274.YokoyamaR,Schneider-StockR,RadigK,WexT,RoessnerA.ClinicopathologicimplicationsofMDM2,p53andK-rasgenealterationsinosteosarcomas:MDM2ampliﬁcationandp53mutationsfoundinprogressivetumors.PatholResPract.1998;194:615–621.275.YoshikawaH,NakaseT,MyouiA,UedaT.Bonemorphoge-neticproteinsinbonetumors.JOrthopSci.2004;9:334–340.276.YotovWV,HamelH,RivardGE,ChampagneMA,RussoPA,LeclercJM,BernsteinML,LevyE.AmpliﬁcationsofDNAprimase1(PRIM1)inhumanosteosarcoma.GenesChromo-somesCancer.1999;26:62–69.277.ZenmyoM,KomiyaS,HamadaT,HiraokaK,KatoS,FujiiT,YanoH,IrieK,NagataK.Transcriptionalactivationofp21byvitaminD(3)orvitaminK(2)leadstodifferentiationofp53-deﬁcientMG-63osteosarcomacells.HumPathol.2001;32:410–416.278.ZhangM,RosenJM.Stemcellsintheetiologyandtreatmentofcancer.CurrOpinGenetDev.2006;16:60–64.279.ZhangY,XiongY,YarbroughWG.ARFpromotesMDM2degradationandstabilizesp53:ARF-INK4alocusdeletionimpairsboththeRbandp53tumorsuppressionpathways.Cell.1998;92:725–734.280.ZhaoGQ.ConsequencesofknockingoutBMPsignalinginthemouse.Genesis.2003;35:43–56.281.ZhouH,RandallRL,BrothmanAR,MaxwellT,CofﬁnCM,GoldsbyRE.Her-2/neuexpressioninosteosarcomaincreasesriskoflungmetastasisandcanbeassociatedwithgeneampli-ﬁcation.JPediatrHematolOncol.2003;25:27–32.282.ZouH,ChoeKM,LuY,MassagueJ,NiswanderL.BMPsig-nalingandvertebratelimbdevelopment.ColdSpringHarbSympQuantBiol.1997;62:269–272.2130Tangetal.ClinicalOrthopaedicsandRelatedResearch123PolyomavirustumorantigenshaveaprofoundeffectongeneexpressioninmouseﬁbroblastsBrittaKlucky1,3,BirgitKoch1,3,4,MartinRadolf2,PeterSteinlein2andErhardWintersberger*,11InstituteofMedicalBiochemistry,DivisionofMolecularBiology,MedicalUniversityofVienna,Dr.Bohrgasse9,A-1030Vienna,Austria;2InstituteofMolecularPathology,A-1030Vienna,AustriaPolyomavirus(Py)largeandsmalltumorantigensto-getherarecompetenttoinduceSphaseingrowth-arrestedmouseﬁbroblasts.Thecapacityofthelargetumorantigentobindthepocketproteins,pRB,p130andp107,isimportantforthetransactivationofDNAsynthesisenzymesandthecyclinsEandA,whiletheinterferenceofsmalltumorantigenwithproteinphosphatasePP2Acausesadestabilizationofthecdk2inhibitorp27,andthusleadstostrongcyclinE-andcyclinA-dependentcdk2activity.Pysmalltumorantigen,inaddition,isabletotransactivatecyclinA.Hence,thisproteinmighthaveamuchwidereffectongeneexpressioninarrestedmouseﬁbroblaststhanhithertosuspected.ThismayhaveaprofoundpartintheknowncapacityofPytoformtumorsinmice.Therefore,itwasinterestingtogainaninsightintothespectrumoftranscriptionalderegulationbyPytumorantigens.Accordingly,weperformedmicroarrayanalysisofquiescentmouseﬁbroblastsintheabsenceandpresenceofsmallorlargetumorantigen.WefoundthattheviralproteinscaninduceorrepressagreatvarietyofgenesbeyondthoseinvolvedintheSphaseinductionandDNAsynthesis.Theresultsofthemicroarrayanalysiswereconﬁrmedforselectedgenesbyseveralmethods,includingreal-timePCR.Interestingly,amutationofthebindingsiteforpocketproteinsincaseofLTandforPP2AincaseofSThasavariableeffectonthederegulationofgenesbytheviralproteinsdependingonthegeneinquestion.Infact,somegenesaretransacti-vatedbyLTaswellasSTcompletelyindependentofaninteractionwiththeirmajorcellulartargets,pocketproteinsandPP2A,respectively.Oncogene(2004)23,4707–4721.doi:10.1038/sj.onc.1207640Publishedonline3May2004Keywords:Tantigens;microarray;geneexpressionIntroductionPolyomavirus(Py)canformsolidtumorsinmanydifferentorgansofnewbornmiceandthusmustbeabletoinfectandreplicateinagreatvarietyofcelltypes(Benjamin,2001).Suchcellsareindiversestagesofdifferentiationandaremostfrequentlygrowtharrested.AsthevirusrequirescellsintheSphaseforthereplicationofitsownDNA,itmustbeabletodrivetheinfectedcellsoutofthequiescentstateintotheSphase.Thisisaccomplishedbytheactivityofthreeearlyviralproteins,thelarge,middleandsmalltumorantigens(henceforthabbreviatedLT,MTandST,respectively).LTisapleiotropicproteinthatspeciﬁcallybindstotheviraloriginofreplicationandcarrieshelicaseactivity.Initsreplicationcapacity,itcombinesfunctionsoftheORCsandtheMCMs(BellandDutta,2002)ofthecellularreplicationmachinery.Inaddition,itisthemajorproteininvolvedincreatingoptimalconditionsforvirusreplicationinthehostcellbyinterferingwiththecellularmechanismsofgrowthcontrol(Moran,1993).Itbindstotheunderphosphorylatedformofthe‘pocketproteins’,p130,p107andp110theretinoblas-tomaprotein(pRB),therebyobstructingthefunctionoftheseproteinsasnegativeregulatorsofmembersofthetranscriptionfactorfamilyE2F.ThisleadstothetranscriptionofavarietyofgeneswhoseproductsplayaroleinDNAreplication(DNAsynthesis-andprecursor-producingenzymes(Ogrisetal.,1993b;Mudraketal.,1994)andintheinitiationandpropaga-tionoftheSphase(cyclinsEandA,Schu¨chneretal.,2001).MTantigenisthemajortransformingproteinofPy.Itinteractswithproteinphosphatase2A(PP2A)andseveralproteinsattheinnersurfaceofthecellmembrane,therebyinitiatingsignaltransductionpath-ways,includingantiapoptoticones(GottliebandVillarreal,2001).Therefore,ithasbeensuggestedthatMTmightservetopreventapoptosis.IncaseofSV40,thisismediatedbytheLTantigenthatbindsandinactivatesp53,acapacitylackinginPyLTprotein(Pipas,1992).InconjunctionwithLTantigen,STofpolyomavirusandofSV40areessentialfortheinitiationoftheSphaseinserum-starvedSwiss3T3cells(Ogrisetal.,1992)andhumandiploidﬁbroblasts(Porrasetal.,1999),respectively.STprotein,likeMT,interactswiththecellularproteinphosphatasePP2A(Campbelletal.,1995),replacingtheBsubunitoftheReceived22August2003;revised5February2004;accepted9February2004;Publishedonline3May2004*Correspondence:EWintersberger;E-mail:Erhard.Wintersberger@univie.ac.at3Theseauthorscontributedequallytothiswork4Presentaddress:InstituteofMolecularPathologyOncogene(2004)23,4707–4721&2004NaturePublishingGroupAllrightsreserved0950-9232/04$30.00www.nature.com/onctrimericenzymewithconsequencesforitsactivityandspeciﬁcity.ThisfunctionplaysanimportantroleintheactivationofthecyclinEandcyclinA-speciﬁcproteinkinase,cdk2.STaccomplishesthisbycausingashiftofthecdkinhibitorp27toitsphosphorylatedform,whichisfollowedbyarapiddestructionofp27bytheubiquitin–proteasomesystem(Schu¨chnerandWinters-berger,1999).Therefore,itisnotsurprisingthatSTisalsomandatoryforthetumorigenictransformationofhumandiploidcells(Hahnetal.,1999)togetherwithLTprotein,mutatedRasandtelomerase(Yuetal.,2001;Hahnetal.,2002).Inthiscontext,itishoweverimportanttorememberthatSTantigensfromPyandfromSV40werealsofoundtocontributetothetransactivationofcyclinA(Porrasetal.,1996;Schu¨chneretal.,2001).STproteinfromSV40hadpreviouslybeenfoundtobecapableoftransactivation,buttheearlierworkconcernedviralpromoters(Loekenetal.,1988;BikelandLoeken,1992;Loeken,1992).ItwasthereforeofinteresttoﬁndoutifSTcanmorewidelyinﬂuencethetranscriptionalpotentialofcells.Itisnoteworthythatboth,LTandST,evolvedtointeractwithwidelyusedregulatorsofcellgrowth,thepocketproteinsandPP2A,respectively.Theseinterac-tionsassurethattherequirementsforvirusmulti-plicationcanbeprovidedbutatthesametimemakesitlikelythatavarietyofreactions,notnecessarilylinkedtoSphaseinduction,willalsobederegulatedbytheviralproteinswithunforeseenconsequencesforthecell.InordertoapprehendthepotentialofPyTantigenstoaffectthetranscriptionalprogrammeofmouseﬁbro-blasts,wecarriedoutamicroarrayanalysisongeneexpressioninquiescentcellsintheabsenceandinpresenceoftheviralprotein.WediscoveredthatTantigenscaninduceorinhibittheexpressionofasurprisinglylargenumberofgenes.ExamplesofsuchgeneswerestudiedinmoredetailandtheeffectofSTontheirexpressionwascomparedtothatoftheLTprotein.ResultsanddiscussionMicroarrayanalysisWehavepreviouslyproducedcelllines(onthebasisofmurineSwiss3T3cells)thatcontaintheinformationforPyLTorSTantigenunderthecontrolofthedexamethasone-responsiveMMTVpromoter(Ogrisetal.,1992).Thesecellsdonotproducetheviralproteinifgrownintheabsenceofthehormone.Afteradditionofdexamethasonetoaﬁnalconcentrationof1mmol/l,viralproteinsbecomedetectableafter4handreachhighlevelsafterabout8h;levelsofTantigenremainhighupto48hafterhormoneaddition.Thelevelofviralproteinreachedundertheseconditionsappearstocorrespondapproximatelytothatproducedininfectedcells.Lowerconcentrationsofdexamethasoneleadtolessviralprotein,whichincaseofLTsufﬁcesfortransactivationbutisinsufﬁcienttoallowthereplicationofaplasmidcarryingaviraloriginofreplication(Ogrisetal.,1993a).Fromthisresultwecanexcludethatourcellsproducelevelsofviralproteinthatarefarbeyondthoseachievedinvirusinfection.Thiscellsystemenabledustostudygeneexpressionwithinthesameserum-starved,quies-centcellsintheabsenceorinpresenceofTantigen.WeusedamousecDNAmicroarraycontainingabout17000cDNAstosearchforgeneswhoseexpressionisalteredbyPySTandPyLT.Cellsweremadequiescentbyserumstarvationfor72handtheculturewasthendividedintotwoequalparts.OnewasusedtoisolateRNAfromnormalquiescentcellskeptintheabsenceofTantigen,thesecondonereceiveddexamethasoneto1mmol/ltoinducetheviralproteinandRNAwasextracted28hlater.ThistimepointwaschosenbecauseearlierworkhadshownthatitcorrespondstotheonsetoftheSphaseincellsexpressingSTandLTproteinstogether(Ogrisetal.,1992).Tantigenexpressionwasdeterminedpriortoandafterhormoneadditioninordertoassuretheexpectedabsence(beforehormonetreat-ment)andpresence(afterhormonetreatment)ofviralprotein(Figure1).Swiss3T3cellscontainingnoviralinformationservedasacontrolforeffectsofdexa-methasonethatwerenotduetotheactivityofTantigen.TotalRNAwasusedforthepreparationofcDNAthatwastherebylabelledwithCy3-dUTPorCy5-dUTP,respectively.ThelabelledcDNAswereusedforhybri-dizationinthemicroarrayanalysis.TheexperimentwasFigure1ControlofT-antigenexpression.Cellswerearrestedfor72handthenincubatedinthepresence(þDex)orintheabsence( Dex)ofdexamethasone(1mmol/lﬁnalconcentration).RNAorproteinwasextractedfromthesecellcultures28hafterinductionofTantigen.Serum-starvedSwiss3T3cells(plusorminusdexamethasone)wereusedasanegativecontrolandb-actinservedasaloadingcontrol.RT–PCR(upperpart)wasperformedwithtotalRNAfromcellsexpressing(þDex)ornotexpressing( Dex)LTorSTantigen.Westernblotanalysis(lowerpart)ofproteinextractsusinganantibodyagainsttheN-terminusofPyTantigens.3T3areSwiss3T3cells,LTareSwiss3T3cellsexpressingLTunderthecontroloftheMMTVpromoter,STare3T3cellsexpressingSTunderthecontroloftheMMTVpromoter.LTRb-cellsexpressamutantofLTantigen(E146N)defectiveinbindingpocketproteins;PP2A-cellsexpressamutantofSTprotein(Ins107AL)defectiveinbindingPP2AModiﬁcationofgeneexpressionbyTantigensBKluckyetal4708Oncogenecarriedouttwicewherebycolorinversionwasper-formed.Genes,whoseexpressionwassigniﬁcantlychangedsolelybyadditionofdexamethasoneto3T3cellsintheabsenceofviralprotein,wereeliminatedfromourselection.Geneswereconsideredasregulatedwhenthepresenceoftheviralproteinresultedinatwo-foldorhigherup-ordownregulation.Undertheseconditions,PySTwasobservedtoupregulate281andtorepress242ofthegenesrepresentedbythemicroarray.TheupregulatedgenesarelistedingroupsaccordingtofunctioninTable1;thedownregulatedgenesareshowninTable2.TheresultsofanidenticalmicroarrayanalysiscarriedoutwithcellsexpressingLTantigenareshowninTables3and4.LTexpressionresultedinanupregulationof222genesandadownregulationof157ofthegenesonourarray.Microarraydataoncellsstimulatedbyadditionofserumwerecarriedoutforcomparison.Here,thetimepointchosenwas18h,whichaccordingtoFACSanalysiscorrespondstotheonsetoftheSphaseinserumstimulatedcells,andhenceapproximatesthe28hpointinquiescentcellsexpressingTantigens.Atthistime,serumadditioninducedtheexpressionof643genesandrepressed537genesonourarray.(Thedataareavailableonrequest).SeveralgenesinducedorrepressedbySTandLTwereselectedforconﬁrmationandextensionofthemicroarraydatabydetailedanalysis.Weﬁrstusedsemiquantitativereversetranscription–polymerasechainreactions(RT–PCR)orimmunoblottingifantibodyagainsttheproteinwasavailabletoconﬁrmtheeffectsoftheviralproteinsusingthe28htimepoint.Consideringthatthistimepointmaynotalwaysrevealtheoptimalinductionorrepressionaccomplishedbytheviralprotein,wethencarriedoutreal-timePCRreactionsonRNAisolated8,18and28hafterinductionoftheviralprotein.Theseseriesofreactionswerecarriedoutwithcellsexpressingwild-typeLTorSTproteinaswellastheLTmutantlackinganinteractionwithpocketproteinsandanSTmutantdefectiveinbindingPP2A.Furthermore,theeffectofdexamethasoneonarrestedSwiss3T3cellsnotcarryinginformationforviralproteinwasalsodeter-mined8,18and28hafteradditionofhormone.Forreasonsofclarity,weshowonlythosedataforthemutantsthatcorrespondtothetimepointswhereoptimaleffectswereattainedwiththewild-typeproteinsandweshowonlythelongest,thatis,the28htimepointfor3T3cellstreatedwithdexamethasone.Moreover,fortwoupregulatedgenes,namelythosecodingforMCM6andMCM7,promoter-luciferaseconstructswerepro-ducedandpromoteractivationwasstudiedaftertransientco-transfectionwithTantigen.ConﬁrmationofmicroarraydataforselectedgenesGenesupregulatedbyviralproteinsFromthegroupsdepictedinTables1and2,weﬁrstselectedexamplesofgeneswhoseproductsareinvolvedintheprogressionoftheG1phaseofthecellcycleandthosethathaveafunctionduringtheSphaseforfurtheranalysis.Thisselectionincludedgeneswhoseexpressionwasderegu-latedtodifferentdegreesbytheviralprotein.Usinginadditiontothewildtype,amutantofSTunabletointeractwithPP2A,itwasobservedthatthismutationaffectstheactivityofSTonallofthegenesexamined,albeittoavariabledegree,dependingonthegeneexamined.Forinstance,whiletheinductionofcyclinD1andthatofc-mycisreducedby80–100%iftheinteractionsiteforPP2Awasmutated,thetransactiva-tionofmcm6andmcm7ismuchlessdependentonaninteractionwithPP2A.Inthiscase,thePP2A-mutantexhibited40%ormoreoftheactivityofthewild-typeST.ItislikelythatatleastthatpartofthecapacitiesofSTthatdoesdependonaninteractionwithPP2Ainﬂuencespromoteractivityindirectly,byderegulatingsignaltransductionpathways(Sonntagetal.,1993;Frostetal.,1994)orbycausingamoredirectchangeinthephosphorylationstatusoftranscriptionalregulators.ThesituationisquitesimilarinthecaseofthedependenceofLTfunctionsonanintactbindingsiteforpocketproteinsexceptthatinthiscasesomeofthegeneschosenwerederegulatedcompletelyindependentofaninteractionofLTwithpocketproteins.ItshouldbepointedoutthatinallexperimentsweusedoneandthesamecelllinesharboringthemutatedversionsofeitherSTorLT.Thevariabilityoftheeffectofthemutationsthereforecannotbeattributedtodifferencesinthecelllinesused.Rather,itindicatesthatSTaswellasLTcantransactivateorrepresscertaingenesbyamechanismindependentofaninteractionwithPP2Aorpocketproteins,respectively.TheseobservationsonindividualgenesagreewellwiththedataobtainedonmicroarrayanalysiscarriedoutwiththePP2AmutantofSTandthepocketproteinmutantofLT,respectively(availableonrequest).Thesedatarevealednotonlyareducedeffectondiversgenesthatareup-ordown-regulatedbytheviralproteins,buttheyinadditiondisclosedgenesthatarederegulatedonlyifthemajorinteractionofLTorSTwaseliminatedbymutation.WhilenothingisknownofpotentialinteractionsofSTwithcellularpartnersotherthanPP2AandchaperonesofthednaKtype,interactionsinadditiontothoseinvolvingpocketproteinsandchaperonesareknownforLT.Forinstance,SV40LTwasreportedtointeractwithcomponentsofthegeneraltranscriptionmachinery(Damaniaetal.,1998).AlthoughsuchaninteractionwasnotsofarshownorlookedforinPyLTantigen,thefunctionalsimilaritybetweenSV40andpolyomaLTsuggeststhatitmaywellexist.Ifso,itislikelytocontributetothetransactivatingcapacityofthisviralprotein.Furthermore,LTproteinsofbothSV40andpolyomaviruswerepreviouslyshowntobindtheco-activatorproteinCPB/p300(Eckneretal.,1996;NemethovaandWintersberger,1999),whichagainmayinﬂuencegeneexpressionindependentofaninteractionwithpocketproteins.WhilethecyclinsEandAwerefoundearliertobetransactivatedbyLTandST,thisstudyincludescyclinD1asafurthertargetforSTantigen.RT–PCRandreal-timePCR(Figure2)supportthedataobtainedinthemicroarrayanalysis.ThisresultisinaccordwithareportonSV40STprotein,whichwasalsoobservedtoinducecyclinD1expressioninamannerdependentonModiﬁcationofgeneexpressionbyTantigensBKluckyetal4709OncogeneTable1Genesinducedtwo-foldorhigherbyPysmallT-antigenincDNAmicroarrayGenBankClonedescriptionFoldinductionCellcycleregulatorsandDNAsynthesisgenesAI850048CyclinD12.53AI323675PCTAIRE-motifproteinkinase32.02AI840227Minichromosomemaintenancedeﬁcient7(S.cerevisiae)2.01AI854509Minichromosomemaintenancedeﬁcient6(S.cerevisiae)2.02AI849847Proliferatingcellnuclearantigen2.06AI840542RAD21homolog(S.pombe)2.30Oncogenes,tumorsuppressors,stressandapoptosisgenesAI849916Polymyositis/sclerodermaautoantigen14.54AI841358Heatshock70kDaprotein84.40AI850962TransducerofERBB2,24.39AI845078Smallproteineffector1ofCdc424.04AI528587c-merproto-oncogene3.88AI841755Aplysiaras-relatedhomologB(RhoB)3.86AI842320Neuroﬁbromatosis23.37AI844365Bcl2-like2.90AI836493Myelocytomatosisoncogene(c-myc)2.88AI848789B-cellCLL/lymphoma7C2.70AI838486Heatshockprotein,105kDa2.67AI852670Cerebralcavernousmalformations12.39AI836313Heatshockprotein,86kDa12.18AI844691Tumordifferentiallyexpressed12.16AI845042AnnexinA52.13AI842572Rho,GDPdissociationinhibitor(GDI)beta2.12AI528760ColdshockdomainproteinA2.09Genesinvolvedintranscription,translation,immuneresponseanddegradationpathwayAI841501RibosomalproteinS3a3.86AI845964RibosomalproteinS173.36AI853670Leucinezipperprotein13.24AI464459CytokineinducibleSH2-containingprotein23.19AI835282Eucaryotictranslationelongationfactor1beta23.14AI662267Homeodomaininteractingproteinkinase13.13AI845514ATP-bindingcassette,subfamilyA(ABC1),member12.99AI843614Retinolbindingprotein1,cellular2.90AI840032Translationallyregulatedtranscript(21kDa)2.86AI836784Splicingfactor,arginine/serine-rich5(SRp40,HRS)2.82AI836484RNAbindingmotifprotein,Xchromosome2.78AI835939Eucaryotictranslationelongationfactor1alpha12.57AI852094Polybindingprotein,cytoplasmic12.47AI323595B-cellreceptor-associatedprotein312.39AI849117RibosomalproteinL10A2.37AI413443Ubiquitin-conjugatingenzymeE2G22.36AI850137Nucleolin2.29AI841821Ia-associatedinvariantchain2.26AI844203Eucaryoticelongationfactor-2kinase2.21AI851284Interferon-relateddevelopmentalregulator12.19AI850329Highmobilitygroupbox12.18AI839283InhibitorofDNAbinding32.10AI852144Pre-B-cellcolony-enhancingfactor2.08AI852911Kruppel-likefactor152.07AI847690RibosomalproteinS4,X-linked2.06AI850396Nuclearfactor,erythroidderived2,-like12.04AI323569Zinc-ﬁngerhomeobox1a2.03AI836652UbiquitinB2.01Cellsurface,signaltransduction,cytoskeletonandmetabolismproteinscontinuationAI853846Fattyacidbindingprotein5,epidermal4.47AI847285Mitogen-activatedproteinkinasekinasekinase64.41AI845630Tyrosine3-monooxygenase/tryptophan5-monooxygenaseactivationprotein4.36AI836976Glutamatedehydrogenase4.06AI848830Isocitratedehydrogenase2(NADP+),mitochondrial3.97AI835559Thymopoietin3.65AI847745Phosphataseandtensinhomolog3.51AI839581Porcupinehomolog(Drosophila)3.46AI427514Metallothionein13.33AI841644Guaninenucleotidebindingprotein,beta2,relatedsequence13.24AI838964Syntrophin,acidic13.16AI845452Procollagen,typeXI,alpha23.10ModiﬁcationofgeneexpressionbyTantigensBKluckyetal4710OncogeneTable1(continued)GenBankClonedescriptionFoldinductionCellsurface,signaltransduction,cytoskeletonandmetabolismproteinscontinuationAI849502Amyloidbeta(A4)precursor-likeprotein23.08AI836893Lamininreceptor1(67kDa,ribosomalproteinSA)3.08AI853686Glutamatereceptor,ionotropic,AMPA3(alpha3)3.01AI851272Dualspeciﬁcityphosphatase143.00AI839368Carbonylreductase12.97AI845051Beta-spectrin32.93AI845046Trans-Golginetworkprotein12.93AI851776MyosinIc2.90AI840685Lysosomalmembraneglycoprotein12.90AI847962Transmembrane4superfamilymember22.86AI844634Actin,alpha1,skeletalmuscle2.82AI849308Glutaredoxin1(thioltransferase)2.80AI840364Neuralprecursorcellexpressed,developmentallydownregulatedgene4b2.77AI840657Silica-inducedgene812.75AI844844Receptor(calcitonin)activitymodifyingprotein22.75AI385536Cadherin22.71AI841041Huntingtin-associatedprotein12.64AI854038SH3domainprotein52.61AI836919Crystallin,alphaB2.60AI845273Aspartate-beta-hydroxylase2.59AI846934Lipin12.59AI849894Guaninenucleotidebindingprotein,beta22.59AI847216Cytochromecoxidase,subunitVIa,polypeptide12.57AI847216Nucleophosmin12.57AI844017Aldo-ketoreductasefamily1,memberB3(aldosereductase)2.53AI847207Microspheruleprotein12.52AI843247Dopaminereceptor42.48AI450702ATPase,Na+/K+transporting,beta3polypeptide2.47AI850974Phosphatidylinositol3-kinase,reg.subunit,polypeptide1(p85alpha)2.46AI854176Muscleblind-like(Drosophila)2.42AI841957Gamma-aminobutyricacid(GABA-A)receptor,subunitalpha62.39AI838730Popeye32.37AI851805Platelet-derivedgrowthfactor,Cpolypeptide2.31AI325068Solutecarrierfamily25(mitoch.carrier;adeninenttranslocator),member52.29AI839744Growtharrestspeciﬁc12.28AI851616PyruvatedehydrogenaseE1alphasubunit2.27AI851427Proteinkinase,cAMP-dependentregulatory,typeIIbeta2.26AI843104Fibroblastgrowthfactorinducible142.26AI854743Adenylatekinase3alphalike2.25AI853659Cut(Drosophila)-like12.25AI851564Acetyl-CoenzymeAdehydrogenase,long-chain2.24AI843768Amyloidbeta(A4)precursorprotein2.23AI427644Epidermalgrowthfactorreceptor2.23AI836347Tubulinalpha22.22AI852430Peripheralmyelinprotein,22kDa2.21AI841311Microtubule-associatedprotein1lightchain32.21AI414231Villin2.19AI842086Basigin2.18AI840757Tubulinalpha12.18AI840676Beta-spectrin2,nonerythrocytic2.18AI853695Integrin-associatedprotein2.18AI852827Catechol-O-methyltransferase2.14AI847067Neuralprecursorcellexpressed,developmentallydownregulatedgene4a2.14AI835817Thymusexpressedacidicprotein2.13AI849996Latexin2.12AI844775Thioredoxin2.10AI848212Fumarylacetoacetatehydrolase2.10AI844421Tissueinhibitorofmetalloproteinase22.10AI841941Tetratricopeptiderepeatdomain2.10AI845316Stearoyl-coenzymeAdesaturase22.07AI834834Gprotein-coupledreceptor,familyC,group5,memberB2.03AI843656ProteinkinaseC,delta2.02AI853012CystatinB2.02AI850110WDrepeatdomain12.00AI839138Upregulatedby1,25-dihydroxyvitaminD-32.00152ESTswithunknownfunctionModiﬁcationofgeneexpressionbyTantigensBKluckyetal4711OncogeneTable2Genesrepressedtwo-foldorhigherbyPysmallT-antigenincDNAmicroarrayGenBankClonedescriptionFoldrepressionCellcycleregulatorsandDNAsynthesisgenesAI323295DNA-damageinducibletranscript32.17Oncogenes,tumorsuppressors,stressandapoptosisgenesAI838312Decorin9.13AI851574Melanomaantigen,familyD,24.70AI450810Promyelocyticleukemia3.81AI842716CytochromeP450,512.58AI842612Melanocyteproliferatinggene12.04Genesinvolvedintranscription,translation,immuneresponseanddegradationpathwayAI854552Interferon-inducedproteinwithtetratricopeptiderepeats39.28AI854626Lymphocyteantigen6complex6.19AI838634Ubiquitin-speciﬁcprotease255.10AI449282Interferon-inducibleGTPase4.22AI848402Histocompatibility2,Tregionlocus103.34AI836367TAPbindingprotein2.93AI836233Proteasome(prosome,macropain)subunit,betatype102.86AI838322SmallinduciblecytokineA21a(leucine)2.81AI451137Interferonactivatedgene2032.77AI528519Complementcomponent32.70AI528713Interferongammainducibleprotein,47kDa2.64AI428543Zinc-ﬁngerprotein2612.63AI447752Nuclearreceptorsubfamily3,groupC,member12.60AI853915Guaninenucleotidebindingprotein,beta42.58AI851597Eucaryotictranslationelongationfactor1alpha22.48AI429495ATP-dependentinterferonresponsive2.43AI841665Matrixmetalloproteinase14(membrane-inserted)2.41AI852236Histocompatibility2,Dregionlocus12.36AI853714CathepsinB2.30AI853077Calpastatin2.27AI852036Nuclearreceptor-bindingSET-domainprotein12.20AI326933Ubiquitin-conjugatingenzyme82.17AI448932T-box22.14AI840449SmallnuclearribonucleoproteinD12.14AI852351MitochondrialribosomalproteinL112.14AI528521SpecialAT-richsequencebindingprotein12.05AI852357Eucaryotictranslationinitiationfactor4A22.01Cellsurface,signaltransduction,cytoskeletonandmetabolismproteinsGenBankClonedescriptionFoldRepressionAI842984TenascinC9.66AI661287Transforminggrowthfactor,betainduced,68kDa9.04AI854636Earlygrowthresponse16.81AI326106Guanylatenucleotidebindingprotein26.53AI449282Frizzledhomolog9(Drosophila)5.16AI835595Secretedphosphoprotein14.64AI836468Myristoylatedalanine-richproteinkinaseCsubstrate4.57AI844874Procollagen,typeI,alpha14.17AI850915UDP-glucoseceramideglucosyltransferase-like3.90AI836323Sortilin13.85AI848233sproutyhomolog2(Drosophila)3.84AI448916Slithomolog2(Drosophila)3.79AI842053PeptidylprolylisomeraseC-associatedprotein3.64AI847324Insulinreceptorsubstrate13.61AI449540Signaltransducerandactivatoroftranscription13.53AI853346ThymidylatekinasefamilyLPS-induciblemember3.52AI528734Stromalcellderivedfactor13.50AI450263Lectin,galactosebinding,soluble63.27AI836324CarboxypeptidaseE3.20AI465143Lectin,galactosebinding,soluble13.13AI846654Heparansulfate6-O-sulfotransferase23.08AI413932Emerin3.03AI840949Argininosuccinatesynthetase12.98AI325230Dopachrometautomerase2.79AI837432Solutecarrierfamily7(cationic,transporter),member102.74AI838652Procollagen,typeI,alpha22.71AI839177Procollagen,typeXII,alpha12.66AI844075LIMonly42.64AI385730Procollagen,typeXI,alpha12.40ModiﬁcationofgeneexpressionbyTantigensBKluckyetal4712OncogeneaninteractionwithPP2A(Watanabeetal.,1996).Immunoblotting(notshown)indicatesthatcyclinD1proteinwashighinarrestedcellsanddidnotchangesigniﬁcantlyafterTantigeninductionorserumaddi-tion,suggestingthattheproteinisratherstableinSwiss3T3cells.PyLTantigentransactivatedcyclinD1aboutsix-fold,whilethecorrespondingproteinfromSV40wasreportedtoinhibitcyclinD1expression(Lukasetal.,1994).C-mycisstronglytransactivatedbyST(Figure2),whileLThadonlyaminoreffect.Thestrongtransactivationofc-mycbySTmaybeparticularlyrelevantasc-mycmodulatestheexpressionofagreatvarietyofgenes(Colleretal.,2000;MenssenandHermeking,2002;Fernandezetal.,2003).ThisraisesthepossibilitythatSTchangestheexpressionofsomegenesthroughitseffectonc-myc.Infact,amongthegenesobservedasregulatedbyc-mycinallthreestudiesreferredtoabovearethosecodingforribosomalproteins,heatshockproteinsandnucleolin,whicharealsofoundtobeupregulatedbySTinouranalysis.ManyproteinsinvolvedinDNAsynthesisandprecursorproductionwerepreviouslyshowntobetransactivatedbyPyLT(Ogrisetal.,1993b;Mudraketal.,1994).ThisincludesPCNA,whichinthisstudywasalsofoundtobeinducedbySTprotein.Thelistalsocontainstwoimportantproteinsofcellularprereplica-tioncomplexes,MCM6andMCM7.BothoftheseproteinsweretransactivatedbyLTandSTantigens(Figure3).GenescodingforMCMproteinsareregulatedbyE2F(Tsurugaetal.,1997;Ohtanietal.,1999);theirinductionbyLTandSTmaythereforeresemblethatoftheotherE2F-controlledgenesreportedpreviously.Wehaveisolatedthemurinepromotersforthemcm6andthemcm7geneandcreatedpromoter-luciferaseconstructsfortransienttransfectionstogetherwithLTorSTortheirmutants(Figure4).Theresultsoftheseassaysconﬁrmedthoseobtainedwithreal-timePCRandRT–PCR.Inagree-mentwiththemoredirectfunctionofLTproteinonE2Fregulatedpromoters,transactivationofthesepromotersintransienttransfectionassaysisconsistentlystrongerbyLTthanbySTantigen.Consideringtheco-ordinatedregulationofallsixMCMproteins(MCM2–7)duringserumstimulationofREF52cells(Ohtanietal.,1999),itislikelythatalsotheotherMCMproteinsaretransactivatedbybothTantigens.SeveraloncogenesandtumorsuppressorsexhibitalteredexpressioninthepresenceofLTorST.AnexampleisthetumorsuppressorproteinTable2(continued)GenBankClonedescriptionFoldrepressionAI853169Stearoyl-CoenzymeAdesaturase12.37Cellsurface,signaltransduction,cytoskeletonandmetabolismproteinscontinuationAI835931BrainproteinI32.36AI427643Gliamaturationfactor,gamma2.35NAVpreB2.34AI838326Serine(orcys)proteinaseinhibitor,cladeH(hsp47),member12.26AI836826Glycoprotein382.26AI450121Peroxisomalbiogenesisfactor132.25AI836381Actin-like2.25AI840949Argininosuccinatesynthetase12.22AI847852Proteintyrosinephosphatase,receptor-type,M2.21AI448959Fibulin22.21AI853088Follistatin-like2.18AI853451Proteinkinase,cAMPdependent,catalytic,alpha2.15AI844939Openreadingframe122.15AI843816Exostoses(multiple)12.13AI847131Ankyrinrepeathookedtozinc-ﬁngermotif2.11AI449353Phosphoinositide-3-kinase,catalytic,gammapolypeptide2.10AI450719Single-strandselectivemonofunctionaluracilDNAglycosylase2.09AI450103Serineproteaseinhibitor62.09AI854719ProstaglandinEsynthase2.07AI854572Coatomerproteincomplex,subunitgamma12.07AI852039Elongationofv.l.chainfattyacids(FEN1/Elo2,SUR4/Elo3,yeast)-like12.07AI893625Syndecan22.07AI844799Phosphatidylinositolmembrane-associated2.04AI847778N-acetylgalactosaminidase,alpha2.04AI846240Phosphatidylinositol3kinase,regulatorysubunit,polypeptide4,p1502.03AI893646Proteintyrosinephosphatase,receptortype,K2.03AI840537Cadherin112.02AI843939Adenylatekinase12.02AI323769Ceruloplasmin2.02AI853322Proteintyrosinephosphatase,receptortype,S2.01AI842633HumanimmunodeﬁciencyvirustypeIenhancer-bindingprotein12.00148ESTswithunknownfunctionModiﬁcationofgeneexpressionbyTantigensBKluckyetal4713OncogeneTable3Genesinducedtwo-foldorhigherbyPylargeT-antigenincDNAmicroarrayGenBankClonedescriptionFoldinductionCellcycleregulatorsandDNAsynthesisgenesAI840227Minichromosomemaintenancedeﬁcient7(S.cerevisiae)4.00AI854509Minichromosomemaintenancedeﬁcient6(S.cerevisiae)3.56AI894115CyclinD13.48AI849847Proliferatingcellnuclearantigen3.03AI837745Telomerasebindingprotein,p232.72AI849171Polymerase(DNAdirected),delta2,regulatorysubunit(50kDa)2.58AI840088ReplicationproteinA22.44AI846943Cyclin-dependentkinase42.32AI844106Thymidylatekinase2.32AI838819MYBbindingprotein(P160)1a2.08Oncogenes,tumorsuppressors,stressandapoptosisgenesAI846348Hypoxiainducedgene12.93AI854800CytochromeP450,512.87AI844365Bcl2-like2.66AI836493Myelocytomatosisoncogene(c-myc)2.61AI840074Ras-GTPase-activatingprotein(GAPo1204)SH3-domain-bindingprotein22.57AI528760ColdshockdomainproteinA2.53AI838255Chaperoninsubunit6a(zeta)2.43AI429136Transforming,acidiccoiled-coilcontainingprotein32.36AI837834t-complexprotein12.25AI841137Differentiallyexpressedinbraintumors2.09AI841116Peroxiredoxin22.07AI841173Rhointeractingprotein32.06AI842297RAS-relatedC3botulinumsubstrate12.04AI854010RAS-like,family2,locus92.04AI842320neuroﬁbromatosis22.01Genesinvolvedintranscription,translation,immuneresponseanddegradationpathwayAI845040Translationallyregulatedtranscript(21kDa)3.00AI836520Histonegenecomplex22.75AI840449SmallnuclearribonucleoproteinD12.74AI836982Proteaseome(prosome,macropain)28subunit,32.56AI849860Stem-loopbindingprotein2.53AI838842RNAbindingmotifprotein32.40AI839283InhibitorofDNAbinding32.29AI843304CCAAT/enhancerbindingprotein(C/EBP),alpha2.20AI835853H2Ahistonefamily,memberZ2.12AI326849Transcriptionalregulatorprotein2.11AI464523T-box52.07AI835911HeterogeneousnuclearribonucleoproteinK2.05AI853852RibosomalproteinS182.02AI847332Interferonalpharesponsivegene,15kDa2.01Cellsurface,signaltransduction,andcytoskeletonandmetabolismproteinsAI834834Gprotein-coupledreceptor,familyC,group5,memberB5.82AI839335Adducin3(gamma)4.90AI852527Importinbeta3.64AI841020Phosphoglyceratekinase13.56AI849502Amyloidbeta(A4)precursor-likeprotein23.54AI851778Connectivetissuegrowthfactor3.44AI849308Glutaredoxin1(thioltransferase)3.43AI840757Tubulinalpha13.31AI326287Tubulinalpha83.26AI528531PyruvatedehydrogenaseE1alphasubunit3.16AI836347Tubulinalpha23.11AI840025Secretedacidiccysteine-richglycoprotein2.90AI850162Laminin,gamma12.85AI427514Metallothionein12.83AI836976Glutamatedehydrogenase2.83AI840604Tubulinalpha42.83AI854035Kelch-likeECH-associatedprotein12.82AI847285Mitogen-activatedproteinkinaseKinasekinase62.75AI835559Thymopoietin2.75AI841394Phosphoglyceratemutase12.70AI841966Proteinkinase,AMP-activated,gamma1noncatalyticsubunit2.61AI837206Prothymosinalpha2.57ModiﬁcationofgeneexpressionbyTantigensBKluckyetal4714Oncogeneneuroﬁbromatosis2(NF2)(LutchmanandRouleau,1995).Figure5showstheinductionofNF2byLTaswellasST,whichisdependentontheinteractionswithpocketproteinsandPP2A,respectively.TheNF2promoterhassomesimilaritytothecyclinApromoterwithwhichitsharesbindingsitesfortranscriptionfactorsSP1,E2FandNF-Y(Kinoetal.,2001).ThismightsuggestthatitstransactivationbythetwoTantigensmayfollowsimilarmechanisms.Surprisingly,however,andinvastcontrasttocyclinA,serumadditiondramaticallyreducedNF2expression,conﬁrm-ingtheresultsofthemicroarrayanalysisofserum-stimulatedcells.ThesamewasobservedwiththegenecodingfortheGproteincoupledreceptor(GPCR)(Figure6).Thisgene,togetherwiththeonecodingformyosin,belongstothelargegroupofgenesinthetableslistedundergenescodingforsignaltransducers,cellsurfaceproteinsandcytoskeletalproteins.BothGPCRandmyosinarealsotargetsoftheLTprotein(Figure6).GenesdownregulatedbyviralproteinsAmongthegenesthatarestronglyrepressedbySTarethosecodingfordecorinandcadherin11(Figure7).Bothoftheseproteinsarelocatedinthecellsurfaceandexhibitvariouscell-type-speciﬁceffectsduringdifferentiationandcellgrowth.Forinstance,cadherin11isupregu-latedduringmyoblasticorosteogenicdifferentiationofC3H10T1/2andC2C12.Incontrast,adipogenicdiffer-entiationofthesecellsaswellasof3T3-L1cellscausesadecreaseofcadherinexpression(Shinetal.,2000).Inhumanosteoblasts,dexamethasonewasreportedtoinhibitcadherin11expression(Lecandaetal.,2000).WefoundthatalsoinSwiss3T3cellsdexamethasoneTable3(continued)GenBankClonedescriptionFoldinductionCellsurface,signaltransduction,andcytoskeletonandmetabolismproteinscontinuationAI850901Parvin,alpha2.56AI851776MyosinIc2.50AI839899RegulatoryfactorX-associatedankyrin-containingprotein2.46AI836844Calmodulin12.46AI450702ATPase,Na+/K+transporting,beta3polypeptide2.45AI894247Tubulin,beta52.44AI849335NeighborofPuncE112.43AI844634Actin,alpha1,skeletalmuscle2.35AI448908Chlorideintracellularchannel4(mitochondrial)2.31AI851107Peripheralmyelinprotein,22kDa2.30AI845765Sterol-C5-desaturasehomolog(S.cerevisae)2.29AI843707TreacherCollinsFranceschettisyndrome1,homolog2.27AI836137Pyruvatekinase32.27AI842299LamininB1subunit12.23AI839138Upregulatedby1,25-dihydroxyvitaminD-32.21AI414231Villin2.21AI850309CoagulationfactorII(thrombin)receptor2.20AI842934Dystroglycan12.20AI849775Osteoblastspeciﬁcfactor2(fasciclinI-like)2.17AI850206Paralemmin2.15AI447993Butyrophilin-like22.14AI854752Radixin2.14AI849985Solutecarrierfamily12,member22.12AI842656Lurchertranscript12.11AI836968Alphaactinin42.11AI847067Neuralprecursorcellexpressed,developmentallydownregulatedgene4a2.09AI853464Pantophysin2.09AI845824sorbitoldehydrogenase12.08AI838504Enhancerofrudimentaryhomolog(Drosophila)2.08AI847962Transmembrane4superfamilymember22.08AI842586TroponinT2,cardiac2.07AI844511STIP1homologyandU-Boxcontainingprotein12.06AI841014Guaninenucleotidebindingprotein,alphastimulating2.06AI836349Junctophilin32.06AI841283Novelnuclearprotein12.05AI662267Homeodomaininteractingproteinkinase12.04AI385637Frizzledhomolog8(Drosophila)2.04AI836694ATPsynthase,H+transporting,mitroch.F1complex,gammapolypept.12.03AI843739FK506bindingprotein12-rapamycinassociatedprotein12.02AI841010Adeninephosphoribosyltransferase2.02AI853846Fattyacidbindingprotein5,epidermal2.02AI838959Actin,alpha2,smoothmuscle,aorta2.01119ESTswithunknownfunctionModiﬁcationofgeneexpressionbyTantigensBKluckyetal4715OncogeneTable4Genesrepressedtwo-foldorhigherbyPylargeT-antigenincDNAmicroarrayGenBankClonedescriptionFoldrepressionCellcycleregulatorsandDNAsynthesisgenesAI840919DNA-damageinducibletranscript32.45AI848752topoisomerase(DNA)IIbeta2.27Oncogenes,tumorsuppressors,stressandapoptosisgenesAI846778Decorin3.86AI852541Tumorrejectionantigengp962.46AI450853Cerebralcavernousmalformations12.45AI843677Erbb2interactingprotein2.40AI528704Rho-associatedcoiled-coilformingkinase12.26AI853115RhoGTPaseactivatingprotein52.21AI834803DnaJ(Hsp40)homolog,subfamilyB,member122.21AI846385RAB23,memberRASoncogenefamily2.06AI848314Naturalkillertumorrecognitionsequence2.05Genesinvolvedintranscription,translation,immuneresponseanddegradationpathwayAI854552Interferon-inducedproteinwithtetratricopeptiderepeats36.57AI852028Ubiquitinspeciﬁcprotease9,Xchromosome3.25AI850966TranscriptionelongationfactorA(SII)12.62AI447752Nuclearreceptorsubfamily3,groupC,member12.48AI836309Eucaryotictranslationinitiationfactor32.47AI528713Interferongammainducibleprotein,47kDa2.46AI846176Histocompatibility2,Tregionlocus102.28AI448195Trans-actingtranscriptionfactor32.26AI449282Interferon-inducibleGTPase2.24AI853077Calpastatin2.20AI841432HeterogeneousnuclearribonucleoproteinH12.05AI449004HeterogeneousnuclearribonucleoproteinA2/B12.00AI845529RibonucleaseP12.00Cellsurface,signaltransduction,andcytoskeletonandmetabolismproteinsAI847805Secretedphosphoprotein15.29AI661287Transforminggrowthfactor,betainduced,68kDa4.94AI450263Lectin,galactosebinding,soluble63.28AI528637Beta-2microglobulin3.22AI326106Guanylatenucleotidebindingprotein23.19AI842984TenascinC3.16AI893625Syndecan23.04AI840134Myristoylatedalanine-richproteinkinaseCsubstrate2.99AI842819Branchedchainaminotransferase1,cytosolic2.93AI850620Matrin32.81AI528734Stromalcellderivedfactor12.73AI838226Glycinetransporter12.45AI843323Latenttransforminggrowthfactorbetabindingprotein22.42AI854587Prolinedehydrogenase2.41AI426812Imprintedandancient2.39AI839302Clusterin2.34AI327322Chondroitinsulfateproteoglycan62.31AI850263Lysosomalmembraneglycoprotein22.31AI323554Crystallin,zeta2.30AI427643Gliamaturationfactor,gamma2.29AI851370Tetratricopeptiderepeatdomain2.27AI848700Kinesinfamilymember5B2.26AI662153Kidneyandrogenregulatedprotein2.21AI854636Earlygrowthresponse12.21AI528639Adenylatecyclase72.18AI852712Gapjunctionmembranechannelproteinalpha12.15AI846016Developmentanddifferentiationenhancing2.14AI838700LymphoidnuclearproteinrelatedtoAF4-like2.13AI839465Neuropilin2.11AI323769Ceruloplasmin2.10AI844503GTPcyclohydrolase12.09AI835169Potassiumvoltage-gatedchannel,subfamilyQ,member22.09AI853162Shortstaturehomeobox22.08AI450790Sideroﬂexin12.08Cellsurface,signaltransduction,andcytoskeletonandmetabolismproteinscontinuationAI840537Cadherin112.01AI326787Lipoproteinlipase2.01AI838607Thrombospondin12.0196ESTswithunknownfunctionModiﬁcationofgeneexpressionbyTantigensBKluckyetal4716Oncogenecausedsomedecreaseofcadherin11expression,buttheeffectofSTproteinwasbyfarstronger(Figure7),excludingthatthiseffectissolelyduetotheadditionofdexamethasonetoourcells.Decorinwasfoundtobedownregulatedinsometumors(forreviews,seeforinstanceSta¨nderetal.,1999;KresseandScho¨nherr,2001).ItbindstoTGF-bandinhibitsitsactivity.Ontheotherhand,itwasfoundtoupregulatep21expressioninsometumorcells.ItsstrongdownregulationinourSTexpressingcellscouldthuscontributetothegrowth-inducingpotentialoftheviralprotein.Interestingly,downregulationofbothofthesegenesbyLTwascompletelyindependentofaninteractionwithpocketproteins.Finally,onegroupofgeneswhoseexpressionnotunexpectedlyisaffectedbyLTandSTinvolvesgenesfortranscriptionfactorsandtranslationalregulators,im-muneresponsegenesandgeneswhoseproductsfunctionindegradationpathways.WhilecomponentsofthetranscriptionmachineryarefrequentlyupregulatedbyTantigens(seeforinstanceFelton-EdkinsandWhite,2002),manygenesoftheimmuneresponseherewerefoundtobedownregulated,thuscreatingconditionsthatwouldallowthevirustoescapethecellularimmuneresponse.Insummary,thismicroarrayanalysisdisclosedanastonishinglylargenumberofgenesthatareup-ordownregulatedaftertheexpressionofPyTantigensinquiescentcells.Allselectedgeneschosenfordocumen-tationoftheirderegulationconﬁrmedthedataobtainedbythemicroarrayanalysis.ConsideringthatthelistinTables1–4stillmissesgenesknowntocodeforSphase-Figure2InductionofcyclinD1andc-myc.Inthisandinallfurtherﬁgures,withtheexceptionofFigure4,cellsweretreatedasinFigure1.Real-timePCRandsemiquantitativeRT–PCRwereperformedwithspeciﬁcprimersasdescribedinMaterialsandmethodsFigure3InductionofMCM6andMCM7.TheprimersandantibodiesusedaredescribedinMaterialsandmethodsModiﬁcationofgeneexpressionbyTantigensBKluckyetal4717Oncogenespeciﬁcenzymesandproteinsthatwerealreadyshownorareexpectedtobetransactivatedbyviralproteins,thetotalnumberofgenesinﬂuencedintheirexpressionbyPyTantigensmaybeevenlarger.Obviously,theselectionpressureontheevolutionofPywastocreateoptimalconditionsforvirusreplicationinmanydifferentcelltypes,thatis,drivingthesedifferentcellsfromthequiescentstateintotheSphase.Thismayrequireinterferencewithdifferentmechanismsofgrowthregulationandhencewithabroadspectrumoftranscriptionalcontrolprocesses.OnemayaskwhyitneedsbothLTandSTtodriveefﬁcientlySwiss3T3cellsoutofthequiescentstateintotheSphase(Ogrisetal.,1992),whenSTaloneissuchanefﬁcientderegulatorofgeneexpression.Thereareseveralexplanationsforthis:(i)comparedwithLT,STisweakininducingsomeDNAsynthesis-andprecursor-producingenzymessuchasthymidinekinase(unpublished).(ii)WefoundearlierthatbothLTandSTarerequiredtoinducesufﬁcientlyhighlevelsofcyclinE/cdk2activity(Schu¨chnerandWintersberger,1999).CyclinE/cdk2isessentialforSphaseinductioninmostvertebratecells.(iii)BytargetingPP2A,anenzymethatisinvolvedinmanyFigure4EffectofLTandSTonthemcm6andmcm7promoters.Transientco-transfectionassayswereperformedusingmcm6andmcm7promoter-luciferaseconstructsandLTorSTexpressingplasmids.FordetailsseeMaterialsandmethods.TheequalexpressionofthewildtypeandmutatedviralproteinswasveriﬁedbyimmunoblottingusingapolyclonalantibodydirectedtowardstheLT/STcommonregionattheN-terminioftheviralproteinsFigure5Inductionoftheneuroﬁbromatosisgene2.TheantibodyusedforimmunoblottingwasNF2(sc-331)fromSantaCruzModiﬁcationofgeneexpressionbyTantigensBKluckyetal4718Oncogenecellularregulatoryprocesses,STmaynotonlyaffectreactionsthatfavorSphaseinductionbutalsosomethathinderthisprocessanditmayrequireLTtoneutralizetheseeffects.WedonotwanttoimplythatallofthegenesderegulatedbytheviralTantigensaredirecttargetsoftheseproteins;theexpressionofsomeofthegenesmaybeaffectedbysecondaryreactionstogeneproductsup-ordown-regulatedbytheTantigens.Still,theirderegulationinquiescentcellsdoesdependontheactivityoftheviralproteins.Anexampleisc-myc,whichwefoundtobestronglyupregulatedbySTbutwhichitselfisanimportanttransactivator.Moreover,theproductsofsomeofthegenesderegulatedbyLTorSTmayhavenoroleinSphaseinductionbuttheymaynonethelesscontributetotumorigenesis.Tumorforma-tionwasoftenconsideredtobeanaccidentalreactionfollowingvirusinfection,initiatedbythecompetenceoftheviralproteinstointerferewithgrowthcontrolandapoptosis.However,asPyisreplicatingratherslowly,theformationoftumorsmayhaveevenbeenofevolutionaryadvantageforthevirus,iftumorcellscreatelonger-lastingconditionsfavorableforvirusreplication.MaterialsandmethodsCellcultureandstabletransfectionsSwiss3T3ﬁbroblastsandderivedcelllinesconditionallyexpressingthePyLTorthePySTantigenunderthecontrolofthedexamethasone-inducibleMMTVpromoter(Ogrisetal.,1992)weregrowninDulbecco’smodiﬁedEaglesmediumcontaining10%fetalcalfserum,penicillin(60mg/ml)andstreptomycin(100mg/ml)ina7.5%CO2atmosphere.Whenthecellsreached80%conﬂuency,theywerearrestedbyserumFigure6UpregulationofthegenesfortheGPCRandformyosin.TheoligonucleotidesusedforthePCRreactionsaredescribedinMaterialsandmethodsFigure7Strongrepressionofthetumorsuppressorproteinscadherin11anddecorinbySTandLTantigens.Theantibodyusedintheimmunoblotofcadherin11isdescribedinMaterialsandmethodsModiﬁcationofgeneexpressionbyTantigensBKluckyetal4719Oncogenedeprivation(ﬁnalconcentrationofFCS0.2%)for72h.Thecellsweretheninducedwithdexamethasoneataﬁnalconcentrationof10 6mol/lfor28h.RNAextractionTotalRNAwasisolatedusingTRIzolreagent(LifeTechnol-ogies/GIBCO-BRL)asrecommendedbythesupplier.MicroarraypreparationThemousemicroarraysusedcontainedasetof17000sequenceveriﬁedmousecDNAclonesprintedontopolyly-sine-coatedslides.Priortouse,thearrayswereUV-cross-linked,rehydratedinwatersteamandchemicallyblockedusing1.37gofsuccineanhydride,90mlN-methyl-pyrrolidoneand10mlof0.2MboricacidpH8.0for15min.Afterblocking,theslideswererinsedin0.1%SDSandprehybri-dizedwithprehybridizationbuffercontaining210mlforma-mide,120ml20SSPE,60ml50Denhardts,6mlsalmonspermDNA(10mg/ml),190mlwaterand15ml20%SDSat501Cfor1h.FluorescentprobepreparationIntotal,100mgRNAin17mlwaterwasprimedwith2mloligo-dT12 18-primer(500mg/ml)at651Cfor5min.Reversetranscriptionwasperformedinamixturecontaining8ml5ﬁrst-strandreactionbufferprovidedwithSuperScripttIIRNaseH Reversetranscriptase(InvitrogenLifeTechnolo-gies),4ml100mMdithiothreitol,4mlof10dNTP(5mMdATP,dCTP,dGTPand2mMdTTP),1mlRNasin(40U/mlPromega),2mlSuperScripttIIRNaseH Reversetranscrip-tase(200U/mlInvitrogenLifeTechnologies),4mlofCy3-dUTPorCy5-dUTP(1nM/mlAmershamPharmacia)andincubatedat421Cfor60min,followedbytheadditionofanother1mlSuperScripttIIRNaseH Reversetranscriptaseforanadditional1hincubation.Thereactionwasstoppedbyincubationat941Cfor3min.TheremainingRNAwaseliminatedbyadding2mlRNaseONEt(6U/ml,Promega),5ml10RNaseONEtreactionbufferandincubatingat371Cfor10min.TheCy3-dUTPandCy5-dUTPlabelledprobeswerepooledandprecipitatedwithblockingsolutioncontain-ing3mgpoly(dA)40 60,6mgtRNA,15mgmouseCot1DNA,33ml10mol/lammoniumacetateand330ml96%ethanolat 801Cfor20min.Thepelletwaswashedwith400ml80%ethanol,dissolvedin10.5mlH2Oandthenmixedwith6ml20SSPE,1.5ml50Denhardtssolution,10.5mlformamideand0.75ml20%SDS.Theprobewasdenaturedat941Cfor1minfollowedbyprehybridizationat501Cfor1h.Itwasthenaddedtothemicroarrayslidesandincubatedat501Covernight.DataanalysisAfterthehybridization,theslideswerewashedin1SSC,0.1%SDS,followedbywashingwith0.2SSC,0.1%SDSandﬁnally0.2SSC.AfterdryingbycentrifugationthemicroarrayswerescannedwithaGenePix4060scanner.AnalysiswasperformedusingGenePixPro4.1microarrayinformationmanagementsystem(JMIMS)developedbyVolkerLeidlandGeraldLo¨fﬂer(ResearchInstitutofMolecularPathology,Vienna).RT–PCRIntotal,10mgRNAwasreversetranscribedtoﬁrst-strandcDNAusingoligo-dT-primerandRevertAidtM-MuLVReverseTranscriptase(MBI),either1/40or1/80wasusedforPCR.Thefollowingprimerswereused:cyclinD1:forward50-CTGTGCGCCCTCCGTATCTTA-30,reverse50-GGCGGCCAGGTTCCACTTGAG-30;mcm6:forward50-TGCACGAGCCTCTTCCCTACT-30,reverse50-TCCCGCATGTCCATCTTATCA-30;mcm7:forward50-AGGCGCTGCTGCTGCTTCTG-30,reverse50-GCCGGCTGTGCTGGTGGAC-30;LTforward50-GAGAGCGGCCACAGTCCAC-30,reverse50-ATCGGGCTCAGCAACACAAG-30;ST:forward50-CAGGCATATAAGCAGCAGTC-30,reverse50-CATCTCGGGTTGGTGTTC-30;Neuroﬁbromatosis2:forward50-AAGCAGCCCAAGACATTCA-30,reverse50-CTCGGGAGGGCAGTAGAC-30;Gprotein-coupledreceptor:forward50-TGCCCCTGCTCCTGGTGATTG-30,reverse50-TAGGCGCAGGCTGGCTTCGTG-30;Myosinforward50-TGGAAGTCCGGCGGCAGAGTC-30,reverse50-CCGGGGGCGAGGCTTGTAAC-30;cadherin11:forward50-ACCCCAAGGCACTCTCCAACC-30;reverse50-TCACCACCCCCTTCATCATCATAG-30;c-Myc:forward50-GCCCGCGCCCAGTGAGGATA-30,reverse50-GCGGCGGCGGTGAGGTC-30;decorin:forward50-CCCCTACCGATGCCAGTGT-30,reverse50-TTGCCGCCCAGTTCTATGAC-30;b-actinforward50-TGGCACCACACCTTCTACAATGAG-30,reverse50-CAAGAAGGAGGCTGGAAAAGAG-30.PCRcycleconditionswerethefollowing:initialdenatura-tionwasfor2minat951Cthiswasfollowedby20–25cyclesconsistingof1.5minat951C,1.5minforannealing(annealingtemperatureswereadjustedforeachprimerpair)and2minat721Cforsynthesis.DilutionsofcDNAwereperformedtodeterminethelinearrangeforeachprimerpair.PCRproductswereresolvedona1.5%agarosegelcontainingethidiumbromideandwerevisualizedwithUVlight.Real-timePCRQuantitativePCRwasperformedusingLightCyclerFastStartDNAMasterSYBRGreenIKitasrecommendedbythesupplier(Roche).ThesameprimersasdescribedinRT–PCRwereusedtoverifytheexpressionoftheselectedgenes.Theb-actingenewaschosenfornormalizationofthedata.ImmunoblottingAfter72hserumstarvationand28hinductionwithdexa-methasone,cellswereharvestedandlysedinbuffer(20mMTris-Cl(pH8.0),100mMNaCl,1mMEDTA,0.5%NP-40)containingcompleteproteaseinhibitorcocktail(BoehringerMannheim)asdescribedelsewhere(Adamczewiskietal.,1993).ProteinconcentrationwasmeasuredwiththeBioRadproteinassay(BioRad)followingthemanufacturer’sinstruc-tions.Equalamountsofproteinwereseparatedonan11%SDS–PAGE,transferredontoanitrocellulosemembraneandprobedwiththeindicatedantibodies.AntibodiesagainstMCM6(sc-9843),NF2(sc-331),cyclinD1(sc-246)andcadherin-11(sc-6463)werepurchasedfromSantaCruzBiotechnology.MCM7(Ab-1)antibodywaspurchasedfromOncogene.b-Actin(AC-74)antibodywaspurchasedfromSIGMA.LTandSTantigensweredetectedbyarabbitpolyclonalantibodydirectedagainstthecommonN-terminalregionoftheseproteins.Antibodybindingwasrevealedusingappropriateperoxidase-conjugatedsecondaryantibodies(Jackson)andECLreagents(Amersham)followingthemanufacturer’sinstruction.ModiﬁcationofgeneexpressionbyTantigensBKluckyetal4720OncogeneTransienttransfectionandluciferasereporterassaysMousemcm6andmcm7promoterswereampliﬁedbyPCRusingthefollowingprimers:mcm6:forward50-CGGGGTACCGCTTCATGGCGTATGCTT-30;reverse50CCGCTCGAGGAGGTCCATGGCGGCGCC-30;mcm7:forward50-CGGGGTACCAGGATACAGTCTTTATAGATGAG-30;reverse50-CCGCTCGAGCGCTGCCGGGGACGGTGT-30.TheampliﬁedfragmentswereinsertedintothepGL3BasicVector(Promega).AsynchronouslygrowingREF52cellswereseededatadensityof5104cellspersix-wellplate.Thenextday,thecellsweretransfectedwithpolyethylenimine(PEI25000)togetherwithplasmidcarryingtheinformationforLTorST(wildtypeormutants)undertheCMVpromoterandaplasmidexpressingb-galactosidaseasdescribedpreviously(Schu¨chneretal.,2001).Subsequently,thecellswerearrestedbyserumdeprivation(0.2%serum)for48h.Cellswerethenharvestedandluciferaseactivitywasmeasuredintheassaybuffer(25mMTricinepH7.8,0.5mMEDTA,0.54mMNa-Tripolypho-sphate,16.3mMMgSO47H2O,0.1%TritonX-100,4.6mMLuciferin,1.2mMATPand5.6mMDTT)usinganAuto-Luminat.Tonormalizethetransfectionefﬁciency,b-galacto-sidaseactivitywasmeasuredasdescribedinSambrooketal.(1989).Theproteinconcentrationwasdeterminedandlikewiseusedfornormalization.AnaliquotofeachextractwasusedfordeterminationofthelevelofTantigenbyimmunoblotting.AcknowledgementsThisworkwassupportedbytheFondszurFo¨rderungderwissenschaftlichenForschung.ReferencesAdamczewiskiJP,GannonJVandHuntT.(1993).J.Virol.,67,6551–6557.BellSPandDuttaA.(2002).Ann.Rev.Biochem.,71,333–374.BenjaminT.(2001).Virology,289,167–173.BikelIandLoekenMR.(1992).J.Virol.,66,1489–1494.CampbellKS,AugerKR,HemmingsBA,RobertsTMandPallasDC.(1995).J.Virol.,69,3721–3728.CollerHA,GrandoriC,TamayoP,ColbertT,LanderES,EisenmanRNandGolubTR.(2000).Proc.Natl.Acad.Sci.USA,97,3260–3265.DamaniaB,LiebermanPandAlwineJC.(1998).Mol.Cell.Biol.,18,3926–3935.EcknerR,LudlowJW,LillNL,OldreadE,AranyZ,ModjtahediN,DeCaprioJA,LivingstonDMandMorganJA.(1996).Mol.Cell.Biol.,16,3454–3464.Felton-EdkinsZAandWhiteRJ.(2002).J.Biol.Chem.,277,48182–48191.FernandezPC,FrankSR,WangL,SchroederM,LiuS,GreenJ,CocitoAandAmatiB.(2003).GenesDev.,17,1115–1129.FrostJA,AlbertsAS,SonntagE,GuanK,MumbyMCandFeramiscoJR.(1994).Mol.Cell.Biol.,14,6244–6252.GottliebKAandVillarrealLP.(2001).Microbiol.Mol.Biol.Rev.,65,288–318.HahnWC,CounterCM,LundbergAS,BeijersbergerRL,BrooksMWandWeinbergRA.(1999).Nature,400,464–468.HahnWC,DessainSK,BrooksMW,KingJE,ElenbaasB,SabatiniDM,DeCaprioJAandWeinbergRA.(2002).Mol.Cell.Biol.,22,2111–2123.KinoT,TakeshimaH,NakaoM,NishiTandYamamotoK.(2001).GenesCells,6,441–454.KresseH.andScho¨nherrE.(2001).JCell.Physiol.,189,266–274.LecandaF,ChengS-L,ShinCS,DavidsonMK,WarlowP,AvioliLVandCivitelliR.(2000).JCell.Biochem.,77,499–506.LoekenM,BikelI,LivingstonDMandBradyJ.(1988).Cell,55,1171–1177.LoekenMR.(1992).J.Virol.,66,2551–2555.LukasJ,Mu¨llerH,BartkovaJ,SpitkovskyD,KjerulffAA,Jansen-Du¨rrP,StraussMandBartekJ.(1994).J.CellBiol.,125,625–638.LutchmanMandRouleauGA.(1995).CancerRes.,55,2270–2274.MenssenAandHermekingH.(2002).Proc.Natl.Acad.Sci.USA,99,6274–6279.MoranE.(1993).Curr.Opin.Genet.Dev.,3,63–70.MudrakI,OgrisE,RothenederHandWintersbergerE.(1994).Mol.Cell.Biol.,14,1886–1892.NemethovaMandWintersbergerE.(1999).J.Virol.,73,1734–1739.OgrisE,MudrakIandWintersbergerE.(1992).J.Virol.,66,53–61.OgrisE,MudrakIandWintersbergerE.(1993a).Oncogene,8,1277–1283.OgrisE,RothenederH,MudrakI,PichlerAandWintersber-gerE.(1993b).J.Virol.,67,1765–1771.OhtaniK,IwanagaR,NakamuraM,IkedaM-a,YabutaN,TsurugaHandNojimaH.(1999).Oncogene,18,2299–2309.PipasJM.(1992).J.Virol.,66,3979–3985.PorrasA.,BennetJ,HoweA,TokosK,BoukN,HengleinB,SathayamangalamS,ThimmapayaBandRundellK.(1996).J.Virol.,70,6902–6909.PorrasA,GaillardSandRundellK.(1999).J.Virol.,73,3102–3107.SambrookJ,FritschEFandManiatisT.(1989).MolecularCloning:ALaboratoryManual,2ndednColdSpringHarborLaboratoryPress:ColdSpringHarbor,NY.Schu¨chnerS,NemethovaM,BelisovaA,KluckyB,HolnthonerWandWintersbergerE..(2001).J.Virol.,75,6498–6507.Schu¨chnerSandWintersbergerE.(1999).J.Virol.,73,9266–9273.ShinCS,LecandaF,SheikhS,WeitzmannL,ChengS-LandCivitellyR.(2000).J.CellBiochem.,78,566–577.Sta¨nderM,NaumannU,WickWandWellerM.(1999).CellTissueRes.,296,221–227.SonntagE,FedorovS,KambayashiC,RobbinsD,CobbMandMumbyMC.(1993).Cell,75,887–897.TsurugaH,YabutaN,HosoyaS,TamuraK,EndoYandNojimaH.(1997).GenesCells,2,381–399.WatanabeG,HoweA,LeeRJ,AlbaneseC,ShuI-W,KarnezisAN,ZonL,KyriakisJ,RundellKandPestellRG.(1996).Proc.Natl.Acad.Sci.USA,93,12861–12866.YuJ,BoyapatiAandRundellK.(2001).Virology,290,192–198.ModiﬁcationofgeneexpressionbyTantigensBKluckyetal4721OncogeneCellcycle-dependentnucleocytoplasmicshuttlingoftheneuroﬁbromatosis2tumoursuppressormerlinTaruMuranen*,1,3,MikaelaGro¨nholm1,3,GHermaRenkema2andOlliCarpe´n11ProgramofNeuroscience,BiomedicumHelsinki,DepartmentofPathology,UniversityofHelsinkiandHelsinkiUniversityHospital,PB63,Helsinki00014,Finland;2InstituteofMedicalTechnology,UniversityofTampereandTampereUniversityHospital,FinlandTheneuroﬁbromatosis2tumoursuppressormerlin/schwannominisstructurallyrelatedtotheezrin–radix-in–moesinfamilyofproteins,whichanchoractincytoske-letontospeciﬁcmembraneproteinsandparticipateincellsignalling.Merlininhibitscellgrowthwithayetunknownmechanism.Asmosttumoursuppressorsarelinkedtocellcyclecontrol,weinvestigatedmerlin’sbehaviourduringcellcycle.Ingliomaandosteosarcomacells,endogenousmerlinwastargetedtothenucleusinacellcycle-speciﬁcmanner.MerlinaccumulatedperinuclearlyattheG2/Mphase,andshiftedtothenucleusatearlyG1.Duringmitosis,merlinlocalizedtomitoticspindlesandatthecontractilering.Nuclearmerlinwasstronglyreducedinconﬂuentcells.BlockingoftheCRM1/exportinnuclearexportpathwayledtoaccumulationofmerlininthenucleus.Activationofthep21-activatedkinaseorproteinkinaseA,whichresultinphosphorylationofmerlin,didnotaffectitsnuclearlocalization.Merlinregulatestheactivityofextracellularsignal-regulatedkinase2(ERK2)andnuclearlocalizationofbothproteinswasinducedbycelladhesion.UnlikeERK2,nuclearlocalizationofmerlinwasnot,however,dependentonintactactincytoskeleton.Theseresultslinkmerlintoeventsrelatedtocellcyclecontrolandmayhelptoresolveitstumoursuppressorfunction.Oncogene(2005)24,1150–1158.doi:10.1038/sj.onc.1208283Publishedonline6December2004Keywords:merlin;NF2;ERM;nucleus;cellcycleIntroductionTheneuroﬁbromatosis2(NF2)geneiscriticallyinvolvedintheformationoftumoursofthenervoussystem,especiallyschwannomasandmeningiomas.IntheNF2disease,inheritedNF2genemutationsresultinmultipletumours,andinallsporadicschwannomasandmostmeningiomassomaticbiallelicinactivationinitiatestumourdevelopment(Baseretal.,2003).ThemechanismbywhichtheNF2geneproductmerlin(schwannomin)functionsasatumoursuppressorisnotknown,althoughinvolvementineventsrelatedtocellcycleregulationhasbeensuggested.Forinstance,overexpressionofmerlininNIH3T3cellsreducesproliferation(LutchmanandRouleau,1995)andtransfectionofmerlinintohumanprimaryschwannomacellsinhibitsproliferationandpromotesG0/G1arrest(Schulzeetal.,2002).Conversely,suppressionofmerlinintumourcellsinducesproliferation(HuynhandPulst,1996)andtargeteddisruptionoftheNF2generesultsinincreasedcellproliferationandtumourformation(McClatcheyetal.,1998;Giovanninietal.,2000).Ingeneral,functionsoftumoursuppressorproteinsincluderegulationofcellularresponsestogrowth-promotingsignals,DNAdamageandcellcyclecheckpoints.Theseactivitiestypicallyrequirenuclearlocalizationofthetumoursuppressorprotein,whichmayoccurinacellcycle-speciﬁcmanner.Regulatednucleocytoplasmicshuttlingandassociationwiththenuclearenvelopeandmicrotubuleshasrecentlybeendemonstratedforseveraltumoursuppres-sorproteins,suchasadenomatouspolyposiscoli(APC),VHLandBRCA1(FabbroandHenderson,2003).Merlinisstructurallyrelatedtotheezrin,radixinandmoesin(ERM-proteins),whichactasmole-cularlinkersbetweenthecytoskeletonandspeciﬁcmembraneproteins(McClatchey,2003).ERM-proteinsaremainlyfoundinactin-richsurfaceprotrusionsoftheplasmamembranesuchasmembranerufﬂes,microspikesandinthecleavagefurrow(Bretscheretal.,2002;Gautreauetal.,2002).MerlinpartlycolocalizeswithERM-proteinsintheseregionsofdynamiccytoskeletalremodelling(Gonzalez-Agostietal.,1996;Sainioetal.,1997;Shawetal.,1998;Gusellaetal.,1999)andformsheterodimerswithERM-proteins(Gro¨nholmetal.,1999),especiallywhenphosphorylatedatS518(Alfthanetal.,2004).Owingtothissubcellulardistribution,merlinhasbeenregardedasauniquetypeoftumoursuppressor,whosegrowthinhibitorymechanismwouldbelinkedtocellsurfaceorganizationandadhesion.Weshowhere,however,thatthesubcellularlocalizationofmerlinismoreversatilethanpreviouslythought.Itsnuclearlocaliza-tionisdependentonthecellcycle,celldensityandadhesion.Received3June2004;revised11October2004;accepted12October2004;publishedonline6December2004*Correspondence:TMuranen;E-mail:taru.muranen@helsinki.ﬁ3TheseauthorscontributedequallytothisworkOncogene(2005)24,1150–1158&2005NaturePublishingGroupAllrightsreserved0950-9232/05$30.00www.nature.com/oncResultsDetectionofnuclearmerlinanditsassociationwithCRM1/exportinpathwayTostudythelocalizationofmerlin,weusedhumanU251gliomaandU2OSosteosarcomatumourcelllines,expressingendogenousmerlin.Undersubconﬂuentconditions,andstainedwiththreedifferentmerlinantibodies(Figure1),merlinwasconcentratedunder-neaththecellmembraneinlinewithearlierstudies.However,asmallfractionofcellsdemonstratedbrightnuclearstaining.Theintensityofnuclearstainingvariedamongcells,fromcellsexhibitingalmostentirelynuclearlabellingtocellswithbothnuclearandsubmembranousstaining.Insubconﬂuentcultures,theamountofcellsdemonstratingnuclearmerlinvaried(dependingontheantibody)from9to17%forU251cells,andfrom13to16%onU2OScells.Toverifythespeciﬁcityofmerlinantisera,293HEKcellsweretransfectedwithmyc-taggedmerlincDNA.Cellswerethendouble-stainedwithmycmAbandmerlinantisera(Figure1c),ortransfectedproteinwasimmunoprecipitatedwithmycmAbandtheprecipitatedmaterialwasblottedwithmerlinantibodies(Figure2c).Bothimmunostainingandco-immunoprecipitationresultsconﬁrmedthattheanti-bodiesspeciﬁcallyrecognisemerlin.Weisolatedthenuclearandcytoplasmicfractionsandimmunoblottedthemformerlin,andfornuclear,membraneandcytoplasmicmarkers(Figure2).Frac-tionationrevealedthepresenceofmerlininthenuclearaswellasinthemembranefractionandthusconﬁrmedtheimmunolocalizationresults.Figure1Endogenousmerlinispresentinthenuclei.(aandb)Immunostainingofsubconﬂuent,nonsynchronizedU251glioma(a)andU2OSosteosarcomacells(b)withthreedifferentmerlinantibodies(1398,A19andKF10)demonstratesnuclearstaininginsomecells.Subconﬂuentcultureswerequantitativelyanalysedfornuclearmerlin;12%ofU251cellsexhibitnuclearmerlin(A19:9.6%;1398:9.9%;KF10:17%)and14%ofU2OSexhibitnuclearmerlin(A19:13.4%;1398:13.5%;KF10:15.7%).Theimageswerechosentoincludecellswithnuclearandthemorefrequentmembrane/cytoplasmicstainingpattern.Totestthespeciﬁcityofthepolyclonalmerlinantibodies,293HEKcellsweretransfectedwithmyc-taggedmerlincDNA(c).CellswerestainedwithmycmAb(green)andwithpolyclonalmerlinantibodies,A19and1398(red).Mycandmerlinantibodiesreactwithtransfectedcellsonlyanddemonstrateanidenticalstainingpattern.Scalebar10mmFigure2SubcellularfractionationofU251andU2OScells.(aandb)U251(a)andU2OS(b)cellswerefractionatedandnuclear(n)andmembrane/cytoplasmic(m)fractionswereanalysedbyWesternblotting.Thethreeantibodiesidentifymerlinbothinthenuclearandinthemembrane/cytoplasmicfractions.ThenuclearmarkerMAT1isdetectedpredominantlyinthenuclearfraction,andthetransmembraneproteinCD44andthemitochondrialproteinporinexclusivelyinthemembrane/cytoplasmicfraction.The293HEKcellsweretransfectedwithmyc-taggedmerlincDNA(c).TransfectedproteinwasimmunoprecipitatedwithmycmAborcontrolX63mAbandtheprecipitatedmaterialwasblottedwithpolyclonal(A19,1398)merlinantibodiesorwithmycmAb.Allantibodiesdetectabandwiththemolecularsizeofmerlin(arrow)inmycbutnotX63mAbimmunoprecipitates.Thebandisalsodetectedintotallysatesoftransfectedcells.Thebandabove51kDacorrespondstoantibodyheavychainNucleocytoplasmicshuttlingofmerlinTMuranenetal1151OncogeneWenextanalysedwhethercelldensityaffectsthedistributionofmerlin.Immunolocalizationanalysisofmerlindemonstratedthepresenceofnuclearmerlininafractionofcellsgrowninsubconﬂuentconditions.Instead,inconﬂuentcells,merlinwaslocalizedonlytothecorticalmembraneandthecytoplasm,withoutadetectablenuclearsignal(Figure3).Laserscanningcytometricquantiﬁcationofcellsdouble-stainedformerlinandDNAveriﬁedthisﬁnding(Figure3).Nucleocytoplasmicshuttlingofproteinsisanactiveprocess,regulatedbyvariousimportandexportpath-ways(Weis,2003).Tostudythetransportofmerlin,weblockedtheCRM1/exportin-mediatednuclearexportwithleptomycinB(LMB)(Kudoetal.,1998).LMBtreatmentofU251cellsresultedinamarkedincreaseinnuclearmerlinasdemonstratedbothbyimmunoﬂuor-escencemicroscopyandlaserscanningcytometry(LSC)(Figure3).After2hLMBtreatment,mostofthesubconﬂuentcellsdemonstratednuclearmerlinandsomenuclearaccumulationwasalsoseeninconﬂuentcells.NuclearlocalizationwasalsoevidentinU2OScellsandtheresultsforbothcelllineswereconﬁrmedwithallmerlinantibodies(notshown).NuclearshuttlingofmerlinislinkedtocellcycleThedifferentialnuclearlocalizationofmerlininsubconﬂuentcellssuggestedthatnucleartargetingmightoccurinacellcycle-speciﬁcmanner.Inordertostudythelocalizationofmerlinindifferentphasesofthecellcycle,subconﬂuentU251cellsweresynchronizedusingnocodazoleormimosinetreatment.Nocodazoledepo-lymerizesmicrotubulesreversiblyandblockscellsattheG2/Mphase,whereasmimosineaffectsthereplicationforkandblockscellsatearlySphase.FACSanalysiswasusedtoconﬁrmtheefﬁciencyofsynchronizationandtomonitorthecellcyclephaseafterblockrelease.Incellsabouttoentermitosis(lateG2/M),merlinwaslocalizedinthecytoplasmandconcentratedtotheperinuclearregion(Figure4).Duringearlymitosis,merlinwascondensedaroundthebreakingnuclearenvelope,especiallyinnuclearenvelopeinvaginations,thatis,regionsinwhichmicrotubulesareconcentratedFigure3CellconﬂuencyandLMBtreatmentaffectnuclearlocalizationofmerlin(aandd).Subconﬂuent(a)orconﬂuent(b)U251cellsweredouble-stainedwithmerlinantibody(A19)andwithaDNA-bindingnuclearprobe(TO-PRO).Incontrasttosubconﬂuentcells,inwhichnuclearmerlinisdetected,merlininconﬂuentcellsislocalizedunderneaththecorticalmembranesandinthecytoplasmandisabsentfromthenucleus.CRM1/exportininhibitorLMBtreatmentofsubconﬂuentcellsresultsinnuclearaccumulationofmerlin(c).IncreasednuclearstainingisalsodetectedinconﬂuentcellsafterLMBtreatment(d).Scalebar10mm.(e)LSCdemonstratesquantitativedifferencesinnuclearmerlincontentinsubconﬂuent,conﬂuentandLMB-treatedcells.Propidiumiodidestaining(redﬂuorescence)wasusedtodeﬁnethenuclearareaandmerlinstaining(green)inthenucleiwasquantiﬁedeitherasmaximumpixelintensity(left)ortotalﬂuorescenceinthenuclei(right).Thepercentageofcellswithmerlin-positivenucleiisshownintoprightcornerofeachplot.ThisisarepresentativeofthreeexperimentsNucleocytoplasmicshuttlingofmerlinTMuranenetal1152Oncogeneintheprophase(BurkeandEllenberg,2002).Aftermitosis,atearlyG1,merlinaccumulatedtothenucleus,andatthispointastrongsignalwasalsodetectedunderneaththecorticalmembrane.ProgressionofthecellcycletolateG1phaseresultedinexportofmerlinfromthenucleus.AtG1/S,merlinconcentratedunder-neaththecorticalmembraneand,lessprominently,totheperinuclearregion.Furtheranalysisofmerlinindividingcellsdemonstratedapatternresemblingmitoticspindlesinmetaphasecellsandconcentrationtothemid-bodyduringcytokinesis(Figure4).SubcellularfractionationofsynchronizedU251cellswasperformedtofurtheranalysethedistributionofmerlinatdifferentcellcyclephases.FACSanalysiswasusedtoconﬁrmthesynchronization(resultsnotshown)andmembraneandnuclearmarkerswereusedtoverifythepurityofsubcellularfractions.Cellstreatedwithmimosineandfractionatedatblockrelease(lateG1/S)or5hlater(Sphase)showedonlyverylittlemerlininthenucleus,whereasthesametreatmentwithnocoda-zoleresultedinstrongmerlinreactivityinthenuclearfractionatthetimeofrelease(G2/M)andaweakerreactivity5hlater(mid-G1)(Figure5).PhosphorylatedmerlinispresentbothinthenuclearandcytoplasmicfractionsMerlinhasbeenshowntophosphorylateatserine518byp21-activatedkinase(PAK)andproteinkinaseA(PKA)(Kissiletal.,2002;Xiaoetal.,2002;Alfthanetal.,2004).Thephosphorylatedandnonphosphory-latedformsofmerlincanbeidentiﬁedbydifferentialmobilityinSDS–polyacrylamidegels(PAGE).AsshowninFigure5,boththehypophosphorylatedandthephosphorylatedformsofmerlinweredetectedatalltimepointsbothinthenuclearandthecytoplasmicFigure5Merlininsubcellularfractionsofsynchronizedcells.U251cellsweretreatedeitherwithnocodazole(Noc),whichblocksthecellcycleatG2/Morwithmimosine(Mimo),whichblocksthecellcycleatthebeginningoftheSphase,afterwhichtheblockwasreleased.Cellswerefractionatedimmediatelyor5hafterreleaseoftheblockandnuclear(n)ormembrane/cytoplasmic(m)fractionswereanalysed.PurityofthefractionswasveriﬁedwithacytoplasmicmarkerCD44andanuclearmarkerMAT1.MerlinwasdetectedwithKF10mAbandtheS518phosphorylatedmerlinwasdetectedwithS518-phospho-speciﬁcantibody.Also,totalextractsofthesynchronizedcellsareincluded.ThecellcyclephaseandsynchronizationwasveriﬁedbyFACSanalysis(notshown)Figure4Subcellularlocalizationofmerlinisdependentoncellcycle.(a–g)U251cellsweresynchronizedwithnocodazoleandstainedformerlin(NF21398pAb,green)andDNA(TO-PRO,red)atvariousphasesofthecellcycleandanalysedbyconfocalmicroscopy.ThecellcyclephasewasveriﬁedbyFACSanalysis.Threedifferentsections(dorsal,middleandventral)areshown.ThecellsattheG2/Mphase(a)(FACSanalysis:G2/M98.3%,G0/G11.5%,S0.2%)showperinuclearaccumulationofmerlin.Atearlymitosis(b),merlinisconcentratedaroundthebreakingnuclearenvelope,andthestainingpatternisretainedattheonsetofmitosis(c).InearlyG1(d),intensenuclearmerlinstainingisdetected(FACSanalysis:G2/M71.9%,G0/G115.6%,S12.5%).LaterintheG1/Sphase(FACSanalysis:G2/M14.0%,G0/G139.1%S46.9%),merlinisabsentfromthenucleusandisconcentratedunderneaththecellmembraneandinthecytoplasm(e).Inmitoticcells,merlinstainingcoincideswithmitoticspindles(f)andduringcytokinesismerlinisseenarounddevelopingnuclearenvelopeandatmid-body(g).Scalebar10mmNucleocytoplasmicshuttlingofmerlinTMuranenetal1153Oncogenefraction.FurtherconﬁrmationforthepresenceofphosphorylatedmerlininbothfractionswasobtainedbyimmunoblottingwithanS518phospho-speciﬁcmerlinantibody(Figure5).Wefurtherstudiedwhetheralterationofthekinaseactivitychangesthedistributionofmerlinatacellularlevel.WetransfectedU251cellswithadominant-negativePAK2construct(inhibitoryCRIBdomain),knowntoinhibitendogenousPAKactivity(Alfthanetal.,2004)and/orincubatedthecellswithH89,whichblocksthePKAsignallingpathway.Thistreatmenthasbeenshowntoeffectivelyblockphosphorylationofmerlin(Alfthanetal.,2004).Inthesecells,nuclearmerlinstainingwasstillevident(Figure6).WealsostudiedtheeffectofactivationofPAKandPKAactivityonthenuclearlocalizationofmerlin.U251cellsweretransfectedwithconstitutivelyactivePAK2con-structandincubatedfor30minwithIBMXandforskolin,whichstimulateendogenousPKAactivityincells.Thistreatmentdidnotinduceanychangesinthenuclearlocalizationofmerlin(Figure6).Theexperi-mentwasalsoperformedwithstimulatedPKAtogetherwithinhibitedPAKandviceversa.Noneofthetreatmentschangedthenuclearlocalizationofmerlin.MerlinistargetedtothenucleusatearlyphaseofcellattachmentDuringmitosis,cellsroundupandareonlylooselyattachedtothesubstratum.Aftercelldivision,theyattachtosubstratummoreﬁrmlyandspreadagain.Westudiedwhetherlocalizationofmerlinwouldbeaffectedbycellattachmentandspreading,whichtakeplaceshortlyaftermitosisatG1.Thiswastestedbyeithertrypsinizingnonsynchronized,subconﬂuentU251cellsor,alternatively,byshakingoffmitoticcells(notshown)andlettingthemreattachforashorttime.CellsatvarioustimepointsofreattachmentwereﬁxedandstainedformerlinandF-actin.Astrongnuclearmerlinstainingwasdetectedatearlyphasesofreattachment,bothaftermitoticshakeoffandtrypsinization(Figure7).Atlatertimepoints(>1h),whenthecellswerespreadandthecorticallamellipodialactinnet-work,typicalofmigratingcells,wasformed,merlinwasagainconcentratedunderneaththemembraneandnuclearlocalizationdisappeared(Figure7).Actincytoskeletonisnotrequiredforadhesion-dependentnucleartargetingofmerlinAdhesionandcellspreadinginducenucleartargetingofphosphorylatedextracellularsignal-regulatedkinase(ERK)viaamechanismthatrequiresintactactincytoskeleton.NucleartargetingofphosphorylatedERKisrequiredforcellcycleprogressionatG1(Aplinetal.,2001;Lohezetal.,2003).MerlinprolongstheG1phaseofthecellcycle(Schulzeetal.,2002),possiblyviainhibitionofphosphorylationofERKandERK-Figure6RegulationofPAKandPKAactivitydoesnothaveadirecteffectonmerlinnuclearlocalization.U251cellsweretransfectedeitherwithdominant-negativePAK2construct(dnPAK)(a)orconstitutivelyactivePAK2(activePAK)(b).dnPAK-expressingcellswereincubatedfor5hwithPKAinhibitorH89beforeﬁxation.CellsexpressingactivePAKwereincubatedfor30minwithIBMXandforskolinbeforeﬁxation.MerlinwasdetectedwithNF21398antibody(red)andtransfectedcellswithMycmAbfordnPAK(green)orHAmAbforconstitutivelyactivePAK(green).Neithertreatmenthasadirecteffectonmerlinnuclearlocalization.Scalebar10mmFigure7Merlinistargetedtothenucleiofattachingcells.U251cellsweretrypsinizedandﬁxed(a)orallowedtoreattachoncoverslips.Attachingcellswereﬁxedafter30(b)or90min(c).MerlinwasstainedwithNF21398Ab(red),nucleuswithTO-PRO(blue)andF-actinwasvisualizedwithOregongreenphalloidin.Merlinisheavilyaccumulatedinthenucleiduringearlyphasesofattachment.Scalebars,(a):5mmand(b,c)10mmNucleocytoplasmicshuttlingofmerlinTMuranenetal1154OncogenedependentElk-1(Limetal.,2003).WewantedtostudywhethermerlinandERKhavesimilarrequirementsforadhesion-dependentnuclearlocalization,andwhethertheycolocalizeincellswithorwithoutintactactincytoskeleton.Inuntreatedadheringcells,merlincolo-calizedwithERK2inthenucleus(Figure8).Whenadheringcellswereeitherserumstarvedorgrowninserum(notshown)andtreatedwithcytochalasinD(CCD),whichdoesnotaffectcellattachmentbutpreventscellspreadingbydisruptingtheactincytoske-leton,merlinstillremainedinthenucleus.Instead,ERK2wasconcentratedoutsidethenuclearmembraneinlinewithpreviousﬁndings(Lohezetal.,2003),andnocolocalizationwasseenbetweenthetwoproteins(Figure8).Thisresultdemonstratesthatmerlin’snuclearlocalizationisnotdependentonthenuclearlocalizationofERK,cellspreadingnoranintactactincytoskeleton.However,celladhesionisrequiredforthenuclearlocalizationofmerlin,sinceinnonadherentcellsmerlinisconcentratedtothesubmembranousregions(Figure7).DiscussionRegulatedmovementbetweenthenucleusandcyto-plasmprovidesanefﬁcient,simpleandrapidwayfortumoursuppressorstocontrolcellgrowth.Indeed,duringrecentyears,manyoftheknowntumoursuppressorshavebeenshowntoundergonucleocyto-plasmicshuttling(FabbroandHenderson,2003).Althoughsomestudies,especiallyusingtransfectedmutatedmerlin,haveshownthatitcanbetargetedtothenucleusandthatitsexportisregulatedbytheCRM1pathway(KresselandSchmucker,2002),merlinisgenerallyregardedasacomponentofthecorticalactincytoskeleton.Therefore,itstumoursuppressormechan-ismhasbeenconsideredunique.MerlinregulatescellgrowthbyprolongingtheG0/G1phaseofthecellcycle(Schulzeetal.,2002),butithasnotbeenevidentastohowasubmembranousproteincoulddothis.Ourcurrentresultsprovideacluebydemonstratingthatendogenousmerlinundergoescellcycle-andanchorage-dependentnucleocytoplasmicshuttlinginanalogywithmanyothertumoursuppressorproteins.Theamino-terminalpartofmerlincontainsanFERMdomainsharedbyseveralcytoskeletalmoleculesincludingband4.1proteins.Severalisoformsofband4.1proteinsaretargetedtothenucleusbynuclearlocalizationsignals(NLS)thatactinahierarchicalmanner(Correas,1991;DeCarceretal.,1995;LallenaandCorreas,1997).AnimportantNLSinband4.1proteinsisastretchofbasicresidues(KKKR),whichissuggestedtobindtoanegativelychargedmotifofimportin(Gascardetal.,1999).Merlincontainsananalogousstretchofbasicresidues(309RRRK312),whichmaybeinvolvedinitsnucleartargeting.Afurtheranalogybetweenmerlinandband4.1proteinisoformsistheirassociationwithmitoticspindlesduringearlymitosis(Kraussetal.,1997;Mattagajasinghetal.,1999).AccordingtoKresselandSchmucker(2002),merlinexon2hasacytoplasmicretentionsignal,whichkeepsmerlininthecytoplasm.Thus,theremaybeseveralsignalmotifswithoppositeeffects,whoseinter-playdictatesthecellcycle-dependentdistributionofmerlin.Unfortunately,ourexperimentswithtransientlytransfectedwild-typemerlinhavenotbeenabletoshowaclearnuclearlocalizationoftheoverexpressedasendogenousprotein.Forthisreason,wehavenottestedhowdisruptionofthepotentialNLSwouldaffectitsnuclearlocalization.Wehypothesizethatthelackofclearnucleartargetingoftransfectedproteinisduetooverexpression,butthereasonforthisdosedependencyinsubcellularlocalizationremainstobestudiedfurther.Timepointassayswithendogenousmerlinimplythattargetingtothenucleusisstrictlycontrolledbycellcyclephase.Merlinisassociatedwithmitoticspindlesduringmitosis(Muranenetal.,inpreparation)andispresentinthenucleusatearlyG1butnotatlateG1,SorG2phase.ThenuclearlocalizationisseeninactivelyproliferatingcellsbutnotincellsinﬂuencedbyFigure8Nuclearlocalizationofmerlinisnotdependentonintactactincytoskeleton.U251cellswereserumstarved,trypsinizedandreattachedonﬁbronectin-coatedcoverslipswithoutserumandincubatedwithout(a)orwithCCD(b).MerlinwasvisualizedwithNF21398Ab(red),ERK2withmAb(green)andnucleiweredetectedwithTO-PRO3nuclearprobe(blue).ConfocalmicroscopicanalysisofuntreatedcellsdemonstratescolocalizationofmerlinandERK2inthenuclei.Inadheringcells,CCDtreatmentpreventsnucleartargetingofERK2,whereasmerlinisstilltargetedtothenuclei.Scalebar10mmNucleocytoplasmicshuttlingofmerlinTMuranenetal1155Oncogeneconﬂuencyorcontactinhibition.AsimilarpatternofexpressionhasalsobeenshownfortheAPCandVHLtumoursuppressors,whichlocalizemostlyinthecytoplasmofconﬂuentcellsandshifttothenucleusinsubconﬂuentcellsandaffectgrowthincellcycle-dependentmanner(Leeetal.,1996;Zhangetal.,2001).Thenucleocytoplasmicshuttlingmayalsopro-videmeansformerlintoaffectcellgrowthinthesamemanner.ImmunolocalizationstudiesofadheringU251cells,eitheraftertrypsinationormitoticshakeoff,indicatethatmerlinaccumulatestothenucleusatearlypointsofcellattachment.AdhesionandanchoragetothesubstratumareknowntoregulatecellcycleprogressionatearlyG1(AssoianandZhu,1997).OneofthekeymoleculesisERK,whoseactivitydependsonintegrin-mediatedcelladhesionandthepresenceofanintactactincytoskeleton.PhosphorylationofERKanditstranslocationfromthecytoplasmtothenucleusisrequiredforcellcycleprogressionatG1.AdownstreamtargetofERKinthenucleusistheElk-1transcriptionfactor.PhosphorylatedElk-1hasincreasedafﬁnitytotheserumresponseelementandenhancestranscriptionofgrowth-relatedproteins(Maraisetal.,1993;Whit-marshetal.,1995;Vanhoutteetal.,2001),ultimatelyleadingtotheinductionofacellcycleproteincyclinD1whichregulatesthepassagethroughG1.BothmerlinandERKarelocalizedinthenucleusofadheringcellsandatearlyG1phaseofthecellcycle.ThisisofinterestinlightofarecentstudythatshowedthatmerlininhibitsphosphorylationofERKaswellasERK-dependentnuclearElk-1phosphorylation(Limetal.,2003).However,inCCD-treatedcellsinwhichElk-1phos-phorylationisimpairedandERKisunabletolocalizetothenucleus(Aplinetal.,2001),merlinisstillfoundinthenucleus.ThisimpliesthatmerlinandERKaretargetedtothenucleusviadifferentpathwaysandthatnuclearlocalizationofmerlindoesnotdependonERK’sactivity.Therearetwoadditionalinterestingmolecularpartnersofmerlin,paxillinandsyntenin,whosenucleocytoplasmicshuttlinghasrecentlybeendemonstrated.Bothofthesemoleculespossesstran-scriptionalpotential(Aplin,2003),andthereforetheirinteractionwithmerlinshouldbestudiedwithanovelperspective.Furthermore,averyrecentstudydemon-stratedthathumanpolyomavirusT-antigen,whichisabletotransformcellsofneuralorigin,isincomplexwithmerlininthenucleusofmalignantperipheralnervesheattumours(Shollaretal.,2004).Interestingly,theauthorsreportthepresenceofmerlininafractionofunsynchronizedtumourcellsinlinewithourﬁndings.Theactivityofmerlinisregulatedbyphosphoryla-tion.Twotypesofkinases,PAK-1/2andPKA,havebeenshowntophosphorylatemerlin(Kissiletal.,2002;Xiaoetal.,2002;Alfthanetal.,2004).TheactivityofPAKsisstronglyregulatedbyadhesion.Therefore,regulationofthenuclearlocalizationofmerlinbyphosphorylationisatemptingpossibility.However,wefoundphosphorylatedmerlinbothinthenuclearandcytoplasmicfractionsanddidnotﬁnddirectevidencethatactivationorinhibitionofPAKand/orPKAwouldhaveanobviouseffectonitsnuclearlocalization.However,wecannotexcludethepossibilitythattherewouldbeanindirectlinkbetweenPAK-dependentphosphorylationofmerlinanditssubcellulartargeting.Inconclusion,ourstudyidentiﬁestwocellcyclephases,mitosisandearlyG1phase,withnovelspeciﬁctargetingofmerlin.Theseobservationsindicatethatmerlinmayshareactivitiesofothertumoursuppressorproteinsandmayprovideanovelbasisfortheunder-standingofthebiologicalfunctionsofmerlin.MaterialsandmethodsCellculture,transfectionsandantibodiesU2OSosteosarcomacellsweremaintainedinDulbecco’smodiﬁedEagle’smediumwith1%nonessentialaminoacids,supplementedwith15%foetalcalfserum(FCS)(PromoCell,Heidelberg,Germany),andU251gliomacellsweremaintainedinDulbecco’sminimumessentialmedium,supplementedwith10%FCS.The293HEKcellsweremaintainedinRPMImediumsupplementedwith10%FCS.Cellswereﬁxedin3.5%paraformaldehyde(pH7.5).CellsweretransfectedwithFugene6(Roche,Mannheim,Germany)reagentandincubatedfor48hbeforeanalysis.PKAwasstimulatedbyIBMX(50mM)andforskolin(25mM)for30minandinhibitedby5hincubationwithH89(20mM)(allprovidedbySigma,StLouis,USA).ConstitutivelyactivePAK(T402Emutant)andtheinhibitoryN-terminalPAK2construct(PAK21-248H82/85L)wereusedasdescribed(Alfthanetal.,2004).Anti-merlinpolyclonalAbA-19sc-331(SantaCruzBiotechnology,SantaCruz,CA,USA),1398NF2(denBakkeretal.,1995),anti-schwannomin(LutchmanandRouleau,1995)andmAbKF10(denBakkeretal.,1995)wereused.HM2175antiserum(Kissiletal.,2002),kindlyprovidedbyDrJKissil(MassachusettsInstituteofTechnology,Cambridge,MA,USA),wasusedtodetectS518phosphorylatedmerlin.Anti-MAT1ﬂ-309(SantaCruzBiotechnology)pAbandCD44mAbHermes-3(Jalkanenetal.,1987)wereusedinWesternblotting.TO-PRO3-iodideprobe(MolecularProbes,Eugene,OR,USA)wasusedforDNAstaining.MycmAb(CovanceResearchProductsInc.,Princeton,NJ,USA)wasusedtodetecttaggedN-terminaldomainofPAK2andHAmAb(Roche)todetecttaggedconstitutivelyactivePAK2.Anti-a-tubulinmAbN356(AmershamPharmaciaBiotech,Buck-inghamshire,England)wasusedtodetecttubulinandpropidiumiodidetostainthenucleiinLSCandFACSanalysis.Anti-porinmAb(MolecularProbes)wasusedasacytoplasmicmarker.RabbitERK2Ab(SantaCruzBiotech-nology)wasusedtodetectERK2andOregongreen-andrhodaminephalloidin(MolecularProbes)wereusedtodetectF-actin.X63mAb(ATCC)wasusedasanegativecontrol.Alexa-488-,Alexa-568-andAlexa-594-conjugatedgoatanti-mouseandgoatanti-rabbitantibodies(MolecularProbes)wereusedassecondaryantibodiesinimmunoﬂuorescenceandHRP-conjugatedrabbitanti-mouseandswineanti-rabbitsecondaryantibodies(DAKOA/S,Glostrup,Denmark)inWesternblotanalysis.Subcellularfractionationandco-immunoprecipitationNuclearextractkit(ActiveMotif,Rixensart,Belgium)wasusedfornuclearandcytoplasmicfractionation.ProteinconcentrationineachfractionwasmeasuredwithBradfordNucleocytoplasmicshuttlingofmerlinTMuranenetal1156OncogeneA595assayandequalamountsofproteinwereloaded.Forimmunoblotting,proteinswereseparatedon8%SDS–PAGE,transferredtonitrocellulosemembranes(Schleicher&Schuell,Dassel,Germany)andimmunoblottedproteinsweredetectedbyenhancedchemiluminescence(AmershamPharmaciaBio-tech).The293HEKcellsweretransfectedwithmyc-taggedmerlincDNAinpcDNA3vector.After48h,thecellswerelysedinELB-NP40buffer.Immunoprecipitationswereper-formedbyadding6mgofmycorX63mAbto300mgofcelllysate.Lysateswereincubatedwiththeantibodiesfor1hatþ41Cbeforetheadditionof30mlofProteinG–Sepharosebeads(AmershamPharmaciaBiotech),afterwhichincubationwascontinuedovernightat41C.Beadswereprecipitatedbycentrifugation(500r.p.m.,5min)andwashedthreetimes(ELB).Beadswereelutedin30mlof2reducingLaemmlibufferat951C.Ameasureof15mlofreactionswasrunonSDS–PAGE(8%).CellcyclesynchronizationandtreatmentsForcellcyclesynchronization,U251andU2OScellsweretreatedwithnocodazole(200–400ng/ml,Calbiochem,SanDiego,CA,USA)orL-mimosine(200–400mM,Calbiochem).After18–24h,theblockwasreleased.Atvarioustimepointsafterrelease,samplesweretakenforFACSanalysis,immuno-ﬂuorescenceandlaserscanningconfocalmicroscopy.Cellswerenotgrowntoconﬂuencyduringtheexperiments.CellsfortheCRM1-dependentnuclearexportinhibitionexperimentweretreatedwithLMB5ng/ml(Sigma)for2h.Cellsfromone10cmplatewerelysedateachtimepointinELB-NP40buffer(150mMNaCl,50mMHEPES(pH7.4),5mMEDTA,0.5%NP40,1mMEDTA,10mMNa4P2O7,50mMNaF,1mMorthovanadate,1.5mMocadaicacidandproteaseinhibitors,0.5%NP40)andcentrifugedfor30minat20000g.ProteinamountsfromeachsupernatantwereequalizedandanalysedbyWesternblotting.Ameasureof5mlofPBSwasswirledoversubconﬂuent10cmplatesandtheplateswereshakenheavilytodetachmitoticcells.Cellswerecollectedandrunontocytocentrifugeslides(700r.p.m.,5min).Fordisruptionofthecytoskeleton,cellswereserumstarvedfor24h,trypsinizedandreattachedfor2honﬁbronectin-coatedcoverslipseitherwithorwithout10%FCSandwith1mMCCD(Sigma).ImmunoﬂuorescenceandlaserscanningconfocalmicroscopyFixedcellswerepermeabilizedin0.1%TritonX-100/PBSandstainedwithmerlinandtubulinantibodiesfollowedbysecondaryantibodies.CoverslipsweremountedinDABCO(Sigma)andMowiol(Calbiochem)andexaminedbyconfocalmicroscopy(LeicaSP2equippedwithArandKrlasers,LeicaMicrosystems,Heerbrugg,Switzerland)usingthesequentialscanningmodeorbyimmunoﬂuorescencemicroscopy(ZeissAxiophotequippedwithAxioCamcooledCCDcamera,CarlZeiss,Esslingen,Germany).Foranalysisofcellswithnuclearmerlinstaining,400–600cellsperantibodywerecalculated.FlowandLSCFlowcytometricanalysiswasperformedwithaFACSCalibur(Beckton-Dickinson,SanJose,CA,USA).Cellsfromone10cmplateweretrypsinized,washedinPBStwice,resuspendedandﬁxedin70%ethanol.Cellsweredyedwithpropidiumiodidefor15minatþ371C,afterwhichtheDNAamountwasmeasuredandanalysed.ForLSC,cellswerestainedwithmerlinantibodyA19followedbyAlexa-488-conjugatedsecondaryantibodyandwithpropi-diumiodide(25mg/mlin50%glycerol)andanalysedwithalaserscanningcytometer(CompuCyteCorp.,Cambridge,MA,USA)usingargonionlaserexcitationat488nm.Fluorescencewascollectedbyphotomultipliertubeswithgreen(530DF30)andred(600DF60)bandpassﬁltersanddigitizedto0.25mm0.5mmpixelresolution.Thenucleiwereidentiﬁedbypropidiumiodidepositivityandmerlinstaininginthenucleicalculated(totalﬂuorescenceandmaximalpixelﬂuorescence).Atotalof500–2000cellspersamplewereanalysed.AbbreviationsAPC,adenomatouspolyposiscoli;CCD,cytochalasinD;ERK2,extracellularsignal-regulatedkinase2;ERM,ezrin–radixin–moesin;LMB,leptomycinB;LSC,laserscanningcytometry;NF2,neuroﬁbromatosis2.AcknowledgementsWethankDrEllenZwarthoffforgenerouslyprovidingthe1398andKF10antibodies,DrJosephKissilforprovidingtheHM2175antibody,HanneAhola,HelenaAhola,TuulaHalmesvaaraandMonicaSchoultzforskillfultechnicalassistanceandKaijaAlfthan,LeenaHeiska,MikkoRo¨ntyandAnuWartiovaaraforfruitfuldiscussionsandassistance.ThisworkwassupportedbytheUSArmyNeuroﬁbromatosisResearchGrantDAMD17-00-0550andtheAcademyofFinland.ReferencesAlfthanK,HeiskaL,Gro¨nholmM,RenkemaHandCarpe´nO.(2004).J.Biol.Chem.,279,18559–18566.AplinAE.(2003).FEBSLett.,534,11–14.AplinAE,StewartSA,AssoianRKandJulianoRL.(2001).J.CellBiol.,153,273–281.AssoianRKandZhuX.(1997).Curr.Opin.CellBiol.,9,93–98.BaserME,EvansRDGandGutmannDH.(2003).Curr.Opin.Neurol.,16,27–33.BretscherA,EdwardsKandFehonRG.(2002).Nat.Rev.Mol.Cell.Biol.,3,586–599.BurkeBandEllenbergJ.(2002).Nat.Rev.Mol.Cell.Biol.,3,487–497.CorreasI.(1991).Biochem.J.,279,581–585.DeCarcerG,LallenaMJandCorreasI.(1995).Biochem.J.,312,871–877.denBakkerMA,RiegmanPH,HekmanRA,BoersmaW,JanssenPJ,vanderKwastTHandZwarthoffEC.(1995).Oncogene,10,757–763.FabbroMandHendersonBR.(2003).Exp.CellRes.,282,59–69.GascardP,NunomuraW,LeeG,WalenskyLD,KraussSW,TakakuwaY,ChasisJA,MohandasNandConboyJG.(1999).Mol.Cell.Biol.,10,1783–1798.GautreauA,LouvardDandArpinM.(2002).Curr.Opin.CellBiol.,14,104–109.GiovanniniM,Robanus-MaandagE,vanderValkM,Niwa-KawakitaM,AbramowskiV,GoutebrozeL,WoodruffJM,BernsAandThomasG.(2000).GenesDev.,14,1617–1630.Gonzalez-AgostiC,XuL,PinneyD,BeauchampR,HobbsW,GusellaJandRameshV.(1996).Oncogene,13,1239–1247.NucleocytoplasmicshuttlingofmerlinTMuranenetal1157OncogeneGro¨nholmM,SainioM,ZhaoF,HeiskaL,VaheriAandCarpe´nO.(1999).J.CellSci.,112,895–904.GusellaJF,RameshV,MacCollinMandJacobyLB.(1999).Biochim.Biophys.Acta,1423,M29–M36.HuynhDPandPulstSM.(1996).Oncogene,13,73–84.JalkanenM,RapraegerA,SaundersSandBernﬁeldM.(1987).J.CellBiol.,105,983–990.KissilJL,JohnsonKC,EckmanMSandJacksT.(2002).J.Biol.Chem.,277,10394–10399.KraussSW,LarabellCA,LockettS,GascardP,PenmanS,MohandasNandChasisJA.(1997).J.CellBiol.,137,275–289.KresselMandSchmuckerB.(2002).Hum.Mol.Genet.,11,2269–2278.KudoN,WolffB,SekimotoT,SchreinerEP,YonedaY,YanagidaM,HorinouchiSandYoshidaM.(1998).Exp.CellRes.,242,540–547.LallenaMJandCorreasI.(1997).J.CellSci.,110,239–247.LeeS,ChenDYT,HumphreyJS,GnarraJR,LinehanWMandKlausnerRD.(1996).Proc.Natl.Acad.Sci.USA,93,1770–1775.LimJY,KimH,KimYH,KimSW,HuhPW,LeeKH,JeunSS,RhaHKandKangJK.(2003).Biochem.Biophys.Res.Commun.,302,238–245.LohezOD,ReynaudC,BorelF,AndreassenPRandMargolisRL.(2003).J.CellBiol.,161,67–77.LutchmanMandRouleauGA.(1995).CancerRes.,55,2270–2274.MaraisR,WynneJandTreismanR.(1993).Cell,73,381–393.MattagajasinghSN,HuangSC,HartensteinJS,SnyderM,MarchesiVTandBenzEJ.(1999).J.CellBiol.,145,29–43.McClatcheyAI.(2003).Nat.Rev.Cancer,3,877–883.McClatcheyAI,SaotomeI,MercerK,CrowleyD,GusellaJF,BronsonRTandJacksT.(1998).GenesDev.,12,1121–1133.SainioM,ZhaoF,HeiskaL,TurunenO,denBakkerM,ZwarthoffE,LutchmanM,RouleauGA,JaaskelainenJ,VaheriAandCarpenO.(1997).J.CellSci.,110,2249–2260.SchulzeKM,HanemannCO,MullerHWandHanenbergH.(2002).Hum.Mol.Genet.,11,69–76.ShawRJ,McClatcheyAIandJacksT.(1998).CellGrowthDiffer.,9,287–296.ShollarD,DelValleL,KhaliliK,OtteJandGordonJ.(2004).Oncogene,23,5459–5467.VanhoutteP,NissenJL,BruggB,GasperaBD,BessonMJ,HipskindRAandCabocheJ.(2001).J.Biol.Chem.,276,5189–5196.WeisK.(2003).Cell,112,441–451.WhitmarshAJ,ShoreP,SharrocksADandDavisRJ.(1995).Science,269,403–407.XiaoGH,BeeserA,ChernoffJandTestaJR.(2002).J.Biol.Chem.,277,883–886.ZhangF,WhiteRLandNeufeldKL.(2001).Mol.Cell.Biol.,21,8143–8156.NucleocytoplasmicshuttlingofmerlinTMuranenetal1158OncogeneThemerlintumorsuppressorinteractswithRalguaninenucleotidedissociationstimulatorandinhibitsitsactivityChungHunRyu1,2,Sae-WoongKim2,KyuHwaLee1,JooYongLee1,HongtaeKim1,WoonKyuLee3,ByungHyuneChoi1,YoungLim4,YoungHoonKim1,Kweon-HaengLee3,Tae-KonHwang2,Tae-YounJun*,1,5andHyoungKyunRha11CatholicNeuroscienceCenter,TheCatholicUniversityofKorea,Seoul137-701,Korea;2DepartmentofUrology,TheCatholicUniversityofKorea,Seoul137-701,Korea;3DepartmentofPharmacology,TheCatholicUniversityofKorea,Seoul137-701,Korea;4DepartmentofOccupationalandEnvironmentalMedicine,TheCatholicUniversityofKorea,Seoul137-701,Korea;5DepartmentofPsychiatry,TheCatholicUniversityofKorea,Seoul137-701,KoreaNeuroﬁbromatosistype2(NF2)isthemostcommonlymutatedgeneinbenigntumorsofthehumannervoussystemsuchasschwannomasandmeningiomas.TheNF2geneencodesaproteincalledschwannominormerlin,whichisinvolvedinregulatingcellgrowthandprolifera-tionthroughprotein–proteininteractionswithvariouscellularproteins.Inordertobetterunderstandthemechanismbywhichmerlinexertsitsfunction,yeasttwo-hybridscreeningwasperformedandRalguaninenucleotidedissociationstimulator(RalGDS),adown-streammoleculeofRas,wasidentiﬁedasamerlin-bindingprotein.ThedirectinteractionbetweenmerlinandRalGDSwasconﬁrmedbothinvitroandintheNIH3T3cells.ThedomainanalysesrevealedthatthebroadC-terminalregionofmerlin(aa141–595)isnecessaryfortheinteractionwiththeC-terminalRas-bindingdomain(RBD)ofRalGDS.FunctionalstudiesshowedthatmerlininhibitstheRalGDS-inducedRalAactivation,thecolonyformationandthecellmigrationinmammaliancells.TheseresultssuggestthatmerlincanfunctionasatumorsuppressorbyinhibitingtheRalGDS-mediatedoncogenicsignals.Oncogene(2005)24,5355–5364.doi:10.1038/sj.onc.1208633;publishedonline27June2005Keywords:NF2;merlin;tumorsuppressor;RalGDS;oncogenicsignalsIntroductionNeuroﬁbromatosistype2(NF2)isadominantlyinheriteddisorderthatpredisposespatientstothedevelopmentofmultiplebenigntumorsofthehumannervoussystemsuchasschwannomasandmeningiomas(Thomasetal.,1994;Louisetal.,1995).TheNF2geneproductisreferredtoaseithermerlinorschwannomin,andhasasequencehomologytothemembersofthe4.1familyproteinssuchasezrin,radixinandmoesin(ERMproteins),whichlinkthecytoskeletontotheplasmamembrane(Rouleauetal.,1993;Trofatteretal.,1993).TheERMproteinshavebeenimplicatedinthecellularremodelingandtheformationofmembranemicrovilliandrufﬂes(Tsukitaetal.,1997).BasedonthesequencehomologywiththeERMproteins,merlinisalsobelievedtofunctionasaproteinlinkingthecellularmembraneandcytoskeleton.However,merlinhasdistinctpropertiesandfunctionsintheregulationofcellgrowthandproliferationthatarenotascribedtoERMproteins(Shermnetal.,1997;Ikedaetal.,1999;Morrisonetal.,2001).Ineffortstodeterminethecellularfunctionofmerlin,severalgroupshaveidentiﬁedpotentialmerlin-interactingproteinssuchasschwannomininteractingprotein1(SCHIP-1),Naþ–Hþexchangerregulatoryfactor(NHERF),bII-spectrine(alsoknownasfodrin),CD44,synthenin,paxillin,hepatocytegrowthfactor-regulatedtyrosinekinasesubstrate(HRS)(alsoknownasHGS),merlin-associatedprotein(MAP)andtrans-activation-responsiveRNA-bindingprotein(TRBP)(Sainioetal.,1997;Murthyetal.,1998;Scolesetal.,1998;Goutebrozeetal.,2000;Scolesetal.,2000;Jannatipuretal.,2001;Fernandez-Valleetal.,2002;LeeIKetal.,2004;LeeJYetal.,2004).Theseproteinsaremostlyassociatedwithandinvolvedinthefunctionofthecellularmembrane.Therefore,merlinmightexertitstumorsuppressoreffectspresumablybymodulatingthemembranereceptor–cytoskeletallinkagethatisessentialforcellgrowthandtheadhesionpathwaysviatheinteractionwiththeseproteins(Kogaetal.,1998;Jannatipuretal.,2001).However,theactionmechanismofmerlinasatumorsuppressorisstillnotfullyunderstoodjustwiththecurrentreports.Inordertoidentifythenovelproteinsimportantinthefunctionofmerlin,yeasttwo-hybridscreeningwasperformedwithhumanbraincDNAlibraryandmerlinproteinasbait.OneofthepositiveclonesencodedRalGDS,whichfunctionsasaRaseffectorandaReceived17November2004;revised7February2005;accepted14February2005;publishedonline27June2005*Correspondence:T-YJun,DepartmentofPsychiatry,TheCatholicUniversityofKorea,505Banpodong,Sochoku,Seoul137-701,Korea;E-mail:ngrc@catholic.ac.krOncogene(2005)24,5355–5364&2005NaturePublishingGroupAllrightsreserved0950-9232/05$30.00www.nature.com/oncGDP/GTPexchangefactor(GEF)fortheRalprotein(Rusanescuetal.,2001).TheactivationofRalGDSanditstarget,Ral,constitutesadistinctdownstreamsignalingpathwayoftheoncogenicRas-inducedcelltransformation(McCormickandWittinghofer,1996;JonesonandBar-Sagi,1997;VojtkandDer,1998).Inaddition,similartotheactiveformofHa-Ras,theconstitutiveactiveRalGDSmutantsynergizeswithRaf-1toinduceatransformationofNIH3T3cells,whichisinhibitedbythedominant-negativemutantofRalA(Uranoetal.,1996;Whiteetal.,1996).Interestingly,manyresearchgroupshavereportedthatthemerlintumorsuppressorinhibitstheRassignalingpathwaysandtheRas-inducedcelltrans-formation(Tikooetal.,1994;KimHetal.,2002).Therefore,theinteractionbetweenRalGDSandmerlinmightnegativelyregulatetheRas–RalGDS–Ralsignal-ingpathwaysandprovideoneofmechanismsofmerlinasatumorsuppressor.ThisreportdemonstratesthedirectinteractionofRalGDSandmerlinbothinvitroandinvivo,andpresentsevidenceforthefunctionalimportanceoftheirinteraction.ResultsIdentiﬁcationofRalGDSasamerlin-bindingproteinInordertoidentifythebindingpartnerofmerlin,thefulllengthofmerlinwasusedasbaitfortheyeasttwo-hybridscreeningwithahumanbraincDNAlibrary.Among2106transformants,25strongpositiveswereisolatedandtestedbyare-transformation.ThepartialnucleotidesequencingofthecDNAfragmentsrevealedthatfourclonesencodedtheC-terminalportionofRalGDS.Thefull-lengthopenreadingframeofRalGDSwasobtainedusingthe50-RACEscreeningofthehumanplacentacDNA.InordertomaptheRalGDS-interactiondomainofmerlin,theGAL4–DBDfusedfull-lengthanddeletionderivativesofmerlinweretestedforthebindingwiththeGAL4-ADfusedfull-lengthorthepartialRalGDS(RalGDS-P)proteinintheyeasttwo-hybridsystem(Figure1a).Theyeastgrowthtestshowedthatboththefull-lengthandRalGDS-PactivelyinteractedwiththeM1,M3andM4deletionmutantsofmerlin,butnotwiththeM2mutantthatdoesnotcontainaBlueBox(BB)(Johnsonetal.,2002;Sunetal.,2002).Theb-galactosidaseassaysshowedaconsistentresultbutalsorevealedthatRalGDSinteractedonlyweaklywiththeM3andM4merlinmutants(Figure1b).Overall,theseresultssuggestthatthebroadC-terminalregion(aminoacids(aa)141–595)ofmerlinisnecessaryforthefullinteractionwiththeC-terminalregionofRalGDS,containingaRBD.MerlinisassociatedwithRalGDSinvitroandinmammaliancellsInordertoconﬁrmthedirectinteractionbetweenRalGDSandmerlin,theGSTpull-downassayswereperformedusingtheGST–RalGDSfusionproteinandthe35S-labeledwild-typeormutantmerlinproteinsproducedbyinvitrotranslation.Theresultshowedthatthefull-lengthmerlinandonlytheM1mutantamongitsfourdeletionmutantsboundspeciﬁcallytoGST–RalGDSimmobilizedontheglutathione-Sepharose4Bbeads(Figure2).TheseresultssuggestthatmerlininteractswithRalGDSinvitroandconﬁrmedthatthe141–595amino-acidregionofmerlinisnecessaryforthisinteraction.WespeculatethattheinteractionFigure1MappingofspeciﬁcdomainsofmerlinresponsiblefortheassociationwithRalGDS.(a)SchematicdiagramofthemerlinandRalGDSconstructsusedintheyeasttwo-hybridassays.ThemerlinproteinswerefusedwithGAL4-DBD,andRalGDSproteinswerefusedwithGAL4-AD.(b)Asummaryoftheyeasttwo-hybridresultsusingRalGDSandmerlinproteins.Theplasmidswereco-transformedintotheyeastcellsandthebindingabilitywastested.Theb-galactosidaseassay(lacZactivity)andthegrowthofyeastcellsintheabsenceofhistidinewereperformedasdescribedinMaterialsandmethods.ThegrowthabilitiesoftheHisþcoloniesareindicatedaseither(þ)or( )MerlinassociateswithRalGDSCHRyuetal5356OncogenebetweentheM3orM4merlinmutantandRalGDSwastooweaktobedetectedintheinvitrobindingassayandtheb-galactosidaseassayinyeast.InordertofurtherdemonstratetheinteractionbetweenRalGDSandmerlininanimalcells,NIH3T3cellswereco-transfectedwiththeplasmidsexpressingFlag-taggedRalGDSandmerlin.Thecelllysatesweresubjectedtoimmunoprecipitationwithanti-Flaganti-body.SubsequentWesternblottingwiththeanti-merlinantibodyrevealedthatmerlininteractedwithRalGDSinNIH3T3cells(Figure3a).Then,weexaminedwhetherendogenousmerlinandRalGDSinteractinintactcells.Whenassessedbyco-immunoprecipitationinNIH3T3cells,endogenousmerlinwasobservedonlyintheRalGDSimmunecomplexbutnotinthecontrolGFPimmunecomplex(Figure3b).Overall,theseresultsindicatethatRalGDSinteractswithmerlininintactcellsattheendogenouslevel.RalGDSco-localizeswithmerlininvivoMerlinisknowntopresentprimarilyinthecytoplasmicmembrane(Chishtietal.,1998)andisalsofoundaroundthemembrane-rufﬂingregionandingranules/vesiclesattheperinuclearregion(Schmuckeretal.,1999).InordertodetermineifRalGDSco-localizeswithFigure2InvitrointeractionofRalGDSandmerlin.(a)TheGSTpull-downassaywithRalGDSandmerlin.Merlinproteinwaslabeledwith[35S]methioninebyinvitrotranslationandincubatedwith2mgofGSTorGST-RalGDSproteinfor2hat41C.Afterextensivewashing,theboundmerlinwasextractedanddetectedwithPhosphorImager(upperpanel).Theamountofaddedmerlininthereticulocytelysateisshowninthemiddlepanel.TheGST–RalGDSfusionproteinsweresubjectedtoSDS–polyacrylamidegelelectrophoresisandsubsequentWesternblottinganalysisusingtheanti-RalGDSantibody(bottompanel).(b)ThebindingofthedeletionmutantsofmerlinwithRalGDS.Eachmutantproteinwaslabeledwith[35S]methioninebyinvitrotranslationandincubatedwith2mgoftheresin-boundGST-RalGDSfor2hat41C.WashinganddetectionofmerlinproteinswereperformedasdescribedaboveusingPhosphorImager(upperpanel).Theamountofmerlinmutantsineachreticulocytelysateisshowninthelowerpanel.Theasterisksindicatethepositionsofmerlinmutantsexpectedfromtheircalculatedmolecularweight.WB:WesternblottingFigure3AssociationofRalGDSandmerlininNIH3T3cells.(a)NIH3T3cellsweretransfectedwith1.2mgofthemerlinexpressionplasmidwithorwithouttheexpressionplasmidforFlag-taggedRalGDSasindicated.Thecelllysatesweresubjectedtoimmuno-precipitationwiththeanti-Flagantibodyandimmunoblottingwiththeanti-merlinantibody(toppanel).Theleveloftheimmunopre-cipitatedFlag-RalGDSwasanalysedbyWesternblotusingtheanti-Flagantibody(middlepanel).Theamountoftheaddedmerlinineachlysateisshowninthebottompanel.(b)TheinteractionofmerlinwithRalGDSattheendogenouslevel.Thecelllysateswereimmunoprecipitatedwithanti-RalGDSoranti-GFPantibody,andimmunoblottedwiththeanti-merlinantibody(toppanel).TheleveloftheimmunoprecipitatedRalGDSwasanalysedbyWesternblottingwiththeanti-RalGDSantibody(middlepanel).TheendogenouslevelofmerlinandRalGDSineachlysateisshowninthetwobottompanels.WB:Westernblotting,IP:immunopreci-pitationMerlinassociateswithRalGDSCHRyuetal5357Oncogenemerlin,theywereco-expressedinNIH3T3cellsandimmunostainedwiththespeciﬁcantibodies.Theﬂuor-escenceimageswereanalysedbyconfocalmicroscopy.Whenexpressedseparately,merlinwasmainlydetectedatthecytoplasmicmembraneandtheperinuclearregion(Figure4a)asexpected,whileRalGDSwasdistributedthroughoutthecytoplasm(Figure4d).Whentheywereco-expressed,theperinuclearmerlinwasdecreasedandRalGDSappearedtobeenrichedatthecytoplasmicmembrane,wheretheyweremainlyco-localized(Figure4e–g).Theco-localizationofmerlinandRalGDSwasalsoobservedattheendogenouslevelinNIH3T3cellswithouttheoverexpressionoftheseproteins(Figure4n–p).Tocorrelatetheresultwiththatofthedomainanalysis,weperformtheexperimentwiththeM1andM2merlinmutants.TheM1merlinmutantshowedacellularlocalizationpatternsimilartothewild-typemerlin,butwasenrichedattheperinuclearregion(Figure4b).However,theM2merlinmutantwasmainlydetectedatthenucleuswithsomecytoplasmiclocalization,whichwasnotnormallyobservedwiththewild-typemerlin(Figure4c).Whenco-expressedwiththeM1orM2mutants,RalGDSwasco-localizedwiththeM1mutant(Figure4h–j)butnotwiththeM2mutant(Figure4k–m),asexpectedfromtheirinvitrointeractionresult.Overall,theseresultssuggestthatboththeoverexpressedandendogenousmerlinareco-localizedwithRalGDSinanimalcells.MerlininhibitstheRalGDSactivityRalGDSisoneoftheRaseffectorsandstimulatestheGDP/GTPexchangeofRal,whichisamemberoftheRassuperfamilyofGTPasesthatcyclesbetweentheactiveGTP-boundandinactiveGDP-boundstates(Feigetal.,1996).Indeed,RalGDSpromotesthereleaseofGDPfromRalandGTPbindinginitsplace,whichactivatesRal.TheactiveGTP-boundRalcanspeciﬁcallyinteractwithadistinctsetofdownstreamtargetproteinssuchasRalBP1(orRLIP)andPOB1(Cantoretal.,1995;Yamaguchietal.,1997;Ikedaetal.,1998).Figure4Co-localizationofmerlinwithRalGDSinNIH3T3cells.NIH3T3cellsweregrownonthechamberslidesandtransfectedwithpcDNA-NF2,pcDNA3.1-M1,pcDNA3.1-M2and/orpcDNA3.1-RalGDSasindicated.Thecellswereﬁxed,permeabilizedandstainedwithanti-merlin(a–c,e,handk)oranti-RalGDS(d,f,iandl)antibodies.TheendogenousmerlinandRalGDSwerealsostainedwithanti-merlin(n)oranti-RalGDS(o)antibodies.Theﬂuorescenceimageswerecapturedusingconfocalmicroscopy.Theco-localizationofmerlinandRalGDSisshownbytheyellowcolorintheoverlayimage(g,j,mandp)MerlinassociateswithRalGDSCHRyuetal5358OncogeneInordertoinvestigatethefunctionalsigniﬁcanceoftheirinteraction,theeffectofmerlinontheRalGDS-mediatedactivationofRalAwasassessedviathebindingactivityofRalAtotheRal-bindingdomainofRalBP1.RalGDSandRalAweretransientlyexpressedinNf2-deﬁcientorwild-typemouseembryoﬁbroblasts(MEFs)incombinationwiththefull-lengthordeletionmutantsofmerlin,andtheRalGDSactivitywasmeasuredindirectlybytheleveloftheGTP-boundactiveRalAproteininthepull-downcomplexofRalBP1.AsshowninFigure5a,RalGDSinducedtheassociationbetweenRalBP1andRalAbothintheNf2 / andNf2þ/þMEFs,butwiththelevelofactiveRalAsomewhathigherinNf2 / MEFthaninNf2þ/þMEFs.Co-expressionofthefulllengthorM1mutantofmerlin,butnotoftheM2mutant,inNf2 / MEFsinhibitedtheirinteraction,whichindicatesthatexogen-ousmerlinreducesRalGDS-mediatedactivationofRalA.Thelevelsoftheoverexpressedproteinsandb-actininthetransfectedcellsweremonitoredbyWesternblotting(Figure5a,fourbottompanels).TheseresultssuggestthattheinteractionbetweenmerlinandRalGDSleadstotheinhibitionofRalAactivation.TheeffectofmerlinontheRalGDS-mediatedactivationofRalAwasalsoobservedinNIH3T3cells(datanotshown).TheeffectofmerlinontheRalGDSactivitywasalsoanalysedbymeasuringtheratioofGTPoverthetotalguaninenucleotidesboundtoRalA.COS7cellsweretransfectedwiththeexpressionplasmidsasabove,andlabeledwith[32P]orthophosphate.Afterimmunoprecipi-tationwiththeanti-RalAantibody,theradiolabeledGTPandGDPwereseparatedbyTLCandquantiﬁedusingaPhosphoImager.Whenco-expressedwithRalA,RalGDSinducedsigniﬁcantlytheRalA-boundGTPcontentinCOS7cells(Figure5b).However,theadditionalexpressionofmerlininhibitedthisRalGDSactivity.TheEGFtreatmentwasusedasapositivecontrolforRalAactivation.TheseresultsstronglysuggestthatmerlincandirectlyinhibittheabilityofRalGDStoactivateRalA.MerlininhibitsthecolonyformationofNIH3T3cellsbyRalGDSandRalASimilartotheactiveRas(12V,37G),RalGDSinducestheformationoffociandgrowthofmorphologicallytransformedNIH3T3cellsinthepresenceofactiveRaf(McCormickandWittinghofer,1996).Moreover,RalproteinisinvolvedintheRas-dependenttransformationofNIH3T3cells(VojtkandDer,1998;Wolthuisetal.,1998;JoffeandAdam,2001).Accordingly,theeffectofmerlinonthecellularfunctionsofRalGDSwasinvestigatedbyacolonyformationassay.NIH3T3cellswereco-transfectedwiththeexpressionvectorsforRalGDSandRalAinthepresenceorabsenceofmerlinanditsdeletionmutants(M1andM2mutants).ThepcDNA3.1plasmidwasusedasthenegativecontrol.ThecellswereselectedwithG418for2weeksandthenumberofcoloniesformedontheplateswascounted.AsshowninFigure6b,thenumberofG418-resistantcoloniesinthepresenceofRalGDSandRalAwasaboutthreetimeshigherthanthecontrol.However,thenumberofcolonieswassigniﬁcantlylowerwheneitherthewild-typemerlinorM1mutantwasco-expressedwiththem.TheM2deletionmutantofmerlinshowednoeffectonthecolonyformationbyRalGDSandRalA.TheexpressionofRalAorRalGDSalonewasnotefﬁcientininducingacolonytransformationofFigure5EffectofmerlinontheRalGDSactivity.(a)Nf2 / andNf2þ/þMEFs(2105)weretransfectedwith1mgeachofRalA,RalGDSand/orexpressionvectorsforthefull-lengthmerlin,theM1andM2mutantsofmerlinasindicated.TheGTP-boundRalAwasquantiﬁedafterprecipitationwiththeresin-boundRalBP1.TheleveloftheactiveRalAwasanalysedwiththeRalAantibody(pull-down).ThecelllysatesweresubjectedtoWesternblottinginordertocontrolthecellularlevelsofRalA,RalGDS,merlinandb-actin(lysate).Theasterisksindicatethepositionsofmerlinanditsmutants(M1andM2)expectedfromtheircalculatedmolecularweight.(b)COS7cells(3105)weretransfectedwith1mgeachofRalA,RalGDSand/ormerlinexpressionvectorsasindicated,andlabeledwith[32P]orthophosphatefor4h.Aftertheimmunopreci-pitationofRalA,theboundguanidinenucleotideswereelutedandseparatedonTLC.TheintensityoftheGDPandGTPspotswasquantiﬁedandtheGTP/(GTPþGDP)ratiowascalculated.Theexperimentswereperformedthreetimesinduplicateandtheresultswereaveraged.ThestandarderrorsareshownonthetopofeachbarMerlinassociateswithRalGDSCHRyuetal5359OncogeneNIH3T3cells(datanotshown)asreported(Whiteetal.,1996).TherepresentativeplateimagesareshowninFigure6a.TheseresultssuggestthatmerlinsuppressestheRalGDSandRalA-mediatedcellgrowth.MerlininhibitstheRalGDS-inducedcellmigrationTheactivationoftheRas–RalpathwaybytheactiveformofRas,RalGDSorRalisshowntoincreasethemotilityofmyoblast(Suzukietal.,2000).Therefore,weinvestigatedwhethertheactivationofRalGDSstimu-latesthemigrationofNIH3T3cellsandmerlininhibitsthestimulatoryeffectofRalGDS.TheNIH3T3celllinesexpressingthecontrolplasmidorRalGDSwereconstructedforthisexperiment.Awound-healingassaywasperformedasdescribedinMaterialsandmethodsinthepresenceofEGFtoinducecellmigration(Melchiorietal.,1990;Gildeaetal.,2002;Takayaetal.,2004).MitomycinCwastreatedtothecellsinordertoavoidtheconfoundingeffectofcellproliferation.ThecontrolandRalGDSstablecellswereinfectedwiththeadenovirusexpressingGFP(Ad-GFP)ormerlin(Ad-NF2)withtheEGFtreatment.AsshowninFigure7a,theRalGDSstablecellsmigratedtothewoundfrontapproximatelythreetimesfasterthanthecontrolcells.However,thismigrationwasreducedapproximatelybythehalfwhenthecellswereinfectedwithAd-NF2.AninfectionofAd-GFPshowednoeffectonthewoundhealingofboththecontrolandRalGDSstablecells(datanotshown).TheeffectofmerlinandRalGDSonthemotilityofNIH3T3cellswasalsoexaminedinamodiﬁedBoydenchamberassay(seeMaterialsandmethodsfordetails).ThecontrolandRalGDSstablecellswereinfectedwithanadenovirusexpressingeitherGFP(Ad-GFP)ormerlin(Ad-NF2)withorwithouttheEGFtreatment.WheninfectedwiththeAd-GFP,theRalGDSstablecellsmigratedfasterthanthecontrolcellsbothinthepresenceorabsenceofEGF(Figure7b).Incontrast,theRalGDSstablecellsshowedareducedmotilitybyaAd-NF2infectionregardlessoftheEGFtreatment,thelevelofwhichwasevenlowerthanthatoftheAd-GFP-infectedcells.Overall,theseresultssuggestthatRalGDSenhancesthemotilityofNIH3T3cellsandmerlincanabolishtheRalGDS-inducedcellmigration.DiscussionInthisstudy,weidentiﬁedRalGDSasamerlin-bindingproteinbyyeasttwo-hybridscreening(Figure1).TheinvitroandinvivobindingexperimentsshowedthatRalGDSandmerlininteractdirectly,evenattheendogenouslevel(Figures2–4),suggestingthebiologicalrelevanceoftheirinteractionunderphysiologicalcon-ditions.RalGDSisknownasoneofRaseffectorproteinsandfunctionsasaguanine-nucleotideexchangefactorforRalprotein,stimulatingthedissociationofGDPfromandthebindingofGTPtoRal.WeshowedthatmerlininhibitstheabilityofRalGDSactivatingRalA,whichsuggeststhatmerlinmightnegativelyregulatetheRalGDS-mediatedsignalingpathways(Figure5).ThebiologicalsigniﬁcanceoftheirinteractionwasalsoshowninthecolonyformationassayinNIH3T3cells.ItwasreportedthattheRalGDS–RalsignalingpathwayisinvolvedintheRas-dependentoutgrowthofNIH3T3cells(Whiteetal.,1996).Inthisstudy,theoverexpressionofmerlininhibitedtheRalGDSandRalA-inducedcolonyformationofNIH3T3cells(Figure6).ThissuggeststhatmerlincansuppresstheFigure6InhibitionofRalGDSandRalAinducedcolonyformationofNIH3T3cellsbymerlin.(a)NIH3T3cells(3105)weretransfectedwith1.2mgeachofpcDNA-Flag-RalGDS,pcDNA3-HA-RalAand/orpcDNA-NF2,pcDNA-M1andpcDNA-M2asindicated.NIH3T3cellsnontransfectedortrans-fectedwithpcDNA3.1wereusedasthenegativecontrols.Thecellswereselectedfor2weekswith400mg/mlG418.Theexperimentswereperformedthreetimesandarepresentativeimagewastaken.(b)Thenumberofcolonyformedin(a)wascountedandtheresultswereaveraged.ThestandarderrorsareshownonthetopofeachbarMerlinassociateswithRalGDSCHRyuetal5360OncogeneRalGDSandRalA-mediatedcellgrowth,whichisinagreementwiththepreviousreports(Shermnetal.,1997;Ikedaetal.,1999;Morrisonetal.,2001).Inadditiontosuppressingcellgrowth,theoverexpressionofmerlinwasreportedtoreversetheHA-ras-inducedmalignantphenotypesofNIH3T3cellsandrestorethecontactinhibitionofthecell(Tikooetal.,1994).ManystudieshaveshownthatmerlininhibitsthediverseRas-mediatedsignalingpathways(KimHetal.,2002;Limetal.,2003;Hirokawaetal.,2004),butnodirecttargetofmerlinhasbeenidentiﬁed.WesuggestherethatinhibitionofRalGDSactivityviadirectinteractioncanbeoneofthemechanismsbywhichmerlinsuppressestheRas-signalingpathways.RalisknowntoregulatemyoblastcellmigrationandtheinitiationofbordercellmigrationduringDrosophilaoogenesis(Leeetal.,1996;Suzukietal.,2000).Incontrast,theeffectofRalGDSonthecellmigrationhasnotbeenreported.Weshowedherethattheover-expressionofRalGDSenhancedthemotilityofNIH3T3cellsandco-expressionofmerlininhibitedtheRalGDS-inducedcellmigration(Figure7).Themigra-tionabilityofcellsisthoughttobeassociatedwiththemetastaticpotentialoftumors(ArveloandPoupon,2001).TheinhibitionoftheRalGDSsignalingpathwaysbyadominant-negativeRalproteinblocksRas-mediatedmetastaticgrowthofcells(Uranoetal.,1996;Luetal.,2000).Inaddition,thegermlineheterozygousNF2mutantmicedevelopsavarietyofaggressivemalig-nanciesnoticeablywiththemetastaticproperty(McClatcheyetal.,1998).Therefore,theinhibitionofRalactivitybymerlinviatheinteractionwithRalGDSmightcontributetotheantimetastaticactivityofmerlin.Currently,themechanismforhowmerlininhibitstheRalGDSactivityisunclear.Merlinhasnoknownenzymaticactivitiesandisbelievedtomodulatevariousprotein–proteininteractionsdependingonitsfoldingstate(Scolesetal.,2002).Therefore,itismostplausiblethatmerlininhibitsRalGDSactivitybyinterferingdirectlywiththeinteractionofRalGDSwithothersignalingproteins.ThedomainanalysisshowedthatmerlininteractswiththeC-terminalRBDofRalGDS(Figures1and2).ThissuggeststhatmerlinmightinterferewiththeinteractionbetweenRasandRalGDS.However,theremightbeadditionalregulationmechan-isms,becausemerlininhibitedtheactivityoftheoverexpressedRalGDSwithoutstimulatingsignalsfromRas(Figures5–7).Inmerlin,theregioncontainingthe‘BlueBox’(BB)sequenceofFERMdomain(aa131–201)isinvolvedintheinteractionwithRalGDS(Figures1and2).DespitemerlinsharingahighsequencehomologywiththeERMproteinsintheFERMdomain,thisseven-residueBB(aa177–183,YQMT-PEM)wasnotconservedintheERMproteins(Sunetal.,2002).Therefore,thisBBsequencemightberesponsiblefortheuniquefunctionofmerlinastumorsuppressoranditsinteractionwithadistinctsetofproteinsincludingRalGDS.Interestingly,weobservedthattheM2merlinmutantthatlackstheBB-containingregionwaslocalizedmainlyinthenucleuswherethewild-typemelinisnotnormallydetected(Figure4).ThissuggeststhattheBBcouldbeinvolvedinthenuclear/cytoplasmicshuttlingofmerlinaspreviouslysuggested(Johnsonetal.,2002;KresselandSchmucker,2002).Inconclusion,thisreportdemonstratesthatRalGDSisanovelbindingpartnerofmerlin,andsuggeststhattheirinteractionmightprovideoneoftheimportantpathwaysregulatingtheoncogenictransformationandthemigrationofcells.However,thedetailedmechanismunderlyingtheirinteractionrequiresfurtherinvestiga-tionstobeelucidated.Figure7SuppressionofRalGDS-inducedcellmigrationofNIH3T3cellsbymerlin.(a)MonolayersofthestableNIH3T3cells(2105)expressingpcDNA3.1(control)orRalGDSwereinfectedwith100moieachofAd-GFPorAd-NF2andtreatedwithEGFandwoundedwithapipettetip.Thehealingofthewoundfrontswasexaminedafter48husingphasecontrastmicroscopy.Arepresentativeimageofthreeindependentexperimentsisshown.(b)ThecontrolandtheRalGDSstableNIH3T3cells(3105)wereplatedonthechamberslidesandinfectedwith100moieachofAd-GFPorAd-NF2asindicated.Thecellsintheupperchamberwereculturedinserum-freeDMEM,andthelowerchamberwasﬁlledwithDMEMcontaining10%FBS.After6h,thecellswerelysedandstainedwithaCyQuantGRdye.Themigrationofcellswasquantiﬁedbytheﬂuorescenceintensities.Theexperimentswereperformedthreetimesinduplicateandtheresultswereaveraged.ThestandarderrorsareshownonthetopofeachbarMerlinassociateswithRalGDSCHRyuetal5361OncogeneMaterialsandmethodsPlasmidsTheyeastplasmidsforthewild-type(WT)merlinanditsdeletionmutants(M1–M4)weregeneratedbycloningthePCRfragmentsintopGBT9,aGAL4DNA-bindingdomainvector(Clontech,PaloAlto,CA,USA).TheBamHIrestrictionsiteswereusedforboththe50-and30-ends.TheplasmidsencodingtheC-terminalorthefulllengthofhumanRalGDSwerealsogeneratedbyPCRcloningintopACT2,aGAL4activationdomainvector(Clontech,PaloAlto,CA,USA),usingEcoRI(50primers)andXhoI(30primers)restrictionsites.ThemammalianexpressionplasmidsfortheWTmerlinanditsdeletionmutants(M1–M4)weredescribedpreviously(KimJYetal.,2002).Themammalianexpressionplasmidforthewild-typeRalGDS(pcDNA-Flag-RalGDS)wasconstructedbyinsertingthePCRfragmentintotheEcoRI–HindIIIsitesofpcDNA3.1-Flag(Invitrogen,SanDiego,CA,USA).AFlagepitopewastaggedattheN-terminalendofRalGDS.TheGST-fusionconstructofthewild-typeRalGDS(pGEX-KG-RalGDS)wasalsogeneratedbyPCRandsubclonedintopGEX-KG(Pharmacia,Piscataway,NJ,USA)usingEcoRI–HindIIIsites.ThemammalianexpressionplasmidofRalA(pcDNA3-HA-RalA)wasakindgiftfromDrTakashiIwamoto.Yeasttwo-hybridscreeningAcDNAencodingthefull-lengthhumanmerlinwasusedasbaitintheyeasttwo-hybridscreensofahumanbraincDNAlibraryinpACT2(Clontech,PaloAlto,CA,USA).ThebaitandthelibraryDNAswereco-transformedtoyeastusingthelithiumacetatemethodasdescribedpreviously(Gietzetal.,1992).ThetransformantswereselectedforgrowthontheLeu ,Trp ,His andAde solidmediacontaining25mM3-aminotriazole(3-AT).Theb-galactosidaseproductionwasassayedbyincubatingfreeze-fracturedcoloniesonnitrocellu-loseinaZ-buffer(60mMNa2HPO4,40mMNaH2PO4,10mMKCl,1mMMgSO4,0.03mMb-mercaptoethanoland2.5mMX-gal)at301C.cDNAcloningThefull-lengthcDNAencodingRalGDSwasclonedusingtheMarathoncDNAAmpliﬁcationsystem(Clontech,PaloAlto,CA,USA).Brieﬂy,50-RACEwasperformedusingthehumanplacentacDNAtemplate.ThePCRconditionwasasfollows:941Cfor1min;ﬁvecyclesof941Cfor30s,721Cfor3min;ﬁvecyclesof941Cfor30s,701Cfor30s,721Cfor3min;and25cyclesof941Cfor30s,681Cfor30s,721Cfor3min.Fromtheexperiment,aB2.7kbcDNAwasobtainedandclonedintheTOPOTACloningvector(InvitrogenCorp,Carlsbad,NM,USA)andthesequencewasveriﬁed.ConstructionofstablecelllinesNIH3T3cellswereobtainedfromtheAmericanTypeCultureCollection(Manassas,VA,USA)andmaintainedinDMEMsupplementedwith10%FBSandantibiotics.Inordertoconstructastablecellline,NIH3T3cellsweretransfectedwithpcDNA-Flag-RalGDSorpcDNA3.1plasmidasacontrol.After48h,thecellsweresplitata10:1ratioandculturedinthemediumcontaining400mg/mlG418for3weeks.TheindividualG418-resistantcolonieswereisolatedandtheoverexpressedRalGDSwasconﬁrmedbyWesternblotting.TransienttransfectionNIH3T3(3105cells)wereplatedona35mmplateandtransfectedwiththeplasmidsusingGenePorter2reagentaccordingtothemanufacturer’sinstruction(GeneTherapySystemInc.).ThetotalamountofthetransfectedDNAwasnormalizedusingthepcDNA3.1plasmidasacarrier.GSTpull-downassayTheGSTfusionproteinencompassingthefull-lengthRalGDSwasexpressedinEscherichiacoliandpuriﬁedasdescribedpreviously(Hoferetal.,1994).Invitrotranslationwasperformedtoobtainwild-typemerlinanditsdeletionmutantslabeledwith[35S]methionineusingtheTNTT7CoupledReticulocyteLysateSystem(Promega,Madison,WI,USA).Forthepull-downassay,2mgofGST-RalGDSwasimmobi-lizedontheglutathione-Sepharose4Bbeadsandincubatedwiththe35S-labeledmerlinproteinsinRIPA-Bbuffer(0.5%NonidetP-40,20mMTris(pH8.0),50mMNaCl,50mMNaF,100mMNa3VO4,1mMDTTand50mg/mlPMSF)for2hat41C.AfterwashingwiththeRIPA-Bbuffer,thesampleswereanalysedbySDS–PAGEandaPhosphorImager.ImmunoprecipitationTheanti-merlin,anti-RalGDS(SantaCruzBiotechnology,Inc.)andanti-Flag(Sigma,Inc.)antibodieswereobtainedfromcommercialsources.Forimmunoprecipitation,NIH3T3cells(3105cells)in35-mmplateweretransfectedwith1.0mgeachoftheexpressionplasmidsasindicatedinFigure3a.After24h,thecellswerelysedintheRIPA-Bbufferfor20minonice.Theinsolublematerialwasremovedbycentrifugationat12000rpmfor20minat41C.Thesupernatantwasincubatedwiththeanti-Flagantibodiesfor5hat41C,andthenincubatedfor2hwiththepre-clearedproteinAagarosebead(Sigma,Inc).Subsequently,thebeadswerewashedthreetimesinRIPAbufferandre-suspendedin50mlof1SDSsamplebuffer.ThesampleswereanalysedbyWesternblottingusingtheanti-merlinantibody.ImmunocytochemistryNIH3T3cells(7104)inachamberslide(NUNC,fourwell)weretransfectedwith1.0mgeachoftheexpressionplasmidsasindicatedinFigure4.After24h,thecellswererinsedwith1PBSandﬁxedwith4%paraformaldehydefor20min.Then,thecellswerepermeabilizedinPBScontaining0.5%TritonX-100for15minandtheslideswereblockedwith0.2%BSAinPBSfor30min.Thechamberslideswereincubatedwithanti-merlin(1:500)andanti-RalGDS(1:100)antibodiesovernightat41C,andrinsedwithPBSﬁvetimes.TheFITC-conjugatedanti-rabbitandtherhodamine-conjugatedanti-goatsecondaryantibodies(SantaCruzBiotechnology,Inc.)wereusedforanti-merlinandanti-RalGDSantibodies,respectively.Thechamberslidesweremountedonglassslidesandtheimageswereacquiredusingconfocallaser-scanningmicroscopy.RalactivityassayinmammaliancellsNf2 / andNf2þ/þMEFs(2105cells)inthe35-mmplateweretransfectedwith1.0mgeachoftheexpressionplasmidsasindicatedinFigure5a.After24h,thecellswerelysedwithlysisbuffer(1%Triton,20mMTris-HCl(pH7.5),10mMMgCl2,150mMNaCl,1mMPMSF,1mMNa3VO4,50mMNaF,10mg/mlleupeptinand10mg/mlaprotinin)for20minonice.Thecelllysateswereincubatedwith2mgofGST-fusedRBDofRalBP1(GST-RalBP1,UpstateBiotechnology,Inc.)for1hatMerlinassociateswithRalGDSCHRyuetal5362Oncogene41C.Then,thebeadswereprecipitatedbycentrifugation,extensivelywashedandanalysedbyWesternblottingusingtheanti-RalAantibody(UpstateBiotechnology,Inc.).Theprin-cipleforassessingtheRalAactivationisdescribedintheResultssection.GDP/GTPexchangeassayofRalGDSinmammaliancellsCOS7cells(3105cells)in35-mmplateweretransfectedwith1.0mgeachoftheexpressionplasmidsasindicatedinFigure5b.After24h,thecellswerestarvedinDMEMwith1.5%FBSfor16h,washedwithserum-freemediaandincubatedinthephosphate-freemediacontaining0.3mCiof[32P]orthophosphatefor5h.Thecelllysateswerepreparedasdescribedabove.RalAproteinwasimmunoprecipitatedwiththeanti-RalAantibodyandwashedextensivelywithwashingbuffer(20mMTris-HCl(pH7.5)and10mMMgCl2).Theradio-labeledGTP/GDPswereelutedwithanelutionbuffer(0.2%SDS,5mMEDTA,5mMGDPand5mMGTP)andseparatedbythin-layerchromatography(TLC)onpolyethy-lenimin-cellulose(Sigma,Inc.).Thesignalswereautoradio-graphed,andtheGTP/(GDPþGTP)ratiowasdeterminedusingthePhosphorImagerandImageQuantsoftware.ColonyformationassayNIH3T3cells(3105cells)onthe35-mmplateweretransfectedwith1.0mgeachoftheexpressionplasmidsasindicatedinFigure6.After48h,thecellsweresplitata2:1ratioandtheG418-resistantcolonieswereselectedwith400mg/mlG418for2weeks.ThecellswereﬁxedinPBScontaining0.2%glutaraldehydeand0.5%formaldehydefor10minoniceandstainedwith0.2%crystalvioletfor10minatroomtemperature.Theaveragenumberofcolonieswasdeterminedfromtheexperimentsperformedthreetimesinduplicate.AdenovirusproductionandinfectionTheadenovirusexpressingmerlin(Ad-NF2)waskindlyprovidedbyDrSSJeun(CatholicUniversityofKorea),andtheadenovirusexpressinggreenﬂuorescentprotein(Ad-GFP)waspurchasedfromNeurogenexCo.,Ltd(Seoul,Korea).ViruseswerepropagatedinHEK293,ahumanembryonickidneycellline.Inordertopurifytheviruses,freezing/thawingofcellsandsubsequentcentrifugationwerepeformed.Theviraltiterwasdeterminedbylimiting-dilutionbioassayinHEK293cellsasdescribedpreviously(Matthews,2002).Theinfectionwasperformedfor2hataconcentrationof100moi/well(35-mmplates).CellmigrationassayThecellmigrationassaywasperformedusingtwomethods:thewound-healingassayandthemodiﬁedBoydenchamberassay.Forthewound-healingassay,thecontrolandRalGDSstablecellswereplatedatadensityof2105cellsina35-mmplateandinfectedwith100moieachoftheadenoviruses.After12h,thecellmonolayerwaswoundedwithapipettetipbyapproximately1mminwidth.ThenthecellswasremovedofdebrisbywashingtwicewithPBSandculturedat371CinDMEMcontaining0.1mg/mlmitomycinCand20ng/mlEGF.After48h,themigrationofthecellsatthewoundfrontwasphotographedusinganinvertedmicroscope.ForthemodiﬁedBoydenchamberassay(96well,8-mmpores,Chemicon,Inc.),thecontrolandRalGDSstablecellswereplatedatadensityof3105cellsina35-mmplateandinfectedwith100moieachoftheadenoviruses.After12h,thestablecellswerestarvedinDMEMcontaining1.5%FBSfor16h,trypsinizedandre-suspendedatadensityof2105cells/mlinserum-freeDMEMinthepresenceorabsenceof20ng/mlEGF.ThecellsuspensionwasplatedontotheupperchamberandDMEMcontaining10%FBSwasplacedinthelowerchamber.Thechamberculturewasincubatedfor6hat371Cand,then,thenonmigratedcellswerewashedofftheuppersurfaceofthemembrane.ThemigratedcellsonthebottomsideweredissociatedwithCellDetachmentBuffer(Chemicon,Inc.),lysedandstainedfornucleicacidswithCyQuantGRdye(MolecularProbes).Thesignalintensitiesweremeasuredusingaﬂuorescencereader(HIDEX,Inc.).Theresultwaspresentedastheaveragevaluesfromthreeindependentexperimentsperformedinduplicates.AcknowledgementsWewishtothankothermembersofthelaboratoryfortheirassistance.WealsothankDrDavidGutmannandDrTakashiIwamotoforprovidinguspcDNA-NF2andpcDNA3-RalAexpressionvector,respectively.ThisstudywassupportedbyagrantoftheKoreanHealth21R&DProject,MinistryofHealthandWelfare,RepublicofKorea(00-PJ3-PG6-GN02-0002,02-PJ10-PG6-GN01-0002).ReferencesArveloFandPouponMF.(2001).ActaCientVenez.,52,304–312.CantorS,UranoTandFeigLA.(1995).Mol.Cell.Biol.,15,4578–4584.ChishtiAH,KimAC,MarfatiaSM,LutchmanM,HanspalM,JindalH,LiuSC,LowPS,RouleauGA,MohandasN,ChasisJA,ConboyJG,GascardP,TakakuwaY,HuangSC,BenzJrEJ,BretscherA,FehonRG,GusellaJF,RameshV,SolomonF,MarchesiVT,TsukitaS,TsukitaS,ArpinM,LouardD,TonksNK,AndersonJM,FanningAS,BryantPJ,WoodsDFandHooverKB.(1998).TrendsBiochem.Sci.,23,281–282.FeigLA,UranoTandCantorS.(1996).TrendsBiochem.Sci.,21,438–441.Fernandez-ValleC,TangY,RicardJ,Rodenas-RuanoA,TaylorA,HacklerE,BiggerstaffJandIacvelliJ.(2002).Nat.Genet.,31,354–362.GietzD,St.JeanA,WoodsRAandSchiestlRH.(1992).NucleicAcidsRes.,20,1425.GildeaJJ,HardingMA,SerajMJ,GuldingKMandTheodorescuD.(2002).CancerRes.,62,982–985.GoutebrozeL,BraultE,MuchardtC,CamonisJandThomasG.(2000).Mol.Cell.Biol.,20,1699–1712.HirokawaY,TikooA,HuynhJ,UtermarkT,HanemannCO,GiovanniniM,XiaoGH,TestaJR,WoodJandMarutaH.(2004).CancerJ.,10,20–26.HoferF,FieldsS,SchneiderCandMartinGS.(1994).Proc.Natl.Acad.Sci.USA,91,11089–11093.IkedaM,IshidaO,HinoiT,KishidaSandKikuchiA.(1998).J.Biol.Chem.,273,814–821.IkedaK,SaekiY,Gonzalez-AgostiC,RameshVandChioccaEA.(1999).J.Neurosurg.,91,85–92.JannatipurM,DionP,KhanS,JindalH,FanX,LaganiereJ,ChishtiAHandRouleauGA.(2001).J.Biol.Chem.,276,33093–33100.JoffeEBandAdamA.(2001).Medicina,61,658–663.JohnsonKC,KissilJL,FryJLandJacksT.(2002).Oncogene,21,5990–5997.MerlinassociateswithRalGDSCHRyuetal5363OncogeneJonesonTandBar-SagiD.(1997).J.Mol.Med.,75,539–587.KimH,LimJY,KimYH,KimH,ParkSH,LeeKH,HanH,JeunSS,LeeJHandRhaHK.(2002).Mol.Cells,14,108–114.KimJY,KimH,JeunSS,RhaSJ,KimYH,KoYJ,WonJ,LeeKH,RhaHKandWangYP.(2002).Biochem.Biophys.Res.Commun.,296,1295–1302.KogaH,ArakiN,TakeshiaH,NishiT,HirotaT,KimuraY,NakaoMandSayaH.(1998).Oncogene,17,801–810.KresselMandSchmuckerB.(2002).Hum.Mol.Genet.,11,2269–2278.LeeIK,KimKS,KimH,LeeJY,RyuCH,ChunHJ,LeeKU,LimY,KimYH,HuhPW,LeeKH,HanSI,JunTYandRhaHK.(2004).Biochem.Biophys.Res.Commun.,325,774–783.LeeJY,KimH,RyuCH,KimJY,ChoiBH,LimY,HuhPW,KimYH,LeeKH,JunTY,RhaHK,KangJKandChoiCR.(2004).J.Biol.Chem.,279,30265–30273.LeeT,FeigLandMontellDJ.(1996).Development,122,409–418.LimJY,KimH,KimYH,KimSW,HuhPW,LeeKH,JeunSS,RhaHandKandKangJK.(2003).Biochem.Biophys.Res.Commun.,302,238–245.LouisDN,RameshVandGusellaJF.(1995).BrainPathol.,5,163–172.LuZ,HorniaA,JosephT,SukezaneT,FrankelP,ZhongM,BychenokS,XuL,FeigLAandFosterDA.(2000).Mol.Cell.Biol.,20,462–467.MatthewsJN.(2002).Dev.Biol.,107,87–94.McClatcheyAI,SaotomeI,MercerK,CrowleyD,GusellaJF,BronsonRTandJacksT.(1998).GenesDev.,12,1121–1133.McCormickFandWittinghoferA.(1996).Curr.Opin.Biotechnol.,7,449–456.MelchioriA,CarloneS,AllavenaG,AresuO,ParodiS,AaronsonSAandAlbiniA.(1990).AnticancerRes.,10,37–44.MorrisonH,ShermanLS,LeggJ,BanineF,IsackeC,HaipekCA,GutmannDH,PontaHandHerrlichP.(2001).GenesDev.,15,968–980.MurthyA,Gonzalez-AgostiC,CorderoE,PinneyD,CandiaC,SolomonF,GusellaJandRameshV.(1998).J.Biol.Chem.,273,1273–1276.RouleauGA,MerelP,LutchmanM,SansonM,ZucmanJ,MarineauC,Hoang-XuanK,DemczukS,DesmazeCandPlougastelB.(1993).Nature,363,515–521.RusanescuG,GotohT,TianXandFeigLA.(2001).Mol.Cell.Biol.,21,2650–2658.SainioM,ZhaoF,HeiskaL,TurunenO,denBakkerM,ZwarthoffE,LutchmanM,RouleauGA,JaaskelainenJ,VaheriAandCarpenO.(1997).J.CellSci.,110,2249–2260.SchmuckerB,TangYandKresselM.(1999).Hum.Mol.Genet.,8,1561–1570.ScolesDR,ChenMandPulstSM.(2002).Biochem.Biophys.Res.Commun.,290,366–374.ScolesDR,HuynhDP,ChenMS,BurkeSP,GutmannDHandPulstSM.(2000).Hum.Mol.Genet.,9,1567–1574.ScolesDR,HuynhDP,MrcosPA,CoulsellER,RobinsonNG,TamanoiFandPulstSM.(1998).Nat.Genet.,18,354–359.ShermnL,XuHM,GeistRT,Saporito-IrwinS,HowellsN,PontaH,HerrlichPandGutmannDH.(1997).Oncogene,15,2505–2509.SunCX,RobbVAandGutmannDH.(2002).J.CellSci.,115,3991–4000.SuzukiJ,YamazakiY,LiG,KaziroYandKoideH.(2000).Mol.Cell.Biol.,20,4658–4665.TakayaA,OhbaY,KurokawaKandMatsudaM.(2004).Mol.Biol.Cell,15,2549–2557.ThomasG,MerelP,SansonM,Hoang-XuanK,ZucmanJ,DesmazeC,MelotT,AuriasAandDelattreO.(1994).Eur.J.Cancer,30A,1981–1987.TikooA,VargaM,RameshV,GusellaJandMarutaH.(1994).J.Biol.Chem.,269,23387–23390.TrofatterJA,MacCollinMM,RutterJL,MurrelJR,DuyaoMP,ParryDM,EldridgeR,KleyN,MenonAGandPulaskiK.(1993).Cell,72,791–800.TsukitaS,YonemuraSandTsukitaS.(1997).TrendsBiochem.Sci.,22,53–58.UranoT,EmkeyRandFeigLA.(1996).EMBOJ.,15,810–816.VojtkABandDerCJ.(1998).J.Biol.Chem.,273,19925–19928.WhiteMA,ValeT,CamonisJH,SchaeferEandWiglerMH.(1996).J.Biol.Chem.,71,16439–16442.WolthuisRM,ZwartkruisF,MoenTCandBosJL.(1998).Curr.Biol.,8,471–474.YamaguchiA,UranoT,GoiTandFeigLA.(1997).J.Biol.Chem.,272,31230–31234.MerlinassociateswithRalGDSCHRyuetal5364OncogeneMOLECULARANDCELLULARBIOLOGY,Aug.2009,p.4250–4261Vol.29,No.150270-7306/09/$08.00⫹0doi:10.1128/MCB.01581-08Copyright©2009,AmericanSocietyforMicrobiology.AllRightsReserved.NF2/MerlinIsaNovelNegativeRegulatorofmTORComplex1,andActivationofmTORC1IsAssociatedwithMeningiomaandSchwannomaGrowth䌤†MarianneF.James,1SangyeulHan,1CarolynPolizzano,1ScottR.Plotkin,2BrendanD.Manning,3AnatO.Stemmer-Rachamimov,4JamesF.Gusella,1andVijayaRamesh1*CenterforHumanGeneticResearch,MassachusettsGeneralHospital,RichardB.SimchesResearchBuilding,185CambridgeStreet,Boston,Massachusetts021141;DepartmentofNeurology2andMolecularNeuro-OncologyLaboratory,DivisionofNeuropathology,4MassachusettsGeneralHospital,55FruitStreet,Boston,Massachusetts;andDepartmentofGeneticsandComplexDiseases,HarvardSchoolofPublicHealth,665HuntingtonAvenue,Boston,Massachusetts021153Received8October2008/Returnedformodiﬁcation7January2009/Accepted12May2009Inactivatingmutationsoftheneuroﬁbromatosis2(NF2)gene,NF2,resultpredominantlyinbenignneuro-logicaltumors,schwannomasandmeningiomas,inhumans;however,mutationsinmurineNf2leadtoabroadspectrumofcanceroustumors.Thetumor-suppressivefunctionoftheNF2protein,merlin,amembrane-cytoskeletonlinker,remainsunclear.Here,weidentifythemammaliantargetofrapamycincomplex1(mTORC1)asanovelmediatorofmerlin’stumorsuppressoractivity.Merlin-deﬁcienthumanmeningiomacellsandmerlinknockdownarachnoidalcells,thenonneoplasticcellcounterpartsofmeningiomas,exhibitrapamycin-sensitiveconstitutivemTORC1activationandincreasedgrowth.NF2patienttumorsandNf2-deﬁcientmouseembryonicﬁbroblastsdemonstrateelevatedmTORC1signaling.Conversely,theexogenousexpressionofwild-typemerlinisoforms,butnotapatient-derivedL64Pmutant,suppressesmTORC1signal-ing.MerlindoesnotregulatemTORC1viatheestablishedmechanismofphosphoinositide3-kinase–Aktormitogen-activatedproteinkinase/extracellularsignal-regulatedkinase-mediatedTSC2inactivationandmayinsteadregulateTSC/mTORsignalinginanovelfashion.Inconclusion,thederegulationofmTORC1acti-vationunderliestheaberrantgrowthandproliferationofNF2-associatedtumorsandmayrestrainthegrowthoftheselesionsthroughnegativefeedbackmechanisms,suggestingthatrapamycinincombinationwithphosphoinositide3-kinaseinhibitorsmaybetherapeuticforNF2.Meningiomasaremesenchymaltumorsthatarisefromthearachnoidlayercoveringthebrainandspinalcordandaccountforapproximately30%ofallprimaryintracranialneoplasms(30).Mostsporadicmeningiomas(60%)displaysomaticinac-tivationoftheNF2gene.GermlinemutationsofNF2areassociatedwithneuroﬁbromatosis2(NF2),adominantlyin-heriteddisordercharacterizedbymultiplenervoussystemtu-mors,includingschwannomasandmeningiomas(33).Al-thoughmostmeningiomasarebenign(WHOgradeI),theyoftencausesigniﬁcantmorbidityduetocompressionoftheadjacentbrainorspinalcord.Benignmeningiomasalsohaverecurrenceratesofupto20%over10years.Tenpercentofmeningiomasareclassiﬁedasatypical(WHOgradeII)oranaplastic(WHOgradeIII)anddisplaymoreaggressiveclin-icalbehavior,withrapidgrowthandincreasedrecurrencerates(6,21).Thecurrentstandardofcareismaximalsurgicalre-section,withadjuvantradiationreservedforprogressivetu-morsorthosewithaggressivefeatures(e.g.,WHOgradeIIorIII).Thetreatmentstrategyformeningiomasthatprogressdespitesurgeryandradiationremainslimited,andcurrentlythereisnoeffectivechemotherapy.Thedevelopmentofeffectivetherapieshasbeenhampered,inpart,byourincompleteunderstandingofthesignalsinﬂuencingmeningiomacellgrowth.Enhancedexpressionofcertainpeptideandsteroidgrowthfactorsandreceptorsinmeningiomatissuesuggeststhatspeciﬁcautocrinegrowth-stimulatoryloopsmaybefunctionallyimportantinmeningiomacellproliferation(20,38).Thescarcityofestablishedmeningiomamodelsthatwouldallowfortheassessmentofgrowth-regulatorymechanismshasalsohamperedprogress.Recently,wehavedevelopedreliablemenin-giomamodelsthatovercomethechallengesofthelowgrowthratesandsenescenceofprimarybenignmeningiomacells(19).BiallelicinactivationoftheNF2geneisdetectedinthemajorityofsporadicmeningiomasandnearlyallschwannomas(11).ThetumorsuppressorgeneNF2encodesmerlin(alsocalledschwannomin),amemberoftheezrin-radixin-moesin(ERM)proteinfamilythatfunctionstolinkmembranepro-teinstothecorticalactincytoskeleton(31,41).LiketheERMproteins,merlinhasbeenimplicatedintheregulationofmem-braneorganizationandcytoskeleton-basedcellularprocessessuchasadhesion,migration,cell-cellcontact,spreading,pro-liferation,andsignaltransduction(27).Thelossofcontact-dependentinhibitionofproliferationisseeninseveraltypesofNF2-deﬁcientcells(23,29).MerlincontrolscellproliferationinresponsetocellcontactviaCD44(28)andfunctionsto-getherwiththerelatedtumorsuppressorExpandedviathe*Correspondingauthor.Mailingaddress:CenterforHumanGeneticResearch,MassachusettsGeneralHospital,RichardB.SimchesResearchBuilding,185CambridgeSt.,Boston,MA02114.Phone:(617)724-9733.Fax:(617)726-3655.E-mail:ramesh@helix.mgh.harvard.edu.†Supplementalmaterialforthisarticlemaybefoundathttp://mcb.asm.org/.䌤Publishedaheadofprinton18May2009.4250Hippo/MstpathwayinbothDrosophilaandsometypesofmammaliancells(14,49).Althoughmerlinisimplicatedinawiderangeofcellularactivities,theprecisemechanismbywhichmerlinmediatesgrowth-inhibitoryfunctionsinhumanarachnoidalandSchwanncellsandthewayinwhichitslossresultsintumorformationinNF2remainpoorlyunderstood.Werecentlyreportedthatprimaryhumanmerlin-deﬁcientmeningiomacellsexhibitastriking,enlarged-cellphenotypecomparedtononneoplasticarachnoidalcellcounterpartsde-rivedfromthesamepatient(19).Interestingly,thetuberoussclerosiscomplex(TSC)tumorsuppressorsyndromeischar-acterizedbywidespreadbenigntumorsthatpossessabnor-mallylargecells(22).MutationsinthetumorsuppressorgenesTSC1andTSC2resultinTSCsyndrome,andthecorrespond-ingproteinproducts,hamartinandtuberin(referredtoasTSC1andTSC2),functiontogetherasacomplexthatpotentlyinhibitsmammaliantargetofrapamycincomplex1(mTORC1)(17).mTORisanevolutionarilyconservedSer/Thrkinasethatexistsinoneoftwodistinctfunctionalcomplexes,TORC1andTORC2.TORC1,whichregulatesautophagy,proteintransla-tion,andribosomebiogenesis,ispotentlyandspeciﬁcallyin-hibitedbyrapamycin(10,46).TORC2,whichislesssensitivetorapamycin,isimportantforcytoskeletalregulationandAkt/proteinkinaseBactivation(16,18,36).TheTSC1-TSC2complexinhibitsmTORC1byactingasaGTPase-activatingproteinforthesmallGTPaseRheb(Rashomologenrichedinbrain).InactivationoftheTSC1-TSC2complexresultsintheaccumulationofGTP-boundRheb,whichactivatesmTORC1(10).Inadditiontonaturallyoccur-ringmutationsintheTSC1andTSC2genes,growthfactorstimulationofthephosphoinositide3-kinase(PI3K)-Aktpath-way,aswellasRas/mitogen-activatedproteinkinase(MAPK)pathways,leadstothephosphorylationandinactivationoftheTSC1-TSC2complexandconsequentactivationofmTORC1(17).TheactivationofmTORC1resultsinthephosphoryla-tionoftwowell-characterizedeffectors,eukaryotictranslationinitiationfactor4E-bindingprotein1(4EBP1)andS6kinase1(S6K1),leadingtoanincreaseinribosomalbiogenesisandtheselectivetranslationofspeciﬁcmRNApopulations.Asacrit-icalregulatorofcellgrowthandproliferation,themTORC1pathwayisdysregulatedinseveralhamartomasyndromes,aswellasinmanycancers(10).Inthisreport,weidentifytheNF2tumorsuppressorprotein,merlin,asanovelnegativeregulatorofthemTORC1pathwaytocontrolcellgrowth(cellsize).WeshowthatmTORC1isconstitutivelyactivatedinmerlin-deﬁcienthumanmeningiomacells,leadingtoincreasedcellsize.Furthermore,wesuggestthattheslowgrowthofmerlin-deﬁcientmeningiomacellsisduetoarapamycin-sensitive,mTORC1-S6K-dependentnega-tivefeedbackloopthatdiminishesPI3K-Aktsignalinginre-sponsetogrowthfactorstimulation.Theﬁndingsofthesestudiesprovideinsightintothemechanismofmerlintumorsuppressoractivityand,moreover,indicatethatrapamycinorrapamycinanalogsincombinationwithPI3Kinhibitorsmayprovidepromiseasnewtherapeuticsinthetreatmentofme-ningiomasandschwannomas.MATERIALSANDMETHODSAntibodiesandreagents.Unlessotherwisestated,allantibodieswereobtainedfromCellSignalingTechnology.ExceptionsincludecyclinD1(BDBioscience),FLAGepitope(M2,Sigma),hemagglutinin(HA)epitope(Covance),andGAPDH(glyceraldehyde-3-phosphatedehydrogenase;ChemiconInternational)antibodies.Merlinrabbitpolyclonalantibody(C26)wasdescribedpreviously(19).Growthfactorsandinhibitorswerefromthefollowingsources:insulin,wortmannin,andnocodazole,Sigma;insulin-likegrowthfactor1(IGF1),AustralBiologicals;andrapamycin,LY294002,andUO126,Calbiochem.Kinaseinhib-itorswerereconstitutedindimethylsulfoxide(DMSO)ormethanolperthemanufacturers’recommendations.Samplecollection.TissuesampleswereobtainedfromtheMassachusettsGeneralHospitaltumorrepositoryandconsistedofexcessdiscardedtissuescollectedfrompatientsundergoingclinicallyindicatedsurgeryfortumorresec-tionorspecimensfromautopsies.Tissueswereharvestedfreshfortheestab-lishmentofcelllinesasdescribedpreviously(19)and/orwereformalinﬁxedorﬂash-frozenonliquidnitrogenforhistologicalandimmunohistochemicalanal-yses.ClinicalinformationregardingdeﬁningsporadicandNF2-associatedtu-morswasbasedondiagnosesfromreferringphysicians,accordingtothepub-lishedguidelinesforthediagnosisofNF2(12).TheInstitutionalReviewBoardoftheMassachusettsGeneralHospital/PartnersHealthCareapprovedthisstudy,andinformedconsentwasobtainedfromallstudysubjects.Immunohistochemistry.Fourbenignmerlin-negativemeningiomasandﬁvevestibularschwannomaswereﬁxedwith4%paraformaldehydeinphosphate-bufferedsaline(PBS)forimmunocytochemistryanalyses.AppropriatecontrolsforantibodiesincludedDU145cellsandnormalnervetissue(negativecontrols)andPTEN-deﬁcientPC3cells(positivecontrols).Parafﬁn-embeddedtissuesec-tionswereimmunostainedusingcommercialrabbitpolyclonalantibodiestophospho-S6,recognizingS235/236and/orS240/244,underconditionsdescribedpreviously(15).Cellculture.Culturesofprimarymeningiomaandarachnoidalcellsfromfreshtissueswereestablishedasdescribedpreviously(19).MeningiomacellsweremaintainedinDulbecco’smodiﬁedEagle’smedium(DMEM)witha4.5-g/literglucosesolutioncontaining15%fetalbovineserum(FBS)and100U/mlpeni-cillinand100␮g/mlstreptomycin.Arachnoidalcellsweremaintainedinamix-tureofimprovedMEMwithL-glutamine(Richter’smodiﬁedmedium[Cellgro;Mediatech,Inc.]),15%FBS,100U/mlpenicillinand100␮g/mlstreptomycin,andinsulin(GibcoLifeTechnologies,Inc.)at4mg/liter.Humanembryonickidney293T(HEK293T)cellsweremaintainedinDMEMcontaining10%FBSand100U/mlpenicillinand100␮g/mlstreptomycin.Nf2⫺/⫺andNf2⫹/⫹mouseembryonicﬁbroblasts(MEFs)werekindlyprovidedbyA.I.McClatchey(Mas-sachusettsGeneralHospital,Boston)anddescribedpreviously(23).Thelitter-mate-derivedpairofTsc2⫹/⫹andTsc2⫺/⫺MEFsamples(bothwiththep53⫺/⫺genotype)wereprovidedbyD.J.Kwiatkowski(BrighamandWomen’sHospital,Boston,MA)anddescribedpreviously(47).TheAC007-hTERTcelllinewasdevelopedbyretrovirallytransducingprimaryarachnoidalcellswiththehumantelomerasereversetranscriptase(hTERT)genebyusingtheretroviralplasmidpBABE-puro-hTERT(7).Foraminoacidwithdrawalstudies,controlandmerlinknockdownarachnoidalcellswerecultivatedinfull-growthmediumpriortotheshiftingofcellsintoDulbecco’sPBSforthetimesindicatedinFig.2E.Forkinaseinhibitorstudies,merlinknockdownarachnoidalcellsweredeprivedofserum(in0.2%FBS)andtreatedwithrapamycin,LY294002,wortmannin,orU0126attheconcentrationsindicatedinFig.4CtoFfor30minpriortolysis.Forwortmannincontrolexperiments,arachnoidalcellsweredeprivedofserum(in0.2%FBS),pretreatedfor15minwith100nMwortmannin,andthenstimulatedfor15minwith25ng/mlIGF1.FortheanalysisofnegativefeedbackinhibitionofAkt,merlin-deﬁcientmeningiomaandmerlinknockdownarachnoidalcellsincompleteme-diumweretreatedwith10nMrapamycinfor24hpriortolysis.Fortheinsulinstimulationassay,controlandmerlinknockdownarachnoidalcellswerestimu-latedwith100nMinsulin.Constructs,virusproduction,andsiRNAs.ThegenerationofFLAG-taggedwild-type(WT)merlinisoforms1and2andmerlinmutantsexpressingS518mutations(S518AandS518D)wasdescribedpreviously(44).FLAG-taggedL64Pmutantmerlinwasgeneratedfromfull-lengthisoform1byusingtheQuikChangesite-directedmutagenesiskit(Stratagene)andsequencedtoverifytheincorporationofthechange.FLAG-taggedwild-typeTSC1andTSC2wereprovidedbyB.D.Manning.FLAG-taggedRhebandHA-S6KwerekindlyprovidedbyJosephAvruch(MassachusettsGeneralHospital,Boston).ThegenerationofalentivirusconstructexpressingWTmerlinisoform1inpCSCW2andofmerlinRNAinterference(RNAi)constructsinpLKOpuro.1wasde-scribedpreviously(19,37).LentiviralparticleswereproducedbytheNeuro-scienceVectorCoreatMassachusettsGeneralHospital.EndogenousTSC2knockdowninHEK293TcellswascarriedoutusingSMARTpoolsmallinter-feringRNAs(siRNAs)perthesuggestionofthemanufacturer(Dharmacon).VOL.29,2009NF2/MERLINREGULATESmTORC1SIGNALING4251Transfectionsandinfections.MammaliantransfectionsusingHEK293Tcells,includingthosewithsiRNAs,wereperformedusingLipofectamine2000asrecommendedbythemanufacturer(Invitrogen).Transfectedcellsweremain-tainedinfull-growthmediumfor48hpriortolysis.Fortheinsulinstimulationexperiments,cellswereserumstarved(in0%FBS)forthelast24-hperiodandthenstimulatedwith100nMinsulinfor15min.TheimmunoprecipitationofHA-S6Kwasperformedusinganti-HAantibody(seeFig.5D).IsogenicpairsofcontrolandmerlinknockdownarachnoidalcellsamplesweregeneratedbytheinfectionofprimaryarachnoidalcellsorAC007-hTERTcellswithlentivirusescontaininganonspeciﬁcscrambledtargetsequence(scr)oramerlin-speciﬁcRNAitargetsequence(m5,m6,orm8)(19).Cellswereinfectedatamultiplicityofinfection(MOI)of10andselectedwithpuromycin(0.4␮g/ml)toobtainstablepools.Unlessotherwisestatedinthetext,controlscrandmerlin(m5)RNAiarachnoidalcellswereserumdeprived(in0.2%FBS)onday7postinfectionandharvestedthefollowingdaytoobtainproteinlysates.Merlin-deﬁcientmeningiomacellsandTsc2⫺/⫺MEFswereinfectedwithmerlinisoform1ataMOIof50or100bylentivirus(pCSCW2)-baseddeliveryandthenharvested3dayspostinfectiontoobtainproteinlysates.Proliferationassays.TodetectNf2⫹/⫹andNf2⫺/⫺MEFcellsinSphase,5-bromo-2⬘-deoxyuridine(BrdU)incorporationwasquantiﬁedusingtheinsitucellproliferationkitFLUOSaccordingtothespeciﬁcationsofthemanufacturer(Roche,Mannheim,Germany).Nf2MEFcellswereplatedontopoly-D-lysine-coatedcoverslips,treatedwithDMSOorrapamycin(20nM)for24h,andincubatedwith10␮MBrdUfortheﬁnal4h.BrdUincorporationwasdetectedusingaﬂuorescein-conjugatedanti-BrdUantibody.BrdU-positiveandDAPI(4⬘,6-diamidino-2-phenylindole)-positivecellsinﬁverandomlychosenﬁeldsperconditionwerecountedusingaTCSSP5confocalmicroscope(Leica,Wetzlar,Germany),andthepercentagesofBrdU-positivecellswerecalculated.Alltheexperimentswereperformedintriplicate.StatisticalanalyseswerecarriedoutusingStudent’stwo-tailedttest.Celllysisandimmunoblotting.MeningiomaandarachnoidalcellsandTsc2MEFcellswereharvestedtoobtaincelllysatesasdescribedpreviously(19).Proteinswereresolvedbysodiumdodecylsulfate-polyacrylamidegelelectro-phoresis,transferredontonitrocellulosemembranes(Bio-Rad),andsubjectedtoimmunoblotanalysesusingappropriateantibodies,horseradishperoxidase-con-jugatedsecondaryantibodies,andanenhancedchemiluminescence(ECL)de-tectionsystem(AmershamPharmaciaBiotechnology).Cellsizeandcellcycleanalysis.Thesizesofprimarymerlinknockdownarachnoidal(AC030)cellsrelativetothoseofscrcontrolcellswithorwithoutrapamycintreatmentweredeterminedbyﬂuorescence-activatedcellsorter(FACS)analyseswithaFACSCaliburinstrument(BectonDickinson)usingforwardscatterheight(FSC-H)values.Stablecellpopulationsweretreatedwith5nMrapamycineveryotherdayfor7days.Cellsweretrypsinizedandresus-pendedinPBScontaining3%FBSand5mMEDTA.Atotalof20,000cellswerecollected,andthemeanFSC-HvalueswereobtainedusingCellQuestsoftware.CellswerestainedbypropidiumiodideforFACSanalysestodeterminethecellsizesinG1-andG2/M-phasepopulations.Culturedmeningiomaandmerlinknockdownarachnoidalcellstreatedwithandwithoutrapamycinwerevisualizedbyphase-contrastimagingusingaNikonEclipseTE2000-UinvertedmicroscopeandphotographedusingaSPOTRTslidercharge-coupleddevicecameraandSPOTimagingsoftware(DiagnosticInstrumentsInc.).RESULTSRapamycininhibitsthegrowthofmerlin-deﬁcientarachnoi-dalandmeningiomacellsinvitro.Werecentlyreportedthathumanprimarymerlin-deﬁcientmeningiomacellsareen-largedduringculturingcomparedtomatchednormalarach-noidalcells.Similarly,arachnoidalcellsinwhichmerlinexpres-sionissuppressedbecomedramaticallylargerthancellstreatedwithcontrolRNAiconstructs(19).Theseﬁndingssug-gestthatpathwaysregulatingincreasedcellsizemaybenega-tivelyregulatedbymerlin.SincetheactivationofthemTORC1pathwayhasemergedasaconservedregulatorymechanisminthecontrolofcellsize(45),weexaminedwhetherthemTORC1-speciﬁcinhibitorrapamycinwouldcounterthein-creasedsizesofmerlin-deﬁcientNF2targetcelltypes.Treat-mentwithrapamycin,ataconcentrationaslowas1nM,concurrentwiththeinitiationofstableknockdownofmerlininarachnoidalcellsblockedanincreaseincellsizecomparedtothatofuntreatedmerlinknockdowncells(Fig.1A).Ananal-ysisofrelativecellsizesbyﬂowcytometryusingthemeanFSC-Hasaparameterdemonstratedthatarachnoidalcellsinwhichmerlinwassuppressedweresigniﬁcantlylargerthancontrolcells,asindicatedbyarightwardshiftinthemeanFSC-H(Fig.1B,left).Rapamycinabolishedtheeffectofmer-linknockdownoncellsize(Fig.1B,right).Additionally,weobservedthatenlarged,activelydividingmerlinknockdownarachnoidalcellstreatedwithrapamycinfor4daysrevertedtoastrikinglysmallersize(seeFig.S1inthesupplementalma-terial).Thereversalofthephenotypeofcellenlargement,relativetothesizesofuntreatedcells,inculturesofmerlin-deﬁcientmeningiomacellstreatedwithrapamycinwasalsoobserved(Fig.1C).TheseﬁndingsindicatethattheinhibitionofmTORC1byrapamycincannotonlypreventbutalsore-verseincreasesinthesizesofmerlin-deﬁcientarachnoidalandmeningiomacells.Merlin-deﬁcientcellsexhibitconstitutivemTORC1signal-ing.WenextexaminedwhetherthemTORC1signalingpath-wayinmerlin-deﬁcientNF2targetcellswasdysregulated.ThelevelsofphosphorylationofribosomalproteinS6,anindicatorofmTORC1activity,inthreeprimarymerlin-deﬁcientmenin-giomacellcultureswereelevatedcomparedtothoseinthreenormalprimaryarachnoidalcelllinesunderconditionsofse-rumdeprivation(Fig.2A).ToexaminewhethertheincreaseinmTORC1signalingwasduetomerlinloss,wesuppressedmerlininarachnoidalcellsbyusingthreedifferenttargetingshorthairpinRNAs(shRNAs;m5,m6,andm8).Thissuppres-sionproducedanincreaseinthephosphorylationofS6atSer235/236andatSer240/244(sequentialS6Ksubstratephos-phorylationsitesofS6)comparedtothatincontrol(scr)RNAiarachnoidalcellsunderconditionsofserumdeprivation.Con-sistentwithincreasedmTORC1-dependentphosphorylationofS6,weobservedincreasedphosphorylationatS2448ofmTORandT389ofp70-S6K,adirectmTORC1substrate,inmerlinknockdowncellscomparedtothatincontrolcells(Fig.2B).Merlinsuppressioninthesecellsalsoresultedindecreased4EBP1mobility(anindicatorofphosphorylation)comparedtothatincontrolcells,conﬁrmingthatbotharmsregulatingmTORC1-mediatedproteinsynthesisareenhanced(Fig.2C).Additionally,wedetectedincreasedexpressionofcyclinD1,adownstreamtargetofmTORC1(1),inmerlinknockdowncells.TheseﬁndingssuggestthatmTORC1isactivatedinagrowthfactor-independentmannerinmerlin-deﬁcientcells.Wetestedwhethermerlinsuppressionresultedinincreasedcellsizeindifferentphasesofthecellcycle.ThesuppressionofmerlinwithtwodifferentshRNAsinarachnoidalcellscausedanincreaseincellsizeinG1andG2/Mphasesofthecellcycle(Fig.2D),indicatingthatcellsizeandaberrantmTORC1signalinginmerlin-deﬁcientcellsdonotreﬂectcellcyclechangesandrepresentbonaﬁdeeffectsonmTORC1.Wealsoexaminedifmerlin-deﬁcientcellsexhibitedelevatedmTORC1signalingcomparedtothatincontrolarachnoidalcellsunderlow-serumconditionsafterSphasearrest,bytreatingcellswithnocodazolefor24hpriortoreplatingthecellsin0.2%FBS–DMEMforanadditional24h.Undertheseconditions,merlin-deﬁcientcellsexhibitedtheactivationofmTORC1,eliminat-ingthepossibilityofmitogenicinputunderlow-serum4252JAMESETAL.MOL.CELL.BIOL.conditions(seeFig.S2inthesupplementalmaterial).WenextexaminedwhetherS6phosphorylationwasappropriatelyter-minatedintheabsenceofnutrientsinNF2-deﬁcientcells.AminoaciddeprivationblockedmTORC1signalinginboththecontrolandmerlinknockdownarachnoidalcells(Fig.2E),suggestingthatmerlindoesnotregulatemTORC1throughnutrient-sensitivepathways.Merlin-deﬁcientmeningiomasandvestibularschwannomasexhibitaberrantmTORC1signalinginvivo.TodeterminewhethermTORC1signalingisaberrantlyregulatedinNF2-associatedtumors,weexaminedthestatusofS6phosphoryla-tioninfourNF2-deﬁcientbenignmeningiomasandﬁveves-tibularschwannomasbyimmunohistochemistryanalyses.Phospho-S6immunostainingofNF2-deﬁcientmeningiomasFIG.1.Rapamycininhibitsthegrowthofprimarymerlin-deﬁcientarachnoidalandmeningiomacells.(A)Primarycontrol(scrRNAi)andmerlinknockdown(m5RNAi)arachnoidal(AC030)cellsweretreatedwithorwithoutrapamycinstartingatday2postinfectionwithlentivirusesexpressingshRNAsandeveryotherdaythereafterfor12days.Phase-contrastimagesdemonstrateanincreaseinthesizesofuntreated(vehicle-treated)merlinRNAiarachnoidalcellscomparedtothoseofscrRNAiarachnoidalcells(originalmagniﬁcation,⫻10).Rapamycin(1and20nM)inhibitstheincreaseinthesizesofmerlinRNAicellscomparedtothoseofvehicle-treatedmerlinRNAiarachnoidalcells.(B)Primarycontrolandmerlinknockdownarachnoidal(AC030)cells,treatedwith(⫹)orwithout(⫺)rapamycin(Rap;10nM)everyotherdayfor10days,wereevaluatedbyFACSanalysestodeterminerelativecellsizes.ThexaxesindicaterelativecellsizesaccordingtoFSC-Hvalues.(Left)Merlinm5RNAiincreasesthesizesofarachnoidalcells,asdeterminedbytherightwardshiftinthemeanFSC-Hhistogramcomparedtothatforcontrolscr-treatedarachnoidalcells.(Right)Rapamycinabolishestheeffectofmerlinm5RNAioncellsize.(C)Theenlargementofcellsinprimarymerlin-deﬁcientMN304meningiomaculturestreatedwithvehicleonlyisinhibitedbytreatmentwithrapamycin(10nM)everyotherdayfor7days(originalmagniﬁcation,⫻10).VOL.29,2009NF2/MERLINREGULATESmTORC1SIGNALING4253showeddiffusecytoplasmicpositivestaining,consistentwiththeactivationofthemTORC1pathway(Fig.3).Thevestibularschwannomasdisplayedafocalstainingpatternwithareasofstrongphospho-S6positivity.Normalnervetissueemployedasanegativecontroldidnotshowphospho-S6staining.Similarpatternsofphospho-S6immunostainingwereobtainedusingantibodiesrecognizingphosphorylationatbothSer235/236andSer240/244.ThesedatasuggestthatmTORC1isactivatedinvivoinNF2-associatedschwannomasandmeningiomas.mTORC1activationuponmerlinlossisPI3K-AktandMAPK/extracellularsignal-regulatedkinase(ERK)indepen-dent.Wenextsoughttounderstandthemechanismofconsti-tutive,growthfactor-independentactivationofmTORC1sig-nalinginmerlin-deﬁcientcells.Sincegrowthfactor-initiatedmTORC1signalingiscommonlymediatedbyupstreamacti-vationofPI3K-Akt,weexaminedwhetherthePI3K-Aktsig-nalingcascadewasdysregulatedinNF2targetcells.Weob-servedthatAktwasnotphosphorylatedatSer473ineitherFIG.2.ThemTORC1pathwayisaberrantlyactivatedinmerlin-deﬁcientNF2targetcelltypesinagrowthfactor-independentmannerbutissensitivetonutrientdeprivation.(A)Threeprimaryarachnoidal(AC028,AC030,andAC032)andthreeprimarymerlin-deﬁcient[merlin(⫺)]meningioma(MN380,MN383,andMN302)celllinesweredeprivedofserum(in0.2%FBS)overnightpriortobeingharvestedtoobtainproteinlysates.S6,acommonmarkerofmTORC1activation,exhibitselevatedphosphorylationinmerlin-deﬁcientMNcellscomparedtothatinnormalarachnoidalcells,withnochangeintotalS6proteinlevels.GAPDHproteinlevelsdemonstrateequivalentsampleloading.p-S6(S235/236),S6phosphorylatedatS235/236.(B)Arachnoidalcellsstablyexpressingthreedifferentlentivirus-mediatedshRNAs(m5,m6,andm8)targetingmerlinexhibitincreasedphosphorylationofmTOR(S2448)andmTORC1effectorsp70-S6K(atThr389)andS6(atS240/244andS235/236),aswellascyclinD1,adownstreamtargetofmTORC1,uponmerlinknockdowncomparedtothatincontrol(scrRNAi)cellsunderconditionsofserumdeprivation(in0.2%FBS).TotallevelsofmTOR,S6,andS6Kproteinswereunchanged.p-mTOR(S2448),mTORphosphorylatedatS2448;p-S6K(T389),S6KphosphorylatedatT389;p-S6(S240/244)andp-S6(S235/236),S6phosphorylatedatS240/244andS235/236,respectively.(C)Merlinknockdowninarachnoidalcells(bym5,m6,andm8)resultsinincreasedaccumulationofphosphorylatedspeciesof4EBP1comparedtothatinscrcontrolRNAicellsunderconditionsofserumdeprivation(in0.2%FBS).4EBP1phosphorylation(detectedbyanti-4EBP1antibody)isreﬂectedby4EBP1electrophoreticmobilityresults.(D)CellcycleevaluationbyFACSanalysisdemonstratesincreasedsizesofmerlinknockdowncells(expressingm5andm8shRNAs)comparedtothoseofscrcontrolcellsinG1andG2/Mphasesofthecellcycle.(E)Toexamineeffectsofmerlindeﬁciencyonnutrientdeprivation,control(scr)andmerlinRNAi(m5)knockdownarachnoidalcellsweregrownovernightwithfullserum(15%FBS)priortobeingshiftedintoDulbecco’sPBSfor0,20,40,or60min.ThephosphorylationofS6(atS240/244)isappropriatelyterminatedinmerlinRNAiarachnoidalcells,similartothatincontrolscrcells.⫺aa,aminoaciddeprivation.4254JAMESETAL.MOL.CELL.BIOL.merlin-deﬁcientmeningiomacellsormerlinknockdownarach-noidalcells,similartothatincontrolarachnoidalcells(Fig.4AandB).Consistentwiththeseﬁndings,PRAS40,adownstreameffectorofAkt(35,42),wasnotphosphorylated(Fig.4B).Tuberin,adirectsubstrateofAkt,alsowasnotphosphorylatedatT1462inmerlinknockdownarachnoidalcells(datanotshown).Inaddition,wedidnotobserveaberrantactivationofvariousgrowthfactorreceptorsuponmerlinloss,consistentwiththeabsenceofAktactivation(seeFig.S3inthesupple-mentalmaterial).Collectively,thesedatasuggestthatPI3K-Aktsignalingisnotdysregulatedinmerlin-deﬁcientmeningi-omacellsandthereforedoesnotcontributetoaberrantmTORC1signaling.Wethenexaminedmerlin-deﬁcientcellsforconstitutiveMAPKsignalingsincepositivegrowthsignalsfromtheRas/MAPKpathwaycanalsostimulatemTORC1activity.ERK-speciﬁcactivationofmTORC1involvesmultisitephosphory-lationoftuberinbybothERKanditsdownstreamtargetp90ribosomalS6kinase(25,32).Interestingly,wedetectedcon-stitutiveERK1/ERK2phosphorylationinbothmerlin-deﬁ-cientmeningiomacellsandmerlinknockdownarachnoidalcells,comparedtocontrolarachnoidalcells,underconditionsFIG.3.Merlin-deﬁcientmeningiomasandvestibularschwannomasexhibitconstitutiveS6phosphorylation.Patient-derivedmerlin-deﬁcientmeningioma(MN258⫺/⫺andMN336⫺/⫺)andvestibularschwannoma(xT1640)tissueswerestainedimmunohistochemicallytodetectS6phos-phorylation(atS240/244andS235/236).Dataarerepresentativeofresultsforfourbenignmerlin-deﬁcientmeningiomasandﬁvebenignvestibularschwannomas.Sectionsofnormalnervetissue(negativecontrol)didnotexhibitS6phosphorylation(originalmagniﬁcation,⫻40).VOL.29,2009NF2/MERLINREGULATESmTORC1SIGNALING4255ofserumdeprivation(Fig.4AandB),suggestingthatmerlinmayregulatemTORC1activitythroughtheRas/MAPKsig-nalingpathway.TofurtherassesstheinvolvementofupstreamsignalingpathwaysintheaberrantactivationofmTORC1signalinginmerlin-deﬁcientcells,weexaminedS6phosphorylationinthepresenceofpharmacologicalinhibitorsthatspeciﬁcallytargetthesepathways.Asexpected,theinappropriateactivationofS6inmerlinknockdownarachnoidalcellswasinhibitedbyrapa-mycin,demonstratingdependenceonmTORC1(Fig.4C).Inaddition,wefoundthatthePI3KinhibitorLY294002blockedS6activation(Fig.4D).SincemTOR,aPI3K-relatedenzyme,isdirectlyinhibitedbyLY294002tothesameextentasPI3Ks(4,43),weexaminedtheresponseofS6activationtowortman-FIG.4.Merlin-deﬁcientmTORC1activationisPI3K-AktandMAPK/ERKindependent.(AandB)Merlin-deﬁcientmeningioma[merlin(⫺)MN](A)andmerlinknockdown(m5,m6,orm8RNAi)(B)arachnoidalcellsexhibitelevatedERK1/ERK2phosphorylationcomparedtothatincontrol(scrRNAi)arachnoidalcells.Incontrast,merlin-deﬁcienttargetcellsexhibitnochangeinthephosphorylationofAkt(AandB)orPRAS40(B),asubstrateofAktandanegativeregulatorofmTORC1,comparedtothatincontrolarachnoidalcells.CellsweretreatedasdescribedinthelegendtoFig.2AandB.(CtoF)Control(scrRNAi)andmerlinknockdown(m5RNAi)arachnoidalcellsweredeprivedofserum(in0.2%FBS)overnight,andthemerlinknockdowncellswerethenincubatedwiththeindicatedconcentrationsofrapamycin(Rap),LY294002,wortmannin(Wm),andUO126for30min.CelllysateswereassayedforS6phosphorylationbyimmunoblotanalyses.⫺,absent.(C)ThemTORC1-speciﬁcinhibitorrapamycinblocksconstitutiveS6activation.(D)ThePI3KinhibitorLY294002blocksS6activationbutdoesnotaffectMAPK/ERKsignaling.(E,top)WortmannindoesnotblockS6activation,indicatingthatmTORC1activationisindependentofPI3K-Aktsignaling.(Bottom)WortmanninpotencyisdemonstratedbytheinhibitionofIGF1-stimulatedAktphosphorylationinarachnoidalcellspretreatedwithwortmannin(100nM),incontrasttothatinuntreatedcells.(F)U0126,aMEK1/MEK2inhibitor,blocksERK1/ERK2phosphorylationbuthasnoeffectonS6phosphorylation.4256JAMESETAL.MOL.CELL.BIOL.nin,whichexhibitsrelativelyhighspeciﬁcityforPI3Ksatcon-centrationsof20to50nM.Inthepresenceof25to200nMwortmannin,wedetectednoinhibitionofS6activationinmer-lin-deﬁcientcells(Fig.4E),conﬁrmingthatPI3K-AktsignalingdoesnotcontributetoconstitutivemTORC1activation.Wort-manninpotentlyinhibitedIGF1-stimulatedAktactivationinpretreatedarachnoidalcells,demonstratingwortmannin’sef-fectiveness(Fig.4E,bottom).Additionally,wefoundthatnei-therLY294002norwortmanninhadanyeffectonERK1/ERK2phosphorylation,indicatingthatERKactivationwasnotdependentonPI3Ksignaling(Fig.4Danddatanotshown).TodeterminewhetherthemechanismofconstitutivemTORC1activationinmerlin-deﬁcientcellsisdependentonRas/MAPKsignaling,wetreatedcellswiththeMEK1/MEK2inhibitorcompoundUO126.UO126completelyinhibitedERK1/ERK2signalinginadose-dependentmannerwithoutaffectingS6phosphorylation,indicatingthatmerlindoesnotregulatemTORC1throughRas/MAPK-dependentsignalingpathways(Fig.4F).Together,theseresultsconﬁrmthatmTORC1activationinmerlin-deﬁcientcellsisnotmediatedbytheactivationofeitherPI3K-AktorRas/MAPKsignalingpathways.ExogenousmerlinexpressioninhibitsmTORC1signaling.Todeterminewhethermerlinoverexpressioncouldinhibitgrowthfactor-mediatedmTORC1activation,full-lengthmer-linisoform1orisoform2wascoexpressedwiththeHA-S6Kreporterininsulin-stimulatedHEK293Tcells.Consistentwiththeﬁndingsofpreviousstudies,RheboverexpressionpotentlyactivatedmTORC1signaling,asindicatedbyS6K(T389)phosphorylation,whereasTSC1andTSC2coexpressioninhib-itedS6Kphosphorylation(Fig.5A).BothmerlinisoformsstronglyinhibitedS6Kactivation(Fig.5A).WenextexaminedwhetheranNF2patient-derivedL64Pmissensemutantorei-theroftwomerlinS518phosphomutantsexpressingS518AorS518D,thoughttorendermerlinactiveorinactive,respec-tively,asatumorsuppressorprotein(39,40),isabletoblockmTORC1activation.Undergrowthconditionswithfullserum,WTmerlinblockedmTORC1activationrelativetothatincellsexpressingacontrolvector;however,theL64PNF2mutantproteindidnot.SimilartoWTNF2protein,bothS518phos-phomutantswerecapableofsuppressingmTORC1activity(Fig.5B).Inagreementwiththisﬁnding,thereintroductionofWTNF2proteinintoNF2-deﬁcientmeningiomacellsbylen-tivirus-mediateddeliveryinhibitedendogenousS6phosphory-lationunderconditionsofserumdeprivation(Fig.5C).Col-lectively,theseﬁndingsshowthatmerlinlossleadstotheactivationofmTORC1andthattheectopicexpressionofei-thermerlinisoform1or2inhibitsmTORC1signaling.WenextexaminedwhethermerlincouldinhibitmTORC1activationinTSC1-TSC2-deﬁcientcells.Asexpected,TSC2knockdownviasiRNAexpressionresultedinincreasedS6K(T389)phosphorylationinHEK293cells;however,NF2pro-teinexpressioninTSC2knockdowncellswasunabletoblockS6Kactivationundergrowthconditionswithfullserum(Fig.5D).Similarly,NF2proteinoverexpressiondidnotinhibitcon-stitutiveS6KactivityinTSC2nullMEFs(Fig.5E),indicatingthatmerlindoesnotresidedownstreamoftheTSC1-TSC2complex.TodeterminewhetherNF2proteinoverexpressioncouldblockRheb-mediatedactivationofmTORC1,wecoex-pressedRhebandNF2protein.AsshowninFig.5F,merlindidnotinhibitelevatedmTORC1activityresultingfromRheboverexpression,conﬁrmingthatmerlinisnotdownstreamofTSC-Rheb.Merlin-deﬁcientcellsexhibitnegativefeedbackregulationofPI3K-Aktsignaling.LikeTSC,NF2isatumorsyndromeinvolvingpredominantlybenignlesions.OnelineofthoughtisthatthelimitedmalignantpotentialofTSC-associatedtumorsisduetotheattenuationofAktsignaling(17).Weexaminedwhethermerlin-deﬁcientcellsweredefectiveingrowthfactor-mediatedactivationofAkt.Weobservedthat,inresponsetoinsulinstimulation,atime-dependentincreaseinAktandS6phosphorylationincontrolRNAiarachnoidalcellsoccurredbutthatAktstimulationwasimpairedinmerlinknockdownarachnoidalcells(Fig.6A).Merlinknockdowncellsdemon-stratedconstitutiveS6activation,withnofurtheractivationinresponsetoinsulinstimulation.ProlongedexposuretothemTORC1-speciﬁcinhibitorrapamycinenhancesPI3K-Aktac-tivationinmanycelllinesbyrelievingphospho-S6K-mediatedPI3K-Aktfeedbackinhibition(26).Theexposureofmerlin-deﬁcientmeningiomacellsandmerlinRNAiarachnoidalcellstorapamycinfor24hresultedintheactivationofAkt(Fig.6B).Collectively,thesedataareconsistentwiththeexistenceofabasalmTORC1-dependentnegativefeedbackloopinmer-lin-deﬁcientcells.Furthermore,rapamycintreatmentresultedindecreasedcyclinD1expressioninbothmerlin-negativeme-ningiomacellsandarachnoidalcellsinwhichmerlinwassup-pressed,indicatingthattheelevationofcyclinD1inmerlin-deﬁcientcellsispartiallymTORC1dependent(Fig.6B,bottom).Nf2ⴚ/ⴚMEFsexhibitconstitutivemTORC1activationandrapamycin-sensitiveproliferation.WealsoexaminedmTORC1signalinginNf2⫺/⫺MEFsandfoundthat,similartohumancelltypes,Nf2-deﬁcientMEFsexhibitedconstitutiveactivationofmTORC1signaling,incontrasttoWTNf2⫹/⫹MEFs,asindicatedbyphospho-S6levelsandthephosphorylationstatusof4EBP1(Fig.7AandB).Furthermore,theobservedincreaseintheproliferationofNf2-deﬁcientMEFscomparedwiththatofNf2⫹/⫹MEFswassigniﬁcantlyreducedwhentheNf2-deﬁ-cientMEFsweretreatedwith20nMrapamycin(Fig.7C),suggestingthattheactivationofmTORC1signalingpartlycontributestotheenhancedproliferationofthesecells.DISCUSSIONInthisstudy,weprovideevidencethattheNF2tumorsup-pressormerlinactsasanovelnegativeregulatorofmTORC1.MerlindeﬁciencyresultsintheconstitutiveactivationofmTORC1signalinginhumanarachnoid/meningiomacellsintheabsenceofgrowthfactorsbuthasanegligibleeffectonnutrient-dependentmTORC1activation.Contrarytothecon-ceptthatunphosphorylatedmerlinisoform1(lackingphos-phorylationatS518andexhibitingaclosedconformation)andnotisoform2isresponsibleforthetumorsuppressorfunction(39,40),wefoundnofunctionaldistinctionintheabilitiesofthemerlinisoformsorthephospho-S518merlinmutants(theS518AandS518Dproteins)tosuppressmTORC1signaling.OurﬁndingsindicatethatneithertheisoformtypenortheS518phosphorylationstatuspredictstumorsuppressoractivityasdeﬁnedbyaberrantmTORC1signaling.Thisresultiscon-sistentwiththeabsenceofNF2-causingmutationsinthecar-VOL.29,2009NF2/MERLINREGULATESmTORC1SIGNALING4257boxy-terminalregionscorrespondingtotheexons(16and17)thatdistinguishthetwoisoforms.AlthoughtheMAPK/ERKsignalingpathwayisaberrantlyregulatedinmerlin-deﬁcientcells,wefoundthatmTORC1activationduetomerlinlossisindependentofeitherPI3K-AktorMAPK/ERKsignaling.TheresultsofourstudiessuggestthatmerlinmayfunctionupstreamoftheTSC1-TSC2complex,themajormTORC1regulatorinthecell.OurdataareconsistentwiththemodelthatmerlinsignalsthroughTSC-RhebtoregulatemTORC1.Merlin-deﬁcientcellsresembleTSCnullcellsinthatthelossofeithertumorsuppressorresultsinhighlevelsofconstitutivemTORC1signaling,adeﬁnitiveabsenceofAktphosphoryla-FIG.5.MerlinexpressioninhibitsmTORC1signaling.(A)HEK293TcellswerecotransfectedwithHA-S6Kandvectoronly(V)orFLAG-taggedRheb,TSC1-TSC2,orNF2proteinisoform1(NF2iso1)orisoform2(NF2iso2).After24h,cellsweresubjectedtoserumstarvation(0%FBS)overnightandstimulatedwithinsulin(150nM)for15min.BothNF2proteinisoformsinhibitS6Kphosphorylationcomparedtothatincellsexpressingthevectoronly.RhebexpressionactivatesandTSC1-TSC2expressioninhibitsthemTORC1pathway.(B)HEK293TcellswerecotransfectedwithHA-S6KandvectoronlyorFLAG-taggedWTNF2proteinormutantNF2proteinconstructsexpressingL64P,S518A,orS518D.SimilartoWTNF2protein,NF2mutantproteinsexpressingS518AandS518DinhibitS6Kactivationinfull-growthmedium(10%FBS),butapatient-derivedmutant(L64P)proteindoesnot.p-NF2(S518),NF2proteinphosphorylatedatS518.(C)Merlin-deﬁcientmeningioma[merlin(⫺)MN]cellsweretransducedwithvectoronlyorNF2protein(MOI,50)andsubjectedtoserumstarvation(0%FBS)overnight.NF2protein-infectedcellsexhibittheinhibitionofS6phosphorylationcomparedtothatinvector-infectedcells.(D)HEK293TcellswerecotransfectedwithHA-S6KandvectoronlyorFLAG-NF2protein,TSC2siRNA(TSC2si),orFLAG-NF2proteinandTSC2siRNAstogether(NF2⫹TSCsi).ImmunoblotanalysesofHAimmunoprecipitations(IP)usingananti-HAantibodyindicatethatS6KphosphorylationisnotinhibitedbyNF2proteininTSC2siRNA-expressingcellsinfull-growthmedium.ThedecreaseinlevelsofS6KphosphorylatedatT389intheNF2⫹TSC2silanecomparedtothoseintheTSC2silaneisduetoreducedlevelsofHA-S6Kexpression.(E)Tsc2⫺/⫺MEFswereinfectedwithvector(MOI,50)orNF2protein(MOIs,50and100)asdescribedinthelegendtopanelC.NF2proteindoesnotinhibitS6KorS6phosphorylationcomparedtothatinvector-infectedcells.Lanes⫺,untransfectedcells.(F)AmongHEK293TcellstransfectedasdescribedinthelegendtopanelD,thosecoexpressingNF2proteinandRhebshownoinhibitionofS6Kphosphorylation.4258JAMESETAL.MOL.CELL.BIOL.tionatS473,andenlargedcells.Merlindeﬁciencyinhumancells,similartoTSCdeﬁciency,resultsinlowerproliferationratesthanthoseoftheirWTcounterpartsundergrowthcon-ditionswithfullserum,perhapsduetotheirdecreasedrespon-sivenesstoserum(19,48).AlthoughthemechanismbywhichmerlinregulatesTSC1-TSC2isunclear,hamartinwasshownpreviouslytointeractwiththeERMfamilyproteinsandtoweaklybindmerlin(13,24).TheTSC1-TSC2proteincomplexhasalsobeenshowntomodulateactincytoskeletonprocesses,focaladhesions,andcellmigration(9),cellularactivitiesthatarealsoregulatedbymerlin/ERMproteins(3,27).ArecentstudysuggestedthatTSC2isinhibitedbyAkt-mediatedphos-phorylationbybeingsequesteredinthecytoplasm,awayfromitsmembrane-boundpartnershamartinandRheb(5).Furtherinvestigationsarenecessarytounderstandwhethermerlinde-ﬁciencyresultsinmTORC1activationbyalteringthelocaliza-tionofTSC1orTSC2,bycausingthedissociationoftheTSC1-TSC2complex,and/orbyaffectingtheRheb–GTPase-FIG.6.AktsignalingisattenuatedincellslackingNF2proteinduetomTORC1-mediatednegativefeedbackinhibition.(A)Control(scrRNAi)andmerlinknockdown(m5RNAi)arachnoidalcellsweredeprivedofserum(in0.2%FBS)overnightandstimulatedwithinsulin(100nM)forthetimesindicated.scrRNAiarachnoidalcellsexhibitatime-dependentincreaseinactivatedAkt(S473)andS6(S235/236)phosphorylation,incontrasttomerlinknockdownarachnoidalcells,whichexhibitimpairedAktphosphorylationandconstitutiveS6activationthatisinsensitivetoinsulinstimulation.(B)Merlin-deﬁcientmeningioma[merlin(⫺)MN]cellsandcontrol(scr)andmerlin(m5)RNAiarachnoidalcellswereincubatedwith(⫹)andwithout(⫺)rapamycin(Rap;10nM)for24h.Untreatedcellsincompletemedium(15%FBS)exhibitS6phosphorylation(atS240/244)andtheattenuationofAktphosphorylation(atS473),resultingfromconstitutiveactivationofanmTORC1-S6Knegativefeedbackloop.Inthepresenceofrapamycin,mTORC1-S6Ksignalingisblocked,preventingS6phosphorylation,andAktphosphorylationisrestoredbyrelieffromnegativefeedback.Underserum-free(SF;0%FBS)conditions,merlin-deﬁcientmeningiomacellsdonotexhibittherestorationofAktsignaling.Inaddition,cyclinD1levelsarereducedinrapamycin-treatedcells,suggestingthatexpressionis,inpart,mTORC1dependent.FIG.7.Nf2-deﬁcient(Nf2⫺/⫺)MEFsexhibitconstitutivemTORC1activationcomparedtoNf2WT(Nf2⫹/⫹)MEFs.(A)Nf2⫺/⫺MEFs,platedconﬂuentlyandsubconﬂuently(subconﬂ),exhibitconstitutiveS6activation,incontrasttoNf2⫹/⫹MEFs,underconditionsofserumstarvation(0%FBS).(B)Nf2⫺/⫺MEFsandTsc2⫺/⫺MEFsexhibitincreasedaccumulationofphosphorylatedspeciesof4EBP1comparedtothatincontrolNf2⫹/⫹andTsc2⫹/⫹MEFs,respectively,underconditionsofserumstarvation(0%FBS).4EBP1phosphorylation(detectedbyanti-4EBP1antibody)isreﬂectedby4EBP1electrophoreticmobilityresults.(C)Rapamycin(Rap)suppressestheproliferationofNf2⫺/⫺MEFcells.Nf2⫹/⫹andNf2⫺/⫺MEFsincubatedwith20nMrapamycinorvehicle(DMSO)for24hwereexaminedforS-phaseentrybyusingBrdUincorporationasdetailedinMaterialsandMethods.DataarepresentedasmeanpercentagesofDAPI-stainedcells⫾standarderrorsofthemeans.*,P⬍0.01forDMSO-treatedcontrolversusrapamycin-treatedgroupsorNf2⫹/⫹versusNf2⫺/⫺MEFcells(n⫽5);⫹,present;⫺,absent.VOL.29,2009NF2/MERLINREGULATESmTORC1SIGNALING4259activatingproteinactivityoftuberin.However,wecannotruleoutthepossibilitythatmerlinmaysignalthroughaparallelpathway(independentofTSC)toregulatemTORC1.ItisalsotemptingtospeculatethatasshownrecentlyforTSCproteins(16),merlinmayalsoregulatemTORC2,whichmayexplainthecytoskeletaldefectscommonlyobservedinNF2protein-deﬁcientcells.OurdataidentifymerlinasyetanothertumorsuppressorproteinthatrestrictsmTORC1signaling.Ithasbeensug-gestedthatthelimitedmalignancypotentialofsometumorsassociatedwithothertumorsuppressorsyndromessuchasTSCsyndromemaybedue,inpart,totheattenuationofAktsignaling,resultingfromtheexistenceofpotentmTORC1-dependentfeedbackloopswhichstronglysuppresssignalingupstreamofthePI3Kpathway.MultiplemechanismsfornegativefeedbacktoAktsignalinghavebeendescribedpreviously(10,17),oneofwhichappearstoinvolveS6K1-dependentphosphorylationofinsulinreceptorsubstrateproteins,renderingthePI3K-Aktpathwayresistanttoinsu-lin/IGF1stimulationinarapamycin-dependentmanner.Insupportofthispossibility,wefoundthatgrowthfactor(in-sulin)-stimulatedphosphorylationofAktisimpairedincellslackingmerlinandthatprolonged(24-h)rapamycintreat-mentcanrestoreAktphosphorylationundergrowthcondi-tionswithfullserum.However,itremainstobeestablishedwhetherthestateofthismTOR-dependentfeedbackmech-anismiswhatdelineatesthemalignancyofthesetumors.OurﬁndingsidentifymTORC1asacriticalregulatorofmeningiomaandschwannomagrowthinvitroandinvivo,suggestingthatmTORinhibitionmayprovidenewavenuesfortargetedtherapiestoarrestthegrowthofthesetumors.Rapa-mycinandrapamycinanalogshaveshownantitumoractivityacrossavarietyofhumancancersinclinicaltrials,andearlysuccessesinthetreatmentofbenignhamartomasyndromeslikeTSChavebeenreported(2,8).However,theexistenceofastrongnegativefeedbackloopfromS6K1toAktsignalingpresentsapotentialtherapeuticproblem,aslosingthisfeed-backinhibitionmaypromotecellsurvivalandchemoresis-tance.Therefore,dualinhibitionofthePI3KpathwayandmTORmaybeaneffectivestrategy.Interestingly,insomecelltypes,prolongedrapamycintreatmentinhibitedmTORC2as-semblyand,consequently,Aktphosphorylation,suggestingthatclinicalresponsestorapamycinmayresultfromtheinhi-bitionofbothmTORCs(34).Givenourﬁndings,webelievethatrapamycinmeritsconsiderationforclinicalstudiesasatherapeuticagent,eitheraloneorincombinationwithPI3Kpathwayinhibitors,againstNF2-associatedtumors.ACKNOWLEDGMENTSWeareindebtedtoJosephAvruch(MGH)forvaluablediscussions.WethankRobertaL.Beauchampforexperttechnicalassistanceandmembersofourlaboratoryforhelpfulcommentsonthemanuscript.ThisworkwassupportedbytheNationalInstituteofHealthgrantsNS024279andMH079213,theS.SydneyDeYoungFoundation,andNeuroﬁbromatosis,Inc.,NewEngland.PackagingandproductionofviralsupernatantsforlentiviralinfectionsweresupportedbytheNIHCoreFacilitygrantNS045776.REFERENCES1.Averous,J.,B.D.Fonseca,andC.G.Proud.2008.RegulationofcyclinD1expressionbymTORC1signalingrequireseukaryoticinitiationfactor4E-bindingprotein1.Oncogene27:1106–1113.2.Bissler,J.J.,F.X.McCormack,L.R.Young,J.M.Elwing,G.Chuck,J.M.Leonard,V.J.Schmithorst,T.Laor,A.S.Brody,J.Bean,S.Salisbury,andD.N.Franz.2008.Sirolimusforangiomyolipomaintuberoussclerosiscom-plexorlymphangioleiomyomatosis.N.Engl.J.Med.358:140–151.3.Bretscher,A.,K.Edwards,andR.G.Fehon.2002.ERMproteinsandmerlin:integratorsatthecellcortex.Nat.Rev.Mol.CellBiol.3:586–599.4.Brunn,G.J.,J.Williams,C.Sabers,G.Wiederrecht,J.C.Lawrence,Jr.,andR.T.Abraham.1996.Directinhibitionofthesignalingfunctionsofthemammaliantargetofrapamycinbythephosphoinositide3-kinaseinhibitors,wortmanninandLY294002.EMBOJ.15:5256–5267.5.Cai,S.L.,A.R.Tee,J.D.Short,J.M.Bergeron,J.Kim,J.Shen,R.Guo,C.L.Johnson,K.Kiguchi,andC.L.Walker.2006.ActivityofTSC2isinhibitedbyAKT-mediatedphosphorylationandmembranepartitioning.J.CellBiol.173:279–289.6.Claus,E.B.,M.L.Bondy,J.M.Schildkraut,J.L.Wiemels,M.Wrensch,andP.M.Black.2005.Epidemiologyofintracranialmeningioma.Neuro-surgery57:1088–1095.7.Counter,C.M.,W.C.Hahn,W.Wei,S.D.Caddle,R.L.Beijersbergen,P.M.Lansdorp,J.M.Sedivy,andR.A.Weinberg.1998.Dissociationamonginvitrotelomeraseactivity,telomeremaintenance,andcellularimmortaliza-tion.Proc.Natl.Acad.Sci.USA95:14723–14728.8.Franz,D.N.,J.Leonard,C.Tudor,G.Chuck,M.Care,G.Sethuraman,A.Dinopoulos,G.Thomas,andK.R.Crone.2006.Rapamycincausesregres-sionofastrocytomasintuberoussclerosiscomplex.Ann.Neurol.59:490–498.9.Goncharova,E.,D.Goncharov,D.Noonan,andV.P.Krymskaya.2004.TSC2modulatesactincytoskeletonandfocaladhesionthroughTSC1-bind-ingdomainandtheRac1GTPase.J.CellBiol.167:1171–1182.10.Guertin,D.A.,andD.M.Sabatini.2007.DeﬁningtheroleofmTORincancer.CancerCell12:9–22.11.Gusella,J.F.,V.Ramesh,M.MacCollin,andL.B.Jacoby.1996.Neuroﬁ-bromatosis2:lossofmerlin’sprotectivespell.Curr.Opin.Genet.Dev.6:87–92.12.Gutmann,D.H.,A.Aylsworth,J.C.Carey,B.Korf,J.Marks,R.E.Pyeritz,A.Rubenstein,andD.Viskochil.1997.Thediagnosticevaluationandmul-tidisciplinarymanagementofneuroﬁbromatosis1andneuroﬁbromatosis2.JAMA278:51–57.13.Haddad,L.A.,N.Smith,M.Bowser,Y.Niida,V.Murthy,C.Gonzalez-Agosti,andV.Ramesh.2002.TheTSC1tumorsuppressorhamartininteractswithneuroﬁlament-Landpossiblyfunctionsasanovelintegratoroftheneuronalcytoskeleton.J.Biol.Chem.277:44180–44186.14.Hamaratoglu,F.,M.Willecke,M.Kango-Singh,R.Nolo,E.Hyun,C.Tao,H.Jafar-Nejad,andG.Halder.2006.Thetumour-suppressorgenesNF2/MerlinandExpandedactthroughHipposignallingtoregulatecellprolif-erationandapoptosis.Nat.CellBiol.8:27–36.15.Han,S.,T.M.Santos,A.Puga,J.Roy,E.A.Thiele,M.McCollin,A.Stemmer-Rachamimov,andV.Ramesh.2004.Phosphorylationoftuberinasanovelmechanismforsomaticinactivationofthetuberoussclerosiscomplexproteinsinbrainlesions.CancerRes.64:812–816.16.Huang,J.,C.C.Dibble,M.Matsuzaki,andB.D.Manning.2008.TheTSC1-TSC2complexisrequiredforproperactivationofmTORcomplex2.Mol.Cell.Biol.28:4104–4115.17.Huang,J.,andB.D.Manning.2008.TheTSC1-TSC2complex:amolecularswitchboardcontrollingcellgrowth.Biochem.J.412:179–190.18.Jacinto,E.,R.Loewith,A.Schmidt,S.Lin,M.A.Ruegg,A.Hall,andM.N.Hall.2004.MammalianTORcomplex2controlstheactincytoskeletonandisrapamycininsensitive.Nat.CellBiol.6:1122–1128.19.James,M.F.,J.M.Lelke,M.Maccollin,S.R.Plotkin,A.O.Stemmer-Rachamimov,V.Ramesh,andJ.F.Gusella.2008.ModelingNF2withhumanarachnoidalandmeningiomacellculturesystems:NF2silencingreﬂectsthebenigncharacteroftumorgrowth.Neurobiol.Dis.29:278–292.20.Johnson,M.D.,A.Woodard,P.Kim,andM.Frexes-Steed.2001.Evidenceformitogen-associatedproteinkinaseactivationandtransductionofmito-genicsignalsbyplatelet-derivedgrowthfactorinhumanmeningiomacells.J.Neurosurg.94:293–300.21.Kleihues,P.,D.N.Louis,B.W.Scheithauer,L.B.Rorke,G.Reifenberger,P.C.Burger,andW.K.Cavenee.2002.TheW.H.O.classiﬁcationoftumorsofthenervoussystem.J.Neuropathol.Exp.Neurol.61:215–229.22.Kwiatkowski,D.J.2003.Tuberoussclerosis:fromtuberstomTOR.Ann.Hum.Genet.67:87–96.23.Lallemand,D.,M.Curto,I.Saotome,M.Giovannini,andA.I.McClatchey.2003.NF2deﬁciencypromotestumorigenesisandmetastasisbydestabilizingadherensjunctions.GenesDev.17:1090–1100.24.Lamb,R.F.,C.Roy,T.J.Diefenbach,H.V.Vinters,M.W.Johnson,D.G.Jay,andA.Hall.2000.TheTSC1tumoursuppressorhamartinregulatescelladhesionthroughERMproteinsandtheGTPaseRho.Nat.CellBiol.2:281–287.25.Ma,L.,Z.Chen,H.Erdjument-Bromage,P.Tempst,andP.P.Pandolﬁ.2005.PhosphorylationandfunctionalinactivationofTSC2byErk:implica-tionsfortuberoussclerosisandcancerpathogenesis.Cell121:179–193.26.Manning,B.D.2004.BalancingAktwithS6K:implicationsforbothmeta-bolicdiseasesandtumorigenesis.J.CellBiol.167:399–403.27.McClatchey,A.I.,andM.Giovannini.2005.Membraneorganizationand4260JAMESETAL.MOL.CELL.BIOL.tumorigenesis—theNF2tumorsuppressor,Merlin.GenesDev.19:2265–2277.28.Morrison,H.,L.S.Sherman,J.Legg,F.Banine,C.Isacke,C.A.Haipek,D.H.Gutmann,H.Ponta,andP.Herrlich.2001.TheNF2tumorsuppressorgeneproduct,merlin,mediatescontactinhibitionofgrowththroughinter-actionswithCD44.GenesDev.15:968–980.29.Okada,T.,M.Lopez-Lago,andF.G.Giancotti.2005.Merlin/NF-2mediatescontactinhibitionofgrowthbysuppressingrecruitmentofRactotheplasmamembrane.J.CellBiol.171:361–371.30.Perry,A.,D.H.Gutmann,andG.Reifenberger.2004.Molecularpathogen-esisofmeningiomas.J.Neurooncol.70:183–202.31.Rouleau,G.A.,P.Merel,M.Lutchman,M.Sanson,J.Zucman,C.Mari-neau,K.Hoang-Xuan,S.Demczuk,C.Desmaze,B.Plougastel,S.M.Pulst,G.Lenoir,E.Bijlsma,L.Fashold,J.Dumanski,P.deJong,D.Parry,R.Eldrige,A.Aurias,O.Delattre,andG.Thomas.1993.Alterationinanewgeneencodingaputativemembrane-organizingproteincausesneuro-ﬁbro-matosistype2.Nature363:515–521.32.Roux,P.P.,B.A.Ballif,R.Anjum,S.P.Gygi,andJ.Blenis.2004.Tumor-promotingphorbolestersandactivatedRasinactivatethetuberoussclerosistumorsuppressorcomplexviap90ribosomalS6kinase.Proc.Natl.Acad.Sci.USA101:13489–13494.33.Ruttledge,M.H.,J.Sarrazin,S.Rangaratnam,etal.1994.EvidenceforthecompleteinactivationoftheNF2geneinthemajorityofsporadicmeningi-omas.Nat.Genet.6:180–184.34.Sabatini,D.M.2006.mTORandcancer:insightsintoacomplexrelation-ship.Nat.Rev.Cancer6:729–734.35.Sancak,Y.,C.C.Thoreen,T.R.Peterson,R.A.Lindquist,S.A.Kang,E.Spooner,S.A.Carr,andD.M.Sabatini.2007.PRAS40isaninsulin-regulatedinhibitorofthemTORC1proteinkinase.Mol.Cell25:903–915.36.Sarbassov,D.D.,S.M.Ali,S.Sengupta,J.H.Sheen,P.P.Hsu,A.F.Bagley,A.L.Markhard,andD.M.Sabatini.2006.ProlongedrapamycintreatmentinhibitsmTORC2assemblyandAkt/PKB.Mol.Cell22:159–168.37.Sena-Esteves,M.,J.C.Tebbets,S.Steffens,T.Crombleholme,andA.W.Flake.2004.Optimizedlarge-scaleproductionofhightiterlentivirusvectorpseudotypes.J.Virol.Methods122:131–139.38.Shamah,S.M.,J.A.Alberta,W.V.Giannobile,A.Guha,Y.K.Kwon,R.S.Carroll,P.M.Black,andC.D.Stiles.1997.Detectionofactivatedplatelet-derivedgrowthfactorreceptorsinhumanmeningioma.CancerRes.57:4141–4147.39.Sherman,L.,H.M.Xu,R.T.Geist,S.Saporito-Irwin,N.Howells,H.Ponta,P.Herrlich,andD.H.Gutmann.1997.InterdomainbindingmediatestumorgrowthsuppressionbytheNF2geneproduct.Oncogene15:2505–2509.40.Surace,E.I.,C.A.Haipek,andD.H.Gutmann.2004.Effectofmerlinphosphorylationonneuroﬁbromatosis2(NF2)genefunction.Oncogene23:580–587.41.Trofatter,J.A.,M.M.MacCollin,J.L.Rutter,J.R.Murrell,M.P.Duyao,D.M.Parry,R.Eldridge,N.Kley,A.G.Menon,K.Pulaski,V.H.Haase,C.M.Ambrose,D.Munroe,C.Bove,J.L.Haines,R.L.Martuza,M.E.MacDonald,B.R.Seizinger,M.P.Short,A.J.Buckler,andJ.F.Gusella.1993.Anovelmoesin-,ezrin-,radixin-likegeneisacandidatefortheneu-roﬁbromatosis2tumorsuppressor.Cell72:791–800.42.VanderHaar,E.,S.I.Lee,S.Bandhakavi,T.J.Grifﬁn,andD.H.Kim.2007.InsulinsignallingtomTORmediatedbytheAkt/PKBsubstratePRAS40.Nat.CellBiol.9:316–323.43.Vanhaesebroeck,B.,S.J.Leevers,K.Ahmadi,J.Timms,R.Katso,P.C.Driscoll,R.Woscholski,P.J.Parker,andM.D.Waterﬁeld.2001.Synthesisandfunctionof3-phosphorylatedinositollipids.Annu.Rev.Biochem.70:535–602.44.Wiederhold,T.,M.F.Lee,M.James,R.Neujahr,N.Smith,A.Murthy,J.Hartwig,J.F.Gusella,andV.Ramesh.2004.Magicin,anovelcytoskeletalproteinassociateswiththeNF2tumorsuppressormerlinandGrb2.Onco-gene23:8815–8825.45.Wullschleger,S.,R.Loewith,andM.N.Hall.2006.TORsignalingingrowthandmetabolism.Cell124:471–484.46.Yang,Q.,andK.L.Guan.2007.ExpandingmTORsignaling.CellRes.17:666–681.47.Zhang,H.,G.Cicchetti,H.Onda,H.B.Koon,K.Asrican,N.Bajraszewski,F.Vazquez,C.L.Carpenter,andD.J.Kwiatkowski.2003.LossofTsc1/Tsc2activatesmTORanddisruptsPI3K-AktsignalingthroughdownregulationofPDGFR.J.Clin.Investig.112:1223–1233.48.Zhang,H.H.,A.I.Lipovsky,C.C.Dibble,M.Sahin,andB.D.Manning.2006.S6K1regulatesGSK3underconditionsofmTOR-dependentfeedbackinhibitionofAkt.Mol.Cell24:185–197.49.Zhao,B.,X.Wei,W.Li,R.S.Udan,Q.Yang,J.Kim,J.Xie,T.Ikenoue,J.Yu,L.Li,P.Zheng,K.Ye,A.Chinnaiyan,G.Halder,Z.C.Lai,andK.L.Guan.2007.InactivationofYAPoncoproteinbytheHippopathwayisinvolvedincellcontactinhibitionandtissuegrowthcontrol.GenesDev.21:2747–2761.VOL.29,2009NF2/MERLINREGULATESmTORC1SIGNALING4261MoleculargeneticanalysisoftheNF2geneinyoungpatientswithunilateralvestibularschwannomasAMohyuddin,WJNeary,AWallace,CLWu,SPurcell,HReid,RTRamsden,ARead,GBlack,DGREvans.............................................................................................................................JMedGenet2002;39:315–322Neurofibromatosistype2(NF2)mustbesuspectedinpatientspresentingwithaunilateralvestibularschwannomaatayoungagewhoarethereforeattheoreticalriskofdevelopingbilateraldisease.Weidentified45patientsaged30yearsorlessattheonsetofsymptomsofaunilateralvestibularschwan-noma.MoleculargeneticanalysisoftheNF2genewascompletedonperipheralbloodsamplesinall45andon28tumoursamples.NopathogenicNF2mutationswereidentifiedinanyofthebloodsam-ples.NF2pointmutationswereidentifiedin21/28(75%)tumoursamplesandlossofheterozygosity(LOH)in21/28(75%)tumoursamples.Bothmutationalhitswereidentifiedin18/28(65%)tumoursamples.Inonemultilobulartumour,one(presumablyfirsthit)mutationwasconfirmedwhichwascom-montodifferentfociofthetumour,whilethesecondmutationaleventdifferedbetweenfoci.ThemolecularfindingsinthispatientwereconsistentwithsomaticmosaicismforNF2andtheclinicaldiag-nosiswasconfirmedwiththepresenceoftwomeningiomasonafollowupMRIscan.AfurtherpatientdevelopedacontralateralvestibularschwannomaonafollowupMRIscaninwhomneitherofthetrun-catingmutationsinthevestibularschwannomawerepresentinblood.Itisimportantwhencounsellingpatientswithunilateralvestibularschwannomastoidentify(1)thoseatriskofbilateraldisease,(2)thoseatriskofdevelopingothertumours,and(3)otherfamilymembersatriskofdevelopingNF2.ComparingtumourandbloodDNAcannotexcludemosaicismintheindexcaseandcannot,therefore,beusedtopredictthoseatriskofdevelopingfurthertumours.However,identificationofbothmutationsoronemutationplusLOHinthetumourandexclusionofthosemuta-tionsinthebloodsamplesofthesibsoroffspringoftheaffectedcasemaybesufficienttorenderfur-therscreeningunnecessaryintheserelatives.Themajority(>95%)ofvestibularschwannomasaresporadicandunilateralandpresentinthefourthandﬁfthdecades.12Inthesecasestheyhavenobroaderclinicalimplicationsforeitherpatientorfamily.Whenbilateral,thetumours23representamanifestationofneuroﬁbromatosistypeII(NF2),anautosomaldominantcondition,whichhasapopulationincidenceof1in33000to1in40000.4ThehallmarkofNF2isthedevelopmentinthesecondandthirddecadesofbilateralvestibularschwannomas.NF2isalsocharacterisedbyapredispositiontothedevelopmentofothertumoursofthecentralandperipheralnervoussystem,includ-ingmeningiomas,gliomas,andspinalschwannomas/neuroﬁbromas.5DiagnosticcriteriaforNF2wereagreedbytheNationalInstitutesofHealthConsensusDevelopmentConfer-encein1987(table1A)andadditionalcriteriadescribedbyEvansetal6in1992(table1B).Thereisevidencetosuggestthatpatientsaged30yearsorlessattheonsetofsymptomsofaunilateralvestibularschwannomaareathighriskofbeingaffectedwithavariantformofNF2.78Approximately10-18%ofNF2casespresentinitiallywithaunilateralvestibularschwannomaratherthanwithbilateraltumours.However,thisisusuallyaccompaniedorprecededbyotherfeaturessuchasmeningiomas,skintumours,symptomaticspinaltumours,orafamilyhistoryofNF2.69–11Vestibularschwannomasarisefromtheinactivationofmerlin,theproteinproductoftheNF2tumoursuppressorgene,whichregulatesSchwanncellgrowth.Sporadictumoursdifferfrominheritedtumoursinthattheﬁrstmutationalhitisacquiredandmaybepresentinmosaicform.SubjectswhoaremosaicforaNF2mutationareatriskoftransmittingthemutationtotheiroffspringifitispresentinthegonads.12TheNF2genewasisolatedin1993,1314afterlinkagestudieshadassignedthegenetochromosome22.15GermlinemutationshavebeenreportedbyseveralworkersinlargeseriesofpatientsaffectedwithNF2.16–19However,onlyabout40%ofdenovocasesofNF2haveanidentiﬁablemutationinlymphocyteDNA.1220AspatientswhopresentwithaunilateralTable1DiagnosticcriteriaforNF2AdiagnosisofNF2ismadeinapatientwhohas(NIHcriteria,1987):BilateralvestibularschwannomasORfamilyhistoryofNF2PLUSunilateralvestibularschwannomaORanytwoof:meningioma,glioma,neurofibroma,schwannoma,posteriorsubcapsularlenticularopacitiesAdiagnosisofNF2canalsobemadeinapatientwhohas(Evansetal6):UnilateralvestibularschwannomaPLUSanytwoof:meningioma,glioma,neurofibroma,schwannoma,posteriorsubcapsularlenticularopacitiesORmultiplemeningiomas(2ormore)PLUSunilateralvestibularschwannomaORanytwoof:glioma,neurofibroma,schwannoma,cataractSeeendofarticleforauthors’affiliations.......................Correspondenceto:MrAMohyuddin,FRCS,UniversityDepartmentofMedicalGeneticsandRegionalGeneticServices,StMary’sHospital,HathersageRoad,ManchesterM13OJH,UK;atai_1999@yahoo.comRevisedversionreceived20February2002Acceptedforpublication26February2002.......................315www.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from vestibularschwannomaatayoungageareatriskofdevelop-ingbilateraldisease,itwouldbevaluabletoidentifythosewhorequirefurtherscreeningforNF2tumours.Therearealsoimplicationsforotherfamilymemberswhocouldrequiretumoursurveillanceandgeneticcounselling.Wehavepreviouslyproposedastrategy,basedontheanaly-sisoftumourDNA,fordistinguishingfamilialandsporadiccasesoftumourscausedbytheinactivationofatumoursup-pressorgene.21Wehavenowappliedthisstrategybycompletelyanalysingtumourmaterialfrom28of45youngpatientswithanapparentlyisolatedunilateralvestibularschwannomatoestablishwhetherthemutationspresentinthetumouraretheresultofagermlinemutationorarelikelytobetheresultofsomaticevents.METHODSPatientsPatientswhopresentedwiththeonsetofﬁrstsymptomsofaunilateralvestibularschwannomawhenaged30yearsorlesswereincludedinthisstudy.Allpatientswhohadafamilyhis-toryofanyneurogenictumourswereexcludedfromthestudy.AllpatientswhowereincludedinthisstudywereexaminedclinicallyforanycutaneousfeaturesofNF2.Patientsunderwentophthalmologicalexaminationtolookforjuvenileposteriorsubcapsularlenticularopacitiesandcorticalopaci-ties.Aneuro-otologicalexamination,whichincludedpuretoneaudiometry,stapedialreﬂexmeasurement,andauditorybrainstemresponsetesting,wasalsoperformed.Magneticresonanceimagingwithgadolinium-DTPAenhancementwasusedtoassessallpatientsafter1990,sothatacontralateralvestibularschwannomaoranyothercranialtumourcouldbeexcluded.Atotalof689patientswhopresentedwithaunilateralves-tibularschwannomawereseenattheneuro-otologyclinicbetweenJanuary1978andDecember1998.Inanearlierstudyweselected93of407ofthesepatientsongeographicalcrite-riaforadetailedstudyofpatientsandfamilieswithaunilat-eralvestibularschwannoma.7Sixpatientswererecruitedfromthisretrospectiveseries.Theremainderoftheserieswererecruitedfrompatientsmeetingtheinclusioncriteria.ThirtypatientswhometthesecriteriafromourhospitalserieswerestudiedbylookingatboththeirclinicalfeaturesandanalysingforNF2mutationsinbothtumourandblood.Theremaining15patientsreferredfromothercentreswithanapparentlyisolatedunilateralvestibularwereanalysedonbloodalone.DNAextractionDNAwasextractedfrombloodandtumour(freshandparaf-ﬁnﬁxed)specimensfrom30outof45cases.DNAwasavail-ableonlyfrombloodintheremaining15samples.GenomicDNAwasextractedfromperipheralbloodlymphocytesusingstandardprocedures.DNAwaspreparedfromfreshandparafﬁnembeddedtumourspecimensaccordingtothemeth-odsdescribedbyWuetal.21Onetumour(case10)appearedtobemultifocalatsurgeryandseparatefociwerebiopsiedandprocessedseparately.MoleculargeneticanalysisGenomicandtumourDNAsampleswereampliﬁedforall17exonsoftheNF2gene.TheprimersforthemajorityofexonsusedwerethosedescribedbyMereletal.18However,theprimerpairsforexons1,2,and3alongwiththereverseexon6andforwardexon8primerwereredesignedtoincludethewholeexonandsplicedonor/acceptorsites(table2).SSCPheteroduplexanalysisSSCP/heteroduplexanalysiswascarriedouton32cmlong8%(49:1acrylamide:bisacrylamideratio)nativepolyacrylamidegelsrunat360Vconstantvoltageforapproximately16hoursat4°C.SSCPandheteroduplexeswerethenvisualisedbysilverstaining.22SamplesthatgaverisetoSSCP/heteroduplexshifts,whichwerepresentatlowlevelsonsilverstainedSSCP/HA(minorityalleles),werereampliﬁedandalargerquantityofthesamplewasloadedontoasecondSSCP/HAgel.Thegelwassubjectedtosilverstainingaspreviouslyexceptthatthefourthsolutionwasreplacedwith50mmol/lEDTA.Thegelsliceswerebrieﬂyrinsedin50µlsterilewaterandDNAwaselutedbycrushingandsoakingovernightin50µlofsterilewater.TheminorityallelesisolatedfromthegelwerethenreampliﬁedbyPCRfromtheeluate.DNAproductspurificationandsequencingThesampleswerepuriﬁedbeforesequencingusingCentricon100columns.A40µlPCRreactionwasaddedto2mlofster-ilewateronthecolumnsaccordingtothemanufacturer’sinstructions.ThepuriﬁedDNAproductswerethenvisualisedona2.5%agarosegeltocheckforrecovery.DNAsequencingreactionswerecarriedoutinbothforwardandreverseorien-tationsforeachsampleusingBigDyeTerminatorv20readyreactionkits.ElectrophoresisandﬂuorescentdetectionofthesequencingreactionswascarriedoutonanAppliedBiosys-tems377Asequencerwith48cmwelltoreadplates.Lossofheterozyosity(LOH)studiesLOHwasdetectedusingacombinationoffourmicrosatellitemarkers:D22S275,23NF2CA3,24D22S268,25andD22S280.26NF2CA3islocatedwithinintron1oftheNF2genewhereasD22S275,D22S268,andD22S280arealltightlylinkedtotheNF2gene.27FormarkersD22S275,NF2CA3,andD22S268.LOHwasdeterminedusingﬂuorescentlylabelledPCRproducts,thelymphocyteandtumourDNApairsbeingampli-ﬁedandsubjectedtosimultaneouselectrophoreticanalysistocomparelymphocyteandtumourDNAusingtheGenescanv2.1.1fragmentanalysisprogram.AdiminutioninrelativeallelesignalstrengthbetweenlymphocyteandtumourDNAofmorethan30%wastakenasindicativeofLOH.ForthemarkerD22S280,LOHwasdeterminedbycomparisonoflymphocyteandtumourDNA.PCRampliﬁcationswereelectrophoresedonnon-denaturinggelsandvisualisedbysil-verstaining.RESULTSThemeanageofonsetofsymptomsinthe30patientswhereblood/tumouranalysiswascarriedoutwas23.1years.Thiscomparedwith47.5yearsforourhospitalbasedseriesof689patientswithunilateralVS.Theaveragedurationfromageofonsetoftheﬁrstsymptomstoageatwhichthepatientswerediagnosedasaffectedwithaunilateralvestibularschwan-nomawas3.7years.Therewere16femalesand14males.TheTable2RedesignedprimersforamplificationofNF2exonsNameForwardprimer(5¢ﬁ3¢)Reverseprimer(5¢ﬁ3¢)NF2Ex1tggccctgaggcctgtgcagcaacgagaacctctcgagcttccacNF2Ex2tgtccttccccattggtttgcagtttcatcgagttctagccNF2Ex3gcttctttgagggtagcacaggtcaactctgaggccaactctgcaNF2Ex6–cccataaaggaatgtaaaccaacNF2Ex8gagcctcagctggcgcttac–316Mohyuddin,Neary,Wallace,etalwww.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from clinicaldetailsaresummarisedintable3.Noneofthepatientshadafamilyhistoryofvestibularschwannomaorothercranialtumours.Caféaulaitpatcheswerefoundoncutaneousexaminationinsixseparatecases,withonecase(case23)havingﬁvecaféaulaitpatches.Subcutaneouslumpswerefoundintwocases(cases9and20),butneitherhadbeenbiopsiedasthesewerenotsuspectedclinicallytobeschwannoma.Allthepatientsselectedforthestudywerefollowedupwithregularclinical,audiologicalandradiologicalexamination.Onepatient(case10)wassubsequentlyalsofoundtohavetwoipsilateralcranialmeningiomasonfollowupMRIscan.Afurtherpatient(case26)developedacontralateralvestibularschwannomathreeandahalfyearsafterundergoingsurgeryforaunilateralves-tibularschwannoma.Twenty-twooutof689patientsinthehospitalserieshadaunilateralvestibularschwannomaoninitialcranialscan,buthadotherNF2featuresorhadaunilateralvestibularschwannomaandafamilyhistory;13ofthesefulﬁlledNF2criteriaandsevenpresentedatlessthan30yearsofage.Allwereexcludedfromthepresentstudypopu-lation.Allother28patientsremainwellwithnocranialtumoursonfollowupMRIscanthreeto20yearsafterinitialdiagnosis.MoleculargeneticanalysisAnalysisoflymphocyteDNAForty-ﬁvepatientsweretestedforgermlinemutationsfromlymphocyteDNAandtwoofthemwerefoundtohavesequencechanges.Themutationsidentiﬁedinthebloodsam-plesofthesetwopatients(cases2and9)wereconsideredtobenon-pathogenicNF2polymorphisms.Aninframedeletion332-4wasidentiﬁedinbloodfromonepatient(case9),whichwassubsequentlyfoundinhisunaffectedmother(ﬁg1A),andwasthoughtnottobepathogenic.Twopathogenicmuta-tionalhitswereidentiﬁedinthetumoursamplefromthepatient.AtruncatingmutationwasidentiﬁedwhichwasnotdetectableinthelymphocyteDNAsample(ﬁg1B).ThetumouralsoshowedclearevidenceofLOHwithmarkersD22S275andD22S268(ﬁg1C).Theallelelostinthetumouristhatcontainingtheinframe3bpdeletionsincethesignalfromthisisdiminished.Asaconsequence,thetruncatingmutationispresumablyontheotherallele.Thepatient’smotherhasnoclinicalfeaturesofNF2,andMRIwithgadolinium-DTPAenhancementshowednoevidenceofvestibularschwannomasorothercranialtumours.Asynony-mouscodonsubstitutionwasalsoidentiﬁedinonefurtherpatient(case2).AnalysisoftumourDNATumoursof28patientswereanalysedforpointmutationsthroughoutthewholecodingsequenceoftheNF2gene.Theresultsoftheanalysisareshownintable4.Pointmutationswereidentiﬁedin21/28tumoursamples(75%).Lossofheterozygosity(LOH)waspresentin21/28tumoursamples(75%).Twomutationalhitswereidentiﬁedin18/28tumours(65%)andasinglemutationaleventestab-lishedin7/28(24%).Inthreeoutof28(11%)tumours,nomutationaleventwasfound.In21/28tumoursamplesthereweretruncatingmutations,withframeshiftdeletionsoccur-ringin11outof21(52%)andnonsensemutationsineightoutof21(38%).Twotumourshadsplicesitemutations(9.5%).Twopatients(cases10and26)havesubsequentlydevelopedsecondNF2relatedtumours.Case10,inwhomaclinicaldiagnosisofNF2hassincebeenconﬁrmedbythepresenceofcranialmeningiomas,developedaunilateralmul-tilobularvestibularschwannoma.AmissensemutationVal219>Metwasconﬁrmedtobecommontotwodifferentfociofthetumour.Intheﬁrstfocus,asecondhitwasnotidentiﬁed.Inthesecondfocus,twofurtherpathogenicmuta-tionswerefoundasminorityalleles(ﬁg2A-C).ThissameTable3Clinicalfeaturesof30youngpatientsdiagnosedwithaunilateralvestibularschwannomaCaseSexAgeatfirstsymptoms(y)Ageatdiagnosis(y)OtherNF2featuresFamilyhistoryConclusionafterDNAstudies1M1826NilNilSporadic2F1923NilNilSporadic3F2427NilNilSporadic4F1922CALpatchesNilSporadic5M1737NilNilSporadic6F2934NilNilUndetermined7F2939NilNilSporadic8M2931NilNilUndetermined9M2529OneCAL:lumpanteriorthighNilSporadic10F2529*2meningiomasNilMosaic11F1820NilNilSporadic12M2526NilNilSporadic13F1724NilNilUndetermined14M2427OneCALpatchNilI6/17exonsanalysed15F2021NilNilSporadic16M1821NilNilSporadic17M3031NilNilUndetermined18M2324OneCALpatchNil5/17exonsanalysed19F1821NilNilInsufficientmaterialfortumouranalysis20M2529OneSClumpNilSporadic21M2224NilNilSporadic22F2125NilNilSporadic23F26285CALpatchesNilSporadic24F3032NilNilSporadic25F2324NilNilSporadic26F26283CaLpatchesandcontralateralVS*NilMosaic27F2629NilNilSporadic28M2930NilNilSporadic29M2426NilNilSporadic30M1416NilNilSporadicCAL=caféaulait.SC=subcutaneous.*OnlyafterinitialassesmentofMRI;sporadicstatusisassumed,althoughmosaicismcannotbeexcluded.PotentialofNF2inpatientswithearlyonsettumours317www.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from biopsyspecimenthatshowedthreeapparentmutationsalsoshowedevidenceofLOH(ﬁg2D).However,themissensemutationwasthepredominantalleleinthisbiopsyspecimen.IntheabsenceofamutationinlymphocyteDNAfromthispatient,theﬁndingswerestronglysuggestiveofmosaicism.Thedaughterofthispatient,whowasthereforedeﬁnedasbeingmosaicforNF2,hassincebeenexcludedascarryingtheprimarymutation,aswellasthesecondarymutationsthatwereidentiﬁedinhermother’stumour;shehasthereforebeenexcludedfromtumoursurveillance.Case26hasgoneontodevelopacontralateralvestibularschwannomathatwasnotdetectedontheoriginalMRIscan.ThispatientcarriedtwotruncatingmutationsinthesameexonintumourDNA;thesecondsplicingmutation(table4)wasinitiallyoverlookedasamutationhadalreadybeeniden-tiﬁedinthatexon.Noabnormalitywasdetectedinherperipheralblood.ShestillhasnootherfeaturesofNF2includingaclearspinalMRIscan.Afurtherattempttoﬁndagermlinemutationwasundertakeninthe10outof28patientsinwhomtwoFigure1Molecularanalysisofcase9.(A)SSCP/HAofexon3.LymphocyteDNAfromboththepatientandhisparentsareindicatedbythepedigree.BoththepatientandhisunaffectedmotherclearlyhaveaSSCPandheteroduplexshift;onsequencingthiswasfoundtobeaninframedeletionofaminoacidresidueGlu112.Thetumoursamplefromthepatient(T)alsoclearlyhasDglu112,althoughtheNF2allelecarryingDglu112showsdiminutionofsignalindicatingalleleloss.(B)SSCP/HAanalysisofexon5.Thetumourfromcase9hasaSSCPandheteroduplexshiftthatisnotpresentwithinhislymphocyteDNAsample(L);onsequencingthisshiftwasfoundtobeanonsensemutation(Tyr153>Stop,nt459>G).TheshiftoriginatingfromTyr>Stopisatapproximatelythesamelevelasthenormalsignal.(C)LOHanalysis.ComparisonoflymphocyteandtumourDNAwiththetwocloselylinkedmicrosatellitemarkersD22S275andD22S268.Anallelewithbothmarkerscanbeseenatmarkedlyreducedintensityindicatingallelelossinthetumourtissue.ThissamplewasnotinformativefortheintragenicmarkerNF2CA3.Mwt=molecularweightmarker.NC=normalcontrol.900150160D22S275ABCMWtLTNCNCMWtTNC1701801908007006005004003002001000Tumour+180016001400120010008006004002000Lymphocytes720150160D22S268170180190640560480400320240160800Tumour+36032028024020016012080400Lymphocytes318Mohyuddin,Neary,Wallace,etalwww.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from mutationalhitswerenotestablishedinthetumour.BloodDNAwasanalysedbyFISHanalysiswithprobesLL96C10andLL4D7(courtesyofJanDumanski)anddosagePCRforexons1,4,8,and15.Nofurthermutationswereidentiﬁed.Nochil-drenoftheunilateralvestibularschwannomaserieshasdevelopedNF2.Thedaughterofthemosaicpatient(case10)hasbeenexcludedfromcarryingthemutationsidentiﬁedinhermother’stumour.Table4SSCP/HAanalysisandLOHstudiesonlymphocyteandtumoursamplesfrom30youngpatientswithaunilateralvestibularschwannomaCaseTissueSSCP/HALOHanalysisMutationClassD22S275NF2CA3D22S268D22S2801L-ve–T1080DGFLOHLOHLOH–2L465C>TSYTD757-795(DLys253>Ser265)IF–LOH–LOH3L-ve–T1443C>G(Tyr481>Stop)NLOHULOH–4L-ve–T459C>A(Tyr153>Stop)N–LOH–N5L-ve–T448-1g>tSP–LOH––6L-ve–T1228C>T(Gln433>Stop)NUUN–7L-ve–T970C>T(Gln324>Stop)NLOHULOH–8L-ve–T-ve–LOHULOH–9LD332-334(DGlu112)IFT459C>G(Tyr153>Stop)NLOHULOH–10L-ve–T1169C>T(Arg57>Stop)NLOHUU–655G>A(Val219>Met)M1600DCFT2655G>A(Val219>Met)MNUU–11L-ve–T1514DTGF–LOH––12L-ve–T479DGFLOHULOH–13L-ve–TD171-216FNRNN–14L-ve–T-vefor16/17exons*––LOH––15L-ve–T1513DCTGTFLOHUU–16L-ve–T169C>T(Arg57>Stop)N–LOH––17L-ve–T-ve––LOH––18L-ve–T-vefor5/17exons*–––––19L-ve–Tinsufficientmaterial–––––20L-ve–T1621DGF–LOH––21L-ve–Tnt1366C>T(Glyn456>stop)––LOH––22L-ve–T447+2t>cSPNUU–23L-ve–T653DGF–LOH––24L-ve–T54insAF–LOH––25L-ve–T-ve––LOH––26L-ve–T737DCF–N––nt810g>aSP27L-ve–T-ve––N––28L-ve–T-ve––N––29L-ve–T265insGF–LOH––30L-ve–T-ve–UUU–Tissue:L=lymphocyteDNA,T=tumourDNA.SSCP/HA:F=frameshift,SP=splicesite,N=nonsense,M=missense,IF=inframedeletion,SY=synonymouscodonsubstitution,–=nomutation,*=insufficientmaterialforcompleteanalysis.LOHanalysis:LOH=lossofheterozygosity,U=uninformative,N=nolossofheterozygosity,NR=noresult,–=nottested.PotentialofNF2inpatientswithearlyonsettumours319www.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from DISCUSSIONVestibularschwannomasarisefromtheinactivationoftheNF2tumoursuppressorgene,whichregulatesschwanncellgrowth.Vestibularschwannomasoriginateinthedistalneuri-lemmalportionofthevestibularnerveatorclosetotheneurilemmal-neuroglialjunction.28Theyarebenignneo-plasmsoftheSchwanncellsheath.Thisstudyhasconﬁrmedourrecentworkwhichshowsthatonlyaverysmallnumberofsubjectswithanisolatedunilat-eralVSarelikelytoharbouragermlinemutationintheNF2geneorgoontodevelopbilateraldisease.11Outofthe45youngunilateralvestibularschwannomapatientsthoughttobeathighriskofdevelopingNF2,onlytwohadidentiﬁablesequencevariationsinbloodsamples(cases2and9).Bothwereconsideredtobenon-pathogenicpolymorphisms.Oneofthetwo(case9)hadanidentiﬁablesequencevariation(lossofaglutamineatposition112intheNterminalregion),which,afterfurtherexaminationofthefamilyandmolecularanaly-sisofhistumour,wasconﬁrmedtorepresentararepolymor-phism.Thisaminoacidchangewasonthesameallelethatshowedlossofheterozygosityandwaspresentinthepatient’smother,whohadnoevidenceofcranialtumoursonMRIaged59years.Oneofthesesubjects,case10,ismosaicforavalinetomethioninemissensemutationatposition219,whichispredictedtoaffectthenormalconformationofthealphaheli-caldomain.Giventhatthischangewasdenovo(notpresentingermlineDNA)andwasconﬁrmedintwoseparatefocioftumour,itishighlylikelytobepathogenic.Theresultsfromonebiopsyfromthemultifocaltumourinthiscaseappearstoshowfourseparatehits,includingLOH.Itislikelythatthisbiopsyhastakenmaterialfromthreeseparatefocioftumour;inthiscasethepredominantallelecontainsthemissensemutationpresentinallthreefoci.ThepresenceofmultifocaltumoursinNF2haspreviouslybeendescribedatthemacroscopiclevel.1029Unliketrulysporadicunilateraltumours,theyoftenappearasa“bunchofgrapes”aroundthevestibularnerveandmayaccountforsomeofthepoorersurgicalandradiotherapyresultsinNF2.10Thisistheﬁrsttimetoourknowledgethatthemultifocalityofaves-tibularschwannomahasbeenprovenatthemolecularlevel.Afurtherlessonisseenincase26wheretwomutationsweredetectedinthesameexontoaccountforaSSCPshift,indicat-ingthattheentiresequenceoftheexonshouldbeexaminedinatumourspecimenwheretwohitsarepossible.Itispossiblethatapredisposingmutationcouldbepresentinthe10patientsinwhomtwohitswerenotestablished.Zucman-Rossietal30havedescribedamutationscreeningstrategy,whichhasraisedtheefﬁciencyofmutationdetectioninNF2patientsto84%intheirseries.OurcombinedstrategyFigure2Molecularanalysisofcase10.(A)SSCP/HAanalysisofexon2.Thefirstsamplefromthetumour(T1)hasaweakSSCPandheteroduplexshiftthatwassequencedasanonsensemutation(Arg57>Stop,nt169c>T).Thisshiftisabsentfromthepatient’slymphocyteDNA(L)andfromthesecondtumoursample(T2).Amutationcontrolhasalsobeenrunfromapatientwhocarriesthesamemutationin50%oftheirlymphocytes(MutC).(B)SSCP/HAanalysisofexon7.Bothtumoursamplesfromcase10(T1andT2)havethesameshiftwhichwassequencedasamissensemutation(Val219>Met,nt655G>A).TheshiftcorrespondingtoVal219>Metisnotpresentatdetectablelevelsinthepatient’slymphocyteDNAsample(L).ThemutationappearstobepresentatahigherlevelinsampleT1.(C)SSCP/HAanalysisofexon15.Averyweakheteroduplexshiftwasobservedinthefirsttumoursample(T1)whichwassequencedas1600DC.Thisshiftwasnotobservedatdetectablelevelsineitherthepatient’slymphocyteDNA(L)orthesecondtumoursample(T2).(D)LOHanalysis.ComparisonoflymphocyteDNAandthetwotumourDNAsampleswiththeintragenicmicrosatellitemarkerNF2CA3.Thefirsttumoursampleshowssignificantbutnotcompletelossofoneallele(arrowed).Therewasnodetectableallelelossinthesecondtumoursample.NC=normalcontrol.150160BACDLT2Mut CNCT1LT2NCT1LT2NCT11701802001902700240021001800150012009006003000Lymphocytes2702402101801501209060300Tumour 1180016001400120010008005004002000Tumour 2+320Mohyuddin,Neary,Wallace,etalwww.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from ofSSCP,FISH,anddosagePCRiscapableofdetectingmorethan90percentofmutationsintheNF2families(unpublisheddatainsecondgeneration).Thestandardmuta-tiondetectiontechniquessuchassinglestrandconformationpolymorphism(SSCP)analysisordenaturinggradientgelelectrophoresis,however,donotdetectmutationsineveryclassicallyaffectedpatient.Also,thesensitivityofSSCPtodetectmutationshasbeenreportedinvariousseriestovaryfrom35-66%.17183132Inpatientswithunilateraltumoursorwithoutafamilyhis-tory,failuretodetectamutationinDNAfromthepatient’sbloodcannotbeusedasameansofanalysingNF2;failurecouldbeeitherbecauseoflowlevelsofmosaicismoramuta-tionundetectedbyourscreeningprotocol.In65%(18/28)oftheseapparentlyhighrisksubjects,ithasbeenpossibletoexcludethepresenceofapathogenicmutationinmorethan10%oflymphocytesbyidentifyingbothhitsinthetumourwithnonebeingdetectableinblood.MosaicisminNF2isnowawelldescribedentity.1220SubjectswhofulﬁlthemodiﬁedNF2diagnosticcriteria(table1B),suchascase10,arejustaslikelytohaveanidentiﬁableNF2mutation12assporadicpatientswhofulﬁltheclassicalcriteriaofbilateralvestibularschwannomas.However,somepatientslikecase10andapre-viouslydescribedcase21havemosaicism,whichappearstobepredominantlyononeside.Whileitis,ofcourse,possiblethatcase10mayeventuallydevelopbilateraldisease,thismaynotbyanymeansbecertain.Thispatternmaythereforebemoreakintopreviousreportsofsegmentaldiseaseinneuroﬁ-bromatosistype1.33Thedatapresentedhere,inconjunctionwiththosefromaretrospectiveanalysisofover300NF2patients,11suggestthatwhileupto18%ofNF2patientsmaypresentinitiallywithaunilateralvestibularschwannoma,thegreatmajorityofthesewillhaveotherfeaturesofNF2atthetimeofdiagnosisoftheireighthnervetumourorhaveapositivefamilyhistoryofNF2.Ofthetwosubjects(cases10and26)inthisstudywhosofarhavegoneontodevelopNF2,one(case10)hadpredictablefeaturesinhertumour,andwhileitisimpossibletoruleoutmosaicisminanyoftheotherpatients,itisunlikelythattheotherswilldevelopNF2.Indeed,onlyﬁvepatientsofourpre-viousseriesofover300NF2patientspresentedwithasporadicunilateralvestibularschwannoma.Thereforeinpatientswithanapparentlysporadicunilateralvestibularschwannoma,iftherearenoNF2relateddiagnosticclinicalfeaturesandnofamilyhistoryofNF2relatedproblems,itishighlyunlikelythattheywilldevelopbilateraldiseaseorpassonapathogenicNF2mutationtotheiroffspring,eveniftheypresentataveryyoungage.Intheseyoungpatients,asmosaicismcannotbeexcluded,afollowupMRIscanofthecraniumisindicatedatﬁveand10yearsafterdiagnosis.34Furthermutationalanalysisofablood-tumourpairwillreduceanyfurthertheoreticalrisk.Oncecompleted,offspringcanbetestedforNF2mutationsidentiﬁedintheparentaltumourinordertoaccountforthesmallresidualriskofgerminalmosaicism.ACKNOWLEDGEMENTSTheﬁrsttwoauthorscontributedjointlytothiswork.WewishtothanktheNHSExecutiveNorthWestandtheBrendaThornleyTrustfortheirﬁnancialsupportforthisresearchworkandMrsCeliaWors-leyforpreparingparafﬁnsectionsoftumoursamples.GBisaWellcomeClinicianScientistFellow......................Authors’affiliationsAMohyuddin,AWallace,CLWu,SPurcell,ARead,GBlack,DGREvans,UniversityDepartmentofMedicalGeneticsandRegionalGeneticServices,StMary’sHospital,HathersageRoad,ManchesterM13OJH,UKWJNeary,WarringtonCommunityHealthCare(NHS)Trust,ChildandFamilyServicesUnit,GuardianHouse,GuardianStreet,WarringtonWA5ITP,UKHReid,DepartmentofPathology,ManchesterRoyalInfirmary,OxfordRoad,ManchesterM139WL,UKREFERENCES1PoolJL,PavaAA,eds.Theearlydiagnosisandtreatmentofacousticnervetumors.1sted.Springfield,Illinois:CCThomas,1957:22.2PoolJL,PavaAA,GreenfieldEC.Acousticnervetumors-earlydiagnosisandtreatment.2nded.Springfield,Illinois:CCThomas,1970:23.3RevillaAG.Neurinomasofthecerebellopontilerecess:aclinicalstudyof160casesincludingoperativemortalityandendresults.BullJohnsHopkinsHosp1947;80:254-7.4EvansDGR,HusonSM,DonnaiD,NearyWJ,BlairV,TeareD,NewtonV,StrachanT,RamsdenRT,HarrisR.Ageneticstudyoftype2neurofibromatosisintheUK.I.Prevalence,mutationrate,fitness,andconfirmationofmaternaltransmissioneffectonseverity.JMedGenet1992;29:841-6.5MartuzaRL,EldridgeR.Neurofibromatosis2(bilateralacousticneurofibromatosis).NEnglJMed1988;318:684-8.6EvansDGR,HusonSM,DonnaiD,NearyWJ,BlairV,NewtonV,HarrisR.Aclinicalstudyoftype2neurofibromatosis.QJMed1992;84:603-18.7NearyWJ,NewtonVE,Laoide-KempSN,RamsdenRT,GriffithG,EvansDGR,HarrisR,StrachanT.Aclinicalgeneticandaudiologicalstudyofpatientsandfamilieswithunilateralvestibularschwannomas.1.Clinicalfeaturesofneurofibromatosisinpatientswithunilateralvestibularschwannomas.JLaryngolOtol1996;110:634-40.8ParryDM,EldridgeR.Neurofibromatosis2:groupsathighrisk.In:ProceedingsoftheFirstInternationalConferenceonAcousticNeuroma.Copenhagen:KuglerPublications,1992:811-14.9ParryDM,EldridgeR,Kaiser-KupferMI,BouzasEA,PikusA,PatronasN.Neurofibromatosis2(NF2):clinicalcharacteristicsof63affectedindividualsandclinicalevidenceforheterogeneity.AmJMedGenet1994;52:450-61.10EvansDGR,RamsdenRT,HusonSM,HarrisR,LyeR,KingTT.Type2neurofibromatosis:theneedforsupraregionalcare?JLaryngolOtol1993;107:401-6.11EvansDGR,LyeR,NearyWJ,BlackG,StrachanT,WallaceA,RamsdenRT.Probabilityofbilateraldiseaseinpeoplepresentingwithaunilateralvestibularschwannoma.JNeurolNeurosurgPsychiatry1999;66:764-67.12EvansDGR,WallaceA,WuCL,TruemanL,RamsdenRT,StrachanT.Somaticmosaicism:acommoncauseofclassicdiseaseintumor-pronesyndromes?Lessonsfromtype2neurofibromatosis.AmJHumGenet1998;63:727-36.13TrofatterJA,MacCollinMM,RutterJL,MurrellJR,DuyaoMP,ParryDM,EldridgeR,KleyN,MenonAG,PulaskiK,HaaseVH,AmbroseCM,MunroeD,BoveC,HainesJL,MartuzaRL,MacDonaldME,SeizingerBR,ShortMP,BucklerAJ,GusellaJF.Anovelmoesin-ezrin-radixinlikegeneisacandidatefortheneurofibromatosis2tumorsuppressor.Cell1993;72:791-800.14RouleauGA,MerelP,LutchmanM,SansonM,ZucmanJ,MarineauC,Hoang-XuanK,DemczukS,DesmazeC,PlougastelB,PulstSM,LenoirG,BijlsmaE,FasholdR,DumanskiJ,deJongP,ParryD,EldridgeR,AuriasA,DelattreO,ThomasG.Alterationinanewgeneencodingaputativemembrane-organizingproteincausesneurofibromatosistype2.Nature1993;363:515-21.15RouleauGA,WerteleckiW,HainesJL,HobbsWJ,TrofatterJA,SeizingerBR,MartuzaRL,SuperneauDW,ConneallyPM,GusellaJF.GeneticlinkageofbilateralacousticneurofibromatosistoaDNAmarkeronchromosome22.Nature1987;329:246-8.16MacCollinMM,RameshV,JacobyLB,LouisDN,RubioMP,PulaskiK,TrofatterJA,ShortMP,BoveC,EldridgeR,ParryDM,GusellaJF.Mutationalanalysisofpatientswithneurofibromatosis2.AmJHumGenet1994;55:314-20.17BournD,CarterSA,MasonS,EvansDGR,StrachanT.Germlinemutationsintheneurofibromatosistype2tumoursuppressorgene.HumMolGenet1994;3:813-16.18MerelP,Hoang-XuanK,SansonM,BijlsmaE,RouleauG,Laurent-PuigP,PulstS,BaserM,LenoirG,SterkersJM,PhilipponJ,RescheF,MautnerVF,FischerG,HulsebosT,AuriasA,DelattreO,ThomasG.Screeningforgerm-linemutationsintheNF2gene.GenesChromCancer1995;12:117-27.19ParryDM,MacCollinMM,Kaiser-KupferMI,PulaskiK,NicholsonHS,BolestaM,EldridgeR,GusellaJF.Germ-linemutationsintheneurofibromatosis2gene:correlationswithdiseaseseverityandretinalabnormalities.AmJHumGenet1996;59:529-39.20KluweL,MautnerVF.Mosaicisminclassicalneurofibromatosis2patients.HumMolGenet1998;7:2051-5.21WuCL,ThakkerN,NearyWJ,BlackG,LyeR,RamsdenRT,ReadAP,EvansDGR.Differentialdiagnosisoftype2neurofibromatosis:moleculardiscriminationofNF2andsporadicvestibularschwannomas.JMedGenet1998;35:973-7.22WallaceAJ.Combinedsinglestrandconformationpolymorphismandheteroduplexanalysis.In:TaylorGR,ed.LaboratorymethodsforthedetectionofmutationsandpolymorphismsinDNA.BocaRaton:CRCPress,1997:79-94.23WeissenbachJ,GyapayG,DibC,VignalA,MorissetteJ,MillasseauP,VaysseixG,LathropM.Asecondgenerationlinkagemapofthehumangenome.Nature1992;359:794-801.PotentialofNF2inpatientswithearlyonsettumours321www.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from 24BournD,StrachanT.HighlypolymorphicdinucleotiderepeatattheNF2gene.HumGenet1995;95:712.25MarineauC,BaronC,DelattreO,ZucmanJ,ThomasG,RouleauGA.DinucleotiderepeatpolymorphismattheD22S268locus.HumMolGenet1993;2:336.26GyapayG,MorissetteJ,VignalA,DibC,FizamesC,MillasseauP,MarcS,BernardiG,LathropM,WeissenbachJ.The1993-94Genethonhumangeneticlinkagemap.NatGenet1994;7:246-339.27SchulerGD,BoguskiMS,StewartEA,SteinLD,GyapayG,RiceK,WhiteRE,RodriguezTomeP,AggarwalA,BajorekE,BentolilaS,BirrenBB,ButlerA,CastleAB,ChiannilkulchaiN,ChuA,CleeC,CowlesS,DayPJ,DiblingT,DrouotN,DunhamI,DupratS,EastC,HudsonTJ.Agenemapofthehumangenome.Science1996;274:540-6.28SkinnerHA.Theoriginofacousticnervetumours.BrJSurg1929;16:440-63.29MartuzaRL,OjemannRG.Bilateralacousticneuromas:clinicalaspects,pathogenesisandtreatment.Neurosurgery1982;10:1-12.30Zucman-RossiJ,LegoixP,DerSarkissianH,CheretG,SorF,BernardiA,CazesL,GiraudS,OllagnonE,LenoirG,ThomasG.NF2geneinneurofibromatosistype2patients.HumMolGenet1998;13:2095-101.31JacobyLB,MacCollinMM,LouisDN,MohneyT,RubioMP,PulaskiK,TrofatterJA,KleyN,SeizingerBR,RameshV,GusellaJF.ExonscanningformutationoftheNF2geneinschwannomas.HumMolGenet1994;3:413-19.32KluweL,BayerS,BaserME,HazimW,HaaseW,FunstererC,MautnerVF.IdentificationofNF2germlinemutationsandcomparisonwithneurofibromatosis2phenotypes.HumGenet1996;98:534-8.33RiccardiVM,EichnerJE.Neurofibromatosis:phenotype,naturalhistoryandpathogenesis.Baltimore:JohnsHopkinsUniversityPress,1986:178-80.34SaeedSR,WoolfordTJ,RamsdenRT,LyeRH.Magneticresonanceimaging:acost-effectivefirstlineinvestigationindetectionofvestibularschwannomas.BrJNeurosurg1995;9:497-503.7ECHO.................................................................................................................WhenHFEgenemutationdoesn’tmakesenseIronaccumulationandprogressofliverdiseaseinchronichepatitisCinfectionarenotduetoHFEmutation,sayThorburnetalfromastudyofScottishpatients.Chronicinfectionresultsinironbuildupinserumandtheliver,withliverﬁbrosis.Ironoverloadintheliverandﬁbrosisarecommontoheredi-taryhaemochromatosis,whichismostlycausedbyhavinghomozygousrecessivemissensemutationsintheHFEgene—eitherCys282TyrorHis63Asp.Somereportssuggestthatthesemutationsmightunder-lieironbuildupinchronichepatitisCinfection.Thepresentconclusioncomesfromaprospectivestudywhichscreened164consecutivepatientswithchronichepatitisCinfectionforHFEmutations,markersofironaccumulationinserumandliver,sever-ityofliverdisease,andviralgenotype.SixtysevenpatientswereheterozygousforHFEmutations:26Cys282Tyr,33His63Asp,andeightCys282Tyr/His63Asp;sevenwerehomozygousforeithermutationandwereexcluded;and90hadnomutation.NoassociationbetweenHFEgenotypeandanyofthemarkersexaminedcouldbefoundwhendataforthe157patientswereanalysedstatistically.Thorburnetalwerecarefultotestthat10non-Caucasianpatientsintheirsampledidnotskewtheresults,nordidprevioustreatmentwithinter-feron,andtheyanalysedtheresultsformenandwomenseparatelyineachofthefourgenotypicgroupstoremoveeffectsofageandmenstruation.RaisedserumironconcentrationsandHFEmutationsmaybeevidentinchronichepatitisCinfection,but,seemingly,theyarenotlinked.mGut2002;50:248–252.PleasevisittheJournalofMedicalGeneticswebsite[www.jmedgenet.com]forlinktothisfullarticle.322Mohyuddin,Neary,Wallace,etalwww.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from schwannomasyoung patients with unilateral vestibular Molecular genetic analysis of the NF2 gene inRamsden, A Read, G Black and D G R EvansA Mohyuddin, W J Neary, A Wallace, C L Wu, S Purcell, H Reid, R Tdoi: 10.1136/jmg.39.5.3152002 39: 315-322 J Med Genet(cid:160) http://jmg.bmj.com/content/39/5/315Updated information and services can be found at: These include:References #BIBLhttp://jmg.bmj.com/content/39/5/315This article cites 28 articles, 9 of which you can access for free at: serviceEmail alertingbox at the top right corner of the online article. Receive free email alerts when new articles cite this article. Sign up in theCollectionsTopicArticles on similar topics can be found in the following collections  (97)Peripheral nerve disease (257)Neuromuscular disease (886)Genetic screening / counselling (630)Epidemiology (356)Clinical diagnostic tests (234)Screening (oncology) (78)Neurooncology (44)CNS cancerNoteshttp://group.bmj.com/group/rights-licensing/permissionsTo request permissions go to:http://journals.bmj.com/cgi/reprintformTo order reprints go to:http://group.bmj.com/subscribe/To subscribe to BMJ go to:group.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells
Alejandra M Petrilli,1 Jeanine Garcia,1 Marga Bott,1 Stephani Klingeman Plati,1 Christine T Dinh,2 Olena R Bracho,2 Denise Yan,2 Bing Zou,2 Rahul Mittal,2 Fred F Telischi,2 Xue-Zhong Liu,2 Long-Sheng Chang,3 D Welling Bradley,3,4 Alicja J Copik,1 and Cristina Fernández-Valle1
Author information ► Article notes ► Copyright and License information ►
Go to:
Abstract
Neurofibromatosis type 2 (NF2) is a genetic syndrome that predisposes individuals to multiple benign tumors of the central and peripheral nervous systems, including vestibular schwannomas. Currently, there are no FDA approved drug therapies for NF2. Loss of function of merlin encoded by the NF2 tumor suppressor gene leads to activation of multiple mitogenic signaling cascades, including platelet-derived growth factor receptor (PDGFR) and SRC in Schwann cells. The goal of this study was to determine whether ponatinib, an FDA-approved ABL/SRC inhibitor, reduced proliferation and/or survival of merlin-deficient human Schwann cells (HSC). Merlin-deficient HSC had higher levels of phosphorylated PDGFRα/β, and SRC than merlin-expressing HSC. A similar phosphorylation pattern was observed in phospho-protein arrays of human vestibular schwannoma samples compared to normal HSC. Ponatinib reduced merlin-deficient HSC viability in a dose-dependent manner by decreasing phosphorylation of PDGFRα/β, AKT, p70S6K, MEK1/2, ERK1/2 and STAT3. These changes were associated with decreased cyclin D1 and increased p27Kip1levels, leading to a G1 cell-cycle arrest as assessed by Western blotting and flow cytometry. Ponatinib did not modulate ABL, SRC, focal adhesion kinase (FAK), or paxillin phosphorylation levels. These results suggest that ponatinib is a potential therapeutic agent for NF2-associated schwannomas and warrants further in vivo investigation.

Keywords: neurofibromatosis type 2, schwannoma, PDGFR, SRC, STAT3
Go to:
INTRODUCTION
Neurofibromatosis type 2 (NF2) is a non-malignant tumor disorder affecting the peripheral and central nervous systems. Although bilateral vestibular schwannomas (VS) are a diagnostic hallmark of the disorder, NF2 patients typically develop multiple meningiomas, ependymomas and other schwannomas as well. VS lead to deafness, tinnitus, imbalance and can cause life-threatening brainstem compression [1]. NF2 is caused by mutations in the NF2 gene that encodes the tumor suppressor protein known as merlin or schwannomin [2, 3]. Merlin belongs to the Band 4.1 family of proteins that link the actin cytoskeleton to membrane receptors and transporters. Merlin modulates the activity of multiple signaling pathways that control cell size, morphology, cell adhesion, proliferation, and survival. These include receptor tyrosine kinase (RTK; e.g. ErbB2/3, PDGFR, EGFR, HGFR), small GTPases, FAK/SRC, the mammalian target of rapamycin (mTOR)/PI3K/AKT, and Hippo pathways [4]. Currently, surgery and radiation are the mainstream treatment options for NF2-associated tumors. Depending on the tumor size and location, there are significant adverse effects associated with their removal. While an understanding of the biological functions of merlin is progressing, well-defined druggable molecular targets have yet to emerge. Increasingly, patients are treated off-label with the anti-angiogenic agent bevacizumab that also reduces edema in schwannomas without affecting the tumor cells. Dosing regimens are being optimized to reduce associated kidney toxicity observed with prolonged bevacizumab treatment [1, 5]. However, to date there are no FDA-approved therapies that target schwannoma cells directly and reduce morbidity and mortality of NF2 patients [1, 6].

Because of the slow-growing and benign nature of NF2 schwannomas, conventional chemotherapeutic agents are unsuccessful. Several RTK inhibitors have been investigated in preclinical studies and clinical trials with limited patient response. These include lapatinib (an EGFR/ErbB2 inhibitor; NCT00973739, NCT00863122), nilotinib (a PDGFR and c-kit inhibitor; NCT01201538), sorafenib (a VEGFR-2, PDFGRβ, and c-kit inhibitor), and axitinib (a VEGFR, c-kit, and PDGFRβ inhibitor; NCT02129647) [1, 7]. We selected ponatinib for evaluation because it is an FDA-approved drug that inhibits a relevant RTK, the PDGFR, and a downstream effector common to several NF2 activated pathways, the non-receptor tyrosine kinase SRC. PDGFR and SRC signaling regulate cell survival, proliferation, migration and angiogenesis in many cell types [8, 9]. PDGFR is over-expressed and activated in VS and primary human schwannoma cells, consistent with merlin's role in downregulating surface levels of growth factor receptors [10–13]. In HEI-193 schwannoma cells, merlin overexpression inhibits cell proliferation by promoting PDGFR internalization and degradation [14]. There is evidence that SRC activity is deregulated in cells with loss of merlin function and thus is a candidate for therapeutic targeting. In human schwannoma cells, SRC activity is increased compared to normal Schwann cells, and in mouse glia cells, merlin inhibits proliferation by modulating SRC activity [15, 16]. Lastly, primary human schwannoma cells treated with the SRC inhibitor SU6656 exhibit decreased transcription of proliferation-associated genes [17]. Thus, an inhibitor that targets both PDGFR and SRC might have therapeutic value for NF2-associated tumors.

Ponatinib (AP24534, brand name: Iclusig®) is a third generation type IIA inhibitor of ABL/SRC tyrosine kinase (TK). It is orally active and initially received accelerated approval in 2012 for adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that are T315I-positive and are not candidates for other TK inhibitors. Ponatinib binds the inactive, DFG-out (aspartic acid, phenylalanine and glycine) ABL/SRC conformation [18, 19]. In a cell-free kinase screen, ponatinib inhibited SRC with IC50 of 5.4nM and PDGFRα and PDGFRβ with IC50 of 1.1nM and 7.7nM, respectively [19].

In this study, we measured the ability of ponatinib to decrease proliferation and survival of merlin-deficient HSC and vestibular schwannoma cells with NF2 mutations. We found that ponatinib caused a G1 cell-cycle arrest and mapped the regulatory signaling cascades modulated by the inhibitor. Our findings support further in vivo evaluation of ponatinib as a candidate drug for NF2 schwannomas.

Go to:
RESULTS
Ponatinib decreases viability of merlin-deficient HSC and vestibular schwannoma (VS) cells

To create a suitable cell line for drug discovery studies, we first authenticated primary HSC based on their expression of human nuclear antigen and Schwann cell markers, S100, PLP, and O4 (Figure ​(Figure1A).1A). We then used lentiviral delivery of NF2-shRNA to reduce expression of merlin in the primary HSC. Merlin levels were stably reduced to nearly undetectable levels in the transduced cells compared to the parental HSC (Figure 1B, C). The merlin-deficient HSC did not contact inhibit but did not form aggregates and grows in multiple layers; many of these merlin-deficient HSC maintained an elongated morphology when cultured in the presence of serum and mitogens (Supplementary Figure 1AB). We measured basal levels of PDGFRα/β and SRC phosphorylation in primary HSC prior to and following knockdown of merlin. We found that depletion of merlin expression was associated with increased levels of p-PDGFRα/β and p-SRC compared to the parental HSC (Figure ​(Figure1B).1B). This finding agrees with previous reports of increased activation of the PDGFR and SRC pathways in human schwannomas compared to normal human nerve [10, 20, 21].

Figure 1
Figure 1
Ponatinib decreases HSC viability
We screened the ability of ponatinib to reduce viability of multiple control and merlin-deficient HSC lines. As controls, we tested the parental wild-type HSC (HSC-WT), HSC expressing a scrambled shRNA construct (HSC-SCR), HSC expressing a Turbo-GFP shRNA (HSC-GFP), and merlin-deficient HSC lines (MD-HSC) expressing shRNA sequences that target the human NF2 gene, (MD-HSC #45, #74 #75 and #77). All control HSC expressed merlin, whereas the HSCs transduced with shRNA constructs targeting the NF2 gene had nearly undetectable merlin levels (Figure ​(Figure1D).1D). We performed 48 hour dose-response viability assays on the seven HSC lines in complete growth medium containing serum and growth factors. The results indicated that ponatinib reduced viability of all of the cell lines in a dose-dependent manner (Figure ​(Figure1E).1E). Under the conditions tested, ponatinib was not selective for MD-HSC over scrambled, GFP or untransduced HSC (IC50 HSC-SCR= 3.3μM, HSC-GFP=2.4 μM, HSC-WT= 2.3 μM, MD-HSC#45= 2.2 μM, MD-HSC#74= 3.3 μM, MD-HSC#75= 1.9 μM and MD-HSC#77=3.7 μM). The average maximal response at 10μM was a 71% decrease in cell viability. However, when control merlin-expressing cell line (HSC-WT) and merlin-deficient HSC (MD-HSC#45) were cultured in the absence of serum and mitogens, merlin-deficient HSC were significantly more sensitive to 0.25 μM ponatinib than the merlin-expressing HSC (Figure 1F,G).

We tested ponatinib's effect on cultured human vestibular schwannoma cells with NF2 mutations. We assessed relative cell viability using a crystal violet assay following 48 hour incubation with ponatinib. Cell viability was reduced by approximately 40% at 2μM in VS1 and VS2 compared to DMSO-treated cells in agreement with the IC50 obtained with our MD-HSC lines. (Figure ​(Figure1H1H).

Ponatinib decreases viability of merlin-deficient HSC independent of the SRC/FAK/paxillin pathway

Ponatinib did not reduce net levels of ABL phos-phorylation in merlin-deficient HSC (Figure ​(Figure2A).2A). Ponatinib induced a dose-dependent increase in the total SRC protein level but did not alter the levels of the other SRC family members, FYN and YES, that play important roles in SC biology as well (Figure ​(Figure2B)2B) [22, 23]. We found a slight increase in SRC-Tyr416 phosphorylation in merlin-deficient HSC treated with 0.3 to 3μM (with a peak at 1μM). The phosphorylation pattern, however, did not coincide with the increase in the SRC protein levels (Figure ​(Figure2B2B).

Figure 2
Figure 2
Ponatinib decreased merlin-deficient HSC viability independent of ABL/SRC/FAK pathway inhibition
Key effectors transducing extracellular matrix adhesion and growth factor-dependent stimuli in Schwann cells are the SRC substrates, FAK and paxillin, a focal adhesion-associated adaptor [24]. FAK is a key mediator of extracellular matrix-integrin and RTK signaling that is upregulated in schwannomas [10]. Upon FAK autophosphorylation at Tyr397, SRC binds the phosphorylated residue and phosphorylates FAK on Tyr576 and Tyr577, resulting in stabilizing the activation loop of FAK in the active conformation and its binding to substrates, thereby providing FAK with maximal activity [25]. In turn, FAK either directly or via SRC, phosphorylates paxillin at Tyr118 [26]. We therefore assessed FAK and paxillin phosphorylation in merlin-deficient HSC treated for 2h with increasing ponatinib concentrations. Western blot analysis showed that ponatinib did not reduce FAK-Tyr576 or Tyr577 or paxillin-Tyr118 phosphorylation similar to the SRC-Tyr416 phosphorylation pattern (Figure ​(Figure2C2C and Supplementary Figure 2). Together the results demonstrate that the ABL, SRC, FAK and paxillin pathways are not inhibited by ponatinib in merlin-deficient HSC.

Ponatinib decreases activation of the PDGFRα/β, PI3K, MEK1/2, ERK1/2 and STAT3 signaling pathways

To identify the signaling pathways modulated by ponatinib, we conducted a series of Western blots of merlin-deficient HSC treated for 2 hours with increasing concentrations of ponatinib. We found that ponatinib reduced phosphorylation of PDGFRα/β at Tyr849/Tyr857, the autophosphorylation sites in the activation loop of these kinases, in a dose-dependent manner without altering the PDGFRα/β protein levels (Figure ​(Figure3).3). In addition, ponatinib reduced phosphorylation of three additional tyrosine residues in PDGFRβ at positions 740, 771 and 1021 (Figure ​(Figure3).3). Phosphorylation of these residues increases affinity for binding and activating PI3K, SRC, the GTPase Activator of Ras (GAP), GRB2, and PLCγ [27]. When cells are stimulated with growth factors, AKT (also known as protein kinase B) and p70 S6 kinase are activated in a phosphatidylinositol 3-kinase (PI3K)-dependent pathway. Thr308 in the AKT activation loop and Thr229 in the p70S6 kinase catalytic domain are phosphorylated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) in vivo and in vitro [28, 29]. Therefore to probe activity of the PI3K pathway in ponatinib-treated cells, we assessed AKT-Thr308 phosphorylation and p70S6 kinase-Thr229 phosphorylation by Western blots. We found that both AKT-Thr308 and p70S6 kinase-Thr229 underwent a dose-dependent decrease in phosphorylation (Figure 4A,B).

Figure 3
Figure 3
Ponatinib inhibited PDGFRα/β phosphorylation in merlin-deficient HSC
Figure 4
Figure 4
Downstream signaling pathways inhibited by ponatinib in merlin-deficient HSC
Previous studies demonstrated that overexpression and activation of PDGFRβ strongly activates MEK1/2 and ERK1/2 in human schwannoma cells leading to enhanced proliferation [10]. We assessed the phosphorylated MEK1/2 and ERK1/2 levels in merlin-deficient HSC after ponatinib treatment. We found that ponatinib treatment was associated with a dose-dependent decrease in MEK1/2-Ser217/Ser221 and ERK1/2-Thr202/Tyr204 phosphorylation in merlin-deficient HSC (Figure ​(Figure4C4C).

Although net inhibition of SRC phosphorylation was not observed, ligand binding to PDGFR promotes receptor binding to SRC and recruitment of STAT3, followed by Tyr705 auto-phosphorylation of STAT3 and its dimerization and translocation into the nucleus to directly drive gene expression needed for cell proliferation [30–32]. Western blot analysis showed that ponatinib decreased STAT3 phosphorylation in a dose-dependent manner in merlin-deficient HSC (Figure ​(Figure4D4D).

Lastly, to further evaluate the contribution of PI3K/AKT, MEK, or STAT3 inhibition downstream to PDGFR responsible for ponatinib's effect, we individually inhibited AKT with perifosine/KRX-0401, MEK with selumetinib/AZD6244, and STAT3 with S3I-201/NSC-74859 and compared the results to ponatinib's effects on cell viability. MEK, AKT or STAT3 inhibition alone only partially decreased merlin-deficient HSC viability. Inhibition of STAT3 with S3I-201 was the least effective, and although selumetinib was more efficacious than perifosine and S3I-201, none of individual inhibitors even at the highest concentration tested (10 μM) matched ponatinib's efficacy (Figure ​(Figure4E).4E). These results suggest that simultaneous inhibition of these three pathways occurs in response to ponatinib and similarly contributes to the loss of viability of merlin-deficient HSC.

Ponatinib arrests merlin-deficient HSC in G1 by decreasing cyclin D1 and increasing p27Kip1 levels

A molecular link between ERK1/2 and STAT3 to proliferation is through cyclin D1 to regulate G1-to-S cell cycle progression. ERK1/2 activity is required for expression of cyclin D1 in the G1 phase of the cell cycle. Moreover, STAT3 transcriptionally regulates cyclin-D1 by binding to its promoter region [33, 34]. We assessed the level of cyclin D1 in merlin-deficient HSC after a 24h incubation with ponatinib. We found that ponatinib strongly decreased cyclin D1 protein levels in a dose-dependent manner (Figure ​(Figure5A).5A). These results suggest that ponatinib reduces the viability of merlin-deficient HSC by inhibiting PDGFRα/β-dependent activation of MEK/ERK and STAT3 pathways, leading to decreased cyclin D1 expression.

Figure 5
Figure 5
Ponatinib arrests merlin-deficient HSC at the G1 phase of the cell cycle
To test the possibility that the decrease in the viability of merlin-deficient HSC by ponatinib was a consequence of cell-cycle blockage due to reduced cyclin D1 expression, we analyzed the distribution of cells among the different phases of the cell cycle. There was a significant increase in the number of cells in the G1 phase when treated with 3 and 5μM ponatinib compared to vehicle controls (72% ±8% and 74% ±7% vs. 47% ±2% of control). This was accompanied by a concomitant decrease in the number of S-phase cells observed in ponatinib-treated samples as compared with control samples (7.5% ±1% for 3μM and 7% ±1% at 5μM vs. 29% ±3% of control) (Figure ​(Figure5B5B–5C). At the lower concentrations (1 through 5μM), ponatinib arrested merlin-deficient HSC at G1, indicating a cytostatic mechanism of action. However, by analyzing the live/dead populations, at a higher concentration (10μM), ponatinib became cytotoxic (Figure ​(Figure5D).5D). The increase in the number of dead cells present in the cells treated with 10μM ponatinib coincides with the decrease in phosphorylated proteins studied here.

Lastly, we analyzed the correlation of the cell-cycle phases with levels of several cell cycle regulators. Cyclin-dependent kinase (Cdk) inhibitor p27 (p27Kip1) is a key negative regulator of Cdk activity in cells progressing from G1 toward S phase [35]. We analyzed the expression of p27Kip1 in conjunction with DNA content by flow cytometry. We found fewer p27Kip1-positive cells in G1 in control cells compared with a large increase in p27Kip1-positive cells in G1 in ponatinib-treated samples (Figure ​(Figure6A).6A). Similarly, we found a greater number of cyclin D1-positive cells in control samples in G1 in contrast to ponatinib-treated samples (Figure ​(Figure6B).6B). This result correlates with that observed from the Western blot experiment (Figure ​(Figure5A).5A). Overlay of the p27Kip1 and cyclin D1 plots with the cell-cycle plots clearly demonstrate that ponatinib induced G1 arrest with associated changes in the cyclin D1 and p27Kip1 levels in merlin-deficient HSC (Supplementary Figure 3AB). Our results are consistent with ponatinib inhibition of PDGFR and downstream PI3K activity leading to a G1 cell-cycle arrest of merlin-deficient HSC by blocking ERK- and STAT3-dependent expression of cyclin D1 (Figure ​(Figure6C6C).

Figure 6
Figure 6
Analysis of G1 regulatory proteins during the cell-cycle in merlin-deficient HSC treated with ponatinib
PDGFRα/β, SRC, STAT 3 and MEK1/2 are highly phosphorylated in human vestibular schwannomas

To assess activation of PDGFRα/β and SRC in human schwannomas, we surveyed a phospho-proteome profile comparing five human vestibular schwannoma specimens with primary normal adult human Schwann cells cultured in the presence of mitogens to stimulate their proliferation. Analysis of phospho-receptor tyrosine kinase and phospho-kinases proteome profiler arrays revealed that schwannomas consistently had higher levels of phosphorylated PDGFRα, PDGFRβ, SRC, MEK and STAT3 compared with control primary HSC (Figure 7 A-D). Schwannomas exhibited averaged 6.6 times higher PDGFRα phosphorylation, 5.4 times higher PDGFRβ phosphorylation, 30 times higher SRC phosphorylation, 5.6 times higher MEK phosphorylation and 7.4 times higher STAT3 phosphorylation compared with control primary HSC (Figure 7 A-D).

Figure 7
Figure 7
PDGFRα/β, SRC, MEK and STAT3 are overactive in human schwannomas
Go to:
DISCUSSION
In this study, we evaluated whether ponatinib, a BCR-ABL/SRC inhibitor approved for use in leukemia, could potentially be repurposed for treatment of NF2 schwannomas. Following merlin depletion, HSC increased the levels of phosphorylated SRC and PDGFRα/β, in agreement with studies in primary human NF2 schwannoma cells [36]. Ponatinib stimulated a robust G1 cell cycle arrest of merlin-deficient HSC in a dose-dependent manner by inhibiting PDGFRα/β and its downstream effectors AKT, p70S6 kinase, MEK/ERK and STAT3, leading to reduced levels of cyclin D1 and increased levels of p27Kip1. Intriguingly, ponatinib did not reduce ABL/SRC/FAK/paxillin net phosphorylation in merlin-deficient HSC. We did not find clear evidence of ABL and SRC inhibition in merlin-deficient HSC treated with ponatinib. However, we found that ponatinib induced a dose-dependent increase in the SRC levels in the HSC. Similar results been reported for SRC inhibition with AZD0530 of Philadelphia chromosome-positive leukaemia cell lines. We speculate that this is due to a compensatory feedback mechanism, suggesting SRC kinase inhibition by ponatinib [37]. Other SRC family members, such as Fyn and Yes, did not change their protein levels in ponatinib-treated cells. In some CML cases of imatinib resistance, upregulation of SRC kinase has been implicated as a BCR-ABL-independent mechanism responsible for imatinib failure [38–40]. Therefore the increase in SRC protein levels observed ponatinib-treated HSC may be an adaptive response. It would be interesting to investigate if other SRC inhibitors, including SU6656, that have anti-proliferative activity in primary human schwannoma cells, also increase SRC levels [20, 41].

Ponatinib lacked selectivity for the merlin-deficient HSC over NF2 wild-type HSC when cultured in the presence of serum and mitogens. This is comparable to results reported by others with the MEK1 inhibitor AZD6244 in primary human schwannoma cells and normal Schwann cells grown in serum-containing medium [21]. Notably, when cells were incubated in growth arresting medium (SCM base + N2 supplement) in the presence of 0.25 μM ponatinib for one week, merlin-deficient HSC showed a greater sensitivity to the drug than merlin-expressing HSC. To maintain fetus derived cell lines amenable to drug discovery studies, we routinely culture these embryonic Schwann cells in the presence of serum and other mitogenic supplements, which induces Schwann cells to proliferate. In contrast, both myelinating and non-myelinating Schwann cells are post-mitotic in normal nerves [42–44]. Only after nerve injury do adult Schwann cells de-differentiate and proliferate as part of the nerve repair process [21, 45–48]. Thus, ponatinib's lack of in vitro selectivity is not a cause for concern for in vivo studies and its potential as a therapeutic for NF2-associated schwannomas.

Ponatinib strongly inhibited PDGFR phosphorylation in merlin-deficient HSC. Studies with other RTK inhibitors that primarily target PDGFR and c-KIT (e.g., nilotinib, imatinib and sorafenib) showed that these RTK inhibitors exhibited strong anti-proliferative activity on primary human schwannoma and HEI-193 cells [10, 12, 41]. Merlin was shown to promote the internalization of activated PDGFRβ, a role consistent with increased expression and activation of mitogenic receptors in NF2 schwannomas [13, 14]. In Schwann cells, PDGFRα and β signaling are central to cell proliferation and survival through the Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways [49–51]. In the four schwannoma samples with chronic merlin loss, the p-AKT Ser473 levels downstream of mTORC2 were reported as consistently reduced across tumor samples relative to normal arachnoid and meningioma tissues, as well as in one immortalized human SC line with acute loss of merlin achieved by an RNAi compared to the immortalized human merlin-expressing SC line [52]. The consistent decrease in mTORC2 signaling activity in schwannoma and merlin-deficient Schwann cells mimics the PDGFR activity results in schwannomas reported by others and our phospho-receptor tyrosine kinase arrays showing a high PDGFR phosphorylation levels in all tumors tested (Figure ​(Figure77 and ​and1)1) [10–12]. Consistent with PDGFR inhibition, we observed a dose-dependent decrease in AKT-Thr308 phosphorylation, a PI3K-dependent phosphorylation site, and a decrease in MEK/ERK phosphorylation, similar to those reported in sorafenib-treated schwannoma cells [10, 53, 54]. Moreover, we demonstrated a dose-dependent reduction of cyclin D1 levels that correlates with STAT3 inactivation. STAT3 induces cyclin D1 transcription by binding its promoter region; and ERK1/2 has plays a critical role for induction of cyclin D1 (Figure ​(Figure6C)6C) [33, 34, 55, 56]. Decreased cyclin-D1 expression together with an increase in the p27Kip1 level are key to the G1 to S phase progression block that we observed in ponatinib-treated HSCs.

Unlike traditional dual SRC/ABL inhibitors, ponatinib is a reversible, third-generation inhibitor that binds the unphosphorylated inactive DFG-out conformation of both enzymes [57]. Ponatinib was designed to overcome resistance-inducing BCR-ABL mutations in CML and ALL treated with the first- and second-generation TK inhibitors. It is considered a pan-BCR-ABL inhibitor because it is potently active on ABL-T315I and fourteen other mutants [19]. Ponatinib shows inhibitory activity against ABL/SRC, PDGFR and other kinases, including the FGFR (fibroblast growth factor receptor), Ephrin receptors, FLT3 (FMS-like tyrosine kinase 3), VEGFR1-3 (vascular endothelial growth factor receptor 1-3), Ret (rearranged during transfection) and KIT (mast/stem cell growth factor receptor) [19]. Ponatinib therapy, similar to other TK inhibitors, is associated with severe adverse events, such as arterial thrombosis and liver toxicity, and older patients (>65 years) had higher risk of experiencing adverse effect than younger patients [58, 59]. In a large group of children and adolescents with CML treated with imatinib, assessment of long term growth revealed growth deceleration in both genders [60]. Therefore, adverse effects of long-term treatment in children should be carefully weighed.

Whereas short-term treatment with ponatinib leads to cytostasis, prolonged treatment could lead to cell death or senescence [61, 62]. These sequelae have been reported for B precursor or T cells from ALL patients treated with ponatinib; the treated cells underwent apoptosis after a G1 cell-cycle arrest by increasing endogenous TNF-related apoptosis-inducing ligand (TRAIL) [63]. Drugs that simply slow schwannoma growth would benefit NF2 patients enormously. If a long-term use of ponatinib is envisioned, we speculate that ponatinib may be used at lower doses in a combinatorial therapeutic approach with other compounds targeting interconnecting pathways, thereby limiting adverse effects. The different mechanisms of kinase inhibition and diverse range and selectivity of small-molecule kinase inhibitors requires that each drug be studied in NF2-relevant cell types, and weighed independently. To this extent, ponatinib treatment effectively reduced viability of merlin-deficient HSC with a robust arrest at the G1 phase. Ponatinib therapy may be applicable to a larger patient population than NF2, considering that merlin inactivation also occurs in sporadic schwannomas. Future in vivo studies addressing ponatinib alone or in combination as an effective therapy for schwannomas in NF2 mouse models are warranted.

Go to:
MATERIALS AND METHODS
Cell cultures and human vestibular schwannomas

The merlin-deficient HSC line was generated from primary fetal HSC purchased from ScienCell (lot #7228) and authenticated by immunostaining for expression of human nuclear antigen, and SC markers, S100, PLP, O4, and Gap43, and Nestin. Cells were transduced with lentiviral particles expressing human NF2 gene-specific shRNA (GenBank accession no. NM_000268; TRCN0000237845; TRCN0000039974; TRCN0000039975 and TRCN0000039977, Sigma-Aldrich), shRNA Scrambled, or Turbo-GFP control (Sigma-Aldrich) and then selected with 0.5 mg/ml puromycin. Wild-type and merlin-deficient HSC were cultured in CellBIND dishes (Corning) in complete Schwann cell media (SCM) from ScienCell (basal Schwann cell medium plus 5% fetal bovine serum, Schwann cell growth supplements which contains growth factors, hormones, and proteins necessary for the culture of normal human Schwann cells and 1X-penicillin/streptomycin) unless otherwise specified. Cells were used between passages 9 to 18. Merlin levels were assessed by Western blotting.

Frozen human schwannomas used in phospho-proteome studies were procured with patient informed consent at The Ohio State University College of Medicine according to Institutional Review Board regulations. Human vestibular schwannoma (VS) cells cultured to test ponatinib efficacy were isolated from dissociated fresh human tumors. Fresh VS specimens were procured with patient informed consent at University of Miami Miller School of Medicine according to Institutional Review Board regulations through the Tissue Bank Core Facility.

Normal primary human SCs, a gift from Dr. Patrick Wood (The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine), were used in phospho-proteome studies, and cultured as previously described [64].

Antibody proteome profiler arrays

Human phospho-RTK (ARY001) and phospho-kinase array (ARY003) kits were purchased from R&D systems. Human schwannoma homogenates and control HSC lysates were prepared and analyzed according to manufacturer's instructions. Arrays were visualized with chemiluminescence and were quantified with ImageJ MicroArray_Profile.jar plugin or Carestream software; mean intensity of duplicate spots was calculated.

Antibodies and inhibitors

Rabbit antibodies against merlin (D1D8), c-ABL, phospho-AKT (Thr308; C31E5E), cyclin-D1 (92G2), FYN, p-MEK1/2 (Ser217/221), PDGFRα and β, SRC (36D10), p-SRC family (Tyr416), p-ERK1/2 (D13.14.4E), YES and mouse antibodies recognizing AKT (40D4), β-Actin (8H10D10), MEK1/2 (L38C12), ERK1/2, p27Kip1 (SX53G8.5) were purchased from Cell Signaling. Rabbit antibodies against p-paxillin (Tyr118) and p-FAK (Tyr577/Tyr576) were purchased from Invitrogen. Rabbit p70S6 kinase (Thr229) was purchased form ThermoFisher Scientific. Rabbit anti-p-ABL (Tyr245), and human nuclear antigen antibodies were obtained from Millipore and antibodies for myelin- proteolipid protein and GAP43 were from Abcam. The anti-S100 antibody was purchased from Dako. Mouse anti-paxillin antibody was from BD bioscience. Secondary antibodies, goat anti-rabbit IgG conjugated with DyLight 800 4X-PEG, goat anti-Mouse IgG conjugated with DyLight 680, were purchased from Cell Signaling. Ponatinib, perifosine/KRX-0401, and selumetinib/AZD6244 were purchased from SelleckChem. The STAT3 inhibitor S3I-201/NSC-74859 was purchased from MedChem Express.

Western blot analysis

Cultured HSCs were lysed in modified RIPA buffer as previously described [65] or in 1X-SDS loading buffer plus 2.5 U/ml benzonase. 10 μg of protein or 10 μl 1X-loading buffer lysate were resolved in 4–20% polyacrylamide gels (Pierce), transferred to PVDF membranes (Immobilon-FL; Millipore), blocked with 5% BSA in TBS, and incubated with primary antibodies overnight at 4°C, and then with their corresponding fluorescence-conjugated secondary antibodies at 1:25,000-1:40,000 dilution. Image acquisition was done using LI-COR® Biosciences Odyssey® Infrared Imaging System and quantification using Odyssey Image Studio Version 3.1software and ImageJ 1.46r.

Immunocytochemistry

Cells were grown on German glass coverslips coated with 200 μg/ml poly-L-lysine (Sigma-Aldrich). HSCs were fixed in 4% paraformaldehyde and immunostained, and stained images were acquired with a Zeiss LSM710 confocal microscope as previously described [64]. Images were processed with ZEN2011 software.

Cell viability assay

HSC were seeded at 2,500 cells/well in 20 μl of phenol-red free SCM (SCM phenol-red free base, 5% serum, Schwann cell growth supplements containing growth factors, hormones, and proteins and 1X-penicillin/streptomycin) in 384-well plates and incubated with increasing concentrations of ponatinib in 0.1% DMSO or vehicle alone for 48h. The CellTiter-Fluor cell viability assay (Promega) was used according to manufacturer's specifications [53].

To evaluate cell viability without artificially stimulating proliferation, control and merlin-deficient HSC were cultured and assayed in growth suppressive medium (SCM base, 1X-penicillin/streptomycin –ScienCell, plus N2 supplement-Invitrogen). Cells were seeded in 24 well plates (Corning-CellBIND) at 60,000 cells/well in four replicates, after 4 days incubation at 37°C, 7% CO2, cells were treated with 0.25μM ponatinib or a vehicle control for one week. Viability was assessed with a crystal violet assay as previously described [64].

To evaluate cell viability of primary VS cells with NF2 mutations, two fresh VS were obtained from the Tissue Bank Core Facility at the University of Miami Miller School of Medicine. VS tumors were cut into 1 mm pieces and dissociated in 0.5 mg/ml collagenase (~150U/ml) and dispase (2.5 mg/ml) in Dulbecco's Modified Eagle Medium (Sigma) for 1h followed by 0.25% Trypsin for 30 minutes at 37°C. Digested tissue was triturated and centrifuged at 1500 rpm at 4°C for 10 minutes. Supernatant was discarded and cells were resuspended and cultured using Schwann Cell Media (ScienCell) on culture flasks pre-treated with 0.1% poly-L-lysine (Sigma) and 25 mg/ml laminin (ThermoScientific). Cells from Passage 2 were then seeded in a 96 well plate (Costar, Corning) at 5,000 cells/well in six replicates. After 24 hours of incubation at 37°C, 5% CO2, cells were treated with ponatinib at different concentrations or 0.05% DMSO for 48h. Viability was assessed with a crystal violet assay as previously described [64].

DNA sequencing of VS

Genomic DNA was isolated and purified using Trizol (Invitrogen) as per the manufacturer's protocol. A total of 17 pairs of primers were designed for the amplification and sequencing of the coding exons and their flanking splice sites using the Primer 3 program (http://bioinfo.ut.ee/primer3-0.4.0/). The complete coding sequences of NF2 were amplified by PCR. DNA (~1 μg) was amplified with NF2-specific primer pairs in 50μL, containing 10X PCR Buffer (pH 8.5), 0.4 mM dNTP mix (Promega Corporation), 0.4 pmol/μL of each primer, and 0.0625 units of Taq DNA polymerase (Eppendorf AG). DNA templates were amplified using the following program: 95°C for 3 min; 35 cycles of 94°C for 50 s, 60°C for 50 s, 72°C for 60 s; and final extension of 72°C for 5 min. Direct sequencing of PCR products were performed on both strands using the ABI Prism BigDye Terminator reaction kit and ABI 3100 DNA sequencer or with Beckman Coulter 2000 XL instrument and appropriate kits.

Cell-cycle and G1 proteins analysis by flow cytometry

The Click-iT EdU, FxCycle stain and Live/Dead fixable dead cell stain kits were purchased from Molecular Probes (ThermoFisher Scientific). Cells were seeded in 6-well plates and treated overnight with an inhibitor or vehicle. On the next day, 10 μM EdU was added to the cultures for 3 h, and then cells were harvested (total 24-h inhibitor incubation), stained with fixable violet live/dead stain, and permeabilized. EdU and DNA labeling was conducted according to manufacturer's instruction. Cell cycle analysis was done on gated live cells. For the cyclin D1/p27Kip1 expression study [66], cultures were treated with an inhibitor or vehicle for 24 h and then harvested, fixed with 4% paraformaldehyde for 10 min at 37°C, chilled for 1 min, and permeabilized for 30 min in 90% methanol. Fixed cells were transferred to a Falcon 5 ml tube through a cell strainer cap, rinsed twice with 0.5% BSA in PBS, and immunostained by incubating for 1h at room temperature with a cyclin D1 (1:400) or p27Kip1 (1:3,000) antibody, followed by a 30-min incubation with a goat anti-rabbit or anti-mouse-Alexa488 secondary antibody. After one wash, cells were resuspended in 1 ml of 0.5% BSA and stained for 30 min with 200nM FxCycle Far Red DNA stain supplemented with 0.1mg/ml of ribonucleaseA (Invitrogen). A BD FACS Canto-II flow cytometer (BD Biosciences) with the BD FACSDiva™ 6.1.3 software was used for data acquisition and FlowJo software was used for data analysis.

Statistical analysis

Statistical analysis was performed using GraphPad Prism v5.0 for Windows. Ponatinib dose-response experiments were analyzed by non-linear regression (four parameters). Other experiments were analyzed by applying two-way ANOVA and Bonferroni multiple comparisons post-test, one-way ANOVA, and Dunnett's multiple comparison post-test or unpaired t-test, two-tailed as noted.
Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders

D. Gareth R. Evans, Hector Salvador, Vivian Y. Chang, Ayelet Erez, Stephan D. Voss, Harriet Druker, Hamish S. Scott and Uri Tabori
DOI: 10.1158/1078-0432.CCR-17-0590 Published June 2017

ArticleFigures & DataInfo & Metrics PDF
Abstract

The neurofibromatoses consist of at least three autosomal-dominant inherited disorders: neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis. For over 80 years, these conditions were inextricably tied together under generalized neurofibromatosis. In 1987, the localization of NF1 to chromosome 17q and NF2 (bilateral vestibular schwannoma) to 22q led to a consensus conference at Bethesda, Maryland. The two main neurofibromatoses, NF1 and NF2, were formally separated. More recently, the SMARCB1 and LZTR1 genes on 22q have been confirmed as causing a subset of schwannomatosis. The last 26 years have seen a great improvement in understanding of the clinical and molecular features of these conditions as well as insights into management. Childhood presentation of NF2 (often with meningioma) in particular predicts a severe multitumor disease course. Malignancy is rare in NF2, particularly in childhood; however, there are substantial risks from benign and low-grade central nervous system (CNS) tumors necessitating MRI surveillance to optimize management. At least annual brain MRI, including high-resolution images through the auditory meatus, and a clinical examination and auditory assessment are required from diagnosis or from around 10 to 12 years of age if asymptomatic. Spinal imaging at baseline and every 2 to 3 years is advised with more frequent imaging if warranted on the basis of sites of tumor involvement. The malignancy risk in schwannomatosis is not well defined but may include an increased risk of malignant peripheral nerve sheath tumor in SMARCB1. Imaging protocols are also proposed for SMARCB1 and LZTR1 schwannomatosis and SMARCE1-related meningioma predisposition. Clin Cancer Res; 23(12); e54–e61. ©2017 AACR.

See all articles in the online-only CCR Pediatric Oncology Series.

Introduction

Neurofibromatosis type 2 (NF2) is an autosomal-dominant monogenic condition caused by mutations in the NF2 gene on chromosome 22q (1, 2). NF2 predisposes to the development of benign nerve sheath tumors that are predominantly schwannomas, meningiomas, and low-grade ependymomas. Recently, a number of related disorders have been characterized with schwannomatosis caused by mutations in SMARCB1 (3) and LZTR1 (4) and a predisposition to brain and spinal meningiomas caused by mutations in SMARCE1 (5). Recommendations for tumor surveillance of gene carriers and members of syndromic families are based upon review of the literature and discussion in the 2016 AACR Childhood Cancer Predisposition Workshop.

NF2

The hallmark of NF2 is the development of bilateral often multifocal eighth cranial nerve schwannomas leading to hearing loss and balance disturbance (Fig. 1A). These predominantly occur on the vestibular branches compressing the cochlear nerve (6, 7). Schwannomas often occur on other cranial nerves except the olfactory and optic nerves, with the greatest deficit perhaps caused by lower cranial nerve involvement (8). Schwannomas also occur on other spinal and peripheral nerve roots, and there are also characteristic “plaque”-like intracutaneous schwannomas that do not appear to occur either in schwannomatosis or sporadically (2, 9, 10). Meningiomas, which are predominantly fibroblastic or atypical, occur throughout the neuroaxis and are associated with increased mortality (11, 12). Intraspinal, low-grade ependymomas also occur and are generally indolent despite their appearances on MRI (9). NF2 typically presents in adulthood with hearing loss and tinnitus (2, 9). However, in childhood, symptoms may first occur due to an apparently isolated meningioma or non-cranial schwannoma (13, 14). Children may also present first with a mononeuropathy affecting the seventh and fourth through sixth nerves or a foot drop or wrist drop secondary to sacral nerve root or lower cervical nerve root/brachial plexus involvement, respectively, although definite tumor disease may not be present on MRI scan. These often leave a deficit, even though at least partial recovery is common (13, 14). Presentation with ocular features, such as retinal hamartoma and cataract, are also not infrequent. The Manchester (modified NIH) diagnostic criteria for NF2 are shown in Table 1. The original NIH criteria (1) were expanded to include patients with no family history who have multiple schwannomas and or meningiomas, but who have yet to develop bilateral eighth nerve tumors. These criteria have been shown to be more sensitive (15), but a newer points-based system has also been developed that may improve sensitivity in childhood (16). Indeed, the first sign of more severe multitumor disease in early childhood is often a non-eighth nerve tumor (13, 14). This has been reemphasized by a study of 53 pediatric patients with meningiomas (17), in which five unsuspected cases of NF2 were uncovered in addition to the nine already known, giving a frequency of 14/33 (42%) of the meningioma series. A little over 50% of NF2-affected individuals present without a family history, and about a third of these are mosaic for the NF2 mutation, as it is present only in a subset of cells, with the initial mutation occurring during embryogenesis (18–20). Indeed, around 63% of NF2 diagnosed in patients <20 years is de novo (230/337; Manchester; unpublished data). The remainder has inherited NF2 from an affected parent, with a usual 50% recurrence risk for subsequent offspring (9). Around 30% of NF2, presents symptomatically in childhood and nearly 50% by 20 years of age (refs. 2, 9, 13, 21; Table 2). There is virtual complete penetrance of NF2, although some mild mutations may mean that individuals in some families may die with hearing loss having never been diagnosed with the condition (22).

Figure 1.
Download figureOpen in new tabDownload powerpoint
Figure 1.
Characteristic imaging findings in a 12-year-old female patient with NF2. A and B, Axial FSE-T2 (A) and post-gadolinium–enhanced fat-suppressed T1-weighted images (B) through the internal auditory canals show bilateral vestibular schwannomas (arrows) with characteristic heterogeneous T2 signal and avid contrast enhancement. C, This same patient with NF2 also had extensive peripheral schwannomas, with whole-brain MRI showing extensive schwannomatous involvement of sacral nerve roots and sciatic nerve (arrow).
View inlineView popup
Table 1.
Manchester diagnostic criteria for NF2 (these include the NIH criteria with additional criteria; refs. 1, 2)
View inlineView popup
Table 2.
Childhood tumor risks to age 16 years in NF2
Genetics of NF2

NF2 is caused by loss-of-function mutations in the NF2 tumor suppressor gene on chromosome 22q (23, 24). The gene contains 17 exons spread over 110 kb. It produces two major mRNA and protein isoforms (also called MERLIN) by alternative splicing. Protein isoform 1 is 595 amino acids produced from exons 1 through 15 and exon 17, whereas the inclusion of alternatively spliced exon 16 alters the C terminus of the protein, replacing 16 amino acids with 11 novel residues (isoform 2). Pathogenic variants have not been identified in the alternatively spliced exons. The gene is expressed at high levels during embryonic development, whereas in adults, high expression is found in Schwann cells, meningeal cells, lens, and nerve. Tumors in NF2 are caused by loss of function of the remaining normal copy of the gene, fulfilling Knudson's two-hit hypothesis, although further mutational events are probably required to drive tumorigenesis (25). In the United Kingdom, large population-based estimates of birth incidence for NF2 showed that between one in 25,000 to 33,000 people would be born with a mutation in the NF2 gene (20, 26, 27). Overall diagnostic disease prevalence is around one in 56,000 (about 10 times more rare than NF1, and as in NF1, prevalence is lower than incidence due to early death and later age at diagnosis) and would be less than one in 150,000 in children due to later age at presentation with symptoms. Risk of transmission is 50% if the parent has inherited NF2 from an affected parent, as the mutation will be in all their cells. However, due to the high rate of mosaicism, there can be less than a 5% chance of transmission if the affected individual has a de novo mosaic point mutation not identifiable in lymphocyte DNA on Sanger sequencing, even if they fulfill classical criteria (19).

Genotype–phenotype correlations

Large studies have determined genotype–phenotype correlations with truncating mutations conferring a more severe disease course than missense mutations, splice site mutations, or large deletions (12, 28–34). The position of the mutation also correlates with mutations in the 3′ end of the gene (exons 14/15) being associated with fewer meningiomas (34) and lower mortality (12).

Many mildly affected individuals have mosaic disease, and children presenting asymmetrically should still be suspected of this (20). Although mosaicism is less frequent in childhood, it still occurs even in a classically affected individual. Indeed of 230 de novo NF2 cases diagnosed with the condition, 36 (15.5%) had proven mosaicism with a further 24 (10.5%) having no mutation identified on blood analysis (Manchester; unpublished data). Mosaicism may account for the milder disease course in many individuals with unfound mutations. However, mosaic mutations tend to be more likely to be the more severe mutations and less likely to be milder missense variants (35). The risk of transmitting to the next generation will be dependent on the proportion of germinal cells affected. However, if an offspring has inherited the mutation, they will be more severely affected than their parent, as the offspring will carry the mutation in all of their cells.

Apart from mosaicism, the nature of the mutation itself is associated with varying degrees of severity with regard to age of onset and number of tumors.

▪ Severe (early onset, multiple tumor disease, early death):

Truncating mutations in exons 2 through 13

▪ Moderately severe: large deletions, splicing mutations exons 1–6

▪ Moderate: exon 1 truncating; splicing 7 through 15, mosaic for truncating (2–13) in blood

▪ Mild [late onset, often only vestibular schwannoma (VS)]: missense, mosaic not present in blood

NF2-Related Disorders

Schwannomatosis is characterized by multiple, usually painful peripheral and spinal nerve schwannomas, and most familial cases are caused by mutations in either SMARCB1 (3) or LZTR1 (4, 36, 37). SMARCB1-related schwannomatosis has clear genotype–phenotype correlations, with rhabdoid tumor disease with rhabdoid tumor being caused by clear loss-of-function mutations and schwannomatosis by hypomorphic mutations (38). This is exemplified by the staining pattern on IHC in the schwannomas being mosaic for SMARCB1 protein in schwannomatosis and with total loss in rhabdoid tumor. There have been occasional families reported with both tumor types, but these are rare. Meningiomas have also been described in SMARCB1 schwannomatosis, but these are uncommon. Unfortunately, there does appear to be a malignancy risk in SMARCB1 schwannomatosis, with malignant peripheral nerve sheath tumors being reported in a number of individuals (39). LZTR1 schwannomatosis has not yet been clearly linked to the risk of other tumors but has now been clearly shown to cause VS (36, 40) and, thus, results in substantial overlap with the Manchester criteria for NF2 (Table 1). Individuals with a unilateral VS and at least two other noncutaneous schwannomas are at least as likely to carry a constitutional mutation in LZTR1 as an NF2 mutation (40). Both SMARCB1- and LZTR1-related schwannomatosis can present in childhood with an isolated schwannoma and should be suspected in addition to NF2. Genetic testing revealed that 30 of 155 (19%) isolated schwannoma patients aged <25 years had a germline NF2 mutation, seven people had a germline SMARCB1 (5%) mutation, and 10 (6%) had a germline LZTR1 mutation (41). Likewise, a predisposition to clear cell brain and spinal meningiomas caused by mutations in the SMARCE1 gene (5) can cause an apparently isolated childhood meningioma, and 17% and 19%, respectively, of apparently isolated meningioma in patients <25 years had a germline NF2 or SMARCE1 mutation, respectively (40). Interestingly, NF2, SMARCB1, and LTZR1 are all tumor suppressors that likely affect a common cytoplasmic signaling cascade that regulates such fundamental cellular processes as chromatin conformation, cell cycle, and proliferation. Thus, when these genes are mutated, either somatically or constitutionally, key events are perturbed and lead to the development of schwannomas. Schwannomas caused by germline SMARCB1 or LZTR1 mutations almost universally show a “three event, four hit” process involving loss of chromosome 22q (and the wild-type copy of SMARCB1/LZTR1 as well as one copy of NF2) and a point mutation in NF2 in the same chromosome arm as the germline SMARCB1/LZTR1 mutation (3, 4, 36–38).

Cancer/Tumor Screening/Surveillance Protocols

Initial diagnostic evaluation

There are several groups of individuals who should be considered at risk of NF2 and investigated further. These groups include those with a family history of NF2, children presenting with a unilateral VS, other cranial spinal or peripheral nerve schwannoma or meningioma, cutaneous schwannomas, or retinal hamartoma. MRI scanning is vital in their further assessment (42).

Clinical assessment.

Although cutaneous features are useful in diagnosis, skin features in NF2 are much more subtle than in NF1. About 70% of NF2 patients have skin tumors, but only 10% have more than 10 skin tumors (2). The tumors appear to be of at least three different types. The most frequent type is a plaque-like lesion, which is intracutaneous, slightly raised, and more pigmented than surrounding skin, often with excess hair (Fig. 2). More deep-seated subcutaneous nodular tumors can often be felt, sometimes on major peripheral nerves. These tumors often occur as a fusiform swelling of the nerve, with thickened nerve palpable on either side. There are also occasional intracutaneous tumors similar to those in NF1. The great majority of these tumors are schwannomas, but occasional definite neurofibromas do occur. Café au lait macules are more common in NF2 than the general population but will only rarely cause confusion with NF1. Ophthalmic examination by a specialized ophthalmologist is important in childhood, and assessment soon after birth may detect juvenile cortical wedge cataracts (and later posterior subcapsular opacities) and amblyopia that can affect vision. MRI with gadolinium enhancement will now detect tumors as small as 1 to 2 mm in diameter on cranial and spinal nerve roots. Many of the small spinal tumors will never lead to symptoms but may aid in diagnosis. Spinal MRI will detect evidence of spinal tumors in 70% to 90% of patients with NF2, although about 50% of children will not have spinal tumors at presentation, particularly if asymptomatic at diagnosis (Tables 1 and 2; refs. 42, 43).

Figure 2.
Download figureOpen in new tabDownload powerpoint
Figure 2.
NF2 plaque lesion on skin of forearm. Slightly raised, slightly pigmented, with excess hair typical of NF2. Clinical features of NF2 (including diagnostic criteria).
Molecular testing.

All children presenting with either clear diagnostic criteria for NF2, including combined retinal hamartomas, or those with an NF2 tumor (any schwannoma/meningioma) presenting in childhood should undergo genetic testing of NF2 ideally in both blood and tumor, although practically most clinics start with analysis of a blood sample. However, if negative, directed testing on blood DNA by next-generation sequencing of any point mutations found in tumor will assess low-level mosaic risk. In addition, those with an isolated noncutaneous schwannoma should be panel tested for NF2, SMARCB1, and LZTR1. Isolated meningiomas should also be tested for SMARCE1 unless the histology is definitively not clear cell. DNA testing with sequencing and deletion analysis [often by performing multiple ligation–dependent probe amplification (MLPA)] detects 95% of mutations in NF2 in individuals from the second affected generation (10, 12, 20). Consideration should be given for cytogenetic tests in a child with NF2-related tumors who has significant learning difficulties and café au lait macules, as ring chromosome 22 cases [r(22)] have an increased risk of schwannomas and meningiomas due to mosaic loss of NF2 in the unstable ring (44). Even in the absence of a germline mutation, somatic mosaicism should be suspected and follow-up from diagnosis should include thorough physical examination on a 3 to 5 yearly basis until 35 to 40 years of age, accompanied by craniospinal MRI (36, 42, 43).

The timing for presymptomatic genetic tests in childhood has been for some years set at 10 to 12 years (42). The risk of symptomatic VS is very small prior to that age, and the tiny tumors often found earlier than 10 years appear to grow very slowly until puberty. Nonetheless, consideration should be given to testing children of those with a more severe genotype, especially with truncating mutations in exons 2 through 13, at an earlier age.

Surveillance

Surveillance protocol once NF2 is established.

The following are recommended on the basis of expert opinion and previous publication (43).

Annual history and physical exam (including audiology with measurement of pure-tone thresholds and Word Recognition Scores).

Annual (consider twice yearly in first year since diagnosis or signs of rapid growth) brain MRI starting at 10 years of age. If baseline imaging shows no characteristic sites of involvement, reduce frequency of screening to every 2 years. Screening may begin earlier in patients with high-risk genotypes or symptomatic diagnoses. Protocols should include high-resolution (1–3 mm slice thickness) imaging through the internal auditory meatus, preferably in at least 2 orthogonal planes. NF2 lesions have variably increased T2 signal but characteristically show avid contrast enhancement (Fig. 1A and B; ref. 45), and imaging should include post-contrast sequences following infusion of gadolinium-based contrast agents (GBCA). Once a diagnosis has been made and lesions are identified by MRI, the first scan performed after diagnosis should be at 6 months to assess tumors' growth rate. Volumetric images (including T2-weighted and post-contrast imaging) should be acquired when assessing response to drug therapy. Although the lesions characteristic of NF2 can be detected by CT, particularly in the skull base, there is currently no role for routine CT-based surveillance in NF2.

Surveillance spinal MRI is recommended at 24- to 36-month intervals beginning at 10 years of age. The interval between scans may be increased if there is no disease detected on baseline imaging. As with brain MRI recommendations, once lesions are detected, the first scan after diagnosis should be at 6 months to evaluate tumor growth rate. For routine spinal MRI surveillance, contrast may be omitted unless patients are symptomatic or carry at-risk mutations such as SMARCB1 or LZTR1. In practice, spinal MRI is often performed together with brain MRI, in which case post-contrast images of the spine are usually obtained.

Whole-body examinations may be obtained (Fig. 1C), including the brain and spine, depending on symptoms and known sites of disease. Although 18F-FDG PET/CT can identify lesions with increased metabolic activity, there is insufficient evidence to recommend 18F-PET/CT (or PET/MRI) for routine screening.

Management of NF2.

NF2 presents complex management issues, and a child with NF2 should be managed by a multidisciplinary team consisting of a pediatric neurosurgeon, otolaryngologist, audiologist, neurologist, ophthalmologist, neuroradiologist, pediatric neuro-oncologist, and geneticist. An adult neurosurgeon specializing in NF2 is also usually involved. There is clear evidence of a mortality benefit (11, 12) with a significantly increased life expectancy for NF2 patients managed at three specialty centers in the United Kingdom [relative risk (RR), 0.3; 95% confidence interval (CI), 0.12–0.98; ref. 11]. This led to the national commissioning of four centers to cover NF2 in England in 2010 (population 53 million; ref. 46), with further improvements in survival (12). It is important to balance the use of microsurgery and radiation treatment, which can have a role in patients who have particularly aggressive tumors, who are poor surgical risks, or who refuse surgery. Although, radiation treatment has received a great deal of attention and short-term results show good “tumor control,” this has to be balanced against longer term risks such as malignancy, especially in childhood (47, 48), and the fact that tumors grow slowly and sometimes not at all for periods of time. Teams experienced in the positioning of brainstem implants can offer partial auditory rehabilitation to those who are deaf, although results are still behind those achievable for cochlear implants. Although the cochlear nerve may be left initially intact after surgery, its blood supply may be damaged. Nonetheless, a few patients can be rehabilitated successfully with a cochlear implant. Because detection of tumors at an early stage is effective in improving the clinical management of NF2, presymptomatic genetic testing is an integral part of the management of NF2 families. Recently, the use of targeted treatments has been highlighted (49, 50, 51). The VEGF antibody bevacizumab has been shown to shrink schwannomas and has been used in children (49–51). However, use in children should be guarded, as tumors rebound when treatment is stopped and potential side effects on growth and fertility are still a concern.

Management and follow-up of NF2 of adulthood.

Management and follow-up should be arranged through a specialized multidisciplinary team that includes, at a minimum, a neurosurgeon, neuro-otologist, neurologist, neuroradiologist, audiologist, specialist nurse, and geneticist, with annual MRI continuing into adulthood and 3 to 5 yearly spinal MRI unless symptomatic or with a fast-growing tumor (43).

Schwannomatosis

Schwannomatosis is less common than NF2 and is even more rare in childhood. Unless a SMARCB1 or LZTR1 mutation is identified, it is a diagnosis that is made after NF2 has been excluded, usually by a combination of cranial imaging to show no evidence of VS, blood NF2 molecular testing, and, potentially, tumor analysis. Analysis of multiple tumors from the patient show different NF2 mutations consistent with somatic mutations rather than identical ones, which would indicate NF2 mosaicism in a patient with negative blood analysis (42). Life expectancy is not usually affected unlike NF2, although pain is a prominent feature. A baseline assessment including full craniospinal MRI should be carried out in late childhood/early adulthood to assess disease, and whole-body MRI can be considered. In Manchester (unpublished data), six of 67 (9%) SMARCB1 presented with symptomatic spinal schwannomas in patients <20 years and in LZTR1 two of 71 (2.6%). Management in adulthood is usually coordinated by a neurologist with pain expertise or a neurofibromatosis specialist. Frequent MRI is not required unless symptomatic.

SMARCE1 meningiomatosis

SMARCE1 meningiomatosis often presents in childhood with an isolated meningioma. This appears to be more likely in males who, like in NF2, have an earlier risk of meningioma disease but a lower later risk (34). Until more information is available about the penetrance and tumor spectrum of the condition, we propose the following screening advice for asymptomatic SMARCE1 mutation carriers: neurologic examination and MRI of the brain and spine yearly from diagnosis until the age of 18 and once every 3 years thereafter, or in between if there are clinical symptoms (53).

Apparent gain-of-function mutations in SMARCB1 and SMARCE1 have been associated with Coffin–Siris syndrome and LZTR1 with Noonan syndrome, but these mutations rarely cause schwannomas/meningiomas (54).

Imaging in related disorders

▪ SMARCB1 schwannomatosis [different protocols for rhabdoid disease–related SMARCB1 mutations are in the CCR Pediatric Oncology Series article by Foulkes and colleagues (55)]—baseline MRI brain and spine at diagnosis, then every 2 to 3 years, beginning at age 10. Consider whole-body MRI and increasing surveillance frequency if symptomatic.

▪ LZTR1—baseline MRI brain and spine at diagnosis, then every 2 tp 3 years, beginning at age 15 to 19 years. Consider whole-body MRI and increasing surveillance frequency if symptomatic.

▪ SMARCE1—baseline MRI brain and spine at diagnosis, then every 1 to 2 years until the age of 18, reducing frequency to once every 5 years if no tumors are identified. If tumor is detected, increase frequency of surveillance to every 2 to 3 years or more frequently if patients become symptomatic.

Conclusions

We outline here recommendations for genetic testing to confirm the presence of either NF2, or related SMARCB1 or LZTR1 schwannomatosis or SMARCE1-related meningioma predisposition. Detailed surveillance protocols dependent on the disorder are provided in Table 3.
834 www.thelancet.com/neurology   Vol 13   August 2014ReviewNeuroﬁ bromatosis type 1: a multidisciplinary approach to careAngela C Hirbe, David H GutmannNeuroﬁ bromatosis type 1 is a relatively common inherited disorder. Patients have a high predisposition to develop both benign and malignant tumours. Although many manifestations of neuroﬁ bromatosis type 1 aﬀ ect the nervous system, other organs and tissues can also be aﬀ ected. Because of the varying features and clinical heterogeneity inherent to this disorder, patients can present to diﬀ erent medical and surgical specialists and, therefore, the association of clinical symptoms with neuroﬁ bromatosis type 1 might not be appreciated. Thus, for prompt diagnosis and to provide optimum care for patients with neuroﬁ bromatosis type 1, clinicians must be aware of the diverse clinical features of this disorder. We advocate a multidisciplinary approach to care, entailing a dedicated team of specialists throughout the lifetime of the patient. As our understanding of this disorder deepens through basic laboratory and clinical investigations, swift implementation of new eﬀ ective treatments becomes feasible.IntroductionNeuroﬁ bromatosis type 1 is a relatively common inherited disorder that aﬀ ects about one in 2500 to one in 3000 people world wide, irrespective of sex or ethnic origin.1,2 Individuals with neuroﬁ bromatosis type 1 are prone to develop benign and malignant tumours of the CNS and peripheral nervous system, in addition to malignant diseases aﬀ ecting other parts of the body.3 Tumours that are commonly associated with the disorder include glioma of the optic pathway, glioblastoma, malig nant peripheral nerve sheath tumour, gastrointestinal stromal tumour, breast cancer, leukaemia, phaeo chromo cytoma, duodenal carcinoid tumour, and rhabdo myo sarcoma (table).4–13Neuroﬁ bromatosis type 1 was ﬁ rst described by Frederich von Recklinghausen in 1882. In 1987, formal diagnostic criteria were published by the National Institutes of Health (panel).14 In this Review, we describe benign and malig-nant features of neuroﬁ bromatosis type 1, focusing on diagnostic strategies, monitoring, and treatment of tumours located in the nervous system and elsewhere. Additionally, we highlight possible future therapeutic directions based on ﬁ ndings of preclinical drug discovery and evaluation studies in genetically engineered mouse models of neuroﬁ bromatosis type 1-associated malignant diseases. Finally, we discuss current and future clinical trials in patients with neuro ﬁ bromatosis type 1.Genetics and genetic testingNeuroﬁ bromatosis type 1 is a dominantly inherited genetic disorder that results from a germline mutation in the NF1 tumour-suppressor gene. NF1 is located on chromosome 17q11.2 and encodes a 220 kDa cytoplasmic protein called neuroﬁ bromin. This protein functions, in part, as a negative regulator of the Ras proto-oncogene, which is a key signalling molecule in the control of cell growth.15 Aﬀ ected individuals start life with one mutated (non-functional) copy and one functional copy of NF1 in every cell in their body. Although many of the clinical features of this syndrome are apparent from birth, complete loss of gene function is needed for formation of tumours, by acquisition of a somatic NF1 mutation in selected cells.16,17About 50% of individuals with neuroﬁ bromatosis type 1 have no family history of the disease and the disease is due to de novo (spontaneous) mutations. With the advent of accurate genetic testing, early genotype-phenotype correlations are beginning to emerge, including the observation that people with genomic microdeletions aﬀ ecting the entire NF1 gene have a more severe phenotype.18,19 For instance, this particular subgroup of Lancet Neurol 2014; 13: 834–43Departments of Medicine (A C Hirbe MD) and Neurology (D H Gutmann MD), Washington University School of Medicine, St Louis, MO 63110, USACorrespondence to:Dr David H Gutmann, Department of Neurology, St Louis, MO 63110, USAgutmannd@neuro.wustl.eduLifetime riskGlioma of the optic pathway15–20%Other brain tumourMore than ﬁ vefold increaseMalignant peripheral nerve-sheath tumour8–13%Gastrointestinal stromal tumour4–25%Breast cancerAbout ﬁ vefold increaseLeukaemiaAbout sevenfold increasePhaeochromocytoma0·1–5·7%Duodenal carcinoid tumour1%Rhabdomyosarcoma1·4–6%Table: Lifetime risk of diﬀ erent tumours in children and adults with neuroﬁ bromatosis type 1Panel: NIH consensus criteria14 for diagnosis of neuroﬁ bromatosis type 1Two or more of the following clinical features are suﬃ  cient to establish a diagnosis of neuroﬁ bromatosis type 1:• Six or more café-au-lait macules (>0·5 cm at largest diameter in a prepubertal child or >1·5 cm in post-pubertal individuals)• Axillary freckling or freckling in inguinal regions• Two or more neuroﬁ bromas of any type or one or more plexiform neuroﬁ bromas• Two or more Lisch nodules (iris hamartomas)• A distinctive osseous lesion (sphenoid wing dysplasia, long-bone dysplasia)• An optic pathway glioma• A ﬁ rst-degree relative with neuroﬁ bromatosis type 1 diagnosed by the above criteriaNIH=National Institutes of Health.www.thelancet.com/neurology   Vol 13   August 2014 835Reviewindividuals with NF1 microdeletions tend to develop neuroﬁ bromas at an earlier age, have a lower mean IQ, manifest abnormal facial features, and are at increased risk of developing malignant peripheral nerve-sheath tumours.19–21 At present, the diagnosis of neuroﬁ bromatosis type 1 is most commonly made using established clinical criteria,14 reserving NF1 genetic testing for unusual presentations or reproductive decision-making.Non-malignant clinical featuresPigmentary abnormalities  Frequently, the earliest clinical manifestation of neuro-ﬁ bromatosis type 1 is café-au-lait macules, which usually develop within the ﬁ rst 2 years of life (ﬁ gure 1). The presence of more than ﬁ ve café-au-lait macules (>0·5 cm in diameter before puberty or >1·5 cm after puberty) is one of the diagnostic criteria for neuro-ﬁ bromatosis type 1. These lesions have no malignant potential and tend to darken with sun exposure and fade with advancing age. For macules that reduce quality of life, individuals can be oﬀ ered dermatological camouﬂ age treatments.22Axillary and inguinal freckling is another common clinical feature of neuroﬁ bromatosis type 1 and is usually detected in aﬀ ected individuals by age 5–8 years. These pigmentary abnormalities are typically the second diagnostic characteristic seen in children with the disorder, generally arising after development of café-au-lait macules. Freckles can also be found in areas where skinfolds are in apposition, including the neck and under the breasts in women.23Lisch nodules are benign melanocytic hamartomas of the iris, typically ﬁ rst noticed in children aged 5–10 years. Nearly all adults with neuroﬁ bromatosis type 1 have Lisch nodules. These pigmented lesions are best detected on slit-lamp examination by an experienced ophthal-mologist.23 Lisch nodules do not impair vision or cause any medical problems.Neuroﬁ bromas  Neuroﬁ bromas are benign Schwann-cell tumours composed not only of neoplastic Schwann cells24,25 but also of non-neoplastic ﬁ broblasts, mast cells, macro-phages, endothelial cells, pericytes, and perineural cells.26–29 There are four subtypes: cutaneous, sub-cutaneous, nodular or diﬀ use plexiform, and spinal.Intracutaneous neuroﬁ bromas develop during late childhood or early adolescence and do not undergo malignant transformation. Owing to an abundance of mast cells associated with the tumours, these tumours might cause local pruritus. Intracutaneous neuro ﬁ bromas can result in substantial discomfort or disﬁ gure ment when hundreds or thousands of these neuroﬁ bromas are present in a patient. In such instances, the tumours can be removed by a plastic surgeon.22 Spinal neuroﬁ bromas can occur at single or multiple nerve roots and are associated with both sensory and motor deﬁ cits.Although neuroﬁ bromas are commonly found on the skin—presenting as subcutaneous, dermal, or exophytic masses—they can also be located deep within the body. Individuals with neuroﬁ bromatosis type 1 generally develop more neuroﬁ bromas as they get older, and some patients can have many deep neuroﬁ bromas without clinical symptoms. In these patients, tumour removal should be led by symptoms—such as pain and functional deﬁ cits—and ﬁ ndings of a risk-beneﬁ t assessment.Plexiform neuroﬁ bromas  Plexiform neuroﬁ bromas typically manifest at birth but can continue to grow during adolescence and early adulthood (ﬁ gure 2). In most individuals, these tumours enlarge most prominently during the ﬁ rst decade of life. Plexiform neuroﬁ bromas develop in about 30–50% of individuals Figure 1: Café-au-lait maculeMacule on a 24-year-old woman with neuroﬁ bromatosis type 1 who was diagnosed as a young child (measuring tape shown for reference). Figure 2: Internal plexiform neuroﬁ bromaCoronal MRI shows an extensive neuroﬁ broma (asterisk) in an 8-year-old boy with neuroﬁ bromatosis type 1. *836 www.thelancet.com/neurology   Vol 13   August 2014Reviewwith neuroﬁ bromatosis type 1. They diﬀ er from cutaneous neuroﬁ bromas in that they arise from multiple nerve fascicles and can grow along the length of a nerve.30 These tumours can also extend into surroun ding structures, causing substantial pain and bone destruction. Importantly, plexiform neuroﬁ bromas have a lifetime risk of malignant transformation. Although the best therapeutic option for symptomatic lesions is surgical removal, this approach is sometimes technically impossible.3Chemotherapy is a potential therapeutic option for plexiform neuroﬁ bromas. In a recent phase 1 trial, pegylated interferon-alfa-2b (antiviral cytokine therapy)was assessed in 30 patients with plexiform neuroﬁ bromas who had radiographic progression before enrolment.31 Reported eﬀ ects were pain reduction (in 11 of 16 patients), decreased tumour mass (13 of 14), and tumour shrinkage or stabilisation (three of four). Similarly, in a phase 2 trial of imatinib (tyrosine kinase inhibitor), 17% of patients with plexiform neuroﬁ bromas had a 20% or more reduction in tumour volume.32 In view of these initial encouraging results, several studies are now in progress to test the use of other biologically targeted therapies, including mammalian target of rapamycin (mTOR) inhibitors and mitogen-activated protein kinase kinase (MEK) inhibitors in these patients.Skeletal deformities  People with neuroﬁ bromatosis type 1 can develop skeletal abnormalities, including osteopenia, scoliosis, sphenoid wing dysplasia, congenital tibial dysplasia, and pseudarthrosis (ﬁ gure 3). Moreover, aﬀ ected individuals tend to be shorter than expected for their age and frequently have low bone-mineral densities.33 In a large registry-based study of neuroﬁ bromatosis type 1, a roughly ﬁ vefold increase in fracture risk was reported for adults older than 40 years, and this risk was about threefold higher in children younger than 16 years.34 Lifestyle modiﬁ cations such as increased exercise and calcium or vitamin D supplementation might be warranted in these patients. Low concentrations of vitamin D have been recorded in people with neuroﬁ bromatosis type 1.33,35–38 In a retro spective study of vitamin D supplementation, loss of bone-mineral density was reduced signiﬁ cantly in adult patients with neuroﬁ bromatosis type 1 whose vitamin D levels were maintained above 30 μg/L, compared with people who had not been supplemented.39 Although this ﬁ nding suggests that all adults should be screened for vitamin D deﬁ ciency and appropriate replacements initiated, prospective studies are needed before practice recom-mendations are changed.Scoliosis can aﬀ ect 10–26% of individuals with neuroﬁ bromatosis type 1, making annual spinal examinations necessary during childhood and early adolescence.40 Mild curvature can be treated with bracing; however, more severe cases might need surgery to stabilise progressive spinal and chest-wall deformity and preserve lung function by minimising constrictive forces.3 The vertical expandable prosthetic titanium rib (VEPTR), which is used to diminish constrictive forces on the lung, has shown promise in clinical trials.41 It is noteworthy that some individuals with neuroﬁ bromatosis type 1 have dystrophic scoliosis with striking curvatures and generally less satisfactory surgical outcomes than those without striking curvatures.Sphenoid wing dysplasia typically presents as a unilateral bony defect aﬀ ecting the orbital plate and the frontal bone. Sometimes, thinning or absence of the sphenoid wing is attributable to the presence of an associated orbital plexiform neuroﬁ broma, but it can occur as an isolated bony abnormality.42 These defects are usually seen in Figure 3: Skeletal abnormalities in individuals with neuroﬁ bromatosis type 1Plain ﬁ lm radiographs showing: (A) dystrophic scoliosis (asterisk) in an 11-year-old girl; (B) tibial bowing (asterisk) in a 10-month-old baby girl; (C) tibial pseudarthrosis (asterisk) in a 9-month-old baby girl; and (D) tibial pseudarthrosis after insertion of an internal rod (asterisk) in a 9-year-old boy. BADC****www.thelancet.com/neurology   Vol 13   August 2014 837Reviewasymptomatic individuals after a careful physical examination in which one eye appears asymmetric or is proptotic or sunken. Congenital tibial dysplasia generally presents as anterolateral bowing of the lower leg, with cortical thinning evident on plain radiographs. The presence of bowing in an infant should warrant prompt radiographic assessment. Repeated fractures with failure to heal can lead to development of pseudarthrosis and, in some cases, limb amputation.43 Referral to a skilled paediatric orthopaedic surgeon is needed to initiate appropriate treatment and avoid this poor outcome.Cardiovascular abnormalities  Individuals with neuroﬁ bromatosis type 1 can develop various cardiovascular abnormalities, ranging from con-genital heart disease to vasculopathy and hyper tension. Echocardiographic data suggest that up to 27% of patients with neuroﬁ bromatosis type 1 have a cardio vascular anomaly,44 and pulmonary artery stenosis accounts for as many as 50% of these abnormalities.45 The prevalence of abnormalities is likely to be an under estimate because a diagnosis is usually made only if symptoms develop. Therefore, all children born with neuroﬁ bromatosis type 1 should have a thorough cardiac examination and any murmurs should be investigated further by a skilled paediatric cardiologist.46Neuroﬁ bromatosis type 1-related vasculopathy includes renal and cerebral artery stenosis, aortic coarctation, and arteriovenous malformations.47 The pathogenesis, clinical spectrum, and natural history of these anomalies remains poorly understood; however, impaired NF1 gene function in vascular endothelial cells results in increased proliferation and growth.27,48,49 Vasculopathy usually aﬀ ects the arterial system, leading to cerebrovascular disease (eg, narrowed or ectatic vessels, vascular stenosis, aneurysm, or moyamoya disease) or renal artery stenosis.47,50,51 Individuals with neuroﬁ bromatosis type 1 who present with a new neurological deﬁ cit should be assessed for both cerebrovascular disease and brain tumour. Moreover, any patient with unexplained hyper-tension should undergo investigation for renal artery stenosis. Laboratory assessments (serum creatinine and electrolytes, plasma renin, and urinalysis), approp riate imaging studies, and arteriography are important. Although essential hypertension remains the most common reason for raised blood pressure in this population, other causes include coarctation of the aorta and phaeochromocytoma. Some of these abnormalities are likely to be congenital; however, whether vascular stenoses are actually present at birth is unclear. Further study is needed to resolve these uncertainties.Neurocognitive deﬁ cits  Neurocognitive deﬁ cits are among the most common manifestations of neuroﬁ bromatosis type 1. Children should undergo neuropsychological screening assess-ments early in life, followed by more detailed testing when appropriate.52 Learning diﬃ  culties can include visuospatial and visuomotor deﬁ cits, language disorders, and ﬁ ne and gross motor deﬁ ciencies. Furthermore, attention-deﬁ cit hyperactivity disorder, autism spectrum disorders, behavioural abnormalities, and psychosocial issues are prevalent in this population.53 Children with neuro ﬁ bro matosis type 1 might beneﬁ t from a multi disciplinary approach, in which educational specialists, paediatric neuro -psychologists, physical thera pists, speech therapists, and occupational therapists work together to maximise abilities and optimise the chance for academic and social success. Pharmacological inter ven tions with treatments such as lovastatin54 or drugs used to treat attention-deﬁ cit hyperactivity disorder (eg, methyl-phenidate) might be of beneﬁ t for some children.Nervous-system tumoursOptic pathway and brainstem gliomas  About 15–20% of individuals with neuroﬁ bromatosis type 1 will develop low-grade glial neoplasms; roughly 80% are in the optic pathway, but some (15%) can be present in the brainstem,22 with rare involvement of the cerebellum, cortex, and subcortical regions.5 Optic pathway gliomas (ﬁ gure 4A) typically present in children with neuro ﬁ bromatosis type 1 who are younger than 7 years.55 These tumours are mainly WHO grade I glial neoplasms—termed pilocytic astrocytomas—and are indistinguishable histologically from gliomas that arise sporadically in individuals without neuroﬁ bromatosis type 1.56 Although many optic pathway gliomas are asymptomatic, up to half can cause clinical symptoms, most commonly resulting in reduced vision; some children present with precocious puberty.57Owing to the frequency of optic pathway gliomas in young children with neuroﬁ bromatosis type 1, all patients who are younger than 13 years should undergo an Figure 4: Low-grade glial neoplasms(A) MRI showing an optic glioma in the left optic nerve (asterisk) of a 4-year-old boy with neuroﬁ bromatosis type 1. (B) MRI showing a brainstem glioma (asterisk) in a 9-year-old boy with neuroﬁ bromatosis type 1.BA**838 www.thelancet.com/neurology   Vol 13   August 2014Reviewophthal mological examination every year by a paediatric neuro-ophthalmologist. Screening MRI is not recom-mended unless children are unable to undertake the ophthalmological assessment and reliable measure ments of visual acuity cannot be obtained.55 On identiﬁ cation of an optic glioma, current recommendations include ophthalmological and MRI studies four times a year for the ﬁ rst year, followed by gradual lengthening of test intervals over the next 2–3 years. A two-line decrease in visual acuity, as measured by a standardised visual assessment procedure such as the Snellen chart, warrants referral to a paediatric neuro-oncologist for treatment.58Surgery plays little part in the treatment of optic pathway gliomas because it can result in permanent neurological damage.58 First-line treatment for most patients with symptomatic tumours is chemotherapy with carboplatin and vincristine.59 Other chemotherapy combinations have been used; however, no randomised trial data are available to support the use of one regimen over another.60 Cranial radiation therapy is not recom-mended for patients with neuroﬁ bromatosis type 1 because of the increased propensity of this population to develop second malignancies, vascular abnormalities, and neuropsychological diﬃ  culties.10,61Brainstem gliomas are the most frequently discovered brain tumor outside of the optic pathway in people with neuroﬁ bromatosis type 1.22 Similar to optic pathway tumours, brainstem gliomas (ﬁ gure 4B) are usually pilocytic astrocytomas; however, they typically present later in the ﬁ rst decade of life. Aﬀ ected children might come to medical attention with cranial neuropathies, lethargy, gait instability, or headaches. Chemotherapy is used to treat clinically progressive tumours, with drugs such as carboplatin or vincristine, as would be administered for other low-grade gliomas in the paediatric population.Glioblastomas  Individuals with neuroﬁ bromatosis type 1 have at least a ﬁ vefold increased risk for developing other brain tumours, including WHO grade IV astrocytomas (glio-blastomas), according to ﬁ ndings of several case reports and small retrospective studies.9,62–64 Glioblastomas usually present in young adults,65 in whom the overall prognosis is poor. Treatment is similar to that for people with sporadic glioblastomas and usually entails gross surgical resection followed by adjuvant radiation and chemotherapy (typically oral temozolomide).Malignant peripheral nerve sheath tumours  Malignant peripheral nerve sheath tumours—sometimes referred to as neuroﬁ brosarcomas or neurogenic sarcomas—are a subtype of sarcoma with a presumed Schwann cell origin. These tumours represent about 3–10% of all soft-tissue sarcomas, and a large proportion arise in individuals with neuro ﬁ bromatosis type 1.66 Malignant peripheral nerve sheath tumours have a prevalence of 0·001% in the general population versus 0·1% in individuals with neuro ﬁ bromatosis type 1.6,67 The cumulative lifetime risk of developing malignant peripheral nerve sheath tumours in a patient with neuroﬁ bromatosis type 1 is about 8–13%.68 Malig-nant peripheral nerve sheath tumours can arise any-where within the body. Risk for developing a malignant peripheral nerve sheath tumour is increased 20-fold in the area of an existing internal plexiform neuroﬁ broma.69 Other risk factors for development of malignant peri-pheral nerve sheath tumours include previous radia tion therapy and large germline mutations encompassing the entire NF1 gene (microdeletions).21Individuals with neuroﬁ bromatosis type 1 who report substantial or diﬃ  cult-to-control pain, a rapid increase in the size of an existing plexiform neuroﬁ broma, a change in tumour consistency (soft to hard), or a new neurological deﬁ cit warrant prompt assessment for malignant peripheral nerve sheath tumours.67 MRI is helpful to deﬁ ne the location and extent of the tumour, but it is not reliable for distinguishing between malignant disease and benign tumours. Over the past decade, ¹⁸F-ﬂ uoro-deoxy glucose (¹⁸F-FDG)-PET has emerged as a highly sensitive and speciﬁ c method for detection of malignant peripheral nerve sheath tumours (ﬁ gure 5).70–72 Needle biopsy can be aﬀ ected by sampling bias and might not allow the treating clinician to exclude a diagnosis of malignant peripheral nerve sheath tumour with conﬁ dence.67 Furthermore, patients with suspected malignant disease should be examined for evidence of metastatic disease (eg, in the lung or bone). In view of the aggressive nature of malignant peripheral nerve sheath tumours, patients should be assessed and managed by a multidisciplinary team including neurologists, radiologists, surgeons, oncologists, and radiation oncolo gists to eﬃ  ciently implement plans for biopsy (non-invasive or open) and treatment.Surgery is the only curative treatment option for patients with malignant peripheral nerve sheath tumours.73 Even with surgical excision, 5-year overall survival rates are poor,6,74 and this cancer represents a substantial cause of mortality in individuals with neuroﬁ bromatosis type 1.9 Some ﬁ ndings suggest that survival is beginning to increase, particularly in women; however, this rise might be attributable to heightened recognition and identiﬁ cation of malignant peripheral nerve sheath tumours at an earlier stage.75 Although radiation therapy could delay time to recurrence, this treatment does not change time to death.67,76 Use of adjuvant chemotherapy is controversial.77,78 In some instances, chemotherapy can be used in the neoadjuvant setting to downstage tumours before resection; however, this practice has not been adopted widely.67 Clinical studies of promising chemotherapy drugs are underway in individuals with neuroﬁ bromatosis type 1-associated malignant peripheral nerve sheath tumours. In patients with metastatic disease, single-agent anthracycline is the most accepted form of palliative care.67,79www.thelancet.com/neurology   Vol 13   August 2014 839ReviewNon-nervous-system tumoursGastrointestinal stromal tumours  Gastrointestinal stromal tumours are of mesenchymal origin and can develop anywhere along the gastro-intestinal tract. Compared with the general population, individuals with neuroﬁ bromatosis type 1 are slightly younger at presentation (median age 50 years vs 60 years)80,81 and about 95% are asymptomatic. Moreover, patients with neuroﬁ bromatosis type 1 and gastro-intestinal stromal tumours more frequently present with multiple tumours compared with the general popu lation.82 The most common symptoms reported are abdominal pain, bleeding, intestinal perforation, and intestinal obstruction.66,83 Gastrointestinal stro mal tumours can be an incidental ﬁ nding during imaging studies, might be spotted during surgery to remove another tumour, or could be diagnosed from presenting symptoms.In the general population, gastrointestinal stromal tumours are associated with increased expression of the KIT and PDGFRA transmembrane receptors. Activation of these receptor tyrosine kinases drives proliferation, providing the scientiﬁ c basis for treatment with imatinib.80,84 By contrast, in patients with neuro ﬁ bro-matosis type 1, gastrointestinal stromal tumours typically do not overexpress KIT or PDGFRA,85 which limits the use of imatinib in this population.86,87 Currently, the only treatment option for neuro ﬁ bromatosis type 1-associated gastro intestinal stromal tumours is surgery, if feasible. Clinical trials of other tyrosine kinase receptor inhibitors (eg, sunitinib) are ongoing in patients with metastatic disease.88Breast cancers  A ﬁ vefold increased risk for breast cancer has been reported in individuals with neuroﬁ bromatosis type 1, mainly aﬀ ecting women younger than 50 years.8,13,89,90 Furthermore, mortality rates in women with neuro-ﬁ bromatosis type 1 and breast cancer are higher than those for women with breast cancer in the general population.91 Although reported studies include only a few patients, relative risks are similar to those for people with a family history of breast cancer. Women age 30–49 years with neuroﬁ bromatosis type 1 could undergo early mammography or MRI;92 however, large prospective studies are needed before formal recom-mendations can be made about screening in this population. Currently, treatment for neuroﬁ bromatosis type 1-associated breast cancer does not diﬀ er from that for women with breast cancer in the general population.Leukaemia and lymphoma  Children with neuroﬁ bromatosis type 1 have at least a sevenfold higher risk for developing myeloid leukaemia compared with children in the general population,93 and the prevalence of chronic myelomonocytic leukaemia, juvenile chronic myelogenous leukaemia, acute lympho-cytic leukaemia, and non-Hodgkin lymphoma is also raised.94,95 However, these tumours are rare in people with neuroﬁ bromatosis type 1. Moreover, no evidence is available to support a diﬀ erence in prognosis between neuroﬁ bromatosis type 1-associated leukaemia and lymphoma relative to the general population. Treatments for neuroﬁ bromatosis type 1-associated leukaemia parallel those used for individuals without neuro-ﬁ bromatosis type 1.95Phaeochromocytoma  Phaeochromocytomas—catecholamine-secreting tumours of the adrenal medulla or other sites in the sympathetic nervous system—are seen at increased frequency in individuals with neuroﬁ bromatosis type 1. These tumours arise in 0·1–5·7% of people with neuroﬁ bromatosis type 1 compared with 0·002–0·008% of the general population. The age of onset (typically the fourth decade of life) is similar in neuroﬁ bromatosis type 1-associated and sporadic cases.12,96 Phaeochromocytomas should be sus-pected in an individual with neuroﬁ bromatosis type 1 who presents with unexplained hypertension, ﬂ ushing, Figure 5: Malignant peripheral nerve-sheath tumours¹⁸F-FDG-PET images showing malignant peripheral nerve-sheath tumours (asterisks) in (A) a 24-year-old woman and (B) a 29-year-old man, both with neuroﬁ bromatosis type 1. FDG=ﬂ uorodeoxyglucose.BA**840 www.thelancet.com/neurology   Vol 13   August 2014Reviewheadaches, sweating, or heart palpitations. Diagnosis is established typically with a combination of imaging studies (CT or MRI of the chest and abdomen or a meta-iodobenzyl -guanidine scan or somatostatin scinti-graphy if CT is negative) and biochemical assessments (eg, the amount of catecholamines in urine).97 Surgery is curative for resectable disease,98 whereas chemotherapy or radio pharmaceutical treatment with ¹³¹I-meta-iodobenzyl-guanidine is used for metastatic or unresectable cancers.99,100Duodenal carcinoids  Carcinoid tumours are neuroendocrine tumours that arise from endocrine cells within the gastrointestinal tract; they are reported in about 1% of individuals with neuro-ﬁ bromatosis type 1.7,101 The most common site for carcinoid tumours is the periampullary region;4,66 therefore, indivi-duals usually present with jaundice and non-speciﬁ c abdominal pain. In patients with neuroﬁ bromatosis type 1, these tumours generally present at a young age.101,102 The diagnosis of carcinoid tumours is typically made with a combination of imaging studies—eg, CT of the chest, abdomen, and pelvis, somatostatin scintigraphy, and endoscopic ultrasound or endoscopy—and measure ment of urinary and serum 5-hydroxyindolectic acid and chroma-granin A, when clinically appropriate.101 Surgical resection should be done if possible; unresectable and metastatic disease is treated generally with somatostatin analogues or chemotherapy.101,103Rhabdomyosarcomas  Rhabdomyosarcomas are non-neurogenic sarcomas composed of small round blue cells that probably originate from the neural crest.66 Children with neuro-ﬁ bromatosis type 1 have about a 20-fold increased risk of developing these tumours.11 Rhabdomyosarcomas most commonly present as palpable masses. Manage ment relies on surgical resection when feasible, whereas adjuvant chemotherapy and radiation therapy might be appropriate for some individuals.104,105Conclusions and future directionsOver the past 15 years, substantial advances have been made in our ability to discover, validate, and translate laboratory-based research ﬁ ndings to the clinical work-place. Many accurate preclinical models of neuro-ﬁ bromatosis type 1-associated malignant disease in genetically engineered mice have been developed and used as platforms to evaluate rational targeted treatments. 106–114 Although these models have some limitations, they have already proven useful in the design and implementation of human clinical trials. After identiﬁ cation of NF1 as a negative Ras regulator,115–117 ﬁ ndings of several preclinical studies in Nf1-deﬁ cient mice have shown that inhibition of down stream targets of Ras attenuates Nf1-deﬁ cient tumour cell growth in vitro and in vivo. For example, in studies of genetically engineered Nf1 mice, rapamycin analogues (eg, everolimus) and MEK inhibitors were eﬀ ec tive biologi cally targeted treatments for neuroﬁ bro ma tosis type 1-associated plexiform neuro ﬁ broma,118,119 and rapamycin analogues and chemokine recep tor inhibitors were assessed for neuroﬁ bromatosis type 1-associated glioma and malignant peripheral nerve sheath tumours.120–123Models of optic pathway glioma109,124 and plexiform neuroﬁ broma108 in genetically engineered Nf1 mice showed that non-cancerous stromal cells (tumour microenvironment) have important roles in tumour development and growth. Loss of Nf1 in Schwann cell and astroglial cell precursors alone was not suﬃ  cient for tumorigenesis; loss of Nf1 expression in Schwann cell or astroglial cell precursors must occur in Nf1+/− mice (genetically comparable with individuals with neuro-ﬁ bromatosis type 1) for neuroﬁ bromas and optic gliomas, respectively, to form.108,109,124 Further investigation of participatory stromal cell types in models of optic pathway gliomas and plexiform neuroﬁ bromas in genetically engineered Nf1  mice indicates an obligatory role for microglia and mast cells, respectively, in the genesis and maintenance of these tumours.125–127 The ﬁ nding that mast cells are important micro-environmental drivers of plexiform neuroﬁ broma growth culminated in use of imatinib to inhibit c-kit function in preclinical studies in Nf1 mice and the translation of these results to human clinical trials.32Although studies of these genetically engineered Nf1 mice hold substantial promise, future studies need to report clearly positive ﬁ ndings to facilitate eﬀ ective translation to human clinical trials. Thus, preclinical response criteria should incorporate the proportion of mice with signiﬁ cant radiographic responses, the durability of these outcomes, and the extent of tumour shrinkage. Pharmacokinetic and pharmacodynamic considerations will also need to be integrated into these criteria to ensure a high likelihood of success in patients.With the establishment of the Neuroﬁ bromatosis Clinical Trials Consortium (NFCTC),128 therapeutic trials in large numbers of individuals with neuroﬁ bromatosis type 1-associated malignant disease can now be under-taken eﬃ  ciently. Up to now, the NFCTC has initiated several clinical trials, including studies of sorafenib for neuroﬁ bromatosis type 1-associated plexiform neuro-ﬁ bromas (NCT00727233), bevacizumab and everolimus for malignant peripheral nerve sheath tumours (NCT01661283), everolimus for progressive neuro-ﬁ bromatosis type 1-associated glioma (NCT01158651), Search strategy and selection criteriaWe searched PubMed between January, 1970, and March, 2014, with the terms: “NF1”, “skin”, “bone”, “cardiovascular”, “neurocognitive”, “plexiform”, “malignancy”, “optic pathway glioma”, “GBM”, “MPNST”, “breast cancer”, “leukemia”, “GIST”, “pheochromocytoma”, “duodenal carcinoids”, and “rhabdomyosarcoma”. We also chose references from selected articles. We did not restrict our search by language.www.thelancet.com/neurology   Vol 13   August 2014 841ReviewMEK inhibitors for children with inoperable neuro-ﬁ bromatosis type 1-associated plexiform neuro ﬁ bromas (NCT01362803), and MEK inhibitors for patients with tumours activated by RAS, RAF, or MEK, including those with mutations in the NF1 gene (NCT01885195).Tumours that develop in patients with neuro ﬁ bromatosis type 1 are heterogeneous from a molecular and cellular perspective and, therefore, represent complex cancers in which distinct cell types and growth-control pathways regulate tumour behaviour. With availability of accurate preclinical mouse models for most tumour types in neuroﬁ bromatosis type 1, a detailed understanding of neuroﬁ bromin-controlled signalling pathways, and avail-ability of a clinical trials infrastructure for rapid drug evaluation, we can now envision a future in which eﬀ ective treatments for people with neuroﬁ bromatosis type 1-associated tumours are imminent.ContributorsACH wrote the manuscript and prepared the ﬁ gures. DHG edited the manuscript.Declaration of interestsWe declare no competing interests.References1 Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neuroﬁ bromatosis 1 in German children at elementary school enrollment. Arch Dermatol 2005; 141: 71–74.2 Huson SM, Harper PS, Compston DA. Von Recklinghausen neuroﬁ bromatosis: a clinical and population study in south-east Wales. Brain 1988; 111: 1355–81.3 Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neuroﬁ bromatosis type 1 revisited. Pediatrics 2009; 123: 124–33.4 Brems H, Beert E, de Ravel T, Legius E. Mechanisms in the pathogenesis of malignant tumours in neuroﬁ bromatosis type 1. Lancet Oncol 2009; 10: 508–15.5 Crouse NR, Dahiya S, Gutmann DH. Rethinking pediatric gliomas as developmental brain abnormalities. Curr Top Dev Biol 2011; 94: 283–308.6 Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors: a clinicopathologic study of 120 cases. Cancer 1986; 57: 2006–21.7 Dayal Y, Tallberg KA, Nunnemacher G, DeLellis RA, Wolfe HJ. Duodenal carcinoids in patients with and without neuroﬁ bromatosis: a comparative study. Am J Surg Pathol 1986; 10: 348–57.8 Madanikia SA, Bergner A, Ye X, Blakeley JO. Increased risk of breast cancer in women with NF1. Am J Med Genet A 2012; 158A: 3056–60.9 Rasmussen SA, Yang Q, Friedman JM. Mortality in neuroﬁ bromatosis 1: an analysis using US death certiﬁ cates. Am J Hum Genet 2001; 68: 1110–18.10 Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neuroﬁ bromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006; 24: 2570–75.11 Sung L, Anderson JR, Arndt C, Raney RB, Meyer WH, Pappo AS. Neuroﬁ bromatosis in children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. J Pediatr 2004; 144: 666–68.12 Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. von Recklinghausen’s disease and pheochromocytomas. J Urol 1999; 162: 1582–86.13 Wang X, Levin AM, Smolinski SE, Vigneau FD, Levin NK, Tainsky MA. Breast cancer and other neoplasms in women with neuroﬁ bromatosis type 1: a retrospective review of cases in the Detroit metropolitan area. Am J Med Genet A 2012; 158A: 3061–64.14 Anon. National Institutes of Health Consensus Development Conference Statement: neuroﬁ bromatosis—Bethesda, MD, USA, July 13–15, 1987. Neuroﬁ bromatosis 1988; 1: 172–78. 15 Gutmann DH, Parada LF, Silva AJ, Ratner N. Neuroﬁ bromatosis type 1: modeling CNS dysfunction. J Neurosci 2012; 32: 14087–93.16 Ruggieri M, Packer RJ. Why do benign astrocytomas become malignant in NF1? Neurology 2001; 56: 827–29.17 Gutmann DH, McLellan MD, Hussain I, et al. Somatic neuroﬁ bromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res 2013; 23: 431–39.18 Kayes LM, Burke W, Riccardi VM, et al. Deletions spanning the neuroﬁ bromatosis 1 gene: identiﬁ cation and phenotype of ﬁ ve patients. Am J Hum Genet 1994; 54: 424–36.19 Cnossen MH, van der Est MN, Breuning MH, et al. Deletions spanning the neuroﬁ bromatosis type 1 gene: implications for genotype-phenotype correlations in neuroﬁ bromatosis type 1? Hum Mutat 1997; 9: 458–64.20 Leppig KA, Kaplan P, Viskochil D, Weaver M, Ortenberg J, Stephens K. Familial neuroﬁ bromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neuroﬁ bromata. Am J Med Genet 1997; 73: 197–204.21 De Raedt T, Brems H, Wolkenstein P, et al. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet 2003; 72: 1288–92.22 Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neuroﬁ bromatosis 1. J Med Genet 2007; 44: 81–88.23 Friedman JM. Neuroﬁ bromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol 2002; 17: 548–54.24 Wu M, Wallace MR, Muir D. Tumorigenic properties of neuroﬁ bromin-deﬁ cient Schwann cells in culture and as syngrafts in Nf1 knockout mice. J Neurosci Res 2005; 82: 357–67.25 Rutkowski JL, Wu K, Gutmann DH, Boyer PJ, Legius E. Genetic and cellular defects contributing to benign tumor formation in neuroﬁ bromatosis type 1. Hum Mol Genet 2000; 9: 1059–66.26 Le LQ, Parada LF. Tumor microenvironment and neuroﬁ bromatosis type I: connecting the GAPs. Oncogene 2007; 26: 4609–16.27 Munchhof AM, Li F, White HA, et al. Neuroﬁ broma-associated growth factors activate a distinct signaling network to alter the function of neuroﬁ bromin-deﬁ cient endothelial cells. Hum Mol Genet 2006; 15: 1858–69.28 Yang FC, Ingram DA, Chen S, et al. Neuroﬁ bromin-deﬁ cient Schwann cells secrete a potent migratory stimulus for Nf1+/– mast cells. J Clin Invest 2003; 112: 1851–61.29 Yang FC, Ingram DA, Chen S, et al. Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell 2008; 135: 437–48.30 Nguyen R, Kluwe L, Fuensterer C, Kentsch M, Friedrich RE, Mautner VF. Plexiform neuroﬁ bromas in children with neuroﬁ bromatosis type 1: frequency and associated clinical deﬁ cits. J Pediatr 2011; 159: 652–55.e2.31 Jakacki RI, Dombi E, Potter DM, et al. Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neuroﬁ bromas. Neurology 2011; 76: 265–72.32 Robertson KA, Nalepa G, Yang F-C, et al. Imatinib mesylate for plexiform neuroﬁ bromas in patients with neuroﬁ bromatosis type 1: a phase 2 trial. Lancet Oncol 2012; 13: 1218–24.33 Tucker T, Schnabel C, Hartmann M, et al. Bone health and fracture rate in individuals with neuroﬁ bromatosis 1 (NF1). J Med Genet 2009; 46: 259–65.34 Heervä E, Koﬀ ert A, Jokinen E, et al. A controlled register-based study of 460 neuroﬁ bromatosis 1 patients: increased fracture risk in children and adults over 41 years of age. J Bone Miner Res 2012; 27: 2333–37.35 Brunetti-Pierri N, Doty SB, Hicks J, et al. Generalized metabolic bone disease in neuroﬁ bromatosis type I. Mol Genet Metab 2008; 94: 105–11.36 Heervä E, Huilaja L, Leinonen P, Peltonen S, Peltonen J. Follow-up of six patients with neuroﬁ bromatosis 1-related osteoporosis treated with alendronate for 23 months. Calcif Tissue Int 2014; published online Jan 4. DOI:10.1007/s00223-013-9835-2.37 Petramala L, Giustini S, Zinnamosca L, et al. Bone mineral metabolism in patients with neuroﬁ bromatosis type 1 (von Recklingausen disease). Arch Dermatol Res 2012; 304: 325–31.38 Stevenson DA, Moyer-Mileur LJ, Murray M, et al. Bone mineral density in children and adolescents with neuroﬁ bromatosis type 1. J Pediatr 2007; 150: 83–88.842 www.thelancet.com/neurology   Vol 13   August 2014Review39 Schnabel C, Jett K, Friedman JM, Frieling I, Kruse HP, Mautner V. Eﬀ ect of vitamin D3 treatment on bone density in neuroﬁ bromatosis 1 patients: a retrospective clinical study. Joint Bone Spine 2013; 80: 315–19.40 Akbarnia BA, Gabriel KR, Beckman E, Chalk D. Prevalence of scoliosis in neuroﬁ bromatosis. Spine 1992; 17 (suppl): S244–48.41 White KK, Song KM, Frost N, Daines BK. VEPTR™ growing rods for early-onset neuromuscular scoliosis: feasible and eﬀ ective. Clin Orthop Relat Res 2011; 469: 1335–41.42 Arrington DK, Danehy AR, Peleggi A, Proctor MR, Irons MB, Ullrich NJ. Calvarial defects and skeletal dysplasia in patients with neuroﬁ bromatosis type 1. J Neurosurg Pediatr 2013; 11: 410–16.43 Alwan S, Armstrong L, Joe H, Birch PH, Szudek J, Friedman JM. Associations of osseous abnormalities in neuroﬁ bromatosis 1. Am J Med Genet A 2007; 143A: 1326–33. 44 Tedesco MA, Di Salvo G, Natale F, et al. The heart in neuroﬁ bromatosis type 1: an echocardiographic study. Am Heart J 2002; 143: 883–88.45 Lin AE, Birch PH, Korf BR, et al. Cardiovascular malformations and other cardiovascular abnormalities in neuroﬁ bromatosis 1. Am J Med Genet 2000; 95: 108–17.46 Friedman JM, Arbiser J, Epstein JA, et al. Cardiovascular disease in neuroﬁ bromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 2002; 4: 105–11.47 Oderich GS, Sullivan TM, Bower TC, et al. Vascular abnormalities in patients with neuroﬁ bromatosis syndrome type I: clinical spectrum, management, and results. J Vasc Surg 2007; 46: 475–84.48 Li F, Downing BD, Smiley LC, et al. Neuroﬁ bromin deﬁ cient myeloid cells are critical mediators of aneurysm formation in vivo. Circulation 2014; 129: 1213–24.49 Bajaj A, Li QF, Zheng Q, Pumiglia K. Loss of NF1 expression in human endothelial cells promotes autonomous proliferation and altered vascular morphogenesis. PLoS One 2012; 7: e49222.50 Rosser TL, Vezina G, Packer RJ. Cerebrovascular abnormalities in a population of children with neuroﬁ bromatosis type 1. Neurology 2005; 64: 553–55.51 Rea D, Brandsema JF, Armstrong D, et al. Cerebral arteriopathy in children with neuroﬁ bromatosis type 1. Pediatrics 2009; 124: e476–83.52 Hyman SL, Shores A, North KN. The nature and frequency of cognitive deﬁ cits in children with neuroﬁ bromatosis type 1. Neurology 2005; 65: 1037–44.53 Acosta MT, Gioia GA, Silva AJ. Neuroﬁ bromatosis type 1: new insights into neurocognitive issues. Curr Neurol Neurosci Rep 2006; 6: 136–43.54 Acosta MT, Kardel PG, Walsh KS, Rosenbaum KN, Gioia GA, Packer RJ. Lovastatin as treatment for neurocognitive deﬁ cits in neuroﬁ bromatosis type 1: phase I study. Pediatr Neurol 2011; 45: 241–45.55 Albers AC, Gutmann DH. Gliomas in patients with neuroﬁ bromatosis type 1. Expert Rev Neurother 2009; 9: 535–39.56 Leonard JR, Perry A, Rubin JB, King AA, Chicoine MR, Gutmann DH. The role of surgical biopsy in the diagnosis of glioma in individuals with neuroﬁ bromatosis-1. Neurology 2006; 67: 1509–12.57 King A, Listernick R, Charrow J, Piersall L, Gutmann DH. Optic pathway gliomas in neuroﬁ bromatosis type 1: the eﬀ ect of presenting symptoms on outcome. Am J Med Genet A 2003; 122A: 95–99.58 Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neuroﬁ bromatosis-1: controversies and recommendations. Ann Neurol 2007; 61: 189–98.59 Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997; 86: 747–54.60 Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol 2012; 30: 2641–47.61 Oh KS, Hung J, Robertson PL, et al. Outcomes of multidisciplinary management in pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys 2011; 81: e481–88.62 Hakan T, Aker FV. Case report on a patient with neuroﬁ bromatosis type 1 and a frontal cystic glioblastoma. Neurol Neurochir Pol 2008; 42: 362–65.63 Gutmann DH, Rasmussen SA, Wolkenstein P, et al. Gliomas presenting after age 10 in individuals with neuroﬁ bromatosis type 1 (NF1). Neurology 2002; 59: 759–61.64 Broekman ML, Risselada R, Engelen-Lee J, Spliet WG, Verweij BH. Glioblastoma multiforme in the posterior cranial fossa in a patient with neuroﬁ bromatosis type I. Case Rep Med 2009; 2009: 757898.65 Huttner AJ, Kieran MW, Yao X, et al. Clinicopathologic study of glioblastoma in children with neuroﬁ bromatosis type 1. Pediatr Blood Cancer 2010; 54: 890–96.66 Patil S, Chamberlain RS. Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist 2012; 17: 101–16.67 Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neuroﬁ bromatosis. Cancer Res 2002; 62: 1573–77.68 Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neuroﬁ bromatosis 1. J Med Genet 2002; 39: 311–14.69 Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 2005; 65: 205–11.70 Ferner RE, Golding JF, Smith M, et al. [18F]2-ﬂ uoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neuroﬁ bromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 2008; 19: 390–94.71 Derlin T, Tornquist K, Münster S, et al. Comparative eﬀ ectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neuroﬁ bromatosis type 1. Clin Nucl Med 2013; 38: e19–25.72 Benz MR, Herrmann K, Walter F, et al. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med 2011; 52: 1684–89.73 Dunn GP, Spiliopoulos K, Plotkin SR, et al. Role of resection of malignant peripheral nerve sheath tumors in patients with neuroﬁ bromatosis type 1. J Neurosurg 2013; 118: 142–48.74 Sordillo PP, Helson L, Hajdu SI, et al. Malignant schwannoma: clinical characteristics, survival, and response to therapy. Cancer 1981; 47: 2503–09.75 Ingham S, Huson SM, Moran A, Wylie J, Leahy M, Evans DG. Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years. Eur J Cancer 2011; 47: 2723–28.76 Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol 2005; 23: 8422–30.77 Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001; 19: 1238–47.78 Sarcoma Meta-analysis Collaboration (SMAC). Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Cochrane Database Syst Rev 2000; 4: CD001419.79 Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol 2011; 22: 207–14.80 Miettinen M, Kopczynski J, Makhlouf HR, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 2003; 27: 625–41.81 Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neuroﬁ bromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006; 30: 90–96.82 Maertens O, Prenen H, Debiec-Rychter M, et al. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet 2006; 15: 1015–23.83 Basile U, Cavallaro G, Polistena A, et al. Gastrointestinal and retroperitoneal manifestations of type 1 neuroﬁ bromatosis. J Gastrointest Surg 2010; 14: 186–94.www.thelancet.com/neurology   Vol 13   August 2014 843Review84 Blay JY, Bonvalot S, Casali P, et al, and the GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566–78.85 Kinoshita K, Hirota S, Isozaki K, et al. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neuroﬁ bromatosis type 1 patients. J Pathol 2004; 202: 80–85.86 Lee JL, Kim JY, Ryu MH, et al. Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neuroﬁ bromatosis type 1. Dig Dis Sci 2006; 51: 1043–46.87 Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients aﬀ ected by neuroﬁ bromatosis type 1. Clin Cancer Res 2008; 14: 4550–55.88 Kalender M, Sevinc A, Tutar E, Sirikci A, Camci C. Eﬀ ect of sunitinib on metastatic gastrointestinal stromal tumor in patients with neuroﬁ bromatosis type 1: a case report. World J Gastroenterol 2007; 13: 2629–32.89 Sharif S, Moran A, Huson SM, et al. Women with neuroﬁ bromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 2007; 44: 481–84.90 Nakamura M, Tangoku A, Kusanagi H, Oka M, Suzuki T. Breast cancer associated with Recklinghausen’s disease: report of a case. Nihon Geka Hokan 1998; 67: 3–9.91 Evans DG, O’Hara C, Wilding A, et al. Mortality in neuroﬁ bromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet 2011; 19: 1187–91.92 Evans DG. Are we ready for targeted early breast cancer detection strategies in women with NF1 aged 30-49 years? Am J Med Genet A 2012; 158A: 3054–55.93 Shannon KM, O’Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neuroﬁ bromatosis and malignant myeloid disorders. N Engl J Med 1994; 330: 597–601.94 Seminog OO, Goldacre MJ. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neuroﬁ bromatosis: population-based record-linkage study. Br J Cancer 2013; 108: 193–98.95 Stiller CA, Chessells JM, Fitchett M. Neuroﬁ bromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 1994; 70: 969–72.96 Walther MM, Keiser HR, Linehan WM. Pheochromocytoma: evaluation, diagnosis, and treatment. World J Urol 1999; 17: 35–39.97 Nguyen-Martin MA, Hammer GD. Pheochromocytoma: an update on risk groups, diagnosis, and management. Hosp Physician 2006; 42: 17–24.98 Manger WM, Eisenhofer G. Pheochromocytoma: diagnosis and management update. Curr Hypertens Rep 2004; 6: 477–84.99 Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 2008; 113: 2020–28.100 Grünwald F, Ezziddin S. ¹³¹I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 2010; 40: 153–63.101 Robertson RG, Geiger WJ, Davis NB. Carcinoid tumors. Am Fam Physician 2006; 74: 429–34.102 Relles D, Baek J, Witkiewicz A, Yeo CJ. Periampullary and duodenal neoplasms in neuroﬁ bromatosis type 1: two cases and an updated 20-year review of the literature yielding 76 cases. J Gastrointest Surg 2010; 14: 1052–61.103 Bettini R, Falconi M, Crippa S, Capelli P, Boninsegna L, Pederzoli P. Ampullary somatostatinomas and jejunal gastrointestinal stromal tumor in a patient with von Recklinghausen’s disease. World J Gastroenterol 2007; 13: 2761–63.104 Stevens MC, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology—SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005; 23: 2618–28.105 Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study IV: results for patients with nonmetastatic disease. J Clin Oncol 2001; 19: 3091–102.106 Mayes DA, Rizvi TA, Cancelas JA, et al. Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neuroﬁ broma formation. Cancer Res 2011; 71: 4675–85.107 Wu J, Williams JP, Rizvi TA, et al. Plexiform and dermal neuroﬁ bromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 2008; 13: 105–16.108 Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neuroﬁ bromas in NF1: Schwann cell origin and role of tumor environment. Science 2002; 296: 920–22.109 Bajenaru ML, Hernandez MR, Perry A, et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 2003; 63: 8573–77.110 Zhu Y, Harada T, Liu L, et al. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development 2005; 132: 5577–88.111 Dasgupta B, Li W, Perry A, Gutmann DH. Glioma formation in neuroﬁ bromatosis 1 reﬂ ects preferential activation of K-RAS in astrocytes. Cancer Res 2005; 65: 236–45.112 Cichowski K, Shih TS, Schmitt E, et al. Mouse models of tumor development in neuroﬁ bromatosis type 1. Science 1999; 286: 2172–76.113 Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF. Mouse tumor model for neuroﬁ bromatosis type 1. Science 1999; 286: 2176–79.114 Le DT, Kong N, Zhu Y, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 2004; 103: 4243–50.115 Ballester R, Michaeli T, Ferguson K, Xu HP, McCormick F, Wigler M. Genetic analysis of mammalian GAP expressed in yeast. Cell 1989; 59: 681–86.116 Martin GA, Viskochil D, Bollag G, et al. The GAP-related domain of the neuroﬁ bromatosis type 1 gene product interacts with ras p21. Cell 1990; 63: 843–49.117 Xu GF, Lin B, Tanaka K, et al. The catalytic domain of the neuroﬁ bromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 1990; 63: 835–41.118 Jessen WJ, Miller SJ, Jousma E, et al. MEK inhibition exhibits eﬃ  cacy in human and mouse neuroﬁ bromatosis tumors. J Clin Invest 2013; 123: 340–47.119 Wu J, Dombi E, Jousma E, et al. Preclincial testing of sorafenib and RAD001 in the Nf(ﬂ ox/ﬂ ox);DhhCre mouse model of plexiform neuroﬁ broma using magnetic resonance imaging. Pediatr Blood Cancer 2012; 58: 173–80.120 Hegedus B, Banerjee D, Yeh TH, et al. Preclinical cancer therapy in a mouse model of neuroﬁ bromatosis-1 optic glioma. Cancer Res 2008; 68: 1520–28.121 Mo W, Chen J, Patel A, et al. CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell 2013; 152: 1077–90.122 Johannessen CM, Johnson BW, Williams SM, et al. TORC1 is essential for NF1-associated malignancies. Curr Biol 2008; 18: 56–62.123 Warrington NM, Gianino SM, Jackson E, et al. Cyclic AMP suppression is suﬃ  cient to induce gliomagenesis in a mouse model of neuroﬁ bromatosis-1. Cancer Res 2010; 70: 5717–27.124 Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH. Astrocyte-speciﬁ c inactivation of the neuroﬁ bromatosis 1 gene (NF1) is insuﬃ  cient for astrocytoma formation. Mol Cell Biol 2002; 22: 5100–13.125 Daginakatte GC, Gutmann DH. Neuroﬁ bromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deﬁ cient astrocyte and glioma growth. Hum Mol Genet 2007; 16: 1098–112.126 Daginakatte GC, Gianino SM, Zhao NW, Parsadanian AS, Gutmann DH. Increased c-Jun-NH2-kinase signaling in neuroﬁ bromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res 2008; 68: 10358–66.127 Riccardi VM. Cutaneous manifestation of neuroﬁ bromatosis: cellular interaction, pigmentation, and mast cells. Birth Defects Orig Artic Ser 1981; 17: 129–45.128 Gutmann DH, Blakeley JO, Korf BR, Packer RJ. Optimizing biologically targeted clinical trials for neuroﬁ bromatosis. Expert Opin Investig Drugs 2013; 22: 443–62.Role of Merlin/NF2 Inactivation in Tumor BiologyAlejandra M. Petrilli, Ph.D.1 and Cristina Fernández-Valle, Ph.D.11Department of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USAAbstractMerlin ((Moesin-ezrin-radixin-like protein, also known as schwannomin) is a tumor suppressor protein encoded by the neurofibromatosis type 2 gene NF2. Loss of function mutations or deletions in NF2 cause Neurofibromatosis type 2 (NF2), a multiple tumor forming disease of the nervous system. NF2 is characterized by the development of bilateral vestibular schwannomas. Patients with NF2 can also develop schwannomas on other cranial and peripheral nerves, as well as meningiomas and ependymomas. The only potential treatment is surgery/radiosurgery which often results in loss of function of the involved nerve. There is an urgent need for chemotherapies that slow or eliminate tumors and prevent their formation in NF2 patients. Interestingly NF2 mutations and merlin inactivation also occur in spontaneous schwannomas and meningiomas, as well as other types of cancer including mesothelioma, glioma multiforme, breast, colorectal, skin, clear cell renal cell carcinoma, hepatic and prostate cancer. Except for malignant mesotheliomas, the role of NF2 mutation or inactivation has not received much attention in cancer, and NF2 might be relevant for prognosis and future chemotherapeutic approaches.This review discusses the influence of merlin loss of function in NF2-related tumors and common human cancers. We additionally discuss the NF2 gene status and merlin signaling pathways affected in the different tumor types and the molecular mechanisms that lead to tumorigenesis, progression and pharmacological resistance.Keywordsmerlin; NF2; schwannoma; tumorigenesis; tumor progression; cancerINTRODUCTIONMerlin is the protein encoded by the tumor suppressor gene, NF2, located on chromosome 22q12. Deletion or loss-of-function mutation of NF2 causes Neurofibromatosis type 2 (NF2), a nervous system tumor-forming disease (1–3). The incidence of NF2 is 1 in 25,000 and it is dominantly inherited, although in 50% to 60% of cases it is caused by de novo Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#termsCorresponding author: Cristina Fernández-Valle, Ph.D., Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, 6900 Lake Nona Blvd., Orlando, FL 32827, U.S.A., ; Email: cfv@ucf.edu, Phone: 407-266-7033, fax: 407-266-7002 CONFLICT OF INTERESTThe authors declare no conflicts of interest.HHS Public AccessAuthor manuscriptOncogene. Author manuscript; available in PMC 2016 May 18.Published in final edited form as:Oncogene. 2016 February 4; 35(5): 537–548. doi:10.1038/onc.2015.125.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptmutations with high frequency of somatic mosaicism (1, 4). NF2 is characterized by formation of bilateral vestibular schwannomas. In addition, patients commonly develop multiple schwannomas on other cranial and peripheral nerves, on spinal nerve roots and as intracutaneous plaques, as well as meningiomas and ependymomas. Schwannomas originate from Schwann cells, while meningiomas originate from cells of the arachnoid layer of the leptomeninges that line the brain and spinal cord (5). NF2 patients may also present ependymomas found mostly in the spinal cord. Intramedullary ependymomas arise from ependymal cells that line the central canal of the spinal cord (6, 7). NF2 patients can eventually develop peripheral neuropathy (1, 4, 8). Electrophysiological studies found that 66% of NF2 patients presented neuropathy, mostly of axonal type (9). In many cases, the neuropathy results from compression produced by the tumor, however, non-tumor-related peripheral neuropathy may be caused by the deleterious effect of merlin loss in neurons (4, 10, 11). Interestingly, schwannomas and meningiomas also develop in non-NF2 patients and commonly exhibit NF2 somatic mutations, epigenetic changes or protein inactivation. Notably, NF2 mutations are present in several malignant cancers including mesotheliomas, breast, prostate, colorectal, hepatic, clear cell renal cell carcinoma, and melanomas.The first symptoms of NF2 usually appear in the late teens or early twenties and include hearing loss with or without tinnitus and dizziness or imbalance caused by the vestibular schwannomas (mostly unilateral at the beginning) that ultimately lead to deafness (1, 4). Other NF2 symptoms depend on the nerve or structure affected by the tumors. Despite the benign nature of schwannomas, their morbidity is based on their location and size and the only currently available treatment is surgical resection. Surgical outcomes, however, are poor because nerve function cannot always be salvaged and some tumors are inoperable due to location. Stereotactic radiosurgery has been explored, but remains controversial because of the potential for subsequent radiation-induced malignant transformation. Thus, the current standard of care, while the subject of continuing debate, consists of initial monitoring followed by surgical schwannoma resection when rapid tumor growth is identified or becomes life threatening (4). Meningiomas, the second most frequent tumors in NF2 patients, are 45–58% intracranial and 20% intradural extramedullary spinal tumors. Similar to schwannomas, associated symptoms relate to tumor location and include headaches (most common) and seizures. On the optic nerve and lower cranial nerves, very small meningiomas may produce compression symptoms and loss of visual acuity (8). Overall, the presence of intracranial meningiomas is associated with poor prognosis and increases the relative risk of mortality (12). The surgical removal of intracranial and spinal meningiomas can be achieved in most cases depending on the anatomical location (4). In line with schwannomas and meningiomas, the recommended treatment for ependymomas is observation while asymptomatic, and maximum surgical resection if symptoms develop or rapid growth is identified. Only for anaplastic ependymomas, rare in NF2, is postoperative adjuvant radiation considered (7, 13).Identification of NF2 as a member of the Band 4.1 FERM gene family predicted a mechanism of action for merlin’s tumor suppressor function (2, 3). FERM domain proteins link plasma membrane receptors to the cortical actin cytoskeleton (3). Merlin shares 64% sequence similarity with family members in the conserved FERM (4.1, ezrin, radixin, moesin) domain at the N-terminus. The FERM domain is followed by an α-helical domain Petrilli and Fernández-VallePage 2Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptand a C-terminal domain (Figure 1a). In contrast to the other ERM proteins, merlin lacks the actin-binding site located in the C-terminal domain, instead it has a unique actin binding motif in the N-terminal domain (14). ERM proteins including merlin form head-to-tail homo- and hetero-dimeric intermolecular, and intramolecular associations. Although merlin’s intramolecular association is more dynamic and weaker compared to other ERMs, it is nonetheless critical for regulating its tumor suppressor activity (15, 16). Merlin can be regarded as a scaffold protein indirectly linking F-actin, transmembrane receptors and intracellular effectors to modulate receptor mediated signaling pathways controlling cell proliferation and survival. These include receptor tyrosine kinase (RTK), cell adhesion, small GTPases, mammalian target of rapamycin (mTOR), PI3K/Akt and hippo pathways (17). However, merlin’s tumor suppressor function is not restricted to regulating events at the plasma membrane. Unraveling the myriad of merlin interactions in relation to tumor suppression has proven to be a daunting task.Merlin’s conformation and activity is regulated by post-translational modifications. Merlin is phosphorylated at Ser10, Thr230 and Ser315 by Akt (also known as protein kinase B, PKB) and controls merlin’s proteasome-mediated degradation by ubiquitination to prevent its interaction with binding partners (18, 19). Merlin-Ser10 is also a substrate for cyclic AMP-dependent protein kinase, also known as protein kinase A (PKA); Ser10 phosphorylation modulates cell morphology by modifying the actin cytoskeleton (20). The most studied phosphorylation site is Ser518 located in the C-terminal. It is a substrate for both p-21 activated kinase (PAK) and PKA and inactivates merlin tumor suppressor activity (21–24). Conversely, myosin phosphatase MYPT1-PP1δ dephosphorylates Ser518 thereby activating its tumor suppressor function (25). Confusion regarding the relationship between activity and conformation for merlin stems from the initial assumption that merlin’s conformation-activity resembles the ERM proteins. Merlin, similar to ERMs is active as a scaffold protein at the plasma membrane where it is phosphorylated at Ser518 and by this means facilitates or promotes receptor mediated signaling events associated with cell proliferation and survival. Following the ERM model, phosphorylated merlin would adopt an open, active configuration at the plasma membrane. In this way, both merlin and ERMs are active as scaffolds in the open conformation (Figure 1b) (26, 27). Dephosphorylation at S518 and thus transition to a closed conformation inactivates its scaffold function but activates its tumor suppressor activity. The closed, head-to-tail conformation of the active tumor-suppressor was believed to be incapable of interaction with growth factor receptors (28–30). Recent results of fluorescence resonance energy transfer analysis of merlin conformational changes, characterization of a series of merlin variants with different degrees of head-to-tail association, and small-angle neutron scattering studies of full-length merlin, have suggested a new conformational model (31–33). The results indicate that in solution both unphosphorylated merlin and a phospho- mimetic, merlin S518D, adopt closed conformations; and both forms are capable of binding partner proteins. Furthermore, unphosphorylated merlin adopts a more open, but still closed, conformation upon binding phoshatidylinositol 4,5 biphosphate lipid whereas the merlinS518D phosphomimetic remains fully closed (31–33) (Figure 1c). The exact relationship between merlin’s conformation, binding partners and sub-cellular localization critical for tumor suppressor activity has yet to be fully understood.Petrilli and Fernández-VallePage 3Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptMerlin is essential for early embryogenesis as evidenced by the finding that mice embryos carrying homozygous Nf2 mutations failed to initiate gastrulation and generally died at E6.5–E7.0 (34). These embryos lacked extra-embryonic ectoderm and failed to form an identifiable mesodermal layer (34). Other conditional knock-out mouse models partially mimic the multifaceted human disease (35–38). Discrepancies between the models and human disease could be caused by several factors, acting individually or in combination, including differences in biological genome/proteome, physiological properties and lifespans; timing of loss of heterozygosity (LOH) or merlin inactivation; and single cell-type targeting for genetic manipulation when NF2 is active globally (39).Another area for further investigation that may reveal essential insights to merlin’s mechanism of action is the production of splice variants for merlin. Two major isoforms are produced by alternative splicing of 17 exons of the NF2 gene. Isoform 1 is the predominant and longest, consisting of 595 amino acids and lacking exon 16, while isoform 2 with 590 amino acids contains exon 16, but has a truncated C-terminal domain (40). A recent publication highlights the importance of Schwann cell-axon interactions in preventing schwannoma formation and the contribution of axonal expression of merlin isoform 2 (10, 11, 41).This review will discuss the contribution of merlin loss of function in NF2-related tumors and common human cancers and the molecular mechanisms that lead to tumorigenesis, tumor progression or pharmacological resistance.MERLIN IN SCHWANNOMAS, MENINGIOMAS AND EPENDYMOMASNF2/merlin statusNF2 mutations cause the development of schwannomas, meningiomas and ependymomas [for an in-depth review on NF2 mutations see ref (1)]. NF2-associated schwannomas exhibit NF2 inactivation and merlin expression is absent (42). Notably, merlin expression assessed by western blot was found to be highly reduced or absent in 11 of 14 sporadic schwannomas, 16 of 19 sporadic meningiomas and 3 of 8 sporadic ependymomas (43). Mutational NF2 inactivation and LOH is the cause of most NF2-associated schwannomas and sporadic schwannomas; however, transcriptional inactivation causes 15.3% of NF2-associated schwannomas and 19.3% of sporadic schwannomas (44). One study reported that methylation of three cis-regulatory elements, CpG sites, in the NF2 promoter elements was found in ~60% of vestibular schwannomas and correlated with decreased promoter activity and mRNA expression (45). By contrast, another study of 35 sporadic vestibular schwannomas reported that in 65% of tumors the NF2 promoter was unmethylated and in the remaining 35% the results were inconclusive (46). At the same time, 50 to 60% of sporadic meningiomas contain NF2 somatic mutations and epigenetic inactivation (47, 48). In another study of 88 sporadic meningiomas, 49% exhibited allelic loss of chromosome 22, 24% had NF2 somatic mutations and 26% had aberrant NF2 promoter methylation, whereas in 17% of the meningiomas, epigenetic NF2 inactivation was the only cause of NF2 deficiency. Similarly, less than 10% of sporadic ependymomas exhibited NF2 promoter methylation (49). In some of the schwannomas and meningiomas without genetic or epigenetic NF2 inactivation, merlin inactivation was caused by μ-calpain constitutive Petrilli and Fernández-VallePage 4Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptactivation that mediated merlin proteolytic cleavage/degradation (50). Finally, a recent meningioma study of 73 patients found a high incidence of TERT promoter activating mutations in meningiomas undergoing malignant transformation in both NF2-related and sporadic meningiomas, whereas no TERT mutations were found in benign tumors. This suggests that TERT independently of NF2 could be used as biomarker of risk of malignant transformation of a meningioma (51).Because NF2 mutations and inactivation are present in ependymomas and both benign and malignant schwannomas and meningiomas, it is reasonable to speculate that NF2 inactivation could be an early tumorigenic event that disrupts key signaling pathways in a specific molecular context leading to tumor development. Although a complete understanding of the biological functions of merlin is lacking, current knowledge of merlin-related signaling pathways and merlin binding partners shed some light on its role in cellular proliferation, survival and tumor development.Signaling pathways regulated by merlinMembrane receptors and RhoGTPase family—Merlin’s tumor suppressor activity was initially related to a role in contact inhibition of cell proliferation. Merlin levels in various cell types were shown to be two- to three-fold higher in high density as opposed to low density cells in cultures. Thus merlin appears necessary for suppression and/or inactivation of receptor-dependent mitogenic signaling pathways. (52, 53). There are several studies supporting this mechanism of action for merlin. First, merlin co-localizes and binds CD44, a recognized cell-cell, cell-substrate adhesion receptor and the major receptor for hyaluronan, an abundant extracellular matrix (ECM) component (54, 55). Binding of merlin unphosphorylated at Ser518 with the cytoplasmic tail of CD44 mediates contact inhibition at high cell density. Consistent with this phenomenon, treatment of sub-confluent cells of various cell types with a soluble glycosaminoglycan hyaluronan rapidly induced merlin dephosphorylation and inhibition of growth and thus activated merlin tumor suppressor activity (52). Furthermore, merlin overexpression in Tr6BC1 mouse schwannoma cells inhibited the binding of fluorescein-labeled hyaluronan to CD44 and inhibited subcutaneous tumor growth in immunocompromised mice, and overexpression of a merlin mutant lacking the CD44 binding domain was unable to inhibit schwannoma growth (56). Collectively, these results indicate that merlin inhibits cell growth by contact inhibition in part by binding CD44 and negatively regulating CD44 function (Figure 2).CD44 signaling through Rac1activation is demonstrated in multiple cell types. Hyaluronan-CD44 interaction in astrocytes and an immortalized mouse mammary epithelial cell line, EpH4, leads to Rac1 signaling activation and actin cytoskeleton rearrangement (57, 58). The activation of Rac1 through CD44 was identified via the interaction of CD44 with Tiam-1, a Rac1 guanine nucleotide exchange factor (GEF) that catalyzes the replacement of the tightly-bound GDP with GTP. In various cell types, the binding of hyaluronan to CD44 stimulates Tiam1-dependent Rac1 signaling and cytoskeleton-mediated tumor cell migration (59, 60). Moreover, expression of constitutively active Rac mutants, as well as activated cell division cycle-42 (Cdc42), induced phosphorylation of merlin at Ser518 and decreased merlin’s association with the actin cytoskeleton. Merlin phosphorylation at Ser518 Petrilli and Fernández-VallePage 5Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptinactivated its growth inhibitory function (Figure 2) (21). In fibroblasts, merlin overexpression inhibited Rac1-induced signaling whereas a merlin S518D phosphomimetic did not. As expected, increased levels of active Rac1 were found in NF2-deficient Schwann cells and human schwannoma samples compared to controls (61–63).Independent of merlin-CD44 interactions, merlin has been shown to modulate Rac signaling by specifying its subcellular localization. For example, in confluent human umbilical vein endothelial cells, merlin suppressed recruitment of Rac to the plasma membrane, and its silencing promoted recruitment of Rac1 to sites of extracellular matrix adhesion, and promoted cell growth (64). In addition, merlin has been shown to inhibit Rac1 signaling responsible for suppression of PAK activation by binding through its FERM domain to the PAK-Cdc42/Rac binding domain (65). In turn, Rac/Cdc42-dependent activation of PAK leads to merlin phosphorylation at Ser518, which inhibits merlin translocation to the plasma membrane in a paxillin-dependent manner, mitigating its inhibitory effect on Rac/Cdc42, and hence, its tumor suppressor activity (Figure 2) (22, 66, 67).In primary rat Schwann cells, CD44 was shown to constitutively associate with the heterodimer receptor tyrosine kinase ErbB2/ErbB3 and CD44 enhanced neuregulin-induced ErbB2-activating phosphorylation (68). ErbB2/ErbB3 receptor expression levels and activation were reported to be elevated in human schwannomas and NF2-deficient cell lines (69–71). Accordingly, merlin was shown to reduce the levels of ErbB2/ErbB3 receptor levels at the plasma membrane. Previously, we showed that activation of ErbB2/ErbB3 receptors in primary rat Schwann cells by neuregulin-1 induced merlin phosphorylation at Ser518 via PKA (72). Significantly, ErbB2 activation was also found to be elevated in NF2-ependymomas (73). ErbB2 activation in mouse Nf2-deficient spinal cord neural progenitor cells was shown to be caused by Rac-mediated retention of the receptor at the plasma membrane (73). Merlin re-expression in Nf2−/− Schwann cells similarly reduced the transport of growth factor receptors ErbB2/ErbB3, insulin-like growth factor 1 receptor (IGF1R) and platelet-derived growth factor receptor (PDGFR). Accordingly, the loss of merlin in Nf2−/− peripheral mouse nerves resulted in elevated levels of these growth factor receptors compared to wild-type before the development of tumors, and importantly, similar overexpression was observed in human Schwannomas (Figure 2) (74–77).In sub-confluent primary Schwann cells, we found that merlin binds to paxillin and mediates merlin localization at the plasma membrane and association with β1-integrin and ErbB2, modifying the organization of the actin cytoskeleton in a cell density-dependent manner (78). We reported that merlin associates with β1-integrin in primary Schwann cells and undifferentiated Schwann cell/neuron co-cultures, and in primary Schwann cell cultures, laminin-1 stimulated integrin signaled though PAK1 and caused merlin Ser518 phosphorylation and inactivation of its tumor suppressor function (72, 79, 80). In sum, multiple lines of evidence have established a feedback regulation loop with merlin being phosphorylated at Ser518 (growth permissive form) via activated Rho small GTPases Rac1/Cdc42 through PAK, and in turn, merlin associating with PAK to inhibit Rac1/Cdc42 signaling (Figure 2). Loss of merlin causes continuous activation of Rac1/Cdc42/PAK signaling, which is associated with cell growth and deregulation of the actin cytoskeleton. Actin cytoskeleton abnormalities have been reported in NF2-deficient human schwannomas Petrilli and Fernández-VallePage 6Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptand the defects were reversed by reintroduction of merlin (81, 82). Related to that, the PAK substrates, LIM domain kinases 1and 2 (LIMK1/2), were also reported to be elevated in human Schwannomas and mouse Schwann cells in which merlin was inactivated compared to normal controls (83). LIMK1/2 phosphorylates and inactivates cofilin, an F-actin severing and depolymerizing agent. Furthermore, it was shown that overactive PAK/LIMK pathway activity contributed to cell proliferation through cofilin phosphorylation and auroraA activation (83). When merlin was inactivated in immortalized Nf2flox2/flox2 mouse embryonic fibroblasts (MEFs) by Adeno-Cre infection, loss of contact inhibition of growth and increased Rac1 and canonical Wnt signaling were observed compared to controls (84). Pharmacological or genetic inhibition of Rac1 in Nf2−/− MEFs reduced the Wnt signaling activation to basal levels as assessed by reporter assay of transactivation of the nuclear β-catenin-dependent T-cell factor 4 transcription factor (84). These findings were corroborated and further studied in human schwannoma cells, in which over-activation of canonical Wnt signaling with elevated nuclear β-catenin, upregulation of c-myc and cyclin D1 target genes and activation of the Rac1/PAK and PDGFR/Src pathways were observed (Figure 2) (85).Soon after merlin was cloned, evidence that merlin inhibits another important member of the Rho GTPases family, Ras, was reported in v-Ha-Ras-transformed NIH3T3cells in which merlin overexpression counteracted the oncogenic role of Ras (86). In immortalized nf2−/− rat Schwann cells, reintroduced merlin acted downstream of receptor tyrosine kinase through the growth factor receptor binding protein 2-Son of sevenless (Grb2-SOS) complex (87). SOS is a GEF that activates Ras by catalyzing the nucleotide exchange (88). Merlin action on Ras signaling is indirect by blocking the assembly of ERM proteins, SOS and the Ras complex (87, 89).Another family of receptor tyrosine kinases activated in schwannomas is the Tyfo3-Axl-Mer (TAM) family. TAM receptors were strongly overexpressed in schwannomas (77). Moreover, increased activation of Axl receptor and Gas6 ligand was also observed in the absence of merlin in primary human schwannoma cells compared to normal Schwann cells, resulting in recruitment and activation of Src and focal adhesion kinase (FAK) signaling (90). Merlin inactivation of Src signaling was also shown in CNS glial cells, where merlin competitively inhibits Src binding to ErbB2 thereby preventing ErbB2-mediated Src phosphorylation and downstream mitogenic signaling. In Nf2−/− glial cells, Src regulated cell growth by sequentially regulating FAK and paxillin activity (91). Primary human schwannoma cells also showed increased cell-matrix adhesion compared to control Schwann cells. Interestingly, it was shown that schwannoma cells release insulin-like growth factor-binding protein 1 which in β1-integrin dependent manner activates Src/FAK signaling (75). In addition, FAK was overexpressed and activated in schwannoma cells where it localized to the nucleus and decreased p53 levels by increasing its export to the cytosol and proteasomal degradation. FAK silencing decreased schwannoma cell proliferation and was associated with increased levels of total and nuclear p53 (75, 92).PI3K/mTOR/Akt and HDAC signaling—In human schwannomas and meningiomas, loss of merlin leads to activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway and Schwann cell proliferation (93–96). Merlin inhibits PI3K activity by binding phosphatidylinositol 3-kinase enhancer-L (PIKE-L), the GTPase that binds and activates Petrilli and Fernández-VallePage 7Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptPI3K (94, 97). Merlin association with PIKE-L disrupts PIKE-L binding to and activation of PI3K. Moreover, neuregulin survival signaling through the ErbB2/ErbB3 receptor activates PI3K in rat Schwann cells through the activation of Akt and inhibition of Bad, a pro-apoptotic Blc-2 family protein (98). We recently showed that PI3K inhibition in merlin-deficient mouse Schwann cells selectively decreased their proliferation. A good number of inhibitors showed strong anti-proliferative activity, causing cell death with diverse kinetics via caspase-dependent apoptosis (99). Inhibition of Akt also inhibits schwannoma and meningioma growth (100, 101). Akt phosphorylation is indirectly regulated by histone deacetylases (HDAC) 1 and 6 through their interaction with protein phosphatase 1 (PP1), which functions as an Akt phosphatase (102, 103). HDAC inhibitors disrupt the PP1-HDAC interaction facilitating Akt dephosphorylation and decrease human meningioma and schwannoma cell proliferation and schwannoma growth in an allograft model and meningioma growth in an intracranial xenograft model (102, 104, 105). Lastly, gene-expression profiling of 49 schwannomas and 7 normal vestibular nerves identified overexpression of the PI3K/Akt/mTOR pathway (Figure 3) (106).Consistent with this last finding, constitutive activation of the mTORC1 signaling pathway has been reported in NF2-schwannomas and meningiomas. Loss of merlin activated mTORC1 signaling independently of Akt or ERK in these tumor cells; however, the molecular mechanism connecting merlin loss to mTORC1 activation remains to be elucidated (107). In orthotopic sciatic nerve allograft mice, syngeneic subcutaneous grafted mice and transgenic P0-SCH-Δ(39-121)-27 mice, pharmacological inhibition of mTORC1 reduced the growth of NF2-schwannomas (108). Western blot analysis of these tumors indicated a strong reduction of phosphorylation of mTORC1 downstream substrates S6 and 4E-BP1 as well as a small increase of Akt phosphorylation in treated mice, analogous to patients’ response to rapamycin treatment that was characterized by Akt activation resulting from the loss of the p71 S6K1 negative feedback loop (43, 109, 110).. In contrast to mTORC1, in Schwann and arachnoidal cells, merlin activates mTORC2 in response to growth factor stimulation. However, attenuation of mTORC2 signaling was not observed in merlin-deficient schwannomas and meningiomas (Figure 3) (111).In addition to alterations in kinases and phosphatase activity, we reported that loss of merlin altered the protein acetylation pattern in mouse Schwann cells. Interestingly, merlin loss correlated with increased expression levels of the deacetylase sirtuin 2 (SIRT2). Inhibiting SIRT2 deacetylase activity with small molecules considerably decreased merlin-null Schwann cell viability via a necrotic mechanism while sparing normal Schwann cells (112).Mammalian hippo pathway—Studies in primary mouse Schwann cells and in vitro assays highlighted the role of merlin modulation of the Schwann cell microtubule cytoskeleton (113). Further studies showed that wild-type merlin is transported throughout the cell by microtubule motors and merlin mutants or depletion of the microtubule motor kinesin-1 suppressed merlin transport and was associated with accumulation of yorkie, a Drosophila homolog of the hippo pathway transcriptional co-activator Yes-associated protein (YAP), in the nucleus (114). It is significant to note that phosphorylation of YAP excludes it from the nucleus in part by binding 14-3-3, and, functional inactivation of YAP seems to be cell-type specific (115).Petrilli and Fernández-VallePage 8Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptIn the canonical hippo pathway, mammalian Ste20-like kinases (Mst1/2; hippo homolog) phosphorylate large tumor suppressor kinases (LATS 1/2), which in turn phosphorylate and inactivate YAP/TAZ, blocking their role as TEAD/MEAD transcription factor co-activators (116–118). Proteomic screening of 68 human schwannomas showed that YAP and YAP transcriptional targets such as Her2, Her3 and PDGFRβ were commonly activated (119). Studies in human meningioma tumors and in paired cell lines—KY21MG1 or MENII-1 meningioma cell lines and AC1 arachnoidal cells—demonstrated that merlin loss was associated with increased YAP expression and nuclear localization. Merlin loss increased arachnoidal cell proliferation, entry into S-phase and cyclinE1 levels, whereas YAP silencing reversed the effect of merlin loss on cell proliferation (120). Merlin negatively regulates the hippo pathway at two cellular locations, the nucleus and cell cortex. Prominent staining of merlin in the nucleus in non-neoplastic human Schwann cells, HEI286, among multiple cell types, was observed using an N-terminal merlin antibody and an optimized immunostaining protocol for detection of nuclear proteins (121). Translocation of merlin to the nucleus allows merlin to bind and inhibit the E3 ubiquitin ligase CRL4DCAF1 (DDB1- and Cul4-Associated Factor 1) (121, 122). CRL4DCAF1 regulates cell proliferation, survival, DNA repair and genomic integrity via ubiquitination of critical regulators. Only unphosphorylated merlin binds DCAF1; transfected merlinS518A bound DCAF1 in HEK293T cells whereas merlinS518D did not bind. Further genetic experiments in HEI286 cells showed that merlin association with DCAF1 suppressed proliferation. In addition, in vitro DCAF1 silencing in mouse Nf2−/− FC-1801 Schwannoma and FH-912 normal control cells caused selective growth inhibition in merlin-null cells compared to control. In support of a proliferative role of DCAF1 in cells with loss of merlin, DCAF1 silencing in FC-1801 cells grown subcutaneously in mouse xenografts decreased tumor growth. Either expression of merlin or DCAF1silencing in FC-1801 schwannoma cells reduced expression of a group of genes regulated by YAP (121). Significantly, silencing of DCAF1 in schwannoma cells isolated from NF2 patients also reduced their proliferation (123). Additional studies showed that CRL4DCAF1 is responsible for LATS1 polyubuquitylation and LATS2 oligoubiquitylation, thereby promoting LATS1proteosomal degradation and inhibition of LATS2 kinase activity, which in turn suppresses YAP phosphorylation. This provides a molecular pathway by which the absence of merlin results in YAP activation (Figure 4) (124).In the mammalian hippo pathway, merlin appears to act upstream and independent of Mst1/2 at the cell cortex. Merlin promoted LATS association to the plasma membrane in mouse Schwann cells. Studies in Nf2−/− mouse Schwann cells (FC-912) revealed low LATS phosphorylation levels and LATS1/2 enrichment in the cytoplasm relative to the membrane fraction compared to control Nf2flox2/flox2 mouse FH-912 Schwann cells. Re-expression of merlin in Nf2−/− FC-912 cells rescued LATS plasma membrane localization (125). Direct binding of wild-type, full-length merlin to the plasma membrane and recruitment of LATS1/2 promoted its phosphorylation by Mst1/2 without regulating intrinsic Mst1/2 enzymatic activity (Figure 4) (125). Deregulation of the actin cytoskeleton resulting from merlin loss also induces cell proliferation signaling through the hippo pathway, and YAP/TAZ have been recently identified as mechanosensors (63, 76, 81–83, 126, 127). Mechanical factors such as stretching, geometry, cell density and rigidity of the substrate influence YAP/TAZ activity (128, 129). Interestingly, F-actin capping and severing proteins Petrilli and Fernández-VallePage 9Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptincluding cofilin restrained YAP/TAZ activity in contact inhibited cells that have low mechanical stress via a mechanism that depended on merlin (130). Consistent with this phenomenon, disruption of F-actin stress fibers with LatrunculinA inhibited YAP nuclear localization and activity (131). The relationship between mechanical factor signaling in schwannomas, meningiomas and ependymomas and merlin loss warrants further study.Additionally, at the cell cortex, components of the cell-cell contact complexes, including angiomotins (Amot), α-catenin and E-cadherin among others, can complex with YAP and TAZ and inhibit their activity by keeping them at the cell junctions and preventing their nuclear localization (132–134). Amot-p130 isoform bound to the WW domains of YAP and blocked LATS1 access to YAP. Interestingly, in 10 human schwannoma samples, Amot staining was abundant by IHC whereas normal human nerve had weak Amot expression (Figure 4) (135).In peripheral nerves, merlin and Amot colocalize in paranodes and Schimidt-Lantermann incisures. Moreover, in cultured Schwann cells, merlin interaction with Amot was demonstrated by co-immunoprecipitation of the endogenous proteins (136). Merlin-Amot interaction was required for merlin regulation of mitogenic MAPK signaling. Consistently, in RT4-67 cells, loss of merlin or presence of patient-derived merlin mutants that fail to bind Amot resulted in a lack of inhibition of c-Raf and ERK phosphorylation. Silencing of Amot in Nf2−/− Schwann cells (SC4) selectively reduced cell proliferation because it did not change the proliferation rate of SC4 with merlin re-expression. Similarly, Amot knockdown decreased tumor growth of SC4 cells in sciatic nerve orthotopic mice. Furthermore, Amot silencing attenuated Rac1 and Ras/MAPK signaling pathway. In HEK293 transfected cells, merlin competed with Rich1, a small GTPase-activating protein, for Amot binding, releasing Rich1 to inactivate Rac1 (Figure 4) (136).MERLIN IN MALIGNANT CANCERSMerlin in mesotheliomaMalignant mesothelioma is an aggressive form of cancer that most commonly develops in the mesothelium of the pleura and peritoneum tissue. It is primarily caused by exposure to asbestos; however, the long latency after exposure suggests that predisposing genetic mutations likely play a role in disease development (137). Interestingly, somatic NF2 mutations are present in a large percentage of malignant mesothelioma patients (138–140). In addition, in human mesothelioma patients without detectable NF2 mutations, merlin was phosphorylated at Ser518 consistent with an inactive tumor suppressor state (141). Furthermore, Nf2 hemizygosity was initially reported to be associated with increased susceptibility to asbestos-induced mesotheliomas in Nf2KO3/+ mice inoculated with crocidolite asbestos fibers. Subsequent DNA analysis of peritoneal mesothelioma cells from these mice showed homozygous Nf2 inactivation (142). Moreover, another Nf2(+/−) mouse line treated with asbestos to induce malignant mesotheliomas phenocopied the human disease (143). The mesothelioma cells from these mice frequently exhibited Nf2 homozygous deletions, supporting a role for LOH in malignant mesothelioma etiology and the possibility that Nf2 heterozygosity increases susceptibility to asbestos-induced mesothelioma. Taken together, such observations support the idea that NF2 mutations or Petrilli and Fernández-VallePage 10Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptdefective merlin tumor suppressor signaling might trigger or contribute to development of mesotheliomas (141).Additional evidence supports a link between merlin-dependent regulatory pathways and mesotheliomas. First, protein kinase C-potentiated phosphatase inhibitor (CPI-17), which is frequently overexpressed in mesothelioma tumors, inhibits merlin phosphatase MYPT1-PP1δ, providing one potential pathway by which merlin’s tumor suppressor function might be inactivated through maintenance of phosphorylation at Ser518 (25). Second, similar to NF2 schwannomas, mesothelioma cells with NF2 inactivation, exhibit activated PAK1 and AKT, and re-expression of merlin in merlin-null human mesothelioma cells (Meso-17) decreases PAK1 activity (144, 145). The loss of merlin was linked to increased cell proliferation via a PAK1-induced increase in cyclin-D1, which resulted in activation of Cdk4 and phosphorylation of retinoblastoma protein (141, 144). The observed upregulation of cyclin-D1 in Meso-17 cells was similar to findings in mouse embryonic fibroblasts from Nf2-deficient mice (144, 146). Further supporting the relationship between merlin and cyclin-D1, reintroduction of merlin into Meso-17 cells by NF2-adenovirus infection resulted in reduced cyclin-D1levels. Finally, an independent analysis of eleven malignant mesothelioma cell lines found activation of mTORC1. Loss of merlin results in integrin-mediated activation of mTORC1 through PAK1, which promotes cell cycle progression by inducing translation of cyclin-D1 mRNA and cyclin-D1 expression (80). The mTORC1 inhibitor rapamycin selectively inhibited proliferation of seven merlin-null mesothelioma cell lines, but not merlin-positive cell lines, suggesting a potential pharmacological target for merlin deficient mesotheliomas (80).An important functional link has been reported in mesothelioma cells between merlin and the hippo pathway (through CRL4-DCAF1). Silencing DCAF1 in Meso-33, merlin-deficient mesothelioma cells reduced their proliferation by arresting the cell cycle in G1 phase. When LATS1/2 was additionally silenced in these cells, cell cycle progression was restored. By contrast, silencing of DCAF1 in normal, Met-5A mesothelial cells resulted only in a moderate reduction of cell proliferation, suggesting that the absence of merlin sensitized cells to DCAF1 inactivation (121). In addition, in a panel of human mesothelioma cell lines, western blot experiments showed that the absence of merlin was accompanied by decreased LATS1 expression and YAP phosphorylation (124). Further confirming merlin’s functional relationship with the hippo pathway in mesothelioma cells, YAP1 expression studies found elevated YAP1 in malignant pleural mesothelioma samples and silencing of YAP1 reduced the growth of NCI-H290 mesothelioma cells carrying NF2 homozygous deletion (147). Notably, NF2 transfection into these cells induced YAP1 phosphorylation at Ser127, YAP1 retention in the cytoplasm and consequent reduction of YAP1 nuclear localization. Moreover, co-immunoprecipitation experiments revealed that merlin interacts with YAP1, although the interaction is not direct (147). Increased proliferation of mesothelioma cells with loss of merlin function was reported to be concurrent with LATS2 inactivation; however, reintroduction of wild-type merlin to Y-Meso-14 cells with homozygous deletion of LATS2 suppressed cell growth. If LATS1 cannot compensate for LATS2 function, the functional link between merlin and the hippo pathway in mesothelioma cells might not be that of a single axis growth suppression pathway (148).Petrilli and Fernández-VallePage 11Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptStudies comparing Meso-33 cells lacking merlin and those with reintroduction of merlin also identified merlin as a microtubule stabilizer (149). Merlin interacts with tubulin and acetylated-tubulin and stabilizes the microtubules by attenuating tubulin turnover—lowering the rates of microtubule polymerization and depolymerization. Thus, merlin is a regulator of both the actin and microtubule cytoskeleton, which links merlin localization throughout the cell with its roles in proliferation, morphology, migration, mitosis, and survival.Loss of merlin in mesotheliomas has been linked not only to increased proliferation, but also increased invasiveness, spreading and migration. Adenoviral transduction of NF2 in Meso-17 and Meso-25 cell lines decreased invasion through Matrigel membranes compared to cells transduced with empty vector. Similarly, re-expression of merlin in these cells decreased the percentage of cells that spread onto fibronectin-coated coverslips and decreased the motility of cells into the scratch area in a classical wound-healing assay (150). Merlin expression in Meso-17 and Meso-25 cells decreased FAK Tyr397 phosphorylation and consequently disrupted FAK-Src and PI3K interaction, providing a mechanism for the observed enhancement of invasion and spreading caused by merlin inactivation(150). Interestingly, research has shown that malignant mesothelioma cells as well as schwannomas and meningiomas with merlin loss have in common deregulation of several pathways (hippo, mTOR, PAK, FAK-Src and PI3K); thus we speculate that treatments for these malignancies might share commonalities.Merlin in other malignant cancersConsidering that Nf2 heterozygous mice are prone to develop cancer—primarily osteosarcomas, fibrosarcomas and hepatocellular carcinomas with Nf2 LOH that frequently metastasize, it is tempting to assume that NF2 patients commonly develop other malignant cancers (151). However, the transformation of schwannomas into malignant peripheral nerve sheath tumors or development of other common cancers in NF2 patients is very rare. Moreover, the incidence of NF2 mutations in common human cancers is low. Although NF2 mutations have been detected in multiple human tumor types, mutational analysis of 315 human carcinoma samples found a low prevalence of NF2 mutations—e.g., NF2 mutations were found in just 2.2% of hepatocellular, acute myelogenous leukemia and squamous cell lung carcinomas(152, 153). In common cancers, methylation of CpG islands has been reported in promoter regions which are non-methylated in control tissue resulting in transcriptional inactivation of tumor suppressors (154, 155). Comprehensive studies of promoter methylation, methyl-binding proteins, DNA methyltransferases and HDACs have not been addressed in NF2-tumors or common cancers in relation to NF2/merlin.The role of cancer stem cells has been gaining increased attention and we foresee merlin taking a place in this discussion. The participation of merlin in the mammalian hippo pathway might suggest a role in stem cell maintenance, differentiation or regulation of the stem cell niche (156–160).Breast and colorectal cancerA low incidence of NF2 mutations in breast cancer was reported by the Japanese National Cancer Center Research Institute (161). More recently, a systematic mutational analysis of Petrilli and Fernández-VallePage 12Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript22 breast and colorectal cancers found NF2 somatic mutations in 4.5% of the samples. Notably, groups of eleven different genes were frequently mutated per tumor demonstrating molecular heterogeneity of cancer (162, 163). Interestingly, PAK1 amplification was identified in ~33% of breast tumor samples, providing a mechanism of MAPK pathway activation and tumorigenesis. PAK1 expression increased merlin Ser518 phosphorylation (inactivation) in a human mammary epithelial cell transformation cell line (HMLE) whereas silencing of NF2 promoted anchorage-independent proliferation (164). The data suggest that despite the low incidence of NF2 somatic mutations in breast cancer, merlin inactivation, together with the inhibitory regulation through PAK1, may contribute to the transformation or maintenance of the tumor state. In the NF2−/− breast cancer MDA-MB-231 cell line, merlin re-expression inhibited YAP/TEAD activity that was eliminated by LATS1/2 silencing. However, LATS1/2 silencing did not rescue YAP/TAZ inhibition by soft extracellular matrix that provides a low mechanical stress, suggesting that cytoskeletal changes caused by merlin loss regulate YAP more powerfully than the core kinase hippo pathway. Overall, YAP signaling is activated in NF2−/− breast cancer cells (130).After the discovery of the NF2 gene, two independent studies found a low rate of somatic NF2 mutations in colorectal carcinomas—2 of 44 tumors in one study and 2 of 24 in another study exhibited mutations (165, 166). However, a recent study reported that 113 of 185 colorectal carcinoma samples lacked one functional copy of the NF2 gene and there was NF2 LOH in 20% of heterozygous samples, more frequently in larger and less differentiated tumors. Moreover, among all the samples, the level of NF2 mRNA expression measured by RT-PCR was significantly lower in poorly differentiated tumors. Similarly, merlin expression assessed by immunostaining was weaker in less differentiated tumors and the proportional fraction of merlin that was phosphorylated was higher in tumors compared to normal mucous tissue (167). This new data suggests a potential relationship between merlin expression and prognosis.Hepatobiliar cancerIn hepatobiliary tumor cell lines, FOCUS and HA22TVGH, a study reported two NF2 homozygous deletions, ex1 and ex2-3, respectively (168). Interestingly, in developing and adult mice, Nf2 deletion in the liver significantly expanded liver progenitor cells without affecting differentiated hepatocytes. These liver progenitor cells increased proliferation by increasing EGFR activity independent of the hippo pathway and associates Nf2 absence in liver progenitor cells with tumor development (169).Deregulation of the hippo pathway occurs in several human carcinomas including liver cancer (170–172). A specific role of merlin in liver was investigated in the Abl-Cre;Nf2flox2/flox2 mice. These mice initially developed bile duct hamartomas and in within a year all developed hepatocellular carcinomas. Their livers showed reduced YAP phosphorylation, increased YAP nuclear localization and reduced LATS membrane association and phosphorylation (125, 173). The data suggest that in hepatocytes merlin is functionally linked to the hippo pathway and acts upstream Mst1/2 by recruiting LATS to the membrane comparable to what has been shown in FH912 Schwann cell line.Petrilli and Fernández-VallePage 13Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptProstate cancerIn prostate cancer, the second leading cause of cancer death in males, inactivation of NF2 reportedly contributes to the progression of the cancer toward a highly invasive and chemoresistant state (174, 175). Studies of merlin expression and merlin Ser518 phosphorylation in several prostate cancer cell lines, including LNCaP, PC3, 22RV1 and LAPC-4, have indicated an overall decrease in merlin expression. In the DUI145 cell line, which exhibits merlin expression, phosphorylated merlin-Ser518 (inactive as tumor suppressor) was abundant and the high levels were sustained at high cell density concurrent with PAK1 activation. In sum, absence or inactivation of merlin in prostate cell lines appears to contribute to tumor development and progression (176).GlioblastomasIn a very aggressive brain tumor, glioblastoma multiforme (GBM), merlin expression was reported to be reduced in 61% (n=23) of tumors. Merlin protein and mRNA levels were decreased by over 50% in GBM compared to normal human astrocytes and brain tissue (177). Another study reported that merlin was absent in 32% (n=53) of tumors and its expression was reduced in the rest, and in one-third of 7 GBM cell lines merlin was missing and re-expression suppressed proliferation (178). In addition, microarray expression analysis of GBM cells revealed that the absence of merlin induced changes in gene expression, decreasing transcripts that activate LATS2 signaling and decreasing expression of transcripts that inhibit the canonical Wnt and RhoA signaling pathway (177). These results were confirmed by RT-PCR, luciferase-reporter assays and western blot, with merlin re-expression resulting in activation of the hippo pathway and inhibition of the canonical (β-catenin) and non-canonical Wnt pathways in GBM cells. Importantly, merlin re-expression decreased GBM cell proliferation in vitro and in subcutaneous and intracranial xenograft mouse models (177). In GBM cell lines that expressed merlin, an alternative mechanism of merlin inactivation was revealed that operated through ezrin interaction. Ezrin was found to be expressed at higher levels in GBM cells and associated with merlin, removing merlin from its cortical localization, prohibiting its inhibitory action on Rac1, and thereby enhancing cell growth (178). Interestingly, a study of U251 glioblastoma cells identified different cell subpopulations, one with a high proliferation rate, spindle morphology, and EGFR and NOTCH1 expression (U251-S), and another with a lower proliferation rate, rhomboid morphology, no NOTCH1 expression and low EGFR expression (U251-R). Notably, both subpopulations exhibited similar merlin expression levels as measured by western blot; however, merlin-Ser518 phosphorylation was higher in U251-S cells regardless of cell density. The disrupted cell-contact inhibition signaling and merlin phosphorylation correlated with increased expression of NOTCH1 and its downstream target gene, HES1, which represses the transcription factor E2F in cell-contact growth arrest. Also increased was the EGFR effector CCND1, the Cdk1 gene, which is essential in the G1-S phase transition, providing an alternative mechanism for glioblastoma cell proliferation regulated by merlin phosphorylation when NF2 is not mutated or epigenetically inactivated (179).Petrilli and Fernández-VallePage 14Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptMedullary thyroid carcinomaNF2 allelic loss has also been reported to be of potential value in determining the risk of recurrence of rare metastatic medullary thyroid carcinomas. Among a tumor suppressor gene panel, NF2 was found to be one of the most frequent allelic losses (75%) in 11 medullary thyroid carcinomas. When considered in association with age and disease stage, NF2 allelic loss helped define high- and low-risk recurrence groups with excellent prognostic certainty (180).MelanomaAfter an initial report of NF2 somatic mutations in 6 of 20 human melanoma samples, a larger study reported only a 5% incidence of NF2 somatic mutation in melanoma (152, 181). Merlin inactivation in WM1552C and MeWo human melanoma cell lines in vitro and in vivo enhanced migration and invasion in addition to cell proliferation. Of interest, transduction of NF2 wild-type in MeWo cells activated Mst1/2 kinases (hippo pathway) as evidenced by increased levels of active phosphorylated Mst1/2 (181). An additional molecular mechanism that contributes to increased melanoma cell motility observed with merlin loss was identified in merlin-deficient MV3 human melanoma cells. Despite decreased Na+/H+ exchanger 1 (NHE1) expression, NH4Cl pre-pulse experiments revealed increased NHE1 activity and over-expression of NHE1 further increased migration, suggesting a functional link between merlin and NHE1 activity (182). Importantly, treatment of the human melanoma cell line A375 (this cell line carries the BRAF gain-of-function V600E mutation) with the RAF inhibitor vemurafenib allowed screening for genes involved in development of drug resistance in surviving cells by negative selection with the new CRISPR-Cas9 technology. NF2 was found, among 18,080 genes screened in the genome-scale CRISPR-Cas9 knockout (GeCKO) library, to have a role in vemurafenib resistance. Experiments comparing resistance between NF2 knockout and knockdown in vemurafenib-treated cells demonstrated that merlin absence was necessary for resistance development and the presence of merlin even at very low levels was sufficient to maintain sensitivity (183). In agreement, a whole exome sequencing and pharmacological response analysis of sixty cell lines of the US National Cancer Institute (NCI-60) showed that cancer cell lines that harbor NF2 mutations were resistant to vemurafenib treatment (184). Taken together, these data implicate NF2 mutations in the development of drug resistance in melanoma rather than oncogenesis and indicate that mutations are typically not of the non-functional passenger alteration variety. This makes treatment of melanoma tumors with loss of merlin function particularly challenging.Interestingly, the Genomics of Drug Sensitivity in Cancer project (a collaboration between the Cancer Genome Project at the Wellcome Trust Sanger Institute - U.K. and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center -U.S.A.) has compiled information about NF2 mutations and drug sensitivity in a large panel of cancer cell lines (185, 186). Supporting the results from the GeCKO library and the NCI-60 screens with vemurafenib, this project found that all cancer cell lines carrying NF2 mutations (22 of 641 lines tested) were less sensitive to SB590885, a B-RAF inhibitor, irrespective of the tissue of origin. In a similar fashion, NF2 mutations increased the resistance to dihydrofolate reductase inhibitors methotrexalate and pyremethamine as well as the JNK inhibitor Petrilli and Fernández-VallePage 15Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptJNK-9L. However, this collaborative project also found instances in which NF2 mutations increased sensitivity to drugs such as dasatinib (ABL, SRC, KIT and PDGFR inhibitor), WH-4-023 (SRC family and ABL inhibitor), PHA-665752 (Hepatocyte Growth Factor Receptor MET inhibitor), 6881640 (WEE1 and CHK1 inhibitor) and FH535 (unknown target) (185). The information can be accessed on their website: http://www.cancerrxgene.org/translation/Gene/1268. Therapeutic resistance is a complex problem. Drug resistance may be related to several factors, i.e., the genomic tumor landscape, development of secondary mutations in the drug target, changes in the tumor microenvironment and activation of bypass or feedback signaling loops. In vemurafenib-resistant melanoma tumors and tumor-matched short-term cultures from clinical trial patients, resistance to vemurafenib was found to develop due to up-regulation of PDGFRβ or an NRas mutation (187). We speculate that NF2 mutations in B-Raf mutated melanomas may help confer resistance to vemurafenib because the absence of merlin per se activates the PDGFR signaling assisting in establishment of a compensatory route. In contrast, NF2 mutations may confer sensitivity to Src, KIT and PDGFR inhibitors because cells with only NF2 inactivation when treated with these inhibitors decreased proliferation and increased apoptosis (76, 91, 188–190). Thus targeting pathways known to be activated by loss of merlin function in combination with drugs targeting the primary gene mutation in cancer cells may decrease development of drug resistance.CONCLUSION AND PERSPECTIVESMerlin’s role as a scaffolding protein can explain how it regulates multiple signaling pathways and integrates extracellular signals to modulate morphology, motility, proliferation and survival. Here we summarized the role of NF2/merlin in NF2-related tumors and common human cancers. Although NF2 mutations are not frequent in common human malignant cancers, when present can affect disease progression, therapeutic approach or prognosis. Moving forward, larger studies evaluating transcriptional NF2 inactivation in common human cancers might require reassessment of its participation. In addition, the multiplicity of signaling pathways affected by merlin loss/inactivation in tumor cells and the differential influence of the microenvironment might guide selection of the most appropriate molecular target/s for therapy. Consequently, combinatorial molecular therapy might represent the most successful pharmacological approach; however, further research and a better understanding of molecular cross-signaling are still required to identify the best therapeutic strategies.A better understanding of the role of merlin loss/inactivation in tumorigenesis and tumor progression is still required. The fact that loss of merlin in humans mostly leads to tumor formation from Schwann, meningeal and ependymal cells, whereas other cell types do not transform despite ubiquitous merlin expression in normal tissues, suggests tissue specific molecular context and microenvironment dependence that requires further elucidation. In addition, the significance of NF2/merlin inactivation in common human cancers deserves more investigation for its potential contribution to progression, prognosis and therapeutics.Petrilli and Fernández-VallePage 16Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptAcknowledgmentsThis work was supported by the National Institute of Health 5R01DC10189 and 5R01NS062825 grants. We thank A.B. Knott for editorial assistance and Dr. C. Vivacharawongse for reviewing the manuscript and helpful discussions.References1. Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet journal of rare diseases. 2009; 4:16. Epub 2009/06/24. [PubMed: 19545378] 2. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993; 363(6429):515–21. Epub 1993/06/10. [PubMed: 8379998] 3. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993; 72(5):791–800. Epub 1993/03/12. [PubMed: 8453669] 4. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, et al. Neurofibromatosis type 2. Lancet. 2009; 373(9679):1974–86. Epub 2009/05/30. [PubMed: 19476995] 5. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. Journal of neuro-oncology. 2010; 99(3):307–14. Epub 2010/09/08. [PubMed: 20821343] 6. Bydon M, Mathios D, Aguayo-Alvarez JJ, Ho C, Gokaslan ZL, Bydon A. Multiple primary intramedullary ependymomas: a case report and review of the literature. The spine journal : official journal of the North American Spine Society. 2013; 13(10):1379–86. Epub 2013/08/31. [PubMed: 23988460] 7. Plotkin SR, O’Donnell CC, Curry WT, Bove CM, MacCollin M, Nunes FP. Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. Journal of neurosurgery Spine. 2011; 14(4):543–7. Epub 2011/02/08. [PubMed: 21294614] 8. Lloyd SK, Evans DG. Neurofibromatosis type 2 (NF2): diagnosis and management. Handbook of clinical neurology. 2013; 115:957–67. Epub 2013/08/13. [PubMed: 23931824] 9. Sperfeld AD, Hein C, Schroder JM, Ludolph AC, Hanemann CO. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain : a journal of neurology. 2002; 125(Pt 5):996–1004. Epub 2002/04/19. [PubMed: 11960890] 10. Schulz A, Baader SL, Niwa-Kawakita M, Jung MJ, Bauer R, Garcia C, et al. Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy. Nature neuroscience. 2013; 16(4):426–33. Epub 2013/03/05. [PubMed: 23455610] 11. Schulz A, Zoch A, Morrison H. A neuronal function of the tumor suppressor protein merlin. Acta neuropathologica communications. 2014; 2(1):82. Epub 2014/07/12. [PubMed: 25012216] 12. Aboukais R, Zairi F, Baroncini M, Bonne NX, Schapira S, Vincent C, et al. Intracranial meningiomas and neurofibromatosis type 2. Acta neurochirurgica. 2013; 155(6):997–1001. discussion Epub 2013/04/06. [PubMed: 23558725] 13. Gilbert MR, Ruda R, Soffietti R. Ependymomas in adults. Current neurology and neuroscience reports. 2010; 10(3):240–7. Epub 2010/04/29. [PubMed: 20425040] 14. Xu HM, Gutmann DH. Merlin differentially associates with the microtubule and actin cytoskeleton. Journal of neuroscience research. 1998; 51(3):403–15. Epub 1998/03/05. [PubMed: 9486775] 15. Gronholm M, Sainio M, Zhao F, Heiska L, Vaheri A, Carpen O. Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. Journal of cell science. 1999; 112(Pt 6):895–904. Epub 1999/02/26. [PubMed: 10036239] 16. Nguyen R, Reczek D, Bretscher A. Hierarchy of merlin and ezrin N- and C-terminal domain interactions in homo- and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP. The Journal of biological chemistry. 2001; 276(10):7621–9. Epub 2000/12/07. [PubMed: 11106646] Petrilli and Fernández-VallePage 17Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript17. Stamenkovic I, Yu Q. Merlin, a “magic” linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Current protein & peptide science. 2010; 11(6):471–84. Epub 2010/05/25. [PubMed: 20491622] 18. Tang X, Jang SW, Wang X, Liu Z, Bahr SM, Sun SY, et al. Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nature cell biology. 2007; 9(10):1199–207. Epub 2007/09/25. [PubMed: 17891137] 19. Laulajainen M, Muranen T, Nyman TA, Carpen O, Gronholm M. Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin. Neoplasia. 2011; 13(7):643–52. Epub 2011/07/14. [PubMed: 21750658] 20. Laulajainen M, Muranen T, Carpen O, Gronholm M. Protein kinase A-mediated phosphorylation of the NF2 tumor suppressor protein merlin at serine 10 affects the actin cytoskeleton. Oncogene. 2008; 27(23):3233–43. Epub 2007/12/12. [PubMed: 18071304] 21. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Developmental cell. 2001; 1(1):63–72. Epub 2001/11/13. [PubMed: 11703924] 22. Xiao GH, Beeser A, Chernoff J, Testa JR. p21-activated kinase links Rac/Cdc42 signaling to merlin. The Journal of biological chemistry. 2002; 277(2):883–6. Epub 2001/11/24. [PubMed: 11719502] 23. Surace EI, Haipek CA, Gutmann DH. Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. Oncogene. 2004; 23(2):580–7. Epub 2004/01/16. [PubMed: 14724586] 24. Alfthan K, Heiska L, Gronholm M, Renkema GH, Carpen O. Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. The Journal of biological chemistry. 2004; 279(18):18559–66. Epub 2004/02/26. [PubMed: 14981079] 25. Jin H, Sperka T, Herrlich P, Morrison H. Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature. 2006; 442(7102):576–9. Epub 2006/08/04. [PubMed: 16885985] 26. Pearson MA, Reczek D, Bretscher A, Karplus PA. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell. 2000; 101(3):259–70. Epub 2000/06/10. [PubMed: 10847681] 27. Scoles DR. The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochimica et biophysica acta. 2008; 1785(1):32–54. Epub 2007/11/06. [PubMed: 17980164] 28. Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. The Journal of cell biology. 2007; 177(5):893–903. Epub 2007/06/06. [PubMed: 17548515] 29. James MF, Beauchamp RL, Manchanda N, Kazlauskas A, Ramesh V. A NHERF binding site links the betaPDGFR to the cytoskeleton and regulates cell spreading and migration. Journal of cell science. 2004; 117(Pt 14):2951–61. Epub 2004/05/27. [PubMed: 15161943] 30. Yogesha SD, Sharff AJ, Giovannini M, Bricogne G, Izard T. Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor. Protein science : a publication of the Protein Society. 2011; 20(12):2113–20. Epub 2011/10/21. [PubMed: 22012890] 31. Hennigan RF, Foster LA, Chaiken MF, Mani T, Gomes MM, Herr AB, et al. Fluorescence resonance energy transfer analysis of merlin conformational changes. Molecular and cellular biology. 2010; 30(1):54–67. Epub 2009/11/04. [PubMed: 19884346] 32. Sher I, Hanemann CO, Karplus PA, Bretscher A. The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state. Developmental cell. 2012; 22(4):703–5. Epub 2012/04/21. [PubMed: 22516197] 33. Ali Khajeh J, Ju JH, Atchiba M, Allaire M, Stanley C, Heller WT, et al. Molecular conformation of the full-length tumor suppressor NF2/Merlin–a small-angle neutron scattering study. Journal of molecular biology. 2014; 426(15):2755–68. Epub 2014/06/03. [PubMed: 24882693] 34. McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes & development. 1997; 11(10):1253–65. Epub 1997/05/15. [PubMed: 9171370] 35. Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of Petrilli and Fernández-VallePage 18Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscripthuman neurofibromatosis type 2. Genes & development. 2000; 14(13):1617–30. Epub 2000/07/11. [PubMed: 10887156] 36. Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes & development. 2002; 16(9):1060–5. Epub 2002/05/10. [PubMed: 12000789] 37. Gehlhausen JR, Park SJ, Hickox AE, Shew M, Staser K, Rhodes SD, et al. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation. Human molecular genetics. 2014 Epub 2014/08/13. 38. Kalamarides M, Peyre M, Giovannini M. Meningioma mouse models. Journal of neuro-oncology. 2010; 99(3):325–31. Epub 2010/08/25. [PubMed: 20734219] 39. Rangarajan A, Weinberg RA. Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nature reviews Cancer. 2003; 3(12):952–9. Epub 2004/01/23. [PubMed: 14737125] 40. Gusella JF, Ramesh V, MacCollin M, Jacoby LB. Merlin: the neurofibromatosis 2 tumor suppressor. Biochimica et biophysica acta. 1999; 1423(2):M29–36. Epub 1999/04/24. [PubMed: 10214350] 41. Schulz A, Kyselyova A, Baader SL, Jung MJ, Zoch A, Mautner VF, et al. Neuronal merlin influences ERBB2 receptor expression on Schwann cells through neuregulin 1 type III signalling. Brain : a journal of neurology. 2014; 137(Pt 2):420–32. Epub 2013/12/07. [PubMed: 24309211] 42. Sainz J, Huynh DP, Figueroa K, Ragge NK, Baser ME, Pulst SM. Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Human molecular genetics. 1994; 3(6):885–91. Epub 1994/06/01. [PubMed: 7951231] 43. Gutmann DH, Giordano MJ, Fishback AS, Guha A. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology. 1997; 49(1):267–70. Epub 1997/07/01. [PubMed: 9222206] 44. Gonzalez-Gomez P, Bello MJ, Alonso ME, Lomas J, Arjona D, Campos JM, et al. CpG island methylation in sporadic and neurofibromatis type 2-associated schwannomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(15):5601–6. Epub 2003/12/05. [PubMed: 14654541] 45. Kino T, Takeshima H, Nakao M, Nishi T, Yamamoto K, Kimura T, et al. Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes to cells : devoted to molecular & cellular mechanisms. 2001; 6(5):441–54. Epub 2001/05/31. [PubMed: 11380622] 46. Koutsimpelas D, Ruerup G, Mann WJ, Brieger J. Lack of neurofibromatosis type 2 gene promoter methylation in sporadic vestibular schwannomas. ORL; journal for oto-rhino-laryngology and its related specialties. 2012; 74(1):33–7. Epub 2012/01/18. 47. Lomas J, Bello MJ, Arjona D, Alonso ME, Martinez-Glez V, Lopez-Marin I, et al. Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas. Genes, chromosomes & cancer. 2005; 42(3):314–9. Epub 2004/12/21. [PubMed: 15609345] 48. Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. The Lancet Neurology. 2006; 5(12):1045–54. Epub 2006/11/18. [PubMed: 17110285] 49. Alonso ME, Bello MJ, Gonzalez-Gomez P, Arjona D, de Campos JM, Gutierrez M, et al. Aberrant CpG island methylation of multiple genes in ependymal tumors. Journal of neuro-oncology. 2004; 67(1–2):159–65. Epub 2004/04/10. [PubMed: 15072463] 50. Kimura Y, Koga H, Araki N, Mugita N, Fujita N, Takeshima H, et al. The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nature medicine. 1998; 4(8):915–22. Epub 1998/08/13. 51. Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain pathology. 2014; 24(2):184–9. Epub 2013/11/23. [PubMed: 24261697] 52. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes & development. 2001; 15(8):968–80. Epub 2001/04/24. [PubMed: 11316791] Petrilli and Fernández-VallePage 19Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript53. Shaw RJ, McClatchey AI, Jacks T. Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. The Journal of biological chemistry. 1998; 273(13):7757–64. Epub 1998/04/29. [PubMed: 9516485] 54. Sainio M, Zhao F, Heiska L, Turunen O, den Bakker M, Zwarthoff E, et al. Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. Journal of cell science. 1997; 110(Pt 18):2249–60. Epub 1997/10/24. [PubMed: 9378774] 55. Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, Konig H, Weg-Remers S, et al. CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Annals of the New York Academy of Sciences. 2000; 910:106–18. discussion 18–20. Epub 2000/07/27. [PubMed: 10911909] 56. Bai Y, Liu YJ, Wang H, Xu Y, Stamenkovic I, Yu Q. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene. 2007; 26(6):836–50. Epub 2006/09/06. [PubMed: 16953231] 57. Bourguignon LY, Gilad E, Peyrollier K, Brightman A, Swanson RA. Hyaluronan-CD44 interaction stimulates Rac1 signaling and PKN gamma kinase activation leading to cytoskeleton function and cell migration in astrocytes. Journal of neurochemistry. 2007; 101(4):1002–17. Epub 2007/04/04. [PubMed: 17403031] 58. Oliferenko S, Kaverina I, Small JV, Huber LA. Hyaluronic acid (HA) binding to CD44 activates Rac1 and induces lamellipodia outgrowth. The Journal of cell biology. 2000; 148(6):1159–64. Epub 2000/03/22. [PubMed: 10725329] 59. Bourguignon LY, Zhu H, Shao L, Chen YW. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. The Journal of biological chemistry. 2000; 275(3):1829–38. Epub 2000/01/15. [PubMed: 10636882] 60. Sherman LS, Gutmann DH. Merlin: hanging tumor suppression on the Rac. Trends in cell biology. 2001; 11(11):442–4. Epub 2001/10/31. [PubMed: 11684412] 61. Kaempchen K, Mielke K, Utermark T, Langmesser S, Hanemann CO. Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Human molecular genetics. 2003; 12(11):1211–21. Epub 2003/05/23. [PubMed: 12761036] 62. Nakai Y, Zheng Y, MacCollin M, Ratner N. Temporal control of Rac in Schwann cell-axon interaction is disrupted in NF2-mutant schwannoma cells. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2006; 26(13):3390–5. Epub 2006/03/31. [PubMed: 16571745] 63. Flaiz C, Ammoun S, Biebl A, Hanemann CO. Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma. Brain pathology. 2009; 19(1):27–38. Epub 2008/05/01. [PubMed: 18445079] 64. Okada T, Lopez-Lago M, Giancotti FG. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. The Journal of cell biology. 2005; 171(2):361–71. Epub 2005/10/26. [PubMed: 16247032] 65. Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Molecular cell. 2003; 12(4):841–9. Epub 2003/10/29. [PubMed: 14580336] 66. Kissil JL, Johnson KC, Eckman MS, Jacks T. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. The Journal of biological chemistry. 2002; 277(12):10394–9. Epub 2002/01/10. [PubMed: 11782491] 67. Thaxton C, Lopera J, Bott M, Baldwin ME, Kalidas P, Fernandez-Valle C. Phosphorylation of the NF2 tumor suppressor in Schwann cells is mediated by Cdc42-Pak and requires paxillin binding. Molecular and cellular neurosciences. 2007; 34(2):231–42. Epub 2006/12/19. [PubMed: 17175165] 68. Sherman LS, Rizvi TA, Karyala S, Ratner N. CD44 enhances neuregulin signaling by Schwann cells. The Journal of cell biology. 2000; 150(5):1071–84. Epub 2000/09/07. [PubMed: 10973996] 69. Ahmad Z, Brown CM, Patel AK, Ryan AF, Ongkeko R, Doherty JK. Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. Otology & neurotology : official Petrilli and Fernández-VallePage 20Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptpublication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2010; 31(3):460–6. Epub 2010/03/03. 70. Hansen MR, Roehm PC, Chatterjee P, Green SH. Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation. Glia. 2006; 53(6):593–600. Epub 2006/01/25. [PubMed: 16432850] 71. Wickremesekera A, Hovens CM, Kaye AH. Expression of ErbB-1 and 2 in vestibular schwannomas. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2007; 14(12):1199–206. Epub 2007/10/30. [PubMed: 17964790] 72. Thaxton C, Lopera J, Bott M, Fernandez-Valle C. Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways. Oncogene. 2008; 27(19):2705–15. Epub 2007/11/14. [PubMed: 17998937] 73. Garcia C, Gutmann DH. Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner. PloS one. 2014; 9(5):e97320. Epub 2014/05/13. [PubMed: 24817309] 74. Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F, et al. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene. 2009; 28(6):854–65. Epub 2008/11/26. [PubMed: 19029950] 75. Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, et al. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. Glia. 2012; 60(11):1721–33. Epub 2012/07/24. [PubMed: 22821509] 76. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer research. 2008; 68(13):5236–45. Epub 2008/07/03. [PubMed: 18593924] 77. Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, et al. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro-oncology. 2010; 12(8):834–43. Epub 2010/06/01. [PubMed: 20511180] 78. Fernandez-Valle C, Tang Y, Ricard J, Rodenas-Ruano A, Taylor A, Hackler E, et al. Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nature genetics. 2002; 31(4):354–62. Epub 2002/07/16. [PubMed: 12118253] 79. Obremski VJ, Hall AM, Fernandez-Valle C. Merlin, the neurofibromatosis type 2 gene product, and beta1 integrin associate in isolated and differentiating Schwann cells. Journal of neurobiology. 1998; 37(4):487–501. Epub 1998/12/19. [PubMed: 9858254] 80. Lopez-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Molecular and cellular biology. 2009; 29(15):4235–49. Epub 2009/05/20. [PubMed: 19451229] 81. Bashour AM, Meng JJ, Ip W, MacCollin M, Ratner N. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Molecular and cellular biology. 2002; 22(4):1150–7. Epub 2002/01/26. [PubMed: 11809806] 82. Pelton PD, Sherman LS, Rizvi TA, Marchionni MA, Wood P, Friedman RA, et al. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene. 1998; 17(17):2195–209. Epub 1998/11/12. [PubMed: 9811451] 83. Petrilli A, Copik A, Posadas M, Chang LS, Welling DB, Giovannini M, et al. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. Oncogene. 2014; 33(27):3571–82. Epub 2013/08/13. [PubMed: 23934191] 84. Bosco EE, Nakai Y, Hennigan RF, Ratner N, Zheng Y. NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation. Oncogene. 2010; 29(17):2540–9. Epub 2010/02/16. [PubMed: 20154721] 85. Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk MA, Hanemann CO. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/beta-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. Neoplasia. 2011; 13(12):1101–12. Epub 2012/01/17. [PubMed: 22247700] Petrilli and Fernández-VallePage 21Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript86. Tikoo A, Varga M, Ramesh V, Gusella J, Maruta H. An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). The Journal of biological chemistry. 1994; 269(38):23387–90. Epub 1994/09/23. [PubMed: 8089100] 87. Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P. Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer research. 2007; 67(2):520–7. Epub 2007/01/20. [PubMed: 17234759] 88. Li N, Batzer A, Daly R, Yajnik V, Skolnik E, Chardin P, et al. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature. 1993; 363(6424):85–8. Epub 1993/05/06. [PubMed: 8479541] 89. Geissler KJ, Jung MJ, Riecken LB, Sperka T, Cui Y, Schacke S, et al. Regulation of Son of sevenless by the membrane-actin linker protein ezrin. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(51):20587–92. Epub 2013/12/04. [PubMed: 24297905] 90. Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, et al. Axl/Gas6/NFkappaB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene. 2014; 33(3):336–46. Epub 2013/01/16. [PubMed: 23318455] 91. Houshmandi SS, Emnett RJ, Giovannini M, Gutmann DH. The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Molecular and cellular biology. 2009; 29(6):1472–86. Epub 2008/12/24. [PubMed: 19103750] 92. Ammoun S, Schmid MC, Zhou L, Hilton DA, Barczyk M, Hanemann CO. The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours. Molecular oncology. 2015; 9(1):236–48. Epub 2014/09/14. [PubMed: 25217104] 93. Hilton DA, Ristic N, Hanemann CO. Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology. 2009; 55(6):744–9. Epub 2009/11/19. [PubMed: 19919586] 94. Rong R, Tang X, Gutmann DH, Ye K. Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(52):18200–5. Epub 2004/12/16. [PubMed: 15598747] 95. Jacob A, Lee TX, Neff BA, Miller S, Welling B, Chang LS. Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2008; 29(1):58–68. Epub 2008/01/18. 96. Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, et al. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005; 11(11):4074–82. Epub 2005/06/03. [PubMed: 15930342] 97. Ye K. Phosphorylation of merlin regulates its stability and tumor suppressive activity. Cell adhesion & migration. 2007; 1(4):196–8. Epub 2007/10/01. [PubMed: 19262146] 98. Li Y, Tennekoon GI, Birnbaum M, Marchionni MA, Rutkowski JL. Neuregulin signaling through a PI3K/Akt/Bad pathway in Schwann cell survival. Molecular and cellular neurosciences. 2001; 17(4):761–7. Epub 2001/04/21. [PubMed: 11312610] 99. Petrilli AM, Fuse MA, Donnan MS, Bott M, Sparrow NA, Tondera D, et al. A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2. American journal of translational research. 2014; 6(5):471–93. Epub 2014/11/02. [PubMed: 25360213] 100. Lee TX, Packer MD, Huang J, Akhmametyeva EM, Kulp SK, Chen CS, et al. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. European journal of cancer. 2009; 45(9):1709–20. Epub 2009/04/11. [PubMed: 19359162] 101. Johnson MD, Okedli E, Woodard A, Toms SA, Allen GS. Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells. Journal of neurosurgery. 2002; 97(3):668–75. Epub 2002/09/26. [PubMed: 12296652] Petrilli and Fernández-VallePage 22Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript102. Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-oncology. 2011; 13(9):983–99. Epub 2011/07/23. [PubMed: 21778190] 103. Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. The Journal of biological chemistry. 2005; 280(46):38879–87. Epub 2005/09/28. [PubMed: 16186112] 104. Jacob A, Oblinger J, Bush ML, Brendel V, Santarelli G, Chaudhury AR, et al. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. The Laryngoscope. 2012; 122(1):174–89. Epub 2011/11/24. [PubMed: 22109824] 105. Burns SS, Akhmametyeva EM, Oblinger JL, Bush ML, Huang J, Senner V, et al. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Cancer research. 2013; 73(2):792–803. Epub 2012/11/16. [PubMed: 23151902] 106. Agnihotri S, Gugel I, Remke M, Bornemann A, Pantazis G, Mack SC, et al. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma. Journal of neurosurgery. 2014:1–100. Epub 2014/09/24. 107. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Molecular and cellular biology. 2009; 29(15):4250–61. Epub 2009/05/20. [PubMed: 19451225] 108. Giovannini M, Bonne NX, Vitte J, Chareyre F, Tanaka K, Adams R, et al. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro-oncology. 2014; 16(4):493–504. Epub 2014/01/15. [PubMed: 24414536] 109. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer research. 2006; 66(3):1500–8. Epub 2006/02/03. [PubMed: 16452206] 110. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS medicine. 2008; 5(1):e8. Epub 2008/01/25. [PubMed: 18215105] 111. James MF, Stivison E, Beauchamp R, Han S, Li H, Wallace MR, et al. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Molecular cancer research : MCR. 2012; 10(5):649–59. Epub 2012/03/20. [PubMed: 22426462] 112. Petrilli A, Bott M, Fernandez-Valle C. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis. Oncotarget. 2013; 4(12):2354–65. Epub 2013/11/22. [PubMed: 24259290] 113. Muranen T, Gronholm M, Lampin A, Lallemand D, Zhao F, Giovannini M, et al. The tumor suppressor merlin interacts with microtubules and modulates Schwann cell microtubule cytoskeleton. Human molecular genetics. 2007; 16(14):1742–51. Epub 2007/06/15. [PubMed: 17566081] 114. Bensenor LB, Barlan K, Rice SE, Fehon RG, Gelfand VI. Microtubule-mediated transport of the tumor-suppressor protein Merlin and its mutants. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(16):7311–6. Epub 2010/04/07. [PubMed: 20368450] 115. Pan D. The hippo signaling pathway in development and cancer. Developmental cell. 2010; 19(4):491–505. Epub 2010/10/19. [PubMed: 20951342] 116. Piccolo S, Dupont S, Cordenonsi M. The Biology of YAP/TAZ: Hippo Signaling and Beyond. Physiological reviews. 2014; 94(4):1287–312. Epub 2014/10/08. [PubMed: 25287865] 117. Kodaka M, Hata Y. The mammalian Hippo pathway: regulation and function of YAP1 and TAZ. Cellular and molecular life sciences : CMLS. 2014 Epub 2014/10/01. 118. Barron DA, Kagey JD. The role of the Hippo pathway in human disease and tumorigenesis. Clinical and translational medicine. 2014; 3:25. Epub 2014/08/07. [PubMed: 25097728] 119. Boin A, Couvelard A, Couderc C, Brito I, Filipescu D, Kalamarides M, et al. Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. Neuro-oncology. 2014; 16(9):1196–209. Epub 2014/02/22. [PubMed: 24558021] Petrilli and Fernández-VallePage 23Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript120. Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia. 2008; 10(11):1204–12. Epub 2008/10/28. [PubMed: 18953429] 121. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell. 2010; 140(4):477–90. Epub 2010/02/25. [PubMed: 20178741] 122. Mori T, Gotoh S, Shirakawa M, Hakoshima T. Structural basis of DDB1-and-Cullin 4-associated Factor 1 (DCAF1) recognition by merlin/NF2 and its implication in tumorigenesis by CD44-mediated inhibition of merlin suppression of DCAF1 function. Genes to cells : devoted to molecular & cellular mechanisms. 2014; 19(8):603–19. Epub 2014/06/11. [PubMed: 24912773] 123. Cooper J, Li W, You L, Schiavon G, Pepe-Caprio A, Zhou L, et al. Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression. Science signaling. 2011; 4(188):pt6. Epub 2011/09/01. [PubMed: 21878678] 124. Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, et al. Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. Cancer cell. 2014; 26(1):48–60. Epub 2014/07/16. [PubMed: 25026211] 125. Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell. 2013; 154(6):1342–55. Epub 2013/09/10. [PubMed: 24012335] 126. Flaiz C, Utermark T, Parkinson DB, Poetsch A, Hanemann CO. Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells. Glia. 2008; 56(5):506–15. Epub 2008/02/02. [PubMed: 18240308] 127. Low BC, Pan CQ, Shivashankar GV, Bershadsky A, Sudol M, Sheetz M. YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. FEBS letters. 2014; 588(16):2663–70. Epub 2014/04/22. [PubMed: 24747426] 128. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes & development. 2007; 21(21):2747–61. Epub 2007/11/03. [PubMed: 17974916] 129. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP/TAZ in mechanotransduction. Nature. 2011; 474(7350):179–83. Epub 2011/06/10. [PubMed: 21654799] 130. Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N, et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell. 2013; 154(5):1047–59. Epub 2013/08/21. [PubMed: 23954413] 131. Wada K, Itoga K, Okano T, Yonemura S, Sasaki H. Hippo pathway regulation by cell morphology and stress fibers. Development. 2011; 138(18):3907–14. Epub 2011/08/13. [PubMed: 21831922] 132. Boggiano JC, Fehon RG. Growth control by committee: intercellular junctions, cell polarity, and the cytoskeleton regulate Hippo signaling. Developmental cell. 2012; 22(4):695–702. Epub 2012/04/21. [PubMed: 22516196] 133. Robinson BS, Moberg KH. Cell-cell junctions: alpha-catenin and E-cadherin help fence in Yap1. Current biology : CB. 2011; 21(21):R890–2. Epub 2011/11/15. [PubMed: 22075429] 134. Schroeder MC, Halder G. Regulation of the Hippo pathway by cell architecture and mechanical signals. Seminars in cell & developmental biology. 2012; 23(7):803–11. Epub 2012/07/04. [PubMed: 22750148] 135. Yi C, Shen Z, Stemmer-Rachamimov A, Dawany N, Troutman S, Showe LC, et al. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Science signaling. 2013; 6(291):ra77. Epub 2013/09/05. [PubMed: 24003254] 136. Yi C, Troutman S, Fera D, Stemmer-Rachamimov A, Avila JL, Christian N, et al. A tight junction-associated Merlin-angiomotin complex mediates Merlin’s regulation of mitogenic signaling and tumor suppressive functions. Cancer cell. 2011; 19(4):527–40. Epub 2011/04/13. [PubMed: 21481793] 137. Pass HI, Vogelzang N, Hahn S, Carbone M. Malignant pleural mesothelioma. Current problems in cancer. 2004; 28(3):93–174. Epub 2004/06/16. [PubMed: 15197388] Petrilli and Fernández-VallePage 24Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript138. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer research. 1995; 55(6):1227–31. Epub 1995/03/15. [PubMed: 7882313] 139. Cheng JQ, Lee WC, Klein MA, Cheng GZ, Jhanwar SC, Testa JR. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes, chromosomes & cancer. 1999; 24(3):238–42. Epub 1999/08/19. [PubMed: 10451704] 140. Baser ME, De Rienzo A, Altomare D, Balsara BR, Hedrick NM, Gutmann DH, et al. Neurofibromatosis 2 and malignant mesothelioma. Neurology. 2002; 59(2):290–1. Epub 2002/07/24. [PubMed: 12136076] 141. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E. Functional inactivation of NF2/merlin in human mesothelioma. Lung cancer. 2009; 64(2):140–7. Epub 2008/10/07. [PubMed: 18835652] 142. Fleury-Feith J, Lecomte C, Renier A, Matrat M, Kheuang L, Abramowski V, et al. Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene. 2003; 22(24):3799–805. Epub 2003/06/13. [PubMed: 12802287] 143. Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer research. 2005; 65(18):8090–5. Epub 2005/09/17. [PubMed: 16166281] 144. Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, et al. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Molecular and cellular biology. 2005; 25(6):2384–94. Epub 2005/03/04. [PubMed: 15743831] 145. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005; 24(40):6080–9. Epub 2005/05/18. [PubMed: 15897870] 146. Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes & development. 2003; 17(9):1090–100. Epub 2003/04/16. [PubMed: 12695331] 147. Yokoyama T, Osada H, Murakami H, Tatematsu Y, Taniguchi T, Kondo Y, et al. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis. 2008; 29(11):2139–46. Epub 2008/08/30. [PubMed: 18725387] 148. Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer research. 2011; 71(3):873–83. Epub 2011/01/20. [PubMed: 21245096] 149. Smole Z, Thoma CR, Applegate KT, Duda M, Gutbrodt KL, Danuser G, et al. Tumor suppressor NF2/Merlin is a microtubule stabilizer. Cancer research. 2014; 74(1):353–62. Epub 2013/11/28. [PubMed: 24282279] 150. Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene. 2006; 25(44):5960–8. Epub 2006/05/03. [PubMed: 16652148] 151. McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes & development. 1998; 12(8):1121–33. Epub 1998/05/30. [PubMed: 9553042] 152. Bianchi AB, Hara T, Ramesh V, Gao J, Klein-Szanto AJ, Morin F, et al. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nature genetics. 1994; 6(2):185–92. Epub 1994/02/01. [PubMed: 8162073] 153. Yoo NJ, Park SW, Lee SH. Mutational analysis of tumour suppressor gene NF2 in common solid cancers and acute leukaemias. Pathology. 2012; 44(1):29–32. Epub 2011/11/15. [PubMed: 22081132] Petrilli and Fernández-VallePage 25Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript154. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Advances in cancer research. 1998; 72:141–96. Epub 1997/10/24. [PubMed: 9338076] 155. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002; 21(35):5427–40. Epub 2002/08/03. [PubMed: 12154405] 156. Larsson J, Ohishi M, Garrison B, Aspling M, Janzen V, Adams GB, et al. Nf2/merlin regulates hematopoietic stem cell behavior by altering microenvironmental architecture. Cell stem cell. 2008; 3(2):221–7. Epub 2008/08/07. [PubMed: 18682243] 157. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA. “Stemness”: transcriptional profiling of embryonic and adult stem cells. Science. 2002; 298(5593):597–600. Epub 2002/09/14. [PubMed: 12228720] 158. Hiemer SE, Varelas X. Stem cell regulation by the Hippo pathway. Biochimica et biophysica acta. 2013; 1830(2):2323–34. Epub 2012/07/25. [PubMed: 22824335] 159. Ramos A, Camargo FD. The Hippo signaling pathway and stem cell biology. Trends in cell biology. 2012; 22(7):339–46. Epub 2012/06/05. [PubMed: 22658639] 160. Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nature cell biology. 2011; 13(8):877–83. Epub 2011/08/03. [PubMed: 21808241] 161. Yaegashi S, Sachse R, Ohuchi N, Mori S, Sekiya T. Low incidence of a nucleotide sequence alteration of the neurofibromatosis 2 gene in human breast cancers. Japanese journal of cancer research : Gann. 1995; 86(10):929–33. Epub 1995/10/01. [PubMed: 7493911] 162. Allison KH, Sledge GW Jr. Heterogeneity and Cancer. Oncology. 2014; 28(9) Epub 2014/09/17. 163. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314(5797):268–74. Epub 2006/09/09. [PubMed: 16959974] 164. Shrestha Y, Schafer EJ, Boehm JS, Thomas SR, He F, Du J, et al. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene. 2012; 31(29):3397–408. Epub 2011/11/23. [PubMed: 22105362] 165. Arakawa H, Hayashi N, Nagase H, Ogawa M, Nakamura Y. Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers. Human molecular genetics. 1994; 3(4):565–8. Epub 1994/04/01. [PubMed: 8069299] 166. Rustgi AK, Xu L, Pinney D, Sterner C, Beauchamp R, Schmidt S, et al. Neurofibromatosis 2 gene in human colorectal cancer. Cancer genetics and cytogenetics. 1995; 84(1):24–6. Epub 1995/10/01. [PubMed: 7497438] 167. Cacev T, Aralica G, Loncar B, Kapitanovic S. Loss of NF2/Merlin expression in advanced sporadic colorectal cancer. Cellular oncology. 2014; 37(1):69–77. Epub 2013/12/11. 168. Pineau P, Marchio A, Nagamori S, Seki S, Tiollais P, Dejean A. Homozygous deletion scanning in hepatobiliary tumor cell lines reveals alternative pathways for liver carcinogenesis. Hepatology. 2003; 37(4):852–61. Epub 2003/04/02. [PubMed: 12668978] 169. Benhamouche S, Curto M, Saotome I, Gladden AB, Liu CH, Giovannini M, et al. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes & development. 2010; 24(16):1718–30. Epub 2010/08/03. [PubMed: 20675406] 170. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer cell. 2009; 16(5):425–38. Epub 2009/11/03. [PubMed: 19878874] 171. Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(4):1431–6. Epub 2010/01/19. [PubMed: 20080598] 172. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(4):1437–42. Epub 2010/01/19. [PubMed: 20080689] Petrilli and Fernández-VallePage 26Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript173. Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Developmental cell. 2010; 19(1):27–38. Epub 2010/07/21. [PubMed: 20643348] 174. Kawana Y, Ichikawa T, Suzuki H, Ueda T, Komiya A, Ichikawa Y, et al. Loss of heterozygosity at 7q31.1 and 12p13-12 in advanced prostate cancer. The Prostate. 2002; 53(1):60–4. Epub 2002/09/05. [PubMed: 12210480] 175. Malhotra A, Shibata Y, Hall IM, Dutta A. Chromosomal structural variations during progression of a prostate epithelial cell line to a malignant metastatic state inactivate the NF2, NIPSNAP1, UGT2B17, and LPIN2 genes. Cancer biology & therapy. 2013; 14(9):840–52. Epub 2013/06/25. [PubMed: 23792589] 176. Horiguchi A, Zheng R, Shen R, Nanus DM. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells. The Prostate. 2008; 68(9):975–84. Epub 2008/03/26. [PubMed: 18361411] 177. Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, Yu Q. Merlin is a potent inhibitor of glioma growth. Cancer research. 2008; 68(14):5733–42. Epub 2008/07/18. [PubMed: 18632626] 178. Morales FC, Molina JR, Hayashi Y, Georgescu MM. Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma. Neuro-oncology. 2010; 12(6):528–39. Epub 2010/02/17. [PubMed: 20156804] 179. Guerrero PA, Yin W, Camacho L, Marchetti D. Oncogenic role of Merlin/NF2 in glioblastoma. Oncogene. 2014 Epub 2014/07/22. 180. Sheikh HA, Tometsko M, Niehouse L, Aldeeb D, Swalsky P, Finkelstein S, et al. Molecular genotyping of medullary thyroid carcinoma can predict tumor recurrence. The American journal of surgical pathology. 2004; 28(1):101–6. Epub 2004/01/07. [PubMed: 14707871] 181. Murray LB, Lau YK, Yu Q. Merlin is a negative regulator of human melanoma growth. PloS one. 2012; 7(8):e43295. Epub 2012/08/23. [PubMed: 22912849] 182. Frontzek F, Nitzlaff S, Horstmann M, Schwab A, Stock C. Functional interdependence of NHE1 and merlin in human melanoma cells. Biochemistry and cell biology = Biochimie et biologie cellulaire. 2014:1–11. Epub 2014/10/03. 183. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014; 343(6166):84–7. Epub 2013/12/18. [PubMed: 24336571] 184. Reinhold WC, Varma S, Sousa F, Sunshine M, Abaan OD, Davis SR, et al. NCI-60 whole exome sequencing and pharmacological CellMiner analyses. PloS one. 2014; 9(7):e101670. Epub 2014/07/18. [PubMed: 25032700] 185. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012; 483(7391):570–5. Epub 2012/03/31. [PubMed: 22460902] 186. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic acids research. 2013; 41(Database issue):D955–61. Epub 2012/11/28. [PubMed: 23180760] 187. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468(7326):973–7. Epub 2010/11/26. [PubMed: 21107323] 188. Sabha N, Au K, Agnihotri S, Singh S, Mangat R, Guha A, et al. Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells. PloS one. 2012; 7(6):e39412. Epub 2012/06/30. [PubMed: 22745749] 189. Mukherjee J, Kamnasaran D, Balasubramaniam A, Radovanovic I, Zadeh G, Kiehl TR, et al. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate). Cancer research. 2009; 69(12):5099–107. Epub 2009/06/11. [PubMed: 19509233] 190. Ammoun S, Schmid MC, Triner J, Manley P, Hanemann CO. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro-oncology. 2011; 13(7):759–66. Epub 2011/07/06. [PubMed: 21727212] Petrilli and Fernández-VallePage 27Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 1. Merlin domain organization and molecular conformation. a) Diagram of merlin structural domains. b) Diagram of merlin molecular conformation based on ERM analogy. c) Diagram of merlin molecular conformation based on experimental data.Petrilli and Fernández-VallePage 28Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 2. Merlin inhibits membrane receptors and RhoGTPase family signaling cascade.Petrilli and Fernández-VallePage 29Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 3. Merlin inhibits PI3K/mTORC1/Akt signaling pathways.Petrilli and Fernández-VallePage 30Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 4. Role of merlin in the activation of the mammalian hippo pathway.Petrilli and Fernández-VallePage 31Oncogene. Author manuscript; available in PMC 2016 May 18.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptNeuroImage: Clinical 4 (2014) 649–658 Contents lists available at ScienceDirect NeuroImage: Clinical j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y n i c l Characterizing the microstructural basis of “unidentiﬁed bright objects”in neuroﬁbromatosis type 1: A combined in vivo multicomponent T2 relaxation and multi-shell diffusion MRI analysis Thibo Billiet a , b , c , d , * , Burkhard M ¨adler e , Felice D’Arco f , Ronald Peeters b , d , Sabine Deprez a , b , c , d , Ellen Plasschaert g , h , Alexander Leemans i , Hui Zhang j , Bea Van den Bergh k , l , Mathieu Vandenbulcke d , m , n , Eric Legius g , h , Stefan Sunaert a , b , c , d , Louise Emsell a , b , c , d a Department of Imaging & Pathology, KU Leuven, Herestraat 49, Leuven 3000, Belgium b Department of Radiology, University Hospitals Leuven, Herestraat 49, Leuven 3000, Belgium c Medical Imaging Research Center (MIRC), Herestraat 49, Leuven 3000, Belgium d Leuven Research Institute for Neuroscience & Disease (LIND), Herestraat 49, Leuven 3000, Belgium e Department of Neurosurgery, University of Bonn, Sigmund-Freud-Straße 25, Bonn 53105, Germany f Department of Diagnostic Imaging and Radiotherapy, University Federico II of Naples, Via de Filippis 107, Salerno 84013, Italy g Department of Human Genetics, KU Leuven, Herestraat 49, Leuven 3000, Belgium h Department of Human Genetics, University Hospitals Leuven, Herestraat 49, Leuven 3000, Belgium i Image Sciences Institute, University Medical Center, Heidelberglaan 100, Utrecht 3584 CX, Netherlands j Department of Computer Science & Centre for Medical Image Computing, University College London, Gower Street, London WC1E 6BT, UK k Department of Psychology, Tilburg University, Tilburg 5000 LE, Netherlands l Department of Health Psychology, KU Leuven, Tiensestraat 102, Leuven 3000, Belgium m Research Group Psychiatry, KU Leuven, Kapucijnenvoer 33, Leuven 3000, Belgium n Department of Psychiatry, University Hospitals Leuven, Herestraat 49, Leuven 3000, Belgium a r t i c l e i n f o Article history: Received 30 January 2014 Received in revised form 14 March 2014 Accepted 8 April 2014 Keywords: Myelin water imaging (MWI) Diffusion tensor imaging (DTI) Diffusion kurtosis imaging (DKI) Neurite orientation dispersion and density imaging (NODDI) Neuroﬁbromatosis type 1 (NF1) Unidentiﬁed bright objects (UBOs) a b s t r a c t Introduction: The histopathological basis of “unidentiﬁed bright objects”(UBOs) (hyperintense regions seen on T2-weighted magnetic resonance (MR) brain scans in neuroﬁbromatosis-1 (NF1)) remains unclear. New in vivo MRI-based techniques (multi-exponential T2 relaxation (MET2) and diffusion MR imaging (dMRI)) provide measures relating to microstructural change. We combined these methods and present previously unreported data on in vivo UBO microstructure in NF1. Methods: 3-Tesla dMRI data were acquired on 17 NF1 patients, covering 30 white matter UBOs. Diffusion tensor, kurtosis and neurite orientation and dispersion density imaging parameters were calculated within UBO sites and in contralateral normal appearing white matter (cNAWM). Analysis of MET2 parameters was performed on 24 UBO–cNAWM pairs. Results: No signiﬁcant alterations in the myelin water fraction and intra- and extracellular (IE) water fraction were found. Mean T2 time of IE water was signiﬁcantly higher in UBOs. UBOs furthermore showed increased axial, radial and mean diffusivity, and decreased fractional anisotropy, mean kurtosis and neurite density index compared to cNAWM. Neurite orientation dispersion and isotropic ﬂuid fraction were unaltered. Conclusion: Our results suggest that demyelination and axonal degeneration are unlikely to be present in UBOs, which appear to be mainly caused by a shift towards a higher T2-value of the intra- and extra- cellular water pool. This may arise from altered microstructural compartmentalization, and an increase in ‘extracellular-like ’ , intracellular water, possibly due to intramyelinic edema. These ﬁndings conﬁrm the added value of combining dMRI and MET2 to characterize the microstructural basis of T2 hyperintensities in vivo. c (cid:2)2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license ( http: // creativecommons.org / licenses / by-nc-nd / 3.0 / ). * Corresponding author. E-mail address: Thibo.Billiet@uzleuven.be (T. Billiet). 2213-1582/ $ - see front matter c (cid:2)2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license ( http: // creativecommons.org / licenses / by-nc-nd / 3.0 / ). http://dx.doi.org/10.1016/j.nicl.2014.04.005 650 T. Billiet et al. / NeuroImage: Clinical 4 (2014) 649–658 1. Introduction Neuroﬁbromatosis type 1 (NF1) is an autosomal dominant genetic disorder, with a prevalence of approximately 1 in 2700 newborns ( Evans et al., 2010 ). The disorder is characterized by multiple caf ´e-au- lait spots, axillary or inguinal freckling, iris Lisch nodules, distinctive osseous lesions and tumors of the nervous system, such as neuroﬁbro- mas and optic pathway gliomas. In addition to these clinical features, cognitive dysfunction is the most common complication of NF1. Ap- proximately 80% of NF1 children experience moderate to severe im- pairment in one or more areas of cognitive functioning ( Hyman et al., 2005 ; Krab et al., 2008 ). 1.1. Unidentiﬁed bright objects NF1 is associated with a number of magnetic resonance (MR) ab- normalities, including volumetric change in both white matter (WM) and gray matter (GM) ( Moore, B.D. 3rd et al., 2000 ; Cutting et al., 2000 ; Steen et al., 2001 ; Greenwood et al., 2005 ). In addition to these gen- eral changes, hyperintense foci, termed “unidentiﬁed bright objects”(UBOs) or T2 hyperintensities are readily detected on T2-weighted MRI scans of children and adolescents with the disorder. Such UBOs are typically found in the cerebellum (dentate nuclei, middle cerebel- lar peduncles, cerebellar deep white matter), brainstem, basal ganglia and thalami ( Itoh et al., 1994 ; Van Es et al., 1996 ; Grifﬁths et al., 1999 ). Fig. 1 shows some examples. UBOs have been described as hamartomas 1 ( Braffman et al. 1988 ), regions of abnormal myelination ( Smirniotopoulos and Murphy 1992 ) or heterotopias 2 ( Bognanno et al. 1988 ). However, as NF1 is rarely lethal, to date only one histological experiment has been conducted to assess UBO microstructure ( DiPaolo et al., 1995 ). In this study, vacuoles of between 5 and 100 μm were found in the myelin sheath, suggesting intramyelinic edema. No evidence of any inﬂammatory reaction or demyelination was found and axonal loss was excluded. Furthermore, the white matter expressed hypocellularity and glial cell proliferation. Although UBOs may be transient and are considered benign, some persist into adulthood and there is increasing evidence correlating their presence with cognitive dysfunction ( B.D. Moore et al., 1996 ; Goh et al., 2004 ; Hyman et al., 2007 ; Feldmann et al., 2010 ; Piscitelli et al., 2012 ). Understanding the pathophysiological substrate of UBOs may provide a basis from which to identify which UBOs are transient, how they respond to pharmacological treatments and how they relate to the risk of cognitive complaints during childhood and adolescence. 1.2. In vivo assessment of UBO microstructure using diffusion MRI and multi-exponential T2 relaxation Diffusion magnetic resonance imaging (dMRI ) ( Le Bihan et al., 1986 ) can be used to investigate UBOs in vivo. dMRI relates the dispersion of water molecules within tissue over a short interval of time (typically in the order of 10 −2 s) to microstructural features reﬂecting cellu- larity, membrane density and neurite orientation. In (over-) simpli- ﬁed terms, water moving most freely, such as in extra-axonal spaces, displays Gaussian diffusion, while water restricted within cells, dis- plays non-Gaussian diffusion. A number of different dMRI models are able to quantify these two types of diffusion, namely diffusion tensor imaging (DTI) ( Basser et al., 1994a ; Basser, 1995 ), diffusion kurto- sis imaging (DKI) ( Jensen and Helpern, 2010 ) and neurite orientation 1 A hamartoma is tissue at its correct physiological site, growing in a disorganized manner, forming a focal but benign malformation. It consists of the same tissue ele- ments as the tissue it resides in. 2 A heterotopia is ectopic tissue (i.e. not at its correct physiological site), co-existing with tissue it resides in. dispersion and density imaging (NODDI) ( Zhang et al., 2012 ), and are summarized in Table 1 . Previous studies using simple dMRI and DTI have reported ele- vated apparent diffusion coefﬁcient (ADC) in T2-hyperintense lesions compared to NAWM in patients ( Alkan et al., 2005 ; Tognini et al., 2005 ) and controls ( Eastwood et al., 2001 ; Alkan et al., 2005 ; Tognini et al., 2005 ; van Engelen et al., 2008 ) and signiﬁcantly decreased fractional anisotropy (FA) values in UBO sites compared to NAWM ( Zamboni et al., 2007 ; Ferraz-Filho et al., 2012a ; Ferraz-Filho et al., 2012b ; Filippi et al., 2012 ). Neither DKI nor NODDI has previously been used to investigate UBOs. Multi-exponential T2 relaxation ( MacKay et al., 1994 ; MacKay et al., 2006 ) is a complementary MRI technique that distinguishes the MR signal arising from different water pools based on T2 relaxation. Typically three water peaks can be identiﬁed in the so-called T2 dis- tribution. In normal human white matter, and in a 3 Tesla magnetic ﬁeld, the water that is trapped between the myelin bilayers exhibits a short T2 relaxation time of around 20 ms, whereas intra- and ex- tracellular water relaxes at an intermediate rate of around 80 ms ( MacKay et al., 1994 ; Whittall et al., 1997 ; Webb et al., 2003 ). The ﬁrst peak in the T2 distribution is therefore attributable to myelin water, while the second peak (around 80 ms) represents combined intra- and extracellular water. CSF has T2 values in the order of seconds. A summary of the measures that can be derived from dMRI and MET2 is provided in Table 1 , and a more detailed overview is provided as Supplementary material (SM1). 1.3. Aim of present study Although ﬁndings from DTI metrics are suggestive of altered tissue microstructure in UBO regions, the lack of speciﬁcity of measures derived from these techniques means that the exact nature of the histopathological changes arising in UBOs remains elusive. The aim of the present study therefore, was to use two novel, advanced white matter imaging approaches: MET2 and DKI / NODDI, in addition to DTI, to reﬁne our understanding of the microstructural basis of UBOs. By extension, a further aim was to demonstrate the utility of combining these techniques to advance our understanding of T2 hyperintensities arising in other pathologies and advancing age. 2. Materials & methods 2.1. Subjects Seventeen NF1 patients with UBOs (7 girls (age 13 ±3 years), 10 boys (age 12 ±3 years)) underwent an MRI scan. Subjects were recruited from the Leuven multidisciplinary neuroﬁbromatosis clinic and the multidisciplinary NF1-outpatient clinic of the Erasmus MC- Sophia Children’s Hospital in Rotterdam. The study was approved by the local Ethical Commission and conducted in accordance with the Declaration of Helsinki. 2.2. Data acquisition Imaging data were acquired using a 3 T MR scanner (Achieva; Philips, Best, the Netherlands) and a 32-channel phased-array head coil. Multi-slice T2-weighted FLAIR images were acquired to identify UBOs. Acquisition parameters were TR / TI = 11,000 ms / 2800 ms, TE = 120 ms, 25 slices, and thickness 4 mm. A spin-echo echo-planar imaging diffusion-weighted scheme was obtained consisting of three b-values (700, 1000 and 2800 s / mm 2 ) acquired along 25, 40 and 75 uniformly distributed directions, re- spectively ( Poot et al., 2010 ). Constant scan parameters were TR / TE = 7800 ms / 90 ms, 50 slices, voxel size 2.5 ×2.5 ×2.5 mm 3 , parallel imaging factor 2. Each diffusion-weighted acquisition was T. Billiet et al. / NeuroImage: Clinical 4 (2014) 649–658 651 Fig. 1. Examples of unidentiﬁed bright objects (UBOs) as seen on T2-weighted FLAIR images of NF1 children. A: Bilateral basal ganglia (top arrows) and hypothalamus (bottom arrows). B: splenium of corpus callosum. C: Globus pallidus. D: Cerebellar white matter. E: Cerebral peduncle. F: Junction of pons and mesencephalon. Note: in this study we only examined white matter UBOs. complemented with a gradient-free image (b = 0) and seven addi- tional b = 0 images were acquired. For MET2 analysis, a 3D GraSE multi-echo sequence was used ( Maedler and MacKay, 2007 ; Prasloski et al., 2012b ). The scan in- cluded 32 echoes with a ﬁrst echo time of 10 ms and a TE of 10 ms (TE = 10 ms, 20 ms, . . . , 320 ms) and EPI read-out factor of 3, TR = 800 ms, 32 mid-axial slices and voxel size 1 ×1 ×2 mm 3 . 2.3. Data analysis 2.3.1. T2-weighted FLAIR An experienced radiologist (FD (cid:3) A) identiﬁed white matter UBOs on T2-weighted FLAIR images. We excluded regions of bilateral T2- hyperintensities from the analysis. The T2-weighted FLAIR images were then resampled to 2.5 mm slice thickness and regions of in- terest (ROIs) were manually delineated around sites of white matter hyperintensities and the contralateral normal-appearing white mat- ter (cNAWM). 2.3.2. dMRI All datasets were visually inspected by looping through the DWIs in all three orthogonal views (axial, sagittal, coronal). Datasets with obvious artifacts (e.g. signal dropout, gross geometric distortion, bulk motion) were excluded. The suitable datasets were then corrected for motion-induced and eddy current induced geometric distortions with appropriate reorientation of the b-matrix using the ExploreDTI Toolbox ( Leemans, 2009 ; Leemans and Jones, 2009 ). Next, the result- ing DWIs were ﬁtted to the DTI model ( Basser et al., 1994b ), the DKI model ( Jensen and Helpern, 2010 ) and the NODDI model ( Zhang et al., 2012 ). Mean diffusivity (MD), radial diffusivity (RD), axial diffusivity (AD) and fractional anisotropy (FA) were estimated from the diffusion tensor, and the kurtosis tensor yielded mean kurtosis (MK). Estimates of neurite density index (NDI), orientation dispersion index (ODI) and the isotropic fraction (FISO) were obtained with the NODDI toolbox 3 . The resampled T2-weighted FLAIR images were registered to the FA image using ANTS ( Friston et al., 2007 ; Avants et al., 2008 ) with diffeomorphic transformations and a pure cross correlation similar- ity metric. The same transformation was applied to all UBO–cNAWM pairs, which were then used as masks on the dMRI parameter maps. All parameter values in the UBO and cNAWM regions of interest were averaged, respectively. 2.3.3. Multi-exponential T2 relaxation The multi-echo data was ﬁrst visually checked for motion arti- facts and datasets with a blurred ﬁrst echo image were discarded. The resampled T2-weighted FLAIR data were then registered with the ﬁrst echo image, using the same approach as described before. This transformation was then applied on all ROIs. Next, decay curves of voxels inside each ROI were averaged and T2 relaxation distribu- tions were calculated using a regularized non-negative least squares algorithm ( Whittall and Mackay, 1989 ), correcting for non-ideal re- focusing pulse ﬂip angles ( Prasloski et al., 2012a ). Inside each ROI, the myelin water fraction (MWF) was deﬁned as the area underneath the T2 distribution between 10 and 35 ms relative to the total area. Intra- and extracellular water fraction (IEWF) was obtained as the relative area fraction between 35 and 220 ms. The geometric mean T2 time (IEW-gmT2) was calculated as described in 3 http: // www.nitrc.org / projects / noddi toolbox ; see Supplementary material SM1 for further information about these parameters. 652 T. Billiet et al. / NeuroImage: Clinical 4 (2014) 649–658 Table 1 Summary of MRI techniques, models and derived parameters used in the present study. Imaging technique Model Measure Abbreviation Measure relates to Scale Diffusion MRI (dMRI) DTI Fractional anisotropy FA Presence of preferred direction of diffusion (i.e. tissue anisotropy) 0–1 (0 = most isotropic, 1 = most anisotropic) Mean diffusivity MD Amount of isotropic diffusion (i.e. not bounded by membranes, e.g. in CSF) Continuous increasing value = increasing amount of diffusion Axial diffusivity AD Amount of isotropic diffusion along direction of maximal diffusion Continuous increasing value = increasing amount of diffusion Radial diffusivity RD Amount of isotropic diffusion perpendicular to direction of maximal diffusion Continuous increasing value = increasing amount of diffusion DKI Mean kurtosis MK Presence of compartments that do not have a Gaussian diffusion proﬁle (i.e. bounded by membranes) Continuous increasing value = more compartmentalization NODDI Neurite density index NDI Density of axons and dendrites based on intracellular diffusion 0–1 (0 = most extracellular diffusion, 1 = most intracellular diffusion) Orientation dispersion index ODI Dispersion of axons and dendrites in the intracellular compartment 0–1 (0 = well-aligned neurites, 1 = highly dispersed neurites) Fraction of isotropic compartment FISO Cerebrospinal ﬂuid (isotropic Gaussian diffusion) 0–1 (0 = no CSF-like ﬂuid, 1 = most CSF-like ﬂuid) Multi-exponential T2 relaxation (MET2) MET2 Myelin water fraction MWF Myelin content 0–1 (0 = least myelin, 1 = most myelin) Intra- and extracellular water fraction IEWF Water molecules in and between axons (or having similar properties) 0–1 (0 = no intra- or extracellular water, 1 = mostly intra- and extracellular water) Geometric mean T2 time IEW-gmT2 Intra- and extra-axonal mobility of water molecules (e.g. long T2 time = high mobility) Continuous increasing value = more loosely bound water molecules Whittall et al. (1997) (see Supplementary material SM1 for further information about these parameters). 2.4. Statistical analysis After obtaining average parameter values in all UBOs and cNAWM ROIs, we assessed whether the data was normally distributed. For each UBO–cNAWM pair and each parameter, an estimate of the ef- fect size was calculated as the difference of UBO and cNAWM values divided by their mean. Next the Lilliefors test was applied on the resulting effect sizes of each parameter. As normality could not be guaranteed for all parameters, a non-parametric testing was used for further statistical analysis. For each parameter, UBO and cNAWM pa- rameter values were therefore compared using a paired Wilcoxon signed ranks test, i.e. parameter of interest in UBO 1 vs. cNAWM 1, parameter of interest in UBO 2 vs. cNAWM 2, etc. This analysis was performed in MATLAB (MathWorks, Natick, MA) using the signrank function. Resulting p -values were then corrected for multiple com- parisons, adopting a 5% false discovery rate (FDR) criterion. Corrected values were deemed signiﬁcant if p < 0.05. 3. Results As can be seen from Table 2 , from the 17 subjects, 30 UBO–cNAWM pairs were obtained for dMRI analysis, of which 24 also yielded suf- ﬁcient MET2 data quality and were located inside the FOV of the 3D GraSE sequence. An example of the evaluated parameter maps is displayed in Fig. 2 . 3.1. dMRI results Fig. 3 summarizes the results from the analysis of diffusional and kurtosis estimates. Compared to regions of cNAWM, T2- hyperintensities showed both increased AD (FDR —p = 0.0061) and RD (FDR —p = 0.0066), leading to an increase of MD (FDR —p = 0.0041). There appeared to be less anisotropy in UBOs than in cNAWM as FA was signiﬁcantly decreased (FDR —p = 0.021). Fur- thermore, a signiﬁcantly decreased MK (FDR —p = 0.0012) in UBOs compared to cNAWM was found, indicating that non-Gaussian diffu- sion was less present in UBOs than in cNAWM. The NODDI model resulted in reduced NDI in UBOs (FDR —p = 0.014) with no signiﬁcant alterations in FISO (FDR —p = 0.51) or in ODI (FDR —p = 0.88). 3.2. Multi-exponential T2 relaxation results Fig. 4 illustrates typical T2 distributions of three UBOs and their cNAWM. Distributions for the remaining UBOs can be found in the Supplementary material SM2. Both ﬁgures illustrate the water frac- tion of the different water pools and the mean T2 of the IEW peak. The statistical results illustrated in Fig. 3 show that the IEW peak in UBOs appears to be shifted to longer T2 relaxation values (IEW-gmT2, FDR —p = 0.0014). MWF (FDR —p = 0.35) and IEWF (FDR —p = 0.86) did not differ signiﬁcantly between UBOs and cNAWM. T. Billiet et al. / NeuroImage: Clinical 4 (2014) 649–658 653 Fig. 2. Example (native space) parameter maps of a UBO in the splenium of the corpus callosum. Red arrows indicate the UBO in the T2-weighted FLAIR image and in parameter maps for which this study found signiﬁcant results. MWF: myelin water fraction; IEWF: intra- and extracellular water fraction; IEW-gmT2: geometric mean T2 time of intra- and extracellular water (s); FA: fractional anisotropy; RD: radial diffusivity (mm 2 s −1 ); AD: axial diffusivity (mm 2 s −1 ); MD: mean diffusivity (mm 2 s −1 ); MK: mean kurtosis (no unit); NDI: neurite density index; ODI: orientation dispersion index: FISO: isotropic fraction. Color bars indicate the scalar value range. 654 T. Billiet et al. / NeuroImage: Clinical 4 (2014) 649–658 Table 2 Subject characteristics and UBO number and locations. Subject Gender Age (years) UBO–cNAWM pairs a Location b 1 F 16.1 1 CCS 2 M 10.1 1 CblP 3 F 11.7 1 CWM 4 F 12.7 2 CblP, CP 5 F 12.1 4 (1) CWM, CWM, pons, CP 6 F 15.8 1 AC 7 F 9.5 4 (1) CS, CP , bulb, CWM 8 M 9.6 2 MES, CWM 9 F 16.1 1 CP 10 M 17.2 3 CWM, pons, CCS 11 M 12.2 2 MES, CWM 12 M 9.4 1 CWM 13 M 9.2 1 CWM 14 M 14.7 1 CP 15 M 8.7 1 CWM 16 M 14.5 1 CWM 17 M 15.4 3 Bulb, CWM, CblP F, female; M, male; CCS = splenium of corpus callosum; CblP = cerebellar peduncle; CWM = cerebellar white matter; CP = cerebral peduncle; AC = anterior commissure; CS = centrum semiovale; MES = mesencephalon; bulb = bulbus. a If different for MET2 and dMRI analysis, the number in between brackets indicates the number of UBO-cNAWM pairs for MET2 analysis. b Underlined locations were not available for MET2 analysis. Fig. 3. Boxplot representation (box containing median and 25th and 75th percentiles) of dMRI and MET2 parameter values. The left side of each panel (dark box) corresponds with values in cNAWM, the right side (light box) with values in contralateral UBOs. Dashed gray lines connect values from one UBO–cNAWM pair. MWF = myelin water fraction; IEWF = intra- and extracellular water fraction; IEW-gmT2 = geometric mean T2 time of the intra- and extracellular water (s); FA = fractional anisotropy; RD = ra- dial diffusivity (mm 2 s −1 ); AD = axial diffusivity (mm 2 s −1 ); MD = mean diffusivity (mm 2 s −1 ); MK = mean kurtosis (no unit); NDI = neurite density index; ODI = orienta- tion dispersion index of neurites; FISO = isotropic fraction. Fig. 4. Typical T2 distribution of UBO (red) and cNAWM (blue). Red and blue vertical dashed lines indicate the IEW-gmT2 of UBO and cNAWM, respectively. The intra- and extracellular water (IEW) peak in the UBO shows a shift towards longer T2 times as illustrated by the red arrows. Vertical dashed lines in black indicate the integration interval for the IEWpeak.Left:cerebral peduncle;middle:splenium of corpus callosum; right: cerebellar white matter. For clarity, the above results are summarized in Table 3 . 4. Discussion To our knowledge, this was the ﬁrst study to investigate non- Gaussian diffusion and multi-exponential T2 relaxation parameters in children with NF1. We demonstrated a lower MK in UBOs com- pared to cNAWM using DKI, and a decreased neurite density (NDI) in UBOs with unchanged neurite orientation dispersion (ODI) and isotropic fraction (FISO) using NODDI. The myelin water fraction and IEWF were also unchanged. In contrast, increased T2 relaxation values of the intra- and extracellular water (IEW-gmT2) in UBOs appeared to be the main cause of T2 hyperintensities. We also conﬁrmed pre- vious ﬁndings of decreased fractional anisotropy (FA) and detected increased axial, radial and mean diffusivity (AD, RD and MD, respec- tively) in UBOs. 4.1. Which microstructural changes may be occurring in the white matter UBOs? The myelin water fraction was not altered signiﬁcantly, suggesting more or less intact myelin layers. This is in line with previous histolog- ical ﬁndings ( DiPaolo et al., 1995 ), although differences in myelin wa- ter content in living and post-mortem tissue mean that ﬁndings from our respective studies cannot be compared equivalently. Margariti et al. (2007) hypothesized that decreased magnetization transfer ratio (MTR) in UBOs represented hypomyelination in their study of NF1 patients and healthy controls. However, decreased MTR may also re- late to an increase in edema or inﬂammation, without demyelination T. Billiet et al. / NeuroImage: Clinical 4 (2014) 649–658 655 Table 3 Results of diffusion MRI and multi-exponential T2 relaxation parameters evaluated in UBOs and compared with cNAWM. FA = fractional anisotropy (%); MD = mean diffusivity (mm 2 s −1 ); AD = axial diffusivity (mm 2 s −1 ); RD = radial diffusivity (mm 2 s −1 ); MK = mean kurtosis (no unit); NDI = neurite density index (%); ODI = orientation dispersion index of neurites (%); FISO = isotropic fraction (%); MWF = myelin water fraction (%); IEWF = intra- and extracellular water fraction (%); IEW-gmT2 = geometric mean T2 time of the intra- and extracellular water (s). An asterisk next to the FDR-corrected p -values indicates signiﬁcance at 95% conﬁdence level. Type of imaging Parameter Direction of signiﬁcant change (UBO compared to cNAWM) FDR-corrected p -value (FDR- p ) DTI FA ↓ 0.021* MD ↑ 0.0041* AD ↑ 0.0061* RD ↑ 0.0066* DKI MK ↓ 0.0012* NODDI NDI ↓ 0.014* ODI –0.88 FISO –0.51 MET2 MWF –0.35 IEW-gmT2 ↑ 0.0014* IEWF –0.86 ( Stanisz et al., 2004 ; Laule et al., 2007a ; Vavasour et al., 2011 ). Given the unaltered MWF found in the present study, our results favor a hypothesis of edema formation. Further evidence comes from our observation of prolonged IEW-gmT2. This suggests that the intra- and extracellular matrix differs substantially between UBO regions and cNAWM, which would be expected in the case of edema or in- ﬂammation ( Stanisz et al., 2004 ). Other possible mechanisms of this prolonged IEW-gmT2 could include glial cell proliferation or reduced exchange between intra- and extracellular water. 4.2. Could UBOs be caused by intramyelinic edema? Having established a plausible hypothesis for edema, is it possi- ble to deduce in which microstructural compartment it is arising? In intramyelinic edema vacuoles are formed in between the myelin layers due to splitting at the intraperiod line. There is some evidence from previous work and our ﬁndings that supports the presence of intramyelinic edema in UBOs. For example: prolonged T2 relaxation times have been found in a biexponential T2 relaxation study of in- tramyelinic edema in cats ( Barnes et al., 1987 ) and a three-pool MET2 model of intramyelinic edema in rats ( Harkins et al., 2013 ) also yielded a distinct long-T2 reservoir. The difference between the latter and our study is mainly that we made no assumptions about the number of water peaks to be found. Water compartments with similar but dis- tinct T2 times may therefore be expressed as a single peak having a prolonged T2 time. In the case of intramyelinic edema, this may explain why most of our UBO samples showed prolonged T2 rather than distinct long-T2 peaks. Diffuse WM lesions of phenylketonuria (PKU) patients are thought to be expressions of hypomyelination or intramyelinic edema, de- pending on treatment status ( Anderson and Leuzzi, 2010 ). Sirrs et al. found that diffuse white matter lesions observed in phenylketonuria (PKU) patients also exhibit prolonged T2 values, in the form of an additional reservoir ( Sirrs et al., 2007 ). In addition to PKU or intramyelinic edema models, prolonged T2 values have also been observed in multiple sclerosis lesions, ( Armspach et al., 1991 ) in which the prolongation could be linked to vacuolization, increases in the amount of extracellular water or reduced exchange between intra- and extracellular water ( Laule et al., 2007b ; Laule et al., 2007c ). These multiple pathological mechanisms underlying prolonged T2 time complicate the interpretation of the origin of the prolonged IEW-gmT2 we ﬁnd in UBOs based on MET2 alone. 4.3. Can we learn more by considering the diffusion measures? In agreement with previous studies, decreased FA and increased MD were found in UBOs compared to cNAWM, suggesting altered tis- sue microstructure. Elevated levels of both AD and RD reveal that the increase in MD is not related to only one or selective directions of dif- fusion. The elevated mean diffusivity levels are in contrast with what is found in PKU, where generally MD is lower in diffuse WM lesions than in NAWM of healthy controls ( Dezortova et al., 2001 ; Phillips et al., 2001 ; Leuzzi et al., 2007 ; Vermathen et al., 2007 ). However, some authors have argued that lower MD in PKU lesions is more probably due to cytotoxic edema ( Dezortova et al., 2001 ; Phillips et al., 2001 ) or accumulation of hydrophilic metabolites ( Leuzzi et al., 2007 ). No- tably, in Maple Syrup Urine Disease (MSUD) brainstem lesions with reduced ADC are observed, which is not the case in similarly located NF1 UBOs. We might expect that intramyelinic vacuoles would lead to increased diffusivity levels as we found in this study. In any case, if in- tramyelinic edema were to be present in NF1, PKU and MSUD lesions, there could be differences (perhaps vacuole size or presence of debris) that may be revealed using combined MET2 and dMRI methods. The DKI model additionally indicated alterations in tissue com- partments displaying non-Gaussian diffusion. However, as with DTI parameters, the interpretation of kurtosis estimates in isolation is limited. The NODDI framework therefore may allow further interpre- tation of DTI and DKI changes by incorporating a three-compartment biophysical tissue model. Reduced NDI and unaltered ODI in UBOs suggest that the reduced FA is mainly caused by a lower neurite density (as deﬁned by the NODDI model) and not so much by increased dispersion of neurite orientations. This could be explained by axonal loss. However, as the MWF and IEWF from MET2 analysis did not change in the UBOs in our study, axonal loss is unlikely to be the primary determinant of reduced neurite density. Rather, the decreased NDI could arise from an increased distance between axons, for example, due to edema. These observations make it difﬁcult to conclude that intramyelinic edema is present. However, edema arising in the extracellular space is less likely. If that were the case, and given the Gaussian diffusion proﬁle of the extracellular space, FISO would be expected to increase, which we did not observe. Intramyelinic edema therefore remains a possible hypothesis. This combined analysis illustrates the complementary nature of dMRI and MET2 when it comes to evaluating T2 hyperintensities such as UBOs. MET2 analysis alone is not able to distinguish whether an increase in IEW-gmT2 is more related to changes in the intra- or extra- cellular water compartment. The NODDI analysis offers an indication of disparity between intra- and extracellular compartments, based on 656 T. Billiet et al. / NeuroImage: Clinical 4 (2014) 649–658 differences in diffusional properties. On the other hand, dMRI mea- sures are less speciﬁc to myelination than the myelin water fraction from MET2 analysis. 4.4. Methodological considerations This study beneﬁts from the application of two advanced, novel MR based techniques, which has allowed us to investigate UBO mi- crostructure in vivo, to a degree not previously possible using con- ventional imaging techniques. However, there remain a number of limitations that should be addressed. Firstly, this is a small-scale exploratory study and the ﬁndings require conﬁrmation in a larger sample. Secondly, as with all studies employing image registration and manually deﬁned ROIs, errors arising from these techniques cannot be ruled out. Of particular importance in this study is the issue of partial volume, where contamination from CSF may inﬂuence the results. To minimize this, we avoided delineating ROIs near to the ventricles. We also used advanced diffeomorphic registration to limit registration errors. Another issue relates to the ROI deﬁnition itself. We used the well-deﬁned boundary on T2-weighted FLAIR to isolate the UBOs, however, it is possible that microstructural changes extend beyond this region ( Mizukoshi et al., 2009 ). We also used cNAWM as a control region, however, it is impossible to precisely deﬁne an equivalent contralateral region, which itself may be subject to other underlying disease-related tissue changes that are not visually appreciable using the imaging method used in this study. A related issue concerns differences in the size and location of ROIs. We used an average measure from each contributing voxel within an ROI. However, the variance of these measures will be inﬂuenced by the size of the ROI delineated. As each ROI was deﬁned by the size of the UBO, this issue was an unavoidable feature of our analysis approach. Regarding the location of the UBOs, in our interpretation we assume that all UBOs and cNAWM have the same underlying microstructure irrespective of location. However, this does not account for known variability in WM microstructure throughout the brain or potential differences between UBOs. For example, some UBOs are transient and others remain. We addressed this in part by limiting our analysis to UBOs located in WM, however, as this is a cross-sectional study, we do not know which, if any of the UBOs included for investigation will disappear over time. Rescanning the patients included in this study in the future will therefore be highly informative. Finally, although the MRI based measures utilized in this study are directly inﬂuenced by tissue microstructure, they remain indi- rect metrics based on simpliﬁed mathematical models and imperfect imaging techniques. While the inclusion of non-Gaussian diffusion in the DKI and the NODDI model is a major improvement over DTI, all three models assume a single dominant orientation of diffusion per voxel, which does not hold true in the majority of voxels which include healthy brain tissue ( Jeurissen et al., 2013 ). It is also unlikely to hold true in UBOs. Directional estimates such as AD and RD should there- fore be interpreted with care, as the directions they describe may not represent directions parallel and perpendicular to axons, respectively. Furthermore, NDI and ODI are designed to quantify the property of the tissue compartment contained within each voxel while eliminat- ing the contamination from free water. An unavoidable issue arises when a voxel is predominantly free water. In such cases, the estimates of NDI and ODI, although they can still be computed numerically, are meaningless or cannot be determined accurately. To take this into account, for the analysis of NDI and ODI we only considered voxels for which FISO < 0.8. As myelin water mapping from MRI data is a relatively recent technique, the analysis is continuously evolving and there are a num- ber of ways to obtain MWF from MET2 or from other techniques such as mcDESPOT ( Deoni et al., 2008 ) or from T2* decay ( Hwang et al., 2010 ; Lenz et al., 2012 ). These different models, data acquisition and post-processing strategies will inﬂuence the estimated MWF. For example, acquisition parameters such as TE or TR may inﬂuence the results. While the TE used in this study allows estimation of the MWF, to obtain the exact position of the myelin peak would re- quire shorter echo spacing. It is also known that shortening TR may increase the estimation of MWF ( Kalantari et al., 2013 ). Our study had a shorter TR compared to other studies. Although the inﬂuence on results from within-subject comparative studies like ours may be limited, this may have contributed to overestimated MWF values in our sample. Similarly, the choice of integration window used to dif- ferentiate the myelin water peak from the intracellular water peak is somewhat arbitrary within an accepted range, and this will also affect MWF estimation. To rule out the effect of integration window choice on our results (10–35 ms for myelin water and 35–220 ms for IEW) we repeated the analysis using ranges that may be found in other studies (10–40 ms, 15–35 ms, 15–40 ms for myelin water and 40–220 ms, 35–200 ms, 40–200 ms for IEW). Although the es- timated MWF did change according to integration window, this did not change the outcome of the statistical analysis. Nevertheless, it is important to note that MWF gives an indication of myelin content but not an exact quantiﬁcation, and there is no consensus on the optimal acquisition or post-processing strategies to apply. For these reasons, the imaging techniques used in this study will always lack the sensitivity and speciﬁcity of ex-vivo histological anal- ysis. Nevertheless, in vivo studies like ours, although imperfect, pro- vide data and insight that are simply not possible with histological analysis. 5. Conclusion We have presented ﬁndings from the ﬁrst multi-modal MET2, DTI, DKI and NODDI study of UBOs in NF1 patients. Results suggest that the NF1 related T2 hyperintensities (UBOs) can be attributed to intracel- lular water obtaining extracellular-like properties, causing increased average T2 time but stable intra- and extracellular water pool frac- tions. The ﬁndings in this initial exploratory study support the hypothe- sis of intramyelinic vacuolization, in the absence of demyelination or axonal damage. Combining advanced diffusion models with multi-exponential T2 relaxation has proven useful in characterizing UBOs and therefore may be beneﬁcial for investigating the microstructural basis of T2 hyperintensities in other pathologies and in normal ageing. Conﬂicts of interest The authors declare that they have no conﬂict of interest. Acknowledgments The authors would like to thank and acknowledge Thomas Prasloski and colleagues at the UBC MRI Research Centre, for assisting with analysis of multi-echo data. Appendix A. Supplementary material Supplementary material associated with this article can be found, in the online version, at http: // dx.doi.org / 10.1016 / j.nicl.2014.04.005 . References Alkan, A., Sigirci, A., Kutlu, R., Ozcan, H., Erdem, G., Aslan, M., et al. 2005. Neuroﬁbro- matosis type 1: diffusion weighted imaging ﬁndings of brain. European Journal of Radiology 56 (2), 229–34. http://dx.doi.org/10.1016/j.ejrad.2005.05.008 , [Compar- ative Study] 15963674 . T. Billiet et al. / NeuroImage: Clinical 4 (2014) 649–658 657 Anderson, P.J., Leuzzi, V., 2010. White matter pathology in phenylketonuria. Molecular Genetics and Metabolism 99 (Suppl. 1), S3–S9. http://dx.doi.org/10.1016/j.ymgme. 2009.10.005 , [Review] 20123467 . Armspach, J.P., Gounot, D., Rumbach, L., Chambron, J., 1991. In vivo determina- tion of multiexponential T2 relaxation in the brain of patients with multiple sclerosis. Magnetic Resonance Imaging 9 (1), 107–13. http://dx.doi.org/10.1016/ 0730- 725X(91)90104- T , 2056848 . Avants, B.B., Epstein, C.L., Grossman, M., Gee, J.C., 2008. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of el- derly and neurodegenerative brain. Medical Image Analysis 12 (1), 26–41. http: //dx.doi.org/10.1016/j.media.2007.06.004 , [Research Support, N.I.H., Extramural] 17659998 . Barnes, D., McDonald, W.I., Johnson, G., Tofts, P.S., Landon, D.N., 1987. Quantitative nuclear magnetic resonance imaging: characterisation of experimental cerebral oedema. Journal of Neurology, Neurosurgery, and Psychiatry 50 (2), 125–33, [Re- search Support, Non-U.S. Gov’t] 3572428 . Basser, P.J., Mattiello, J., LeBihan, D., 1994. Estimation of the effective self-diffusion tensor from the NMR spin echo. Journal of Magnetic Resonance. Series B 103 (3), 247–54. http://dx.doi.org/10.1006/jmrb.1994.1037 , 8019776 . Basser, P.J., Mattiello, J., LeBihan, D., 1994. MR diffusion tensor spectroscopy and imag- ing. Biophysical Journal 66 (1), 259–67. http://dx.doi.org/10.1016/S0006-3495(94) 80775-1 , 8130344 . Basser, P.J., 1995. Inferring microstructural features and the physiological state of tis- sues from diffusion-weighted images. NMR in Biomedicine 8 (7–8), 333–44, [Re- view] 8739270 . Bognanno, J.R., Edwards, M.K., Lee, T.A., Dunn, D.W., Roos, K.L., Klatte, E.C., 1988. Cranial MR imaging in neuroﬁbromatosis. AJR. American Journal of Roentgenology 151 (2), 381–8. http://dx.doi.org/10.2214/ajr.151.2.381 , 3134807 . Braffman, B.H., Bilaniuk, L.T., Zimmerman, R.A., 1988. The central nervous system man- ifestations of the phakomatoses on MR. Radiologic Clinics of North America 26 (4), 773–800, [Review] 3132730 . Cutting, L.E., Koth, C.W., Burnette, C.P., Abrams, M.T., Kaufmann, W.E., Denckla, M.B., 2000. Relationship of cognitive functioning, whole brain volumes, and T2-weighted hyperintensities in neuroﬁbromatosis-1. Journal of Child Neurology 15 (3), 157–60, [Research Support, U.S. Gov’t, P.H.S.] 10757470 . Deoni, S.C.L, Rutt, B.K, Arun, T., Pierpaoli, C., Jones, D.K., 2008. Gleaning multicomponent T1 and T2 information from steady-state imaging data. Magnetic resonance in medicine : ofﬁcial journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 60 (6), 1372–87. Dezortova, M., Hajek, M., Tintera, J., Hejcmanova, L., Sykova, E., 2001. MR in phenylketonuria-related brain lesions. Acta Radiologica 42 (5), 459–66, [Research Support, Non-U.S. Gov’t] 11552882 . DiPaolo, D.P., Zimmerman, R.A., Rorke, L.B., Zackai, E.H., Bilaniuk, L.T., Yachnis, A.T., 1995. Neuroﬁbromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. Radiology 195 (3), 721–4, [Case reports] 7754001 . Eastwood, J.D., Fiorella, D.J., MacFall, J.F., Delong, D.M., Provenzale, J.M., Greenwood, R.S., 2001. Increased brain apparent diffusion coefﬁcient in children with neuroﬁ- bromatosis type 1. Radiology 219 (2), 354–8, [Research Support, U.S. Gov’t, P.H.S.] 11323456 . Evans, D.G., Howard, E., Giblin, C., Clancy, T., Spencer, H., Huson, S.M., et al. 2010. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. American Journal of Medical Genetics. Part A 152A (2), 327–32. http://dx.doi.org/10.1002/ajmg.a.33139 , [Research Support, Non-U.S. Gov’t] 20082463 . Feldmann, R., Schuierer, G., Wessel, A., Neveling, N., Weglage, J., 2010. Develop- ment of MRI T2 hyperintensities and cognitive functioning in patients with neu- roﬁbromatosis type 1. Acta Paediatrica (Oslo, Norway: 1992) 99 (11), 1657–60. http://dx.doi.org/10.1111/j.1651-2227.2010.01923.x , 21039823 . Ferraz-Filho, J.R., da Rocha, A.J., Muniz, M.P., Souza, A.S., Goloni-Bertollo, E.M., Pavarino- Bertelli, E.C., 2012. Diffusion tensor MR imaging in neuroﬁbromatosis type 1: ex- panding the knowledge of microstructural brain abnormalities. Pediatric Radiology 42, 449–54. http://dx.doi.org/10.1007/s00247- 011- 2274- 1 , 22033857 . Ferraz-Filho, J.R., da Rocha, J.A., Muniz, M.P., Souza, A.S., Goloni-Bertollo, E.M., Pavarino- Bertelli, E.C., 2012. Unidentiﬁed bright objects in neuroﬁbromatosis type 1: con- ventional MRI in the follow-up and correlation of microstructural lesions on diffusion tensor images. European Journal of Paediatric Neurology: EJPN: Ofﬁ- cial Journal of the European Paediatric Neurology Society 16 (1), 42–7. http: //dx.doi.org/10.1016/j.ejpn.2011.10.002 . Filippi, C.G., Bos, A., Nickerson, J.P., Salmela, M.B., Koski, C.J., Cauley, K.A., 2012. Magnetic resonance diffusion tensor imaging (MRDTI) of the optic nerve and optic radiations at 3 T in children with neuroﬁbromatosis type I (NF-1). Pediatric Radiology 42 (2), 168–74. http://dx.doi.org/10.1007/s00247- 011- 2216- y , 21858653 . Friston, K., Ashbumer, J., Kiebel, S., Nichols, T.E., Penny, W., 2007. Statistical Parametric Mapping: The Analysis of Functional Brain Images. Elsevier. Goh, W.H., Khong, P.L., Leung, C.S., Wong, V.C., 2004. T2-weighted hyperintensities (unidentiﬁed bright objects) in children with neuroﬁbromatosis 1: their impact on cognitive function. Journal of Child Neurology 19 (11), 853–8, 15658789 . Greenwood, R.S., Tupler, L.A., Whitt, J.K., Buu, A., Dombeck, C.B., Harp, A.G., et al. 2005. Brain morphometry, T2-weighted hyperintensities, and IQ in children with neu- roﬁbromatosis type 1. Archives of Neurology 62 (12), 1904–8. http://dx.doi.org/ 10.1001/archneur.62.12.1904 , [Comparative Study Research Support, N.I.H., extra- mural] 16344348 . Grifﬁths, P.D., Blaser, S., Mukonoweshuro, W., Armstrong, D., Milo-Mason, G., Cheung, S., 1999. Neuroﬁbromatosis bright objects in children with neuroﬁbromatosis type 1: a proliferative potential? Pediatrics 104 (4), e49, [Research Support, Non-U.S. Gov’t] 10506274 . Harkins, K.D., Valentine, W.M., Gochberg, D.F., Does, M.D., 2013. In-vivo multi- exponential T2, magnetization transfer and quantitative histology in a rat model of intramyelinic edema. NeuroImage: Clinical 2, 810–17. http://dx.doi.org/10.1016/j. nicl.2013.06.007 , 24179832 . Hwang,D., Kim,D.H., Du,Y.P., 2010.Invivo multi-slicemapping ofmyelin watercontent using T2* decay. NeuroImage 52 (1), 198–204. Hyman, S.L., Gill, D.S., Shores, E.A., Steinberg, A., North, K.N., 2007Journal of Neurology, Neurosurgery, and Psychiatry 78 (10), 1088–91. http://dx.doi.org/10.1136/jnnp. 2006.108134 , [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non- P.H.S.] 17299016 . Hyman, S.L., Shores, A., North, K.N., 2005. The nature and frequency of cognitive deﬁcits in children with neuroﬁbromatosis type 1. Neurology 65 (7), 1037–44. http://dx. doi.org/10.1212/01.wnl.0000179303.72345.ce , [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.] 16217056 . Itoh, T., Magnaldi, S., White, R.M., Denckla, M.B., Hofman, K., Naidu, S., et al. 1994. Neuroﬁbromatosis type 1: the evolution of deep gray and white matter MR ab- normalities. AJNR. American Journal of Neuroradiology 15 (8), 1513–19, [Research Support, U.S. Gov’t, P.H.S.] 7985572 . Jensen, J.H., Helpern, J.A., 2010. MRI quantiﬁcation of non-Gaussian water diffusion by kurtosis analysis. NMR in Biomedicine 23 (7), 698–710. http://dx.doi.org/10.1002/ nbm.1518 , [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review] 20632416 . Jeurissen, B., Leemans, A., Tournier, J.D., Jones, D.K., Sijbers, J., 2013. Investigating the prevalence of complex ﬁber conﬁgurations in white matter tissue with diffusion magnetic resonance imaging. Human Brain Mapping 34 (11), 2747–66. http://dx. doi.org/10.1002/hbm.22099 , [Research Support, Non-U.S. Gov’t] 22611035 . Kalantari, S., Komeilizadeh, N., Vavasour, I., Sahebjavaher, R., MacKay, A, 2013. Variation of myelin water fraction as a function of TR. In: Proceedings of the International Society for Magnetic Resonance in Medicine. International Society for Magnetic Resonance in Medicine. Scientiﬁc Meeting and Exhibition, Salt Lake City, Utah, USA 21, p. 1226. Krab, L.C., Aarsen, F.K., de Goede-Bolder, A., Catsman-Berrevoets, C.E., Arts, W.F., Moll, H.A., et al. 2008. Impact of neuroﬁbromatosis type 1 on school perfor- mance. Journal of Child Neurology 23 (9), 1002–10. http://dx.doi.org/10.1177/ 0883073808316366 , [Research Support, Non-U.S. Gov’t] 18827266 . Laule, C., Vavasour, I.M., Kolind, S.H., Li, D.K., Traboulsee, T.L., Moore, G.R., et al. 2007. Magnetic resonance imaging of myelin. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 4 (3), 460–84. http://dx.doi. org/10.1016/j.nurt.2007.05.004 , [Research Support, Non-U.S. Gov’t Review]. Laule, C., Vavasour, I.M., Kolind, S.H., Traboulsee, A.L., Moore, G.R., Li, D.K., et al. 2007. Long T2 water in multiple sclerosis: what else can we learn from multi-echo T2 relaxation? Journal of Neurology 254 (11), 1579–87. http://dx.doi.org/10.1007/ s00415- 007- 0595- 7 , [Research Support, Non-U.S. Gov’t] 17762945 . Laule, C., Vavasour, I.M., Madler, B., Kolind, S.H., Sirrs, S.M., Brief, E.E., et al. 2007. MR evidence of long T2 water in pathological white matter. Journal of Magnetic Resonance Imaging: JMRI 26 (4), 1117–21. http://dx.doi.org/10.1002/jmri.21132 , 17896375 . Lenz, C., Klarh ¨ofer, M., Schefﬂer, K., 2012. Feasibility of in vivo myelin water imaging using 3D multigradient-echo pulse sequences. Magnetic resonance in medicine : ofﬁcial journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 68 (2), 523–8. Le, Bihan D., Breton, E., Lallemand, D., Grenier, P., Cabanis, E., Laval-Jeantet, M., 1986. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 161 (2), 401–7, 3763909 . Leemans, A., ExploreDTI: A graphical toolbox for processing, analyzing, and visualizing diffusion MR data. in: Proceedings of the International Society for Magnetic Res- onance in Medicine, 17 (2009). International Society for Magnetic Resonance in Medicine. Scientiﬁc Meeting and Exhibition, Honolulu, pp. 3537 Leemans, A., Jones, D.K., 2009. The B-matrix must be rotated when correcting for subject motion in DTI data. Magnetic Resonance in Medicine: Ofﬁcial Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 61 (6), 1336–49. http://dx.doi.org/10.1002/mrm.21890 , 19319973 . Leuzzi, V., Tosetti, M., Montanaro, D., Carducci, C., Artiola, C., Antonozzi, I., et al. 2007. The pathogenesis of the white matter abnormalities in phenylketonuria. A mul- timodal 3.0 tesla MRI and magnetic resonance spectroscopy ( 1 H MRS) study. Journal of Inherited Metabolic Disease 30 (2), 209–16. http://dx.doi.org/10.1007/ s10545- 006- 0399- 4 , 17245558 . MacKay, A., Laule, C., Vavasour, I., Bjarnason, T., Kolind, S., Madler, B., 2006. Insights into brain microstructure from the T2 distribution. Magnetic Resonance Imaging 24 (4), 515–25. http://dx.doi.org/10.1016/j.mri.2005.12.037 , 16677958 . MacKay, A., Whittall, K., Adler, J., Li, D., Paty, D., Graeb, D., 1994. In vivo visualization of myelin water in brain by magnetic resonance. Magnetic Resonance in Medicine : Ofﬁcial Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 31 (6), 673–7, [Research Support, Non-U.S. Gov’t] 8057820 . Maedler, B., MacKay, A. (2007), Towards Whole Brain Myelin Imaging. Paper Pre- sented at the International Society for Magnetic Resonance in Medicine, Berlin, Germany. Margariti, P.N., Blekas, K., Katzioti, F.G., Zikou, A.K., Tzouﬁ, M., Argyropoulou, M.I., 2007. Magnetization transfer ratio and volumetric analysis of the brain in macrocephalic patients with neuroﬁbromatosis type 1. European Radiology 17 (2), 433–8. http: //dx.doi.org/10.1007/s00330- 006- 0323- 1 , 16733674 . Mizukoshi, W., Kozawa, E., Kuramochi, A., Uchino, A., Kimura, F., 2009. Quantitative assessment of water diffusion changes in brains of children with neuroﬁbromatosis type I using apparent diffusion coefﬁcient. Neuroradiology Journal 21 (6), 839–43, 24257055 . 658 T. Billiet et al. / NeuroImage: Clinical 4 (2014) 649–658 Moore, B.D., Slopis, J.M., Schomer, D., Jackson, E.F., Levy, B.M., 1996. Neuropsycholog- ical signiﬁcance of areas of high signal intensity on brain MRIs of children with neuroﬁbromatosis. Neurology 46 (6), 1660–8, [Research Support, Non-U.S. Gov’t] 8649566 . Moore, B.D. 3rd, Slopis, J.M., Jackson, E.F., De, Winter A.E., Leeds, N.E., 2000. Brain vol- ume in children with neuroﬁbromatosis type 1: relation to neuropsychological sta- tus. Neurology 54 (4), 914–20. http://dx.doi.org/10.1212/WNL.54.4.914 , [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.] 10690986 . Phillips, M.D., McGraw, P., Lowe, M.J., Mathews, V.P., Hainline, B.E., 2001. Diffusion- weighted imaging of white matter abnormalities in patients with phenylke- tonuria. AJNR. American Journal of Neuroradiology 22 (8), 1583–6, [Case reports] 11559511 . Piscitelli, O., Digilio, M.C., Capolino, R., Longo, D., Di, Ciommo V., 2012. Neuroﬁ- bromatosis type 1 and cerebellar T2-hyperintensities: the relationship to cog- nitive functioning. Developmental Medicine and Child Neurology 54 (1), 49–51. http://dx.doi.org/10.1111/j.1469-8749.2011.04139.x ,[Letter ResearchSupport, Non-U.S. Gov’t] 22107256 . Poot, D.H., den Dekker, A.J., Achten, E., Verhoye, M., Sijbers, J., 2010. Optimal experi- mental design for diffusion kurtosis imaging. IEEE Transactions on Medical Imaging 29 (3), 819–29. http://dx.doi.org/10.1109/TMI.2009.2037915 , [Research Support, Non-U.S. Gov’t] 20199917 . Prasloski, T., Madler, B., Xiang, Q.S., MacKay, A., Jones, C., 2012. Applications of stim- ulated echo correction to multicomponent T2 analysis. Magnetic Resonance in Medicine: Ofﬁcial Journal of the Society of Magnetic Resonance in Medicine / Soci- ety of Magnetic Resonance in Medicine 67 (6), 1803–14. http://dx.doi.org/10.1002/ Mrm.23157 , 22012743 . Prasloski, T., Rauscher, A., MacKay, A.L., Hodgson, M., Vavasour, I.M., Laule, C., et al. 2012. Rapid whole cerebrum myelin water imaging using a 3D GRASE sequence. Neuroimage 63 (1), 533–9. http://dx.doi.org/10.1016/j.neuroimage.2012.06.064 , [Research Support, Non-U.S. Gov’t]. 22776448 . Sirrs, S.M., Laule, C., Madler, B., Brief, E.E., Tahir, S.A., Bishop, C., et al. 2007. Normal-appearing white matter in patients with phenylketonuria: water content, myelin water fraction, and metabolite concentrations. Radiology 242 (1), 236–43. http://dx.doi.org/10.1148/radiol.2421051758 , [Research Support, Non-U.S. Gov’t] 17185670 . Smirniotopoulos, J.G., Murphy, F.M., 1992. The phakomatoses. AJNR. American Journal of Neuroradiology 13 (2), 725–46, [Review] 1566725 . Stanisz, G.J., Webb, S., Munro, C.A., Pun, T., Midha, R., 2004. MR properties of excised neural tissue following experimentally induced inﬂammation. Magnetic Resonance in Medicine : Ofﬁcial Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 51 (3), 473–9. http://dx.doi.org/10. 1002/mrm.20008 , [Comparative Study research support, non-U .S. Gov’t]. Steen, R.G., Taylor, J.S., Langston, J.W., Glass, J.O., Brewer, V.R., Reddick, W.E., et al. 2001. Prospective evaluation of the brain in asymptomatic children with neuroﬁ- bromatosis type 1: relationship of macrocephaly to T1 relaxation changes and structural brain abnormalities. AJNR. American Journal of Neuroradiology 22 (5), 810–17, [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.] 11337320 . Tognini, G., Ferrozzi, F., Garlaschi, G., Piazza, P., Patti, A., Virdis, R., et al. 2005. Brain ap- parent diffusion coefﬁcient evaluation in pediatric patients with neuroﬁbromatosis type 1. Journal of Computer Assisted Tomography 29 (3), 298–304, 15891494 . van Engelen, S.J., Krab, L.C., Moll, H.A., de Goede-Bolder, A., Pluijm, S.M., Catsman- Berrevoets, C.E., et al. 2008. Quantitative differentiation between healthy and disordered brain matter in patients with neuroﬁbromatosis type I using diffusion tensor imaging. AJNR. American Journal of Neuroradiology 29 (4), 816–22. http:// dx.doi.org/10.3174/ajnr.A0921 , [Research Support, Non-U.S. Gov’t] 18339726 . Van Es, S., North, K.N., McHugh, K., De, Silva M., 1996. MRI ﬁndings in children with neuroﬁbromatosis type 1: a prospective study. Pediatric Radiology 26 (7), 478–87, [Research Support, Non-U.S. Gov’t] 8662066 . Vavasour, I.M., Laule, C., Li, D.K., Traboulsee, A.L., MacKay, A.L., 2011Journal of Magnetic Resonance Imaging: JMRI 33 (3), 713–18. http://dx.doi.org/10.1002/jmri.22441 , [Research Support, Non-U.S. Gov’t] 21563257 . Vermathen, P., Robert-Tissot, L., Pietz, J., Lutz, T., Boesch, C., Kreis, R., 2007. Charac- terization of white matter alterations in phenylketonuria by magnetic resonance relaxometry and diffusion tensor imaging. Magnetic Resonance in Medicine : Ofﬁ- cial Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 58 (6), 1145–56. http://dx.doi.org/10.1002/mrm.21422 , [Research Support, Non-U.S. Gov’t] 18046700 . Webb, S., Munro, C.A., Midha, R., Stanisz, G.J., 2003. Is multicomponent T2 a good measure of myelin content in peripheral nerve? Magnetic Resonance in Medicine : Ofﬁcial Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 49 (4), 638–45. http://dx.doi.org/10.1002/mrm. 10411 , [Research Support, Non-U.S. Gov’t] 12652534 . Whittall, K.P., MacKay, A.L., Graeb, D.A., Nugent, R.A., Li, D.K., Paty, D.W., 1997. In vivo measurement of T2 distributions and water contents in normal human brain. Mag- netic Resonance in Medicine : Ofﬁcial Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 37 (1), 34–43, [Research Support, Non-U.S. Gov’t] 8978630 . Whittall, K.P., Mackay, A.L., 1989. Quantitative interpretation of NMR relaxation data. Journal of Magnetic Resonance 84 (1), 134–52. http://dx.doi.org/10.1016/ 0022- 2364(89)90011- 5 . Zamboni, S.L., Loenneker, T., Boltshauser, E., Martin, E., Il’yasov, K.A., 2007. Contribution of diffusion tensor MR imaging in detecting cerebral microstructural changes in adults with neuroﬁbromatosis type 1. AJNR. American Journal of Neuroradiology 28 (4), 773–6, 17416837 . Zhang, H., Schneider, T., Wheeler-Kingshott, C.A., Alexander, D.C., 2012. NODDI: practi- cal in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage 61 (4), 1000–16. http://dx.doi.org/10.1016/j.neuroimage.2012.03.072 , [Research Support, Non-U.S. Gov’t] 22484410 . 1Scientific RepoRts | 7: 2502  | DOI:10.1038/s41598-017-02768-zwww.nature.com/scientificreportsMerlin is required for coordinating proliferation of two stem cell lineages in the Drosophila testisMayu Inaba1,2,3,4, Dorothy R. Sorenson2, Matt Kortus2, Viktoria Salzmann1,2 & Yukiko M. Yamashita1,2,3Although the mechanisms that balance self-renewal and differentiation of a stem cell lineage have been extensively studied, it remains poorly understood how tissues that contain multiple stem cell lineages maintain balanced proliferation among distinct lineages: when stem cells of a particular lineage proliferate, how do the other lineages respond to maintain the correct ratio of cells among linages? Here, we show that Merlin (Mer), a homolog of the human tumor suppressor neurofibromatosis 2, is required to coordinate proliferation of germline stem cells (GSCs) and somatic cyst stem cells (CySCs) in the Drosophila testis. Mer mutant CySCs fail to coordinate their proliferation with that of GSCs in multiple settings, and can be triggered to undergo tumorous overproliferation. Mer executes its function by stabilizing adherens junctions. Given the known role of Mer in contact-dependent inhibition of proliferation, we propose that the proliferation of CySCs are regulated by crowdedness, or confluency, of cells in their lineage with respect to that of germline, thereby coordinating the proliferation of two lineages.The balance between stem cell self-renewal and differentiation is critical for maintenance of functional tissues. Asymmetric stem cell division balances the number of stem cells and differentiated cells of a particular lineage1, 2. However, tissues that contain multiple stem cell lineages must further coordinate the proliferation rates among distinct lineages such that the correct ratio of all cell types is maintained within the tissue. The lack of coordina-tion among multiple stem cell lineages may cause unbalanced proliferation of a certain lineage with respect to others, leading to disruption of tissue architecture. Such disruption can be a triggering event for more complex pathologies, including tumorigenesis and tissue degeneration. Indeed, recent findings reveal the presence of coor-dination between multiple stem cells that share the niche3, 4. However, the mechanisms by which proliferation of multiple stem cell lineages is coordinated remain poorly explored.Drosophila testis contains two stem cell populations, germline stem cells (GSCs) and somatic cyst stem cells (CySCs), which cohere to and regulate each other. Both stem cell types attach to hub cells at the apical tip of the testis (Fig. 1A)5. Each GSC is encapsulated by a pair of CySCs, whereas the differentiating daughter of the GSC, gonialblast (GB), is encapsulated by a pair of cyst cells (CCs; differentiating daughters of CySCs). Encapsulation of germ cells by somatic cells is essential for GSC maintenance and germ cell differentiation6. These relationships between germline and somatic lineages create the necessity for coordinated proliferation between GSCs and CySCs. Indeed, we have shown that mitotic indices of GSCs and CySCs is 1:2 in ratio7, indicating the presence of mechanism(s) that coordinate their proliferation. However, underlying mechanisms of their coordination remain unknown.Merlin (Mer) is a homolog of the neurofibromatosis 2 (Nf2) tumor suppressor gene, which is mutated in a rare cancer neurofibromatosis type 2, characterized by central and peripheral nervous system tumors derived from Schwann cells8, 9. Mer’s function to regulate cell proliferation is conserved through evolution10, 11. Mer encodes a protein closely related to ezrin, radixin, and moesin (ERM) proteins, and functions to stabilize the membrane-cytoskeleton interface. In cell culture models, Mer has been shown to function in contact-dependent inhibition of proliferation (‘contact inhibition’ in short) through stabilization of adherens junctions and regulation 1Life Sciences Institute, Center for Stem Cell Biology, Ann Arbor, Michigan, United States. 2Department of Cell and Developmental Biology, School of Medicine, Ann Arbor, Michigan, United States. 3Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan, United States. 4Present address: 263 Farmington Ave. E6053, Department of Cell Biology, UConn Health, Farmington, CT, 06030, USA. Correspondence and requests for materials should be addressed to Y.M.Y. (email: yukikomy@umich.edu)Received: 28 February 2017Accepted: 18 April 2017Published: xx xx xxxxOPENwww.nature.com/scientificreports/2Scientific RepoRts | 7: 2502  | DOI:10.1038/s41598-017-02768-zFigure 1. Mer protein localizes to the surfaces of CySCs and CCs. (A) Diagram of the Drosophila testicular stem cell niche. GSCs and CySCs are attached to the hub cells, where each GSC is encapsulated by a pair of CySCs. GB, the differentiating daughter of a GSC, which will become spermatogonia (SGs), is encapsulated by a pair of CCs generated by CySC divisions. (B and C) The wild-type testis apical tip shows Mer protein localization on the cell surface (arrowheads). The pseudocolor of immunofluorescent staining is shown in the colored text. GSCs are indicated by white dots. Bar, 10 µm. Hub (*). (D) RNAi-mediated knockdown of Mer in the CySC lineage (c587 > MerRNAi). Residual cytoplasmic staining can be seen in the germline. (E) RNAi-mediated Mer knockdown in the germline (nos > MerRNAi).www.nature.com/scientificreports/3Scientific RepoRts | 7: 2502  | DOI:10.1038/s41598-017-02768-zof signaling events at the cell cortex9, 12. Contact inhibition is characterized by halted proliferation of cells in culture, when cells reach confluence. Transformed cells override contact inhibition and maintain proliferation, yielding a multilayered stack of cells. Contact inhibition is triggered by cell-cell contact, where the adherens junc-tion plays a key role in sensing confluency and inhibiting further proliferation. In mouse models, Mer is required for tissue homeostasis in the liver, where Mer mutation leads to overgrowth of the tissue13, 14. However, it is not well understood how the contact inhibition mechanism elucidated through cell culture models applies to in vivo settings, where multiple cell types are organized into complex tissue architecture.Here we show that Mer is required to prevent excess proliferation of CySCs in relation to GSCs in the Drosophila testis. In Mer mutant testes, CySCs’ proliferation is not well coordinated with GSCs, leading to an increase in the number of CCs. This lack of coordination is further highlighted when CySC proliferation is stim-ulated by expression of bone morphogenetic protein ligand decapentaplegic (Dpp). Although Dpp’s activity to stimulate CySC proliferation is normally masked by the Mer-dependent mechanism that suppresses excess CySC proliferation, the combination of Dpp stimulation and Mer mutation leads to unlimited proliferation of CySCs/CCs. In another setting, in which germ cells are depleted, wild type CySCs cease proliferation, whereas Mer mutant CySCs continue to proliferate, demonstrating Mer’s role to suppress CySC proliferation in the absence of germ cell proliferation. We further provide evidence that Mer’s function to regulate CySC/CC proliferation involves E-cadherin. We propose that Mer regulates coordination of proliferation between GSCs and CySCs by limiting excess proliferation of CySCs via the mechanism equivalent to contact inhibition. Our work provides insights into how tissues composed of multiple cell types might achieve coordinated proliferation rates to main-tain tissue homeostasis.ResultsMer protein localizes to the cell cortex of somatic CySCs and CCs at the apical tip of the Drosophila testis. Using the anti-Mer antibody described previously15, we found that Mer protein localizes to the cell cortex at the apical tip of the Drosophila testis (Fig. 1B and C). GSCs were identified by expression of Vasa, a germline-specific protein, and attachment to the hub. CySCs and their recent daughters were identified by the expression of the transcriptional repressor Zfh-116. By using these markers and anti-Mer antibody, Mer was clearly observed on the plasma membrane of cells in the apical tip of the testes. Because germ cells and somatic cells closely associate with each other, it is impossible to distinguish whether Mer protein localizes to the germ cell cortex or the somatic cell cortex. In some cases, however, membrane localization was observed between two somatic cells (Fig. 1B and C, arrowheads), suggesting that Mer protein localizes to the somatic cell cortex. This notion was further confirmed by lineage-specific, RNAi-mediated knockdown of Mer. When Mer was knocked down in the CySC lineage (c587-gal4 > UAS-MerRNAi), the membrane localization of Mer protein was almost com-pletely abolished (Fig. 1D). In contrast, when Mer was knocked down in the germline (nos-gal4 > UAS-MerRNAi), the cortical localization of Mer protein remained intact (Fig. 1E), suggesting that the majority of observed cortical localization of Mer protein is due to its expression in the CySC lineage. Furthermore, the phenotype of MerRNAi in the CySC lineage recapitulates the loss-of-function allele (Merts1, see below), suggesting that Mer mainly functions in the CySC lineage in the Drosophila testis.Mer is required to suppress excess numbers of cyst cells. To examine the function of Mer in the Drosophila testis, we used a temperature sensitive, loss-of-function allele of Mer (Merts1) and RNAi-mediated knockdown of Mer (MerRNAi) in the CySC lineage (c587-gal4 > UAS-MerRNAi). To assess possible changes in the GSC/CySC/CC populations, we used above-mentioned Vasa and Zfh-1, as well as the transcription factor Traffic jam (Tj): Tj marks CySCs and CCs at early stages of differentiation17, a slightly broader range of CCs compared to the population marked by Zfh-1.In wild type/control testes, due to coordinated proliferation of GSCs and CySCs7, we barely observed excess germ cells that were not associated with any CCs, or excess CCs that were not associated with any germ cells. Accordingly, CCs positive for Tj were well interspersed among germ cells in control testis (Fig. 2A). In con-trast, we found that Merts1 or MerRNAi testes contained higher number of CCs (~140 Tj+ cells in MerRNAi testes and ~160 Tj+ cells in Merts1 testes compared to ~100 Tj+ cells in control testes, Fig. 2B and C), and we often observed excess CCs that did not apparently touch any germ cells (Fig. 2B, white circle, and D). Excess CCs were not due to increased CySC number (Zfh-1+ cell number) or division rate (Supplementary Figure S1A). Also, both in wild type and Mer mutant testes, the only somatic cells observed in mitosis were CySCs (Supplementary Figure S1B, C, 100% for N = 48 for Merts1 control, N = 66 for Merts1 at 29 °C, N = 57 for c587-gal4 control, N = 114 c587-gal4 > UAS-MerRNAi), excluding the possibility that Mer mutant CCs divide to increase in number. In addi-tion, the increase of Tj+ cells in Mer mutant testes was unlikely due to a defect in CC differentiation, since we observed normal expression patterns of Eyes absent (Eya), a marker for differentiated CCs (Supplementary Figure S2).It is well established that Mer functions via the regulation of the Hippo pathway in many cell types exam-ined. Mer acts upstream of the Hippo pathway to ultimately downregulate the function of the pro-proliferative transcription factor Yki, leading to suppression of cell proliferation8, 10, 18, 19. Overexpression of yki can mimic the loss of function of Hippo pathway components. However, we found no significant changes in the number of GSCs or Tj+ CCs upon overexpression of wild-type yki or a constitutive-active form of yki in the CySC lineage (Supplementary Figure S3), suggesting that Mer functions independently of yki to regulate the number of CCs. RNAi-mediated knockdown of hippo using independent RNAi lines had no effect on Tj+ CC number, either (Supplementary Figure S3). These results suggest that the CySC proliferation by Mer is unlikely mediated by the canonical Hippo pathway. Hippo-independent function of Mer is reminiscent of Nf2 function reported in mouse liver13 and culture cells20. It was recently shown that Hippo pathway is active in CC lineage and that hippo mutant CySCs outcompete wild type CySCs in the niche21. This suggests that CySCs’ proliferation within its own lineage www.nature.com/scientificreports/4Scientific RepoRts | 7: 2502  | DOI:10.1038/s41598-017-02768-zis under the regulation of Hippo pathway, whereas CySCs’ coordinated proliferation in relation to germline is regulated by Mer, independent of Hippo pathway. How these two pathways may together regulate overall CySC proliferation awaits future investigation.Adherens junction between CCs is compromised in Mer mutant testes. Because the Hippo path-way is apparently not involved in Mer-mediated regulation of CC number, we sought other mechanisms that could explain Mer mutant phenotypes in the Drosophila testis. In cultured cells, Mer/Nf2 plays a role in the contact-dependent inhibition of proliferation via its ability to regulate the adherens junctions8, 22, 23. Therefore, we examined possible effect(s) of Merts1 mutation on adherens junctions. In wild-type testes, we observed that E-cadherin, a major component of adherens junctions, localized to the cell-cell junction between CCs (Fig. 3A,B, arrows), in addition to its well-characterized localization to the hub-GSC and hub-CySC interface (Fig. 3A, aster-isk), where E-cadherin supports anchorage of GSCs and CySCs to the hub24–27. In Merts1 mutants, E-cadherin localization at hub cells was not visibly affected (Fig. 3C, asterisk). However, its localization between CCs was less prominent, compared to wild type (Fig. 3C). Similarly, GFP-Armadillo (Arm, β-catenin), another component of adherens junctions, was observed between somatic cells in control (Fig. 3D) but not in Merts1 mutant (Fig. 3E), suggesting that Mer is required for adherens junction stability between CCs.We further characterized the cell-cell junctions in Merts1 mutants using transmission electron microscopy (TEM). We observed electron dense cell-cell junctions at the CC-CC interface in control testis (Fig. 3F, arrows). Figure 2. CCs are increased in number upon loss of Mer function.(A and B) The testis apical tip stained for Tj (green), Vasa (blue), adducin-like (Add), and fasciclin III (Fas III, red) in a control (A) and (Merts1) mutant (B) testis. Circles in (B) indicate Tj+ cells without clear association with germ cells (“lone CCs”). GSCs are indicated by white dots. Hub (*). Bar, 10 µm. (C) The number of Tj+ cells/testis in control, Merts1, and c587 > MerRNAi testes. Data are expressed as the mean ± SD, and p values were obtained using the Student’s t test (two-tailed) by comparing to wild type. N = 15 testes for data point. (D) The frequency of testes containing lone CCs in control and Mer mutants. N ≥ 40 testes for data point.www.nature.com/scientificreports/5Scientific RepoRts | 7: 2502  | DOI:10.1038/s41598-017-02768-zSuch electron-dense junctions between two CCs were consistently observed along the cell-cell interface. In con-trast, we found that the cell-cell junction between two somatic cells was significantly weaker in Merts1 mutants (Fig. 3G, arrows), and patches that lacked electron-dense junctional structures were frequently observed in Merts1 mutants (Fig. 3G, double-headed blue arrows). Although its significance remains unclear, we frequently observed vesicular compartment resembling multivesicular bodies in Merts1 mutant CCs (Fig. 3G, yellow arrowhead). The TEM analysis, combined with immunofluorescent staining analysis of multiple adherens junction markers, sug-gests that Mer is required for stabilization of cell-cell adhesion between CCs.Mer mutant CySCs are triggered to undergo tumorous overproliferation upon stimulation by the bone morphogenetic protein (BMP) ligand Dpp. A moderate increase in the number of CCs in the Mer mutant/RNAi testes suggests that Mer is required for suppressing CySC proliferation. Contact-dependent inhibition of proliferation is a mechanism that safe-guards against overproliferation of cells, making cells resistant to stimulation by mitogens. Therefore, defects in contact-dependent inhibition may not have a profound effect in the absence of mitogens.We reasoned that, if Mer regulates CySC proliferation via the mechanism of contact inhibition, Mer mutant may not exhibit severe phenotypes unless stimulated by mitogens. Based on this idea, we examined a poten-tial effect of ectopically expressing signaling ligands in Merts1 mutant background. Dpp, Hedgehog (Hh), Delta (Dl), Wingless (Wg), or Spitz (Spi, an Egf ligand), which are known to be expressed in the Drosophila testicular Figure 3. Mer is required for stability of adherens junction between CCs. (A–C) Apical tip of a wild-type (A and B) and Merts1 mutant (C) testis stained for E-cadherin (Blue), Vasa (Green), and Add (Red). GSCs are indicated by white dots. Hub (*). Bar, 10 µm. (D and E) Apical tip of wild-type (D) and Merts1 mutant (E) testis visualized for Arm-GFP (Green), Vasa (Blue), and Add (Red). (F and G) Transmission electron microscopy showing junctions between two somatic cells in a wild-type (F) and Merts1 (G) testis. Arrows indicate cell-cell junctions. Blue, double-headed arrows in (F) indicate gaps in cell-cell junction structure. We noted that Merts1 mutant somatic cells have numerous multilamellar bodies (yellow arrowhead), although its meaning is currently unclear. Bar, 500 nm.www.nature.com/scientificreports/6Scientific RepoRts | 7: 2502  | DOI:10.1038/s41598-017-02768-zniche16, 28–33, were expressed in wild type or Merts1 mutant background (+; nos-gal4 > UAS-ligand or Merts1; nos-gal4 > UAS-ligand) and its effect was examined. Expression of Hh, Dl, Wg or Spi did not cause any detectable defects in tissue architecture in wild type or Merts1 background (Supplementary Figure S4). Overexpression of Dpp in wild type background led to expansion of SGs due to its known role to suppress differentiation (Fig. 4B double-headed arrow)30–32, 34, 35. However, overall architecture of the tissue was maintained with differentiation progressing along the apical-to-basal axis of the testis. In contrast, when Dpp overexpression was combined with Merts1, massive proliferation of CySC/CCs were observed, leading to perturbed tissue architecture due to tumor-ous overproliferation of cells (Fig. 4C–H). The numbers of Tj+ CCs as well as Zfh-1+ CySCs increased dramat-ically in Merts1 Dpp-expressing testes compared to Dpp-expressing testis in wild type background (Fig. 4C–F). We often observed large clusters of Tj+ CC cells, especially near the Fas III-positive hub–like clusters (Fig. 4F, circles), indicating that Merts1 mutant CySCs overproliferated without coordinating with germ cells. Moreover, in Merts1 Dpp-expressing testes, hub cells were enlarged (Fig. 4D, 48% of testes, N = 42), or multiple hub-like clusters were observed (Fig. 4C and E, 33% of testes, N = 42). These hub-like cells may be derived from transformation of CySCs/CCs to hub-like fate associated with expansion of CySC/CC pool36. In a Merts1 mutant background, not only CySCs, but also CCs as well as hub-like cells, underwent cell division visualized by mitotic cell marker phosphor-histone H3 (Fig. 4G and H, 0 mitotic CCs/testis in Merts1 control, N = 117 testes, 0.64 mitotic CCs/testis in Merts1; nos-gal4 > UAS-Dpp, N = 120 testes), whereas CCs or hub cells never underwent mitosis in a wild-type background25, 36 or in Dpp-overexpressing testis. These results indicate that Merts1 mutant somatic cells are sensi-tive to proliferative stimuli due to expression of Dpp. Importantly, the fact that Dpp overexpression in wild type background does not cause CySC/CC expansion suggests that wild type CySCs/CCs are resistant to stimulation by Dpp.Dpp pathway in CySCs functions to promote CySC mitosis separately from its known function in germ cells. Based on the results described above, we hypothesized that CySCs/CCs are normally prevented from overproliferation by the function of Mer, and that Dpp has a mitogenic effect on CySCs/CCs. Dpp over-expression in wild type background would not lead to CySC/CC overproliferation because Mer prevents them from overproliferating. Mer mutant CySCs/CCs would not overproliferate on its own, either, because mitogenic stimulation (Dpp) is limited. Only when combined, however, ectopically expressed Dpp stimulates Mer mutant CySCs/CCs, leading to overproliferation.This hypothesis postulates that Dpp has a mitogenic activity on CySCs/CCs. To test in which cell type Dpp sig-naling must be active to stimulate the proliferation of Merts1 mutant CySCs/CCs, we first expressed a constitutively active form of Tkv (Tkv*), the receptor for Dpp, in germ cells of Mer mutant testes (Merts1; nos-gal4 > UAS-tkv*): Unlike the expression of the ligand (Dpp), which can be secreted and act in both autocrine and paracrine man-ners, the receptor (Tkv) would be confined within the cell in which the expression is driven. Expression of Tkv* in germ cells in combination with Merts1 did not cause tumorous overproliferation, although a spermatogonial tumor was observed consistent with the role of Tkv in the germline to suppress differentiation (Supplementary Figure S5A, double-headed arrow)30–32, 34, 35. This result suggests that Dpp-Tkv pathway does not operate in germ cells to stimulate CySC/CC proliferation. Instead, this result suggests that Dpp-Tkv pathway operates in CySC/CCs to stimulate their proliferation.Strikingly, expression of Tkv* in the CySC lineage (c587-gal4 > tkv*) was sufficient to induce CySC overprolif-eration even in the wild type background (Supplementary Figure S5B,C). This result has two important implica-tions. First, it supports the idea that Dpp-Tkv signaling in CySC lineage functions to promote their proliferation. Second, the fact that overexpression of Tkv* is sufficient to drive CySC/CC proliferation even without Mer muta-tion indicates that Mer functions downstream of Dpp secretion/reception but upstream of Tkv activation. Taken together, these results suggest that Dpp functions as a mitogen for CySC lineage, and CySC proliferation is con-trolled at least at two levels: limiting available Dpp and Mer-dependent mechanism that makes CySCs resistant to stimulation by Dpp.Mer functions with E-cadherin in regulating CC number. Nf2/Mer mediates contact-dependent inhi-bition of proliferation through regulation of adherens junction22, 23. The results described above (Fig. 3) are con-sistent with Mer’s role in regulating adherens junction. To gain further insights into the relationship between Mer and E-cadherin in suppressing proliferation of CySCs/CCs, we examined potential genetic interactions between these two genes in regulating CC number.We first tested whether expression of wild-type E-cadherin (UAS-DEFL) might be able to suppress the increase in Tj+ CC number due to MerRNAi. As described above, MerRNAi in the CySC lineage caused a moderate but sig-nificant increase in Tj+ CC number. Expression of E-cadherin in MerRNAi background reduced Tj+ CC num-ber significantly (Fig. 5A), suggesting that the phenotypes of MerRNAi comes at least partly from destabilized adherens junction. We next tested whether expression of E-cadherin can suppress the increase in Tj+ CC num-ber due to combinatory effect of MerRNAi and ectopic Dpp expression. Similar to the case of Merts1, the increase in Tj+ CC number in MerRNAi testis was further enhanced by co-expression of Dpp (Fig. 5A, ~100 Tj+ CCs in c587-gal4 > UAS-MerRNAi compared to ~250 Tj+ CCs in c587-gal4 > UAS-MerRNAi, UAS-dpp). Such increase in Tj+ CC number was dramatically suppressed by co-expression of E-cadherin (Fig. 5A, ~150 Tj+ CCs), suggesting that increased stability of adherens junction can rescue defects caused by loss of Mer function.If an increase in Tj+ CC number in MerRNAi is due to, at least in part, destabilized adherens junctions, weaken-ing adherens junctions by overexpressing a dominant-negative E-cadherin mutant (UAS-dCR4h, an E-cadherin mutant that lacks the extracellular domain37) might be sufficient to make CySCs/CCs sensitive to Dpp overex-pression. Indeed, combined expression of Dpp and dCR4h significantly increased Tj+ CC number, even in the absence of the Mer mutation or RNAi (Fig. 5B), demonstrating that CCs with weakened cell-cell junctions are www.nature.com/scientificreports/7Scientific RepoRts | 7: 2502  | DOI:10.1038/s41598-017-02768-zFigure 4. Ectopic expression of Dpp drives tumorous CySC/CC expansion in the Mer mutant. (A–C) The apical tip of the testis in Merts1 (A), nos > dpp (B), and Merts1; nos > dpp (C) stained for Tj (Green), Vasa (Blue), Add, and Fas III (Red). Bar, 50 µm. (D) The apical tip of the testis from Merts1; nos > dpp stained for Zfh-1 (Green), Vasa (Blue), and Fas III (Red). (E) The apical tip of the testis from Merts1; nos > dpp stained for Tj (Green), Vasa (Blue), and Fas III (Red). Expansion of hub cells are shown by arrows. (F) The apical tip of the testis from Merts1; nos > dpp stained for Tj (Green), Vasa (Blue), and Fas III (Red). Clusters of Tj+ CCs are indicated by white circles. (G and H) Examples of mitotic somatic cells [positive for phosphorylated histone H3 (pH3)] away from the hub (G) and within the expanded hub-like structure (H) in a Merts1; nos > dpp testis. Hub (*).www.nature.com/scientificreports/8Scientific RepoRts | 7: 2502  | DOI:10.1038/s41598-017-02768-zmore susceptible to stimulation by Dpp. Taken together, these data support the model, in which Mer functions to stabilize adherens junctions, which in turn suppresses excess proliferation of CySCs.Mer is required to prevent CySC overproliferation in the absence of germ cells. While the sen-sitivity of Mer mutant CySCs/CCs to Dpp overexpression reveals that they are defective in preventing overpro-liferation, Dpp is not normally expressed broadly in the testis30. Thus, our experimental model described above (ectopic expression of Dpp) might be somewhat artificial, although it highlights the defective nature of Mer mutant in preventing CySC proliferation. To further address the role of Mer in preventing excess proliferation of CySCs/CCs in coordination with germ cells, we examined the effect of germ cell depletion on CySCs/CCs in Mer mutant. Bam is a master regulator of differentiation38, and its expression in germ cells (nos-gal4 > UAS-bam) results in complete loss of germ cells by the time of eclosion. In a wild-type background, bam-induced germ cell depletion was associated with underdeveloped testicular structure, frequently containing few or no Tj+ cells (Fig. 6A–C, F, type I and II testes). Compared to the wild-type testis that has an average of ~100 Tj+ cells (Fig. 2C), bam-expressing testes contain much fewer Tj+ cells, indicating that CySCs responded to the lack of germ cells and ceased proliferation during development. In stark contrast to the wild-type testis depleted of germ cells, the Merts1 mutant testes depleted of germ cells (Merts1; nos-gal4 > UAS-bam) often exhibited overproliferation of Tj+ CCs (Fig. 6D–F, type III and IV). CCs in such testes maintained proliferation, as assessed by the presence of phosphorylated histone H3 (pH3) (Fig. 6D and E, arrowheads, and 6G). Similar results were obtained even when bam was turned on after eclosion by temperature shift (Merts1; nos-gal4ΔVP16, tub-gal80ts > UAS-bam)(Fig. 6H), suggesting that Mer-dependent prevention of CySC/CC proliferation in response to germ cell depletion operates during development as well as adult tissue homeostasis.Taken together, these results suggest that Mer is required for suppressing CySC proliferation when not accom-panied by germ cell proliferation. We propose that Mer prevents CySC overproliferation via a mechanism similar to contact-dependent inhibition of proliferation, wherein ‘overcrowding’, or confluency, of CySCs/CCs in relation to germ cells suppresses CySC proliferation.DiscussionDespite its paramount importance in tissue development and maintenance, the mechanisms by which multiple stem cell lineages coordinate proliferation remain poorly understood. Does one lineage have instructive or per-missive roles over the other lineage(s)? Do they crosstalk to coordinate proliferation? How do the tissues sense the correct number and/or ratio of cells among multiple lineages to maintain the functional tissue? Our previous study using overexpression of Cdc25, a major mitotic regulator, suggested that CySCs have a permissive (but not instructive) role over GSC proliferation7. However, how CySC proliferation might be coordinated with GSC proliferation remains unclear.The present study showed that Mer is an important regulator of CySC division. We propose Mer functions in a manner reminiscent of Nf2’s role in contact-dependent inhibition of proliferation9, 12, 23. In the absence of Mer function, the number of CCs mildly increased in relation to germ cells, leading to extra CCs. Such a phenotype could be easily missed, as Mer mutant testes show only a slight increase in CC number and maintain an overall normal tissue architecture. However, Mer’s requirement for the regulation of CySC proliferation was revealed in a sensitized background. First, when cell proliferation was stimulated by ectopic expression of Dpp, Mer mutant CySCs/CCs underwent tumorous overproliferation. Importantly, Dpp overexpression in a wild-type background does not lead to tumorous overgrowth of CySCs/CCs, suggesting that Mer plays a role to make CySCs/CCs resist-ant to mitogenic stimulation. Second, Mer mutant CySCs/CCs continue to proliferate in the absence of germ cells due to overexpression of Bam, a master regulator of differentiation.By drawing a parallel between the established role of Nf2 in contact inhibition and that of Mer in preventing CySC/CC overproliferation, we propose that ‘confluency’ of one lineage (e.g. CySC lineage) with respect to the Figure 5. E-cadherin functionally interacts with Mer and Dpp in regulation of CySC/CC proliferation. (A) Tj+ CC number in control, MerRNAi, and MerRNAi; nos > dpp testes in the presence or absence of E-cadherin overexpression. N = 15 testes for each data point. (B) Tj+ CC number in control, c587 > dCR4h, c587 > dpp, and c587 > dCR4h, dpp testes. c587-gal4 was combined with tub-gal80ts, and expression was induced upon eclosion by shifting young males from 18 °C to 29 °C for 7 days. N ≥ 15 testes for each data point. p values were obtained using the Student’s t test (two-tailed).www.nature.com/scientificreports/9Scientific RepoRts | 7: 2502  | DOI:10.1038/s41598-017-02768-zother lineage (e.g. germline) serves as a mechanism to coordinate the proliferation of two lineages in a given tissue. In this scenario, CySCs proliferate until they and their progeny occupy the surface of germline, reaching ‘confluency’, at which point contact inhibition mechanism mediated by Mer and adherens junctions halts CySC division. Once GSCs divide, it would increase ‘substrate surface’ (i.e. surface generated by production of more germ cells) on which CySC lineage can proliferate, until their progeny reach to confluency again. In this man-ner, GSC and CySC divisions would balance their proliferation to maintain correct ratio of cell numbers. Taken together, our study illuminates the mechanism by which two distinct stem cell populations within a tissue coor-dinate their proliferation to maintain tissue homeostasis, and provide insights into how contact inhibition may operate in tissues in the in vivo context.Figure 6. Mer is required to prevent CySC/CC overproliferation in the germ cell-depleted testis. (A–C) The apical tip of the testis from nos > bam stained for Tj, FasIII, and phosphorylated histone H3 (pH3). The testis apical region is marked by white lines. Terminal epithelium (TE). Bar, 50 µm. (D and E) The apical tip of the testis from Merts1 nos > bam. Overproliferated Tj+ cells stained for FasIII (D’ and E’). Arrowheads indicate mitotic somatic cells. (F) Summary of the testis phenotype upon depletion of germ cells in the wild-type or Merts1 background. Types I–IV correspond to the designations in A–E. n ≥ 27 testes for each data point. (G) The mitotic index in testes expressing bam in a wild-type or Merts1 mutant background. N = 30 testes for each data point. (H) The number of Tj+ cells in wild-type and Merts1 background after induction of germ cell loss by expression of bam upon eclosion. N ≥ 10 testes for each data point. p values were obtained using the Student’s t test (two-tailed) by comparing to control at corresponding time points.www.nature.com/scientificreports/10Scientific RepoRts | 7: 2502  | DOI:10.1038/s41598-017-02768-zMaterials and MethodsFly Husbandry and Strains. All fly stocks were raised in standard Bloomington medium. The following fly stocks were used: Merts1 39; a gift from Ilan Davis), c587-gal440, nos-gal441, UAS-MerRNAi (GD1484 from the Vienna Drosophila Research Center), UAS-tkv*42; a gift from Ting Xie), UAS-Bam43 a gift from Dennis McKearin), UAS-DEFL37; a gift from Hiroki Oda), hs-FLP; act > stop > gal4 UAS-GFP44; a gift from Yu Cai), UAS-dpp, UAS-yki, UAS-ykiS168A, socs36EEY06665, and Df(2L)Exel7070 (obtained from the Bloomington Stock Center). These strains are described in Flybase (http://flybase.org). nos-gal4 without VP1645 is denoted as nos-gal4ΔVP16 to distinguish it from nos-gal4-VP16 that was generated by41, which has been often referred to as nos-gal4. nos-gal4ΔVP16 was combined with tubulin-gal80ts to achieve temperature-dependent, temporal control of UAS-bam expression.Merts1 flies were raised at 18 °C and shifted to 29 °C upon eclosion for 2–3 days before analysis. Expression of Dpp or DEFL under the c587-gal4 driver was performed by raising flies at 18 °C to avoid lethality during develop-ment and shifted to 25 °C upon eclosion for 2–3 days before analysis. Other fly crosses were performed at 25 °C. Control experiments were conducted with matching temperature-shift schemes.Immunofluorescent Staining. Immunofluorescent staining was performed as described previously46. Briefly, testes were dissected in phosphate-buffered saline (PBS) and fixed in 4% formaldehyde in PBS for 30–60 minutes. Next, testes were washed in PBST (PBS +0.1% Tween 20) for at least 30 minutes, followed by incubation with primary antibody in 3% bovine serum albumin (BSA) in PBST at 4 °C overnight. Samples were washed for 60 minutes (three times for 20 minutes each) in PBST, incubated with secondary antibody in 3% BSA in PBST at 4 °C overnight, and then washed for 60 minutes (three times for 20 minutes each) in PBST. Samples were then mounted using VECTASHIELD with 4′,6-diamidino-2-phenylindole (DAPI). The primary antibod-ies used were as follows: mouse anti-adducin-like [1:20, developed by H. D. Lipshitz and obtained from the Developmental Studies Hybridoma Bank (DSHB)], anti-Fasciclin III (1:100, developed by C. Goodman and obtained from DSHB), anti-βPS (1:20, developed by D. Brower and obtained from DSHB), anti-E-cadherin (1:20, developed by T. Uemura and obtained from DSHB), rabbit anti-Thr3-phosphorylated histone H3 (1:200; Upstate), rat anti-Vasa (1:40; developed by A. Spradling and D. Williams, and obtained from DSHB), rabbit anti-Zfh-1 (1:4000; a gift from Ruth Lehmann), guinea pig anti-Tj (1:400, a gift from Dorothea Godt), and guinea pig anti-Mer (1:2000, a gift from Rich Fehon). AlexaFluor-conjugated secondary antibodies were used at a dilu-tion of 1:200. Images were taken using a Leica TCS SP5 or SP8 confocal microscope with a 63 × oil immersion objective (NA = 1.4) and processed using Adobe Photoshop software.Transmission Electron Microscopy. Drosophila testes were dissected in 1 × PBS and fixed in 2% glutaral-dehyde/2% paraformaldehyde (EM grade) in 0.1 M cacodylate (pH 7.4) for 5 minutes at room temperature. This step was followed by an additional 25-minute fixation on ice. The tissue was rinsed three times for 10 minutes each in cacodylate buffer and then post-fixed for 30 minutes in 2% osmium tetroxide in the same buffer on ice. Next, the samples were rinsed in double-distilled water and then stained en bloc for 1 hour in aqueous 7% uranyl acetate. The samples were then dehydrated in increasing concentrations of ethanol, treated with propylene oxide, and embedded in Epon epoxy resin. Semi-thin sections were stained with toluidine blue for tissue identification. Selected regions of interest were serially sectioned (70-nm thickness) and mounted on Formvar/carbon-coated slotted grids. The grids were post-stained with uranyl acetate and lead citrate, and samples were examined using a Philips CM100 electron microscope at 60 kV. Images were recorded digitally using a Hamamatsu ORCA-HR digital camera system, which was operated using AMTsoftware (Advanced Microscopy Techniques Corp., Danvers, MA).References 1. Morrison, S. J. & Kimble, J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 441, 1068–1074 (2006). 2. Chen, C., Fingerhut, J. M. & Yamashita, Y. M. The ins(ide) and outs(ide) of asymmetric stem cell division. Curr Opin Cell Biol 43, 1–6, doi:10.1016/j.ceb.2016.06.001 (2016). 3. Chang, C. Y. et al. NFIB is a governor of epithelial-melanocyte stem cell behaviour in a shared niche. Nature 495, 98–102, doi:10.1038/nature11847 (2013). 4. Issigonis, M. et al. JAK-STAT signal inhibition regulates competition in the Drosophila testis stem cell niche. Science 326, 153–156, doi:10.1126/science.1176817 (2009). 5. Matunis, E. L., Stine, R. R. & de Cuevas, M. Recent advances in Drosophila male germline stem cell biology. Spermatogenesis 2, 137–144, doi:10.4161/spmg.21763 (2012). 6. Fuller, M. T. & Spradling, A. C. Male and female Drosophila germline stem cells: two versions of immortality. Science 316, 402–404 (2007). 7. Inaba, M., Yuan, H. & Yamashita, Y. M. String (Cdc25) regulates stem cell maintenance, proliferation and aging in Drosophila testis. Development 138, 5079–5086, doi:10.1242/dev.072579 (2011). 8. McClatchey, A. I. & Fehon, R. G. Merlin and the ERM proteins–regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol 19, 198–206, doi:10.1016/j.tcb.2009.02.006 (2009). 9. Cooper, J. & Giancotti, F. G. Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett 588, 2743–2752, doi:10.1016/j.febslet.2014.04.001 (2014). 10. Boggiano, J. C. & Fehon, R. G. Growth control by committee: intercellular junctions, cell polarity, and the cytoskeleton regulate Hippo signaling. Developmental cell 22, 695–702, doi:10.1016/j.devcel.2012.03.013 (2012). 11. Fehon, R. G., McClatchey, A. I. & Bretscher, A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 11, 276–287, doi:nrm2866 [pii] 10.1038/nrm2866 (2010). 12. McClatchey, A. I. & Yap, A. S. Contact inhibition (of proliferation) redux. Current opinion in cell biology, doi:10.1016/j.ceb.2012.06.009 (2012). 13. Benhamouche, S. et al. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev 24, 1718–1730, doi:10.1101/gad.1938710 (2010). 14. Zhang, N. et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 19, 27–38, doi:10.1016/j.devcel.2010.06.015 (2010).www.nature.com/scientificreports/11Scientific RepoRts | 7: 2502  | DOI:10.1038/s41598-017-02768-z 15. McCartney, B. M. & Fehon, R. G. Distinct cellular and subcellular patterns of expression imply distinct functions for the Drosophila homologues of moesin and the neurofibromatosis 2 tumor suppressor, merlin. J Cell Biol 133, 843–852 (1996). 16. Leatherman, J. L. & Dinardo, S. Zfh-1 controls somatic stem cell self-renewal in the Drosophila testis and nonautonomously influences germline stem cell self-renewal. Cell Stem Cell 3, 44–54 (2008). 17. Li, M. A., Alls, J. D., Avancini, R. M., Koo, K. & Godt, D. The large Maf factor Traffic Jam controls gonad morphogenesis in Drosophila. Nat Cell Biol 5, 994–1000 (2003). 18. Zhao, B., Li, L., Lei, Q. & Guan, K. L. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 24, 862–874, doi:10.1101/gad.1909210 (2010). 19. Yin, F. et al. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 154, 1342–1355, doi:10.1016/j.cell.2013.08.025 (2013). 20. Hikasa, H., Sekido, Y. & Suzuki, A. Merlin/NF2-Lin28B-let-7 Is a Tumor-Suppressive Pathway that Is Cell-Density Dependent and Hippo Independent. Cell Rep 14, 2950–2961, doi:10.1016/j.celrep.2016.02.075 (2016). 21. Amoyel, M., Simons, B. D. & Bach, E. A. Neutral competition of stem cells is skewed by proliferative changes downstream of Hh and Hpo. EMBO J 33, 2295–2313, doi:10.15252/embj.201387500 (2014). 22. Lallemand, D., Curto, M., Saotome, I., Giovannini, M. & McClatchey, A. I. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 17, 1090–1100, doi:10.1101/gad.1054603U-10546R (2003). 23. Curto, M., Cole, B. K., Lallemand, D., Liu, C. H. & McClatchey, A. I. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 177, 893–903, doi:10.1083/jcb.200703010 (2007). 24. Yamashita, Y. M., Jones, D. L. & Fuller, M. T. Orientation of asymmetric stem cell division by the APC tumor suppressor and centrosome. Science 301, 1547–1550 (2003). 25. Cheng, J., Tiyaboonchai, A., Yamashita, Y. M. & Hunt, A. J. Asymmetric division of cyst stem cells in Drosophila testis is ensured by anaphase spindle repositioning. Development 138, 831–837, doi:10.1242/dev.057901 (2011). 26. Voog, J., D’Alterio, C. & Jones, D. L. Multipotent somatic stem cells contribute to the stem cell niche in the Drosophila testis. Nature 454, 1132–1136, doi:10.1038/nature07173 (2008). 27. Inaba, M., Yuan, H., Salzmann, V., Fuller, M. T. & Yamashita, Y. M. E-cadherin is required for centrosome and spindle orientation in Drosophila male germline stem cells. PLoS ONE 5, doi:10.1371/journal.pone.0012473 (2010). 28. Terry, N. A., Tulina, N., Matunis, E. & DiNardo, S. Novel regulators revealed by profiling Drosophila testis stem cells within their niche. Dev Biol 294, 246–257 (2006). 29. Schulz, C., Wood, C. G., Jones, D. L., Tazuke, S. I. & Fuller, M. T. Signaling from germ cells mediated by the rhomboid homolog stet organizes encapsulation by somatic support cells. Development 129, 4523–4534 (2002). 30. Kawase, E., Wong, M. D., Ding, B. C. & Xie, T. Gbb/Bmp signaling is essential for maintaining germline stem cells and for repressing bam transcription in the Drosophila testis. Development 131, 1365–1375 (2004). 31. Shivdasani, A. A. & Ingham, P. W. Regulation of stem cell maintenance and transit amplifying cell proliferation by tgf-Beta signaling in Drosophila spermatogenesis. Curr Biol 13, 2065–2072 (2003). 32. Schulz, C. et al. A Misexpression Screen Reveals Effects of bag-of-marbles and TGFbeta Class Signaling on the Drosophila Male Germ-Line Stem Cell Lineage. Genetics 167, 707–723 (2004). 33. Michel, M., Kupinski, A. P., Raabe, I. & Bokel, C. Hh signalling is essential for somatic stem cell maintenance in the Drosophila testis niche. Development 139, 2663–2669, doi:10.1242/dev.075242 (2012). 34. Chen, D. & McKearin, D. Dpp Signaling Silences bam Transcription Directly to Establish Asymmetric Divisions of Germline Stem Cells. Curr Biol 13, 1786–1791 (2003). 35. Chen, D. & McKearin, D. Gene circuitry controlling a stem cell niche. Curr Biol 15, 179–184 (2005). 36. Dinardo, S., Okegbe, T., Wingert, L., Freilich, S. & Terry, N. lines and bowl affect the specification of cyst stem cells and niche cells in the Drosophila testis. Development 138, 1687–1696, doi:10.1242/dev.057364 (2011). 37. Oda, H. & Tsukita, S. Nonchordate classic cadherins have a structurally and functionally unique domain that is absent from chordate classic cadherins. Dev Biol 216, 406–422 (1999). 38. Ohlstein, B. & McKearin, D. Ectopic expression of the Drosophila Bam protein eliminates oogenic germline stem cells. Development 124, 3651–3662 (1997). 39. MacDougall, N. et al. Merlin, the Drosophila homologue of neurofibromatosis-2, is specifically required in posterior follicle cells for axis formation in the oocyte. Development 128, 665–673 (2001). 40. Decotto, E. & Spradling, A. C. The Drosophila ovarian and testis stem cell niches: similar somatic stem cells and signals. Dev Cell 9, 501–510 (2005). 41. Van Doren, M., Williamson, A. L. & Lehmann, R. Regulation of zygotic gene expression in Drosophila primordial germ cells. Curr Biol 8, 243–246 (1998). 42. Xie, T. & Spradling, A. C. decapentaplegic is essential for the maintenance and division of germline stem cells in the Drosophila ovary. Cell 94, 251–260 (1998). 43. Chen, D. & McKearin, D. M. A discrete transcriptional silencer in the bam gene determines asymmetric division of the Drosophila germline stem cell. Development 130, 1159–1170 (2003). 44. Wang, L., Li, Z. & Cai, Y. The JAK/STAT pathway positively regulates DPP signaling in the Drosophila germline stem cell niche. J Cell Biol 180, 721–728 (2008). 45. Inaba, M., Buszczak, M. & Yamashita, Y. M. Nanotubes mediate niche-stem-cell signalling in the Drosophila testis. Nature, doi:10.1038/nature14602 (2015). 46. Cheng, J. et al. Centrosome misorientation reduces stem cell division during ageing. Nature 456, 599–604 (2008).AcknowledgementsWe thank Ilan Davis, Ting Xie, Ruth Lehmann, Liz Gavis, Drothea Godt, Dennis McKearin, Hiroki Oda, Yu Cai, Rich Fehon, Cheng-Yu Lee, the Bloomington Drosophila Stock Center, and the Developmental Studies Hybridoma Bank for reagents; Krystyna Pasyk and Bruce Donahoe at the University of Michigan Microscope Imaging Laboratory for EM studies; Andrea McClatchey, Rich Fehon, Michael Hortsch, Sun-Kee Kim, and Kent Christensen for comments and advice; and the Yamashita lab members for discussion. This work was supported by Howard Hughes Medical Institute (to Y.M.Y.).Author ContributionsM.I. and Y.M.Y. designed and conducted experiments. M.K. and V.S. conducted experiments. D.R.S. conducted transmission electron microscopy. M.I. and Y.M.Y. interpreted the data, prepared figures and wrote the manuscript.www.nature.com/scientificreports/12Scientific RepoRts | 7: 2502  | DOI:10.1038/s41598-017-02768-zAdditional InformationSupplementary information accompanies this paper at doi:10.1038/s41598-017-02768-zCompeting Interests: The authors declare that they have no competing interests.Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-ative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not per-mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2017BioMed CentralPage 1 of 11(page number not for citation purposes)Orphanet Journal of Rare DiseasesOpen AccessReviewNeurofibromatosis type 2 (NF2): A clinical and molecular reviewD GarethREvansAddress: Medical Genetics Research Group, Regional Genetics Service and National Molecular Genetics Reference Laboratory, Central Manchester Foundation Trust, St Mary's Hospital, Manchester M13 0JH, UKEmail: D GarethREvans-dgr.evans@virgin.netAbstractNeurofibromatosis type 2 (NF2) is a tumour-prone disorder characterised by the development ofmultiple schwannomas and meningiomas. Prevalence (initially estimated at 1: 200,000) is around 1in 60,000. Affected individuals inevitably develop schwannomas, typically affecting both vestibularnerves and leading to hearing loss and deafness. The majority of patients present with hearing loss,which is usually unilateral at onset and may be accompanied or preceded by tinnitus. Vestibularschwannomas may also cause dizziness or imbalance as a first symptom. Nausea, vomiting or truevertigo are rare symptoms, except in late-stage disease. The other main tumours are schwannomasof the other cranial, spinal and peripheral nerves; meningiomas both intracranial (including opticnerve meningiomas) and intraspinal, and some low-grade central nervous system malignancies(ependymomas). Ophthalmic features are also prominent and include reduced visual acuity andcataract. About 70% of NF2 patients have skin tumours (intracutaneous plaque-like lesions or moredeep-seated subcutaneous nodular tumours). Neurofibromatosis type 2 is a dominantly inheritedtumour predisposition syndrome caused by mutations in the NF2 gene on chromosome 22. Morethan 50% of patients represent new mutations and as many as one-third are mosaic for theunderlying disease-causing mutation. Although truncating mutations (nonsense and frameshifts) arethe most frequent germline event and cause the most severe disease, single and multiple exondeletions are common. A strategy for detection of the latter is vital for a sensitive analysis.Diagnosis is based on clinical and neuroimaging studies. Presymptomatic genetic testing is anintegral part of the management of NF2 families. Prenatal diagnosis and pre-implantation geneticdiagnosis is possible. The main differential diagnosis of NF2 is schwannomatosis. NF2 represents adifficult management problem with most patients facing substantial morbidity and reduced lifeexpectancy. Surgery remains the focus of current management although watchful waiting withcareful surveillance and occasionally radiation treatment have a role. Prognosis is adversely affectedby early age at onset, a higher number of meningiomas and having a truncating mutation. In thefuture, the development of tailored drug therapies aimed at the genetic level are likely to providehuge improvements for this devastating condition.Disease name and synonymsNeurofibromatosis type 2(NF2), Bilateral acoustic neu-rofibromatosis, Central neurofibromatosis. OMIM#101000DefinitionNeurofibromatosis type 2 (NF2) is a dominantly inher-ited tumour prone disorder characterised by the develop-ment of multiple schwannomas and meninigiomas [1].Published: 19 June 2009Orphanet Journal of Rare Diseases 2009, 4:16doi:10.1186/1750-1172-4-16Received: 24 March 2009Accepted: 19 June 2009This article is available from: http://www.ojrd.com/content/4/1/16© 2009 Evans; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Orphanet Journal of Rare Diseases 2009, 4:16http://www.ojrd.com/content/4/1/16Page 2 of 11(page number not for citation purposes)The disease can be diagnosed when a pathogenic muta-tion in the NF2 gene is identified or when the criteria intable 1[1] are fulfilled.EpidemiologyWhen using established clinical diagnostic criteria [1] andbased on mutations in the NF2 gene [2,3] assessment ofthe frequency of NF2 in the population can be made. Thisis complicated by the high rate of mosaicism [4]. Therehave only been two epidemiological studies of NF2 one inNorth West England [5,6], [Evans DG et al. Birth inci-dence and prevalence of tumour prone syndromes: esti-mates from a UK genetic family register service. Am J MedGenet 2009. unpublished] and one in Finland [7]. Theincidence of NF2 was initially reported as 1:33–40,000individuals in a 4 million population in England [5]. Dis-ease prevalence was somewhat lower at 1: 200,000. How-ever, a recent update suggests that the incidence may be ashigh as 1:25,000 [6]. Disease prevalence has now risen toaround 1 in 60,000 due to earlier diagnosis and better sur-vival due to improved treatment [Evans DG et al. Birthincidence and prevalence of tumour prone syndromes:estimates from a UK genetic family register service. Am JMed Genet 2009. unpublished]. A lower incidence of 1 in87,410 was reported in a 1.7 million population in Fin-land [7].Clinical descriptionNF2, in contrast to neurofibromatosis type 1 (NF1) ischaracterised by the development of schwannomas, men-ingiomas and ependymomas, with the great majority ofpatients developing bilateral schwannoma involvementof the superior vestibular branch of the eighth cranialnerve [1]. Although the disease is still classified as "neu-rofibromatosis", neurofibromas are relatively infrequent.The first clear description of NF2 was in 1822 by Wishart[8]. NF1 was fully delineated in the late nineteenth cen-tury by von Recklinghausen. However, it was the eminentHarvey Cushing, who described bilateral eighth nervetumours occuring as part of von Recklinghausen diseasein 1916 [9]. This description is largely responsible for theconfusion between the two conditions which continuedfor many years. Indeed, the literature prior to 1985 hasmany NF2 cases being described as part of von Reckling-hausen disease, with bilateral vestibular schwannomas(VS) being included in a major patient series [10].The hallmark of NF2 is the development of bilateral VS.VS usually present with hearing loss, tinnitus or imbal-ance or a combination of the three symptoms. The othermain tumour features are schwannomas of the other cra-nial, spinal and peripheral nerves; meningiomas bothintracranial (including optic nerve meningiomas) andintraspinal; and some low-grade central nervous system(CNS) malignancies (ependymomas and gliomas). Fourlarge clinical studies have now confirmed this clinical pic-ture [1,11-13] (Table 2). Individuals may present with cra-nial meningiomas or a spinal tumour long before theappearance of a VS.The majority of individuals with NF2 present with hearingloss, which is usually unilateral at time of onset. The hear-ing loss may be accompanied or preceded by tinnitus. VSmay also cause features such as dizziness or imbalance asthe first symptom. Nausea, vomiting or true vertigo arerare symptoms except in late stage disease.A significant proportion of cases (20–30%) present withsymptoms from an intracranial meningioma (headaches,seizures), spinal tumour (pain, muscle weakness, paraes-thesia), or cutaneous tumour [1,11-13]. Indeed, the firstsign of more severe multi-tumour disease in early child-hood is often a non-8th nerve tumour (including a cutane-ous tumour), or an ocular presentation [14]. Adultpresentation is thus quite different to paediatric presenta-tion, in which VS accounts for as little as 15–30% of initialsymptoms. There also appears to be a tendency to monon-europathy, particularly affecting the facial nerve causing aBell's-like palsy, which does not fully recover years beforethe detection of a VS. Some children present with a polio-like illness with wasting of muscle groups in a lower limb,which again does not fully recover. In adulthood, a moregeneralised symptomtatic severe polyneuropathy occursin about 3–5% of patients, often associated with an"onion bulb" appearance on nerve biopsy [1]. This canprogress, leading to severe muscle wasting and even death.However, around 40% of patients will show evidence ofpolyneuropathy on nerve conduction studies [15].Table 1: Diagnostic criteria for Neurofibromatosis type 2 (these include the NIH criteria with additional criteria)Main criteriaAdditional criteriaBilateral vestibular schwannomas (VS) or family history of NF2 plusUnilateral VS plus any two of: meningioma, glioma, neurofibroma, schwannoma, and posterior subcapsular opacities1) Unilateral VS oror2) Any two of: meningioma, glioma, neurofibroma, schwannoma, posterior subcapsular lenticular opacitiesMultiple meningioma (two or more) plus unilateral VS or any two of: glioma, neurofibroma, schwannoma, and cataractNF2 – Neurofibromatosis type 2; NIH – National Institutes of Health; VS – vestibular schwannomasOrphanet Journal of Rare Diseases 2009, 4:16http://www.ojrd.com/content/4/1/16Page 3 of 11(page number not for citation purposes)Ophthalmic features are also prominent in NF2. Patientsoften suffer from reduced visual acuity of various causes.Between 60–80% of patients have cataracts [1,10,11],which are usually presenile posterior subcapsular lenticu-lar opacities that rarely require removal. However, corticalwedge opacities may be present from near birth. Opticnerve meningiomas can cause visual loss in the first yearsof life and extensive retinal hamartomas can also affectvision. Misdiagnosis of both of these abnormalities asretinoblastoma has led to the eye being removed in thefirst few years of life.The skin is a useful aid to diagnosis, but cutaneous fea-tures in NF2 are much more subtle than in NF1. About70% of NF2 patients have skin tumours, but only 10%have more than ten skin tumours. The tumours appear tobe of at least three different types. The most frequent typeis a plaque-like lesion, which is intra-cutaneous, slightlyraised and more pigmented than surrounding skin, oftenwith excess hair. More deep-seated subcutaneous nodulartumours can often be felt, sometimes on major peripheralnerves. These tumours occur as a fusiform swelling of thenerve with thickened nerve palpable on either side. Thereare also occasional intracutaneous tumours similar tothose in NF1. The great majority of these tumours areschwannomas, but occasional definite neurofibromas dooccur.EtiopathogenesisNF1 and NF2 were eventually recognised as separategenetic and clinical diseases with the localisation of therespective genes to chromosome 17 and 22 [16,17]. Thiswas followed by the formal clinical delineation at aNational Institutes of Health (NIH) consensus meeting inthe USA in 1987 [18]. It is now clear that NF2 is a geneti-cally homogeneous condition, with no evidence foranother genetic cause of classical NF2 (bilateral VS).Seizinger et al. were the first to show loss of constitutionalheterozygosity of chromosome 22, with DNA markers lostin tumours from a patient with NF2 [19]. As such NF2 wasone of the first inherited tumour prone disorders to belocalised to a specific genetic location. Linkage studiesthen confirmed that all affected members of the large fam-ily carried the same copy of chromosome 22q. The NF2gene was then isolated by the simultaneous discovery ofconstitutional and tumour deletions in a gene coding fora cell membrane-related protein, which has been termedmerlin or schwannomin by the two groups who isolatedit [2,3].Table 2: Clinical characteristics of Neurofibromatosis type 2 patients in four studiesCharacteristicStudyKanter et al. [11]Evans et al. [1]Parry et al. [12]Mautner et al. [13]Number of cases731206348Number of families17753244Sporadic cases0451744Mean age at onset (years)20 (of 59)222017Intracranial meningiomas (%)18454958Spinal tumours (%)NA266790Skin tumours (%)32 (of 73)68 (of 100)6764Café-au-lait macules (%)42 (of 31)43 (of 100)47NACataract (%)NA38 (of 90)8162Intracranial astrocytoma (%)NA4.11.6NAEpendymoma (%)NA2.53.26Optic sheath meningioma (%)1NA4.14.881In Mautner et al., the frequency of optic nerve sheath tumours is for all histological types (i.e., schwannomas and meningiomas).Orphanet Journal of Rare Diseases 2009, 4:16http://www.ojrd.com/content/4/1/16Page 4 of 11(page number not for citation purposes)Constitutional mutationsStandard mutation techniques, such as Single Strand Con-formational Polymorphism (SSCP) analysis or Denatur-ing Gradient Gel Electrophoresis, detected between 35%and 66% of pathogenic mutations [20-23]. The majorityof these mutations were truncating mutations, leading toa smaller and probably non-functional protein product.Early studies suggested that missense mutations (whichresult in a complete protein product) and large deletions(which result in no protein product) both caused predom-inantly mild phenotypes. Larger studies of detailed geno-type/phenotype correlations in multiple families haveconfirmed this finding [21-26]. Phenotype is more varia-ble in patients with splice-site mutations, with milder dis-ease in patients with mutations in exons 9–15 [26,27].Definitive evidence from effects on survival have beenestablished with missense mutation patients having statis-tically greater survival than nonsense and frameshiftmutations [26]. As in other tumour prone disorders thefrequency of large genomic rearrangements did notbecome apparent until some time after the gene wascloned, due to the poor availability of methods to allowroutine clinical screening for their presence. About half ofthese are detectable with standard cytogenetic analysiswith FISH [28]. A small number of constitutional abnor-malities such as chromosome translocations and ring 22would still need a cytogenetic analysis to confirm theirpresence. The majority of large scale rearrangements arenow routinely detected by Multiplex Ligation-dependantProbe Amplification (MLPA) and are known to accountfor around 15% of NF2 germline aberrations [28,29]. Thecommonest of this class of mutations is a deletion of theNF2 promoter, exon 1 and most of intron 1 and deletionsof the whole gene, indeed combined these two accountfor over half of all MLPA abnormalities (Table 3). The dif-fering frequency of the various types of NF2 mutationbetween familial, sporadic and mosaic cases can be seenin Table 4. This represents the output from one centrededicated to whole gene analysis with the great majorityof patients having been screened by a technique capableof the detection of large deletions or duplications. Moreextensive lists of NF2 mutations described worldwide areavailable online and in recent reviews [30-32], but theseare less likely to reflect the true ratios of different classesof mutations, as a variety of different techniques havebeen used. The sensitivity of genetic testing usingsequence analysis and MLPA can be derived from column1 (Table 1). Ninety-three per cent of mutations have beenidentified in the second generation of NF2 families. Of themissing eight families six have been subjected to moredetailed analysis including RNA analysis. Two putativesplicing variants deep in the introns have been identifiedbased on Protein Truncation Testing and intronicsequencing (Messaien L, personal communication), butno other mutations have been found.A considerable proportion of NF2 patients, particularlymilder cases, have mosaic disease, in which only a propor-tion of cells contain the mutated NF2 gene. The initiatingmutation occurs after conception, leading to two separatecell lineages. The proportion of cells affected depends onhow early in development the mutation occurs. Recentevidence suggests that up to 20–30% of NF2 cases withouta family history of the disease are mosaic, carrying themutation in too small a proportion or none of their lym-phocytes to be detected from a blood sample [4,33-35].This accounts for the milder disease course in many indi-viduals with unfound mutations, and since only a subsetof germ cells (or none) will carry the mutation, there isless than a 50% risk of transmitting the disease to theiroffspring. However, if an offspring has inherited themutation, they will have a typical phenotype and usuallybe more severely affected than their parent, since the off-spring will carry the mutation in all of their cells. One ofthe features that suggested that mosaicism existed in NF2was that NF2 mutations were harder to find in blood inisolated non inherited cases than in patients who hadinherited the disease from an affected parent. Mosaicismmay be particularly likely in NF2 if the tumours are pre-dominantly on one side of the body. The mosaic muta-tion can be detected by analysing tumour material froman affected individual. If an identical mutation is found intwo tumours from that individual, their offspring can betested for the presence of the mutation. Also when twoalterations, either: two mutations or one mutation plusone allele loss, are found in on tumour, one of these mustbe the constitutional one. Thus offspring can be tested forboth abnormalities and potentially exclude inheritingNF2.C > T transitions leading to a nonsense mutation are themost common mutations in the NF2 gene [30-32]. Theseaccount for the only significant variation in mutation fre-quency across the NF2 gene apart from the lack of muta-tions in exons 16 and 17 and a relatively low frequency inexon 9 [30].Somatic mutationsThere are notable similarities, but also differencesbetween the distribution and type of germline andsomatic NF2 mutations. Among germline mutations inclassic NF2, nonsense mutations are more common thanframeshift mutations by a ratio of 1.3:1, but this ratio isreversed for somatic mutations [36]. In both situationsNF2 nonsense mutations, C > T transitions in CGAcodons and non-CGA codons are the most common sin-gle base-pair transitions. However there is a markedabsence of mutations in exons 14 and 15 in sporadic men-ingioma. One recently reported phenomenon is theincreasing drift from nonsense mutations in the germlineand early somatic mutations to a predominance ofOrphanet Journal of Rare Diseases 2009, 4:16http://www.ojrd.com/content/4/1/16Page 5 of 11(page number not for citation purposes)frameshift mutations in the tumours of older patientswith vestibular schwannoma [36]. This is likely to be dueto a deficiency in certain DNA repair pathways in olderpatients [36].Although it is thought that effectively all schwannomasrequire inactivation of the NF2 gene, no reports apartfrom those studying NF2 protein have confirmed a 100%knock out of both copies of the NF2 gene. This is likely tobe due to diversity of mechanisms that inactivate the gene.The standard approach of mutational analysis and Loss ofConstitutional Heterozygosity (LOH) on tumours willdetect involvement of NF2 in about 80–90% of schwan-nomas, but both copies can only be confirmed as affectedin about 50–60% of cases. The mechanism of LOH is alsonot straightforward, whilst most cases involve loss ofTable 3: MLPA abnormalities in 62 unrelated familiesMLPA abnormalityNumber of occasions (mosaic)Exon 1-intron1 (deletes intronic CA repeat)18 (3)Whole gene (exons 1–17) deletion16 (2)Exons 5–17 deletion3 (2)Exons 2–3 deletion2Exons 2–10 deletion2Exons 13–15 deletion1Exons 1–16 deletion2 (1)Exons 1–10 deletion3 (1)Exons 1–3 deletion1Exons 1–4 deletion2 (1)Exons 1–2 deletion1 (1)Exons 15–17 deletion1Exons 8–17 deletion1Exons 8–15 deletion1Exon 3 deletion1Exon 7 deletion1Exon 5 deletion1Exons 12–14 duplication1Exons 10–16 duplication1Exon 2 deletion1Exon 8 deletion1Exons 2–4 deletion1MLPA- Multiplex Ligation-dependant Probe AmplificationOrphanet Journal of Rare Diseases 2009, 4:16http://www.ojrd.com/content/4/1/16Page 6 of 11(page number not for citation purposes)chromosome 22 or at least the long arm, a proportion arenow known to be due to mitotic recombination withessentially two identical copies of a mutated NF2 geneand distal 22q [37]. This mechanism is now thought to bea primary cause of NF2 inactivation in schwannomatosis.It is now known that between 20–40% of sporadicschwannomas are inactivated by NF2 methylation [38,39]and in a similar fashion to TP16 this could involve bothcopies of NF2 and explain why some tumours do not har-bour identifiable point mutations or LOH. Approximately60% of sporadic meningiomas have NF2 gene involve-ment and promoter methylation again plays a significantrole [40].DiagnosisThe Manchester (modified NIH) diagnostic criteria forNF2 are shown in Table 1. The original NIH criteria havebeen expanded to include patients with no family historywho have multiple schwannomas and or meningiomas,but who have not yet developed bilateral 8th nervetumours. Patients who have asymmetric involvement arelikely to be mosaic [41]. At very young ages (< 18 years)individuals presenting with an apparently isolated menin-gioma [14] or vestibular schwannoma [42] are have a20% and 10% likelihood respectively of developing NF2.However after 20 years of age this rate drops dramaticallyand the diagnosis becomes very unlikely after 30 years ofage [42].Diagnostic methods(cid:129) Clinical and family history(cid:129) Examination including cutaneous and ophthalmic(Slit lamp)(cid:129) Craniospinal MRI(cid:129) Molecular analysisDifferential diagnosisThe main differential diagnosis of NF2 is schwannomato-sis and some patients with multiple non cranial schwan-nomas turn out to have mosaic NF2 [34,35]. However,patients fulfilling the most sensitive Manchester criteriaare unlikely to be misclassified [43].Antenatal diagnosis and genetic counsellingNF2 is an autosomal dominant disease with usually a50% risk of transmission from an affected individual totheir offspring. This was first confirmed in a large familyreported by Gardner and Frazier in 1930. 50–60% ofpatients have no family history and represent de novomutations in the NF2 gene [1-3]. Individuals who inherita pathogenic mutation in the NF2 gene will almost alwaysdevelop symptoms by 60 years of age [7]. Exceptionally,patients particularly in the pre MRI era will have not beendiagnosed in their lifetime. Although the transmissionrate is 50% in the second generation and beyond, the riskof transmission in an apparently isolated patient withNF2 is less than 50% due to mosaicism [4].Because detection of tumours at an early stage is effectivein improving the clinical management of NF2, pre-symp-Table 4: Mutations identified in 529 families with Neurofibromatosis type 2 in the Manchester (UK) genetics laboratoryType of mutationDetection in 2nd generation (n = 108)Detection in sporadic non mosaic patients (% non mosaic)Mosaic mutations (% of mosaic)TotalSplice site35 (32%)43 (22%)3 (4%)80 (15%)MLPA positive23 (20%)28 (14%)11 (15%)62 (12%)FSD18 (17%)36 (18%)20 (26%)74 (13%)Nonsense16 (15%)67 (35%)28 (37%)111 (22%)Missense7 (6%)5 (3%)1 (1%)13 (2.5%)FSI3 (3%)11 (7%)6 (8%)20 (4%)IFD1 (1%)13 (4%)5 (1%)Ring 22003 (4%)3Not found7 (7%)230 (55%)158166/529 (31%)Total108191/421 (45%)72529Orphanet Journal of Rare Diseases 2009, 4:16http://www.ojrd.com/content/4/1/16Page 7 of 11(page number not for citation purposes)tomatic genetic testing is an integral part of the manage-ment of NF2 families. Once a mutation has beenidentified in an affected individual, a 100% specific test isavailable for the family. However, mutation screeningmay not reveal the causative mutation. Predictive diagno-sis by linkage analysis using intragenic markers or markersflanking the NF2 gene is also possible in the great majorityof families with two or more living affected individuals. Inthe absence of a genetic test a cumulative age at onsetcurve [44] can be used. Age at onset curves aid geneticcounselling; for example, the risk of having inherited NF2for an asymptomatic at-risk individual 25 years of age,prior to screening, drops to 25%. The risk to an unaffected30 year old with a normal scan would be < 10%. Tumouranalysis plays a vital role in providing genetic testing forthe offspring of sporadic patients. Indeed analysis shouldif possible first be carried out on tumour so that a targetedapproach can be used on the blood sample. If both muta-tional events are identified in the NF2 gene in a tumourand neither is present in the blood the patient must bemosaic for one of these mutations [33-35,45,46]. Even ifonly LOH is identified this still allows exclusion of NF2 in50% of offspring if they can be shown to have inheritedthe allele "lost" in the tumour [35,46]. At-risk individualswho are shown not to have inherited the mutated NF2gene do not need further follow-up.Even in the absence of identifying a mutation the residualrisk of NF2 can be substantially reduced in the child of anapparently isolated case. In particular patients presentingwith asymmetric disease over 40 years of age with negativemutation analysis in blood would have a very low chanceof transmitting NF2 to their children (Table 5).Because of the severity of NF2 there is a demand for pre-natal diagnosis and pre-implantation genetic diagnosis.Use of the techniques above means that this is possible inthe great majority of families.Screening protocolChildren of affected patients should be considered to beat 50% risk of NF2 and screening for NF2 can start at birth.Cataracts can affect vision in early life and other tumourimplications are present in the first ten years of life, partic-ularly cranial meningiomas. Formal screening for VSshould start at ten years, as it is rare for tumours tobecome symptomatic before that time even in severelyaffected families. Annual audiological tests includingauditory brainstem response are still a useful adjunct toMRI [44]. Surgery is unlikely to be more successful fortumours < 6 mm than for tumours sized 6 mm, but VSgrowth is higher in younger patients, so for asymptomaticat-risk individuals without tumours, MRI screening everytwo years for those < 20 years old and every 3–5 years forthose age > 20 years should be sufficient. The initial MRIscan could be at around 12 years of age, or 10 years inseverely affected families. Once tumours are present, MRIscreening should probably be at least annual. Spinaltumours are seen in 60–80% of NF2 patients on MRI [47-50]. While only 25–30% of patients with spinal tumoursrequire a spinal operation from a symptomatic tumour, afull annual neurological examination is probably a wiseprecaution with Spinal MRI only every 3 years or if thereTable 5: Transmission risks to offspring for isolated cases of Neurofibromatosis type 2 before and after negative mutation testing. NumberPRE testing Mosaic inferredPRE testing Transmission riskPOST genetic negative testing in blood Mosaic inferredPOST genetic negative testing in blood Transmission risk< 20 BVS8512%45%46%30% 1 in 3< 20 UVS2142%33%87%11% 1 in 920–29 BVS6727%36%78%16% 1 in 620–29 UVS2778%19%97%8% 1 in 1230–39 BVS5450%28%88%11% 1 in 930–39 UVS1985%12%98%6% 1 in 1640+ BVS5363%22%93%9% 1 in 1140+ UVS3490%10%99%5% 1 in 20Results are based of outcomes of testing in first affected family members and on age at onset and laterality of presentation with vestibular schwannomas (VS).BVS – presentation with bilateral VS; UVS – initial presentation with unilateral VSOrphanet Journal of Rare Diseases 2009, 4:16http://www.ojrd.com/content/4/1/16Page 8 of 11(page number not for citation purposes)are new symptoms. If no tumours are present on the ini-tial scan a further scan 5–10 years later may be reasonable.In most families it is now possible to develop a genetic testso that screening can be targeted to affected individualsonly. Identifying the affected patient's mutation not onlyallows testing of at risk relatives, but may also give impor-tant indicators as to the patient's own prognosis. As 25–30% of NF2 patients are mosaic frozen tumour should betaken at operation (with patient consent) for genetic tests.NF2 managementNF2 presents many difficult management dilemmas. Themainstay of management of NF2 is surgical removal ofsymptomatic cranial and spinal tumours. The timing ofremoval of vestibular schwannomas is a more difficultarea. Surgical results are certainly far better when man-aged by an experienced team [50-52]. There is clear evi-dence of a reduction in mortality with a significantlyincreased life expectancy for NF2 patients managed at 3specialty centres in the UK (OR 0.34) [53]. It is importantto balance the use of microsurgery and radiation treat-ment, which can have a role in patients who have particu-larly aggressive tumours, or who are poor surgical risks, orwho refuse surgery. Teams experienced in the positioningof brainstem implants can offer partial auditory rehabili-tation to those who are deaf, although results are stillbehind those achievable for cochlear implants. Althoughthe cochlear nerve may be left initially intact after surgeryits blood supply may be damaged, nonetheless a fewpatients can be rehabilitated successfully with a cochlearimplant.OutcomesEven with improvements in microsurgery and with use ofradiation therapy, the great majority of individuals withNF2 become completely deaf. The tumours in NF2 aremore difficult to treat than those of sporadic unilateral VS,as NF2 VS are often multifocal, appearing "like a bunch ofgrapes" around the vestibular nerve in particular. There isevidence for a histological difference, with NF2 VS beingmore lobular and less vascular then their sporadic coun-terparts [54]. This leads to a greater risk of facial nervedamage in NF2. Loss of facial nerve function is one of themost feared aspects of the condition for many sufferers,although in good surgical hands this complication is nowmuch less common [50,52]. Patients may also be severelydisabled by a combination of poor balance, visual prob-lems and weakness due to spinal tumours. Indeed, manyNF2 patients become wheelchair-bound in early adult-hood. Many patients with multi-tumour disease die intheir twenties and thirties. In view of the multiplicity ofproblems affecting many patients it is strongly recom-mended that NF2 patients are managed by a multidiscipli-nary team in specialist centres [52].Specialty centresA typical NF2 specialist centre will require involvement ofa number of key staff members.Permanent clinic staffNeurosurgeon, Otolaryngologist, physician (neurologist/geneticist), clinic nurse/patient link worker and a dedi-cated clinic secretary.Clinic equipment: lightwriter/pallantype/voice activatedsoftware.In order to minimise patient visits morning scanning withlunchtime radiological review and an afternoon clinic ispreferable.Each clinic should have access to a namedNeuroradiologist, ophthalmologist, peripheral nerve sur-geon, plastic surgeon, neurologist/geneticist (if notinvolved in main clinic), hearing therapist, physiothera-pist, paediatrician.Patients should be given the option of a radiation therapyopinion, which will only be available at a few centres.Managing affected childrenNF2 is being recognised more and more frequently inchildhood often before VS have developed. Recognitionof the more severe disease course with early presentationand the more atypical features such as mononeuropathyare important.SurgeryVS in NF2 are more difficult to treat than those of sporadicunilateral VS because NF2-related VS are often multifocalin the eighth nerve complex, and the potential for associ-ated facial nerve schwannomas. Surgery to remove VS inNF2 almost always leads to total deafness with loss of thecochlear nerve. Despite the great improvement in VS sur-gery over the last three decades, facial nerve damage andother adverse outcomes remain a real possibility duringtumour removal, especially in the hands of less experi-enced VS surgeons. Facial weakness may threaten thehealth of the eye as a result of loss of the protective blinkreflex. and as the lacrimal gland is also supplied by thefacial nerve the loss of tear production will increase thisrisk. If facial nerve damage coexists with loss of cornealsensation from damage to the trigeminal nerve then theeye becomes exceptionally vulnerable to corneal ulcera-tion and blindness.The cornerstone of modern NF2 management is conserva-tion of function, and the maintenance of "quality of life".The mere presence of a tumour is not an indication for itsremoval. Serious thought must be given to the benefitsOrphanet Journal of Rare Diseases 2009, 4:16http://www.ojrd.com/content/4/1/16Page 9 of 11(page number not for citation purposes)that are sought and the risks and complications of the sur-gery, and the treatment must be tailored to the needs ofthe individual patient [52]. Attempts at hearing preserva-tion surgery should be limited to experienced centres whocan offer a realistic chance of maintaining both the coch-lear nerve, but also cochlea function. If hearing is lost afterapparent cochlear nerve preservation the patient may stillbe suitable for a cochlear implant. In many if not mostinstances the best policy will be to observe VS to decide onthe best time to balance surgical morbidity against thealmost inevitable loss of hearing.The principle of minimal interference for VS appliesequally to schwannomas on other cranial nerves, tointracranial meningiomas, and to spinal tumours. It isvery uncommon to have to remove a schwannoma grow-ing on a cranial nerve other than the eighth because thesetumours appear to have a much slower growth patternthan NF2 VS. Spinal tumours are mostly considered forexcision if they are clearly producing symptoms or physi-cal signs. In the absence of any dramatic growth oftumours, the head should be scanned every year and thespine every 3 years.Radiation therapyIt is important to balance the use of microsurgery andradiation treatment, which has a role in patients who arepoor surgical candidates, or who refuse or wish to avoidsurgery because of its associated risks. Radiation therapyshould be mentioned as a management option, even if thetumour is larger than the size criterion for treatment. Theupper limit of size for radiotherapy is generally a maxi-mum intracranial diameter of 3 cm [55]. The patientshould be aware of the management options even if thetumour is not suitable for a particular treatment modality.In NF2 cases selected for radiosurgery tumour controlrates are of the order of 50%, with 40% retaining pre-treat-ment hearing for at least 3 years [56]. This is nonethelesssubstantially worse than for sporadic vestibular schwan-nomas.Surgeons should use clinical judgement as to when to rec-ommend radiation therapy [52]. Follow-up for life withinterval scanning is necessary, although this would berequired for NF2 anyway. Patients should be made awareof the variable reported outcomes of the treatment andthe risk of the radiation-induced malignant change, whichhas been reported disproportionately more in NF2 thansporadic patients [57,58]. The tumour may also be moredifficult to excise after radiotherapy, and that reportedfacial nerve outcomes after surgery following stereotacticradiation therapy are frequently poor [59].New therapiesThe NF2 protein appears to impact on multiple intracellu-lar signalling pathways. These pathways include the PI3-kinase/Akt, Raf/MEK/ERK and mTOR pathways [60]. Inparticular, studies using NF2-derived tumour tissue revealelevated levels of phosphorylated Akt. More recently, Akt-dependent phosphorylation of Merlin on 2 residues (Thr-230 and Ser-315) has been shown to target Merlin forubiquitin-dependent degradation. Although no PI3kinase or Akt inhibitors have yet been approved for treat-ment, there are multiple compounds in development –primarily for oncology indications. The Raf/MEK/ERKpathway has been implicated in NF2 tumorigenesis inpart through identification of elevated levels of phospho-ERK and phospho-MEK.The progress being made in cellular research especiallywith regard to pathways in which the NF2 gene productinteracts raises the hopes of targeted therapy. Targeting theERK1/, AKT, integrin/focal adhesion kinase/Src/Ras sign-aling cascades, PDGFRbeta, phosphatidylinositol 3-kinase/protein kinase C/Src/c-Raf pathway, VEG-F andother pathways [60,61] means that drugs such as avastin,elotinib [62], lapatinib and sorafenib [63] may well bearfruit.PrognosisNF2 remains a life limiting and life spoiling condition.Patients diagnosed prior to 1990 had only a 15 year lifeexpectancy from diagnosis [1,64]. Improvement in man-agement and early diagnosis are improving these out-comes but many people with NF2 still die very young.Prognosis is adversely affected by early age at onset,number of meningiomas and having a truncating muta-tion [52].Unresolved questions1. What is the most appropriate molecular/cell biolog-ical target(s) for therapy2. What are the long term safety issues of radiationtreatments and does fractionated radiotherapy offeradvantages over sterotactic or gamma knife treatmentConclusionNF2 remains a condition that is life spoiling and life lim-iting. Multidisciplinary management with early diagnosisare mainstays of management. Hopefully new targetedtherapies will revolutionise the outcomes in this condi-tion.AbbreviationsNF2: neurofibromatosis type 2; MRI: magnetic resonanceimaging; NF1: neurofibromatosis type 1; VS: vestibularschwannomas; CNS: central nervous system; NIH:National Institutes of Health; SSCP: single strand confor-mational polymorphism; MLPA: multiplex ligation-dependant probe amplification; LOH: loss of constitu-tional heterozygosity.Orphanet Journal of Rare Diseases 2009, 4:16http://www.ojrd.com/content/4/1/16Page 10 of 11(page number not for citation purposes)Competing interestsThe author declares that they have no competing interests.References1.Evans DGR, Huson S, Donnai D, Neary W, Blair V, Newton V, HarrisR: A clinical study of type 2 neurofibromatosis.  Q J Med 1992,84:603-618.2.Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C,Hoang-xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, LenoirG, Bijlsma E, Fashold R, Dumanski J, de Jong P, Parry D, Eldridge R,Aurias A, Delattre O, Thomas G: Alteration in a new geneencoding a putative membrane-organizing protein causesneuro-fibromatosis type 2.  Nature 1993, 363:515-521.3.Troffater JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, EldridgeR, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CM, MunroeD, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, ShortPM, Buckler AJ, Gusella JF: A novel moesin-, ezrin-, radixin-likegene is a candidate for the neurofibromatosis 2 tumor sup-pressor.  Cell 1993, 72:791-800.4.Evans DGR, Wallace A, Trueman L, Strachan T: Mosaicism in clas-sical neurofibromatosis type 2: a common mechanism forsporadic disease in tumor prone syndromes?  Am J Hum Genet1998, 63:727-736.5.Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Teare D, Ram-sden RT, Harris R: A genetic study of type 2 neurofibromatosisin the north west of England and the UK: I. Prevalence,mutation rate, fitness and confirmation of maternal trans-mission effect on severity.  J Med Genet 1992, 29:841-846.6.Evans DGR, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R:Incidence of Vestibular Schwannoma and Neurofibromato-sis 2 in the North West of England over a 10 year period:higher incidence than previously thought.  Otol Neurotol 2005,26(1):93-97.7.Antinheimo J, Sankila R, Carpén O, Pukkala E, Sainio M, JääskeläinenJ: Population-based analysis of sporadic and type 2 neurofi-bromatosis-associated meningiomas and schwannomas.Neurology 2000, 54(1):71-76.8.Wishart JH: Case of tumours in the skull, dura mater, andbrain.  Edinburgh Med Surg J 1822, 18:393-397.9.Cushing H: Tumors of the nervus acusticus and the syndromeof the cerebello-pontine angle.  WB Saunders, Philadelphia, USA;1917. 10.Crowe FW, Schull WJ, Neal JV: A clinical pathological andgenetic study of multiple neurofibromatosis.  Springfield, Illi-nois, USA: Charles C. Thomas; 1956. 11.Kanter WR, Eldridge R, Fabricant R, Allen JC, Koerber T: Centralneurofibromatosis with bilateral acoustic neuroma. Genetic,clinical and biochemical distinctions from peripheral neurofi-bromatosis.  Neurol 1980, 30:851-859.12.Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, PatronasN: Neurofibromatosis 2 (NF2): Clinical characteristics of 63affected individuals and clinical evidence for heterogeneity.Am J Med Genet 1994, 52:450-451.13.Mautner VF, Lindenau M, Baser ME, Hazim W, Tatagiba M, Haase W,Samii M, Wais R, Pulst SM: The neuroimaging and clinical spec-trum of neurofibromatosis 2.  Neurosurg 1996, 38:880-885.14.Evans DGR, Ramsden R, Birch J: Paediatric presentation of type2 neurofibromatosis.  Arch Dis Child 1999, 81:496-499.15.Sperfeld AD, Hein C, Schroder JM, Ludolph AC, Hanemann CO:Occurrence and characterization of peripheral nerveinvolvement in neurofibromatosis type 2.  Brain 2002,125:996-1004.16.Seizinger BR, Rouleau GA, Ozelius LG, Ozelius LJ, Faryniarz AG, Ian-nazzi J, Hobbs W, Roy JC, Falcone B, Huson S: Genetic linkage ofvon Recklinghausen neurofibromatosis to the nerve growthfactor receptor gene.  Cell 1987, 49:589-594.17.Rouleau G, Seizinger BR, Ozelius LG, Hobbs WJ, Trofatter JA, Seiz-inger BR, Martuza RL, Superneau DW, Conneally PM, Gusella JF:Genetic linkage analysis of bilateral acoustic neurofibroma-tosis to a DNA marker on chromosome 22.  Nature 1987,329:246-248.18.National Institutes of Health Consensus Development ConferenceStatement on Neurofibromatosis: Arch Neurol.  1987, 45(5):575-578.19.Seizinger BR, Martuza RL, Gusella JF: Loss of genes on chromo-some 22 in tumorigenesis of human acoustic neuroma.Nature 1986, 322:644-647.20.MacCollin M, Ramesh V, Jacoby LB, Louis DN, Rubio MP, Pulaski K,Trofatter JA, Short MP, Bove C, Eldridge R: Mutationalanalysis ofpatients with neurofibromatosis 2.  Am J Hum Genet 1994,55:314-320.21.Parry DM, MacCollin M, Kaiser-Kupfer MI, Pulaski K, Nicholson HS,Boleseta M, Eldridge R, Gusella JF: Germ-line mutations in theneurofibromatosis 2 gene: correlations with disease severityand retinal abnormalities.  Am J Hum Genet 1996, 59:529-539.22.Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han F-y,Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, MichelsV, Riccardi VM, Weksberg R, Kitamura K, Bradburn JM, Hall BD,Propping P, Rouleau GA: Type of mutation in the neurofi-bromatosis type 2 gene (NF2) frequently determines sever-ity of disease.  Am J Hum Genet 1996, 59:331-342.23.Kluwe L, Bayer S, Baser ME, Hazim W, Haase W, Funsterer C, Maut-ner VF: Identification of NF2 germ-line mutations and com-parison with neurofibromatosis 2 phenotypes. [publishederratum in Hum Genet 1997;99(2):292].  Hum Genet 1996,98:534-538.24.Kluwe L, MacCollin M, Tatagiba M, Thomas S, Hazim W, Haase W,Mautner VF: Phenotypic variability associated with 14 splice-site mutations in the NF2 gene.  Am J Med Genet 1998,77:228-233.25.Evans DGR, Trueman L, Wallace A, Mason S, Strachan T: Genotype/phenotype correlations in type 2 neurofibromatosis: evi-dence for more severe disease with truncating mutations.  JMed Genet 1998, 35:450-455.26.Baser ME, Kuramoto L, Joe H, Kuramoto L, Joe H, Friedman JM, Wal-lace AJ, Ramsden RT, Evans DG: Genotype-Phenotype Correla-tions for Nervous System Tumors in Neurofibromatosis 2: APopulation-Based Study.  Am J Hum Genet 2004, 75:231-239.27.Baser ME, Kuramoto L, Woods RH, Friedman JM, Wallace AJ, Ram-sden RT, Olschwang S, Bijlsma E, Kalamarides M, Papi L, Kato L, EvansDG: The location of constitutional neurofibromatosis 2(NF2) splice-site mutations is associated with the severity ofNF2.  J Med Genet 2005, 42(7):540-6.28.Tsilchorozidou T, Menko F, Lalloo F, Kidd A, Da Silva R, Smith P, Mal-colmson A, Dore J, Madan K, Brown A, Yovos JG, Tsaligopoulos M,Vogiatzis N, Wallace A, Evans DGR: Constitutional rearrange-ments of chromosome 22 as a cause of neurofibromatosistype 2.  J Med Genet 2004, 41(7):529-534.29.Kluwe L, Nygren AO, Errami A, Heinrich B, Matthies C, Tatagiba M,Mautner V: Screening for large mutations of the NF2 gene.Genes Chromosomes Cancer 2005, 42(4):384-391.30.Baser ME: Neurofibromatosis 2 (NF2) mutation databases.[http://www.hgmd.cf.ac.uk/nf2/].31.Baser ME, the contributors to the International NF2 Database Muta-tion: The distribution of constitutional and somatic muta-tions in the neurofibromatosis 2 gene.  Hum Mutat.  2006,27(4):297-306.32.Ahronowitz I, Xin W, Kiely R, Sims K, Maccollin M, Nunes FP: Muta-tional spectrum of the NF2 gene: a meta-analysis of 12 yearsof research and diagnostic laboratory findings.  Hum Mutat2007, 28(1):1-12.33.Kluwe L, Mautner VF, Heinrich B, Dezube R, Jacoby LB, Friedrich RE,MacCollin M: Molecular study of frequency of mosaicism inneurofibromatosis 2 patients with bilateral vestibularschwannomas.  J Med Genet 2003, 40:109-114.34.Moyhuddin A, Baser ME, Watson C, Purcell S, Ramsden RT, HeibergA, Wallace AJ, Evans DGR: Somatic mosaicism in neurofi-bromatosis 2:prevalence and risk of disease transmission tooffspring.  J Med Genet 2003, 40:459-463.35.Evans DG, Ramsden RT, Shenton A, Gokhale C, Bowers NL, HusonSM, Wallace A: Mosaicism in NF2 an update of risk based onuni/bilaterality of vestibular schwannoma at presentationand sensitive mutation analysis including MLPA.  J Med Genet2007, 44(7):424-428.36.Evans DGR, Maher ER, Baser ME: Age-related shift in the muta-tion spectra of germline and somatic NF2 mutations: hypo-thetical role of DNA repair mechanisms.  J Med Genet 2005,42(8):630-632.37.Warren C, James LA, Varley JM, Ramsden RT, Evans DG: IdentifyingRecurrent Regions of Chromosome Loss and Gain in 76 Ves-Publish with BioMed Central   and  every scientist can read your work free of charge"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."Sir Paul Nurse, Cancer Research UKYour research papers will be:available free of charge to the entire biomedical communitypeer reviewed and published immediately upon acceptancecited in PubMed and archived on PubMed Central yours — you keep the copyrightSubmit your manuscript here:http://www.biomedcentral.com/info/publishing_adv.aspBioMedcentralOrphanet Journal of Rare Diseases 2009, 4:16http://www.ojrd.com/content/4/1/16Page 11 of 11(page number not for citation purposes)tibular Schwannomas Using Comparative Genomic Hybrid-isation (CGH).  J Med Genet 2003, 40(11):802-806.38.Kino T, Takeshima H, Nakao M, Nishi T, Yamamoto K, Kimura T,Saito Y, Kochi M, Kuratsu J-i, Saya H, Ushio Y: Identification of thecis-acting region in the NF2 gene promoter as a potential tar-get for mutation and methylation-dependent silencing inschwannoma.  Genes Cells 2001, 6:441-454.39.Gonzalez-Gomez P, Bello MJ, Alonso ME, Lomas J, Lopez-Marin I,Arjona D, de Campos JM, Vaquero J, Isla A, Lassaletta L, Gutierrez M,Sarasa JL, Rey JA: CpG island methylation in sporadic and neu-rofibromatosis type 2-associated schwannomas.  Clin CancerRes 2003, 9:5601-5606.40.Lomas J, Bello MJ, Arjona D, Alonso ME, Martinez-Glez V, Lopez-Marin I, Aminoso C, de Campos JM, Isla A, Vaquero J, Rey JA:Genetic and epigenetic alteration of the NF2 gene in spo-radic meningiomas.  Genes Chrom Cancer 2005, 42:314-319.41.Evans DGR, Ramsden RT, Shenton A, Gokhale C, Bowers NL, HusonSM, Wallace A: What are the implications in individuals withunilateral vestibular schwannoma and other neurogenictumors?  J Neurosurg 2008, 108(1):92-96.42.Evans DGR, Ramsden RT, Shenton A, Gokhale C, Bowers NL, HusonSM, Wallace A: Should NF2 mutation screening be undertakenin patients with an apparently isolated vestibular schwan-noma?  Clin Genet 2007, 71(4):354-358.43.Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG:Evaluation of diagnostic criteria for neurofibromatosis 2.Neurology 2002, 59(11):1759-1765.44.Evans DGR, Newton V, Neary W, Baser ME, Wallace A, MacLeod R,Jenkins JPR, Gillespie J, Ramsden R: Use of MRI and audiologicaltests in pre-symptomatic diagnosis of type 2 neurofibroma-tosis (NF2).  J Med Genet 2000, 37:944-947.45.Mohyuddin A, Neary WJ, Wallace AJ, Purcell S, Wu C-L, Reid H,Ramsden RT, Read AP, Evans DGR: Molecular genetic exclusionof NF2 in young patients diagnosed with a unilateral vestibu-lar schwannoma.  J Med Genet 2002, 39:315-322.46.Kluwe L, Freidrich RE, Tatagiba M, Mautner V: Presymptomaticdiagnosis for children of sporadic neurofibromatosis 2patients, a method based on tumor analysis.  Genet Med 2002,4:27-30.47.Mautner VF, Lindenau M, Baser ME, Tatagiba M, Haase W, Samii M,Wais R, Pulst SM: The neuroimaging and clinical spectrum ofneurofibromatosis 2.  Neurosurg 1996, 38:880-885.48.King A, Biggs N, Ramsden RT, Wallace A, Gillespie J, Evans DGR: Spi-nal tumors in neurofibromatosis type 2: is emerging knowl-edge of genotype predictive of natural history?  J NeurosurgSpine 2005, 2(5):574-579.49.Patronas NJ, Courcoutsakis N, Bromley CM, Katzman GL, MacCollinM, Parry DM: Intramedullary and spinal canal tumors inpatients with neurofibromatosis 2: MR imaging findings andcorrelation with genotype.  Radiology 2001, 218(2):434-442.50.Evans DGR, Ramsden R, Huson SM, Harris R, Lye R, King TT: Type2 neurofibromatosis: the need for supraregional care?  J Laryn-gol Otol 1993, 107:401-406.51.Slattery WH, Brackmann DE, Hitselberger W: Hearing preserva-tion in neurofibromatosis type 2.  Am J Otol 1998, 19:638-643.52.Evans DGR, Baser ME, O'Reilly B, Rowe J, Gleeson M, Saeed S, KingA, Huson S, Kerr R, Thomas N, Irving R, MacFarlane R, Ferner R,McLeod R, Moffat D, Ramsden R: Management of the patient andfamily with Neurofibromatosis 2: A consensus conferencestatement.  Brit J Neurosurg 2005, 19:5-12.53.Baser ME, Friedman JM, Aeschilman D, Joe H, Wallace AJ, RamsdenRT, Evans DGR: Predictors of the risk of mortality in neurofi-bromatosis 2.  Am J Hum Genet 2002, 71:715-723.54.Sobel RA, Wang Y: Vestibular (acoustic) schwannomas: histo-logical features in neurofibromatosis 2 and in unilateralcases.  J Neuropathol Exp Neurol 1993, 52:106-113.55.Rowe JG, Radatz M, Walton L, Kemeny AA: Stereotactic radiosur-gery for type 2 neurofibromatosis acoustic neuromas:patient selection and tumour size.  Stereotact Funct Neurosurg2002, 79:107-116.56.Rowe JG, Radatz MW, Walton L, Soanes T, Rodgers J, Kemeny AA:Clinical experience with gamma knife stereotactic radiosur-gery in the management of vestibular schwannomas second-ary to type 2 neurofibromatosis.  J Neurol Neurosurg Psychiatry2003, 74(9):1288-1293.57.Baser ME, Evans DGR, Jackler RK, Sujansky E, Rubenstein A: Malig-nant peripheral nerve sheath tumors, radiotherapy, and neu-rofibromatosis 2.  Brit J Cancer 2000, 82:998.58.Evans DGR, Birch JM, Ramsden RT, Sharif S, Baser ME: Malignanttransformation and new primary tumours after therapeuticradiation for benign disease: substantial risks in certaintumour-prone syndromes.  J Med Genet 2006, 43(4):289-94.59.Friedmann RA, Slattery WH, Brackmann DE, Shwartz MS, Hit-selberger WE: Resection of Acoustic Neuroma followingFailed Stereotactic Radiosurgical Treatment: Facial nerveoutcome.  In Fourth International Conference on Vestibular Schwannomaand Other CPA Lesions. Conference Proceedings Edited by: Baguley DM,Ramsden RT, Moffat DA. Pubs: Immediate Proceedings, Bungay, Nor-folk, UK:29-30. 60.Evans DG, Kalamarides M, Hunter-Schaedle K, et al.: ConsensusRecommendations to Accelerate Clinical Trials for Neurofi-bromatosis Type 2.  Clin Cancer Res 2009 in press.61.Hanemann CO: Magic but treatable? Tumours due to loss ofmerlin.  Brain 2008, 131(Pt 3):606-615.62.Plotkin SR, Singh MA, O'Donnell CC, Harris GJ, McClatchey AI,Halpin C: Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.  Nat ClinPract Oncol 2008, 5(8):487-491.63.Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO: Dissectingand targeting the growth factor-dependent and growth fac-tor-independent extracellular signal-regulated kinase path-way in human schwannoma.  Cancer Res 2008, 68(13):5236-5245.64.Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Newton V, Stra-chan T, Harris R: A genetic study of type 2 neurofibromatosis:II Guidelines for genetic counselling.  J Med Genet.  1992,29(12):846-852.DissectingandTargetingtheGrowthFactor–DependentandGrowthFactor–IndependentExtracellularSignal-RegulatedKinasePathwayinHumanSchwannomaSylwiaAmmoun,1ChristineFlaiz,1NataliaRistic,1JenniferSchuldt,2andC.OliverHanemann11ClinicalNeurobiology,PeninsulaCollegeforMedicineandDentistry,Plymouth,UnitedKingdom;and2DepartmentofNeurology,ZentrumfuerKlinischeForschung,UniversityofUlm,Ulm,GermanyAbstractSchwannomasaretumorsofthenervoussystemthatoccursporadicallyandinpatientswiththecancerpredispositionsyndromeneurofibromatosistype2(NF2).SchwannomasandallNF2-relatedtumorsarecausedbylossofthetumorsuppressormerlin.Usingourhumaninvitromodelforschwannoma,weanalyzedextracellularsignal-regulatedkinase1/2(ERK1/2)andAKTsignalingpathways,theirupstreamgrowthfactorreceptors,andtheirroleinschwan-nomacellproliferationandadhesiontofindnewsystemictherapiesforthesetumorsthat,todate,areverydifficulttotreat.WeshowherethathumanprimaryschwannomacellsshowanenhancedbasalRaf/mitogen-activatedprotein/ERKkinase/ERK1/2pathwayactivitycomparedwithhealthySchwanncells.Duetoastrongandprolongedactivationofplatelet-derivedgrowthfactorreceptorB(PDGFRB),whichishighlyoverexpressed,ERK1/2andAKTactivationwasfur-therincreasedinschwannoma,leadingtoincreasedprolifer-ation.Usingspecificinhibitors,wediscoveredthatERK1/2activationinvolvestheintegrin/focaladhesionkinase/Src/RassignalingcascadesandPDGFRB-mediatedERK1/2activationistriggeredthroughthephosphatidylinositol3-kinase/proteinkinaseC/Src/c-Rafpathway.Duetothecomplexityofsignalsleadingtoschwannomacellproliferation,potentialnewtherapeuticagentsshouldtargetseveralsignalingpathways.ThePDGFRandc-Rafinhibitorsorafenib(BAY43-9006;BayerPharmaceuticals),currentlyapprovedfortreatmentofad-vancedrenalcellcancer,inhibitsbothbasalandPDGFRB-mediatedERK1/2andAKTactivityanddecreasescellproliferationinhumanschwannomacells,suggestingthatthisdrugconstitutesapromisingtooltotreatschwannomas.Weconcludethatourschwannomainvitromodelcanbeusedtoscreenfornewtherapeutictargetsingeneralandthatsorafenibispossiblecandidateforfutureclinicaltrials.[CancerRes2008;68(13):5236–45]IntroductionSchwannomasarecommontumorsofthenervoussystemoccurringsporadicallyandinpatientswiththeinheritedcancerpredispositionsyndromeneurofibromatosistype2(NF2).SchwannomasarepurelyderivedfromSchwanncellsandlackthetumorsuppressorproteinmerlin(1).MerlinisstructurallyrelatedtotheERMfamilyproteins(ezrin,moesinandradixin;refs.2,3)thatactaslinkersbetweentheactincytoskeletonandthecellmembrane(4).Usingourinvitromodelforhumanschwannoma,wehavepreviouslyshownthatmerlinlossleadstoenhancedproliferationanddecreasedapoptosis(5),increasedcell-matrixadhesion(duetotheoverexpressionofintegrins;ref.6),anddecreasedcell-celladhesion(7).TheRhoGTPasesRac1andCdc42andtheirdownstreameffectorp21-activatedkinase(PAK)areactivatedinhumanprimaryschwannomacellsandhavebeenlinkedtotheaforementionedcharacteristicsofschwannomacells(8,9).PAKinhibitsmerlininanegativefeedbackloop(10,11),andPAKinhibitionleadstodecreasedproliferationratesandrufflinginmerlin-deficientcelllines(12).PAKcancross-talkwiththeextracellularsignal-regulatedkinase1/2(ERK1/2)signalingpathway.TheERK1/2signalingpathwayisinvolvedinratSchwanncelldedifferentiation(13),integrin-mediatedcellmotil-ity,adhesion(14),andproliferation(15).ERK1/2thatisactivatedinmouseandratschwannomacelllines(16)isinhibitedbymerlinindifferentcelllines(17).WethereforeanalyzedERK1/2pathwayinhumanprimaryschwannomasandassesseditsroleincellproliferationandadhesiontoidentifypotentialtherapeutictargetsforthetreatmentofschwannomas.MerlinadditionallyinhibitstheAKTsignalingpathway(18,19),whichisimportantforratSchwanncellsurvival(20).ActivationofERK1/2andAKTcascadesistriggeredbysurfacereceptors,suchasintegrinsandreceptortyrosinekinases(21).Onecandidateisplatelet-derivedgrowthfactorreceptorh(PDGFRh),whereininternalizationanddegradationismerlin-dependentinhumanschwannomacelllineHEI193(18).Moreover,PDGFRhinteractsdirectlywithintegrins(22),whichareoverexpressedinhumanprimaryschwannomacells(6).WethusinvestigatedtheroleofPDGFRhandothergrowthfactorreceptorsactingupstreamoftheERK1/2andAKTpathwaysinhumanprimaryschwannomacells.WeshowthatERK1/2andsubsequentenhancedproliferationoccurthroughastrongandprolongedactivationofPDGFRhafterstimulationofhumanprimaryschwannomacellswiththePDGFRh-specificagonist,platelet-derivedgrowthfactor-DD(PDGF-DD).Inaddition,schwannomacellsdisplayanenhancedbasalERK1/2activitycomparedwithSchwanncells.StrongAKTactivitywasalsoobservedinschwannomacellsuponstimulationwithPDGF-DD.Usingspecificinhibitors,wecharacterizedthemechanismsofERK1/2andAKTactivation.BasalERK1/2activationinvolvestheintegrin/focaladhesionkinase(FAK)/Src/Rassignalingcascade,andPDGFRh-mediatedERK1/2activationinvolvesthephosphatidylinositol3-kinase(PI3K)/proteinkinaseC(PKC)/Src/c-Rafpathway.Cross-talkbetweenERK1/2andAKTcascadeswasalsoobserved.Basedonourdata,weconcludethatNote:SupplementarydataforthisarticleareavailableatCancerResearchOnline(http://cancerres.aacrjournals.org/).Requestsforreprints:C.OliverHanemann,ClinicalNeurobiology,PeninsulaCollegeforMedicineandDentistry,TheJohnBullBuilding,TamarSciencePark,ResearchWay,PlymouthPL68BU,UnitedKingdom.Phone:44-1752-437-418;Fax:44-1752-517-846;E-mail:oliver.hanemann@pms.ac.uk.I2008AmericanAssociationforCancerResearch.doi:10.1158/0008-5472.CAN-07-5849CancerRes2008;68:(13).July1,20085236www.aacrjournals.orgResearchArticleResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from multiplecascadesunderlieschwannomadevelopmentandthere-foresuggestthatpotentialtherapeuticagentsshouldtargetsev-eralsignalingpathways.WethereforetestedthePDGFRandc-Rafinhibitorsorafenib(BAY43-9006;BayerPharmaceuticals),currentlyapprovedforthetreatmentofadvancedrenalcellcancer(RCC;ref.23).WehereshowthatsorafenibinhibitsbothbasalandPDGFRh-mediatedERK1/2andAKTactivityanddecreasesproliferationofhumanschwannomacells,suggestingthatthisdrugcouldbeausefultoolinthetreatmentofschwannomas.MaterialsandMethodsIsolationandcultureofhumanSchwannandschwannomacells.HumanSchwanncellsfromhealthynervedonorsandschwannomacellsfrompatientswithNF2(afterinformedconsent)wereisolated,aspreviouslydescribed(24,25).DiagnosisofNF2wasestablishedbyclinicalcriteria(26).Cellwereharvestedandresuspendedinproliferationmedium(GFM):DMEM,10%FCS,0.5Amol/Lforskolin,10nmol/Lhheregulin,0.5mmol/L3-isobutyl-1-methylxanthine(IBMX),and2.5Ag/mLinsulin,asdescribedinref.25.Chemicals.GF109203X,LY294002,SU6656,U0126(kindlysuppliedbyProf.JyrkiKukkonen,UniversityofHelsinki),IPA-3(kindlysuppliedbyDr.JeffreyRPeterson,FoxChaseCancerCenter),AG1296,5-bromo-2¶-deoxyuridine(BrdUrd)andFTI-277werefromCalbiochem.12-O-tetrade-canoylphorbol-13-acetate(TPA),GW5074,t-octylphenoxypolyethoxyethanol(TritonX-100),polyoxyethylenesorbitanmonolaurate(Tween20),insulin,andIBMXwerefromSigma.Wortmannin(kindlysuppliedbyProf.JyrkiKukkonen,UniversityofHelsinki)wasfromTocrisCooksonLtd.,PDGF-DDfromR&DSystems.Hoechst33352wasfromMolecularProbes(Eugene),andsorafenib(BAY43-9006)waskindlysuppliedbyBayerPharmaceuticals(WestHaven).Allinhibitorswereadded30minbeforePDGF-DDstimulation.Immunoblotting.Cellswereculturedinprecoated35-mmplatestof70%confluency,serum-starvedfor24h,stimulated,andlysed(5).Theimmunoblottingwasperformed,asdescribedinrefs.8,9.Membraneswereincubatedwithantiactivemitogen-activatedproteinkinase(MAPK;anti-pThr183-pTyr185-ERK1/2;1:2,000;Promega),anti–phosphorylatedAKT(Ser473;1:500;CellSignaling),anti–phosphorylatedMAPK/ERKkinase1/2(MEK1/2)(Ser298;1:500;CellSignaling),anti–phosphorylatedMEK1/2(Ser217/221;1:500;CellSignaling),anti–phosphorylatedc-Raf(Ser338;1:500;CellSignaling),anti–phosphorylatedFAK(p-FAK;Y925;1:500;CellSignaling),anti–p-FAK(Y861;1:500;Stressgen),andanti–p-FAK(Y397;1:200:Chemicon)primaryantibodies,followedbyincubationwithappropriatehorseradishperoxidase–conjugatedsecondaryantibodies(Bio-Rad).Enhancedchemiluminescence(Amersham)wasusedfordetection.RhoGDIwasusedasaloadingcontrol,asithaspreviouslybeenshownnottoberegulatedinoursystem(27)incontrasttostandardload-ingcontrols.DensitiesofbandswerequantifiedusingFluorS-Multi-Imager(Bio-Rad).AfterstrippingandblockingtotalERK,MEK,FAK,andAKTlevelsweredeterminedusinganti–totalMAPK(ERK1/2,1:500;Promega),MEK1/2(1:500;CellSignaling),FAK(1:500;Upstate),andAKT(1:500;CellSignaling)antibodies.TheexpressionlevelsofPDGFRh,epidermalgrowthfactor(EGF)receptor(EGFR),ErbB2,andErbB3weredetectedusinganti-PDGFRh(1:500)andanti-EGFR(1:500;CellSignaling),anti-ErbB2(NeuC18;1:1000),andanti-ErbB3(1:1000)antibodiesfromSantaCruzBiotechnology.Raspull-down.Cellsweregrownuntilf70%confluence,starvedfor24h,stimulatedwith100ng/mLofPDGF-DDfor3mininthepresenceorabsenceoftheRasinhibitorFTI-277andlysed.Raspull-downexperimentswereperformedusingtheEZ-DetectRasactivationkit(Promega)accordingtomanufacturer’sprotocol.Westernblottingwasperformed,asdescribedabove,usingananti-Rasantibody(1:500;Promega).Immunocytochemistry.Cellswereserumstarvedfor24hbeforestimulation,andimmunocytochemistrywasperformed,asdescribedinrefs.8,9.Anti–activeMAPK(anti-pThr183-pTyr185-ERK1/2;1:2,000;Promega)andanti–p-FAKY397antibodieswereusedfordetectionofactiveERK1/2andFAK,respectively.AppropriateCy3orALEXAFluor488–labeledsecondaryantibodieswereused(1:500;Sigma).Adhesionassay.Cellswereseededontoprecoated24-wellplatesfor3h(28)usingdifferentconditions:DMEM,100ng/mLPDGF-DD,andGFM.Adhesionassaywasperformedasdescribed(6).BrdUrdincorporationandnuclearstainingforcellgrowth.Cellswerecultivatedon96-wellplates(Nunc)for72h,labeledwith10Amol/LBrdUrdfor24h,fixedwith4%paraformaldehyde,andincubatedwith2mol/LHCl.Cellswereblockedin2%(w/v)bovineserumalbuminandincubatedwithanti-BrdUrd(1:100;Calbiochem)followedbyALEXAFluor488–labeledsecondaryantibody(1:500;MolecularProbes).Nucleiwerestainedwith5Ag/mLHoechst33342for30min.Dividingcells(BrdUrdpositive)andtotalcellnumbers(Hoechst33342)weremanuallycounted.Allinhibitorswereadded30minbeforestimulation.Dataanalysis.Student’stwo-tailedttestwasusedforpairwisecomparisonsandANOVA,followedbyTukey’sposthoctest,wasusedformultiplecomparisons.Alltheexperimentswereperformedminimumintriplicates,whereinatleastthreeindependentbatchesofcellsfromdifferentindividualswereused.Forcellcounting,allcellsinthewellwerecounted.nsmeans(notsignificant)P>0.05,*indicatesP<0.05;**indicatesP<0.01,and***indicatesP<0.001.Significantvaluesareindicatedonlyforthedatainwhichtheresultsarenotself-evident.Infigures,meanFSEisgiven.ResultsStrongActivationofERK1/2inHumanPrimarySchwannomaCellsIncubationofserum-starvedcellswithcompletemedium(GFM)for10minutes,3hours,and24hoursproducedahigherphosphorylation/activationintensityofERK1/2inschwannomacellscomparedwithSchwanncells(Fig.1A).Inadditiontobandsat42/44kDa,wealsoobservedweakbutspecificbands(confirmedbylibrarysearchesoftherecognizedepitopeusingPhospho.ELMscreening)atf300kDa,whichdisplayedthesamepatternofactivityasthelowermolecularweightbands.ThedatainFig.1ArepresenttotalERK1/2activityincells(combineddataof42/44kDaand300kDabands).MaximalphosphorylationofERK1/2occurredinbothcelltypes10minutespoststimulationandwas3-foldhigherinschwannomacellsthaninSchwanncells.Furthermore,westimulatedschwannomacellswithvariouscomponentspresentinGFMandobservedthatserumphos-phorylatedERK1/2tothelevelscomparablewithGFM,whereasinsulin,forskolin,IBMX,andh-heregulinevokedonlyweaktomoderatesignalsevenwhenusedathighconcentrations(Fig.1BandC).Stimulationofschwannomacellswith100ng/mLPDGF-DDincreasedlevelsofphosphorylatedERK1/2by7-foldcomparedwithbasal,thesamemagnitudeasserumandGFM(Fig.1BandC).100ng/mLofEGFandfibroblastgrowthfactoracidic(FGFa),whosefunctionalitywastestedinNIH3T3andPC12cells,didnottriggerERK1/2activationinschwannomacells(Fig.1C).Inlinewiththis,schwannomacellsshownoexpressionofEGFR(SupplementaryFig.S1).Moreover,SchwannandschwannomacellsexpresssimilarlevelsofErbB2andErbB3receptors(Fig.1D)andhheregulinevenathighconcentrations(100nmol/L)displayedmuchlowerpotencytowardERK1/2activationthanPDGF-DD(100ng/mL;Fig.1BandC).PDGFRBActivationLeadstoStrongandSustainedActivationofMEK1/2andERK1/2inSchwannomaCellsPDGF-DD(100ng/mL)inducedstrongandlong-lastingMEK1/2andERK1/2activityinschwannomacells(Fig.2A).AswithGFM,inadditionto42/44kDabands,specificphosphorylatedERK1/2(p-ERK1/2)bandswerealsoobservedat300kDa.The300-kDaDissectingandTargetingERKPathwayinHumanSchwannomawww.aacrjournals.org5237CancerRes2008;68:(13).July1,2008Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from bandswerestrongeruponPDGF-DDstimulationthanuponGFMstimulationanddisplayedhigherERK1/2activityinschwannomacellscomparedwithSchwanncellsalready10minutesafterstimulationincontrastto42/44kDabandswherethesignificantdifferencewasseenonlyafter1hour(Fig.2A,comparerows2and3,top).Thespecificityof300-kDabandswasestimatedbyPhos-pho.ELMscreeningandbyusing2Amol/LTPA.DespitestrongERK1/2activityat42/44kDa,nobandat300kDawasobserveduponTPAstimulation,suggestingthat300kDabandsarespecificforPDGF-DDstimulation(Fig.2B).Thus,toshowtotalERKactivityincells,Fig.2A(bottom)showscombineddatafrom42/44kDaand300kDabands.MaximalMEK1/2/ERK1/2phosphorylationoccurred10minutesafterstimulationandpersistedatleastupto1hourat60%to70%(MEK1/2)and40%(ERK1/2)ofmaximalresponseanddeclinedtobasallevelsafter24hours.Incomparison,Schwanncellsdisplayedaweakerandonlytransientactivity,whichdeclinedtoalmostbasallevelsalreadywithin1hourafterstimulation.AKTisStronglyActivatedinSchwannomaCellsuponPDGFRBStimulationAKTshowedstrongandsustainedphosphorylation/activationatSer473inschwannomacellsuponstimulationwith100ng/mLPDGF-DD(Fig.2C)andwasobservedonlyatitsexpectedmolecularweightsize(60kDa).Maximalactivitywasreached10minutespoststimulationandremainedhigherthanbasalupto24hours.Schwanncellsincontrastdisplayedmuchweaker(maximalresponsewasapprox-imatelytwicelowerthaninschwannomacells)andtransientAKTactivity,whichdecreasedtobasallevelsatalready1hourpost-stimulation.TotalMEK1/2,ERK1/2,andAKTexpressionremainedunchangedduringallthisconditions,andnodifferencebetweenschwannomaandSchwanncellswasdetected(Fig.2A,middleandbottomandFig.2C,bottom).PDGFRBisOverexpressedinSchwannomaCellsPDGFRhisoverexpressedinschwannomacells(f2-fold)comparedwithSchwanncells(Fig.3A).Also,schwannomacellsdisplaypostponedandimpairedPDGFRhdegradationasitslevelsweredecreasedonlybyf35%within1hourofstimulationandbyf65%after24hours(Fig.3B)incontrasttoSchwanncellswherethedecreasewasmorepronounced(f85%;Fig.3CandD).ThedecreaseinPDGFRhphosphorylationwasslightlyfasterthanitsdegradation:itdecreasedbyf50%(frommaximum)1hourafterstimulationandwasabolished24hourspoststimulation(Fig.3B)followingthesamepatternasphosphorylatedMEK1/2(p-MEK1/2)andp-ERK1/2activationcourse(seeFig.2C,middleandbottom).APDGFRB-IndependentPathwayContributestoERK1/2ActivationinSchwannomaCellsInadditiontoPDGF-DDmediatedMEK1/2andERK1/2activation,ourdata(Fig.2A;0hours)alsoshowsincreasedbasallevelsofphosphorylatedMEK1/2andERK1/2inschwannomacellsFigure1.TheroleofPDGFRhinschwannomacellsignaling.A,schwannomacellsdisplaystrongandlong-lastingERK1/2activationcomparedwithSchwanncells.Time-responsecurvesforERK1/2activationuponGFM(completemedium)stimulationinSchwann(NF2+/+)andschwannoma(NF2 / )cells.BandC,PDGF-DDisapotentERK1/2activatorinschwannomacells.B,ERK1/2phosphorylationinschwannomacellsafter10minstimulationwithGFM,FCS,insulin,hheregulin,forskolin,IBMX,andPDGF-DD.C,ERK1/2phosphorylationafter10minstimulationofschwannomacellswithhheregulin,PDGF-DD,FGFa,andEGFandPC12andNIH3T3cellswithFGFaandEGF,respectively.D,ErbB2andErbB3areequallyexpressedinSchwannandschwannomacells.InallexperimentsbutD,cellswerestarvedfor24hbeforethestimulation.Thephosphorylated/activatedlevelsofERK1/2andreceptorexpressionweredetectedbyWesternblot.A,dataarenormalizedtomaximumGFMstimulation(100%).B,dataarenormalizedtothebasallevel(nonstimulatedcells).D,dataarenormalizedtoNF2+/+.AlldataarecorrectedtoloadingcontrolRhoGDI.InA,theerrorbarsat0and10mintimepointforNF2+/+arenotvisiblebecauseofverylowSD.CancerResearchCancerRes2008;68:(13).July1,20085238www.aacrjournals.orgResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from comparedwithSchwanncells.BecausebothMEK1/2andERK1/2areequallyexpressedinSchwannandschwannomacells(seeFig.2A),wecanexcludeMEK1/2andERK1/2overexpressionasareasonforenhancedactivityandtestedthefollowingpossibilities:(a)cross-talkoftheRac/PAKpathwaywithc-Raf/MEK1/2/ERK1/2and(b)involvementofintegrinswhichareoverexpressedandactivatedinschwannomacells(6)andhavebeenreportedtoleadtotheactivationofERK1/2viatheFAK/Src/Raspathway(29).TheRac/PAKpathwayisnotinvolvedintheincreasedbasalactivityofMEK1/2andERK1/2inschwannomacells.Inbasalconditions,c-RafwasonlyfaintlyphosphorylatedatPAKphosphorylationsite(Ser338;Fig.4A,top).MEK1/2,however,wasphosphorylatedatSer298(PAKphosphorylationsite)inbothSchwannandschwannomacells,butnodifferenceinthephosphorylationintensitywasobservedbetweenthesetwocelltypes(Fig.4A,middle).Additionally,PAKinhibitorIPA-3didnotdecreasebasalERK1/2activity.TheERK1/2activitywasinsteadpotentiated,whichpossiblyoccurredduetocellularstress(Fig.4A,bottom)ashasbeenobservedpreviously(30).Thus,itisunlikelythatPAKcontributestotheenhancedbasalERK1/2activation.IncreasedbasalMEK1/2andERK1/2activityinschwan-nomacellsismediatedviatheintegrin/FAK/src/Raspathway.WethuslookedattheFAK/Src/Raspathway.IncreasedRas-GTPlevels,indicativeforRasactivity,weredetectedbyRaspull-downanalysesinserum-starvedschwannomacellscomparedwithSchwanncells(Fig.4B).TocouplebasalMEK1/2activitytoRasandSrc,weusedH-RasinhibitorfarnesylproteintransferaseinhibitorFTI-277andselectiveSrcfamilykinaseinhibitorSU6656(4Amol/L).Bothinhibitorsdecreasedsignificantlybasalp-MEK1/2levels,suggestingRasandSrctobeinvolvedinthepathwaytowardbasalMEK1/2activation(Fig.4C).FAKisoverexpressedanddisplaysstrongbasalactivityinschwannomacells.Focaladhesionkinase(FAK)isatyrosinekinasethatisactivatedafterintegrin-mediatedattachmentoftheFigure2.Time-responsecurvesforMEK1/2,ERK1/2,andAKTphosphorylation.AandC,schwannomacellsdisplaystrongandlong-lastingactivationofMEK1/2,ERK1/2,andAKT.Schwann(NF2+/+)andschwannomacells(NF2 / )werestarvedfor24handstimulatedforthetimeindicatedwithPDGF-DD(100ng/mL).MEK1/2(A,topandmiddle),ERK1/2(A,topandbottom),andAKT(C)phosphorylation/activationwasassessedbyWesternblot.A,topandB,uponPDGF-DDstimulationofERK1/2,specificbandsat300kDa(inadditionto42/44kDa)areobserved.TPA(2Amol/L,10min)activatesERK1/2onlyatthe42/44kDalevel.A(middleandbottom)andC(bottom),theexpressionofMEK1/2,ERK1/2,andAKTremainsunchangedduringPDGF-DDstimulationanddisplaysnodifferencebetweenSchwannandschwannomacells.Cellswerestarvedfor24handstimulatedforthetimeindicatedwithPDGF-DD(100ng/mL).TheexpressionofMEK1/2,ERK1/2,andAKTwasassessedbyWesternblot.InA(bottom;p-MEK1/2andp-ERK1/2)andC(bottom;p-AKT),thedataarenormalizedtothemaximumPDGF-DDstimulation(100%),andinA(bottom;totalMEK1/2andtotalERK1/2)andC(bottom;totalAKT),thedataarenormalizedtobasalNF2+/+.Emptysquares(A,middleandbottomandC,bottom),basallevelsfor24hstimulation.AlldataarecorrectedtoloadingcontrolRhoGDI.DissectingandTargetingERKPathwayinHumanSchwannomawww.aacrjournals.org5239CancerRes2008;68:(13).July1,2008Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from cellstotheextracellularmatrixandplaysanessentialroleinintegrinsignalingandtumorgenesis(31).Upontheinteractionofintegrinswiththeextracellularmatrix,FAKisautophosphorylatedatY397.IffurtherphosphorylatedbySrcatY925,FAKislinkedtotheRas/Raf/MEK1/2/ERK1/2pathway(30),andatY861,itsautophos-phorylationisenhanced(32).OverexpressionandincreasedbasalactivityofFAKwereobservedinschwannomacellscomparedwithSchwanncells(Fig.4D).FAKwasstronglyphosphorylatedatY397(Fig.4D,second,third,andfourthpanels),Y861,andY925(Fig.4D,secondandthirdpanels)inschwannomacells.ThephosphorylationintensityofFAKatallsitesinvestigatedwasnotaffectedbyPDGF-DD(Fig.4D,thirdpanel).TofurtherinvestigatetherelationshipbetweenFAKactivation,integrins,andbasalERK1/2activity,weanalyzedthecellularlocalizationofp-ERK1/2andp-FAKusingimmunofluorescencedoublelabeling.p-ERK1/2andp-FAKY397colocalizeatfocaladhesionsinschwannomacells(Fig.4D,fourthpanel),suggestingthatthebasalERKactivationisduetointegrin-mediatedactivationoftheFAK/Src/Raspathway.PDGFRB-MediatedERK1/2ActivationEmploysPKC-Src-c-RafandInvolvesTwoDifferentCompartmentsTodefineaspecificmediatorinthePDGFRh-mediatedsignalingcascadestowardERK1/2andAKTactivationinschwannomacells,weperformedadissectionofthesepathwaysbyusingavarietyofdifferentspecificinhibitors.ThespecificityofsignalinguponPDGF-DDstimulationwasconfirmedbyusingthePDGFRhinhibitorAG1296(20and40Amol/L;Fig.5B).Wefirstfocusedon42/44kDabands.RasoftenplaysanessentialroleintheactivationoftheERK1/2viadifferentmediators(33);however,themainpathwaysareeitherviadirectcouplingtoc-Raforviaindirectc-RafactivationthroughthePI3K/phosphatidylino-sitol3-phosphate–dependentkinase-1(PDK1)/PKCcascade(34).TheadditionofPDGF-DD(100ng/mL)for3minutesdidnotfurtherenhanceRasactivity(Fig.5AandSupplementaryFig.S2A,comparerows1and2),despitestrongERK1/2activationatthattimepoint(datanotshown).Additionally,FTI-277(30Amol/L)didnotinhibitPDGF-DD–mediatedERK1/2activity(Fig.5B,top,row9andSupplementaryFig.S3,comparerows2and3),sug-gestingthatinschwannomacellsRasisactivatedindependentlyofPDGFRh.TheproperfunctionoftheFTI-277isshownviaRaspull-down(SupplementaryFig.S2AandB).WenextinvestigatedtheinvolvementofPI3K,whichactseitherviaRasorviadirectcouplingtophosphorylatedPDGFR(35),resultinginelevatedphosphatidylinositol-3,4,5-trisphosphatelev-els,PKCactivationviaPDK1,andfinallyERK1/2activation.Thenonsubtype-selectivePI3Kinhibitorswortmannin(300nmol/L)andLY294002(10Amol/L;ref.36)reducedPDGF-DD–mediatedERK1/2activationby40%to60%(Fig.5B,top,columns6and7).InthePI3K-mediatedcascadetowardactivationofERK1/2,PKCcanbeoneofthemediators.WeassessedtheroleofPKCusingtheinhibitoroftheclassicandthenovelPKCisoenzymesGF109203X(37)andbyprolongedexposureofthecellstothePKCactivatorTPA(38).BothGF109203X(10Amol/L)andTPA(100nmol/L)stronglyinhibitedPDGF-DD–mediatedERK1/2activationbyf60%and40%,respectively(Fig.5B,top,columns4and5).Figure3.Theexpression,activation,anddegradationofPDGFRhinSchwann(NF2+/+)andschwannoma(NF2 / )cells.A,PDGFRhisoverexpressedinschwannomacells.SchwannandschwannomacellswereculturedinGFMandPDGFRhexpressionestimated.BandC,thedegradationandinactivationofPDGFRhispostponedinschwannomacells.B,schwannomacellswereserumstarvedfor24handstimulatedwithPDGF-DD(100ng/mL)forthetimeindicated,andphosphorylation/activationandexpressionofPDGFRhwereestimated.CandD,Schwannandschwannomacellswereserumstarvedfor24handstimulatedwith100ng/mLPDGF-DDfor24h,andtheexpressionofPDGFRhwasestimated.Westernblotmethodwasusedinalltheexperiments.A,dataarenormalizedtoNF2+/+.B,dataarenormalizedtobasallevel(nonstimulatedcells)forPDGFRhandtothemaximumPDGF-DDstimulation(100%)forphosphorylatedPDGFRh.C,dataarenormalizedtothebasallevel(nonstimulatedcells).EmptytriangleinB,basallevelfor24hstimulation.AlldataarecorrectedtoloadingcontrolRhoGDI.CancerResearchCancerRes2008;68:(13).July1,20085240www.aacrjournals.orgResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from SrcfamilyproteinkinasesinteractwiththeERK1/2pathwayviaphosphorylationandactivationofc-RaforPKCy(39).OurdatashowthatPDGFRhactivationinschwannomacellsleadstothephosphorylationofc-RafattheSrcphosphorylationsitesY340/341(datanotshown).WethusinvestigatedtheinvolvementofSrcinPDGF-DD–mediatedERK1/2activationusingtheselectiveSrcfamilykinaseinhibitorSU6656(4Amol/L)thatstronglyinhibitedERK1/2activity(Fig.5B,top,column8).Figure4.DissectionofthesignalingpathwaytowardbasalERK1/2activationinschwannomacells.Thefollowingmoleculeswereinvestigated:PAK(A)Ras(BandC),Src(C),andFAK(D).Inallexperiments,thecellswereserumstarvedfor24h,followedbystimulationfor10minwithcompletemedium(GFM;A)and100ng/mLPDGF-DD(D,thirdpanel).WesternblotmethodwasusedinallexperimentsbutD(fourthpanel),Raspull-downwasusedinB,andimmunocytochemistryinD,fourthpanel.A,PAKisnotinvolvedinERK1/2activationinbasalconditions.Schwannomacellswerestarvedfor24handstimulatedwithGFMfor10min.Thebasal-andGFM-stimulatedphosphorylationofc-RafSer338(PAKphosphorylationsite)andbasallevelsofphosphorylatedMEK1/2Ser298(PAKphosphorylationsite)inschwannomacellswereestimatedbyWesternblot(A,topandmiddle).CellswerepretreatedwiththePAKinhibitorIPA-3(20Amol/L)for10minandlysed,andthelevelsofbasalERK1/2weredetermined(A,bottom).B,Rasisstronglyactivatedinschwannomacellsinserum-freeconditions.ActiveRas(Ras-GTP)levelsinSchwann(NF2+/+)andschwannoma(NF2 / )cellswereestimatedbyRaspull-downandWesternblotafterthecellswereserumstarvedfor24h.C,RasandSrcareinvolvedinMEK1/2activationinbasalconditions.CellswerepretreatedwithfarnesylproteintransferaseinhibitorFTI-277(30Amol/L)andwithSrcinhibitorSU6656(4Amol/L)for30min,andthelevelofphosphorylatedMEK1/2wasdetermined.D,FAKisoverexpressedandstronglyactivatedinschwannomacells.FAKexpressioninSchwann(NF2+/+)andschwannoma(NF2 / )cellswasestimatedbyWesternblotafterthecellswereserumstarvedfor24h(firstpanel).FAKisstronglyphosphorylated/activatedinschwannomacells(NF2 / )comparedwithSchwanncells(NF2+/+).Thecellswereserumstarvedfor24h,andthelevelsofphosphorylated/activatedFAK(Y397,Y861,andY925)inSchwannandschwannomacellswereestimatedbyWesternblot(secondpanel).BasalFAKactivityisnotfurtherregulatedbyPDGF-DD.Thecellswereserumstarvedfor24handstimulatedfor10minwith100ng/mLPDGF-DD.Thebasal-andPDGF-DD–stimulatedlevelsofp-FAK(Y397,Y861,andY925)inschwannomacellswereestimatedbyWesternblot(thirdpanel).PhosphorylatedERK1/2andp-FAKcolocalizeatfocaladhesionsinschwannomacells.Thecolocalizationofp-FAKwithphosphorylatedERK1/2infocaladhesionswasperformedaftercellswereserumstarvedfor24h.Whitearrowheads,colocalizingp-ERK1/2andp-FAKY397inthefocaladhesions(fourthpanel).BandD(firstandsecondpanels),dataarenormalizedtoNF2+/+.CandD(thirdpanel),dataarenormalizedtothebasal(nonstimulatedcells).DottedlinesinC,noninhibitedbasalresponseandcomparisonstononinhibitedresponse(100%).AllWesternblotdataarecorrectedtoloadingcontrolRhoGDI.DissectingandTargetingERKPathwayinHumanSchwannomawww.aacrjournals.org5241CancerRes2008;68:(13).July1,2008Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from Additionally,weexploredtheinvolvementofc-RafusingthespecificinhibitorGW5074(5Amol/L)thatdecreasedERK1/2activityby80%(Fig.5B,top,column2).PAKisnotinvolvedinPDGFRh-mediatedERK1/2activationinschwannomacells,asPDGF-DDtreatmentdidnotleadtophosphorylationofeitherc-RafatthePAKphosphorylationsite(Ser338)orMEK1/2atthePAKphosphorylationsite(Ser298;Fig.5C,firstandsecondpanels).MoreoverPAKinhibitorIPA-3displayednoeffectonPDGF-DD–stimulatedactivityofMEK1/2andERK1/2(Fig.5C,thirdpanel,lines1and3)excludingPAKasamediatorofthisERK1/2cascadeactivation.UsingthesameinhibitorsasforinvestigationoftheERK1/2pathway,weshowthatPDGF-DD–mediatedAKTactivationfollowsthetraditionalpathwayengagingPI3Ksincetheinhibitorswortman-nin(300nmol/L)andLY294002(10Amol/L)stronglyinhibitedAKTphosphorylation(Ser473;Fig.5B,bottom,columns7and8).Thus,PDGFRh-mediatedERK1/2activationdisplayedatthe42/44kDalevelisindependentofRasandPAKbutusesPI3K-PKC-Src-c-Raf–dependentpathwayandcross-talkwithAKTatthelevelofPI3K.Despitesimilarities,suchasinvolvementofc-Raf,PKC,andSrc(Fig.5B,comparetopandmiddle,columns2,4,5,and8)andbypassingRas(Fig.5B,comparetopandmiddle,column9)theactivityoftheERK1/2pathwayat42/44kDaand300kDadifferregardingtheinvolvementofMEK1/2,PI3K(Fig.5B,comparetopandmiddle,columns3,6,and7),andPAK(Fig.5C,thirdpanel,lines2and3).IncontrasttoERK1/2activationatthe42/44kDalevelthatdependsonPI3KandMEK1/2,the300-kDabandsareindependentfromthosekinases.TheengagementofPAKalsodiffersbecausePDGF-DDmediatedERK1/2activityatthe300-kDalevelisalmostcompletelyinhibitedbythePAKinhibitorIPA-3(Fig.5Cthirdpanel,line2)whereasthis,at42/44kDa,wasunaffected(Fig.5C,thirdpanel,line3).AdditionaldataobtainedbyimmunocytochemistryshowedthatIPA-3completelyabolishedtheERK1/2activityinfocaladhesionsandmembraneandalsoeliminatedthep-ERK1/2clusteringinthedot-likestructuresinthecytosol.However,thetotalERK1/2activityinthecytosolwasunaffected,thusconfirmingWesternblotdataandsuggestingPAKactingasascaffoldinacomplexcontainingERK(Fig.5C,fourthFigure5.ThedissectionofthePDGF-DD–mediatedcascadesinschwannomacells.TheERK1/2signalingpathwaywasinvestigatedbyanalyzingtheinvolvementofRas(AandB);MEK1/2,PKC,PI3K,andSrc(B);PDGFRhandc-Raf(BandD);andPAK(C).TheAKTsignalingpathwaywasinvestigatedbyanalyzingtheinvolvementofMEK1/2,PKC,PI3K,andSrc(B)andPDGFRhandc-Raf(BandD).Inallexperiments,thecellswereserumstarvedfor24hbeforethestimulationwithPDGF-DD(100ng/mL;A–D)orcompletemedium(GFM;C,firstpanel)for10min(A;3min).Thedetectionofphosphorylated/activatedproteinswasperformedbyWesternblottinginallexperimentsbutC(fourthpanel),whereimmunocytochemistrymethodwasused.InA,Raspull-downwasperformedbeforeWesternblotting.InB,thecellswerepretreatedwithPDGFhinhibitor(AG1296),c-Rafinhibitor(GW5074),MEK1/2inhibitor(U0126),PKCinhibitor(GF109203X),orwithPKCactivatorTPA,PI3Kinhibitors(WortmanninandLY294002),Srcinhibitor(SU6656),andfarnesylproteintransferaseinhibitor(FTI-277)beforestimulation.C,couplingofPAKtoERK1/2cascadewasestimatedusinganti-phosphorylatedc-RafSer338(firstpanel),anti–p-MEK1/2Ser298(secondpanel)antibodies,andPAKinhibitorIPA-3(20Amol/L;thirdandfourthpanels).Fourthpanel,thecellswerestimulatedwithPDGF-DD(100ng/mL)for10minwithandwithoutIPA-3(20Amol/L)andstainedforp-ERK1/2(green)andpaxillin(afocaladhesionmarker,red).Whitearrowheads,dot-likestructuresinthecytosol;redarrowheads,focaladhesions(visualizedbypaxillinstaininginred);whitearrows,membranestaining.D,cellswerepretreatedwithsorafenib(Bay43-9006)beforethestimulation.Inalltheexperiments,theinhibitorswereadded30minbeforethestimulationandTPAwasadded24hbeforethestimulationandIPA3for10min.DottedlinesinB,noninhibitedPDGF-DDresponseandcomparisonstononinhibitedresponse(100%).D,dataarenormalizedtothebasallevels(nonstimulatedcells).AllWesternblotdataarecorrectedtoloadingcontrolRhoGDI.CancerResearchCancerRes2008;68:(13).July1,20085242www.aacrjournals.orgResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from panel).Thus,ourdataindicatethatPDGF-DD–mediatedERK1/2activationatthe300-kDalevelengagesc-Raf,PKC,src,andPAKandlocalizestothedifferentcellularcompartmentsthanactiveERK1/2observedatthe42/44kDalevel.Insummary,wefoundtwomajormechanismsconvergingtowardERK1/2activationinschwannomacells:(a)basalactivationviaintegrins/src/FAK/Rasand(b)PDGFRh-mediatedviathePI3K-PKC-c-RafandPKC-PAK-c-RafpathwayswerethefirstmentionedcrosstalkwithandstronglyactivateAKT(Fig.6D).Wethuschosesorafenib(1and10Amol/L),aninhibitorofPDGFRandc-Raf(Fig.6D)alreadyusedinclinic,whichefficientlyinhibitedbothbasal-andPDGF-DD–stimulatedERK1/2andAKTactivity(Fig.5D),suggestingthatthiscompoundhasapotentialtherapeuticeffectonschwannoma.PDGFRBInducesEnhancedCellProliferation,butnotAdhesion,viaERK1/2inSchwannomaCellsWenextassessedthefunctionalroleofPDGFRh-mediatedERK1/2activationinschwannomacells.Adhesion.First,weperformedanadhesionassay(6)wherecellswereculturedinthreedifferentconditions:DMEMonly,DMEMwith100ng/mLPDGF-DD,andcompletemedium(GFM).OnlyGFMbutnotPDFG-DDaloneinducedschwannomacelladhesion(datanotshown);thus,itisunlikelythatPDGFRhaloneplayaroleinthisprocess.Proliferation.WehavepreviouslyshownthatschwannomacellsdisplayanincreasedproliferationratecomparedwithSchwanncells(40).AsPDGFisapotentgrowthfactorinseveralcelltypes,wetesteditsmitogenicpotencyinourinvitromodel.Theadditionof100ng/mLPDGF-DDfor72hoursresultedinanincreaseoftotalcellnumber(determinedbyHoechst33342stainingofthenucleus)byf40%inschwannomacells,whereasnomitogeniceffectonSchwanncellswasdetected(Fig.6A)underourcultureconditions.AdditionalexperimentsmeasuringBrdUrdincorporationrevealedthatschwannomacellsdisplayedbasalproliferationactivity,whichwasstronglypotentiatedbyPDGF-DDbyf80%(Fig.6BandC),indicatingthatPDGF-DDisapotentmitogenforhumanprimaryschwannomacells.BothMEK1/2andPDGFRinhibitorsU0126(1Amol/L)andAG1296(20Amol/L),respectively,stronglyreducedPDGF-DD–mediatedaswellbasalcellproliferation(Fig.6B),suggestingthattheERK1/2pathwayisinvolvedinPDGFRh-mediatedproliferationinschwannomacells.Next,wetestedsorafenib(0.1,0.5,and1Amol/L),aPDGFRandc-RafinhibitorthatiscurrentlyapprovedforclinicaluseinadvancedRCC.Interestingly,0.5Amol/LsorafenibeffectivelyinhibitedPDGF-DDbutnotbasaland1Amol/LinhibitedbothPDGF-DD–mediatedandbasalproliferationinschwannomacells(Fig.6C),suggestingthatthiscomponentcouldbeusedforschwannomatreatment.DiscussionWeshowstrongandprolongedERK1/2pathwayactivationinhumanprimaryschwannomacellscomparedwithprimarySchwanncells.PDGFRhisstronglyoverexpressedinhumanprimaryschwannomacellsinagreementwithapreviousobservationinhumanschwannomatissue(18).InsulinandhFigure6.Signalingpathwaysinvolvedintheenhancedproliferationofschwannomacells.A,Schwann(NF2+/+)andschwannomacells(NF2 / )wereculturedfor72hwithorwithoutPDGF-DD.Totalcellamountwasestimatedbynuclearstainingwith5Ag/mLHoechst33342andcellcounting.BandC,schwannomacellswereincubatedwithU0126(MEK1/2inhibitor),AG1296(PDGFRhinhibitor),andU0126togetherwithAG1296(B)andsorafenib(PDGFRhandRafinhibitor;C)withandwithoutPDGF-DDfor72h.BrdUrd(10Amol/L)wasaddedduringthelast24hoftheexperiment.Theamountofproliferatingcells(BrdUrd-positive)wasassessedbycellcounting.Inallexperiments,thedataarenormalizedtothebasallevel(nonstimulatedcells).D,signalingpathwaystargetedbysorafenibinschwannomacells.MerlindeficiencyleadstotheactivationofRas,overexpressionandactivationofintegrins,andoverexpressionandpostponeddegradationofPDGFRh.RasandintegrinstriggerbasalERK1/2activityviaFAK,whichisstronglyoverexpressedandphosphorylated/activatedbySrc.BasalERK1/2activityisfurtherpotentiatedviaPDGFRh-mediatedPI3K/PKC/Src/c-Raf/MEK1/2andcascade.PAKactsasascaffoldinacomplexcontainingactiveERK1/2.DissectingandTargetingERKPathwayinHumanSchwannomawww.aacrjournals.org5243CancerRes2008;68:(13).July1,2008Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from heregulinactivateERK1/2onlyweakly,evenwhenusedathighconcentrations.FGFaandEGFfailtoactivateERK1/2.Additionally,theexpressionlevelsofErbB2andErbB3receptorsareequalinhumanschwannomaandSchwanncells.EGFRispresentintheratschwannomacelllineRT4(datanotshown),butnotinhumanprimarySchwannandschwannomacells.Thus,PDGFRhisacrucialreceptorsignalingthroughERK1/2pathwayinhumanschwannoma.InadditiontotheactivationoftheERK1/2pathway,PDGF-DDalsoevokesastrongandprolongedAKTresponseinschwannomacellscomparedwithSchwanncells.AlthoughPDGFRhisimportantfortheactivationoftheAKTpathway,asshownhere,wecannotexcludethat,indifferentphysiologicmilieu,othergrowthfactorscouldalsobeinvolvedinactivationofthispathway.PDGFRhdisplaysapostponeddegradationinschwannomacellscomparedwithSchwanncells,inagreementwithapreviousstudyonhumanschwannomacelllineHEI193(18).Thereceptoractivityisprolongedand,1hourafterstimulation,decreasedonlyby50%ofmaximumresponse.ThekineticsofPDGFRdeactivationisusuallymuchfaster,asshowninfibroblasts,wherealready20minutesafterstimulationtheactivitydroppedby75%(41).Ourdatasuggestthatoneoffunctionsofmerlinistoregulatethereceptoractivity.PDGFRhphosphorylation/activitydisplaythesamepatternasMEK1/2andERK1/2activity,butdivergefromAKT,whichexhibitstrongactivityeven24hoursafterstimulation.Thus,inschwannomacells,AKTactivationisregulatednotonlyatthePDGFRhlevelbutpossiblyalsobypositivefeedbackmechanismsdownstreamofthereceptor,e.g.,saturationofPI3Kactivity(41),prolongationofsignalinginendosomes(42),oractivationofphosphataseinhibitors(43).ThesehumandataextendtheobservationsmadeintheratschwannomacelllineRT4andinamouseNF2 / Schwanncellline,wherereceptorexpres-sionandfunctionwerenotaffectedbymerlin(16).Inadditiontostrongandlong-lastingPDGF-DD–mediatedMEK1/2andERK1/2activity,schwannomacellsdisplaystrongerbasalactivityofthesekinasescomparedwithSchwanncells.ThiscouldinvolveeitherRac/PAKorintegrin-mediatedpathways.PAKcanbeexcludedasanactivatorofERK1/2at42/44kDalevel,whichisthemainERK1/2bandinbasalconditions,asc-RafisnotphosphorylatedatitsPAKphosphorylationsite(Ser338)andanalysisofthePAK-dependentphosphorylationsiteonMEK1/2(Ser298)showsthatschwannomaandSchwanncellsdisplaysimilarphosphorylationlevels.Also,thePAKinhibitorIPA-3inhibitedneitherbasal-norPDGF-DD–stimulatedMEK1/2andERK1/2activity.ThisisanunexpectedfindingbecausetheRac1/PAKpathwayisstronglyup-regulatedinschwannomacells(8)andPAKisknowntoactasascaffoldtoenhanceERK1/2activity(44).However,wefoundinsteadthatERK1/2activityatthe300-kDalevel,prominentafterPDGFstimulation,isdependentfromPAKthatlikelyactsasascaffold.Moreover,theactivationoftheERK1/2atthe300-kDaleveldisplaysalsootherdifferencesfromthisat42/44kDa,asitbypassesPI3KandMEK1/2.Apotentialexplanationcouldbehiddenbindingsitesforthoseinhibitorscausedbycomplexformation.Immunocytochemistryalsoshowthedifferentialdistributionofp-ERK1/2inschwannomacells(nucleus,cytosol,membrane,andfocaladhesions).OurdatathussuggestthatPDGF-DDmediatestheactivationofERK1/2indifferentcellularcompartmentswhichdisplaydifferentmolecularbackground.Wenexttestedtheroleofintegrinsthatareup-regulatedinschwannoma(6)andmayactivateERK1/2viatheFAK/src/Raspathway(29).WedetectedenhancedbasalactivityofRas,MEK1/2,andERK1/2andincreasedexpressionandactivationofFAKinschwannomacells.Additionally,p-FAKcolocalizeswithp-ERK1/2infocaladhesions.Moreover,blockingofRasandSrcinhibitbasalMEK1/2activity.Takentogether,theseresultsindicatethatinteg-rinsarelikelytocontributetoERK1/2activationinschwannomacellsviatheFAK/src/Raspathwayunderbasalconditions.Wethinkthatinbasalconditionsschwannomacellsdisplayactivationoftheintegrin/FAK/Srccascade,aswellasincreasedlevelsofactiveRas,which,uponcouplingtop-FAK(Y925),leadstoactivationofERK1/2.AsthestimulationofPDGFRhstronglypotentiatesERK1/2andAKTactivity,weconsiderthatthisreceptoranditsdownstreamsignalingpathwaysisimportantforschwannomadevelopment.Todefineapotentialtherapeutictargetforschwannomatreatment,weperformedadissectionofthecascadesdownstreamofPDGFRhinadditiontobasalactivation.OurdatasuggestcooperationbetweenPI3K,PKC,andSrcinPDGF-DD–mediatedERK1/2activation.AlthoughRasisstronglyactivatedinschwannomacellsandimplicatedinbasalsignalingtowardERK1/2activation,itisnotfurtheractivatedbyPDGF-DDandisnotinvolvedinthePDGFRh-mediatedpathway.ThiscouldbeexplainedbyapossibleuncouplingofRasfromthereceptor.DifferentRasisoformslocalizetodistinctmicrodomainswithinplasmamembraneanddifferentintracellularcompartmentsleadingtodiversesignaloutputsdespiteinteractionwithsimilaractivatorsandeffectors(45).RasinsensitivitytoPDGF-DDcouldalsobeexplainedbyeithersaturatedbasalactivityofRasoranegativefeedbackfrombasalERK1/2toGrb2-Sos(Ras-GEF;ref.46).Ourdatasomehowcontradictspreviousfindings,showingRasinvolvedinPDGFRh-mediatedERK1/2activation(16).ThisdiscrepancymaybedowntotheuseofratschwannomacelllinecausedbydifferentmutationanddisplayingmalignantpropertiesbyMorrisonandcolleagues,whereaswefocusedourstudyonprimaryhumanschwannoma.WeshowthatPDGF-DDengagesdifferentpathwaystoactivateERK1/2thatislocalizedtodifferentintracellularcompartmentsanddetectedatdifferentmolecularweightlevelsbyWesternblot.Thep-ERK1/2pathwayat42/44kDa(cytosol)favorsamodelinwhichc-RafisactivatedbySrcandPKC,wherethelaterisactivatedbyPI3K(viaPDK1),whichdirectlybindstophosphor-ylated/activatedPDGFRh(Fig.6D;refs.47,48).PI3KactsalsoasaconvergencepointtotheactivationofAKT(Fig.6D).Thep-ERK1/2pathwayat300-kDalevel(focaladhesions)engagesc-Raf,PKC,Src,andPAK.OurdatathusfittopreviousobservationsshowingthatERK1/2activityistightlyregulatedbymerlin(17)andinvolvedinratSchwanncellsdedifferentiation(13)andintegrin-mediatedcellmotilityandadhesion(14),whichisdramaticallydisregulatedinmerlin-deficientschwannomacells(6).WhereastransientERK1/2activityisimportantfornormalcellfunction,astrongandlong-lastingERK1/2activationcanbemitogenic(49,50).WeshowincreasedproliferationofschwannomacellsuponstimulationwithPDGF-DD,whereasnoeffectswereobservedinSchwanncells.ThiscouldbeexplainedeitherbytheshortandweakERK1/2activityinthosecellsorarequirementforadditionalfactorsintheculturemedium,suchasinsulin-likegrowthfactors(51).InhibitionofMEK1/2decreasesPDGF-DD–mediatedproliferationtobasallevels,suggestingthatERK1/2path-wayisinvolvedinthisprocess.Additionally,bothMEK1/2andPDGFRhinhibitionsignificantlyinhibitedbasalcellproliferation,suggestingthatboththeintegrin/FAK/src/RascascadeandPDGFRh-mediatedsignaling,possiblyviaautocrinemechanisms,areinvolvedinschwannomacellproliferation.CancerResearchCancerRes2008;68:(13).July1,20085244www.aacrjournals.orgResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from Basedonthisevidence,weconsiderPDGFRh-mediatedsignalingtobeinvolvedinschwannomadevelopment.Additionally,theintegrin-mediatedFAK/src/RascascadecontributestobasalERK1/2activity,therebypotentiatingthePDGFRh-specificpathway(Fig.6D;ref.16).Becausedifferentpathwaysareinvolvedinschwannomacellproliferation,wesuggestthatacombinedtherapytargetingdifferentproteinsmightbeappropriatefortreatingschwannoma.Promisingtherapeuticagentincludesorafenib,aPDGFRandRafinhibitoralreadyapprovedforuseinpatientswithadvancedRCC,asitinhibitsefficientlybothbasalandPDGF-DD–mediatedERK1/2andAKTactivationandproliferationinhumanprimaryschwannomacells.DisclosureofPotentialConflictsofInterestNopotentialconflictsofinterestweredisclosed.AcknowledgmentsReceived10/11/2007;revised3/4/2008;accepted4/9/2008.Grantsupport:Children’sTumorFoundationandPeninsulaCollegeofMedicineandDentistry.Thecostsofpublicationofthisarticleweredefrayedinpartbythepaymentofpagecharges.Thisarticlemustthereforebeherebymarkedadvertisementinaccordancewith18U.S.C.Section1734solelytoindicatethisfact.WethankProf.JyrkiKukkonen(UniversityofHelsinki)forGF109203X,LY294002,SU6656,U0126,andwortmannin,BayerPharmaceuticalsforsorafenib(BAY43-9006),andDr.JeffreyRPeterson(FoxChaseCancerCenter)forIPA-3.DissectingandTargetingERKPathwayinHumanSchwannomawww.aacrjournals.org5245CancerRes2008;68:(13).July1,2008References1.McClatcheyAI,GiovanniniM.Membraneorganizationandtumorigenesis-theNF2tumorsuppressor,Merlin.GenesDev2005;19:2265–77.2.RouleauGA,MerelP,LutchmanM,etal.Alterationinanewgeneencodingaputativemembrane-organizingproteincausesneuro-fibromatosistype2(seecom-ments).Nature1993;363:515–21.3.TrofatterJA,MacCollinMM,RutterJL,etal.Anovelmoesin-,ezrin-,radixin-likegeneisacandidatefortheneurofibromatosis2tumorsuppressor.Cell1993;75:826.4.BretscherA,EdwardsK,FehonRG.ERMproteinsandmerlin:integratorsatthecellcortex.NatRevMolCellBiol2002;3:586–99.5.UtermarkT,KaempchenK,AntoniadisG,HanemannCO.Reducedapoptosisratesinhumanschwannomas.BrainPathol2005;15:17–22.6.UtermarkT,KaempchenK,HanemannCO.Patholog-icaladhesionofprimaryhumanschwannomacellsisdependentonalteredexpressionofintegrins.BrainPathol2003;13:352–63.7.FlaizC,UtermarkT,ParkinsonDB,PoetschA,HanemannCO.Impairedintercellularadhesionandimmatureadherensjunctionsinmerlin-deficienthumanprimaryschwannomacells.Glia2008;56:506–15.8.KaempchenK,MielkeK,UtermarkT,LangmesserS,HanemannCO.UpregulationoftheRac1/JNKsignalingpathwayinprimaryhumanschwannomacells.HumMolGenet2003;12:1211–21.9.FlaizC,KaempchenK,MatthiesC,HanemannCO.Actin-richprotrusionsandnonlocalizedGTPaseactiva-tioninmerlin-deficientschwannomas.JNeuropatholExpNeurol2007;66:608–16.10.KissilJL,WilkerEW,JohnsonKC,EckmanMS,YaffeMB,JacksT.Merlin,theproductoftheNf2tumorsuppressorgene,isaninhibitorofthep21-activatedkinase,Pak1.MolCell2003;12:841–9.11.HirokawaY,TikooA,HuynhJ,etal.Acluetothetherapyofneurofibromatosistype2:NF2/merlinisaPAK1inhibitor.CancerJ2004;10:20–6.12.PeltonPD,ShermanLS,RizviTA,etal.Rufflingmembrane,stressfiber,cellspreadingandproliferationabnormalitiesinhumanschwannomacells.Oncogene1998;17:2195–209.13.HarrisinghMC,Perez-NadalesE,ParkinsonDB,MalcolmDS,MudgeAW,LloydAC.TheRas/Raf/ERKsignallingpathwaydrivesSchwanncelldedifferentia-tion.EMBOJ2004;23:3061–71.14.SawhneyRS,CooksonMM,OmarY,HauserJ,BrattainMG.Integrina2-mediatedERKandcalpainactivationplayacriticalroleincelladhesionandmotilityviafocaladhesionkinasesignaling:identifica-tionofanovelsignalingpathway.JBiolChem2006;281:8497–510.15.MelocheS,PouyssegurJ.TheERK1/2mitogen-activat-edproteinkinasepathwayasamasterregulatoroftheG1-toS-phasetransition.Oncogene2007;26:3227–39.16.MorrisonH,SperkaT,ManentJ,GiovanniniM,PontaH,HerrlichP.Merlin/neurofibromatosistype2sup-pressesgrowthbyinhibitingtheactivationofRasandRac.CancerRes2007;67:520–7.17.LimJY,KimH,JeunSS,KangSG,LeeKJ.Merlininhibitsgrowthhormone-regulatedRaf-ERKspathwaysbybindingtoGrb2protein.BiochemBiophysResCommun2006;340:1151–7.18.FraenzerJT,PanH,MinimoL,Jr.,SmithGM,KnauerD,HungG.OverexpressionoftheNF2geneinhibitsschwannomacellproliferationthroughpromotingPDGFRdegradation.IntJOncol2003;23:1493–500.19.RongR,TangX,GutmannDH,YeK.Neurofibroma-tosis2(NF2)tumorsuppressormerlininhibitsphos-phatidylinositol3-kinasethroughbindingtoPIKE-L.ProcNatlAcadSciUSA2004;101:18200–5.20.LiY,TennekoonGI,BirnbaumM,MarchionniMA,RutkowskiJL.NeuregulinsignalingthroughaPI3K/Akt/BadpathwayinSchwanncellsurvival.MolCellNeurosci2001;17:761–7.21.MeierF,SchittekB,BuschS,etal.TheRAS/RAF/MEK/ERKandPI3K/AKTsignalingpathwayspresentmoleculartargetsfortheeffectivetreatmentofad-vancedmelanoma.FrontBiosci2005;10:2986–3001.22.HeldinCH,WestermarkB.Mechanismofactionandinvivoroleofplatelet-derivedgrowthfactor.PhysiolRev1999;79:1283–316.23.EscudierB,EisenT,StadlerWM,etal.Sorafenibinadvancedclear-cellrenal-cellcarcinoma.NEnglJMed2007;356:125–34.24.HanemannCO,RosenbaumC,KupferS,WoschS,StoegbauerF,MuellerHW.ImprovedculturemethodstoexpandSchwanncellswithalteredgrowthbehaviourfromCMT1Apatients.GLIA1998;23:89–98.25.RosenbaumC,KluweL,MautnerVF,FriedrichRE,MuellerHW,HanemannCO.Isolationandcharacter-izationofSchwanncellsfromneurofibromatosistype2patients.NeurobiolDis1998;5:55–64.26.NationalInstitutesofHealthConsensusDevelop-mentConferenceStatementonAcousticNeuroma,December11-13,1991.TheConsensusDevelopmentPanel.ArchNeurol1994;51:201–7.27.HanemannCO,Bartelt-KirbachB,DieboldR,KampchenK,LangmesserS,UtermarkT.DifferentialgeneexpressionbetweenhumanschwannomaandcontrolSchwanncells.NeuropatholApplNeurobiol2006;32:605–14.28.MilnerR,WilbyM,NishimuraS,etal.DivisionoflaborofSchwanncellintegrinsduringmigrationonperipheralnerveextracellularmatrixligands.DevBiol1997;185:215–28.29.SchlaepferDD,HunterT.Focaladhesionkinaseoverexpressionenhancesras-dependentintegrinsignal-ingtoERK2/mitogen-activatedproteinkinasethroughinteractionswithandactivationofc-Src.JBiolChem1997;272:13189–95.30.DeaconSW,BeeserA,FukuiJA,etal.Anisoform-selective,small-moleculeinhibitortargetstheautoregu-latorymechanismofp21-activatedkinase.ChemBiol2008;15:322–31.31.HehlgansS,HaaseM,CordesN.Signalingviaintegrins:implicationsforcellsurvivalandanticancerstrategies.BiochimBiophysActa2007;1775:163–80.32.LeuTH,MaaMC.Tyr-863phosphorylationenhancesfocaladhesionkinaseautophosphorylationatTyr-397.Oncogene2002;21:6992–7000.33.BosJL.Allinthefamily?NewinsightsandquestionsregardinginterconnectivityofRas,Rap1andRal.EMBOJ1998;17:6776–82.34.LeGoodJA,ZieglerWH,ParekhDB,AlessiDR,CohenP,ParkerPJ.ProteinkinaseCisotypescontrolledbyphosphoinositide3-kinasethroughtheproteinkinasePDK1.Science1998;281:2042–5.35.WymannMP,ZvelebilM,LaffargueM.Phosphoinosi-tide3-kinasesignalling-whichwaytotarget?TrendsPharmacolSci2003;24:366–76.36.VlahosCJ,MatterWF,HuiKY,BrownRF.Aspecificinhibitorofphosphatidylinositol3-kinase,2-(4-morpho-linyl)-8-phenyl-4H-1-benzopyran-4-one(LY294002).JBiolChem1994;269:5241–8.37.ToullecD,PianettiP,CosteH,etal.Thebisindolylma-leimideGF109203XisapotentandselectiveinhibitorofproteinkinaseC.JBiolChem1991;266:15771–81.38.BindelsRJ,DempsterJA,RamakersPL,WillemsPH,vanOsCH.EffectofproteinkinaseCactivationanddown-regulationonactivecalciumtransport.KidneyInt1993;43:295–300.39.SteinbergSF.DistinctiveactivationmechanismsandfunctionsforproteinkinaseCdelta.BiochemJ2004;384:449–59.40.SchulzeKM,HanemannCO,MullerHW,HanenbergH.Transductionofwild-typemerlinintohumanschwannomacellsdecreasesschwannomacellgrowthandinducesapoptosis.HumMolGenet2002;11:69–76.41.ParkCS,SchneiderIC,HaughJM.Kineticanalysisofplatelet-derivedgrowthfactorreceptor/phosphoinosi-tide3-kinase/Aktsignalinginfibroblasts.JBiolChem2003;278:37064–72.42.HaughJM,LauffenburgerDA.Analysisofreceptorinternalizationasamechanismformodulatingsignaltransduction.JTheorBiol1998;195:187–218.43.HeinrichR,NeelBG,RapoportTA.Mathematicalmodelsofproteinkinasesignaltransduction.MolCell2002;9:957–70.44.BeeserA,JafferZM,HofmannC,ChernoffJ.RoleofgroupAp21-activatedkinasesinactivationofextracel-lular-regulatedkinasebygrowthfactors.JBiolChem2005;280:36609–15.45.HancockJF.Rasproteins:differentsignalsfromdifferentlocations.NatRevMolCellBiol2003;4:373–84.46.DongC,WatersSB,HoltKH,PessinJE.SOSphosphorylationanddisassociationoftheGrb2-SOScomplexbytheERKandJNKsignalingpathways.JBiolChem1996;271:6328–32.47.ChongH,VikisHG,GuanKL.MechanismsofregulatingtheRafkinasefamily.CellSignal2003;15:463–9.48.TallquistM,KazlauskasA.PDGFsignalingincellsandmice.CytokineGrowthFactorRev2004;15:205–13.49.RooversK,AssoianRK.IntegratingtheMAPkinasesignalintotheG1phasecellcyclemachinery.Bioessays2000;22:818–26.50.PouyssegurJ,VolmatV,LenormandP.Fidelityandspatio-temporalcontrolinMAPkinase(ERKs)signal-ling.BiochemPharmacol2002;64:755–63.51.StewartHJ,BradkeF,TaberneroA,MorrellD,JessenKR,MirskyR.RegulationofratSchwanncellPoexpressionandDNAsynthesisbyinsulin-likegrowthfactorsinvitro.EurJNeurosci1996;8:553–64.Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from 2008;68:5236-5245. Cancer Res(cid:160)(cid:160) Sylwia Ammoun, Christine Flaiz, Natalia Ristic, et al. (cid:160) Kinase Pathway in Human SchwannomaIndependent Extracellular Signal-Regulated-Growth FactorDependent and-Dissecting and Targeting the Growth Factor(cid:160) Updated version(cid:160)  http://cancerres.aacrjournals.org/content/68/13/5236Access the most recent version of this article at:(cid:160) MaterialSupplementary(cid:160)  http://cancerres.aacrjournals.org/content/suppl/2008/06/19/68.13.5236.DC1Access the most recent supplemental material at:(cid:160) (cid:160) (cid:160) (cid:160) (cid:160) Cited articles(cid:160)  http://cancerres.aacrjournals.org/content/68/13/5236.full.html#ref-list-1This article cites 51 articles, 17 of which you can access for free at:(cid:160) Citing articles(cid:160)  /content/68/13/5236.full.html#related-urlsThis article has been cited by 16 HighWire-hosted articles. Access the articles at:(cid:160) (cid:160) (cid:160) E-mail alerts related to this article or journal.Sign up to receive free email-alerts(cid:160) SubscriptionsReprints and (cid:160) .pubs@aacr.orgDepartment atTo order reprints of this article or to subscribe to the journal, contact the AACR Publications(cid:160) Permissions(cid:160) .permissions@aacr.orgDepartment atTo request permission to re-use all or part of this article, contact the AACR PublicationsResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)UvA-DARE (Digital Academic Repository)Germline SMARCB1 mutation and somatic NF2 mutations in familial multiplemeningiomasChristiaans, I.; Kenter, S.B.; Brink, H.C.; van Os, T.A.M.; Baas, F.; van den Munckhof, P.;Kidd, A.M.J.; Hulsebos, T.J.M.Published in:Journal of Medical GeneticsDOI:10.1136/jmg.2010.082420Link to publicationCitation for published version (APA):Christiaans, I., Kenter, S. B., Brink, H. C., van Os, T. A. M., Baas, F., van den Munckhof, P., ... Hulsebos, T. J.M. (2011). Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. Journalof Medical Genetics, 48(2), 93-97. DOI: 10.1136/jmg.2010.082420General rightsIt is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s),other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).Disclaimer/Complaints regulationsIf you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, statingyour reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Askthe Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam,The Netherlands. You will be contacted as soon as possible.Download date: 31 Mar 2017GermlineSMARCB1mutationandsomaticNF2mutationsinfamilialmultiplemeningiomasIChristiaans,1SBKenter,2HCBrink,1TAMvanOs,1FBaas,2PvandenMunckhof,3AMJKidd,4TJMHulsebos2ABSTRACTBackgroundMultiplemeningiomasoccurin<10%ofmeningiomapatients.Theirdevelopmentmaybecausedbythepresenceofapredisposinggermlinemutationintheneuroﬁbromatosistype2(NF2)gene.Thepredisposinggeneinpatientswithnon-NF2associatedmultiplemeningiomasremainstobeidentiﬁed.Recently,SMARCB1wasreportedtobeapotentialpredisposinggeneformultiplemeningiomasinafamilywithschwannomatosisandmultiplemeningiomas.However,involvementofthisgeneinthedevelopmentofthemeningiomaswasnotdemonstrated.ResultsFiveaffectedmembersofalargefamilywithmultiplemeningiomaswereinvestigatedforthepresenceofmutationsinSMARCB1andNF2.Amissensemutationwasidentiﬁedinexon2ofSMARCB1asthecausativegermlinemutationpredisposingtomultiplemeningiomas;furthermore,itwasdemonstratedthat,inaccordancewiththetwo-hithypothesisfortumourigenesis,themutantallelewasretainedandthewild-typeallelelostinallfourinvestigatedmeningiomas.Inaddition,independentsomaticallyacquiredNF2mutationswereidentiﬁedintwomeningiomasofonepatientwithconcomitantlossesofthewild-typeNF2allele.ConclusionItisconcludedthat,analogoustothegeneticeventsinasubsetofschwannomatosisassociatedschwannomas,afour-hitmechanismoftumoursuppressorgeneinactivation,involvingSMARCB1andNF2,mightbeoperativeinfamilialmultiplemeningiomasassociatedmeningiomas.INTRODUCTIONMeningiomasareamongthemostcommonintra-cranialprimarytumours(20%ofallbraintumours),usuallyoccurringasslowlygrowingsporadicsolitarylesions.1Theyalsodevelopinabout50%ofpatientswithneuroﬁbromatosistype2(NF2).ThehallmarkofNF2isthepresenceofbilateralvestibularschwannomas.Schwannomasatotherlocationsarefoundinmorethan50%ofpatients.2e4NF2patientscarryaheterozygousgermlinemutationintheNF2geneandthewild-typecopyofthisgeneisoftenfoundtobelostintheNF2associatedtumours.5e7Multiplemeningiomasoccurin<10%ofpatientswithmeningioma.8ThesemaybeNF2associatedandinthosecasesdevelopastheconsequenceofthepresenceofapredisposingNF2germlinemutation.Non-NF2associatedmultiplemeningi-omasmayoccurassporadicorfamilialcases.ThelimitednumberofmeningiomasoffamilialmultiplemeningiomapatientsinvestigatedthusfardidnotdisplaysomaticorconstitutionalNF2mutations.910ThemultipletumoursofsporadicpatientswerefoundtocarryanidenticalsomaticNF2mutation,whichwasnotpresentintheirconstitutionalDNAs.9e13ThismightbeexplainedbyspreadviathecerebrospinalﬂuidordistantmetastasisofasingletumourorasaconsequenceofmosaicismwithundetectablecontributionoftheNF2mutationtotheconstitutionalDNA.Alter-natively,thenon-NF2sporadicandfamilialcasessuggestthatagenedifferentfromNF2isimplicatedinthedevelopmentofnon-NF2associatedmultiplemeningiomas.Thiscontentionissupportedbyanearlierlinkagestudyinafamilywithmeningiomasinwhicha15cMregionaroundandincludingNF2wasexcludedfromharbouringthemeningiomapredisposinggene.14SMARCB1isapredisposinggeneinschwanno-matosis,whichischaracterisedbythepresenceofmultipleschwannomasintheabsenceofvestibularschwannomas.Thegeneisinvolvedinabout30e40%ofthefamilialcases,butinnomorethan10%ofthesporadiccases.Intheschwannomasofthesepatients,thewild-typecopyofSMARCB1isfoundtobeinactivated,usuallybydeletion.Inaddition,somaticallyacquiredNF2mutationshavebeenfoundinschwannomasofpatientswithagermlineSMARCB1mutation.15e18WewonderedwhetherSMARCB1mightbeapredisposinggeneinmultiplemeningiomasaswell.SupportforthiscandidacyisgivenbythelocationofSMARCB1,whichisproximaltomarkerD22S1,thatisoutsidetheregionexcludedbylinkageanalysis.14Furthermore,somaticSMARCB1mutationshavebeenshowntooccurinsporadicmeningiomas,albeitatlowfrequency,thatis<3%oftumours.19e21EvidencefortheinvolvementofSMARCB1inmultiplemeningiomaswasrecentlyreportedbyBaccietal,22whoshowedtheinheri-tanceofagermlineSMARCB1mutationinafamilywithschwannomatosisandmultiplemeningiomas.However,themutationalstatusofSMARCB1(andofNF2)inthemeningiomasofthepatientswasnotclariﬁed.Inanotherrecentstudy,nogermlineSMARCB1mutationcouldbedetectedin47patientswithmultiplemeningiomas,includingeightfamilialcases.23Inthisstudy,weinvestigatedalargefamilywiththreemembersaffectedbymultiplemeningiomasandtwowithasinglemeningioma.WeidentiﬁedthecausativegermlineSMARCB1mutationsegre-gatingwith(multiple)meningiomasinthisfamilyanddemonstratedinactivationbydeletionofthewild-typecopyofSMARCB1andadditionalbi-allelic1DepartmentofClinicalGenetics,AcademicMedicalCenter,Amsterdam,TheNetherlands2DepartmentofNeurogenetics,AcademicMedicalCenter,Amsterdam,TheNetherlands3DepartmentofNeurosurgery,AcademicMedicalCenter,Amsterdam,TheNetherlands4CanterburyHealthLaboratories,Christchurch,NewZealandCorrespondencetoDrTheoJMHulsebos,DepartmentofNeurogenetics,AcademicMedicalCenter,RoomK2-216,Meibergdreef9,Amsterdam1105AZ,TheNetherlands;t.j.hulsebos@amc.uva.nlReceived29June2010Revised12August2010Accepted23August2010PublishedOnlineFirst7October2010JMedGenet2011;48:93e97.doi:10.1136/jmg.2010.08242093Originalarticle group.bmj.com on October 17, 2012 - Published by jmg.bmj.comDownloaded from andindependentinactivationofNF2inmeningiomasofthepatients.PATIENTSANDMETHODSPatientsInformedconsentwasobtainedfromallfamilymembersforusingtheirbodymaterials.Theproband(III-6inﬁgure1)wasreferredtoouroutpatientclinicwithasuspecteddiagnosisofNF2becauseofmultiplemeningiomas.Attheageof34yearsshepresentedwithepilepsy.CTofthebrainshowedthreeextra-axiallesionsalongthefalxcerebri,whichweresuspectedofbeingmeningiomas.Twolesionswereresectedandpathologicalexaminationconﬁrmedthediagnosisofmeningioma.Attheageof51years,ourprobanddevelopedsensoryproblemsandparaplegiaofthelegs.MRIofthebrainandspinalcordshowedanintraduralextramedullarylesionatthoraciclevel(T)7,suspectedofbeingameningioma.Thelesionwasremovedandturnedouttobeapsammomatousmeningioma,WHOgradeI.Herfamilyhistoryrevealedatwinsister(III-7inﬁgure1)withachestwallschwannomaatage37.Atage49,shedevelopedepilepsyandbrainMRIshowedmultipleextra-axiallesions,whichwereonhistologytransi-tional/mixedmeningiomasgradeI.SheunderwentadditionalsurgeryforaspinalﬁbroblasticmeningiomaatT4,multipleschwannomasofthechestwallandelbow,andwasdiagnosedwithmultiplespinallesionssuspectedofbeingschwannomas.Thefatherofthesetwinsistersdiedatage63fromcoronaryarterydisease.Twoofhis10siblingshadbeenundergonesurgeryformeningioma.Anuncleofourproband(II-6inﬁgure1)developedleft-sideddeafnesscausedbyacerebellopontineanglemass,suspectedofbeingavestibularschwannoma,atage56.Atage64,aspinalﬁbroblasticmeningiomaatT1wasremoved;morerecently,atage77,hedevelopedgaitdifﬁcultiesandMRIshowedmultiplespinalintraduralextramedullarylesions,suspectedofbeingmeningiomas.Anauntofourproband(II-9inﬁgure1)underwentsurgeryonaspinalpsammomatousmeningiomaatT10atage53.AﬁbrousmeningiomaatT6wasremovedfromthespinalcordofherdaughter(III-1inﬁgure1)attheageof40years.Noneoftheaffectedfamilymembershadneuroﬁbromas,café-au-laitspotsorfreckling.Theirclinicalcharacteristicsaresummarisedintable1.DNAandRNAsamplesAfrozentissuesampleofabrainmeningiomaM1ofpatientIII-6andformalinﬁxed,parafﬁnembedded(FFPE)tissuesamplesofonemeningiomaeachofpatientsII-6,II-9,andIII-1,andthebrainandspinalcordmeningiomas(M1,M2)ofpatientIII-6,wereavailableformolecularanalysis.DNAwasextractedandpuriﬁedfrombloodsamplesandthetumourtissuesamplesaccordingtostandardmethods.DNAextractedfromthemeningiomaofpatientII-9wastooheavilydegradedforreliablemolecularanalyses.TotalRNAwasextractedandpuriﬁedfromanotherpartofthefrozentissuesampleofmeningiomaM1ofpatientIII-6usingTRIzolLSReagentaccordingtotheprotocolofthemanufacturer(Invitrogen,Leek,TheNetherlands).Onemicro-gramoftotalRNAwasusedtosynthesisecDNAwithrandomprimingaccordingtostandardmethods.MicrosatelliteanalysisGenotypingoffamilymembersandlossofheterozygosity(LOH)analysisoftumourswereperformedbyusingthechromosome22-speciﬁcmicrosatellitemarkersoftheABIPrismLinkageMappingSetversion2.5-HD5andadditionalmarkerD22S929.PrimersequencesforthelattermarkerweretakenfromLegoixetal.24DatawereanalysedwithGenemappersoftwareversion4.0.(AppliedBiosystems,FosterCity,California,USA).MutationanalysisSMARCB1andNF2weresequencedbyusinggenomicorcDNAassubstrateforampliﬁcationbyPCR.PrimersequencesformutationanalysisoftheSMARCB1andNF2exonshavebeenpublishedpreviously.15Forimprovedperformance,someSMARCB1primerswerenewlydesigned(sequencesavailableonrequest).IndegradedDNAextractedfromFFPEmaterial,theSMARCB1exon2segmentharbouringthemissensemutationwassequencedbyusingforwardprimer59eCCCTTATAATGAGCCTTCTTGCTe39andreverseprimer59-TCTTCCACAGTGGCTAGTCG-39,gener-atingaPCRproductof116bp.ThecDNAproductfrommeningiomaM1ofpatientIII-6wassequencedbyusingforwardprimer59-GACGGCGAGTTC-TACAT-39inexon1andreverseprimer59-TTTTACCATGT-GACGATGCAA-39atthe39-endofexon2,generatingaPCRproductop148bp.AllsequencereactionswereperformedusingABIBigDyev3.1chemistry,andtheproductsweresequencedwithanABI3730capillarysystem(AppliedBiosystems).SequenceswereanalysedwithCodonCodeAligner(CodonCodeCorp,Dedham,Massachusetts,USA).TheHomoloGeneprograminPubMedwasusedtoperformaminoacidsequencealignments(http://www.ncbi.nlm.nih.gov/pubmed).ThePolyPhenandSIFTprogramswereusedtopredicttheimpactofaminoacidsubstitutionsonproteinfunctionandstructure(http://genetics.bwh.harvard.edu/pphandhttp://sift.jcvi.org,respectively).RESULTSSequencingofthenineexonsofSMARCB1inconstitutionalDNAofprobandIII-6revealedamissensemutationinexon2,Figure1GenotypingofSMARCB1andﬂankingmicrosatellitemarkersinconstitutionalblood(B)andcorrespondingmeningioma(M)DNAofaffectedmembersinamultiplemeningiomasfamily.Patientswith(multiple)meningiomasaremarkedbybluesymbols.Diamondsymbolsindicatefamilymemberswithinsufﬁcientclinicaldetails(underclinicalandmolecularinvestigation).Thewild-typeandmutantalleleofSMARCB1areindicatedbyCandT,respectively.MarkerallelesaregivenbythelengthoftheirPCRproducts(bp).94JMedGenet2011;48:93e97.doi:10.1136/jmg.2010.082420Originalarticle group.bmj.com on October 17, 2012 - Published by jmg.bmj.comDownloaded from c.143C/T,P48L(ﬁgure2),whichalsoprovedtobepresentinconstitutionalDNAoftheotheraffectedfamilymembers(III-7,II-6,II-9,andIII-1).Themutationwasnotfoundinconstitu-tionalDNAofmorethan100controlindividuals.TheprolineresiduethatisreplacedbyleucineintheresultingSMARCB1proteinisevolutionarilyconservedacrossallspeciesforwhichsequenceinformationisavailable(datanotshown).InsilicoanalyseswiththePolyphenandSIFTprogramspredictedthattheaminoacidsubstitutionaffectsSMARCB1proteinfunctionandisprobablydamaging.Thefourmeningiomasthatwereavailableformolecularanalysisallshowedlossofthewild-typeCallele,asdemon-stratedinﬁgure2forthebrain(M1)andspinalcord(M2)meningiomaoftheproband(III-6).Inaccordancewiththis,genotypingwithﬂankingmarkersrevealedretentionofthechromosome22segmentcontainingthemutantT-alleleintheinvestigatedtumours,asexempliﬁedinﬁgure2formarkerD22S1174.Thedataaresummarisedinﬁgure1.ToinvestigatewhethertheretainedSMARCB1allelewastranscribed,weextractedtotalRNAfromfrozentissueofmeningiomaM1andreversetranscribeditintocDNA.ThecDNAsequencedemonstratesthatastablemRNAistranscribedfromtheretainedmutantallele(ﬁgure2).Schwannomatosisassociatedschwannomasharboursomati-callyacquiredNF2mutations.Consideringtheapparentanalogywithschwannomatosis,wewonderedwhetherthesemutationsmightalsobepresentinthemeningiomasofthefamilyunderstudy.AlthoughattemptsweremadetosequenceNF2inallavailablemeningiomas,reliablesequencescouldonlybederivedfromthefrozentumourM1andthefreshlyﬁxedtumourM2,bothofprobandIII-6.Wefoundamissensemutationinexon4ofmeningiomaM1(c.422T/G,p.L141R)andanonsensemutationinexon8(c.773G/A,p.W258X)ofmeningiomaM2,bothbeingabsentinthecorrespondingconstitutionalDNAofthepatient(ﬁgure3).Theleucineresidueatposition141isevolutionarilyconserved(datanotshown).ThePolyphenandSIFTprogramspredictedthattheaminoacidsubstitutioncausedbythemissensemutationaffectsNF2proteinfunctionandisprobablydamaging.Thesequencerecordingsindicatelossofthewild-typealleleinbothtumours.Thisissubstanti-atedbyLOHanalysiswiththeintragenicNF2markerD22S929,whichshowsconsiderablelossofthe132bpalleleintumourM1aswellastumourM2(ﬁgure3).Finally,wesequencedallexonsoftheNF2geneinconstitutionalDNAoftheaffectedfamilymembers(III-6,III-7,II-6,II-9,III-1),butdidnotdetectanydeviationfromthewild-typesequence.Table1ClinicalcharacteristicsofaffectedfamilymembersPatientSex(M/F)Age(years)atdiagnosisPresentingsymptomMeningiomas(n,location)Schwannomas(n,location)III-6F34Epilepsy3cranial,1spinaleIII-7F37ChestwallmassMultiplecranial,1spinalMultiplechestwall,multiplespinal,1elbowII-6M56DeafnessMultiplespinal1vestibularII-9F53Paresislegs1spinaleIII-1F40Sensoryproblemslegs1spinaleFigure2Sequenceanalysisofpartofexon2ofSMARCB1andlossofheterozygosity(LOH)analysiswithmarkerD22S1174inbloodandmeningiomaDNAsofpatientIII-6.Left:presenceofthemutantTalleleinconstitutionalblood(B)DNAandconsiderablelossofthewild-typeCalleleingenomicandcDNAofmeningiomaM1andingenomicDNAofmeningiomaM2.Right:PresenceoftwoallelesofmarkerD22S1174inbloodDNAandconsiderablelossofthe145bpallele,markedbyarrow,inmeningiomaM1andM2DNA.JMedGenet2011;48:93e97.doi:10.1136/jmg.2010.08242095Originalarticle group.bmj.com on October 17, 2012 - Published by jmg.bmj.comDownloaded from Inaddition,weperformedmultipleligationdependentprobeampliﬁcation(MLPA)analysisoftheNF2geneinconstitutionalDNAofpatientIII-7.However,thisanalysisdidnotrevealanydeletionsorduplications.DISCUSSIONWeidentiﬁedthegermlinemutationc.143C/TinSMARCB1thatmostprobablypredisposestothedevelopmentofmultiplemeningiomas.Themutationsegregateswiththepresenceof(multiple)meningiomasinthisfamilyand,inaccordancewithKnudsons’two-hithypothesisfortumourigenesis,25remainsinthefourinvestigatedmeningiomas,eachwithlossofthewild-typeSMARCB1allelebyLOH(ﬁgure2).Thecausativenatureofthismissensemutationmaybeinferredfromourinsilicoanalyses,whichdemonstratedthattheprolineresidueatposi-tion48isevolutionaryconservedandthatthechangetoleucineaffectsSMARCB1proteinfunctionandisprobablydamaging.Theimportanceofprolineatthatpositionisfurthermoresupportedbytheﬁndingofanothermissensemutationcausingitsreplacement(c.142C/T,p.P48S)inamalignantrhabdoidtumourofthekidney.26AnothermissensemutationintheSMARCB1gene,c.92A/T,p.E31V,wasrecentlyidentiﬁedasthepredisposinggeneticeventinafamilywithschwannomatosisandmultiplemeningioma.22RNAstudiesinwholebloodoftwopatientsinthisfamilydemonstratedabsenceoftranscriptsfromthemutantSMARCB1allele.We,however,detectedastabletranscriptderivedfromthemutantSMARCB1allelethatwasretainedinmeningiomaM1ofpatientIII-6(ﬁgure2).Accord-ingly,wefounduniformstainingofnucleiwithaSMARCB1antibody(anti-BAF47)inallfourmeningiomas,suggestingthatanintactSMARCB1proteinwasformed(datanotshown).Thepresenceofaleftsidedcerebellopontineanglemass,probablyavestibularschwannoma,inpatientII-6andofmultipleschwannomasinpatientIII-7suggestthattheSMARCB1mutationinthisfamilymaypredisposetothedevelopmentofschwannomasaswell.However,thevestibularschwannomawasdiagnosedatage56andsuchasporadicunilateraltumourisnotuncommonatthatageinthegeneralpopulation.27Unfortunately,theschwannomaswerenotavail-abletofurtherinvestigatethepossibleinvolvementofSMARCB1.Aschwannomaanalysedinthefamilywithschwannomatosisandmultiplemeningiomasindeeddisplayedbi-allelicinactivationofSMARCB1.22Twootherschwannoma-tosisfamilies,eachwithonepatientdevelopingoneortwomeningiomas,havebeenreported.However,thestatusofSMARCB1inthesetumourswasnotinvestigated.16172829Consideringthefrequentoccurrenceofmeningiomasinthegeneralpopulation,1itcannotbeexcludedthattheirassociationwithschwannomatosisinthelatterfamilieswascoincidental.Ontheotherhand,themissensemutationinSMARCB1inourfamily,affectingaminoacidresidue48,andmostprobablyalsointhefamilypresentedbyBaccietal,22affectingnearbyaminoacidresidue31,clearlypredisposetothedevelopmentofmultiplemeningiomas.Therefore,itispossiblethattheprefer-enceformeningiomadevelopmentis,atleastinpart,deter-minedbytypeandlocationoftheSMARCB1mutation.Alternatively,theco-occurrenceofschwannomasandmeningi-omasinsomeSMARCB1familiesandthesoleoccurrenceofschwannomasinmostotherSMARCB1familiesmaypointtotheexistenceofmodifyinggenessegregatinginthesefamiliesandaffectingthephenotypicexpressionoftheSMARCB1mutation.Ourﬁnding,andthatofBaccietal,22thatmeningi-omasarepartoftheschwannomatosistumourspectrummayrequirethediagnosticcriteriaforthisdiseasebereconsidered.FurtherinvestigationofthepossibleassociationoftypeandlocationoftheSMARCB1mutationandthedevelopmentofmultiplemeningiomasandofpossiblemodifyingfactorswillrequiretheidentiﬁcationandclinicalevaluationofadditionalcarriersofthemutatedgeneinourfamilyandinothermultiplemeningiomaspatientsandfamilies.WeidentiﬁedadditionalindependentsomaticmutationsintheNF2geneinthebrain(M1)andspinalcord(M2)meningi-omasofpatientIII-6(ﬁgure3).Themissensemutationinexon4inmeningiomaM1causedreplacementoftheevolutionaryconservedleucineresidueatposition141intheNF2proteinanditschangeintoarginineaffects,accordingtotheinsilicoanal-yses,proteinfunctionandisprobablydamaging.Theimpor-tanceofleucineatposition141isfurthermoresupportedbytheﬁndingofanothermissensemutationcausingitsreplacement(c.422T/C,p.L141P),whichwasreportedasaconstitutionalNF2mutationinapatientwithbilateralschwannomas.30Theexon8mutationinmeningiomaM2isatypicalNF2nonsensemutation,causingtruncationoftheprotein.30InaccordancewithKnudsons’two-hitmodel,lossofthewild-typecopyofNF2byLOHoccurredinbothtumours.25Theﬁndingoftwocausativehits(NF2mutationanddeletion)inthesemeningi-omasandourfailuretodetectaconstitutionalNF2mutationordeletionintheaffectedfamilymembersstronglyargueagainstthisgeneasbeingthemultiplemeningiomapredisposinggeneinthisfamily.Summarisingourdata,weconcludethat,analogoustothegeneticeventsinasubsetofschwannomatosisassociatedschwannomas,16e18afour-hitmechanismoftumoursuppressorgeneinactivation,involvingSMARCB1andNF2,mightalsobeoperativeinfamilialmultiplemeningiomasassociatedmenin-giomas.Inarecentstudy,nogermlineSMARCB1mutationsweredetectedin47patientswithmultiplemeningiomas,includingeightfamilialcases.23GermlineSMARCB1mutationsareinfrequentlyfoundinsporadicschwannomatosispatientsFigure3Sequenceanalysisofpartofexons4and8ofNF2andlossofheterozygosity(LOH)analysiswithmarkerD22S929inbloodandmeningiomaofpatientIII-6.Left:presenceofthemutantGalleleinexon4inmeningiomaM1DNAandthemutantAalleleinexon8inmeningiomaM2DNA,butabsenceofthesemutantallelesinconstitutionalblood(B)DNA.Right:PresenceoftwoallelesofmarkerD22S929inbloodDNAandconsiderablelossofthe132bpallele,markedbyarrow,inmeningiomaM1andM2DNA.96JMedGenet2011;48:93e97.doi:10.1136/jmg.2010.082420Originalarticle group.bmj.com on October 17, 2012 - Published by jmg.bmj.comDownloaded from (<10%ofcases).Itispossiblethat,asinfamilialschwannoma-tosis(30e40%ofcases),SMARCB1involvementismorefrequentinfamilialmultiplemeningiomas.Alternatively,othergenesmightbeimplicatedaspredisposinggeneticfactorsinbothdiseases.AcknowledgementsWethankthefamilymembersfortheirparticipationinthisstudy.WeareindebtedtoDrDTroost(NeuropathologyDepartment,AcademicMedicalCenter,Amsterdam),DrMGHavenith(PathologyDepartment,IsalaClinics,Zwolle),DStomphorst(PathologyDepartment,LeidenUniversityMedicalCenter,Leiden),andMWaaijer(PathologyDepartment,MedicalCenterAlkmaar,Alkmaar)forprovidingtumourmaterials.CompetinginterestsNone.PatientconsentObtained.ProvenanceandpeerreviewNotcommissioned;externallypeerreviewed.REFERENCES1.ClausEB,BondyML,SchildkrautJM,WiemelsJL,WrenschM,BlackPM.Epidemiologyofintracranialmeningioma.Neurosurgery2005;57:1088e95.2.EvansDG,HusonSM,DonnaiD,NearyW,BlairV,TeareD,NewtonV,StrachanT,RamsdenR,HarrisR.Ageneticstudyoftype2neuroﬁbromatosisintheUnitedKingdom.I.Prevalence,mutationrate,ﬁtness,andconﬁrmationofmaternaltransmissioneffectonseverity.JMedGenet1992;29:841e6.3.ParryDM,EldridgeR,Kaiser-KupferMI,BouzasEA,PikusA,PatronasN.Neuroﬁbromatosis2(NF2):clinicalcharacteristicsof63affectedindividualsandclinicalevidenceforheterogeneity.AmJMedGenet1994;52:450e61.4.MautnerVF,LindenauM,BaserME,HazimW,TatagibaM,HaaseW,SamiiM,WaisR,PulstSM.Theneuroimagingandclinicalspectrumofneuroﬁbromatosis2.Neurosurgery1996;38:880e5.5.BijlsmaEK,MerelP,BoschDA,WesterveldA,DelattreO,ThomasG,HulsebosTJ.AnalysisofmutationsintheSCHgeneinschwannomas.GenesChromosomesCancer1994;11:7e14.6.Me´relP,Hoang-XuanK,SansonM,BijlsmaE,RouleauG,Laurent-PuigP,PulstS,BaserM,LenoirG,SterkersJM,etal.Screeningforgerm-linemutationsintheNF2gene.GenesChromosomesCancer1995;12:117e27.7.LamszusK,VahldiekF,MautnerVF,SchichorC,TonnJ,StavrouD,FillbrandtR,WestphalM,KluweL.Alleliclossesinneuroﬁbromatosis2-associatedmeningiomas.JNeuropatholExpNeurol2000;59:504e12.8.NahserHC,GroteW,Lo¨hrE,GerhardL.Multiplemeningiomas.Clinicalandcomputertomographicobservations.Neuroradiology1981;21:259e63.9.HeinrichB,HartmannC,Stemmer-RachamimovAO,LouisDN,MacCollinM.Multiplemeningiomas:investigatingthemolecularbasisofsporadicandfamilialforms.IntJCancer2003;103:483e8.10.EvansDG,WatsonC,KingA,WallaceAJ,BaserME.Multiplemeningiomas:differentialinvolvementoftheNF2geneinchildrenandadults.JMedGenet2005;42:45e8.11.StanglAP,WellenreutherR,LenartzD,KrausJA,MenonAG,SchrammJ,WiestlerOD,vonDeimlingA.Clonalityofmultiplemeningiomas.JNeurosurg1997;86:853e8.12.ZhuJJ,MaruyamaT,JacobyLB,HermanJG,GusellaJF,BlackPM,WuJK.Clonalanalysisofacaseofmultiplemeningiomasusingmultiplemoleculargeneticapproaches:pathologycasereport.Neurosurgery1999;45:409e16.13.EcksteinO,Stemmer-RachamimovA,NunesF,HochD,OjemannR,MacCollinM.MultiplemeningiomasinbrainandlungduetoacquiredmutationoftheNF2gene.Neurology2004;62:1904e5.14.PulstSM,RouleauGA,MarineauC,FainP,SiebJP.Familialmeningiomaisnotallelictoneuroﬁbromatosis2.Neurology,1993;43:2096e8.15.HulsebosTJ,PlompAS,WoltermanRA,Robanus-MaandagEC,BaasF,WesselingP.GermlinemutationofINI1/SMARCB1infamilialschwannomatosis.AmJHumGenet2007;80:805e10.16.BoydC,SmithMJ,KluweL,BaloghA,MaccollinM,PlotkinSR.AlterationsintheSMARCB1(INI1)tumorsuppressorgeneinfamilialschwannomatosis.ClinGenet2008;74:358e66.17.HadﬁeldKD,NewmanWG,BowersNL,WallaceA,BolgerC,ColleyA,McCannE,TrumpD,PrescottT,EvansDG.MolecularcharacterisationofSMARCB1andNF2infamilialandsporadicschwannomatosis.JMedGenet2008;45:332e9.18.SestiniR,BacciC,ProvenzanoA,GenuardiM,PapiL.Evidenceofafour-hitmechanisminvolvingSMARCB1andNF2inschwannomatosis-associatedschwannomas.HumMutat2008;29:227e31.19.BruderCE,DumanskiJP,KedraD.ThemouseorthologofthehumanSMARCB1geneencodestwospliceforms.BiochemBiophysResCommun1999;257:886e90.20.SchmitzU,MuellerW,WeberM,Se´venetN,DelattreO,vonDeimlingA.INI1mutationsinmeningiomasatapotentialhotspotinexon9.BrJCancer2001;84:199e201.21.RieskeP,ZakrzewskaM,PiaskowskiS,Jasko´lskiD,SikorskaB,PapierzW,ZakrzewskiK,LiberskiPP.MolecularheterogeneityofmeningiomawithINI1mutation.MolPathol2003;56:299e301.22.BacciC,SestiniR,ProvenzanoA,PaganiniI,ManciniI,PorﬁrioB,VivarelliR,GenuardiM,PapiL.SchwannomatosisassociatedwithmultiplemeningiomasduetoafamilialSMARCB1mutation.Neurogenetics2010;11:73e80.23.HadﬁeldKD,SmithMJ,TrumpD,NewmanWG,EvansDG.SMARCB1mutationsarenotacommoncauseofmultiplemeningiomas.JMedGenet2010;47:567e8.24.LegoixP,LegrandMF,OllagnonE,LenoirG,ThomasG,Zucman-RossiJ.Characterisationof16polymorphicmarkersintheNF2gene:applicationtohemizygositydetection.HumMutat1999;13:290e3.25.KnudsonAGJr.Mutationandcancer:statisticalstudyofretinoblastoma.ProcNatlAcadSciUSA1971;68:820e3.26.Se´venetN,Lellouch-TubianaA,SchoﬁeldD,Hoang-XuanK,GesslerM,BirnbaumD,JeanpierreC,JouvetA,DelattreO.SpectrumofhSNF5/INI1somaticmutationsinhumancancerandgenotype-phenotypecorrelations.HumMolGenet1999;8:2359e68.27.BaserME,FriedmanJM,EvansDG.Increasingthespeciﬁcityofdiagnosticcriteriaforschwannomatosis.Neurology2006;66:730e2.28.EvansDG,MasonS,HusonSM,PonderM,HardingAE,StrachanT.Spinalandcutaneousschwannomatosisisavariantformoftype2neuroﬁbromatosis:aclinicalandmolecularstudy.JNeurolNeurosurgPsychiatry1997;62:361e6.29.MacCollinM,WillettC,HeinrichB,JacobyLB,AciernoJSJr,PerryA,LouisDN.Familialschwannomatosis:exclusionoftheNF2locusasthegermlineevent.Neurology2003;60:1968e74.30.AhronowitzI,XinW,KielyR,SimsK,MacCollinM,NunesFP.MutationalspectrumoftheNF2gene:ameta-analysisof12yearsofresearchanddiagnosticlaboratoryﬁndings.HumMutat2007;28:1e12.JMedGenet2011;48:93e97.doi:10.1136/jmg.2010.08242097Originalarticle group.bmj.com on October 17, 2012 - Published by jmg.bmj.comDownloaded from doi: 10.1136/jmg.2010.0824202010 2011 48: 93-97 originally published online October 7,J Med Genet(cid:160)I Christiaans, S B Kenter, H C Brink, et al.(cid:160)meningiomas mutations in familial multipleNF2 mutation and somatic SMARCB1Germline  http://jmg.bmj.com/content/48/2/93.full.htmlUpdated information and services can be found at: These include:References http://jmg.bmj.com/content/48/2/93.full.html#related-urlsArticle cited in: (cid:160) http://jmg.bmj.com/content/48/2/93.full.html#ref-list-1This article cites 30 articles, 12 of which can be accessed free at:serviceEmail alertingthe box at the top right corner of the online article.Receive free email alerts when new articles cite this article. Sign up inCollectionsTopic (1086 articles)Molecular genetics (cid:160) (cid:149) (69 articles)Neurooncology (cid:160) (cid:149) (37 articles)CNS cancer (cid:160) (cid:149)(cid:160)Articles on similar topics can be found in the following collectionsNotes http://group.bmj.com/group/rights-licensing/permissionsTo request permissions go to: http://journals.bmj.com/cgi/reprintformTo order reprints go to: http://group.bmj.com/subscribe/To subscribe to BMJ go to: group.bmj.com on October 17, 2012 - Published by jmg.bmj.comDownloaded from Vol.4,715-722,September1993CellGrowth&Differentiation715IdentificationandCharacterizationofGenesDifferentiallyExpressedinMeningiomas1MaureenMurphy,MarkJ.Pykett,PeterHarnish,KlausD.Zang,andDonnaI..George2DepartmentofGenetics,UniversityofPennsylvaniaSchoolofMedicine,Philadelphia,Pennsylvania19104-6145[M.M.,M.j.P.,P.H.,D.L.G.l,andDepartmentofHumanGenetics,UniversityofSaarland,6650HomburgJSaar,Germany1K.D.Z.lAbstradMeningiomasarecommontumorsderivedfromthethinmembranethatsurroundsthebrainandspinalcord.Currently,themolecularmechanismsresponsiblefortheinitiationandprogressionofthesetumorsarelargelyunknown.Towardtheelucidationofsuchmechanisms,wehaveformulatedanexperimentaldesignutilizingthetechniqueofsubtradivehybridizationthatisaimedatidentifyingthechangesingeneexpressionbetweenintracranialmeningiomasandtheirnormalprecursorcells,leptomeningealcells.Wereportheretheidentificationandinitialcharaderizationofthreegeneswhoseexpressionisalteredoraberrantinmeningiomacelllinesandtumorsrelativetoculturesofnormalleptomeningealcells.ComplementaryDNAprobesfromoneofthesegenesdetedtranscriptsofalteredsizeinseveralmeningiomasrelativetonormalleptomeningealcells.Anotherofthesegenesdemonstratesdecreasedexpressioninmeningiomasandintumorsassociatedwiththedisorderneurofibromatosis2.Athirdgeneisolatedbythisprocedureisdifferentiallyexpressedinbothmeningiomasandbreastcarcinomas.Therefore,thedecreasedexpressionofthesegenesmayplayrolesingrowth-regulatorypathwaysthatareabrogatednotonlyinmeningiomas,butinothertumortypesaswell.IntrodudionMeningiomasareoneofthemostcommontumorsofthecentralnervoussystem.Derivedfromtheleptomeningealmembranesurroundingthebrainandspinalcord,thesetu-morsaccountforupto20%ofallprimaryintracranialtu-morsand25%ofintraspinalneoplasticlesions(1).Clinicallyandhistologically,meningiomascompriseaheterogeneousgroupoftumors,withuptoninedifferentpathologicalandhistologicalsubtypes(1,2);atpresent,thebasisforthishet-erogeneityisunclear.Althoughmeningiomasaregenerallysolitaryandsporadic,familialassociationsofthesetumorshavefrequentlybeenreported(1);theseoccuroften,al-thoughnotalways,inassociationwiththedisorderNF3-2.NF-2isanautosomal-dommnantlyinheriteddisorderpredis-posingaffectedindividualstomultipletumortypesinthecentralnervoussystem,suchasastrocytomas,schwanno-mas,meningiomas,andependymomas;thehallmarkofthedisorderisconsideredtobethepresenceofbilateralyes-tibularschwannomas(3).Cytogeneticstudiesofbothsporadicandfamilialmenin-giomas(4-6),coupledwithrecentanalysesoflossofhet-erozygosityofcertainDNAmarkersinthesetumors(7),havedemonstratedthatlossofgeneticmaterialfromchromosome22issignificantlymorefrequentthanalterationsofotherchromosomesandoccursinupto70%ofmeningiomas(8).Thesedatahaveledtothehypothesisthatthealterationofatumorsuppressorgeneonchromosome22isinvolvedinthegenesisofbothsporadicandfamilialmeningiomas.Thistumorsuppressorgene,whichwerefertoasthemeningiomasusceptibilitylocus,ormsl,hasbeenlocalizedcytogeneti-callyandviadeletionmappingtochromosome22q12-qter(9-11).BecauselinkageanalysesindicatethattheNF-2dis-orderislinkedtolociinthisregionofchromosome22(12,13),anddeletionsoflocifromthischromosomehavebeendetectedintumorsfrompatientsdiagnosedwithNF-2(14),ithasbeenhypothesizedthatthetumorsuppressorgenesinvolvedintheinitiationofmeningiomasandNF-2areal-lelic(15);however,somestudiesindicatethatthesetumorsuppressorsmayrepresenttwoseparatelocionchromo-some22(16).Cytogenetically,meningiomasareoneofthebestchar-acterizedsolidtumorsinhumans.Inadditiontolossofge-neticmaterialfromchromosome22,thesetumorsdisplayother,lessfrequentcytogeneticalterations.Inparticular,re-arrangementsofchromosomes1pand11p,aswellaslossesofgeneticmaterialfromchromosomes8,14,and17,havebeendocumentedtooccurasnonrandomgeneticchangesinthesetumors(17-19).Itisgenerallyfeltthatthesenon-random,secondarychromosomalaberrationsandlossesrepresenttheinactivationofothertumorsuppressorloci,whosefunctionallossmaycontributetomeningiomapro-gression,aggressiveness,orchanceforrecurrence.Recently,subtractivehybridizationhasbeensuccessfullyutilizedintheisolationofcandidategenesforgeneticdis-ease(20,21)andinthedefinitionofthechangesingeneexpressionthatoccurduringthegenesisandprogressionofdifferenttypesofcancer,suchasneuroblastoma(22)andcancersofthebreast(23),liver(24),andlung(25).Werea-sonedthatsuchanapproachwasidealforthestudyofme-ningiomas.Wedescribeheretheuseoftwodifferentsub-Received6/7/93;accepted6/17/93.1ThisprojectwassupportedbytheCooperativeHumanTissueNetwork,whichisfundedbytheNationalCancerInstitute,andbyNIH-USPHSGrantNS30025,awardedtoD.L.G.;M.M.andM.J.P.weresupportedinpartbyNIH-USPHSTrainingGrants5-T32-GM07229and5-T32-GMO7170.2Towhomrequestsforreprintsshouldbeaddressed,atUniversityofPenn-sylvaniaSchoolofMedicine,Room445ClinicalResearchBuilding,422Cu-neBoulevard,Philadelphia,PA19104-6145.3Theabbreviationsusedare:NF,neurofibromatosis;LMC,leptomeningealcells;kb,kilobase(s);bp,basepair(s);RT-PCR,reversetranscription-polymerasechainreaction;ER,estrogenreceptor;IGFBP,insulin-likegrowthfactor-bindingprotein;cDNA,complementaryDNA;SSC,standardsalinecitrate;SDS,sodiumdodecylsulfate;mac,meningiomaalteredexpressioncDNA;ATCC,AmericanTypeCultureCollection;poly(A)(cid:1),polyadenylated.Sccoofstrand(cid:1)adthKionowpolymersas.transformatIonIntoE.coil+I(cid:1)neem(cid:1)Sutersofon(cid:1)IS_adlo(cid:1)Subtracted(cid:1)-,LMC.T(cid:1)996(cid:1)nw+Diltorentialecre(cid:1)wasiobeNedcOttAfromLMCand12896Fig.1.Subtractivehybridizationschemefortheisolationofsequencesen-richedinorspecifictothenormalLMCcDNAlibrary.Leftside,constructionoftheplasmidsubtractionlibrary:rightside,generationofthephagesub-tractionlibrary;thelatterutilizestworoundsofsubtractionfollowedbyPCRtoincreasesensitivity.ss,singlestranded.716GenesDifferentiallyExpressedinMeningiomastractivehybridizatjonprotocolsthatservedtoenrichforcDNAsequencespresentlargelyorexclusivelyinnormalLMCrelativetoameningiomacellline.TheseprotocolsenabledtheidentificationofthreegenesthatareexpressedinnormalLMCbutshowalteredordifferentialexpressioninseveralmeningiomas.Theidentificationandcharacteriza-tionoftheseandothersuchalteredgenesislikelytobeacriticalsteptowarduncoveringtheetiologyandpathologyofthesefrequenttumorsandmayhaveaddedimplicationsforunderstandingthetransformationpathwaystakenbyothertumortypesaswell.ResultsTwodifferentprotocolswereutilizedfortheconstructionandscreeningofsubtractionlibrariesfromnormallepto-meningealcellsandthemeningiomacelllineT2898,asoutlinedbrieflyinFig.1.Inbothcases,subtractivehybrid-izationwasperformedsuchthattheselibrarieswouldbeenrichedforsequencesfoundlargelyorexclusivelyinnor-malLMC,relativetothemeningiomacelllineT2898.Theconstructionoftheplasmid12898subtractionlibraryin-corporatedoneroundofhybridizationandsubtraction,asshowninFig.1;thislibrarywasscreenedwithsimilarlymade“subtractedprobes”madefrommRNAfromnormalLMCandanothermeningiomacellline,designatedT2966.Inanefforttoincreasetheefficiencyofsubtraction,thephageT2898subtractionlibrarywasgenerated;thecon-structionofthislibraryincorporatedtworoundsofhybrid-izationandsubtraction,eachfollowedbyamplificationofLMC-enrichedsequencesviathepolymerasechainreaction.ThephageT2898subtractionlibrarywasdifferentiallyscreened,asdescribedin“MaterialsandMethods.”(cid:1)onstructlonandScreeningofSubtractionLibraries2ugLMCascOttA60ugas1’2886msnlnglomscOttA+‘(cid:1)(cid:1)‘b,Idiz.dtoCoTp8000StreptevidinIncubation/Phenolextraction,61011precIpitation/\pcnw(cid:1)Sp6fll--+Removalof-eequenceeAdditionofScoreadaptorsI60ugas12896menlngiomecOttA+(cid:1)toCoTx8000Sbaptev(cid:1)Incubation/Phenolextraction,E10Hpradon+thor(cid:1)pecmcoligomerLigationkiloLambdaZapN+Fromsubtractedprobeanddifferentialscreeningsofthesetwosubtractionlibraries,30plasmidandphagecloneswererecoveredforsecondaryNorthernanalysis.Ofthese,fouruniquecDNAclonesdetectedapatternorlevelofhybrid-izationinnormalleptomeningealcelltotalRNAthatwasdifferentintheT2898and/or12966meningiomas.Twooftheseclones,althoughofdistinctsequence,hybridizedtothesamepatternofRNAinNorthernanalysesandlikelyrepresentthesamegene.ThethreecDNAclonespresentedinthisstudy,containinginsertsofl.1,0.42,and0.3kb,weredesignatedmac25,mac30,andmacPi,respectively.Themac25GeneIsDifferentiallyExpressedinMenin-giomas,butnotinOtherTumorsofNeuroedodermalOn-gin,IncludingThoseAssociatedwithNF-2.ThecDNAclonedesignatedmac25hybridizestoasingleabundanttranscriptofapproximately1.1kbinRNAisolatedfromcul-turesofnormalIeptomeningealcells(Fig.2A,Lane1)andfromtheLTAg2Bimmortalizedlineofthesecells(Lane10),aswellasinRNAisolateddirectlyfromnormalleptomen-ingealtissue(Lane14).However,asdepictedinFig.2,thiscDNAdetectsdecreasedlevelsofthe1.1-kbtranscriptinRNAisolatedfromseveralmeningiomacelllines(Fig.2A,Lanes2,3,and11-13).Additionally,themac25cDNAprobedetectstheaddedpresenceofahighermolecularweighttranscript,ofapproximately4.0kb,inthespinalme-ningiomaT2966(Fig.2A,Lane3).Furthermore,transcriptshybridizingtothemac25probearevirtuallyundetectableinRNAisolatedfromseveralmeningiomasolidtumors(Fig.2A,Lanes4-9).Incontrast,thesesamesamplesexhibitcom-parablelevelsoftranscriptsfor(cid:1)32-microglobulin(Fig.2A,82M,Lanes1-14),aswellasribosomalRNA(datanotshown).Transcriptlevelsofthemac25genewerenotfoundtobesignificantlydecreasedinRNApreparedfromotherneuro-ectodermallyderivedtumorsortumorcelllines,relativetolevelsinnormalLMC.AsshowninFig.28,significantlevelsofmac25transcriptarepresentinRNAisolatedfromaneu-roblastoma(Lane3),aneurofibroma(Lane5),andagliomacellline(Lane6).Additionally,inanefforttoextendthesestudiestoothertumorsfoundinthedisorderneurofibroma-tosis2,weanalyzedthelevelofexpressionofmac25inRNAisolatedfromaspinalschwannomafromaNF-2patient,aswellasinasporadicspinalschwannoma(Fig.28,Lanes4and6,respectively);inbothsamples,levelsofmac25RNAwereindistinguishablefromthatinculturedLMC(Lane1).Therefore,thedecreasedexpressionofthemac25geneap-pearslimitedtocertainmeningiomacelllinesandsolidtu-morsandisnotcommontoallneuroectodermallyderivedtumors,nortoalltumorsassociatedwiththedisorderNF-2.NorthernblotanalysisofRNAfromnormalmousetissuesindicatesthatthemac25geneisexpressedinabroadspec-trumoftissues,suchasbrain,lung,heartandskeletalmuscle,testes,ovary,andpregnantuterus;thehighestlevelsofmac25transcriptswerefoundinthelattertwotissues(datanotshown).Themac25GeneIsAlsoDifferentiallyExpressedinBreastCarcinomasandHasHomologytoGenesEncodingInsulin-likeGrowthFador-bindingProteins.Therearenu-merousreportsintheliteraturethatindicateastatisticallysignificantclinicalassociationbetweentheoccurrenceofmeningiomasandbreastcarcinoma(26-28).Therefore,inadditiontoexaminingtheexpressionofisolatedmacgenesintumorsassociatedwiththedisorderNF-2,wewerealsointerestedinexaminingtheexpressionofthesegenesinbreastcarcinomasamples.AsdepictedinFig.3,wefoundB.--++CellGrowth&Differentiation717A.10MCT2898T2966SolidTumorsMeningiomaCellLines4.01.1123456789#{149}(cid:1)0mac251011121314B2MOtherTumors/Celllinesmac25B2M(cid:1)(cid:1)(cid:1)Fig.2.A,Northernanalysisofmac25geneexpressioninmeningiomacelllinesandtumors.TenpgoftotalRNAarepresentineachlane;equalloadingsandRNAintegrityarecontrolledbylevelsofribosomalRNA,aswellasRNAforf32-microglobulin(B2M).RNAsamplesineachlaneare:Lane1,normalleptomeningealcells;Lane2,T2898meningiomacellline;Lane3,T2966meningiomacellline;Lanes4-9,meningiomatumorsND1,ND2,A287B,A244,A009,andA188,respectively;Lane10,LTAg2BimmortalizedLMC;Lanes11-13,meningiomacelllinesT2896,T2921,andT2891;Lane14,normalleptomeningealtissue.B,Northernanalysisofmac25expressionin:Lane1,LTAg2Bleptomeningealcells;Lane2,asporadicspinalschwannoma;Lane3,aneuroblastoma;Lane4,aspinalschwannomafromapatientdiagnosedwithNF-2;Lane5,aneurofibroma;Lane6,U-373Mggliomacellline.TenpgoftotalRNAareloadedineachlane.BreastcarcinomasMeningiomasIII567891011++-mac25-estrogenreceptorFig.3.Northernanalysisofmac25geneexpressioninbreastcarcinomasandmeningiomas,comparedtothepositive)+)ornegative(-)presenceofmRNAfortheestrogenreceptorinthesecelllines.ThepresenceofERmRNAwasmeasuredbyaRT-PCRassay.Lane1,RNAfromnormalbreastlineHs578Bst;Lanes2-8,breastcarcinomacelllinesHs578T,ZR-75-30,ZR-75-1,MDA-MB-157,MDA-MB-231,BT-483,andT-47D,respectively;Lane9,ND1meningioma;Lane10,T2888meningiomacellline;Lane11,LTAg2Bleptomeningealcells.thatthemac25geneisexpressedathighlevelsinsomebreastcarcinomacelllines,yetitisundetectablyexpressedinothers(Lanes2-8).Intotal,wefoundmac25expressedathighlevelsinfourbreastcarcinomacelllines,butabsentinexpressioninthree.Itisunlikelythatthedifferencesinlevelsofthistranscriptrepresenttissue-specificchanges,asallsevenofthesecelllinesrepresentedadvancedstagecar-cinomasfrommammaryductalepithelium.Wenotedthattwoofthemac25nonexpressingbreastcarcinomacelllineshadbeenpreviouslyreportedtobepositiveforestrogenreceptorprotein(29).Therefore,wesoughttodeterminewhethertheexpressionofthesetwogenesmightbeinverselycorrelatedinthiscelltype.AsshowninFig.3,wefoundthatthepresenceofERmRNA,asmeasuredinaRT-PCRassay,negativelycorrelateswithmac25geneexpressioninacelllinefromnormalbreasttissue(Hs578Bst;Fig.3,Lane1),andinsevenofeightbreastcarcinomacelllines(Lanes2-8).Onecellline(MDA-MB-453)expressedneitherRNA,however(datanotshown),norwereweabletodetectthepresenceofERmRNAinanyofourmeningiomas(Fig.3,Lanes9-11).Theinversecorre-lationbetweenERandmac25geneexpressioninbreastcar-A.12345678910111213141234567891011mac30losFig.5.A,Northernanalysisoflevelsofmac30geneexpressioninmenin-giornatumorsandcelllines,relativetolevelsoff32-microglobulin(B2M).TenpgoftotalRNAarefrom:Lane1,normalLMC;Lane2,T2966meningiomacellline;Lane3,ND1meningioma;Lane4,ND2meningioma;LaneS,T2898meningiomacellline;Lanes6and11,LTAg2BLMC;Lanes7-1O,meningiomacelllinesT2896,T2921,T2891,andT2888,respectively;Lanes12-14,me-ningiomasA244,A009,andA188,respectively.B,Northernanalysisofmac30expressioninnormalandtransformedhumancelllinesandtissue.Ten(cid:1)igofRNAarefrom:Lane1,normalhumanfibroblasts;Lane2,HeLa;Lane3,RD-ES;Lane4,CoIo32ODM;Lane5,K-562;Lane6,Sk-mel-2;Lane7,U-373Mgglioma;Lane8,Tu-87;Lane9,Hs578T;Lane10,LTAg2B;Lane11,normalleptomeninges.718GenesDifferentiallyExpressedinMeningiomas20mac25PAGLLLLLLPLSSSSSSDTCGPCEPASCPPLPPL11111111I1111IIIIII11111111atiiiiuiiIliii11111111111111RVWLVLLLLTVQVGVTAGAPWQCAPCSAEKLALCPPVSA_IGF#{149}BP192GCLLGETRDA#{212}G#{212}#{212}PM#{212}ARGEGEP#{212}GGGGAGRGY#{212}APGME#{212}III1111111111111111III111111III1111111111111111III111111SCSEVTRSAGCGCCPMCALPLGAACGVATAR__CARGLSC102Fig.4.Aminoacidhomologyattheaminoterminusofthepredictedmac25pr(cid:1)I)teintotheamino-terminal102aminoacidsofthehumanIGFBP-1.In75aminoacids,theseproteinsare37%identicaland75%similar.#{149},conservedcysteineresidues,knowntohecriticaltothefunctionofIGFBPs.cinomacelllinesmayindicatethatthemac25geneises-trogenregulatedinthesecells;however,theabsenceofdetectableERmRNAinourmeningiomassuggeststhatothervariablesmustcontributetothedecreasedexpressionofthisgeneinthesetumors.AsearchoftheGenBankdatabasewiththefull-lengthnucleotidesequenceofthemac25cDNAindicatesthatthesequenceofthisgenehasnotbeenreportedpreviously.Aproteinhomologysearchrevealedthatthe281-aminoacidproteinrepresentingthelargestopenreadingframeofthisgenepossessesasignificantdegreeofhomologyattheaminoterminustotheaminoterminiofseveralmembersoftheIGFBPfamily.Importantly,thishomology,detailedforIGFBP-1inFig.4,includes11ofthe12cysteineresiduesknowntobecriticalforthefunctionofinsulin-likegrowthfactor-bindingproteins(30).AsmightbeexpectedwithaputativememberoftheIGFBPfamily,themac25genedem-onstratesaveryhighspeciesconservation;severalgenomicfragmentshybridizetothemac25cDNAprobeinmultiplespecies,suchasrat,mouse,dog,andmonkey,atwashingstringenciesashighas0.3XSSCat55#{176}C(datanotshown).Preliminarychromosomalmappingstudiesusingarodent!humansomaticcellhybridpanelindicatethatthemac25genemapstohumanchromosome4(datanotshown).Themac3OGeneDemonstratesDecreasedExpressioninMeningiomasandSchwannCellTumors.Themac30cDNA,likemac25,wasisolatedasapositivecloneinthescreeningoftheplasmidT2898subtractionlibrarywithsubtractedprobesmadefromtheT2966meningiomacellline.This421-bpcDNAhybridizestotwotranscriptsofapproximately2.3and2.8kbinRNAisolatedfromnor-malleptomeningealcells(Fig.5A,Lane1)andfromim-mortalizedculturesofthesecells(Lanes6and11).WhenhybridizedtoaNorthernpanelcontainingtotalRNAiso-latedfromfivemeningiomacelllines(Fig.5A,Lanes2,5,and7-10),aswellasRNAprepareddirectlyfromsixme-ningiomatumors(Lanes3,4,and12-14),thiscDNAprobedetectssignificantlydecreasedexpressionofthisgene.Incontrast,thesesamplesdemonstratecomparablelevelsoff32-microglobulin(Fig.5A,Lanes1-14)andribosomalRNA(datanotshown).Thusfar,transcriptshybridizingtomac30havebeendetectedatlevelscomparabletothatinnormalLMCinover30celllinesfromnormalandtransformedhu-mantissue(see,forexample,Fig.58,Lanes1-11),includingalleightbreastcarcinomacelllines(see,forexample,Lane9),aswellasRNAisolateddirectlyfromleptomeningealtissue(Lane11).Thesedataindicatethatthemac3Ogeneislikelytobenormallyubiquitouslyexpressed,andfurther-more,thatitsdown-regulationisnotcommontoalltrans-formedcells.28Smac3018SB.B2MIneffortstoagainextendthesestudiestothedisorderneu-rofibromatosis2,weanalyzedseveralNF-2tumorsforex-pressionofmac30.UsingaRT-PCRassaytomoreaccuratelydetectmac30transcriptsintumors,wefoundexpressionofmac30tobedramaticallydecreasedinRNApreparationsfromtwovestibularschwannomasandonespinalschwan-noma,allfrompatientsdiagnosedwithneurofibromatosis2(Fig.6A,Lanes2-4),inasporadicvestibularschwannoma(Lane5),andinasporadicspinalschwannoma(Lane6).Somewhatsurprisingly,wealsofoundthemac30genetobesimilarlydecreasedinexpressioninseveralneurofibromas,whichareSchwanncelltumorsoftheperipheralnervoussystemcharacteristicofthedisorderNF-1(Ref.31;Fig.6A,Lanes8-10).Nodecreaseinlevelsofmac3ORNAwerefoundinothertumorsofneuralcrestorigin[forexample,inaneuroblastoma(Fig.6A,Lane7));furthermore,atranscripthybridizingtothiscDNAisclearlypresentinRNAisolatedfromculturesofimmortalizedratSchwanncells(Fig.6B,Lane1).Therefore,decreasedexpressionofthisgeneap-pearstobelimitedtomeningiomatumorsandcelllines,aswellastoSchwanncelltumors,includingthoseassociatedwiththedisordersNF-1andNF-2.Sequenceanalysisofa2.0-kbmac30cDNAandasearchoftheGenBankdatabaseindicatethatthesequenceofthisgenehasnotbeenpreviouslyreportedand,furthermore,thatmac3Dsequencesdonotcontainanysignificanthomologiestopreviouslyreportedgenes.Chromosomalmappingusingarodent/humansomaticcellhybridpanelindicatesthatthisgeneresidesonhumanchromosome17(datanotshown).FurthermappingwiththesomaticcellhybridVII-2HAT(32),whichcontainsthesinglehumantranslocationchromosome(llcen-11pl5::17q21-17qter),indicatesthatthisgenere-sidesonchromosome17q21-qter(datanotshown).ThemacPicDNADetectsTranscriptsofAlteredSizeinManyMeningiomas.Inordertoincreasethesensitivityofoursubtractivehybridizationprotocol,wegeneratedaCellGrowth&Differentiation719A.LMCNF-2tumorsNBNF:1tumors-RIdH2Omac30actin123456789101112IB.Fig.6.A,RT-PCRanalysisofRNAlevelsofmac30andj3-actinintumorsassociatedwiththedisordersNF-2andNE-i.Lane1,normalLMC;Lanes2and3,NF-2vestibularschwannomas;Lane4,NF-2spinalschwannoma;Lane5,sporadicvestibularschwannoma;Lane6,sporadicspinalschwannoma;Lane7,neuroblastoma;Lanes8-10,NF-1neurofibromas;Lane11,minus-reversetranscriptasecontrol;Lane12,watercontrol.B,Northernanalysisofmac3OexpressioninRNAfromanimmortalizedratSchwanncellline(C4+Zn;Lane1)andLTAg2BLMC(Lane2(.RNAblotwaswashedinO.3XSSCat55CCandexposedtofilmfor48h.Arrow,sizeofthemac3Otranscriptinratcells;similarlevelsofatranscriptofthissizeareevidentinRNAfromadultmousebrainaswellascatleptomeningealcultures(notshown(.28S(cid:1),J(cid:1)*fjo18SFig.7.NorthernanalysisofmacPigeneexpressionin:Lane1,normalLMC;Lane2,LTAg2BimmortalizedLMC;Lane3,12898meningiomacellline;Lane4,T2966meningiomacellline;Lane5,ND1meningioma;Lane6,T2921meningiomacellline;Lane7,HeLacells;Lane8,K-562cells;Lane9,RD-EScellline.TenpgoftotalRNAareloaded/lane.phagesubtractionlibrarythatincorporatedtworoundsofsubtraction,eachfollowedbyamplificationofLMC-enrichedsequencesbythepolymerasechainreaction.Dif-ferentialscreeningofthiscDNAlibraryyieldedtheisolationofthemacPicDNA,whichhybridizestotranscriptsofap-proximately5.0,3.5,and3.0kbinnormalandimmortalizedleptomeningealcellRNA(Fig.7,Lanes1and2).InRNAfromthemeningiomaT2898,themacPiprobedetectsde-creasedlevelsofatranscriptthatisconsistentlyreducedinsizerelativetothenormal3.0-kbmessage(Fig.7,Lane3).InRNAsamplesrunlongerforgreaterseparation,thissizedifferenceappearsontheorderof100-200bp(datanotshown).Therefore,inadditiontobeingdecreasedinex-pressionintheT2898meningioma,the3.0-kbmacPltran-scriptmayalsocontainsequencespresentinnormalLMCthataredeletedintheT2898tumor.IntheT2966menin-giomacellline,themajorhybridizingmacPltranscripthasamolecularsizegreaterthan3.0kb,whereasthenormal5.0-kbmessageisundetectable(Fig.7,Lane4).Additionally,RNAisolatedfromanothermeningiomacontainsanabun-danttranscriptofapproximately6kbthathybridizestomacPlprobe(Fig.7,Lane5);yet,othermeningiomashavedemonstratedapatternofhybridizationindistinguishablefromnormalLMC(see,forexample,Fig.7,Lane6).AnalysisofthehybridizationpatternofthemacPigeneinseveralnormalandtransformedhumancelllines,aswellasRNAisolateddirectlyfromnonmeningealtumors,indicatesthattheexpressionofthe5.0-kbtranscriptmaybeubiqui-tous,whereastheexpressionofthe3.0-and3.5-kbtran-scriptsmayberestrictedtonormalLMCandsomemenin-giomas(see,forexample,Fig.7,Lanes7-9).Atpresent,ithasnotbeendeterminedwhetherthethreetranscriptsthathybridizetomacPiinnormalLMCRNAarederivedfromthesameorhomologousgenes.Sequenceanalysisofthe300-bpmacPicDNAclone,aswellasa2.5-kbcDNAfromthisgene,hasrevealednosignificantsequencehomologytosequencesintheGenBankdatabase.DiscussionInthisreport,wedescribetheuseofsubtractivehybridiza-tiontoidentifymRNAdifferencesbetweenapopulationofnormalleptomeningealcellsandameningiomacellline.ItwasexpectedthatcDNAclonesisolatedinthisstudycouldbeclassifiedintoatleastoneofthefollowingcategories:(a)clonesrepresentinggenesinwhichthealterationinexpres-sionisaccompaniedbygenomicmutation;(b)geneswhoseexpressionislostduetotheinitiallossoffunctionofthemslgeneproduct;and(c)geneswhoseexpressionislostinme-ningiomasduetoachangeindifferentiationstateinthesetumorsrelativetonormalLMC.Thefirstclassofgenesin-cludescandidatetumorsuppressorgenes;theunderstandingofthefunctionandcharacteristicsofthelattertwoclassesofgeneswillbecriticaltowardtheunderstandingofthefunc-tionofthenormalms/geneandmayfurtherelucidatesomeaspectsofthebiologyofmeningiomas.Forexample,theexistenceofahormonalinfluenceontheclinicalcourseofmeningiomashaslongbeenacknowl-edged.Thesetumors,whicharemorefrequentinwomen,haveoftenbeenfoundtobecomeclinicallysymptomaticfollowingpregnancyormenstruation(1).Furthermore,theoccurrenceofmeningiomashasbeenfoundtobestatisti-callyassociatedwiththeincidenceofbreastcarcinomainwomen(26-28).Thebasisfortheseassociationsisincom-pletelyunderstood,however;numerousstudieshavefailedtofindconclusiveevidenceinmeningiomasforthewide-spreadpresenceoffunctionalreceptorsforeitherestrogenorprogesterone,althoughthepresenceofandrogenreceptorshasbeenreported(33,34).Wehavefoundthatthemac25genehasthepotentialtoencodeaproteinwithhomologytoafamilyofgrowthfactor-bindingproteinsandisalteredinexpressioninbothmeningiomasandbreastcarcinomas.Furthermore,theexpressionofmac25isinverselycorrelatedinbreastcarcinomaswiththepresenceofmRNAfortheestrogenreceptor.Additionalstudiesonthenormalfunctionofthemac25genemayhelpelucidateboththenatureofthe720GenesDifferentiallyExpressedinMeningiomashormonalcomponenttomeningiomagrowthaswellastheclinicalassociationbetweenthesetumortypes.Thusfar,wehavefoundnoevidenceforgrossgenomicalterationofeitherthemac25ormac30genesinanyofourmeningiomatumorsorcelllines,indicatingthatthede-creasedexpressionofthesegenesmaybecausedbyapo-tentiallossofdifferentiationstateinthesetumorsorthatthelowexpressionstatusofthesegenesmaybeamarkerforaparticularcelltypeintheleptomeningesthatispredisposedtotumorformation.Alternatively,thedecreasedexpressionofthesegenesmayresultfromtheinactivationofan“up-stream”tumorsuppressorgene.Ourfindingthatthemac30genedemonstratesmarkedlyreducedexpressioninbothmeningiomasandothertumorsassociatedwiththedisorderNF-2raisesthepossibilitythattheupstreamgeneinfluencingmac30geneexpressionmaybethemeningiomasuscepti-bilitylocus,assumingthatthesetwodisordersarecausedbyinactivationofthesametumorsuppressorgene;thishypoth-esisobviouslyawaitsthecloningofthemslgene.Wewerequitesurprisedtofindthemac30genesimilarlydecreasedinexpressioninSchwanncelltumorsassociatedwithNF-1;thedecreasedexpressionofthisgeneinthesetumorsalone,butnotinculturesofratSchwanncells,suggeststhatme-ningiomasandSchwanncelltumorsmayshareacommonpathwayoftransformationthatinvolvesornecessitatesthedecreasedexpressionofmac30.Todate,wehavenotyetdeterminedthenatureofthesizealterationsinthemacPigeneinourmeningiomas.Althoughitispossiblethatthisgenehassufferedmutationsthataffecttranscriptsizeinthesetumors,itisalsopossiblethatthisgeneissubjecttoextensivealternativesplicinginthesecells.Inthelatterevent,itmightbeexpectedthatdifferentspliceformsofthisgenecouldbecorrelatedwithphenotypicvan-ables,suchasmeningiomasubtype,makingthisgeneusefulasaphenotypicmarkerinclinicalstudies.Additionally,ourfindingthatthemajortranscriptforthemacPigeneislikelytobelimitedinexpressiontoleptomeningealcellsfacilitatesitsuseasamarkerspecificformeningiomas.Ourunderlyinghypothesisforthisstudywasthatgenesfoundtobeconsistentlydown-regulatedorotherwisealteredinexpressioninmeningiomasrelativetotheirpre-cursorcelltypewouldbecandidatesforgenesintimatelyinvolvedwithmechanismsofgrowthcontrolanddifferen-tiation.Thishypothesisisvalidatedbyourfindingthattwoofthegenesidentifiedinthisstudyhavebeenfoundtobealteredinexpressioninothertumortypesaswell.Furthercharacterizationofthesethreegenes,aswellasidentifica-tionandcharacterizationofothersuchaberrantlyexpressedgenes,willundoubtedlyleadtoabetterunderstandingofthetransformationpathwayutilizedbythesecommontumors.MaterialsandMethodsCellLinesandCellCulture.Normalhumanleptomeningealcellswereestablished,characterized,andmaintainedasde-scnibed(35).TheLTAg2Blineofimmortalizedleptomenin-gealcellswasestablishedfromprimaryculturesbytrans-fectionwithanSV4OlargeTantigenexpressionconstruct,asdetailed(35).MeningiomacelllinesT2898,T2966,T2896,T2921,T2891,andT2888wereestablishedandcharacterizedbyoneofus(K.D.Z.);thesecellsweregrowninDulbecco’smodifiedEagle’smediumsupplementedwith15%fetalbovineserumand100units/mIofpenicillinandstreptomycin.ThecelllineC4+ZnisanimmortalizedratperipheralSchwanncelllinekindlyprovidedbyGeorgeDeVnies(MedicalCollegeofVirginia)andwasculturedasdescribed(36).ThecelllineTu-87,fromarhabdoidtumorofthebrain,waskindlyprovidedbyKuangLinYing(Chil-drensHospitalofLosAngeles)andwasculturedasdescribed(37).BreastcarcinomastudiesutilizedATCCcelllinesHs578Bst(normalhumanbreast),Hs578T,andBT-483,main-tamedinDulbecco’smodifiedEagle’smedium;ZR-75-1,ZR-75-30,andT-47D,maintainedinRPMI1060;andMDA-MB-157,MDA-MB-231,andMDA-MB-453,maintainedinLiebovitz’sL-15medium;allmediaweresupplementedwith10%fetalbovineserumandantibiotics.Othercelllinesex-aminedforexpressionofcertaingenesincludedATCCcelllinesRD-ES,HeLa,Colo32ODM,K-562,Sk-mel-2,andU-373Mg;theselineswereculturedaccordingtoATCCguidelines.RNAIsolationandNorthernandSouthernBlots.TotalcellularRNAwasisolatedfromexponentiallygrowingtissueculturecellswithguanidinehydrochloride,asdescribed(38),andpoly(A)(cid:1)RNAwaspreparedusingPoly(A)Quickcolumns,accordingtothemanufacturer’sinstructions(Stratagene).Snap-frozenmeningiomas,normalleptomen-ingealtissue,vestibularschwannomas(acousticneuromas),peripheralneurofibromas,andaspinalschwannomawereprovidedbytheCooperativeHumanTissueNetwork,partoftheNationalDiseaseResearchInterchange.AdditionalNF-2tumorswerekindlyprovidedbyVincentRiccardi(NFInsti-tute);neuroblastomatumorswerekindlyprovidedbyRogerKennett(UniversityofPennsylvania).RNAfromtumorsampleswasisolatedwithRNAzol,accordingtorecommen-dationsmadebythesupplier(Cinna-Biotecx),exceptthatfrozentumortissuewasthinlyslicedwithasterilescalpeljustpriortohomogenization.Insomecases,theseRNAsamplesweretreatedwithRNase-freeDNaseI(Pharmacia)toeliminatecontaminatinggenomicDNA,usingprotocolsderivedfromthesupplier.NorthernandSouthernblotswerepreparedaccordingtopreviouslypublishedprotocols(39,40),modifiedslightlytoincludehybridizationofnitrocel-lulosefiltersinthepresenceofhepanin(41).cDNAfragmentsusedasprobesonNorthernandSouthernblotswerelabeledusingrandomoligonucleotides(42).Probesusedinthesestudiesconsistedofeitherthefull-length1.1-kbmac25cDNA,orbases146-567ofthe2.0-kbmac30cDNA,orthefull-length300-bpmacPicDNA.RNAfilterswerewashedin0.3XSSC(0.045MNaCl-0.0045Msodiumcitrate)-0.1%SDSat55#{176}C.ChromosomalmappingstudiesutilizedDNAfromtheNationalInstituteofGeneralMedicalScienceshuman/rodentsomaticcellhybridmappingpanelno.1(Co-nellInstituteforMedicalResearch),alongwithDNAfromthechromosomehybridVII-2HAT,whichcontainsasinglehumantranslocationchromosomecontainingsequencesfrom17q21-qter(32).DNAblotswerewashedin0.1XSSC-0.1%SDSat65#{176}C.cDNALibraryConstrudionandSubtradionLibraryConstrudion.cDNAlibrariesweregeneratedintheplas-midvectorpcDNAII(Invitrogen)frompoly(A)RNAfromprimaryculturesofleptomeningealcellsandthemenin-giomacelllineT2898,accordingtostandardprotocols(38).TheselibrarieswererandomlyandoligodTprimedandweresizeselectedabove100bp.Single-strandedcDNAwasiso-latedfromtheselibrariesusingtheM13rescuetechnique(43)withthephageR408usingprotocolsfromthepcDNAIImanufacturer,withthefollowingmodifications:200p1ofeachunamplifiedcDNAlibrarywereusedtoinoculate20mlofLBbroth-50mg/mIampicillin-10mivimagnesiumsul-fateandincubatedwithshakingtoanabsorbanceofa600=0.3.Thiswasinoculatedwith1X1Oilplaque-formingunitsCellGrowth&Differentiation721ofR408helperphageandincubatedwithshakingat37#{176}Cfor30mm.Then80mlofLB-ampicillin-10msamagnesiumsulfatewereadded,andthiswasincubatedwithshakingfor6-9h.Allmanipulationsofsingle-strandedDNAwerecar-nedoutusingsiliconizedplasticware(Sigma).Double-strandedDNAwasremovedfromsingle-strandedpreparationsusingamagnesium-phenolextractionandre-stnictionendonucleasedigestionprotocol,asdescribed(44).Biotinylationofsingle-strandedDNAfromthetumorlibraryusingphotobiotinacetate(Sigma),andremovalofexcessbiotin,wasperformedasdetailed(44).Tomakethesub-tractionlibraries,2pgofLMCsingle-strandedcDNAwereaddedto60pgofbiotinylatedT2898tumorcDNA,alongwith250ngofabiotinylated350-bppieceofDNAthatispresentasaninsertonlyinnonrecombinantformsofthevectorpcDNAII(Invitrogen).TheseDNAswereethanolpre-cipitatedtogether,resuspendedin5(cid:1)ilofdH2O,andaddedto5p1of2Xhybridizationsolution[1MNaCI-100mtvi4-(2-hydroxyethyl)-1-piperazineethanesulfonicacid,pH7.6-4mMEDTA-80%deionizedformamide(44)];thissolutionwasheatedto100#{176}Cfor3mm,snapcooled,andincubatedat52#{176}Cforover24h.Subtractionofhybridizedandexcessbiotinylatedsequenceswasperformedexactlyasdescribed(45),exceptthat100pgofyeasttRNA(GIBCO/BRL)wereusedascarriertoaidprecipitationinethanol.PrecipitatedcDNA,enrichedforLMC-specificsequences,waseitherin-cubatedwithT7promoterprimerandKlenowpolymerase(Pharmacia)togeneratedouble-strandedDNAandusedtotransformcompetentDH5aF’cells(GIBCO/BRL)togenerateaplasmidsubtractionlibrary(38),orwasamplifiedbyPCRforuseingeneratingaphagesubtractionlibrary.ThephagesubtractionlibrarywasgeneratedbyPCRam-plificationofnonsubtractedsequenceswithprimersspecificfortheSp6andT7promotersofthepcDNAIIvector.PCRwascarriedoutina1OO-plreactionthatwas25ms(cid:1)Tnis-HCI,pH9.5,50mMpotassiumchloride,10mivimagnesiumchlo-ride,0.2mMeachdCTP,dATP,dTTP,anddGTP,5ng4ileachprimer,and3unitsofHotTubpolymerase(Amersham),usingthefollowingprogram:94#{176}Cfor60s,40#{176}Cfor60s,and72#{176}Cfor120sfor35cycles,followedby5mmat72#{176}C.Amplifiedsequenceswereextractedwithphenol-chloroform(1:1),digestedwithXmaIIltoremovevectorse-quences,asrecommended(NewEnglandBiolabs),andbluntendedwithKlenowpolymerase(38).EcoRladaptors(Stratagene)wereligatedtorecoveredcDNA(38);unligatedadaptorswereeliminatedafterseparationona1%agarosegel(SeakemFMC).ThiscDNAwasisolatedfromaganoseusingagelextractionsystem(Qiagen)andresubtractedwith60(cid:1)igofbiotinylatedtumorcDNAexactlyasoutlinedabove.DoublysubtractedcDNAwasamplifiedbyPCRasabovewiththeEcoRladaptor-specificoligo5’-CGCTACGAAT-TCGGCACGAG-3’usingthefollowingprogram:94#{176}Cfor60s,32#{176}Cfor60s,and72#{176}Cfor120sfor15cycles,followedby94#{176}Cfor605,60#{176}Cfor60s,72#{176}Cfor120sfor25cycles,and5mmat72#{176}C.ThisPCRproductwasdigestedwithEcoRIasrecommended(NewEnglandBiolabs)andusedtogenerateaphagesubtractionlibraryinLambdaZapII(Strata-gene)followingprotocolsfurnishedbythesupplier.SubtnadioncDNALibraryScreening.DuplicateliftsofthephagesubtractionlibraryweredifferentiallyscreenedusingradiolabeledcDNAfromLTAg2BorT2898cellsthatwasgeneratedasdescribed(46),exceptthat7(cid:1)ilofrandomhexamers(Pharmacia;90a260units/mI)and3.0(cid:1)igofoligo-dT(Phanmacia)wereusedtoprimereversetranscnip-tion,and500pCiof[32P]dCTPwereadded(Amersham;>3000Ci/mmol).Duplicatefilterswerehybridizedat5x106cpm/mlofhybridizationsolution,washedat55#{176}Cin0.3XSSC-0.1%SDS,andexposedtoKodakXAR-5filmfor12-36h.Subtractedprobes,usedtoscreentheplasmidT2898sub-tractionlibrary,weregeneratedbyhybridizingradiolabeledcDNAfromLTAg2Bcellstoa5-foldexcessofpoly(A)(cid:1)RNAfromtheT2966celllineandsubtractingasoutlinedabove.Aftersubtraction,precipitatedcDNAwastreatedat45#{176}Cfor20mmwith0.5NNaOH,reprecipitatedwithethanol,anduseddirectlyasaprobe.Filterswerehybridizedat>1x10(cid:1)cpm/ml,washedat55#{176}Cin0.3xSSC-0.1%SDS,andtreatedwithaProteinaseKsolutiontoreducebackgroundhybrid-ization(47);thesefilterswereexposedonKodakXAR-5filmfor21days.ReverseTranscniption-PolymeraseChainReadion.FivepgoftotalRNAwerereversetranscribedwithmunineMoloneyleukemiavirusreversetranscniptaseusingcondi-tionsrecommendedbythesupplier(GIBCO/BRL)ina30-(cid:1)jIreaction,using4uIof90a26(cid:1)Jmlrandomhexamers(Phar-macia)asprimers.Onep1ofthisreactionwasusedina1OO-plPCRreaction.PCRwasperformedasdescribedaboveusingthefollowingprogram:94#{176}Cfor60s,60#{176}Cfor60s,and72#{176}Cfor60sfor20cycles,followedby72#{176}Cfor10mm.Sampleswereextractedwithphenol-chloroform(1:1)andethanolprecipitatedbeforeelectrophoresison1%agarose;formac30,thesegelswereblottedovernightandhybridizedasdescribed(40).Primersformac3Owere5’-GCTGCGTGAAGTGGCTGCTGGGCCT-3’(sense)and5’-TAGGGGCTCCGCAACATGAAA-3’(antisense).Primersforactinwere5’-CTACAATGAGCTGCGTGTGGC-3’(sense)and5‘-CAGGTCCAGACGCAGGATGGC-3’(antisense).Primersforthehumanestrogenreceptor,kindlyprovidedbyC.RichardLyttle(UniversityofPennsylvania),were5’-GGAGACATGAGAGCTGCCAAC-3’(sense)and5’-CCAG-CAGCATGTCGAAGATC-3’(antisense).AllreactionsweremonitoredforcontaminationwithgenomicDNAbyinclu-sionofacontrolincubatedwithoutreversetranscniptase.cDNALibraryScreeningandSequenceAnalysisofcDNA.cDNAlibrariesscreenedforlargercDNAclonesin-cludedaskinfibroblastcDNAlibrary(Stratagene)andaHeLacDNAlibrary(courtesyofThomasKadesch,UniversityofPennsylvania).DNAsequencingwasperformedusingthedideoxychainterminationmethodofSangeretal.(48),withSequenaseenzyme(U.S.Biochemical).SequenceanalysesanddatabasesearcheswereperformedusingtheWisconsinGCGprogram(49).NucleotideSequenceAccessionNumbers.Nucleotidesequencedataforthe1.1-kbmac25cDNAandthe2.0-kbmac30cDNAweresubmittedtotheGenBankdatabaseandassignedtheaccessionnumbersLi9182andLi9183,re-spectively.AcknowledgmentsTheauthorswishtothankVincentRiccardiforsupportandfortumorsamplesandJohnLandersandDaleHainesforcriticalreadingofthemanuscript.References1.Russell,D.S.,andRubenstein,L.J.PathologyofTumorsoftheNervousSystem,pp.449-532.Baltimore:Williams&Wilkins,1989.2.Scheithauer,B.W.Tumorsofthemeninges:proposedmodificationsoftheWorldHealthOrganizationclassifications.ActaNeuropathol.,80:343-354,1990.3.Martuza,R.L.,andEldridge,R.Medicalprogress:neurofibromatosis2.N.EngI.J.Med.,318:684-688,1988.722GenesDifferentiallyExpressedinMeningiomas4.Zankl,H.,andZang,K.D.Cytologicalandcytogeneticalstudiesonbraintumors.IV.IdentificationofthemissingGchromosomeinhumanmenin-giomasasnumber22byfluorescencetechnique.Hum.Genet.,14:167-169,1972.5.Zang,K.D.Cytologicalandcytogeneticalstudiesonhumanmeningioma.CancerGenet.Cytogenet.,6:249-274,1982.6.Meese,E.,Blin,N.,andZang,K.D.Lossofheterozygosityandtheoriginofmeningioma.Hum.Genet.,77:349-351,1987.7.Seizinger,B.R.,deIaMonte,S.,Atkins,L.,Gusella,J.F.,andMartuza,R.L.Molecular-geneticapproachtohumanmeningioma:lossofgenesonchromosome22.Proc.NatI.Acad.Sci.USA,84:5419-5423,1987.8.Zankl,H.,andZang,K.D.Correlationsbetweenclinicalandcytogeneticaldatain180meningiomas.CancerGenet.Cytogenet.,1:351-356,1980.9.Dumanski,J.P.,Carlbom,E.,Collins,V.P.,andNordenskjold,M.Deletionmappingofalocusonhumanchromosome22involvedintheoncogenesisofmeningioma.Proc.NatI.Acad.Sci.USA,84:9275-9279,1987.10.Herzog,R.,Gottert,E.,Henn,W.,Zang,K.,Blin,N.,Trent,j.,andMeese,E.Large-scalephysicalmappingwithintheregion22q12.3-13.1inmenin-gioma.Genomics,10:1041-1046,1991.11.LeKanne-Deprez,R.H.,Green,N.A.,vonBiezen,N.A.,Hagemeijer,A.,vanDrune,E.,Koper,j.W.,Avezaat,C.J.J.,Bootsma,D.,andZwarthoff,E.C.At(4;22)inameningiomapointstothelocalizationofaputativetumor-suppressorgene.Am.I.Hum.Genet.,48:783-790,1991.12.Rouleau,G.A.,Wertelecki,W.,Haines,J.L.,Hobbs,W.J.,Trofatter,J.A.,Seizinger,B.R.,Martuza,R.L.,Superneau,D.W.,Conneally,P.M.,andGusella,J.F.GeneticlinkageofbilateralacousticneurofibromatosistoaDNAmarkeronchromosome22.Nature(Lond.),329:246-248,1987.13.Wertelecki,W.,Rouleau,G.,Superneau,D.W.,Forehad,L.W.,Willi-ams,J.P.,Haines,J.L.,andGusella,J.F.Neurofibromatosis2:clinicalandDNAlinkagestudiesofalargekindred.N.Engl.j.Med.,319:278-283,1988.14.Seizinger,B.R.,Martuza,R.L.,andGusella,j.F.Lossofgenesonchro-mosome22intumorigenesisofhumanacousticneuroma.Nature(Lond.),322:644-647,1986.15.Seizinger,B.R.,Rouleau,G.,Ozelius,L.J.,Lane,A.H.,St.George-Hyslop,P.,Huson,S.,Gusella,j.F.,andMartuza,R.L.Commonpathogeneticmechanismforthreetumortypesinbilateralacousticneurofibromatosis.Sci-ence(WashingtonDC),236:317-319,1987.16.Dumanski,J.P.,Rouleau,G.A.,Nordenskjold,M.,andCollins,V.P.Moleculargeneticanalysisofchromosome22in81casesofmeningioma.CancerRes.,50:5863-5867,1990.17.Maltby,E.L.,Ironside,J.W.,andBattersby,R.D.E.Cytogeneticstudiesin50meningiomas.CancerGenet.Cytogenet.,31:199-210,1988.18.Rey,j.A.,Bello,M.j.,deCampos,J.M.,Kusak,M.E.,andMoreno,S.Chromosomalinvolvementsecondaryto-22inhumanmeningiomas.Can-cerGenet.Cytogenet.,33:275-290,1988.19.Rey,I.A.,Bello,M.J.,deCampos,J.M.,andKusak,M.E.Incidenceandoriginofdicentricchromosomesinculturedmeningiomas.CancerGenet.Cytogenet.,35:55-60,1988.20.Bowes,C.,Danciger,M.,Kozak,C.A.,andFarber,D.B.IsolationofacandidatecDNAforthegenecausingretinaldegenerationintherdmouse.Proc.NatI.Acad.Sci.USA,86:9722-9726,1989.21.Travis,G.H.,Brennan,M.B.,Danielson,P.E.,Kozak,C.A.,andSutcliffe,I.G.Identificationofaphotoreceptor-specificmRNAencodedbythegeneresponsibleforretinaldegenerationslow(rds).Nature(Lond.),338:70-73,1989.22.Shtivelman,E.,andBishop,j.M.ExpressionofCD44isrepressedinneuroblastomacells.Mol.Cell.Biol.,11:5446-5453,1991.23.Lee,S.W.,Tomasetto,C.,andSager,R.Positiveselectionofcandidatetumor-suppressorgenesbysubtractivehybridization.Proc.NatI.Acad.Sci.USA,88:2825-2829,1991.24.Schweinfest,C.,Henderson,K.W.,Gu,J-R.,Kottaridis,S.,Besbaes,S.,Panotopoulous,E.,andPapas,I.S.SubtractivehybridizationcDNAlibrariesfromcoloncarcinomaandhepaticcancer.GeneAnal.Tech.,7:64-70,1990.25.Wieland,I.,Bohm,M.,andBogatz,S.IsolationofDNAsequencesde-letedinlungcancerbygenomicdifferencecloning.Proc.NatI.Acad.Sci.USA,89:9705-9709,1992.26.Schoenberg,B.S.,Christine,B.W.,andWhisnant,J.P.Nervoussystemneoplasmsandprimarymalignanciesofothersites:theuniqueassociationbetweenmeningiomasandbreastcancer.Neurology,25:705-712,1975.27.Burns,P.E.,jha,N.,andBain,G.0.Associationofbreastcancerwithmeningioma:areportoffivecases.Cancer(Phila.),58:1537-1539,1986.28.Knuckey,N.W.,Stoll,j.,andEpstein,M.H.Intracranialandspinalme-ningiomasinpatientswithbreastcarcinoma:casereports.Neurosurgery,25:112-117,1989.29.Price,j.E.Thebiologyofmetastaticbreastcancer.Cancer(Phila.),66:1313-1320,1990.30.Ooi,G.I.Insulin-likegrowthfactor-bindingproteins(IGFBPs):morethanjust1,2,3.Mol.Cell.Endocrinol.,71:C39-C43,1990.31.Riccardi,V.M.,andEichner,J.E.Neurofibromatosis:Phenotype,HistoryandPathogenesis.Baltimore:JohnsHopkinsUniversityPress,1986.32.George,D.L.,Phillips,J.A.,Francke,U.,andSeeburg,P.H.Thegenesforgrowthhormoneandchorionicsomatomammotropinareonthelongarmofchromosome17inregionq21-qter.Hum.Genet.,57:138-141,1981.33.Schrell,W.M.H.,Adams,E.F.,Fahlbusch,R.,Greb,R.,Jirikowski,G.,Prior,R.,andRamalho-Ortiago,J.Hormonaldependencyofcerebralme-ningiomas.Part1.Femalesexsteroidreceptorsandtheirsignificanceasspe-cificmarkersforadjuvantmedicaltherapy.J.Neurosurg.,73:743-749,1990.34.Adams,E.F.,Schrell,W.M.H.,Fahlbusch,R.,andThierauf,P.Hormonaldependencyofcerebralmeningiomas.Part2.Invitroeffectofsteroids,bro-mocriptine,andepidermalgrowthfactorongrowthofmeningiomas.J.Neu-rosurg.,73:750-755,1990.35.Murphy,M.,Chen,J-N.,andGeorge,D.L.Establishmentandcharac-terizationofahumanleptomeningealcellline.J.Neurosci.Res.,30:475-483,1991.36.Tennekoon,G.I.,Yoshino,J.,Peden,K.W.C.,Bogbee,j.,Rutkowski,J.L.,Kishimoto,Y.,DeVries,G.H.,andMcKhann,G.M.Transfectionofneo-natalratSchwanncellswithSV-40largeTantigengeneundercontrolofthemetallothioneinpromoter.J.CellBiol.,105:2315-2325,1987.37.Karnes,P.5.,Iran,I.N.,Ho,H.Y.,Boquiren,D.I.,Cui,M.Y.,Weissman,B.E.,Bogenmann,E.,lsaacs,H.,Shimada,H.,Barranger,J.A.,andYing,K.L.Theestablishmentofamalignantrhabdoidtumorcelllinewithaspecificchromosomaltranslocation,t(11p;22q).CancerGenet.Cytogenet.,41:B17,1989.38.Sambrook,J.,Fritsch,E.F.,andManiatis,T.MolecularCloning:ALabo-ratoryManual,2nded.NewYork:ColdSpringHarborPress,1989.39.George,D.L.,Scott,A.F.,Trusko,S.,Glick,B.,Ford,E.,andDorney,D.J.StructureandexpressionofamplifiedcKi-rasgenesequencesinYlmouseadrenaltumorcells.EMBOJ.,4:1199-1203,1985.40.George,D.L.,andPowers,V.E.CloningofDNAfromdoubleminutesofYlmouseadrenocorticaltumorcells:evidenceforgeneamplification.Cell,24:117-123,1981.41.Singh,L.,andJones,K.W.Theuseofheparinasasimple,cost-effectivemeansofcontrollingbackgroundinnucleicacidhybridizationprocedures.NucleicAcidsRes.,12:5627-5638,1984.42.Feinberg,A.P.,andVogelstein,B.AtechniqueforradiolabelingDNArestrictionendonucleasefragmentstohighspecificactivity.Anal.Biochem.,132:6-13,1983.43.Vieira,J.,andMessing,J.Preparationofsingle-strandedplasmidDNA.MethodsEnzymol.,153:3-11,1987.44.Rubenstein,J.L.R.,Brice,A.E.,Ciaranello,R.D.,Denney,D.,Porteus,M.H.,andUsdin,I.B.Subtractivehybridizationsystemusingsingle-strandedphagemidswithdirectionalinserts.NucleicAcidsRes.,18:4833-4842,1990.45.Sive,H.L.,andSt.John,I.Asimplesubtractivehybridizationtechniqueemployingphotoactivatiblebiotinandphenolextraction.NucleicAcidsRes.,16:10937,1988.46.Kriegler,M.GeneTransferandExpression:ALaboratoryManual,pp.139-146.NewYork:StocktonPress,1990.47.Yancopoulos,G.D.,OItz,E.M.,Rathburn,G.,Berman,J.E.,Smith,R.K.,Lansford,R.D.,Rothman,P.,Okada,A.,Lee,G.,Morrow,M.,Kaplan,K.,Prockop,S.,andAlt,F.W.Isolationofcoordinately-regulatedgenesthatareexpressedindiscretestagesofB-celldevelopment.Proc.NatI.Acad.Sci.USA,87:5759-5763,1990.48.Sanger,F.,Nicklen,S.,andCoulsen,A.R.DNAsequencingwithchain-terminatinginhibitors.Proc.NatI.Acad.Sci.USA,74:5463-5467,1977.49.GeneticsComputerGroup.ProgramManualfortheGCGPackage,ver-sion7.WI:GeneticsComputerGroup,1991.ARTICLESNATURE CELL BIOLOGY  VOLUME 8 | NUMBER 1 | JANUARY 2006 27    The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosisFisun Hamaratoglu1,2, Maria Willecke2,3, Madhuri Kango-Singh2, Riitta Nolo2, Eric Hyun1,2, Chunyao Tao2, Hamed Jafar-Nejad4 and Georg Halder1,2,5,6Merlin, the protein product of the Neurofibromatosis type-2 gene, acts as a tumour suppressor in mice and humans. Merlin is an adaptor protein with a FERM domain and it is thought to transduce a growth-regulatory signal. However, the pathway through which Merlin acts as a tumour suppressor is poorly understood. Merlin, and its function as a negative regulator of growth, is conserved in Drosophila, where it functions with Expanded, a related FERM domain protein. Here, we show that Drosophila Merlin and Expanded are components of the Hippo signalling pathway, an emerging tumour-suppressor pathway. We find that Merlin and Expanded, similar to other components of the Hippo pathway, are required for proliferation arrest and apoptosis in developing imaginal discs. Our genetic and biochemical data place Merlin and Expanded upstream of Hippo and identify a pathway through which they act as tumour-suppressor genes.During normal development, the number of cells in growing tissues is controlled by regulating the generation of new cells through cell prolif-eration and by apoptosis, which eliminates excess or damaged cells that may be harmful to the organism1,2. Deregulation of these processes can lead to tumour formation3. Recently, a novel tumour-suppressor pathway that coordinately regulates cell proliferation and apoptosis was identified via genetic studies in Drosophila4,5. It is composed of the serine/threonine kinases Hippo (Hpo) and Warts (Wts); the adaptor molecule Salvador (Sav); Mats (Mob as tumour suppressor), a regulator of Wts; and Yorkie (Yki), a transcriptional coactivator6–16. Mutations in Hpo, Sav, Wts, Mats or overexpression of Yki result in overgrown tissues containing excess cells. Extra cells in these mutants are generated by deregulated cell prolif-eration and resistance to apoptotic stimuli that normally eliminate excess cells. All five proteins are highly conserved between flies and vertebrates and, in both systems, Hpo acts upstream of Wts6–17. However, factors that act upstream of Hpo remain to be identified.Here, we identify two upstream components of the Hpo signalling pathway: the Neurofibromatosis type-2 (NF2) encoded protein Merlin (Mer), and a related protein Expanded (Ex). Mutations in the NF2 tumour-suppressor gene underlie neurofibromatosis type-2, a familial cancer syndrome that shows development of tumours in the central nerv-ous system18–20. Several lines of evidence further support the idea that Mer acts as a tumour-suppressor gene. For example, heterozygous Nf2 mutant mice spontaneously develop a wide range of highly metastatic tumours21; cultured Nf2-deficient cells fail to undergo contact-dependent growth arrest22, and Mer overexpression suppresses cell proliferation23,24. Mer is a member of the protein 4.1 superfamily of adaptor proteins18,19 and is thought to transduce a signal from membrane receptors to intrac-ellular downstream components20,24,25. However, although Mer has been shown to interact with several proteins, including PAK1, CD44, HRS, PIKE-L, NHE-RF and ERM, how Mer functions as a tumour-suppressor gene is poorly understood20,24–26. We further investigated the function of Mer as a growth suppressor in vivo, taking advantage of the genetic tools that are available in Drosophila.The growth-suppressing function of Mer is conserved in Drosophila, where it acts partially redundant with another FERM domain protein, Ex27–29. Mer and Ex colocalize to adherens junctions22,27,30, where they may transduce a growth-suppressing signal from an unknown recep-tor20,24,25. Null mutations in mer and ex are lethal in Drosophila29,31, but animals that are homozygous for hypomorphic mutations of either mer or ex survive and show slight overgrowth of adult structures, such as wings29–31. Mutations in mer and ex show dominant genetic interactions and clones that are doubly mutant for mer and ex have defects in growth control and differentiation27. However, the cellular basis for these phe-notypes and the pathway through which mer and ex act as tumour-sup-pressor genes are not known22,25,27.1Program in Developmental Biology, Baylor College of Medicine, Houston, TX 77030, USA. 2Department of Biochemistry and Molecular Biology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. 3Interfakultäres Institut für Zellbiologie, Abt. Genetik der Tiere, Universität Tübingen, 72076 Tübingen, Germany. 4Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA. 5Program in Genes and Development, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.6Correspondence should be addressed to G.H. (e-mail: ghalder@mdanderson.org)Received 27 October 2005; accepted 17 November 2005; published online: 11 December 2005; DOI: 10.1038/ncb1339print ncb1339.indd   27print ncb1339.indd   2713/12/05   3:31:47 pm13/12/05   3:31:47 pmNature  PublishingGroup ©200628 NATURE CELL BIOLOGY  VOLUME 8 | NUMBER 1 | JANUARY 2006ARTICLESRESULTSMutations in merlin and expanded cause tissue overgrowthTo define the functions of mer and ex in growth control and to identify the pathway downstream of Mer and Ex, we analysed the phenotypes of mer;ex double-mutant clones during development (see Methods). For this analysis, we used previously identified null alleles of mer and ex28,29, as well as new ex alleles that we isolated in a genetic screen (see Supplementary Information, Fig. S1). We found that clones of cells dou-bly mutant for mer and ex produced pronounced outgrowths in diverse adult structures, such as antennae, thorax, wings and legs (Fig. 1a–d; and data not shown). Therefore, mer and ex are general growth regulators that are required to restrict the size of adult structures.To determine the cause of the overgrowth phenotypes, we studied cell proliferation and apoptosis in tissues lacking Mer and Ex function. We focused our analysis on the developing eye, where defects in the regulation of cell proliferation and apoptosis are readily detectable32. The Drosophila eye develops from the eye imaginal disc, a single-cell-layered epithelial sheet that grows during the larval stages33. After photorecep-tor, cone and pigment cells are determined, extra cells are eliminated by apoptosis32, generating a perfect lattice of the different cell types, which can be visualized during the pupal stage (Fig. 1e). In mer;ex double-mutant cell clones, this pattern is disrupted and the retina contains a large excess of interommatidial pigment cells (Fig. 1f, f’). The size of mutant cells appeared normal, although the morphology of photorecep-tors and the numbers of cone cells were often abnormal. In contrast to double-mutant clones, mer or ex single-mutant retinae showed only a few extra interommatidial cells (Fig. 1g, h), further supporting that mer and ex can partially substitute for each other. Notably, the mer;ex dou-ble-mutant phenotypes are remarkably similar to those of hpo mutants (Fig. 1i)6,8–10, but are distinct from the phenotypes of mutations in other growth control genes, such as TSC1 (Tuberous Sclerosis Complex 1), which affects cell size (Fig. 1j, j’)34,35. Therefore, Mer and Ex, like Hpo, regulate the number of cells in epithelial tissues.Merlin and Expanded regulate cell-cycle arrest and Cyclin E transcriptionThe observation that mer;ex double-mutant retinae have more interom-matidial cells raised two questions: How are these extra cells generated and why are they not eliminated by apoptosis? First, we examined the effects of mer and ex on cell proliferation by monitoring bromodeoxyu-ridine (BrdU) incorporation, which marks cells in S-phase. During the third larval stage, a wave of differentiation — the morphogenetic fur-row — sweeps across the eye disc from posterior to anterior32,33. Cells anterior to the furrow are undifferentiated and divide asynchronously. dcbajj'hf'efimer;exwtwtmer;exwtTSC1TSC1hpoexmermer;exmer;exgFigure 1 merlin and expanded regulate tissue size. (a, b) Scanning electron micrographs (SEMs) of a wild-type (wt) fly head (a) and a head with mer4;exe1 double-mutant clones (b) in the antenna (arrow), resulting in massive tissue overgrowth. (c, d) SEM images of a wild-type thorax and a thorax with mer4;exe1 double-mutant clones (arrow). (e-j’) Mid-pupal retinae stained with anti-Discs large (Dlg) antibodies that localize to apicolateral junctions and visualize cell outlines. (e) Wild-type retina. (f, f’) Retina with a mer4;exe1 double-mutant clone marked by the absence of green fluorescent protein (GFP) expression (red in f). (f’) shows the Dlg staining only. The mutant area shows excess interommatidial cells. (g) mer4 and (h) exBQ mutants display few extra interommatial cells. (i) hpo42–47 and (j, j’) TSC1IQ69 mutant retinae. Absence of GFP (red) marks the mutant clone in (j) and (j’) shows Dlg only. The phenotype of mer4;exe1 double-mutant tissues is similar to hpo42–47 but distinct from TSC1IQ69 mutants. Scale bar (j’), 20 µm.print ncb1339.indd   28print ncb1339.indd   2813/12/05   3:31:52 pm13/12/05   3:31:52 pmNature  PublishingGroup ©2006NATURE CELL BIOLOGY  VOLUME 8 | NUMBER 1 | JANUARY 2006 29   ARTICLESBehind the furrow, cells either differentiate into photoreceptor cells or undergo one additional round of cell division — referred to as the second mitotic wave — before they differentiate into the remaining photorecep-tor, cone, pigment and bristle cells32,33. mer;ex mutant cells properly syn-chronized their cell cycles in the furrow (Fig. 2a’, asterisk) and progressed through the second mitotic wave (Fig. 2a’, arrow). In contrast to wild-type cells, however, cells in mer;ex mutant clones displayed ectopic BrdU incorporation after the second mitotic wave (Fig. 2a–a’’, arrowhead). This ectopic DNA synthesis is followed by cell division, as seen by ectopic phosphorylated histone H3 expression, which marks mitotic chromo-somes (not shown). Mutant cells, therefore, failed to arrest the cell cycle after the second mitotic wave and instead continued to proliferate. Cyclin E is a limiting factor for S-phase entry in imaginal-disc cells36, and we found that it was upregulated in mer;ex double-mutant cells (Fig. 2b–b’’). This regulation was at the level of transcription, as shown by elevated expression of a Cyclin E reporter gene37 (Fig. 2c–c’’). The repression of Cyclin E expression is probably an important downstream effect of Mer and Ex that regulates cell proliferation. We conclude that Mer and Ex are required for proper cell-proliferation arrest.Merlin and Expanded regulate apoptosisAlthough the defects in proliferation arrest generate extra cells, this is not sufficient to explain the overgrowth phenotype that is seen in mer;ex mutant tissues. This is because developing tissues compensate by elimi-nating extra cells by apoptosis. We therefore addressed why the extra interommatidial cells in mer;ex double-mutant retinae survived, whereas extra cells are eliminated by apoptosis in wild-type retinae32. We found that loss of Mer and Ex function suppressed the wave of apoptosis that normally eliminates extra interommatidial cells during the pupal stage (Fig. 3a, a’). We then tested whether Mer and Ex regulate the expression of the anti-apoptotic gene Drosophila Inhibitor of Apoptosis Protein-1 (diap1)38, a target of Hpo signalling6–12,15. Indeed, mer;ex mutant clones had higher levels of DIAP1 protein (Fig. 3b–b’) and cells autonomously upregulated the expression of a lacZ enhancer trap39 insertion in the diap1 gene (Fig. 3c–d’), indicating that this upregulation was at the level of diap1 transcription. This extra DIAP1 may protect cells from apop-tosis that is induced during development. We conclude that Mer and Ex are required for developmentally induced apoptosis that normally eliminates extra cells. The combination of the defects in cell-cycle exit and apoptosis observed in mer;ex clones generates extra cells that then evade apoptosis and produce overgrowths in the adult.Merlin and Expanded act genetically upstream of HippoThe phenotypes of mer;ex double-mutant tissues are strikingly similar to those of mutations in hpo, sav and wts. Mutations in all of these genes cause extra interommatidial cells, ectopic BrdU incorporation posterior to the morphogenetic furrow and cell-autonomous elevation of Cyclin E and DIAP1 expression within mutant cells. This combination of phe-notypes is not observed for mutations in other known growth control genes, and therefore suggests that Mer and Ex interact with Hpo signal-ling. In addition, we found that the loss of one copy of wts enhanced the imaginal-disc overgrowth phenotypes of hypomorphic mutations in ex (see Supplementary Information, Fig. S2a–d), and that loss of one copy of ex enhanced the larval lethality caused by hypomorphic wts mutations (see Supplementary Information, Fig. S2e). Based on these observations, we hypothesized that Mer and Ex act in Hpo signalling. In the next set of experiments, we tested this hypothesis using overexpression of Ex and Hpo in different mutant backgrounds. We focused on the overexpres-sion of Ex and Hpo because ectopic Mer, Wts or Sav cause only weak phenotypes11 (and data not shown).We and others previously reported that overexpression of Hpo hyper-activates Hpo signalling and causes a reduction in cell proliferation and induces apoptosis, phenotypes that are opposite to those of its loss-of function phenotypes (Fig. 4a, a’, f, f’)6–8,10. Similarly, overexpression of Ex during eye development induced apoptosis, reduced cell proliferation and severely disrupted eye development (Fig. 4b, b’)30,31. These effects are not caused only by induction of apoptosis, because the phenotypes of ectopic Ex or Hpo are not completely rescued when we inhibited apop-tosis by coexpression of the caspase inhibitor p35 or DIAP1 (Fig. 4a–c, a’–c’; and data not shown)8,31. Although coexpression of p35 with Ex gave only a partial rescue, loss of Hpo function reversed the ectopic Ex cbaa''a'b''b'c''c'*GFP**CycE*BrdUGFPCycE-ZGFPBrdUGFPCycEGFPGFPCycE-ZFigure 2 merlin and expanded regulate cell-cycle arrest and the expression of Cyclin E. All panels show third instar eye imaginal discs containing mer–;ex– double-mutant clones marked by the absence of green fluorescent protein (GFP) expression (green in a, b, c, and grayscale in a’’, b’’, c’’). The disc in (a-a’’) is labelled for bromodeoxyuridine (BrdU) incorporation (red in a, grayscale in a’). Wild-type cells arrest in G1 in the morphogenetic furrow (asterisk) and non-differentiating cells go through one synchronous S phase in the second mitotic wave (arrows). mer4;exe1 mutant cell clones show ectopic cell proliferation posterior to the second mitotic wave (arrowheads). (b-b’’) mer4;exe1 mutant cells have increased levels of Cyclin E (CycE) protein (red in b, grayscale in b’) both anterior and posterior to the morphogenetic furrow (asterisk). (c-c’’) mer4;exAP50 mutant cells have elevated levels of lacZ expression from the 16.4 lacZ Cyclin E reporter construct (CycE-Z)37 (red in c, grayscale in c’). Anterior is to the left for all discs. All alleles shown are null alleles. Scale bar (c’’), 50 µm.print ncb1339.indd   29print ncb1339.indd   2913/12/05   3:31:56 pm13/12/05   3:31:56 pmNature  PublishingGroup ©200630 NATURE CELL BIOLOGY  VOLUME 8 | NUMBER 1 | JANUARY 2006ARTICLESphenotypes. Therefore, the loss of Hpo function reversed the loss of interommatidial cells, the disruption of ommatidial morphology and the reduction in eye size caused by overexpressed Ex. As a result, hpo mutant eyes that overexpressed Ex showed the same phenotype as hpo mutant eyes (Fig. 4d, d’, e, e’). Therefore, Ex requires Hpo for its function. On the other hand, the phenotypes caused by Hpo overexpression were not sup-pressed by loss of ex or in mer;ex double-mutant clones (Fig. 4f, f’, g, g’, k, k’). Together, these results indicate that Hpo acts downstream of Ex.In support of this model, the effects of both overexpressed Ex and overexpressed Hpo were suppressed by loss of wts, which is known to act downstream of Hpo6,8,10,17 (Fig. 4i–j’, l, l’). Furthermore, loss of one copy of the wts gene partially suppressed the phenotypes of ectopic Ex, further indicating that Wts acts downstream of Ex and that Wts is required for the effects of Ex (Fig. 5a–c, a’–c’).In addition to the defects in morphology and interommatidial cell number caused by the overexpression of Ex and Hpo, we used the induc-tion of apoptosis in third instar eye discs as a readout. Overexpression of Ex or Hpo posterior to the morphogenetic furrow induced a stripe of dying cells. The cell death induced by overexpressed Ex was suppressed in hpo or wts mutant clones, but loss of mer and ex had no effect on Hpo-induced cell death (Fig. 5d–f’). Overexpressed Ex therefore requires Hpo to induce cell death but not vice versa. We conclude that Mer and Ex act genetically upstream of Hpo and Wts.Merlin and Expanded regulate Warts phosphorylation and Yorkie activityHaving established that Mer and Ex act upstream of Hpo genetically, we investigated whether Mer and Ex affected Wts phosphoryla-tion. Previous analyses showed that Hpo induces phosphorylation of Wts, and that the phosphorylation status of Wts is a readout for Hpo pathway activity8. In S2 cells, overexpression of Hpo and Sav induces phosphorylation of Wts, which is visualized as a shift in Wts mobility (Fig. 6a)8. We found that coexpression of Mer and Ex led to a further shift in Wts mobility (Fig. 6a). This shift was due to protein phosphorylation, as it could be reversed by phosphatase treatment (Fig. 6b). In addition, overexpression of Mer and Ex were sufficient to induce phosphorylation of Wts without overexpression of Hpo and Sav (Fig. 6a). Possibly, endogenous Hpo and Sav are sufficient to medi-ate this effect. Whereas coexpression of Mer and Ex led to a complete shift in Wts mobility, overexpression of Mer without Ex led to an incomplete shift of Wts, and overexpression of Ex alone had no effect on Wts mobility (Fig. 6a). Therefore, Mer and Ex act synergistically to induce phoshorylation of Wts in cultured cells. Although Mer and Ex affect the phosphorylation status of Wts, they did not immuno-precipitate with Hpo, Sav or Wts in vitro or in vivo (data not shown). Thus, Mer and Ex may only transiently associate with Hpo-containing complexes, or other, as yet unidentified, components may link Mer and Ex to Hpo and Wts.Huang et al. recently identified the transcriptional coactivator Yorkie (Yki) as a downstream target of Wts16. Activated Wts phosphorylates Yki and suppresses its transcriptional activator function16. In S2 cells a Gal4-DNA-binding domain–Yki fusion protein can activate a UAS–luciferase reporter construct and this activity is suppressed by coexpression of Hpo, Sav and Wts16. We found that Ex and Mer also downregulated the activity of Yki, and reduced it to a level similar to that achieved by expression of Hpo, Sav and Wts (Fig. 6c). Coexpression of Ex and Mer with Hpo, Sav and Wts led to an even stronger reduction of Yki activity (Fig. 6c). This effect is specific because the expression of Mer, Ex, Hpo, Sav and Wts did not affect the activity of full-length Gal4 (Fig. 6d). These experiments show that Mer and Ex regulate the activity of Yki, which is currently the most downstream component known in the Hpo signal-transduction pathway.GFPDIAP1-Zc'cb'ba'ad'dGFPTUNELGFPDIAP1**TUNELDIAP1DIAP1-ZGFPDIAP1-ZDIAP1-ZFigure 3 merlin and expanded are required for developmentally induced apoptosis and regulate DIAP1 expression. All panels show third instar eye imaginal discs containing mer–;ex– double-mutant clones marked by the absence of green fluorescent protein (GFP) expression (green in a’, b’, c’, d’). (a, a’) Confocal image showing TUNEL labelling to detect dying cells (grayscale in a, red in a’) of a pupal retina 25 h after pupariation with mer4;exe1 mutant cells. Scale bar, 50 µm. (b, b’) mer4;exe1 mutant clones upregulated DIAP1 expression (grayscale in b, red in b’). Arrowheads point to a mutant area and asterisks mark the basal levels of DIAP1 expression in a wild-type area. Scale bar, 50 µm. (c, c’) mer4;exAP50 mutant clones (arrowheads) upregulated the expression of a lacZ enhancer trap insertion into the DIAP1 gene (grayscale in c, red in c’). Scale bar, 50 µm. (d, d’) Close up of a region of the disc in (c, c’), showing that upregulation of DIAP1–lacZ (DIAP1-Z) in mer;ex mutant clones was cell autonomous (arrowhead points to the clone boundary). Anterior is to the left for all discs. All alleles used are null alleles. Scale bar, 20 µm.print ncb1339.indd   30print ncb1339.indd   3013/12/05   3:32:01 pm13/12/05   3:32:01 pmNature  PublishingGroup ©2006NATURE CELL BIOLOGY  VOLUME 8 | NUMBER 1 | JANUARY 2006 31   ARTICLESHippo signalling regulates the expression of Merlin and ExpandedIt was previously observed that the levels of Ex protein are elevated in mer mutant cells27. We therefore tested whether this negative regula-tion was due to Hpo signalling. Indeed, we found that the expression of mer and ex is tightly regulated by Hpo signalling. Cells that are mutant for hpo, sav or wts had highly elevated levels of both Ex and Mer proteins (Fig. 7a–b’, and see Supplementary Information, Fig. S3). The subcellular localization of Mer and Ex to the apical-lateral mem-brane was, however, not affected (Fig. 7c–d’). The upregulation was due to derepressed transcription, because we detected elevated levels of ex transcripts in discs with hpo or wts mutant clones (Fig. 7e–h, and data not shown), and because the expression of a lacZ enhancer trap insertion into the ex locus, which reports the transcription of the ex locus, was strongly induced in wts and sav mutant clones (Fig. 7i–i’; and data not shown). Significantly, Mer and Ex were derepressed in hpo, wts or sav mutant clones in different discs independently of the developmental stage of the discs or the position of the clones. The negative-feedback regulation of mer and ex expression by Hpo dcaGMR-exe'hijc'b'a'd'efgwts-/-GMR-hpo; wts-/-ex-/-GMR-hpo; ex-/-GMR-hpohpo-/-GMR-ex; hpo-/-GMR-ex;GMR-p35wtj'f'h'g'i'GMR-hpo; ex-/- mer-/- clonesGMR-ex; wts-/- clonesk'l'klbFigure 4 Expanded acts genetically upstream of Hippo. Panels (a-j) show scanning electron microscopy images of adult eyes and panels (a’-j’) display mid-pupal retinae stained for anti-Discs large (Dlg). Panels (k-l’) show pupal retinae carrying mer;ex (k-k’) and wts (l-l’) mutant clones that are marked by the absence of green fluorescent protein expression (green in k, l). Retinae are stained for Dlg (red in k, l and gray in k’, l’). The genotypes of the animals are indicated above the panels. GMR refers to GMR–gal4-driven overexpression of the indicated transgenes (UAS–ex, UAS–hpo or UAS–p35). GMR–gal4 drives expression of these transgenes in the developing eye posterior to the morphogenetic furrow. Mutant heads were generated via eyFLP-mediated mitotic recombination to generate heads that were entirely mutant for the indicated mutations. For experiments shown in panels (d, d’, e, e’, g’, i, j, j’ and k–l’), the mutant chromosome was flipped against a chromosome marked with ubiGFP. (h’) shows an exBQ homozygous mutant retina and, in (g, h, i’), ex and wts mutant chromosomes were flipped against chromosomes carrying a cell lethal mutation. The null mutations mer4, hpo42-47, exBQ and wtsx1 were used. Scale bar (a’), 20 µm.print ncb1339.indd   31print ncb1339.indd   3113/12/05   3:32:05 pm13/12/05   3:32:05 pmNature  PublishingGroup ©200632 NATURE CELL BIOLOGY  VOLUME 8 | NUMBER 1 | JANUARY 2006ARTICLESsignalling is therefore a general effect. Indeed, it is not uncommon that the expression of signalling-pathway components is regulated in a feedback loop by the pathway itself40. This strong and tissue-independent regulation of mer and ex expression by Hpo signalling therefore supports the idea that they act together in a signalling path-way and may provide an important feedback mechanism to keep Hpo signalling in a steady state.The identification of mer and ex as transcriptional target genes of Hpo signalling leads to a model in which both Mer and Ex regulate the expression of themselves. Indeed, we corroborated that the levels of Ex are elevated in mer mutant cells (Fig. 7k, k’)27 and we found that Mer is upregulated in ex mutant clones (Fig. 7l, l’). In addition, we found elevated levels of Ex in cells mutant for a strong hypomorphic ex allele, exAP49, which encodes a protein that is truncated after the FERM domain and that is still recognized by the anti-Ex antibodies (Fig. 7m, m’; and see Supplementary Information, Fig. S1). Moreover, expression of lacZ from the ex enhancer trap insertion was strongly induced in mer;ex double-mutant cells (Fig. 7j, j’). Therefore, like other components of the Hpo signalling pathway, Mer and Ex negatively regulate the expression of mer and ex, thereby supporting the model in which Mer and Ex act in Hpo signalling.Hippo hyperactivation rescues transcriptional defects in expanded mutant cellsOnce we identified mer and ex as ubiquitous targets of Hpo signalling, we used the expression of mer and ex as readouts for Hpo pathway activity in epistasis experiments. We thus tested whether hyperactivation of Hpo was sufficient to suppress the induction of Ex expression in exAP49 mutant cell clones. To do this experiment, we used the GMR–gal4 driver to overexpress Hpo specifically posterior the morphogenetic furrow. As expected, in such discs, exAP49 mutant clones still upregulated Ex anterior to the furrow where Hpo was not overexpressed (Fig. 7m, m’, asterisk). However, the hyperac-tivation of Hpo posterior to the furrow suppressed the upregulation of Ex in exAP49 mutant clones (Fig. 7n, n’, arrowhead). Hpo activation is therefore sufficient to rescue transcriptional defects in ex mutant cells.Finally, we tested whether ectopic Hpo could suppress endogenous Ex. Clones of cells overexpressing Hpo alone or in combination with DIAP1 (to suppress cell death caused by overexpression of Hpo) showed reduced levels of Ex (Fig. 7o–o’’’; and data not shown). These cells, how-ever, showed normal levels of Dlg at the apicolateral junctions indicating that loss of Ex was not due to general defects in cell architecture. The results indicate that in wild-type cells, the activity of the Hpo pathway is in a steady state and can be positively or negatively modulated.ee'dd'GMR-ex ; hpo-/-GMR-hpo ; mer-/- ex-/-Drice*GFPDrice*Drice*GFPDrice*a'GMR-ex; wtsx1/+GMR-exwtab'bc'cff'Drice*GFPDrice*GMR-ex ; wts-/-Figure 5 Merlin and Expanded act upstream of Hippo and Warts. Panels (a-c) show scanning electron microscopy images of the eyes of adult male flies. The genotypes of the animals are indicated above the panels. GMR–ex refers to GMR–gal4-driven overexpression of a UAS–ex transgene. wt, wild type. (a’-c’) show higher magnification images of the panels above them. Removal of one copy of wts partially suppresses the reduced and rough-eye phenotype caused by overexpression of Ex. (d-f’) Anti-Drice labelling of third instar eye imaginal discs with indicated genotypes. (d, d’) hpo42–47 or (e, e’) wtsx1 mutant clones suppress cell death induced by overexpressed Ex, whereas (f, f’) mer4;exBQ double-mutant clones do not suppress ectopic Hpo-induced cell death. Panels (d, e, f) show Drice labelling only. Mutant areas are marked by the absence of green fluorescent protein (GFP; red in d’, e’, f’). Arrowheads point to mutant areas and anterior is to the left for all discs. Scale bar (f’), 50 µm.print ncb1339.indd   32print ncb1339.indd   3213/12/05   3:32:20 pm13/12/05   3:32:20 pmNature  PublishingGroup ©2006NATURE CELL BIOLOGY  VOLUME 8 | NUMBER 1 | JANUARY 2006 33   ARTICLESDISCUSSIONOur data functionally link the tumour-suppressor functions of Mer and Ex with Hpo signalling. We propose a model in which Mer and Ex act together to transduce a growth-regulatory signal from an unknown receptor to Hpo and Wts, which in turn regulate the expression of target genes to promote proliferation arrest and apoptosis (Fig. 8). We provided several lines of evidence that place the activities of Mer and Ex upstream of Hpo and Wts. First, the phenotypes induced by overexpression of Ex in imaginal discs are reversed by removing either Hpo or Wts, whereas Hpo-induced phenotypes do not require the activity of Mer and Ex. Second, hyperactivation of Hpo is sufficient to rescue the transcriptional defects of ex mutant cells. Third, Mer and Ex act synergistically to induce phosphorylation of Wts. Fourth, Mer and Ex regulate the activity of Yki, a Wts target, in a cell-culture-based assay. Together, these data support a model in which Mer and Ex act upstream and through Hpo signalling to perform their tumour-suppressor functions in Drosophila (Fig. 8).Does Mer act through Hpo signalling in vertebrates? All currently known components of the Hpo signalling pathway in Drosophila are highly conserved in vertebrates, where they have been implicated in regulating cell proliferation and apoptosis. Mice and humans have two Wts homologues, Lats1 and Lats2, and mice deficient for Lats1 develop soft-tissue sarcomas and ovarian tumours41–43. Therefore, Lats1 acts as a tumour-suppressor gene in vertebrates. Sav may also have an effect on tumorigenesis, because the human orthologue of Sav, Sav1, is mutated in cancer cell lines11. Vertebrates have two Hpo homologues, Mst1 and Mst2 and, as in Drosophila, they promote apoptosis and regulate cell-cycle exit44. Therefore, the Hippo signalling pathway regulates proliferation and apoptosis in vertebrates.Human Mer has been shown to physically interact with several other pro-teins in vitro and in cell culture cells20,24,25. However, how these interactions contribute to the tumour-suppressor function of Mer is unclear20,24,25. So far, none of these components have been linked to Mst1/2 signalling, but the Hpo signalling pathway has only recently been discovered. Notably, using BLAST searches, we found two vertebrate homologues of Ex we called Ex1 and Ex2 (see Supplementary Information, Fig. S1). Therefore, all known components of the Hpo signalling pathway are conserved in vertebrates. Importantly, not only the genes but also the mechanisms of signal transduc-tion seem to be conserved between Drosophila and vertebrates. Vertebrate Lats1 and Mst2 can rescue the lethality and overgrowth phenotypes of wts and hpo mutants8,43 and Mst1/2 bind to Sav1 and phosphorylate and activate Lats1/2 (ref. 17). Due to this apparent conservation of the components and mechanisms that operate downstream of Mer and Ex in Drosophila and in vertebrates, Mer and the two Ex homologues may function as tumour-sup-pressor genes through the Hpo homologues Mst1/2. Our data that links Mer to Hpo signalling may therefore have important implications for the study and treatment of neurofibromatosis and other cancers. METHODSDrosophila stocks. Mutant clones were induced using the FLP/FRT system45,46. To generate of marked double-mutant clones, we recombined p{w+ mer+}27 with a FRT40A ubiGFP chromosome. Flies with mer;ex double-mutant clones had the following genotype: y w mer4FRT19A/ Y; FRT40A exe1/FRT40A p{w+ mer+} ubiGFP; hsFLP MKRS/+, except for those seen in Figs 2c–c’’ and 3c–d’, in which we used exAP50 because exe1 is an enhancer trap itself. After mitotic recombination took place, non-green-fluorescent-protein (GFP)-expressing cells were homozygous mutant for ex and lacked the mer rescue construct; they were, therefore, double mutant for mer and ex. To generate ex, mer, hpo, wts, sav or TSC1 mutant clones, the following alleles were flipped against corresponding ubiGFP marked FRT chromosomes: exe1 (null)31, exBQ (null; see Supplementary Information, Fig. S1), exAP49 (hypomorph, see Supplementary Information, Fig. S1), mer4 (null)29, hpo42–47 (null)8, wtsx1 (null)14, wtsP2 (hypomorph)13, savshrp1 (null)1,2 and TSC1IQ69 (ref. 6). Overexpression was achieved using the UAS–GAL4 system47 and the following stocks: UAS–ex (ref. 30), UAS–hpo (ref. 6), UAS–p35 (ref. 38) and GMR–gal4. Overexpression clones of Hpo and DIAP1 were induced using the flp-out tech-nique48 and the following stocks: ywhsflp; act<y+<Gal4, UASGFPnls/CyO and UAS–DIAP1 (obtained from B.Hay, Caltech, USA). Other stocks used were: ex697/CyO (ref. 31), DIAP1–lacZ (ref. 38) and CycE–lacZ (16.4 construct37).aTransfected withα-HA (Ex)18765432WHSEMW−−EMW−−−−.W−−−−WHS−−W−−−−W−−−MW−−E−α-HA (Mer)α-Savα-Hpoα-V5 (Wts)α−αTubWtsHpoSavExMer18765432W−−−−WHSEM+WHSEMWHS−−WHS−−+W−−EM+W−−−−W−−−−+α-V5 (Wts) western blotWtsHpoSavExMerPP2A9W−−EMb0400300200100500−+−−−−+−−−−−−+HSWEMGal4DBDGal4-FLHpo Sav WtsExMerd04030201050607080−+−−−+−−−−−+HSW−−Gal4DBDGal4DBD-YkiHpo SavWtsExMer−+HSWEM−+−−EM−+−−E−−+−−−MFold activationFold activationc−+−W−−−+−WEMFigure 6 Merlin and Expanded regulate Warts phosphorylation and activity. (a) Mer and Ex act synergistically to induce Wts phosphorylation. Western blots of lysates from S2 cells overexpressing different combinations of epitope-tagged proteins, as indicated on the top of the panel. Western blots were probed with indicated antibodies. Wts, Mer and Ex were detected by probing against their tags, whereas Hpo, Sav and αTub were detected with antibodies raised against the native proteins. Note that on the Hpo blot, the endogenous Hpo protein is also detected and migrates faster than the overexpressed Hpo, which carries a Myc tag. (b) Phosphatase (PP2A) treatment reversed the mobility shift of Wts induced by Hpo, Sav, Mer and Ex. Note low phoshorylation levels of overexpressed Wts, which is also diminished by phosphatase treatment (lanes 6 vs. 7). (c) The coactivator activity of Yki is negatively regulated by Mer and Ex. S2 cells were transfected with UAS–luc (Gal4-responsive luciferase reporter) plasmid along with plasmids expressing the Gal4 DNA-binding domain-Yki fusion protein and plasmids expressing Hpo, Sav, Wts, Ex and Mer as indicated. Luciferase activities normalized to that induced by the Gal4 DNA-binding domain (Gal4DBD) alone are plotted. Error bars represent standard deviations from three independent transfections. (d) The transcriptional activator function of the full-length Gal4 (Gal4-FL) is not affected by expression of Hpo, Sav, Wts, Mer and Ex.print ncb1339.indd   33print ncb1339.indd   3313/12/05   3:32:28 pm13/12/05   3:32:28 pmNature  PublishingGroup ©200634 NATURE CELL BIOLOGY  VOLUME 8 | NUMBER 1 | JANUARY 2006ARTICLESGMR-hpo;ex clonesc'cb'ba'ad'dEx in ex clonesi'ihgfej'jk'kl'lEx in hpo clonesEx in mer cloneswts clonesex mRNAex mRNA in wts clones ex mRNA in wts clones Ex inMer in ex clonesMer in hpo clonesExExExExMerMerGMR-hpo*m'mn'nEx-Z in wts clonesEx-Z in mer, ex clonesEx-ZEx-ZExDlgEx in >>Hpo DIAP1ExGFPo'oo'''o''*Figure 7 Hippo signalling regulates Merlin and Expanded expression and ectopic Hippo is sufficient to rescue expanded mutant phenotypes. Mer and Ex protein levels are elevated in clones of Hpo pathway mutants, whereas their subcellular localization is not affected. (a-b’) hpo42–47 mutant clones in eye-antennal imaginal discs, marked by the absence of green fluorescent protein (GFP; green in a’ and b’), have increased levels of Ex (grayscale in a, red in a’) and Mer (grayscale in b, red in b’) proteins. Upregulation of Ex and Mer is particularly prominent in the morphogenetic furrow (arrows). Arrowheads point to mutant clones. Scale bar (a), 50 µm. (c-d’) Z-sections through wing imaginal discs with wtsx1 mutant clones that are marked by the absence of GFP (green in c’ and d’). Localization of Ex (grayscale in c, red in c’) and Mer (grayscale in d, red in d’) is not altered in wtsx1 mutant cells, whereas protein levels are elevated. (e) Third instar eye imaginal disc bearing wtsP2 mutant clones marked by the absence of GFP. (f) ex mRNA expression in a wild-type eye-antennal imaginal disc detected by in situ hybridization. (g, h) Increased levels of ex mRNA are detected in discs with wtsP2 mutant clones. Arrows point to the morphogenetic furrow and arrowheads mark patches of upregulated ex expression. (i-j’) Eye imaginal discs bearing wtsx1 or mer4;exe1 mutant clones and showing the expression of β-Gal driven by an enhancer trap insertion into the ex gene. Grayscale in (i, j) shows β-Gal expression only. Scale bar (j), 50 µm. (k, k’) Higher levels of Ex protein (grayscale in k, red in k’) are present in mer4 mutant clones in a wing disc marked by the absence of GFP (arrowhead). (l, l’) exe1 mutant clones (GFP-negative) upregulate Mer expression (grayscale in l, red in l’). (m, m’) exAP49 mutant clones (GFP-negative, arrowheads) have elevated levels of Ex protein (grayscale in m, red in m’) both anterior and posterior to the morphogenetic furrow (arrow). (n, n’) Upregulation of Ex (grayscale in n, red in n’) in exAP49 mutant clones is suppressed by ectopic expression of Hpo behind the morphogenetic furrow. Asterisk marks Ex upregulation anterior to the furrow. Arrowheads point to the mutant clones with repressed Expanded expression. Hpo overexpression was driven by GMR–gal4, which drives expression posterior, but not anterior to the morphogenetic furrow (arrow). White bar marks the region of GMR–hpo expression. Ex overexpression is therefore only suppressed posterior to the furrow, where Hpo is expressed. (o-o’’’) Wing imaginal disc with clones overexpressing Hpo and DIAP1 downregulate the expression of Ex (gray in o’ and red in o and o’’’), although do no affect Dlg (blue in o, gray in o’’). Clones overexpressing Hpo and DIAP1 are marked by the coexpression of GFP (green in o and o’’’). Scale bar (o’’’), 100 µm. Anterior is to the left for all discs. print ncb1339.indd   34print ncb1339.indd   3413/12/05   3:32:31 pm13/12/05   3:32:31 pmNature  PublishingGroup ©2006NATURE CELL BIOLOGY  VOLUME 8 | NUMBER 1 | JANUARY 2006 35   ARTICLESScanning electron microscopy, immunohistochemistry, in-situ hybridization and cell-death assays. Scanning electron microscopy (SEM) of adult flies was car-ried out following the hexamehyldisilazane (HMDS) method12. Antibody stain-ings of imaginal discs were performed as described previously12. The following antibodies were used (dilutions and source in parentheses): mouse α-Dlg (1:300; DSHB); rabbit α-Drice (1:2000; B. Hay); guinea-pig α-Mer (1:4000; R. Fehon, Duke University, USA); guinea-pig α-Ex (1:2000; R. Fehon); rabbit α-Ex (1:1500; A. Laughon, University of Wisconsin, USA); mouse α-BrdU (Becton-Dickinson, Franklin Lakes, USA; 1:50); mouse α-DIAP-1 (1:200; B. Hay); and mouse α-CycE (1:40 ). Secondary antibodies were donkey Fab fragments from Jackson Immuno Research (West Grove, PA). BrdU incorporation was carried out as described previously, by incorporating BrdU for 1 h12. For the in situ hybridization to detect expanded transcripts, the Drosophila cDNA clone UG24F8 was used as a template to generate DIG-labelled RNA probes (Roche, Indianapolis, IN). TUNEL labelling was performed on imaginal discs and pupal retinae using an in situ cell-death detection kit (Roche)6.Cell culture. N-terminal tagged HA-Ex and HA-Mer were constructed using the pAc5.1 vector. All other constructs were gifts from Duojia Pan, Johns Hopkins University, USA8,16. Drosophila S2 cells, cultured in Schneiders’s medium con-taining 10% fetal bovine serum and antibiotics were transiently transfected using Cellfectin (Invitrogen, Carlsbad, CA) and collected 48 h after transfection. Lysis was performed in RIPA Buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 5 µg ml–1 aprotinin, 5 µg ml–1 leupeptin and phosphatase inhibitors (Roche)), and Western blots were performed accord-ing to standard protocols. Antibodies used were: α-V5 (Invitrogen); α-HA (CRP, Cumberland, VA); and α-Hpo, α-Sav and α-αTub (Sigma, St Louis, MO). α-Hpo and α-Sav antibodies were raised in guinea pigs against native His-tagged proteins.For phosphatase treatments, cells were lysed in IP buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 0.5% NP40, 1 mM PMSF, 5 µg ml–1 aprotinin, 5 µg ml–1 leupeptin) and V5-Wts proteins were immunoprecipitated. Beads were washed three times in phosphatase treatment buffer (50 mM Tris-HCl, pH 7.5, 0.1 mM EDTA, 0.5 mM MgCl2, 0.5 mM MnCl2, 0.5 mM CaCl2) and 0.3 units of PP2A (Upstate, Charlottesville, VA) were added in a total volume of 75 µl, followed by 30 min incubation at 37°C. The reaction was terminated by addition of an equal volume of 2× SDS sample buffer.Luciferase reporter gene assays were performed by transfecting 20 ng of Yki–Gal4 or Gal4–FL plasmids with 3 ng of UAS–luc plasmid in triplicates, with or without plasmids expressing Ex, Mer, Hpo, Sav or Wts in 24-well plates. Luciferase assays were performed using the Dual Luciferase Reporter Assay System (Promega, Madison, WI) and a 20/20n Luminometry System with Single Auto-Injector (Promega).Note: Supplementary Information is available on the Nature Cell Biology website.ACKNOWLEDGEMENTS We thank R.G. Fehon, A. Laughon, M. Mlodzik, B. Hay, D. Pan, P. Bryant, the Bloomington Drosophila Stock Center and the Developmental Studies Hybridoma Bank (University of Iowa) for fly stocks, antibodies and plasmids. We thank K.K. Norga for his help with the isolation of new ex alleles. We thank K.Dunner for technical help with the scanning electron microscopy analysis, which were performed, along with DNA sequencing, at the M. D. Anderson core facilities supported by a National Cancer Institute Cancer Center support grant. We also thank L. McCord for her help with artwork. Special thanks to M. Acar for his invaluable advice and help with the cell-culture experiments. We thank the members of the X. Chen laboratory for their help with antibody production. We thank R. Behringer, H.J. Bellen, A. Bergmann, K.-W. Choi, V. Dion, N. Giagtzoglou, P.R. Hiesinger, G. Lozano, G. Mardon, R. Johnson, J. Kunz and members of the Halder Lab for discussions. This work was supported by a National Institutes of Health grant to G.H, The Odyssey Fellowship and The Theodore N. Law Award for Scientific Achievement to M.K.S., and a BRASS Scholarship to E.H. H.J.N. is supported by HHMI and by a NIH Medical Genetics Research Fellowship Program grant.COMPETING FINANCIAL INTERESTSThe authors declare that they have no competing financial interests.Published online at http://www.nature.com/naturecellbiology/Reprints and permissions information is available online at http://npg.nature.com/reprintsandpermissions/1. Johnston, L. A. & Gallant, P. Control of growth and organ size in Drosophila. Bioessays 24, 54–64 (2002).2. Conlon, I. & Raff, M. Size control in animal development. Cell 96, 235–244 (1999).3. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).4. Ryoo, H. D. & Steller, H. Hippo and its mission for growth control. Nature Cell Biol. 5, 853–855 (2003).5. Hay, B. A. & Guo, M. Coupling cell growth, proliferation, and death. Hippo weighs in. Dev. Cell 5, 361–363 (2003).6. Udan, R. S., Kango-Singh, M., Nolo, R., Tao, C. & Halder, G. Hippo promotes prolifera-tion arrest and apoptosis in the Salvador/Warts pathway. Nature Cell Biol. 5, 914–920 (2003).7. Pantalacci, S., Tapon, N. & Leopold, P. The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nature Cell Biol. 5, 921–927 (2003).8. Wu, S., Huang, J., Dong, J. & Pan, D. hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 114, 445–456 (2003).9. Harvey, K. F., Pfleger, C. M. & Hariharan, I. K. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 114, 457–467 (2003).10. Jia, J., Zhang, W., Wang, B., Trinko, R. & Jiang, J. The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes Dev. 17, 2514–2519 (2003).11. Tapon, N. et al. salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 110, 467–478 (2002).12. Kango-Singh, M. et al. Shar-pei mediates cell proliferation arrest during imaginal disc growth in Drosophila. Development 129, 5719–5730 (2002).13. Justice, R. W., Zilian, O., Woods, D. F., Noll, M. & Bryant, P. J. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 9, 534–546 (1995).14. Xu, T., Wang, W., Zhang, S., Stewart, R. A. & Yu, W. Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development 121, 1053–1063 (1995).15. Lai, Z. C. et al. Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell 120, 675–685 (2005).16. Huang, J., Wu, S., Barrera, J., Matthews, K. & Pan, D. The Hippo signaling path-way coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell 122, 421–434 (2005).17. Chan, E. H. et al. The Ste20-like kinase Mst2 activates the human large tumor sup-pressor kinase Lats1. Oncogene 24, 2076–2086 (2005). 18. Rouleau, G. A. et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363, 515–521 (1993).19. Trofatter, J. A. et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 75, 826 (1993).20. McClatchey, A. I. Merlin and ERM proteins: unappreciated roles in cancer development? Nature Rev. Cancer 3, 877–883 (2003).merexdiap1cyclin ESavWts/MatsHpoMer/Ex?YkiFigure 8 Model of the Hpo signalling pathway. Mer and Ex act upstream of Hpo and regulate the expression of mer, ex, diap1 and cyclin E transcription. Mer/Ex may transduce the signal of an, as yet unknown, growth-regulating cell-surface receptor.print ncb1339.indd   35print ncb1339.indd   3513/12/05   3:32:34 pm13/12/05   3:32:34 pmNature  PublishingGroup ©200636 NATURE CELL BIOLOGY  VOLUME 8 | NUMBER 1 | JANUARY 2006ARTICLES21. McClatchey, A. I. et al. Mice heterozygous for a mutation at the Nf2 tumor suppres-sor locus develop a range of highly metastatic tumors. Genes Dev. 12, 1121–1133 (1998).22. Lallemand, D., Curto, M., Saotome, I., Giovannini, M. & McClatchey, A. I. NF2 defi-ciency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 17, 1090–1100 (2003).23. Lutchman, M. & Rouleau, G. A. The neurofibromatosis type 2 gene product, schwan-nomin, suppresses growth of NIH 3T3 cells. Cancer Res. 55, 2270–2274 (1995).24. Xiao, G. H., Chernoff, J. & Testa, J. R. NF2: the wizardry of merlin. Genes Chromosom. Cancer 38, 389–399 (2003).25. Bretscher, A., Edwards, K. & Fehon, R. G. ERM proteins and merlin: integrators at the cell cortex. Nature Rev. Mol. Cell. Biol. 3, 586–599 (2002).26. Rong, R., Tang, X., Gutmann, D. H. & Ye, K. Neurofibromatosis 2 (NF2) tumor suppres-sor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc. Natl Acad. Sci. USA 101, 18200–18205 (2004).27. McCartney, B. M., Kulikauskas, R. M., LaJeunesse, D. R. & Fehon, R. G. The Neurofibromatosis-2 homologue, Merlin, and the tumor suppressor expanded function together in Drosophila to regulate cell proliferation and differentiation. Development 127, 1315–1324 (2000).28. Boedigheimer, M. & Laughon, A. Expanded: a gene involved in the control of cell proliferation in imaginal discs. Development 118, 1291–1301 (1993).29. LaJeunesse, D. R., McCartney, B. M. & Fehon, R. G. Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localiza-tion. J. Cell Biol. 141, 1589–1599 (1998).30. Boedigheimer, M. J., Nguyen, K. P. & Bryant, P. J. Expanded functions in the apical cell domain to regulate the growth rate of imaginal discs. Dev. Genet. 20, 103–110 (1997).31. Blaumueller, C. M. & Mlodzik, M. The Drosophila tumor suppressor expanded regu-lates growth, apoptosis, and patterning during development. Mech. Dev. 92, 251–262 (2000).32. Baker, N. E. Cell proliferation, survival, and death in the Drosophila eye. Semin. Cell Dev. Biol. 12, 499–507 (2001).33. Wolff, T. & Ready, D. F. The beginning of pattern formation in the Drosophila com-pound eye: the morphogenetic furrow and the second mitotic wave. Development 113, 841–850 (1991).34. Potter, C. J., Huang, H. & Xu, T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 105, 357–368 (2001).35. Tapon, N., Ito, N., Dickson, B. J., Treisman, J. E. & Hariharan, I. K. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105, 345–355 (2001).36. Richardson, H., O’Keefe, L. V., Marty, T. & Saint, R. Ectopic cyclin E expression induces premature entry into S phase and disrupts pattern formation in the Drosophila eye imaginal disc. Development 121, 3371–3379 (1995).37. Jones, L., Richardson, H. & Saint, R. Tissue-specific regulation of cyclin E transcrip-tion during Drosophila melanogaster embryogenesis. Development 127, 4619–4630 (2000).38. Hay, B. A., Wassarman, D. A. & Rubin, G. M. Drosophila homologs of baculovirus inhibi-tor of apoptosis proteins function to block cell death. Cell 83, 1253–1262 (1995).39. Ryoo, H. D., Bergmann, A., Gonen, H., Ciechanover, A. & Steller, H. Regulation of Drosophila IAP1 degradation and apoptosis by reaper and ubcD1. Nature Cell Biol. 4, 432–438 (2002).40. Niehrs, C. & Meinhardt, H. Modular feedback. Nature 417, 35–36 (2002).41. Turenchalk, G. S., St John, M. A., Tao, W. & Xu, T. The role of lats in cell cycle regulation and tumorigenesis. Biochim. Biophys. Acta 1424, M9–M16 (1999).42. St John, M. A. et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nature Genet. 21, 182–186 (1999).43. Tao, W. et al. Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nature Genet. 21, 177–181 (1999).44. Dan, I., Watanabe, N. M. & Kusumi, A. The Ste20 group kinases as regulators of MAP kinase cascades. Trends Cell Biol. 11, 220–230 (2001).45. Xu, T. & Rubin, G. M. Analysis of genetic mosaics in developing and adult Drosophila tissues. Development 117, 1223–1237 (1993).46. Newsome, T. P., Asling, B. & Dickson, B. J. Analysis of Drosophila photoreceptor axon guidance in eye-specific mosaics. Development 127, 851–860 (2000).47. Brand, A. H. & Perrimon, N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118, 401–415 (1993).48. Struhl, G. & Basler, K. Organizing activity of wingless protein in Drosophila. Cell 72, 527–540 (1993).print ncb1339.indd   36print ncb1339.indd   3613/12/05   3:32:37 pm13/12/05   3:32:37 pmNature  PublishingGroup ©2006SUPPLEMENTARY INFORMATIONWWW.NATURE.COM/NATURECELLBIOLOGY 1FQNLDEEK---QLLYDFPWTNVGKLVFVGKKFEILPDGLPSARYQEVDRAP---QLLYDLPWPHVGKLAFLGKKLEIQLDGLPAAQLGGESTNSSSNPETTTSLWPNITKLSFERKKFEIRSG----ESAQDGSSTA------TTFQWPHIGKLSFDRKKFEIRSG----DSHs11--------------------------------------MNKLNFHNNRVMQDRRSVCIFLPNDESLNIIINVKILCHQLLVQVCDLLRLK---DCHLFGLSVIQNNEHVYHs21MAVPPRGRGIDPARTNPDTFPPSGARCMEPSPERPACSQQEPTLGMDAMASEHRDVLVLLPSREQLRLAVGVKATGRELFQQVCNVASIR---DAQFFGLCVVRNNEYIFDm1----------------------MRAFCTVSAPLEVCASSAEQLSPGSRFLALR---LLGQQQPKTLYFLVDAKSRVREVYTQTCLHFATQGMLDTELFGLAVLIDGEYMFAg1----------------------MRAFCTVSAPLEVCAPPSRPLPPGTRFLALK---LLGTPQPRTLYFLVEAKSRVREVYAQTCHHFSKQGMLDTELFGLAVLIDGEYLFHSs170MELSQKLYKYCPKEWKKEASKGIDQ-FGPPMIIHFRVQYYVENGRLISDRAARYYYYWHLRKQVLHSQCVLR--EEAYFLLAAFALQADLGNFKRNKHYGK---------HSs2108MDLEQKLSKYFSKDWKKERNEGNEK-PRAPFVAFLRVQHYVENGRVISDHRARHLYYCHLKERVLRSQCAHR--EEAYFLLAACALQADLGEHRESAHAGR---------Dm86ADPESKLSKYGPKSWRSSHTHGLDANGRPLLELHFRVQFYIESPFMLKDETSRHNYYLQLRHNILQRDLPREQADEALVFLAGLALQADLGDAPPGTSNSKDDSGEETLAAg86ADPESKLSKYGPKSWRSSHTHGLDANGKPLLELHFRVQFYIESPLMLRDEVSRHNYYLQLKYNAVNRDLPKECSEQSLLLLGGLSLQADLGDSAPEDAGTTLPTTPSIKTHs1168-----------------------------------------YFEPEAYFPSWVVSKRGKDYILKHIPN---------MHKDQFALTASEAHLKYIKEAVRLDDVA-VHYYHs2206-----------------------------------------YFEPHSYFPQWIITKRGIDYILRHMPT---------LHRERQGLSPKEAMLCFIQEACRLEDVP-VHFFDm196SPSNGGRGLSATTTLPKISKRANERMLRLSTYVASTSKRETIPLPPSLPPNGADYYRIEDYLPSGLHTPWARSAMRACHREHLGMATAEAELLYIQQACSLHETINAHTYAg196ATSS-------TATVPNTSSATSSSTSSNSSTTSACSPNPSAGGAPSVSSPSVEYFRPDEYLNPALRSAWGIAAVTTCHRDNRGLSRADAETHFIREACNLNEAVNAHVFHs1227RLYKDKRE-IEASLTLGLTMRGIQIKLIYYTGCPMRSRHLLQLLSNSHRLYMNLQPVLRHIRKLEENHs2265RLHKDKKE-GRPTVILGLALRGVHIKLVYYTGCTWRSRHLLHLLRASHQLHLRVRPTLQQLRQREEADm306RMRLAKSEQGSGSAWFVVYAKGIKIRITLYAASDEKNKLLLTLCKDTHQWSMKLAARLKEVSKREEEAg299RMKQSKNETGLGTVALSIYAKGIRIKITLYSTNDDKNKMILALCRETHQFSMKIAPRLTEAIKREEEHs1333EEKK----------------------QYRESYIS------------------DNLDLDMDQLE-K---------------------------------------------Hs2371EEKQ----------------------HYRESYIS------------------DELELDLASR------------------------------------------------Dm412EAAESQRLHASYACSRSLLLPYKSKNEQRISVISSTSSNTTSGIVSDRVHSEDELEIMINTPP-APLAAPSTESLALAHLLDRPSVSRQTSSVGQMSLKDLEEQLAALSVAg399ESSCIHG--YPYLCSRALNLPYKSKSDQRISVISSTSSNTTSGIVSDRVHSEDELEIMINTPPTATLAAPSTESLALAHLLDCPSVSRQTSSVGQVSLKELEGTFAALSVHs1357-------------------------------------------------------------------------------------RSRASGSSAGSMKHKRLSRHSTAS-Hs2393--------------------------------------------------------------------------------------SFPGSGVSSQHCPHCLSRHSADS-Dm521RPQDASSNGATIVTNSSVQRNSMGTTANDSSTATD------------SPSSQHNTGSQCSSTC------------------STVVVTSPVNGAGASSSGAPIPVHSTSSSAg507GRTGSVVNAAGSLVPCSSGGSNTNNCANSDSGSVEGKPDRPGKECESSPSSQHNIGSQCSSTCSTVVVATDCLSLPQSSTATSTTTISNGGGSNSTMVQATISPDRRQTSHs1381---------------------------------------------------------------------------------------------------------HSSSHHs2416---------------------------------------------------------------------------------------------------------HGSSYDm601LELGFSHTAQNSALSETSPDDFLSTSAREETESVSGASGVYTLAHGAPPTETSGVYTMHSSELTGQSSEIDESEKSSHYGMFQPQKLEETHVS------------HSDSVAg617TCSSLVLGFSHTAQNSTLSVATSTCLDHDINEEEEETHSGVYTIAHVPPTETSGVYTMNSSELTGQSSEIAESESHESSHYGSFQPCQSEMADPLEPVDSVDGDYHRPRLHs1386TSGIEADTKPRDTGPEDSYSSSAIHRKLKTCSSMTSHGSSHTSGVESGG---------------KDRLEEDLQDDEI----------------EMLVDDPRD----LEQMHs2421TSGIKANSWLRES---------------------R----------------------------------------------------------EMSVDVPLE----VHGLDm699DGKKKEDFRPRSDSNVSTGSSFRGDGSDPTDNKHSLLSAEELTNLIVGRGTYPSRKTVSSSLHSDCDYVTLPLGDQG----------------EEEVDQPPAPPPPYSARAg727DSGLNSEFRMRSDSTVSAAGSFRGDGSDPTDNKHSLLSAEELTDLIVGRGTYPSRKTVSHTLDSDCDYVTLPLPLEGESYLQGSEDTAPTEDEYDDEQQPPPPPPPYNAHHs1461NEESLEVSPDMCIYITEDMLMSRKLNGHSGLIVKEIGSSTSSSSETVVKLRGQSTDSLP------------------------------------QTICRKPKTSTDRHSHs2448HEKEPSSSP-----------R----TSRSHPSTRGDSQATRQEPCTEVRTRGQSAEAVH------------------------------------QIQEMTAGVSEEQHSDm793HEKTGLCGPPIAKPIPKPIAVVAP-KPDSPPCSPPVPPAPIPAPPPAIRRRDPPPYSISSKPRPTSLISVSSSAHPAPSAAGSMSSLKSEEVTARFITTRPQISILKAHTAg837HETTGLRGPDIRSPAPP------AATDPEAPAIPLRDPPPYPQKPIAMRKSPILPPALPVTPSVLTTAPVS------------------EEVPARFITTRPQINILKAHAHs1535LSLDD------------------------IRLYQKDFLRIAGLCQDTAQSYTFGCG------------------HELDEEGLYCNSCLAQQCINIQDAFP----------Hs2507HGLDD------------------------MQLHQLALHPAP-----TSLSHTFHR----------------------------ALDCRLAGPCETRATLP----------Dm902SLIPDGAKPSYAAPHHCSSVASSNGSVCSHQLSQQSLHNSNYAGGSQASLHHHHVPSHHRHSGSAAIGIVPYGLHKSTASLHHQQSCVLLPVIKPRQFLAPPPPSLPRQPAg923SVVGETPK---------------------PSFAAPTVNNIGNLAQATPPPPPPPVP-----------------------TGIPGQLARSQIELYQQQLYS----------Hs1593-------------------------------------------------------VKRTSKYFSLDLTHDEVP-EFVV--------------------------------Hs2550-------------------------------------------------------SKRSSNCLALDLFGEAPPQEFVV--------------------------------Dm1012PPPPPPNHPHLASHLYEREMARKQLELYQQQLYSDVDYVIYPIQDPAVSQQEYLDAKQGSLLAAMAQAAPPPPHHPYLAMQVS---------PAIYRSTPYLPLTLSTHSAg979----------------------------------DVDYVIYPIQDPSISQQEYLDAKQGSILAAMAQSPPPPPYLAYHTVRAHNRSWDACKNHAIYRSTPYLSMALSSNSHs1--------------------------------------------------------------------------------------------------------------Hs2--------------------------------------------------------------------------------------------------------------Dm1113RYASTQNLSDTYVQLPGPGYSPLYSPSMASLCSSYEPPPPPPLHPAALAAAAAAG--------------AGSSSSSMFARSRSDDNILNSLDLLPKGKRLPPPPPPPYVNAg1055RYASTQNLSDTYVQLPG-AYSPLYSPSVASLCSSYEPPPPPPLRPRPMVSSKASAGSMQPNGGAHLSMASAGPSPALFARSRSDDNILNSVESTPKIRRHPPPPPPPPYEHs1--------------------------------------------------------------------------------------------------------------Hs2--------------------------------------------------------------------------------------------------------------Dm1209R----RLKKPPMPAPSEKPPPIPSKPIPSRMSPIPPRKPPTLNPHHANSPLTKTSSGAQWAGERPRPDLGLGLGLNRGNNSILAQLQAFNVAQSHAQAQAQALDIALLREAg1164SKKAIRKPPLPLPTPMEKLIPKPPMAVPSPSQPVVPAFNPERPPEVPAKPTPPKPSGPSAKLQAQIKKQYPDFDLSTVASMVDQQPVN----------DHTSIDIKTLREHs1--------------------------------------------------------------------------------------------------------------Hs2--------------------------------------------------------------------------------------------------------------Dm1315KSKHLDLPLISALCNDRSLLKQTKVVINPKTGQEMPTSSAQPSGATTNGVANSSAGAGTLSKARKGSTVSHRHPQDKLPPLP-------VQQLAEANNYVIDPAVMMKQQAg1264KSKHLDLPLISALMHDRSLLKQTRAFVMP----------KHPKANVSNGLPKGAGGGSGLAKPRKTS-ASHRHPNDKLPPLPGQTGPGQTGPTAEGNNYVMDP-------Hs1----------Hs2----------Dm1418QQQQQQQHNKAg--------baD.melanogaster  ExH.sapiens  Ex1A.gambiae  ExFERM domainBQ*BB1172*11429H.sapiens  Ex21135516141572AP49*AP50Δ*Figure S1 Expanded mutant alleles and human Expanded homologs. (a) Schematic representation of the protein structures of the Drosophila melanogaster, Anaphilis gambiae, and Homo sapiens Ex homologues. Regions of conserved domains are shaded. Arrows indicate the positions of the mutations in the four newly isolated ex alleles. The mutations in alleles exBQ, exBB1172, and exAP49 result in premature STOP codons (asterisk) at amino acid positions 32, 223 and 986, respectively. exAP50 has a rearrangement which result in a frameshift. The ExAP50 protein is truncated after amino acid 129 followed by 34 unrelated aminoacids with no homology to sequences in GenBank. (b) Sequence alignment of Drosophila Ex (Dm), human Ex1 and Ex2 (Hs1, Hs2), and mosquito Ex (Ag). Identical residues are on black background and similar residues are shaded. The FERM domains are boxed.© 2006 Nature Publishing Group  SUPPLEMENTARY INFORMATION2 WWW.NATURE.COM/NATURECELLBIOLOGYFigure S2 Genetic interaction between mutations in expanded and warts. (a-d) Phase-contrast images of wing imaginal discs of third instar wandering larvae (141-157 hours old after egg laying, raised at 25°C) with the following genotypes (a) exAP49/+; wtsx1/+, (b) exAP49 homozygote, (c) exAP49/AP49; wtsx1/+(d) wild-type. Heterozygosity for both ex and wts does not cause overgrowth. However, heterozygosity for wts enhances the overgrowth phenotype of exAP49 homozygous mutant wing imaginal discs. All images were taken at the same magnification. (e) Heterozygosity for ex697, a weak hypomorph, enhances the larval lethality of wtsP2 homozygotes. The graph shows the percentage of animals with the indicated genotypes pupating compared to the number that would be expected if they had wild-type viability. These numbers were calculated by counting the number of pupae with the indicated genotypes and comparing it to the number of pupae carrying a balancer chromosome in the stocks wtsP2/ TM6B and ex697/ CyO GFP; wtsP2/ TM6B raised at 25 °C.© 2006 Nature Publishing Group  SUPPLEMENTARY INFORMATIONWWW.NATURE.COM/NATURECELLBIOLOGY 3Figure S3 Hippo signalling regulates Merlin and Expanded expression in a tissue independent manner. (a-b’) wtsx1 mutant clones in eye-antennal imaginal discs marked by the absence of GFP (green in a’ and b’), have increased levels of Ex (grayscale in a, red in a’) and Mer (grayscale in b, red in b’) proteins. Upregulation of Ex and Mer is especially prominent in the morphogenetic furrow. (c, c’) Higher levels of Ex protein (grayscale in c, red in c’) is present in savshrp1 mutant clones marked by the absence of GFP in a third instar wing imaginal disc. (d, d’) wtsx1 mutant clones (GFP negative) in a third instar wing imaginal disc upregulate Mer expression (grayscale in d, red in d’).© 2006 Nature Publishing Group  Validationofthep21-ActivatedKinasesasTargetsforInhibitioninNeurofibromatosisType2ChunlingYi,1ErikW.Wilker,2MichaelB.Yaffe,2AnatStemmer-Rachamimov,3andJosephL.Kissil11MolecularandCellularOncogenesisProgram,TheWistarInstitute,Philadelphia,Pennsylvania;2CenterforCancerResearch,MassachusettsInstituteofTechnology,Cambridge,Massachusetts;and3DepartmentofPathology,MassachusettsGeneralHospital,Boston,MassachusettsAbstractNeurofibromatosistype2(NF2)isadominantlyinheritedcancerdisordercausedbymutationsattheNF2genelocus.Merlin,theproteinproductoftheNF2gene,hasbeenshowntonegativelyregulateRac1signalingbyinhibitingitsdownstreameffectorkinases,thep21-activatedkinases(Pak).GiventheimplicationofPaksintumorigenesis,itisplausiblethatmerlin’stumorsuppressivefunctionmightbemediated,atleastinpart,viainhibitionofthePaks.Wepresentdataindicatingthisisindeedthecase.First,analysisofprimaryschwannomasamplesderivedfromNF2patientsshowedthatinasignificantfractionofthetumors,theactivityofPak1washighlyelevated.Second,weusedshRNAstoknockdownPak1,2,and3inNIH3T3cellsexpressingadominant-negativeformofmerlin,NF2BBA(NIH3T3/NF2BBA),andfindthatsimultaneousknockdownofPak1-3inthesecellssignificantlyreducedtheirgrowthratesinvitroandinhibitedtheirabilitytoformtumorsinvivo.Finally,whileattemptingtosilencePak1inratschwannomacells,wefoundthatthesecellswereunabletotoleratelong-termPak1inhibitionandrapidlymovedtorestorePak1levelsbyshuttingdownPak1shRNAexpressionthroughamethylation-dependentmechanism.ThesedatasuggestthatinhibitingPakcouldbeabeneficialapproachforthedevelopmentoftherapeuticstowardNF2.Inaddition,thefindingthattheshRNA-mediatedPak1suppressionwassilencedrapidlybymethylationraisesquestionsaboutthefutureapplicationofsuchtechnologiesforthetreatmentofdiseasessuchascancer.[CancerRes2008;68(19):7932–7]IntroductionThehallmarkofneurofibromatosistype2(NF2),whichaffects1in30,000to40,000ofthepopulation,isthedevelopmentofbilateralvestibularschwannomas(VS)attheeighthcranialnerve.MostNF2patientsgoontodevelopmultiplecranialandspinalschwannomas,meningiomas,andlessfrequently,intraspinalependymomas,withsymptomsincludingauditory,visual,andmotorimpairments.Currently,riskysurgicalexcisionistheonlytreatmentoption,andthetumorswillinevitablyrecur,leadingtoahighearlymortalityrateamongNF2patients(1).Merlin,theproteinencodedbytheNF2gene,iscloselyrelatedtotheERM(ezrin,radixin,andmoesin)proteins,containinganNH2-terminalFERMdomainfollowedbyacoiled-coildomain.Thecarboxyl-terminaldomain(CTD)ofmerlinisuniqueandlackstheconventionalactin-bindingmotiffoundinERMproteins.MerlinCTDcanassociatewithitsNH2-terminalFERMdomain,forminga‘‘closed’’andfunctionallyactiveconfiguration.Phosphorylationofmerlinatserine518disruptsthisintramolecularinteractionandsuppressesitsgrowthinhibitoryactivity.Thisphosphorylationismediatedbyp21-activatedkinases(Pak),whichbindtoactivated(GTPbound)Rac/Cdc42andfunctionastheirdirecteffectors(2,3).Inaddition,ithasbeenshownthatmerlinS518canalsobephosphorylatedbythecyclicAMP-dependentproteinkinase(PKA),whereasitsdephosphorylationinvolvesthemyosinphosphataseMYPT-1-PP1y(4,5).SeverallinesofevidenceindicatethatmerlinisnotonlyregulatedbytheRac-PakaxisbutalsofunctionsasaninhibitorofRacsignaling.Specifically,merlinoverexpressionsuppressesRac1-inducedactivationofc-Jun-NH2-terminalkinaseandactivatorprotein–1transcriptionalactivity,whereaslossofmerlinresultsintheopposite(6).Inaddition,merlininhibitionviadominant-negativemutantsorsiRNAenablesRac1recruitmenttoplasmamembraneandalleviatescontactinhibitioninconfluentcells(7).Furthermore,increasedlevelsofactivatedRacwithdisruptedtemporalcontrolhavebeenreportedinprimaryNF2-mutantschwannomacells(8,9).Finally,merlinoverexpressioninSchwanncellssuppressesPak1activity,whereasablationofmerlininMEFsleadstoPak1activation(7,10,11).TheinhibitoryactivityofmerlintowardPak1hasbeenattributedtoitsdirectinteractionwiththeRac-bindingdomainofPak1,whichinterfereswiththebindingofactivatedRactoPak1(10,12).Inthisstudy,weexaminewhetherinhibitingPakcanreversethetransformedandcancerphenotypesthatarisefromNF2deficiency.WefindthatPak1ishyperactiveinprimaryschwannomasisolatedfromNF2patientsandthatsuppressionofthePaksviashRNAsreducestheabilityofNF2mutantcellstogrowinvitroandformtumorsinaxenograftmodelofNF2.MaterialsandMethodsSchwannomabiopsies.FrozentissuesamplesfromNF2patientsthatunderwentsurgeryinMassachusettsGeneralHospital(MGH),werereceivedfromtheMGHBrainTumortissuerepository,undertheapprovaloftheMGHInstitutionalReviewBoard.Two-dimensionalgelanalysis.Frozentumorsamplesweremincedandproteinwasextractedinsamplebuffer(9.8mol/LUrea,2%CHAPS,5Al/mL0.5%IPGbufferpH4–7,DTT15mg/mL).Allsubsequentstepswereperformedaspreviouslydescribed(10).Cellcultureconditions.RT4andNIH3T3cellsweregrowninlow-glucoseDME,10%FCS,1nonessentialaminoacids,and100IU/mLpenicillin-streptomycin.TransfectionswereperformedwithLipofect-amine2000(Invitrogen),followingmanufacturer’sinstructions.ToinhibitDNAmethylation,5-aza-2¶-deoxycytidine(5-aza;Sigma)wasaddedtothemedia(5ng/mL).Note:SupplementarydataforthisarticleareavailableatCancerResearchOnline(http://cancerres.aacrjournals.org/).Requestsforreprints:JosephL.Kissil,WistarInstitute,3601SpruceStreet,Philadelphia,PA19104.Phone:215-898-3874;Fax:215-898-3792;E-mail:jkissil@wistar.org.I2008AmericanAssociationforCancerResearch.doi:10.1158/0008-5472.CAN-08-0866CancerRes2008;68:(19).October1,20087932www.aacrjournals.orgResearchArticleResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from KnockdownofPak1,2,and3usinglentiviraldeliveredshRNAs.ForsilencingendogenousPak1,2,and3inNIH3T3andRT4cells,severalsequencesweretestedandthefollowingtargetingsequenceswereselectedbasedontheirknockdownefficiency:Pak1,‘‘5¶-GGATTCTGTGCACAGA-TAA’’and‘‘5¶-GGAATGGATGGCTCTGTCA’’;Pak2,‘‘5¶-GAGATTATGGA-GAAATTAA’’;Pak3,‘‘5¶-GGAATTAATTATTAATGAA.’’DNAoligoscontainingindividualtargetingsequenceswereclonedintopLenti-lox3.7(pLL3.7)aspreviouslydescribed(13).TheresultingvectorswerecotransfectedwithpackagingvectorsVSVGandD8.9into293Tcellsandviralsupernatantwascollected48and72hposttransfection.Forinfection,cellswereincubatedwiththeviralsupernatantovernightandinfectedcells[greenfluorescentprotein(GFP)positive]wereselectedbyflowcytometry.Westernblotanalysis.Proteinextractswerepreparedwithradio-immunoprecipitationassaybuffer[50mmol/LTRIS-HCl(pH7.5),1%NonidetP-40,0.25%sodiumdeoxycholate,150mmol/LNaCl,1mmol/LEGTA,1mmol/Lsodiumorthovanadate,and1mmol/LNaF].Thefollowingantibodieswereusedaccordingtomanufactures’instructions:Pak1(N-20),Pak3(N-19),merlin(C-18;SantaCruz);Pak2(2608;CellSignaling);anda-tubulin(AC42)andh-actin(AC40;Sigma).Cellproliferationassays.Thirtythousandcellsperwellwereplatedin12-welldishesintriplicateforeachcellline.Atindicatedtimepoints,cellsfromindividualwellsweretrypsinizedandcountedusingaCoultercounter(Z1series;BeckmanCoulter).Cellswerefedevery3dthroughouttheassay.StatisticalanalysiswasperformedusingStudent’sttest.Tumorigenicityassays.Cellsweretrypsinized,washed,andresus-pendedat107cells/mLinPBS.Cells(106;100AL)wereinjecteds.c.intotheflanksof5-wk-oldnudemice(BALB/cnu/nu;TheJacksonLaboratory).Miceweremonitoredandtumordiametersweremeasuredweeklyafterinjections.Bisulfitesequencing.GenomicDNAwasfirstdigestedwithSacI,precipitated,anddissolvedindouble-distilledwater(ddH2O).Onemicroliterof6NNaOHwasaddedto19ALddH2Ocontaining2AgofthedigestedDNA,andincubatedat37jCfor15¶.Subsequently,120ALbisulfiteconversionsolution(107AL4.04MNaHSO3,7AL10mmol/LHydroquinone,and6AL6NNaOH)wasaddedtotheDNAsolution,andbisulfiteconversionwascarriedout(30"at95jCfollowedby15¶at50jCfor15cycles).Bisulfite-treatedDNAwasthendesalted(WizardDNAcleanupkit;Promega)andelutedin50ALTEbuffer.6NNaOH(2.5AL)wasaddedtotheelutedDNAandincubatedatRTfor5¶.DNAwasprecipitatedandresuspendedin30ALddH2O.Onemicroliterwasusedastemplateina20ALnestedPCRreactionwiththefollowingprimers:‘‘5¶-TTTAAAA-GAAAAGGGGGGATT’’and‘‘5¶-TCTCAAAACACACAATTACT.’’Onemicroli-terofthefirstroundwasusedastemplateforasecondroundofPCRusingthenestedprimers:‘‘5¶-AGGGGAAAGAATAGTAGATATAA’’and‘‘5¶-TTAAC-CRAAACAAAAAATAACC.’’TheresultingPCRproductwaspurifiedandsequencedusingprimer‘‘5¶-AGGGGAAAGAATAGTAGATATAA.’’Senescence-associatedB-Galassay.CellswerewashedthricewithPBSandfixedwith0.2%glutaraldehydefor5¶.AfterthreewasheswithPBS,cellswereincubatedovernightwithX-galsolution[1mg/mLX-gal,150mmol/LNaCl,2mmol/LMgCl2,5mmol/LK3Fe(CN)6,5mmol/LK4Fe(CN)6,and40mmol/LNaPi(pH6.0)at37jC].ResultsElevatedlevelsofPak1activityinprimaryschwannomatumorsamples.TheactivationofPak1involvesitsphosphoryla-tionatmultiplesites(10,14,15).Wehavepreviouslyestablishedatwo-dimensionalgelapproachtomonitorthephosphorylationstateofPak1,whichhasbeenshowntoaccuratelyreflecttheactivationstateofPak1inthecell(7,10).Byuseofthisapproach,weexaminedthestatusofPak1inprimaryschwannomasamplesisolatedfromNF2patients.Myelinatednervefromapatientwithwild-typeNF2wasusedascontrol.AsshowninFig.1A,Pak1migratesasasinglespottowardtheneutralpHrangein‘‘normal’’myelinatednerve,indicatingthatPak1ismostlyunphosophory-lated/inactive.Incontrast,withtheexceptionofsamplext3224,18ofthe19schwannomasamplesweanalyzeddisplayedvariousformsofphosphorylatedPak1(Fig.1AandB),indicativeofFigure1.Pak1isactivatedinschwannomasfromNF2patients.A,analysisofPak1activationbytwo-dimensionalgelelectrophoresiscoupledtoWesternblotanalysis.Arrowheads,variousphosphorylatedformsofPak1.B,summaryofPak1phosphorylationstatusinprimaryschwannomas.Allsampleswerenormalizedforvariationsinsampleloadingbycomparisontoactinasaninternalstandard.ValidationofPaksasTargetsinNeurofibromatosiswww.aacrjournals.org7933CancerRes2008;68:(19).October1,2008Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from Pak1activation.In6ofthe19samples,asexemplifiedbysamplext1441,themajorityofthePak1proteinsexistedinhighlyacidicforms,suggestiveofhyper-phosphorylation(Fig.1AandB).In12ofthe19samples,multipleformsofhypophosphorylatedorhyper-phosphorylatedPak1werepresent,asrepresentedbysamplext1729.ThesedatasuggestthatinprimarytumorsfromNF2patients,Pak1existsinaphosphorylated/activatedform.ThisisconsistentwithpreviousfindingsthatmerlinactsasadirectinhibitorofPak1(7,10).shRNA-mediateddepletionofPak1,2,and3inhibitstheproliferationandtumorigenicityofNIH3T3/NF2BBAcells.WehavepreviouslyshownthatexpressionofNF2BBA,adominant-negativeformofmerlin,inNIH3T3cellsinducedtransformation,lossofcontactinhibition,andtumorformationwheninjectedinnudemice(16).BecausePak1isthemostabundantmemberofthePakfamilyinNIH3T3cells,wefirstexaminedtheeffectofPak1inhibitioninthesecells.Weinfectedwild-typeNIH3T3orNIH3T3/NF2BBAcellswitheitheranemptylentiviralvectororvectorsharboringPak1-specificsmallhairpinRNAs(shRNA)andselectedinfected(GFPpositive)cellsbyflowcytometry.AsshowninFig.2A,Pak1proteinlevelsweresignificantlyreducedincellsinfectedwithlentivirusescarryingPak1shRNAs.Followingthegrowthkineticsofthesefourdifferentcelllines,wefoundthat,consistentwithpreviousfindings,NIH3T3/NF2BBAcellsgrowfasterthanwild-typeNIH3T3cells(Fig.2B).However,weobservednosignificantdifferencesingrowthratesbetweencellsinfectedwithemptyvectorsandthosewithPak1shRNAs(Fig.2B).WeinjectedthesefourcelllinesintonudemiceandfoundthatNIH3T3/NF2BBAcellsexpressingPak1shRNAsstilldevelopedtumorsofsimilarsizecomparedwithcontrolNIH3T3/NF2BBAcells(Fig.2C).Therefore,inhibitionofPak1aloneisnotsufficienttocountertheeffectofmerlinimpairmentinNIH3T3/NF2BBAcells.SimilarresultswereobtainedwheneitherPak2orPak3wasknockeddownindividuallyinNIH3T3/NF2BBAcells(SupplementaryFig.S1).BecausePak1,2,and3sharehighsequencehomologies,wereasonedthatthelossofindividualPakislikelycompensatedbytheothertwomembersofPaks.Toinvestigatethispossibility,weinfectedNIH3T3withlentivirusescarryingshRNAsspecificforPak1,Pak2,andPak3.AsshowninFig.3A,theseNIH3T3cellsshowedsignificantreductionofallthreePaks.WecharacterizedtherespectiveproliferationkineticsofNIH3T3andNIH3T3/NF2BBAcellsinfectedwithcontrollentivirusesorthoseexpressingshRNAsagainstPak1to3.IncontrasttothelackofeffectobservedinPak1ablationalone,knockdownofallthreePaksdramaticallyreducedthegrowthratesoftheNIH3T3/NF2BBAcells(Fig.3B;Supplemen-taryFig.S1),indicatingthatdepletionofallthreePakssuccessfullyreversedthehyperproliferativeeffectofmutantmerlininourcellularmodel.KnockdownofPak1-3alsodecreasedtheprolifer-ationrateofwild-typeNIH3T3cells,buttoamuchlesserextend,comparingtothedramaticeffectsobservedintheNIH3T3/NF2BBAcells(Fig.3B).WenextinjectedNIH3T3/NF2BBAcellscarryingemptyvectorsorPak1-3shRNAssidebysideintotheflanksofnudemiceandfollowedthedevelopmentoftumorsoverthecourseofseveralweeks.Inagreementwithourpreviousstudy(16),thecontrolNIH3T3/NF2BBAcells(leftflanks)quicklydevelopedintotumors,reachinganaveragediameterof160mmby3weekpostinjection(Fig.3C;SupplementaryTableS1).Incomparison,NIH3T3/NF2BBAcellsexpressingPak1-3shRNAs(rightflanks)resultedineithernotumorsormuchsmallertumorsataconsiderablydelayedrate.Theaveragediameteroftumorsthateventuallydevelopedfromthesecellswascloseto10mmat3weekspostinjection(Fig.3C;SupplementaryTableS1).TheseresultsindicatethatsimultaneoussuppressionofallthreePakscanatleastpartiallyinhibittheabilityofNf2BBAtoinducetumorformationinaxenograftmodelofNF2,whichcorroborateourhypothesisthatinhibitingPakscouldserveasapotentialtreatmentforNF2.ToinvestigatewhatcausedtheeventualdevelopmentofsmalltumorsfrominjectedNIH3T3/NF2BBAcellsexpressingPak1-3shRNAsinsomeofthemice,weisolatedthetumorsfrombothflanksofthesemiceandexaminedtheexpressionlevelsofPak1,2,and3.AsshowninFig.3D,intwoofthemiceexamined(#7007and#7049),theexpressionofatleasttwoofthePakswaspartiallyrestoredtosimilarlevelsofthoseintumorsfromcontrolNIH3T3/NF2BBAcells.Thismayexplainwhythesecellsdideventuallyformtumors.Inathirdmouse(#7045),thelevelsofallthreePaksFigure2.Pak1knockdownonNIH3T3cellsisinsufficienttoinhibitcelltransformationduetoimpairedNF2function.NIH3T3(WT)orNIH3T3/NF2BBA(NF2BBA)cellswereinfectedwithemptylentiviruses(Lenti)orlentivirusesharboringPak1shRNAs(Lenti-Pak1sh).A,Pak1expressionlevelsweredeterminedbyWesternblotanalysis.Actinwasusedasaninternalstandard.B,cellularproliferationkinetics.Cells(3104)fromeachofthecelltypesabovewereplatedintriplicateinto12-wellplates.Cellswereharvestedandcountedatday0,1,2,3,and4.Thedataarerepresentativeofthreeindependentexperiments.Points,mean;bars,SD.C,tumorformationcapability.Cells(106)wereinjectedintotherearflanksofseverecombinedimmunodeficientmice.Fourmicewereusedforeachcellline.Tumorsweremeasured15dafterinjections.CancerResearchCancerRes2008;68:(19).October1,20087934www.aacrjournals.orgResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from remainedlowinthetumordevelopedfromPak-shRNAexpressingNIH3T3/NF2BBAcells(Fig.3D),indicatingthatadditionalmecha-nismsinvolvedinoffsettingthelossofPakinthesecells.SchwannomacellsaredependentonPak1andsilencePak1shRNAexpressionviadenovomethylation.BecauseNF2patientsprimarilydevelopSchwanncelltumors,wenextexaminedtheeffectofPakknockdowninawell-characterizedratschwannnomacellline,RT4.UnlikeNIH3T3cellsinwhichallthreePaksareexpressed,RT4cellsexpresspredominantlyPak1(SupplementaryFig.S2).WeinfectedRT4cellswithlentivirusescarryingthesamePak1-specificshRNAsthatwereusedinNIH3T3cells(Figs.2and3),andasexpected,RT4cellsshowedsignificantlyreducedPak1expressionaftertheinfection(Fig.4A).However,thePak1levelsinRT4cellsinfectedwithPak1shRNAswerequicklyrestored,withintwotothreepassages,tosimilarlevelsfoundincontrolRT4cells(Fig.4A).Correspondingly,theexpressionlevelofGFP,apositiveselectionmarkerinthelentiviralvector,pLenti-lox3.7,intowhichPak1shRNAswerecloned,droppedrapidlyduringthefirsttwotothreepassagesoftheinfectedRT4cells(Fig.4A).GiventherapidnatureofrestorationinPak1levelsandconcurrentdown-regulationofGFPexpression,wesuspectedthatRT4cellsmighthaveusedanepigeneticmechanism,namelyDNAmethylation,tosilencePak1shRNAexpressionandrestorelevelsofPak1.Totestwhetherthisisindeedthecase,wecarriedoutbisulfitesequencingtodirectlyexaminethemethylationstatusonthef200bppromoterregioninpLenti-lox3.7thatdrivesPak1shRNAexpression.AsshowninFig.4B,multipleCpGsiteswereindeedmethylatedwithinthisrelativelysmallregioninhighpassageRT4cellscarryingpLenti-Pak1shRNAs.TofurtherconfirmthatmethylationisresponsibleforsilencingPak1shRNAexpression,weaddedthemethylationinhibitor5-azaintothecellculturemediumofRT4cellscarryingemptyvectorsorPak1shRNAs,whichhadbeenpassedatleast8timesanddisplayedsimilarPak1expressionlevels(Fig.4C).Thecellswereculturedforseveraldaysinthepresenceof5-aza,andPak1expressionlevelswereexaminedatdifferenttimepoints.Incontrasttowhatweobservedwiththesecellswithout5-azatreatment(Fig.4A),afteronlyasingledayof5-azatreatment,Pak1levelsweresignificantlyloweredinRT4cellscarryingPak1shRNAswhencomparedwithcontrolRT4cells(Fig.4C).WewereabletosustainthissuppressionofPak1expressionforatleast3daysoftreatment(Fig.4C).Thus,RT4cellsevadePak1inhibitionbyshuttingdownPak1shRNAexpressionthroughmethylationofthepLenti-lox3.7promoter.WethenmeasuredthegrowthratesofRT4cellscarryingemptyvectorsorPak1shRNAsinthepresenceorabsenceof5-aza.Intheabsenceof5-aza,RT4cellsinfectedwithPak1shRNAsshowedonlyslightlyreducedgrowthratecomparedwithcontrolRT4cells(Fig.4D).Inthepresenceof5-aza,controlRT4cellsgrewrelativelyslowerthanuntreatedcells(Fig.4D).Thisisnotsurprising,consideringthat5-azaisaglobalmethylationinhibitor.Insharpcontrast,however,RT4cellscarryingPak1shRNAscompletelyfailedtogrowundercultureconditionsthatincluded5-aza(Fig.4D).Thedifferenceisalsoobviousinthemorphologiesofthesecells.Comparedwiththemostlyspindle-shapeduntreatedor5-aza–treatedcontrolRT4cells,thePak1-shRNA–infectedRT4cellsgrowninthepresenceof5-azaareenlargedandflattened,displayingamorphologyconsistentwithcellularsenescence(Fig.4E).Thesecellsalsostainedpositiveforthesenescence-associatedexpressionofh-galactosidaseactivity,indicatingthatFigure3.KnockdownofPak1-3issufficienttoinhibitcellulartransformationduetoimpairedNF2function.TheeffectsofsimultaneousPak1+2+3knockdownwereexaminedinNIH3T3orNIH3T3/NF2BBAcellsinfectedwithemptylentivirusorlentivirusesharboringPak1+2+3shRNAs.A,WesternblotanalysisofPak1,2,and3levels.Actinwasusedasaninternalstandard.B,assessmentofcellularproliferation.Cells(3104)wereplatedintriplicateinto12-wellplates.Cellswereharvestedandcountedatday0,1,2,3,4,5,and6.Thedataarerepresentativeofthreeindependentexperiments.Points,mean;bars,SD.C,tumorsizedistributioninseverecombinedimmunodeficientmice.Tumorformationwasassessedbyinjecting5105NIH3T3-NF2BBAcellsinfectedwithemptyvirus(Lenti)intotheleftflanksand5105ofNIH3T3/NF2BBA-Lenti-PAK1-3shintotherightflanksofthesamemice.Fivemicewereusedintotal.Thesizeoftumorswasmeasured23dafterinjection.Horizontallines,averagetumordiameters.D,Westernblotanalysisoftumorsdissectedfrommice#7007,#7045,and#7049.L,tumorsfromleftflankarisingfromNIH3T3/NF2BBA/Lenticells;R,tumorsfromrightflankarisingfromNIH3T3/NF2BBA/Lenti-PAK1-3shcells.ValidationofPaksasTargetsinNeurofibromatosiswww.aacrjournals.org7935CancerRes2008;68:(19).October1,2008Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from sustainedexpressionofPak1shRNAsinRT4cellsleadstoinhibitionofPak1expression,resultingincellularsenescence(Fig.4E).Importantly,RT4cellstransientlytransfectedwithPak1siRNAs,whichshouldnotbesusceptibletomethylation-mediatedsilenc-ing,didnotproliferateduringthefirstfewdaysposttransfection(SupplementaryFig.S2A).ConsistentwiththenotionthatPak1isthedominantPakinRT4cells,cotransfectionofPak2siRNAswithPak1siRNAsfailedtofurtherreducethegrowthrateofRT4cells(SupplementaryFig.S2B).Takentogether,weconcludedthatRT4cellsrequirePak1forproliferationandquicklymovetosilencePak1shRNAexpressionthroughdenovomethylation.DiscussionWehaveshownforthefirsttimethatPak1ishighlyactivatedinprimaryschwannomasfromNF2patients.ThisisconsistentwithourhypothesisthatmerlinfunctionsasatumorsuppressorbyblockingPakactivation.Employingbothcellularandanimalmodels,wedirectlytestedthishypothesis.WefoundthatthesimultaneousknockdownofallthreePaksisrequiredtocounterthehyperproliferationandtumor-formingcapacityofNIH3T3cellsharboringtheNF2BBAallele.Takentogether,theseresultsvalidatePaksaspotentialtargetsforthedevelopmentofNF2therapeutics.PreviousstudieshavelinkedPak1tocancerandtransformationanduseofPakinhibitorstoreversecellulartransformationhavealsobeenreported(17–19).However,thesestudiesareinconclu-sive,astheinhibitorsusedarebroad-rangekinaseinhibitorsthatdonotspecificallyinhibitPaks.Therefore,theimportantnextstepistodevelopspecificPakinhibitorsandtestthemincellularandanimalmodelsofNF2.AnotherinterestingfindinginthisstudyisthatdifferentcelltypesresponddifferentlytoPak1inhibition.AlthoughknockdownofPak1isinconsequentialinNIH3T3cells(Fig.2),Pak1ablationinRT4cellsleadstogrowtharrest(Fig.4D;SupplementaryFig.S2).Inaddition,NIH3T3cellsmaintainedreducedPak1expressionmediatedbyPak1shRNAsevenafterover20passages(datanotshown),whereasRT4cellsquicklysilencedPak1shRNAviadenovomethylation(Fig.4AandB).ThesedifferencessuggestthatalthoughPak1isprobablythedominantPakinRT4cells,itfunctionsredundantlywithPak2andPak3inNIH3T3cells.However,becausePak1,2,and3arehighlyhomologous,especiallywithintheircatalyticdomains,itismostlikelythatanyPakinhibitorswillworkequallywellonallthreePakisoforms.Therefore,thesecelltypedifferencesinPakfunctionshouldnotaffecttheeffectivenessofPakinhibitors.Figure4.RatschwannomacellsaredependentonPak1expression.A,WesternblotanalysisofPak1expressioninRT4cellsatvariouspassagesafterinfectionwithlentivirusesharboringaPak1specificshRNA.RT4cellsinfectedwithemptylentivirusvectorwereusedascontrol.Actinservesasaninternalloadingcontrol.B,methylationanalysisofLenti-shPak1promoterinRT4cells.ThegenomicDNAwasisolatedfromRT4cellsatpassage6afterinfectionwithlentivirusesharboringaPak1-specificshRNAandsubjectedtobisulfiteconversion,methylation-specificPCRs,anddirectsequencing.*,cytosinesintheoriginalsequencethathavebeencompletelyorpartiallyconvertedtouracils;arrowheads,unconverted/methylatedcytosines.C,WesternblotanalysisofPak1expressioninRT4cellsinfectedwithemptylentivector( )orPak1shRNA(+)treatedwith5-aza.The5-azawasaddedtotheculturemediumat5ng/mLfinalconcentration.Thecellswereharvestedandanalyzedatday0,1,2,and3intothetreatment.D,assessmentofcellularproliferation.Cells(4104)wereplatedintriplicateinto12-wellplatesandcellswereharvestedandcountedatday0,1,2,3,and4.Thedataarerepresentativeofthreeindependentexperiments.Points,mean;bars,SD.E,imagesofRT4cellsinfectedwithvectororPak1shRNAafter3dofcultureinthepresence(+5-aza)orabsence( 5-aza)of5-aza.Inthebottompanel,RT4cellswerefirstfixedandstainedwithX-gal.ImagesweretakenusingNikonCoolpix995digitalcameraunderLeicaDM1Llightmicroscopeat10magnification.CancerResearchCancerRes2008;68:(19).October1,20087936www.aacrjournals.orgResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from Finally,virus-deliveredshRNAhavebeenproposedasapotentialtherapeutictoolintreatinghumandiseasessuchascancer(20).Asdescribedinthisstudy,anshRNAtargetinganessentialgene,inourcase,Pak1inRT4cells,canbesilenceddirectlybyDNAmethylation.FurtherresearchshouldbecarriedouttoinvestigatewhetherothercelltypescanalsousesimilarmechanismstosilencestablyintegratedforeignshRNAandhowfrequentlysucheventscanoccur.Addressingthesequestionswouldbeprudentbeforeanyfutureapplicationofsuchtechnologiesasatreatmentmodality.DisclosureofPotentialConflictsofInterestNopotentialconflictsofinterestweredisclosed.AcknowledgmentsReceived3/7/2008;revised7/14/2008;accepted7/22/2008.Grantsupport:DepartmentofDefenseNeurofibromatosisResearchProgram.C.YiisarecipientofRuthL.KirschsteinNRSAfellowship.Thecostsofpublicationofthisarticleweredefrayedinpartbythepaymentofpagecharges.Thisarticlemustthereforebeherebymarkedadvertisementinaccordancewith18U.S.C.Section1734solelytoindicatethisfact.WethankDr.JoanneThorvaldsenforadviceonbisulfitesequencing.ValidationofPaksasTargetsinNeurofibromatosiswww.aacrjournals.org7937CancerRes2008;68:(19).October1,2008References1.YohayKH.Thegeneticandmolecularpathogen-esisofNF1andNF2.SeminPediatrNeurol2006;13:21–6.2.KissilJL,JohnsonKC,EckmanMS,JacksT.Merlinphosphorylationbyp21-activatedkinase2andeffectsofphosphorylationonmerlinlocalization.JBiolChem2002;277:10394–9.3.XiaoGH,BeeserA,ChernoffJ,TestaJR.p21-activatedkinaselinksRac/Cdc42signalingtomerlin.JBiolChem2002;277:883–6.4.AlfthanK,HeiskaL,GronholmM,RenkemaGH,CarpenO.CyclicAMP-dependentproteinkinasephosphorylatesmerlinatserine518independentlyofp21-activatedkinaseandpromotesmerlin-ezrinhetero-dimerization.JBiolChem2004;279:18559–66.5.JinH,SperkaT,HerrlichP,MorrisonH.TumorigenictransformationbyCPI-17throughinhibitionofamerlinphosphatase.Nature2006;442:576–9.6.ShawRJ,PaezJG,CurtoM,etal.TheNf2tumorsuppressor,merlin,functionsinRac-dependentsignal-ing.DevCell2001;1:63–72.7.XiaoGH,GallagherR,ShetlerJ,etal.TheNF2tumorsuppressorgeneproduct,merlin,inhibitscellprolifer-ationandcellcycleprogressionbyrepressingcyclinD1expression.MolCellBiol2005;25:2384–94.8.KaempchenK,MielkeK,UtermarkT,LangmesserS,HanemannCO.UpregulationoftheRac1/JNKsignalingpathwayinprimaryhumanschwannomacells.HumMolGenet2003;12:1211–21.9.NakaiY,ZhengY,MacCollinM,RatnerN.TemporalcontrolofRacinSchwanncell-axoninteractionisdisruptedinNF2-mutantschwannomacells.JNeurosci2006;26:3390–5.10.KissilJL,WilkerEW,JohnsonKC,EckmanMS,YaffeMB,JacksT.Merlin,theproductoftheNf2tumorsuppressorgene,isaninhibitorofthep21-activatedkinase,Pak1.MolCell2003;12:841–9.11.MorrisonH,SperkaT,ManentJ,GiovanniniM,PontaH,HerrlichP.Merlin/neurofibromatosistype2sup-pressesgrowthbyinhibitingtheactivationofRasandRac.CancerRes2007;67:520–7.12.HirokawaY,TikooA,HuynhJ,etal.Acluetothetherapyofneurofibromatosistype2:NF2/merlinisaPAK1inhibitor.CancerJ2004;10:20–6.13.RubinsonDA,DillonCP,KwiatkowskiAV,etal.Alentivirus-basedsystemtofunctionallysilencegenesinprimarymammaliancells,stemcellsandtransgenicmicebyRNAinterference.NatGenet2003;33:401–6.14.BuchwaldG,HostinovaE,RudolphMG,etal.ConformationalswitchandroleofphosphorylationinPAKactivation.MolCellBiol2001;21:5179–89.15.ChongC,TanL,LimL,ManserE.ThemechanismofPAKactivation:auto-phosphorylationeventsinbothregulatoryandkinasedomainscontrolactivity.JBiolChem2001;22:22.16.JohnsonKC,KissilJL,FryJL,JacksT.CellulartransformationbyaFERMdomainmutantoftheNf2tumorsuppressorgene.Oncogene2002;21:5990–7.17.TangY,ChenZ,AmbroseD,etal.Kinase-deficientPak1mutantsinhibitRastransformationofRat-1fibroblasts.MolCellBiol1997;17:4454–64.18.VadlamudiRK,AdamL,WangRA,etal.Regulatableexpressionofp21-activatedkinase-1promotesanchor-age-independentgrowthandabnormalorganizationofmitoticspindlesinhumanepithelialbreastcancercells.JBiolChem2000;275:36238–44.19.HoweAK,JulianoRL.Regulationofanchorage-dependentsignaltransductionbyproteinkinaseAandp21-activatedkinase.NatCellBiol2000;2:593–600.20.LuPYXF,WoodleMC.InvivoapplicationofRNAinterference:fromfunctionalgenomicstotherapeutics.AdvGenet2005;54:117–42.Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from 2008;68:7932-7937. Cancer Res(cid:160)(cid:160) Chunling Yi, Erik W. Wilker, Michael B. Yaffe, et al. (cid:160) Inhibition in Neurofibromatosis Type 2Validation of the p21-Activated Kinases as Targets for(cid:160) Updated version(cid:160)  http://cancerres.aacrjournals.org/content/68/19/7932Access the most recent version of this article at:(cid:160) MaterialSupplementary(cid:160)  http://cancerres.aacrjournals.org/content/suppl/2008/09/26/68.19.7932.DC1Access the most recent supplemental material at:(cid:160) (cid:160) (cid:160) (cid:160) (cid:160) Cited articles(cid:160)  http://cancerres.aacrjournals.org/content/68/19/7932.full.html#ref-list-1This article cites 20 articles, 10 of which you can access for free at:(cid:160) Citing articles(cid:160)  /content/68/19/7932.full.html#related-urlsThis article has been cited by 12 HighWire-hosted articles. Access the articles at:(cid:160) (cid:160) (cid:160) E-mail alerts related to this article or journal.Sign up to receive free email-alerts(cid:160) SubscriptionsReprints and (cid:160) .pubs@aacr.orgDepartment atTo order reprints of this article or to subscribe to the journal, contact the AACR Publications(cid:160) Permissions(cid:160) .permissions@aacr.orgDepartment atTo request permission to re-use all or part of this article, contact the AACR PublicationsResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from American Journal of EpidemiologyCopyright O 2000 by The Johns Hopkins University School of Hygiene and Public HealthAll rights reservedVol. 151, No. 1Printed h) U.SA.NF1 Gene and Neurofibromatosis 1Sonja A. Rasmussen1 and J. M. Friedman2Neurofibromatosis 1 (NF1), also known as von Recklinghausen disease, is an autosomal dominant conditioncaused by mutations of the NF1 gene, which is located at chromosome 17q11.2. NF1 is believed to becompletely penetrant, but substantial variability in expression of features occurs. Diagnosis of NF1 is based onestablished clinical criteria. The presentation of many of the clinical features is age dependent. The average lifeexpectancy of patients with NF1 is probably reduced by 10-15 years, and malignancy is the most commoncause of death. The prevalence of clinically diagnosed NF1 ranges from 1/2,000 to 1/5,000 in most population-based studies. A wide variety of NF1 mutations has been found in patients with NF1, but no frequently recurringmutation has been identified. Most studies have not found an obvious relation between particular NF1 mutationsand the resulting clinical manifestations. The variability of the NF1 phenotype, even in individuals with the sameNF1 gene mutation, suggests that other factors are involved in determining the clinical manifestations, but thenature of these factors has not yet been determined. Laboratory testing for NF1 mutations is difficult. A proteintruncation test is commercially available, but its sensitivity, specificity, and predictive value have not beenestablished. No general, population-based molecular studies of NF1 mutations have been performed. At thistime, it appears that the benefits of population-based screening for clinical features of NF1 would not outweighthe costs of screening. Am J Epidemiol 2000;151:33-40.neurofibromatosis; neurofibromatosis 1GENEThe neurofibromatosis 1 (NF1) gene is located atchromosome 17qll.2. NF1 and its protein product,neurofibromin, were characterized in 1990 (1, 2). Thegene is large, spanning 350 kilobases of genomicDNA, and contains 60 exons (3). Neurofibrominbelongs to a family of proteins that serve as negativeregulators of the ras oncogene (4). Neurofibromin isbelieved to act as a tumor suppressor, but the proteinhas other functions as well. The proposed tumor sup-pressor function is supported by the findings ofsomatic "second hit" mutations of the NF1 gene inbenign and malignant tumors from NF1 patients (5, 6).NF1 is an autosomal dominant condition with virtu-ally 100 percent penetrance by adulthood (7). About50 percent of NF1 cases result from new mutations.Germline mosaicism has been observed (8) and mustReceived for publication March 25, 1999, and accepted for publi-cation August 19, 1999.Abbreviations: NF1, neurofibrofnatosis 1; NF2, neurofibromatosis 2.' Centers for Disease Control and Prevention, Division of BirthDefects and Developmental Disabilities, Atlanta, GA.2 Department of Medical Genetics, University of British Columbia,Vancouver, British Columbia, Canada.Reprint requests to Dr. Sonja A. Rasmussen, Centers for DiseaseControl and Prevention, 4770 Buford Highway NE, MS F-45, Atlanta,GA 30341.be considered when counseling unaffected parents ofcases with new mutations. The NF1 mutation rate isamong the highest observed in humans, with estimatesranging from about 1/7,800 to 1/23,000 gametes (7, 9).About 90 percent of new mutations occur on the pater-nally derived chromosome (10, 11). The exception islarge deletions, which are usually of maternal origin(12, 13).GENE VARIANTSAs of February 1999, the NF1 Genetic AnalysisConsortium documented more than 240 different con-stitutional NF1 mutations in its database(http://www.nf.org/nflgene/). Table 1 summarizes thetypes of mutations identified thus far. The majority ofmutations lead to a truncated protein product; onlyabout 10 percent involve amino acid substitutions, andfewer than 2 percent are 3' untranslated region muta-tions. However, it should be noted that the types ofmutations identified are largely dependent on the tech-niques used for mutation detection. This may result inan overrepresentation of mutation types that are moreeasily identified (e.g., large gene deletions) and anunderrepresentation of those that may be more difficultto identify (e.g., mutations in the 3' untranslatedregion). None of the methods used for NF1 mutationdetection are capable of identifying all mutation types.3334 Rasmussen and FriedmanTABLE 1. Summary of NF1 mutation types*TVpe of mutationChromosome abnormalityDeletion of entire geneMulti-exon deletionSmall deletionLarge InsertionSmall InsertionStop mutationAmino acid substitutionIntron mutation3' untranslated region mutationTotalNo. of cases41838553274329254246• Reported to the NF1 Genetic Analysis Consortium(http://www.nf.org/nf1gene/) as of February 1999.Mutations have been identified throughout the gene.While some recur in different families, no true"hotspots" have been found in NFL The most fre-quently recurring alteration is a nonsense mutation inexon 31 (R1947X) that accounts for 1-2 percent of theNF1 mutations identified (14).At this time, no information is available on the fre-quency of different mutations in different populationsand ethnic groups.DISEASESClinical features of NF1Neurofibromatosis 1 (NF1), also known as vonRecklinghausen disease, is the condition most com-monly associated with NF1 gene mutations. Early dis-cussions of NF1 referred to the condition as "neurofi-bromatosis" and included cases of the much lessfrequent condition, neurofibromatosis 2 (NF2).However, these conditions are both clinically andgenetically distinct. The most characteristic lesions ofNF2 are bilateral schwannomas on the vestibular por-tion of the eighth cranial nerve; such tumors are rarelyseen in NF1 patients. NF2 results from mutations inthe NF2 gene on chromosome 22.Despite advances in understanding of the moleculargenetics of NF1, its diagnosis remains a clinical one,based on diagnostic criteria established by a NationalInstitutes of Health consensus conference (15, 16). Adiagnosis of NF1 by these criteria requires the pres-ence of two or more of the following: 1) six or morecaf6-au-lait macules more than 5 mm in greatest diam-eter in prepubertal individuals and more than 15 mm ingreatest diameter after puberty; 2) two or more neu-rofibromas of any type or one plexiform neurofibroma;3) freckling in the axillary or inguinal regions; 4) anoptic pathway tumor; 5) two or more Lisch nodules(iris hamartomas); 6) a distinctive osseous lesion, suchas sphenoid wing dysplasia or thinning of the cortex oflong bones (with or without pseudarthrosis); or 7) afirst-degree relative (parent, sibling, or child) withNF1 diagnosed by the above criteria.Some of these features, including caf6-au-lait spots,freckling in non-sun-exposed areas, and iris Lisch nod-ules, are not of clinical significance beyond their use-fulness in making a diagnosis of NF1. Benign cuta-neous and subcutaneous neurofibromas are present innearly all patients with NF1 by adulthood, and theirnumber in an individual varies widely from only a fewto hundreds or more. While these lesions are primarilyof cosmetic significance, they may be disfiguring andresult in significant psychologic distress. In contrast,about 15 percent of individuals with NF1 have plexi-form neurofibromas (17). These tumors may extendinto contiguous tissues, causing serious functionalimpairment and even death and appear to be the site ofmalignant peripheral nerve sheath tumor development.Optic pathway tumors are observed in about 20 percentof the children with NF1, but most such tumors do notcause ophthahnologic or other symptoms (18). Bonychanges, such as pseudarthrosis, appear to occur inabout 5 percent of the cases (17). Often these changesare benign; however, some patients are severelyaffected, with long-bone bowing leading to fractureand, in some cases, requiring amputation (19).Several other features are often associated with NF1,including macrocephaly, scoliosis, short stature,hypertension, and high-T2-signal-intensity lesions onmagnetic resonance imaging of the brain (16). Mostindividuals with NF1 have normal intelligence, but30-60 percent have learning disabilities (20).Individuals with NF1 also appear to be at increasedrisk for malignancy, but the magnitude of this is diffi-cult to estimate, given the paucity of epidemiologicstudies. In an investigation of a Danish cohort of 212NF1 patients followed for 42 years, a relative risk of4.0 (95 percent confidence interval: 2.8, 5.6) wasobserved for malignant neoplasms or benign centralnervous system tumors among probands. Since theprobands had been identified initially through hospi-tals and might represent a bias toward more severelyaffected cases, the relative risk was also determined foraffected relatives; this risk was 1.5 (95 percent confi-dence interval: 0.9, 2.4). The risk was greater forfemales than for males (21).Certain types of cancers occur more frequently inindividuals with NFL Malignant peripheral nervesheath tumors, often referred to as neurofibrosarcomas,are the most common malignancy occurring withincreased frequency in NFL These aggressive tumorsare relatively resistant to therapy and are often lethalAm J Epidemiol Vol. 151, No. 1, 2000NF1 Gene and Neurofibromatosis 1 35(22). Central nervous system tumors, including opticpathway tumors, other astrocytomas, ependymomas,medulloblastomas, and others, also occur more fre-quently in NF1 patients (23). In addition, individualswith NF1 have an increased risk for myeloidleukemias, with over a 200-fold relative risk forchronic myelomonocytic leukemia (24). The increasedrisk for malignancies in NF1 is compatible with thefinding that the NF1 protein serves as a down-regulatorof the ras oncogene (4). An increased risk for malig-nancy could be predicted to result from inactivation ofthis tumor suppressor function through NF1 mutation.The presentation of most NF1 features is age depen-dent. Caf6-au-lait spots may be present at birth andincrease in number in early childhood. Skinfold freck-ling is most often observed next. Neurofibromas fre-quently first appear or increase in number betweenages 10 and 20 years. Lisch nodules of the iris areoften not present in childhood but are seen in nearly alladults with NF1 (17).Prevalence of NF1For several reasons, NF1 is a difficult condition forwhich to determine an accurate prevalence number.First, the wide variability in expression means that mildcases may escape ascertainment in studies dependent onan affected individual coming to medical attention.Second, the age-dependent presentation of most NF1features means that examination of young children maymiss cases that are truly affected with the condition.Third, the increased mortality seen in individuals withNF1 (see Mortality of NF1, below) reduces the preva-lence in later adulthood. Prevalence studies are summa-rized in table 2 and suggest that NF1 is one of the mostcommon autosomal dominant conditions. The preva-lence does not appear to differ by gender. The wide vari-ation in prevalence estimates may reflect differences indiagnostic criteria and methods of case ascertainment ofthe studies; however, the variation may also representtrue differences between populations, perhaps due to afounder effect (particularly in smaller populations) orother factors. One study (25) demonstrated differencesin NF1 prevalence among various ethnic groups, with ahigher prevalence in individuals of North African andAsian origins (1/522 and 1/1,052, respectively) and alower frequency among individuals of European andNorth American backgrounds (1/1,562). These differ-ences were statistically significant, and case ascertain-ment in this study was based on a mandatory physicalTABLE 2. Studies of the prevalence of neurofibromatosis 1StudysiteNo.screenedEthnic originof populationstudiedMethodofascertainmentAge ofcasesascertainedEstimatedprevalenceReferenceMichigan 252,092 Residents of MichiganUSSR 94,000 Primarily "Russian"Surveys of general hospital admissionsand state Institutions for the mentallyretarded and "epileptic" (estimateextrapolated from these populations)Screening examination for 6-cafe-au-laltspots as part of evaluation for militaryduty; detailed examination for thoseinitially identifiedSwedenSoutheastWalesNew ZealandItalyIsraelFinland440,082668,100113,7002,375,304374,440732,000Residents of Goteberg,SwedenResidents of southeastWalesBritish descent with"substantial Scotscomponent"Northeast ItalyPrimarily from Europe,North America, Asia,North Africa, and IsraelResidents of northernFinlandMedical record review, letters to medicalInstitutions and physicians, assessmentof family members of affected casesMedical record review, letters to physicians,assessment of family members ofaffected casesMedical record review, letters to physicians,assessment of family members ofaffected casesCases from genetics service and fromcomputerized hospital dataPhysical examination as part of evaluationof fitness for military dutyMedical record reviewAll ages16 years1/2,500-1 /3.300* 551/7,80Ot20 years and older 1/4,6005657AllegesAlleges17 yearsAll ages1/4,150*1/2,1901/6,7111/9601/3,71658592522* Estimated incidence at birth.t Assumes that about three quarters of the cases of NF1 would be ascertained through mass medical examination for at least six cafe-au-lart spots.X Corrected estimate based on possible "missed," mildly affected cases, especially in children.Am J Epidemiol Vol. 151, No. 1, 200036 Rasmussen and Friedmanexamination for fitness for military service, suggestingthat referral bias was not responsible for the observeddifferences. The question of the true prevalence of NFland whether it differs significantly between populationswill require further study.Mortality of NF1The best available mortality data are from apopulation-based study of NFl patients living inGoteberg, Sweden (26). Adults (age 20 years andolder) with NFl were ascertained through multiplemedical specialities. The average age at the time ofascertainment was 43.6 ± 15.4 years for the 70 patientsfollowed. Cases were followed for 12 years. Over thistime period, 22 of the 70 NFl patients died; 5.1 deathswere expected on the basis of the general Swedishpopulation. Of these 22 deaths, 13 were women andnine were men, with 1.7 and 3.4 deaths expected in thepopulations, respectively, leading the authors to sug-gest that women may be affected more than men. Thestudy showed a significantly reduced life expectancyin patients with NFl (p < 0.001), with a mean age atdeath of NFl patients of 61.6 years compared with alife expectancy in the general population of 75 years.Malignancy was the most common cause of death,occurring in 12 (55 percent) of the patients (26, 27).Hypertension significantly associated with mortality;10 of 12 patients with high blood pressure died duringthe observation period.NF1 risk factorsPaternal age has been shown to be significantlyadvanced in sporadic cases of several other autosomaldominant disorders, but whether paternal age isadvanced in sporadic cases of NFl is not clear. A studyin Texas (28) recently addressed this question. Paternalage was obtained from the birth certificates of cases(identified as NFl patients seen in two specialty neu-rofibromatosis clinics) and birth certificates of controls(two per case, chosen at random from the same year andcounty of birth). Fathers of NFl patients were 1.5 yearsolder than were fathers of controls at the birth of thechild, but this difference was not statistically significant(p = 0.07) (28). It appears that the paternal age effect insporadic cases of NFl is either small or nonexistent.ASSOCIATIONSNFl is the condition most commonly associatedwith NFl gene mutations. For NFl, the penetrance isbelieved to be virtually 100 percent by adulthood (29);that is, individuals with an NFl gene mutation haveclinical manifestations of NFl, usually by age 6 years.Most studies have not found an obvious relationbetween particular NFl mutations and resulting clini-cal manifestations in a patient. However, attempts atgenotype-phenotype correlation in NFl are con-founded by the effect of age, which increases the fre-quency of disease manifestations and the likelihood ofserious complications in all patients. In addition, thereis no consensus regarding how to define NFl severity.Some studies of patients with large NFl gene dele-tions indicate that they may have earlier onset of cuta-neous neurofibromas and more often have dysmorphicfacial features and mental retardation than do mostNFl patients (13, 30, 31). However, not all NFlpatients with this phenotype have a large gene deletion(32), and some with large gene deletions have an unre-markable NFl phenotype (33), raising questions aboutthis genotype-phenotype relation. The presence of amore severe phenotype may be a function of theamount of flanking DNA involved in the deletionrather than of the NFl gene deletion itself.Certain variants of NFl have been associated eitherwith specific NFl mutations or with linkage to theNFl gene, at least in some cases. These includeWatson syndrome (characterized by pulmonic steno-sis, caf6-au-lait spots, short stature, and cognitiveimpairment) (34, 35); familial multiple caf6-au-laitspots (without other NFl features) (36-38); familialspinal neurofibromatosis (characterized by spinaltumors and, sometimes, caf6-au-lait spots, but not byother features of NFl) (39, 40); and encephalocranio-cutaneous lipomatosis (characterized by unilaterallipomatous growths, ipsilateral ophthalmologic andbrain malformations, mental retardation, and seizures)(41). It appears that these variants may be allelic toNFl, at least in some families.Patients with segmental neurofibromatosis have fea-tures of NFl confined to a particular area of the body(e.g., one side of the body) (42). While it has been pos-tulated that segmental neurofibromatosis results froma somatic mutation in the NFl gene, this postulate hasnot yet been molecularly demonstrated. Somaticmosaicism for the NFl gene has been reported in atleast four cases (33, 43-45), but all of these casesshowed typical NFl, suggesting that the somatic muta-tion occurred early in embryonic development.Noonan syndrome is an autosomal dominant condi-tion characterized by webbing of the neck, unusualfacies, short stature, and congenital heart disease (oftenpulmonic stenosis). Features of Noonan syndrome,often without a cardiovascular malformation, havebeen observed in many patients with NFl. About 13percent of patients with NFl specifically examined forNoonan syndrome features had a Noonan syndromephenotype (46); this frequency of co-occurrence seemsAm J Epidemiol Vol. 151, No. 1, 2000NF1 Gene and Neurofibromatosis 1 37unlikely if NFl and Noonan syndrome are independentdisorders. In some families, NFl and Noonan syn-drome have been shown to segregate as independentautosomal dominant traits, and Noonan syndrome isnot linked to the NFl locus in families without featuresof NFl. In other instances, features of both Noonansyndrome and NFl appear to result from mutations ofthe NFl gene, and these phenotypes segregate together(46). It appears that the concurrence of NFl andNoonan syndrome may have several different causes(47), but this question awaits further study.NFl and the associated clinical presentations dis-cussed above are the only conditions known to becaused by NFl gene mutations. No studies of the NFlgene in the general population have been performed.INTERACTIONSThe wide variability of the NFl phenotype, even inindividuals with the same NFl gene mutation, sug-gests that other factors are involved in determiningclinical manifestations. These may include other mod-ifying genes, environmental factors, and chance. Thusfar, little is known about the relative contribution ofthese to the NFl phenotype.A study of 175 individuals in 48 families, includingsix monozygotic twin pairs, evaluated variation of theNFl phenotype with degree of relation (48). The num-ber of caf6-au-lait spots and of neurofibromas showeda high correlation between monozygotic twins, a lowercorrelation between first-degree relatives, and the low-est correlation among more distant relatives. The studyalso looked at the presence or absence of plexiformneurofibromas, optic gliomas, scoliosis, epilepsy, andreferral for remedial education. With the exception ofplexiform neurofibromas, these traits also showedfamilial clustering. The authors concluded that muchof the phenotypic variation in NFl is related to trait-specific "modifying genes."It has been suggested that environmental factorsinfluence NFl phenotype; however, no convincingevidence has been presented to support the involve-ment of any particular environmental factor. Riccardi(49) has suggested that mechanical trauma (in the formof injury to the skin) may often precede the develop-ment of neurofibromas, but the evidence for involve-ment of this factor is anecdotal.The role of stochastic factors (chance) in the occur-rence of some NFl manifestations has also beenhypothesized. Chance may be involved in determiningwhich cells are affected by a somatic mutation and atwhat point in development somatic mutation occurs.Major questions remain about how the NFl phenotypeis determined, but it is likely that the NFl genotype,modifying genes, environmental factors, and chanceall play a role in the clinical manifestations of NFlgene mutations.LABORATORY TESTSLaboratory testing for NFl mutations is difficult.Although a variety of approaches has been used singlyor in combination in research laboratories, none hasbeen shown to be appropriate for routine clinical use.A protein truncation test is available commercially forNFl mutation testing, but its sensitivity, specificity, andpositive predictive value in a large group of patientshave not been reported. In this test, RNA is reverse tran-scribed, and the complementary DNA product is used toperform in vitro transcription and translation. Truncatedneurofibromin proteins are identified by separating theprotein products using an sodium dodecyl sulfate-poly-acrylamide gel (50). Mutations may then be confirmedby direct DNA sequencing. False-positive results arepossible when truncated proteins are not confirmed bysequencing (16). In addition, the protein truncation testcannot detect mutations that do not result in a truncatedprotein, such as missense mutations and large deletions,or mutations in which the RNA is unstable and, thus, isunavailable for reverse transcription. The ability of theprotein truncation test to detect mosaic mutations isunknown (16). However, it appears that the risk for bothfalse positives (when a finding of a truncated protein isnot confirmed by DNA sequencing) and false negativesmay be significant with this test. Published studies of thesensitivity of the protein truncation test have been small;about 70 percent of the cases meeting NFl diagnosticcriteria (13 of 20 cases in one study (50) and 11 of 15cases in another (51)) had a positive result on the proteintruncation test Thirty-seven (77 percent) of 48 cases thatmet NFl diagnostic criteria referred for commercial test-ing are reported to have had a positive protein truncationtest result (T. Brown, LabCorp, Research Triangle Park,North Carolina, personal communication, 1999). Noinformation is available on the specificity or positivepredictive value of the protein truncation test. When theprotein truncation test is negative, further molecularstudies may be helpful in identifying the mutation, butthese studies are currently available only on a researchbasis.In familial NFl cases (when two or more family mem-bers are affected), linkage analysis can be performed.The availability of intragenic microsatellite NFl markershas increased the proportion of families in which linkagestudies will be informative and has also increased thediagnostic accuracy (52) to an average of 90 percent.Given that NFl is easily diagnosed clinically inmost affected individuals over age 6 years, the need forlaboratory testing is limited to specific circumstances.One of these is for prenatal diagnosis when one of theAm J Epidemiol Vol. 151, No. 1, 200038 Rasmussen and Friedmanparents has NFL If the causative mutation has beenidentified, direct testing for this specific mutation canbe performed on chorionic villus or amniotic fluidsamples. However, the severity of NF1 cannot be pre-dicted prenatally; only the presence or absence of themutation can be identified. Because of the wide vari-ability in NF1 clinical expression, many families donot find prenatal diagnosis of NF1 acceptable (16).In families in which there are multiple affected rela-tives, linkage analysis can also be used for prenataldiagnosis. Once again, only the presence or absence ofthe affected allele can be predicted, not the severity ofthe clinical manifestations.The other situation in which laboratory testing maybe considered is in children at risk for NF1, beforeclinical diagnostic criteria are met. The child may be atrisk because of a family history or because of havingsome features (typically caf6-au-lait spots), but notsufficient features to meet the established diagnosticcriteria. While the ability to confirm or rule out thediagnosis with a laboratory test would be helpful, thesechildren are at particular risk for possible stigmatiza-tion and unnecessary medical intervention if a false-positive test results (16). Therefore, following thechild on a regular basis for appearance of NF1 compli-cations and sufficient clinical criteria to assure thediagnosis is likely to be a better option at this time.POPULATION TESTINGNo general, population-based studies using moleculartesting to identify NF1 mutations have been performed.This type of study seems unnecessary since individualsover age 6 years with NF1 mutations can usually beidentified by physical and ophthalmologic examination.Clinical methods of NF1 ascertainment have beenperformed to estimate the prevalence of the conditionin research studies in different populations (seePrevalence of NF1, above). However, population-based screening of individuals for clinical features ofNF1 has not received substantial support. This is, inpart, due to the difficulty of the effort: Careful physi-cal examination for NF1 features is time consuming,unlike other population-based screening methodsbased on a simple laboratory test. In addition, sincemany NF1 features are age dependent, diagnosis in achild under age 3 years is often challenging. However,most adult individuals with NF1 can be identified as aresult of a regular physical examination, even in theabsence of a screening program.An important question is whether an early NF1 diag-nosis, achieved through a screening program, wouldlead to prevention of NF1 complications. Since pri-mary prevention of NF1 complications is not presentlypossible, this beneficial effect would be confined to thepossibility that early recognition of complications mayresult in improved treatment. Several studies haveassessed whether screening of individuals alreadyknown to have NF1 for complications is helpful. Arecent paper suggests that the vast majority of abnor-malities identified through a comprehensive screeningprogram (consisting of ophthalmologic consultationwith slit-lamp examination, chest radiograph, abdomi-nal ultrasonography, neuroimaging, and analysis ofcatecholamine levels) did not result in therapeuticaction (53). Studies such as these have led many NF1experts to suggest that a careful clinical evaluation forNF1 complications on an annual basis (or more often,if necessary) by a physician familiar with NF1 is opti-mal for affected individuals (16). Regular ophthalmo-logic examination is also recommended for childrenwith NF1 (18). Unfortunately, no studies are availablethat address the more general question of whether anearlier NF1 diagnosis, made through a screening pro-gram, would lead to improved treatment.Another valid concern when considering whether apopulation-based screening program may be beneficialis the effect that early diagnosis may have on familyplanning (avoidance of future pregnancies or utilizationof prenatal diagnosis). In a recent survey, the majorityof parents preferred an early diagnosis of NF1 in theirchild; however, NF1 diagnosis did not usually result inavoidance of future pregnancies, and while prenataldiagnosis was viewed favorably, only a few parentssaid they would actually terminate an affected preg-nancy (54). All of these issues will need to be taken intoaccount in the discussion regarding population-basedscreening (whether using molecular methods or clinicalmethods); however, at this time, it appears that the ben-efits of early diagnosis do not outweigh the potentialcosts of a population-based screening program.REFERENCES1. Cawthon RM, Weiss R, Xu GF, et al. A major segment of theneurofibromatosis type 1 gene: cDNA sequence, genomicstructure, and point mutations. Cell 1990;62:193-201.2. Wallace MR, Marchuk DA, Anderson LB, et al. Type 1 neu-rofibromatosis gene: identification of a large transcript dis-rupted in three NF1 patients. Science 1990;249:181-6.3. Li Y, O'Connell P, Breidenbach HH, et al. Genomic organizationof the neurofibromatosis 1 gene(NFl). Genomics 1995;25:9—18.4. Xu GF, Lin B, Tanaka K, et al. The catalytic domain of theneurofibromatosis type 1 gene product stimulates ras GTPaseand complements ira mutants of 5. cerevisiae. Cell1990;63:835-41.5. Colman SD, Williams CA, Wallace MR. Benign neurofibro-mas in type 1 neurofibromatosis (NF1) show somatic deletionsof the NF1 gene. Nat Genet 1995; 11:90-2.6. Side L, Taylor B, Cayouette M, et al. Homozygous inactivationof the NF1 gene in bone marrow cells from children with neu-rofibromatosis type 1 and malignant myeloid disorders. N EnglAm J Epidemiol Vol. 151, No. 1, 2000NF1 Gene and Neurofibromatosis 1 39J Med 1997;336:1713-20.7. Huson SM, Compston DAS, Clark P, et al. A genetic study ofvon Recklinghausen neurofibromatosis in southeast Wales. I.Prevalence, fitness, mutation rate, and effect of parental trans-mission on severity. J Med Genet 1989^26:704-11.8. Lizaro C, Ravella A, Gaona A, et al. Neurofibromatosis type 1due to germ-line mosaicism in a clinically normal father. NEngl J Med 1994;331:1403-7.9. Riccardi VM. Neurofibromatosis: phenotype, natural history,and pathogenesis. 2nd ed. Baltimore, MD: The Johns HopkinsUniversity Press, 1992.10. Jadayel D, Fain P, Upadhyaya M, et al. Paternal origin of newmutations in von Recklinghausen neurofibromatosis. Nature1990;343:558-9.11. Stephens K, Kayes L, Riccardi VM, et al. Preferential mutationof the neurofibromatosis type 1 gene in paternally derivedchromosomes. Hum Genet 1992;88:279-82.12. Lazaro C, Gaona A, Ainsworth P, et al. Sex differences inmutational rate and mutational mechanism in the NF1 gene inneurofibromatosis type 1 patients. Hum Genet 1996;98:696-9.13. Upadhyaya M, Ruggieri M, Maynard J, et al. Gross deletionsof the neurofibromatosis type 1 (NF1) gene are predominantlyof maternal origin and commonly associated with a learningdisability, dysmorphic features and developmental delay. HumGenet 1998;102:591-7.14. Dublin S, Riccardi VM, Stephens K. Methods for rapid detec-tion of a recurrent nonsense mutation and documentation ofphenotypic features in neurofibromatosis type 1 patients. HumMutat 1995;5:81-5.15. National Institutes of Health Consensus DevelopmentConference. Neurofibromatosis: conference statement. ArchNeurol 1988;45:575-8.16. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnosticevaluation and multidisciplinary management of neurofibro-matosis 1 and neurofibromatosis 2. JAMA 1997;278:51-7.17. Friedman JM, Birch PH. Type 1 neurofibromatosis: a descrip-tive analysis of the disorder in 1728 patients. Am J Med Genet1997;70:138-43.18. Iisternick R, Louis DN, Packer RJ, et al. Optic pathwaygliomas in children with neurofibromatosis 1: consensus state-ment from the NF1 Optic Pathway Glioma Task Force. AnnNeurol 1997;41:143-9.19. Stevenson DA, Birch PH, Friedman JM, et al. Descriptiveanalysis of tibia] pseudarthrosis in patients with neurofibro-matosis 1. Am J Med Genet 1999;84:413-19.20. North KN, Riccardi V, Samango-Sprouse C, et al. Cognitivefunction and academic performance in neurofibromatosis 1:consensus statement from the NF1 Cognitive Disorders TaskForce. Neurology 1997;48:1121-7.21. Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up ofvon Recklinghausen neurofibromatosis. Survival and malig-nant neoplasms. N Engl J Med 1986;314:1010-15.22. Poyhonen M, Niemela S, Herva R. Risk of malignancy and deathin neurofibromatosis. Arch Pathol Lab Med 1997;121:139-43.23. Cohen BH, Kaplan AM, Packer RJ. Management of intracra-nial neoplasms in children with neurofibromatosis type 1 and2. The Children's Cancer Study Group. Pediatr Neurosurg1990-91;16:66-72.24. Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis andchildhood leukaemia/lymphoma: a population-basedUKCCSG study. Br J Cancer 1994;70:969-72.25. Garty BZ, Laor A, Danon YL. Neurofibromatosis type 1 inIsrael: survey of young adults. J Med Genet 1994;31:853-7.26. Zoller M, Rembeck B, Akesson HO, et al. Life expectancy,mortality and prognostic factors in neurofibromatosis type 1: atwelve-year follow-up of an epidemiological study inGOteborg, Sweden. Acta Derm Venereol 1995:75:136-40.27. Zoller M, Rembeck B, Oden A, et al. Malignant and benigntumors in patients with neurofibromatosis type 1 in a definedSwedish population. Cancer 1997;79:2125-31.28. Bunin GR, Needle M, Riccardi VM. Paternal age and sporadicneurofibromatosis 1: a case-control study and consideration ofthe methodologic issues. Genet Epidemiol 1997; 14:507-16.29. Carey JC, Laub JM, Hall BD. Penetrance and variability inneurofibromatosis: a genetic study of 60 families. BirthDefects Orig Art Ser 1979;15:271-81.30. Cnossen MH, van der Est MN, Breuning MH, et al. Deletionsspanning the neurofibromatosis type 1 gene: implications forgenotype-phenotype correlations in neurofibromatosis type 1?Hum Mutat 1997;9:458-64.31. Leppig KA, Kaplan P, Viskochil D, et al. Familial neurofibro-matosis 1 microdeletions: cosegregation with distinct facialphenotype and early onset of cutaneous neurofibromata. Am JMed Genet 1997;73:197-204.32. Tonsgard JH, Yelavarthi KK, Cushner S, et al. Do NF1 genedeletions result in a characteristic phenotype? Am J Med Genet1997;73:80-6.33. Rasmussen SA, Colman SD, Ho VT, et al. Constitutional andmosaic large NF1 gene deletions in neurofibromatosis type 1.J Med Genet 1998;35:468-71 .34. Allanson JE, Upadhyaya M, Watson GH, et al. Watson syn-drome: is it a subtype of type 1 neurofibromatosis? J MedGenet 1991:28:752-6.35. Tassabehji M, Strachan T, Sharland M, et al. Tandem duplica-tion within a neurofibromatosis type 1 (NF1) gene exon in afamily with features of Watson syndrome and Noonan syn-drome. Am J Hum Genet 1993;53:90-5.36. Charrow J, Listemick R, Ward K Autosomal dominant multi-ple caf£-au-lait spots and neurofibromatosis-1: evidence ofnon-linkage. Am J Med Genet 1993;45:606-8.37. Brunner HG, Hulsebos T, Steijlen PM, et al. Exclusion of theneurofibromatosis 1 locus in a family with inherited caf6-au-lait spots. Am J Med Genet 1993;46:472^1.38. Abeliovich D, Gelman-Kohan Z, Silverstein S, et al. Familialcafe-au-lait spots: a variant of neurofibromatosis type 1. J MedGenet 1995;32:985-6.39. Pulst SM, Riccardi VM, Fain P, et al. Familial spinal neurofi-bromatosis: clinical and DNA linkage analysis. Neurology1991;41:1923-7.40. Poyhonen M, Leisti E-L, Kytola S, et al. Hereditary spinalneurofibromatosis: a rare form of NF1? J Med Genet 1997;34:184-7.41. Legius E, Wu R, Eyssen M, et al. Encephalocraniocutaneouslipomatosis with a mutation in the NF1 gene. J Med Genet1995:32:316-19.42. Hager CM, Cohen PR, Tschen JA. Segmental neurofibromato-sis: case reports and review. J Am Acad Dermatol 1997;37:864-9.43. Colman SD, Rasmussen SA, Ho VT, et al. Somatic mosaicismin a patient with neurofibromatosis type 1. Am J Hum Genet1996:58:484-90.44. Ainsworth PJ, Chakraborty PK, Weksberg R. Example ofsomatic mosaicism in a series of de novo neurofibromatosistype 1 cases due to a maternally derived deletion. Hum Mutat1997:9:452-7.45. Wu BL, Boles RG, Yaari H, et al. Somatic mosaicism for dele-tion of the entire NF1 gene identified by FISH. Hum Genet1997:99:209-13.46. Colley A, Donnai D, Evans DGR. Neurofibromatosis/Noonanphenotype: a variable feature of type 1 neurofibromatosis. ClinGenet 1996;49:59-64.47. Carey JC. Neurofibromatosis-Noonan syndrome. Am J MedGenet 1998:75:263-4.48. Easton DF, Ponder MA, Huson SM, et al. An analysis of vari-ation in expression of neurofibromatosis (NF) type 1 (NF1):evidence for modifying genes. Am J Hum Genet 1993;53:305-13.49. Riccardi VM. Genotype, malleotype, phenotype, and random-ness: lessons from neurofibromatosis-1 (NF-1). Am J HumGenet 1993;53:301-4.50. Heim RA, Kam-Morgan LNW, Binnie CG, et al. Distributionof 13 truncating mutations in the neurofibromatosis 1 gene.Hum Mol Genet 1995;4:975-81.51. Park VM, Pivnick EK. Neurofibromatosis type 1 (NF1): a pro-tein truncation assay yielding identification of mutations in73% of patients. J Med Genet 1998:35:813-20.Am J Epidemiol Vol. 151, No. 1, 200040 Rasmussen and Friedman52. Lazaro C, Gaona A, Ravella A, et al. Prenatal diagnosis of neu-rofibromatosis type 1: from flanking RFLPs to intragenicmicrosatellite markers. Prenat Diagn 1995; 15:129-34.53. Wolkenstein P, Freche B, Zeller J, et al. Usefulness of screen-ing investigations in neurofibromatosis type 1: a study of 152patients. Arch Dermatol 1996,132:1333-6.54. Cnossen MH, Smit FJ, de Goede-Boldcr A, et al. Diagnosticdelay in neurofibromatosis type 1. Eur J Pediatr 1997;156:482-7.55. Crowe FW, Schull WJ, Neel JV. A clinical, pathological, andgenetic study of multiple neurofibromatosis. Springfield, IL:Charles C Thomas, 1956.56. Sergeyev AS. On the mutation rate of neurofibromatosis.Humangenetik 1975;28:129-38.57. Samuelsson B, Axelsson R. Neurofibromatosis. A clinical andgenetic study of 96 cases in Gothenburg, Sweden. Acta DermVenereol Suppl (Stockh) 1981;95:67-71.58. Fuller LC, Cox B, Gardner RJM. Prevalence of vonRecklinghausen neurofibromatosis in Dunedin, New Zealand.Neurofibromatosis 1989;2:278-83.59. Clementi M, Barbujani G, Turolla L, et al. Neurofibromatosis-1: a maximum likelihood estimation of mutation rate. HumGenet 1990;84:116-18.APPENDIX 1. INTERNET SITESGeneral resourcesMarch of Dimes:http://www.noah.cuny.edu/pregnancy/march_of_dimes/birth_defects/neurofib.htrnlNational Organization for Rare Disordershttp://206.105.18.10/nord/rdb_sum/3.htmGenetic databasesGeneCardshttp://bioinfo.weizmann.ac.il/cards-bin/carddisp?NFl&search=NFl&suff=txtGeneClinicshttp://www.geneclinics.org/profiles/nfl/Genome Databasehttp://gdbwww.gdb.Org/gdb-bin/genera/accno7GDB:120231Human Gene Mutation Databasehttp://www.uwcm.ac.uk/uwcm/mg/search/120231 .htmlNNFF International NF1 Genetic Mutation Analysis Consortiumhttp://www.nf.org/nflgene/Online Mendelian Inheritance in Man (OMIM).http://www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmim7162200Educational resourcesMassachusetts General Hospital Neurofibromatosis Clinichttp://neurosurgery.mgh.harvard.edu/NFclinic.htmNational Institute of Neurological Disorders and Strokehttp://www.ninds.nih.gov/patients/disorder/neurofib/neurofib.htmSupport groupsNational Neurofibromatosis Foundationhttp://www.nf.org/Neurofibromatosis, Inc.http://nfinc.org/Neurofibromatosishttp://touch.ch/neurofibromatosis/Mainfrl.htmlThe Neurofibromatosis Associationhttp://www.users.zetnet.co.uk/neurofibromatosis/Other websitesAmerican Academy of Pediatrics Policy Statement: Health Supervision for Children with Neurofibromatosishttp://www.aap.org/policy/00923.htmlWorld Wide Neurofibromatosis Clinicians Forumhttp://www.neurofibromatosis.org/mdl2.htmAm J Epidemiol Vol. 151, No. 1, 2000[CANCERRESEARCH62,1573–1577,March1,2002]MeetingReportInternationalConsensusStatementonMalignantPeripheralNerveSheathTumorsinNeurofibromatosis11RosalieE.Ferner2andDavidH.Gutmann3DivisionofClinicalNeurosciences,DepartmentofNeuroimmunology,Guy’sKing’sandSt.Thomas’SchoolofMedicine,London,SE11ULUnitedKingdomAbstractNeurofibromatosis1(NF1)isanautosomaldominanttumorpredispo-sitionsyndromeinwhichaffectedindividualshaveagreatlyincreasedriskofdevelopingmalignantperipheralnervesheathtumors(MPNSTs).Thesecancersaredifficulttodetectandhaveapoorprognosis.Becausepatientsmaypresenttospecialistsfromwidelydifferingdisciplines,theassociationwithNF1isoftennotappreciated,andthereisnocohesivepatternofcare.Amultidisciplinarygroupof33cliniciansandscientistswithspecialistknowledgeinMPNSTandNF1reviewedthecurrentpublishedandunpublisheddatainthisfield,anddistilledtheircollectiveexperiencetoproduceaconsensussummaryonMPNSTinNF1.Theknownclinical,pathological,andgeneticinformationonMPNSTinNF1wascollated,andadatabasewasestablishedtorecordinformationinauniformmanner.SubgroupswithahigherriskofdevelopingMPNSTwereidentifiedwithintheNF1population.Theconsortiumformulatedproposalsandguidelinesforclinicalandpathologicaldiagnosis,surgicalmanagement,andmedicaltreatmentofMPNSTinindividualswithNF1.Amultidisciplinaryteamapproachtothemanagementofthiscomplexdisorderisadvocated.Progresscanbemadebyadoptingtheguidelinesproposedbythisconsortiumandbywidespreaddisseminationofstan-dardizedinformation.CollaborativeresearchshouldbepromotedwiththeaimofharnessingadvancesinmoleculargeneticstodeveloptargetedtherapiesforMPNSTinpeoplewithNF1.IntroductionNF14isanautosomaldominantneurocutaneousdisorder,withanestimatedbirthincidenceof1in2500(1).TheNF1geneonchro-mosome17q11.2wasidentifiedbypositionalcloning,anditsproteinproduct,neurofibromin,functionsasatumorsuppressor(2–4).Oneofthefunctionsofneurofibroministoreducecellproliferationbyacceleratingtheinactivationoftheproto-oncogenep21-ras,whichhasapivotalroleinmitogenicintracellularsignalingpathways(4).ThecardinalanddefiningfeaturesofNF1arecafe´aulaitmacules,neurofibromas,skinfoldfreckling,irisLischnodules,andcharacter-isticosseousdysplasia(5).Thecomplicationsofthedisorderarelegionandmayinvolveanyofthebodysystems(6).IndividualsaffectedwithNF1harboranincreasedriskofdevelop-ingbothbenignandmalignanttumors,supportingtheclassificationofNF1asatumorpredispositionsyndrome.ThemostcommontumorinindividualswithNF1istheneurofibroma,aheterogeneousbenignperipheralnervesheathtumor(7,8).Neurofibromasmayappearasdiscrete,dermalneurofibromas,focalcutaneousors.c.growths,dumbbell-shapedintraforaminalspinaltumors,ornodularordiffuseplexiformneurofibromas.Plexiformneurofibromasarecomposedofthesamecelltypesasdermalneurofibromasbuthaveanexpandedextracellularmatrixandoftenhavearichvascularsupply.Theydevelopalonganerveandmayinvolvemultiplebranches,nerveroots,andplexi.Impingementonsurroundingstructuresmaycausefunctionalcompromise,andsofttissueandbonehypertrophymayoccur(9).Plexiformneurofibromaswereclinicallyvisiblein30%of125NF1patientsinaSouthWalespopulationstudy(10).Fortyfourpercentofplexiformneurofibromas(32of72patients)werediagnosedbefore5yearsofageinoneclinic-basedstudy(11)suggestingthatmanyplexiformneurofibromasarecongenitallesions.Multipleplexiformneurofibromasoccurin9–21%ofcases(10–12).AlthoughMPNSTcandevelopinindividualsinthegeneralpopulation,individualswithNF1haveasignificantlyincreasedrisk.Thesetumorsarisefrequentlyinpreexistingplexiformneurofibromas,whichareveryuncommoninpeoplewhodonothaveNF1.MPNSTsareoftendifficulttodetect,metastasizetothelung,liver,brain,softtissue,bone,regionallymphnodes,skin,andretroperitoneum,andhaveapoorprognosis(13).BecausepatientswithMPNSTsmaypresenttospecialistsfromwidelydifferingdisciplines,theassociationwithNF1isoftennotappreciated,andthereisnoconsistentorwidelyacceptedpatternofcare.Aims.Inthisuniquemeeting,theaimwastoestablishaninterna-tional,multidisciplinaryconsortiumofexpertsonMPNSTandNF1.Thepurposewastocollatetheknownclinicalandgeneticinformationaboutthesetumorsandtosetupastandardizeddatabasetorecordinformationinauniformmanner.Inaddition,thegoalwastoformu-lateguidelinesforclinicalandpathologicaldiagnosis,surgicalman-agement,andmedicaltreatment.Moreover,strategieswereproposedfordevelopingtargetedtherapiesforNF1-associatedMPNSTs,takingintoaccounttherecentadvancesinmolecularbiology.MaterialsandMethodsAninternational,multidisciplinarygroupofcliniciansandscientistswithaspecialistinterestinsofttissuesarcomas(MPNST)andNF1wasinvited.Invitationsweresenttocliniciansworkinginspecialistsofttissuesarcomacentersorlargeneurofibromatosisclinicsandtoindividualswithresearchpublicationsinthesefields.Thecurrentknowledgeinthisfieldwasreviewedbasedonpersonalexpertiseandthemedicalliterature.Subsequently,thespecialistspooledtheircollectiveexperiencetoproduceaconsensusgroupsummaryonMPNSTinNF1.ResultsClinicalConsensusGroup.ItisgenerallyacceptedthatMPNSTsoccurinabout2–5%ofNF1patientscomparedwithanincidenceof0.001%inthegeneralpopulation(13).However,theremaybedif-ferencesincross-sectionalversuslongitudinaldeterminationsofriskReceived10/9/01;accepted1/04/02.Thecostsofpublicationofthisarticleweredefrayedinpartbythepaymentofpagecharges.Thisarticlemustthereforebeherebymarkedadvertisementinaccordancewith18U.S.C.Section1734solelytoindicatethisfact.1SupportedbyWellcomeTrust,TheBritishNeurofibromatosisAssociation,andCellPathways,Inc.2Towhomrequestsforreprintsshouldbeaddressed,atDivisionofClinicalNeuro-sciences,DepartmentofNeuroimmunology,SecondFloorHodgkinBuilding,Guy’sKing’sandSt.Thomas’SchoolofMedicine,LondonBridge,LondonSE11UL,UnitedKingdom.Phone:44-207-848-6122;Fax:44-207-848-6123;E-mail:rosalie.ferner@kcl.ac.uk.3D.H.G.wastheleaderofthefollowingworkinggroups:MedicalConsensusGroup,SurgeryConsensusGroup,PathologyConsensusGroup,OncologyConsensusGroup,andMolecularBiologyConsensusGroup.MembersofthegroupsarelistedintheAppendix.4Theabbreviationsusedare:NF1,neurofibromatosis1;MPNST,malignantperipheralnervesheathtumor;MRI,magneticresonanceimaging;18FDG,18F-fluorodeoxyglucose;PET,positronemissiontomography.1573forMPNST,andthelifetimeriskforMPNSTcouldbeashighas10%(14).Themajorityofpatientspresentinthesecondandthirddecadesoflife,andtendtobeyoungerthantheircounterpartswithMPNSTsinthegeneralpopulation(13).WehavealsoidentifiedMPNSTsinNF1patientsasyoungas7yearsandasoldas63yearsofage.CliniciansshouldbealertedtothepossiblediagnosisofMPNSTwhenapatientwithNF1developsunremittingpainnototherwiseexplained,rapidincreaseinsizeofaplexiformneurofibroma,changeinconsis-tencyfromsofttohard,oraneurologicaldeficit.MostNF1-associatedMPNSTsappeartoarisewithinpreexistingplexiformneurofibromas.ThisobservationsuggeststhatindividualswithNF1andplexiformneurofibromaswarrantincreasedsurveillancefordevelopmentofMPNST,andthosewithmanyorveryextensiveplexiformneurofibromasmayhavethehighestrisk.However,thenaturalhistoryofplexiformneurofibromashasnotbeenclearlyde-fined,andthesetumorsmayundergoperiodsofrapidgrowthfollowedbyperiodsofrelativequiescence.Assuch,rapidgrowthisnotalwaysapreludetomalignancy.ThisissueiscurrentlybeingaddressedbyaninternationalstudyusingclinicalassessmentandvolumetricMRI(ClinicalCoordinator,BruceKorf,Boston,MA).Thereisnoevidencethatdermalneurofibromasorflatsuperficialplexiformneurofibromasundergomalignanttransformation,andtheydonotrequireclosemonitoring.Nodularplexiformtumorsassociatedwithlargeperipheralnervesheathsandextensivetumorsinvolvingthebrachial,lumbar,orsacralplexusmaygiverisetoMPNSTsand,therefore,meritheightenedawareness.Plexiformneurofibromas,whicharemorecentrallylocatedandaremoreextensive,appeartohaveahigherlikelihoodofundergoingmalignantchange.Individualswitha“neurofibromatous”neuropathymightalsohaveanincreasedriskofdevelopingMPNST,becausetheydevelopdermalneurofibro-masinearlychildhoodandhavediffuseplexiforminvolvementofthespinalnerverootsandperipheralnerves(15).PatientsinwhomamicrodeletionoftheNF1locusisdetectedtendtohavehighernumbersofdiscretedermalneurofibromasatearlieragesandmighthaveahigherincidenceofMPNSTthantheoverallNF1population(16).TheincreasedriskofMPNSTinthisgroupcouldbereadilytestedbycomparingthefrequencyofNF1microde-letionsdetectedbyfluorescenceinsituhybridizationofperipheralbloodlymphocytesinNF1patientswithandwithoutMPNST.MPNSTsareoftendifficulttodetect,becausetheclinicalindicatorsofmalignancymayalsobefeaturesofactive,benignplexiformneurofibromas.AMRIshouldbeperformedtolocatethesite,extent,andchangeinsizeoftheplexiformneurofibroma,butitdoesnotreliablydeterminemalignanttransformation.Thediffusenatureoftheplexiformneurofibromamayprecludetotalremovalbecauseofim-pingementonsurroundingstructuresandneurologicaldeficit.PETwiththeglucoseanalogue18FDGisadynamicimagingtechnique,whichpermitsthevisualizationandquantificationofglu-cosemetabolismincellsandreflectstheincreaseinmetabolisminmalignanttumors(17,18).Aretrospectivestudyof18NF1patientsdemonstratedthat18FDGPETisapotentiallyuseful,noninvasivemethodfordetectingmalignantchangeinplexiformneurofibromas(19).However,thedistinctionbetweenlow-gradeMPNSTsandbe-nignplexiformneurofibromaswasnotclearinallofthecases.Itisrecommendedthataprospectivestudywithclinical,radiological,andpathologicalcorrelationbeundertakentoevaluatethevalueof18FDGPETinthedetectionofmalignantchangeinNF1.Thenewtracer18F-thymidine,whichdetectsDNAturnover,mightbehelpfulindistinguishinglow-gradeMPNSTsfromactive,benignplexiformneurofibromasinfuturePET-basedstudies.ScrupulousdocumentationofinformationonNF1patientswithMPNSTwillplayavitalpartinoptimizingthemanagementofthiscondition.Datashouldberecordedinastandardizeddatabase,whichshouldbecirculatedtosarcomaunitsandtospecialistsinneurology,genetics,surgery,andoncology,whoarelikelytoencounterthesepatients.Demographicdetails,confirmationofthediagnosisofNF1,historyofcancerintheindividualandfamily,clinicalandradiologicalfeaturesoftheMPNST,andpathologicaldescriptionofthetumorneedtobeincluded.Documentationoftreatmentmodalitiesandoutcomeisessential.ItisanticipatedthatmolecularanalysisofconstitutionalDNAandtumormaterialmayplayapivotalroleindeterminingtherapeuticprotocols.PathologyConsensusGroup.Theoptionsfordiagnosisincludefineneedleaspiration,Tru-Cutneedlebiopsy,openincisionalbiopsy,andexcisionalbiopsy.Fineneedleaspirationisinadequatefortheassessmentoftumortypeandgrade,becausedissociatedtumorcellsareobtainedandarchitecturalrelationshipslost.Tru-Cutneedlebi-opsyisthemethodofchoicewhenundertakeninamultidisciplinaryteamsettingusingexpertradiological,surgical,andpathologicaladvice.Ifsufficienttissuecoresaretakenandthespecimenissentfresh,techniquescanbeusedsuchasimprintcytologytoensurethattumortissueispresent.Representativefreshtissuecorescanbesnapfrozeninliquidnitrogenformolecularbiologicalstudiesandresearch.Anopenincisionalbiopsyprovidesmoretissuefordiagnosisandancillarystudies,butthesampleislimitedtoonesite.Forthisreason,itisnecessarytoensurethatthesampleisrepresentativeandincludestheareassuspectedofmalignancy.Thecombinationofopeninci-sionalbiopsywithmultipleTru-Cutneedlebiopsiesfromdifferentareasmayovercomethisdifficulty.Thistechniqueshouldbecarefullyplannedsothatfuturesurgicalresectionmarginsarenotcompro-mised.Anexcisionalbiopsyshouldbereservedforsmall,superfi-ciallylocatedtumors,whichcanberesectedwithaclearmargin.Thisprovidesthemostmaterialfordiagnosisandresearch.Thetechniqueoftargetedbiopsyusing18FDGPETandmagneticresonanceregis-trationisbeingdevelopedinspecialistcentersandmaybeofpotentialbenefitinthemanagementofthisgroupofheterogeneoustumors.TheminimumhistologicalexaminationshouldcomprisesectionsstainedwithconventionaltinctorialstainsincludingH&Eandretic-ulin.Inaddition,immunohistochemicalstainsforS100protein,theskeletalmusclemarkersdesminandmyogenin,andaproliferationmarker(MIB1)arerequired.Otherspindlecelltumorsmaybeex-cludedwithappropriateimmunohistochemicalmarkers.Inthefuture,theremightbeaplacefortheroutineapplicationofstainsforknowntumorsuppressorgenesoroncogenes(p53,erbB2,p16,andp27),formolecularanalysisofNF1andNF2expression,andfordeterminationofRASactivity(see“MolecularBiologyConsensusGroup”).ThepathologicalfeaturesofMPNSTrevealafusiformorgloboidmassassociatedwithanerve.Necrosis,pseudocysticchange,orhemorrhagemaybefound.Histologically,thetumoriscomposedofspindlecellsarrangedincellularfascicles(20).Divergentdifferenti-ationmayoccur,includingrhabdomyoblasticchangeencounteredinthemalignanttritontumorvariant(20,21).Thepathologicalcriteriaformalignancyincludeinvasionofsur-roundingtissuesbytumorcells,vascularinvasion,markednuclearpleiomorphism,necrosis,andthepresenceofmitoses(20).Evenasinglemitoticfiguremaybesignificant,particularlyinatumorwithhypercellularityandnuclearatypia.Thesignificanceofthemitosesdependsontheprognosticvalueofincreasedcellproliferation.There-fore,themostclinicallyrelevantquestionishowbesttodeterminemalignanttransformationinthesetumors.Themethodsavailableforassessinggrowthrateincludedirectcountingofobservedmitoticfigures,theestimationofproliferationindexusingimmunostains,flowcytometry,othermoleculartechniques,orthedetectionofanimbalancebetweenapoptosisandproliferation.Theaccuratepredic-tionofbiologicalbehaviormaydependontheinterpretationofacombinationofhistologicalandimmunohistochemicalfeatures.1574THEMALIGNANTPERIPHERALNERVESHEATHTUMORGROUPThereisahistologicalspectrumofperipheralnervesheathtumorsrangingfromtheclearlybenigntotheclearlymalignant,anditisoftenpossibletodistinguishbetweenhigh-gradeandlow-gradetumors.However,asignificantnumberoftumors,theso-called“atypicalneurofibromas”donotfitintoanydefinedgradingsystem(20,22,23).Thesemaybelocallyaggressivebutarelesslikelytometastasize.Inaddition,thereareafewhistologicallylow-gradetumorsthatbehaveaggressively.Theapplicationofmoleculartechniquestode-terminethegeneexpressionprofilesofgeneexpressioninthesetumorsmayhelppathologiststopredictbiologicalbehaviorandoutcomemoreaccurately.Thecorrelationwithnewimagingtech-niquesmayalsohelptoresolvethisissue.SurgeryConsensusGroup.Theaimofsurgeryiscompletere-movalofthelesionwithtumor-freemargins(13).Biopsyofthelesionisessentialbeforesurgeryisundertaken(see“PathologyGroup”statement).Smalllesionsshouldbewidelyresected,andlargertumorsshouldbeaswidelyexcisedaspossible(ⱖ10cm)toavoidcentripetalspread.Reconstructionofthenerveaftersurgeryforbrachialandlumboscaralplexuslesionsisnotadvocated,becauseitdoesnotrestoreusefulfunctionandmaycompromisetheadequacyofthesurgicalexcision.AmputationmaybeindicatedforextensivetumorsandforMPNST,whichrecurafterapparentlyadequateexcision.PatientsshouldhavebaselineMRI2–3monthsaftersurgery.Ad-ditionalimagingstudiesandtheirtimingwilldependonthepatientsymptomsandthenatureoftheprimarytumor.18FDGPETmightbeausefulscreeninginvestigationinthefuture,becauseitprovidesbothalocalandabody-widescanwithinasingleinvestigationforthisgroupof“at-risk”patients.OncologyConsensusGroup.ItisnotclearwhetherpatientswithNF1andMPNSThaveadifferentclinicalcourseorresponsetotreatmentcomparedwiththeircounterpartsinthegeneralpopulation.ThecurrentmanagementofMPNSTshouldbeidenticaltothatofanyothersofttissuetumorinthatsuccessfultreatmentdependsoncom-pletesurgicalexcision.Radiotherapyprovideslocalcontrolandmaydelaytheonsetofrecurrencebuthaslittleeffectonlong-termsur-vival.Adjuvantradiotherapyshouldbegivenwhereverpossibleforintermediate-tohigh-gradelesionsandforlow-gradetumorsafteramarginalexcision.Chemotherapyforadultsofttissuesarcomasisusuallyconfinedtothetreatmentofmetastaticdisease.Fewdrugshavebeenshowntobeeffective,andtreatmentcomprisessingleagentdoxorubicinoracombinationofdoxorubicinandifosfamide(24).Althoughsuchtreat-mentisnotcurative,itmayachieveusefulpalliationformanypatients,andcomplete,long-lastingremissionsareobservedinrareinstances.Moreover,itmaybeusefulinthepreoperativesettingtodownstagepatientswithunresectableprimaries.MPNSTappearstobeofintermediatechemosensitivity,lessre-sponsivethansynovialsarcoma,butmorechemosensitivethanrefrac-torydiseasessuchasalveolarsoftpartsarcoma.Thepartialresponseratewiththebestavailablechemotherapyislikelytobeintherangeof25–30%(24).Controversysurroundstheuseofadjuvantchemo-therapy.Ameta-analysishasshownasignificantbenefitat10yearsintermsofprogression-freesurvivalforbothlocalanddistantrelapse(25).However,themagnitudeofanyoverallsurvivalbenefitissmall(⬃4%andnotstatisticallysignificant).Chemotherapymightbeusedtoimprovelocaldiseasecontrolformarginallyresectedlesionsatsiteswhereanadequatedoseofradiotherapyisdifficulttodeliver.Recentadvancesinsarcomatherapyhaveresultedfromanim-provedunderstandingofthemolecularbiologyofindividualdiseases.Thediscoveryofmutationsinthec-kitgene,resultinginoverexpres-sionofaconstitutivelyactivatedc-kitmoleculeingastrointestinalstromaltumors,hasbeenofparamounttherapeuticimportance.ThishasnotonlyresultedinCD117overexpressionbecomingthehallmarkdiagnostictestforthisdiseasebuthasleadtoanewformoftreatmentforadiseasethatwashithertountreatable.ThereceptortyrosinekinaseinhibitorSTI571(Glivec)isapotentinhibitorofKITandhasbeenreportedtoresultindramatictumorregressionsinthesepatients,whichthusfarappeartobedurable(26).Similarly,itisthehopethatnewagents,whichtargettheRAS-RAF-mitogen-activatedprotein/ERKkinase-extracellularsignal-regulatedkinasepathway,mayproveeffectiveagainstMPNSTinNF1.Inthesetumors,lossoftheinhibitingfunctionofneurofibrominresultsinincreasedp21-rassignaling.Anti-RASpathwaydrugsin-cludefarnesyltransferaseinhibitors,whichblocktheabilityofRAStoreachthemembranewhereitisactivated(27).However,therearenowspecificinhibitorsoftargetsdownstreamofRAS,suchasmitogen-activatedprotein/ERKkinase,thatarealsobeingdevelopedforclinicalstudy.GiventhesuccessofGlivec,itisclearthattyrosinekinaseinhibitorscanbedevelopedthatarebothselectiveandeffec-tive,andhopefullyoneoftheseagentswillproveeffectiveagainstMPNSTs.MolecularBiologyConsensusGroup.SignificantprogresshasbeenmadeinrecentyearsinelucidatingthemoleculargeneticsandbiologyofMPNSTinNF1.SurgicalspecimensandcelllinesfrompatientswithMPNSTandNF1exhibitlossofNF1gene(neurofibro-min)expressionandhighlevelsofRASactivity(28–30).StudiesofbenignneurofibromasfromNF1patientshavedemonstratedthatlossofNF1geneexpressionandincreasedRASactivationaloneisnotsufficientforMPNSTformation,andthatadditionalgeneticalter-ations(p27-Kip1,p53,andp16)arerequiredformalignanttransfor-mation(31–35).ThegenerationofmicewithtargetedmutationsintheNF1genehasconfirmedthisnotioninthatlossofNF1expressionappearstobesufficientfortheformationoftumorswithpathologicalfeaturesofplexiformneurofibromas,whereasMPNSTdevelopmentisdependentonfunctionalinactivationofp53(36,37).Ourabilitytomoreaccuratelypredicttumorbehaviorandresponsetotherapyislikelytoderivefromstudiesaimedatdefiningthemolecularchangesseeninthesetumors.AvarietyofdifferentgeneticalterationshavebeenreportedinMPNSTs,butitisnotclearthatanyofthesearecausallyrelatedtotumorigenesisormalignantprogres-sion.Moreover,itisnotknownwhetherasubsetofthesechangeswillpredicttheclinicalcourseordefinewhetheraspecificformoftherapyislikelytobemoreefficacious.AdditionalresearchisrequiredtodefinetheintracellularsignalingpathwayabnormalitiesprimarilyresponsibleforplexiformneurofibromaorMPNSTgrowth,andtodelineatewhichspecificdownstreameffectorsofRASmediateRASmitogenicsignaling.Similarly,researcheffortstodefinethegeneticchangesinadditiontoNF1lossthatarerequiredforplexiformneurofibromamalignanttransformationalsomayidentifyadditionaltherapeutictargetsforMPNSTdrugdesign.ThesestudieshavethepotentialtoidentifygeneexpressionprofilesthatarespecificallyassociatedwithparticularMPNSTsubtypesorplexiformneurofibro-masmostlikelytoundergomalignantchange(“molecularfinger-print”).TheimportanceofaninternationaltissuebankforMPNSTstofacilitatebasicscienceandtranslationalresearchcannotbeoverstated.Thiswouldinvolvestoringfresh-frozenspecimens,correspondingnormalnervespecimenswhenavailable,andnormaltissueorblood,aswellasparaffinsections.Thesespecimensneedtobewellchar-acterizedpathologicallyandtobelinkedtomolecular,pathological,andclinical-epidemiologicalpatientdata.BothNF1-associatedandsporadicMPNSTsshouldbestoredinthistumorbanktodeterminewhetherthenotedmolecularandclinical-epidemiologicalcharacter-isticsaresimilarinthesetwogroups.Conclusions.MPNSTisadevastatingcomplicationofNF1,whichshouldbemanagedbymultidisciplinaryteamsofcliniciansand1575THEMALIGNANTPERIPHERALNERVESHEATHTUMORGROUPscientistswithexpertiseinthediagnosisandtreatmentofthisdisease.ClinicalandmoleculargeneticstudiesshouldidentifyNF1patientswhoareathighriskofdevelopingMPNST.Theestablishmentofaninternationaldatabasewillpermitthestandardizedrecordingofclin-ical,pathological,andtreatmentdata,andoutcomemeasures.ThedevelopmentofimagingmethodssuchasPETscanningwillaidindistinguishingMPNSTfrombenignplexiformneurofibromas.Recentadvancesinmoleculargeneticshaveprovidedexcitingopportunitiestodeveloptargetedtherapiesforthesetumors,whichwillbehelpedbytheestablishmentofaninternationaltissuebank.Ourabilitytotranslatetheseadvancesintorationalclinicaltrialsrepresentsthechallengefortheimmediatefuture.AcknowledgmentsWethankBruceKorfforcriticalinsightsduringthepreparationofthisdocumentandJ.M.Friedmanforeditorialcomments.SusanHusonproposedthetopicforthisconsensusmeeting.RosalieE.FernerandDavidH.GutmannorganizedtheMPNSTConsensusGroupwithassistancefromMeenaUpadhyaya,DavidViskochil,andRobertaTweedy(BritishNeurofibromatosisAssociation).APPENDIXMedicalConsensusGroup.GarethEvans,DepartmentofMedicalGenetics,St.Mary’sHospital,Manchester,UnitedKingdom;RosalieFerner,DepartmentofClinicalNeurosciences,GKTSchoolofMedicine,Guy’sHospital,London,UnitedKingdom;JanM.Friedman,DivisionofMedicalGenetics,UniversityofBritishColumbia,Vancouver,Canada;SusanHuson,DepartmentofMedicalGenetics,ChurchillHospital,Oxford,UnitedKingdom;ViktorMautner,DepartmentofNeurology,KlinikumNord,Ochsenzoll,Hamburg,Germany;MichaelO’Doherty,ClinicalPETCenter,GKTSchoolofMedicine,St.Thomas’Hospital,London,UnitedKingdom;DavidViskochil,DivisionofMedicalGenetics,UniversityofUtah,SaltLakeCity,UT.SurgeryConsensusGroup.RolfeBirch,PeripheralNerveInjuryUnit,RoyalNationalOrthopaedicHospital,London,UnitedKingdom;IvoDeWever,DepartmentofSurgicalOncology,UniversityHospital,Leuven,Belgium;RheinhardFriedrich,Depart-mentofSurgery,UniversityHospital,Hamburg-Eppendorf,Germany;HenkGiele,De-partmentofPlasticSurgery,RadcliffeInfirmary,Oxford,UnitedKingdom;RobertGrimer,DepartmentOfOrthopaedics,RoyalOrthopaedicHospital,Birmingham,UnitedKingdom;JonathanLucas,SoftTissueTumorUnit,DepartmentofOrthopaedics,Guy’sandSt.Thomas’Hospitals,London,UnitedKingdom;MichaelSmith,SoftTissueTumorUnit,DepartmentofOrthopaedics,Guy’sandSt.Thomas’Hospitals,London,UnitedKingdom;MeirionThomas,SarcomaandMelanomaUnit,RoyalMarsdenHospital,London,UnitedKingdom.PathologyConsensusGroup.CherylCoffin,DivisionofPediatricPathology,Uni-versityofUtahSchoolofMedicine,SaltLakeCity,UT;SusanRobinson,DepartmentofNeuropathology,King’sCollegeHospital,London,UnitedKingdom;AnnSandison,DepartmentofPathology,CharingCrossHospital,London,UnitedKingdom;SusanStandring,DivisionofNeuroscience,Guy’sKing’sandSt.Thomas’SchoolofMedicine,London,UnitedKingdom;AndreasvonDeimling,DepartmentofNeuropathologyCharite´,HumboldtUniversity,Berlin,Germany.OncologyConsensusGroup.AdrianJones,DepartmentofRadiotherapy,ChurchillHospital,Oxford,UnitedKingdom;IanJudson,CRCCenterforCancerTherapeutics,InstituteofCancerResearch,Sutton,UnitedKingdom;ChrisMitchell,DepartmentofPediatricOncology,JohnRadcliffeHospital,Oxford,UnitedKingdom;RifPamukcu,CellPathways,Inc.,Horsham,PA;MikeStevens,DepartmentofPediatricOncology,BirminghamChildren’sHospital,Birmingham,UnitedKingdom;JeremyWhelan,TheMeyersteinInstituteofOncology,TheMiddlesexHospital,London,UnitedKingdom.MolecularBiologyConsensusGroup.AbhijitGuha,LabattsBrainTumorCenter,TheHospitalforSickChildren,Toronto,Ontario,Canada;DavidGutmann,DepartmentofNeurology,WashingtonUniversitySchoolofMedicine,St.Louis,MO;ChrisJones,DepartmentofPathology,UniversityofWalesCollegeofMedicine,Cardiff,UnitedKingdom;EricLegius,CenterforHumanGenetics,UniversityHospital,Leuven,Belgium;AnneMudge,MRCLaboratoryforMolecularBiology,UniversityCollege,London,UnitedKingdom;ThorstenRosenbaum,Children’sHospital,Heinrich-HeineUniversity,Dussledorf,Germany;MeenaUpadhyaya,InstituteofMedicalGenetics,UniversityofWalesCollegeofMedicine,Cardiff,UnitedKingdom.REFERENCES1.Huson,S.M.,Clark,P.,Compston,D.A.S.,andHarper,P.S.AgeneticstudyofvonRecklinghausenneurofibromatosisinSouthEastWales.1:prevalence,fitness,mu-tationrate,andeffectofparentaltransmissiononseverity.J.Med.Genet.,26:704–711,1991.2.Viskochil,D.,Buchberg,A.M.,Xu,G.,Cawthon,R.M.,Stevens,J.,Wolff,R.K.,Culver,M.,Carey,J.C.,Copeland,N.G.,Jenkins,N.A.,White,R.,andO’Connell,P.Deletionsandatranslocationinterruptaclonedgeneattheneurofibromatosistype1locus.Cell,62:187–192,1990.3.Wallace,M.R.,Marchuk,D.A.,Anderson,L.B.,Letcher,R.,Odeh,H.M.,Saulino,A.M.,Fountain,J.W.,Brereton,A.,Nicholson,J.,Mitchell,A.L.,Brownstein,B.H.,andCollins,F.S.Type1neurofibromatosisgene:identificationofalargertranscriptdisruptedinthreeNF1patients.Science(Wash.DC),249:181–186,1990.4.Xu,G.F.,O’Connell,P.,Viskochil,D.,Cawthon,R.,Robertson,M.,Culver,M.,Dunn,D.,Stevens,J.,Gesteland,R.,White,R.,andWeiss,R.Theneurofibromatosistype1geneencodesaproteinrelatedtoGAP.Cell,62:599–608,1990.5.NationalInstitutesofHealthConsensusDevelopmentConferenceStatementNeuro-fibromatosis.Arch.Neurol.,45:575–578,1988.6.Ferner,R.E.Clinicalaspectsofneurofibromatosis1.In:M.UpadhyayaandD.N.Cooper(eds.),Neurofibromatosis1fromGenotypetoPhenotype,pp.21–38.Oxford:BiosScientificPublishersLtd.,1998.7.vonRecklinghausen,F.D.U¨berdieMultiplenFibromederHautundIhreBeziehungzudenMultiplenNeuromen.Berlin:AHirschwald,1882.8.Harkin,J.C.Pathologyofnervesheathtumors.Ann.NYAcad.Sci.,486:147–154,1986.9.Korf,B.R.,Huson,S.M.,Needle,M.,Ratner,N.,Rutkowski,L.,Short,P.,Tonsgard,J.,andViskochil,D.Reportoftheworkinggrouponneurofibroma,pp.4–27.TheNationalNeurofibromatosisFoundation,Inc.,1997.10.Huson,S.M.,Harper,P.S.,andCompston,D.A.S.VonRecklinghausenNeurofi-bromatosis.AclinicalandpopulationstudyinSouthEastWales.Brain,111:1355–1381,1988.11.Waggoner,D.J.,Towbin,J.,Gottesman,G.,andGutmann,D.H.Aclinic-basedstudyofplexiformneurofibromasinneurofibromatosis1.Am.J.Med.Genet.,92:132–135,2000.12.Friedman,J.M.,andBirch,P.H.Type1neurofibromatosis.Adescriptiveanalysisofthedisorderin1,728patients.Am.J.Med.Genet.,70:138–143,1997.13.Ducatman,B.,Scheithauer,B.,Piepgras,D.,Reiman,H.M.,andIlstrup,D.M.Malignantperipheralnervesheathtumors:aclinicopathologicstudyof120cases.Cancer(Phila.),57:2006–2021,1986.14.McGaughran,J.,Harris,D.I.,Donnai,D.,Teare,D.,McLeod,R.,Kingston,H.,Super,M.,Harris,R.,andEvans,D.G.R.Aclinicalstudyoftype1neurofibroma-tosisinNorthWestEngland.J.Med.Genet.,36:197–203,1999.15.Ferner,R.E.,Upadhyaya,M.,Osborn,M.,andHughes,R.A.C.Neurofibromatousneuropathy.J.Neurol.,243:S20,1996.16.Leppig,K.A.,Kaplan,P.,Viskochil,D.,Weaver,M.,Ortenberg,J.,andStephens,K.Familialneurofibromatosis1microdeletions:cosegregationwithdistinctfacialphe-notypeandearlyonsetofcutaneousneurofibromata.Am.J.Med.Genet.,73:197–204,1997.17.Strauss,L.G.,andConti,P.S.TheapplicationsofPETinclinicaloncology.J.Nucl.Med.32:623–648,1991.18.Lucas,J.D.,O’Doherty,M.J.,Wong,J.C.H.,Bingham,J.B.,McKee,P.H.,Fletcher,C.D.M.,andSmith,M.A.Evaluationoffluorodeoxyglucosepositronemissiontomographyinthemanagementofsofttissuesarcomas.J.BoneJointSurg.Br.Vol.,80:441–447,1998.19.Ferner,R.E.,Lucas,J.D.,O’Doherty,M.J.,Hughes,R.A.C.,Smith,M.A.,Cronin,B.F.,andBingham,J.B.Evaluationof18fluorodeoxyglucosepositronemissiontomographyinthedetectionofmalignantperipheralnervesheathtumorsinneuro-fibromatosis1.J.Neurol.Neurosurg.Psychiatry,68:353–357,2000.20.Enziger,F.M.,andWeiss,S.W.Benigntumorsofperipheralnerves:malignanttumorsoftheperipheralnerves.In:W.Sharon,WeissandJ.R.,Goldblum(eds.),SoftTissueTumors,Ed.4,pp.1111–1263.St.Louis,MO:Mosby,2001.21.Masson,P.Recklinghausen’sNeurofibromatosis.SensoryNeuromasandMotorNeuromas.LibmanAnniversaryVolumes2,pp.793–802.NewYork:NewYorkInternationalPress,1932.22.Lin,B.T-Y.,Weiss,L.M.,andMedeiros,L.J.Neurofibromaandcellularneurofi-bromawithatypia.Areportof14tumors.Am.J.Surg.Pathol.,21:1443–1449,1997.23.Coffin,C.M.,andDehner,L.P.Cellularperipheralneuraltumors(neurofibromas)inchildrenandadolescents:aclinicopathologicalandimmunohistochemicalstudy.Pediatr.Pathol.,10:351–361,1990.24.Santoro,A.,Tursz,T.,Mouridsen,H.,Verveij,J.,Steward,W.,Somers,R.,Buesa,J.,Casali,P.,Spooner,D.,andRankin,E.DoxorubicinversusCYVADICversesdoxorubicinplusifosfamideinfirst-linetreatmentofadvancedsofttissuesarcomas:arandomizedstudyoftheEORTCSoftTissueandBoneSarcomaGroup.J.Clin.Oncol.,13:1537–1545,1995.25.SarcomaMeta-analysisCollaboration.Adjuvantchemotherapyforlocalisedresecta-blesoft-tissuesarcomainadults:meta-analysisofindividualdata.Lancet,350:1647–1654,1997.26.VanOosterom,A.T.,Judson,I.,Verweij,J.,DiPaola,E.,VanGlabbeke,M.,Dimitrijevic,S.,andNielsen,O.STI571,anactivedruginmetastaticgastro-intestinalstromaltumors(GIST)anEORTCPhaseIstudy.Proc.Am.Soc.Clin.Oncol.,20:,2001.27.Cox,A.D.Farnesyltransferaseinhibitors:potentialroleinthetreatmentofcancer.Drugs,61:723–732,2001.28.Guha,A.,Lau,N.,Huvar,I.,Gutmann,D.,Provias,J.,Pawson,T.,andBoss,G.Ras-GTPlevelsareelevatedinhumanperipheralnervetumors.Oncogene,12:507–513,1996.29.Basu,T.N.,Gutmann,D.H.,Fletcher,J.A.,Glover,T.W.,Collins,F.S.,andDownward,J.Aberrantregulationofrasproteinsinmalignanttumorcellsfromtype1neurofibromatosispatients.Nature(Lond.),356:663–664,1992.30.DeClue,J.E.,Papageorge,A.G.,Fletcher,J.A.,Diehl,S.R.,Ratner,N.,Vass,W.C.,andLowy,D.R.Abnormalregulationofmammalianp21rascontributestomalignanttumorgrowthinvonRecklinghausen’s(type1)neurofibromatosis.Cell,69:265–273,1992.1576THEMALIGNANTPERIPHERALNERVESHEATHTUMORGROUP31.Kluwe,L.,Friedrich,R.E.,andMautner,V.F.AlleliclossoftheNF1geneinNF1-associatedplexiformneurofibromas.CancerGenet.Cytogenet.,113:65–69,1999.32.Rutkowski,J.L.,Wu,K.,Gutmann,D.H.,Boyer,P.J.,andLegius,E.Geneticandcellulardefectscontributingtobenigntumorformationinneurofibromatosistype1.Hum.Mol.Genet.,9:1059–1066,2000.33.Sherman,L.S.,Atit,R.,Rosenbaum,T.,Cox,A.D.,andRatner,N.SinglecellRas-GTPanalysisrevealsalteredRasactivityinasubpopulationofneurofibromaSchwanncellsbutnotfibroblasts.J.Biol.Chem.,275:30740–30745,2000.34.Nielsen,G.P.,Stemmer-Rachamimov,A.O.,Ino,Y.,Moller,M.B.,Rosenberg,A.E.,andLouis,D.N.Malignanttransformationofneurofibromasinneurofibro-matosis1isassociatedwithCDKN2A/p16inactivation.Am.J.Pathol.,155:1879–1884,1999.35.Kourea,H.P.,Cordon-Cardo,C.,Dudas,M.,Leung,D.,andWoodruff,J.M.Theemergingroleofp27kipinmalignanttransformationofneurofibromas.Am.J.Pathol.,155:1885–1891,1999.36.Cichowski,K.,Shih,T.S.,Schmitt,E.,Santiago,S.,Reilly,K.,McLaughlin,M.E.,Bronson,R.T.,andJacks,T.Mousemodelsoftumordevelopmentinneurofibro-matosistype1.Science(Wash.DC),286:2172–2176,1999.37.Vogel,K.S.,Klesse,L.J.,Velasco-Miguel,S.,Meyers,K.,Rushing,E.J.,andParada,L.F.Mousetumormodelforneurofibromatosis1.Science(Wash.DC),286:2176–2179,1999.1577THEMALIGNANTPERIPHERALNERVESHEATHTUMORGROUPHealthSupervisionforChildrenWithNeurofibromatosis368PEDIATRICSVol.96No.2August1995CommitteeonGeneticsThissetofguidelinesisdesignedtoassistthepediatricianincaringforthechildinwhomthediagnosisofneurofibromatosishasbeenmade.Al-thoughthepediatrician’sfirstcontactwiththechildisusuallyduringinfancy,occasionallythepregnantwomanwhohasbeengiventheprenataldiagnosisofneurofibromatosiswillbereferredforadvice.There-fore,theseguidelinesofferadviceforthissituationaswell.Atleasttwodistincttypesarerecognized-neurofi-bromatosis1,orNF-1(previouslyknownasvonReck-linghausendiseaseorgeneralizedneurofibromatosis),andneurofibrornatosis2,orNF-2(previouslyknownasbilateralacousticneurofibromatosis).ThisdiscussionaddressesonlyissuesconcerningthediagnosisandmanagementofNF-1.18NeurofibrornatosisIisaprogressive,multisystemdisorderaffectingaboutIin3,000individuals.9ANationalInstitutesofHealth(NIH)ConsensusDe-velopmentConference’#{176}regardingNF-1demarcatedsevenfeatures,ofwhichtwoormorearerequiredtoestablishfirmlythediagnosisofNF-1:I.Sixormorecafe-au-laitspots(CLS)ormacules,greaterthanorequalto5mmindiameterinprepubertalpatientsand15mmindiameterinpostpubertalpatients;2.Twoormoreneurofibromataofanytype,oroneplexiformneurofibroma;3.Frecklingintheaxillaryoringuinalregion;4.Opticglioma;5.TwoormoreLischnodules(irishamartomas);6.Adistinctiveosseouslesionsuchassphenoiddys-plasiaorcorticalthinningoflongbones,withorwithoutpseudarthrosis;or7.Afirst-degreerelative(parent,sibling,orchild)withNF-1accordingtotheprecedingcriteria.Diagnosisinnonfamilialpediatriccasesmaybedifficultbecausecertainclinicalfeaturesareage-de-Therecommendationsinthisstatementdonotindicateanexclusivecourseoftreatmentorproceduretobefollowedforchildrenwithneurofibroma-tosis,butaremeanttosupplementanticipatoryguidelinesavailablefortreatingthenormalchildprovidedintheAAPpublication,“GuidelinesforHealthSupervision.”Theyareintendedtoassistthepediatricianinhelpingchildrenwithneurofibromatosistoparticipatefullyinlife.Diagnosisandtreatmentofneurofibromatosisareconstantlychanging.Therefore,pedia-triciansareencouragedtoviewtheseguidelinesinlightofevolvingscien-tificinformation.Clinicalgeneticists,particularlythoseassociatedwithNFspecialtyclinics,andotherspecialistsmaybeavaluableresourceforthepodiatricianseekingadditionalinformationorconsultation.Variations,tak-ingintoaccountindividualcircumstances,maybeappropriate.PEDIATRICS(ISSN00314005).Copyright©1995bytheAmericanAcad-emyofPediatrics.pendent.Forthesamereason,theseverityofNF-1inlaterlifemaybeunderestimatedinanaffectedchild.CongenitallesionsincludeCLSand,lesscorn-monly,axillaryfrecklingandneurofibromata.Someaffectedchildrenhavenocharacteristiclesionsatbirth.CLStendtoincreaseinsizeandnumberthroughoutearlychildhood.Laterinchildhood,neu-rofibromatabecomeevidentasskinnodulesortagslocatedincutaneousorsubcutaneoustissues,orassubcutaneousmassesinvolvingdeeptissues(plexi-formneurofibromas).Skinoverlyingplexiformneu-rofibromassometimesshowshyperpigmentationandhypertrichosis.Neurofibromatacanbefoundinallorgansystems,givingrisetospecificsymptomsdependingonsize,location,anddegreeofencroach-mentonsurroundingtissues.Markedgrowthoftheselesionscanoccuranytimeinchildhoodbutparticularlyinadolescenceandpregnancy.COMPLICATIONSThecomplicationsofNF-1resultfromdirectin-volvementofmultiplesystemsbyneurofibromata,anincreasedriskformalignancy(mostlyfibrosarco-masbutalsoothermalignancies,includingleuke-mia),’1andpoorlyunderstoodassociationssuchasmentalretardation,shortstature,andneurologicandvascularchangesunassociatedwithneurofibrornata.Sarcomatouschangesmayoccurinneurofibrornata,characteristicallyindeeplesions.Pain,rapidgrowth,andnewlocalizingneurologicfindingssometimessuggestmalignantchanges,whichareotherwisedifficulttodetect.Amongtheunusualbutmoreseriouscomplica-tionsofwhichthefamilyshouldbeawareareopticgliomas(leadingtoblindness)andotherbrainandnervetumors,hypertension,kyphosisand/orscoli-osis(leadingtodiminishedpulmonaryfunction),gastrointestinalbleedingsecondarytogastrointesti-nalneurofibromata,facialdisfigurementfromneu-rofibromata,andpseudarthroses.Deathmayresultfromsomeofthesecomplications.Forunknownreasons,NF-1isassociatedwithanincreasedincidenceofmentalretardation,al-thoughitisusuallynotsevere.Learningproblems,speechretardationofanonspecificnature,hyper-activity,seizures,andEEGchangesarealsocorn-monlyreported.12”3Ifseizuresarepresent,intra-cranialtumorsmustbeexcluded,althoughoftennospecificetiologyfortheseizuredisorderisfound.PersonswithNF-1tendtoshowsubtleneurologicabnormalitiesinvolvingfinecoordina-tion,balance,andgait.ThereportedincidenceofcomplicationsinNF-1by guest on May 2, 2017Downloaded from AMERICANACADEMYOFPEDIATRICS369variesfromstudytostudymostlybecauseofbi-asedpatientselectionbyageandspecialtyreferral,butalsobecauseofinconsistentdiagnosticcriteriaandvariableutilizationofimagingtechniques.Generallycomplicationsareoverestimatedbe-causemoststudiesinvolvepatientsinhospitalsorreferralclinics.’4AboutonethirdofpatientswithNF-1showseriouscomplications,andaboutonehalfaremildlyaffected.However,becauseoftheextremedegreeofvariabilityevenwithinafamily,itisnotpossibletopredicttheclinicalfeaturesinaspecificperson.GENETICSTransmissionofNF-1isbyanautosomaldomi-nantmodeofinheritance.Inabouthalfofthepa-tients,theconditionisduetoanewmutation.Insuchinstancestheparents(bothphenotypicallynor-malinregardtoNF-1)arenotatincreasedriskcomparedwiththenormalpopulationtohavean-otherchildaffectedwiththisdisorder.However,thepersonswithnewmutationsareat50%risktotrans-mitthegenetotheiroffspring.ThemutantNF-1genehasahighpenetrancerate,andonlyrarelydoesapersonknowntohavethismutationshownoclinicalmanifestations.TheNF-1genehasbeenlocalizedtochromosome17atbandq11.2.1(cid:1)’7Neurofibromin,theproteinproductofthenonmutatedgenelocus,isthoughttoactasatumorsuppressorundernormalconditionsbydown-regulatinganothercellproteinthaten-hancescellgrowthandproliferation.18Pointmuta-tionsanddeletionshavebeenidentifiedwithintheNF-1gene,givingrisetodiminishedfunctionofneurofibromininaffectedpersons.DNAanalysisfortheneurofibromatosismutationisnotyetcommer-ciallyavailable,butlinkagestudiesusingDNAmarkershavebeenaccuratein95%to99%ofthepatientsstudied.19Linkageanalysis,however,re-quiresstudyofseveralfamilymembersandisnotapplicabletoallpatients.CLINICALMANAGEMENTThemultiorganoccurrenceofneurofibromasandtheircomplicationsoftenrequirescarefromavarietyofmedicalandsurgicalspecialists.Thepediatricianshouldcoordinatesuchcare.PatientswithmorethanminimalmanifestationsofNF-1maybenefitfromreferraltoamultidisciplinaryneurofibromatosis(NF)clinicforprimaryorspecialtycare.SuchclinicsareavaluableconsultationresourceforpediatricianscaringforpatientswithNF-1.Treatmentisaimedatthecomplicationsastheyoccur.Someoftheproblems,suchasrenalarterystenosis,ifdetectedearly,canbemanagedsuccess-fully.Enlargingtumorscansometimesbeman-agedbyobservationandsurgery.However,surgi-calremovalofaneurofibromacompromisinganessentialorgansystemmaynotbepossiblebe-causeofaninaccessiblesiteorinfiltrationintosurroundingtissue.Ifmalignancies(includingleu-kemia)develop,treatmentisthesameasforchil-drenwithoutNF-1.InthemedicalsupervisionofachildwithNF-1,anumberofareasrequireongoingassessmentandperiodicreviewthroughoutlife(Table),includingthefollowing:I.Evaluatethechildfornewneurofibromasandprogressionoflesions.Examinetheskincarefullyforsignsofplexiformneurofibromasthatmayimpingeonorinfiltrateunderlyingstructures.2.Checkthechild’sbloodpressure.Becauserenaldisease(particularlyrenalarterystenosis),aorticstenosis,pheochromocytomas(morecommoninadults)andadrenaltumorsmayoccur,regularandcarefulbloodpressuremeasurementsareimportant.Avarietyofvascularhypertrophiclesionsmaybefound.3.Evaluateneurodevelopmentalprogress.4.Evaluatethechildforskeletalchanges.Lookforscoliosis,vertebralangulation,andlimbabnor-malities.Sometimeslocalizedhypertrophyofaleg,arm,orotherpartofthebodyresultsfromplexiformneurofibromata.5.Ifanycomplicationsoccurorifneurocutaneouslesionsappeartoberapidlyadvancing,refertotheappropriatespecialist.6.RecommendavailableresourcesforpatientswithNF-1(eg,NFclinics,supportgroups,andindivid-ualNF-1families).Supplybooksandpamphlets(obtainablefromtheNationalNFFoundation).TheNationalNFFoundationcanalsoprovidefurtherinformationandcliniclocations.Thead-dressofthisorganizationappearsintheAcknowl-edgmentssection.THEPRENATALVISITAttimesthepediatricianmaybecalledontocoun-selafamilywhenoneoftheparents-to-beisaffectedandthefetushasbeendiagnosedtohaveNF-1byDNAstudies.Inthissituation,thefamilymostlikelyalreadyhasbeencounseledaboutthedisorderanditsinheritancepattern.However,thepediatricianmaybecalledupontoreviewtheinformationandtoassistthefamilyinthedecision-makingprocess.Asappropriate,thepediatricianmaydiscussthefollow-ingissueswiththefamily:1.Reviewtheprenataldiagnosis.2.Explainthemechanismforoccurrenceofthedis-orderinthefetusandtherecurrencerate.3.Reviewtheprognosis,manifestations,variability,andprogressivenatureofthedisorder.4.Reviewthetreatmentsandinterventionsthatarecurrentlyavailable.Thisdiscussionshouldin-dudetheefficacy,complications,sideeffects,andcostorotherburdensofthesetreatments.5.Discusstheoptionsavailabletothefamilyformanagementandrearingofthechild.Incasesofearlyprenataldiagnosis,thismayincludediscus-sionofpregnancytermination,aswellascontin-uationofthepregnancyandrearingthechildathome,adoption,etc.6.Whenappropriate,considerreferringtoaclinicalgeneticistforamoreextendeddiscussionofdin-icalfindings,recurrencerates,futurereproductiveoptions,andevaluationoftherisksofdiseaseforotherfamilymembers.by guest on May 2, 2017Downloaded from TABLE.HealthSupervisionGuidelinesforChildrenWithNeurofibromatosis*370HEALTHSUPERVISIONFORCHILDRENWITHNEUROFIBROMATOSISPrenatalInfancyImo-iyEarlyChildhood1-5yLateChildhood5-13yAdolescence13-21yNeonatal24691215182434Annual’Annual1momomomomomomomoyr’yr(cid:1)DiagnosisDNAanalysis#{149}PhenotypereviewS#{149}Geneticcounseling#{149}#{149}4ReproductiveOptionsforParentsAdoption/termination#{149}Futurereproductiveplanning#{149}#{149}#{149}AnticipatoryGuidanceFamilysupport#{149}#{149}#{149}#{149}S#{149}#{149}#{149}#{149}#{149}#{149}#{149}#{149}Supportgroups#{149}#{149}#{149}#{149}Long-termplanning#{149}#{149}#{149}44Sexualandreproductiveissues#{149}MedicalEvaluationandTreatment5Growth0000000000000Bloodpressure0000000000000Skinexamination0000000000000Boneexamination/scoliosis0000000000000Neurologicalexamination0000000000000Visionscreening5/05/05/05/05/0S/Or’55S/0(cid:1)S/Os5/065/(cid:1)6S/OsHearingscreeningSSSSSS/OhSSSSS/OsS/0S/OSexualmaturation00DiagnosticImagingExaminations5PsychosocialEvaluationDevelopmentandbehavior5/05/05/05/05/05/05/05/05/05/0S/Os5/05/0Pre-schoolprogramSSSchoolplacement/performanceS/0S/OPsychological/socialadjustmentSSSSSSSSIntrafamilyrelationshipsSSSSSSSSSS*AssurecompliancewiththeAmericanAcademyofPediatrics“RecommendationsforPreventivePediatricHealthCare.”.=tobeperformed;S=subjective,byhistory;0=objective,byastandardtestingmethod.I=Advisesemi-annualvisits,asindicated.25e-(cid:1)discussion.3=Orattimeofdiagnosis.4=Onceinthistimeperiod.5=Asneededforsignificantabnormalitiesand/ornewsigns.6=Refertospecialist.7.InformthemthatinmanypartsofthecountrytherearespecialtyNFclinicsthatareavailableforguidance,therapy,andconsultation.HEALTHSUPERVISIONFROMBIRTHTO1MONTH-NEWBORNSExaminationI.Confirmthediagnosisbythepresenceofcutane-ousmanifestations.UseofaWood’slampmaybehelpfulinidentifyingCLS.Axillaryfrecklingissometimespresentatbirth.2.BeawarethatnormalexaminationresultsdonotexcludeNF-1.3.Allfirst-degreerelativesshouldbeadvisedtohaveaphysicalexamination,includingaslitlampexaminationoftheirisesforLischnodules,whicharefoundin>90%ofadultswiththisdisorderbutareuncommoninchildrenunder3yearsofage.4.SomespecialistsadviseaninitialimagingstudyforopticgliomawhenthediagnosisofNF-1ismade.”2#{176}TheNIHConsensusDevelopmentCon-ference’#{176}didnotrecommendcomputedtomogra-phyormagneticresonanceirnagingstudiesforasymptomaticpatientswithNF-1,however,andgenerallyrecommendedspecialstudiesonlywhenclinicallyindicated.AnticipatoryGuidance1.ReviewthenaturalhistoryandgeneticsofNF-1.2.Advisetheparentstoreportanyunusualornewsymptoms.3.Stresstheneedforregularlyscheduledvisits,in-cludingcarefulneurologicandbloodpressureevaluations.HEALTHSUPERVISIONFROM1MONTHTO1YEAR-INFANCYExamination1.Comparetheinfant’sgrowthanddevelopmentwithfiguresongrowthcharts.Asagroup,chil-drenwithNF-1areshorterthanaveragebuthavelargerheads.2.ExaminethepatientforthepresenceofCLS.In-formthefamilythatnewonesmayappearandby guest on May 2, 2017Downloaded from AnticipatoryGuidanceappropriatespecialists.AMERICANACADEMYOFPEDIATRICS371preexistingCLSoftenincreaseinsize.ReassurethefamilythatCLShavenoclinicalsignificance.3.Checkforproptosis,arapidlyincreasingheadsize,andfocalneurologicsigns.4.Performacarefulphysicalexaminationforskele-talabnormalities,especiallyinthespineandlegs.Thisisparticularlyimportantbeforethechildbe-ginstobearweight.5.Refertheinfanttoappropriatespecialists,asmdi-cated.6.Checktheinfant’sneurodevelopmentalprogressateachvisit.AnticipatoryGuidanceI.Reviewthefamily’spsychologicalsupportandintrafamilialrelationships.2.Advisetheparentstousesunprotection(sun-screen)ontheinfant.Sunexposuredeepenspig-mentinCLS.Althoughthisisusuallyofcosmeticsignificanceonly,melanomaandbasalcellcarci-nomahavebeenreportedinadultswithNF-1(cid:1)213.Ifnecessary,reviewfuturepregnancyplanningforparents.HEALTHSUPERVISIONFROM1TO5YEARS-EARLYCHILDHOODExaminationI.Examinethechildforneurofibromataandnewfreckling(whichcanappearinanyintertriginousarea).AssureparentsthatCLSandfrecklinghaveonlycosmeticsignificance.2.Considertakingphotographstodocumentlesionsizeforfuturereference.3.Evaluatethechild’svision.4.Recommendthatthechildreceiveanophthalmo-logicalexaminationannually.5.Iftherearevisualchanges,persistentheadaches,seizures,amarkedincreaseinheadsize,oraplexiformneuromaofthehead,obtaincomputedtomographyormagneticresonanceimagingofthehead.6.Assessthechild’sspeech.AnticipatoryGuidanceI.Provideanti-pruriticmedicationasnecessary.Pruritismaybefoundwithcutaneousneurofibro-mata.2.Reviewthechild’spreschoolprogram.3.Obtainapsychologicalevaluationofthechildforassessmentoflearningabilities.Thechildmaybenefitfromspecialpreschooleducationpro-gramsandspeechtherapy.4.Referthechildforanaudiogrambeforeheorsheentersapreschoolorschoolprogram.5.Discussindicationsforsurgery,asappropriate.Ifthereisachangeinthesizeofsuperficialneuro-fibromataorevidenceofaspace-occupyinginter-nallesion,referthechildtoanNFclinicorotherHEALTHSUPERVISIONFROM5TO13YEARS-LAThCHILDHOODExaminationI.Examinethechildforskintumorscausingdis-figurementandobtainaconsultationwithaspecialistifsurgeryisdesiredtoimproveappear-anceorfunction.Severecosmeticdisfigurementismoreoftenseeninadultsthaninchildren.2.Evaluatethechildforsignsofpuberty.Prematureonsetofsexualmaturationordelayedpubertymayoccur.Ifsexualprecocityispresent,evaluatethechildforpresenceofopticgliomaorhypotha-lamiclesion.20’(cid:1)3.Checkforsignsoflearningdisabilities,hyperac-tivity,andbehaviorproblems.4.Reviewthechild’ssocialadjustment.AnticipatoryGuidanceI.Reviewthechild’sdevelopmentandappropriate-nessofschoolplacement.2.Referthechildtoaclinicalpsychologistorchildpsychiatristforfurtherevaluationandtherapyasindicated.3.Reviewtheeffectsofpubertyonthedisease.4.Discussthepossibilityofthegrowthofneurofi-bromataduringadolescenceandpregnancy.HEALTHSUPERVISIONFROM13TO21YEARSOROLDER-ADOLESCENCETOEARLYADULTHOODExaminationI.Refertheadolescentforanophthalmologicalex-arninationannually.2.Examinetheadolescentforsignsofpubertyorhypogonadism.3.Performaneurologicalexaminationtocheckfordeepplexiformneurofibromata.4.Obtainasurgicalconsultationwithaspecialistifsignsofpressureondeepstructuresarefound.I.DiscussthegeneticsofNF-1orrefertheadoles-centforgeneticcounseling.2.Discusssexuality.3.Discussbirthcontrol,includingtherisksandbenefitsofbirthcontrolpills,andreproductiveoptions.4.DiscusstheeffectofpregnancyonNF-l,ifappro-priate.WomenwithNF-1mayhavecomplicationsduringpregnancybecauseofenlargementoftheneurofibromata.(cid:1)’245.Reviewtheprenataldiagnosisbycurrentlyavail-ablemolecularDNAstudiesanditsapplicabilitytothepatientwithNF-l,orreferthepatienttoageneticist.6.Facilitatetransfertoadultmedicalcare.COMMI-i-I-EEONGENETICS,1994TO1995MargrettaR.Seashore,MD,ChairpersonSechinCho,MDFranklinDesposito,MDJackSherman,MDRebeccaS.Wappner,MDMiriamG.Wilson,MDby guest on May 2, 2017Downloaded from 372HEALTHSUPERVISIONFORCHILDRENWITHNEUROFIBROMATOSISLIAISONREPRESENTATIVESFelixdelaCruz,MDNationalInstitutesofHealthJamesW.Hanson,MDAmericanCollegeofMedicalGeneticsJaneLin-Fu,MDHealthResourcesandServicesAdministrationPaulG.McDonough,MDAmericanCollegeofObstetriciansandGynecologistsGodfreyOakley,MDCentersforDiseaseControlandPreventionAAPSEcrIoNLIAISONBethA.Pletcher,MDSectiononGeneticsandBirthDefectsACKNOWLEDGMENTSForfurtherinformationpleasecontact:NationalNeurofibroma-tosisFoundation,95PineStreet,16Fuller,NewYork,NY10005;Telephone:1-800-323-7938or(212)344-6633.REFERENCES1.DunnDW.Neurofibromatosisinchildhood.CurrProblPediatr.1987;17:445-4972.HusonSM.Recentdevelopmentsinthediagnosisandmanagementofneurofibromatosis.ArchDisChild.1989;64:745-7493.1-lusonSM,HughesRAC,eds.TheNeurofibromatoses:APathogeneticandClinicalOverview.London,England:ChapmanandHall;19944.ListernickR,CharrowJ.Neurofibromatosistype1inchildhood.IPediatr.1990;116:845-8535.ObringerAC,MeadowsAT,ZackaiEH.Thediagnosisofneurofibro-matosis-linthechildundertheageof6years.AJDC.1989;143:717-7196.RiccardiVM.Type1neurofibromatosisandthepediatricpatient.CurrProblPediatr.1992;22:66-1067.RiccardiVM.Neurofibromatosis:Phenotype,NaturalHistoryandPathogen-esis.2nded.Baltimore,MD:TheJohnsHopkinsUniversityPress;19928.RubensteinAE,KorfBR,eds.Neurofibromatosis:AHandbookforPatients,FamiliesandHealth-careProfessionals.NewYork,NY:ThiemeMedicalPublishers;19909.CroweFW,SchullWJ,NeelJV.AClinical,Pathological,andGeneticStudyofMultipleNeurofibromatosis.Springfield,IL:CharlesCThomas;195610.NationalInstitutesofHealth(NIH)ConsensusDevelopmentConfer-enceStatement:neurofibromatosis.Neurofibromatosis.1988;1:172-17811.HopeDG,MulvihillJJ.Malignancyinneurofibromatosis.AdoNeurol.1981;29:33-5612.EldridgeR,DencklaMB,BienE,etal.NeurofibromatosistypeI(Reck-linghausen’sdisease):neurologicandcognitiveassessmentwithsiblingcontrols.AJDC.1989;143:833-83713.HofmanKJ,HarrisEL,BryanRN,DencklaMB.Neurofibromatosistype1:thecognitivephenotype.IPediatr.1994;124:S1-S814.CareyJC,LaubJM,HallBD.Penetranceandvariabilityinneurofibromatosis:ageneticstudyof60families.BirthDefects:OriginalArticleSeries.1979;15:271-28115.BarkerD,WrightE,NguyenK,etal.GeneforvonRecklinghausenneurofibromatosisisinthepericentricregionofchromosome17.Sci-ence.1987;236:1100-110216.FountainJW,WallaceMR.BreretonAM,etal.PhysicalmappingofthevonRecklinghausenneurofibromatosisregiononchromosome17.AmIHumGenet.1989;44:58-6717.LedbetterDH,RichDC,O’ConnellP,LeppertM,CareyJC.PreciselocalizationofNFlto17q11.2bybalancedtranslocation.AmIHumGenet.1989;44:20-2418.GutmannDH,CollinsPS.TheneurofibromatosistypeIgeneanditsproteinproduct,neurofibromin.Neuron.1993;10:335-34319.HofmanKJ,BoehmCD.Familialneurofibromatosistype1:clinicalexperiencewithDNAtesting.IPediatr.1992;120:394-39820.ListernickR,CharrowJ,GreenwaldMJ,EsterlyNB.Opticgliomasinchildrenwithneurofibromatosistype1.1Pediatr.1989;114:788-79221.KnightWA,MurphyWK,GottliebJA.Neurofibromatosisassociatedwithmalignantneurofibromas.ArchDermatol.1973;107:747-75022.LaueL,ComiteF,HenchK,etal.Precociouspubertyassociatedwithneurofibromatosisandopticgliomas:treatmentwithluteimzinghor-monereleasinghormoneanalogue.AJDC.1985;139:1097-110423.BlicksteinI,LancetM,ShohamZ.Theobstetricperspectiveofneurofi-bromatosis.AmJObstetGynecol.1988;158:385-38824.WeissmanA,JakobiP.ZaidiseI,DruganA.Neurofibromatosisandpregnancy:anupdate.IReprodMed.1993;38:890-896by guest on May 2, 2017Downloaded from  1995;96;368PediatricsCommittee on Genetics, 1994 to 1995Health Supervision for Children With Neurofibromatosis(cid:160)(cid:160) ServicesUpdated Information & /content/96/2/368including high resolution figures, can be found at:Citations /content/96/2/368#related-urlsThis article has been cited by 2 HighWire-hosted articles:Permissions & Licensing /site/misc/Permissions.xhtmlor in its entirety can be found online at: Information about reproducing this article in parts (figures, tables) Reprints /site/misc/reprints.xhtmlInformation about ordering reprints can be found online:Online ISSN: 1098-4275.Copyright © 1995 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007.has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, itby guest on May 2, 2017Downloaded from  1995;96;368PediatricsCommittee on Genetics, 1994 to 1995Health Supervision for Children With Neurofibromatosis(cid:160)(cid:160)(cid:160) /content/96/2/368the World Wide Web at: The online version of this article, along with updated information and services, is located on(cid:160)ISSN: 0031-4005. Online ISSN: 1098-4275.PrintIllinois, 60007. Copyright © 1995 by the American Academy of Pediatrics. All rights reserved. by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village,it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication,by guest on May 2, 2017Downloaded from original articleThe new england journal of medicinen engl j med 361;4 nejm.org july 23, 2009358Hearing Improvement after Bevacizumab  in Patients with Neurofibromatosis Type 2Scott R. Plotkin, M.D., Ph.D., Anat O. Stemmer-Rachamimov, M.D.,  Fred G. Barker II, M.D., Chris Halpin, Ph.D., Timothy P. Padera, Ph.D.,  Alex Tyrrell, Ph.D., A. Gregory Sorensen, M.D., Rakesh K. Jain, Ph.D.,  and Emmanuelle di Tomaso, Ph.D.From the Departments of Neurology (S.R.P.), Pathology (A.O.S.-R.), and Radia-tion Oncology (T.P.P., A.T., R.K.J., E.T.); the Cancer Center (S.R.P.); the Neurosurgical Service (F.G.B.); and the A.A. Martinos Center for Biomedical Imaging (A.G.S.) — all at Massachusetts General Hospi-tal; and the Department of Audiology, Massachusetts Eye and Ear Infirmary (C.H.) — all in Boston. Address reprint requests to Dr. Plotkin at Yawkey 9E, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114, or at splotkin@partners.org. This article (10.1056/NEJMoa0902579) was published on July 8, 2009, at NEJM.org.N Engl J Med 2009;361:358-67.Copyright © 2009 Massachusetts Medical Society.AbstractBackgroundProfound hearing loss is a serious complication of neurofibromatosis type 2, a ge-netic condition associated with bilateral vestibular schwannomas, benign tumors that arise from the eighth cranial nerve. There is no medical treatment for such tumors.MethodsWe determined the expression pattern of vascular endothelial growth factor (VEGF) and three of its receptors, VEGFR-2, neuropilin-1, and neuropilin-2, in paraffin-embedded samples from 21 vestibular schwannomas associated with neurofibro-matosis type 2 and from 22 sporadic schwannomas. Ten consecutive patients with neurofibromatosis type 2 and progressive vestibular schwannomas who were not candidates for standard treatment were treated with bevacizumab, an anti-VEGF monoclonal antibody. An imaging response was defined as a decrease of at least 20% in tumor volume, as compared with baseline. A hearing response was defined as a significant increase in the word-recognition score, as compared with baseline.ResultsVEGF was expressed in 100% of vestibular schwannomas and VEGFR-2 in 32% of tumor vessels on immunohistochemical analysis. Before treatment, the median an-nual volumetric growth rate for 10 index tumors was 62%. After bevacizumab treat-ment in the 10 patients, tumors shrank in 9 patients, and 6 patients had an imaging response, which was maintained in 4 patients during 11 to 16 months of follow-up. The median best response to treatment was a volumetric reduction of 26%. Three patients were not eligible for a hearing response; of the remaining seven patients, four had a hearing response, two had stable hearing, and one had progressive hear-ing loss. There were 21 adverse events of grade 1 or 2.ConclusionsVEGF blockade with bevacizumab improved hearing in some, but not all, patients with neurofibromatosis type 2 and was associated with a reduction in the volume of most growing vestibular schwannomas.Copyright © 2009 Massachusetts Medical Society. All rights reserved. Downloaded from www.nejm.org at EMORY UNIVERSITY on September 17, 2009 . Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis 2n engl j med 361;4 nejm.org july 23, 2009359Neurofibromatosis type 2 is a domi-nantly inherited genetic condition with a birth prevalence of 1 in 25,000.1 Bilateral vestibular schwannomas (also known as acoustic neuromas), which are benign tumors composed of neoplastic Schwann cells that arise from the eighth cranial nerve, are the hallmark of neuro-fibromatosis 2. These tumors cause progressive hearing loss in most patients with neurofibroma-tosis type 2, who commonly lose all functional hearing during early adulthood or middle age. Standard therapy for growing sporadic, unilateral vestibular schwannomas includes surgical remov-al or radiation therapy. Both treatments usually achieve tumor control, but at the frequent cost of hearing loss in the affected ear.2,3Treatment options are limited for patients with neurofibromatosis type 2 and a growing vestibu-lar schwannoma ipsilateral to the only ear with hearing. Results of surgery and radiation ther-apy for vestibular schwannomas associated with neurofibromatosis type 2 are worse than for sporadic tumors, because rates of tumor control are reduced and iatrogenic hearing loss is more frequent.4-6 Although the morbidity of active treatment can be prohibitively high, the conse-quences of unchecked tumor growth (including progressive brain-stem compression) are also se-vere. Currently, no medical treatments for tumors associated with neurofibromatosis type 2 are available, and a safe and effective treatment for these patients is needed.Vascular endothelial growth factor (VEGF) is a critical mediator of tumor angiogenesis and ves-sel permeability.7-9 VEGF and its receptor VEGFR-1 have been detected in schwannomas, and in-creased levels of these factors correlate with increased rates of tumor growth.10-14 Although schwannomas are not considered vascular tumors, the non–VEGF-related, antiangiogenic compound AGM-1470 inhibits angiogenesis and reduces the growth of nerve-sheath tumors in mouse mod-els.15 The VEGF-neutralizing antibody bevacizu-mab has been approved by the Food and Drug Administration for use in the treatment of can-cers, but no studies have been performed in pa-tients with neurofibromatosis type 2 or vestibu-lar schwannomas.Here we describe a retrospective study of 10 consecutive patients with neurofibromatosis type 2 and growing vestibular schwannomas who were treated with bevacizumab. We chose this agent on the basis of tumor immunohistochemical analyses suggesting a potential pathophysio-logical role for the VEGF pathway in vestibular schwannomas. We provide radiologic and audio-logic evidence that bevacizumab treatment of-fered durable clinical benefit to some patients, including a reduction in tumor volume and an improvement in chronic hearing loss.MethodsImmunohistochemical AnalysesParaffin-embedded tissue sections from 21 schwan-nomas associated with neurofibromatosis type 2, 22 sporadic schwannomas, and 9 normal spinal-nerve roots were immunostained with the follow-ing antibodies: CD31, VEGF, VEGFR-2, platelet-derived growth factor receptor α (PDGFR-α), PDGFR-β, neuropilin-1, neuropilin-2, semaphorin 3A, and semaphorin 3F. Semiquantitative analy-sis was performed by two authors, who scored the intensity of tumor-cell and blood-vessel stain-ing on a scale of 0 (no staining) to 3 (strong staining). A customized software analysis tool was used to determine the number of vessels, perimeter, the minor axis of best fitted ellipse (representative of vessel diameter), and the total surface covered by vascular spaces. The same method was used, with the substitution of either VEGFR-2 or neuropilin-2 labeling, to determine the proportion of vessels expressing these VEGF receptors (for details, see the Supplementary Ap-pendix, available with the full text of this article at NEJM.org).Selection of PatientsWe offered bevacizumab on a compassionate-use basis to patients who fulfilled the clinical diag-nostic criteria for neurofibromatosis type 2,16 had evidence of progressive vestibular schwan-nomas, and were considered poor candidates for surgery and radiation therapy or declined these treatments. Consecutive patients who met these criteria and had received at least one bevacizu-mab dose as of August 1, 2008, were included in the analysis.Clinical EvaluationsThe intervals for clinical evaluations were deter-mined before treatment of the first patient. Base-Copyright © 2009 Massachusetts Medical Society. All rights reserved. Downloaded from www.nejm.org at EMORY UNIVERSITY on September 17, 2009 . The new england journal of medicinen engl j med 361;4 nejm.org july 23, 2009360line magnetic resonance imaging (MRI) and au-diology were performed within 1 month before starting treatment. Clinical evaluation, which in-cluded a physical examination, complete blood count, blood chemical analysis, and urinalysis, was performed every 2 to 4 weeks during treat-ment. Tumor response was monitored with the use of serial MRI scanning at clinical visits at months 1, 3, and 6 and every 3 months thereaf-ter. Tumor volumetric analysis was performed as described previously.17 To investigate whether tumor shrinkage might be related, in part, to a decrease in intratumoral vasogenic edema, we sub-sequently determined the mean apparent diffu-sion coefficient (a measure of the magnitude of diffusion of water molecules within tissue and a marker of edema on imaging with MRI18) with-in vestibular schwannomas at baseline. Dynam-ic contrast-enhanced MRI (DCE-MRI) was per-formed in Patient 6 to evaluate changes in blood flow and vascular permeability after treatment.18 Hearing response was monitored with the use of serial audiologic evaluations, including determi-nation of pure-tone thresholds and word-recog-nition scores (for details, see the Supplementary Appen dix).19,20 Data regarding toxic effects were collected monthly during routine clinic visits, and adverse events were scored according to the Common Terminology Criteria for Adverse Events, version 3.0.Definitions of imaging and Hearing ResponsesWe established definitions of imaging and hear-ing responses after noting a clinical benefit in the first patient. An imaging response was de-fined as a decrease of at least 20% in tumor vol-ume, as compared with the pretreatment base-line.21 Volumetric changes of 15% or 20% have been used to define response and progression in early-phase trials involving patients with plexi-form neurofibromas associated with neurofibro-matosis type 1.22,23A hearing response was defined as a signifi-cant increase in the word-recognition score, as compared with the baseline score.24 Patients were eligible for a hearing response if their pre-treatment word-recognition score allowed for hearing improvement above the upper limit of the critical-difference threshold (i.e., a word-recognition score of 94% or less). Patients with surgically disrupted auditory nerves were not eligible for a hearing response. We used pub-lished guidelines25 to determine significant dif-ferences between word-recognition scores to com-pare each patient’s scores after treatment with baseline values.Study OversightThe institutional review board at Massachusetts General Hospital approved the retrospective chart review and tumor-specimen collections. All pa-tients provided written informed consent for treatment. The authors vouch for the complete-ness and veracity of the data and data analyses. Bevacizumab was provided as part of clinical care; Genentech, the maker of bevacizumab, had no role in the study.Statistical AnalysisFor analyses of morphologic features, microvas-cular density, and measures of diameter and pe-rimeter, we used Bartlett’s test for the equality of multiple variances to analyze between-group dif-ferences in variance. Analysis-of-variance esti-mate models were then built and appropriate post hoc testing was performed on the basis of Bartlett’s test results. For measures with equal variances, Tukey’s test was used. For measures with unequal variances, the Games–Howell test was used. A P value of less than 0.05 was consid-ered to indicate statistical significance.ResultsImmunohistochemical AnalysesIn normal peripheral nerves, the ligands VEGF, semaphorin 3A, semaphorin 3F, and the recep-tors VEGFR-2 and neuropilin-1 were consistently expressed in both Schwann cells and vascular endothelial cells; neuropilin-2 was seen in all Schwann cells but in less than 5% of blood ves-sels (Fig. 1A, and Fig. 1 in the Supplementary Appendix). In the schwannomas, tumor cells had expression patterns of VEGF, neuropilin-1, and neuropilin-2 that were similar to those in normal nerve. In contrast, VEGFR-2 was expressed in about half of all schwannomas, and semaphorin 3A and semaphorin 3F were expressed in only 20% of schwannomas and at reduced intensity (Fig. 1A and 1B, and Fig. 2 in the Supplementary Appendix).Copyright © 2009 Massachusetts Medical Society. All rights reserved. Downloaded from www.nejm.org at EMORY UNIVERSITY on September 17, 2009 . Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis 2n engl j med 361;4 nejm.org july 23, 2009361VEGFR-2 was found in 32% of vessels in tu-mors associated with neurofibromatosis type 2 and in sporadic tumors. In contrast, all vessels expressed neuropilin-1 (similar to normal nerve), and about 10% of vessels expressed neuropilin-2 (Fig. 1C). Most tumor cells showed little or no expression of PDGFR-α or PDGFR-β. More than 50% of tumor specimens expressed both PDGFR-α and PDGFR-β on the vascular endothelium, con-sistent with an angiogenic phenotype (Fig. 3 in the Supplementary Appendix).Morphometric analysis revealed that schwan-nomas associated with neurofibromatosis type 2 showed a greater microvascular density (22 ves-sels per square millimeter) and a larger vessel diameter (mean, 14.2 μm), and perimeter (mean, 91 μm) than normal nerve (with 18 vessels per square millimeter and a mean vessel diameter of 7.9 μm and perimeter of 47 μm) (Fig. 1D).PatientsThe baseline characteristics of the 10 patients in the study are shown in Table 1. All patients were poor candidates for standard treatment, since eight were at high risk for complete hearing loss and one for bilateral lower cranial-nerve palsies, and one patient had declined surgery or radia-tion. Patients 1 through 5 had been treated previ-ously with erlotinib chemotherapy26 but stopped treatment because of either toxic effects (Patient 1) or tumor growth (Patients 2 through 5).TreatmentSix men and four women with a median age of 25 years (range, 16 to 53) received intravenous beva-cizumab at a dose of 5 mg per kilogram of body weight every 2 weeks. The median annual growth rate in tumor volume before treatment was 62% (range, 9 to 121). The median duration of treat-ment was 12 months (range, 3 to 19), and six patients were followed for at least 1 year. Six pa-tients continued to be treated with bevacizumab at the end of the study. Patient 1 stopped treat-ment after 19 months because of slow growth of a vestibular schwannoma, which caused brain-stem compression; the tumor was subsequently resected. Patient 5 discontinued bevacizumab temporarily as she awaited surgical removal of a nonvestibular schwannoma. Patient 7 stopped bevacizumab after 3 months because of progres-sive growth of a spinal meningioma; he died of complications after surgery to resect the tumor 5 months later. Patient 8 stopped treatment after 8 months because of progressive growth of a ves-tibular schwannoma and hearing loss.imaging ResponseOf the 10 tumors, 9 shrank after bevacizumab treatment, and 6 had an imaging response (Ta-ble 1, and Fig. 4 in the Supplementary Appendix). The median best response to treatment was 26% shrinkage (range, 44% shrinkage to 32% growth). Of six tumors that had an objective imaging re-sponse, the response was maintained in four tu-mors at the last imaging follow-up 11 to 16 months after the initiation of treatment. Three tumors remained stable (i.e., ranging from a 19% reduc-tion to a 19% increase in volumetric growth, as compared with baseline) during bevacizumab treatment, and one patient had an increase in tumor volume of 32%.A strong correlation was observed between the mean apparent diffusion coefficient at base-line within tumors and the percent decrease in volume at 3 months (Pearson’s r correlation, −0.87; r 2 = 0.75; P = 0.001) (Fig. 2A). In the single patient with complete DCE-MRI data (Patient 6), a measure of blood flow and vascular permeabil-ity decreased by 68%, tumor blood volume de-creased by 77%, tumor blood flow decreased by 51%, mean transit time decreased by 9%, and the average vessel size decreased by 70% at 3 months (Fig. 2B). Twelve months after the initiation of treatment, measures of blood flow and vascular permeability continued to fall. Although the amount of gadolinium enhancement decreased over time, the enhancement pattern within ves-tibular schwannomas did not change noticeably during treatment (Fig. 2C).Hearing ResponseSeven patients were considered eligible for a hear-ing response. Of the other three patients, two had normal hearing ipsilateral to index vestibular schwannomas at baseline (and thus could not improve), and one had undergone surgical resec-tion of both auditory nerves. A hearing response was observed in four of seven eligible patients (57%) (Fig. 5 in the Supplementary Appendix). The hearing benefit of bevacizumab was large for Patient 2, whose word-recognition score in-creased from 8% to 98%, and for Patient 3, whose Copyright © 2009 Massachusetts Medical Society. All rights reserved. Downloaded from www.nejm.org at EMORY UNIVERSITY on September 17, 2009 . The new england journal of medicinen engl j med 361;4 nejm.org july 23, 2009362word-recognition score increased from 34% to 76%. Both Patient 2 and Patient 3 regained useful hearing, and they were able to resume school and work, respectively. Patient 4, whose word-recog-nition score increased from 0% to 40%, reported better speech-reading (lip-reading), and Patient 5, whose word-recognition score increased from 76% to 94%, also reported improvement in face-to-face conversation. Patients with a hearing re-sponse showed progressive improvement in word recognition, which began about 8 weeks after the initiation of treatment and continued to improve for as long as 16 months (Fig. 5 in the Supple-mentary Appendix). Among the four patients who 36p6Normal Peripheral NerveSchwannomaCExpression of VEGFR-2 and NRP-2 in SchwannomasDDistribution and Differences in MorphometryAImmunohistochemical Analysis100No. of Vessels (per mm2)6040301050200CD31VEGFR-2NRP-2CD31VEGFR-2NRP-2NF2SporadicAUTHOR:FIGURE:JOB:4-CH/TRETAKESIZEICMCASEEMailLineH/TComboRevisedAUTHOR, PLEASE NOTE: Figure has been redrawn and type has been reset.Please check carefully.REG FEnon1st2nd3rdPlotkin1 of 207-23-09ARTIST:ts36104ISSUE:BExpression of VEGF Pathway Members100Positive Cases (%)8090706040301050200VEGFSEMA-3ASEMA-3FVEGFR-2NRP-2NRP-1Schwann cells in normalnerve rootsLigandsReceptors100Microvascular Density (per mm2)608040200NerveNF2SporadicP=0.006P=0.0330Diameter (µm)2025151050NerveNF2SporadicP<0.001P<0.001140Perimeter (µm)100120408060200NerveNF2SporadicP=0.008P=0.001P<0.001NF2-related schwannomasSporadic schwannomasVEGFVEGFR-2NRP-2SEMA-3FVEGFVEGFR-2NRP-2SEMA-3FMMAASCopyright © 2009 Massachusetts Medical Society. All rights reserved. Downloaded from www.nejm.org at EMORY UNIVERSITY on September 17, 2009 . Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis 2n engl j med 361;4 nejm.org july 23, 2009363had a hearing response, the result was durable for 11 to 16 months.Of the three patients who did not have a hear-ing response, Patient 1 had had no word recog-nition for at least 8 months before treatment, Patient 8 had a decline in word recognition (44% to 16%) after starting treatment despite initial tumor shrinkage, and Patient 10 had stable hear-ing despite a sustained reduction in tumor vol-ume. Although Patient 1 did not have a hearing or an imaging response, he had clinical improve-ment that may have been related to treatment. Before treatment, he was receiving hospice care because of intractable headache and vomiting associated with critical brain-stem compression. Within 4 weeks after starting therapy, his head-aches and vomiting resolved, and he returned to high school. He remained clinically improved for 19 months of treatment but then required resec-tion of his vestibular schwannoma for tumor growth. Four of five patients reported subjective improvement in baseline tinnitus, and one noted no change.Adverse EffectsA total of 21 grade 1 or 2 adverse events were reported, including increased levels of aspartate aminotransferase (4 events) and alanine amino-transferase (3 events), proteinuria (3 events), hyper-tension (2 events), delayed wound healing (2 events), hyperkalemia (2 events), hyperbilirubinemia (2 events), uterine bleeding (1 event), hypocalcemia (1 event), hypophosphatemia (1 event), and hypo-magnesemia (1 event). Two patients had infected vascular access ports requiring removal. In this small sample of patients, no patients had throm-boembolic events, hemorrhage, congestive heart failure, gastrointestinal perforation, or reversible posterior leukoencephalopathy. No patient dis-continued treatment because of adverse events, and no grade 3 or 4 adverse events were reported.DiscussionOur study showed that bevacizumab treatment was followed by clinically meaningful hearing improvement, tumor-volume reduction, or both in some, but not all, patients with neurofibromato-sis type 2 who were at risk for complete hearing loss or brain-stem compression from growing vestibular schwannomas. Our findings confirm that VEGF is produced by schwannoma tumor cells10-14 and suggests that this growth factor may participate in tumor growth and hearing loss associated with vestibular schwannomas. The imaging findings indicate that the mean apparent diffusion coefficient at baseline might be a po-tential marker for volumetric response to anti-VEGF therapy. The DCE-MRI data, though limit-ed, further suggest that bevacizumab normalizes the function of tumor vessels and potentially re-stores a more normal blood–nerve barrier.These findings have implications for patients Figure 1 (facing page). Angiogenic Profile of Vestibular Schwannomas.Panel A shows immunohistochemical analysis of mem-bers of the vascular endothelial growth factor (VEGF) pathway in normal peripheral nerve and schwannoma. In normal nerve, staining for VEGF highlights Schwann cells (arrows), and staining for VEGF receptor 2 (VEGFR-2) highlights vessels (arrowheads). Staining for neuropilin-2 (NRP-2) and semaphorin 3F (SEMA-3F) highlights Schwann cells in normal nerve. In schwannomas, VEGF staining highlights tumor cells (arrowhead) and blood vessels (arrow); VEGFR-2 staining highlights some ves-sels (arrowheads), whereas others remain unstained (ar-rows). Tumor cells stain diffusely for NRP-2 but not for SEMA-3F. In all panels, brown staining shows positivity for the given antigen, and blue labels the nuclei, with the letter A denoting axon, the letter M myelin, and the letter S Schwann cell. Panel B shows the percentage  of samples with expression of more than 1 on a scale of 0 (no staining) to 3 (strong staining) for the known members of the VEGF pathway (ligands and receptors). SEMA-3F and SEMA-3A are expressed in all nerve roots (3 intensity). In samples from patients with neurofibro-matosis type 2 (NF2), 58% of the tumors have completely negative staining for SEMA-3F, and 22% are negative for SEMA-3A. In samples from patients with sporadic tumors, 44% of tumors are negative for SEMA-3F, and 33% are negative for SEMA-3A. Since none of the samples were scored as 2 or 3, no bar is shown for SEMA-3A. Panel C shows the quantification of the number of vessels per square millimeter expressing VEGFR-2 and NRP-2 in vestibular schwannomas associated with neurofibroma-tosis type 2 and sporadic vestibular schwannomas. CD31 was used to count the total number of vessels per square millimeter. There were no significant differences between tumors associated with neurofibromatosis type 2 and sporadic tumors. Panel D shows statistical analysis of the morphometric measures. Diameter, perimeter, and microvascular density were all significantly smaller for the 470 vessels analyzed in normal peripheral nerve roots than in either schwannomas associated with neu-rofibromatosis type 2 (1215 vessels from 20 patients) or sporadic schwannomas (2104 vessels from 17 patients). The perimeters (or surface area, data not shown) were significantly larger in tumors associated with neurofi-bromatosis type 2 than in sporadic tumors.Copyright © 2009 Massachusetts Medical Society. All rights reserved. Downloaded from www.nejm.org at EMORY UNIVERSITY on September 17, 2009 . The new england journal of medicinen engl j med 361;4 nejm.org july 23, 2009364Table 1. Baseline Characteristics of the Patients and Outcomes after Treatment with Bevacizumab.Patient No.AgeSexInheritancePrevious ChemotherapyIndication  for TreatmentBaseline Tumor SizeBaseline Annual Growth Rate Treatment DurationMaximum Change  in Tumor VolumeImaging Response*Hearing Response†yrcm3%mo%116MFamilialErlotinibBrain-stem com-pression24.911819−5Stable diseaseStable hearing222FFounderErlotinibHearing loss10.47517‡−30Imaging responseHearing response323MFounderErlotinibHearing loss19.512115‡−28Imaging responseHearing response426FFounderErlotinibHearing loss2.22615‡−14Progressive diseaseHearing response518FFounderErlotinibHearing loss28.96512−44Imaging responseHearing response653MFounderNoneHearing loss2.55812‡−32Imaging responseNot eligible732MFamilialNoneBrain-stem com-pression38.7533−24Imaging responseNot eligible844FFounderNoneHearing loss2.298−27Progressive diseaseProgressive hearing loss932MFounderNoneHearing loss2.51410‡+32Progressive diseaseNot eligible1018MFounderNoneHearing loss22.6788‡−17Stable diseaseStable hearing* An imaging response was defined as a decrease in tumor volume of at least 20% on MRI, as compared with baseline. Progressive disease was defined as an increase in tumor volume of at least 20%, as compared with baseline. Stable disease was defined as a change in tumor volume ranging from a reduction of 19% to an increase of 19%, as compared with baseline.† A hearing response was defined as an increase in the word-recognition score above the critical-difference threshold, as compared with baseline. Progressive hearing loss was defined as a decrease in the word-recognition score below the critical-difference threshold, as compared with baseline. Stable hearing was defined as a change in the word-recognition score within the critical-difference threshold.‡ This patient was still receiving bevacizumab at the end of the study period.Copyright © 2009 Massachusetts Medical Society. All rights reserved. Downloaded from www.nejm.org at EMORY UNIVERSITY on September 17, 2009 . Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis 2n engl j med 361;4 nejm.org july 23, 2009365with neurofibromatosis type 2 and for the study of vestibular schwannoma biology. First, the re-duced expression of VEGFR-2 on tumor vessels suggested that interfering with the function of VEGF receptors might be less effective than tar-geting VEGF directly, which prompted our choice of bevacizumab for treatment. Our data suggest that the current understanding of VEGF-mediat-ed angiogenesis — that VEGF is secreted by tumor cells and then binds to and activates VEGFR-2 on endothelial cells — may be more complex in schwannomas, in which vessels ex-press different VEGF receptors. Further work is needed to understand the role of the sema-phorin–neuropilin axis in these tumors.Second, VEGF inhibition can lead to modest but relevant decreases in the volume of vestibu-lar schwannomas. This effect is notable, given the lack of sensitivity of benign nervous-system tumors to standard cytotoxic chemotherapy. Third, in some patients, VEGF inhibition can lead to a relatively rapid (<12 weeks) improvement in hear-ing, as reflected by word-recognition scores, with sustained improvement for up to 16 months. Ob-servational studies have shown that word-recog-nition scores deteriorate over time in patients with vestibular schwannomas and that signifi-cant improvement is not expected.27 We posit 22p3CImaging Response in Patient 2BPermeability Changes in Patient 6ACorrelation between Mean ADC at Baseline and Change in Tumor VolumeAUTHOR:FIGURE:JOB:4-CH/TRETAKESIZEICMCASEEMailLineH/TComboRevisedAUTHOR, PLEASE NOTE: Figure has been redrawn and type has been reset.Please check carefully.REG FEnon1st2nd3rdPlotkin2 of 207-23-09ARTIST:ts36104ISSUE:T1-WeightedImagesT2-WeightedImages30Change in Volume from Baseline (%)−30−20−10−40102008001000120014001600r2=0.75ADC ValueBaselinePermeability1 Mo3 Mo9 Mo12 Mo0.1650.2900.1310.2050.1070.2250.1080.1480.0090.004Figure 2. Changes in Magnetic Resonance Imaging (MRI) Measures during Treatment with Bevacizumab.Panel A shows the correlation between mean apparent diffusion coefficients (ADCs) at baseline and subse-quent changes in tumor volume for the 10 patients after 3 months of treatment with bevacizumab. Panel B shows dynamic contrast-enhanced MRIs of Patient 6, with mea-sures of blood flow and vascular permeability indicat-ing the permeability of vestibular schwannomas (with the most permeable areas shown in white and the least permeable areas in dark red). At baseline, permeability is high for both tumors but decreases progressively during 12 months of treatment, as shown by the values beneath the images. Panel C shows representative cra-nial T1-weighted MRI scans of Patient 2 after the admin-istration of contrast material at baseline (left) and after 9 months of treatment (right). T2-weighted scans are also shown at the same time points. The overall decrease in tumor volume (30%) can be seen by comparing the tumor outline at baseline (yellow line) with the outline after 3 months of treatment with bevacizumab (red line). The enhancement pattern in vestibular schwan-nomas did not change noticeably during treatment with bevacizumab.Copyright © 2009 Massachusetts Medical Society. All rights reserved. Downloaded from www.nejm.org at EMORY UNIVERSITY on September 17, 2009 . The new england journal of medicinen engl j med 361;4 nejm.org july 23, 2009366that improvement is due to a reduction in intra-neural edema, as well as tumor shrinkage. This assertion is supported by the time course of hearing improvement, the correlation between the mean apparent diffusion coefficient and tu-mor shrinkage, and the changes in intratumoral vascular permeability, as seen on DCE-MRI. This mechanism is consistent with the vascular-normalization hypothesis28 and previous studies of anti-VEGF therapy in malignant brain tu-mors.18,29To date, four of our six patients with an imag-ing response and all four patients with a hearing response have continued to respond to therapy for 11 to 16 months. This suggests that response to anti-VEGF therapy can be durable for progres-sive vestibular schwannomas associated with neurofibromatosis type 2. In contrast, the median time to progression for recurrent glioblastoma treated with antiangiogenic therapy is about 16 weeks.18,30 Patients with benign tumors who benefit from anti-VEGF therapy present unique clinical challenges: they may have prolonged sur-vival during which unanticipated delayed toxic effects could become manifest, and the implica-tions of stopping therapy are unknown, with the potential for rebound tumor growth when mono-clonal treatment is stopped.18Although the need for an effective medical therapy for patients with neurofibromatosis type 2 is clear, the risk of toxic effects deserves care-ful consideration. In our preliminary experience, toxic effects were limited to grade 1 or 2 adverse events during follow-up of up to 16 months, which is not long in comparison with the ex-pected survival of these young patients. The ab-sence of many common toxic effects of bevaci-zumab in our patients may have reflected their relative youth, the lack of other medical condi-tions, and the small number of patients who were treated.Our results show an interesting biologic effect of bevacizumab treatment on vestibular schwan-nomas associated with neurofibromatosis type 2. However, we treated only patients with neurofi-bromatosis type 2 who were at imminent risk for severe neurologic consequences and not those with less advanced symptoms or patients with sporadic vestibular schwannomas. Additional re-search will be necessary to determine the opti-mal drug regimen, duration, and adverse-effect profile for long-term anti-VEGF therapy for ves-tibular schwannomas associated with neurofibro-matosis type 2.Supported by the Harvard Medical School Center for Neurofi-bromatosis and Allied Disorders; Neurofibromatosis, Inc., New England; the Children’s Tumor Foundation; a grant (NF050202, to Dr. Plotkin) from the Neurofibromatosis Research Program of the Department of Defense; a Claflin Award (to Dr. di Tomaso); grants (P01NS024279, to Dr. Stemmer-Rachamimov; and P01CA80124, to Dr. Jain) from the National Institutes of Health; and grants from the Federal Share/National Cancer Institute Pro-ton Beam Program (to Drs. di Tomaso and Jain).Dr. Plotkin reports receiving consulting fees from Novartis and grant support from Pfizer; Dr. Sorensen, receiving grant support from AstraZeneca, Exelixis, Schering-Plough, Genentech, Novartis, Takeda/Millennium, and Siemens Medical Solutions and consulting fees from AstraZeneca, Bayer Healthcare, Genen-tech, Mitsubishi Pharma, Novartis, and Takeda/Millennium; and Dr. Jain, receiving consulting fees from AstraZeneca, Dyax, Enlight, and Millennium and lecture fees from Roche Pharma-ceuticals and Pfizer, having an equity interest in Enlight and SynDevRx, and receiving grant support from AstraZeneca and Dyax. No other potential conflict of interest relevant to this article was reported.We thank Marybeth Singh for her clinical care and Drs. Mei-yun Wang, Poe-jou Chen, and Dominique Jennings for their work in analyzing the imaging data.ReferencesEvans DG, Moran A, King A, Saeed S, 1. Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibro-matosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 2005;26:93-7.Samii M, Gerganov V, Samii A. Im-2. proved preservation of hearing and facial nerve function in vestibular schwannoma surgery via the retrosigmoid approach in a series of 200 patients. J Neurosurg 2006; 105:527-35.Flickinger JC, Kondziolka D, Niranjan 3. A, Lunsford LD. Results of acoustic neu-roma radiosurgery: an analysis of 5 years’ experience using current methods. J Neu-rosurg 2001;94:1-6.Brackmann DE, Fayad JN, Slattery WH 4. III, et al. Early proactive management of vestibular schwannomas in neurofibroma-tosis type 2. Neurosurgery 2001;49:274-80.Combs SE, Volk S, Schulz-Ertner D, 5. Huber PE, Thilmann C, Debus J. Manage-ment of acoustic neuromas with fraction-ated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys 2005;63:75-81.Samii M, Matthies C, Tatagiba M. 6. Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 ves-tibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 1997; 40:696-705.Folkman J. Tumor angiogenesis: ther-7. apeutic implications. N Engl J Med 1971; 285:1182-6.Carmeliet P, Jain RK. Angiogenesis in 8. cancer and other diseases. Nature 2000; 407:249-57.Nagy JA, Benjamin L, Zeng H, Dvorak 9. AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogen-esis. Angiogenesis 2008;11:109-19.Brieger J, Bedavanija A, Lehr HA, 10. Maurer J, Mann WJ. Expression of angio-Copyright © 2009 Massachusetts Medical Society. All rights reserved. Downloaded from www.nejm.org at EMORY UNIVERSITY on September 17, 2009 . Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis 2n engl j med 361;4 nejm.org july 23, 2009367genic growth factors in acoustic neurino-ma. Acta Otolaryngol 2003;123:1040-5.Cayé-Thomasen P, Baandrup L, Jacob-11. sen GK, Thomsen J, Stangerup SE. Immu-nohistochemical demonstration of vascu-lar endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 2003;113:2129-34.Cayé-Thomasen P, Werther K, Nalla A, 12. et al. VEGF and VEGF receptor-1 concen-tration in vestibular schwannoma homo-genates correlates to tumor growth rate. Otol Neurotol 2005;26:98-101.Saito K, Kato M, Susaki N, Nagatani 13. T, Nagasaka T, Yoshida J. Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibro-matosis type 2-associated schwannomas. Clin Neuropathol 2003;22:30-4.Uesaka T, Shono T, Suzuki SO, et al. 14. Expression of VEGF and its receptor genes in intracranial schwannomas. J Neuro-oncol 2007;83:259-66.Takamiya Y, Brem H, Ojeifo J, Mineta 15. T, Martuza RL. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 1994;34: 869-75.Mulvihill JJ, Parry DM, Sherman JL, 16. Pikus A, Kaiser-Kupfer MI, Eldridge R. NIH conference: neurofibromatosis 1 (Recklinghausen disease) and neurofibro-matosis 2 (bilateral acoustic neurofibro-matosis): an update. Ann Intern Med 1990;113:39-52.Harris GJ, Plotkin SR, MacCollin M, 17. et al. Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosur-gery 2008;62:1314-9.Batchelor TT, Sorensen AG, di Tomaso 18. E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tu-mor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95.Monsell EM. New and revised report-19. ing guidelines from the Committee on Hearing and Equilibrium, American Acad-emy of Otolaryngology-Head and Neck Surgery Foundation, Inc. Otolaryngol Head Neck Surg 1995;113:176-8.Hirsh IJ, Davis H, Silverman SR, 20. Reynolds EG, Eldert E, Benson RW. Devel-opment of materials for speech audiome-try. J Speech Hear Disord 1952;17:321-37.Plotkin SR, Halpin C, Blakely JO, et al. 21. Suggested response criteria for phase II antitumor drug studies for neurofibroma-tosis type 2 related vestibular schwanno-ma. J Neurooncol 2009;93:61-77.Babovic-Vuksanovic D, Ballman K, 22. Michels V, et al. Phase II trial of pirfeni-done in adults with neurofibromatosis type 1. Neurology 2006;67:1860-2.Babovic-Vuksanovic D, Widemann BC, 23. Dombi E, et al. Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr Neurol 2007;36:293-300.Thornton AR, Raffin MJ. Speech-dis-24. crimination scores modeled as a binomial variable. J Speech Hear Res 1978;21:507-18.Halpin C, Rauch SD. Using audiomet-25. ric thresholds and word recognition in a treatment study. Otol Neurotol 2006;27: 110-6.Plotkin SR, Singh MA, O’Donnell CC, 26. Harris GJ, McClatchey AI, Halpin C. Audi-ologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol 2008;5:487-91.Caye-Thomasen P, Dethloff T, Hansen 27. S, Stangerup SE, Thomsen J. Hearing in patients with intracanalicular vestibular schwannomas. Audiol Neurootol 2007;12: 1-12.Jain RK. Normalization of tumor vas-28. culature: an emerging concept in anti-angiogenic therapy. Science 2005;307:58-62.Kamoun WS, Ley CD, Farrar CT, et al. 29. Edema control by cediranib, a vascular endothelial growth factor receptor-target-ed kinase inhibitor, prolongs survival de-spite persistent brain tumor growth in mice. J Clin Oncol 2009;27:2542-52.Fine HA, Figg WD, Jaeckle K, et al. 30. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18: 708-15.Copyright © 2009 Massachusetts Medical Society.receive immediate notification when  a journal article is released earlyTo be notified when an article is released early  on the Web and to receive the table of contents  of the Journal by e-mail every Wednesday evening,  sign up through our Web site at  NEJM.org.Copyright © 2009 Massachusetts Medical Society. All rights reserved. Downloaded from www.nejm.org at EMORY UNIVERSITY on September 17, 2009 . Aspirin intake may stop growth of tumors that cause hearing loss
Date:
January 24, 2014
Source:
Massachusetts Eye and Ear Infirmary
Summary:
Researchers have demonstrated, for the first time, that Aspirin intake correlates with halted growth of vestibular schwannomas (also known as acoustic neuromas), a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.
Share:

FULL STORY
Researchers from Massachusetts Eye and Ear, Harvard Medical School, Massachusetts Institute of Technology and Massachusetts General Hospital have demonstrated, for the first time, that aspirin intake correlates with halted growth of vestibular schwannomas (also known as acoustic neuromas), a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.

Motivated by experiments in the Molecular Neurotology Laboratory at Mass. Eye and Ear involving human tumor specimens, the researchers performed a retrospective analysis of over 600 people diagnosed with vestibular schwannoma at Mass. Eye and Ear. Their research suggests the potential therapeutic role of aspirin in inhibiting tumor growth and motivates a clinical prospective study to assess efficacy of this well-tolerated anti-inflammatory medication in preventing growth of these intracranial tumors.

“Currently, there are no FDA-approved drug therapies to treat these tumors, which are the most common tumors of the cerebellopontine angle and the fourth most common intracranial tumors,” explains Konstantina Stankovic, M.D., Ph.D., who led the study. “Current options for management of growing vestibular schwannomas include surgery (via craniotomy) or radiation therapy, both of which are associated with potentially serious complications.”

The findings, which are described in the February issue of the journal Otology and Neurotology, were based on a retrospective series of 689 people, 347 of whom were followed with multiple magnetic resonance imaging MRI scans (50.3%). The main outcome measures were patient use of aspirin and rate of vestibular schwannoma growth measured by changes in the largest tumor dimension as noted on serial MRIs. A significant inverse association was found among aspirin users and vestibular schwannoma growth (odds ratio: 0.50, 95 percent confidence interval: 0.29-0.85), which was not confounded by age or gender.

“Our results suggest a potential therapeutic role of aspirin in inhibiting vestibular schwannoma growth,” said Dr. Stankovic, who is an otologic surgeon and researcher at Mass. Eye and Ear, Assistant Professor of Otology and Laryngology, Harvard Medical School (HMS), and member of the faculty of Harvard’s program in Speech and Hearing Bioscience and Technology.
Ayurvedic Treatment for Brain Tumor and Alternative Treatment for Tumors
Brain tumors - Ayurvedic Treatment of Brain Tumor
Types of brain tumors: -

There are many types of brain tumors and so are many ways to treat them. Convention medical advices should not be ignored. The listed ayurvedic medicines are traditional bhasma medicines described in ancient ayurvedic texts as treatment of cancers and various tumours. These can be considered as alternative treatment of tumours. All these should be taken under the supervision or guidance of an Ayurvedic expert and as an alternative treatment for Brain tumors.

In my practice, I have seen wonderful results, with these bhasma medicines recommended in ayurvedic texts as tumor healing traditional medicines. It is better to contact us personally by meeting ( especially if one affords to meet). If the patients are located far off, then atleast talk to Dr. Vikram Chauhan and discuss the case before starting anything.You can call at +91-172-521-4030 and fix the appointment for tele-talk. You can send scanned reports and other documents via e mail.

Gliomas: - Gliomas as a group are considered the most common type of brain tumor. A glioma is a tumor that grows from a glial cell, which is a supportive cell in the brain. There are two types of supportive cells: astrocytes and oligodendrocytes. Therefore, most gliomas are called either astrocytoma or oligodendroglioma, or a mixture of both. Gliomas are graded (how much the tumor appears like normal brain tissue) from I to IV based on their degree of aggressiveness. A grade I glioma is a benign tumor, while grades II through IV are tumors with an increasing degree of aggressiveness and are therefore considered increasingly malignant in potential.

Types of gliomas:
v      Astrocytoma is the most common type of glioma. Astrocytomas begin in cells called astrocytes in the cerebrum or cerebellum. Glioblastoma multiforme (also called grade IV astrocytoma) is a very aggressive form of astrocytoma.
v      Oligodendroglioma is a tumor that develops from cells called oligodendrocytes. These cells are responsible for producing the myelin that surrounds nerves.
v      Brain stem gliomas begin in the glial cells in the brain stem.
v      Ependymomas, which begin in the ependyma (the cells that line the passageways in the brain where cerebrospinal fluid is made and stored.
v      Mixed tumors, which are composed of more than one of the glial cell types.

Non-glioma tumors:-

Non-glioma tumors begin in other types of cells in the CNS, and are described as either benign (noncancerous) or malignant (cancerous).
v     Meningioma is the most common primary non-glioma brain tumor. It begins in the meninges surrounding the brain and spinal column and is most often benign. Meningioma can cause significant symptoms if it grows and presses on the brain or spinal cord.
v     Acoustic schwannoma (also called acoustic neuroma) is a rare tumor that begins in the vestibular nerve and is normally benign.
v     Craniopharyngioma is a benign tumor that begins near the pituitary gland. These tumors are rare.
v     Medulloblastoma, which begins in granular cells in the cerebellum, is most common in children and is most often malignant.
v     Primary CNS lymphoma is a form of lymphoma (cancer that begins in the lymphatic system) that starts in the brain.
v     The pineal and pituitary glands, located near the base of the brain, are the location of about a small no. of all brain tumors.

(2) Risk Factors: -

Age: - Children and older adults are two groups most likely to be diagnosed with brain tumors.

Gender: - Men are generally more likely than women to develop gliomas, while women are more likely to be affected by meningiomas.

Home/occupational exposures: - Occupational exposures to solvents, pesticides, oil products, rubber, or vinyl chloride may increase the risk of developing a brain tumor, although there is no scientific evidence to date. Black hair dye has also been researched as a potential cause of brain tumors, although the data remains inconclusive at this time.

Some genetic conditions: - Some genetic conditions, such as von Hippel-Lindau disease, Turcot syndrome, or neurofibromatosis, increase the risk of developing a brain tumor.

Exposure to infections, viruses, and allergens: - Infection with the Epstein-Barr virus increases the risk of CNS lymphoma. Several types of other viruses have been shown to cause brain tumors in experimental animal studies; however, more data is needed in order to determine if exposure to infections, other viruses, or allergens affect brain tumor risk.

Electromagnetic fields: - Electromagnetic fields, such as energy from power lines or from cell phone use, may or may not increase the risk of developing a brain tumor.

Ethnicity: - In the United States, whites have higher rates of gliomas but lower rates of meningioma than blacks. The rate of malignant brain tumors in Japan is less than half the rate of Northern Europe.

Ionizing radiation: - Treatment with ionizing radiation (including x-rays) has shown, in some cases, to be a risk factor for brain tumors.

(3) Signs and Symptoms: -

    *   Headaches, which may be severe and may worsen with activity or in the early morning.
    *  Seizures
    *  Personality or memory changes
    *  Nausea or vomiting
    *  Vision changes such as blurred
Specific Symptoms related to Vision
Symptoms specific to the location of the tumor includes
    *     Pressure or headache near the tumor
    *     Loss of balance and difficulty with fine motor skills
    *    Changes in judgment, including loss of initiative, sluggishness, and muscle weakness or paralysis (Frontal lobe of the cerebellum)
    *     Partial or complete loss of vision (occipital lobe of the cerebellum)
    *    Changes in speech, hearing, memory, or emotional state including aggressiveness and problems understanding or retrieving words (temporal lobe of the cerebellum)
    *   Altered perception of touch or pressure, arm or leg weakness on one side of the body, confusion with left and right sides of the body (parietal lobe of the cerebellum)
    *   Inability to look upward (pineal tumor)
    *   Lactation, altered menstrual periods, and growth in hands and feet in adults (pituitary tumor)

 (4) Diagnosis as per modern science: -

(a) Imaging tests
     Magnetic resonance Imaging
     Magnetic Resonance Spectroscopy
     Computerized Tomography
     Positron emission tomography
     Myelogram
(b) Neurological hearing and vision tests.

(c) Blood tests
(d) Lumbar puncture
(e) Electroencelography
(f) Cerebral arteriogram
(g) Stereotactic biopsy
(h) Evoked potentials

(5) Staging: -

Malignant (cancerous) tumours of the brain and spinal cord (the central nervous system [CNS]) differ in several important ways from tumors in other parts of the body. In the rest of the body, the most deadly aspect of a malignant tumor is its ability to spread throughout the body. In contrast, tumors starting in the brain or spinal cord can spread to other parts of the CNS, but they almost never spread to other organs. The dangerous aspect of these tumors is that they can interfere with essential, normal functions of the brain.

 (1) Ayurvedic Treatment for Brain Tumors and other cancers   - The below mentioned combination of classical ayurvedic medicines is given. These can be used along with ongoing conventional treatment like radiotherapy, surgery or chemotherapy. These are Ayurvedic medicines in proper dosage for adult patient. For Children, the dosage will be 1/4th of this.


Hirak Bhasm 300 mg
Swarn Bhasm 500 mg
Rajat Bhasm 2.5 gm
Swarn basant malti Ras 1 gm
Abharak Bhasm (Sahasar Putti ) 2 gm
Swarn makshik Bhsam 5 gm
Rasraj Ras 1 gm
Bhrami Vati with gold 2 gm
Yogender Ras 1 gm
Shila sandoor 1 gm
Navratan kalp amrit Ras 2 gm
Raj Mrigank  Ras 1 gm
Hemgarbh potli Ras 1 gm
Vaikrant Bhasm 2.5 gm
Vrhit vangeshvar Ras 1 gm
Basant kusmakar Ras 1 gm
Vrhit sutshekhar Ras 1 gm
Dhatri Loh 5 gm
 Kalmegh Navayas Loh 5 gm
Punarva Mandoor 5 gm
Tamar Bhasm 1 gm
Giloy Satv 10 gm
Mukta Pishti 2 gm
Parval Panchmamrit Ras 5 gm
Vriht Vaat Chintamani Ras 1 gm

Mix all the above medicines and make Sixty ( 60 )  equal dose sachets.Take one sachet twice a day with one to two teaspoonful of honey and half teaspoonful of almond oil or with milk.

These should be taken for at least 6 months. The results are evident within first few days of treatment. Along with these Sachets, The following are also recommended -

(2) Capsules Cruel 30- Take one cap once a day with water.
(3) Capsules Cancer Gaj Kesari 30 -  Take one caps once a day.
(4)  Cap. Ashwagandha - 2 twice daily
(5) Cap. Curcumin - 2 twice daily
(6) Cap. Bramhi - 2 twice daily
(7) Tab. Kachnaar Guggul -2 twice daily


Check this video on CURCUMIN Capsules - one of the medicine given for tumour treatment in Ayurveda
BevacizumabTreatmentforMeningiomasinNF2:ARetrospectiveAnalysisof15PatientsFabioP.Nunes1,2,VanessaL.Merker1,3,DominiqueJennings4,PaulA.Caruso5,EmmanuellediTomaso6,AlonaMuzikansky7,FredG.BarkerII8,AnatStemmer-Rachamimov6,ScottR.Plotkin1,3*1NeurologyDepartment,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmerica,2GeneticsDepartment,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmerica,3StephenE.andCatherinePappasCenterforNeurooncology,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmerica,4A.A.MartinosCenterforBiomedicalImaging,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmerica,5DepartmentofRadiology,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmerica,6PathologyDepartment,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmerica,7BiostatisticsCenter,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmerica,8NeurosurgicalService,MassachusettsGeneralHospital,Boston,Massachusetts,UnitedStatesofAmericaAbstractBevacizumabtreatmentcanresultintumorshrinkageofprogressivevestibularschwannomasinsomeneurofibromatosis2(NF2)patientsbutitseffectonmeningiomashasnotbeendefined.TodeterminetheclinicalactivityofbevacizumabagainstNF2-relatedmeningiomas,wemeasuredchangesinvolumeofmeningiomasinNF2patientswhoreceivedbevacizumabfortreatmentofprogressivevestibularschwannomas.Aradiographicresponsewasdefinedasa20%decreaseintumorsizebyvolumetricMRIanalysis.Inaddition,wedeterminedtheexpressionpatternofgrowthfactorsassociatedwithtumorangiogenesisinparaffin-embeddedtissuesfrom26unrelatedmeningiomas.Atotalof48meningiomasin15NF2patientswereincludedinthisstudywithamedianfollowuptimeof18months.Avolumetricradiographicresponsewasseenin29%ofthemeningiomas(14/48).Tumorshrinkagewasnotdurable:themediandurationofresponsewas3.7monthsandthemediantimetoprogressionwas15months.Therewasnosignificantcorrelationbetweenpre-treatmentgrowthrateandmeningiomaresponseinregressionmodels.TissueanalysisshowednocorrelationbetweentumormicrovasculardensityandexpressionofVEGFpathwaycomponents.Thisdatasuggeststhat,incontrasttoschwannomas,activationofVEGFpathwayisnottheprimarydriverofangiogenesisinmeningiomas.OurresultssuggestthataminorityofNF2-associatedmeningiomasshrinkduringbevacizumabtherapyandthattheseresponseswereofshortduration.Theseresultsarecomparabletopreviousstudiesofbevacizumabinsporadicmeningiomas.Citation:NunesFP,MerkerVL,JenningsD,CarusoPA,diTomasoE,etal.(2013)BevacizumabTreatmentforMeningiomasinNF2:ARetrospectiveAnalysisof15Patients.PLoSONE8(3):e59941.doi:10.1371/journal.pone.0059941Editor:RussellO.Pieper,UniversityofCalifornia-SanFrancisco,UnitedStatesofAmericaReceivedDecember3,2012;AcceptedFebruary19,2013;PublishedMarch21,2013Copyright:ß2013Nunesetal.Thisisanopen-accessarticledistributedunderthetermsoftheCreativeCommonsAttributionLicense,whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalauthorandsourcearecredited.Funding:ThisworkwassupportedbyaUnitedStatesNationalInstitutesofHeathgrant(5-T32-GM007748-32)toFPN.Thefundershadnoroleinstudydesign,datacollectionandanalysis,decisiontopublish,orpreparationofthemanuscript.CompetingInterests:Theauthorshavedeclaredthatnocompetinginterestsexist.*E-mail:splotkin@partners.orgIntroductionMeningiomasarethemostcommontypeofbraintumor,accountingfor34%ofallcentralnervoussystemtumors.[1]Despitethehighprevalenceofmeningiomasinthegeneralpopulation,therearecurrentlynomedicaltreatmentsavail-able.[2,3]Forsporadicmeningiomasthatrequireactivetreatment,surgeryandradiationtherapyareusuallyeffective.Meningiomasareevenmorecommoninneurofibromatosis2(NF2)patients,withacumulativeincidenceof80%byage70,[4]andareamajorcauseofmorbidityandmortalityinthesepatients.[5,6]ThelackofeffectivemedicaltherapyformeningiomasrepresentsasignificantchallengeintheclinicalmanagementofNF2patients.Unlikepatientswithsporadictumors,NF2patientsoftenhavemultiplemeningiomas,vestibularschwannomas,andependymomas.Themultiplicityoftumorsmakesurgeryandradiationtherapyforalltumorsimpracticable.Neovascularizationisnecessaryfortumorgrowthbeyond2–3mm,[3]thepointatwhichdiffusionalonebecomesinsufficienttomeetbasictumormetabolicrequirements,[7]andisdrivenbytumorproducedangiogenicfactorssuchasvascularendothelialgrowthfactor(VEGF)thatstimulatethegrowthoftumorcapillaries.BevacizumabisahumanizedmonoclonalantibodythatneutralizestheactivityofVEGF.[8]BevacizumabpreventsthebindingofallVEGFisoformstoVEGFreceptors,andiscurrentlyapprovedbytheFoodandDrugAdministration(FDA)forclinicaluseinrecurrentglioblastoma,metastaticcolorectalcancer,advancednonsquamousnon-smallcelllungcancer,andmetastatickidneycancer(www.fda.govon02/05/2012).WehaverecentlyshownthattreatmentwithbevacizumabcanleadtohearingimprovementandtumorshrinkageinsomeNF2patientswithprogressivevestibularschwannomas.[9]TissueanalysisofschwannomassuggestedactivationoftheVEGFpathwayduetodecreasedexpressionofSEMA3,anangiogenesisinhibitor.Theeffectsofbevacizumabonmeningiomasarenotclear.Todate,twocasereportsandtwocaseserieshavebeenpublishedonbevacizumabuseinintracranialmeningiomas,withanecdotalreportsofmeningiomaresponsetobevacizumab.[10–13]Wepresentherearetrospectiveanalysisoftumorresponsein48intracranialmeningiomasfrom15NF2patientstreatedwithbevacizumabforprogressivevestibularschwannoma.PLOSONE|www.plosone.org1March2013|Volume8|Issue3|e59941MethodsEthicsStatementThisresearchstudywasapprovedbythePartnersHumanResearchCommitteeInstitutionalReviewBoard.Requirementforinformedconsentwaswaivedforthisretrospectiveanalysisofclinicaldata.PatientsBetween2007and2011,atotalof31NF2patientsweretreatedatourcenterusingbevacizumabforprogressivevestibularschwannomas.Ofthese31patients,16alsohadintracranialmeningiomas(55%).TwopatientswereexcludedfromthestudybecauseofincompatibilitybetweentheMRIscanformatperformedatanoutsidefacilityandourvolumetricanalysissoftware.WeincludedoneadditionalNF2patientwhounderwentsurgicalresectionofbilateralvestibularschwannomasandwastreatedusingbevacizumabforasingleprogressivemeningioma.Atotalof48meningiomasand18vestibularschwannomasin15NF2patientswereincludedintheanalysis.Patientsreceivedbevacizumab5mg/kgI.V.every2weeksaspartofclinicalcarefortheirvestibularschwannoma.Higherdosesusedformalignantbraintumors(e.g.,10mg/kg)werenotusedinordertominimizeriskoftoxicity.BrainMRIscanswereperformedwithinabout1monthpriortostartoftreatment,andapproximatelyevery3monthsafterthestartoftreatmenttomonitortumorresponse.AdverseeventswereclassifiedaccordingtotheCommonTerminologyCriteriaforAdverseEvents,version4.VolumetricanalysisCommercialsoftware(Alice;HaydenImageProcessingGroup/ParexelInternationalCorp,Waltham,MA)wasusedtocreatethevolumetricmeasurementsoncontrastenhancedT1-weightedaxialimages.Onceoutliningwascomplete,actualvolumemeasure-mentswerecalculatedinMatlab(TheMathWorks,Natick,MA)bycountingthenumberofvoxelsinagivenimageandmultiplyingthecountbythevolumeofasinglevoxel(ascalculatedusingthein-planeandthrough-planeimageresolution).AmaximumnumberofeighttumorsperpatientcanbemeasuredusingtheAlicesoftware.Inpatientswithmorethan8tumors,volumetricanalysiswasfirstperformedonvestibularschwannomasandthenonmeningiomas(fromlargesttosmallest).Totalintracranialtumorvolumewasdefinedasthesumofthevolumeofallintracranialmeningiomasmeasuredinapatient.WeusedclinicallyindicatedMRIsperformedpriortostartofbevacizumabtherapytodeterminepre-treatmentmeningiomaannualgrowthrate(AGR).Tumorgrowthratewasdefinedas(tumorvolume–baselinetumorvolume)/baselinetumorvolume.Tumorcontoursforvolumetricanalysisweredelineatedbyasingleresearcher(FN)whowasblindedforpatientidentity,timeofscan,andtreatmentstatus(pre-orpost-bevacizumab).AlltumorcontourswereperformedusingT1post-contrastaxialMRIscans.Aftercontourswerecompleted,aneuroradiologist(PC)with10yearsofpost-fellowshipacademicexperiencereviewedthecontours.Fortumorswithindistinctboundaries,theneuroradiol-ogistreviewedaxial,sagittal,andcoronalslicesofpre-andpost-contrastT1-weighted,T2-weighted,diffusion-weightedimages,FLAIR,susceptibility,FIESTAimages,andCTscanswhenavailable.Detailsofthemethodologyusedfordeterminingtumorcontoursareavailableinthesupplementalmaterial(TextS1).DefinitionofimagingresponseAradiographicresponsewasdefinedasadecreaseintumorvolumeof$20%atanytimecomparedwithbaselinevolume.Tumorprogressionwasdefinedasanincreaseinvolumeof$20%whencomparedtobaseline.Stablediseaseincludedallotherresponses.Asustainedradiographicresponsewasdefinedasadecreaseintumorvolumeof$20%whencomparedtobaselineatthetimeofthelastscan.Durationofresponsewasdeterminedasthetimeintervalfromthefirstandlastscansshowingadecreaseinvolume$20%frombaseline,evenifinterimscansdidnotmeetradiographicresponsecriteria.Timetoprogressionwasdefinedasthetimefromfirstdoseofbevacizumabtothefirstscandateinwhichthemeningiomagrew$20%involumecomparedtobaselinemeasurements.RegressionAnalysisWeanalyzedeachoutcomeofinterestonaper-tumorbasisandonaper-patientbasis.Intheper-tumoranalysis,eachtumorwasconsideredanindependenteventwithnoclusteringeffectforindividualpatientswithmultipletumors.Intheper-patientanalysis,weaccountedfortheclusteringeffectofmultipletumorsinindividualpatientsbyusingaregressionmodelthatincludedarandomeffect.Detailsontheregressionmodelusedareavailableinthesupplementalmaterial.Inbothanalyses,wecalculatedthetumorgrowthrateduringthepre-andpost-treatmentperiodsusingallscansavailable(upto4yearsbeforeinitiationoftreatment).Wealsoperformedtheanalysesusingonlythescansinthe12monthsimmediatelypriortoinitiationoftherapytodeterminepre-treatmentannualtumorgrowthrate.Wewantedtodeterminewhetherrelativechangeintumorvolume(percentchangefrombaseline)orabsolutechangeintumorvolumewouldcorrelatewithradiographicresponsetotreatment.Therefore,tumorgrowthratewasrepresentedasrelativechangeintumorvolumefrombaseline(percentageresponse)andasabsolutedifferenceintumorvolumefrombaseline.Wethencorrelatedpre-treatmentgrowthrateswithpost-treatmentgrowthratesusingpatientdemographicinformation(ageatthestartoftreatmentandgender),tumorsizeatbaseline,andtumorlocationascovariates.StatisticalanalysiswasperformedwithSASsoftware(version9.2,SASInstituteInc,NC,USA).APvalueof,.05wasconsideredtobestatisticallysignificant.ImmunohistochemistryInaparallelanalysis,wedeterminedtheexpressionpatternofgrowthfactorsassociatedwithtumorangiogenesisinparaffin-embeddedtissuesof13unrelatedNF2-relatedmeningiomasand13sporadicmeningiomasfromsurgeriesatMassachusettsGeneralHospital.AsimilaranalysisforNF2-relatedandsporadicschwannomaswasreportedpreviously.[9]Fivemicron-thicksec-tionswerecutandimmunostainedwiththefollowingantibodies:CD31(Dako,prediluted),aSMA(Sigma,1:100),VEGF(SantaCruzorNeomarker1:100),VEGFR2,PDGFR-a,PDGFR-b(CellSignaling;1:250,1:100and1:100respectively),Neuropilin-1(Chemicon,1:40),Neuropilin-2(R&DBiosystem,1:500),Sema-phorin3A(Millipore,1:100)andSemaphorin3F(Chemicon1:250).Semiquantitativeanalysiswasperformedbytwoauthorswhoscoredtheintensityofstainingoftumorcellsandbloodvesselsonascalefrom0(nostaining)to3(strongstaining).Forcalculationofmicrovasculardensityanddiameter,CD31labelingwasusedtohighlightvessels.Thequantificationusedatleast5fieldsofconfirmedtumortissueat200xmagnificationwithanaverageof100vesselscountedpersection.AcustomizedsoftwareanalysistoolcompatiblewithImageJ(http://rsb.info.nih.gov/ij/)wasthenusedtodeterminethenumberofvessels,perimeter,theminoraxisofbest-fittedellipse(representativeofthevesseldiameter),andthetotalsurfacecoveredbyvascularspaces.ThesamemethodwasusedsubstitutingeitherVEGFR2orNRP2BevacizumabTreatmentforMeningiomasinNF2PLOSONE|www.plosone.org2March2013|Volume8|Issue3|e59941labelingtodeterminethepercentageofvesselsexpressingtheseVEGFreceptors.Consecutivesectionswereusedtoallowsimilarareasofthetumortobequantifiedinallcases.ResultsAtotalof48meningiomasand18vestibularschwannomasfrom15NF2patients(7men,8women)wereincludedinthisstudy.PatientandtumorcharacteristicsarelistedinTable1.ThemeannumberofMRIscansperpatientusedforanalysisoftumorresponsewas8(range,4–14).Themedianpatientageatthestartoftreatmentwas29.5years(range,16–63years).Themean(median)volumesofmeningiomasandvestibularschwannomasatthebeginningoftreatmentwere6.2cm3(1.9cm3),and9.8cm3(4.3cm3),respectively.Themeanvolumetricgrowthratepriortotreatmentwas11.6%peryearandmedianfollowuptimewas18months(range10to37months).Bevacizumabwasoverallwelltolerated,withonlyfourgrade3adverseevents(hypertension,elevatedliverenzymes,menorrhagia,irregularmenses),andtwograde4events(bothassociatedwithwoundhealingproblems,includingvascularaccesscomplicationsandtracheostomywoundhealingdelays).Aradiographicresponsewasseenin29%oftumors(14/48tumors)usingper-tumoranalysisandwasseenin7%ofpatients(1/15patientsusingaper-patientanalysis)(Figure1).Tumorshrinkagewasnotdurable,withonly5/14respondingmeningi-omasmaintainingaradiographicresponseatthelastfollowup.Themediandurationofmeningiomaresponsewas3.7months(range0to25months),withsixmeningiomashavingasinglescanmeetingcriteriaforradiographicresponse(decreaseinmeningi-omavolume$20%).Overall,29/48meningiomas(60%)progressedduringthestudy.Themediantimetoprogressionwas15monthsonper-tumoranalysis(Figure2)andwas20monthsonper-patientanalysis.Progression–freesurvivalat6-and12-monthswas85%and62%,respectively,onper-tumorbasis.Progression-freesurvivalat6-and12-monthswas93%and79%,respectivelyonper-patientbasis.Theradiographicresponserateforvestibularschwannomasinthiscohortwas39%(7/18tumors)whenusingwholebrainMRIscansandwas44%(8/18tumors)whenusinginternalauditoryTable1.Patientandtumorcharacteristics.CharacteristicsN(%)GenderFemale8(53%)Male7(47%)Age,20y2(13%)20–29y7(47%)30–39y2(13%)40–49y3(20%).50y1(7%)Totalmeningiomasanalyzedperpatient1–2meningiomas8(53%)3–4meningiomas3(20%).4meningiomas4(27%)Medianmeningiomabaselinevolume1.9cm3Distributionofmeningiomavolumeatbaseline(n=48),2cm325(52%)2–10cm316(34%)10–20cm34(8%).20cm33(6%)MeningiomaPre-TreatmentAnnualGrowthRate11.6%(range,-240%to546%)MeningiomalocationOrbital/Skullbase10(21%)Convexity/Falx34(71%)Posteriorfossa4(8%)Medianvestibularschwannomavolumeatbaseline4.3cm3Distributionofvestibularschwannomavolumeatbaseline(n=18),2cm35(27%)2–10cm37(39%)10–20cm33(17%).20cm33(17%)doi:10.1371/journal.pone.0059941.t001BevacizumabTreatmentforMeningiomasinNF2PLOSONE|www.plosone.org3March2013|Volume8|Issue3|e59941Figure1.RadiographicResponseofMeningiomastoBevacizumab.Waterfallplotofbestradiographicresponseforindividualmeningiomas(A)andfortotalmeningiomavolumeinpatients(B).doi:10.1371/journal.pone.0059941.g001BevacizumabTreatmentforMeningiomasinNF2PLOSONE|www.plosone.org4March2013|Volume8|Issue3|e59941canal(3mmslices,nogap).ThedifferenceinresponseratebetweenthecohortofNF2patientswithmeningiomas(44%response)andtheentiretreatedNF2cohortof31patients(55%,datanotshown)wasnotstatisticallysignificant(Fisherexacttwotail=.79).Atotalof47meningiomaswereincludedinregressionanalysestoidentifyclinicalfactorsassociatedwithpost-treatmentgrowthrate.Foronemeningioma,nopre-treatmentscanswereavailableforanalysis.GrowthrateestimatesandstatisticalresultsaresummarizedonTable2.Therewasnosignificantcorrelationbetweenpre-treatmentandpost-treatmentgrowthratesforindividualmeningiomasusingper-tumoranalysis(p=.33).Thisfindingpersistedwhenpre-treatmentgrowthwascalculatedusingonlythe12monthsimmediatelypriortotreatment(p=.79).Therewasnosignificantdifferenceintheresultswhentumorresponsewascalculatedusingabsolutechangeintumorvolumeorpercentchangeintumorvolume(p=0.72).Whenonlymeningiomaswithapre-treamtentgrowthrate$20%andwithbaselinevolume$1cm3wereincludedintheanalysis,radiographicresponsewasseeninonlyoneoutoffivemeningiomas(20%oftumors).Figure3showsthecorrelationbetweenmeningiomabestresponseandpre-treatmentgrowthrate.Intheper-patientanalyses,therewasnosignificantassociationbetweenpre-treatmenttumorgrowthandtumorresponsewhenusingpercentagechangeintumorvolume(p=.23),orabsolutechangeintumorvolume(p=.37).Therewasnodifferenceintheresultswhenpre-treatmentperiodincludedonlythe12monthsimmediatelypriortostartoftherapy.Interestingly,therewasaFigure2.TimetoProgressionforMeningiomaTreatedwithBevacizumab.A.Kaplan-Meiercurvefortimetoprogressionconsideringeachmeningiomaasanindependentevent(per-tumoranalysis).Progressionwasconsideredasanincreaseintumorvolumeof20%ormore.B.Kaplan-Meiercurvefortimetoprogressionusingtotalintracranialmeningiomavolumeforeachpatientasanindependentevent(per-patientanalysis).Timetoprogressionwas15monthsforindividualtumorsand20monthsonper-patientanalysis.Progression-freerateatsixmonthswashigherintheper-patientanalysisat93%,comparedto85%fortheper-tumoranalysis.doi:10.1371/journal.pone.0059941.g002BevacizumabTreatmentforMeningiomasinNF2PLOSONE|www.plosone.org5March2013|Volume8|Issue3|e59941correlationbetweenincreasedpost-treatmentgrowthrateandmalegender(p=.07),andolderage(p=.04).ImmunohistochemicalanalysisofmeningiomasshowednosignificantdifferenceintheexpressionofcomponentsoftheVEGFangiogenesispathway(VEGF,VEGFR2,PDGFR-a,PDGFR-b,neuropilin-1,neuropilin-2,semaphorin3A,andsemaphorin3F)betweensporadicmeningiomasandNF2-associ-atedmeningiomas.MicrovasculardensitywassignificantlygreaterinsporadicmeningiomascomparedtoNF2-relatedmeningiomas(52vessels/mm2vs.32vessels/mm2;t-testp=.01).Therewasnosignificantdifferenceofaverageperimeterordiameterbetweenthetwogroups.DiscussionMedicaltreatmentsformeningiomasaredesperatelyneededforpatientswithmeningiomasthatcannotbeadequatelytreatedwithsurgeryandradiation.Thelistofdrugswithoutaclearbenefitforthesetumorscontinuestogrowandincludestamoxifen,[14]irinotecan,[15]temozolomide,[16]octreotide,[17,18]mifepris-tone,[19]erlotinib,[20]gefitinib,[20]imatinib,[21]andalpha-interferon.[22,23]Althoughinitialresultswithhydroxyureawerepromising,[24]furtherstudiesshowedthatradiographicresponsetohydroxyureainmeningiomasisuncommon.[25,26]OurresultsforNF2-relatedmeningiomasarecomparabletocaseseriesofsporadicmeningiomastreatedwithbevacizumab[12,13].Thesestudies,whichincludedallgradesofmeningiomas,reportedmedianPFSof18226monthsandradiographicresponseratesof027%.BecausemultiplemeningiomasarecommoninNF2patients,weanalyzedourdataonaper-tumorbasisandonaper-patientbasis.Usingper-tumoranalysis,themedianPFSwas15months;usingper-patientanalysis,thePFSwas20months.Theper-tumorradiographicresponseratewas29%inourseriesandexceededtherateinpreviousreports;however,thedurabilityofresponsewasshort.Thiscontrastswiththedurabilityofresponseinschwannoma.[9]Theseresultssuggestthattheclinicalbenefitoftumorshrinkageinourpatientswasminimal.Analysisoftumorgrowthratecanbedeterminedasarelativechange(percentage)intumorvolumefrombaseline,orasanabsolutevolumechangefrombaselinemeasurement.Theuseofrelativechangeisthestandardmethodusedforradiographicresponsetotreatment,whetherlinearmeasurementsorvolumetricanalysismethodsareusedinthestudy.[27]Weanalyzedourdatainbothwaystoaccountforpotentialbiasinthedeterminationofresponseratebasedontumorsizeatbaseline.Relativechangesintumorvolumeareusuallylargerinsmalltumors,leadingtobiasinthestatisticalanalysiswhensmallerandlikelyasymptomatictumorsareincludedinthestudy.Instead,largertumorsaremorelikelytohavelargerabsolutevolumechangesthansmalltumors,evenifonlyasmallpercentagechangeintotalvolumehasoccurred.DuetothebiologyofVEGFinhibitors,suchasbevacizumab,wedecidedtodeterminedresponserateusingbothrelativechangeintumorvolume,aswellasabsolutechangesinvolumefrombaselineforcomparison.Inthisretrospectiveanalysis,neithermeasurementofpre-treatmentgrowthratewasfoundtobesignificantlyassociatedwithtreatmentresponse.Thismaybeduetopoorresponsetotreatmentseeninthisstudy,smallsamplesize,orselectionbiasfromthisretrospectivestudy.Althoughtherewasastatisticalassociationbetweenolderpatientsandmeningiomaresponsetotreatment,therelativeeffectonresponsewassmall,andlikelynotclinicallyrelevant.WehavepreviouslyshownthattreatmentwithbevacizumabcanleadtotumorshrinkageofvestibularschwannomasinpatientsTable2.SummaryofRegressionAnalysisResultsforGrowthRateEstimatesinPer-TumorandPer-PatientModels.Per-tumorAnalysisPer-patientAnalysisFactorPercentageChangeinTumorVolumeAbsoluteChangeinTumorVolumePercentageChangeinTumorVolumeAbsoluteChangeinTumorVolumeParameterEstimatep-valueParameterEstimatep-valueParameterEstimatep-valueParameterEstimatep-valueTumorGrowthbyMonthUsingAllScans20.0530.3320.0110.7220.0660.2320.0250.37TumorGrowthbyMonthUsinglast12months20.0140.790.0020.9420.0160.5620.040.43MaleGenderN/AN/AN/AN/A20.0150.0720.060.33AgeN/AN/AN/AN/A20.00070.0420.0040.09doi:10.1371/journal.pone.0059941.t002BevacizumabTreatmentforMeningiomasinNF2PLOSONE|www.plosone.org6March2013|Volume8|Issue3|e59941withNF2,[9]withfollowupstudyshowingradiographicresponsein55%ofvestibularschwannomas,andhearingimprovementin57%inourcohortof31patients.[28]Inthesesamepatients,radiographicresponsesformeningiomaswereseeninonly29%ofmeningiomasandwereshort-lived..Thedifferenceinresponseratebetweenvestibularschwannomasandmeningiomasdoesnotseemtocorrelatewithdegreeofangiogenesis,sinceexpressionofVEGFinthetumor,expressionofVEGFR2intumorbloodvessels,andmicrovasculardensityaregreaterinmeningiomasthaninvestibularschwannomas.[9]However,immunohistochem-icalanalysisofexpressionoftheVEGFpathwaycomponentsshowsdifferentpatternsinschwannomasandmeningiomas.Inourpreviousstudy,analysisoftheVEGFangiogenesispathwayinschwannomasshowedverylowexpressionofSEMA3(angiogen-esisinhibitor)andapositivecorrelationbetweenVEGF/SEMA3expressionratioandtumormicrovasculardensity;consistentwiththehypothesisthattheangiogenesisinschwannomaswasdrivenbyactivationoftheVEGFpathway.Incontrast,inthisstudy,wefoundarobustexpressionofSEMA3inmeningiomas(NF2associatedandsporadic)andfurthermore;therewasnocorrelationbetweenexpressionofVEGFpathwaycomponentsandtumormicrovasculardensity.ThesefindingssuggestthattheVEGFpathwaymaynotbeanimportantdrivingforceofangiogenesisinmeningiomasandmayexplainthedifferentresponseratesobservedforthetwotypesoftumors.Currently,prospectivestudiesofbevacizumab(NCT01125046)andcombinationofbevacizumabandeverolimus(NCT00972335)areunderwayforpatientswithsporadicrecurrentorprogressivemeningiomas.ConclusionNF2-relatedmeningiomaswerenoteffectivelytreatedbybevacizumabinthisanalysisofNF2patientstreatedfortheirprogressivevestibularschwannomas.Wedidnotidentifyanypredictorsoftumorresponsetobevacizumabinourcohort.PathologicanalysisofcomponentsoftheVEGFangiogenesispathwayandoftumormicrovasculardensityinmeningiomasshowedrobustexpressionofSEMA3(anangiogenesisinhibitorthatwasnotexpressedinschwannomas)andincontrastofourfindingsinschwannomas,therewasnocorrelationbetweenexpressionofVEGFpathwaycomponentsandtumormicrovas-culardensityinmeningiomas.ThesefindingssuggestthattheVEGFpathwaymaynotbeadrivingforceinangiogenesisinmeningiomasandmayexplainlimitedclinicalresponseinmeningiomas.Figure3.MeningiomaBestResponseComparedtoPre-treatmentGrowthRate.Scatter-plotofmeningiomabestresponsevs.relativechangeintumorvolumepriortotreatment.Horizontaldashedlinesshowthresholdforradiographicresponseat20%decreaseintumorvolumeposttreatment,andverticaldashedlineseparatestumorswithpositivegrowthpriortotherapy.doi:10.1371/journal.pone.0059941.g003BevacizumabTreatmentforMeningiomasinNF2PLOSONE|www.plosone.org7March2013|Volume8|Issue3|e59941SupportingInformationTextS1Methodsfordeterminingtumorvolumeandperformingregressionanalysis.(DOC)AcknowledgmentsTheauthorswouldliketothankDrs.RobertMartuzaandStevenGreenbergfortheirguidanceandcriticalreviewofthismanuscript.AuthorContributionsImaginganalysis:FPNPACDJ.Conceivedanddesignedtheexperiments:FPNEdTSRPFGBASR.Performedtheexperiments:FPNVLMDJPACEdT.Analyzedthedata:FPNAMDJASRSRP.Contributedreagents/materials/analysistools:EdTAM.Wrotethepaper:FPNSRPFGBASR.References1.CBTRUS(2012March)CBTRUSStatisticalReport:PrimaryBrainandCentralNervousSystemTumorsDiagnosedintheUnitedStatesin2004222008.2.BriaC,WegnerRE,ClumpDA,VargoJA,MintzAH,etal.(2011)Fractionatedstereotacticradiosurgeryforthetreatmentofmeningiomas.JCancerResTher7:52257.3.NordenAD,DrappatzJ,WenPY(2009)Advancesinmeningiomatherapy.CurrNeurolNeurosciRep9:2312240.4.SmithMJ,HiggsJE,BowersNL,HallidayD,PatersonJ,etal.(2011)Cranialmeningiomasin411neurofibromatosistype2(NF2)patientswithprovengenemutations:clearpositionaleffectofmutations,butabsenceoffemaleseverityeffectonageatonset.JMedGenet48:2612265.5.BaserME,FriedmanJM,AeschlimanD,JoeH,WallaceAJ,etal.(2002)Predictorsoftheriskofmortalityinneurofibromatosis2.AmJHumGenet71:7152723.6.NunesF,MacCollinM(2003)Neurofibromatosis2inthepediatricpopulation.JChildNeurol18:7182724.7.RosenLS(2002)Clinicalexperiencewithangiogenesissignalinginhibitors:focusonvascularendothelialgrowthfactor(VEGF)blockers.CancerControl9:36244.8.FerraraN,HillanKJ,GerberHP,NovotnyW(2004)Discoveryanddevelopmentofbevacizumab,ananti-VEGFantibodyfortreatingcancer.NatRevDrugDiscov3:3912400.9.PlotkinSR,Stemmer-RachamimovAO,BarkerFG,HalpinC,PaderaTP,etal.(2009)Hearingimprovementafterbevacizumabinpatientswithneurofibroma-tosistype2.NEnglJMed361:3582367.10.GoutagnyS,RaymondE,SterkersO,ColombaniJM,KalamaridesM(2011)RadiographicregressionofcranialmeningiomainaNF2patienttreatedbybevacizumab.AnnOncol22:9902991.11.PuchnerMJ,HansVH,HaratiA,LohmannF,GlasM,etal.(2010)Bevacizumab-inducedregressionofanaplasticmeningioma.AnnOncol21:244522446.12.LouE,SumrallAL,TurnerS,PetersKB,DesjardinsA,etal.(2012)Bevacizumabtherapyforadultswithrecurrent/progressivemeningioma:aretrospectiveseries.JNeurooncol109:63270.13.NayakL,IwamotoFM,RudnickJD,NordenAD,LeeEQ,etal.(2012)Atypicalandanaplasticmeningiomastreatedwithbevacizumab.JNeurooncol109:1872193.14.GoodwinJW,CrowleyJ,EyreHJ,StaffordB,JaeckleKA,etal.(1993)AphaseIIevaluationoftamoxifeninunresectableorrefractorymeningiomas:aSouthwestOncologyGroupstudy.JNeurooncol15:75277.15.ChamberlainMC,Tsao-WeiDD,GroshenS(2006)SalvagechemotherapywithCPT-11forrecurrentmeningioma.JNeurooncol78:2712276.16.ChamberlainMC,Tsao-WeiDD,GroshenS(2004)Temozolomidefortreatment-resistantrecurrentmeningioma.Neurology62:121021212.17.JohnsonDR,KimmelDW,BurchPA,CascinoTL,GianniniC,etal.(2011)PhaseIIstudyofsubcutaneousoctreotideinadultswithrecurrentorprogressivemeningiomaandmeningealhemangiopericytoma.NeuroOncol13:5302535.18.SchulzC,MathieuR,KunzU,MauerUM(2011)Treatmentofunresectableskullbasemeningiomaswithsomatostatinanalogs.NeurosurgFocus30:E11.19.GrunbergSM,WeissMH,RussellCA,SpitzIM,AhmadiJ,etal.(2006)Long-termadministrationofmifepristone(RU486):clinicaltoleranceduringextendedtreatmentofmeningioma.CancerInvest24:7272733.20.NordenAD,RaizerJJ,AbreyLE,LambornKR,LassmanAB,etal.(2009)PhaseIItrialsoferlotiniborgefitinibinpatientswithrecurrentmeningioma.JNeurooncol.21.WenPY,YungWK,LambornKR,NordenAD,CloughesyTF,etal.(2009)PhaseIIstudyofimatinibmesylateforrecurrentmeningiomas(NorthAmericanBrainTumorConsortiumstudy01208).NeuroOncol11:8532860.22.ChamberlainMC,GlantzMJ(2008)Interferon-alphaforrecurrentWorldHealthOrganizationgrade1intracranialmeningiomas.Cancer113:214622151.23.KabaSE,DeMonteF,BrunerJM,KyritsisAP,JaeckleKA,etal.(1997)Thetreatmentofrecurrentunresectableandmalignantmeningiomaswithinterferonalpha-2B.Neurosurgery40:2712275.24.SchrellUM,RittigMG,AndersM,KochUH,MarschalekR,etal.(1997)Hydroxyureafortreatmentofunresectableandrecurrentmeningiomas.II.Decreaseinthesizeofmeningiomasinpatientstreatedwithhydroxyurea.JNeurosurg86:8402844.25.LovenD,HardoffR,SeverZB,SteinmetzAP,GornishM,etal.(2004)Non-resectableslow-growingmeningiomastreatedbyhydroxyurea.JNeurooncol67:2212226.26.MasonWP,GentiliF,MacdonaldDR,HariharanS,CruzCR,etal.(2002)Stabilizationofdiseaseprogressionbyhydroxyureainpatientswithrecurrentorunresectablemeningioma.JNeurosurg97:3412346.27.EisenhauerEA,TherasseP,BogaertsJ,SchwartzLH,SargentD,etal.(2009)Newresponseevaluationcriteriainsolidtumours:revisedRECISTguideline(version1.1).EurJCancer45:2282247.28.PlotkinSR,MerkerVL,HalpinC,JenningsD,McKennaMJ,etal.(2012)Bevacizumabforprogressivevestibularschwannomainneurofibromatosistype2:aretrospectivereviewof31patients.OtolNeurotol33:104621052.BevacizumabTreatmentforMeningiomasinNF2PLOSONE|www.plosone.org8March2013|Volume8|Issue3|e59941
Bee Propolis Stops Tumors from Neurofibromatosis and Cancer
Wednesday, April 29, 2009 by: Barbara L. Minton
Tags: propolis, health news, Natural News



Most Viewed Articles
Today	Week	Month	Year
EXPERIMENT: I sank four ammo cans full of ammunition to the bottom of a pond for one year… here’s what happened when I opened them - NaturalNews.com
Health Ranger: The five supplements I take every day as I’m approaching the age of fifty - NaturalNews.com
16 Reasons to eat cantaloupe this summer - NaturalNews.com
Johnson & Johnson caught in another scandal, forced to pay $33 million settlement over recalled nonprescription meds - NaturalNews.com
Amish farmer facing 68 years in federal prison for making homemade products - NaturalNews.com
High-rise building with 27 floors goes up in flames, yet doesn’t uniformly collapse like WTC 7… ever wonder why? - NaturalNews.com
Carrie Fisher was on cocaine and heroin at the time of her death, autopsy finds - NaturalNews.com
600 strains of an aerosolized thought control vaccine already tested on humans; deployed via air, food and water
Weather Channel founder tells CNN “climate change is a hoax” … 31,000 scientists agree - NaturalNews.com
Neil deGrasse Tyson becomes the voice of EVIL, narrating new propaganda film “Food Evolution” produced by Monsanto shills and pesticide pushers - NaturalNews.com
Massive embezzlement scheme ensnares Leonardo DiCaprio and his non-profit foundation - NaturalNews.com
Italian court rules mercury and aluminum in vaccines cause autism: US media continues total blackout of medical truth
Broccoli sprout extract can replace toxic metformin drugs in type-2 diabetes; sulforaphane found to control blood sugar levels - NaturalNews.com
Amazon now looking to put clothing retailers out of business with new “Prime wardrobe” service - NaturalNews.com
The Conspiracy Against Saturated Fat: Dr. Jack Wolfson responds to the American Heart Association’s ignorant attack on coconut oil - NaturalNews.com
Microbiome - Gut health discoveries revealed - NaturalNews.com
Scary, infectious SUPERBUG just spread to five more U.S. states, including some in the Midwest - NaturalNews.com
Progressives STUNNED to learn that all medicinal nutrients in herbs and plants are made out of carbon dioxide - NaturalNews.com
Popular on Facebook
538
Dear Donald Trump: Blockade the lying mainstream media and recognize the independent media as America's real free press
51
Kellogg's found to have financial ties to the money man for cop-killing left-wing HATE groups: George Soros
Delicious8
diaspora
PrintEmailShare(NewsTarget) Honeybees are some of the most amazing creatures ever created by nature. They play a vital role in much of the food supply through pollination, and they provide people with a healthy natural alternative to sugar. Some of the most interesting aspects of bees are the substances they make to use themselves. Propolis is a natural resin found in young tree buds. Bees collect it for use as a glue to seal their homes. Propolis is an exceedingly complex product that contains substances that prevent and treat diseases ranging from cancer to the common cold. Recent research has documented the ability of propolis to suppress the growth of human tumors from neurofibromatosis and cancer.

Compound from propolis halts tumor process in clinical trials

Neurofibromatosis is a genetic disorder that can produce coffee colored skin patches, but it is best known for producing tumors on nerve tissue including the nerves involved in hearing. Tumors from neurofibromatosis can grow anywhere else in the body including the brain and spinal cord, and if surgically removed, they can return. The condition of neurofibromatosis can be life threatening.

Neurofibromatosis affects one in every 3000 people. The body processes that form neurofibromatosis tumors are responsible for about 70% of human cancers.

Propolis halted neurofibromatosis tumor growth in a group of cancer patients taking part in a study by scientists at Universitaets Klinikum Eppendorf in Hamburg, Germany. Dysfunction of the NF1 or NF2 gene coding is the major cause of neurofibromatosis. Researchers had previously demonstrated that the human gene PAK1 is essential for the growth of both NF1 and NF2 tumors. Although several attempts have been made to develop anti-PAK1 drugs, none have been successful.

Since bee propolis contains anticancer ingredients caffeic acid phenethyl ester (CAPE) and artepillin C (ARC), both of which block the oncogenic PAK1 signaling pathways, its potential therapeutic effects on NF tumors were explored in vivo. It was demonstrated that a CAPE-rich extract of propolis mixed with water completely suppressed the growth of human NF1 and caused an almost complete regression of human NF2 (Schwannoma), that had been grafted in mice. The scientists stressed that although CAPE is not used clinically due to its poor bioavailability, it can be made soluble with the addition of lipids (fats). (Phytotherapy Resources, February)

In an earlier study, this German team identified CAPE's anti-cancer abilities. CAPE is a natural compound found in some foods, but is highly concentrated in bee propolis. Previously, propolis had been known only to have anti-cancer function through its profound ability to boost the immune system.

Clinical trials to test the compound on humans are ongoing. So far, cancer patients taking part have seen their tumor growth halted. The compound's effect on neurofibromatosis, melanoma and pancreatic cancer is being investigated. Although the trials are still in early stages, the majority of patients have shown no further growth of their tumors. Those in charge of the study believe that several other PAK-1 dependent diseases such as AIDS and Fragile X mental retardation syndrome can be impacted by the compound.

Propolis is effective against cancer of the larynx

Scientists in Brazil recently investigated the effects of propolis on human laryngeal epidermoid carcinoma. They incubated cells with different concentrations of bee propolis for different time periods. Then they analyzed morphology and number of viable cancerous cells. Their data showed that propolis exhibited the ability to kill cancerous cells in a dose and time dependent manner. (Evidence Based Complementary and Alternative Medicine, October 22, 2007)

Propolis keeps tumors from setting up their own blood supplies

In other recent research, researchers examined the ability of propolis components to stop tumors from developing their own blood supplies. When blood supply to a tumor is cut off, it can no longer receive nutrients to fuel its growth. Acacetin, apigenin, artepillin C, CAPE, chrysin, p-coumaric acid, galangin, kaempherol, pinocembrin, and quercetin were studied for their antioxidant activity as well.

Two of the components, CAPE and quercetin, possessed strong inhibitory effects on tube formation and endothelial cell proliferation, and coincidentally showed strong antioxidant activity. Artepillin C, galangin, and kaempferol also possessed strong ability to block tumor blood supply. Each had strong antioxidant activity although not to the degree of CAPE and quercetin. In contrast, acacetin, apigenin, and pinocembrin possessed a considerable degree of effect against blood supply formation, although they demonstrated low antioxidant activity. The scientists noted the potential for these compounds to be developed into pharmaceutical drugs for the treatment of human tumors. (Molecular Nutrition and Food Research, December 8, 2008)

Bee propolis rejuvenates the immune system

The first double-blind study of propolis involved a team of five doctors led by Professor S. Scheller in Poland, who found that propolis had the power to prolong the prime of life by stimulating the immune system to release substances that protect against cellular deterioration. In addition, propolis boosted the destruction of potentially harmful foreign bacteria and stimulated the formation of antibodies to build immunity to many diseases. This strengthening of cellular defense helps build resistance to aging and illness.

Phagocytes are the white blood cells that serve as the primary defense against bacterial infections. Their activity was found to be increased by propolis.

As people reach their 30s and 40s, the immune system generally begins to weaken, increasing susceptibility to disease. Propolis offers wide spectrum activity though its broad range of flavonoids and other cell-building compounds, such as vitamins, minerals and enzymes. Flavonoids from propolis can block the release of histamine by stabilizing cell membrane lipids. Flavonoids guard against deposits of aging lypofuscins, which is fatty pigment in the heart, brain, nerves and liver.

Here are some comments from Dr. Scheller about his findings regarding propolis as quoted in Carlson Wade's article Can Bee Propolis Rejuvenate the Immune System:

"There was an increase in general physical performance, also sexual, and above all intellectual.

"In the gastro-enterological area, we found a favorable effect on infectious changes in the mucous membranes of the stomach and intestines.

"There was an accelerated and intensified regeneration of injured tissue on traumatically or infectiously altered tissues.

"There were no unequivocally negative changes in the white blood picture or in the liver or kidney values. Among other things, this substantiates the absence of side effects of propolis as well as its non-toxicity.

"In our paper, we particularly studied the effect on the immune system and documented further positive effects of propolis on circulation, metabolism, physical well-being and infectious diseases.

"Simulate the immune system, and it is possible to control the aging process and enjoy a long and healthy life. Propolis holds the key to this form of inner rejuvenation."

Propolis is effective against a variety of bacteria and viruses

A bee hive is a busy place crammed full of bustling bodies. These conditions would make them very susceptible to bacterial and viral infections, which could destroy the hive the way the Bubonic Plague ravaged Europe in the 17th century. Yet bees are able to prevent infection by using sap from young trees that has antibiotic properties. They gather the sap, remetabolize it with their nectar secretions, and take it back to the hives. There they spread it all over the place so that every bee will brush against it and become immunized. The tree antibiotic becomes the bee antibiotic.

Studies have documented the ability of propolis against Staphylococcus aureus that causes deadly infections in hospitals. Researchers found that extracts of propolis inhibited the growth of the bacteria.

Another study documented that propolis inhibited the activity of streptococcal bacteria species that cause dental cavities. Japanese researchers reported that propolis fed laboratory rats had far fewer cavities than those given a regular diet.

Researchers in Brazil recently evaluated the antimicrobial activity of two experimental pastes containing propolis extract associated with calcium hydroxide against polymicrobial cultures collected from molars of children. The paste was effective in controlling dental infections. (Brazilian Dental Journal, 2008)

Propolis is equally effective against viral infection. Several journals have documented its ability to fight upper respiratory infections, such as those caused by the common cold and influenza viruses. It has been shown to prevent viruses from reproducing, but it must be used throughout the infection period.

For more information see:
Carcinogenesisvol.29no.11pp.2139–2146,2008doi:10.1093/carcin/bgn200AdvanceAccesspublicationAugust25,2008YAP1isinvolvedinmesotheliomadevelopmentandnegativelyregulatedbyMerlinthroughphosphorylationToshihikoYokoyama1,HirotakaOsada1,2,HidekiMurakami1,YoshioTatematsu1,TetsuoTaniguchi1,YutakaKondo1,YasushiYatabe3,YoshinoriHasegawa4,KaoruShimokata5,YoshitsuguHorio6,ToyoakiHida6andYoshitakaSekido1,1DivisionofMolecularOncology,AichiCancerCenterResearchInstitute,1-1Kanokoden,Chikusa-ku,Nagoya464-8681,Japan,2DepartmentofCellularOncology,NagoyaUniversityGraduateSchoolofMedicine,65Tsurumai-cho,Showa-ku,Nagoya466-8550,Japan,3DepartmentofPathologyandMolecularDiagnostics,AichiCancerCenterHospital,1-1Kanokoden,Chikusa-ku,Nagoya464-8681,Japan,4DepartmentofRespiratoryMedicine,NagoyaUniversitySchoolofMedicine,65Tsurumai-cho,Showa-ku,Nagoya466-8550,Japan,5DepartmentofBiomedicalSciences,CollegeofLifeandHealthSciences,ChubuUniversity,1200Matsumoto-cho,Kasugai487-8501,Japanand6DepartmentofThoracicOncology,AichiCancerCenterHospital,1-1Kanokoden,Chikusa-ku,Nagoya464-8681,JapanTowhomcorrespondenceshouldbeaddressed.Tel:þ81527642993;Fax:+81527642993;Email:ysekido@aichi-cc.jpWepreviouslyreportedtheresultsofbacterialartiﬁcialchromo-somearraycomprehensivegenomichybridizationofmalignantpleuralmesotheliomas(MPMs),includingtwocaseswithhigh-levelampliﬁcationinthe11q22locus.Inthisstudy,wefoundthattheYAP1geneencodingatranscriptionalcoactivatorwaslocal-izedinthisampliﬁedregionandoverexpressedinbothcases,suggestingitasacandidateoncogeneinthisregion.WeanalyzedtheinvolvementofYAP1inMPMproliferation,aswellasitsfunctionalandphysicalinteractionwithMerlinencodedbytheneuroﬁbromatosistype2(NF2)tumorsuppressorgene,whichisfrequentlymutatedinMPMs.YAP1-RNAinterferencesup-pressedgrowthofamesotheliomacelllineNCI-H290withNF2homozygousdeletion,probablythroughcell-cyclearrestandap-optosisinduction,whereasYAP1transfectionpromotedthegrowthofMeT-5A,animmortalizedmesothelialcellline.WealsofoundthattheintroductionofNF2intoNCI-H290inducedphos-phorylationatserine127ofYAP1,whichwasaccompaniedbyreductionofnuclearlocalizationofYAP1,whereasnuclearlocal-izationofaYAP1S127Amutantwasnotaffected.Furthermore,resultsofimmunoprecipitationandinvitropull-downassaysin-dicatedaphysicalinteractionbetweenMerlinandYAP1.TheseresultssuggestthatYAP1isinvolvedinmesothelialcellgrowthandthatthetranscriptionalcoactivatoractivityofYAP1isfunc-tionallyinhibitedbyMerlinthroughtheinductionofphosphory-lationandcytoplasmicretentionofYAP1.ThisistheﬁrstreportofnegativeregulatorysignalingfromMerlintoYAP1inmamma-liancells.FuturestudiesoftranscriptionaltargetsofYAP1inMPMsmayshedlightonthemolecularmechanismsofMPMdevelopmentandleadtonewtherapeuticstrategies.IntroductionAmalignantpleuralmesothelioma(MPM)isahighlylethalneoplasmthatisthoughttodevelopfrompleuralmesothelialcells,withexpo-suretoasbestosplayingacrucialroleintumordevelopment(1–4).PatientswithanMPMareusuallydiagnosedatanadvancedstageandthetumorsarerefractorytoconventionaltherapeuticmodalities;thus,theirprognosisisverypoor,eventhoughadvancementsinchemo-therapeuticalmodalitiesthatcombinecisplatinandantifolate,suchaspemetrexedorraltitrexed,havebeenmade(5,6).Thelonglatencyperiodbetweenasbestosexposureandtumorappearanceimpliesthatmultiplegeneticchangesarerequiredformalignanttransformationofmesothelialcells(7,8).AccumulatedgeneticstudieshaveidentiﬁedthattumorsuppressorgenesarecrucialforMPMdevelopment,in-cludingfrequentinactivationofp16INK4a/p14ARFat9p21(9–11)andneuroﬁbromatosistype2(NF2)at22q12(12–14).TheNF2geneisresponsibleforNF2syndrome(15)andencodesMerlin(alsoknownasschwannomin),anezrin/radixin/moesinfamilyproteinthathasbeenshowntobeinvolvedincytoskeletaldynamics,growthfactorreceptorsignalingandcelladhesion(16,17).Tofurtherelucidatethealterationsofoncogenesandtumorsuppres-sorgenesresponsibleforMPMdevelopment,wepreviouslycarriedoutbacterialartiﬁcialchromosome(BAC)arraycomprehensivegenomichybridization(CGH)analysesofMPMspecimensfromatotalof22in-dividualsandreportedseveraldistinctchromosomalalterationsinclud-inghighcopyampliﬁcationof11q22(18).Inthepresentstudy,wefoundthattheYAP1gene,whichwasoriginallyclonedasapartnerofYeskinase(19),resideswithinthe11q22ampliﬁcationregionandthatYAP1isinvolvedinmesothelialcellgrowth.Furthermore,wefoundthatYAP1activitymaybenegativelyregulatedviaMerlinsignalinginmesothelialcells.Toourknowledge,thisistheﬁrstknownreportoftheexistenceofnegativeregulatorysignalingfromMerlintoYAP1inmammaliancells,whichmayplayacrucialroleingrowthregulationofmesothelialcellsanddevelopmentofmalignantmesothelioma.MaterialsandmethodsArrayCGHanalysisandquantitativepolymerasechainreactionanalysesofcopynumberandexpressionGenome-widearrayCGHanalysisof22individualMPMsusingmicroarrayswith2304BACandP-1phage-derivedartiﬁcialchromosomeclonescoveringthewholehumangenomeataresolutionofroughly1.3Mbwaspreviouslyreported(18).Todeterminetheprecisecopynumberswithintheampliﬁcation,quantita-tivepolymerasechainreaction(PCR)usingcustomTaqManprobes(AppliedBiosystems,FosterCity,CA)correspondingtothegenomicsequencesofsevengenes(PGR,TRPC6,ANGPTL5,YAP1,BIRC2,MMP13andAB08258)dis-persedwithinthe3MbregionweredesignedandusedtogetherwithTaqManPCRmastermix(AppliedBiosystems)andanABI7500system(AppliedBio-systems),accordingtothemanufacturer’sinstructions.Thecopynumberoftheleucine-richrepeatcontainingthe4Cgene(alsocalledNGL1)localizedat11p12wasusedasacontrol.Toexaminetheexpressionofgeneswithineachampliﬁ-cation,TaqManexpressionprobes(AppliedBiosystems)forANGPTL5,YAP1,BIRC2andBIRC3wereused,andquantiﬁcationwasperformedasabove.ConstructionofRNAinterferencevectorsandexpressionvectorsToconstructRNAinterference(RNAi)vectors,shorthairpin(sh)oligonucleo-tideswereinsertedintoaplasmidcontainingtheU6promoterandapuromy-cin-resistantgene(20).TwosholigonucleotidesweredesignedfortwodifferentsequenceswithintheYAP1openreadingframe(YAP1-sh1,GGCCATGCTGTCCCAGATGAATandYAP1-sh2,GGAGATGGAATGAA-CATAGAAT).Inaddition,controlvectors,YAP1-scr1andgreenﬂuorescentprotein(GFP)-sh,wereconstructedusingoligonucleotideswithscrambledse-quencesforYAP1-sh1(GGCTGCCATTCGCGACATGAAT)andGFPopenreadingframe(GFP-sh,GCAAGCTGACCCTGAAGTTCA).YAP1cDNAwaspurchasedfromOriGene(Rockville,MD)andinsertedintopcDNA(Invitrogen,Carlsbad,CA)andpEGFP-C1(Clontech,MountainView,CA)vec-tors.Thephosphorylation-defectivemutantYAP1wasconstructedbyinvitromutagenesisatcodon127fromserinetoalanine(S127A),asthephosphoryla-tionofserine127wasreportedtoinduceaninteractionbetween14-3-3andcytoplasmicretention(21).NF2cDNAwasampliﬁedwithreversetranscription–PCRandclonedintopcDNA(Invitrogen)andthelentivirusvec-torpLentiLox3.7.TheNa(þ)/H(þ)exchangerregulatoryfactor1(NHERF1)/ezrin/radixin/moesin-bindingphosphoprotein50kDgeneexpressionconstructsAbbreviations:BAC,bacterialartiﬁcialchromosome;CGH,comprehensivegenomichybridization;EGFP,enhancedgreenﬂuorescentprotein;GST,glu-tathioneS-transferase;MPM,malignantpleuralmesothelioma;NF2,neuroﬁ-bromatosistype2;NHERF1,Na(þ)/H(þ)exchangerregulatoryfactor1;PCR,polymerasechainreaction;RNAi,RNAinterference;SDS,sodiumdodecylsulfate;sh,shorthairpin.ÓTheAuthor2008.PublishedbyOxfordUniversityPress.Allrightsreserved.ForPermissions,pleaseemail:journals.permissions@oxfordjournals.org2139werekindlyprovidedbyDrMaria-MagdalenaGeorgescu(UniversityofTexasM.D.AndersonCancerCenter)andDrMarthaC.Nowycky(UniversityofMedicineandDentistryofNewJersey).CellcultureandcolorimetricandﬂowcytometryanalysesAmalignantmesotheliomacellline(NCI-H290),agiftfromDrAdiF.Gazdar(UniversityofTexasSouthwesternMedicalCenter),andanon-malignantme-sothelialcellline(MeT-5A),purchasedfromAmericanTypeCultureCollec-tion(Rockville,MD),wereculturedasdescribedpreviously(18).YAP1-RNAivectorsweretransfectedintoNCI-H290orMeT-5AcellsusingLipofectamine2000(Invitrogen).Forcellproliferationanalysis,transfectedcellsweretreatedwithpuromycinat1lg/mlfor10days,thenstainedusingTetracolorOne(Seikagaku,Tokyo,Japan),afterwhichabsorbancewasdeterminedat450nm.Foranalysisofthecellcycleandsub-G1population,transfectedcellsweretreatedwithpuromycinat1lg/mlfor24h,afterwhichtheculturemediumanddeadcellswereremoved.Residualandviablecellswerefurtherculturedwithoutpuromycinfor24h,thenharvestedandstainedwithpropidiumiodideforﬂowcytometryanalysis,asdescribedpreviously(20).ImmunoblottinganalysisForpreparationofnuclearandcytoplasmicfractions,cellswereincubatedinhypotonicbufferwith0.5%NP-40,thenthenucleiwerepelletedusingabriefcentrifugation,asdescribedpreviously(22).Forimmunoblottinganalysis,afterharvestingthecellswithlysisbuffer,proteinconcentrationwasdeterminedwithaDCProteinassaykit(Bio-Rad,Hercules,CA).Thesameamountsofproteinsampleswereappliedtosodiumdodecylsulfate(SDS)–polyacrylamidegelelectrophoresis,thenelectrotransferredtoImmobilon-Ppolyvinylidenediﬂuor-idemembranes.Eachmembranewasincubatedwithanti-V5-tag(Invitrogen)forV5-taggedNF2,anti-YAP1(CellSignalingandAbnova,Taipei,Taiwan)andanti-S127phospho-YAP1(CellSignaling,Danvers,MA)antibodies,thenvisu-alizedusinganECLdetectionkit(GEHealthcare,AmershamPlace,UK).ImmunoﬂuorescentmicroscopicanalysisNCI-H290cellsweretransfectedwithexpressionvectorsfortheenhancedgreenﬂuorescentprotein(EGFP)-fusedYAP1wild-typeorS127AmutanttogetherwithV5-taggedNF2oranemptyvectorandculturedoncoverglassslides.Thetransfectedcellswerethenﬁxed,permeabilizedandincubatedwithanti-V5andAlexaFluor568-conjugatedanti-mouseantibodiesandexaminedwithaconfocalmicroscope(LSM510,CarlZeissMicroImagingGmbH,Jena,Germany).Immunoprecipitationandinvitropull-downassaysForimmunoprecipitationanalyses,293TcellsweretransfectedwiththeEGFP-fusedwild-typeorS127AmutantYAP1constructstogetherwithV5-taggedNF2oranemptyvector.Immunoprecipitatesoflysatestransfectedwiththeanti-V5antibodyweresubjectedtoSDS–polyacrylamidegelelectrophoresisandimmunoblottingwithvariousantibodies.Forinvitropull-downassays,humanNF2full-lengthcDNAswereinsertedintoapGEX-KGvector(AmershamPharmaciaBiotech,Uppsala,Sweden)toexpressbacterialglutathioneS-transferase(GST)–Merlinfusionprotein.GST–MerlinorGST-aloneproteinswerepuriﬁedfromthetransformedbacteriallysatesbyincubationwithglutathionesepharosebeads(GEHealthcare).TheYAP1proteinexpressedwithaninvitrotranscription/translationsystem(Promega,Madison,WI)orcelllysateof293Ttransfectantswereincubatedwithbeadscontaining3lgofimmobilizedGST-aloneorGST–Merlinfusionproteinsfor3hat4°C,thenwashedfourtimes.ProteinsboundtoGSTproteinswereelutedbyboilinginSDSsamplebuffer,thenseparatedbySDS–poly-acrylamidegelelectrophoresisandimmunoblottedwithvariousantibodies.ResultsPrecisemappingof11q22ampliﬁcationregioninmalignantmesotheliomasWepreviouslyreportedtheresultsofgenome-widearrayCGHanal-ysesofMPMsderivedfrom22individuals,inwhichitwasnotablethattwoprimaryMPMcases(KD1033andKD1041)showedtwodiscreteandsigniﬁcanthigh-levelampliﬁcationsinthechromosome1p32and11q22regions(18).SincewedemonstratedthattheJUNproto-oncogeneresidedinthe1p32ampliﬁcationregion,whoseex-pressionwasshowntobeinducedbyasbestosexposureinratpleuralmesothelialcells(23)andwhoseampliﬁcationwasrecentlydemon-stratedinaggressivesarcomas(24),wespeculatedthatthe11q22ampliﬁcationregionmayalsoharboranimportanttargetgenewhoseoverexpressionisinvolvedinMPMcellgrowth.Toidentifythetargetgene,wepreciselydeterminedtheextentoftheampliﬁedregionsfromthesetwocasesthatwereoverlappedandboundedbyRP11-40B14andRP11-652L13BACprobes,withonlytwoBACprobes(RP11-203C2andRP11-864G5)includedbetweenthem(Figure1A).WithquantitativePCRanalysisusingTaqManprobes,thecopynum-bersofsevengenes(PGR,TRPC6,ANGPTL5,YAP1,BIRC2,MMP13andAB08258)whichdispersedwithinthe3-Mb-longregionwereinvestigated.Asexpected,bothtumorswereshowntocarryhighcopynumbersoftheANGPTL5,YAP1,BIRC2andMMP13genes,whilenogainsweredetectedinTRPC6andAB08258genes,indicatingthattheextentofthecommonampliﬁcationregionwas1Mbinlengthincluding14candidategenes(Figure1B).Inaddition,comparingwitheachgeneampliﬁcationlevelcarefully,bothANGPTL5andYAP1showedabouta2-foldgreaterincreaseincopynumbersthanBIRC2andMMP13inKD1033,whileeachampliﬁcationlevelofthefourgeneswassimilarinKD1041(Figures1Band2C).Thisresultsuggestedthattheampliﬁcationofthecentromerichalfregionin-cludingANGPTL5andYAP1mightbemoreimportantthanthatoftelomericregionincludingtheBIRC2andMMPclusterduringthedevelopmentofthoseMPMs,atleastinKD1033.OverexpressionofYAP1andBIRC2inmalignantmesotheliomasTodeterminewhichgeneresidinginthe1MbampliﬁcationregionwasthemostresponsibleforthedevelopmentoftheseMPMcases,wenextstudiedtheexpressionlevelsofeachgeneusingreal-timereversetranscription–PCRanalysis.Amongthefourgenesinthecentromerichalfampliﬁcationregion,ANGPTL5,YAP1andBIRC2wereoverex-pressedinKD1033,whereasYAP1,BIRC2andBIRC3inKD1041,indicatingthatonlyYAP1andBIRC2,butnotANGPTL5orBIRC3,werecommonlyoverexpressedinthesetumors(Figure2A).TheseresultsstronglysuggestthatthemostprobabletargetgenesinthisampliﬁcationregionareYAP1andBIRC2.Meanwhile,wealsoex-aminedtheexpressionlevelsofseveralMMPclustergenes,butdidnotdetectanyoverexpression,againsuggestingthatampliﬁcationofthetelomerichalfregionwasnotsigniﬁcant(datanotshown).TheimmunohistochemicalstainingresultsalsoclearlydemonstratedtheoverexpressionofYAP1inKD1033(Figure2B,leftpanel),thoughnormalpleuralmesothelialcellsdidnotshowanyYAP1signals(arrowheadsinFigure2B,rightpanel).Next,todeterminewhetherotherMPMsnotshowntohaveclearampliﬁcationinBAC/P-1phagederivedartiﬁcialchromosomearrayCGHanalysismayalsohaveamoreconﬁnedampliﬁcationorde-regulationoftheYAP1andBIRC2genes,weexaminedthecopynumbersaswellasexpressionlevelsofthesegenesusing12addi-tionalprimaryMPMcases(Figure2CandD)and13MPMcelllines(datanotshown).However,ampliﬁcationofthesegenesintheseMPMspecimensandcelllineswasnotdetected,exceptforKD1033andKD1041,norwastheresigniﬁcantupregulationoftheothersobserved(Figure2CandD).TheseresultssuggestthateventhoughsigniﬁcantoverexpressionoftheYAP1andBIRC2genescanoccur,ampliﬁcationofthesegenesisarelativelyinfrequenteventinMPMs.InvolvementofYAP1inmesothelialcellproliferationTodeterminecancer-promotingrolesofthesegenesinmesotheliomacells,weﬁrstfocusedontheYAP1genesinceitspositiverolehasalsobeensuggestedinothermalignancies(25,26).WesynthesizedtwoYAP1-RNAivectors,YAP1-sh1andYAP1-sh2,tosuppressendoge-nousYAP1expression,ascramblecontrolvector,YAP1-scr1,andaGFP-RNAivector,GFP-sh.ThesevectorsweretransfectedintoMPMcelllineNCI-H290cells,andexpressionlevelsofendogenousYAP1proteinwereexamined.BothYAP1-RNAivectorseffectivelyreducedtheexpressionlevelsofYAP1to30and10%,respectively,whereasthecontrolvectors(GFP-shandYAP1-scr1)didnotdemon-strateanysuppression(Figure3A).WethenstudiedtheeffectsofYAP1-RNAioncellproliferationofmesothelioma.BothYAP1-RNAivectorsdemonstratedsigniﬁcantsuppressionofcellproliferation,withYAP1-sh2showingcompleteabolitionofcellproliferation(Figure3B).FlowcytometryanalysisrevealedthatcellstransfectedbyYAP1-sh2showedG1arrestandinductionofasub-G1populationT.Yokoyamaetal.2140andthosebyYAP1-sh1amoderateinductionofthesub-G1population(Figure3CandD).Incontrast,thecontrolvectorsdidnotshowanygrowth-suppressiveeffect.Furthermore,wetransfectedaYAP1expressionvectorintotheimmortalizedmesothelialcelllineMeT-5AtoﬁgureoutwhetherYAP1hasgrowth-promotingactivityinmesothelialcells.YAP1over-expressionmoderatelysupportedcellproliferationinalow-serumconditionof1%fetalcalfserum,whereasitdidnotdemonstrateclearpromotionofcellproliferationintheusualcondition(fetalcalfserum5%)(Figure3E).FunctionalinteractionbetweenYAP1andMerlinSincetheMerlin-encodingNF2geneisfrequentlyalteredinMPMs,andtheMerlin–Hippo–WartspathwayinDrosophilaisknowntonegativelyregulateYorkie,theDrosophilaorthologofYAP1throughitsphosphorylation(27),theresultsshownabovestronglysuggestedthatMerlin,asanupstreammolecule,mayfunctionallyinteractwithandalsosuppressYAP1inhumanmesothelialcells.Inordertoconﬁrmthishypothesis,wecotransfectedtheNF2andYAP1expressionvectorsintoNCI-H290cellscarryingahomozygousde-letionoftheNF2geneandstudiedwhetherexogenousMerlinhasaneffectonthephosphorylationstatusofYAP1usingtheantibodyagainstphosphorylatedserine127(S127)ofYAP1,acriticalphos-phorylationsitethathasbeenindicatedtoinduceinactivationofYAP1astranscriptioncoactivatorthroughtheinductionofcytoplas-micretention(21).Wefoundthatcotransfectionsigniﬁcantlyin-ducedthephosphorylationofYAP1atS127(Figure4A).TofurtherdemonstrateYAP1S127phosphorylationbytheactivatedformofMerlin,wealsosynthesizedlentivirusvectorsforfull-lengthNF2andtruncatedfour-point-one/ezrin/radixin/moesin(FERM)-NF2whichtranslates340aminoacidsoftheaminoterminalandtransfectedintoNCI-H290cells.Asexpected,S127phosphoryla-tionofYAP1wasinducedbyfull-lengthNF2inadose-dependentmanner,butnotwithtruncatedFERM-NF2(Figure4B).Next,wedeterminedwhetherphosphorylationofYAP1proteininduceditscytoplasmiclocalization,resultinginYAP1inactivationasatranscriptionalcoactivator.WetransfectedNCI-H290cellswithEGFP-fusedwild-typeorS127AmutantYAP1,togetherwithNF2oranemptyvector,andstudiedthesubcellularlocalizationusingimmu-noblotting(Figure4C)andimmunoﬂuorescence(Figure4D).Immu-noblottingoffractionatedlysates,alsodepictedasabargraphintheﬁgure,clearlyshowedthatwild-typephospho-YAP1wasscarcelydetectableinthenuclearfractions,whereasthetotalYAP1proteinwaslocalizedinboththenucleusandcytoplasm(Figure4C).Inaddition,thenuclearproportionofmutantYAP1washigherthanthatofwild-typeYAP1(Figure4C).TheseresultssuggestedthatFig.1.Mappingofampliﬁedregionof11q22locusintwoMPMcases.(A)Detailsofarray-CGHresultsof11q22ampliﬁcationintwoMPMcases.ThesignalratiosfromarrayCGHanalysesoftwoprimaryMPMcases(KD1033andKD1041)wereplottedforallBACclonesbasedonchromosomeposition,andtheresultsindicateddiscreteandsigniﬁcantampliﬁcationsatthe11q22region.Ampliﬁcationsinbothcasesweresimilarwithina3-Mb-longregion,whichwasboundedbyRP11-40B14andRP11-652L13,andincludedonlytwoBACprobes(RP11-203C2andRP11-864G5),representedbyopensquaresandcloseddiamonds,respectively.(B)CopynumberanalysesusingquantitativePCRwithTaqManprobes.Genesandregisteredtranscriptswithinthe3-Mb-longregionareshown.Tofurtherdeterminetheboundariesoftheampliﬁedregions,thecopynumbersofsevengenes(PGR,TRPC6,ANGPTL5,YAP1,BIRC2,MMP13andAB08258,indicatedbyboxes)wereinvestigatedusingTaqManprobes.Fourgenes(ANGPTL5,YAP1,BIRC2andMMP13)showedhighcopynumbersinthetwoMPMcases,suggestingthatbothcarriedquitesimilar1-Mb-longampliﬁcations.YAP1isinvolvedinmesotheliomadevelopmentandnegativelyregulatedbyMerlinthroughphosphorylation2141phosphorylationnegativelyregulatesnuclearlocalizationandtran-scriptionalactivityofYAP1protein.AlthoughMerlininducedphos-phorylationofYAP1,thenuclearproportionofwild-typetotalYAP1wasnotsigniﬁcantlyreduced,probablybecauseoftheexistenceofYAP1-alonetransfectants.Next,weperformedimmunoﬂuorescencetofurtherconﬁrmthatthesubcellularlocalizationofYAP1proteinisdependentonphos-phorylationinducedbyMerlin.NCI-H290cellsweretransfectedwithanEGFP-fusedwild-typeorS127AmutantYAP1construct,togetherwithNF2oranemptyvector.Boththewild-typeandmu-tantYAP1proteinswerefoundtobelocalizedinboththenucleiandcytoplasmoftheemptyvector-cotransfectedcells(Figure4D).Incontrast,cotransfectionoftheNF2vectorclearlyreducednuclearlocalizationofthewild-typeYAP1proteins,butnotthemutantYAP1protein.Inaddition,immunohistochemicalstainingofnuclearaccumulationofYAP1intheMPMcasewithYAP1geneampliﬁ-cation(arrowheadsinFigure2B,leftpanel)alsosupportedtheideathatYAP1localizationinnucleiofthetestedcelllineswasnotduetoanartiﬁcialevent.PhysicalinteractionbetweenYAP1andMerlinSincethesetransfectionexperimentsindicatedafunctionalrelation-shipbetweenMerlinandYAP1,wenextstudiedwhetherthesemol-eculesphysicallyinteractwitheachother.WeimmunoprecipitatedMerlinfromthelysatesof293TcellsthatwerecotransfectedwithNF2and/orYAP1expressionvectorsandtheninvestigatedwhetherYAP1couldbecoprecipitatedwithMerlin(Figure5A).TheresultsclearlydemonstratedthecoprecipitationofYAP1withMerlin,indi-catingaphysicalinteractionbetweenthem.Interestingly,theanti-phospho-YAP1antibodydidnotshowanysignals,whiletheS127AmutantYAP1alsointeractedwithMerlinasdidwild-typeYAP1(Figure5A),suggestingthatMerlinmayalsointeractwithunphos-phorylatedYAP1.Fig.2.AlterationsofcopynumberandexpressionofYAP1andBIRC2.(A)ExpressionanalysesoftheANGPTL5,YAP1,BIRC2andBIRC3genesindicatedthatYAP1andBIRC2wereoverexpressedincommoninbothMPMcaseswithampliﬁcation.(B)ImmunohistochemicalstainingofYAP1.ImmunohistochemicalanalysisclearlydemonstratedoverexpressionandnuclearaccumulationofYAP1inKD1033(leftpanel),whereasnormalpleuralmesothelialcellsdidnotshowanyYAP1signals(arrowheads,rightpanel).(C)ExpressionanalysisinprimaryMPMcases.Inanexaminationof14primaryMPMcasesandthenormalmesothelialcelllineMeT-5A,thetwoMPMcasesshowedthegreatestamountofupregulatedexpressionsoftheYAP1andBIRC2geneswithampliﬁcation.(D)CopynumberanalysisofprimaryMPMcases.Inanexaminationof14MPMcasesandthenormalmesothelialcelllineMeT-5A,onlythetwoMPMcasesdemonstratedampliﬁcationoftheYAP1andBIRC2genes.T.Yokoyamaetal.2142TofurtherconﬁrmthephysicalinteractionbetweenYAP1andMerlin,wepreparedGST-aloneorGST—Merlin-boundglutathionebeadsandthenperformedinvitropull-downassays(Figure5B).First,weconductedapull-downassayusinginvitro-translatedYAP1pro-tein;however,noassociationbetweenYAP1andGST–Merlinwasdetected(SupplementaryFigure1),whichsuggestedthatYAP1wasnotdirectlyassociatedwithMerlin.Next,weperformedapull-downassayusingthelysateof293TcellstransfectedwiththeYAP1ex-pressionvector,asweconsideredthatthecelllysatepossiblycon-tainedendogenousmoleculesthatcouldbridgeYAP1andMerlin.Thepull-downassayusingthe293TcelllysateclearlydemonstratedthatYAP1wasassociatedwithGST–Merlin(Figure5B,lane2).Inaddi-tion,wealsostudiedtheeffectsofNHERF1/ezrin/radixin/moesin-bindingphosphoprotein50kDbecauseitwasreportedtobeassoci-atedwithYAP1(28)aswellaswithMerlin(29),andweconsideredthatitmightbridgetheYAP1andMerlinproteins.However,NHERF1seemedunabletoenhancetheYAP1–Merlinassociation,thoughNHERF1boundtoGST–Merlin(Figure5B,lane4).TheseresultsindicatethatYAP1isindirectlyassociatedwithMerlin,prob-ablythroughanendogenousbridgingmoleculeotherthanNHERF1.DiscussionInthepresentstudy,wedemonstratedthattheYAP1geneislocalizedinthehigh-level11q22ampliﬁcationregion,whichwepreviouslyreportedinastudyoftwocaseswithMPMs,andthatYAP1togetherwithBIRC2areoverexpressedinthesetumors.WealsofoundthatupregulationofYAP1inducedmesothelialcellproliferation,whereasitsdownregulationinhibitedthatproliferation.Furthermore,Merlin-dependentphosphorylationinhibitsthenuclearlocalizationofYAP1,whichmightresultininactivationofYAP1transcriptionalactivity.Ampliﬁcationsatthe11q22locushavebeenreportedforseveraldifferenttypesofhumancancer(25,30–33).Ampliﬁcationsatmousechromosome9qA1,thesyntenicregionofhumanchromosome11q22,havealsobeenshowninmousemammaryandlivercancers(25,26).Furthermore,duringpreparationofthepresentmanuscript,MPMcelllinescarryingchromosomalgainatthe11q22locuswerealsoreported(34).Theseﬁndings,togetherwithourpreviousarrayCGHanalysisonmalignantmesotheliomas,suggestedasigniﬁcantrolefor11q22ampliﬁcationincarcinogenesis.Inthepresentstudy,wedemonstratedthat,amongtheseveralcandidateoncogenesatthe11q22ampliﬁcationregion,boththeYAP1andBIRC2geneswerecommonlyoverexpressedinthetwoMPMtissues,suggestingthatYAP1andBIRC2werethemostlikelytargetgenes.WefocusedonYAP1primarilybecausepreviousreportshavesuggesteditsonco-genicactivityofYAP1(25,26).InvitrotransfectionassaythatutilizedknockdownoroverexpressionofYAP1indicatedthatYAP1promotesgrowthofmesotheliallineagecells,andcotransfectionexperimentsstronglysuggestedthatMerlininhibitsthetranscriptionalactivatoractivityofYAP1throughinductionofphosphorylationandinhibitionFig.3.InvolvementofYAP1incellproliferation.(A)KnockdownofendogenousYAP1inMPMcelllineNCI-H290.BothYAP1-RNAivectors,YAP1-sh1andYAP1-sh2,showedeffectivesuppressionofthelevelofYAP1protein,whereasthecontrolvectors,GFP-shandYAP1-scr1,showednoinhibition.(B)InhibitionofNCI-H290proliferationbyYAP1-RNAi.ColorimetricassayresultsdemonstratedthatboththeYAP1-sh1andYAP1-sh2vectorsinducedsigniﬁcantsuppressionofcellproliferation.YAP1-sh2inhibitedproliferationtoagreaterdegreeascomparedwithYAP1-sh1,consistentwiththeRNAieffect.(C)Cell-cyclearrestbyYAP1-RNAi.YAP1-sh2clearlyinducedG1arrestofNCI-H290cells.(D)Inductionofsub-G1populationbyYAP1-RNAi.Thesub-G1populationofNCI-H290cellswasinducedbybothYAP1-RNAivectors,thoughinductionbyYAP1-sh2wasgreater.(E)PromotionofMeT-5AcellproliferationbyYAP1overexpression.AlthoughYAP1overexpressiondidnotshowacleareffectintheusualcondition[fetalcalfserum(FCS)5%],YAP1overexpressionmoderatelypromotedcellproliferationinthelow-serumcondition(FCS1%).YAP1isinvolvedinmesotheliomadevelopmentandnegativelyregulatedbyMerlinthroughphosphorylation2143ofnuclearlocalization.Toourknowledge,thepresentresultsaretheﬁrsttoshowthatYAP1isregulatedbyMerlinthroughinductionofphosphorylation,indicatingthatYAP1isadownstreameffectorofMerlintumorsuppressorsignalinginmammals.OurﬁndingsalsosuggestthatYAP1mayplayacrucialroleinMPMdevelopmentbecauseMerlintumorsuppressorsignalingisfrequentlyalteredinthosetumors.RecentgeneticandbiochemicalanalysesofDrosophilademon-stratedthatcellproliferationandorgansizearenegativelyregulatedbyakinasecascadeofHippoandWarts(alsocalledLats)andthattwomembrane-associatedproteins,MerlinandExpanded,functionup-streamofthiskinasecascade(35).Yorkie,theDrosophilaorthologofYAP1,isacriticaltargetofthegrowth-inhibitoryHippo–Warts/Latskinasecascadeandapotentialoncogenebecauseitsoverexpres-sioninducestissueovergrowthandapoptosisinhibitionthroughthetransactivationofcycEanddiap1expression(27,36).Drosophilarescueexperimentsalsoindicatedevolutionaryconservationofthesignalingcomponents,thatisthemammalianLATS1,MOB1,MST2andYAPgenes,whichareorthologsoftheDrosophilaWarts,Mats,HippoandYorkigenes,respectively.Duringthepreparationofthismanuscript,Zhaoetal.(37)clearlydemonstratedthattheS127phosphorylationofYAP1wascatalyzedbyLATS1andthatYAP1inactivationplayssigniﬁcantrolesincellcontactinhibitionandtissuegrowthregulation.However,thesignalingpathwayfromMerlintoYAP1hasnotbeenclearlydemonstratedinmammaliancells.YAP1hasbeenreportedtobindtoandregulatetheactivitiesofvarioustranscriptionalregulators,includingp73,RUNX2,ERBB4,andseveralTEAdomain/transcriptionenhancerfactor-typetranscrip-tionfactors,andalsoshowntofunctionasanoncogeneinmammals(25,26),possiblythroughanassociationwithRUNX2(38,39)andERBB4(19,40).YAP1isphosphorylatedatS127,leadingtoitsassociationwith14-3-3,whichsequestratesYAP1inthecytoplasmandinhibitsitscoactivatoractivity(21,41).Thepresentresultsdem-onstratedthatMerlininducesphosphorylationofYAP1S127andinhibitsitsnuclearlocalization.Merlin–YAP1signalingisconceiv-able,because,basedonconservedDrosophilasignaling,MerlinmayactivatetheMST2–LATS1kinasecascade,whileitalsoappearstobindtounphosphorylatedYAP1protein.Fig.4.FunctionalinteractionbetweenYAP1andMerlin.(AandB)InductionofYAP1phosphorylationbyMerlin.(A)NF2-nullNCI-H290cellsweretransfectedwithYAP1andNF2expressionvectors.CotransfectionofNF2signiﬁcantlyinducedphosphorylationoftheYAP1S127residue.(B)Eitherfull-lengthortruncatedNF2wasintroducedintoNCI-H290cellswithalentivirus.PhosphorylationofYAP1wasinducedbythefull-lengthNF2lentivirusinadose-dependentmanner,whereasthetruncatedNF2FERMlentivirusdidnothaveanycleareffect.(C)Immunoblottingofcytoplasmicandnuclearfractions.NCI-H290cellsweretransfectedwithwild-type(wt)orphosphorylation-defectiveS127Amutant(mut)YAP1andNF2expressionvectors.Immunoblotsofnuclearandcytoplasmicfractionsoftransfectantsclearlyshowedthatphospho-YAP1wasmainlylocalizedinthecytoplasm,asdetectedbytheanti-S127phospho-YAP1antibody,thoughtotalYAP1waslocalizedinboththenucleusandcytoplasm.Inaddition,thenuclear/cytoplasmicratioofYAP1andphospho-YAP1proteinswasmeasuredwithadensitometerandindicatedwithabargraph,whichclearlydemonstratesthetightcytoplasmicretentionofwild-typephospho-YAP1protein.NosignalsweredetectedinmutantYAP1transfectantswiththeanti-phospho-YAP1antibody(asterisks).Resultsofimmunoblottingwithantibodiesagainsta-tubulinandnuclearlaminB1indicatedthatproperfractionationoccurred.(D)ReductionofYAP1nuclearlocalizationbyNF2.NCI-H290cellsweretransfectedwithexpressionvectorsoftheEGFP-fusedwild-type(wt)orS127Amutant(mut)YAP1,togetherwiththevectorcontrolorV5-taggedNF2.Boththewild-typeandmutantYAP1proteinslocalizeinboththenucleiandcytoplasmofH290cells.CotransfectionofNF2reducednuclearlocalizationofwild-typeYAP1,whereasthelocalizationofmutantYAP1wasnotaffectedbyNF2.Fig.5.PhysicalinteractionbetweenYAP1andMerlin.(A)Immunoprecipitation:293TcellsweretransfectedwithV5-taggedNF2and/orYAP1expressionvectors,thenMerlinwasimmunoprecipitatedwiththeanti-V5antibodyandcoprecipitationwithYAP1wasstudied.Bothwild-typeandS127AmutantYAP1werecoprecipitatedwithMerlin.Theanti-phospho-YAP1antibodydidnotshowanyclearsignals.(B)Invitropull-downassay.Celllysatesof293TcellsweretransfectedwithaYAP1orNHERF1vector,thenincubatedwithGST-aloneorGST—Merlin-boundbeads.Immunoblotsofbead-boundproteins(Bound)andtheinitialcelllysates(Input)areshown.BothYAP1andNHERF1proteinsboundtoGST–Merlin,thoughNHERF1didnotenhancetheassociationofYAP1withGST–Merlin.IntheimmunoblotofboundNHERF1,non-speciﬁcbandsareindicatedbyasterisks.T.Yokoyamaetal.2144YAP1hasalsobeenreportedtopromoteapoptosisthroughanassociationwithp73(21,42,43).Inaddition,arecentreportdemon-stratedthatLATS1wasactivatedbytumorsuppressorRASSF1AtophosphorylateYAP1andpromotenuclearlocalizationoftheYAP1–p73complex,resultinginapoptosisinduction(44).Therefore,YAP1maypromotebothcellgrowthandapoptosis,dependingontheasso-ciatedtranscriptionfactors.Inthiscontext,overexpressionofBIRC2andBIRC3genes,whichcolocalizeat11q22andencodeapoptosisinhibitors,mightbeessentialforexhibitionoftheoncogenicactivityofYAP1incancerswith11q22ampliﬁcation,withourcasesbeingconsistentwiththisidea.TheNF2geneisfrequentlyinactivatedinMPMs,indicatingthatdownregulationofMerlinsignalingisessentialforMPMdevelop-ment.TheantiproliferativeeffectofMerlininNF2-deﬁcientmeso-theliomacellshasbeensuggestedtobeinducedbyrepressingcyclinD1expression(45),attenuatingfocaladhesionkinasephosphoryla-tion(46)orinteractingwithNF2-associatedguanosinetriphosphate-bindingprotein(47).Nf2(þ/ )miceexposedtoasbestosexhibitacceleratedformationofhighlymalignantmesothelialtumors(48,49).Inaddition,inarecentstudy,conditionalknockoutmousemodelsdevelopedbyinactivatingNf2togetherwithp16Ink4a/p19arf,p53orboth,developedmalignantmesotheliomasatahighinci-dence,supportingthenotionthatNf2inactivationisimportantforthepathogenesisofthesetumors(50).OurresultsrevealedthattheYAP1genecanalsobeanactivatingtargetforasubsetofMPMs,whichwascoincidentallyfoundtobeadownstreameffectoroftheMerlincascade.However,thoughYAP1maybeimportantinthesubsetofMPMwith11q22ampliﬁcation,itsrelevanceinthevastmajorityofMPMcasesisunknownatpresent.Therefore,preciseanalysisoftumorsuppressorsignalinginNF2–MST–WARTS/LATS–YAP1isneededtoshedlightonthemolecularmechanismsofMPMdevelopmentingreaterdetail.Preliminaryanalysisofim-munohistochemicalstainingofYAP1revealedoverexpressionandnuclearlocalizationofYAP1inasubsetofMPMcases,indicatingthefrequentinvolvementofYAP1inMPMdevelopment.Neverthe-less,thepresentresultsprovidenewinsightsintogeneticalterationsinMPMsandcluesfordevelopmentofanewmoleculartargettherapyforpatientswiththesetumors.SupplementarymaterialSupplementaryFigure1canbefoundathttp://carcin.oxfordjournals.org/FundingSpecialCoordinationFundforPromotingScienceandTechnologyfromtheMinistryofEducation,Culture,Sports,ScienceandTech-nology(H18-1-3-3-1);Grant-in-AidforScientiﬁcResearchfromJapanSocietyforthePromotionofScience(18390245).AcknowledgementsWethankDrMasashiKondoandDrNoriyasuUsamifortheirhelpfulcom-mentsandspecialencouragement.DrMaria-MagdalenaGeorgescuandDrMarthaC.Nowyckyfortheconstructs,andDrAdiFGazdarforthecellline.ConﬂictofInterestStatement:Nonedeclared.References1.Carbone,M.etal.(2002)Thepathogenesisofmesothelioma.Semin.Oncol.,29,2–17.2.Pass,H.I.etal.(2004)Malignantpleuralmesothelioma.Curr.Probl.Cancer,28,93–174.3.Robinson,B.W.etal.(2005)Advancesinmalignantmesothelioma.N.Engl.J.Med.,353,1591–1603.4.Ramos-Nino,M.E.etal.(2006)Cellularandmolecularparametersofme-sothelioma.J.Cell.Biochem.,98,723–734.5.Vogelzang,N.J.etal.(2003)PhaseIIIstudyofpemetrexedincombinationwithcisplatinversuscisplatinaloneinpatientswithmalignantpleuralmesothelioma.J.Clin.Oncol.,21,2636–2644.6.vanMeerbeeck,J.P.etal.(2005)RandomizedphaseIIIstudyofcisplatinwithorwithoutraltitrexedinpatientswithmalignantpleuralmesotheli-oma:anintergroupstudyoftheEuropeanOrganisationforResearchandTreatmentofCancerLungCancerGroupandtheNationalCancerInstituteofCanada.J.Clin.Oncol.,23,6881–6889.7.Ascoli,V.etal.(2001)DNAcopynumberchangesinfamilialmalignantmesothelioma.CancerGenet.Cytogenet.,127,80–82.8.Sugarbaker,D.J.etal.(2008)Transcriptomesequencingofmalignantpleu-ralmesotheliomatumors.Proc.NatlAcad.Sci.USA,105,3521–3526.9.Ladanyi,M.(2005)ImplicationsofP16/CDKN2Adeletioninpleuralme-sotheliomas.LungCancer,49(suppl.1),S95–S98.10.Musti,M.etal.(2006)Cytogeneticandmoleculargeneticchangesinmalignantmesothelioma.CancerGenet.Cytogenet.,170,9–15.11.Pei,J.etal.(2006)High-resolutionanalysisof9plossinhumancancercellsusingsinglenucleotidepolymorphism-basedmappingarrays.CancerGenet.Cytogenet.,170,65–68.12.Sekido,Y.etal.(1995)Neuroﬁbromatosistype2(NF2)geneissomati-callymutatedinmesotheliomabutnotinlungcancer.CancerRes.,55,1227–1231.13.Bianchi,A.B.etal.(1995)Highfrequencyofinactivatingmutationsintheneuroﬁbromatosistype2gene(NF2)inprimarymalignantmesotheliomas.Proc.NatlAcad.Sci.USA,92,10854–10858.14.Cheng,J.Q.etal.(1999)FrequentmutationsofNF2andalleliclossfromchromosomeband22q12inmalignantmesothelioma:evidenceforatwo-hitmechanismofNF2inactivation.GenesChromosomesCancer,24,238–242.15.Baser,M.E.(2006)Thedistributionofconstitutionalandsomaticmutationsintheneuroﬁbromatosis2gene.Hum.Mutat.,27,297–306.16.Sun,C.X.etal.(2002)Protein4.1tumorsuppressors:gettingaFERMgripongrowthregulation.J.CellSci.,115,3991–4000.17.McClatchey,A.I.etal.(2005)Membraneorganizationandtumorigenesis—theNF2tumorsuppressor,Merlin.GenesDev.,19,2265–2277.18.Taniguchi,T.etal.(2007)Genomicproﬁlingofmalignantpleuralmeso-theliomawitharray-basedcomparativegenomichybridizationshowsfrequentnon-randomchromosomalalterationregionsincludingJUNampliﬁcationon1p32.CancerSci.,98,438–446.19.Komuro,A.etal.(2003)WWdomain-containingproteinYAPassociateswithErbB-4andactsasaco-transcriptionalactivatorforthecarboxyl-terminalfragmentofErbB-4thattranslocatestothenucleus.J.Biol.Chem.,278,33334–33341.20.Osada,H.etal.(2005)ASH1geneisaspeciﬁctherapeutictargetforlungcancerswithneuroendocrinefeatures.CancerRes.,65,10680–10685.21.Basu,S.etal.(2003)AktphosphorylatestheYes-associatedprotein,YAP,toinduceinteractionwith14-3-3andattenuationofp73-mediatedapopto-sis.Mol.Cell,11,11–23.22.Hayashita,Y.etal.(2005)ApolycistronicmicroRNAcluster,miR-17-92,isoverexpressedinhumanlungcancersandenhancescellproliferation.CancerRes.,65,9628–9632.23.Heintz,N.H.etal.(1993)Persistentinductionofc-fosandc-junexpressionbyasbestos.Proc.NatlAcad.Sci.USA,90,3299–3303.24.Mariani,O.etal.(2007)JUNoncogeneampliﬁcationandoverexpressionblockadipocyticdifferentiationinhighlyaggressivesarcomas.CancerCell,11,361–374.25.Zender,L.etal.(2006)Identiﬁcationandvalidationofoncogenesinlivercancerusinganintegrativeoncogenomicapproach.Cell,125,1253–1267.26.Overholtzer,M.etal.(2006)TransformingpropertiesofYAP,acandidateoncogeneonthechromosome11q22amplicon.Proc.NatlAcad.Sci.USA,103,12405–12410.27.Huang,J.etal.(2005)TheHipposignalingpathwaycoordinatelyregulatescellproliferationandapoptosisbyinactivatingYorkie,theDrosophilaHomologofYAP.Cell,122,421–434.28.Mohler,P.J.etal.(1999)Yes-associatedprotein65localizesp62(c-Yes)totheapicalcompartmentofairwayepitheliabyassociationwithEBP50.J.CellBiol.,147,879–890.29.Murthy,A.etal.(1998)NHE-RF,aregulatorycofactorforNa(þ)-Hþexchange,isacommoninteractorformerlinandERM(MERM)proteins.J.Biol.Chem.,273,1273–1276.30.Bissig,H.etal.(1999)Evaluationoftheclonalrelationshipbetweenprimaryandmetastaticrenalcellcarcinomabycomparativegenomichy-bridization.Am.J.Pathol.,155,267–274.31.Imoto,I.etal.(2001)IdentiﬁcationofcIAP1asacandidatetargetgenewithinanampliconat11q22inesophagealsquamouscellcarcinomas.CancerRes.,61,6629–6634.YAP1isinvolvedinmesotheliomadevelopmentandnegativelyregulatedbyMerlinthroughphosphorylation214532.Dai,Z.etal.(2003)AcomprehensivesearchforDNAampliﬁcationinlungcanceridentiﬁesinhibitorsofapoptosiscIAP1andcIAP2ascandidateoncogenes.Hum.Mol.Genet.,12,791–801.33.Baldwin,C.etal.(2005)Multiplemicroalterationsdetectedathighfre-quencyinoralcancer.CancerRes.,65,7561–7567.34.Zanazzi,C.etal.(2007)Geneexpressionproﬁlingandgenecopy-numberchangesinmalignantmesotheliomacelllines.GenesChromosomesCan-cer,46,895–908.35.Hamaratoglu,F.etal.(2006)Thetumour-suppressorgenesNF2/MerlinandExpandedactthroughHipposignallingtoregulatecellproliferationandapoptosis.Nat.CellBiol.,8,27–36.36.Pan,D.(2007)Hipposignalinginorgansizecontrol.GenesDev.,21,886–897.37.Zhao,B.etal.(2007)InactivationofYAPoncoproteinbytheHippopath-wayisinvolvedincellcontactinhibitionandtissuegrowthcontrol.GenesDev.,21,2747–2761.38.Yagi,R.etal.(1999)AWWdomain-containingyes-associatedprotein(YAP)isanoveltranscriptionalco-activator.EMBOJ.,18,2551–2562.39.Vitolo,M.I.etal.(2007)TheRUNX2transcriptionfactorcooperateswiththeYES-associatedprotein,YAP65,topromotecelltransformation.CancerBiol.Ther.,6,856–863.40.Aqeilan,R.I.etal.(2005)WWdomain-containingproteins,WWOXandYAP,competeforinteractionwithErbB-4andmodulateitstranscriptionalfunction.CancerRes.,65,6764–6772.41.Vassilev,A.etal.(2001)TEAD/TEFtranscriptionfactorsutilizetheacti-vationdomainofYAP65,aSrc/Yes-associatedproteinlocalizedinthecytoplasm.GenesDev.,15,1229–1241.42.Strano,S.etal.(2001)PhysicalinteractionwithYes-associatedproteinenhancesp73transcriptionalactivity.J.Biol.Chem.,276,15164–15173.43.Strano,S.etal.(2005)ThetranscriptionalcoactivatorYes-associatedpro-teindrivesp73gene-targetspeciﬁcityinresponsetoDNAdamage.Mol.Cell,18,447–459.44.Matallanas,D.etal.(2007)RASSF1AelicitsapoptosisthroughanMST2pathwaydirectingproapoptotictranscriptionbythep73tumorsuppressorprotein.Mol.Cell,27,962–975.45.Xiao,G.H.etal.(2005)TheNF2tumorsuppressorgeneproduct,merlin,inhibitscellproliferationandcellcycleprogressionbyrepressingcyclinD1expression.Mol.Cell.Biol.,25,2384–2394.46.Poulikakos,P.I.etal.(2006)Re-expressionofthetumorsuppressorNF2/merlininhibitsinvasivenessinmesotheliomacellsandnegativelyregulatesFAK.Oncogene,25,5960–5968.47.Lee,H.etal.(2007)IdentiﬁcationandcharacterizationofputativetumorsuppressorNGB,aGTP-bindingproteinthatinteractswiththeneuroﬁbro-matosis2protein.Mol.Cell.Biol.,27,2103–2119.48.Fleury-Feith,J.etal.(2003)HemizygosityofNf2isassociatedwithin-creasedsusceptibilitytoasbestos-inducedperitonealtumours.Oncogene,22,3799–3805.49.Altomare,D.A.etal.(2005)Amousemodelrecapitulatingmolecularfeaturesofhumanmesothelioma.CancerRes.,65,8090–8095.50.Jongsma,J.etal.(2008)Aconditionalmousemodelformalignantmeso-thelioma.CancerCell,13,261–271.ReceivedApril9,2008;revisedAugust10,2008;acceptedAugust20,2008T.Yokoyamaetal.2146BMB   ReportsBMB Rep. 2016; 49(7): 357-358www.bmbreports.org*Corresponding author. E-mail: ej70@uos.ac.krhttp://dx.doi.org/10.5483/BMBRep.2016.49.7.104Received 24 June 2016Keywords: LRP6, Merlin, NF2, PAK, Wnt/-cateninAbbreviations: dnPAK1, dominant-negative form of PAK1; NF2, Neurofibromatosis type II; PAK, p21 activated kinase; PIP2, phos-phatidylinositol 4,5 bisphosphate; Wnt-CM, Wnt3a-conditionedmediaPerspective to: Kim et al. (2016), Merlin inhibits Wnt/-catenin signaling by blocking LRP6 phosphorylation, Cell Death and Differentiation, 10 June 2016; doi:10.1038/cdd.2016.54ISSN: 1976-670X (electronic edition)Copyright ⓒ 2016 by the The Korean Society for Biochemistry and Molecular BiologyThis is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/li-censes/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Merlin, a regulator of Hippo signaling, regulates Wnt/-catenin signalingSoyoung Kim & Eek-hoon Jho*Department of Life Science, University of Seoul, Seoul 02504, KoreaMerlin, encoded by the NF2 gene, is a tumor suppressor that exerts its function via inhibiting mitogenic receptors at the plasma membrane. Although multiple mutations in Merlin have been identified in Neurofibromatosis type II (NF2) disease, its molecular mechanism is not fully understood. Here, we show that Merlin interacts with LRP6 and inhibits LRP6 phosphorylation, a critical step for the initiation of Wnt signaling. We found that treatment of Wnt3a caused phosphorylation of Merlin by PAK1, leading to detachment of Merlin from LRP6 and allowing the initiation of Wnt/-catenin signaling. A higher level of -catenin was found in tissues from NF2 patients. Enhanced proliferation and migration caused by knockdown of Merlin in glioblastoma cells were inhibited by suppression of -catenin. Conclusively, these results suggest that sustained Wnt/-catenin signaling activity induced by abrogation of Merlin-mediated inhibition of LRP6 phosphoryla-tion might be a cause of NF2 disease. [BMB Reports 2016; 49(7): 357-358]Merlin, a tumor-suppressive protein encoded by NF2 gene, is mainly localized to the plasma membrane. It interacts with a number of membrane proteins. Merlin exerts its tumor suppressive effects on multiple mitogenic signaling pathways via modulating interaction with growth factor receptors. Furthermore, Merlin activates the Hippo pathway and turns off YAP/TAZ mediated expression of genes involved in proliferation and anti-apoptosis (Pan et al. 2010. Dev cell 19, 491-505). Recent studies have suggested that Merlin can inhibit Wnt/-catenin signaling through inhibiting phosphorylation of -catenin, thus blocking the translocation of -catenin from membrane to nucleus by inhibiting dissociation of -catenin from adherens junction (Bosco et al. 2010. Oncogene 29, 2540-9; Zhou et al. 2011. Neoplasia 13, 1101-12). Although the functional relationship between growth factor receptor and Merlin has been extensively studied, the role of Merlin in Wnt/-catenin signaling at receptor level has not been demonstrated. Our study showed that active Merlin, a de-phosphorylated form of Merlin on Ser 518, is a binding partner of Wnt co-receptor LRP6. Interaction between Merlin and LRP6 was inhibited by incubation with Wnt-conditioned media (Wnt-CM). We also showed that knockdown of Merlin enhanced Wnt reporter activity whereas overexpression of Merlin inhibited Wnt reporter activity. In addition, secondary axis induced by the injection of a constitutive active form of LRP6 into ventral side of Xenopus embryos was significantly reduced by the co-injection of Merlin. Overall, these data suggest that Merlin can inhibit Wnt/-catenin signaling via interaction with LRP6.Except for Merlin, mutations in components of Hippo pathway are uncommon in human cancer. It seems that the increase in the level of YAP/TAZ alone may not be enough to cause human cancer. Additional mutations are required. Our results showed that not the level of YAP, a terminal regulator of Hippo pathway, but -catenin was significantly increased in all schwannomas isolated from NF2 patients compared to that in normal adjacent tissues. We found that enhanced glioblastoma cell growth and migration induced by the suppression of Merlin were restored by depletion of -catenin. Thus, our data illustrate that NF2 disease with Merlin mutations might be caused mainly by the activation of Wnt/-catenin signaling in addition to enhanced YAP/TAZ signaling.LRP6 phosphorylation is critical for the activation of Wnt/-catenin signaling. We showed that Merlin interacted with LRP6 and suppressed Wnt/-catenin signaling upstream of -catenin by blocking phosphorylation of LRP6. We have previously demonstrated that formation of PIP2 by Arf1, a small G protein, is necessary for the phosphorylation of LRP6 (Kim et al. 2013. Oncogene 32, 3390-3396). Similarly, our current finding revealed that PIP2 could be used as a docking Perspective Merlin, a regulator of Hippo signaling, regulates Wnt/-catenin signalingSoyoung Kim and Eek-hoon Jho358BMB Reportshttp://bmbreports.orgFig. 1. Schematic model. (A) Wnt-off condition. In the absence of Wnt or below a certain threshold of Wnt, active merlin bind to LRP6 and inhibits Wnt/-catenin signaling. (B) In the presence of Wnt, the level of PIP2 is increased, which could be used as a docking site for PAK1. Active PAK1 phosphorylates Merlin on Ser518, resulting in detachment of Merlin from LRP6 and allowing activation of LRP6 for the initiation of Wnt/-catenin signaling.site for PAK1 (p21 activated kinase). In the presence of Wnt3a-CM, activated PAK1 (p21 activated kinase) can bind to PIP2 and phosphorylate Merlin on Ser 518, thus inducing the detachment of Merlin from LRP6 and allowing phosphorylation of LRP6 for the initiation of Wnt/-catenin signaling (Fig. 1). Overall, our current study reveals that active Merlin can bind to LRP6 and inhibit the initiation of Wnt/-catenin signaling, which may block non-specific activation of Wnt/- catenin signaling until the level of Wnt ligand is above certain threshold. Although we showed that the detachment of Merlin from LRP6 allowed the activation of Wnt/-catenin signaling, the role of detached Merlin from LRP6 in the regulation of Hippo signaling needs to be further studied in the future. Specific regulation of Wnt/-catenin signaling with minimal influence of other signaling pathways is extremely valuable for the purpose of developing therapeutics. Small molecules that may control the interaction between Merlin and LRP6 could be very specific modulators of Wnt/-catenin signaling. ACKNOWLEDGEMENTS This work was supported by the 2015 Research Fund of the University of Seoul, Korea. Merlin/NF2SuppressesTumorigenesisbyInhibitingtheE3UbiquitinLigaseCRL4DCAF1intheNucleusWeiLi,1,8LiruYou,1,8JonathanCooper,1,4GaiaSchiavon,1AngelaPepe-Caprio,1LuZhou,5RyoheiIshii,6MarcoGiovannini,7C.OliverHanemann,5StephenB.Long,2HediyeErdjument-Bromage,3PengboZhou,6PaulTempst,3andFilippoG.Giancotti1,*1CellBiologyProgram2StructuralBiologyProgram3MolecularBiologyProgramMemorialSloan-KetteringCancerCenter,NewYork,NY10065,USA4Sloan-KetteringDivision,WeillGraduateSchoolofMedicalSciences,CornellUniversity,NewYork,NY10065,USA5PeninsulaCollegeofMedicineandDentistry,UniversityofPlymouth,PlymouthPL68BU,UK6DepartmentofPathologyandLaboratoryMedicine,WeilCornellMedicalCollege,NewYork,NY10065,USA7HouseEarInstitute,CenterforNeuralTumorResearch,LosAngeles,CA90057,USA8Theseauthorscontributedequallytothiswork*Correspondence:f-giancotti@ski.mskcc.orgDOI10.1016/j.cell.2010.01.029SUMMARYCurrentmodelsimplythattheFERMdomainproteinMerlin,encodedbythetumorsuppressorNF2,inhibitsmitogenicsignalingatorneartheplasmamembrane.Here,weshowthattheclosed,growth-inhibitoryformofMerlinaccumulatesinthenucleus,bindstotheE3ubiquitinligaseCRL4DCAF1,andsuppressesitsactivity.DepletionofDCAF1blocksthepromitogeniceffectofinactivationofMerlin.Conversely,enforcedexpressionofaMerlin-insensi-tivemutantofDCAF1counteractstheantimitogeniceffectofMerlin.Re-expressionofMerlinandsilencingofDCAF1implementasimilar,tumor-suppressiveprogramofgeneexpression.Tumor-derivedmutationsinvariablydisruptMerlin’sabilitytointeractwithorinhibitCRL4DCAF1.Finally,deple-tionofDCAF1inhibitsthehyperproliferationofSchwannomacellsfromNF2patientsandsuppressestheoncogenicpotentialofMerlin-deﬁ-cienttumorcelllines.WeproposethatMerlinsuppressestumorigenesisbytranslocatingtothenucleustoinhibitCRL4DCAF1.INTRODUCTIONThetumorsuppressorNF2,whichisinactivatedinthefamilialcancersyndromeNeuroﬁbromatosistype2,encodesforMerlin,amemberoftheEzrin/Radixin/Moesin(ERM)familyofproteins.TheprevalenceofNF2mutationsinsporadictumors,especiallySchwannomas,meningiomas,andmalignantmesotheliomas,andthepredispositionofheterozygousNf2mutantmicetodevelopmultiplemalignanttumortypessuggestthatMerlinhasarelativelybroadtumor-suppressorfunction(McClatcheyandGiovannini,2005;Okadaetal.,2007).DespiteextensiveresearchonMerlin’sroleasatumorsuppressor,itsbiologicalfunctionremainspoorlyunderstood.ClassicalERMproteins,whichconsistofanN-terminalFERMdomain,acoiled-coildomain,andaC-terminalsegmentcon-taininganactin-bindingmotif,switchbetweenaclosedconfor-mation,presumeddormant,andanopenconformation,whichmediateslinkageofcertaincelladhesionreceptorstotheactincytoskeleton(Bretscheretal.,2002).ThesequencehomologyofMerlintoERMproteinsanditsapparentlyprevalentlocaliza-tiontothecorticalcytoskeletonhaveledtothehypothesisthatMerlinfunctionsatorneartheplasmamembranetoinhibitthetransmissionofpromitogenicsignals(McClatcheyandFehon,2009).However,Merlindoesnotcontainacanonicalactin-bindingmotif.Inaddition,itistheclosedformofMerlinthatsuppressestumorigenesisandistherebyconsidered‘‘active.’’Infact,manytumor-derivedmissensemutationsarepredictedtodisrupttheclosedconformation(Okadaetal.,2007).TheinterconversionbetweentheclosedandtheopenformofMerlinispromotedbythep21-activatedkinasePAK,whichphosphorylatesMerlinatS518,disruptingtheintramolecularC-terminaltail-FERMinteraction,whichmaintainstheproteinintheclosedconformation(Kissiletal.,2002;Xiaoetal.,2002).Cadherin-mediatedadhesioninhibitsPAK,causinganaccumu-lationofthedephosphorylated,growth-inhibitoryformofMerlin.Conversely,integrin-dependentadhesiontothematrixactivatesPAK,causinginactivationofMerlinand,thereby,presumablyremovingablocktocell-cycleprogression(Okadaetal.,2005).Accordingly,inactivationofMerlininducesexitfromcontactinhibition(Lallemandetal.,2003;Lallemandetal.,2009;Okadaetal.,2005)andacceleratesprogressionthroughtheG1phaseofthecellcycle(Lo´pez-Lagoetal.,2009).TheseresultssuggestCell140,477–490,February19,2010ª2010ElsevierInc.477Figure1.MerlinAssociateswithCRL4DCAF1intheNucleus(A)Cos7cellsweretransfectedwiththeindicatedFH-tagged(FH;FLAG-HA)formsofMerlin,lysedinRIPA,andsubjectedtoTAP.ProteinswereseparatedbySDS-PAGEandstainedwithColloidalBlue.DotspointtotheFH-taggedbaitsandasteriskstothe169and127kDbandsidentiﬁedbymassspectrometryasDCAF1andDDB1,respectively.(B)293TcellsweretransfectedwithFH-DCAF1oremptyvector.TotallysatesandFlagimmunoprecipitates(M2)weresubjectedtoimmunoblottingwithanti-bodiestotheindicatedproteins.(C)Asin(B),withtransfectionoftheindicatedconstructsandimmunoprecipitationwithanti-FLAG(M2)orcontrol(C)antibodies.(D)Asin(B),withcotransfectionofMyc-Merlinoremptyvectorandimmunoprecipitationwithanti-FLAG(M2)orcontrol(C).Tocontrolforthespeciﬁcityoftheanti-P-Merlinantibodies,theindicatedsamplewastreatedwithcalfintestinalalkalinephosphatase(CIP)priortoSDS-PAGE.EndogenousMerlinwasdetecteduponlongerexposure.(E)Meso-33cellsweretransientlytransfectedwiththeindicatedconstructsandsubjectedtodouble-immunoﬂuorescentstainingwithanti-HAandanti-Mycfol-lowedbyDAPI.(F)HeLacellswereinfectedwithlentiviralvectorsencodingashRNAtargetingMerlinoracontrolshRNAandsubjectedtoimmunoblotting(left)orstainingwithafﬁnity-puriﬁedantibodiestotheN-terminalsegmentofMerlinfollowedbyDAPI(right).(G)Theindicatedcellswerestainedasin(F).478Cell140,477–490,February19,2010ª2010ElsevierInc.thatMerlinintegratesantitheticsignalsfromcadherinsandintegrinstoregulatecell-cycleprogression.Merlinexertsinhibitoryeffectsonmultiplemitogenicsignalingpathways.TheclosedformofMerlinsuppressestherecruitmentofRactotheplasmamembraneandtheactivationofPAK(Kaempchenetal.,2003;Kissiletal.,2003;Okadaetal.,2005)andinhibitstheactivationofmTORC1independentlyofAkt(Jamesetal.,2009;Lo´pez-Lagoetal.,2009).Furthermore,MerlininhibitstheRas-ERKandPI-3K-Aktpathwaysandfocaladhesionkinase(FAK)-Srcsignaling(Ammounetal.,2008;Jinetal.,2006a;Poulikakosetal.,2006;Rongetal.,2004).Finally,MerlincooperateswiththerelatedERMproteinExpandedtoactivatetheHippotumor-suppressorpathwayinDrosophila(Choetal.,2006;Hamaratogluetal.,2006).However,thecontri-butionofeachoftheidentiﬁedpathwaystoNF2-dependenttumorigenesishasnotbeendeﬁned.Althoughyeasttwo-hybridscreensandotherapproacheshaveledtotheidentiﬁcationofseveralMerlin-bindingproteins,thebiochemicalfunctionofMerlinand,hence,themechanismthroughwhichitsuppressestumorigenesishaveremainedelusive.ThisstudyshowsthattheclosedformofMerlinentersthenucleus,bindstotheE3ubiquitinligaseCRL4DCAF1,andinhibitsitsactivity.Geneticevidenceindicatesthatthisinhibitoryinteractionisessentialfortumorsuppression.RESULTSTheClosedFormofMerlinBindstoDCAF1,theSubstrateReceptoroftheE3UbiquitinLigaseCRL4DCAF1Tandemafﬁnitypuriﬁcation(TAP)revealedthatMerlin,taggedateitheritsNoritsCterminus,associateswithproteinsdisplay-inganapparentmolecularweightof169kDand127kD(Figure1A).Thetwoproteinswererecoveredinsimilaramounts,eachatanapparentratioof1:5toMerlin.Importantly,thetumor-derivedmutantL64P,whichlackstumor-suppressoractivity(Gutmannetal.,2001),didnotassociatewiththeseproteins(Figure1A).MALDI-reTOF-MSfollowedbypeptidemassﬁngerprintingandmassspectrometricsequencingunequivocallyidentiﬁedthe127kDproteinasDDB1(DNADamage-Bindingprotein1)andthe169kDproteinasDCAF1(DDB1-andCul4-AssociatedFactor1)(Figure1A).NanoLC-MS/MSindicatedthatwild-typeMerlin,butnotMerlin-L64P,interactsalsowithCul4B,albeitatalowerapparentstoichiom-etry(TableS1availableonline).PriorstudieshaveestablishedthatDDB1functionsasaSKP1-likeadaptortorecruitWD40domain-containingsubstraterecep-tors,suchasDDB2,CSA(theCockaynesyndromeproteinA),andDet1-COP1totheE3ligaseCul4-Roc1(LeeandZhou,2007,andreferencestherein;O’ConnellandHarper,2007,andreferencestherein).DCAF1,whichwasoriginallyidentiﬁedasthecellularreceptorfortheHIVproteinVpranddesignatedVprBP,isoneofseveraladditionalWD40domainsubstratereceptorsabletocombinewithDDB1tomediateassemblyofdistinctCul4(CRL4)ligases(LeeandZhou,2007).Inagreementwiththemassspectrometricanalysis,immunoblottingindicatedthatFH-MerlincombineswithDCAF1,DDB1,andCul4,butnotDYRK2orEDD(Figure1B),componentsofthealternativeEDD-DYRK2-DDB1-VprBPE3ligasecomplex(MaddikaandChen,2009).TheseobservationsindicatethatMerlininteractsselectivelywiththeE3ligaseCRL4DCAF1.SinceMerlinformedastoichiometriccomplexwithDCAF1butnotDDB1uponcotransfectioninCos7cells(FigureS1A),wehypothesizedthatMerlinbindsdirectlytoDCAF1butindirectlytoDDB1.Totestthishypothesis,weexaminedtheabilityofGST-fusionproteinscomprisingeithertheFERMorthehelicalandC-terminaldomainofMerlintobindtoinvitrotranslatedDCAF1orDDB1.AsshowninFigureS1B,theFERMdomainofMerlinbounddirectlytoDCAF1butnotDDB1,whereasthehelicalandC-terminalsegmentsdidnot(FigureS1B).Thus,Merlinbindsdirectly,throughitsFERMdomain,toDCAF1.ToexaminewhethertheconformationaltransitionbetweentheopenandtheclosedformregulatesMerlin’sbindingtoCRL4DCAF1,wetestedthebehavioroftwowell-characterizedphosphorylationmutants.Merlin-S518A,whichcannotbephos-phorylatedatS518andisstabilizedintheclosedconformation,associatedefﬁcientlywithDCAF1andDDB1intransfected293Tcells.Incontrast,thephosphorylationsitemimeticmutantMerlin-S518D,whichisthoughttomaintainanopenconforma-tion,displayeddramaticallydiminishedbindingtoDCAF1andDDB1(Figure1C).Asanticipated,EzrinandMerlin-L64Pex-hibitedessentiallynobindinginthisassay.InagreementwiththemodelthattheclosedformofMerlinselectivelyinteractswithCRL4DCAF1,immunoblottingwithanti-P-MerlinantibodiesindicatedthatthefractionofrecombinantMerlinboundtoFH-DCAF1isnotdetectablyphosphorylatedatS518(Figure1D).Thus,theunphosphorylated,closedformofMerlininteractsspeciﬁcallywithCRL4DCAF1,whereastheopenformandawell-characterizedtumor-derivedmutantdonot,raisingthepossibilitythatMerlinsuppressescellproliferationandtumori-genesisbybindingtoCRL4DCAF1.MerlinAssociateswithCRL4DCAF1intheNucleusToidentifythecellularcompartmentwhereMerlininteractswithCRL4DCAF1,wecotransfectedMyc-taggedDCAF1andHA-taggedMerlinintoMerlin-deﬁcientMeso-33mesotheliomacells.Thesecellsundergogrowtharrestfollowingre-expressionofMerlinandthereforerepresentanexcellentmodeltostudythetumor-suppressorfunctionofMerlin(seebelow).Immunoﬂuo-rescentstainingindicatedthatMyc-DCAF1localizesinthenucleusinMeso-33cells(Figure1E),suggestingthatCRL4DCAF1functionsinthiscompartmentlikeotherCRL4ligases(Leeand(H)MCF-10Acellsweresubjectedtosubcellularfractionation.Equalamountsofproteinsfromthenuclear(NF)andnonnuclear(CM;cytosol+crudemembranes)fractionweresubjectedtoimmunoblottingwithantibodiestotheindicatedproteins.(I)Equalamountsofproteinsfromthenonnuclear(CM)andnuclear-soluble(NS)fractionofHeLacellsandMerlinimmunoprecipitateswereimmunoblottedasindicated.Anti-Cul4recognizesCul4-Aaswellasahighermolecularweightband,possiblycorrespondingtoneddylatedCul4-AorCul4-B(asterisk).SeealsoFigureS1.Cell140,477–490,February19,2010ª2010ElsevierInc.479Zhou,2007;O’ConnellandHarper,2007).Interestingly,inaddi-tiontolocalizingunderneaththeplasmamembrane,HA-Merlinalsoaccumulatedinthenucleus(Figure1E).Subcellularfraction-ationconﬁrmedtheseresults(FigureS1C).WereasonedthatpoorpermeabilizationofthenuclearmembraneorepitopemaskingmayhavehampereddetectionofMerlininthenucleusinpreviousimmunoﬂuorescencestudies(withtheexceptionofMuranenetal.,2005).Tostudythelocaliza-tionofendogenousMerlin,wedesignedaﬁxationandpermeabi-lizationprotocolabletocircumventthesepotentialproblems(seetheExperimentalProcedures).Usingthisprotocol,wefoundthatamonospeciﬁcantibodytotheN-terminalsegmentofMerlingeneratesprominentnuclearstaininginmultiplecelltypes,includingHeLasquamouscarcinomacellsandnonneoplasticHEI286Schwanncells,LP9mesothelialcells,andMCF-10Amammaryepithelialcells(Figures1Fand1G).ThispatternofstainingwasspeciﬁcbecauseitwassuppressedbysilencingofMerlin(Figure1F)andcouldbereproducedbyusinganantibodytoaC-terminalepitope(FiguresS1DandS1E).Finally,biochem-icalfractionationconﬁrmedthatMerlinandDCAF1accumulateinthenucleusinmultiplecelltypes(Figure1HandFigureS1F).Thus,MerlincanenterthenucleusandbindtoDCAF1.ManyCRL4ligasesassociatewithDNAorchromatinduringthecellcycleorinresponsetoDNAdamage(O’ConnellandHarper,2007).However,subnuclearfractionationindicatedthatbothDCAF1andMerlinaccumulateinthesolublenuclearfractionanddonotmoveintothechromatinfractionduringcell-cycleprogressionorinresponsetoUV-inducedDNAdamage(W.L.andF.G.G.,unpublisheddata),consistentwiththehypothesisthatCRL4DCAF1performsafunctiondistinctfromthatofotherknownCRL4ligases.Interestingly,coimmuno-precipitationanalysisshowedthatMerlincombineswithDCAF1,DDB1,andCul4inthesolublenuclearfraction,butnotinthenonnuclearfraction,despitethepresenceofabundantamountsofthesecomponents(Figure1I).Thissuggeststhatassociationwithacofactor,dissociationofaninhibitor,oraposttranslationalmodiﬁcationoccurringinthenucleuspromotetheassociationofMerlinwithCRL4DCAF1.Takentogether,theseresultsindicatethattheclosed,growth-inhibitoryformofMerlinbindstoCRL4DCAF1inthenucleus.MerlinIsNotaSubstrateofCRL4DCAF1ConstitutivelyactivatedAktcanpromotephosphorylationandproteasome-mediateddegradationofMerlin(Tangetal.,2007),andoverexpressionstudieshavesuggestedthatCRL4DCAF1mediatesthisprocess(HuangandChen,2008).However,experimentswithCycloheximideindicatedthatMerlinexhibitsahalf-lifefarexceeding24hrinseveralcelltypes(Fig-ureS2A).Inaddition,treatmentwiththeproteasomeinhibitorMG132didnotstabilizerecombinantMerlininCos7cells,andMerlin-S518DandMerlin-L64P,whichdonotinteractwithCRL4DCAF1,didnotdisplayincreasedstabilityinthisassay(FigureS2B).Finally,knockdownofDCAF1didnotcauseincreasedaccumulationofMerlininmultiplecelltypesunderstandardcultureconditions,orinHeLacellsacutelyexposedtomitogens(FiguresS2CandS2D).Infact,depletionofDCAF1decreasedthelevelsofMerlin,especiallyshortlyaftermitogenicstimulation,suggestingthatbindingtoDCAF1stabilizesMerlin(FigureS2D).TheseresultsarguethatMerlinisnottargetedfordegradationbyCRL4DCAF1andsuggestthatMerlinfunctionsupstream,notdownstream,ofCRL4DCAF1.MerlinInhibitsCRL4DCAF1ToexaminetheeffectofMerlinontheubiquitylatingactivityofCRL4DCAF1,wesetupaninvivoubiquitylationassay.Cos7cellsweretransfectedwithFH-DCAF1andMyc-ubiquitin,treatedwithMG132tostabilizeubiquitylatedproducts,andimmunopre-cipitatedwithanti-FlagtoisolateCRL4DCAF1andassociatedubiquitylatedproducts.Immunoblottingwithanti-MycantibodyrevealedthatFH-DCAF1isolatedfromMG132-treatedcellsco-precipitateswithubiquitylatedspeciesofapparentmolecularweightrangingfrom55to300kD,suggestingthatCRL4DCAF1ubiquitylatesinvivooneormoresubstratesandthattheseremainassociatedwiththeenzymethroughoutimmunoprecipi-tation(Figure2A,left).Incontrast,FH-DCAF1isolatedfromuntreatedcellscontainedamodestamountofubiquitylatedspeciesofapparentmolecularweightrangingfrom180to250kD.CotransfectionofincreasingconcentrationsofHA-Merlincausedadose-dependentsuppressionoftheaccumulationofubiquitylatedproducts,suggestingthatMerlinsuppressestheubiquitylatingactivityofCRL4DCAF1(Figure2Aleft).Immunoblot-tingwithanti-HAantibodyindicatedthatMerlindoesnotbecomeubiquitylateduponassociationwithDCAF1,consistentwiththenotionthatMerlinisaregulatorandnotasubstrateoftheligase(Figure2Aright).ImmunoblottingoftotallysatesprovidedacontrolfortheexpressionlevelsofrecombinantproteinsandindicatedthattreatmentwithMG132partiallystabilizesDCAF1(FigureS2E).TheseobservationssuggestthatMerlinbindstoCRL4DCAF1andsuppressesitsabilitytomediateubiquitylationoftargetproteins.Toconﬁrmthishypothesis,weexaminedwhetheramutantformofDCAF1unabletobindtoMerlinmediatesenhancedCRL4DCAF1ligaseactivityincellsexpressingendogenousMerlin.DeletionmappingindicatedthattheGST-FERMdomainofMerlinbindsdirectlytoa90aaC-terminalsegmentofDCAF1invitro(FigureS2F).Immunoprecipitationexperimentscon-ﬁrmedthatDCAF1(1–1417)lackingthisC-terminalsegmentcombineswithendogenousDDB1butnotwithHA-MerlininCos7cells(Figure2B).Interestingly,thismutantretainedtheabilitytointeractwiththeHIVproteinVpr(Figure2B),suggestingthatitisnotgrosslymisfoldedandindicatingthatMerlinandVprbindtodistinctsitesonDCAF1.Inaddition,mutationofthedoubleDxRboxonthebottomsurfaceoftheWD40propellerfoldofDCAF1(R1247/1283A)disruptedtheassociationofDCAF1withDDB1,aspreviouslyreported(Jinetal.,2006b),butnotwithMerlin(FigureS2G),indicatingthatdistinctsegmentsofDCAF1mediateinteractionwithDDB1andwithMerlin.Notably,invivoubiquitylationassaysrevealedthatligasecomplexescontainingDCAF1(1–1417)exhibithigherapparentenzymaticactivitythanthosecontainingwild-typeDCAF1inCos7cells(Figure2C).PretreatmentwithMG132causedalargeincreaseintheactivityofCRL4containingwild-typeDCAF1buthadonlyasmalleffectonCRL4containingDCAF1(1–1417)(Fig-ure2CandFigureS2E),suggestingthatthelatterisamorepotentE3ligase.TheseresultssuggestthatdeletionoftheMerlinbindingsegmentofDCAF1leadstoconstitutiveactivationof480Cell140,477–490,February19,2010ª2010ElsevierInc.CRL4DCAF1,consistentwiththenotionthatMerlininhibitstheE3ligaseactivity.Finally,wetestedtheeffectofdepletionofMerlinonCRL4DCAF1activity.Cos7cellswereinfectedwithlentivirusesen-codingacontrolshorthairpinRNA(shRNA)orashRNAtargetingMerlinandthensubjectedtoinvivoubiquitylationassay.TheresultsindicatedthatdepletionofMerlincausesasigniﬁcantincreaseinCRL4DCAF1ligaseactivity(Figure2D).TheeffectoftheshRNAtargetingMerlinwasspeciﬁc,becauseitwassup-pressedbyoverexpressionofHA-MerlinbutnotofHA-Ezrin,whichdoesnotassociatewithFH-DCAF1(FiguresS2HandS2I).Together,theresultsofpositiveexpression,mutationalactivation,anddepletionprovidecompellingevidencethatMerlinfunctionsasanegativeregulatorofCRL4DCAF1(seeFigure2Eforahypotheticalmodel).CRL4DCAF1MediatestheHyperproliferationCausedbyInactivationofMerlinRecentstudieshaveimplicatedCRL4DCAF1inDNAreplicationandprogressionthroughtheG2phaseofthecellcycle(Hreckaetal.,2007;McCalletal.,2008).ToexaminewhetherMerlinsuppressescellproliferationbyinhibitingCRL4DCAF1,wesilencedDCAF1inNF2mutantMeso-33mesotheliomacellsusingasmartpoolofsmallinterferingRNAs(siRNAs)(Fig-ureS3A).SincelossofMerlinpromotesprogressionthroughG1(Lo´pez-Lagoetal.,2009),weexaminedwhetherlossofDCAF1affectsthisspeciﬁcphaseofthecellcycle.BrdUincor-porationexperimentsrevealedthatdepletionofDCAF1inhibitstheabilityofG0synchronizedMeso-33cellstoprogressthroughG1andenterSphaseinresponsetomitogens(Figure3A).DeconstructionofthesmartpoolindicatedthateachindividualsiRNAinthepoolwasabletoinhibitexpressionofDCAF1andcellproliferation,asexpectedfromspeciﬁcinhibition(FiguresS3BandS3C).Incontrast,silencingofDCAF1exertedamoderategrowthinhibitoryeffectinnormalmesothelialMet-5Acells(Figure3BandFigureS3D),suggestingthatMerlin-deﬁ-cientcellsaremoresensitivetoinactivationofDCAF1thantheirnormalcounterpart.TofurtherexploretheroleofCRL4DCAF1intheproliferationofMerlin-deﬁcienttumorcells,wedesignedashRNAabletotargetFigure2.MerlinInhibitsCRL4DCAF1-Depen-dentUbiquitylation(A)Cos7cellsweretransfectedwith3mgFH-DCAF1and2mgMyc-UbiquitinincombinationwiththeindicatedamountsofHA-MerlinandtreatedwithMG132orleftuntreated.Flagorcontrolimmunoprecipitates(M2andC,respec-tively)weresubjectedtoimmunoblottingwithanti-Myctovisualizeubiquitylatedproteins(left)oranti-HAtovisualizeDCAF1andMerlin(right).UpperarrowpointstoDCAF1andlowerarrowtoMerlin.(B)Cos7cellsweretransfectedwithFH-DCAF1orFH-DCAF1(1–1417)incombinationwithHA-Merlin(toppanel)orHA-Vpr(bottompanel).Flagorcontrolimmunoprecipitatesweresub-jectedtoimmunoblotting.LevelsofexpressionofDCAF1,DDB1,andMerlinorVprwereveriﬁedbyimmunoblottingaliquotsoftotallysates.(C)Asin(B),withcotransfectionofMyc-UbiquitinandtreatmentornotwithMG132.Flagorcontrolimmunoprecipitateswereimmunoblottedwithanti-Myc(left)oranti-HA(right).(D)Cos7cellsstablyinfectedwithlentiviralvectorsencodingacontrolshRNAorashRNAtargetingMerlinweresubjectedtoimmunoblotting(left)ortransfectedwithFH-DCAF1andMyc-UbiquitinfollowedbyimmunoblottingofFlagorcontrolimmunoprecipitateswithanti-Myc(middle)oranti-HA(right).(E)HypotheticalmodelofMerlin-mediatedinhibi-tionofCRL4DCAF1.MerlinisproposedtofunctionasacompetitiveinhibitorofCRL4DCAF1.Bluehexagons,threebpropellerfoldsofDDB1,whichcontactCul4(B)andDCAF1(AandC);yellowhexagon,WD40domainofDCAF1;yellowsticks,doubleDxRboximplicatedinbindingtoDDB1;S,substrate;Ub,ubiquitin;Mer,closedMerlin.SeealsoFigureS2.Cell140,477–490,February19,2010ª2010ElsevierInc.481bothhumanandmouseDCAF1.SilencingofDCAF1withthisshRNAinhibitedphosphorylationofRbandentryintotheSphaseinMeso-33cells(FigureS3E).FACSanalysisofunsyn-chronizedMeso-33cellsconﬁrmedthatdepletionofDCAF1predominantlyinhibitsprogressionthroughG1(controlMeso-33:23%G1,68%S,9%G2/M;DCAF1-depletedMeso-33:59%G1,35%S,6%G2/M).Re-expressionofDCAF1fromeitheramoderateorastrongpromoterrescuedphosphorylationofRbandcell-cycleprogression,conﬁrmingthespeciﬁcityoftheshRNAtargetingDCAF1(FigureS3E).WethereforeusedthisshRNAtosilenceDCAF1inFC-1801Schwannomacells,whichwerederivedfromNF2conditionalknockoutmice,andtheirnormalcounterpart,theFH-912cells.Notably,inactivationofDCAF1causedamoreprofoundgrowthinhibitioninMerlinnullFC-1801cellsascomparedtoMerlin-positiveFH-912cells(FigureS3F),conﬁrmingthatCRL4DCAF1isrequiredfortheprolif-erationofMerlin-deﬁcienttumorcellsbuttoalesserdegreeforthatofnormalcells.TheseobservationssuggestthatCRL4DCAF1isakeycomponentoftheoncogenicsignalingpathwayacti-vatedbylossofMerlin.ToexaminewhetherCRL4DCAF1isrequiredforexitfromcontactinhibitionafterinactivationofMerlin,wesilencedMerlininconﬂuenthumanumbilicalveinendothelialcells(HUVECs).Asanticipated,thismanipulationinducedasigniﬁcantfractionofconﬂuentHUVECstoenterintoSphase(Figure3C).Notably,depletionofDCAF1witheachoftwodistinctsiRNAssuppressedthisunscheduledevent(Figure3C),suggestingthatMerlininducescontactinhibitionthroughinhibitionofCRL4DCAF1.ToconﬁrmthatCRL4DCAF1functionsdownstreamofMerlin,weconductedanadditionalgeneticepistasisexperimentinHEI-286Schwanncells,whichareimmortalizedbutnotneoplastic.SilencingofMerlincausedthesecellstoundergoacceleratedprogressionthroughG1andentryintoSphaseinresponsetogrowthfactors(Figure3D),inagreementwiththeobservationthatMerlincontributestorestrainingG1progression(Lo´pez-Lagoetal.,2009).InactivationofDCAF1revertedthehyperproliferationcausedbydepletionofMerlinbutdidnotaffecttherateofgrowthofcontrolcellsexpressingMerlin(Figure3D),providingadditionalevidencethatCRL4DCAF1medi-atesthegrowthinhibitoryeffectofMerlin.IfMerlinsuppressescellproliferationbyinhibitingCRL4DCAF1,expressionofamutantformofDCAF1unabletointeractwithMerlinshouldcounteracttheantimitogeniceffectofMerlin.Totestthisprediction,wetransfectedMeso-33cellswithFH-Merlin,aloneorincombinationwithwild-typeDCAF1orDCAF1(1–1417),andsubjectedthemtoBrdUincorporationassay.Interestingly,expressionofDCAF1(1–1417)fullyrescuedMeso-33cellsfromundergoinggrowtharrestuponintroductionofMerlin,whereaswild-typeDCAF1hadonlyamoderateeffect(Figure3E).Wenotethat,inspiteofitshigherlevelofexpression,Figure3.DCAF1MediatesHyperproliferationandLossofContactInhibitioninMerlin-DeﬁcientCells(AandB)Meso-33cells(A)andMet-5acells(B)weretransfectedwithaSMARTpoolofsiRNAstargetingtheadaptorproteinAP3b,DCAF1,oracontrolnontargetingpool,deprivedofgrowthfactorsfor24hr,incubatedwithBrdUinthepresenceofmitogensfor24hr,andsub-jectedtoanti-BrdUstainingfollowedbycounterstainingwithDAPI.Thegraphshowsthepercentage(±standarderrorofthemean[SEM])ofBrdU+cellsandthepicturesshowrepresentativeﬁelds.(CandD)HUVECs(C)andHEI286humanSchwanncells(D)weretransfectedwithacontrolsi-RNAortwodistinctsi-RNAstargetingDCAF1,aloneorincombinationwithapreviouslyvalidatedsi-RNAtargetingMerlin(Okadaetal.,2005).Cellsweredeprivedofgrowthfactorsfor24hr,platedunderconﬂuent(C)orsparse(D)conditionsonﬁbronectin,andsubjectedtoBrdUincorporationinthepresenceofmitogensfor24hrfollowedbyanti-BrdUstaining.Thegraphsshowthepercentage(±SEM)ofBrdU+cells.Immunoblottingwasusedtoverifytheefﬁciencyofknockdown.(E)Meso-33cellsweretransientlytransfectedwiththeindicatedmgofvectorsencodingHA-Merlin,aloneorincombinationwithFH-DCAF1orFH-DCAF1(1–1417),andsubjectedtoimmunoblotting(left)andBrdUincorporationassay(right).Theanti-HAblotsincludingFH-DCAF1andHA-Merlinwereexposedforthesametime.Thegraphshowsthepercentage(±SEM)ofBrdU+cells.SeealsoFigureS3.482Cell140,477–490,February19,2010ª2010ElsevierInc.Merlindidnotbindstoichiometricallytowild-typeDCAF1undertheseexperimentalconditions(FigureS3G).Presumably,tran-sienttransfectionsaturatesthecellularmachinerythatmodiﬁesMerlintoenableittobindtoCRL4DCAF1inMeso-33cells.Takentogether,theseresultsprovidestrongevidencethatMerlinsuppressescellproliferationbyinhibitingCRL4DCAF1.Merlin-MediatedInhibitionofCRL4DCAF1ActivatesaGrowth-InhibitoryGeneExpressionProgramCRL4ligasescanregulategeneexpressionbypromotingubiq-uitylationofhistonesandrecruitmentofenzymesinvolvedinchromatinremodelingorhistonemethylationorbyinducingproteasome-mediateddegradationoftranscriptionfactors(O’ConnellandHarper,2007).ToexaminewhetherMerlincontrolsgeneexpressionthroughinhibitionofCRL4DCAF1,wecomparedthegeneexpressionprogramactivatedbyexpressionofMerlinordepletionofDCAF1inNf2 / FC-1801mouseSchwannomacells.Unsupervisedclusteringof1566probesetsdifferentiallyexpresseduponexpressionofwild-typebutnotL64PmutantMerlinoruponspeciﬁcdepletionofDCAF1re-vealedlargelyoverlappingchangesingeneexpression(Figure4A).Infact,expressionofMerlinanddepletionofDCAF1inducedaconcordantupregulationordownregulationof855probesets(54%)(Figure4BandFigureS4A).Inspiteofthisconsiderablefunctionaloverlap,expressionofMerlinandknockdownofDCAF1alsoinducedspeciﬁceffectsongeneexpression(Figure4B).TheseresultsindicatethatMerlinregu-latesgeneexpressionlargelythroughinhibitionofCRL4DCAF1butalsosuggestthatMerlinhasCRL4DCAF1-independentfunctions.IngenuitypathwayanalysisrevealedthatexpressionofMerlinandinactivationofCRL4DCAF1causeaconcordantdownregula-tionofgenespromotingcell-cycleprogressionandupregulationofgenesinvolvedingrowtharrestandapoptosis(Figure4C).Inaddition,thesetwomanipulationsdownregulatedseveralcelladhesiongenes,suchastheintegrinasubunitsItga6andItga7,theintegrincounter-receptorVcam1,andtheintegrin-linkedkinaseIlk,andupregulatedtheRhoeffectorsRock1andFigure4.ExpressionofMerlinandDepletionofDCAF1InduceaLargelyOverlappingGeneExpressionProgram(A)FC-1801cellswereinfectedwithlentiviralvectorsencodingashRNAtargetingDCAF1(sh-DCAF1),acontrolshRNA(sh-Control),wild-typeMerlin,Merlin-L64P,orsh-DCAF1incombinationwithwild-typeMerlinandsubjectedtoDNAmicroarrayanalysis.Unsupervisedclusteringof1566probesetsdifferentiallyexpressedR2foldinatleastoneofthetwomajorcomparisons(sh-DCAF1versussh-ControlandMerlin-WTversusMerlin-L64P).Valueswerenormalizedtoparentaluninfectedcells.(B)VenndiagramshowstheoverlapbetweenthelistofgenesdifferentiallyexpresseduponexpressionofMerlin-WTorsilencingofDCAF1(R2-foldchange).Coregulatedgenes(885)areidentiﬁedasdifferentiallyexpressedR2-foldinoneofthetwocomparisonsanddisplayingaconsensualsigniﬁcantchangeintheothercomparison(p%0.01bytheANOVAtest).(C)Sixhundredandsixty-sevengenescoregulateduponexpressionofMerlin-WTorsilencingofDCAF1(R2-foldchangeinbothcomparisons)weresubjectedtoingenuitypathwayanalysis.Bothdownregulated(353)andupregulated(314)genesareincludedinthecategoryofbiologicalfunctions.Representativedown-regulatedgenesareshowninblue,andrepresentativeupregulatedgenesinredinorderofdecreasingaveragefoldchange.SeealsoFigureS4.Cell140,477–490,February19,2010ª2010ElsevierInc.483Limk1.IngenuityanalysisofcanonicalpathwaysindicatedthatexpressionofMerlinandlossofDCAF1inhibitintegrinandPDGFsignalingaswellasthesignalingpathwaysjointlyregu-latedbyintegrinsandreceptortyrosinekinases(FigureS4B).Interestingly,thesetwomanipulationsalsoledtodownregula-tionoftheintegrinsignalingcomponentBcar3,whichhasbeenimplicatedinrecruitmentofp130CAStolamellipodiaandinacti-vationofRac(Schrecengostetal.,2007).AsurveyofthegenescoordinatelyregulatedbyexpressionofMerlinorlossofDCAF1revealedadditionalfeaturesofthegeneexpressionprogramactivatedbyMerlinthroughinhibitionofCRL4DCAF1.Inadditiontoexpandingthecategoryofgenesinvolvedincelladhesionandreceptortyrosinekinasesignaling,thisanalysisrevealedthatMerlinregulates,throughCRL4DCAF1,severalgenesinvolvedinintracellulartrafﬁckingandafractionoftheknownHippopathwaytargetgenes(FigureS4C).TheseobservationssuggestthatMerlin’sinhibitionofCRL4DCAF1activatesabroadtumor-suppressivegeneexpressionprogram.IntramolecularAssociationoftheFERMDomainwiththeC-TerminalTailPromotesNuclearAccumulationofMerlinInordertoobtaininsightintotheregulationoftheassociationofMerlinwithCRL4DCAF1,westudiedthemechanismthatenablesMerlintoaccumulateinthenucleus.PreliminaryexperimentsindicatedthatMerlin’stranslocationinthenucleusdoesnotrequireDCAF1(W.L.andF.G.G.,unpublisheddata).SinceMerlindoesnotcontainacanonicalnuclearimportsequence,weexaminedtheabilityoftheFERMdomainandofthea-helicalandC-terminaldomainoftheproteintolocalizetothenucleus.TheFERMdomainofMerlin(1–341)accumulatedinthenucleusofMeso-33cellstoasigniﬁcantlylargerdegreeascomparedtowild-typeMerlin.Incontrast,thea-helicalandC-terminaldomainoftheprotein(341–595)failedtolocalizetothenucleusunderthesameconditions(FiguresS5AandS5B).TheseresultsindicatethattheFERMdomainofMerlinissufﬁcientfornucleartranslocationandsuggestthattheC-terminalportionoftheproteinmayexertaninhibitoryrole.SincethisportionofMerlincontainsanuclearexportsignal(KresselandSchmucker,2002),itispossiblethatthissignalismaskedintheclosedconformer.Toexaminewhetherantimitogenicsignals,suchascell-to-celladhesionandgrowthfactordeprivation,regulatetheaccumula-tionofMerlininthenucleus,wemonitoredthesubcellularlocal-izationoftheunphosphorylatedandphosphorylatedformofMerlinundervariousgrowthconditions.Mobilityshiftassayandimmunoblottingwithanti-P-Merlin(S518)indicatedthatthedephosphorylatedformofMerlin,whichwasprevalentinconﬂuentcellsespeciallyiftheywerenotexposedtomitogens,accumulatedpredominantlyinthenucleus,whereasMerlinphosphorylatedatS518remainedlargelyconﬁnedtothenon-nuclearfractionunderallconditions(FiguresS5CandS5D).Toconﬁrmthattheclosed,growth-inhibitoryformofMerlinaccumulatespreferentiallyinthenucleus,weexaminedthesubcellulardistributionofMerlin-S518A,whichcannotbephosphorylatedbyPAK,andMerlin-S518D,whichmimicsthephosphorylatedformoftheprotein.Notably,Merlin-S518Aaccumulatedinthenucleustoasigniﬁcantlyhigherextentthandidwild-typeMerlin(FigureS5E).Incontrast,Merlin-S518Ddisplayeddefectivenuclearaccumulation,suggestingthatPAK-mediatedphosphorylationinhibitsnuclearlocalizationofMerlin.Inagreementwiththishypothesis,adominantnegativeformofPAKenhancednuclearaccumulationofMerlin(W.L.andF.G.G.,unpublisheddata).Thus,intramolecularassociationoftheFERMdomainwiththeC-terminaltailpromotesnuclearaccumulationofMerlin,whereasphosphorylationofS518inhibitsthisprocess.Tumor-DerivedMutationsPreventMerlin’sAbilitytoInteractwithortoInhibitCRL4DCAF1MostNF2missensemutationsmaptotheFERMdomain(Ahro-nowitzetal.,2007).TofurtherstudytherelevanceofMerlin’sinteractionwithCRL4DCAF1fortumorsuppression,weexaminedseveralofthesemutations.L46R,F62S,L64P,L141P,A211D,andE270GhavebeenfoundintwoormoreunrelatedNF2patientsorareknowntotrackwithdiseaseinindividualfamiliesandarethereforebonaﬁdepathogenicmutations.Incontrast,G197C,whichwasidentiﬁedinasinglepatientaffectedbymildbilateralSchwannoma,mayrepresentapolymorphismorapassengermutation(Ahronowitzetal.,2007).StructuralconsiderationssuggestthatL46R,F62S,L64P,L141P,andA211DdisruptthehydrophobiccoreofsubdomainAorB,whereasE270Gsimplyremovesasurfacechargefromsubdo-mainC(Figures5A–5C).Incontrast,G197Ccanbeaccommo-datedbyaslightadjustmentofthesurfaceloopinwhichitresides,withoutoverteffectsontheoverallstructureofsubdo-mainB,anddoesnotintroduceordeleteacharge(Figure5C).Toevaluatetheirgrowth-suppressivefunction,weintroducedMerlinandmutantsthereofintoMeso-33cells.Asanticipated,wild-typeMerlinandMerlin-S518AsuppressedprogressionthroughG1andentryinSphaseinthesecells,whereasMerlin-S518Dinhibitedproliferationtoamuchsmallerdegree(Figure5D).Notably,allthebonaﬁdepathogenicmutantswerefoundtobedevoidofgrowthinhibitoryactivityinMeso-33cells.Incontrast,MerlinG197Csuppressedproliferationaseffectivelyaswild-typeMerlin,suggestingthatthisisnotapathogenicmutation(Figure5D).Toexaminetheabilityoftumor-derivedmutantsofMerlintointeractwithCRL4DCAF1incells,wesub-jectedCos7cellsexpressingFH-Merlinandmutantsthereoftocoimmunoprecipitation.Remarkably,allthebonaﬁdetumor-derivedmutantformsofMerlindidnotinteractwithCRL4DCAF1invivo,whereasthecontrolmutantG197Cassociatedwiththeligaseasefﬁcientlyaswild-typeMerlinunderthesamecondi-tions(Figure5E,seeFigure1CforL64P),providingevidencethatMerlinneedstocombinewithCRL4DCAF1tosuppresstumorigenesis.ToobtaininsightintothemechanismthroughwhicheachofthesepathogenicmissensemutationsimpairsassociationofMerlinwithCRL4DCAF1invivo,weﬁrstassessedtheireffectonnuclearaccumulationoftheprotein.Biochemicalfraction-ationindicatedthatL46R,L64P,L141P,andA211Daccumu-lateinthenucleustoamuchsmallerdegreethanwild-typeMerlinorG197C(Figures6Aand6B).Defectivenucleartrans-locationanddecreasedlevelofexpression,presumablyarisingfromdeﬁcientproteinstability,contributedtovaryingdegreestoinhibitaccumulationofeachofthesemutantsintothe484Cell140,477–490,February19,2010ª2010ElsevierInc.nucleus.Atthetwooppositeendsofthespectrum,L46RandL141didnotaccumulateinthenucleusinspiteofnearwild-typelevelsofexpression,suggestingthatthesetwomutationsaffectpredominantlynucleartranslocation,whereasA211Dnuclearlevelswerelowlargelyasaconsequenceofreducedexpression(Figures6Aand6B).Incontrast,F62SandE270translocatedintothenucleusasefﬁcientlyaswild-typeMerlin,althoughtheamountsofthelatterinthenucleusappearedtobereduced.Theseresultssuggestthatdefectivestabilityandnucleartranslocationcontributetoimpairtheinteractionofcertaintumor-derivedmutantformsofMerlinwithCRL4DCAF1.Toexaminetheabilityoftumor-derivedmissensemutantstointeractwithCRL4DCAF1invitro,weengineeredeachmutationintoafusionproteincomprisingtheisolatedFERMdomainofFigure5.SeveralPathogenicMissenseMutationsDisruptBindingofMerlintoCRL4DCAF1InVivo(A)Tumor-derivedmutants(redsticks)areshowninthecontextoftheoverallstructureoftheFERMdomainofhumanMerlin(coloredribbons;PDB1ISN).Thea-helicalcoiled-coildomainfromthecrystalstructureoftheclosedformofSpodopterafrugiperdaMoesin(thingraya-carbontrace;PDB2I1K),whichishighlyhomologoustohumanMerlin,isshownforreference.Thecoiled-coildomainwaspositionedbysuperimposingtheFERMdomainsfromthestructuresofMerlinandMoesin,whichhavearootmeansquaredeviationfora-carbonatomsof1.3A˚andshare62%sequenceidentity.(B)Close-upviewoftumor-derivedmutations(redsticks)locatedinsubdomainA(greenribbon)inthecrystalstructureofhumanMerlin.Residuesincontactwithmutatedresiduesaredrawnassticksandcoloredaccordingtoatomtype(carbon,yellow;sulfur,green).(C)SubdomainBrepresentedasin(B),withoxygenasmagentasticks.Redsphere,G197.(D)Meso-33cellsweretransientlytransfectedwithemptyvectororvectorsencodingwild-typeMerlinorindicatedmutants.Asynchron-izedcellsgrowingin10%fetalcalfserumweresubjectedtoBrdUincorporationassay.Thegraphindicatesthepercentage(±SEM)ofBrdU-positivecells.Picturesshowrepresentativeﬁeldsofcellstrans-fectedwithindicatedvectorsandstainedwithanti-BrdU(red)andDAPI(blue).(E)Cos7cellsweretransfectedwithFH-taggedversionsofwild-typeMerlinorindicatedmutants.Flagorcontrolimmunoprecipitates(M2andC,respectively)andtotallysateswereimmunoblottedasindicated.SeealsoFigureS5.Merlin,whichwehadshownbindsefﬁcientlytoinvitrotranslatedDCAF1.AsshowninFigures6Cand6D,GST-FERM-A211DboundtoDCAF1invitroalmostasefﬁcientlyaswild-typeGST-FERMorGST-FERM-G197C,suggestingthattheA211DmutantdoesnotinteractinvivowithCRL4DCAF1becauseitdoesnotaccumulateinthenucleustosufﬁcientlevels(Figures6Aand6B).AlltheothermutantFERMdomainsdis-playeddecreasedabilitytobindtorecombinantDCAF1:L46R,L64P,andE270Gdidnotbindatallunderourexperimentalconditions,whereasF62SandL141Pdisplayeddefectivebinding(Figures6Cand6D).SinceF62SandE270Gwereabletoaccumulateinthenucleustonormalornear-normallevels(Figures6Aand6B),weinferthattheydonotcombineinvivowithCRL4DCAF1becausetheyareunabletointeractdirectlywithDCAF1withsufﬁcientafﬁnity.Notably,theE270Gmutationsimplyremovesachargefromasurfaceexposedlooponsub-domainC(Figure5A),implicatingthisloopininteractionwithDCAF1andconﬁrmingthehighspeciﬁcityoftheinteractionofMerlinwithDCAF1.Incontrast,bothdefectivenuclearaccumu-lationanddeﬁcientbindingtoDCAF1contributetotheinabilityofL46R,L64P,andL141PtointeractwithCRL4DCAF1invivo.Together,theseexperimentsindicatethatthesixtumor-derivedmissensemutantsthatwehavetesteddonotcombinewithCRL4DCAF1invivo,owingtodefectiveaccumulationinthenucleus,deﬁcientbindingtoDCAF1,oracombinationofthetwomechanisms.WhilemutationsthatintroducestopcodonswithintheFERMdomainarelikelytogiverisetomisfoldedandunstableproteinCell140,477–490,February19,2010ª2010ElsevierInc.485products,certainnonsensemutationsdeleteonlytheC-terminaldomain—astructuralperturbationthatmayaffecttheabilityofMerlintomaintainaclosedconformation.Toexaminewhethertumor-derivednonsensemutationsaffecttheabilityofMerlintointeractwithortosuppressCRL4DCAF1,weexaminedtwoFigure6.PathogenicMutationsDisrupttheAbilityofMerlintoAccumulateintheNucleus,toBindtoDCAF1,ortoInhibitCRL4DCAF1(A)Meso-33cellsweretransientlytransfectedwithFH-taggedversionsofwild-typeMerlinortheindicatedmutantsandsub-jectedtosubcellularfractionation.Equalamountsofproteinsfromthenonnuclear(CM)andnuclear(NF)fractionsweresub-jectedtoimmunoblotting.(B)TheamountofMerlinorindicatedmutantspresentinnuclearandnonnuclearfractionswasestimatedbydensitometryoftheblotin(A).Top:ratioofMerlinorindicatedmutantspresentinnuclearversusnonnuclearfractions.Bottom:amountofeachMerlinmutantpresentinthenucleusasapercentageoverthewild-typevalue.(C)Invitro-translatedandTNT-labeledDCAF1wasincubatedwith0.5,1,and2mgGSTfusionproteinscomprisingtheFERMdomainofwild-typeMerlinorindicatedmutants.GST-boundDCAF1wasdetectedbyblottingwithHRP-streptavidin.(D)Densitometricanalysisof(C).Thegraphshowsthebindingvaluesinarbitraryunits.(E)Cos7cellsweretransfectedwiththeindicatedFH-taggedformsofMerlinandsubjectedtoimmunoprecipitationwithcontrol(C)oranti-FlagMab(M2)followedbyimmunoblotting.(F)Cos7cellsweretransfectedwithFH-DCAF1andHA-UbiquitinincombinationwiththeindicatedMyc-taggedconstructsoremptyvectorandtreatedwithMG132.Flagorcontrolimmunopre-cipitateswereimmunoblottedwithanti-HA(left).Totallysateswereimmunoblottedwithanti-Myc(right).prevalenttruncationmutants:Merlin466X,whichlackstheC-terminalportionofthea-helicaldomainaswellastheC-terminaldomain,andMerlin341X,whichretainstheFERMdomainbutlacksboththea-helicalandtheC-terminaldomains(Ahronowitzetal.,2007).CoimmunoprecipitationindicatedthatthesetwoMerlinmutantsretaintheabilitytointeractwithCRL4DCAF1invivo(Figure6E).Infact,progressivedeletionfromtheCterminusresultedinincreased,asopposedtodecreased,bindingofMerlintotheligase.SincetheisolatedFERMdomainofMerlinaccumu-latesinthenucleustoalargerextentthanthewild-typeprotein,whereastheC-terminalportionofMerlinincludingthea-helicalandC-terminaldomainremainsinthecytoplasm(FigureS5B),itispossiblethatincreasednuclearaccumulationfacilitatestheinterac-tionoftumor-derivedtruncationsmutantswithCRL4DCAF1.Interestingly,inspiteofitsincreasedabilitytobindtoCRL4DCAF1invivo,theFERMdomainofMerlindidnotsuppressCRL4DCAF1ligaseactivityinvivoasefﬁcientlyaswild-typeMerlin(Figure6F),indicatingthatthea-helicalandC-terminaldomainscontributetoMerlin’sinhibitoryactivity.Theseresultssuggestthatthetumor-derivedtruncationmutantsofMerlinthatretaintheFERMdomainareabletointeractwithCRL4DCAF1butfailtosuppressitsactivity.Theobservationthatseveraldistincttumor-derivedmutationsimpairMerlin’sabilitytotranslocateintothenucleus,tobindtoDCAF1,ortoinhibitCRL4DCAF1activityprovidesstronggeneticevidencethatMerlinsuppressestumorigenesisbyinhibitingCRL4DCAF1.486Cell140,477–490,February19,2010ª2010ElsevierInc.InactivationofDCAF1SuppressestheTumorigenicPotentialofMesotheliomaandSchwannomaCellsTotestwhetherCRL4DCAF1isrequiredforNF2-dependenttumor-igenesis,wesilencedDCAF1inMeso-33andFC-1801cells(Figures7Aand7B).KnockdownofDCAF1inhibitedtheabilityofbothmesotheliomaandSchwannomacellstogrowinsoftagar(Figure7CandFigureS6A).Incontrast,depletionofDCAF1didnotaffecttheabilityofRas-V12orv-SrctransformedcellstoexpresselevatedlevelsofCyclinD1andp-Rbandtoprolif-erateunderadherentconditionsorinsoftagar(FiguresS6BandS6C),suggestingthatinactivationofCRL4DCAF1speciﬁcallyinhibitsthemalignantpropertiesofMerlin-deﬁcienttumorcells.Meso-33cellsaswellasotherMerlin-deﬁcientmesotheliomacelllinesdidnotgiverisetotumorsuponsubcutaneousorintra-pleuralinjectioninmice.Incontrast,theFC-1801cells,whichexpressrobustlevelsofDCAF1,gaverisetosizeabletumorsinlessthan4weeksuponsubcutaneousinjectioninnudemice(Figure7D).SilencingofDCAF1withtwodistinctshRNAsin-hibitedtumorgrowthinvivobyapproximately75%atday24.Thiseffectwashighlyspeciﬁc,asmoderateoverexpressionofashRNA-resistantformofDCAF1rescuedtheabilityofFC-1801cellsexpressingoneofthetwoshRNAstargetingDCAF1togiverisetosubcutaneoustumors(Figure7E).Infact,thetumorsgeneratedbythesecellsgrewatamuchfasterpaceascomparedtothosegeneratedbyparentalFC-1801cells(byapproximately2-fold,compareFigures7Dand7E,dataarefromthesameexperiment),suggestingthatelevatedlevelsofDCAF1canpromotetumorigenesis.ToexploretherelevanceofourﬁndingstothepathogenesisofNF2,weexaminedwhetherDCAF1affectstheabilityofprimaryhumanSchwannomacellsderivedfromNF2patientstoprolif-erateinvitro.SilencingofDCAF1suppressedtheabilityofthesecellstoprogressthroughG1andenterintoSphaseinresponsetomitogens.Incontrast,knockdownofDCAF1didnotsigniﬁ-cantlyaffecttheproliferationofcontrolhumanSchwanncells(Figure7F).Together,theseresultsindicatethatCRL4DCAF1isnecessaryforNF2-dependenthyperproliferation,anchorage-independentgrowth,andtumorigenesis.DISCUSSIONThemechanismbywhichMerlinsuppressestumorigenesishasremainedelusivesincethediscoveryoftheNF2gene.Thisstudyrevealsthattheclosed,growth-inhibitoryformofMerlintranslo-catestothenucleus,bindstotheE3ubiquitinligaseCRL4DCAF1,andsuppressesitsabilitytoubiquitylatetargetproteins.MultipleconverginglinesofevidenceindicatethatMerlin’sinhibitionofCRL4DCAF1activityisrequiredtoinducegrowtharrestandsuppresstumorigenesis.Notably,analysisofseveraltumor-derivedmutantsindicatesthatsomedisplayimpairednucleartranslocation,othersfailtointeractwithDCAF1,andstillothersbindtoDCAF1butdonotsuppressCRL4DCAF1E3ligaseactivity.Furthermore,silencingofDCAF1reversestheconsequencesofMerlininactivationinnormalcellsandsuppressestheabilityofMerlin-deﬁcienttumorcellstogrowinsoftagarandinnudemice.Theseﬁndingsindicatethatentryintothenucleusandinhi-bitionofCRL4DCAF1areintegralcomponentsofthemechanismbywhichMerlinsuppressestumorigenesis.ThemechanismsthroughwhichantimitogenicsignalsinduceMerlintoinhibitCRL4DCAF1arelikelytobecomplex.Ourresultssuggestthatthesesignalspromote,largelythroughinhibitionofPAK,accumulationoftheclosedformofMerlin,whichFigure7.SilencingofDCAF1SuppressestheTumorigenicPotentialofMerlin-DeﬁcientCells(A)Meso-33cellswereinfectedwithlentiviralvectorsencodingtwodistinctshRNAstargetingDCAF1(sh-1andsh-2)oracontrolshRNA(sh-Contr.)andsubjectedtoimmunoblotting.(B)FC-1801cellstreatedasin(A).Cellsinfectedwithsh-1werealsoinfectedwitharetroviralvectorencodingashRNA-resistantversionofDCAF1orwithemptyvector.Immunoblottingwasasindi-cated.(C)Meso-33cellsinfectedwiththeindicatedlenti-viralvectorsweresubjectedtosoftagarassay.Thegraphillustratesthetotalnumber(±SEM)ofcoloniespresentineachwellafter2weeksofculture.Representativeimagesareshown.(DandE)TwomillionFC-1801cellsinfectedwiththeindicatedlentiviralvectorswereinjectedsubcutaneouslyinnudemice.(D)showstheincreaseinvolume(±SEM)overtimeoftumorsgeneratedbycellsinfectedwithlentivirusesencodingacontrolshRNA(sh-Control)ortwodistinctshRNAstargetingDCAF1(sh-1andsh-2).(E)showstheincreaseinvolume(±SEM)overtimeoftumorsgeneratedbycellsinfectedwithsh-1andeitheraretroviralvectorencodingashRNA-resistantversionofDCAF1oremptyvector.Datawereobtainedfromthesameexperiment.Notethedifferentscaleoftheyaxesofthetwographs.(F)PrimarySchwanncellsfromtwonormalindividuals(NF2+/+)andSchwannomacellsfromtwoNF2patients(NF2 / )wereinfectedwithlentivirusesencodingashRNAtargetingDCAF1(sh-2)oracontrolshRNA(sh-Co.),deprivedofgrowthfactors,restimulatedwithmitogensinthepresenceofBrdU,andsubjectedtoanti-BrdUstaining.Thegraphshowsthepercentage(±SEM)ofBrdU+cells.SeealsoFigureS6.Cell140,477–490,February19,2010ª2010ElsevierInc.487translocatesintothenucleus.Merlindoesnotcontainaclassicalimportin-anuclearlocalizationsequencebuthasaC-terminalCRM1-dependentnuclearexportsignal(KresselandSchmucker,2002).MutationalanalysissuggeststhattheFERMdomainisnecessaryandsufﬁcientfornuclearentry,whereastheC-terminalcoiled-coildomaininhibitsthisprocessunlessitisfoldedbackandinteractswiththeFERMdomain.Inadditionorinstead,unfoldingoftheC-terminalhelicaldomainmayexposethenuclearexportsignalandtherebyfacilitateMerlin’sexitfromthenucleus.Interestingly,otherFERMdomainproteins,suchastheisoformsHandRofband4.1andFAK,appeartoshuttleinandoutofthenucleusthroughsimilarconformationaltransitions(Gascardetal.,1999;Limetal.,2008;Luqueetal.,1998).Uponenteringthenucleus,theclosedformofMerlinbindstotheC-terminalsegmentofDCAF1.OurresultsindicatethatMerlinisnotasubstrateofCRL4DCAF1butexertsitsantimito-genicfunctionbyblockingDCAF1-dependentrecruitmentorubiquitylationofCRL4DCAF1substrates.SincesubdomainAoftheFERMdomainofMerlinconsistsofanubiquitin-likefold(Shimizuetal.,2002),Merlinmayfunctionasaninhibitorypseu-dosubstrateforCRL4DCAF1.ReconstitutionofCRL4DCAF1ligaseactivityinvitrowillbenecessarytodirectlytestthismodel.Irre-spectiveofthespeciﬁcmechanismbywhichMerlininhibitsCRL4DCAF1,severallinesofevidencesupporttheconclusionthatthisinhibitoryinteractionrestrainscellproliferation.First,inactivationofMerlinenablesnormalcellstoexitfromcontactinhibitionandtoundergocellcycleprogression,whiledepletionofDCAF1suppressesbotheffects.Second,enforcedexpres-sionofaMerlin-insensitivemutantofDCAF1counteractstheantimitogeniceffectofMerlin.Third,depletionofDCAF1sup-presseshyperproliferationinMerlin-deﬁcientSchwannomaandmesotheliomacellsbutinhibitstheirnormalcounterparttoalesserextent,consistentwiththehypothesisthatlossofMerlinactivatesoncogenicsignalingthroughCRL4DCAF1.Finally,silencingofDCAF1suppressestheabilityofprimaryhumanSchwannomacellsfromNF2patientstoproliferateinvitro,sug-gestingthatderegulatedCRL4DCAF1activitycontributestothepathogenesisofNF2.CRL4ligaseshavebeenimplicatedinchromatinremodeling,DNAreplication,andtheresponsetoDNAdamage(LeeandZhou,2007;O’ConnellandHarper,2007).Forexample,CRL4DDB2promotestheubiquitylationofseveralhistonesandtheDNArepaircomponentsDDB2andXPC,restrictingthethresholdofDNAdamageresponseandinhibitingUV-inducedskincarcinogenesis,CRL4CSAmediatesubiquitylationofCSB,aSWI2/SNF2ATP-dependentchromatinremodelingenzyme,andCRL4DET1-Cop1promotesubiquitylationandproteasome-mediateddegradationofthetranscriptionfactorc-Jun(reviewedinLeeandZhou,2007andO’ConnellandHarper,2007;Liuetal.,2009).AlthoughthephysiologicalsubstratesofCRL4DCAF1havenotbeenidentiﬁed,ourresultssuggestthatCRL4DCAF1broadlyregulatesgeneexpression.Infact,expressionofMerlinanddepletionofDCAF1causesimilarchangesintheexpressionofseveralhundredgenes,suggestingthatMerlincontrolsawidegeneexpressionprogramthroughinhibitionofCRL4DCAF1.Notably,thisprogramincludestheinhibitionofgenesinvolvedinpromotingprogressionthrougheachphaseofthecellcycleaswellastheupregulationofgenesinvolvedingrowtharrestandapoptosis.Parenthetically,wespeculatethatknockdownofDCAF1maycauseanaccumulationofMerlin-deﬁcientcellsinG1becauselossofMerlinspeciﬁcallyderegulatesthisphaseofthecellcycle.Inaddition,wehaveobservedthatMerlincontrols,throughCRL4DCAF1,theexpressionofgenesinvolvedinreceptortyrosinekinaseandadhesionsignaling,intracellulartrafﬁcking,andasubsetofHippopathwaytargetgenes.TheabilityofCRL4DCAF1toregulatethesegenesmayexplainsomeoftheeffectsthatMerlinhasbeenreportedtoexertonreceptortyrosinekinaseandadhesionsignaling(Ammounetal.,2008;Curtoetal.,2007;Kissiletal.,2003;Lallemandetal.,2009;Okadaetal.,2005;Poulikakosetal.,2006;Shawetal.,2001).Theobservationthatre-expressionofMerlinanddepletionofDCAF1induceageneexpressionprogramofsimilarbreadth,speciﬁcity,andscopereinforcesthemodelthatMerlinsuppressestumorigenesisthroughinhibitionofCRL4DCAF1.Theanalysisoftumor-derivedmutations,inparticularmissensemutations,hasprovidedconsiderableinsightintothefunctionofimportanttumorsuppressors,suchasP53,RB,PTEN,andAPC.WehavestudiedsixpathogenicmissensemutationsmappingtotheFERMdomainofMerlinandfoundthateachofthemimpairstheabilityofMerlintoaccumulateinthenucleusand/orbindtoDCAF1.BothtypesofdefectsdisrupttheassociationofMerlinwithCRL4DCAF1.Incontrast,severetruncationmutants,suchas341X,displayincreasedaccumula-tioninthenucleusandinteractionwithCRL4DCAF1invivobutfailtosuppressligaseactivity.Amongthemissensemutations,L64R,F62S,andL64P,locatedinsubdomainA,disruptbindingtoDCAF1invitro,whereasL141PandA211D,mappingtosub-domainB,donot.Furthermore,E270G,whichremovesasinglechargefromthesurfaceofsubdomainC,drasticallyreducesbindingtoDCAF1invitro.TheseresultsimplicatesubdomainsAandCininteractionwithDCAF1andsuggestthatmutationsinotherportionsoftheprotein,suchassubdomainBandthehelicalsegment,mayaffectnuclearlocalizationdeterminantsordisrupttheclosedconformationthatisrequiredfornuclearaccumulation.TheobservationthatmanypathogenicNF2muta-tionsdisrupt,andseveralothersarepredictedtodisrupt,theabilityofMerlintointeractwithortosuppressCRL4DCAF1providesstronggeneticevidencethatMerlinsuppressestumor-igenesisbyinhibitingthisE3ligase.Inconclusion,ourresultsindicatethatNF2-dependenttumor-igenesisarisesfromtheinabilityofmutantMerlintoenterintothenucleusandtosuppressCRL4DCAF1-dependentgeneexpres-sion.Thisdelineatedtumor-suppressorpathwaybearsantitheticresemblancetotheWnt/b-cateninpathway,whereanintercel-lularsignalhijacksthecytoskeletalcomponentb-catenintopromoteoncogenicgeneexpressioninthenucleus(Clevers,2006).Identiﬁcationofthesubstrate(s)ofCRL4DCAF1andeluci-dationofthemechanismthroughwhichthisligaseexertsitspro-proliferativeandanti-apoptoticroleshouldhelptogeneratetargetedtherapiesforNF2mutanttumors.EXPERIMENTALPROCEDURESMaterialsandStandardProtocolsCells,antibodies,vectors,andothermaterialsaredescribedintheExtendedExperimentalProcedures.Theprotocolsusedforimmunoprecipitation,GST488Cell140,477–490,February19,2010ª2010ElsevierInc.pulldown,subcellularfractionation,andimmunoblottingareoutlinedintheExtendedExperimentalProcedures.TAPandMassSpectrometryCos7cellstransientlyexpressingFH-taggedMerlinorMerlin-L64PwerelysedinRIPAbufferandsubjectedtoTAPusingtheFLAGHATandemAfﬁnityPuriﬁcationKit(SigmaTP0010).ProteinswereseparatedbySDS-PAGE,visualizedwithGelcode(Pierce),andsubjectedtoMALDI-reTOF-MS/MS.Alternatively,gelstacksweresubjectedtonanoLC-MS/MS.SeedetailsintheExtendedExperimentalProcedures.ImmunoﬂuorescentStainingCellswereﬁxedwith4%paraformaldehydeinPBSfor20minandincubatedinpermeabilizationbuffer(PDT:0.3%sodiumdeoxycholateand0.3%TritonX-100inPBS)for30minonice.Fixationandpermeabilizationwithorganicsolvents,suchasmethanoloracetone,orﬁxationwithparaformaldehydefollowedbypermeabilizationwith0.5%TritonX-100alonefor20mindidnotallowefﬁcientdetectionofMerlininthenucleus.Afterﬁxationandpermeabi-lization,cellswereincubatedovernightat4CwithprimaryantibodiesdilutedinPDT.AfterwashingwithPDT,cellswereincubatedwithsecondaryanti-bodiesdilutedinPDTfor2hrat4C.CellswerewashedwithPDT,rinsedwithPBS,andmountedinGelvatol.Whenindicated,nucleiwerestainedwithDAPI.UbiquitylationAssayCos7cellsweretransfectedwithindicatedplasmidsand,whenindicated,treatedwith25mMMG132for6hr.Lysateswereincubatedwitheitheranti-FlagbeadsorcontrolmouseIgGbeads.Elutedproductsweresubjectedtoimmunoblotting.DetailedproceduresaredescribedintheExtendedExperi-mentalProcedures.BrdUIncorporationAssayCellsweresynchronizedinG0bygrowthfactordeprivationorgrowthtohighdensityandthenstimulatedwithmitogensfor24hrinthepresenceofBrdU.Anti-BrdUstainingwasusedtomeasureprogressionthroughG1andentryinSphase.SeedetailsintheExtendedExperimentalProcedures.GeneExpressionandSilencingRetroviralandlentiviralvectorsencodingrecombinantproteinsorshRNAsweregeneratedaspreviouslydescribed(Pylayevaetal.,2007).SequencesforshRNAsanddetailedproceduresaredescribedintheExtendedExperi-mentalProcedures.DNAMicroarrayAnalysisFC-1801cellswereleftuntreatedortransducedwithlentivirusesencodingsh-control,sh-DCAF1,Merlin-WT,Merlin-L64P,oracombinationofvirusesencodingsh-DCAF1andMerlin-WTandwereplatedintriplicateatsubconﬂu-entdensityincompletemedium.ComplementaryDNAs(cDNAs)werehybrid-izedtoGeneChipMouseGenome430a2.0Arraychips(Affymetrix).RawdataareavailableinGeneExpressionOmnibus(accessionnumberGSE19305).DataanalysisisdescribedintheExtendedExperimentalProcedures.SoftAgarandTumorigenicityAssayForsoftagarassay,cellsweretrypsinized,resuspendedincompletemedium,andplatedin0.34%lowmeltingtemperatureagarose(FMCBioproducts)incompletemedium.Meso-33cellswereseededat23104andFC-1801at63104perwellin6-wellUltraLowClusterPlates(Costar).Fortumorigenicityassay,23106FC-1801cellsweresuspendedincalcium/magnesium-freePBSandinjectedsubcutaneouslyintotherightﬂankofnudemice.Tumorvolumesweredeterminedbycalipermeasurement.ACCESSIONNUMBERSTheDNAmicroarraydatasetreportedinthispaperhasbeendepositedintheGeneExpressionOmnibusofNCBIwiththeaccessionnumberGSE19305.SUPPLEMENTALINFORMATIONSupplementalInformationincludesExtendedExperimentalProcedures,sixﬁgures,andonetableandcanbefoundwiththisarticleonlineatdoi:10.1016/j.cell.2010.01.029.ACKNOWLEDGMENTSWethankJ.Brugge,S.Jhanwar,andD.Limforcelllines,M.Paganoforconstructs,L.FabrizioandM.Yanevaforhelpwithmassspectrometry,andmembersoftheGiancottilaboratoryfordiscussions.ThisworkwassupportedbytheBakerStreetFoundationandNationalInstitutesofHealth(NIH)CancerCenterSupportGrantP30CA08748.W.L.isrecipientofaYoungInvestigatorAwardfromtheChildren’sTumorFoundation.P.Z.wassupportedbyNIHgrantR01CA098210.Received:January22,2009Revised:August7,2009Accepted:January16,2010Published:February18,2010REFERENCESAhronowitz,I.,Xin,W.,Kiely,R.,Sims,K.,MacCollin,M.,andNunes,F.P.(2007).MutationalspectrumoftheNF2gene:ameta-analysisof12yearsofresearchanddiagnosticlaboratoryﬁndings.Hum.Mutat.28,1–12.Ammoun,S.,Flaiz,C.,Ristic,N.,Schuldt,J.,andHanemann,C.O.(2008).Dissectingandtargetingthegrowthfactor-dependentandgrowthfactor-independentextracellularsignal-regulatedkinasepathwayinhumanschwannoma.CancerRes.68,5236–5245.Bretscher,A.,Edwards,K.,andFehon,R.G.(2002).ERMproteinsandmerlin:integratorsatthecellcortex.Nat.Rev.Mol.CellBiol.3,586–599.Cho,E.,Feng,Y.,Rauskolb,C.,Maitra,S.,Fehon,R.,andIrvine,K.D.(2006).DelineationofaFattumorsuppressorpathway.Nat.Genet.38,1142–1150.Clevers,H.(2006).Wnt/beta-cateninsignalingindevelopmentanddisease.Cell127,469–480.Curto,M.,Cole,B.K.,Lallemand,D.,Liu,C.H.,andMcClatchey,A.I.(2007).Contact-dependentinhibitionofEGFRsignalingbyNf2/Merlin.J.CellBiol.177,893–903.Gascard,P.,Nunomura,W.,Lee,G.,Walensky,L.D.,Krauss,S.W.,Takakuwa,Y.,Chasis,J.A.,Mohandas,N.,andConboy,J.G.(1999).Decipheringthenuclearimportpathwayforthecytoskeletalredcellprotein4.1R.Mol.Biol.Cell10,1783–1798.Gutmann,D.H.,Hirbe,A.C.,andHaipek,C.A.(2001).Functionalanalysisofneuroﬁbromatosis2(NF2)missensemutations.Hum.Mol.Genet.10,1519–1529.Hamaratoglu,F.,Willecke,M.,Kango-Singh,M.,Nolo,R.,Hyun,E.,Tao,C.,Jafar-Nejad,H.,andHalder,G.(2006).Thetumour-suppressorgenesNF2/MerlinandExpandedactthroughHipposignallingtoregulatecellproliferationandapoptosis.Nat.CellBiol.8,27–36.Hrecka,K.,Gierszewska,M.,Srivastava,S.,Kozaczkiewicz,L.,Swanson,S.K.,Florens,L.,Washburn,M.P.,andSkowronski,J.(2007).LentiviralVprusurpsCul4-DDB1[VprBP]E3ubiquitinligasetomodulatecellcycle.Proc.Natl.Acad.Sci.USA104,11778–11783.Huang,J.,andChen,J.(2008).VprBPtargetsMerlintotheRoc1-Cul4A-DDB1E3ligasecomplexfordegradation.Oncogene27,4056–4064.James,M.F.,Han,S.,Polizzano,C.,Plotkin,S.R.,Manning,B.D.,Stemmer-Rachamimov,A.O.,Gusella,J.F.,andRamesh,V.(2009).NF2/merlinisanovelnegativeregulatorofmTORcomplex1,andactivationofmTORC1isassociatedwithmeningiomaandschwannomagrowth.Mol.Cell.Biol.29,4250–4261.Jin,H.,Sperka,T.,Herrlich,P.,andMorrison,H.(2006a).TumorigenictransformationbyCPI-17throughinhibitionofamerlinphosphatase.Nature442,576–579.Cell140,477–490,February19,2010ª2010ElsevierInc.489Jin,J.,Arias,E.E.,Chen,J.,Harper,J.W.,andWalter,J.C.(2006b).AfamilyofdiverseCul4-Ddb1-interactingproteinsincludesCdt2,whichisrequiredforSphasedestructionofthereplicationfactorCdt1.Mol.Cell23,709–721.Kaempchen,K.,Mielke,K.,Utermark,T.,Langmesser,S.,andHanemann,C.O.(2003).UpregulationoftheRac1/JNKsignalingpathwayinprimaryhumanschwannomacells.Hum.Mol.Genet.12,1211–1221.Kissil,J.L.,Johnson,K.C.,Eckman,M.S.,andJacks,T.(2002).Merlinphos-phorylationbyp21-activatedkinase2andeffectsofphosphorylationonmerlinlocalization.J.Biol.Chem.277,10394–10399.Kissil,J.L.,Wilker,E.W.,Johnson,K.C.,Eckman,M.S.,Yaffe,M.B.,andJacks,T.(2003).Merlin,theproductoftheNf2tumorsuppressorgene,isaninhibitorofthep21-activatedkinase,Pak1.Mol.Cell12,841–849.Kressel,M.,andSchmucker,B.(2002).NucleocytoplasmictransferoftheNF2tumorsuppressorproteinmerlinisregulatedbyexon2andaCRM1-depen-dentnuclearexportsignalinexon15.Hum.Mol.Genet.11,2269–2278.Lallemand,D.,Curto,M.,Saotome,I.,Giovannini,M.,andMcClatchey,A.I.(2003).NF2deﬁciencypromotestumorigenesisandmetastasisbydestabiliz-ingadherensjunctions.GenesDev.17,1090–1100.Lallemand,D.,Manent,J.,Couvelard,A.,Watilliaux,A.,Siena,M.,Chareyre,F.,Lampin,A.,Niwa-Kawakita,M.,Kalamarides,M.,andGiovannini,M.(2009).MerlinregulatestransmembranereceptoraccumulationandsignalingattheplasmamembraneinprimarymouseSchwanncellsandinhumanschwannomas.Oncogene28,854–865.Lee,J.,andZhou,P.(2007).DCAFs,themissinglinkoftheCUL4-DDB1ubiquitinligase.Mol.Cell26,775–780.Lim,S.T.,Chen,X.L.,Lim,Y.,Hanson,D.A.,Vo,T.T.,Howerton,K.,Larocque,N.,Fisher,S.J.,Schlaepfer,D.D.,andIlic,D.(2008).NuclearFAKpromotescellproliferationandsurvivalthroughFERM-enhancedp53degradation.Mol.Cell29,9–22.Liu,L.,Lee,S.,Zhang,J.,Peters,S.B.,Hannah,J.,Zhang,Y.,Yin,Y.,Koff,A.,Ma,L.,andZhou,P.(2009).CUL4AabrogationaugmentsDNAdamageresponseandprotectionagainstskincarcinogenesis.Mol.Cell34,451–460.Lo´pez-Lago,M.A.,Okada,T.,Murillo,M.M.,Socci,N.,andGiancotti,F.G.(2009).LossofthetumorsuppressorgeneNF2,encodingmerlin,constitutivelyactivatesintegrin-dependentmTORC1signaling.Mol.Cell.Biol.29,4235–4249.Luque,C.M.,Lallena,M.J.,Alonso,M.A.,andCorreas,I.(1998).Analternativedomaindeterminesnuclearlocalizationinmultifunctionalprotein4.1.J.Biol.Chem.273,11643–11649.Maddika,S.,andChen,J.(2009).ProteinkinaseDYRK2isascaffoldthatfacilitatesassemblyofanE3ligase.Nat.CellBiol.11,409–419.McCall,C.M.,MilianideMarval,P.L.,Chastain,P.D.,2nd,Jackson,S.C.,He,Y.J.,Kotake,Y.,Cook,J.G.,andXiong,Y.(2008).Humanimmunodeﬁciencyvirustype1Vpr-bindingproteinVprBP,aWD40proteinassociatedwiththeDDB1-CUL4E3ubiquitinligase,isessentialforDNAreplicationandembryonicdevelopment.Mol.Cell.Biol.28,5621–5633.McClatchey,A.I.,andFehon,R.G.(2009).MerlinandtheERMproteins—regulatorsofreceptordistributionandsignalingatthecellcortex.TrendsCellBiol.19,198–206.McClatchey,A.I.,andGiovannini,M.(2005).Membraneorganizationandtumorigenesis—theNF2tumorsuppressor,Merlin.GenesDev.19,2265–2277.Muranen,T.,Gro¨nholm,M.,Renkema,G.H.,andCarpe´n,O.(2005).Cellcycle-dependentnucleocytoplasmicshuttlingoftheneuroﬁbromatosis2tumoursuppressormerlin.Oncogene24,1150–1158.O’Connell,B.C.,andHarper,J.W.(2007).Ubiquitinproteasomesystem(UPS):whatcanchromatindoforyou?Curr.Opin.CellBiol.19,206–214.Okada,T.,Lopez-Lago,M.,andGiancotti,F.G.(2005).Merlin/NF-2mediatescontactinhibitionofgrowthbysuppressingrecruitmentofRactotheplasmamembrane.J.CellBiol.171,361–371.Okada,T.,You,L.,andGiancotti,F.G.(2007).SheddinglightonMerlin’swizardry.TrendsCellBiol.17,222–229.Poulikakos,P.I.,Xiao,G.H.,Gallagher,R.,Jablonski,S.,Jhanwar,S.C.,andTesta,J.R.(2006).Re-expressionofthetumorsuppressorNF2/merlininhibitsinvasivenessinmesotheliomacellsandnegativelyregulatesFAK.Oncogene25,5960–5968.Pylayeva,Y.,Guo,W.,andGiancotti,F.G.(2007).Analysisofintegrinsignalingingeneticallyengineeredmousemodelsofmammarytumorprogression.MethodsEnzymol.426,439–461.Rong,R.,Tang,X.,Gutmann,D.H.,andYe,K.(2004).Neuroﬁbromatosis2(NF2)tumorsuppressormerlininhibitsphosphatidylinositol3-kinasethroughbindingtoPIKE-L.Proc.Natl.Acad.Sci.USA101,18200–18205.Schrecengost,R.S.,Riggins,R.B.,Thomas,K.S.,Guerrero,M.S.,andBouton,A.H.(2007).Breastcancerantiestrogenresistance-3expressionregulatesbreastcancercellmigrationthroughpromotionofp130Casmembranelocal-izationandmembranerufﬂing.CancerRes.67,6174–6182.Shaw,R.J.,Paez,J.G.,Curto,M.,Yaktine,A.,Pruitt,W.M.,Saotome,I.,O’Bryan,J.P.,Gupta,V.,Ratner,N.,Der,C.J.,etal.(2001).TheNf2tumorsuppressor,merlin,functionsinRac-dependentsignaling.Dev.Cell1,63–72.Shimizu,T.,Seto,A.,Maita,N.,Hamada,K.,Tsukita,S.,Tsukita,S.,andHakoshima,T.(2002).Structuralbasisforneuroﬁbromatosistype2.CrystalstructureofthemerlinFERMdomain.J.Biol.Chem.277,10332–10336.Tang,X.,Jang,S.W.,Wang,X.,Liu,Z.,Bahr,S.M.,Sun,S.Y.,Brat,D.,Gutmann,D.H.,andYe,K.(2007).Aktphosphorylationregulatesthetumour-suppressormerlinthroughubiquitinationanddegradation.Nat.CellBiol.9,1199–1207.Xiao,G.H.,Beeser,A.,Chernoff,J.,andTesta,J.R.(2002).p21-activatedkinaselinksRac/Cdc42signalingtomerlin.J.Biol.Chem.277,883–886.490Cell140,477–490,February19,2010ª2010ElsevierInc.426	VOLUME 16 | NUMBER 4 | APRIL 2013 nature neurOSCIenCeartICleSNeurons of both the peripheral nervous system (PNS) and central nervous system (CNS) are highly polarized complex cellular units. During development, several morphological steps are required for normal functioning and plasticity of the developing nervous system. New neurons migrate to their appropriate locations, extend axons and dendrites into the correct target regions, and form synapses with their partners. These distinct morphological processes depend on the spatiotemporal control of intrinsic neuronal signaling networks in which the Rho family of small GTPases are important regulatory components1. The signaling mechanisms that establish these highly plastic neuronal processes are well characterized, but the manner in which these neurons achieve and maintain more stable structures, such as axon radial growth over far-reaching distances, throughout life is less well understood.Neurofilaments are at least one component known to be required to promote and maintain radial growth also known as axonal cal-iber2. Neurofilaments are neuron-specific intermediate filaments composed of NF-H (200 kDa), NF-M (150 kDa) and NF-L (68 kDa) subunits. To date, transcriptional upregulation3 and/or extensive side-arm phosphorylation of the NF-M or NF-H subunits4 are thought to determine structural integrity in axons2, whereas the upstream signaling mechanisms that control and modify neurofilaments are not well characterized. Nefl (which encodes NF-L) gene disruption in mice results in loss of neurofilaments and subsequent failure of axons to grow radially5. Neurofilament abnormalities in humans have been documented in a number of neurological diseases, including several inherited neuropathies2. Inherited genetic mutations related to neurofilaments induce axonal alterations that result in nerve damage, leading to typical neuropathic symptoms, such as loss of sensation, pain or muscular weakness6.NF2 is a hereditary tumor syndrome caused by inactivation of the NF2 tumor suppressor gene encoding merlin. Apart from gliogenic tumors in the PNS and CNS, most NF2 patients develop peripheral neuropathies7,8. NF2-related neuropathy mostly appears in a sym-metric and distal manner and occurs in the absence of compressive spinal or peripheral tumors8, indicating a systemic, rather than focal, etiology. This suggests the involvement of factors other than gross tumor burden.We identified a function for merlin in neurons of the developing CNS9. At least two alternatively spliced merlin variants are expressed: merlin isoform 1 (merlin-iso1), which lacks exon 16, and merlin-iso2, which contains exon 16 and encodes a C-terminally truncated pro-tein. Merlin-iso1 has been established as a tumor suppressor, but little is known about merlin-iso2’s function. We found that both merlin 1Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena, Germany. 2Institute of Anatomy, Anatomy and Cell Biology, University of Bonn, Bonn, Germany. 3Inserm U674, Université Paris, Paris, France. 4Institute of Molecular Cell Biology and Center for Sepsis Control and Care, Jena University Hospital, Friedrich Schiller University, Jena, Germany. 5Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA. 6Department of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 7Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 8Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK. 9Institute of Neuropathology, RWTH Aachen, University Hospital Aachen, Aachen, Germany. 10House Ear Institute, Center for Neural Tumor Research, Los Angeles, California, USA. 11Present address: Inserm U944, CNRS U7212, Université Paris, Institut Universitaire d’Hématologie, Paris, France. 12These authors contributed equally to this work. Correspondence should be addressed to H.M. (helen@fli-leibniz.de).Received 10 September 2012; accepted 30 January 2013; published online 3 March 2013; doi:10.1038/nn.3348Merlin isoform 2 in neurofibromatosis type 2–associated polyneuropathyAlexander Schulz1, Stephan L Baader2,12, Michiko Niwa-Kawakita3,11,12, Marie Juliane Jung1, Reinhard Bauer4, Cynthia Garcia5, Ansgar Zoch1, Stephan Schacke1, Christian Hagel6, Victor-Felix Mautner7, C Oliver Hanemann8, Xin-Peng Dun8, David B Parkinson8, Joachim Weis9, J Michael Schröder9, David H Gutmann5, Marco Giovannini10 &  Helen Morrison1The autosomal dominant disorder neurofibromatosis type 2 (NF2) is a hereditary tumor syndrome caused by inactivation of the NF2 tumor suppressor gene, encoding merlin. Apart from tumors affecting the peripheral and central nervous systems, most NF2 patients develop peripheral neuropathies. This peripheral nerve disease can occur in the absence of nerve-damaging tumors, suggesting an etiology that is independent of gross tumor burden. We discovered that merlin isoform 2 (merlin-iso2) has a specific function in maintaining axonal integrity and propose that reduced axonal NF2 gene dosage leads to NF2-associated polyneuropathy. We identified a merlin-iso2–dependent complex that promotes activation of the GTPase RhoA, enabling downstream Rho-associated kinase to promote neurofilament heavy chain phosphorylation. Merlin-iso2–deficient mice exhibited impaired locomotor capacities, delayed sensory reactions and electrophysiological signs of axonal neuropathy. Sciatic nerves from these mice and sural nerve biopsies from NF2 patients revealed reduced phosphorylation of the neurofilament H subunit, decreased interfilament spacings and irregularly shaped axons.npg© 2013 Nature America, Inc. All rights reserved.nature neurOSCIenCe	VOLUME 16 | NUMBER 4 | APRIL 2013 427artICleS isoforms were able to restrict dendritic morphogenesis through inhi-bition of the small GTPase Rac1 (ref. 9). Our finding suggest that merlin, a known tumor suppressor, is involved in controlling highly plastic neuronal processes such as dendrites in the developing brain. We hypothesize that merlin may also function in the development and maintenance of more stable structures such as axons, and suggest that the specific loss or reduction of merlin in neurons may contribute to NF2-related polyneuropathy.RESULTSMerlin-iso2 mediates neurofilament phosphorylation Using isoform-specific antibodies, we detected both merlin isoforms in cerebellar Purkinje cell somata (Fig. 1a,b) and dendrites in the molecular layer. Only isoform 2 was localized to axonal processes run-ning from Purkinje cells toward the white cerebellar matter (Fig. 1a,b and Supplementary Fig. 1).Merlin-iso2–positive signals in Purkinje cells began to appear between postnatal days 9 and 15 (P9 and P15) in Purkinje cell axons (Fig. 1 and Online Methods), coinciding with a period of Purkinje cell axonal maturation characterized by extensive neurofilament phos-phorylation and diameter adjustment10. In addition, we detected predominant merlin-iso2 expression in cells belonging to the PNS, including sciatic nerve axons (Supplementary Fig. 2) and axons of primary dorsal root ganglion (DRG) cells (Fig. 1c,d).We used primary neuronal monocultures independent of the associated influence of glial cells and the murine embryonic carci-noma P19 cell line, which are known to differentiate into neuronal cells11, to investigate whether merlin-iso2 affects axon–intrinsic morphogenesis. Specific knockdown of merlin-iso2 or of both isoforms in isolated primary cerebellar neurons decreased axonal diameter, whereas merlin-iso1–specific knockdown had no detect-able influence (Fig. 1e and Supplementary Fig. 3a). Concordantly, overexpression of merlin-iso2 elicited a substantial increase  in axonal diameter compared with overexpression of merlin-iso1 (Fig. 1f). The decrease in axonal diameter resulting from merlin-so2 protein reduction could be rescued by the expression of human merlin-iso2 in mouse P19 cells (Fig. 2).We investigated whether the merlin-iso2 effect on axonal caliber is mediated through neurofilament regulation. Although the total amount of neurofilaments remained unaffected (data not shown), the phosphorylation status of NF-H in primary cerebellar neurons was decreased by merlin-iso2 knockdown, but merlin-iso1 knockdown (Fig. 2a). Accordingly, merlin-iso2 overexpression led to a robust neurofilament phosphorylation in P19 cells, whereas merlin-iso1 overexpression had only minor effects (Fig. 2b). Taken together, these findings establish a specific intrinsic neuronal role of merlin-iso2 in the regulation of neurofilament phosphorylation that leads to radial axonal growth.Axonal merlin-iso2 involves RhoA signaling Neurofilaments are phosphorylated by several serine/threonine kinases2. Because merlin lacks any endogenous kinase activity, we screened for serine/threonine kinases that were involved in mer-lin and/or neurofilament signaling (Supplementary Table 1). We monitored whether the knockdown of each tested kinase could pre-vent or decrease neurofilament phosphorylation following merlin-iso2 overexpression in vitro. One of the kinases that we identified,  Rho-associated kinase (ROCK), has been reported to directly phos-phorylate neurofilaments in vitro12. Overexpression of merlin-iso2 aePrimary cerebellarneuronsfP19 cellsMerlin-iso1MLbMerlin-iso2MLAxMerlin-iso2pNF-HcMerlin-iso1pNF-HdScrambled Nf2siRNA Nf2siRNA Nf2-iso1vc2.04.03.02.01.001.5n.s.n.s.*******1.00.50Mean axon caliber (µm)Mean axon caliber (µm)iso1iso2Merlinvciso1iso2ActinScrambled Nf2siRNA Nf2siRNA Nf2-iso1siRNA Nf2-iso2Merlin-iso2Merlin-iso1ActinsiRNA Nf2-iso2Merlin-iso2pNF-HMergedMerlin-iso1pNF-HMergedFigure 1 Merlin-iso2 expressed in axons, mediates neurofilament phosphorylation and axonal radial growth. (a,b) Merlin-iso1 (a) and merlin-iso2 (b) immunolabeling in the cerebellar cortex at postnatal day 15. Merlin-iso2 was expressed in Purkinje cell axons (Ax arrow). Arrowheads indicate Purkinje cell somata. Molecular layer (ML) is mainly composed of Purkinje cell dendrites. Scale bars represent 75 µm and 15 µm (magnified images). White boxes indicate areas shown at higher magnification. We quantified merlin-iso2 expression in Purkinje cell axons during postnatal development (P3–15) and in adults (P3, 0%; P5, 0%;  P9, 5.15%; P15, 45.53%; adult, 96.92%; n = 50 axons from 2 mice for each investigated age). (c,d) Merlin isoform–specific immunolabeling (green) in primary DRG neurons. Co-staining with phosphorylated neurofilaments (pNF-H, red) indicates expression in axons. Merlin-iso1 was present in axonal growth cones (arrows) and merlin-iso2 was detected along the whole axon. Scale bars represent 20 µm. (e,f) Quantification of axon diameters following specific knockdown (duplexes) in primary cerebellar neurons (**P < 0.01, t = 4.119, degrees of freedom (df) = 20;  ***P < 0.001, t = 5.809, df = 20; n = 393 cells from 3 mice; mean + s.e.m.; n.s., not significant, P = 0.16). Scrambled control (scrambled Nf2), both isoforms (siRNA Nf2), merlin-iso1 (siRNA Nf2-iso1), merlin-iso2  (siRNA Nf2-iso2) or following overexpression in differentiated P19 cells are shown in e. Empty vector control (vc), merlin-iso1 (iso1), merlin-iso2 (iso2) are shown in f (**P < 0.01, t = –8.201, df = 19; n = 460 cells; mean + s.e.m.; n.s., not significant, P = 0.07). Immunoblots for actin (loading control), merlin-iso1 and merlin-iso2 or merlin were used to confirm knockdown and overexpression. Merlin overexpression migrated  as a doublet; the upper band representing phosphorylated merlin and the  lower band represented dephosphorylated merlin. For full-length blots  and quantitations, see Supplementary Figure 3.npg© 2013 Nature America, Inc. All rights reserved.428	VOLUME 16 | NUMBER 4 | APRIL 2013 nature neurOSCIenCeartICleSand simultaneous silencing of ROCK using siRNA prevented mer-lin-iso2–specific NF-H phosphorylation (Fig. 2d), suggesting that merlin-iso2 acts upstream of ROCK.To elucidate how merlin-iso2 regulates ROCK, we examined the activity of the GTPase RhoA, an upstream regulator of ROCK. Merlin-iso2, but not merlin-iso1, overexpression activated RhoA in P19 cells (Fig. 2e). In primary neurons, merlin-iso2 overexpression was mim-icked by the application of a Rho activator (CN01), as indicated by increased RhoA activity, NF-H phosphorylation and an increase in axonal caliber (Fig. 2f). Furthermore, application of the same Rho activator alone could rescue the axonal caliber decrease following merlin-iso2 repression in P19 cells (Fig. 2c).In addition to the CNS, we found that merlin-iso2 function is important in PNS neurons. We isolated glia-free primary DRG cells whose axons (known as afferents) relay sensory information into the CNS. A merlin-iso2–specific knockdown in these cells resulted in a decrease in neurofilament phosphorylation (Fig. 3a). We also examined the effect of merlin loss using genetically engi-neered mice bearing complete isoform-specific knockouts of merlin,  designated Nf2-iso1−/− and Nf2-iso2−/−. We confirmed merlin  isoform–specific knockout at the protein level in forebrain and hind-brain lysates (Supplementary Fig. 4c). As expected, neurofilament phosphorylation was predominantly reduced in Nf2-iso2−/− brains (Supplementary Fig. 4c). Similar to CNS nerve cells, in vitro DRG neurons isolated from Nf2-iso2−/− mice had smaller axonal diameters than wild-type control and Nf2-iso1−/− mice (Fig. 3b). Moreover,  Nf2-iso2−/− DRG neurons could be rescued by expression of merlin-iso2,  with a substantial RhoA activation accompanied by neurofilament phosphorylation and subsequent radial axonal growth (Fig. 3c and Supplementary Fig. 4d). Transfection of a constitutively active form of RhoA (RhoA 63L) into DRG cells13 resulted in an increase in  neurofilament phosphorylation and axonal caliber growth (Fig. 3d).These data indicate that RhoA activity contributes to axonal diam-eter adjustment in both the CNS and PNS. Our data imply that part of  merlin-iso2’s mechanism of action involves activation of RhoA, enabling downstream ROCK to promote neurofilament phosphorylation.Merlin assembles a multi–protein complex Guanine nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs) and GDP dissociation inhibitors (GDIs) are con-sidered to be the primary determinants in neuronal Rho regulation. Our data indicate that merlin is involved in controlling Rho activity, specifically axonal caliber growth in neurons in vitro. We therefore explored how merlin-iso2 might operate in the axon to promote Rho signaling.Because merlin has been suggested to interact with the gua-nine nucleotide dissociation inhibitor RhoGDI14, as well as with p190RhoGAP (unpublished observations), in other cell types, we hypothesized the existence of a neurofilament-associated multi- protein complex in which merlin-iso2 regulates RhoA activity in neurons. Both RhoGDI and p190RhoGAP were expressed in DRG cell axons (Supplementary Fig. 4f and 5a). The reduction of either RhoGDI or p190RhoGAP in neuronal cells led to an increase in Rho activity, neurofilament phosphorylation and radial axonal growth (Fig. 3e and Supplementary Fig. 5c,d), establishing the importance of these regulatory components per se in axonal Rho activity control.In wild-type mouse sciatic nerves, the levels of the two major merlin  isoforms, RhoA and RhoGDI remained unchanged during develop-ment (Supplementary Fig. 5e–g). The level of p190RhoGAP appeared to be higher at birth (P0) and was reduced around P20, coinciding with axonal maturation characterized by extensive neurofilament phosphorylation (Supplementary Fig. 5g).Notably, the sciatic nerves of adult Nf2-iso2−/− mice (P60) showed reduced levels of active RhoA (RhoA-GTP) and reduced  aPrimary cerebellar neuronsScrambledNf2Scrambled Nf2siRNANf2siRNANf2-iso1siRNANf2-iso2siRNA Nf2-iso2siRNA Nf2-iso2P19 cellsP19 cellsP19 cellsMean axon caliber (µm)2.01.51.00.50siRNANf2-iso2ScrambledNf2siRNANf2-iso2siRNANf2-iso2scr ROCK1scr ROCK1siRNA ROCK1vciso1iso2iso2pNF-HMerlinActinpNF-HMerlinMerlinMerlinpNF-HPlasmidiso2iso2vcActinActinActinbcd+––****+ iso2 (h)**+ CN01P19 cellsiso2iso1vceMerlinActinRhoARhoA-GTP***Mean axon caliber (µm)iso2vcCN015.04.03.02.01.00MerlinRhoA-GTPpNF-HPlasmidCN01Primary cerebellar neuronsiso2vc––+vcActinfFigure 2 Merlin mediates neurofilament  phosphorylation via the Rho-ROCK pathway.  (a) Merlin-specific knockdown in cerebellar neurons,  either both isoforms (siRNA Nf2), merlin-iso1  (siRNA Nf2-iso1) or merlin-iso2 (siRNA Nf2-iso2)  compared with scrambled control (scrambled Nf2)  (n = 3). (b) Merlin overexpression in differentiated  P19 cells. Empty vector control (vc) was compared  with merlin-iso1 (iso1) and merlin-iso2 (iso2)  (n = 3). (c) Quantification of axon diameters following  knockdown duplexes against murine merlin-iso2  (siRNA Nf2-iso2) compared with scramble control  (scrambled Nf2) (*P < 0.01, t = 3.738, df = 26,  n = 102 cells, mean + s.e.m.), co-transfection with human merlin-iso2 (+iso2) or treatment with Rho activator (+CN01) (**P < 0.01, t = –4.782,  df = 27; ***P < 0.001, t = –5.596, df = 24; n = 112 cells, mean + s.e.m.). Right, immunoblot for merlin and actin confirmed effective knockdown and transfection levels (n = 3). (d) ROCK knockdown prevented merlin-iso2–induced neurofilament phosphorylation. P19 cells were treated with scrambled control duplexes (scr) and empty vector control, scr and merlin-iso2 overexpression (iso2), siRNA ROCK and merlin-iso2 overexpression (ROCK1/iso2)  (n = 3). (e) P19 cells were measured for RhoA-GTP level after merlin-iso2 (iso2) and merlin-iso1 (iso1) overexpression compared with empty vector control (vc) (n = 3). (f) RhoA-GTP level was measured in cerebellar neurons after treatment with Rho activator (CN01) or overexpression with merlin-iso2 (iso2) compared with vector control (vc) (n = 3). Right, radial axonal growth (*P < 0.05, t = –2.381, df = 23, n = 98 cells from 3 mice; **P < 0.01,  t = –3.804, df = 22, n = 116 cells from 3 mice; mean + s.e.m.). For full-length blots and quantitations, see Supplementary Figures 3 and 4.npg© 2013 Nature America, Inc. All rights reserved.nature neurOSCIenCe	VOLUME 16 | NUMBER 4 | APRIL 2013 429artICleSphosphorylated neurofilaments (Fig. 3f). However, the total protein amounts of p190RhoGAP, RhoA and RhoGDI remained unchanged, indicating that the reduction of merlin-iso2 has no effect on the expression and/or stability of these components in adult mice.Using immunoprecipitation, we confirmed the existence of a multi-protein complex and examined its composition. Antibodies to RhoGDI co-precipitated both merlin isoforms, as well as p190RhoGAP from primary granule cell lysates (Fig. 3g). Antibodies to merlin–iso2 and merlin–iso1 both co-precipitated p190RhoGAP from sciatic nerve lysates (Fig. 3h). The fact that merlin-iso2 dif-fers from merlin-iso1 in the C terminus, a precise function distinct from the C-terminal merlin-iso1 is suggested. We tested whether a C-terminal fragment of merlin-iso2 was sufficient to associate with neurofilaments. Indeed, only the C-terminal merlin-iso2 co- immunoprecipitated with phosphorylated neurofilaments (Fig. 3i and Supplementary Fig. 6), indicating that, although both full-length isoforms can form a complex with RhoGDI and p190RhoGAP,  merlin-iso2 likely acts locally in axons.We examined the interaction between merlin and RhoGDI in vitro (Supplementary Fig. 7). No interaction was detected in vitro using purified merlin full-length proteins (Supplementary Fig. 7a,b).  An interaction could only be shown with the FERM domain of  merlin (N terminus, shared by the two isoforms) using both purified GST- and His-tagged RhoGDI. We next tested whether merlin acts as a RhoGDI displacement factor (that is, releases inactive RhoA-GDP from RhoGDI to result in RhoA activation). In an in vitro Rho activity assay15, addition of a Rho GEF induced a rapid nucleotide exchange. Addition of RhoGDI sufficiently inhibited this exchange by maintaining RhoA in its inactive form. Inclusion of N-terminal merlin (FERM domain) did not affect the intrinsic RhoA GTP loading or the activity of Rho GEF toward RhoA (Supplementary Fig. 7c) and was unable to induce release of RhoGDI from RhoA (Supplementary Fig. 7c). Taken together, at least in this in vitro assay, we could not detect merlin-dependent inhibition of RhoGDI. Other partners might be required for a complete merlin-dependent RhoGDI displacement from RhoA in vivo. In addition, in vivo full-length merlin has distinct molecular conformations16 that may be required to bind and control RhoGDI activity coordinating RhoA signal activation.Analysis of merlin isoform–specific knockout miceThe availability of isoform-specific Nf2 knockout mice enabled us to test merlin-iso2–specific functions in an intact nervous system and to determine whether merlin-iso2 loss contributes to an axonal pathogenesis of NF2-associated polyneuropathy. On the basis of our in vitro data, we expected these mice to display axonal structure alterations resulting from irregular neurofilament phosphorylation. Because aberrant axonal signals can induce secondary Schwann cell changes in older mice17, we studied young mice (2 months old), which allowed us to concentrate on specific axonal changes. Our initial  studies revealed that both mouse lines appeared to be devoid of NF2- typical tumors, suggesting a compensatory potential for the two major merlin isoforms (unpublished data).eNf2-iso2–/– DRG cellspNF-HRhoGDIActinscr arhgdiasiRNA arhgdiacNf2-iso2–/– DRG cellsiso2vcpNF-HMerlin-iso2ActinRhoA-GTPbPrimary DRG cellsNf2-iso1+/+Nf2-iso1–/–Nf2-iso2–/–Nf2-iso2+/+Mean axon caliber (µm)n.s.***1.51.00.50Primary DRG cellsaScrambledNf2siRNANf2-iso2pNF-Hiso2ActinvcRhoAwtRhoA63LMean axon caliber (µm)n.s.**1.51.00.50dPrimary DRG cellsvcRhoA wtRhoA 63LpNF-HActinRhoARhoA-GTPp190RhoGappanNF-HpNF-HActinRhoARhoA-GTPRhoGDINf2-iso2–/–Nf2-iso1–/–fSciatic nerve lysatesWild typegPrimary cerebellar neuronsIPLysatelgGRhoGDIp190RhoGapMerlin-iso2Merlin-iso1RhoGDIhSciatic nerve lysatesIPLysateIgGMerlin-iso1Merlin-iso2p190RhoGapMerliniFlag IPP19 cellsvcN-termiso2C-termiso1C-termpNF-HMerlin(anti-Flag)RhoGDIFigure 3 Merlin assembles a multi-protein complex relevant for Rho activation. (a) Merlin-iso2–specific knockdown (siRNA Nf2-iso2) in primary DRG neurons compared with scrambled duplex control (scr Nf2) (n = 3). (b) DRG neurons were isolated from isoform-specific knockout mice and axonal calibers were measured. Nf2-iso2−/− mice compared with Nf2-iso1−/− and wild-type controls (Nf2-iso2+/+ and Nf2-iso1+/+) (***P < 0.001, t = –2.687, df = 28, n = 365 cells from 3 mice, mean + s.e.m.; n.s., not significant, P = 0.11). (c) DRG neurons prepared from Nf2-iso2−/− transfected with merlin-iso2 (iso2) compared with empty vector control (vc) (n = 3). (d) Wild-type DRG cells transfected with constitutively active RhoA mutant (RhoA 63L) compared with wild-type RhoA (RhoA wt) and empty vector control (vc) (n = 3). Right, radial axon growth in vitro (**P < 0.01, t = –3.045, df = 65,  n = 361 cells from 3 mice, mean + s.e.m.; n.s., not significant). (e) Knockdown of RhoGDI (siRNA arhgdia) compared with scrambled control duplexes  (scr arhgdia) in Nf2-iso2−/− DRGs (n = 3). (f) Sciatic nerve lysates from Nf2-iso2−/− mice compared with Nf2-iso1−/− mice and wild-type mice (n = 4). (g) Immunoprecipitation (IP) of endogenous RhoGDI from primary neurons compared with IgG control (n = 3). (h) Immunoprecipitation from sciatic nerve lysates using merlin-specific antibodies (merlin-iso1 and merlin-iso2) compared with IgG control (n = 3). (i) Flag-tagged merlin N-terminal fragments (N-term), C-terminal (iso2 C-term and iso1 C-term) and empty vector control (vc) were transfected into P19 cells and immunoprecipitated with antibody to Flag (n = 4). For full-length blots and quantitations, see Supplementary Figures 4–6.npg© 2013 Nature America, Inc. All rights reserved.430	VOLUME 16 | NUMBER 4 | APRIL 2013 nature neurOSCIenCeartICleSSciatic nerve axons of Nf2-iso2−/− mice exhibited morphologi-cal abnormalities, such as misshaped and dysmorphic axons and accumulations of densely packed neurofilaments and mitochondria (Fig. 4a,b). Axonal shrinkage resulting from an irregular bending of the axonal surface led to a strong reduction in the solidity factor in both heterozygous (Nf2-iso2+/−) and homozygous (Nf2-iso2−/−) mice (Fig. 4c). Loss of merlin-iso1 had no effect on the roundness of axons. Even young merlin-iso2–deficient mice (P7) displayed a significant reduction in the solidity factor (P < 0.05; Fig. 4d), indicating that the observed phenotype originates in the early period of axonal structure maintenance. This abnormal phenotype, including axonal atrophy with shrunken and collapsed axons of peripheral nerves, resembles that described in mice with a neurofilament mutation18. Although we detected a high number of shrunken axons in Nf2-iso2−/− mice, the total number of axons and the overall axon caliber in sciatic nerve sections appeared to be unaffected (Supplementary Fig. 8a). Immunohistochemical analysis of longitudinal sciatic nerve sections from Nf2-iso2−/− mice, including Nf2-iso2−/− DRG cells cultured for 14 d (data not shown), revealed no obvious signs of degeneration, Nf2-iso2+/+Nf2-iso2–/–d Axons of younganimalseNeuromuscular junctionsNF-HBTXSolidity factor1.000.950.900.850.80**bMyelinatedaxons2,0001,5001,000500Dysmorphic axons per mm20aSciatic nerve sectionsNf2-iso2+/+Nf2-iso2–/–Nf2-iso2+/+Nf2-iso2–/–Nf2-iso2+/–*****cMyelinated axons1.000.950.90<3>53–5<3>53–5Solidity factorSolidity factor0.850.801.000.950.900.850.80**********n.s.n.s.n.s.Nf2-iso2+/+Nf2-iso2+/–Nf2-iso2–/–Nf2-iso2+/+Nf2-iso2+/–Nf2-iso2–/–Nf2-iso1+/+Nf2-iso1+/–Nf2-iso1–/–Figure 4 Axon structure abnormalities in Nf2-iso2−/− mice. (a) Electron micrographs of sciatic nerve axons from Nf2-iso2−/− mice compared  with Nf2-iso2+/+ mice. Arrow indicates densely packed neurofilaments and mitochondria. Scale bars represent 1 µm. (b) More dysmorphic sciatic nerve axons were found in Nf2-iso2+/− and Nf2-iso2−/− than in Nf2-iso2+/+ mice (**P < 0.01, t = –3.401, df = 29; ***P < 0.001,  t = –5.578, df = 34; n = 542 axons from 3 mice, mean + s.e.m.).  (c) The mean solidity factor was decreased in myelinated axons in sciatic nerve cross sections from Nf2-iso2+/− and Nf2-iso2−/− mice compared with Nf2-iso2+/+ mice, whereas loss of merlin-iso1 (Nf2-iso1−/−,  Nf2-iso1+/− and Nf2-iso1+/+ mice) had no significant effect (*P < 0.05,  t = –5.196, df = 165; **P < 0.01, t = –7.135, df = 183; ***P < 0.001, t = –5.871, df = 169; n.s., not significant; n = 1,488 axons from 3 mice, mean + s.e.m.). Axons were categorized according to their diameter  (x axis represents axon calibers in µm). (d) Sciatic nerve axons of young P7 Nf2-iso2+/− and Nf2-iso2−/− mice showed comparable solidity factors (*P < 0.05, t = –5.677, df = 1,039, n = 1,512 axons from 3 mice, mean + s.e.m.). (e) Gastrocnemius muscle fibers of Nf2-iso2+/+ and Nf2-iso2−/− mice were stained with silver impregnation (top) and immunohistochemically for acetylcholine receptor and myelinated nerve fibers (bottom). Muscle fibers are equal in size, without signs of dying muscle cells or accumulation of fat cells or connective tissue. Muscle fibers appear straight and not wrinkled and the cell bodies (arrows) are arranged along the border of the muscle fiber, not centrally. We detected equal amounts of myelinated nerve fibers by NF-H staining and  normal amounts and sizes of endplates by bungarotoxin (BTX) staining  (n = 2 mice per genotype). Scale bars represent 100 µm.Myelinated sciatic nerve axonsa**Interfilament distance (nm)806040200Nf2-iso1+/+Nf2-iso1+/–Nf2-iso1–/–bMyelinated axons8060******4020Interfilament distance (nm)0Nf2-iso2+/+Nf2-iso2+/–Nf2-iso2–/–cAxons of young animals******Interfilament distance (nm)801006040200Nf2-iso2+/+Nf2-iso2+/–Nf2-iso2–/–dSciatic nervespNF-HMpz-creMpz-cre;Nf2loxP/loxPMerlinActinFigure 5 Reduced interfilament distances in Nf2-iso2−/− mice. (a) Representative electron micrograph of a myelinated sciatic nerve axon. Upper right, 20,000× magnification. Scale bars represent 500 nm and 100 nm (inset). Single neurofilament molecules can be identified as black dots in the axoplasm. (b) Distances between single neurofilaments were quantified in sciatic nerve axons of adult Nf2-iso2+/− and Nf2-iso2−/− mice compared with Nf2-iso2+/+ mice, and adult Nf2-iso1+/− and Nf2-iso1−/− mice compared with Nf2-iso1+/+ mice (*P < 0.05, t = –4.396, df = 2,968; ***P < 0.001, t = –6.346, df = 3,021; n = 3,298 distances from 3 mice, mean + s.e.m.). (c) Young Nf2-iso2+/− and Nf2-iso2−/− mice compared with Nf2-iso2+/+ mice (***P < 0.001, t = –6.117, df = 1,066, n = 1,454 distances from 3 mice, mean + s.e.m.). (d) Sciatic nerve lysates from Mpz-cre; Nf2loxP/loxP mice showed slightly elevated levels of neurofilament phosphorylation compared with control littermates (Mpz-cre) (n = 4). For full-length blots and quantitations, see Supplementary Figure 8.npg© 2013 Nature America, Inc. All rights reserved.nature neurOSCIenCe	VOLUME 16 | NUMBER 4 | APRIL 2013 431artICleSsuch as spheroid formations or amyloid precursor protein (APP) accumulations, along axons (Supplementary Fig. 8b). As no classi-cal signs of axonal degeneration were detected, we propose that the number of normal functional axons was decreased. However, because axonal integrity is thought to be essential for myelin maintenance, it is possible that an active neurodegeneration may occur in older Nf2-iso2−/− mice. Axonal targeting also appeared to be normal in merlin isoform–specific knockout mice, despite the morphological axonal alterations. Silver impregnation and immunohistochemical staining for acetylcholine receptors and myelinated nerve fibers of gastrocnemius muscles did not show relevant alterations concerning muscular structure or nerve targeting (Fig. 4e), indicating proper muscle innervation in Nf2-iso2−/− mice.Given that phosphorylation events equate to addition of repulsive negative charges, neurofilament phosphorylation results in a larger distance between single neurofilament molecules4. Accordingly, axons of both heterozygous and homozygous Nf2-iso2−/− mice showed decreased interfilament distances as a result of reduced neurofilament phosphorylation (Fig. 5a,b). In contrast, Nf2-iso1−/− axons showed only a slight reduction in interfilament spacing. Again, comparable effects of merlin-iso2 loss could be detected in young mice at P7 (Fig. 5c).As merlin has important tumor suppressive functions in Schwann cells of the PNS19, axonal structure and shape alterations in  Nf2-iso2−/− mice could be indirectly determined by modified Schwann cell signals. In an established NF2 mouse model in which both merlin  isoforms are conditionally deleted in Schwann cells (Mpz-cre;  Nf2loxP/loxP mice)20, neurofilament phosphorylation was slightly increased, as was the distance between single neurofilaments  (Fig. 5d and Supplementary Fig. 8c). These findings indicate that the described axonal changes in Nf2-iso2−/− sciatic nerves are of axonal origin and are not a product of merlin loss in Schwann cells.We next tested whether the described morphological alterations are causative for neuropathic symptoms in vivo. Hot plate testing  measuring pain sensitivity revealed that both heterozygous and homozygous Nf2-iso2−/− mice had prolonged withdrawal laten-cies to thermal stimuli compared with wild-type littermates and  Nf2-iso1−/− mice (Fig. 6a), indicating thermal hypoalgesia and impaired responses to noxious thermal stimuli. Rotarod test-ing revealed that Nf2-iso2−/− mice also displayed deficits in motor function. After 5 d of training, they had a mean latency to fall of 115 s compared with 217 s for wild-type littermates (Fig. 6b). Even  Nf2-iso2+/− mice showed a relevant phenotype (155 s).Electrophysiological measurements on sciatic nerves in vivo revealed similar nerve conduction velocities (mainly determined by myelination and reduced in demyelinating neuropathies) in Nf2-iso1−/− and Nf2-iso2−/− mice (Fig. 6c). In contrast, compound mus-cle action potential amplitudes (reflecting axonal functionality) were greatly reduced in Nf2-iso2−/− mice, indicative of axonal neuropathy (Fig. 6d). Apart from minor effects following proximal stimulation (possibly because of additional alterations in other tissues as a result of complete isoform-specific knockout of merlin), merlin-iso1 loss had no relevant influence (Fig. 6d). These results clearly correlate both homozygous and heterozygous merlin-iso2 inactivation with axonal neuropathy development. These findings are consistent with clinical findings suggesting that polyneuropathy in NF2 patients occurs in the absence of associated tumors (schwannomas)8,21 and that germline NF2 mutations cause merlin haploinsufficiency and polyneuropathy in patients22.NF2 patient–derived mutations and specimensWe analyzed sural nerve biopsy sections from NF2 patients carry-ing germline NF2 mutations who presented clinically with severe  neuropathy21. Immunohistochemical analysis revealed reduced phos-pho-neurofilament staining per vital axon compared with healthy control biopsies (Fig. 7a and Supplementary Fig. 9a). Ultrastructural analysis revealed intrinsic axonal structure abnormalities that closely resembled those of Nf2-iso2−/− mice in vivo and neurons in vitro. Sural nerve axons of the same patients exhibited reduced interfilament distances compared with healthy control samples (Supplementary Fig. 9b). In addition, non-myelinated fibers frequently displayed irregularly shaped axons containing accumulations of condensed mitochondria and neurofilaments (Fig. 7b), as well as aggregations of pleomorphic vesicles and dense bodies (Fig. 7c) that could not be found in biopsies of healthy control individuals (Fig. 7d).In vitro, the C-terminal nonsense NF2 mutation C784T, which was previously reported to provoke axonal type neuropathy determined by electrophysiological means8, could not induce neurofilament dElectrophysiology n.s.*******************n.s.aHot plate testcElectrophysiology n.s.n.s.n.s.15Mean withdrawal latency (s)Nerve conduction velocity (m s–1)Amplitude (mV)105080Nf2-iso1+/+Nf2-iso1–/–Nf2-iso2+/+Nf2-iso2+/–Nf2-iso2–/–Nf2-iso1+/+Nf2-iso1–/–Nf2-iso2+/+Nf2-iso2+/–Nf2-iso2–/–Nf2-iso1+/+Nf2-iso1–/–Nf2-iso2+/+Nf2-iso2+/–Nf2-iso2–/–60Distal stimulationProximal stimulation604020050403020100bRotarod test******n.s.250Nf2-iso1+/+Nf2-iso1–/–Nf2-iso2+/+Nf2-iso1+/–Nf2-iso2–/–Latency to fall (s)20015010050012345Day of practiceFigure 6 Behavioral abnormalities in Nf2-iso2−/− mice. (a) Hot plate test measuring response to thermal stimuli revealed greater withdrawal latencies for Nf2-iso2+/− and Nf2-iso2−/− mice than for Nf2-iso2+/+  mice (***P < 0.001, t = –4.557, df = 39; n.s., not significant,  t = 0.007, df = 15; n = 8 mice per group, mean + s.e.m.). (b) Rotarod performance of mice trained for 5 consecutive days. Nf2-iso2+/− and Nf2-iso2−/− mice showed weakened performances compared with  Nf2-iso2+/+, Nf2-iso1+/+ and Nf2-iso1−/− mice (***P < 0.001, t = 6.417, df = 32; n.s., not significant; n = 8 mice per group, mean + s.e.m.).  (c) Nerve conduction velocities (n = 6 mice per group; n.s., not significant) in Nf2-iso2+/−, Nf2-iso2−/− and Nf2-iso1−/− mice compared with Nf2-iso2+/+ and Nf2-iso1+/+ mice (mean + s.e.m.). (d) Compound muscle action potential amplitudes recorded after proximal and distal sciatic nerve stimulation. Amplitudes in both Nf2-iso2+/− and Nf2-iso2−/−  mice were markedly reduced, suggesting axonal-type neuropathy, compared with Nf2-iso2−/−, Nf2-iso2+/+ and Nf2-iso1+/+ mice (*P < 0.05,  t = 6.912, df = 12, t = 7.280, df = 10; ***P < 0.001; n.s., not significant, t = 3.377, df = 10; n = 6 per group, mean + s.e.m.).npg© 2013 Nature America, Inc. All rights reserved.432	VOLUME 16 | NUMBER 4 | APRIL 2013 nature neurOSCIenCeartICleSphosphorylation or axonal diameter growth in P19 cells (Fig. 7e). This mutation was still able to form a complex with p190RhoGAP, but could not bind RhoGDI (Fig. 7f), demonstrating the importance of the merlin-RhoGDI complex at least in intact cells. Furthermore, these findings were associated with a loss of RhoA activation (Fig. 7e) and indicate that NF2 patients lacking the intact C terminus of one NF2 allele in neurons fail to regulate Rho-ROCK–dependent  neurofilament phosphorylation, leading to insufficient axonal  structure maintenance.DISCUSSIONWe found that the ubiquitously expressed tumor suppressor protein merlin (specifically merlin-iso2) functions intrinsically in neurons to regulate axonal integrity and propose that reduced NF2 gene dosage  in axons is relevant in NF2-related polyneuropathy. Specifically,  we found that merlin-iso2 regulates RhoA, leading to downstream ROCK activity, which promotes neurofilament phosphorylation and ulti-mately controls the growth of axonal diameter in vitro and axon structure maintenance in vivo. Consequently, merlin-iso2 reduction resulted in inhibition of RhoA and neurofilament hypophosphorylation.Irregular neurofilament phosphorylation has been previously reported to coincide with axonal dysfunction23 and increased axon vulnerability24. Several neuropathic disorders display altered  neurofilament phosphorylation levels2. Our results highlight impor-tance of neurofilament modulation and provide, to the best of our knowledge, the first in vivo evidence that Rho-ROCK signals are important for neurofilament phosphorylation and the consequent maintenance of axonal structure.While exploring how merlin-iso2 operates in the axon, we iden-tified a merlin-dependent multi-protein complex. Both RhoGDI and p190RhoGAP, important determinants for Rho activity control, were found to associate with neuronal merlin. Our data suggest that axonally expressed merlin-iso2, coupled to neurofilaments, acts as a tethering system, fine-tuning local RhoA signals in the axon. A NF2 patient–derived mutation causing severe polyneuropathy (C784T)21, which maintains p190RhoGAP interaction, but results in deficient RhoGDI binding, was unable to promote Rho activity and radial axon growth in vitro, illustrating the importance of the merlin-RhoGDI complex in intact cells. This scaffold-mediated assembly provides a versatile tool for the spatiotemporal organization of signal transduc-tion. Specific merlin signaling hubs defined to cellular substructures such as axons enable Rho-ROCK signals to promote phosphorylation of neurofilaments, which is important for axon structure.Our data contribute to the mechanistic understanding of why NF2 patients suffer from polyneuropathy even in the absence of nerve damaging tumors. Merlin was originally identified as a tumor sup-pressor protein and is known to be involved in gliogenic tumor development. It is assumed, but not proven, that the cause of nerve damaging processes associated with NF2 disease is a result of sec-ondary problems, such as compressive glial cell tumors (schwanno-mas)8,22,25 or hyperproliferative Schwann cells (tumorlets)8. We found that NF2 patients have axon-intrinsic ultrastructural irregularities and fP19 cellsvciso2 wtiso2C784Tp190RhoGapMerlinMerlinRhoGDIFlag IP6528eP19 cellsapNF-HpNF-HpNF-HpNF-HHealthycontrol biopsyNF2patientbiopsyNF2 sural nerve biopsiesvciso2 wtiso2 C784T65pNF-H2.0vciso2wtiso2C784TMean axon caliber (µm)MerlinMerlinActinRhoARhoA-GTP281.51.00.50***n.s.bNF2 sural nerve biopsycNF2 sural nerve biopsydControl sural nerve biopsyFigure 7 NF2 patient biopsies display neurofilament  hypophosphorylation. (a) Sural nerve sections stained for  pNF-H (red). Scale bars represent 100 µm. Green staining  is nonspecific background staining detected with a different  laser. (b,c) Representative electron micrographs showing  non-myelinated axons of NF2 patients carrying a C-terminal  germ line mutation. Scale bars represent 0.2 µm.  An increased number of mitochondria of normal size (arrows),  increased density of neurofilaments (arrowhead) with some  glycogen granules, rare microtubules and components of  the axoplasmic reticulum (patient A) are shown in b.  An axon is shown in c with neurofilaments surrounded by  vesicles of various shapes and sizes (arrows) and some dense  bodies (arrowhead), indicating early stage of axonopathy (patient B). (d) Electron microscopic cross section of  normal unmyelinated axon from the sural nerve biopsy (control patient, age 41) illustrating normal density of  cytoskeletal components. Scale bar represents 0.2 µm. (e) P19 cells measured for RhoA-GTP level after transfection  with patient-derived nonsense merlin mutation C784T (iso2 C784T), merlin-iso2 (iso2 wt) and empty vector  control (vc) (n = 3). Right, radial axon growth in vitro (***P < 0.001, t = –8.786, df = 23; n.s., not significant,  t = –2.436, df = 25; n = 397 cells, mean + s.e.m.). Note that iso2 C784T resulted in a truncated protein (30 kDa).  (f) P19 cells transfected with Flag-tagged merlin–iso2 (iso2 wt) and C784T mutant (iso2 C784T) (n = 3). The white arrowhead indicates an unspecific band in all three lanes. The black arrowhead points to immunoprecipitated truncated merlin (iso2 C784T). For full-length blots and quantitations,  see Supplementary Figure 9.npg© 2013 Nature America, Inc. All rights reserved.nature neurOSCIenCe	VOLUME 16 | NUMBER 4 | APRIL 2013 433artICleSreduced phosphorylated neurofilaments relative to normal healthy controls, indicating that the nerve damage in NF2 patients develops from an inner axonal process resulting from reduced merlin protein levels. This neuron-intrinsic impairment was verified in our mouse model, in which the specific loss of merlin-iso2, or even a reduction in the merlin-iso2 dosage, resulted in nerve damage and neuropathic symptoms without the appearance of Schwann cell–derived tumors. Despite the described axonal abnormalities, we could not detect  classical signs of axon degeneration in Nf2-iso2−/− mice. We observed a phenotype resembling ‘axonal atrophy’, with shrunken and collapsed axons of peripheral nerves as have described previously in the con-text of neurofilament mutations18. We detected neuropathy of axonal origin in mutant mice and propose that the loss of merlin-iso2 leads to a reduction of functional axons.Our findings are unexpected for this tumor suppressor and rele-vant for a complete understanding of the spectrum of nervous system abnormalities in the human NF2 disease. It is reasonable to assume that the signaling pathway downstream of merlin that we describe has a broader implication for other hereditary neuropathies whose mecha-nisms remain elusive. Elucidation of the signaling pathways of radial axonal growth and maintenance is will be necessary to fully understand nerve regeneration and protection from axonal degeneration.METHODSMethods and any associated references are available in the online version of the paper.Note: Supplementary information is available in the online version of the paper.AcknowledgmenTSThe authors would like to thank U. Petz, C. Poser and S. Ramrath for their expert technical assistance, H. Rosemann, F. Kaufmann and D. Galendo for their skilled breeding and husbandry of animals, and R.E. Ferner for discussions and support. Mpz-cre mice were kindly provided M.L. Feltri (Hunter James Kelly Research Institute). This work was supported by Sonderforschungsbereich 604, Deutsche Forschungsgemeinschaft MO 1421/2–1 and Krebshilfe 107089. A.S. is recipient  of a Young Investigator Award from the Children’s Tumor Foundation.AUTHoR conTRIBUTIonSA.S. and H.M. conceived and designed the study. H.M. supervised the experimental program and prepared the manuscript. A.S. performed and analyzed the majority of the experiments and prepared the manuscript. S.L.B. performed the nerve section analysis of both knockout mice and patient biopsies, as well as their analysis. M.N.-K. and M.G. generated the Nf2-iso1−/− and Nf2-iso2−/− mice. R.B. designed the electrophysiological experiments and participated in data acquisition. C.G. and D.H.G. synthesized isoform-specific merlin antibodies. A.Z. and M.J.J. participated in the behavioral analysis of merlin knockout mice and the preparation of primary cell cultures. S.S. conducted nucleotide exchange and binding assays. X.-P.D. and D.B.P. provided tissue samples of Mpz-cre; Nf2loxP/loxP mice. C.H. and V.-F.M. provided NF2 patient biopsy sections for immunohistochemistry. C.O.H. provided NF2 patient biopsy sections for ultrastructural analysis. J.W. and J.M.S. performed the ultrastructural analysis of human NF2 patient biopsies. comPeTIng FInAncIAl InTeReSTSThe authors declare no competing financial interests.Reprints and permissions information is available online at http://www.nature.com/reprints/index.html.1. Luo, L. Rho GTPases in neuronal morphogenesis. Nat. Rev. Neurosci. 1, 173–180 (2000).2. Perrot, R., Berges, R., Bocquet, A. & Eyer, J. Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration.  Mol. Neurobiol. 38, 27–65 (2008).3. Zhu, Q., Couillard–Despres, S. & Julien, J.P. Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. Exp. Neurol. 148, 299–316 (1997).4. de Waegh, S.M., Lee, V.M. & Brady, S.T. Local modulation of neurofilament phosphorylation, axonal caliber and slow axonal transport by myelinating Schwann cells. Cell 68, 451–463 (1992).5. Dubois, M., Strazielle, C., Julien, J.P. & Lalonde, R. Mice with the deleted neurofilament of low molecular weight (Nefl) gene. 2. Effects on motor functions and spatial orientation. J. Neurosci. Res. 80, 751–758 (2005).6. England, J.D. & Asbury, A.K. Peripheral neuropathy. Lancet 363, 2151–2161 (2004).7. Asthagiri, A.R. et al. Neurofibromatosis type 2. Lancet 373, 1974–1986 (2009).8. Sperfeld, A.D., Hein, C., Schroder, J.M., Ludolph, A.C. & Hanemann, C.O. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain 125, 996–1004 (2002).9. Schulz, A. et al. Merlin inhibits neurite outgrowth in the CNS. J. Neurosci. 30, 10177–10186 (2010).10. Gianola, S. & Rossi, F. Evolution of the Purkinje cell response to injury and regenerative potential during postnatal development of the rat cerebellum. J. Comp. Neurol. 430, 101–117 (2001).11. Jones–Villeneuve, E.M., McBurney, M.W., Rogers, K.A. & Kalnins, V.I. Retinoic acid induces embryonal carcinoma cells to differentiate into neurons and glial cells.  J. Cell Biol. 94, 253–262 (1982).12. Hashimoto, R. et al. Domain- and site-specific phosphorylation of bovine NF-L by Rho-associated kinase. Biochem. Biophys. Res. Commun. 245, 407–411 (1998).13. Moorman, J.P., Luu, D., Wickham, J., Bobak, D.A. & Hahn, C.S. A balance of signaling by Rho family small GTPases RhoA, Rac1 and Cdc42 coordinates cytoskeletal morphology, but not cell survival. Oncogene 18, 47–57 (1999).14. Maeda, M., Matsui, T., Imamura, M. & Tsukita, S. Expression level, subcellular distribution and rho-GDI binding affinity of merlin in comparison with Ezrin/Radixin/Moesin proteins. Oncogene 18, 4788–4797 (1999).15. Yamashita, T. & Tohyama, M. The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI. Nat. Neurosci. 6, 461–467 (2003).16. Sherman, L. et al. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15, 2505–2509 (1997).17. Bremer, J. et al. Axonal prion protein is required for peripheral myelin maintenance. Nat. Neurosci. 13, 310–318 (2010).18. Elder, G.A., Friedrich, V.L. Jr., Margita, A. & Lazzarini, R.A. Age-related atrophy of motor axons in mice deficient in the mid-sized neurofilament subunit. J. Cell Biol. 146, 181–192 (1999).19. Giovannini, M. et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 14, 1617–1630 (2000).20. Feltri, M.L. et al. Conditional disruption of beta 1 integrin in Schwann cells impedes interactions with axons. J. Cell Biol. 156, 199–209 (2002).21. Hagel, C. et al. Polyneuropathy in neurofibromatosis 2: clinical findings, molecular genetics and neuropathological alterations in sural nerve biopsy specimens. Acta Neuropathol. 104, 179–187 (2002).22. Hanemann, C.O., Diebold, R. & Kaufmann, D. Role of NF2 haploinsufficiency in NF2-associated polyneuropathy. Brain Pathol. 17, 371–376 (2007).23. Jackson, S.J., Pryce, G., Diemel, L.T., Cuzner, M.L. & Baker, D. Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 134, 261–268 (2005).24. Morrison, J.H. et al. A monoclonal antibody to non-phosphorylated neurofilament protein marks the vulnerable cortical neurons in Alzheimer’s disease. Brain Res. 416, 331–336 (1987).25. Iseki, C. et al. Rinsho Shinkeigaku [A case of neurofibromatosis type 2 (NF2) presenting with late–onset axonal polyneuropathy] 49, 419–423 (2009).npg© 2013 Nature America, Inc. All rights reserved.nature neurOSCIenCedoi:10.1038/nn.3348ONLINE METHODSexperimental animals. All mice handled in strict adherence to local govern-mental and institutional animal care regulations (Thüringer Landesamt für Lebensmittelsicherheit und Verbraucherschutz). Nf2-iso1−/− and Nf2-iso2−/− mice were generated by M.N.-K. and M.G. (unpublished data) and purchased from Riken BioResource (C57BL/6 background). Average day of birth, on the 19th day of pregnancy, was defined as P0 and adult was defined as P60. Behavior and electrophysiology tests, immunohistochemistry and electron microscopy were carried out on mice or tissue taken from 8-week-old mice unless otherwise stated. All of the mice used for this study were age and gender matched, as well as derived from group housing. Genotyping was performed by PCR of tail biopsies. For Nf2-iso1−/− mice, the primers Nf2 insert (5′-CCT CAA GCC CAA GGC AGA AGA-3′) and Nf2 insert2a (5′-CCT CAG AGT GAG GCA GTC TTC TAG G-3′) were used, yielding 267 bp or 391 bp products for wild-type or knockout alleles, respectively. For Nf2-iso2−/− mice, primers Nf2 (5′-CAG TAC ACC TGA GGT CAC TGT CTC-3′) and Nf2 insert2a were used to generate 235 bp and 378 bp products for knockout and wild-type alleles, respectively.Immunohistochemistry. Mice were perfused transcardially using phosphate- buffered saline (PBS), followed by 4% paraformaldehyde (vol/vol) in PBS. Following dissection, brains were post-fixed in the same fixative overnight at 20 °C. Floating sections were cut to 50 µm thicknesses or to 8 µm thickness for paraffin-embedded  sections. Floating sections were heated in 10 mM sodium citrate buffer  (pH 9) at 80 °C for 30 min and, after cooling, incubated in 2% non-fat dry milk (vol/vol) for 30 min. Sections were treated with 0.5% Triton X-100 (vol/vol) for  30 min and incubated in 0.2% gelatine and 2% goat serum (vol/vol) diluted in PBS for 2 h. Sections were submersed in primary antibody solution overnight at 4 °C. For primary antibodies, we used antibodies to calbindinD-28k (rabbit polyclonal, 1:2,000, Swant, clone CB38), MBP (mouse monoclonal, 1:500, clone MAB384, Millipore Bioscience Research Reagents) phospho-neurofilament (SMI31, 1:500, Hiss Diagnostics), merlin (A-19, 1:200, Santa Cruz Biotechnology), and merlin-iso1 (WA27, 1:100) and merlin-iso2 (WA28, 1:100) (D.H.G.)26. The rabbit poly-clonal merlin antibodies were raised after repeated immunizations and peptide purification (WA27, C-PQAQGRRPICI; WA28, C-LTLQSAKARVAFFEEL). After vigorous washings, sections were incubated with the secondary antibody solu-tion (Alexa488- and Alexa546-conjugated goat antibodies to mouse or rabbit, 1:500 in PBS, A-11034 and A-11030, Invitrogen) at 20 °C for 2 h. Sections were counterstained using Hoechst 34580 (1 µg ml−1 PBS, 5 min), washed for at least  1 h and embedded in Mowiol. Merlin-specific staining was confirmed previously9 and we tested the antibody to merlin-iso2 antibody on tissues from Nf2-iso2−/− mice (Supplementary Fig. 2).Paraffin-embedded sections were rehydrated, boiled in 10 mM sodium citrate buffer (pH 9) for 30 min in a microwave and subsequently treated with 0.5% Triton X-100 for 10 min. Sections were incubated in 0.2% gelatine and 2% goat serum diluted in PBS for at least 2 h. Sections were submersed in the primary antibody solution overnight at 4 °C. For primary antibodies, we used antibodies  to phospho-neurofilament (SMI31, 1:500, Hiss Diagnostics), merlin-iso1  (WA-27, 1:100), merlin-iso2 (WA-28, 1:100) and APP (rabbit polyclonal anti-body, Calbiochem, 1:500, 171610). After vigorous washings, sections incubated with secondary antibody solution (Alexa488- and Alexa546-conjugated goat antibodies to mouse or rabbit, 1:500 in PBS, Invitrogen) at 20 °C for 2 h. Finally, specimens were washed in PBS, counterstained using Hoechst 34580 (1 µg ml−1 PBS, 5 min), dehydrated and embedded.Immunocytochemistry. P19 cells, primary cerebellar neurons or DRG cells were grown on coverslips and fixed with 4% paraformaldehyde in PBS for 20 min. After washing in PBS, cells were permeabilized with 0.3% Triton X-100 for 1 min and incubated for 2 h in 1% bovine serum albumin (vol/vol). Cells incubated with primary antibodies at 20 °C for 1 h. For primary antibodies, we used antibody to phosphor-neurofilament (SMI31, 1:200, Hiss Diagnostics), RhoGDI (A-20, 1:100, Santa Cruz Biotechnology), growth-associated protein (GAP-43, clone H-100, 1:400, Santa Cruz Biotechnology), APP (rabbit poly-clonal antibody, Calbiochem, 1:100), merlin-iso1 (WA-27, 1:50), merlin–iso2  (WA-28, 1:50) and p190RhoGAP (mouse monoclonal antibody, Sigma, clone D2D6, 1:100). After extensive rinsing in PBS, cells were incubated with  secondary antibodies (Alexa488-conjugated antibody to rabbit, 1:500; Alexa546-conjugated antibody to mouse, 1:500) for 1 h. Cells were washed in PBS and counterstained with Hoechst 34580 (1:1,000 in PBS) for 5 min. Cells were mounted on cover plates with a Mowiol-based mounting medium.developmental appearance of merlin in Purkinje cell axons. Axonal expression of merlin-iso2 determined by colocalization of merlin (iso2) with the Purkinje cell–specific marker calbindin. Continuous calbindin-positive signals in the granular layer of the mouse cerebellum with lengths of more than 20 µm were analyzed for additional merlin staining. Note the methodical difference with apparent discrepant results in a previous study9. There, the appearance of merlin in the proximal axon initial segment was monitored.Immunoblotting. Immunoblotting was performed as described previously27. For primary antibodies, we used antibodies to merlin (clone A-19, 1:500), actin (clone I-19, 1:1,500, Santa Cruz Biotechnology), RhoA (1:500, Upstate), phospho- neurofilament (SMI31, 1:500, Hiss Diagnostics), pan-axonal neurofilament (SMI312, 1:500, Hiss Diagnostics), Flag (clone M2, 1:1,000, Sigma-Aldrich), RhoGDI (A-20, 1:500, Santa Cruz Biotechnology), merlin-iso1 (WA-27, 1:500), merlin-iso2 (WA-28, 1:500) and p190RhoGap (mouse monoclonal antibody, Sigma, clone D2D6, 1:1,000). Western blot results were quantified using gel  analysis software by ImageJ. Density values were normalized to actin and appro-priate controls of transfection or wild-type tissue.Pulldowns to detect active RhoA. A detection kit was used (Active Rho Pull-Down and Detection Kit, Pierce Biotechnology) according to manufacturer instructions. Precipitates and total lysates were resolved on a 10% SDS-PAGE gel and immunoblotted using antibody to RhoA (1:500, Upstate). Total lysates were used as loading controls. Pulldown assays were repeated at least three times in each case.P19 cell culture. P19 cells11 purchased from ATCC (CRL-1825) maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf  serum (vol/vol). Induction of neuronal phenotype, aggregates were gener-ated on bacterial-grade dishes and treated with 5 × 10−7 M all-trans retinoic acid (Sigma) for 4 d. Cells were re-plated on cell culture dishes in the absence  of retinoic acid.Primary dissociated cerebellar cultures. Primary dissociated cerebellar cultures (referred to as cerebellar granular cells) were established from cerebellar tissue of 8-d-old pups (C57BL/6 mice) as described previously28. Cells were grown  at a density of 200,000 cells cm−2 in defined neurobasal medium with B27  supplement (Invitrogen).dRg culture. Cells were prepared from 4–6-d-old mice (P4–6) as described29. Arabinofuranosyl cytidine (Sigma, C1768, working concentration of 10 µM) was used to assure glial-free conditions.Transfection procedures. P19 cells were transfected 3–4 d after plating using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. Transfection efficiency averaged around 45 to 50%. For siRNA knockdown experiments, primary cells were transfected using Dharmafect 3 according to the manufacturer’s instructions (Dharmacon, Thermo Scientific). Using siGLO RNA, a transfection rate of 75% was obtained. For overexpression studies, primary neurons were transfected according to a method described previously30.For inhibition of merlin expression, the following oligonucleotides were used: si-nf2 5′-UAC CGA GCU UCG ACA UUA UUG-3′ (knockdown of both major merlin isoforms), si-iso1 5′-AAA GAA GGC CAC UCG GGA CUU-3′, si-iso2 5′-UAG GUC UUC UGC CUU GGG CUU-3′ and scr-nf2 5′-AAU CCG GUU GCA UAG UUC AUG-3′ (untargeted control). For RhoGDI knockdown, siRNA was purchased from Santa Cruz Biotechnology (sc-36416). For overexpression of merlin, pcDNA3-based Nf2 full-length sequences for isoform 1 and 2 was used. Backbone vector pcDNA3 used as control. Merlin fragment constructs used: N-terminus amino acids (aa) 1–299; C-terminus merlin-iso1 aa 300–595; C-terminus of merlin-iso2 aa 300–590. QuikChange Site–Directed Mutagenesis Kit (Stratagene) was used according to the manufacturer’s instructions.For knockdown of p190RhoGAP, we used the pGIPZ plasmid containing shRNA against the ARHGAP35 gene according to manufacturers recommen-dation (Open Biosystems, Oligo ID: V3LHS_349456, GeneID: 2909; antisense npg© 2013 Nature America, Inc. All rights reserved.nature neurOSCIenCedoi:10.1038/nn.3348sequence: TCCAGGTAGACATAGTCCT). The shRNA was directed against the human gene, but is homologous to rat and mouse. In brief, shRNA was co-transfected with pMD.G-VSVG and pCMVdelR8.91 packaging plasmids into HEK293T cells using Lipofectamine 2000. After 48 h, the supernatant  containing viral particles was harvested, sterile filtered and used for trans-duction of DRG cells. Thus, DRG cells were incubated with viral particles in DMEM/5% fetal bovine serum for 16 h and subsequently grown in DMEM/10% fetal bovine serum.Quantification of axonal diameter in vitro. Diameters of axonal processes of differentiated P19 cells, primary cerebellar neurons and DRG cells were measured 3 d after transfection. To identify axonal processes, cells were co-stained with the axonal markers GAP-43 and phospho-neurofilaments p(NF-H) (Supplementary Fig. 3a). Using the ImageJ plugin NeuronJ, axons longer than a cell soma were measured and scaled in micrometers. Processes that could be clearly distinguished from processes of neighboring cells were evaluated. Changes of axon calibers  in vitro are also referred to as changes in radial axon growth.microscopy and image acquisition. Confocal images were obtained with a Leica TCS SP5 laser-scanning microscope. Images were acquired with a 40× objective (HCX APO 40.0X 0.75 DRY, NA = 0.75) at a pinhole size of three airy discs and a resolution of 0.73 × 0.73 × 0.50 µm3. Images were taken from a single optical planes (voxel size = 189 nm). Epifluorescent images of dissociated neurons were obtained with a Leica DMIRE2 microscope equipped with a Leica DFC350FX camera. All digital processing was performed using Adobe Photoshop 6.0. For all images, only linear adjustments of the brightness and contrast were performed.RhoA activation. Rho activator #CN01 (Cytoskeleton) was used according to the manufacturer’s recommendations.Analysis of axonal caliber and myelination in merlin knockout mice. Analysis was carried out on semi-thin and thin sections of the sciatic nerve obtained from transcardially perfused Nf2-iso1−/−, Nf2-iso2−/−, Nf2-iso1+/−, Nf2-iso2+/− and wild-type mice. Mice were perfused with a solution containing 3% para-formaldehyde and 3% glutaraldehyde (vol/vol) in 0.1 M phosphate buffer  (pH 7.4). Sections were post-fixed for 1 h and kept in fixative that included 3% sucrose (vol/vol). Sections were obtained from the mid part of the sciatic nerve reaching from gluteal to the popliteal regions. Sectioning and staining was per-formed as described31. Images of toluidine blue were stained semithin sections taken using an Axioskop 2 MOT (Carl Zeiss) equipped with a 100× immersion oil objective and an Olympus XC50 digital camera (Olympus). Standardized settings for camera sensitivity, resolution (2,576 × 1,932 pixels) and brightness of illumination were used for all micrographs. Thin sections were analyzed with an electron microscope (EM910, Carl Zeiss) equipped with an integrated TRS 1K digital camera (Carl Zeiss). Image analysis was carried out using ImageJ version 1.43u. RGB color images obtained from semi-thin sections were split into single channels, and the green channel was chosen for measurements. The picture was contrasted using the auto function. Using the freehand selection tool, the axon and the myelin was grossly circumscribed and the area was adapted using the ABSnake PlugIn (gradient threshold varied between 20 and 30, 10–20 iterations per image). Low-contrasted myelin sheaths were surrounded manually. Based on measured areas, we calculated the thicknesses of the axons and myelin sheaths. Providing a measure for bending of the transversely cut axonal surface, the axon was surrounded as described above and solidity factor was measured using the implemented ImageJ software tools (shape descriptor). Solidity factor describes the area covered by a given structure in relation to the smallest convex area, which covers this structure, that is, the solidity factor of a round circle or ellipse would be 1, while whereas circle with an invagination would give a factor smaller than 1.  This solidity factor is superior to the circularity factor often used for measuring changes in surface structures, as it provides a factor to measure changes in sur-face curvatures independent of the plane of section. Changes of axon structure  in vivo are also referred to as axon structure maintenance or integrity. Three pairs of mice from the same litter were used for experiments. Electron microscopical images were taken from 50-nm-thick sections. Neurofilaments are easily iden-tified by size and compact structure. The positions of all neurofilaments in a defined area covering only tangentially cut neurofilaments were measured and distances to their neighbors evaluated. The nearest neighbor of a neurofilament was defined as the average distance of the three nearest neighbors of a neurofila-ment. The values provided in Figure 5b–d are derived from 300 to 800 distances measured per genotype. At least two mice were taken per genotype. Axon calibers were classified as described previously32.muscle preparations and immunostainings. Preparations were carried out as described before33. BTX (Invitrogen, conjugated to Texas Red) was used at a concentration of 1 µg ml−1, and antibody to N52 (Sigma) was used at a dilution of 1:500. Silver staining was done as described34. Images were taken with standard bright-field upright microscopes. Images of fluorescent stains were taken using the Leica laser-scanning microscope LSM TCS SP2. Pictures shown are maximum projections of ten images taken at a distance of 1 µm.co-immunoprecipitation. Co-immunoprecipitation studies were performed  as described previously27.kinase screening assay. We selected 23 serine/threonine kinases on the basis of reports of their association with merlin and/or neurofilament signaling (Supplementary Table 1). Appropriate siGENOME SMARTpool duplexes (Thermo Fisher) targeting kinases were transfected into neuronally differenti-ated P19 cells. Medium was replaced after 24 h, following plasmid transfection of either an empty vector control or merlin-iso2. After 2 additional days, cells were lysed, and subjected to SDS-PAGE and immunoblotting to determine the phos-phorylation state of heavy subunit neurofilaments (pNF-H). Consistent results were obtained in three consecutive experiments in 24-well plate format.Sural nerve biopsies of nF2 patients. Biopsy sections for immunohistochem-istry were provided by C.H. For phospho-neurofilament analysis, specimens of two healthy control males (57 and 52 years of age) were compared with nerve tissue from two NF2 patients (both 36 years of age), referred to as patients 718 and 21.3 in ref. 21. Sections were stained for phosphorylated neurofila-ment epitopes using antibody to SMI31 (Fig. 7a). Monochrome single-channel images were excused from fluorescent background staining by threshold setting to a range of 95 to 255 (Fig. 7a). By means of ImageJ plugin Analyze Particles, total area covered by phospho-neurofilament staining was determined as pixel2 per µm2 and subsequently divided by the number of vital axons. Taking the total axon number into account, the decrease was not simply a result of loss of fibers. Quantifications of interfilament distances (Supplementary Fig. 9b) was performed as described above.NF2 sural nerve biopsies for ultrastructural analysis of non-myelinated fibers (mutation in patient A: A1447-2G, age 37; mutation in patient B: 1594 ins3 del59, age 27) were kindly provided by C.O.H. Nerve specimens were fixed in 3.9% phosphate-buffered glutaraldehyde, embedded in epoxy resin and processed for electron microscopy as described previously23.The immunohistochemical and ultrastructural studies were performed on archival tissue that was processed and diagnosed in the Institutes of Neuropathology in Hamburg and Aachen. According to the law for hospitals in Hamburg (Germany) and North Rhine–Westphalia (Germany), samples of closed cases that were processed and investigated in a medical institution may be used for research purposes by the same institution without need for a separate written informed consent from the patients.gST-pulldown assays. GST-RhoGDI (in pGEX2T vector backbone). For pull-down assays from bacteria lysates, frozen pellets of bacteria induced for protein expression were resuspended and lysed in buffer containing 50 mM Tris pH 7.5, 100 mM NaCl, 0.5% CHAPS (vol/vol) and protease inhibitor cocktail. Samples were sonicated on ice for 5–10 min and cell debris was collected for 15 min at 12,000g and 4 °C. Cleared lysates were diluted in 1 ml of pulldown buffer and incubated with GST alone or GST-tagged proteins bound to glutathione beads for 1.5-2 h rotating at 4 °C. Four washing steps were performed with 1 ml of pulldown buffer. Simultaneously, beads were spun down at 5,000g for 30 s and boiled in 2× SDS sample buffer and analyzed by subsequent SDS-PAGE and western blotting.Protein interactions in vitro. We applied 1.5 µg of purified His-RhoGDIα  (aa 24–204, Fitzgerald) or 3 µg bovine serum albumin (BSA) point-wise on dry nitrocellulose membrane. Membrane was blocked in 5% skimmed-milk (vol/vol) npg© 2013 Nature America, Inc. All rights reserved.nature neurOSCIenCedoi:10.1038/nn.3348in TBS-Tween for 1 h followed by 2.5-h incubation with 5 µg ml−1 purified Merlin FERM domain or BSA in 0.5% CHAPS, 50 mM Tris (pH 7.5) and 100 mM NaCl at 20 °C, respectively. After three washes with TBS-Tween, membranes were treated with antibody to merlin (A-19, 1:750) for 1 h at 20 °C, followed by incuba-tion with horseradish peroxidase–coupled antibody to rabbit (1:2,000) for 1 h.nucleotide exchange assay. Assay was performed on the basis of a Rho GEF exchange assay kit (Cytoskeleton BK100) according to manufacturers recom-mendation. In brief, 2× exchange reaction buffer contained 1.5 µM mant-GTP in 40 mM Tris (pH 7.5), 100 mM NaCl and 20 mM MgCl2. Samples containing a final concentration of 2 µM RhoA, 3 µM His-RhoGDI (aa 24–204, Fitzgerald) and 4 µM merlin FERM domain (aa 1–313, 50 mM Tris (pH 7.5), 300 mM NaCl) were pre-incubated on ice for 30 min in a black 384 round bottom well plate (Corning). The 2× exchange buffer was added to a final concentration of 0.75 µM of mant-GTP. Samples immediately analyzed with a Mithras LB 940 Multimode Microplate Reader (Berthold Technologies) at 20 °C. Fluorescence emission was recorded at 460 nm after excitation with lamp energy of 5,000 (5.72 W) at 355 nm every 20 s. The hDbs GEF (human Dbl Big Sister) fragment was added to a final concentration of 0.5 µM and a total reaction volume of 15 µl. Measurement measured for 6 h. Control protein samples components replaced by BSA.Rotarod test. Measures motor coordination and proprioception. Determines time that mice can stay on a rotating rod, referred to as latency to fall. To increase test sensitivity, we used a program accelerating the rod from 1 to 50 rpm in  4.2 min (accelerates at 1 rpm per 5 s). Each mouse underwent the same 5-d proce-dure passing two sessions per d including two trials each session. Mice still on the apparatus at 252 s were scored as 252 s. Rotating on the rod for two consecutive rotations without running equaled falling event. Day 5 performances were used for statistical analysis using Bonferroni correction.Hot plate test. The hot plate test measures response to thermal stimuli. Mice were placed on a horizontal surface that was heated to 55 °C. Subsequently, the latency for hind paw withdrawal was measured, with a 60-s cut-off time to prevent severe tissue damage.electrophysiology. An investigation of the sciatic nerve conduction character-istics in 8-week-old mice was performed as described previously35 in a blinded way. Statistical analysis, results of six gender-matched mice per genotype  were quantified.Statistical evaluation. Differences between Nf2-iso1−/− and Nf2-iso2−/− mice and their appropriate wild-type littermates were determined. For all quantitative analyses, we compared two independent groups of experiments. To demonstrate their com-parable distribution, we performed Levene’s test for equal variances. Comparisons between groups were made with unpaired t tests unless stated otherwise (SPSS soft-ware, Statistical Package for the Social Sciences). For each experiment we calculated the P value, the t value and the degrees of freedom. Differences were considered to be significant when P < 0.05. All values are presented as means and their s.e.26. Scherer, S.S. & Gutmann, D.H. Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells. J. Neurosci. Res. 46, 595–605 (1996).27. Morrison, H. et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 15, 968–980 (2001).28. Baader, S.L. & Schilling, K. Glutamate receptors mediate dynamic regulation of nitric oxide synthase expression in cerebellar granule cells. J. Neurosci. 16, 1440–1449 (1996).29. Malin, S.A., Davis, B.M. & Molliver, D.C. Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity. Nat. Protoc. 2, 152–160 (2007).30. Watanabe, S.Y. et al. Calcium phosphate–mediated transfection of primary cultured brain neurons using GFP expression as a marker: application for single neuron electrophysiology. Neurosci. Res. 33, 71–78 (1999).31. Jankowski, J., Miething, A., Schilling, K. & Baader, S.L. Physiological purkinje cell death is spatiotemporally organized in the developing mouse cerebellum. Cerebellum 8, 277–290 (2009).32. Michailov, G.V. et al. Axonal neuregulin-1 regulates myelin sheath thickness. Science 304, 700–703 (2004).33. Mundegar, R.R., Franke, E., Schafer, R., Zweyer, M. & Wernig, A. Reduction of high background staining by heating unfixed mouse skeletal muscle tissue sections allows for detection of thermostable antigens with murine monoclonal antibodies. J. Histochem. Cytochem. 56, 969–975 (2008).34. Mulisch, M.W.U. Romeis–Mikroskopische Technik (Spektrum Akademischer Verlag, 2010).35. Xia, R.H., Yosef, N. & Ubogu, E.E. Dorsal caudal tail and sciatic motor nerve conduction studies in adult mice: technical aspects and normative data. Muscle Nerve 41, 850–856 (2010).npg© 2013 Nature America, Inc. All rights reserved.ReviewCancerandCentralNervousSystemTumorSurveillanceinPediatricNeuroﬁbromatosis1D.GarethR.Evans1,2,HectorSalvador3,VivianY.Chang4,5,6,AyeletErez7,StephanD.Voss8,KamiWolfeSchneider9,HamishS.Scott10,SharonE.Plon11,andUriTabori12,13AbstractAlthoughtheneuroﬁbromatosesconsistofatleastthreeauto-somaldominantlyinheriteddisorders,neuroﬁbromatosis1(NF1),neuroﬁbromatosis2(NF2),andschwannomatosis,NF1representsamultisystempleiotropicconditionverydifferentfromtheothertwo.NF1isageneticsyndromeﬁrstmanifestinginchildhood;affectingmultipleorgans,childhooddevelopment,andneurocognitivestatus;andpresentingtheclinicianwithoftencomplexmanagementdecisionsthatrequireamultidisciplinaryapproach.Moleculargenetictesting(seearticlefordetaileddis-cussion)isrecommendedtoconﬁrmNF1,particularlyinchildrenfulﬁllingonlypigmentaryfeaturesofthediagnosticcriteria.AlthoughcancerriskisnotthemajorissuefacinganindividualwithNF1duringchildhood,theconditioncausessigniﬁcantlyincreasedmalignancyriskscomparedwiththegeneralpopula-tion.Speciﬁcally,NF1isassociatedwithhighlyelevatedrisksofjuvenilemyelomonocyticleukemia,rhabdomyosarcoma,andmalignantperipheralnervesheathtumoraswellassubstantialrisksofnoninvasivepilocyticastrocytoma,particularlyopticpathwayglioma(OPG),whichrepresentamajormanagementissue.Until8yearsofage,clinicalassessmentforOPGisadvisedevery6to12months,butroutineMRIassessmentisnotcurrentlyadvisedinasymptomaticindividualswithNF1andnosignsofclinicalvisualpathwaydisturbance.Routinesurveillanceforothermalignanciesisnotrecommended,butcliniciansandparentsshouldbeawareofthesmallrisks(<1%)ofcertainspeciﬁcindividualmalignancies(e.g.,rhabdomyosarcoma).Tumorsdocontributetobothmorbidityandmortality,especiallylaterinlife.Asinglewhole-bodyMRIshouldbeconsideredattransitiontoadulthoodtoassistindeterminingapproachestolong-termfollow-up.ClinCancerRes;23(12);e46–e53.Ó2017AACR.Seeallarticlesintheonline-onlyCCRPediatricOncologySeries.IntroductionTheneuroﬁbromatoses,includingneuroﬁbromatosis1(NF1),neuroﬁbromatosis2(NF2),andschwannomatosis,haveformostoftheirknownexistencebeenlumpedtogetherasasingleentity.ThiswaslargelyduetothesigniﬁcantinﬂuenceoftherenownedneurosurgeonHarveyCushing,whodescribedthatbilateraleighthnervetumorswerepartofvonReckling-hausendiseaseintheearly20thcentury(1).TheclinicalandgeneticdistinctionbetweenNF1andNF2wasnotfullyrecog-nizeduntilthepastthreedecades,andinpriorreports,NF1andNF2werefrequentlyreferredtointerchangeably(2).Gradually,beginninginthelatter20yearsofthe20thcentury,thediffer-encesinclinicalpresentationandgeneticetiologyresultedinthedeﬁnitionoftwodistinctconditions,NF1,formerlyvonRecklinghausenneuroﬁbromatosis,andNF2,previouslybilat-eralacoustic/centralneuroﬁbromatosis.Theconditionswereeventuallyrecognizedasdistinctandseparatemolecularenti-ties,withthelocalizationoftheirrespectivegenestochromo-somes17qand22q(3,4),andsubsequentlyandformally,clinicallydelineatedatanNIH(Bethesda,Maryland)consensusmeetingin1987(5).Thegeneanddisease-associatedmutationsforNF1wereidentiﬁedin1990(6)andforNF2in1993(7–9).EvidenceconsistentlysuggeststhatclassicalNF1andNF2fulﬁllingNIHcriteriaarebothheterogeneousconditions.ThereareadditionalconditionswithphenotypicoverlapwithclassicNF1and/orNF2.Familieswithmultiplecafeaulait(CAL)maculesandmacrocephalywithoutneuroﬁbromasorothertypicalNF1featuresmayhaveeitherathreebase-pairdeletion(c.2970_2972delAAT)inNF1(10)oraSPRED1mutation(11),andathirdtypeofneuroﬁbromatosiscalledschwanno-matosisisnowaccepted(12–14),withclinicalandtumorfeaturesthatoverlapwithNF2.Recommendationsfortumorsurveillanceofgenecarriersandmembersofsyndromicfamiliesarebaseduponreviewoftheliteratureanddiscussioninthe2016AACRChildhoodCancerPredispositionWorkshop.1ManchesterCentreforGenomicMedicine,UniversityofManchester,Manche-ster,UnitedKingdom.2ManchesterAcademicHealthScienceCentre,SaintMary'sHospital,CentralManchesterUniversityHospitalsNHSFoundationTrust,Manchester,UnitedKingdom.3DepartmentofPediatricOnco-HematologyandDevelopmentalTumorBiologyLaboratory,HospitalSantJoandeDeu,Barce-lona,Spain.4DepartmentofPediatrics,DivisionofPediatricHematology-Oncol-ogyChildren'sDiscoveryandInnovationInstitute,UniversityofCalifornia,LosAngeles,California.5JonssonComprehensiveCancerCenter,UniversityofCalifornia,LosAngeles,California.6DavidGeffenSchoolofMedicine,LosAngeles,California.7WeizmannInstituteofScience,Rehovot,Israel.8Depart-mentofRadiology,BostonChildren'sHospital,HarvardMedicalSchool,Boston,Massachusetts.9Hematology,Oncology,andBoneMarrowTransplant,Univer-sityofColoradoDenver,Children'sHospitalColorado,Aurora,Colorado.10DepartmentofGeneticsandMolecularPathology,CentreforCancerBiology,anSAPathology&UniSAalliance,Adelaide,Australia.11DepartmentofPediat-rics,BaylorCollegeofMedicineandTexasChildren'sHospital,Houston,Texas.12DivisionofHaematology/Oncology,UniversityofToronto,Toronto,Ontario,Canada.13ResearchInstituteandTheArthurandSoniaLabattBrainTumourResearchCentre,TheHospitalforSickChildren,Toronto,Ontario,Canada.CorrespondingAuthor:D.GarethR.Evans,UniversityofManchester,OxfordRoad,ManchesterM139WL,UnitedKingdom.Phone:161-276-6206;Fax:161-276-6145;E-mail:gareth.evans@cmft.nhs.ukdoi:10.1158/1078-0432.CCR-17-0589Ó2017AmericanAssociationforCancerResearch.CCRPEDIATRICONCOLOGYSERIESClinCancerRes;23(12)June15,2017e46on June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from NF1ClinicalmanifestationsDiagnosticcriteria.TheNIHdiagnosticcriteriaforNF1areshowninTable1(5).Whenthesecriteriaareused,misdiagnosisorconfusionisunlikelyunlessadiagnosisismadebasedononlypigmentarycriteria.Patientswithsegmentalneuroﬁbromatosis(neuroﬁbromatosisfeatureslimitedtooneareaofthebody)canfulﬁllthesecriteria,andcliniciansshouldnoteanysegmentalinvolvement,asthismaymeanthechildhasapartialor"mosaic"formofNF1.Cliniciansneedtobeawarethatasubsetofindi-vidualsandfamilieswithmultipleCALmacules,withoutotherNF1primaryfeatures,mayhavemutationsintheSPRED1gene,aconditioncalledLegiussyndrome(11).Furthermore,patientswithconstitutionalmismatchrepairdeﬁciencysyndrome(CMMRD)canfulﬁllthecriteriaforNF1buthaveaverydifferentcancerspectrumandmuchhighercancerpenetrance[seetheCCRPedi-atricOncologySeriesarticlebyTaboriandcolleagues(15)].AhighindexofsuspicionforCMMRDisrecommendedinchildrenwithNF1featureswhoarefromconsanguineousfamilies,havethecancerstypicalofCMMRD(i.e.,high-gradeglioma,colorectalpolypsandcarcinoma,andhematopoieticmalignancies,especial-lyacutelymphoidleukemiaandlymphoma),and/orhavefamilyhistoryofcancersuggestiveofLynchsyndrome,and/orlackthecharacteristicdevelopmentalissuestypicallyseeninNF1.NF1clinicalfeaturesNF1clinicalfeaturesincludesomeofthediagnosticcriteriacategories(Table1).Inchildhood,CALmaculesaresmall,asreﬂectedinthediagnosticcriteria,buttheybecomelargerandoftenmergeasindividualsage.Theytypicallyhavealinearratherthanragged-edgeborderandareoftendescribedassimilartothe"coastofCalifornia"incontrasttothe"coastofMaine"appearanceobservedinindividualswithMcCune–Alb-rightsyndromeorCMMRD.TheCALmaculesinNF1oftenfadeinlaterlifeandmaybelesseasytorecognizewithoutaWood'slight/lamp.CALmaculesareﬂatwithnoassociatedhairandhavenopropensityformalignanttransformation.Frecklingusuallyoccursinnon–sun-exposedskin,withtheaxillamorefrequentlyaffectedthanthegroin.FrecklingusuallyappearslaterthantheCALmacules.NeuroﬁbromasonandundertheskinarethecharacteristicfeatureofNF1.Theseoftenstartaspinkish-purple,raised,softlesionsthatcanthentrans-formintomore"wart"-likegrowths.Plexiformtumors,whichlikelyrepresentanearlyembryonicorigintumor,areoftenvisiblefrombirthwithdiffuseinvolvementoftheskinandunderlyingstructures.Approximately2%to3%ofpatientswithNF1haveunsightlyplexiformtumorsaffectingtheheadandneck(16,17).Theoverlyingskinisoftenhyperpigmentedandloseselasticity,leadingtoagravityeffectof"sagging"ofthetumor.Subcutaneousnodulartumorsoccurasgrowthsonperipheralnerves,whichareseparatefromtheoverlyingskin.Thesetumorsmayappearasfusiformswellingsonmoremajornerveroutesandcanbepainfultothetouch.Thedeeperfusiformsubcutaneousandplexiformtumorsmayundergomalignantchangetomalignantperipheralnervesheathtumor(MPNST).Althoughthisisuncommoninchildhood,malig-nanttransformationcanoccurbeginninginadolescenceandveryrarelyearlier(Table2).TheappearanceofirisLischnodules(benignhamartomas)typicallyoccursearlyinchild-hoodandusuallyprecedestheappearanceofcutaneousneu-roﬁbromas.Lischnodulesofmelanocyticoriginappearaslightbrownish-orangeout-swellingsfromthelatticeworkoftheiris,incontrasttoirisnevi,whichareﬂatandusuallydarkbrownorblack.Ophthalmicexaminationbyslitlampis,therefore,ausefuldiagnosticaidinequivocalcases.Anothercommonfeatureinchildhoodarespotsontheskincalledxanthogra-nulomasthatareself-limiting.Theyusuallyappearbetween2and6yearsofage,disappearingwithinayear,andhavebeenlinkedtoanapparentincreasedriskofleukemia,(18)althoughthisassociationisnottotallycompelling.GeneticsandepidemiologyAnumberofstudieshaveaddressedthegenetics,prevalence,andincidenceofNF1(19).Theautosomaldominantinheri-tancepatternofNF1hasbeenconﬁrmedformanyyears(2).Atleast50%ofcasespresentasdenovomutationsofthegeneandappearasisolatedcases.NF1hasabirthincidenceofonein1,900to2,800(20,21)andadiagnosticprevalenceofonein4,150to4,950(20,21).Theprevalenceislowerthanbirthincidenceduetoundiagnosedcasesinpopulationsandanearliermeanageatdeath.ThehighestfrequencywasreportedinanIsraelistudyofmilitaryrecruits,withaprevalenceofaroundoneper1,000(22);however,thiswasbasedlargelyonthepresenceofCALmaculesandcouldrepresentafoundereffectforathreebase-pairdeletioninNF1oraSPRED1mutation(10,11,20).NearlyallchildrenwhoinheritanNF1mutationfromtheirparentcanbediagnosedonthebasisofpigmentaryfeaturesinveryearlychildhood;however,clinicaldiagnosisindenovocasesmaytakelonger.Indeed,recentmolecularevidenceshowsthatalthoughthesensitivityforNF1mutationdetectionbasedonRNAanalysisisaround96%(23–26),childrenmeetingNIHcriteriabasedsolelyonpigmentaryfeatures(e.g.,6CALmacules)onlyappeartohaveapprox-imatelya67%chanceofhavingNF1versus8%to10%havingLegiussyndrome(26).Fortheremainderofindividualsmeet-ingsomecriteria,particularlythosewithmoreragged-edgeCALpatchesandahistoryofmalignantcancers,considerationshouldbegiventoCMMRD,asthediagnosesmaybeconfusedgiventheoverlappingNIHcriteriaandsimilartumorspectrum[e.g.,neuroﬁbromaandopticpathwayglioma(OPG);ref.27].OtherconditionssuchasLEOPARDsyndrome(Noonansyn-dromewithmultiplelentigines)andotherRASopathiesmayalsopresentwithpigmentaryfeaturesmimickingNF1.ClinicalcourseandchildhoodtumorriskNF1iswidelyvariableinitsclinicalcourse.ThisvariationisfrequentlygreatevenwithinfamilieswithanidenticalNF1mutation(28).Assuch,predictingdiseaseseverityisdifﬁcult.Childrenwithearlymanifestationsofamoreseverediseasecourse,suchasmultipletumors,mayhaveundergonelossinearlydevelopmentofthewild-typeNF1allele,haveaTable1.DiagnosticcriteriaforNF1(twoormoremustbepresent)1.SixormoreCALmacules,thegreatestdiameterofwhichismorethan5mminprepubertalpatientsandmorethan15mminpostpubertalpatients2.Twoormoreneuroﬁbromasofanytype,oroneplexiformneuroﬁbroma3.Axillaryoringuinalfreckling4.Opticglioma5.TwoormoreLischnodules6.Adistinctiveosseouslesionsuchassphenoiddysplasiaorpseudarthrosis7.Aﬁrst-degreerelativewithNF1accordingtotheprecedingcriteriaNeuroﬁbromatosis1www.aacrjournals.orgClinCancerRes;23(12)June15,2017e47on June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from constitutionalwholegermlinedeletionoftheNF1gene,orinheritedapatternofmodiﬁergenesthatalterthephenotype(28).Diagnosisofoneclinicalfeaturedoesnotusuallyimplyahighriskofanothercomplication,althoughthereareexceptions.Forexample,OPGisassociatedwithahigherriskofsymptomaticgliomasoccurringelsewhereinthebrain(oftenlaterinchild-hood;ref.29),andthepresenceofmultiplesubcutaneousperiph-eralnerveneuroﬁbromasincreasestheriskofMPNST(30–32).LargestudiesinwhichchildrenwithNF1havebeenscreenedwithMRIscansindicatethatapproximately15%haveatleastaunilateralOPG(33).ItisunclearhowmanychildrenwhohaveanOPGdetectedbysurveillanceimagingwilleverdevelopsymp-toms,asstudiesthathavenotspeciﬁcallyscreenedusingimagingﬁndmuchlowerratesofbetween0.7%and6%(16,17,29).SymptomaticOPGsusuallypresentbetweenbirthand6yearsofage,peakingataround3to4yearsandhavingamorebenigncoursethansporadicOPG(33,34).However,adultonsetofsymptomsdoesoccur.Brainstemgliomasarelessfrequentandaffectapproximately1%to2%ofpatientsbutaremorefrequentinthosewithopticglioma(Table2;ref.29).Approximately2%ofindividualswithNF1presentwithsymptomsfromspinaltumorsthatrequiresurgery,butonMRIimaging,morethan60%appeartohavespinalnerverootinvolvementinadulthood(27).Itisnotclearwhysofewspinaltumorspresentsymptomatically,whichisincontrasttoNF2.Othernonneoplastic,NF1-associatedcentralnervoussystem(CNS)lesionsincludemacrocephaly(45%withheadcircumference>97thpercentile),aqueductstenosis(<1%),andneuroﬁbromatosis-associatedwhitemattertractenhance-mentorvacuolationchangesonT2-weightedMRI(33%–78%;refs.35–37).MalignanciesinNF1.MPNSTMPNSTisararetumoroccurringinonlyonepermillionannuallyinthegeneralpopulation,andbetween20%and50%ofpatientswithMPNSTshaveNF1(38),withNF1patientshavingan8%to12%lifetimerisk(38,39).MPNSTsarerareinchildhood,andarapidlygrowingdeep-seatedtumorwithpainorneurologicdeﬁcitneedstobeinvestigated.MRIoftenshowsaheterogenoustumor,and18F-FDGPETimag-ingisusefulindifferentiatingabenignplexiformtumorfrommalignantchange,withanumberofstudiesshowingincreasedFDGuptakeassociatedwithMPNST(39–41).Indeed,FDGPET/CT–guidedbiopsyhasbeenadvocatedasameansofincreasingthelikelihoodofobtainingaccuratebiopsyspecimensinpatientswithlargeplexiformneuroﬁbromas(42)."Atypicalneuroﬁbro-mas"areatransitionphasefromapurebenignnodularplexiformneuroﬁbromatoMPNST.NotallatypicalneuroﬁbromaswilleventuallydevelopintoMPNST,butthereisanincreasedrisk,andthesetumorsshouldbeconsideredpremalignantlesions.Atotal-bodyMRIisabletoidentifynodularneuroﬁbromaswithanincreasedgrowthratesuspectedofatypicalneuroﬁbroma.Indi-vidualswithNF1withanatypicalneuroﬁbromatendtohavemorethanoneatypicalneuroﬁbroma,andasagroup,theseindividualshaveahighriskofdevelopingMPNSTs.GliomasHigh-gradegliomasoccuratincreasedfrequencyinNF1andareoftenassociatedwiththepresenceofanopticglioma(29).Overall,theyoccurin<1%ofpatients(22,27),andduetotheirrarity,achildwithNF1andhigh-gradegliomashouldbeinves-tigatedforCMMRDifanNF1mutationhasnotbeenpreviouslyidentiﬁed.JuvenilemyelomonocyticleukemiaJuvenilemyelomonocyticleuke-miaisadeﬁnitiveNF1complication.Itisgenerallythoughttobeincurableexceptbyautologousbonemarrowtransplantationbutoccursinonlyaboutonein300NF1patients(43),withnoneoccurringinonelargepopulation–basedseriesof1,404patientswithNF1(44).Embryonalrhabdomyosarcoma(eRMS)AlthoughtheprevalenceofembryonalrhabdomyosarcomainNF1populationshadbeenestimatedashighas1.4%to6%,largerseriesconﬁrmariskoflessthan1%(17,45,46)butstillhigherthaninthegeneralpopu-lation.Theurogenitalsystemisthemostcommonanatomicsiteinvolved,althoughotherlocalizationshavebeenreported(orbitisthesecondmostfrequentlocalization).eRMSinNF1patientsarecharacterizedbyparticularlyearlyonset(0–5years)Table2.NF1:tumorfeatures,withtypicalagesatpresentationandchildhoodriskDiseasefeatureFrequency(pediatricrisk)in%AgeofpresentationSeriesHuson(15)McGaughran(16)UpdateforkeytumorsaPatientsinseries1355231,500Peripheralneuroﬁbromas>9960(20–60)7yearsPlexiformneuroﬁbromasAllplexiforms3015(15)0–18yearsLargelesionsofheadandneck1.26(6)0–3yearsCNStumorsOpticglioma(symptomatic)1.55(5–6)6%ChildhoodOtherCNStumors1.52.0(1)2%LifelongSpinalneuroﬁbromas1.52.0(0.2)0.2%LifelongMalignancyMalignantperipheralnervesheathtumors1.55(0.2)0.2%bLifelongEmbryonalrhabdomyosarcoma1.50.2(0.2)0.3%0–5Gastrointestinaltumorsc(neuroﬁbromasandGISTs)2.22.0(0)0%LifelongPheochromocytoma0.70.4(0.2)0%10yearsDuodenalcarcinoid1.52(0.1)0%10yearsGlomustumorsinnailbeds00.2(0.1)0%Adults(usually)Abbreviation:GIST,gastrointestinalstromaltumor.aUpdatebasedon1,500NF1patientsintheManchesterregister.b0.5%byage20years.cFrequencyofGISTinadulthoodhasbeenfoundtobeashighas6%,butthismayreﬂectMRIsurveillancedetectingasymptomatictumors.CCRPEDIATRICONCOLOGYSERIESClinCancerRes;23(12)June15,2017ClinicalCancerResearche48on June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from andmalesexpredominance.Allthecasesreportedarehistolog-icallyembryonaltype.Theprognosisandoverallsurvivalareequivalenttonon-NF1eRMS.Becauseoftheirlocation,eRMSinNF1aretypicallysymptomaticatpresentation,andtogetherwiththegoodprognosisandlowincidenceinNF1populations,thereareinsufﬁcientdatatorecommendanyroutinescreeningforeRMS.EndocrinetumorsandothertumorsDuodenalendocrine(carcinoid)tumorsandpheochromocytomaoccurinNF1withafrequencyofaround1%(Table2),buttheyarerareinchildhood."Glomus"tumorscanoccuraspainfulswellingsinthenailbedsandarebeingincreasinglyrecognized(47).Gastrointestinalstromaltumorswerepreviouslycalledgastrointestinalneuroﬁbromasandoccursymptomaticallyinaround2%ofpatientswithNF1butagain,rarelyinchildhood.Previousguidelines.GuidelinesformanagementofNF1havebeenpublishedbyseveraldifferentprofessionalorganiza-tionsandconcentrateonthediagnosisandmanagementofOPG(48–51).GeneticSummaryTheNF1geneonchromosome17qistheonlyknowngenetocausetypicalNF1.Thegenecontains62codingexonsspreadover282kb.TherearemultipleNF1pseudogenesinthegenomethatcancomplicatemutationanalysis.ItproducesmultiplemRNAandproteinisoformsbyalternativesplicingandalsobyRNAediting.TheNF1geneencodesneuroﬁbromin,alarge2,839aminoacidcytoplasmicproteinthatispredom-inantlyexpressedinneurons,Schwanncells,oligodendrocytes,lung,colon,muscle,andleukocytes(19).Themultidomainproteinregulatesseveralintracellularprocesses,includingtheRAS/ERK/MAPkinasecascadeandcytoskeletalassembly.Mostdescribedmutationsresultintruncatedproteinsandarespreadthroughoutthegene.LossoffunctionofbothallelesoftheNF1tumorsuppressorgeneleadstolossoftheNF1protein(neu-roﬁbromin)inthecausativeprecursorcell.ThiscauseslossoftumorsuppressorfunctionleadingtoahighriskoftumordevelopmentduetodecreasedRASsignalinginhibitionand,hence,toincreasedproliferation,particularlyincellsofneuralcrestorigin.NF1isautosomaldominantlyinheritedwithvirtuallycom-pletebutvariablepenetrance.Theﬁrstgenotype–phenotyperelationshipreportedwasbasedonwholegenedeletions(48).Theselargedeletionsoccurin2%to7%ofindividualswithNF1andareassociatedwithlargerbodysize,intellectualdisability,andgreatertumorburdenaswellasa2-to3-foldgreaterriskofMPNST(23–26,52).OtherclearcorrelationswerereportedlaterwithcertainnontruncatingmutationsbeingassociatedwithamilderformofNF1(26,53–55).Inparticular,anin-framedeletion(c.2970_2972delAAT;ref.53)appearstocauseaCALmacules–onlytypeofNF1withouttumorrisk,similartoSPRED1causingLegiussyndrome(11).Othermis-sensemutations(particularlyatresiduep.Arg1809)causeaNoonan-likeassociationwithpulmonarystenosis(54,55),whereascertainmissensemutationscauseaseverespinalformofNF1characterizedbyabsenceofpigmentaryfeatures,leadingtodiagnosticchallengesinchildhoodduetorelativeabsenceofCALmacules(56).GenetictestingrecommendationsTheclinicalcriteriafordiagnosingNF1havehistoricallybeenbasedonmeetingtwoormoreofthecriterialistedinTable1.Previously,NF1moleculartestingwasnotroutinelyrecom-mendedunlessneededforreproductivedecisionmakinginpatientswithaclinicaldiagnosisofNF1,asmoleculardiag-nosiswouldnotaltermanagementforindividualswithanestablishedclinicaldiagnosis.Thisclassicparadigmisshifting,however,basedonnewknowledgethatavarietyofsyndromeshaveoverlappingfeatureswithNF1butaverydifferentclinicalcourseandontheemergingtherapeuticbeneﬁtsobservedwithtargetedtherapiesaimedattheRAS/MAPKpathwayinchildrenwithNF1(57).Achildwhomeetsoneormoreclinicalcriterion(asoutlinedinTable1)shouldnowhaveNF1moleculargenetictesting(sequencinganddeletion/duplicationanalysis)offeredtoconﬁrmifNF1isthecorrectdiagnosis,asamisdi-agnosiscouldleadtoinappropriatesurveillance.AmutationwillbedetectedonRNAanalysisin67%ofindividualswhomeetpigmentary-onlycriteriaandapproximately95%to96%whomeetclinicaldiagnosticcriteria(23–26).Ifamutationisnotdetected,however,severalotherconditions,somewithcancerriskassociatedandotherswithout,maybecontributingtothephenotype.Someexamplesincludepigmentaryabnor-malitiesduetomutationsinSPRED1,CMMRDduetobiallelicTable3.Summaryofrecommendationsforchildhoodmanagement1.GenetictestingChildrenconsideredatriskofNF1especiallywith6þCALmaculesordiagnosedwithNIHcriteriashouldideallyhavegenetictestingoftheNF1genewithanRNA-basedapproachandtestingofSPRED1ifpigmentaryfeaturesonly2.GenetictestingThosetestingnegativeshouldbeconsideredforapanelofgenesincludingGNAS,MLH1,MSH2,MSH6,NF2,PMS2,PTPN11,SOS1,andSPRED1(ifnotalreadytested)3.GeneralAnnualhistoryandphysicalexam(includingskinandneurologicexamandalsobloodpressure,height,weight,andpubertaldevelopment)Tumorsurveillance4.OPGChildrenwithNF1shouldhave6–12monthlyophthalmicassessmentsfrombirthto8years.Onebaselineassessmentofcolorvisionandvisualﬁeldsshouldbeundertakenwhenthechildisdevelopmentallyable.5.MPNSTAssesswithhistoryandclinicalexaminationannuallyfortypicalsignsofMPNST:anynondermalneuroﬁbromawithrapidgrowth,lossofneurologicfunction,orincreasingpainorchangeinconsistency6.JMMLAssessforriskofJMMLinNF1inchildrenwithjuvenilexanthogranulomas7.InternalburdenAbaselinewhole-bodyMRIshouldbeconsideredbetweenages16and20yearstoassessinternaltumorburdentodetermineadultfollow-upregimen8.RoutineMRIMRIsurveillanceisnotcurrentlyrecommendedunlesssymptomaticorwithanalreadydiagnosedtumor.Speciﬁcbiochemicalorimagingsurveillancefortumorswithabsoluterisksinchildhoodbelow1%isnotrecommendedsuchasforpheochromocytoma,neuroendocrinetumors,MPNST,ornon-opticglioma.Abbreviation:JMML,juvenilemyelomonocyticleukemia.Neuroﬁbromatosis1www.aacrjournals.orgClinCancerRes;23(12)June15,2017e49on June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from MLH1,MSH2,MSH6,orPMS2mutations(58),RASopathysyndromes(suchasLEOPARD/Noonan)duetomutationsinPTPN11,orMcCune–AlbrightsyndromeduetomutationsinGNAS(Table3;refs.11,27,59).GiventhepredominanceofNF1andLegiussyndromeastheunderlyingdiagnoses,mostcentersbegingenetictestingwiththeNF1andSPRED1genes(Fig.1).Ifnegative,thenconsiderationofalargerpanelorwhole-exomeanalysisisundertaken.Forcoun-triesinwhichpanelanalysisisavailable,theprimaryconcernsdiscussedbytheworkshopcommitteewere2-fold.First,initiatingﬁrst-tiertestingwithapanelthatincludesNF1andSPRED1ispreferredpriortomovingontoalargerpanelthatmightresultinincidentalﬁndingofsingleheterozygousmismatchrepairmuta-tionsassociatedwithadult-onsetLynchsyndromeinchildhoodunrelatedtothechild'sphenotype.Second,predictivegenetictestingforadultonsetconditionsgenerallyshouldbedeferredunlessaninterventioninitiatedinchildhoodmayreducemor-bidityormortality(59,60).IfanNF1orSPRED1mutationisnotdetected,however,theriskofidentifyingLynchsyndromeisoutweighedbythepotentialbeneﬁtofearlyCMMRDdetectioninthissubpopulation.Ingeneral,foranyhereditarygenepanel,thelikelihoodofidentifyingvariantsofuncertainsigniﬁcance(VUS)increasesasmoregenesareevaluated,withmanypanelstudiesinadultsresultinginonaveragemorethanoneVUSperpaneltestreported(61).ByonlypursuingpanelsinchildrenwithoutamoleculardiagnosisofNF1,fewerpatientswillhavetheuncer-taintyofVUSthanifallpatientspursuedpaneltestinginclud-ingNF1asaﬁrsttier.Therefore,werecommendthealgorithmpresentedinFig.1.Ideally,NF1genetictestingshouldbeperformedonlymphocytesusingacombinedDNA/RNA–basedapproach.Ifnomutationisdetectedinisolatedcases,testingforNF1mutationsfrommela-nocyteculturesfromatleasttwopigmentarylesionsmaybeconsideredtoevaluateformosaicism,especiallyintheabsenceoffamilyhistoryofclinicalfeaturesofNF1.Priortopanel/exometesting,childrencouldbereferredtosubspecialtyclinicsifnotalreadyinoneandthenproceedtoadditionaltesting.Cancer/TumorScreening/SurveillanceProtocolsOPGdoesnotaffectoverallsurvivalofchildrenwithNF1(unlikeinchildrenwithsporadicOPG;ref.34),andlittleisknownaboutthenaturalhistoryofOPG.Nonetheless,thereisaclearneedtomakeanearlydiagnosisofOPGbeforesignif-icantlossofvisionoccurs.AsthegreatestriskofdevelopingOPGisduringchildhood(especiallyinchildren<7yearsofNo pathogenic mutation detectedPathogenic mutation detectedNo further/reﬂex testing*Panel/exome testing should include**CMMRD genes AND melanocytetesting of pigmentary lesion shouldbe considered in isolated casesClinical feature(s) of NF1:NF1 sequencing anddeletion/duplication analysis© 2017 American Association for Cancer ResearchFigure1.SummaryofexpertrecommendationsforgenetictestingandclinicalmanagementofNF1.,Next-generationsequencingpanel/focusedexomeshouldincludeatleastGNAS,MLH1,MSH2,MSH6,NF2,PMS2,PTPN11,SOS1,andSPRED1(ifnotalreadytested)andeitherreﬂexto,orinclude,deletion/duplicationanalysisofeachgene.SPRED1canbetestedasacombinedﬁrst-linetestwithNF1inthosechildrenwithpigmentary-onlycriteria.Alternatively,thoseisolatedcaseswithpigmentary-onlyphenotypecouldbetestedforapanel/exomeﬁrstincenterswithsufﬁcientexpertisetointerpretandcommunicatevariantsofuncertainsigniﬁcance,particularlyiftheCALmaculesarenottypicalforNF1(raggededges).Ifnomutationisdetectedonpanel/exome,however,RNAtestingforNF1maystillberequired,asDNA-basedapproachesarelesssensitive.,CMMRDgenes:MLH1,MSH2,MSH6,PMS2.Notethat(i)ifCMMRDisstronglysuspected,PMS2isnotcoveredwellinmostpanels,and(ii)CMMRDgenesmaybeexcludedfrompanelswhenfamilyhistoryclearlysuggestsdominantinheritanceoffeaturestoreducethechanceofanincidentalﬁndingofLynchsyndromeinchildhood.CCRPEDIATRICONCOLOGYSERIESClinCancerRes;23(12)June15,2017ClinicalCancerResearche50on June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from age),ophthalmologicexamsshouldstartwhentheNF1diag-nosisisestablishedandcontinuethroughoutchildhood.Thesecandetectbothvisuallossandchangesovertimethatwillrequiretherapy.AlthoughthegoldstandardforthediagnosisofanOPGisMRI,earlydetectionofanasymptomaticOPGhasnotbeenproventoreducetheincidenceofvisualloss,nordoesaninitialnormalMRIexcludethedevelopmentofasubsequentOPG.AstreatmentforanOPGisnotrequiredintheabsenceofpro-gressivevisualdisturbanceorproptosis,mostpreviousproto-colsdonotrecommendroutinescreeningbyMRI,asthiswouldneedtobecarriedoutfrequently,oftenrequiringsedation,andasmanyastwothirdsoftheOPGswouldneverbecomesymptomatic(48–50).Newer(bio)imagingtechniques,suchasmagneticresonancediffusiontensorimagingordiffusiontensortractography,areunderfurtherstudytodetectmicrostructuralabnormalitiesinthevisualpathwaythatcanpredictvisualfunctionbutdonotyethaveanestablishedroleinroutinesurveillance,particularlygiventheneedforsedationinyoungerpatients.Inaddition,otheremergingnoveltechnologies,suchasopticalcoherencetomography(OCT;refs.62,63),areevenmorepromisingandmayenableearlydetectionofopticnervedamage,especiallyinearlychildhoodwhenophthalmologicexaminationisdifﬁcult.OCTmeasuresthewidthoftheretinaandcanmeasurenervelossevenbeforethatismeasurablebyvisionassessment.TheOCTtechnologyisevolving,andnewerhandheldspectraldomainOCTdevicesthatpartiallyaccountfordifferencesinaxiallengthoftheeyeinchildrenhaveledtoincreasedenthusiasmforuseofOCTinmonitoringneuroﬁbromatosis-relatedopticnervepathology,althoughtheneedforsedationinyoungerpatientslimitsitsuniversalapplication.AlthoughOCTdataareencouraging,itisnotyetreadytobeaddedasarobusttoolforvisualsurveillanceinyoungchildrenwithNF1.Similarly,thereisnotenoughevi-dencetorecommendtheuseofvisualevokedpotentialsasascreeningtoolinOPG.CliniciansshouldbeawarethattheriskofotherCNStumors,althoughlow(1%–2%),isstillmuchhigherthaninthegeneralpopulation.Inchildhood,theyareusuallylow-gradegliomas,areoftenlocatedintheposteriorfossa(brain-stemandcerebellum),andhavealowgrowthrate.Mostofthemdonotproduceprogressivesymptoms,butfamiliesshouldbeinformedabouttheclinicalwarningsigns.Acom-prehensiveannualhistoryandneurologicexaminationmaybeusefulindetectingtheselesions.Thisriskofothermalignanttumorsinchildhood,includingMPNST,isgenerally<1%and,therefore,belowthethresholdtosuggestclinicalbeneﬁtbysurveillance(Table2).However,parentsshouldbealertedtothepotentialformalignanttransformationofexistingplexi-formneuroﬁbromasduringadolescence.Nonetheless,ifnewemergingtherapies,suchasMEKinhibitors,showbeneﬁts(theyalreadydoforbenignplexiforms)additionaltotumortreatment,thenearlierdetectionmaywellbewarranted.Surveillance1.Annualhistoryandphysicalexam[includingskinandneurologicexam,andalsobloodpressure(renalarterystenosis/pheochromocytomarisk),height,weight,andpubertaldevelopment].2.Ophthalmicassessment[detailedophthalmologicprotocol(ideallyinspecialistcenter);refs.51,64].3.AssesswithhistoryandclinicalexaminationannuallyfortypicalsignsofMPNST:anynondermalneuroﬁbromawithrapidgrowth,lossofneurologicfunction,orincreasingpainorchangeinconsistency.HaveincreasedsuspicioninthosewithfeaturesinTable4.Youngchildrendonotcomplainofvisualimpairmentuntilitisadvancedandsometimesonlywhentheyhavebilateralvisualloss.Parentsneedtobealerttopossiblesignsofvisualproblemssuchasfailuretopickupsmalltoysandbumpingintoobjects.Furthermore,visualassessmentisoftenproblem-aticinthosewithcognitivedeﬁcits.Quantitativetestingmethods(telleracuitycards)existforchildrenasyoungas6monthsofageandarereliablemeasuresofvisualacuity(VA;ref.65).Inolderchildren(usuallyatdevel-opmentalageof3years),testingmethodsmeasuretheabilitytorecognize("recognitionacuity")aﬁgure(e.g.,Leasymbols)orletters(e.g.,HOTVorSnellen).Colorvisioncanbeobtainedat5yearsandcomprehensiveperipheralvisualﬁeldsat8years(whereasmorebasicconfrontationvisualﬁeldscanbeobtainedmuchearlier).Besidesvisionlossandproptosis,OPGcanalsopresentasendocrinedisturbances(precociousordelayedpuberty,increasedgrowthvelocity)orhydrocephalus,andphysiciansshouldbeawareofthepossibilityofanunderlyingOPGifanyoftheseoccur.SurveillanceforOPGshould,therefore,include:*Sixto12monthlyophthalmicassessmentsfrombirthto8years(63,65),includingobjectiveandquantitativeVA[telleracuitycardsandwhenthechildismatureenoughforamorereliableVAtesting(e.g.,HOTV)],confrontationvisualﬁelds,pupillaryreﬂexes,andfundusexam.Every1to2yearsthereafteruntil20yearsofage.*Onebaselineassessmentofcolorvisionandvisualﬁeldsshouldbeundertakenwhenthechildismatureenoughtocopewiththetest.*Inspecializedsettingswhereavailable,OCTineveryophthalmologicassessmentmaybeconsideredasanobjectivemeasureofaxonalintegrity/axonallossandthicknessofretinalnerveﬁberlayer.*Duringscreening,ifavisionlossisdetected,andonceothercausesareexcluded(refractiveerror,opacities,etc.),arepeatedtestin2weeksshouldbeobtained.Ifvisionlosspersists,anMRIwouldbeindicated.Table4.FeaturesthatshouldheightenawarenessaboutlikelihoodofMPNSTFeatureHowtoassessLargeinternalnodularneuroﬁbromaburdenWhole-bodyMRIHardandpainfulsubcutaneousneuroﬁbroma(s)ClinicalhistoryandexaminationPreviouslyirradiatedbodyregionClinicalhistoryGermlineNF1microdeletionincludingSUZ12MutationtestingAtypicalneuroﬁbroma(neuroﬁbromawithregionsofhypercellularityandnuclearatypia)PrevioushistoryandbiopsyAcutesymptom/signPainespeciallythatwakespersonatnightMRIandFDGPETFocalneurologicsign/lossoffunctionMRIandFDGPETRapidgrowthofaneuroﬁbromaorpartofaplexiformMRIandFDGPETNeuroﬁbromatosis1www.aacrjournals.orgClinCancerRes;23(12)June15,2017e51on June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from OncediagnosedwithOPG[refertomultidisciplinaryteam(MDT)]:*Follow-upunderneuro-oncologyMDT*Mayrequirechemotherapytreatment,butradiotherapynotrecommended(29)*Threeto6monthlyMRIsRecommendationsfortransitiontoadulthoodYoungadultswithNF1shouldbecounseledonthefutureriskofMPNSTandthecardinalsigns.Womenages30to50shouldbeadvisedoftheincreasedbreastcancerrisksof4-to5-fold(39,66)andtoaccessextrabreastscreeningaccordingtoguidelinesformoderate(20%)lifetimeriskorhighriskifadditionalfamilyhistoryofbreastcancer.BecauseoftheriskofMPNSTbeingassociatedwithhighinternaltumorburden,whole-bodyMRIshouldbeconsideredbetweenages16and20yearstoassessthis(30–32,52,67).NF1-affectedindividualswithhighinternaltumorburdenand/orwholegenedeletions(52)shouldbereferredtoaspecialistNF1networkclinicforlong-termfollow-upandsurveillance.AlladultswithNF1shouldhaveatleastannualbloodpressurechecksandaccesstospecialistclinicsiftheydevelopcardinalfeaturesofMPNST,gastrointestinalstromaltumors,orotherNF1-relatedmajorcomplications.ConclusionsThisreportmakesanumberofrecommendationsforthediagnosisandsurveillanceofchildrenandyoungadultswithNF1,whicharesummarizedinTable3.DisclosureofPotentialConﬂictsofInterestS.E.Plonisaconsultant/advisoryboardmemberforBaylorGenet-ics.Nopotentialconﬂictsofinterestweredisclosedbytheotherauthors.ReceivedMarch1,2017;revisedApril28,2017;acceptedMay2,2017;publishedonlineJune15,2017.References1.CushingH.Tumoursofthenervusacusticusandthesyndromeofthecerebello-pontineangle.Philadelphia:W.B.Saunders;1917.2.CroweFW,SchullWJ,NealJV,editors.Aclinicalpathologicalandgeneticstudyofmultipleneuroﬁbromatosis.Springﬁeld(IL):CharlesC.Thomas;1956.3.SeizingerBR,RouleauGA,OzeliusLG,LaneAH,FaryniarzAG,ChaoMV,etal.GeneticlinkageofvonRecklinghausenneuroﬁbromatosistothenervegrowthfactorreceptorgene.Cell1987;49:589–94.4.RouleauG,WerteleckiW,HainesJL,HobbsWJ,TrofatterJA,SeizingerBR,etal.GeneticlinkageanalysisofbilateralacousticneuroﬁbromatosistoaDNAmarkeronchromosome22.Nature1987;329:246–8.5.Nationalinstitutesofhealthconsensusdevelopmentconferencestatementonneuroﬁbromatosis.ArchNeurol1987;45:575–9.6.ViskochilD,BuchbergAM,XuG,CawthonRM,StevensJ,WolffRK,etal.Deletionsandatranslocationinterruptaclonedgeneattheneuroﬁbro-matosistype1locus.Cell1990;62:187–92.7.TroffaterJA,MacCollinMM,RutterJL,MurrellJR,DuyaoMP,ParryDM,etal.Anovelmoesin-,ezrin-,radixin-likegeneisacandidatefortheneuroﬁbromatosis2tumorsuppressor.Cell1993;72:791–800.8.RouleauGA,MerelP,LutchmanM,SansonM,ZucmanJ,MarineauC,etal.Alterationinanewgeneencodingaputativemembrane-orga-nizingproteincausesneuro-ﬁbromatosistype2.Nature1993;363:515–21.9.NarodSA,ParryDM,ParboosinghJ,LenoirGM,RuttledgeM,FischerG,etal.Neuroﬁbromatosistype2appearstobeageneticallyhomogenousdisease.AmJHumGenet1992;51:486–96.10.UpadhyayaM,HusonSM,DaviesM,ThomasN,ChuzhanovaN,Gio-vanniniS,etal.Anabsenceofcutaneousneuroﬁbromasassociatedwitha3-bpin-framedeletioninexon17oftheNF1gene(c.2970_2972delAAT):EvidenceofaclinicallysigniﬁcantNF1genotype-phenotypecorrelation.AmJHumGenet2007;80:140–51.11.BremsH,ChmaraM,SahbatouM,DenayerE,TaniguchiK,KatoR,etal.Germlineloss-of-functionmutationsinSPRED1causeaneuroﬁbromato-sis1-likephenotype.NatGenet2007;39:1120–6.12.MacCollinM,WoodﬁnW,KronnD,ShortMP.Schwannomatosis:aclinicalandpathologicstudy.Neurology1996;46:1072–9.13.MacCollinM,WillettC,HeinrichB,JacobyLB,AciernoJSJr,PerryA,etal.Familialschwannomatosis:exclusionoftheNF2locusasthegermlineevent.Neurology2003;60:1968–74.14.HulsebosTJ,PlompAS,WoltermanRA,Robanus-MaandagEC,BaasF,WesselingP.GermlinemutationofINI1/SMARCB1infamilialschwan-nomatosis.AmJHumGenet2007;80:805–10.15.TaboriU,HansfordJR,AchatzMI,KratzCP,PlonSE,FrebourgT,etal.Clinicalmanagementandtumorsurveillancerecommendationsofinher-itedmismatchrepairdeﬁciencyinchildhood.ClinCancerRes2017;23:e32–e37.16.HusonSM,HarperPS,CompstonDA.VonRecklinghausenneuroﬁbro-matosis.Aclinicalandpopulationstudyinsouth-eastWales.Brain1988;111:1355–81.17.McGaughranJM,HarrisDI,DonnaiD,TeareD,MacLeodR,WesterbeekR,etal.Aclinicalstudyoftype1neuroﬁbromatosisinNorthWestEngland.JMedGenet1999;36:192–6.18.ZvulunovA,BarakY,MetzkerA.Juvenilexanthogranuloma,neuroﬁbro-matosis,andjuvenilechronicmyelogenousleukemia.Worldstatisticalanalysis.ArchDermatol1995;131:904–8.19.FernerRE,GutmannDH.Neuroﬁbromatosistype1(NF1):diagnosisandmanagement.HandbClinNeurol2013;115:939–55.20.EvansDG,HowardE,GiblinC,ClancyT,SpencerH,HusonSM,etal.Birthincidenceandprevalenceoftumourpronesyndromes:estimatesfromaUKgeneticfamilyregisterservice.AmJMedGenet2010;152A:327–32.21.UusitaloE,Lepp€avirtaJ,KoffertA,SuominenS,VahteraJ,VahlbergT,etal.Incidenceandmortalityofneuroﬁbromatosis:atotalpopulationstudyinFinland.JInvestDermatol2015;135:904–6.22.GartyBZ,LaorA,DanonYL.Neuroﬁbromatosistype1inIsrael:surveyofyoungadults.JMedGenet1994;31:853–7.23.MessiaenLM,CallensT,MortierG,BeysenD,VandenbrouckeI,VanRoyN,etal.ExhaustivemutationanalysisoftheNF1geneallowsidentiﬁcationof95%ofmutationsandrevealsahighfrequencyofunusualsplicingdefects.HumMutat2000;15:541–55.24.SabbaghA,PasmantE,ImbardA,LuscanA,SoaresM,BlancheH,etal.NF1molecularcharacterizationandneuroﬁbromatosistypeIgenotype-phe-notypecorrelation:theFrenchexperience.HumMutat2013;34:1510–8.25.ProsE,GomezC,MartínT,FabregasP,SerraE,LazaroC.NatureandmRNAeffectof282differentNF1pointmutations:focusonsplicingalterations.HumMutat2008;29:E173–93.26.EvansDG,BowersN,Burkitt-WrightE,MilesE,GargS,Scott-KitchingV,etal.ComprehensiveRNAanalysisoftheNF1geneinclassicallyaffectedNF1affectedindividualsmeetingNIHcriteriahashighsensitivityandmutationnegativetestingisreassuringinisolatedcaseswithpigmentaryfeaturesonly.eBioMedicine2016;7:212–20.27.WimmerK,RosenbaumT,MessiaenL.Connectionsbetweenconstitu-tionalmismatchrepairdeﬁciencysyndromeandneuroﬁbromatosistype1.ClinGenet2017;91:507–19.28.EastonDF,PonderMA,HusonSM,PonderBAJ.Ananalysisofvariationinexpressionofneuroﬁbromatosis(NF1):evidenceofmodifyinggenes.AmJHumGenet1993;53:305–13.29.SharifS,FernerR,BirchJ,GattamaneniR,GillespieJ,EvansDGR.SecondprimarytumoursinNeuroﬁbromatosis1(NF1)patientstreatedClinCancerRes;23(12)June15,2017ClinicalCancerResearche52CCRPEDIATRICONCOLOGYSERIESon June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from foropticglioma:substantialriskspostradiotherapy.JClinOncol2006;24:2570–5.30.NguyenR,JettK,HarrisGJ,CaiW,FriedmanJM,MautnerVF.Benignwholebodytumorvolumeisariskfactorformalignantperipheralnervesheathtumorsinneuroﬁbromatosistype1.JNeurooncol2014;116:307–13.31.MautnerVF,AsuagborFA,DombiE,F€unstererC,KluweL,WenzelR,etal.Assessmentofbenigntumorburdenbywhole-bodyMRIinpatientswithneuroﬁbromatosis1.NeuroOncol2008;10:593–8.32.TuckerT,WolkensteinP,RevuzJ,ZellerJ,FriedmanJM.AssociationbetweenbenignandmalignantperipheralnervesheathtumorsinNF1.Neurology2005;65:205–11.33.ListernickR,CharrowJ,GreenwaldMJ,EsterlyNB.Opticgliomasinchildrenwithneuroﬁbromatosistype1.JPediatr1989;114:788–92.34.SinghalS,KerrB,BirchJ,LashfordL,EvansDGR.ClinicalcharacteristicsofsymptomaticsporadicandNF1relatedopticgliomata:implicationsformanagement.ArchDisChild2002;87:65–70.35.RodriguesACJr,Ferraz-FilhoJR,TorresUS,daRochaAJ,MunizMP,SouzaAS,etal.Ismagneticresonancespectroscopycapableofdetectingmetabolicabnormalitiesinneuroﬁbromatosistype1thatarenotrevealedinbrainparenchymaofnormalappearance?PediatrNeurol2015;52:314–9.36.RoyA,BarbarotS,CharbonnierV,Gayet-DelacroixM,StalderJF,RoulinJL,etal.Examiningthefrontalsubcorticalbrainvulnerabilityhypothesisinchildrenwithneuroﬁbromatosistype1:areT2-weightedhyperintensitiesrelatedtoexecutivedysfunction?Neuropsychology2015;29:473–84.37.Ferraz-FilhoJR,JosedaRochaA,MunizMP,SouzaAS,Goloni-BertolloEM,Pavarino-BertelliEC.Unidentiﬁedbrightobjectsinneuroﬁbroma-tosistype1:conventionalMRIinthefollow-upandcorrelationofmicrostructurallesionsondiffusiontensorimages.EurJPaediatrNeurol2012;16:42–7.38.EvansDGR,BaserME,McGaughranJ,SharifS,DonnellyB,MoranA.Malignantperipheralnervesheathtumoursinneuroﬁbromatosis1.JMedGenet2002;39:311–4.39.UusitaloE,RantanenM,Kallionp€a€aRA,P€oyh€onenM,Lepp€avirtaJ,Yl€a-OutinenH,etal.Distinctivecancerassociationsinpatientswithneuro-ﬁbromatosistype1.JClinOncol2016;34:1978–86.40.EvansDG,HowardE,WildingA,InghamSL,MoranA,Scott-KitchingV,etal.Mortalityinneuroﬁbromatosis1.EurJHumGenet2011;19:1187–91.41.FernerRE,LucasJD,O'DohertyMJ,HughesRA,SmithMA,CroninBF,etal.Evaluationof(18)ﬂuorodeoxyglucosepositronemissiontomography((18)FDGPET)inthedetectionofmalignantperipheralnervesheathtumoursarisingfromwithinplexiformtumoursinneuroﬁbromatosis1.JNeurolNeurosurgPsychiat2000;68:353–7.42.WarbeyVS,FernerRE,DunnJT,CalonjeE,O'DohertyMJ.[18F]FDGPET/CTinthediagnosisofmalignantperipheralnervesheathtumoursinneuroﬁbromatosistype-1.EurJNuclMedMolImaging2009;36:751–7.43.TsaiLL,DrubachL,FaheyF,IronsM,VossS,UllrichNJ.[18F]-Fluorodeox-yglucosepositronemissiontomographyinchildrenwithneuroﬁbroma-tosistype1andplexiformneuroﬁbromas:correlationwithmalignanttransformation.JNeurooncol2012;108:469–75.44.BrahmiM,ThiesseP,RanchereD,MognettiT,PinsonS,RenardC,etal.DiagnosticaccuracyofPET/CT-guidedpercutaneousbiopsiesformalig-nantperipheralnervesheathtumorsinneuroﬁbromatosistype1patients.PLoSOne2015;10:e0138386.45.PatilS,ChamberlainRS.NeoplasmsassociatedwithgermlineandsomaticNF1genemutations.Oncologist2012;17:101–16.46.CrucisA,RicherW,BrugieresL,BergeronC,Marie-CardineA,StephanJL,etal.RhabdomyosarcomasinchildrenwithneuroﬁbromatosistypeI:anationalhistoricalcohort.PediatrBloodCancer2015;62:1733–8.47.DeSmetL,SciotR,LegiusE.Multifocalglomustumoursoftheﬁngersintwopatientswithneuroﬁbromatosistype1.JMedGenet2002;39:e45.48.GutmannDH,AylesworthA,CareyJC,KorfB,MarksJ,PyeritzRE,etal.Thediagnosticandmulti-disciplinarymanagementofneuroﬁbromatosis1andneuroﬁbromatosis2.JAMA1997;278:51–7.49.CassimanC,LegiusE,SpileersW,CasteelsI.Ophthalmologicalassess-mentofchildrenwithneuroﬁbromatosistype1.EurJPediatr2013;172:1327–33.50.FernerRE,HusonS,ThomasN,MossC,WillshawH,EvansDG,etal.GuidelinesforthediagnosisandmanagementofIndividualswithNeu-roﬁbromatosis1(NF1).JMedGenet2007;44:81–8.51.FisherMJ,AveryRA,AllenJC,Ardern-HolmesSL,BilaniukLT,FernerRE,etal.FunctionaloutcomemeasuresforNF1-associatedopticpathwaygliomaclinicaltrials.Neurology2013;81:S15–24.52.DeRaedtT,BremsH,WolkensteinP,VidaudD,PilottiS,PerroneF,etal.ElevatedriskforMPNSTinNF1microdeletionpatients.AmJHumGenet2003;72:1288–92.53.UpadhyayaM,HusonSM,DaviesM,ThomasN,ChuzhanovaN,Gio-vanniniS,etal.Anabsenceofcutaneousneuroﬁbromasassociatedwitha3-bpin-framedeletioninexon17oftheNF1gene(c.2970_2972delAAT):EvidenceofaclinicallysigniﬁcantNF1genotype-phenotypecorrelation.AmJHumGenet2007;80:140–51.54.RojnueangnitK,XieJ,GomesA,SharpA,CallensT,ChenY,etal.HighincidenceofnoonansyndromefeaturesincludingshortstatureandpulmonicstenosisinpatientscarryingNF1missensemutationsaffect-ingp.Arg1809:genotype-phenotypecorrelation.HumMutat2015;36:1052–63.55.Ben-ShacharS,ConstantiniS,HalleviH,SachEK,UpadhyayaM,EvansGD,etal.Increasedrateofmissense/in-framemutationsinindividualswithNF1-relatedpulmonarystenosis:anovelgenotype-phenotypecorre-lation.EurJHumGenet2013;21:535–9.56.BurkittWrightEM,SachE,SharifS,QuarrellO,CarrollT,WhitehouseRW,etal.CanthediagnosisofNF1beexcludedclinically?Alackofpigmentaryﬁndingsinfamilieswithspinalneuroﬁbromatosisdemonstratesalimi-tationofclinicaldiagnosis.JMedGenet2013;50:606–13.57.DombiE,BaldwinA,MarcusLJ,FisherMJ,WeissB,KimA,etal.Activityofselumetinibinneuroﬁbromatosistype1-relatedplexiformneuroﬁbromas.NEnglJMed2016;375:2550–60.58.WimmerK,KratzCP,VasenHF,CaronO,ColasC,Entz-WerleN,etal.EU-ConsortiumCareforCMMRD(C4CMMRD).Diagnosticcriteriaforcon-stitutionalmismatchrepairdeﬁciencysyndrome:suggestionsoftheEuro-peanconsortium'careforCMMRD'(C4CMMRD).JMedGenet2014;51:355–65.59.RadtkeHB,SeboldCD,AllisonC,HaidleJL,SchneiderG.Neuroﬁ-bromatosistype1ingeneticcounselingpractice:recommendationsoftheNationalSocietyofGeneticCounselors.JGenetCouns2007;16:387–407.60.AmericanAcademyofPediatrics.Ethicalandpolicyissuesingenetictestingandscreeningofchildren.Pediatrics2013;131:620–2.61.YorczykA,RobinsonLS,RossTS.Useofpaneltestsinplaceofsinglegenetestsinthecancergeneticsclinic.ClinGenet2015;88:278–82.62.AveryRA,CnaanA,SchumanJS,ChenCL,GlaugNC,PackerRJ,etal.Intra-andinter-visitreproducibilityofganglioncell-innerplexiformlayermea-surementsusinghandheldopticalcoherencetomographyinchildrenwithopticpathwaygliomas.AmJOphthalmol2014;158:916–23.63.LeeH,ProudlockFA,GottlobI.Pediatricopticalcoherencetomographyinclinicalpractice-recentprogress.InvestOphthalmolVisSci2016;57:69–79.64.CaenS,CassimanC,LegiusE,CasteelsI.Comparativestudyoftheophthalmologicalexaminationsinneuroﬁbromatosistype1.Pro-posalforanewscreeningalgorithm.EurJPaediatrNeurol2015;19:415–22.65.FisherMJ,AveryRA,AllenJC,Ardern-HolmesSL,BilaniukLT,FernerRE,etal.FunctionaloutcomemeasuresforNF1-associatedopticpathwaygliomaclinicaltrials.Neurology2013;81(21Suppl1):S15–S24.66.SharifS,MoranA,HusonSM,IddendenR,ShentonA,HowardE,etal.WomenwithNeuroﬁbromatosis1(NF1)areatamoderatelyincreasedriskofdevelopingbreastcancerandshouldbeconsideredforearlyscreening.JMedGenet2007;44:481–4.67.AhlawatS,FayadLM,KhanMS,BredellaMA,HarrisGJ,EvansDG,etal.Currentwhole-bodyMRIapplicationsintheneuroﬁbromatoses:NF1,NF2,andschwannomatosis.Neurology2016;87:S31–9.www.aacrjournals.orgClinCancerRes;23(12)June15,2017e53Neuroﬁbromatosis1on June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 2017;23:e46-e53. Clin Cancer Res(cid:160)(cid:160) D. Gareth R. Evans, Hector Salvador, Vivian Y. Chang, et al. (cid:160) Pediatric Neurofibromatosis 1Cancer and Central Nervous System Tumor Surveillance in(cid:160) Updated version(cid:160)  http://clincancerres.aacrjournals.org/content/23/12/e46Access the most recent version of this article at:(cid:160) (cid:160) (cid:160) (cid:160) (cid:160) Cited articles(cid:160)  http://clincancerres.aacrjournals.org/content/23/12/e46.full.html#ref-list-1This article cites 65 articles, 17 of which you can access for free at:(cid:160) (cid:160) (cid:160) E-mail alerts related to this article or journal.Sign up to receive free email-alerts(cid:160) SubscriptionsReprints and (cid:160) .pubs@aacr.orgTo order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at(cid:160) Permissions(cid:160) .permissions@aacr.orgTo request permission to re-use all or part of this article, contact the AACR Publications Department aton June 25, 2017. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from PriorityReportWhole-ExomeSequencingRevealsFrequentGeneticAlterationsinBAP1,NF2,CDKN2A,andCUL1inMalignantPleuralMesotheliomaGuangwuGuo1,2,JuliannChmielecki1,2,ChandraGoparaju3,AdrianaHeguy4,IgorDolgalev4,MicheleCarbone5,SaraSeepo1,MatthewMeyerson1,2,6,andHarveyI.Pass3AbstractMalignantpleuralmesothelioma(MPM)isanaggressiveneoplasmassociatedwithasbestosexposure.Althoughpre-viousstudiesbasedoncandidategeneapproacheshaveidentiﬁedimportantcommonsomaticmutationsinMPM,thesestudieshavefocusedonsmallsetsofgenesandhaveprovidedalimitedviewofthegeneticalterationsunderlyingthisdisease.Here,weperformedwhole-exomesequencingonDNAfrom22MPMsandmatchedbloodsamples,andiden-tiﬁed517somaticmutationsacross490mutatedgenes.Integrativeanalysisofmutationsandsomaticcopy-numberalterationsrevealedfrequentgeneticalterationsinBAP1,NF2,CDKN2A,andCUL1.OurstudypresentstheﬁrstunbiasedviewofthegenomicbasisofMPM.CancerRes;75(2);264–9.Ó2014AACR.IntroductionMalignantpleuralmesothelioma(MPM)isarareandhighlyaggressivetumorofserosalsurfacesassociatedwithexposuretoasbestos,whoseincidenceisincreasingworldwide(1).EffectivetreatmentforMPMisdifﬁcultduetodelaysindiagnosis,nonuniformityofstaging,andthelackofeffectivemedicaltherapy.AlthoughseveralmajoradvancesinthemanagementofpatientswithMPMhavebeenmadeinthepastfewyears,includingtheuseofpemetrexedandcisplatinum,currentlyavailabletreatmentsstillappeartoprovideonlymodestbeneﬁt(1).Previousgeneticanalyseshaveidentiﬁedseveralkeygenet-icalterations,includinginactivationofCDKN2A(2),NF2(3),andBAP1(4).Inaddition,frequentlossesofchromosomearms1p,3p,4q,6q,9p,13q,14q,and22qandgainsofchromosomearms1q,5p,7p,8q,and17qhavebeenreportedinMPM(5).ThesestudiesprovidebroadinsightsintothebiologyofMPMandidentiﬁcationofnewtargetsfortherapy.However,nocomprehensiveanalysisofMPMgenomesusingnext-genera-tionsequencinghaveyetbeenreported.Advancesintechnologiesforhigh-throughputsequencingofDNAhaveenabledthecomprehensivecharacterizationofsomat-icmutationsindifferentcancertypesatanunprecedentedreso-lution(6).Inparticular,exomesequencingrepresentsacost-andlabor-efﬁcientstrategytoidentifymutationsinprotein-codingexonsinthehumangenome.Inrecentyears,exomesequencinghasbeensuccessfullyappliedtoavarietyofhumancancers,enablingcancergenomediscoverieswiththepotentialtotranslateintoadvancesincancerdiagnosisandtreatmentaswellasbasiccancerbiology(7).Here,weperformedexomesequencingongenomicDNAfrom22MPMtissuesandmatchednormalsamples.WefoundfrequentinactivationofBAP1,NF2,CUL1,andCDKN2Abysomaticmutationsand/orcopy-numberalterations.Wealsoobservedfrequentalterationsinseveralcanonicalcancer-relat-edpathways.Insummary,ourdataprovideaﬁrstviewofthecomprehensivelandscapeofsomaticgenomealterationsinMPM.MaterialsandMethodsPatientsamplescollectionandpreparationAll22tumorsandmatchedbloodsampleswereobtainedfromindividualsdiagnosedwithMPMattheNewYorkUni-versity(NYU)GeneralThoracicSurgeryService(SupplementaryTableS1).Allpatientsampleswerecollectedintheoperatingroom,immediatelysnap-frozeninliquidnitrogenwithin10minutesofcollection,andthenstoredat 80C.Bloodwaswithdrawnbeforetheinitiationofanesthesiaforserum,plas-ma,andperipheralbloodmononuclearcells(PBMC).ThePBMCs,cryopreservedafterprocessing,wereusedfornormalgenomicDNAmatchedtothespecimensandwereprocessedasperthemanufacturer'sspeciﬁcations(BectonDickinson;BDCPTvacutainertubes).Percentagesoftumorwithinthetumorsrangedfrom70%to90%basedonhistologicexamination,and1BroadInstituteofHarvardandMIT,Cambridge,Massachusetts.2DepartmentofMedicalOncologyandCenterforCancerGenomeDiscovery,Dana-FarberCancerInstitute,Boston,Massachusetts.3DepartmentofCardiothoracicSurgery,NYULangoneMedicalCen-ter,NewYork,NewYork.4GenomeTechnologyCenter,NYULangoneMedicalCenter,NewYork,NewYork.5UniversityofHawaiiCancerCenter,Honolulu,Hawaii.6DepartmentofPathology,HarvardMedicalSchool,Boston,Massachusetts.Note:SupplementarydataforthisarticleareavailableatCancerResearchOnline(http://cancerres.aacrjournals.org/).CorrespondingAuthor:HarveyI.Pass,DepartmentofCardiothoracicSurgery,NYULangoneMedicalCenter,530FirstAvenue,9VNewYork,NY10016.Phone/fax:212-263-7417;E-mail:Harvey.Pass@nyumc.orgdoi:10.1158/0008-5472.CAN-14-1008Ó2014AmericanAssociationforCancerResearch.CancerResearchCancerRes;75(2)January15,2015264on April 13, 2017. © 2015 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Published OnlineFirst December 8, 2014; DOI: 10.1158/0008-5472.CAN-14-1008 histologiesofthespecimensincludedbiphasic(threetumors),desmoplastic(onetumor),andepithelial(18tumors).Eachsubjectwasproperlyinformedbeforerecruitmentforthestudy,accordingtotheregulationsoftheNYUethicsreviewboards.Beforewhole-exomesequencing,germlineSNPanalysiswasperformedontumor–bloodpairstoconﬁrmtheiridentities;alltumorsmatchedtheirnormalpairs.MassivelyparallelsequencingForwhole-exomesequencing,genomicDNAsfromtumor–bloodpairswerefragmentedandsubjectedtowhole-exomecapturewiththeSureSelectHumanAllExon50-MbKit(AgilentTechnologies)followingstandardprotocols.ExomecapturelibrarieswerethensequencedontheIlluminaHiSeqplatformaccordingtostandardprotocols(8).SomaticmutationcallingMutationanalysisofexomesequencingdatawasperformedasdescribedpreviously(8).Brieﬂy,basicreadalignmentandsequencequalitycontrolweredonebyusingthePicardandFirehosepipelinesattheBroadInstitute.MappedgenomeswereprocessedbytheBroadFirehosepipelinetoperformadditionalqualitycontrol,variantcalling(MuTectalgorithm;ref.9),andmutationsigniﬁcanceanalysis(MutSigalgorithm;ref.10).ValidationofrecurrentlymutatedgenesinadditionalMPMsTheexonicregionsofrecurrentlymutatedgenesPIK3C2B,RDX,andTAOK1weredeterminedusingtheRefSeqtranscriptdataretrievedfromtheUCSCGenomeBrowser,yielding67regions.SpeciﬁcprimersweredesignedusingPrimer3,toamplifytheexonicregionswithabufferofatleast100bpsonbothendswithatotallengthof500to1,500bps(Supple-mentaryTableS2).TheregionsofinterestwereampliﬁedbyPCRreactionsusingatouchdownPCRprotocolwithKapaHiFiHotStartpolymerase(KapaBiosystems).ThetouchdownPCRmethodconsistedof:1cycleof95Cfor5minutes;3cyclesof95Cfor30seconds,64Cfor15seconds,72Cfor30seconds;3cyclesof95Cfor30seconds,62Cfor15seconds,72Cfor30seconds;3cyclesof95Cfor30seconds,60Cfor15seconds,72Cfor30seconds;37cyclesof95Cfor30seconds,58Cfor15seconds,72Cfor30seconds;1cycleof70Cfor5minutes.AllampliconsforeachsamplewerepooledandusedtogeneratelibrarieswithuniqueindicesusingtheNexteraDNASamplePreparationKit(Illumina),whichgeneratessmallerfragmentsrandomlywithineachamplicon.SequencingofampliconswascarriedoutonanIlluminaMiSeqinstrumentwith2150bpspaired-endreads.Theaveragecoverageofeachgenewasapproximately900.Somaticmuta-tionsineachgeneweredetectedbythesamemethodsasdescribedindiscoverystage.Copy-numberproﬁlingWeanalyzedcopynumberinthewhole-exomesequencingbygeneratingcopy-numbersegmentsbasedonpublishedmethods(11),andthenappliedGISTIC2(12)toidentifyfocalregionsofsomaticcopy-numberalterations(SCNA)asdescribedprevious-ly.AsigniﬁcantSCNAregionwasdeﬁnedashavingaQvaluethresholdof0.25fromthepermutation-derivednulldistribution.TheoutputoffocalGISTIC2wasusedtodeﬁnethekeypeaksofampliﬁcationsanddeletions.PathwayenrichmentanalysisWeperformedpathwayenrichmentanalysisusingWebGestalt(http://bioinfo.vanderbilt.edu/webgestalt/)byexaminingthedistributionofgeneswithsomaticmutationsorcopy-numberchangeswithintheKEGGdatabase.ThesigniﬁcanceofmutationenrichmentwasdeterminedbyahypergeometrictestandwasadjustedformultipletestingwiththeBenjamini–HochbergFDR.ResultsLandscapeofsomaticmutationsinMPMWecapturedandsequencedtheexomesfrompairedtumorandbloodDNAsamplesfrom22MPMcases(SupplementaryTableS1).Onaverage,3.5Gbofhigh-qualitysequencingdataweregeneratedforeachsample,resultingincoverageoftargetedexomeregionstoameandepthof89orgreater(Table1).Morethan88.2%ofthetargetedregionswerecoveredsufﬁcientlyforconﬁdentvariantcalling(14readsintumorsand8readsinnormalsamples).Bystatisticalcom-parisonofpairedtumor/bloodsequencedata(seeMaterialsandMethods),mutationanalysisidentiﬁedatotalof517somaticmutations(SupplementaryTableS3),including134synonymousmutations,295missensemutations,25nonsensemutations,25splice-sitechanges,and38smallcodinginser-tions/deletions(indels).ComparisonofsomaticmutationsfromthisstudywiththeCOSMICdatabase(13)yielded53mutationsacross46previouslyreportedmutatedgenes.Of295missensemutations,136werepredictedtohaveahighprob-abilityofbeingdeleteriousbyPolyPhen(14).Wedetectedameanof23somaticmutationspertumor(range251)correspondingtoanaverageof0.79mutationspermega-base(range,0.07–1.71),aconsiderablysmallernumbercom-paredwithothertypesofmalignanttumors(SupplementaryTableS4).Threeofthe22tumors,NYU589,NYU1396,andNYU269,harboredsmallnumbersofsomaticmutationswithtwo,twoandthreemutations,respectively;despitehighestimatedhistologicpurity,wewereunabletodeterminesamplepuritybyDNAanalysis(15),andthereforeareuncertainwhetherthelowmutationraterepresentslowtumorpurityorabiologicfeatureofthesetumors.Themutationspectruminthe22MPMswasdominatedbyC:G!T:Atransitions(SupplementaryFig.S1),asnotedinseveralotheradultcancers(16).SigniﬁcantlymutatedgenesinmesotheliomaProtein-alteringmutationsoccurredacross490genes,ofwhich97%(477/490)weremutatedinonlyasingleindivid-ual.ToidentifysigniﬁcantlymutatedgenesthatwerelikelytobeimplicatedinMPMtumorigenesis,weconsideredgenesthatweremutatedinatleasttwotumorsandweresigniﬁcantlymoremutatedthanthebackgroundmutationrate(Qvalue<0.1),ascalculatedbyMutSig(10).Weidentiﬁedthreesignif-icantlymutatedgenes(BAP1,NF2,andCUL1)meetingthesetwocriteria(Fig.1)and10additionalgenesthatwererecur-rentlybutnotsigniﬁcantlymutated(SupplementaryTableS3).BAP1hasthehighestprevalenceofprotein-alteringmutationsidentiﬁedinthisMPMcohort(8/22tumors¼36%),consistentwithearlierMPM-sequencinganalyses(4).BAP1encodesanucle-arubiquitincarboxyterminalhydrolase(17).WefoundeightmutationsinBAP1,sevenofwhich(threenonsensemutations,threeframe-shiftindels,and1splicesitechange)werepredictedtotruncatetheencodedprotein(P<0.001;Fig.2A),consistentwithGeneticLandscapeofMalignantPleuralMesotheliomawww.aacrjournals.orgCancerRes;75(2)January15,2015265on April 13, 2017. © 2015 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Published OnlineFirst December 8, 2014; DOI: 10.1158/0008-5472.CAN-14-1008 atumor-suppressorfunctionfortheBAP1proteininMPM.AgermlinemutationatsplicesiteinBAP1wasalsofoundinthecaseNYU754(T>Cmutationat52,441,334inchromosome3).WealsofoundinactivationofNF2,anothercommoneventinMPM(3),bytruncatingmutationsinthreecases(14%).AllmutationsinNF2werereportedintheCOSMICdatabase.Interestingly,wealsofoundonedinucleotidemutationandonemissensemutationinCUL1(Fig.2B),whichisanessentialTable1.Landscapeofsomaticmutationsintheexomesof22MPMsCaseIDTumorbasessequencedNormalbasessequencedTumorexomecoverageNormalexomecoverageCallablepositionsCallable(%)PointmutationsCodingindelsMutationrate(perMb)NYU2693.551093.14109107.3952.9410788.9210.1NYU2742.941093.3210988.8100.32.9210788.33111.08NYU3213.581093.05109108.292.22.94107893021.07NYU4603.691094.23109111.5127.82.9510789.32210.77NYU5173.121094.1010994.21242.9310788.62931.08NYU5873.821093.78109115.7114.32.9710789.92310.79NYU5893.761093.97109113.71202.9710789.7020.07NYU6473.101093.3010993.899.82.9410788.93001NYU6583.031093.3310991.8100.62.94107892821NYU6953.601093.9109108.993.52.9210788.31230.51NYU7543.641094.20109110127.12.94107892620.94NYU8723.761093.64109113.7109.92.94107894651.71NYU9293.391093.67109102.61112.9610989.42210.77NYU9373.411093.28109103.1992.94107893921.37NYU9393.011093.9910991.1120.52.9210988.32430.91NYU11623.111093.4210994.1103.42.9210788.42420.88NYU11893.461093.34109104.71012.9310788.4910.34NYU12453.051094.3510992.2131.62.9210788.21500.51NYU12833.971093.30109119.999.72.9610789.62741.03NYU13533.081093.6810993.2111.22.91107881110.41NYU13633.371093.00109101.890.82.9310788.52710.95NYU13964.151094.11109125.4124.22.9710789.7200.07NOTE:Themutationratewascalculatedbydividingthetotalnumberofsomaticmutationsbythetotalnumberofcallablenucleotidepositions(14intumorand8inmatchednormalsamples).14%9%36%864200.52.03.5NF2CUL1BAP10.00.51.01.5020406080100%Syn.Nonsyn.020406080100Sample indexAllelic fraction−log10(Q value)SynMissenseSplice siteNonsenseFrame shiftIn frame indelOther nonsyn.# of Mutations/MbDouble_nullIndel+nullA->mutC->(G/A)*Cp(A/C/T)->T*CpG->T# of MutationsFigure1.SigniﬁcantlymutatedgenesinMPM.Signiﬁcantlymutatedgenes(Qvalue<0.1)identiﬁedbyexomesequencingaresortedverticallybyaQvalue.Topbargraph,somaticmutationfrequencyfor22MPMs.Themiddlematrix,BAP1,NF2,andCUL1somaticmutationstatuswithleft-adjacentbargraph,indicatingthetotalnumberofmutationsandpercentageoffrequencyforeachgene.Theboxplotsbelowthematrixrepresentthedistributionsofallelicfractionsobservedineachtumor.Bottomplot,eachtumor'ssomaticmutationspectrumasapercentageofallmutations(rightaxis).Guoetal.CancerRes;75(2)January15,2015CancerResearch266on April 13, 2017. © 2015 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Published OnlineFirst December 8, 2014; DOI: 10.1158/0008-5472.CAN-14-1008 componentoftheSCF(SKP1–CUL1–F-boxprotein)E3ubiquitinligasecomplexandplaysanimportantroleinproteindegradationandproteinubiquitination.AllmutationsinCUL1werepredictedtoaffectproteinfunctionbyPolyPhen(14)andonemissensemutation(E485K)wasalsoidentiﬁedintheCOSMICdatabase.TheotherrecurrentlymutatedgenesInthisstudy,13geneswererecurrentlymutatedintwoormoreMPMs(SupplementaryTableS3).BesidesBAP1,NF2,andCUL1,fourrecurrentlymutatedgenes(RDX,TP53,PIK3C2B,andTAOK1)harboredhighermutationratesthanthebackgroundwithasigniﬁcancethresholdatamoderatelystringentlevel(P<0.01;SupplementaryTableS5).TP53harboredsomaticmuta-tionsintwocases,consistentwithpreviouslyreportedfrequenciesinMPM(4).Toourknowledge,thethreenovelrecurrentlymutatedgenes(RDX,PIK3C2B,andTAOK1)havenotbeenidentiﬁedinMPM,althoughmutationsinthesegeneshavebeenreportedinmanycancertypesintheCOSMICdatabase(13).RDX,encodingacytoskeletalproteinthatmaybeimportantinlinkingactintotheplasmamembrane,issubjecttotwosomaticmutationsinthiscaseseries(S497RandQ48P).PIK3C2BencodesaproteinthatbelongstothePI3Kfamilyandissomaticallymutatedintwocases.TAOK1,encodingaserine/threoninepro-teinkinaseinvolvinginvariousprocessessuchastheMAPKsignalingpathwayandmitoticanaphase,wasalsomutatedintwocases.TofurtherevaluatethemutationprevalenceofRDX,PIK3C2B,andTAOK1inMPM,wedeterminedthecodingsequencingofthethreegenesinanadditional10tumor-normalpairsfrompatientswithMPMand9mesotheliomacelllinesbyhigh-throughputdeepsequencing.However,nosomaticmutationsinthesethreegeneswerefoundinthe10tumorsamples.AllmutationsdetectedinmesotheliomacelllineswereknownSNPsandnoneofthemwerepresentintheCOSMICdatabase.Copy-numberalterationsinMPMWeproﬁledthe22MPMsforSCNAsusingexomesequencingdatausingpreviouslydescribedmethods(11)andfoundpre-dominantlossof22pand22qharboringNF2(SupplementaryFig.S2),afrequentgeneticalterationinMPM(3).WealsoappliedGISTIC2(12)analysistoexomesequencingdatatoidentifyrecurrentfocalSCNAs,yieldingsixregionsoffocaldeletionthatencompass505genes(SupplementaryTableS6).Amongtheseregions,themostcommonfocaldeletion,alteredin10tumors(45%),encompassedaregionat9p21containingCDKN2AandCDKN2B(SupplementaryFig.S3),whichisawidelyreportedgenomicalterationinMPM(2).Consistentwithourpreviousstudy(18),wefoundthatMIR31(microRNA31),amicroRNAgenelocatedat9p21nearCDKN2A,wasfrequentlydeletedineight(36%)tumors(SupplementaryFig.S4).SigniﬁcantlyalteredpathwaysToconstructacomprehensiveviewofthecommongeneticalterationsunderlyingtheMPM,weperformedintegrativepath-wayanalysisofthesomaticmutationsandfocalSCNAs.WeidentiﬁedanumberofpathwayswithrecurrentalterationsinMPM,includingthecellcycle,MAPK,andWntsignalingpathway(SupplementaryTableS7).Thecellcyclewasthemostfrequentlyalteredpathway,withalterationsin12ofthetumors(55%),includingthealterationsinCDKN2A/B,CUL1,andTP53.GeneswithintheMAPKandWntsignalingpathwayswerealteredin11andseventumors,respectively.DiscussionInthisstudy,weanalyzedsomaticmutationsin22MPMscomparedwithmatchednormalsamplesusingwhole-exomesequencing.Wedetectedmorethan500somaticmutationsandshowedthat490genesweresomaticallymutatedinatleastoneofthetumors.IntegratingmutationandSCNAdata,wefoundthatBAP1,NF2,andCDKN2A,knowntobealteredgenesinMPM,werethethreemostfrequentlyalteredgenesdetectedinourstudy(Fig.3).Wealsofoundfrequentgeneticalterationsinthecellcycle,MAPKsignaling,andWntsignalingpathway.TheresultsareconsistentwithapreviousstudyofMPMusingbothCGHarraysandSangersequencing(4).Thetumor-suppressorBAP1,oneofseveralclassesofdeu-biquitinatingenzyme,maybeinvolvedinregulationofBAP1p.Q85_splicep.C91Yp.R264fsp.Q280*p.Q372*p.I499fsp.E653*p.A683fsInteraction with BRCA1HBM-like motifNuclear localization signalSplice siteNonsenseMissenseFrame shift IndelMissensep.A471Sp.A471Vp.E485KCUL1AB01002003004005006007000100200300400500600700Figure2.SomaticmutationsinBAP1andCUL1.ThetypesandrelativepositionsofsomaticmutationsareshowninthepredictedproteinsequencesofBAP1(A)andCUL1(B).Mutationstatuswascolorcodedbytypesofmutation.GeneticLandscapeofMalignantPleuralMesotheliomawww.aacrjournals.orgCancerRes;75(2)January15,2015267on April 13, 2017. © 2015 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Published OnlineFirst December 8, 2014; DOI: 10.1158/0008-5472.CAN-14-1008 transcription,regulationofcellcycleandgrowth,andresponsetoDNAdamageandchromatindynamics(17).Frequentmuta-tionsinBAP1havebeenreportedinmanytypesofcancer,includinguvealmelanoma(19),renalcancer(20),andMPM(4).Inthepresentstudy,ninetumors(41%)harboredsomaticmutationsorSCNAsinBAP1.Wealsofound11geneticalterationsinNF2,acomponentoftheHipposignalingpath-way.Apreviousstudyreported10inactivatinghomozygousdeletionsormutationsofLATS2,anothermemberoftheHippopathway,among45MPMtumortissuesorcancercelllines(21),althoughnomutationsinLATS2wasfoundinourstudy.ThesestudiessuggestthattheHipposignalingpathwaymaybeimplicatedinMPMtumorigenesis.However,nosomaticmuta-tionsingenesoftheHippopathwayotherthanNF2andLATS1werefoundinourstudy(SupplementaryTableS8).WealsofoundsigniﬁcantrecurrenceofmutationsinCUL1,ageneinwhichmutationshavenotbeenpreviouslyreportedinMPM,intwotumors.CUL1encodesacorecomponentofSCFE3ubiquitin–proteinligasecomplexesthatmediatetheubiquitina-tionofproteinsinvolvedincell-cycleprogression,signaltrans-duction,andtranscription.Finally,weusedexomesequencingdatatoidentifysomaticCNAsandfoundsixsigniﬁcantfocaldeletions.Amongthem,thedeletionof9p21centeredonCDKN2Awasthemostcommoneventoccurringin10of22MPMs.Moreover,sevenofCDKN2A-deletedtumorsalsoharboredgeneticalterationsinNF2(P¼0.19).NosomaticsubstitutionsandcodingindelswerefoundinCDKN2Ainourcohort.OurstudypresentstheﬁrstunbiasedviewofsomaticmutationsinMPM.However,onelimitationofourstudyisthatwehaveonlyanalyzedasmallnumberoftumorsanalyzed;thus,thesequenc-ingoflargerMPMcohortswillbenecessarytodetermineamorecomprehensivegenomiclandscapeforMPMaswellasamorepreciseprevalencefrequencyforthemutatedgenesdetectedinouranalysis.Inaddition,furtherfunctionalstudyfornovelmutatedgenessuchasCUL1willberequiredtodeﬁnetheirrolesinMPM.DisclosureofPotentialConﬂictsofInterestM.CarbonehasapendingpatentapplicationonBap1andprovidescon-sultationformesotheliomaexpertiseanddiagnosis.M.MeyersonreportsreceivingacommercialresearchgrantfromBayer,hasownershipinterest(includingpatents)in,andisaconsultant/advisoryboardmemberforFoun-dationMedicine.Nopotentialconﬂictsofinterestweredisclosedbytheotherauthors.Authors'ContributionsConceptionanddesign:J.Chmielecki,M.Carbone,M.Meyerson,H.I.PassDevelopmentofmethodology:G.Guo,A.Heguy,I.DolgalevAcquisitionofdata(providedanimals,acquiredandmanagedpatients,providedfacilities,etc.):A.Heguy,H.I.PassAnalysisandinterpretationofdata(e.g.,statisticalanalysis,biostatistics,computationalanalysis):G.Guo,J.Chmielecki,A.Heguy,I.Dolgalev,M.Carbone,M.MeyersonWriting,review,and/orrevisionofthemanuscript:G.Guo,A.Heguy,M.Meyerson,H.I.PassAdministrative,technical,ormaterialsupport(i.e.,reportingororganizingdata,constructingdatabases):C.Goparaju,S.Seepo,H.I.PassStudysupervision:M.Meyerson,H.I.PassOther(projectmanagement):S.SeepoAcknowledgmentsTheauthorsthankCheng-ZhongZhangandAndrewCherniackforhelpfuldiscussions.GrantSupportThisworkwassupportedbytheBroadInstitutethroughagrantfromtheNationalHumanGenomeResearchInstituteattheNIH(U54HG003067:EricS.Lander,principalinvestigator),andbyNCIEDRN5U01CA111295-07(H.I.Passasprincipalinvestigator),theStephenE.BannerLungCancerFoundation,andBelluckandFox.J.ChmieleckiwassupportedbyanAmericanCancerSocietyAstraZenecaPostdoctoralFellowship.ReceivedApril14,2014;revisedSeptember23,2014;acceptedOctober28,2014;publishedOnlineFirstDecember8,2014.References1.RobinsonBW,LakeRA.Advancesinmalignantmesothelioma.NEnglJMed2005;353:1591–603.2.IlleiPB,RuschVW,ZakowskiMF,LadanyiM.HomozygousdeletionofCDKN2Aandcodeletionofthemethylthioadenosinephosphorylasegeneinthemajorityofpleuralmesotheliomas.ClinCancerRes2003;9:2108–13.3.ThurneysenC,OpitzI,KurtzS,WederW,StahelRA,Felley-BoscoE.FunctionalinactivationofNF2/merlininhumanmesothelioma.LungCancer2009;64:140–7.4.BottM,BrevetM,TaylorBS,ShimizuS,ItoT,WangL,etal.ThenucleardeubiquitinaseBAP1iscommonlyinactivatedbysomaticmutationsand3p21.1lossesinmalignantpleuralmesothelioma.NatGenet2011;43:668–72.5.JeanD,DaubriacJ,LePimpec-BarthesF,Galateau-SalleF,JaurandMC.Molecularchangesinmesotheliomawithanimpactonprognosisandtreatment.ArchPatholLabMed2012;136:277–93.6.MwenifumboJC,MarraMA.Cancergenome-sequencingstudydesign.NatRevGenet2013;14:321–32.7.GarrawayLA,LanderES.Lessonsfromthecancergenome.Cell2013;153:17–37.8.ImielinskiM,BergerAH,HammermanPS,HernandezB,PughTJ,HodisE,etal.Mappingthehallmarksoflungadenocarcinomawithmassivelyparallelsequencing.Cell2012;150:1107–20.9.CibulskisK,LawrenceMS,CarterSL,SivachenkoA,JaffeD,SougnezC,etal.Sensitivedetectionofsomaticpointmutationsinimpureandheteroge-neouscancersamples.NatBiotechnol2013;31:213–9.10.GetzG,HoﬂingH,MesirovJP,GolubTR,MeyersonM,TibshiraniR,etal.Commenton"theconsensuscodingsequencesofhumanbreastandcolorectalcancers."Science2007;317:1500.11.DulakAM,StojanovP,PengS,LawrenceMS,FoxC,StewartC,etal.Exomeandwhole-genomesequencingofesophagealadenocarcinomaidentiﬁesre-currentdrivereventsandmutationalcomplexity.NatGenet2013;45:478–86.12.MermelCH,SchumacherSE,HillB,MeyersonML,BeroukhimR,GetzG.GISTIC2.0facilitatessensitiveandconﬁdentlocalizationofthetargetsoffocalsomaticcopy-numberalterationinhumancancers.GenomeBiol2011;12:R41.CDKN2AMIR31NF2BAP1CUL1TP53RDXTAOK1PIK3C2BDeletionTruncating mutationMisense mutationFigure3.Integrativedisplayofsomaticmutationsandcopy-numberalterationsin22MPMs.Fivetumorshadnoalterationsinthegeneslisted.CancerRes;75(2)January15,2015CancerResearch268Guoetal.on April 13, 2017. © 2015 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Published OnlineFirst December 8, 2014; DOI: 10.1158/0008-5472.CAN-14-1008 13.ForbesSA,BindalN,BamfordS,ColeC,KokCY,BeareD,etal.COSMIC:miningcompletecancergenomesintheCatalogueofSomaticMutationsinCancer.NucleicAcidsRes2011;39:D945–50.14.SunyaevS,RamenskyV,KochI,LatheWIII,KondrashovAS,BorkP.Predictionofdeleterioushumanalleles.HumMolGenet2001;10:591–7.15.CarterSL,CibulskisK,HelmanE,McKennaA,ShenH,ZackT,etal.AbsolutequantiﬁcationofsomaticDNAalterationsinhumancancer.NatBiotechnol2012;30:413–21.16.GreenmanC,StephensP,SmithR,DalglieshGL,HunterC,BignellG,etal.Patternsofsomaticmutationinhumancancergenomes.Nature2007;446:153–8.17.JensenDE,ProctorM,MarquisST,GardnerHP,HaSI,ChodoshLA,etal.BAP1:anovelubiquitinhydrolasewhichbindstotheBRCA1RINGﬁngerandenhancesBRCA1-mediatedcellgrowthsuppression.Oncogene1998;16:1097–112.18.IvanovSV,GoparajuCM,LopezP,ZavadilJ,Toren-HaritanG,RosenwaldS,etal.Pro-tumorigeniceffectsofmiR-31lossinmesothelioma.JBiolChem2010;285:22809–17.19.HarbourJW,OnkenMD,RobersonED,DuanS,CaoL,WorleyLA,etal.FrequentmutationofBAP1inmetastasizinguvealmelanomas.Science2010;330:1410–3.20.Pena-LlopisS,Vega-Rubin-de-CelisS,LiaoA,LengN,Pavia-JimenezA,WangS,etal.BAP1lossdeﬁnesanewclassofrenalcellcarcinoma.NatGenet2012;44:751–9.21.MurakamiH,MizunoT,TaniguchiT,FujiiM,IshiguroF,FukuiT,etal.LATS2isatumorsuppressorgeneofmalignantmesothelioma.CancerRes2011;71:873–83.www.aacrjournals.orgCancerRes;75(2)January15,2015269GeneticLandscapeofMalignantPleuralMesotheliomaon April 13, 2017. © 2015 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Published OnlineFirst December 8, 2014; DOI: 10.1158/0008-5472.CAN-14-1008 2015;75:264-269. Published OnlineFirst December 8, 2014.Cancer Res(cid:160)(cid:160) Guangwu Guo, Juliann Chmielecki, Chandra Goparaju, et al. (cid:160)  in Malignant Pleural MesotheliomaCUL1, and CDKN2A, NF2, BAP1Whole-Exome Sequencing Reveals Frequent Genetic Alterations in (cid:160) Updated version(cid:160)  10.1158/0008-5472.CAN-14-1008doi:Access the most recent version of this article at:(cid:160) MaterialSupplementary(cid:160)  http://cancerres.aacrjournals.org/content/suppl/2014/12/06/0008-5472.CAN-14-1008.DC1Access the most recent supplemental material at:(cid:160) (cid:160) (cid:160) (cid:160) (cid:160) Cited articles(cid:160)  http://cancerres.aacrjournals.org/content/75/2/264.full.html#ref-list-1This article cites 21 articles, 7 of which you can access for free at:(cid:160) Citing articles(cid:160)  /content/75/2/264.full.html#related-urlsThis article has been cited by 7 HighWire-hosted articles. Access the articles at:(cid:160) (cid:160) (cid:160) E-mail alerts related to this article or journal.Sign up to receive free email-alerts(cid:160) SubscriptionsReprints and (cid:160) .pubs@aacr.orgTo order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at(cid:160) Permissions(cid:160) .permissions@aacr.orgTo request permission to re-use all or part of this article, contact the AACR Publications Department aton April 13, 2017. © 2015 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Published OnlineFirst December 8, 2014; DOI: 10.1158/0008-5472.CAN-14-1008 NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferationEmily E. Bosco1, Yoko Nakai1, Robert F. Hennigan2, Nancy Ratner1, and Yi Zheng1,*1Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave. Cincinnati, OH 452292Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, 3125 Eden Ave. Cincinnati, Ohio 45229AbstractThe neurofibromatosis type 2 (NF2) tumor suppressor gene encodes merlin, a membrane/cytoskeleton protein necessary for maintenance of contact inhibition of growth in cells. Biallelic inactivation of NF2 is known to cause multiple cancers in both humans and mice. However, the mechanism through which merlin exerts its tumor suppressive function remains obscure. In this report we reveal that NF2 knockout mouse embryonic fibroblasts (MEFs) lost contact inhibition of cell proliferation and contained significantly increased canonical Wnt signaling. Inhibition of Rac1, whose activity is inversely regulated by NF2, through the use of a dominant negative mutant, small hairpin RNA, or a small molecule inhibitor in the NF2-deficient cells, was able to suppress the elevated Wnt signals as shown by reduced activity of the T-cell factor 4 (TCF4) transcription factor. Dominant negative TCF4 or Rac1 mutant, as well as a small molecule inhibition of Wnt, were able to curb the NF2 deficiency-elicited cell proliferation at the confluent state. Thus, Rac1-mediated canonical Wnt signaling is essential for the loss of contact inhibition in NF2-deficient cells.KeywordsRac1; NF2/merlin; neurofibromatosis type 2; wnt signaling; contact inhibition; proliferationIntroductionThe ezrin-radixin-moesin (ERM) family molecule, merlin, is the protein product of the NF2 tumor suppressor gene which is inactivated in familial neurofibromatosis type 2 (NF2) as well as other types of sporadic tumors including schwannomas, mesotheliomas, and meningiomas. The NF2 tumor suppressor gene is unique in that it exerts its tumor Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms *Correspondence: Yi Zheng, Division of Experimental Hematology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, Tel: (513) 636-0595; Fax: (513) 636-3768, Yi.Zheng@cchmc.org. Contribution: E.E.B. and Y.N. performed experiments, analyzed results, and made the figures; R.F.H provided key reagents, N.R. collaborated on experimental design, E.E.B. and Y.Z. designed the research and wrote the paper.Conflict-of-interest disclosure: The authors declare no competing financial interests.HHS Public AccessAuthor manuscriptOncogene. Author manuscript; available in PMC 2010 October 29.Published in final edited form as:Oncogene. 2010 April 29; 29(17): 2540–2549. doi:10.1038/onc.2010.20.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptsuppressive functions from the cell-environment interface rather than from within the cell to impact cell proliferation (McClatchey and Giovannini, 2005). A hallmark of NF2- deficient cells is the loss of contact inhibition of proliferation (Johnson et al., 2002; Lallemand et al., 2003; Morrison et al., 2001). Several studies have proposed that the lack of association of merlin with Rac1 GTPase, CD44, or paxillin might be responsible for the destabilization of cell-cell contacts that allow for the loss of contact inhibition in NF2-deficient cells (Fernandez-Valle et al., 2002; Morrison et al., 2001; Okada et al., 2005). A recent study has provided the first mechanistic insight by attributing this characteristic of NF2-deficient cells to their inability to silence EGFR signaling at confluency (Curto et al., 2007). Despite these observations, our understanding of the mechanisms through which the loss of the cell membrane associated protein, merlin, transduces the growth signal to the nucleus that is necessary for cell proliferation at confluency remains rudimentary.Rac1, a member of the Rho GTPase family of signal transducers, is a pleiotropic regulator of multiple signaling pathways including MAPK, JNK/SAPK, NF-kB, and PI-3K, allowing it to regulate a diverse set of cellular processes. Rac1 is a modifier of tumorigenesis and its overexpression or overactivation occurs in many tumor types (Fritz et al., 1999; Jordan et al., 1999). Studies have shown that Rac1 signaling is critical in both tumor formation and progression due to its involvement in cell migration, cell cycle progression, and Ras-induced foci formation (Sahai and Marshall, 2002). Because the Wnt signal transduction pathway has been established as a critical modifier of tumorigenesis, several studies have focused on linking Rac1 activity with Wnt signaling. Until recently it was thought that Rac1 may affect noncanonical, or β-catenin independent, Wnt signaling (Malliri and Collard, 2003) and is involved in canonical Wnt signaling only in cells containing stabilized pools of β-catenin (Esufali and Bapat, 2004). However, a recent work in osteoblast development indicates that Rac1 is critical for the nuclear translocation of β-catenin and subsequent activation of T-cell factor (TCF4) (Upadhyay et al., 2008; Wu et al., 2008). Yet, whether the physiologically relevant association of Rac1 with canonical Wnt signaling in osteoblasts is applicable to potential pathological context has not been investigated.Although the functional relationship between merlin, Rac1, and its downstream effector PAK has been extensively studied, the contribution of Rac1 signaling to the loss of contact inhibition in NF2-deficient cells has not been demonstrated. It has been shown that levels of active Rac1 are increased in NF2-deficient cells (Ammoun et al., 2008; Kaempchen et al., 2003; Nakai et al., 2006). Further, merlin knockdown promotes the recruitment of Rac1 to matrix adhesions which correlates with release of cells from contact inhibition (Okada et al., 2005). Together, these studies suggest a mechanism by which Rac1 could modulate signaling to the nucleus in the context of NF2-deficiency.In the present work, we provide the first evidence that Rac1-mediated canonical Wnt signaling contributes to the loss of contact inhibition in NF2-deficient cells. Specifically, we show that Rac1 is required for canonical Wnt signaling in the pathological context of NF2 tumor suppressor loss. In addition, we found that loss of NF2 increases the transcriptional activity of the nuclear pool of β-catenin in a Rac-dependent manner. One downstream consequence of this is increased amount and transcriptional activation of cell cycle promoting factors, c-myc and cyclin D1, which may be the mechanism by which NF2-Bosco et al.Page 2Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptdeficient cells are able to transduce signals from the cell membrane to the nucleus to achieve loss of contact inhibition. Our studies show that Rac1-mediated canonical Wnt signaling is critical for the loss of contact inhibition phenotype of NF2-deficient cells and the Rac1-Wnt signaling axis could serve as a new node of therapy for NF2-associated disease.Materials and MethodsCell culture, viral infection, and growth assaysNF2flox2/flox2 MEFs were a kind gift from Dr. Marco Giovannini (House Ear Institute, Los Angeles, CA). Clones of spontaneously immortalized MEFs were selected and used throughout the study. All cells were maintained in DMEM supplied with 10% FBS, 2mM L-glutamine, and 100 U/mL penicillin/streptomycin at 37°C in air containing 5% CO2. In this study, all primary cells were between passages 3 and 5. NF2 deletion was achieved by infection with replication defective recombinant adenovirus expressing green fluorescent protein (Ad-GFP) or GFP in addition to Cre recombinase (Ad-GFP Cre). Adenovirus was used at approximately 2×107 virus particles per dish to achieve an infection efficiency of 90–95% as determined by GFP immunofluorescence. Cells were cultured for at least 4 days post-adenoviral infection prior to use, while the passage number and length of time post-infection remained consistent throughout all experiments unless otherwise stated. Infections of cells with retrovirus encoding MIEG3 or MIEG3-Rac1 N17 or lentivirus encoding shRNA to Rac1 or scrambled control (Sigma PLKO shGly plasmid) were performed according to standard protocol and cells were sorted based on GFP (MIEG3) or YFP (shRNA) expression 48 hours post infection. Cell growth assays were performed by trypsinization and counting by trypan blue exclusion every three days. All assays were performed at sub-confluency unless otherwise stated. For studies in the confluent condition, 4×106 cells were seeded in a 10cm tissue culture dish, whereas sub-confluent studies were performed with approximately 5×105 cells in the same size dish.Genomic PCR analysis of recombination and quantitative PCRGenomic PCR analysis was performed to verify adenoviral-Cre-mediated recombination in primary and immortalized MEFs. Total genomic DNA was extracted using the Blood and Tissue DNA kit (Quiagen, Valencia, CA) according to the manufacturers protocol and amplified using the PCR conditions and the following primers as previously described (Giovannini et al., 2000): P4) 5’ CTT CCC AGA CAA GCA GGG TTC, P5) 5’ GAA GGC AGC TTC CTT AAG TC, P6) 5’ CTC TAT TTG AGT GCG TGC CAT G. RNA was extracted using the RNeasy mini kit (Quiagen, Valencia, CA) and cDNA was synthesized from 1µg of RNA with the SuperScript RT-PCR system (Invitrogen, Carlsbad, CA) according to the manufacturers protocol. cDNAs were amplified by quantitative PCR using TaqMan gene expression assays for cyclin D1, c-myc, and gapdh with TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA) according to the manufacturers protocol. Assays were run on an ABI Prism 7900 HT sequence detection system (Applied Biosystems, Foster City, CA).Bosco et al.Page 3Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptTransfection, Reporter assay, and BrdU incorporationCells were cotransfected with either TCF4-luciferase (TOPflash), TCF4-mutant-luciferase (FOPflash) (Upstate biotechnology, Lake Placid, NY), or cyclin D1-luciferase (generously provided by Dr. Karen Knudsen, Thomas Jefferson University, Philadelphia, PA.) reporter plasmids and a plasmid encoding beta-galactosidase for normalization using FuGENE 6 Transfection Reagent (Roche, Nutley, NJ). 48 hours post-transfection, reporter activity was measured by Luciferase assay kit (Promega, Madison, WI) following manufacturer’s protocol. Wnt3A (R&D Systems, Minneapolis, MN) stimulation for reporter assay was performed for 8 hours prior to cell harvest and NSC23766 treatment lasted 24 hours prior to harvest. All reporter assays were performed on nonconfluent cells unless otherwise stated and at least three times in triplicate. Untreated control cells were normalized to 1. Cells were transfected with pSFG or pSFG-dnTCF4 plasmids (a kind gift of Dr. Fanxin Long, Washington University, St. Louis, MO) and subjected to TCF4 -reporter assay as described above. For S phase analysis, cells were transfected with MIEG3, MIEG3-Rac1 N17, pSFG or pSFG-dnTCF4 and H2B-GFP and sorted by flow cytometry based upon GFP expression and were then cultured for 24 hours. Next, cells were labeled with BrdU (GE Healthcare, Little Chalfont Buckinghamshire, UK) for 1 hour prior to fixation and staining for BrdU/ PI FACS analysis as previously described (Bosco et al., 2004) using a FACSCanto flow cytometer and FACSDiva software (BD Biosciences, San Diego, CA). PKF115-584 was kindly provided by Novartis (Basel, Switzerland) and used at 10µM in cell cuclture for 18 hours.Immunoblotting and immunofluorescenceWhole-cell lysates were prepared by cell extraction using lysis buffer containing 20 mM Tris-HCl (pH 7.6), 100 mM NaCl, 10 mM MgCl2, 1% Triton X-100, 0.2% sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 10 µg/mL of leupeptin, 1 µg/mL of aprotinin, and 1 mM dithiothreitol for 30 min. Equal amounts of protein, as determined by Bradford assay, were resolved by SDS-PAGE. Specific proteins were detected by standard immunoblotting procedures using the following primary antibodies: (Thermo Fisher Scientific, Fremont, CA,1:500 dilution) Cyclin D1 Ab-3 (Cell Signaling, Danvers, MA, 1:500 dilution) phospho-PAK1 (Thr 423)/PAK2 (Thr 402), phospho-Akt (S473), merlin (9168), (BD Biosciences, San Diego, CA, 1:500 dilution) Rac1, β-catenin (610153), (Millipore, Billerica, MA, 1:500) active β-catenin (05-665), (Abcam Inc., Cambridge, MA, 1:500) phospho-β-catenin Y142 (27798-50), (Sigma-Aldrich, St. Louis, MO, 1:500) Actin. Wnt3A (R&D Systems, Minneapolis, MN) stimulation for immunoblot was performed for 1 hour prior to cell harvest. For immunofluorescence, cells were cultured on coverslips prior to fixation with 3.7% formaldehyde (Sigma-Aldrich). Cells were permeabilized using .5% triton X-100 (Sigma-Aldrich, St. Louis, MO) and stained for immunofluorescence using the previously mentioned antibody for β-catenin and 4’,6-diamidino-2-phenylindole (Invitrogen, Carlsbad, CA).Bosco et al.Page 4Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptResultsThe phenotypes of NF2 loss in primary cells are maintained in immortalized NF2-deficient MEFsIn the literature many of the seminal studies that define the role of merlin in maintaining cellular contacts have been performed in primary mouse embryonic fibroblasts (MEFs). These works have been the cornerstone of our understanding of the tumor suppressor merlin. In this study, primary NF2flox2/flox2 MEFs were infected with an adenovirus encoding Cre recombinase (Ad-GFP Cre) or a control adenovirus (Ad-GFP), and the cells were harvested for genomic PCR of the NF2 gene to validate functional deletion 96 hours post infection. Concurrently, spontaneously immortalized clones were derived from these two cell types. The genomic deletion of NF2 in the immortalized cells was confirmed by the smaller size of the PCR product upon infection with Cre recombinase (442 bp as compared to 338 bp) and was comparable to the deletion evident in the primary lines (Figure 1A, left panel). By immunoblotting for merlin, we show an efficient loss of the merlin protein following infection in the immortalized cells (Figure 1A, right panel). To ensure that our immortalized cell model has maintained the published phentoypes of NF2-deficiency in primary MEFs, contact inhibiton and adherens junction stability were examined. NF2-deficiency indeed conferred loss of contact inhibition of proliferation in the immortalized cells as shown by growth assay (Figure 1B). Similarly, at confluency destabilization of adherens junctions in immortalized NF2-/- cells was reflected by a reduction in the level and diffused distribution of β-catenin at the cell junction as well as the cytoplasm (Figure 1C). These phenotypes are similar to what was reported in the primary cell cultures in Lallemand et al. (Lallemand et al., 2003). Although the localization of β-catenin to adherens junctions is disrupted in the NF2-deficient cells upon confluency, the total amount of cellular β-catenin remains similar in both cell types as assessed by immunoblot (Figure 1D). These data are also in agreement with previous findings by Curto et al (Curto et al., 2007) that NF2-deficiency results in a loss of contact inhibition and reduced adherens junction, and thus validate our immortalized cell model.NF2-deficiency increases canonical Wnt signalingNext we sought to understand whether NF2-deficient cells could have an increase in nuclear β-catenin activity since the junctional levels are reduced, yet the total levels remain similar to that of wild type cells. Nuclear β-catenin has a relatively fast turnover that is difficult to detect and we, similar to Curto et al (Curto et al., 2007), did not identify significant differences in the protein levels of the nuclear fraction of β-catenin by Western blotting (data not shown). Therefore, we instead measured transactivation of the TCF4 transcription factor by reporter assay since it is directly responsive to nuclear β-catenin. In both primary (Figure 2 left panel) and immortalized cells (Figure 2 right panel), we observed a four- to six- fold increase in TCF4 transcription factor activity (TOPflash) when NF2 was excised, whereas the TCF-mut showed minimal activation in all samples (FOPflash). Because the hyperactive Wnt signaling and the loss of contact inhibition phenomena are shared between the primary and immortalized cells, all subsequent experiments are carried out with the immortalized cell line.Bosco et al.Page 5Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptRac1 is necessary for the elevated Wnt activity in NF2-/- cellsIn order to probe the signaling events that contribute to the Wnt pathway hyperactivation in the absence of merlin, NF2-proficient and -deficient cells were harvested for immunoblot. Similar to what has been shown in Schwann cells (Ammoun et al., 2008; Kaempchen et al., 2003; Nakai et al., 2006), active Rac1 signaling was increased in the NF2-deficient cells as two downstream effectors of Rac1, PAK and Akt, became hyperactivated (Figure 3A). Previous studies by the Clevers lab revealed that active β-catenin, or the fraction that is dephosphorylated on ser37 and Thr 41, is indicative of the transcriptionally active portion of β-catenin in the cell (van Noort et al., 2002). In addition, recent reports have shown that phospho-β-catenin Y142 is a phosphorylation event which marks dissociation of β-catenin from adherens junctions leading to a switch toward its nuclear accumulation (Aberle et al., 1996; Brembeck et al., 2004; Sampietro et al., 2006). In the absence of merlin, we found that the levels of nuclear β-catenin, as determined by both “active” or NH2-terminally dephosphorylated β-catenin and phospho-β-catenin Y142, were elevated as compared to total β-catenin levels. Concomitantly, increased levels of one of the TCF4 transcription factor targets, cyclin D1, was evident in the NF2-deficient cells, further confirming the elevated canonical Wnt signaling in these cells (Figure 3A). To verify that the heightened level of cyclin D1 protein in the absence of merlin was transcriptionally active, we performed a reporter assay with NF2-proficient and -deficient cells transfected with the cyclin D1-luc reporter. NF2-/- cells displayed a 3.5 fold increase in cyclin D1 transcriptional activity as compared to control cells (Figure 3B). Together, these results indicate that Rac1 and canonical Wnt signaling are significantly increased in the absence of merlin.To dissect the functional relationship between Rac1 and the canonical Wnt pathway, Rac1 activity was inhibited by either using the dominant negative Rac1 mutant, (Rac1 N17), the Rac1 specific small molecule inhibitor (NSC23766), or lentiviral shRNA to Rac1, matched with a scrambled control (shSCR). A TCF4-luciferase reporter assay was performed in wild type cells that had been transduced with a retrovirus encoding either the MIEG3-Rac1 N17 mutant or control MIEG3 alone. This was also executed in cells transduced with lentivirus expressing YFP- tagged shRac1 or shSCR. Cells were sorted by flow cytometry for GFP expression (encoded by MIEG3 virus) or YFP expression (encoded by sh lentivirus) prior to transfection with the reporter constructs and a subset were treated with 100 µM NSC23766 24 hours prior to harvest and/or 100ng/ml Wnt3a 8 hours prior to harvest. As expected, treatment of control MIEG3 infected cells with Wnt3a significantly induced TCF4 reporter activity more than 8 fold over untreated cells (results were nearly identical with shSCR controls and are not shown). This induction of TCF4 transactivation was abrogated by pharmacological, shRNA, and dominant negative Rac1 inhibition (Figure 4A, left panel). Wild type cells transduced with lentivirus encoding YFP-tagged shSCR or shRac1 were sorted based upon YFP expression and immunoblotted to validate the Rac1 gene knockdown prior to use in the aforementioned luciferase reporters (Figure 4A, right panel). The results of these reporter assays are in agreement with a recent study in the osteoblast model (Wu et al., 2008) indicating that Rac1 activity is a critical component of the canonical Wnt signaling pathway.Bosco et al.Page 6Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptTo understand the contribution of Rac1 to the regulation of the canonical Wnt pathway in a pathological context, similar experiments were performed in Ad-GFP or Ad-GFP Cre infected NF2flox2/flox2 immortalized MEFs. Wnt3a stimulation resulted in heightened TCF4 transactivation, and this effect was increased in the absence of NF2. However, TCF4 transactivation was completely blocked in NF2-/- cells by Rac1 targeting either through the use of the dominant negative Rac1 mutant, MIEG3-Rac1 N17, or shRac1. This inhibitory effect of Rac1 targeting on TCF4 transctivation was also evident on the Wnt3a stimulated wild type cells (Figure 4B). This result indicates that Rac1 is necessary for the elevation of canonical Wnt pathway signaling in the absence of merlin.The c-myc and cyclin D1 genes are well characterized downstream targets of the Wnt pathway. To verify the enhancing effect of Rac1 on Wnt signaling in the NF2-deficient cells, we performed quantitative PCR to determine the relative abundance of both genes with respect to a GAPDH control. Ad-GFP or Ad-GFP Cre infected cells were transduced with MIEG3-Rac1 N17 or MIEG3 alone and sorted based upon GFP expression. Cells were then plated at confluency to determine the impact of Rac1 blockade on the induction of c-myc and cyclin D1, which are important for cell proliferation and therefore could exhibit inappropriately high levels upon loss of contact inhibition. As shown in Figure 4C, the levels of both genes are elevated in the control infected NF2-/- cells, and dominant negative inhibition of Rac1 was able to reduce the expression of both genes to levels comparable to those in NF2-proficient cells. This data indicates that Rac1 contributes to the increase in c-myc and cyclin D1 in the NF2-/- cells under confluent conditions.Wnt signaling contributes to the loss of contact inhibition in NF2-deficient MEFsWe next sought to determine the effect of the increased β-catenin activity on the loss of contact inhibition of proliferation of the NF2-deficient cells by using a dominant negative mutant of TCF4 (dnTCF4). DnTCF4 is an N-terminal deletion of TCF4 that is unable to bind β-catenin yet retains the ability to bind to DNA, thus is effective in blocking transcriptionally active β-catenin from binding DNA (Tetsu and McCormick, 1999). First, we either transfected Ad-GFP or Ad-GFP Cre infected cells with pSFG-control DNA or pSFG-dnTCF4 and sorted the cells by flow cytometry, prior to performing a TCF4 reporter assay. dnTCF4 was found to efficiently block TCF4 transactivation in response to Wnt3a stimulation and restored the level of TCF4 hyperactivation in NF2-/- cells to levels comparable to the wild-type cells (Figure 5A), indicating that Wnt pathway inhibition was functional. Second, we tested whether dnTCF4 was able to inhibit the elevated TCF4 activity in the NF2-/- cells at confluency. As shown in Figure 5B, upon dnTCF4 expression, the TCF4 transcriptional activity in the confluent NF2-deficient cells was attenuated approximately 10-fold. These results suggest that the loss of contact inhibition in NF2-deficient cells at confluency is associated with Wnt pathway hyperactivation. Third, we have examined the cell proliferative activity in the confluent state using a BrdU incorporation assay. Not surprisingly, the number of Ad-GFP infected cells that were able to enter S phase was greatly reduced as compared to the Ad-GFP Cre infected controls at confluency, and dnTCF4 did not significantly effect the ability of the Ad-GFP infected cells to enter S-phase. In contrast, the Ad-GFP Cre infected cells exhibited ~60% decrease in proliferative capacity following dnTCF4 transfection (Figure 5C). The results of these Wnt signaling inhibition Bosco et al.Page 7Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptexperiments indicate that merlin-deficient cells depend on Wnt/TCF4 signaling to achieve the loss of contact inhibition. To directly test the requirement of active Rac1 for loss of contact inhibition in the merlin-deficient cells, Ad-GFP or Ad-GFP Cre infected cells were transduced with a virus encoding either MIEG3 alone or MIEG3-Rac1 N17. Similar to Figure 5C, BrdU/ PI analysis revealed that Ad-GFP infected cells are contact inhibited and their cell cycle progression was thus unaffected by dominant negative Rac1 (Figure 5D). However, Ad-GFP Cre infected cells exhibited a two fold increase in BrdU incorporation at confluency which was abrogated by the addition of Rac1 N17, indicating that Rac1 activity significantly contributes to loss of contact inhibition in NF2-/- cells. When dnTCF4 and Rac1 N17 were cointroduced into the NF2-/- cells, a similar degree of inhibition of BrdU incorporation at confluency was evident as compared to dnTCF4 or Rac1 N17 expression alone (data not shown). These data further suggest that Rac1 and β-catenin signal in the same pathway to impact the loss of contact inhibition in NF2-/- cells.Small molecule inhibition of wnt-signaling suppresses the loss of contact inhibition of NF2 cellsTo demonstrate the therapeutic relevance of the proposed dependence of NF2-deficient cells on the Rac mediated Wnt pathway to achieve loss of contact inhibition, a natural small molecule inhibitor of the Wnt pathway, PKF115-584 (Lepourcelet et al., 2004) was utilized. Similar to the dnTCF4 mutant, the PKF115-584 small molecule prevents the formation of the β-catenin-TCF4 complex, thereby inhibiting its ability to bind DNA (Lepourcelet et al., 2004). Treatment of the MEF cells in our study with 10µM PKF115-584 for 18 hours was able to abrogate expression of the β-catenin downstream target, cyclin D1, with minimal toxicity and thus is the dose we proceeded with in further experiments. Consistent with what has been observed in acute myeloid leukemia cell lines (Minke et al., 2009), inhibition of β-catenin expression itself was also evident following treatment with the Wnt inhibitor (Figure 6A, right panel). To determine the effectiveness of PKF115-584 on TCF4 transactivation, Ad-GFP and Ad-GFP Cre infected NF2 floxed MEFs were treated with DMSO control or 10µM PKF115-584 for 18 hr in combination with Wnt3a stimulation in the final 8 hours prior to harvesting for TCF4 reporter assay. PKF115-584 was able to significantly inhibit the activation of TCF4 in response to Wnt3a, independent of the activity of NF2 (Figure 6A, left panel). To specifically examine the ability of PKF115-584 to block Wnt signaling in NF2-deficient cells at confluency, the Ad-GFP and Ad-GFP Cre infected cells were seeded into confluent conditions and treated with PKF115-584 or vehicle control prior to the TCF4 reporter assay. The small molecule inhibitor was effective in blocking the hyperactivation of TCF4 in the NF2-deficient cells at confluency, and showed minimal effect on the already reduced level of TCF4 transactivation in NF2-proficient cells (Figure 6B). Lastly, to verify that such Wnt pathway inhibition can affect cell cycle progression at confluency, NF2-proficient and –deficient cells cultured in confluent conditions were treated with vehicle control or PKF115-584 for 18 hr, pulsed with BrdU for the final 1 hr, and harvested for BrdU FACS analysis. As shown in Figure 6C, PKF115-584 completely blocked the ability of the Ad-GFP Cre infected cells to proliferate at confluency. These results suggest that the dependence of NF2-deficient cells on Wnt signaling for the loss of contact inhibition could be useful in reversing this phenotype.Bosco et al.Page 8Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptDiscussionLoss of contact inhibition of cell proliferation is the signature phenotype of cells lacking the tumor suppressor merlin. Associated with loss of contact inhibition, merlin-deficient cells are known to contain defective adherens junctions at confluency with unstablized cadherin-catenin complexes (McClatchey and Giovannini, 2005). The issue of how proliferative signals arise from the sites of cell-cell junctions and are transduced to the nucleus to promote inappropriate cell cycle progression remains unresolved. Recent evidence in primary MEFs has implicated persistent EGFR signaling in the inappropriate proliferation of NF2-/- cells, suggesting that merlin restrains EGFR activity at the cell membrane (Curto et al., 2007). Our current work provides new evidence that the relationship of merlin with EGFR is not the only mechanism by which NF2-/- cells are able to escape contact inhibition.Similar to the observations in Curto et al. (Curto et al., 2007), we show that the total level of β-catenin is unaltered by the loss of merlin. But in contrast to that study, we found a significant increase in transcriptionally active β-catenin upon merlin deletion. This is established by several means. First, we found that increased TCF/LEF transcription factor activity (Figure 2A), which is a direct downstream target of activated β-catenin in the nucleus, exists in the absence of merlin. Second, NF2-/- cells contained an increase in both active β-catenin, and phospho-β-catenin Y142 levels (Figure 3A), which have been shown to be markers for β-catenin that is being translocated from the cell membrane to the nucleus. Third, elevations in the mRNA (Figure 4C) and transcriptional activity (Figure 3B) of downstream targets of activated β-catenin were evident in the absence of merlin. Thus, we believe that deregulated canonical Wnt signaling is associated with NF2 loss of function. To examine whether the increased nuclear β-catenin activity could be a causal event in the ability of NF2-/- cells to inappropriately proliferate at confluency, we were able to restore basal levels of TCF/LEF transcriptional activity to the NF2-/- cells either through the use of a dominant negative TCF4 construct or a small molecule Wnt pathway inhibitor, PFK115-584 (Figure 5B, Figure 6B). Suppressing either the elevated TCF or Rac1 activities in the merlin-deficient cells significantly reduced the capacity of NF2-deficient cells to enter S phase at confluency (Figure 5C–5D, Figure 6C). Collectively, our results show that the elevated nuclear β-catenin activity in NF2 deficient cells contributes to the growth phenotype of the cells at confluent state.Like many classical tumor suppressors, merlin’s activity is governed by its phosphorylation state. Several seminal papers in the study of neurofibromatosis type 2 have linked merlin activity to its phosphorylation induced by Rac1-GTP and its downstream effector PAK (Kissil et al., 2002; McClatchey and Giovannini, 2005; Shaw et al., 2001). The ser518 phosphorylation of merlin weakens its self- and cytoskeletal- associations, inactivates its growth suppressive properties, and potentiates Rac-dependent signaling (Gutmann et al., 1999; Kissil et al., 2002; Xiao et al., 2002). This opposing relationship between Rac1 and merlin is strengthened by observations that overexpression of merlin inhibits the Rac1 signaling axis, specifically PAK1 and JNK, and downregulates cyclin D1 (Kaempchen et al., 2003; Kissil et al., 2002; Xiao et al., 2002). Moreover, it is also established that NF2-/- cells contain very high levels of active Rac1 (Ammoun et al., 2008; Kaempchen et al., 2003; Nakai et al., 2006). Thus, in light of the recent evidence that Rac1 is critical for canonical Bosco et al.Page 9Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptWnt pathway signaling (Wu et al., 2008), we have examined the relationship between active Rac1 and the elevated Wnt signaling in the context of NF2-deficiency induced inappropriate proliferation. We first confirmed that Rac1 is necessary for canonical Wnt signaling in the NF2 loss of function context, a pathologically relevant model system (Figure 4A), as previous experiments in osteoblasts and NIH 3T3 cells do not address such a relevance (Wu et al., 2008). Next, we found that Rac1 activity was indeed responsible for the elevation in canonical Wnt signaling in NF2-deficient cells, as Rac1 inhibition with a dominant negative mutant, small molecule inhibitor, or shRNA eliminated TCF4 transcriptional activation (Figure 4B), and transcription of downstream targets c-myc and cyclin D1 (Figure 4C). Although our data do not define a mechanism through which Rac1-GTP can impact Wnt signaling in the context of merlin loss, it could be envisioned to occur through various Rac effectors, such as the MAPK, Akt, or JNK (Chadee et al., 2006; Tang et al., 2007; Wu et al., 2008). Because the inhibitory effect of Rac1 N17 together with dnTCF4 on the confluent NF2-/- cell proliferation was comparable to that by Rac1 N17 or dnTCF4 alone (Figure 5; data not shown), it is likely that Rac1 and TCF4 activities do not synergize and may act as a part of the same pathway containing NF2-Rac1-β-catenin-contact inhibition.Recent advances in the study of NF2 have indicated that merlin is a tumor suppressor that is capable of modulating a wide range of signaling pathways that influence cell growth, motility and apoptosis. Similar to our results in MEFs, a recent study in high grade human gliomas has also concluded that NF2 loss results in an increase in Wnt signaling, specifically TCF transcription factor activity (Lau et al., 2008). This work found that merlin acts to increase expression of molecules that inhibit canonical Wnt signaling (Dkk-1 and Dkk-3) and decrease expression of molecules that activate Rac1/ RhoA signaling (Vav3) (Colomba et al., 2008; Lyons and Burnstein, 2006). With the glioma model in mind, it is possible that elevated levels of active Rac1 in the absence of merlin are due to unrestrained Vav3 activity in NF2-associated tumors as well and could serve as another potential point of therapeutic intervention in the disease.Because schwannomas are benign and relatively slow-growing they do not respond well to traditional chemotherapy and often result in morbidity. Treatment strategies are centered on local tumor control by repeated surgeries and radiation which can have detrimental effects on the nerves and are made more challenging by tumor location and multiplicity. Thus, new pharmacological treatment strategies are urgently needed. Because NF2 patients typically suffer from schwannomas and meningiomas, further study is necessary in these disease models in order to apply our observations. In this context, our work provides new insight into the tumor suppressive activity of merlin and suggests that targeting the Rac-Wnt pathway could serve as a novel therapeutic strategy for neurofibromatosis type 2 associated disease.AcknowledgementsThe authors would like to thank all members of the Zheng lab for thought provoking discussions. This work was supported by grants from National Institutes of Health, USA (Y.Z.), and an NIH Training Program in Cancer Therapeutics Grant (E.E.B.).Bosco et al.Page 10Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptReferencesAberle H, Schwartz H, Hoschuetzky H, Kemler R. Single amino acid substitutions in proteins of the armadillo gene family abolish their binding to alpha-catenin. J Biol Chem. 1996; 271:1520–1526. [PubMed: 8576147] Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res. 2008; 68:5236–5245. [PubMed: 18593924] Bosco EE, Mayhew CN, Hennigan RF, Sage J, Jacks T, Knudsen ES. RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res. 2004; 32:25–34. [PubMed: 14704340] Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hammerschmidt M, Birchmeier W. Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions. Genes Dev. 2004; 18:2225–2230. [PubMed: 15371335] Chadee DN, Xu D, Hung G, Andalibi A, Lim DJ, Luo Z, et al. Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc Natl Acad Sci U S A. 2006; 103:4463–4468. [PubMed: 16537381] Colomba A, Courilleau D, Ramel D, Billadeau DD, Espinos E, Delsol G, et al. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. Oncogene. 2008; 27:2728–2736. [PubMed: 17998938] Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. Contact-dependent inhibition of EGFR signaling by NF2/Merlin. J Cell Biol. 2007; 177:893–903. [PubMed: 17548515] Esufali S, Bapat B. Cross-talk between Rac1 GTPase and dysregulated Wnt signaling pathway leads to cellular redistribution of beta-catenin and TCF/LEF-mediated transcriptional activation. Oncogene. 2004; 23:8260–8271. [PubMed: 15377999] Fernandez-Valle C, Tang Y, Ricard J, Rodenas-Ruano A, Taylor A, Hackler E, et al. Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet. 2002; 31:354–362. [PubMed: 12118253] Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer. 1999; 81:682–687. [PubMed: 10328216] Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, et al. Conditional biallelic NF2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 2000; 14:1617–1630. [PubMed: 10887156] Gutmann DH, Sherman L, Seftor L, Haipek C, Hoang Lu K, Hendrix M. Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading. Hum Mol Genet. 1999; 8:267–275. [PubMed: 9931334] Johnson KC, Kissil JL, Fry JL, Jacks T. Cellular transformation by a FERM domain mutant of the NF2 tumor suppressor gene. Oncogene. 2002; 21:5990–5997. [PubMed: 12203111] Jordan P, Brazao R, Boavida MG, Gespach C, Chastre E. Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene. 1999; 18:6835–6839. [PubMed: 10597294] Kaempchen K, Mielke K, Utermark T, Langmesser S, Hanemann CO. Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet. 2003; 12:1211–1221. [PubMed: 12761036] Kissil JL, Johnson KC, Eckman MS, Jacks T. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem. 2002; 277:10394–10399. [PubMed: 11782491] Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 2003; 17:1090–1100. [PubMed: 12695331] Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, Yu Q. Merlin is a potent inhibitor of glioma growth. Cancer Res. 2008; 68:5733–5742. [PubMed: 18632626] Bosco et al.Page 11Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptLepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004; 5:91–102. [PubMed: 14749129] Lyons LS, Burnstein KL. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol. 2006; 20:1061–1072. [PubMed: 16384856] Malliri A, Collard JG. Role of Rho-family proteins in cell adhesion and cancer. Curr Opin Cell Biol. 2003; 15:583–589. [PubMed: 14519393] McClatchey AI, Giovannini M. Membrane organization and tumorigenesis-the NF2 tumor suppressor, Merlin. Genes Dev. 2005; 19:2265–2277. [PubMed: 16204178] Minke KS, Staib P, Puetter A, Gehrke I, Gandhirajan RK, Schlosser A, et al. Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol. 2009; 82:165–175. [PubMed: 19067737] Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 2001; 15:968–980. [PubMed: 11316791] Nakai Y, Zheng Y, MacCollin M, Ratner N. Temporal control of Rac in Schwann cell-axon interaction is disrupted in NF2-mutant schwannoma cells. J Neurosci. 2006; 26:3390–3395. [PubMed: 16571745] Okada T, Lopez-Lago M, Giancotti FG. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol. 2005; 171:361–371. [PubMed: 16247032] Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer. 2002; 2:133–142. [PubMed: 12635176] Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu W. Crystal structure of a beta-catenin/BCL9/Tcf4 complex. Mol Cell. 2006; 24:293–300. [PubMed: 17052462] Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, et al. The NF2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell. 2001; 1:63–72. [PubMed: 11703924] Tang X, Jang SW, Wang X, Liu Z, Bahr SM, Sun SY, et al. Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol. 2007; 9:1199–1207. [PubMed: 17891137] Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999; 398:422–426. [PubMed: 10201372] Upadhyay G, Goessling W, North TE, Xavier R, Zon LI, Yajnik V. Molecular association between beta-catenin degradation complex and Rac guanine exchange factor DOCK4 is essential for Wnt/beta-catenin signaling. Oncogene. 2008; 27:5845–5855. [PubMed: 18641688] van Noort M, Meeldijk J, van der Zee R, Destree O, Clevers H. Wnt signaling controls the phosphorylation status of beta-catenin. J Biol Chem. 2002; 277:17901–17905. [PubMed: 11834740] Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell. 2008; 133:340–353. [PubMed: 18423204] Xiao GH, Beeser A, Chernoff J, Testa JR. p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem. 2002; 277:883–886. [PubMed: 11719502] Bosco et al.Page 12Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptBosco et al.Page 13Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 1. NF2-deficiency confers a loss of contact inhibition and adherens junction instability in immortalized MEFs(A) Primary and immortalized MEFs were infected with adenovirus encoding GFP or GFP-Cre. Cells were harvested 4 days post infection and genomic DNA was purified for PCR of the NF2 gene (left panel) or cells were processed for immunoblot with an antibody to merlin (right panel). Actin served as a loading control. (B) Immortalized cells from A were plated at a concentration of 1×105 and counted every 3 days. (C) Immortalized cells from A were plated on coverslips, grown to confluency, and starved of serum for 48 hours prior to immunofluorescent staining for β-catenin (red). DAPI is a nuclear stain (blue). Images were taken at equal exposures. (D) Cells from A were harvested for immunoblotting for the total levels of β-catenin. Actin served as a loading control.Bosco et al.Page 14Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 2. NF2 loss results in an increase in Wnt signalingAd-GFP or Ad-GFP Cre infected primary (left panel) or immortalized (right panel) MEFs were transfected with TCF4-luc (TOPflash) or TCF4-mut-luc (FOPflash) and β-gal plasmids and luciferase reporter assay was performed.Bosco et al.Page 15Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 3. Wnt and Rac1 signaling are elevated in NF2-/- cells(A) Immortalized cells infected with Ad-GFP and Ad-GFP Cre were harvested and a Western blot was performed to analyze the levels of total Rac1, pPAK, pAkt ser 473, active β-catenin, pβ-catenin Y142, total β-catenin, and cyclin D1. Actin served as a loading control. (B) Cells from A were transfected with cyclin D1-luc and β-gal plasmids prior to harvest for reporter assay.Bosco et al.Page 16Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 4. Rac1 activity is necessary for elevated Wnt signaling in NF2-deficient MEFsBosco et al.Page 17Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript(A) Wild type MEF cells were transduced with retrovirus expressing either MIEG3 control or a MIEG3-Rac1N17 mutant and sorted by flow cytometry based on GFP positivity. Cells were then transfected with TCF4-luc (TOPflash) or TCF4-mut-luc (FOPflash) and β-gal plasmids and were stimulated with Wnt3a for 1 hour prior to harvest for reporter assay. Cells were treated with NSC23766 for 24 hours prior to reporter assay harvest where indicated. Data is represented as TCF4-luc/TCF4-mut-luc and the activity of the untreated MIEG3 infected cells are set to 1. (B) Ad-GFP or Ad-GFP Cre infected immortalized MEFs were subsequently infected with retrovirus encoding MIEG3, or MIEG3-Rac1 N17 and sorted by GFP expression 48 hours later. This population of cells was transfected with TCF4-luc (TOPflash) or TCF4-mut-luc (FOPflash) and β-gal plasmids and stimulated with Wnt3a prior to harvesting for reporter assay. Data is represented as TCF4-luc/TCF4-mut-luc and normalized to the activity of the untreated MIEG3, Ad-GFP infected cells. (C) Retrovirally transduced cells from B were harvested at confluency for quantitative PCR analysis of c-myc (left panel) and cyclin D1 (right panel) with respect to a GAPDH control.Bosco et al.Page 18Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptBosco et al.Page 19Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 5. Wnt signaling contributes to the loss of contact inhibition in NF2-deficient MEFs(A) Ad-GFP or Ad-GFP Cre infected MEFs were cotransfected with TCF4-luc (TOPflash) or TCF-mut-luc (FOPflash), β-gal, and pSFG-control or pSFG-dnTCF4 prior to Wnt stimulation and reporter assay. Data is represented as TCF4-luc/TCF4-mut-luc and normalized to the activity of the untreated pSFG-control, Ad-GFP infected cells. (B) Cells from A were grown to confluency prior to harvest for luciferase reporter assay and the activity of the pSFG-control, Ad-GFP infected cells was set to 1. (C) Cells from A were grown to confluency and pulsed with BrdU for 1 hour prior to fixation and staining for BrdU/ PI followed by FACS analysis. Data is normalized to the Ad-GFP pSFG-control Bosco et al.Page 20Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptinfected cells which is set to 1, and a student t-test was run to determine statistical significance p<.05. (D) Ad-GFP or Ad-GFP Cre infected cells were cotransfected with MIEG3 alone or MIEG3-Rac1 N17, and sorted based on GFP expression. Sorted cells were plated at confluency and pulsed with BrdU for 1 hour prior BrdU/ PI analysis as in C. Data is normalized to the Ad-GFP control MIEG3 infected cells which is set to 1, and significance was determined by student t-test (p<.05).Bosco et al.Page 21Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptBosco et al.Page 22Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 6. Small molecule inhibition of Wnt signaling restores NF2-deficient cells elevated TCF4 activity and inappropriate proliferation to levels comparable to wild type cells(A) Ad-GFP or Ad-GFP Cre infected MEFs were cotransfected with TCF4-luc (TOPflash) or TCF-mut-luc (FOPflash), and β-gal, prior to 24 hour treatment with 10µM PKF115-584, Wnt stimulation and reporter assay. Data is represented as TCF4-luc/TCF4-mut-luc and normalized to the activity of the untreated DMSO vehicle control, Ad-GFP infected cells (left panel). Ad-GFP Cre infected MEFs were treated with 10µM PKF115-584 for 18 hours prior to harvest for immunoblot to verify inhibition of β-catenin and cyclin D1. Actin served as a loading control. (B) Cells from A were grown to confluency prior to harvest for luciferase reporter assay and normalized to the activity of the untreated DMSO vehicle control which was set to 1. (C) Upper panel: Ad-GFP or Ad-GFP Cre infected MEFs were grown to confluency, treated with either DMSO vehicle or 10µM PKF115-584, and pulsed with BrdU for 1 hour prior to harvest for BrdU/ PI analysis. Data is normalized to the Ad-Bosco et al.Page 23Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptGFP infected, DMSO treated control cells which are set to 1. Lower panel: Representative histograms from FACS analysis are displayed.Bosco et al.Page 24Oncogene. Author manuscript; available in PMC 2010 October 29.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptCell, Vol. 72, 791400, March 12, 1993, Copyright 0 1993 by Cell Press A Novel Moesin-, Ezrin-, Radixin-like Gene Is a Candidate for the Neurofibromatosis 2 Tumor Suppressor James A. Trofatter,’ Mia M. MacCoiiin,l Joni L. Rutter,’ Jill R. Murreil,’ Mabel P. Duyao,’ Diiys M. Parry,* Rosweii Eidridge,3 Nikolai Kiey,’ Anii G. Nlenon,5 Karen Pulaski,’ Voiker H. Haase,’ Christine M. Ambrose,’ David Munroe,’ Catherine Bove,’ Jonathan L. Haines,’ Robert L. Martuza,’ Marcy E. MacDonald,’ Bernd R. Seizinger,’ M. Priscilla Short,’ Alan J. Buckler,’ and James F. Gusella’ ‘Molecular Neurogenetics Unit Massachusetts General Hospital and Harvard Medical School Charlestown, Massachusetts 02129 %iinicai Epidemiology Branch National Cancer institute Bethesda, Maryland 20892 %jS Public Health Service Bethesda, Maryland 20892 40ncology Drug Discovery Bristol-Myers Squibb Pharmaceutical Research institute Princeton, New Jersey 08543 5Department of Molecular Genetics University of Cincinnati Medical Center Cincinnati, Ohio 45267 ‘Center for Cancer Research Massachusetts institute of Technology Cambridge, Massachusetts 02139 ‘Department of Neurosurgery Georgetown University Medical Center Washington, DC 20007 Summary Neurofibromatosis 2 (NF2) is a dominantly inherited disorder characterized by the occurrence of bilateral vestibuiar schwannomas and other central nervous system tumors including multiple meningiomas. Ge- netic linkage studies and investigations of both spo- radic and familial tumors suggest that NF2 is caused by inactivation of a tumor suppressor gene in chromo- some 22q12. We have identified a candidate gene for the NF2 tumor suppressor that has suffered nonover- lapping deletions in DNA from two independent NF2 families and alterations in meningiomas from two un- related NF2 patients. The candidate gene encodes a 587 amino acid protein with striking similarity to sev- eral members of a family of proteins proposed to link cytoskeietai components with proteins in the ceil membrane. The NF2 gene may therefore constitute a novel class of tumor suppressor gene. introduction Neurofibromatosis (NF) is a term used to describe two major human genetic disorders both of which display au- tosomai dominant inheritance and involve tumors of the nervous system, but are distinct clinical entities (Mulvihili et al., 1990). NFl, or von Reckiinghausen NF, is more common (incidence of 1 in 4000) and is characterized by the highly variable expression of an array of features that include neurofibromas, cafe-au-iait macuies, Lisch nod- ules of the iris, and a predisposition to certain malignant tumors (Riccardi, 1981; Riccardi and Eichner, 1986). it is caused by defects in a chromosome 17 gene that has recently been isolated and characterized (Viskochii et al., 1990; Cawthon et al., 1990; Wallace et al., 1990). The NF7 gene product, termed neurofibromin, is a large protein with a GTPase-activating protein-related domain and is presumably involved in modulating a signal transduction pathway whose disruption can lead to tumor formation (Bailester et al., 1990; Buchberg et al., 1990; Xu et al., 1990; DeCiue et al., 1992; Basu et al., 1992). By contrast, NF2, which occurs in about 1 of 40,000 live births (Evans et al., 1992), is characterized by bilateral schwannomas that develop on the vestibular branch of the eighth cranial nerve. Pressure from these tumors often causes hearing loss and vestibular symptoms in the sec- ond and third decade. Other tumors of the brain, especially meningiomas, and schwannomas of other cranial nerves and spinal nerve roots (Martuza and Eldridge, 1988) as well as posterior capsular lens opacities (Kaiser-Kupfer et al., 1989) are common and are generally present in the young adult. The NF2gene is highly penetrant, and individ- uals with it have a 95% chance of developing bilateral vestibuiar schwannomas. NF2 is often more severe than NFl, with teenage or early adulthood onset of multiple slow growing tumors that can gradually cause deafness, balance disorder, paralysis, or increasing neurological problems necessitating repeated surgical procedures. NF2 was shown to be genetically distinct from NFl by linkage studies that assigned the NF2 gene to chromo- some 22 (Rouleau et al., 1987; Wertelecki et al., 1988; Rouleau et al., 1990; Narod et al., 1992). The tumor types that occur in NF2 are found more frequently in the general population as solitary, sporadic tumors. Since frequent loss of alleles on chromosome 22 from both sporadic ves- tibular schwannomas and meningiomas and from their counterparts in NF2 had been noted previously, the iocai- ization of the inherited defect to the same chromosome region suggested that the NF2 locus encodes a recessive tumor suppressor gene (Knudson, 1971) whose inactiva- tion leads to tumor formation (Seizinger et al., 1986, 1987a, 1987b). A number of studies of both sporadically occurring tumors and tumors from NF2 patients have pro- vided consistent support for this hypothesis (Couturier et al., 1990; Rouieau et al., 1990; Fiedler et al., 1991; Fon- taine et al., 1991a, 1991b; Bijlsma et al., 1992; Wolff et al., 1992). The combined use of family studies and tumor deletion mapping has progressively narrowed the location of NF2 within the q12 band of chromosome 22, defining a candidate region in which to search for the genetic defect (Rouieau et al., 1990; Wolff et al., 1992). Here, we report a gene from the NF2 region that has suffered nonoveriap- Cell 792 1234 kbp - 600 -230 - 200 Figure I. Pulsed-Field Gel Analysis of Lymphoblast DNA from NF2 Patients DNA in agarose blocks was digested with Notl, subjected to electropho- resis, blotted, and hybridized to a radiolabeled 4 kb NEFH probe. Lane 1, GUS6274 (affected NF2 unrelated to lanes 3 and 4); lane 2, GUS7670 (normal human); lane 3, GUS5068 (affected daughter); lane 4, GUS5069 (affected mother). ping and interstitial deletions in four independent NF2 pa- tients, suggesting that it encodes the Nf2 tumor suppres- sor. This candidate gene encodes a novel protein related to the moesin (membrane-organizing extension spike Not I 17Okbp 230 Not I protein)-ezrin (cytovillin)-radixin family of cytoskeleton- associated proteins (Gould et al., 1989; Turunen et al., 1989; Funayama et al., 1991; Lankes and Furthmayr, 1991; Sato et al., 1992). This protein, which we have named merlin (for moesin-ezrin-radixin-like protein), may represent a new class of tumor suppressor whose function is mediated by interactions with the cytoskeleton. Results Scanning the NF2 Candidate Region for Rearrangement The NF2 candidate region on chromosome 22 lies be- tween D22S7 and D22S28 and is estimated to encompass 6 Mb of band q12 (Frazer et al., 1992). Since some germ- line NF2 mutations might involve a deletion of the tumor suppressor gene as has been found in Wilms’ tumor and retinoblastoma (Riccardi et al., 1978; Francke et al., 1979; Dryja et al., 1986), we set out to scan the candidate region for such alterations. Pulsed-field gel blots containing lymphoblast DNAs from various NF2 patients were probed for several loci in the candidate region, including D22S7, D22S15,022828,022532, 022S42,022846, D22S56, the leukemia inhibitory factor gene, and the neurofilament heavy chain gene (NE/%). This analysis revealed that in a lymphoblast cell line (GUS5069) derived from a female kbp Not I > 20kbp NEFH 5’ 3’ ml9 7c4 3D;1’- 47All 4D7 - 02AT - 9769 1OHll 24A7 2rJn6 121610 103w- X X X L 4 W t......- l-l STS: 96T3 96T7 Probes: B A C . . . . . . . . . * 5’ 3’ Figure 2. Physical Map of the Chromosome 22 Region Surrounding the NF2 Deletions Notl sites were determined by pulsed-field gel analysis and confirmed in cosmids. Cosmids were named according to their standardized library coordinates. The enlarged region shows details of the merlin gene vicinity with deleted regions denoted by underlying brackets. Probes used in the deletion analysis: A, 14 kb Hindlll fragment from cosmid 96ClO; 6, 8.5 kb Hindlll fragment from 26H6 that spans the T3 end of 96ClO; C, B kb Hindlll end fragment from the T7 end of 96ClO; 96T3 (primer pair: 5’-CAGATTGTTCATTCCAAGTGG-3’and S-ACCCTGAGGAATCCACTACC-3’, product size = 124 bp) and 96T7 (5’-TGCACACACATCCTlTTCAC3’and 5’-GAGAGAGACTGCTGTCTCAAAMW, product size = 92 bp) are STSs derived from the T3 and T7 ends of 96C10, respectively. X, Xhol recognition site. Arrows indicate the orientation of transcription and approximate genomic coverage of cDNA JJA-1. 7;; Tumor Suppressor Gene Figure 3. Complete Nucleotide and Predicted Amino Acid Sequences of the Merlin JJR-1 cDNA Clone Common moesin-ezrin-radixin domain spans amino acid residues l-350. Arrow indicates where poly(A) addition has occurred in two independent clones (JJR-6 and JJR-9). NF2 patient, a probe for the NEFH locus hybridized to apparently altered fragments of reduced size with both Not1 and Nrul. In Notl-digested DNA (Figure 1) the NEFH probe de- tected fragments of approximately 600 kb, 400 kb, and 230 kb in most lymphoblast cell lines. We were unable to confirm that the 600 kb fragment originates from chromo- some 22, leaving the possibility that it may derive from hybridization to a related locus (A. G. M. et al., unpublished data). Variable intensity of the 230 kb fragment in many samples suggested that it resulted from partial digestion of the 400 kb fragment. In GUS5069, additional fragments of approximately 370 kb and 200 kb were observed, con- sistent with the possibility of a deletion within the region common to the 400 kb and 230 kb fragments. The alter- ation was transmitted along with NF2 from the patient to her affected daughter (represented by GUS5066) (Fig- ure 1). Chromosome Walking toward the Putative Deletion To isolate DNA corresponding to the region of chromo- some 22 apparently deleted in GUS5069, a bidirectional cosmid walk was initiated from NEFH. At each step, single restriction fragments of the cosmids were used as probes on pulsed-field gels to establish the location of the putative deletion relative to NEFH. On the 5’side of NEFH, we soon identified a Notl site that was rarely cleaved in lymphoblast DNA. Probes beyond the Notl site detected the same -400 kb Not1 fragment along with a 170 kb fragment of variable intensity. Thus, infrequent cleavage of this Notl site divides the 400 kb fragment into fragments of 230 kb and 170 kb. Since the putative deletion in GUS5069 affects the 230 kb fragment but not the 170 kb fragment, we con- tinued to walk only 3’of NEFH, again probing pulsed-field gel blots containing DNA from GUS5069. The Notl pulsed-field gel map, a minimal set of clones representing the cosmid walk, and the extent of the geno- mic deletion (see Figure 5b) are shown in Figure 2. The deletion was reached when we tested a probe (Figure 2, probe A) from cosmid 96ClO that failed to detect the al- tered Notl fragment in GUS5069. However, various probes from cosmids 28H6 and 121GlO did detect the altered fragment. To estimate the extent of deletion, probes B and C (Figure 2) were tested. Probe B is an 6 kb Hindlll fragment from 26H6 that overlaps with the T3 end of 96ClO. Probe C is a 9 kb Hindlll fragment from the T7 end of 96ClO. Probe B detected both the normal and the altered Notl pulsed-field gel fragments, but probe C de- tected only the normal fragment. For more precise analysis of the deletion, the altered chromosome 22 from GUS5069 was segregated from its normal counterpart in human X hamster somatic cell hy- brids. We created sequence-tagged site (STS) assays for the T3 and T7 ends of 96ClO and tested hybrids containing the separated chromosomes 22. In contrast with the above hybridization results, the T3 end of 96ClO was absent in hybrid GUSH1 34A3, which contains the deleted chromo- some, but present in GUSH134A10, which contains the Cell 794 123456789 kb -9.5 -2.4 -0.2 Figure 4. Northern Blot Analysis of RNA Derived from Human Tumor Cell Lines RNA was size fractionated by electrophoresis in formaldehyde-aga- rose, blotted, and hybridized as described in Experimentaf Procedures. The blot was hybridized with a radiolabeled probe corresponding to bases 1256-1942 of the JJR-1 cDNA. Lane I, SK-N-NE neuroblastoma; lane 2, T96G glioblastoma; lane 3, WERI retinoblastoma; lane 4, MCF-7 breast carcinoma; lane 5, HOS osteosarcoma; lane 6, HEPGP, liver carcinoma; lane 7, CATA kidney carcinoma; lane 6. SW460 colon carcinoma; lane 9, EJ bladder carcinoma. normal chromosome. Moreover, the T7 assay was positive in both hybrids. The locations of probes 6 and C and of both STS assays were confirmed on the cosmid walk. Thus, the failure of probe C to detect the altered fragment suggests that the deletion spans most but not all of this sequence. Similarly, the other deletion breakpoint must occur within the region spanned by probe 6. Therefore, the combination of hybridization and polymerase chain reaction (PCR) results indicates that the deletion must en- compass almost all of 96ClO and up to an additional 5 kb of 26H6. This 35-45 kb region is expanded below the cosmid walk in Figure 2. Identification and Characterization of the Merlin cDNA Exon amplification (Buckler et al., 1991), which produces cloned “trapped exons,” was applied to cosmids 26H6, 96C10,121GlO, 123F5,10Hll, and 7C4 surrounding the site of the NF2 deletion as a rapid method of obtaining exonic probes for cDNA cloning. Each exon clone can represent a single exon or multiple exons spliced together in the trapping procedure. We obtained and sequenced 24 exon clones, 6 of which displayed sequence similarity with the cytoskeieton-associated proteins moesin, ezrin, and radixin (see below). The latter exons were used to screen human frontal cortex and hippocampus cDNA libraries. Figure 3 shows the complete DNA sequence of JJR-1, the longest clone obtained in cDNA screening. This se- quence contains eight of the cloned exon segments as shown in Figure 5a. The cDNA is 2256 bp long and shows no evidence of a poiy(A) tail. However, two shorter cDNA clones, JJR6 and JJR-9, which overlapped the restriction map of JJR-1, had apparent poly(A) tails beginning at base 2230. JJR-1 contains an open reading frame of 1761 bp encoding a predicted protein of 69 kd. There are two in- frame stop codons within 60 bp upstream of the putative initiator methionine. The JJR-1 cDNA spans at least 50 kb of genomic DNA and is transcribed in the same orientation as NEFH, as shown by the arrows in Figure 2. Both the JJR-1 DNA sequence and the predicted protein product were used to search for similarity in nucleic acid and protein data bases using the BLAST network service of the National Center for Biotechnology Information (Altschul et al., 1990). The DNA sequence displayed signif- icant similarity to moesin and ezrin genes from several species, including humans (P = 9.0e-125 and 9.0e-I”), to mouse radixin (1 .le-lo*) and to Echinococcus multilocu- laris tegument protein (2.4emZ1). Striking similaritywas also detected at the amino acid level with these same proteins (2.5e+, 5.0e-‘46, 2.7e-le, and 7.6e-73, respectively) and to a potential product of a sequence tag from Caenorhabditis elegans (3.7e-43). Weaker similarities were detected to the sequences of two protein-tyrosine phosphatases, PTP- MEG and PTP-Hl (1.3e-I7 and 9.6e-16, respectively), to erythrocyte protein 4.1 (9.9e-‘3 and to a wide range of myosin, tropomyosin, and paramyosin proteins. Because this novel gene is most closely related to moesin, ezrin, and radixin (450/o-47% identity), we have called it merlin. Northern blot analysis using total RNA from various cul- tured human tumor cell lines (Figure 4) revealed two major hybridizing species of 2.6 kb and 7 kb, and a less intensely hybridizing RNA of 4.4 kb. A similar pattern was detected in poly(A)’ RNA from various human tissues, including heart, brain, lung, skeletal muscle, kidney, pancreas, and liver (weakly), indicating that the merlin gene is expressed widely. The apparent poly(A) tails detected in JJR-6 and JJR-9 suggest that these clones may have derived from the - 2.6 kb RNA. The JJR-1 clone likely derived from one of the larger RNAs that apparently has a much longer 3’ untranslated region. However, it cannot be excluded that the larger RNAs arise by alternative splicing that alters the length and composition of the coding sequence or by hybridization to related family members. Nonoverlapping Deletions Interrupt the Candidate NF2 Gene To determine whether the deletion detected in GUS5069 interrupts the merlin gene, we prepared exon probes from across the coding sequence (Figure 5a) and analyzed Southern blots containing DNA from GUSH134A3 and from GUSH13481, two independent hybrid lines con- taining the deleted chromosome 22. The results for probes I and II, shown in Figure 5b, demonstrate that the probe I sequence was absent from both hybrids, while the probe II sequence was present in both. Thus, the genomic deie- tion truncates the merlin gene within the coding sequence between probes I and II, removing the 5’ end. In a search for additional alterations in the merlin gene, we scanned blots of restriction-digested DNA from 33 un- related NF2 patients using the cDNA as probe. One pa- tient, represented by cell line GUS5722, displayed altered fragments with several restriction enzymes suggestive of a small - 3-4 kb genomic deletion. This patient was ana- lyzed in the Southern blots shown in Figure 5c. Probes Ill, 7;; Tumor Suppressor Gene a 243 2003 cDNA Trapped exons: Probe: b I 123456 459 666 818 561 693 I II II 123456 3’ 1029 1104 1216 1665 1793 iid3 i2i7 1;40 III c III 123 IV 123 123 kbp b -2.3 - 2.0 Figure 5. Detection of Genomic Germline Deletions in NF2 Patients (a) Location of trapped exons in JJR-1 cDNA. The closed box in the cDNA indicates the open reading frame; thin lines indicate both 5’ and 3’ untranslated regions. Probe names correspond to those used in (b) and (c). Probe II represents base pairs 616-693 of JJR-1 and is overlapped by another trapped product. These overlapping products may have arisen from partial digestion of the cosmid or alternative splicing in COS7 cells occurring during exon amplification analysis. (b) Southern blot analysis of GUS5069 X hamster hybrid cell lines harboring the altered chromosome 22. DNA samples were digested with BamHI, size fractionated in agarose gels, blotted, and hybridized with radiolabeled probes indicated above each panel. Lane 1, GUS1323 (human control); lane 2, CHTG49 (hamster control); lane 3, GUSH134A3 (hybrid with deleted homolog);lane 4, GUSH134Bl (hybrid with deleted homolog); lane 5, GM10666 (chromosome 22-only hybrid); lane 6, Eye3FA6 (hybrid containing chromosome 22 and smaller portions of two to three other chromo- somes). (c) Southern blot analysis of NF2 patient lymphoblast DNA. Samples were digested with EcoRI, size fractionated, blotted, and hybridized with radiolabeled probes indicated above each panel. Lane 1, GUS1323 (human control); lane 2, GUS5069 (NF2 affected); lane 3, GUS5722 (NF2 affected). Probe V comprises multiple exons and recognizes multiple genomic fragments. IV, and V all reside on the same 21 kb EcoRl fragment. In GUS5722, probes Ill and V detect both the normal EcoRl fragment and a second fragment reduced in size by the deletion. Probe IV fails to detect the altered fragment in GUS5722 because it lies within the region deleted. We have performed PCR amplification of first strand cDNA from GUS5722 and confirmed the presence of two types of PCR product (Figure 6A). Direct sequencing revealed that the novel PCR product was missing bases 1559 to 1792 of the cDNA, representing deletion of at least two exons. The absence of this segment would remove 76 amino acids from the protein, while leaving the reading frame intact. The GUS5722 cell line was generated from a member of a large NF2 kindred (family 3 in Narod et al., 1992) and the deletion was present in 5 affected members and absent in 11 unaffected members of this pedigree. The presence of nonoverlapping deletions affecting the merlin gene in two independent families suggests that this gene represents the Nf2 tumor suppressor. We searched for additional alterations by single-strand conformational polymorphism (SSCP) analysis of PCR-amplified first strand cDNA from tumor and lymphoblast samples. We used mRNA from four primary cultures of meningiomas (three from NF2 patients with a family history of the disor- der, and one from a probable new mutation to NF2) and analyzed only selective regions of the mRNA. Two of the tumors yielded aberrant patterns. A meningioma from a female patient likely to have NF2 (see Experimental Procedures) displayed a reduced size for the expected nondenatured PCR product on SSCP gels (Figure 6B). The vastly reduced level of the normal- sized PCR product suggests that this tumor had lost alleles in this region of chromosome 22. However, lymphocyte DNA was not available from this patient to confirm this. Cell 796 A. 123456 B. 123456 C. 123456 Figure 6. Analysis of Alterations in RNA (A) PCR analysis of RNA from lymphoblasts of affected NF2 patients. RNA PCR was per- formed as described in Experimental Proce- dures. Samples were subjected to electropho- resis in a 15% agarose gel and visualized by staining with ethidium bromide and ultraviolet illumination. The products seen correspond to RNA sequence encompassed by bases 1258 to 1947 (primer pair: 5’.AGGAGGCTGAAC- GCACGAG-B’and 5’-TGGTATTGTGCTTGCT- GCTG-3’). Lanes 1,2, and 4, lymphoblastsfrom independent NF2 patients; lane 3, GUS5068; lane 5, normal control lymphoblast; lane 6, GUS5722. (6 and C) SSCP analysis of RNA samples de- rived from primary cultures of meningioma tu- mors from NF2 patients, Lane 1, undenatured PCR product from the tumor in lane 2; lanes 2, 3, 4, and 5, denatured PCR product from independent primary NF2 meningiomas; lane 6. denatured PCR product from GUS5068 lymphoblast. The PCRs amplified the following segments: in (B), base pairs 1709-l 947 (primer pair: 5’-CTTCAACCTCATTGGTGACAG-3’ and 5’-TGGTATTGTGCTTGCTGCTG-3); in (C) base pairs 457-730 (primer pair: B’-AGGTACTGG- ATCATGATGTTTC-3’ and 5’-TTTGGAAGCAATTCCTCTTGG-3rj. All lanes contain a proportion of undenatured product, detected by comparison with lane 1. Direct sequence analysis of the PCR product confirmed the presence of a 4 bp deletion that removes bases 1781 to 1784 thereby altering the reading frame and generating a shorter protein. A meningioma from a male patient with NF2 displayed an altered pattern on SSCP analysis (Figure 6C). This meningioma was known to have lost heterozygosity on chromosome 22 based on prior comparison of polymor- phic markers in blood and tumor DNA. Thus, the tumor suppressor model would suggest that the normal homolog had been lost and that the remaining copy of the gene represented the altered NF2 allele. Direct sequence analy- sis revealed a single base pair deletion at position 488 (Figure 3) which introduced a frameshift that dramatically alters the predicted protein by introducing a stop codon within 100 bases. Discussion The delineation of nonoverlapping germline deletions af- fecting different portions of the same chromosome 22 gene in two independent NF2 families suggests strongly that the Nf2 tumor suppressor has been found. It is con- ceivable that one or both of these two deletions also affect a second gene in the area. However, for such a gene to supplant our candidate as the Nf2 tumor suppressor, it would have to be affected by both deletions and must therefore be composed of exons interspersed with those of the merlin gene. The larger of the deletions truncates the 5’ end of the merlin gene, removing at least 112 amino acids. In addition, the extent of this deletion suggests that the 5’ regulatory elements may also be missing. The smaller germline deletion removes 78 amino acids from the C-terminal portion of the protein. One would anticipate that such alterations would have drastic consequences for the function of the merlin protein. However, ultimate proof that this locus is NF2 will require reversal of the tumor phenotype by reintroduction of the merlin gene. The 4 bp and single base pair deletions in meningiomas from unrelated NF2 patients could arguably be of somatic origin and unrelated to the inherited predisposition. How- ever, the almost exclusive expression of the altered copy of the merlin gene suggests that the normal sequence has been lost as a somatic event in tumor formation. This is consistent with the tumor suppressor model and would suggest that the frameshift alterations actually represent germline mutations in these patients, further implicating the merlin gene. The merlin protein encoded at the candidate NF2 locus is a novel member of a growing family of proteins that have been proposed to act as links between the cell membrane and the cytoskeleton (Luna and Hitt, 1992; Sato et al., 1992). All members of the family, which includes moesin, ezrin, radixin, erythrocyte protein 4.1, and talin, contain a homologous domain of - 200 amino acids near the N-ter- minus, followed by a segment that is predicted to be rich in a helixstructure, and a highly charged C-terminal domain. Where they have been characterized from more than one mammalian species, members of this family are remark- ably conserved. Moreover, highly related genes have been detected in the nematode, C. elegans (Waterston et al., 1992) and in the parasitic cestode, E. multilocularis (Frosch et al., 1991). Although most distantly related to merlin, protein 4.1 and talin are the best studied members of this family of proteins and have been most revealing concerning their apparent function. Protein 4.1 plays acritical role in maintaining mem- brane stability and cell shape in the erythrocyte by con- necting the integral membrane proteins glycophorin and protein 3 (the anion channel) to the spectrin-actin lattice of the cytoskeleton (Leto and Marchesi, 1984; Conboy et al., 1986). Genetic defects in protein 4.1 lead to one form of hereditary elliptocytosis (Tchernia et al., 1981; Delau- nay et al., 1991). The binding site for glycophorin in protein 4.1 has been mapped to the N-terminal domain, sug- gesting that the homologous region in other family mem- NFZ Tumor Suppressor Gene 797 1 100 Hmmn Woesin .PKl..W..TIoAE. EP ..... ..tK.LFD.V..T.GLRE.YTFGLOY...K....ULK..K~...DV.KE.P..F.F.AKFYPE ... Mcuac Rdixin .PK...VR..TIIDAE. EF.......tY.LFD.V..T.GLRE.UFFGLOY...K....ULK..K~...DV.KE.P..F.F.AKF.PE ... Hmm Ezrin .PK...VR..TW)AE. EF ..... ..OX.LFD.V..T.GLRE.U.fGL.V...K...Y....V.KE.P..F.F.AKFYPE ... Hllyn krlin MSFSSLKRKOPKTFTVRIVTIAEbl EFWCEHKWlCKDLFDLVCRTLGLRElNFFGLOY TIKDTVAWaOKKVLDSDVSKEEPVTFllFLAKFVPENAE Ech.nult. twmmt .LKR...KT..VR..T ..... EF ..... ..G.DLFD.V.RT.GlRE.U.FG.OY.........L..DKK....D........F.F..KFY~N .E Hunnn myth. 4.1 ...... ..D....E...E...KG.DL...VC..L.L.E...FGL..........VL...K ....... ..P..F.F..KFYP .... 101 200 Hmn Moesin EEL.O.IlO.LFFLO~..IL...IYCPPE..VLLASYA~.~~....VHK.G.LA...LLP.RV . . . . . . . . ..UEERI..U..EHRG..R..A..E Nwsc Rdlxin EEL.OEITP.LFFLOVK..IL...lYCPPE..VLLASYA~Y~V....HK.G.LA...lLP.RV......T.E.YEERI..U..EHRG..R....IIE Wunm Ezrin EEL.O.IlO.LFFLOVI..IL...lY~~..VLL.SYA~.GDY...VKK.G.L..E.l.P.RV......l...YE.RI..U.AEWRG...D.A ..E Hlmm merlin EELMEITOHLFFLOVXKOILDEKIYCPPEASVLLASYAMAYlODYDPSVHKRGFLAOEELLPKRVlNLYQlTPEMlEERITA~AERRCRARDEAEIK Ech.mlt. tewnmt EEL.O..T...F.L~..I...KIYCP....VLLASYA..A~G.YDP ...... L....L .... ..Y..T.E.Y.ERI.A.Y..H....R..A ... Ham-o myth. 4.1 .L...I 1 ... ..LO....I......C......LL.sY..O...~YDP..”.........L.P ..... .EE ....... ..R......A ..E 201 300 llmmn Mowin YLKIAQ)LEIIYGVNYF.I.NKKG.EL.LGWALGL.lY....RLlPKI.F~.EIRNIS..DK.F.lK P.DKK...F.F....LR.NK.IL.lC.G Mouse Radixin YLKI~LEIIYGMIYF.I.NKKGlEL.LGWALGl.IY.....LTPKI.FW.EIRWIS..DK.F.IK P.DKK...F.F....LR.NK.IL.LC.G Htmn Ezrin YLKIAPOLEIIYG.NYF.I.NKKGT.L.L~ALGL.IY.....LTPKI.FPV.EIRNIS..DK.F.IK P.DKK...F.F....LR.NK.ILOLC.C Hmm Wcrlin YLKIAWLEIIYCWYFAIRNKKCTELLLG~AlGLnllDPENRlTPKlSF~ElRNISY~KEFTlK PLDKKIDVFKFNSSKLRVNKLlLPLCIG Ech.nult. tegumnt YL.IAWLEIIYGV..F.I.NKKGT.L.LGYO*LCL.lY.P.N.L.PKI.FW.EIRN.S..DK.F.IK P.DK....F.F...K...NK.IL.LC.G Hwn myth. 4.1 .L..A..L.WYCV.........G....LGV...GL..Y....R... FW.....ISY....F.lK..............F.....R..K.....C.. 301 400 “Ian” lloesin NH.L.WRRK.D..EMQIUMREEK..KPIIER..L..EK..RE.AE......ER.......RL.O..E....A...L......A..L..... Mouse Radixin NK.L.~RRRK.D..EMMRE....KO.ER..L..EK..RE.AE......ER.......RL.O..E....A...L......A..L....O Hmmn Ezrin NH.L.IRRRK.D..EMQI~OAREEK..KO.ERP.L..EK..RE..ER......R.......RL....E....A...L......A..L.E ... Illnan merlin NHDLF”RRRKADSLEVOWKAPREEKARKOMRORLAREKWREEAERTRDELER RLLWKEEATWNEALWSEETADLLAEKAO Echxult. te,m,ent NN.L.WRRRK.DS.EVOO”K.OA.EE...K..ERORL..E...R.E .E .. . .................... A.. ...... E...L L.. ... Hwn ervth. 4.1 .H ..F R....D........A ............ A...O......R.....ER.......R.L........A..........A......A ....... 401 500 Hunen Moesin .. ..EA..LA....EAE.........................E.................EA....O..O...E........L ...... llouc Radixin . ..EEA..L......AE.....I...A...............E.........E.......EA.........A.E.....K..L.........P . Wmmn Ezrin . ..EEA..L......A..........A...............E.........E...R...E.........EA.......K..L.........P . Wmmn Merlin ITEEEAKLLAO~EAEOE~RI~TAIRTEEEKRLIIEOYYLEAEVLAL~EESERRAKE~GLK~LOEAREAERRAK~L LEIATKPT Ech.mlt. tcgmmt .. ..L..............K.......EE.........E.................E ..O A....RR . ..I. Hmmn crvth. 4.1 ..................................... ..KR...............R.E.......E.........E .................... ..T 501 600 Wmn Roesin P .................... S.DL .... M.... .E.E.....EK....O..L..L..E ......... .TA.D..H.EN. R.G..K ..T Lowe Radixin .PP..P ................ S..L ......... .E.E.V....K......OL..L..E ......... .T..D.LH.EN. ..G..K ..T Hunan Errin .P...P...................S..L ......... .E.......EK....O.OL..L..E ......... .T..DI.HNEN. R.G..K ..T Humn Merlin YPP”NPIPAPLPPDIPSFNLIGDSLSFDFI(DTD MKRLWEIEKEKVEYIKKSKHLOEOLNELKTEIEAlKLKER ETALDILHNENSDRCGSSKHNT Ech.nult. tewmnt ......... ..S............K ......... ..E...V....K...LO..L..LK.E ........... ..D..H..N. R.G..K ..T Hunan cryth. 4.1 ..P...........................D...................E......E.....K..I.......R.......Dl.H .............. 6Gl 623 Humn Moesin . . . . . . . ..K.R...FE..* Mouse Rdixin . . . . . . . ..K.....FE..* llmm Ezrin . . . . . . . ..K.R...FE.L* Hum Merlin IKKLTLOSAKSRVAFFEEL. Ech.“ult. tepment . . . . . . . . . ..RV..FE..* H”w,n l ryth. 4.1 . . . . . ..K..V....E....* Figure 7. Comparison of Sequence Identities in Merlin-Related Proteins The program PILEUP of the GCG package (Devereux et al., 1964) was used to generate an optimal alignment of the protein products translated from the following GenSank files: human moesin (M69066); mouse radixin (S66620); human ezrin (X51521); E. multilocularis tegument protein (M61166); human erythrocyte protein 4.1 (M14993). Only amino acid identities are shown; nonidentical residues are indicated by dots, and gaps introduced by the program are represented by empty spaces. bers might also bind to proteins in the membrane (Let0 et al., 1988). Interestingly, a related domain is also found in two protein-tyrosine phosphatases, PTP-MEG and PTP- Hl, perhaps allowing these enzymes to associate with the membrane or the cytoskeleton (Gu et al., 1991; Yang and Tonks, 1991). Binding of protein 4.1 tospectrin is mediated by the a-helical region of the protein, suggesting that the analogous segments of the other family members might also bind to cytoskeletal components (Correas et al., 1988). Talin, a large protein found in regions of focal adhe- sions at cell-cell or cell-substrate contacts, appears to behave similarly, binding to the integrins in the cell mem- brane and to vinculin, thereby connecting the extracellular adhesion matrix to the cytoskeleton (Rees et al., 1990; Luna and Hitt, 1992). Moesin, ezrin, and radixin are highly related proteins (- 70%-75% amino acid identity) that have each been postulated to provide a link between the cytoskeleton and the cell membrane. Each of these proteins shares 450/o- 47% amino acid identity with merlin. Moesin, originally proposed as a receptor for heparan sulfate, has been found at or near the membrane in filopodia and other cell surface protrusions (Lankes and Furthmayr, 1991; Furth- mayr et al., 1992). Ezrin (cytovillin) has been seen in asso- ciation with microvilli and cellular protrusions in many cell types (Pakkanen, 1988; Gould et al., 1989; Turunen et al., 1989; Hanzel et al., 1991; Birgbauer et al., 1991). Rapid redistribution of ezrin to regions of membrane remodeling, such as microvillar formation and membrane ruffling in response to growth factor stimulation, may be regulated by phosphorylation of the protein on both tyrosine and serine residues(Bretscher, 1989; Krieg and Hunter, 1992). Radixin was isolated from the cell-cell adherens junction, where it is proposed to cap actin filaments and provide for Cdl 798 their attachment to thecell membrane(Tsukitaet al., 1989; Funayama et al., 1991). Interestingly, in mitotic cells, ra- dixin is concentrated at the cleavage furrow (Sato et al., 1991). Merlin possesses an N-terminal domain that is similar to protein 4.1 (28% identity) and to talin (21% identity), but is much more closely related to moesin, ezrin, and radixin (Figure 7). Amino acid identity between merlin and the three latter proteins is concentrated in the first 342 resi- dues (- 63% identity). Like these other family members, the merlin protein is predicted to have avery long a-helical domain spanning 160-170 amino acids, beginning around residue 300. The first third of this domain overlaps with the region of strongest homologyto moesin, ezrin, and radixin. The remaining stretch, however, shows limited similarity with these proteins and with a wide variety of myosins and tropomyosins. The C-terminal region of merlin contains a hydrophilic domain analogous to those of the other family members. The similarity in structure of merlin to the other members of this family suggests that it too may normally act as a link between the cytoskeleton and the cell mem- brane and may thus represent a new class of tumor sup- pressor gene. The cytoskeleton of mammalian cells is a complicated latticework of many different kinds of interconnected fila- ments (Luna and Hitt, 1992). It participates in a wide range of crucial cellular activities, including determining and al- tering shape, movement, cell division, cell-cell communi- cation, cell anchorage, and organization of the intracellu- lar milieu (Bernal and Stahel, 1985). A defect in a protein that connects some component of this network to the plasma membrane could affect any of these processes and have a consequent effect on growth control. Whether inactivation of the merlin protein disregulates growth by disrupting a signal transduction pathway, by altering an- chorage dependence, by upsetting the cell cycle regula- tion, or by some other mechanism remains to be deter- mined. However, the characteristic structure of the merlin protein suggests that a search for its membrane and cy- toskeletal binding targets might provide a logical route to exploring this question. Experimental Procedures NF2 Cell Lines Lymphoblast cell lines were established (Anderson and Gusella, 1964) from affected members of NF2 pedigrees and from their unaffected relatives. Diagnosis of NF2 conformed to the criteria set forward by the National Institutes of Health Consensus Development Conference on neurofibromatosis (Mulvihill et al., 1990), except for the patient whose meningioma displayed a 4 bp deletion. This patient had a right vestibu- larschwannomaand multiple meningiomas. Although shedid not have a history of NF2, she probably represents a new mutation. Primary meningioma cells were cultured as described (Logan et al., 1990) and analyzed after less than five passages. Somatic cell hybrids were prepared by fusing GUS5069 lympho- blasts with a Chinese hamster cell line deficient in hypoxanthine phos- phoribosyltransferase activity (CHTG49; Athwall and McBride, 1977) using GIBCO PEG 4000. Fused cell lines were selected by their ability to grow in media containing hypoxanthine. aminopterin, and thymi- dine. Hybrids were screened for the chromosome 22 homologs using the polymorphic simple sequence repeat marker, TOPIP (Trofatter et al., 1992). Control hybrids GM10886 and EyeSFAG (NA10027) are described in the listing of the National Institute of General Medical Sciences Human Genetic Mutant Cell Repository collection (Cornell Institute, Camden NJ). DNA/RNA Blotting DNA was prepared from cultured cells, and DNA blots were prepared and hybridizedas described(Gusellaet al., 1979; Gusellaet al., 1983). For pulsed-field gel analysis, agarose DNA plug preparation and elec- trophoresis were carried out as described (Bucan et al., 1990). RNA was prepared, and Northern blotting was performed as described by Buckler et al. (1991). Cosmld Walking The NEFH probe used for blot analysis and to initiate cosmid walking was pJL215, representing a 4.4 kb Kpnl-Xbal genomic fragment con- taining exon 4 and 3’ untranslated region (Lees et al., 1988). Cosmid walking was performed in an arrayed cosmid library prepared from DNA of flow-sorted human chromosome 22 (LL22NC03; Lawrence Livermore National Laboratory). Cosmid overlaps were identified ei- ther by hybridization of whole cosmid DNA or isolated fragments to filter replicas of the gridded arrays or by PCR screening of row and column DNA pools. STSs were developed by direct cosmid sequencing using the T3 or T7 end primers (McClatchey et al., 1992a). cDNA Isolation and Characterization Human frontal cortex and hippocampus cDNA libraries in ZAPII (Stra- tagene) were screened using exon probes isolated and prepared as describedbyBuckleretal.(1991).cDNAclonesand trappedexonwere sequenced as described (Sanger et al., 1977). Direct PCR sequencing was performed as described (McClatchey et al., 1992b). Screening for variations by SSCP analysis followed the procedure described by Ambrose et al. (1992). RNA was reverse transcribed using oligo(dT) primer (BRL reverse transcriptase) to prepare first strand cDNA. Por- tions of the cDNA were amplified using the following primer sets: 5’~CCAGCCAGCTCCCTATGGATG-3’ and Y-AGCTGAAATGGAAT- ATCTGAAG-3’ to amplify base pairs 824-2100 and 5’-GCClTCTCC- TCCCTGGCCTG-3’ and 5’-GATGGAG’ITCAATTGCGAGATG-3’ to amplify base pairs 314-1207. These cold PCR products were then reamplified with specific regional primers for SSCP as described in Figure 6. Acknowledgments The authors thank the members of the Massachusetts General Hospi- tal Neurosurgery Service, Dr. Michael C. Schneider (Genetics), Dr. Robert Levinthal (Neurosurgery), and Dr. Lauren Langford (Neuropa- thology) of the Baylor College of Medicine for tumor specimens, Dr. Pieter DeJong (Lawrence Livermore National Laboratory) for the LL22NC03 sorted chromosome 22 cosmid library, Dr. Guy Rouleau for NF2 blood samples, Dr. Nick Dracopoli and Dr. Vijaya Ramesh for tumor cell line RNA, and Dr. Greg Elder and Dr. Robert Lazzarini for the NEFH probe. We also thank Barbara Jenkins, Mary Anne Anderson, Jayalakshmi Srinidhi, Heidi Snyder, and Kenneth D’Arigo for technical support. This work was supported by National Institutes of Health (NIH) grants NS24279, HG00317, and HGO0872 and grants from Bristol- Myers Squibb, Inc., Neurofibromatosis Inc.-Mass Bay Area and the Milton M. Ratner Foundation. J. A. T. is supported by NIH NRSA HG00016. M. M. M. isafellowof the Howard Hughes Medical Institute. A. G. M. and N. K. received Junior Investigator awards from the Na- tional Neurofibromatosis Foundation. M. P. D. and C. M. A. received fellowships from the Huntington’s Disease Society of America and the Hereditary Disease Foundation, respectively. Received February 5, 1993. References Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990). Basic local alignment search tool. J. Mol. Biol. 217. 403-410. Ambrose, C., James, M., Barnes, G., Lin, C., Bates, G., Altherr, M., Duyao, M., Groat, N., Church, D., Wasmuth, J. J., Lehrach, H.. Hous- man, D.. Buckler, A., Gusella, J. F., and MacDonald, M. E. (1992). A novel G protein-coupled receptor kinase cloned from 4~16.3. Hum. Mol. Genet. 1. 697-703. ;;; Tumor Suppressor Gene Anderson, M. A., and Gusella, J. F. (1984). Use of cyclosporin A in establishing Epstein-Barr virus-transformed human lymphoblastoid cell lines. In Vitro 20, 858-858. Athwall, Ft. S., and McBride, 0. W. (1977). Serial transfer of a human gene to rodent cells by sequential chromosome-mediated gene trans- fer. Proc. Natl. Acad. Sci. USA 74, 2943-2947. Ballester, R., Marchuk, D., Boguski, M., Saulino, A., Letcher, R., Wigler, ht., and Collins, F. (1990). The NF7 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63, 851-859. Basu, T. N., Gutmann, D. H., Fletcher, J. A., Glover, T. W., Collins, F. S., and Downward, J. (1992). Aberrant regulation of fas proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356, 713-715. Bernal, S. D., and Stahel, Ft. A. (1985). Cytoskeleton-associated pro- teins: their role as cellular integrators in the neoplastic process. Crit. Rev. Oncol. Hematol. 3, 191-204. Bijlsma, E. K., Brouwer-Mladin. R., Bosch, D.A., Westerveld, A., and Hulsebos, T. J. (1992). Molecular characterization of chromosome 22 deletions in schwannomas. Genes Chromosom. Cancer 5201-205. Birgbauer, E., Dinsmore, J. H., Winckler, B., Lander, A. D., and Solo- mon, F. (1991). Association of ezrin isoforms with the neuronal cy toskeleton. J. Neurosci. Res. 30, 232-241. Bretscher, A. (1989). Rapid phosphorylation and reorganization of ez- rin and spectrin accompany morphological changes induced in A-431 cells by epidermal growth factor. J. Cell Biol. 108, 921-930. Bucan, M., Zimmer, M., Whaley, W. L., Poustka, A., Youngman, S., Allitto, B.A., Ormondroyd, E., Smith, B., Pohl, T. M., MacDonald, M., Bates, G., Richards, J.,Volinia, S., Gilliam, T.C., Sedlacek,Z., Collins, F. S., Wasmuth, J. J., Shaw, D. J., Gusella, J. F., Frischauf, A. M.. and Lehrach. H. (1990). Physical maps of 4~18.3, the area expected to contain the Huntington’s disease mutation. Genomics 6, 1-15. Buchberg, A. M., Cleveland, L. S., Jenkins, N. A., and Copeland, N. G. (1990). Sequence homology shared by neurofibromatosis type-l gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature 347, 291-294. Buckler, A. J., Chang, D. D., Graw, S. L., Brook, J. D.. Haber, D. A., Sharp, P. A., and Housman, D. E. (1991). Exon amplification: a strategy to isolate mammalian genes based on RNA splicing. Proc. Natl. Acad. Sci. USA 88,4005-4009. Cawthon, R. M., Weiss, R., Xu, G., Viskochil, D., Culver, M., Stevens, J., Roberston, M., Dunn, D., Gesteland, R., O’Connell. P., and White, R. (1990). A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62, 193-201. Conboy, J., Kan, Y. W., Shohet, S. B., and Mohandas, N. (1988). Molecular cloning of protein 4.1, a major structural element of the human erythrocyte membrane skeleton. Proc. Natl. Acad. Sci. USA 83, 95 12-95 16. Correas. I., Leto, T. L., Speicher, D. W., and Marchesi, V. T. (1988). Identification of the functional site of erythrocyte protein 4.1 involved in spectrin-actin associations. J. Biol. Chem. 261, 3310-3315. Couturier, J., Delattre, O., Kujas, M., Philippon, J., Peter, M., Rouleau, G., Aurias, A., and Thomas, G. (1990). Assessment of chromosome 22 anomalies in neurinomas by combined karyotype and RFLP analyses. Cancer Genet. Cytogenet. 45, 55-62. DeClue, J. E., Papageorge. A. G., Fletcher, J. A., Diehl, S. R., Ratner, N., Vass, W. C., and Lowy, D. R. (1992). Abnormal regulation of mam- malian ~21’~ contributes to malignant tumor growth in von Reckling- hausen (type 1) neurofibromatosis. Cell 69, 265-273. Delaunay, J., Alloisio, N., Merle, L., and Baklouti, F. (1991). The ge- netic disorders of the red cell skeleton. Nouv. Rev. Fr. Hematol. 33, 63-70. Devereux, J., Haeberli, P., and Smithies, 0. (1984). A comprehensive set of sequence analysis programs for the VAX. Nucl. Acids Res. 72, 387-395. Dryja, T. P., Rapaport, J. M., Joyce, J. M.. and Petersen, R. A. (1988). Molecular detection of deletions involving band q12 of chromosome 13 in retinoblastomas. Proc. Natl. Acad. Sci. USA 83, 7391-7394. Evans, D. G. R., Huson, S. M., Donnai. D., Neary, W., Blair, V., Teare. D., Newton, V., Strachan, T., Ramsden, R., and Harris, R. (1992). A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness and confirmation of maternal trans- mission effect on severity. J. Med. Genet. 29, 841-848. Fiedler, W., Claussen, U., Ludecke, H. J., Senger, G., Horsthemke, B., Geurts Van Kessel. A., Goertzen, W., and Fahsold, R. (1991). New markers for the neurofibromatosis-2 region generated by microdissec- tion of chromosome 22. Genomics 10, 788-791. Fontaine, B., Hanson, M. P., Vonsattel, J. P., Martuza, R. L., and Gusella, J. F. (1991a). Loss of chromosome 22 alleles in human spo- radic spinal schwannomas. Ann. Neurol. 29, 183-196. Fontaine, B., Sanson, M., Delattre, 0.. Menon, A., Rouleau, G. A., Seizinger, B. R., Jewell, A. F., Hanson, M. P., Aurias, A., Martuza, R. L., and Gusella, J. F. (1991b). Parental origin of chromosome 22 loss in sporadic and NF2 neuromas. Genomics 70, 280-283. Francke, U., Holmes, L. B., Atkins, L., and Riccardi, V. M. (1979). Aniridia-Wilms’ tumor association: evidence for specific deletion of 11~13. Cytogenet. Cell Genet. 24, 185-192. Frazer, K. A., Boehnke, M., Budarf, M. L., Wolff, R. K., Emanuel, B. S., Myers, R. M., and Cox, D. R. (1992). A radiation hybrid map of the region on human chromosome 22 containing the neurofibro- matosis type 2 locus. Genomics 74, 574-584. Frosch, P. M., Frosch, M., Pfister, T., Schaad, V., and Bitter-Suer- mann, D. (1991). Cloning and characterisation of an immunodominant major surface antigen of Echinoccccus mu/ti/ocu/aris. Mol. Biochem. Parasitol. 48, 121-l 30. Funayama, N., Nagafuchi, A., Sato, N., Tsukita, S., and Tsukita, S. (1991). Radixin is a novel member of the band 4.1 family. J. Cell Biol. 775, 1039-1048. Furthmayr, H., Lankes, W., and Amieva, M. (1992). Moesin, a new cytoskeletal protein and constituent of filopodia: its role in cellular functions. Kidney Int. 47, 865-670. Gould, K. L., Bretscher, A., Esch, F. S., and Hunter, T. (1989). cDNA cloning and sequencing of the protein-tyrosine kinase substrate, ezrin, reveals homology to band 4.1. EMBO J. 8, 4133-4142. Gu, M., York, J. D., Warshawsky, I., and Majerus, P. W. (1991). Identifi- cation, cloning, and expression of a cytosolic megakaryocyte protein- tyrosine-phosphatase with sequence homology to cytoskeletal protein 4.1. Proc. Natl. Acad. Sci. USA 88, 58675871. Gusella, J. F., Varsanyi-Breiner, A., Kao, F. T., Jones, C., Puck, T. T., Keys, C., Orkin, S., and Housman, D. E. (1979). Precise localization of the human 8-globin gene complex on chromosome 11. Proc. Natl. Acad. Sci. USA 76,5239-5243. Gusella, J. F., Wexler, N. S., Conneally, P. M., Naylor, S. L., Anderson, M. A., Tanzi, R. E., Watkins, P. C., Ottina, K., Wallace, M. R., Saka- guchi, A. Y., Young, A. B., Shoulson, I., Bonilla, E., and Martin, J. B. (1983). A polymorphic DNA marker genetically linked to Huntington’s disease. Nature 306, 234-238. Hanzel, D.. Reggio, H., Bretscher, A., Forte, J. G., and Mangeat, P. (1991). The secretion-stimulated 80K phosphoprotein of parietal cells is ezrin, and has properties of a membrane cytoskeletal linker in the induced apical microvilli. EMBO J. 10, 2363-2373. Kaiser-Kupfer, M. I., Freidlin. V., Datiles, M. B., Edwards, P. A., Sher- man, J. L., Parry, D., McCain, L. M., and Eldridge, R. (1989). The association of posterior capsular lens opacities with bilateral acoustic neuromas in patients with neurofibromatosis type 2. Arch. Ophthalmol. 107. 541-544. Knudson, A. G. (1971). Mutation and cancer: a statistical study. Proc. Natl. Acad. Sci. USA 68, 820-823. Krieg, J., and Hunter, T. (1992). Identification of the two major epider- mal growth factor-induced tyrosine phosphorylation sites in the micro- villar core protein ezrin. J. Biol. Chem. 267, 19258-19265. Lankes, W. T., and Furthmayr, H. (1991). Moesin: a member of the protein4.1-talin-ezrinfamilyof proteins. Proc. Natl. Acad. Sci. USA88, 8297-8301. Lees, J. F., Shneidman, P.S., Skuntz, S. F., Carden, M. J.. and Lazzar- ini. R. A. (1988). The structure and organization of the human heavy Cell 600 neurofilament subunit (NF-l-l) and the gene encoding it. EMBO J. 7, 1947-l 955. Leto, T. L., and Marchesi, V. T. (1984). A structural model of human erythrocyte protein 4.1. J. Biol. Chem. 259, 4603-4606. Leto, T. L., Correas, I., Tobe, T., Anderson, Ft. A., and Marchesi, V. T. (1966). Structure and function of human erythrocyte, cytoskeletal protein 4.1. In Membrane Skeletons and Cytoskeletal Membrane Asso- ciations, V. Bennett, C. M. Cohen, S. Lux, and J. Palek, eds. (New York: Alan R. Liss, Inc.), pp. 201-209. Logan, J. A., Seizinger. 8. R., Atkins, L., and Martuza, Ft. L. (1990). Loss of the Y chromosome meningiomas: a molecular genetic ap- proach. Cancer Genet. Cytogenet. 45, 41-47. Luna, E. J., and Hitt, A. L. (1992). Cytoskeleton-plasma membrane interactions. Science 258, 955-964. Martuza, R. L.. and Eldridge, R. (1988). Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N. Engl. J. Med. 378, 684-688. McClatchey, A. I., Lin. C. S., Wang, J., Hoffman, E. P., Rojas. C., and Gusella, J. F. (1992a). The genomic structure of the human skeletal muscle sodium channel gene. Hum. Mol. Genet. 7, 521-527. McClatchey, A. I., Van den Bergh. P., Pericak-Vance, M. A., Raskind, W., Verellen, C., McKenna-Yasek, D., Rao, K., Haines, J. L., Bird, T., Brown, R. H., Jr., and Gusella, J. F. (1992b). Temperature-sensitive mutations in the III-IV cytoplasmic loop region of the skeletal muscle sodium channel gene in paramyotonia congenita. Cell 68, 769-774. Mulvihill. J. J., Parry, D. M., Sherman, J. L., Pikus, A., Kaiser-Kupfer, M. I., and Eldridge, R. (1990). NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann. Intern. Med. 113, 39-52. Narod, S. A., Parry, D. M., Parboosingh, J., Lenoir, G. M., Ruttledge, M., Fischer, G., Eldridge, R.. Martuza, R. L., Frontali, M., Haines, J., Gusella, J. F.. and Rouleau, G. A. (1992). Neurofibromatosis type 2 appearsto beagenetically homogeneousdisease.Am. J. Hum. Genet. 57, 486-496. Pakkanen. R. (1988). lmmunofluorescent and immunochemical evi- dence for the expression of cytovillin in the microvilli of a wide range of cultured human cells. J. Cell. Biochem. 38, 65-75. Rees, D. J. G., Ades, S. L., Singer, S. J., and Hynes, R. 0. (1990). Sequence and domain structure of talin. Nature 347, 685-689. Riccardi, V. M. (1981). von Recklinghausen neurofibromatosis. N. Engl. J. Med. 305, 1617-1627. Riccardi, V. M., and Eichner, J. E. (1986). Neurofibromatosis: Pheno- type, Natural History, and Pathogenesis (Baltimore: Johns Hopkins University Press). Riccardi, V. M., Sujansky, R.. Smith, A. C., and Francke, U. (1978). Chromosomal imbalance in theaniridia-Wilms’tumor association: 1 lp interstitial deletion. Pediatrics 61, 604-610. Rouleau, G. A., Wertelecki, W., Haines, J. L., Hobbs, W. J., Trofatter, J. A., Seizinger, B. R., Martuza, R. L., Superneau, D. W., Conneally, P. M., and Gusella, J. F. (1987). Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 329, 246-248. Rouleau, G. A., Seizinger, B. R., Wertelecki, W., Haines, J. L., Su- perneau, D. W., Martuza, R. L., and Gusella, J. F. (1990). Flanking markers bracket the neurofibromatosis type 2 (NF2) gene on chromo- some 22. Am. J. Hum. Genet. 46, 323-328. Sanger, T., Nicklen, S., and Coulson, A. R. (1977). DNA sequencing with chain-termination inhibitors. Proc. Natl. Acad. Sci. USA 74,5463- 5467. Sato, N., Yonemura, S., Obinata,T.,Tsukita, S.. and Tsukita, S. (1991). Radixin, a barbed end-capping actin-modulating protein, is concen- trated at the cleavage furrow during cytokinesis. J. Cell Biol. 173,321- 330. Sato, N., Funayama, N., Nagafuchi. A., Yonemura, S., Tsukita, S., and Tsukita, S. (1992). A gene family consisting of ezrin, radixin and moesin. Its specific localization at actin filament/plasma membrane association sites. J. Cell Sci. 703, 131-143. Seizinger, 8. R., Martuza, R. L., and Gusella, J. F. (1986). Loss of genes on chromosome 22 in tumorigenesis of human acoustic neu- roma. Nature 322, 644-647. Seizinger, B. R., Rouleau, G. A., Ozelius, L. J., Lane, A. H., St. George- Hyslop, P.. Huson, S., Gusella, J. F., and Martuza, R. L. (1987a). Common pathogenetic mechanism for three tumor types in bilateral acoustic neurofibromatosis. Science 236, 317-319. Seizinger, B. R., de la Monte, S., Atkins, L., Gusella, J. F., and Martuza, R. L. (1987b). Molecular genetic approach to human meningioma: loss of genes on chromosome 22. Proc. Natl. Acad. Sci. USA 84, 5419- 5423. Tchernia, G., Mohandas, N., and Shohet, S. B. (1981). Deficiency of skeletal membrane protein band 4.1 in homozygous hereditary ellipto- cytosis. Implications for erythrocyte membranestability. J. Clin. Invest. 68, 454-460. Trofatter, J. A., Gusella, J. F., and Haines, J. L. (1992). Dinucleotide repeat polymorphism at the 7OPlPP locus. Hum. Mol. Genet. 7, 455. Tsukita, S., Hieda, Y., and Tsukita, S. (1989). A new 82-kd barbed end-capping protein (radixin) localized in the cell-to-cell adherens junc- tion: purification and characterization, J. Cell Biol. 708, 2369-2382. Turunen, O., Winqvist, R., Pakkanen, R., Grzeschik, K. H., Wahlstrom, T., and Vaheri, A. (1989). Cytovillin. a microvillar Mr 75,000 protein. cDNA sequence, prokaryotic expression, and chromosomal localiza- tion. J. Biol. Chem. 264, 16727-16732. Viskochil, D., Buchberg, A. M., Xu, G., Cawthon, R. M., Stevens, J., Wolff, R. K., Culver, M.. Carey, J. C.. Copeland, N. G., Jenkins, N. A., White, R., and O’Connell, P. (1990). Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus, Cell 62, 187-192. Wallace, M. R., Marchuk, D. A., Anderson, L. B.. Letcher, R., Odeh, H. M., Saulino, A. M., Fountain, J. W., Brereton, A., Nicholson, J., Mitchell, A. L., Brownstein. B. l-l., and Collins, F. S. (1990). Type 1 neurofibromatosis gene: identification of a larger transcript disrupted in three NFl patients. Science 249, 181-186. Waterston, R., Martin, C., Craxton, N., Huynh, C., Coulson, A., Hillier, L., Durbin. R. K., Green, P., Shownkeen, R., Halloran, N., Hawkins, T., Wilson, R.. Berks, M., Du, Z., Thomas, K.. Thierry-Mieg, J., and Sulston. J. (1992). A survey of expressed genes in Caenorhabditis elegans. Nature Genet. 7, 114-123. Wertelecki, W., Rouleau, G. A., Superneau, D. W.. Forehand, L. W., Williams, J. P., Haines. J. L., and Gusella, J. F. (1988). Neurofibro- matosis 2: clinical and DNA linkage studies of a large kindred. N. Engl. J. Med. 379, 276-283. Wolff, R. K., Frazer, K. A., Jackler, R. K., Lanser, M. J., Pitts, L. H., and Cox. D. R. (1992). Analysis of chromosome 22 deletions in neurofi- bromatosis type P-related tumors. Am. J. Hum. Genet. 57, 478-485. Xu, G.. O’Connell, P.. Viskochil. D., Cawthon, R., Robertson, M., Cul- ver, M., Dunn, D., Stevens J., Gesteland, R., White, R., and Weiss, R. (1990)Theneurofibromatosistype 1 geneencodesaprotein related to GAP. Cell 62, 599-608. Yang, Ct.. and Tonks, N. K. (1991). Isolation of a cDNA clone encoding a human protein-tyrosine phosphatase with homology to the cytoskele- tal-associated proteins band 4.1, ezrin, and talin. Proc. Natl. Acad. Sci. USA 88, 5949-5953. GenBank Accession Number The accession number for the sequence reported in this paper is Lll353. Note Added in Proof The 1 bp deletion detected in the NF2 meningioma is also present in lymphoblasts from this patient, indicating that it is a germline deletion. SpecialIssueSpectral-DomainOpticalCoherenceTomographyFindingsinNeuroﬁbromatosisType2VanessaWaisberg,1LuizOswaldoCarneiroRodrigues,2M´arcioBittarNehemy,1MariaFrasson,1andD´eboraMarquesdeMiranda31DepartmentofOphthalmology,ClinicalHospitalofFederalUniversityofMinasGerais,BeloHorizonte(MG),Brazil2DepartmentofClinicalMedicineandNeuroﬁbromatosisReferenceCenter,ClinicalHospitalofFederalUniversityofMinasGerais,BeloHorizonte(MG),Brazil3DepartmentofPediatricsandINCTMolecularMedicine,ClinicalHospitalofFederalUniversityofMinasGerais,BeloHorizonte(MG),BrazilCorrespondence:VanessaWaisberg,AvenidaBrasil,691/401,BeloHori-zonte,MG,30140-000,Brazil;vanessawaisberg@hotmail.com.Submitted:December14,2015Accepted:May14,2016Citation:WaisbergV,RodriguesLOC,NehemyMB,FrassonM,deMirandaDM.Spectral-domainopticalcoher-encetomographyﬁndingsinneuroﬁ-bromatosistype2.InvestOphthalmolVisSci.2016;57:OCT262–OCT267.DOI:10.1167/iovs.15-18919PURPOSE.Neuroﬁbromatosistype2(NF2)isanautosomal-dominantdisease,characterizedbybilateralvestibularschwannomas,multiplecentralnervoussystem(CNS)tumors,skintumors,andjuvenilecataract.Thepresentstudyassessedretinalabnormalitiesusingspectral-domainopticalcoherencetomography(SD-OCT)inacaseseriesofNF2patients.METHODS.NineNF2patientsfromtheneuroﬁbromatosisoutpatientreferencecenteroftheFederalUniversityofMinasGerais,inBrazil,weresubmittedtoacompleteanamnesisandadetailedophthalmicevaluation,includingSD-OCT,todetectretinallesions.RESULTS.OfthenineNF2patientsevaluated,ﬁvehadanearlyonset(<20years)ofNF2,andfourpatientshadalateonset(>20years)ofsymptoms.SD-OCTscansrevealedretinalabnormalitiesineverypatientwithearlyonset(EOS)andintwopatientswithlateonset(LOS)ofthedisease.IntheEOSgroup,SD-OCTscansrevealedﬂame-shapedepiretinalmembranes(ERM)withpeculiarcharacteristicsinfoureyesofthreepatients.TwopatientshadﬁneundulationsoftheinnerretinalsurfacewithasubtleERM.RetinalhamartomaswerepresentinfoureyesofthreepatientswithEOS;intwoeyes,theyweresubclinicalandweredetectedonlybySD-OCTscans.IntwopatientswithLOSandonepatientwithEOS,SD-OCTscansrevealedretinaltuftsofanerveﬁberlayer.CONCLUSIONS.SD-OCTrevealedERMinmostpatientswithNF2,thereforeitmaybeavaluableexamforevaluatingNF2patients.EpiretinalmembranesinNF2hasuniquefeatures,distinguishingitfromidiopathicERMormembranesassociatedwithotherdiseases.Wesuggestthatﬂame-shapedERMseemstobespeciﬁcforNF2andthatERMcanbeconsideredasanimportantdiagnosticsignofNF2.Keywords:neuroﬁbromatosistype2,opticalcoherencetomography,retina,vestibularschwannoma,epiretinalmembraneNeuroﬁbromatosiscomprisesatleastthreedistinctdisorderscausedbymutationsindifferentgenes1asfollows:neuroﬁbromatosis1(NF1)iscausedbymutationsthatinactivatetheneuroﬁbromingeneonchromosome17q2;neuroﬁbromatosis2(NF2)iscausedbyinactivatingmutationsofthemerlingeneonchromosome22q3,4;andSchwannoma-tosis,iscausedbygermlinemutationsintheSMARCB1(orINI1)gene.5Neuroﬁbromatosis2isanautosomal-dominantdisease,whichischaracterizedbybilateralvestibularschwannomas,multiplecentralnervoussystem(CNS)tumors,skintumors,andjuvenilecataract.6,7Itsestimatedincidenceliesbetween1in33,0008livebirthsand1in87,410livebirths.9Thefollowingtwoclinicalsubtypeshavebeenproposed:(1)theseveresubtype,orWishartsubtype,whichusuallypresentsanageonsetatapproximately20andareseentoenhanceCNStumorsformationsinadditiontobilateralvestibularschwan-noma,exhibitingrapidclinicalprogression,7,10,11and(2)themildsubtype,orGardnersubtype,whichoftenlackssymptomswithinthethirddecadeofthepatient’slife,andpresentswithfewtumorsotherthanvestibularschwannoma,whichhasarelativelybenignclinicalcourse.7,10,12AlthoughNF2isinheritedinanautosomal-dominantmanner,approximatelyhalfofthecasesinaffectedindividualsarecausedbysporadicmutation,andthereisahighrateofmosaicism.13,14Awell-deﬁnedspectrumofocularfeaturesisassociatedwithNF2.OcularabnormalitiesassociatedwithNF2areposteriorsubcapsular/capsularorcorticallenticularopacities,RPEhamartomas,retinalhamartomas,epiretinalmembranes(ERM),paralyticstrabismus,andopticnervesheathmeningi-omas.15–17Opticalcoherencetomography(OCT)isanoninvasivediagnostictechniquethatrendersaninvivocross-sectionalviewoftheretina.SD-OCTtechnologyusesinfraredlighttoproduceimagesoftheretinawithveryhighresolution(<7lm).Opticalcoherencetomographyandnear-infraredreﬂec-tance(NIR)havebeenshowntobevaluabletoolstoevaluateNF1patients.ChoroidalnodulesdetectedbyNIRandSD-OCThavehighspeciﬁcityasdiagnosticindicatorsofNF1.18,19iovs.arvojournals.orgjISSN:1552-5783OCT262ThisworkislicensedunderaCreativeCommonsAttribution-NonCommercial-NoDerivatives4.0InternationalLicense.Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935468/ on 06/25/2017EvaluationofperipapillaryRNFLthicknesshasbeenproposedasanoninvasivetestingmethodtodetectearlysignsofopticpathwaygliomasinchildrenwithNF1.20,21ThereislittleinformationaboutOCTinNF2,probablybecauseNF2ismuchrarerthanNF1.Thereshouldbemorestudiesontheprevalence,signiﬁcance,relevance,andimpactofophthalmo-logicﬁndingsonNF2.Epiretinalmembranesisasemitranslu-cent,avascular,ﬁbrocellularmembraneontheinnerretinalsurfacethatiscausedbyproliferatingchangesatthevitreoretinalinterface.Epiretinalmembranescanbeidiopathicorsecondarytoawidevarietyofintraocularconditions.IdiopathicERMismostcommoninpatientsovertheageofﬁfty.EpiretinalmembraneshavebeendescribedasanNF2ocularﬁndingsince1992,anditsincidencevariesamongauthorsfrom30%to80%.15,16,22–24Sisk25associatedERMwithaseverephenotypeofNF2.ThegoldstandardexamfordiagnosingandanalyzingERMisSD-OCT.Scheﬂer26describedOCTcharacteristicsofERMinthreepatientswithNF2.ThisdescriptionreportedanERMwithuniquefeatures,whichweredescribedasseveralcelllayersthickwithcurlededgesstretchingintothevitreoretinalinterface.ConsideringthatSD-OCTisanoninvasiveandeasilyperformedexam,thepresentstudyaimstoevaluateretinalabnormalitiesusingSD-OCTinagroupofNF2patientstocharacterizethefrequencyandrelevanceofERMforNF2.METHODSPatientsBetweenFebruary2014andJune2015,weevaluatedninepatientswithNF2.PatientswereclinicallyexaminedinaneuroﬁbromatosisoutpatientreferencecenteroftheFederalUniversityofMinasGerais,BeloHorizonte,Brazil.TheNF2diagnosiswasconﬁrmedbyneuroimaging.NoneofthenineNF2patientswereparentallyrelated.Nineage-andsex-matchingcontrolswithnohistoryofneurologicorophthal-mologicdisorderswereincluded.Eyeexaminationwasperformedin18NF2eyes,anditincludedmeasurementofthevisualacuityandbiomicroscopybeforeandafterpupillarydilatation,withspecialattentiontothepresenceofirishamartomasandlensopacities,dilatedfundusexamination,colorfundusphotography,infraredphotography,fundusautoﬂuorescence,andSD-OCT.SD-OCTwasaccomplishedin17NF2eyes;inoneeye,OCTscanswerenotperformed,duetoadensesubcapsularlensopacity.OpticalcoherencetomographyexaminationswereperformedbymeansofSpectralisHRAþOCT(HeidelbergEyeExplorerVersion1.9.10.0–AcquisitionSoftwareVersion:6.0.11.0;HeidelbergEngineering,Heidelberg,Germany).Acquisitionprotocolsincludedatleastonecross-hairscan,a208315819B-scansmacularcube,a208315819B-scansmacularcubewithenhanced-depthimaging(EDI)andmodewithadditionalhorizontalandverticalsinglelinesorcube,tocoveranylesiondetectedbyclinicalexaminationorfundusphotography.ThestudywasapprovedbytheethicscommitteeoftheClinicalHospitaloftheFederalUniversityofMinasGeraisandfollowedtheprinciplesoftheDeclarationofHelsinki.OCTImageAnalysisTwotrainedophthalmologistsindependentlyanalyzedtheimagesforqualitativeOCTvariables,andquantitativemea-surementsofanatomicalfeaturesandaseniormaskedinvestigatorprovidedarbitrationincasesofdisagreement.TheimageswereevaluatedforthepresenceofERM,typeofERM,presenceofvitreousmacularadhesion(VMA),fovealdeformation,retinalfoldsorundulations,internallimitingmembrane(ILM)disruption,ellipsoidzonedisruption(EZD),centralmacularthickness(CMT),andretinalnerveﬁberlayer(RNFL)thickness.Theinnercircleof1-mmradiusofEarlyTreatmentDiabeticRetinopathyStudymapwasdeﬁnedasCMT.RESULTSDemographicsDemographicdataareshowninTable1.TheoveralldelaybetweentheonsetofsymptomsanddiagnosisofNF2averaged6.7years.Oftheninepatients,ﬁvehadanearlyonset(EOS)ofNF2(<20years),andthedelaybetweentheﬁrstsymptomsanddiagnosisinthisgroupwasanaverageof7.8years(range,1–18years;Table1).Theinitialsymptomsoftheseﬁvepatientswereunspeciﬁcsymptoms,suchasconvulsion,strabismus,chestpain,inferiorlimbparesis,andcaf´eaulaitspots.Lateonset(LOS)ofNF2(>20years)wasobservedinfourofninepatients,andthedelaybetweentheﬁrstsymptomsanddiagnosisaveraged5.5years(range,0–14years).Theinitialsymptomsofthesefourpatientswerealsounspeciﬁc,includinginferiorlimbsparesis,facialpalsy,facialpain,andcervicalpain.SpeciﬁcNF2OcularFindingsNeuroﬁbromatosis2-speciﬁcocularﬁndingswereobservedineightofninepatients,allﬁvepatientsintheEOSgroup,andthreeintheLOSgroup.Cataractswerenotedinﬁveofninepatients(3withEOSand2withLOS).Cataractswerevisuallyimpactingfoureyesofthreepatients.OnepatientintheEOSgrouphadchronic-appearingretinaldetachmentandretinalhamartomaintherighteye.EpiretinalmembraneswerenotedinallﬁvepatientsintheEOSgroup;threepatientshadthickERMwithpeculiarcharacteristicsonSD-OCTscans,andtwopatientshadsubtleERMwithﬁneundulationsontheinnerretinalsurface.RetinalhamartomaswerenotedinfoureyesofthreepatientsintheEOSgroup.Inbotheyesofpatientsevenretinalhamartomasweresubclinical,detectedonlybySD-OCT.Allpatientswithepiretinalmembraneandretinalhamartomawereintheearlyonsetgroup.TwopatientswithLOShadsubtleretinalabnormalitiesthatweredetectedexclusivelybySD-OCT;theseabnormalitiesweresmallelevationsofRNFLthatwerecompatiblewithRNFLtufts.StrabismuswasnotedintwopatientsintheEOSgroup.PatientswithanearlyonsethadmoreNF2-speciﬁcocularﬁndings(Table2).TABLE1.PatientDemographicsPatientN8SexSymptomDuration,yAgeatLastVisit,yDelayinDiagnosis,y1M35002F33303*M202884*M1719155*M81436F1237127*F163218*F62419F214814*Patientswithearlyonset.SD-OCTFindingsinNeurofibromatosisType2IOVSjSpecialIssuejVol.57jNo.9jOCT263Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935468/ on 06/25/2017OtherOphthalmologicFindingsNonspeciﬁcophthalmologicﬁndingsweredetectedinfourpatients.Exposurekeratopathywasfoundinthreepatients(2withEOSand1withLOS),carunculanevusinonepatientintheLOSgroup,opticdiscedemainthreeeyesoftwopatientsintheEOSgroup,andopticnerveatrophyinoneeyeofapatientintheEOSgroup.OpticalCoherenceTomographyQuantitativeAnalysis.Themeancentralmacularthick-ness(CMT)was269635lmincontroleyesand311683lminallNF2eyes.IntheEOSeyes,CMTwas3526101lm;intheLOSeyes,CMTwas268617lm.Thetotalmacularvolume(TMV)was8.79þ 0.18mm3incontroleyesand8.66þ 0.78mm3inallNF2eyes.IntheEOSeyes,theTMVwas8.68þ 1.12mm3;intheLOSeyes,theTMVwas8.64þ 0.24mm3.TheSDshowsgreatvariabilityinthethicknessandvolumemeasurementsintheEOSeyes(Table3).ThemeanperipapillaryRNFLthicknessinEOSpatientswas153þ 104lminthesuperiorsector,97þ 77lminthenasalsector,170þ 125lmintheinferiorsectorand64þ 18lminthetemporalsector.InLOSpatientsthemeanperipapillaryRNFLthicknesswas144þ 14lminthesuperiorsector,70þ 13lminthenasalsector,139þ 12lmintheinferiorsectorand75þ 8lminthetemporalsector.ThegreatvariabilityinperipapillarythicknessobservedinEOSgroupwasrelatedtoopticnerveatrophyinoneeyeandopticdiscedemaintreeeyes.QualitativeAnalysis.SD-OCTscansrevealedretinalabnormalitiesinallpatientswithEOSandintwopatientswithLOS.AthickanddenseERMatthemacula,withaﬂame-shapedappearanceextendingintothevitreous,wasobservedinfoureyesofthreepatientswithEOS(Fig.1).Inthreeeyeswithaﬂame-shapedERM,therewaslossoffovealcontour.TheseERMswerenotvisuallysigniﬁcant,despitethemarkedretinalthickeningandfovealdeformation.UndulationsoftheinnerretinalsurfacewithasubtleERMwereobservedinthreeeyesoftwopatientswithEOS(Fig.2).IntwoeyesoftwopatientswithLOSandoneeyeofapatientwithEOS,SD-OCTscansrevealedsmallfocalelevationsattheretinasurface(Fig.3).ChoroidalabnormalitiesweredetectedintwoeyesoftwopatientswithEOS.Oneeyepresentedwithapalcoidchoroidalnoduleandtheothereyepresentedwithalocalizedreductioninchoroidalthicknessattheperifovealregion.Qualitativeabnormalitieswerenotobservedincontrolsubjects.TheSD-OCToffourretinalhamartomasinfoureyesrevealedtumorswithdifferentaspects.Inbotheyesofapatient,tumorshadahighlyinternallyreﬂectiveandtranslu-centmasswithcleardelineationoftheexternalretinallayersandRPE.TheseendophytictumorsseemtobeconﬁnedtotheRNFLandganglioncelllayer(Figs.4A,4B).TwohamartomasinanothertwopatientswereassociatedwithERMontheirsurfaceanddisplayedretinaldisorganizationofmultiplelayerswithdisruptionoftheellipsoidzone(Figs.4C,4D).Atthemacula,theellipsoidzonewaspreservedinalleyes,theVMAwaspresentinalleyes,andnoeyespresentedcystoidmacularedema(Table3).Itisinterestingtonotethatmostoftheﬁndingswerepresentinonlyoneeyefromeachpatient;withtheexceptionsofpatients7and8.TheﬁrstofthesepatientspresentedbilateralsubclinicalretinalhamartomasandsubtleERMwithundulationsoftheinnerretinalsurfaceandtheTABLE2.IncidenceofOcularSpeciﬁcFindingsinPatientsWithNeuroﬁbromatosisType2OcularFindingAll9PatientsEarlyOnset(n¼5)LateOnset(n¼4)EyesPatients%ofn¼9EyesPatients%ofn¼5EyesPatients%ofn¼4Cataract8555.563602250ERM7555.575100000Hamartoma4333.34360000Strabismus2222.22240000TABLE3.Spectral-DomainOpticalCoherenceTomography:FeaturesinNeuroﬁbromatosisType2EyesPatientsCMTTMVFlame-ShapedERMSubtleERMRNFLElevationRetinalHamartomaEZDVMA1-OD253lm8.57mm3     þ1-OS251lm8.75mm3  þ  þ2-OD261lm8.32mm3  þ  þ2-OS249lm8.33mm3     þ3-ODRDRDRDRDRDþRDRD3-OS267lm7.97mm3 þ   þ4-ODCATCATCATCATCATCATCATCAT4-OS555lm9.79mm3þ    þ5-OD443lm9.59mm3þ þ  þ5-OS332lm9.19mm3     þ6-OD286lm8.91mm3     þ6-OS284lm8.95mm3     þ7-OD283lm6.35mm3 þ þ þ7-OS320lm8.75mm3 þ þ þ8-OD364lm9.44mm3þ    þ8-OS257lm8.41mm3þ  þþþ9-OD291lm8.77mm3     þ9-OS275lm8.53mm3     þVMA,vitreomacularadhesion;CME,cystoidmaculaedema;RD,retinaldetachment;CAT,cataract.SD-OCTFindingsinNeurofibromatosisType2IOVSjSpecialIssuejVol.57jNo.9jOCT264Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935468/ on 06/25/2017secondpatientwasobservedtohavebilateralﬂame-shapedERM.DISCUSSIONNeuroﬁbromatosis2isararediseasewithalifelongpotentialforunpredictabletumorgrowth.Earlydiagnosisandcompre-hensivefollow-uparechallenging.MostoftheophthalmicﬁndingsinNF2areprobablycongenital,buttheymaybecomesymptomaticovertime.15,27OcularNF2-speciﬁcﬁndingsusuallyappearbeforeneurologicalsymptomsandhearingloss;therefore,theyareextremelyusefulinearlydiagnosis,allowingforbetterplanningoftherapyinyoungpatientswithNF2.27–29SD-OCTscansrevealedretinalabnormalitiesinsevenofninepatientswithNF2.AllpatientswithretinalabnormalitiesonSD-OCThadbilateralvestibularschwannomas.Itispossiblethatthetwopatientswithunilateralvestibularschwannomaandwithoutretinaabnormalitiesweremosaics,whichoccursinapproximately25%ofNF2patients.13,14IncreaseinCMTfoundinEOSgroupwasprobablyduetotractioneffectsoftheERMinthreepatients.OnepatientwithEOSpresentedaperifovealhamartomathatcausedfovealdeformationandincreasedinCMTinbotheyes.Commonfeaturesamongourpatientsincludedﬂame-shapedERM,retinalundulationswithasubtleERM,focalelevationsofRNFL,andretinalhamartomas.Twoofourpatient’slesionsweresubclinicalretinalhamarto-masthatwereonlydetectedbySD-OCTscans.Theﬂame-shapedappearanceonOCTscansofERMinfoureyesofthreepatientswithanearlyonsetofNF2weresufﬁcientlydistinct,allowingtheestablishmentofapattern.Scheﬂeretal.26describedtheOCTcharacteristicsofapeculiarERMinthreeNF2patientswithaseverephenotype.Inoneofthecasesdescribed,theuniqueOCTﬁndingswerethesolereasonsthediagnosisofNF2wasestablished.McLaughlinetal.30describedocularhistopathologicﬁnd-ingsina32-year-oldwomanwhodiedfromNF2complications.TheyfoundathinERMintherighteyeconsistingofspindledandcuboidalcells,consistentwithaglialorigin.Inthelefteye,theyfoundathickERMconsistingofcordsthatarepredominantlycuboidalcells,whichareconsistentwithM¨ullercellsandanastrocyteorigin.Hanetal.31describedthehistologicfeaturesofanERMthatwassurgicallyremovedina2-year-oldchild.TheyfoundahighlycellularmembranewithuptofourlayersofcellsofindeterminateoriginandspeculatedFIGURE1.(A)SD-OCToftherighteyeofpatient8showinganERMwithﬂame-shapedappearanceextendingtothevitreous.ThereismilddisorganizationoftheinternalretinallayersandvitreouspartialdetachmentwithVMA.(B)SD-OCTofthelefteyeshowingaﬂame-shapedERMwithpreservationoftheretinalcontourandmicroarchitecture.(C)SD-OCTofthelefteyeofcase4showingaseveral-layerERMextendingintothevitreousandevidentretinalthickeningwithpreservationoftheellipsoidzone.(D)SD-OCTdemonstratingathickERMwithaﬂameshapeappearanceextendingintothevitreous,whichissimilartocase4.Therearefoldsontheretinasurfaceandmarkedretinalthickening.Theellipsoidzoneispreserved.FIGURE2.(A)SD-OCTofthelefteyeofpatient3showingﬁneundulationsontheretinalsurface,withpreservationoftheretinalmicroarchitectureandwithasubtleERM.(B)SD-OCTofthelefteyeofpatient7showingspeculatedundulationsoftheretinasurfacewithoutanevidentERM.Theellipsoidzoneispreserved.(C)SD-OCToftherighteyeofpatient7showingﬁneundulationsoftheretinalsurface,similartopatient3.SD-OCTFindingsinNeurofibromatosisType2IOVSjSpecialIssuejVol.57jNo.9jOCT265Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935468/ on 06/25/2017thattheNF2ERMishamartomatousinorigin.Chanetal.32describedthehistopathologicandimmunohistochemistryﬁndingsofsevenNF2eyes,andtheyfoundERMandretinalhamartomasinalleyes.TheyalsofoundretinaltuftsarisingfromRNFLinfoureyesofthreepatients.Someofourpatient’simagesshowremarkablesimilaritytotheRNFLtuftsfoundinhistopathologicsectionsofNF2eyesthatwerepreviouslydescribedbyChan.Tothebestofourknowledge,thisistheﬁrstdescriptionofSD-OCTfeaturesofsuchlesions.EpiretinalmembranesassociatedwithNF2maybedirectlyrelatedtodysplasicM¨ullercells.M¨ullercellsarethepredominantglialelementoftheretina.TheyprovidethemechanicalsupporttotheretinaandproducethebasementmembranematerialthatformstheILM.ExperimentalmodelsofculturedsensoryretinasuggestthatM¨ullercellsmightcontributetothedevelopmentofacellularmembraneincaseofILMdisruption.33Owingtotheabnormaladherensjunctions,M¨ullercellsthathavelosttheirwild-typeNF2allelemaynotbeabletoelongateandestablishradialpolarity,leadingtoepiretinalaccumulation.31M¨ullercells,liketheothermaincelltypesaffectedinNF2,areglialcellswithepithelialfeatures,suggestingthatthissubsetofglialcellsisparticularlysensitivetoNF2loss.Neuroﬁbromatosis2hamartomasresultfrommutationsinthecytoskeletalproteinencodedinthelongarmofchromosome22,whichfunctionsasatumorsuppressor.34IthasbeensuggestedthatNF2-ERMandretinalhamartomasrepresentdifferentaspectsofthesamepatholog-icalprocess.32ItispossiblethattheretinaltuftsandundulationsoftheretinalsurfacefoundinsomeofourpatientsarealsorelatedtodysplasicM¨ullercells.Inconclusion,ourstudyshowedthatSD-OCTdepictedretinaandvitreousalterationsinmostpatientswithNF2,anditisavaluabletoolforevaluatingthesepatients.EpiretinalmembranesandsubclinicalhamartomasthatareevidentonSD-OCTcanbedifﬁculttoidentifywiththefundusexam.EpiretinalmembraneinNF2hasuniquefeaturesthatdistinguishitfromidiopathicERMormembranesassociatedwithotherdiseases.Therefore,thedetectionofthispeculiarERMinayoungpatientisverysuggestiveofNF2.TheNF2diagnosticcriteriamaybeabsentattheinitialclinicalpresentationinchildren,anditisprobablythemainreasonforthedelayeddiagnosisintheNF2EOSgroup.Althoughthispaperreportsasmallnumberofpatientsﬂame-shapedERMappearstobespeciﬁcforNF2,anditsinclusionintheclassicaldiagnosticcriteriacouldbeveryuseful.FIGURE3.(A)SD-OCTofcase2showingdisruptionofILMwithafocalelevationofRNFLandpreservationofretinalmicroarchitecture.(B)SD-OCTofcase1showingsmallfocalelevationsatthelefteyefovea.Thefovealcontourandellipsoidzonearepreserved.(C)SD-OCTofcase5showingasmallfocalelevationofRNFLsimilartocases2and1.FIGURE4.(A)SD-OCTofthelefteyeofpatient7,showingaretinalhamartomainvolvingtheRNFLandganglionlayer.Externallayersandellipsoidzonearepreserved.(B)SD-OCToftherighteyeofpatient7showingaretinalhamartomathatissimilartotheoneinthefelloweye.(C)SD-OCTofaretinalhamartomawithanERMassociatedwithadetachedretinaofpatient3.(D)SD-OCTofthelefteyeofpatient8,showingaretinalhamartomawithdisorganizationoftheinternalandexternalretinallayers,whichisassociatedwithERManddisruptionoftheellipsoidzone.SD-OCTFindingsinNeurofibromatosisType2IOVSjSpecialIssuejVol.57jNo.9jOCT266Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935468/ on 06/25/2017AcknowledgmentsSupportedbyFederalUniversityofMinasGerais–Brazil(BeloHorizonte,MG,Brazil)andINCTdeMedicinaMolecular,CNPq/FAPEMIG/CAPES(BeloHorizonte,MG,Brazil).Disclosure:V.Waisberg,None;L.O.C.Rodrigues,None;M.B.Nehemy,None;M.Frasson,None;D.M.deMiranda,NoneReferences1.NIHconferencestatement.Neuroﬁbromatosis1(vonReck-linghausendisease)andneuroﬁbromatosis2(bilateralacousticneuroﬁbromatosis).AnnInternMed.1990;113:39–52.2.SeizingerBR,RouleauGA,OzeliusLJ,etal.GeneticlinkageofvonRecklinghausenneuroﬁbromatosistothenervegrowthfactorreceptorgene.Cell.1987;49:589–594.3.RoleauG,SeizingerBR,OzeliusLG,etal.GeneticlinkageanalysisofbilateralacousticneuroﬁbromatosistoaDNAmarkeronchromosome22.Nature.1987;329:246–248.4.CooperJ,GiancottiFG.MolecularinsightsintoNF2/Merlintumorsuppressorfunction.FEBSLett.2014;16:2743–2752.5.RodriguesLO,BatistaPB,Goloni-BertolloEM,etal.Neuroﬁ-bromatosispart1–diagnosisanddifferentialdiagnosis.ArqNeuropsiquiatr.2014;72:241–250.6.EvansDGR.Neuriﬁbromatosistype2(NF2):aclinicalandmolecularreview.OrphanetJRareDis.2009;4:16.7.EvansDG,HusonSM,DonnaiD,etal.Aclinicalstudyoftype2neuroﬁbromatosis.QJMed.1992;84:603–618.8.EvansDG,HowardE,GiblinC,etal.Birthincidenceandprevalenceoftumor-pronesyndromes:estimatesfromaUKfamilygeneticregisterservice.AmJMedGenet.2010;152A:327–332.9.AntinheimoJ,SankilaR,Carp´enO,PukkalaE,SainioM,J¨a¨askel¨ainenJ.Population-basedanalysisofsporadicandtype2neuroﬁbromatosis-associatedmeningiomasandschwanno-mas.Neurology.2000;54:71–76.10.ParryDM,EldridgeR,Kaiser-KupferMI,etal.Neuroﬁbroma-tosis2(NF):clinicalcharacteristicsof63affectedindividualandclinicalevidenceforheterogeneity.AmJMedGenet.1994;52:450–461.11.EldridgeR,ParryDM,Kaiser-KupferMI.Neuroﬁbromatosis2:clinicalheterogeneityandnaturalhistoryin39individualin9familiesand16sporadiccases.AmJHumGenetSuppl.1991;49:A676.12.GardnerWJ,FrazierCH.Bilateralacousticneuroﬁbromatosis:aclinicalstudyandﬁeldsurveyofafamilyofﬁvegenerationswithbilateraldeafnessinthirty-eightmembers.ArchNeurolPsychiatry.1930;23:266–302.13.KluweL,MautnerV,HeinrichB,etal.Molecularstudyoffrequencyofmosaicisminneuroﬁbromatosis2patientswithbilateralvestibularschwannomas.JMedGenet.2003;40:109–114.14.KluweL,MautnerVF.Mosaicisminsporadicneuroﬁbromato-sis2patients.HumMolGenet.1998;7:2051–2055.15.KayeLD,RothnerAD,BeauchampGR,MeyersSM,EstesML.OcularﬁndingsassociatedwithneuroﬁbromatosistypeII.Ophthalmology.1992;99:1424–1429.16.BoschMM,BoltshauserE,HarpesP,LandauK.Ophthalmo-logicﬁndingsandalong-termcourseinpatientswithneuroﬁbromatosistype2.AmJOphthalmol.2006;141:1068–1077.17.FeuchtM,GrifﬁthsB,Niem¨ullerI,HaaseW,RichardG,MautnerVF.Neuroﬁbroamtosis2leadstohigherincidenceofstrabismologicalandneuro-ophthalmologicaldisorders.ActaOphthalmol.2008;86:882–886.18.ViolaF,VillaniE,NatacciF,etal.Choroidalabnormalitiesdetectedbynear-infraredreﬂectanceimagingasanewdiagnosticcriterionforneuroﬁbromatosis1.Ophthalmology.2012;119:369–375.19.AbdolrahimzadehS,FelliL,PlaterotiR,etal.Morphologicandvasculaturefeaturesofthechoroidandassociatedchoroid-retinalthicknessalterationsinneuroﬁbromatosistype1.BrJOphthalmol.2015;99:789–793.20.ChangL,EI-DairiMA,FrempongTA,etal.Opticalcoherencetomographyintheevaluationofneuroﬁbromatosistype1subjectswithopticpathwaygliomas.JAAPOS.2010;14:511–517.21.Topcu-YilmazP,KasimB,KiratliH.Investigationofretinalnerveﬁberlayerthicknessinpatientswithneuroﬁbromatosis1.JpnJOphthalmol.2014;88:172–176.22.LandauK,YasargilGM.Ocularfundusinneuroﬁbromatosistype2.BrJOphthalmol.1993;77:646–649.23.MeyersSM,GutmanFA,KayeLD,RothnerAD.Retinalchangesassociatedwithneuroﬁbromatosis2.TransAmOphthalmolSoc.1995;93:245–257.24.FeuchtM,KluweL,MautnerVF,RichardG.Correlationofnonsenseandframeshiftmutationswithseverityofretinalabnormalitiesinneuroﬁbromatosis2.ArchOphthalmol.2008;126:1376–1380.25.SiskRA,BerrocalAM,ScheﬂerAC,DubovySR,BauerMS.Epirretinalmembranesindicateaseverephenotypeofneuroﬁbromatosistype2.Retina.2010;30:51–58.26.ScheﬂerAC,DubovySR,BerrocalAM.Opticalcoherencetomographycharacteristicsofepiretinalmembranesinneuro-ﬁbromatosisi2.OphthalmicSurgLasersImaging.2008;39:73–77.27.ParryDM,MacCollinMM,Kaiser-KupferMI,etal.Germ-linemutationsintheneuroﬁbromatosis2gene:correlationswithdiseaseseverityandretinalabnormalities.AmJHumGenet.1996;59:529–539.28.EvansDGR,BirchJM,RamsdenRT.Paediatricpresentationoftype2neuroﬁbromatosis.ArchDisChild.1999;81:496–499.29.ParryA,GianniniC,RaghavanR,etal.AggressivephenotypicandgenotypicfeaturesinpediatricandNF2-associatedmeningiomas:aclinicopathologicstudyof53cases.JNeuro-patholExpNeurol.2001;60:994–1003.30.McLaughlinME,PepinSM,MacCollinMM,ChoopongP,LessellS.Ocularpathologicﬁndingsofneuroﬁbromatosistype2.ArchOphthalmol.2007;125:389–394.31.HanDP,ChinM,SimonsKB,AlbertDM.Surgicalremovalofanatypicalmacularepiretinalmembraneinneuroﬁbromatosistype2:clinicopathologiccorrelationandvisualoutcome.ArchOphthalmol.2012;130:1337–1339.32.ChanC,KochCA,Kaiser-KupferMI,etal.Lossofheterozy-gosityfortheNFgeneinretinalandopticnervelesionsofpatientswithneuroﬁbromatosis2.JPathol.2002;198:14–20.33.SongBJ,KoMK,ChoeJK.UltrastructuralchangeoftheM¨ullercellinthecultureofsensoryretina.KoreanJOphthalmol.1995;9:84–88.34.SchachatAP,ShieldsJA,FineSL,etal.Combinedhamartomasoftheretinaandretinalpigmentepithelium.Ophthalmology.1984;91:1609–1615.SD-OCTFindingsinNeurofibromatosisType2IOVSjSpecialIssuejVol.57jNo.9jOCT267Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935468/ on 06/25/2017Vol. 269, No. 38, Issue of September 23, pp. 23387-23390,  1994 THE JOURNAL OF BIOUK~ICAL CHEMISTRY 0 1994 by The  American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A. An Anti-Ras  Function of Neurofibromatosis  Type 2 Gene Product  (NF2/Merlin)* (Received  for publication, May 25, 1994, and  in revised form, July 13, 1994) Anjali TikooS, Mikael  VargaS, Viaya  Rameshl, James  Gusellal,  and  Hiroshi  Marutatll From the $Ludwig Institute for Cancer Research,  Royal Melbourne Hospital, Victoria 3050, Australia, and the §Molecular  Neurogenetics  Unit,  Neuroscience  Center, Massachusetts General Hospital East, Charlestown, Massachusetts 02129-9142 Previously,  we  have  cloned a  candidate  for  the  595- amino  acid  neurofibromatosis  type 2 tumor  suppressor called NF2  or  Merlin, with  striking  sequence  similarity in its N-terminal  half  to  an  F-actin-binding  protein  fam- ily  called TERM, which  includes  galin,  ezrin,  radixin, and  moesin  (Trofatter, J. A, MacCollin, M. M., Rutter, J. L., Murrell, J. R., Duyao, M. P.,  Parry, D. M.,  Eldridge, R., Kley,  N.,  Menon, A. G., Pulaski, K., Haase, V. H., Ambrose, C. M.,  Munro, D., Bove, C., Haines, J. L., Martuza, R. L., MacDonald, M. E.,  Seizinger, B. R.,  Short, M. P.,  Buckler, A. J., and  Gusella, J. F. (1993) Cell 72,  7914300). In an attempt  to  determine  whether NF2 serves as a tumor suppressor  and  if so whether its N-terminal  half  is in- volved in its anti-oncogenicity,  both  full-length NF2  and its N-terminal half (NFg-N,  residues  9-359)  have  been expressed  in  v-Ha-Ras-transformed  NIH/3T3 cells. Like neurofibromatosis  type 1 (NF1)  fragments  (Nur-E- Kamal, M. S. A, Varga, M., and  Maruta, H. (1993) J. Biol. Chem. 268,22331-223371, full-length NF2  can reverse  the Ras-induced  malignant  phenotype, Le. anchorage-inde- pendent  growth in a soft agar,  and  restore  contact  inhi- bition of cell growth,  indicating  that NF2 is indeed  a tumor  suppressor.  Furthermore,  NF2-N  also  suppresses the  Ras-induced  malignant  phenotype,  although  it  ap- pears  to  be less effective  than  the  full-length NF2.  These observations  indicate  that  the  anti-Ras  function of NF2 resides  in  part in its N-terminal half. Thus,  NF2  appears to be a new  member of the  tumor  suppressor  family of actin-cytoskeleton-associated  proteins,  which  includes vinculin,  a-actinin,  tropomyosin-1,  gelsolin,  and  tensin. Oncogenic mutants of Ha-Ras, Ki-Ras, or N-Ras are found in around 30%  of total  human carcinomas, notably in 50% and 90% of colon and  pancreatic carcinomas,  respectively (1). On- cogenic mutants of Ras  are locked in  the  active GTP-bound form (2). Their  intrinsic  GTPase  activity is low and no  longer stimulated by GTPase-activating  proteins (GAPS)’ such as and Medical  Research  Council ofAustralia  and the Anti-Cancer  Council * This  work  was  supported in part by grants from the National  Health of Victoria (to H. M.) and  National Institutes of Health  Grant NS24279 (to V. R. and J. G.). The  costs of publication of this article were  defrayed in part by the payment of page  charges.  This  article  must  therefore be hereby  marked  “advertisement”  in  accordance  with  18  U.S.C.  Section 1734  solely to indicate this fact. %I.: 613-347-3155. 1 To  whom  correspondence  should be addressed. Fax: 613-347-1938; ’ The abbreviations used are: GAP, GTPase-activating  protein; PCR, GAP1, which is 1044  amino acids, and NF1,  which is 2818 amino  acids  (3, 4). We have shown  previously that neurofibromatosis type 1 (NF1) fragments of 338 and 91 amino  acids  (NF338  and  NF91) can  reverse  the  malignant phenotype, i.e. anchorage-independ- ent  growth  in a soft agar, caused by Ras mutants  such  as v-Ha-Ras (5). This was  the  first  demonstration that a target of the  tumor  suppressor  NF1 is the Ras-GTP complex as  these NF1  fragments  bind  the Ras-GTP complex directly (5). Dys- function or deletion of NF1 develops schwannomas  and  other tumors  (neurofibromatosis 1) in  central  nervous  system of hu- man (6). We and  another  group recently cloned a candidate for the neurofibromatosis  2 tumor  suppressor  gene located on hu- man chromosome 22q12 (7, 8). This  gene encodes  a protein of 595 amino  acids called NF2 or Merlin (7,8). Point  mutations or truncation of NF2  have  also  been found to be closely associated with development of schwannomas  and  other  central  nervous system  tumors  including  multiple  meningiomas (7-11). Inter- estingly, NF2  shares  around 50% sequence identity  in its N- terminal  half  (residues 1-358) with  the corresponding domains of several  members of an F-actin-binding  protein family  called TERM, which includes  talin,  gzrin, _radixin, and  goesin  (7, 8). Very recently, at least four distinct actin-cytoskeleton-asso- ciated  proteins  were  shown  to  act as tumor  suppressors (12- 15); overexpression of vinculin and  a-actinin  can  reverse SV40-induced malignant  transformation (12, 131, whereas tro- pomyosin-1 and gelsolin can  reverse  malignant  transformation caused by Ras  mutants  such as v-Ha-Ras and v-Ki-Ras (14,151. Interestingly, expression of the  genes encoding these four actin- binding  proteins is strongly  suppressed  when  normal cells are transformed by SV-40 virus or Ras oncogenes (14). It  is now clear that constitutive expression of these  genes  in SV40- or Ras-transformed cells results  in  reversion of the  malignant state (12-15). Although NF2 is expressed widely in various human  tissues (71, it still remains  to  be clarified whether NF2 expression is  down-regulated by Ras or other oncogenes. In  this  paper we demonstrate for the  first  time that (i) over- expression of NF2  can  reverse  the v-Ha-Ras-induced  anchor- age-independent  growth of NIW3T3 cells in a soft agar, (ii) the anti-Ras function of NF2  resides  in  its  N-terminal  half,  and (iii) the level of NF2 mRNA is  not down-regulated by v-Ha-Ras. EXPERIMENTAL  PROCEDURES Construction  of Plasmids  Expressing  Full-length NF2 and Its N- terminal  Half in  Mammalian  Cells-An  EcoRI DNA fragment of 1.8 kilobases  encoding  full-length  human NF2 (7, 8) was  prepared  from JJR-1 cDNA(7) by polymerase  chain  reaction (PCR),  and subcloned into retroviral vector pMV7 (16), which  also  expresses a neomycin resistance selectable  marker.  The  orientation of the insert was  determined by HindIII  digestion,  as  one  HindIII  site is located 100 base  pairs  down- stream of the EcoRI insertion site (16)  and the other  around codon  497 of NF2 DNA (8). Another  EcoRI  DNAfragment of 1.1 kilobases  encoding the N-terminal  half of  NF2 (NF2-N,  residues  1-359)  was  also  prepared by  PCR, and subcloned into vector  pMv7 in  essentially the same  man- ner  as described  for full-length NF2.  The orientation of the NFP-N insert was  determined by HindIII  digestion, as a second HindIII site is located  around  codon  289 of NF2-N (8). The resultant two  plasmids, called  NF2/pMV7  and  NF2-N/pMV7,  respectively,  were  purified  by  CsCl density  gradient  centrifugation for transfection. polymerase  chain reaction; RT, reverse transcriptase; ACAP, actin-cy- toskeleton-associated  protein; MAP kinase,  mitogen-activated  protein kinase; MEK, MAP kinase  kinase. 23387 23388 NF2 Suppresses  Ras-induced  Malignancy Effect of NF2 and NF2-N Dansfection on the Colony-forming Ability of v-Ha-Ras-transformed Cells in Soft Agar-v-Ha-Ras-transformed NIW3T3 cells were  transfected  with  either NF2/pMV7 or NF2-N/pMV7 as complexes with liposomes as described previously (17).  A  parallel transfection  with  vector pMV7 alone  was  also  carried  out  to  serve as a negative  control.  The  resultant  G4.18-resistant  transfectants  were cloned in  the presence of 400 pg/ml G418 (a neomycin analogue)  as described previously (5).  The colony formation  in  a soft agar  (anchorage- independent  growth) of NF2/pMV7 and NF2-N/pMV7 clones, in com- parison  with pMV7 clones, was  examined by incubating 1000 cells/plate at 37 "C for 3 weeks  under  standard  culture  conditions  (5).  The colonies were  stained  with  crystal violet and  counted. Reverse Danscriptase (RT) PCR Analysis of NF2, NF2-N, and u-Ha- Ras Expression-Total RNAs from both the  parental  v-Ha-Ras  trans- formants  and NF2/NF2-N transfectants  were  isolated by the method of Chomczynski and Sacchi (18). 5 pg of each  total RNA preparation  was then used as a  template  to  synthesize  v-Ha-Ras  and  NF2/NF2-N cDNAs by avian  myeloblastosis  virus  reverse  transcriptase  (Promega)  and  a Riboclone cDNA synthesis  kit  (Promega),  using  the  corresponding  an- tisense PCR primers  including the  last  several codons (17). To compare the  amount of these cDNAs between  the  Ras  transformants  and  NF2/ NF2-N transfectants,  the  same  aliquots of all cDNA preparations  were then  used as PCR templates for Taq  DNA polymerase  to  amplify exog- enous  (human) or endogenous  (mouse)  NF2, NF2-N, or  v-Ha-Ras cDNA sequences  using the corresponding  pairs of sense  and  antisense  primers under  essentially  the  same  conditions as those  described previously (17, 19).  Under  these PCR conditions, the  amount of PCR products  is linearly  proportional  to  the  initial  amount of cDNAs used as  templates and  is  far below the  saturation  point.  The  titration  curves  were  drawn based on incorporation of la-"YPldGTP  into the PCR bands,  using both cloned v-Ha-Ras  and  NF2 DNAs at various  concentrations (0.1-10 pg) as  the  standard PCR  templates  (data  not  shown). The  human  and  mouse  NF2  amino acid sequences are 98% identical (20,  21),  therefore,  some  pairs of the  sense/antisense PCR primers cor- responding  to  the  human  NF2  base  sequences  are  able  to  amplify  the corresponding  base  sequences of mouse  NF2 cDNA as well. For in- stance,  sense  primer S and  antisense  primer B, corresponding  to codons 9-14 and codons 354-359 of human  NF2  (8), respectively, can  be  used  to amplify  both  mouse  and  human  sequences,  whereas  antisense  primers A  and C, corresponding  to codons 335/336-340 (AGCGAGGCGCTGC- CGC) and codons 590-595 (8), respectively, can  be  used for amplifying only human,  and  not  mouse,  sequences.  Thus, PCR primers  C  and  A were  used  to quantitate  the levels of exogenous human  NF2  and NF2-N mRNAs, respectively, whereas PCR primer B was  used  to  compare levels of endogenous  mouse  NF2 mRNAs between  normal  and  Ras- transformed  NIW3T3 cells or compare  levels of endogenous  (mouse) NF2 mRNAs in  parental  Ras  transformants  and exogenous (human) NF2/NF2-N mRNAs in NF2/NF2-N  transfectants. RESULTS Anti-Ras Action of NF2-Using a retroviral vector pMV7, we have overexpressed  full-length NF2  in v-Ha-Ras-transformed NIW3T3 cells under  the control of long terminal  repeats,  and examined  the effects of NF2 on their  growth,  in  particular  the anchorage-independent  growth  in a soft agar, which correlates with  their malignancy. As shown in Fig. 1 (top  panel 1, very few NF2-overexpressing cells (N) formed large colonies in a  soft agar.  Under  the  same conditions, parental  transformed cells (5") formed many  large colonies. Each of these  large colonies contains more than 100 cells. Furthermore,  although  these NF2  transfectants  still formed small colonies, the  number of small colonies derived from NF2  transfectants  was only about 10% of that derived from parental  transformed cells (see Table I, experiment 1). A quantitative RT PCR analysis of both v-Ha- Ras  and  NF2 mRNAs levels (see Fig. 1, bottom panel)  has confirmed that  this  dramatic reduction in both  size and  number of colonies was  due  to expression of NF2,  and  not  due  to  any reduction or loss of v-Ha-Ras  expression. Thus,  these  data clearly indicate  that,  like  NF1  fragments (51, full-length NF2 can  reverse a malignant phenotype caused by v-Ha-Ras. NF2 Restores Contact Inhibition of Cell Growth-Normal fi- broblasts  such as NIW3T3 cells in a  liquid culture  cease to grow when they form a  confluent  monolayer on a glass or plas- tic  substratum.  This phenomenon is called contact  (or  density- ANTI-RAS ACTION OF NF2 T N vRAS NF2 v-Ha-Ras  transformants by NF2.  v-Ha-Ras  transformants (T),  but not FIG. 1. Top panel,  suppression of anchorage-independent  growth of NF2  transfectants (N), grow rapidly  in soft agar  and form large colonies in an anchorage-independent  manner. For details,  see  Table I. Bottom panel,  expression of v-Ha-Ras  and  NF2  genes in NF2  transfectants.  The steady-state  levels of both  v-Ha-Ras  and  human  NF2 mRNAs in NF2- transfected clones (A and B), transfectants  with vector alone (V, 1 and 21, and  parental  v-Ha-Ras  transformants (P) were  estimated by a semi- quantitative RT PCR analysis  using  total RNAs extracted from each clone. 600, v-Ha-Ras PCR product of 600 bp; arrowhead,  NF2 PCR product of 1.8 kb; S, standard DNAs (I-kb  ladder). TABLE  I Soft agar colony-forming ability of NF2 and NF2-N transfectants derived from v-Ha-Ras  transformants after 1000 cells of each  transfectant  are  plated,  is  shown.  Each  pre- The  total  number of colonies formed in soft agar  per  plate,  2  weeks sented  value  was  the  average of the  data from two independent  experi- ments,  and  the  standard  deviation  in  each  case  was  less  than  5%. Experiment 1 (NF2) Experiment 2 (NFP-N) Vector pMV7 only 720 (100%) Vector pMV7 only 826 (100%) NF2  transfectants NF2-N Transfectants Clone A 58 (8%) Clone G  122  (15%) Clone R 69 (10%) Clone H  142  (18%) Clone C 101 (14%) Clone I 153  (19%) Clone D 111 (16%) Clone J 257  (32%) Clone E 111 (16%) Clone K 264 (33%) Average (13%) Average (23%) dependent)  inhibition of cell growth (or division).  Interestingly, when  the cells are  transformed by v-Ha-Ras or many  other oncogenes, they lose this  contact inhibition and continue to grow, piling up on  one another  after  they  have formed the confluent monolayer. Interestingly,  NF2 transfectants derived from v-Ha-Ras-transformed cells are contact-inhibited  (see Fig. 2). In a  liquid culture, both the control v-Ha-Ras transformants and  their  NF2  transfectants grow at  the  almost  same  rate  until they form a  confluent monolayer. However, at confluence, NF2 transfectants cease to grow (as do normal  NIW3T3 fibroblasts), whereas control transformed cells continue to proliferate (Fig. 2). The Anti-Ras  Function of NF2 Resides in  Part  in  Its  N-ter- minal Half-NF2 shares a high sequence identity  (around 50%), mainly  in  the  N-terminal domain  (NF2-N, residues 1-358), with  several  other  members of an F-actin-binding pro- tein family (TERM) including  talin,  ezrin,  radixin,  and moesin (7).  The  remaining domain of NF2  has no sequence homology to any  domains of the TERM proteins. Thus, if its  actin binding is sufficient for anti-Ras action of NF2, NF2-N is expected to NF2 Suppresses  Ras-induced  Malignancy 23389 Control 1 /+ /=NF2= / 0 2 4 6 8 ~~ ~ ~ Incubation Time. Day FIG. 2. NF2 restores contact inhibition of cell growth that is lost in  v-Ha-Ras transformants. In a liquid culture,  the  v-Ha-Ras transformants (Control,  cross) and  their  NF2  transfectants (NFZ, solid square) grow at  the almost  same  rate  until  they form a confluent mono- layer  (day 5-6). Then only NF2  transfectants  cease  to grow (as normal fibroblasts),  whereas control transformants  continue  to grow and pile up on top of each  other. suppress v-Ha-Ras-induced malignant  transformation. As shown in Table  I (experiment 21, NF2-N transfection indeed significantly reduces  the colony-forming ability of v-Ha-Ras transformants  in a  soft agar,  but  its  anti-Ras action (average 77% suppression)  appears to be less efficient than  that of full- length NF2 (average 87% suppression).  Quantitative RT PCR analysis  has revealed again  that NF2-N transfectants  express both  NF2-N  (Fig. 3)  and v-Ha-Ras (data not known), clearly indicating  that reduction of Ras-induced  malignancy is  due to NF2-N expression and  not  due  to a loss of v-Ha-Ras  expression. These observations confirmed our prediction that  the  anti-Ras function of NF2  resides  in  part  in  its highly  conserved  N-ter- minal  half, which most likely binds  actin  filaments  (F-actin). NF2 mRNA Level Is Not Affected by v-Ha-Ras-Expression of the four distinct  tumor  suppressor  genes encoding actin cy- toskeleton-associated proteins (vinculin, a-actinin, gelsolin, and  tropomyosin-l), which can  suppress SV40- or Ras-induced malignancies, are down-regulated by either SV40 virus  or on- cogenic Ras  mutants  (14).  Thus, we have compared the  steady- state levels of NF2 mRNA between normal  and v-Ha-Ras- transformed mouse NIW3T3 cells by a quantitative RT PCR technique  using a pair of oligonucleotide primers, B (antisense) and S (sense),  that can amplify both  mouse and  human NF2 cDNAs (for detail,  see  “Experimental Procedures”). As shown in Fig. 3 (right panel), no significant difference in  the  NF2 mes- sage level could be detected  between normal (N) and  Ras-trans- formed (2‘) cells, and  the endogenous (mouse)  NF2 mRNA level in both cases  is  far lower than  the exogenous (human) NF2-N mRNAleve1 in NF2-N transfectants  (R), clearly indicating  that v-Ha-Ras does not affect the  steady-state level of NF2 mRNAs. Using another  pair of primers, A (antisense)  and S, which could amplify the exogenous (human)  NF2 message of 1.0 kb  in NF2-N transfectants (R, l-R4)  but  not  the endogenous (mouse) NF2 cDNAs in  either normal cells (N) or Ras  transformants (2’) (Fig. 3, left panel), we have confirmed that  the 1.1-kb PCR RT N S The  human NF2-N mRNAs could be detected only in NFP-N-transfected FIG. 3. Left pand. vxprt’ss”ron  of NF2-N gene in SI.’2-S transfectants. clones (R, 14), but not  in  either v-Ha-Ras transformants (7’) or normal fibroblasts (N). when primers  A  (human-specific)  and S were  used for semi-quantitative RT PCR analysis.  The arrow indicates  human NF2-N PCR product of 1 kb (codons 9-340). P, PCR product  generated from a plasmid DNA carrying  NF2-N; S, standard DNAs (1-kb  ladder). Right panel, effect of v-Ha-Ras on expression of mouse NF2 gene.  Using  prim- ers B (common to both human  and  mouse)  and S, the  steady-state  levels of endogenous  (mouse)  NF2 mRNAs in  normal (N) and  v-Ha-Ras-trans- formed (T) cells were  compared by semi-quantitative RT PCR analysis. No significant difference in NF2 mRNA level between normal  and v-Ha- Ras-transformed cells could be detected. NF2-N indicates mouse/ human  NF2-N PCR products of 1.1  kb (codons 9-359). R, total  human NF2-N/mouse NF2 level in  NF2-N  transfectants; S, standard DNAs (1-kb  ladder). products generated by primers B and S from both normal  and Ras-transformed cells (Fig.  3, right panel)  are indeed derived from mouse  NF2 mRNAs, and  not from a human NF2 cDNA contaminant  (this conclusion was verified further by subse- quent sequencing). The deduced human  and mouse NF2  amino acid sequences are 98% identical (20, 21). DISCUSSION We have shown here  that both full-length NF2 and  its N- terminal  half  (NF2-N) can reverse  the  malignant phenotype induced by an oncogenic Ras  mutant,  but full anti-Ras action of NF2  seems to require  its  C-terminal half  (NF2-C) as well. The partial  requirement of NF2-C for full anti-oncogenicity appears to be compatible  with  previous  observations that majority of mutations associated  with  neurofibromatosis  2  cause  C-termi- nal  truncations  (7,8),  suggesting  that  the C-terminal  domain is required for a potential  tumor  suppressor activity of NF2.  In fact, our  preliminary  results  indicate  that  an NF2-C fragment (residues 354-595) is anti-oncogenic as NF2-N.2 Interestingly, one NF2  patient,  represented by cell line GUS5722 (7), was found to  carry  an  NF2  mutant  that lacks 78 amino acids  (resi- dues 447-524) in  the C-terminal  domain (7).  This  missing do- main  contains two slightly  overlapping Pro-rich decapeptide motifs (residues  478-495), which potentially could bind SH3 domains of some intracellular signal transducers  such  as  the N-terminal domain of GAP1 (a Ras GTPase-activating  protein of 120 kDa)  and  the C termini of myosin Is (single-headed myosin isoenzymes). The domain NF2-N is highly homologous to several other members of the TERM family of F-actin-binding proteins  (7,8). In fact, our  preliminary  results  indicate  that NF2-N at least co-sediments with purified  F-actin in Thus,  it  appears that  NF2 belongs to a tumor  suppressor family of actin-cy- toskeleton-associated proteins (ACAPs). This family includes at least four other ACAPs, i.e. vinculin, a-actinin, tropomyo- sin-1, and gelsolin (12-15). However, it  still  remains  to be clari- fied whether  their  F-actin  binding  is absolutely  required for their anti-oncogenicity. How  do these actin-binding  proteins block the oncogenic Ras  signal  transduction pathway? It  was conceivable that expression of NF2 gene, like  other members of this  tumor  suppressor gene family, could be suppressed by v- ’ A. Tikoo and  H.  Maruta,  unpublished  observations. ‘A. Tikoo and H. Maruta,  unpublished  observation. 23390 NF2 Suppresses Ras- Ha-Ras,  and  the  constitutive expression of NF2  gene  might be necessary to  modulate  the action of the  Ras  mutant. However, we have  demonstrated  here  that v-Ha-Ras does not affect steady-state levels of NF2 mRNAs in NIW3T3 cells. Alterna- tively, NF2 overexpression could lead to overproduction of actin or other ACAPs, which in  turn  suppress Ras-induced malig- nant  transformation. Interestingly, it was recently  reported that overexpression of the serum-responsive factor, which ac- tivates  a-actin gene,  can  also suppress Ras-induced malignant transformation of NIW3T3 cells (24). Thus, we are  currently examining  levels of actin  and  other F-actin-binding proteins  in NF2 transfectants.  It  is equally possible that  the NF2-F-actin complex might  bind either  Ras or one of the downstream tar- gets of Ras (Raf, MAP kinase, MEK (MAP kinase  kinase), or a target  farther downstream), and therefore it could block the Ras-target  interaction  as  small  fragments of NF1  and  N-termi- nal domain of Raf (FJ).~ Thus, we are  currently  trying  to find out which step of Ras  signal  transduction  pathway (or kinase cas- cade) is blocked by NF2. An interaction of Ras with  F-actin  itself or an actin-contain- ing complex has been observed previously (25). Interestingly, it was  demonstrated recently that a key role of Ras-GTP complex in Raf-induced activation of MEK is to  recruit cytoplasmic Sed Thr  kinase Raf to  the cytoskeleton (a detergent-insoluble  frac- tion)  located underneath  the  plasma  membranes where  activa- tion of Raf takes place (26), but  the  nature of this cytoskeleton still  remains  to be determined. A rapid  disruption of F-actin stress fibers (but  neither microtubules  nor intermediate fila- ments) is one of the  early  intracellular  events  that follow ma- lignant  transformation induced by  SV40 virus, Ras, or other oncogenes (27). Overexpression of an N-terminal  domain of GAP1 (GAPlN,  residues  1-445), which contains a pair of SH2 domains and a single SH3 domain,  also causes disruption of actin  stress fibers (28). These  observations indicate  that GAPlN  acts as a downstream target of Ras  in  this  intracellular event  and  suggest  the possibility that actin-cytoskeleton plays a key role in regulation of Ras-induced  activation of Raf. In  this context, it is of interest to note that (i) another mo- nomeric G  protein (or GTPase) called Rho is  required for orga- nization of F-actin  stress fibers (291, and  (ii) p190, a GAP spe- cific for Rho, directly interacts  with  GAPlN (22, 30, 31). GAPlN  binds p190 only when p190 is phosphorylated at spe- cific tyrosine residues (22). p190 activates Rho GTPase through its  C-terminal domain  (23, 31); however, it  is possible that  its N-terminal domain, which contains a G  protein or GTPase motif, might  act  as a  GTP-activated signal  transducer  as  Ras and Rho (30). Perhaps p190 acts  as a downstream target of Rho for organizing actin  stress fibers and  GAPlN somehow inter- feres  with the action of p190 by forming a complex with tyro- sine-phosphorylated p190. NF2 and  other actin-binding tumor suppressors  might  serve  as  the downstream targets of p190 or form a complex with GAPlN,  thereby  interfering  with GAF'lN- p190 interaction  to antagonize the oncogenic action of Ras mutants. Acknowledgments-We are  grateful  to  Masha  Fridman  for  skillful induced Malignancy assistance  during  preparation of mRNAs and  Northern  blot  analysis, Giovanna D'Abaco for technical advice, and Dr. Tony Burgess  for con- sistent  encouragement  and  support, as well as invaluable  advice  and comment  throughout  this work. We also  thank  the  JBC  reviewers for their  comments, which were  helpful in improving the  manuscript. REFERENCES 2. Polakis, P., and McCormick, F. (1993) J. Bid. Chem. 268,9157-9160 1. Bos, J. L. (1989) Cancer Res. 49, 46824689 3. Vogel, U. S. A., Dixon, R.  A., Schaber, M.  D., Diehl, R. E., Marshall, E. M., 4. Marchuk, D. A,, Saulino, A.  M., Tavakkol, R., Wallace, M.  R., Andersen, L.  B., Scolnick, E. M., Sigal, I. S., and Gibbs, J. B. (1988) Nature 335, 90-93 Mitchel1,A. L., Gutmann, D. H., Boguski, M., and Collins, F. (1991) Genom- 5. Nur-E-Kamal, M. S. A,, Varga. M., and  Maruta, H. (1993) J. Bid. Chem. 268, ics 11,931-940 22331-22337 6. Xu, G., OConnell, P., Viskochil, D., Cawthorn, R., Robertson, M., Culver, M., Dunn, D., Stevens, J., Gesteland, R., White, R., and Wiess, R. (19901 Cell 62, 599-608 7.  Trofatter, J. A., MacCollin, M. M., Rutter, J. L., Murrell, J. R., Duyao, M. P., Ambrose, C. M., Munro, D., Bove, C.,  Haines, J. L., Martuza, R. L., Mac- Parry, D. M., Eldridge,  R., Kley,  N., Menon, A. G., Pulaski, K., Haase, V H., Donald, M. E., Seizinger, B.  R., Short, M.  P., Buckler, A. J., and  Gusella, J. 8. Rouleau, G. A., Merel, P., Lutchman, M., Sanson, M., Zucman, J., Marineau, E (1993) Cell 72, 791-800 C., Hoang-Xuan, IC, Demczuk, S., Desmaze, C., Plougastel, B., Pulst, S. M., Lenoir, G., Bijlsmal, E., Fashold, R., Dumanski, J., De Jong, P., Panyl, D., Eldridge, R., Aurias, A., Delattre, O., and  Thomas, G. (1993) Nature 363, 515-521 9. Bianchi, A. B.,  Hara, T., Ramesh, V, Gao, J., Klein-Szanto, A. J. P., Morin, F., Menon, A. G., Trofatter, J. A,,  Gusella, J. F., Seizinger, B. R., and Kley,  N. 10. Twist, E. C., Ruttledge, M. H., Rousseau, M., Sanson, M., Rapi, L., Merel, P., (1994) Nature  Genet. 6, 185-192 Delattre, O., Thomas, G., and  Rouleau, G.  A. (1994) Hum. Mol. Genet. 3, 147-151 11. Jacaby, L. B., MacCollin, M., Louis, D. N., Mohney, T., Rubio, M. P., Pulaski, K., Hum. Mol. Genet. 3,413419 Trofatter, J. A,, Kley, N., Seizinger, B., Ramesh, V., and Gusella, J. F. (1994) 12. Fernandez, J. L.  R., Geiger, B., Salomon, D., Sabanay, I., Zoeller, M., and 13. Glueck, U., Kwiatkowski, D., and Ben-Ze'ev, A. (1993) Proc.  Natl.  Acad. Sci. Ben-Ze'ev,  A. (1992) J. Cell Bid. 119,427438 14. Prasad, G. L., Fulder, R. A., and Cooper, H. L. (1993) Proc. Natl.  Acad.  Sci. U. S. A. 90,383-387 15. Muellauer,  L.,  Fujita, H., Ishizaki, A,, and  Kuzumaki, N. (1993) Oncogene 8, U. S. A. BO, 7039-7043 16. Kirschmeir, P. T., Housey, G. M., Johnson, M. D., Perkins,A. S., and  Weinstein, 2531-2536 17. Nur-E-Kamal, M. S. A,,  Sizeland,  A,,  DAbaco, G., and  Maruta, H. (1992) J. I. B. (1988) DNA 7,219-225 18. Chomczynski, P., and Sacchi, N. (1987)Anal. Biochem. 162, 156-159 Bid. Chem. 267, 1415-1418 19. Fath, I., Schweighoffer, E, Rey, I, Multon, M. C., Boiziau, J., Duchesne, M., and Tocque, B. (1994) Science 264,971-974 20. Hara, T., Bianchi, A.  B., Seizinger, B.  R., and Kley, N. (1994) Cancer Res. 54, 330-335 21. Haase, V. H.,  Trofatter, J. A., MacCollin, M., Tarttelin, E., Gusella, J. F., and Ramesh, V (1994) Hum. Mol. Genet. 3,407411 22. Ellis, M., Moran, M., McCormick, F., and  Pawson, T. (1990) Nature 343,377- 381 23. Morii, N., Kumagai, N., Nur-E-Kamal, M. S. A,, Narumiya, S., and  Marut.a,  H. (1993) J. Biol. Chem. 268,27160-27163 24. Kim, J. H., Johansen, F. E.,  Robertson, N., Catino, J. J., Prywes, R., and Kumar, C.  C. (1994) J. Biol. Chem. 269, 13740-13743 25. Maruta,  H. (1989) in Ras Oncogenes (Spandidos, D. A,,  ed) pp. 255-260, Plenum  Publishing Co., New York 26. Stokoe, D., MacDonald, S. G., Cadwallader, IC, Symons, M., and Hancock, J. F. (1994) Science 264,1463-1467 27. Weber, K., Lazarides, E., Goldman, R. D., Vogel, A,, and Pollack, R. (1974) Cold Spring Harbor Symp. Quant. Biol. 39,363-369 28. McGlade, J., Brunkhorst, B., Andersen, D., Mbamalu, G., Settleman, J., Dedhar, S., Rozakis-Adcock, M.,, Chen, L. B., and Pawson, T. (1993) EMBO J. 12, 3073-3081 29. Patterson, H. F., Self, A. J., Garret, M.  D., Just, I., Aktories, K., and Hall, A. 30. Settleman, J., Narashimhan, V., Foster, L. C., and Weinberg, R. A. (1992) Cell (1990) J. Cell Biol. 111, 1001-1007 M. Fridman, A. Tikoo, M. Varga, A. Murphy, and H. Maruta, sub- mitted for publication. 31. Settleman, J., Albright, C. F., Foster, L. C.,  and Weinberg, R.  A. (1992) Nature 69,539-549 359,153-154 THEJOURNALOFCELLBIOLOGYJCB: ARTICLE© The Rockefeller University Press  $15.00The Journal of Cell Biology, Vol. 177, No. 5, June 04, 2007 893–903http://www.jcb.org/cgi/doi/10.1083/jcb.200703010JCB893IntroductionThe identifi cation and study of tumor suppressor genes has provided insight into the normal mechanisms of cell prolifera-tion control (Sherr, 2004). Most tumor suppressors function intracellularly to control the cell division cycle; however, the interface between a cell and its environment also plays a critical role in tumor development and metastasis. The product of the neurofi bromatosis type 2 (NF2) tumor suppressor gene, Merlin, localizes to and appears to act at this interface (McClatchey and Giovannini, 2005). Loss of NF2 function is associated with the development of multiple cancers in humans and mice (McClatchey et al., 1998; Giovannini et al., 2000; Baser et al., 2002). In humans, NF2 mutations are associated with familial and sporadic nervous system tumors and with other sporadic cancers such as mesothelioma, whereas heterozygous Nf2 mutant mice develop bone, liver, and other tumors that are highly meta-static. Treatment strategies for NF2 are currently limited given the often intractable location and multiplicity of tumors, to-gether with their tendency to recur. Surgical approaches are the current standard therapy and pharmacological treatments are not available.Merlin is closely related to the ERM (Ezrin/Radixin/Moesin) proteins that are thought to organize cortical membrane domains that interface with the extracellular environment, via linking membrane-associated proteins to the actin cytoskeleton (Bretscher et al., 2002; Lallemand et al., 2003; McClatchey, 2003; Ramesh, 2004). Although Merlin can functionally and physically interact with several proteins, including p21-activated kinase (Kissil et al., 2003; Hirokawa et al., 2004), CD44 (Morrison et al., 2001) and the two PDZ domain –containing adaptors EBP50/NHE-RF1 and E3KARP/NHE-RF2 (Murthy et al., 1998; Nguyen et al., 2001), the mechanism whereby Merlin controls cell proliferation remains poorly understood (McClatchey and Giovannini, 2005).We have recently found that a signature of Nf2 defi ciency in several types of primary cells, including both mesenchymal and epithelial cells, is a failure to undergo contact-dependent inhibition of proliferation and to establish stable cadherin-mediated adherens junctions (AJs) between cells (Lallemand et al., 2003). Merlin is regulated by cell–cell contact (Shaw et al., 1998), local-izes to AJs, and physically associates with AJ components. Although core cadherin–catenin complexes are present in the membrane of Nf2−/− cells, stable AJ structures are not maintained. Defective AJs and loss of contact-dependent inhibition of prolif-eration may explain the tumorigenic and metastatic consequences of Nf2 defi ciency. However, the nature of the mitogenic signals that drive proliferation of Nf2−/− cells with defective AJs is not known; indeed, the general mechanism of contact-mediated inhi-bition of proliferation is not well understood.Here we present novel mechanistic insight into a critical role for the NF2 tumor suppressor, Merlin, in coordinating the processes of AJ stabilization with contact-dependent inhibition of epidermal growth factor receptor (EGFR) activity. In the Contact-dependent inhibition of EGFR signaling by Nf2/MerlinMarcello Curto, Banumathi K. Cole, Dominique Lallemand, Ching-Hui Liu, and Andrea I. McClatcheyMGH Center for Cancer Research and Harvard Medical School Department of Pathology, Charlestown, MA 02129The neuroﬁ bromatosis type 2 (NF2) tumor suppres-sor, Merlin, is a membrane/cytoskeleton-associated protein that mediates contact-dependent inhibition of proliferation. Here we show that upon cell–cell contact Merlin coordinates the processes of adherens junction stabilization and negative regulation of epidermal growth factor receptor (EGFR) signaling by restraining the EGFR into a membrane compartment from which it can neither signal nor be internalized. In conﬂ uent Nf2−/− cells, EGFR activation persists, driving continued proliferation that is halted by speciﬁ c EGFR inhibitors. These studies deﬁ ne a new mechanism of tumor suppression, provide mecha-nistic insight into the poorly understood phenomenon of contact-dependent inhibition of proliferation, and suggest a therapeutic strategy for NF2-mutant tumors.Correspondence to Andrea I. McClatchey: mcclatch@helix.mgh.harvard.eduD. Lallemand’s present address is INSERM U674, Fondation Jean Dausset-CEPH, 75010 Paris, France.Abbreviations used in this paper: AJ, adherens junction; EGFR, epidermal growth factor receptor; ERM, Ezrin/Radixin/Moesin; FERM, four-point-one, ERM; LDC, liver-derived epithelial cell; MEF, mouse embryo ﬁ broblast; NF2, neuroﬁ bromatosis type 2; OB, osteoblast; pTyr, phosphotyrosine; RTK, receptor tyrosine kinase; Tr-EGF, Texas red–conjugated EGF.The online version of this article contains supplemental material.JCB • VOLUME 177 • NUMBER 5 • 2007 894absence of Merlin, confl uent cells are unable to silence mitogenic signaling from the EGFR, and their continuous proliferation is blocked by specifi c pharmacological inhibitors of the EGFR. Upon cell–cell contact, Merlin associates with EGFR via NHE-RF1 and prevents both ligand-induced EGFR  internalization and the association of EGFR with its canonical effectors, pre-cluding downstream signaling. Our data are consistent with a model whereby upon cell contact Merlin restrains EGFR into a membrane compartment from which it can neither signal nor be internalized. These studies reveal a novel mechanism of tumor suppressor function, linking the function of Merlin to that of a well-known oncogene and suggesting a possible therapeutic strategy for NF2 mutant tumors.ResultsCell density–dependent regulation of EGFR by MerlinOur previous studies suggest that due to their inability to es-tablish stable AJs, Nf2−/− cells continue to proliferate after reach-ing confl uence. However, these studies do not reveal the source of mitogenic signals that drive the continued proliferation of confl uent Nf2−/− cells—in essence the mechanism whereby Nf2- expressing cells normally undergo contact-dependent inhibition of proliferation. We could not detect altered β-catenin activity, nuclear localization, or changes in specifi c cadherin expression in these cells, suggesting that activated β-catenin does not drive the overproliferation of confl uent Nf2−/− cells (Fig. S1, available at http://www.jcb.org/cgi/content/full/jcb.200703010/DC1; not depicted); in fact, normal levels of cadherin-associated β-catenin are present in the membranes of confl uent Nf2−/− cells (Lallemand et al., 2003). Instead, confl uent Nf2−/− cells exhibit sustained activation of signaling molecules that are not known β-catenin targets (Fig. 1 E).Alternatively, accumulating evidence suggests that cadherin-dependent cell adhesion can control mitogenic signaling by nega-tively regulating receptor tyrosine kinases (RTKs) at the plasma membrane (Takahashi and Suzuki, 1996; Grazia Lampugnani et al., 2003; Qian et al., 2004). To determine whether Merlin function is important for contact-dependent inhibition of RTK signaling, we compared the profi le of protein tyrosine phos-phorylation in wild-type and Nf2−/− mouse embryo fi broblasts (MEFs) as they progress to high cell density with an increasing area of cell–cell contact in the presence of serum (see Fig. S2 A for a defi nition of confl uence; available at http://www.jcb.org/cgi/content/full/jcb.200703010/DC1). As shown in Fig. 1 A, tyrosine phosphor ylation of multiple proteins in a total membrane fraction was sharply down-regulated in confl uent wild-type MEFs but not in confl uent Nf2−/− MEFs. Upon serum depriva-tion, phosphotyrosine (pTyr) levels declined in both confl uent wild-type and Nf2−/− membranes, indicating their dependence upon soluble growth factors (Fig. 1 A, right). Thus, in prolifer-ating wild-type MEFs, serum growth factors maintain a physio-logical level of tyrosine kinase activity that is down-regulated as Figure 1. Persistent EGFR signaling in multi-ple types of conﬂ uent Nf2 −/− cells. (A) Tyrosine-phosphorylated proteins in total membrane preparations from MEFs at increasing stages of conﬂ uence. At early conﬂ uence (*) in the presence of serum, wild-type (top) and Nf2−/− (bottom) cells display a similar pattern of pTyr; (see Fig. S2 for the deﬁ nition of conﬂ uence). Progression to late conﬂ uence is accompanied by marked down-regulation of tyrosine kinase activity in wild-type, but not Nf2−/− cells (left). In contrast, both wild-type and Nf2−/− cells can down-regulate membrane pTyr after se-rum starvation (right). Actin = loading control. (B) EGFR activation, detected with an antibody against phosphorylated Y845, parallels the pTyr content observed in response to increasing conﬂ uence and serum starvation. In wild-type MEFs, pEGFR levels decrease as conﬂ uence progresses, but remain high in Nf2−/− cells in a serum-dependent manner. (C) Phosphor-ylation of multiple EGFR tyrosine residues is down-regulated in wild-type late-conﬂ uent primary MEFs and OBs grown in serum, but persist in the absence of Merlin. (D) Mem-branes of conﬂ uent Nf2−/− LDCs display high pEGFR levels that are markedly reduced upon adenoviral reintroduction of Nf2wt, but not mu-tant Nf2L64P. Nf2L64P is underrepresented in the membrane fraction, but comparable to that of Nf2wt in the total cell extract (tce). (E) Persistent activation of multiple EGFR targets is evident in membrane extracts from conﬂ uent Nf2−/− cells compared with wild-type. Phosphorylated active forms are indicated by the letter “p” preceding the name of the protein. All experi-ments were performed at least three times.MERLIN INHIBITS EGFR SIGNALING • CURTO ET AL.895confl uence progresses; this down-regulation is  defective in the absence of Merlin.Genetic cooperativity has been demonstrated between NF2 and EGFR pathway mutations in Drosophila (LaJeunesse et al., 2001). Moreover, the EGFR localizes to cell junctions, regulates cell adhesion, and can be negatively modulated by cadherin-dependent cell contact (Hoschuetzky et al., 1994; Takahashi and Suzuki, 1996; Pece and Gutkind, 2000; Betson et al., 2002; Qian et al., 2004). However, the basis of coordination between cell–cell contact and EGFR activity is not known. Given the prominent pTyr-containing protein of 170 kD (the molecular weight of EGFR) apparent in confl uent Nf2−/− membranes (Fig. 1 A), we used antibodies against active, phosphorylated EGFR (pEGFR) to monitor EGFR activation in confl uent wild-type and Nf2−/− cells. We found that the steady-state levels of active EGFR also diminished with increasing cell density in membranes of wild-type MEFs but persisted in Nf2−/− MEFs (Fig. 1 B).To determine whether EGFR deregulation is a general signature of Nf2 defi ciency, we examined EGFR activation in confl uent primary osteoblasts (OBs) and liver-derived epithelial cells (LDCs), two key targets of Nf2-associated tumorigenesis in mice (McClatchey et al., 1998; Giovannini et al., 2000). Neither Nf2−/− OBs nor LDCs undergo contact-dependent inhibition of proliferation (Fig S2 B; see Fig. 6). Like MEFs, wild-type OBs down-regulate membrane pTyr and pEGFR at high cell density in the presence of serum, whereas Nf2−/− OBs maintain elevated levels of both (Fig. 1 C; not depicted). Similarly, confl uent Nf2−/− LDCs retain high levels of pEGFR (Fig. 1 D). Reintro-duction of wild-type Nf2 (Nf2wt) into Nf2−/− MEFs, OBs, and LDCs restores contact-dependent inhibition of proliferation, electrondense AJs, and low levels of both pTyr and pEGFR (Fig. 1 D, Fig. 2 B; Fig. S2 C; not depicted). In contrast, a version of Merlin containing a patient-derived missense mutation (Nf2L64P) fails to stably localize to AJs (Lallemand et al., 2003; Fig. 3 C), inhibit proliferation, or reduce pEGFR levels (Fig. 1 D). Multiple tyrosine residues on the EGFR and multiple EGFR targets remain phosphorylated in confl uent Nf2−/− cells, suggesting that a program of EGFR signaling fails to be down-regulated (Gschwind et al., 2004) (Fig. 1, C and E). These data indicate that a continuous physiological activation of the EGFR persists in the membranes of confl uent Nf2−/− cells; this is consistent with the fact that they do not proliferate faster than wild-type cells, but proliferate continuously despite reaching confl uence. Thus, three different cell types all fail to undergo contact-dependent inhibition of proliferation and to down-regulate EGFR signaling at high cell density in the absence of Merlin.Merlin controls the activity and membrane distribution of EGFR upon cell–cell contactTo understand how Merlin normally controls EGFR activity, we examined EGFR signaling as wild-type cells reach high density. Confl uent epithelial cells of breast and kidney origin become unresponsive to stimulation by EGF and other growth factors via a cadherin-dependent mechanism (Takahashi and Suzuki, 1996; Qian et al., 2004). Accordingly, we found that while acute EGF stimulation of confl uent Nf2-expressing cells does induce tyro-sine phosphorylation of the receptor itself, activation of EGFR effectors such as Src and Raf does not increase, suggesting that signal propagation from the activated EGFR is prevented once wild-type cells reach high cell density (Fig. 2 A). In contrast, stimulation of confl uent Nf2−/− cells results in a slight increase in the already elevated membrane phosphotyrosine content (Fig. 2 A). Reintroduction of Nf2wt but not Nf2L64P restored the block of EGFR signaling at high cell density (Fig. 2 B). Merlin does not appear to be a general  inhibitor of RTK activation because signaling from the IGF-I receptor, including its ability Figure 2. Merlin prevents EGFR signaling in conﬂ uent cells. (A) In late-conﬂ uent (L) wild-type MEFs, EGF-induced pTyr is limited to the EGFR with-out concomitant activation of EGFR downstream effectors such as Src and Raf. Increased membrane pTyr is already present in late-conﬂ uent Nf2−/− MEFs. The response to IGF-I is not prevented by Merlin. (EGF: 40 ng/ml, 30 min; IGF-I: 100 ng/ml, 30 min) (E = early conﬂ uence; co = loading controls). (B) Reintroduction of Nf2wt but not Nf2L64P abrogates persistent membrane pTyr in late-conﬂ uent Nf2−/− MEFs; as in wild-type MEFs, EGF stimulation of Nf2wt-expressing MEFs affects pTyr of only the EGFR itself. (C) Surface EGFR turnover in late-conﬂ uent OBs. Conﬂ uent wild-type and Nf2−/− OBs were surface biotinylated at 4°C for 1 h and then shifted to 37°C in the presence of serum. At the indicated time points, the amount of biotinylated EGFR remaining in the cell was evaluated in both the total bio-tinylated fraction and in EGFR immunoprecipitates. Compared with wild-type OBs (top panels), Nf2−/− OBs (bottom panels) show accelerated clearing of surface-biotinylated EGFR. All experiments were performed at least three times.JCB • VOLUME 177 • NUMBER 5 • 2007 896to transactivate the EGFR (Roudabush et al., 2000), occurs in confl uent MEFs regardless of the Nf2 status (Fig. 2 A).Induced phosphorylation of EGFR without activation of downstream targets in confl uent, Nf2-expressing cells suggested that in this context the ability of the activated receptor to acquire signaling competence might be physically restricted by Merlin at cell confl uence. Because Merlin is membrane associated and internalization of liganded EGFR is intimately linked to its signal-ing output (Sorkin and Von Zastrow, 2002), we asked whether the absence of Merlin had any effect on the surface levels of EGFR. We biotin-labeled cell surface proteins in confl uent wild-type and Nf2−/− OBs. Although major differences in the levels of surface EGFR were not detected in wild-type and Nf2-expressing cells, clearance of EGFR was more rapid in confl uent Nf2−/− cells, consistent with an increased rate of activation and inter-nalization (Fig. 2 C).Merlin prevents EGFR internalization and effector association in contacting cellsTo further explore the role of Merlin in EGFR membrane  localization we used Texas red–conjugated EGF (Tr-EGF) to visually track the EGFR in the presence and absence of Merlin. For these experiments we chose to use epithelial LDCs that are amenable to immunofl uorescence localization analyses. In con-fl uent Nf2−/− LDCs we found that within 30 min after stimula-tion Tr-EGF localizes to intracellular vesicles in virtually every cell, consistent with ligand-activated EGFR internalization (Fig. 3 A and Fig. S3 A, available at http://www.jcb.org/cgi/content/full/jcb.200703010/DC1). We then generated mosaic cultures to compare Nf2−/− LDCs to neighboring cells into which Nf2wt or Nf2L64P were reintroduced. Tr-EGF internaliza-tion was prevented by expression of Nf2wt that, like EGFR, is enriched at cell–cell boundaries (Fig. 3 B and Fig. S3 B), but Figure 3. Control of EGFR internalization and signaling by Merlin is contact dependent. (A–F) Internalization of ﬂ uorescent Tr-EGF (2 μg/ml, 30 min) in conﬂ uent LDCs. (green = Merlin; red = Tr-EGF; blue = DAPI). (A) Tr-EGF containing vesicles are found within virtually every Nf2−/− LDC cell. (B) Internal-ized Tr-EGF is rarely observed in cells expressing wild-type Merlin. Dotted lines demarcate non-internalizing Nf2wt-expressing cells. (C) Tr-EGF internaliza-tion is not prevented in cells expressing Nf2L64P or, (D) in cells that express Nf2wt but are situated at the free edge of a scrape wound. In these cells, Tr-EGF internalization occurs along the free edge itself. (E and F) Disruption of intercellular adhesion by Ca2+ depletion promotes Tr-EGF internalization in conﬂ uent Nf2wt-expressing LDCs. E = 10 min; F = 30 min after Tr-EGF addition. Bar, 10 μm. (G) Average percentage distribution of ligand-internalizing cells in rela-tion to Merlin expression and cell density. 200 Nf2wt or Nf2L64P-expressing cells enclosed within a conﬂ uent monolayer, or Nf2wt cells situated at the free edges of nonconﬂ uent cultures, were scored in each of four separate experiments. Cells with internalized Tr-EGF were designated as positive (error bars, ± SD). (H) Disruption of intercellular adhesion by Ca2+-depletion restores EGFR signaling in Nf2wt-expressing LDCs. EGF (40 ng/ml, 30 min) was added to starved LDCs after 30 min preincubation in EGTA/Ca2+-free medium.MERLIN INHIBITS EGFR SIGNALING • CURTO ET AL.897not by Nf2L64P, which is excluded from cell–cell boundaries (Fig. 3 C; Lallemand et al., 2003). An identical response was seen after basolateral exposure to Tr-EGF (not depicted). Inter-nalization of fl uorescent transferrin proceeded similarly in the presence or absence of Merlin (Fig. S3 C). Importantly, Nf2wt did not prevent Tr-EGF internalization from the free edge of cells bordering a scrape wound or small colony (Fig. 3, D and G; not depicted), consistent with the hypothesis that Merlin limits EGFR internalization specifi cally upon cell–cell contact. In fact, disruption of cadherin-based intercellular adhesion by EGTA/Ca2+ depletion resulted in the appearance of internalized Tr-EGF (Fig. 3, E and F) and increased EGFR signaling in Nf2wt-expressing cells (Fig. 3 H). Importantly, endogenous levels of Merlin also prevented EGFR internalization in similar mosaic cultures (Fig. S3 D).These results suggest that upon cell contact Merlin func-tions to physically restrict ligand-activated EGFR from signaling. This interpretation is supported by the altered distribution of pEGFR in fractionated Triton-insoluble membranes in the ab-sence of Merlin (Fig. 4 A). Although EGF stimulation of confl uent wild-type cells yields the appearance of pEGFR that is confi ned to higher density fractions (II and III) that also contain Merlin, both pEGFR and Merlin are excluded from frac-tion I (Fig. 4 A). In contrast, upon EGF stimulation of confl uent Nf2−/− cells, a substantial pool of pEGFR appears in the lowest density fraction (I; Fig. 4 A). These results suggest that the physical state of pEGFR is altered in the absence of Merlin. Merlin, EGFR, and AJ components are all normally enriched in the Triton-insoluble membrane fraction, a poorly defi ned bio-chemical compartment enriched in signaling molecules and cyto skeletal components and variously referred to as detergent-resistant membranes, lipid rafts, cholesterol-rich domains, etc. (Adams et al., 1996; Roepstorff et al., 2002; Lucero and Robbins, 2004; Stickney et al., 2004). Notably, the membrane distribution of Rac and RhoGDI, two proteins implicated in Merlin func-tion, is unaffected by the absence of Merlin; in fact, in contrast to a recent report (Okada et al., 2005), we do detect recruitment of Rac to detergent-resistant membranes in both the presence and absence of Merlin (Fig. 4 A; not depicted). Consistent with this interpretation, reintroduction of Nf2wt but not Nf2L64P alters the solubility of EGFR in confl uent LDCs (Fig. S4 A, available at http://www.jcb.org/cgi/content/full/jcb.200703010/DC1).As shown in Figs. 1 and 2, the propagation of signaling from the activated EGFR to its downstream targets is blocked in confl uent Nf2-expressing cells. Therefore, we asked whether Merlin directly interferes with the ability of ligand-activated EGFR to interact with its canonical signaling effectors. Consistent with established models of EGFR activation, EGF stimulation of confl uent Nf2−/− LDCs causes EGFR to interact with Cbl, Grb2, Sos, and PLCγ; however, these interactions do not occur in the presence of Merlin (Fig. 4 B). Reintroduction of Nf2wt, but not Nf2L64P, prevents EGFR association with its immediate effectors in response to EGF despite phosphorylation of the EGFR itself (Fig. 4 B); in fact, we do not detect changes in the responsiveness of EGFR to EGF ligand (Fig. S4 B). Impor-tantly, under these conditions wild-type Merlin, but not Nf2L64P, physically associates with the EGFR (Fig. 4 B). Altogether, these data suggest that Merlin prevents EGFR from interact-ing with its immediate targets by sterically hindering the inter-action and/or by sequestering the EGFR into a non-signaling membrane compartment from which both access to its down-stream effectors and internalization are impeded. These data also indicate that Merlin acts at a step that precedes endocytosis of the activated EGFR. Indeed, EGF-induced Src activation and EGFR interaction with Grb2 and Cbl, early events that are re-quired for EGFR internalization, do not occur in confl uent Nf2-expressing cells (Wilde et al., 1999; Stang et al., 2004; Johannessen et al., 2006).The PDZ domain–containing adaptor NHE-RF1 mediates Merlin–EGFR associationNHE-RF1 is a PDZ domain–containing adaptor that interacts with Merlin and the ERM proteins (Reczek et al., 1997; Murthy et al., 1998; for review see Bretscher et al., 2002)  and is thought to play an important role in controlling the surface availability of certain membrane receptors including the β-adrenergic re-ceptor and cystic fi brosis transmembrane conductance regulator (for review see Weinman et al., 2006). Importantly, recent stud-ies indicate that NHE-RF1 can also interact with and alter the surface availability of the EGFR (Lazar et al., 2004). This raises Figure 4. Merlin controls EGFR membrane dis-tribution and access to downstream effectors. (A) Optiprep gradient fractionation of Triton-insoluble membranes from late-conﬂ uent wild-type and Nf2−/− MEFs reveals altered physical distribution of pEGFR in Nf2−/− cells after EGF stimulation (40 ng/ml, 30 min). In wild-type cells, pEGFR appears predominantly in fractions II and III, where Merlin is also present; both are excluded from the lowest density fraction I. In the absence of Merlin a unique pool of pEGFR appears in fraction I. In contrast, distribution of the small GTPase Rac is independent of Merlin status. (B) After reintroduction into Nf2−/− LDCs, Nf2wt but not Nf2L64P complexes with EGFR and prevents its interaction with multiple signal-ing effectors in re sponse to EGF (40 ng/ml, 10 min). Experimental conditions are as in Fig. 1 D. All experiments were performed at least three times.JCB • VOLUME 177 • NUMBER 5 • 2007 898the possibility that Merlin regulates the surface availability of EGFR via NHE-RF1. To determine whether NHE-RF1 medi-ates the association between Merlin and EGFR, we performed shRNA-mediated knockdown of NHE-RF1 expression in Nf2wt-expressing LDCs. Lentiviral expression of a shRNA targeting NHE-RF1 revealed that reduced NHE-RF1 expression nearly eliminated the association of Nf2wt and EGFR (Fig. 5 A). In contrast, Nf2wt associates with Ezrin regardless of the level of NHE-RF1 expression (Fig. 5 B). Importantly, NHE-RF2 does not detectably associate with EGFR in these cells and shRNA-mediated knockdown of NHE-RF2 expression has little effect on the association between Merlin and EGFR (Fig. 5 C; not depicted). These data suggest that Merlin–EGFR association is mediated specifi cally by NHE-RF1.Adhesion-dependent function of MerlinMerlin localizes to AJs and is required for AJ stabilization (Lallemand et al., 2003). Our previous studies suggest that upon cell–cell contact, Merlin is recruited to and activated at nascent AJs; indeed, Merlin also associates with E-cadherin in epithe-lial cells (Lallemand et al., 2003). The simplest interpretation of our data is that active, cadherin-associated Merlin “captures” the NHE-RF1–EGFR complex, thereby retaining it. Consistent with this hypothesis, we found that the association between EGFR and E-cadherin in confl uent Nf2-expressing cells is NHE-RF1 dependent, whereas the association of Merlin with E-cadherin is NHE-RF1 independent (Fig. 5, A and D). A key prediction of this model is that the association between Merlin and both NHE-RF1 and EGFR is dependent on cell–cell contact; indeed, as shown in Fig. 5 (E and F), the association between Merlin and NHE-RF1 or EGFR is dramatically enhanced with in-creasing cell density. In contrast, the association between EGFR and NHE-RF1 is not adhesion dependent (Fig S5 A, available at http://www.jcb.org/cgi/content/full/jcb.200703010/DC1). Importantly, after acute disruption of intercellular contacts by Ca2+ depletion, Merlin rapidly dissociates from EGFR (Fig. 5 F), indicating that cell–cell adhesion is a strict determinant for EGFR–Merlin association.Pharmacological inhibition of EGFR inhibits proliferation of conﬂ uent Nf2−/− cellsTo determine whether EGFR activation is responsible for the persistent tyrosine phosphorylation of membrane proteins and proliferation of confl uent Nf2−/− cells, we treated Nf2−/− MEFs, OBs, and LDCs with pharmacologic EGFR inhibitors. Both Compound 56 and Gefi tinib (Iressa), potent specifi c inhibitors of EGFR kinase activity (Gschwind et al., 2004), eliminated the high membrane pTyr content in confl uent Nf2−/− cells of all three cell types in the presence of serum  (Fig. 6 A; not  depicted). The specifi city of each compound was demonstrated by its ability to block EGF- but not PDGF-induced membrane pTyr (Fig. 6 A; not depicted). Importantly, before confl uence, EGFR inhibitors had only a modest effect on the proliferation of pri-mary Nf2−/− MEFs, OBs, and LDCs in the presence of serum Figure 5. NHE-RF1–mediated, contact-dependent asso-ciation of Merlin and EGFR. (A) Immunoprecipitation of EGFR from total membrane extracts of Nf2wt-expressing LDCs with and without lentiviral NHE-RF1 shRNA expres-sion revealed that the association of both Nf2wt and E-cadherin with the EGFR are nearly eliminated by NHE-RF1 knockdown. (B) Immunoprecipitation of Ezrin reveals that the association of Nf2wt with Ezrin occurs in a NHE-RF1–independent manner. (C) NHE-RF2 knockdown does not affect EGFR-Merlin association. (D) The association between Nf2wt and E-cadherin is not affected by NHE-RF1 down-regulation. (E) Immunoprecipitation of NHE-RF1 from total membrane extracts of subconﬂ uent (s) and con-ﬂ uent (c) Nf2wt-expressing LDCs revealed that the associa-tion between Nf2wt and NHE-RF1 occurs only in conﬂ uent conditions. Total IgG is shown as a control for the NHE-RF1 immunoprecipitations. (F) Immunoprecipitation of EGFR from total membrane extracts of Nf2wt-expressing LDCs when sparse (s), conﬂ uent (c), and after cell–cell contact disruption by incubation in Ca2+-depleted medium for 45 min (d). Complexing of Merlin and EGFR markedly increases from sparse to conﬂ uent cells and is abrogated by acute loss of intercellular contacts. All experiments were performed at least three times.MERLIN INHIBITS EGFR SIGNALING • CURTO ET AL.899(Fig. 6, B and C; not depicted), indicating that proliferation of non-contacting cells can be sustained by serum-derived signals other than those mediated by EGFR. However, EGFR inhibition halted proliferation at high cell density; thus, Nf2−/− cells can undergo contact-dependent inhibition of proliferation if EGFR activity is blocked. As shown in Fig. 6 D, EGFR inhibition did not restore permanent contact-dependent inhibition of prolifera-tion to Nf2−/− cells because withdrawal of the inhibitor led to re-entry into the proliferative state despite the high cell density. These results suggest that EGFR inhibitors, already in clinical use for several human cancers, could also be of therapeutic benefi t for NF2-defi cient tumors. In fact, EGFR inhibitors may actually be more effi cacious in preventing the physiologic EGFR activation that persists in confl uent Nf2−/− cells rather than the high levels driven by oncogenic EGFR mutations. Notably, signaling via EGFR family members (ErbBs) is critical for the proliferation and survival of Schwann cells, the principle target of NF2-associated tumorigenesis in humans (Garratt et al., 2000).DiscussionThe discovery, in 1993, that the NF2 tumor suppressor, Merlin, is a member of a family of membrane/cytoskeleton-associated proteins suggested a novel mechanism of tumor suppression (Rouleau et al., 1993; Trofatter et al., 1993). Amidst the identifi -cation of many Merlin-interacting proteins and Merlin-controlled activities, a clear role for Merlin in controlling contact-dependent inhibition of proliferation has emerged (Morrison et al., 2001; Johnson et al., 2002; Lallemand et al., 2003). Loss of contact-dependent inhibition of proliferation is a signature of cell trans-formation, but the molecular basis of this phenomenon is not known. Our previous work identifi ed a role for Merlin in stabi-lizing AJs between cells, but did not pinpoint the mitogenic sig-nal that drives proliferation in the absence of Merlin and normal AJs (Lallemand et al., 2003). An intimate relationship between RTK activity and AJ stability clearly exists, but its molecular un-derpinnings are only beginning to emerge (for review see Brunton et al., 2004). We have now found that Merlin directly interferes with EGFR signaling in a contact-dependent manner, providing key insight into the molecular basis of contact-dependent inhibi-tion of proliferation and directly linking the functions of a novel tumor suppressor and a well-known oncogene.The aberrant cell–cell communication and persistent EGFR signaling in confl uent Nf2−/− cells, together with the localization of EGFR to AJs, suggests that Merlin normally co-ordinates the processes of AJ stabilization and negative regula-tion of the EGFR by establishing their interdependence as they occur. Our data are consistent with a model wherein the following sequence of events occurs (Fig. 7 A): Merlin is recruited to nascent AJs (Lallemand et al., 2003) where it is activated and begins to stabilize the developing junctions and sequester a pool of EGFR into a compartment from which it does not have access to its immediate downstream targets and cannot be inter-nalized. Whether Merlin is in an “open” or “closed” conformation at this stage remains to be established; although many studies suggest that “active” Merlin is not phosphorylated at serine 518, it is not clear whether this hypophosphorylated form of Merlin is consistently self-associated. The ensuing localized reduction of EGFR tyrosine kinase activity at contact sites, in turn, may further stabilize AJs, perhaps via altering the phosphorylation of AJ components such as p120 (see Fig. 1 E) and/or the activity of Rac. Indeed, while initial stages of AJ formation are accom-panied by increased tyrosine kinase activity and activation of the small GTPase Rac, a classic target of EGFR signaling that mediates dynamic membrane/cytoskeletal remodelling at cell–cell interfaces (Pece and Gutkind, 2000; Betson et al., 2002; Goodwin et al., 2003), later stages are often associated with nega-tive regulation of both EGFR and Rac (Brunton et al., 2004). This could explain previously reported roles for Merlin in nega-tively regulating both Rac and its effector Pak and in modu-lating actin cytoskeleton remodelling (James et al., 2001; Shaw et al., 2001; Kissil et al., 2003; Manchanda et al., 2005). Al-though the precise mechanism whereby Merlin associates with the actin cytoskeleton is not yet clear, we have found that as-sociation with the cortical actin cytoskeleton is necessary for the growth-suppressing and EGFR-inhibiting activities of Merlin (Cole, B.K., personal communication).Molecularly, our studies indicate that Merlin directly links the AJ and EGFR. Indeed, the trilobed structure of the four-point-one, ERM (FERM) domain appears well-designed for as-sembling multiple proteins (Pearson et al., 2000). We found that the association between Merlin and EGFR is mediated by the tandem PDZ domain–containing adaptor NHE-RF1, which is known to interact with the third lobe of the ERM FERM domain Figure 6. Pharmacological inhibitors of EGFR arrest proliferation of Nf2 −/− cells. (A) Tyrosine phosphorylation of membrane proteins in late-conﬂ uent Nf2−/− MEFs is eliminated by the EGFR inhibitor Compound 56. In the presence of the inhibitor (added 2 h before EGF addition), pTyr in-duction is blocked after stimulation with EGF (40 ng/ml) but not PDGF (35 ng/ml) for 30 min. Similar speciﬁ city was observed for Geﬁ tinib (not depicted). Proliferation of Nf2−/− OBs (B) and LDCs (C) at high cell density is inhibited by Geﬁ nitib. (D) Inhibition of EGFR by Geﬁ tinib does not per-manently restore contact inhibition of growth in LDCs. All experiments were performed at least three times. (Error bars, ± SD).JCB • VOLUME 177 • NUMBER 5 • 2007 900(Finnerty et al., 2004; Terawaki et al., 2006). NHE-RF1 can as-sociate with and is thought to regulate the surface abundance of several different receptors (for review see Weinman et al., 2006). In fact, it has been reported that NHE-RF1 stabilizes and slows the down-regulation of surface EGFR (Lazar et al., 2004); how-ever, neither this nor other studies have explored how functional specifi city is applied to such a wide range of receptor interac tions, and it is not clear how temporal and spatial regulation of NHE-RF1–associated receptors is achieved. Our studies suggest that Merlin confers one such level of specifi city by locally engaging NHE-RF1–associated EGFR at the AJ.The ERM proteins also interact with NHE-RF1 and are required for stable apical localization of NHE-RF1 in the in-testinal epithelium (Saotome et al., 2004). However, the ERM proteins likely engage a distinct subset of NHE-RF–associated receptors. Consistent with the tendencies of the ERM proteins and Merlin to be apically or apical-junctionally concentrated, respectively, the ERM proteins appear to be functionally dedi-cated to the apical membrane and Merlin to the junctional domain (Fig. 7 B). By analogy to the roles of Merlin in both stabilizing the association between adhesion proteins and the actin cytoskeleton and locally “capturing” NHE-RF1–EGFR complexes, Ezrin may stabilize the association between the apical membrane and cortical cytoskeleton while capturing apical NHE-RF receptor complexes (Fig. 7 B). Indeed, Ezrin is required for establishing or maintaining the integrity of the apical surface of intestinal epithelial cells in vivo (Saotome et al., 2004). In contrast to Merlin, Ezrin does not associate with EGFR or E-cadherin, mediate contact-dependent inhibition of proliferation, or effect EGFR internalization/signaling in the cells studied here (Fig. S5 B), and overproliferation is not detected in the ERM-defi cient intestine (Saotome et al., 2004).It is clear that AJs are continuously remodelled both in confl uent monolayers in culture and in tissues in vivo. In vivo, Figure 7. Molecular and spatial attributes of Merlin function. (A) Model depicting the mechanism of Merlin-mediated coordination of AJ stabilization and EGFR down-regulation. In non-contacting cells (1), Merlin does not associate with cadherin or EGFR; however, upon cell–cell contact (2), Merlin is recruited to nascent junctions and activated, stabilizing the interaction between junctional proteins and the cortical cytoskeleton. Activated Merlin then “captures” NHE-RF1-associated EGFR (3), preventing it from internalizing or signaling. Active Merlin is likely hypophosphorylated and could be in an “open” or “closed” (self-associated) conformation; indeed, more than two conformational states of Merlin may exist. Although Merlin lacks the C-terminal actin-binding domain present in the ERM proteins, some studies suggest that Merlin can interact directly with ﬁ lamentous actin via the FERM domain. Despite an abundance of evidence linking Merlin physically and functionally to the actin cytoskeleton, the precise mechanism whereby Merlin associates with the actin cytoskeleton remains unclear. (B) Although Merlin and the ERM proteins can all interact with NHE-RF1 and NHE-RF1 can, in turn, interact with several mem-brane receptors, Merlin may be functionally dedicated to the junctional domain and the ERM proteins to the apical domain. In this way, spatial and temporal regulation of NHE-RF1–associated receptors may be achieved.MERLIN INHIBITS EGFR SIGNALING • CURTO ET AL.901all cells in solid tissues are in contact and junctional remodel-ing and cell proliferation must be exquisitely coordinated.  Localization to intercellular adhesions may render the EGFR uniquely able to sense and modulate changes in cell contact and to fi ne-tune its activity accordingly. Our molecular model of Merlin-mediated coordination of AJ stabilization and EGFR down- regulation provides ample opportunity for fl exibility. For example, phosphor ylation or phospholipid binding may alter Merlin self-association and/or membrane distribution, coordinately affecting junction stability and EGFR signaling. Indeed, both hypo- and hyperphos phorylated forms of Merlin are associated with EGFR (Fig. 4 B, Fig. 5 A), suggesting that S518 phos-phorylation may regulate Merlin-associated EGFRs. We found that the association of Merlin with E-cadherin and with NHE-RF1–EGFR are both contact dependent; however, it is interest-ing to note that while the association of Merlin with E-cadherin and NHE-RF1 is maintained after acute disruption of inter-cellular contacts (not depicted), the association between Merlin and EGFR is rapidly lost, suggesting disengagement of NHE-RF1–EGFR in this specifi c context. Our studies also indicate that the status of cell–cell contact has profound implications for the propagation of EGFR signaling. Conversely, in the context of EGFR-driven tumorigenesis, a critical line of investigation will be to determine whether oncogenic variants of the EGFR can evade the contact-dependent inhibition of signaling imposed by Merlin.Pharmacologic EGFR inhibition abolished the persistent tyrosine phosphorylation of membrane proteins and the prolif-eration of three types of Nf2−/− cells in the presence of serum, suggesting that EGFR activation is necessary and suffi cient to cause these phenotypes. This also suggests a novel avenue of therapeutic exploration for NF2. However, given that NHE-RF1 can associate with multiple receptors, Merlin may well affect other receptors by a similar mechanism. In fact, the results pre-sented here are complementary to those of Maitra et al. (2006), who reported altered surface availability of EGFR and other membrane receptors in Drosophila tissues lacking both Merlin and the related tumor suppressor, Expanded. Similarly, Merlin could coordinate regulation of EGFR or other receptors with alter-native adhesion receptors such as CD44; it has been proposed that Merlin mediates contact-dependent inhibition of prolifera-tion via CD44 in other cell types (Morrison et al., 2001). Indeed, the theme of Merlin-mediated coordination of cell adhesion and membrane receptor signaling is echoed by recent work in Drosophila suggesting that Merlin inhibits signaling through the Hippo/Warts/Yorkie pathway (Huang et al., 2005; Hamaratoglu et al., 2006), corresponding to the conserved Mst/Lats/Yap path-way in mammals. Activation of this pathway in response to extracellular signals appears to be coordinately regulated by Merlin and Expanded, which signals from the Fat cadherin re-ceptor (Bennett and Harvey, 2006; Silva et al., 2006; Willecke et al., 2006). However, neither the source of that extracellular signal nor the signaling receptor(s) involved have been identifi ed in mammals or fl ies (Edgar, 2006). The data presented here in-dicate that Merlin could regulate signaling through this pathway by directly coordinating EGFR signaling output with cadherin-dependent intercellular adhesion.Materials and methodsCell culture and expression vectorsWild-type and Nf2−/− primary MEFs were prepared as described previ-ously (Lallemand et al., 2003). Wild-type primary OBs were prepared from calvaria of Nf2ﬂ ox2/ﬂ ox2 newborn mice as described previously (Ducy and Karsenty, 1995). Nf2 deletion in OBs was achieved via adenoviral expression of the Cre-recombinase as we described for MEFs (Lallemand et al., 2003). Primary MEFs and OBs were used between passages 3 and 6. Epithelial Nf2−/− LDCs were derived by liver-speciﬁ c, deletion of Nf2 in vivo by crossing Nf2ﬂ ox2/ﬂ ox2 mice to transgenic Alb-Cre mice (Postic et al., 1999) (B6.Cg-Tg(Alb-cre)21Mgn/J; Jackson Laboratories). In brief, the liver of a 12-wk-old Alb-Cre;Nf2ﬂ ox2/ﬂ ox2 mouse was removed, minced, dissociated in Liver Disso-ciation Medium (Invitrogen), and cultured in 10% FBS-DME. Wild-type epi-thelial embryonic liver cells were derived from the liver of a day-14.5 Nf2ﬂ ox2/ﬂ ox2 embryo as described by Strick-Marchand and Weiss (2002), and subsequently adapted to the standard growth conditions used for all other cell lines. Clonal cell lines were established by limiting dilution. The generation and use of adenoviral vectors expressing Nf2wt and Nf2L64P have been described previously (Lallemand et al., 2003).AntibodiesPrimary antibodies against the following antigens were from Upstate Bio-technology (active-β-catenin: ABC, 05–665, 1:1,000 dilution); Transduction Laboratories (pTyr: RC20, 610023; β-catenin: 610153; E-cadherin: 610182; p120ctn: 610133; p120ctn-pY228: 612536; Caveolin-pY14: 611338; c-Cbl: 610441; Grb2: 610111; Sos1: 610095; PLCγ: 610027; Rac1: 612652; all at 1:1,000 or 2,000 dilution); Santa Cruz Biotechnol-ogy, Inc. (Merlin: sc331, 1:40,000 dilution; EGFR: sc1005); Cell Signaling (EGFR-pY845: 2231; EGFR-pY992: 2235; EGFR-pY1068: 2234; STAT3-pY705: 9131; STAT5-pY694: 9351; Shc-pY239/240: 2434; MAPK-pT202/Y204: 5120; AKT-pS473: 9271; Raf-pS259: 9421, all at 1:1,000 dilution); Biosource International (Src: 44–656; Src-pY418: 44–660, used at 1:1,000); Abcam (EBP50/NHERF-I: ab3452); NeoMarker (EGFR: Ab17; Ezrin: Ab1); Sigma-Aldrich (actin: A-2547). Monoclonal anti-Merlin 1C4 (a gift of Vijaya Ramesh, Massachusetts General Hospital, Boston, MA) was used at 1:1,000. Polyclonal anti-NHE-RF2 (B70; gift of Anthony Bretscher, Cornell University, Ithaca, NY) was used at 1:1,000. HRP-conjugated secondary antibodies to rabbit, mouse, or rat were from GE Healthcare.Subcellular fractionation and Western blot analysisEqual protein amounts of total cell and membrane extracts were analyzed by Western blot as described previously (Lallemand et al., 2003) with one modiﬁ cation: the membrane pellet was directly solubilized in RIPA buffer containing 0.5% SDS. For density-gradient separation, postnuclear membrane pellets from three 150-mm dishes of late conﬂ uent MEFs were lysed on ice for 30 min in Triton-lysis buffer (1% Triton X-100, 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, and 10 mM β-glycerophosphate plus protease and phosphatase inhibitors), resuspended in buffer A (250 mM sucrose, 1 mM EDTA, 20 mM tricine, and 1% Triton X-100 and inhibitors) containing 35% Optiprep, sequentially overlayed with 25, 15, 5, and 0% Optiprep-buffer A and centrifuged for 3.5 h at 160000 g. Fractions collected at the interfaces I = 0–5%, II = 5–15%, III = 15–25%, IV = 25–35%, and the pellet V > 35%, were resuspended in RIPA buffer and analyzed (7 μg/lane) by immunoblotting.Immunoﬂ uorescence and ligand-internalization assayLDCs plated on glass coverslips were infected with Ad.Nf2wt or Ad.Nf2L64P when ⵑ50% conﬂ uent. After 4–5 d, conﬂ uent monolayers were serum starved in 1% BSA in DME for 2 h, incubated for 30 min at 37°C with 2 μg/ml Tr-EGF (E3480; Molecular Probes) or 10 μg/ml Alexa Fluor 488-Transferrin (T13342; Molecular Probes), and ﬁ xed in 4% PFA-cytoskeletal buffer (10 mM MES, pH 6.3, 2 mM EGTA, 3 mM MgCl2, and 138 mM KCl) for 15 min at room temperature. After permeabilization in 0.2% Triton X-100, cells were incubated with primary anti-NF2 antibody (sc331; 1:300 in 1% BSA-PBS) overnight at 4°C. After incubation with FITC- or rhodamine-conjugated anti–rabbit secondary antibody (Jackson Immuno-research Laboratories; 1:200), coverslips were mounted with Vectashield (Vector Laboratories). To create noncontacting free edges in Ad.Nf2wt-infected LDCs, monolayers growing in 10% FBS-DME were scrape-wounded with a pipet tip, allowed to recover for ⵑ6 h, and starved (2 h) before adding Tr-EGF as described above. To disrupt intercellular adhesion by depletion of extracellular Ca2+, monolayers were serum starved for 2 h, washed twice in Ca2+-free DME (Invitrogen), incubated in 2 μg/ml Tr-EGF, 1% BSA, and 5 mM EGTA in Ca2+-free DME and ﬁ xed as above at the indicated JCB • VOLUME 177 • NUMBER 5 • 2007 902time points. Images were acquired using a 63× 1.4NA oil objective lens (Carl Zeiss MicroImaging, Inc.) on an Axioplan microscope (Carl Zeiss MicroImaging, Inc.) with IP Lab software and a Sony CCD camera. Final images were prepared using Adobe Photoshop 7.0.Surface biotinylation and immunoprecipitationLate conﬂ uent MEFs or OBs were serum starved overnight in DME, shifted to 4°C, rinsed twice in cold PBS and incubated for 1 h with 0.5 μg/ml EZ-Link Sulfo-NHS-LC-Biotin (Pierce Chemical Co.) in PBS. After quenching the re action (50 mM NH4Cl, 1 mM MgCl2, and 0.1 mM CaCl2 for 10 min) and rinsing in PBS, cells were returned to 10% FBS-DME at 37°C and lysed in Triton-lysis buffer containing 60 mM Octylglucoside (n-Octyl-β-D-glucopyranoside; Calbiochem) at the indicated time points. Normalized extracts (600 μg total protein/400 μl) were precleared with protein A–Sepharose prebound to normal rabbit IgG for 2 h at 4°C. Anti-EGFR antibody (Ab17, Neo-Marker; 8 μg/sample) or streptavidin-coupled agarose beads (50 μl; Pierce Chemical Co.) were added to precleared extracts and incubated overnight at 4°C. The following day, EGFR-containing immunocomplexes were precipitated with protein A–Sepharose beads (40 μl, 2 h, at 4°C). Beads from either immunoprecipitation or biotin pull-down were washed ﬁ ve times in the above buffer and boiled 5 min in 2× sample buffer. Com-plexes were separated by 8% SDS-PAGE and analyzed by Western blot as described above. Biotinylated-immunoprecipitated EGFR was detected with HRP-conjugated streptavidin. Immunoprecipitations of EGFR (Ab17; 8 μg) and E-cadherin (3 μg) from LDCs were from total membrane extracts in the above Triton-Octylglucoside buffer (800 μg total protein/400 μl). To disrupt intercellular adhesion by depletion of extracellular Ca2+, conﬂ uent monolayers were washed twice in PBS/5 mM EGTA, and incubated in Ca2+-free DME (Invitrogen) containing 10% Ca2+-chelated FBS for 45 min.Cell proliferationMEFs, OBs (5 × 104) or LDCs (7.5 × 104) were seeded in triplicate 15-mm wells in 5% FBS-DME. The following day, 1 μM Geﬁ tinib (Iressa; AstraZeneca) or 0.5 μM Compound 56 (Calbiochem) were added to culture wells; cells were trypsinized and counted every other day. Fresh medium with or with-out inhibitors was added each day of counting. For drug withdrawal, 1 μM Geﬁ tinib was added to LDCs daily until day 5 post-seeding, when half of the wells were returned to 5% FBS-DME only. Beginning that day, cells were counted and fresh medium with or without inhibitor was added to the re-maining wells every other day.shRNA-mediated knockdownSeveral shRNA constructs against NHE-RF1 (#68583-68587) and NHE-RF2 (#68613-68615, 68617) in the lentiviral pLKO.1 vector were ob-tained from Open Biosystems and tested for NHE-RF1/2 knockdown in Nf2−/− LDCs; #68587 and #68617 were used for experiments. Lentiviral production and infection was performed as described previously (Bailey et al., 2006).Online supplemental materialFig. S1 shows level and distribution of adhesion molecules in various cell types used in this work. Fig. S2 deﬁ nes conﬂ uence states in mesenchymal cells and shows transmission electron micrographs that reveal restoration of electrondense AJs upon expression of Nf2wt in LDCs. Fig. S3 shows in-ternalization of ﬂ uorescent EGF and transferrin in LDCs, EGFR localization in LDCs, and inhibition of ﬂ uorescent EGF internalization in conﬂ uent em-bryonic liver cells expressing endogenous Nf2. Fig. S4 shows decreased EGFR solubility in the presence of Merlin and a similar dose dependency of EGFR auto-phosphorylation in the presence or absence of Merlin. Fig. S5 shows that the association of endogenous EGFR and NHE-RF1 is contact independent and reveals the lack of association between Ezrin and EGFR or Ezrin and E-cadherin in LDCs. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200703010/DC1.We would like to thank Marco Giovannini (INSERM, Paris, France) for providing Nf2ﬂ ox2/ﬂ ox2 mice and for many stimulating discussions. We would also like to thank Spyros Artavanis-Tsakonas, Silvia Fre, and Jeff Settleman for helpful discussions and for commenting on the manuscript; Tony Bretscher for providing the polyclonal anti-NHE-RF2 antibody; Vijaya Ramesh (Massachusetts General Hospital, Boston, MA) for providing the monoclonal anti-NF2 antibody; and William Fowle for transmission electron microscopy.This work was supported by the Department of Defense Neuroﬁ bromatosis Research Program (NFRP) and National Institutes of Health (A.I.M.).Submitted: 2 March 2007Accepted: 4 May 2007ReferencesAdams, C.L., W.J. Nelson, and S.J. Smith. 1996. Quantitative analysis of cadherin-catenin-actin reorganization during development of cell-cell adhesion. J. Cell Biol. 135:1899–1911.Bailey, S.N., S.M. Ali, A.E. Carpenter, C.O. Higgins, and D.M. Sabatini. 2006. Microarrays of lentiviruses for gene function screens in immortalized and primary cells. Nat. Methods. 3:117–122.Baser, M.E., J.M. Friedman, A.J. Wallace, R.T. Ramsden, H. Joe, and D.G. Evans. 2002. Evaluation of clinical diagnostic criteria for neurofi broma-tosis 2. Neurology. 59:1759–1765.Bennett, F.C., and K.F. Harvey. 2006. Fat cadherin modulates organ size in Drosophila via the Salvador/Warts/Hippo signaling pathway. Curr. Biol. 16:2101–2110.Betson, M., E. Lozano, J. Zhang, and V.M. Braga. 2002. Rac activation upon cell-cell contact formation is dependent on signaling from the epidermal growth factor receptor. J. Biol. Chem. 277:36962–36969.Bretscher, A., K. Edwards, and R.G. Fehon. 2002. ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell Biol. 3:586–599.Brunton, V.G., I.R. MacPherson, and M.C. Frame. 2004. Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochim. Biophys. Acta. 1692:121–144.Ducy, P., and G. Karsenty. 1995. Two distinct osteoblast-specifi c cis-acting ele-ments control expression of a mouse osteocalcin gene. Mol. Cell. Biol. 15:1858–1869.Edgar, B.A. 2006. From cell structure to transcription: Hippo forges a new path. Cell. 124:267–273.Finnerty, C.M., D. Chambers, J. Ingraffea, H.R. Faber, P.A. Karplus, and A. Bretscher. 2004. The EBP50-moesin interaction involves a bind-ing site regulated by direct masking on the FERM domain. J. Cell Sci. 117:1547–1552.Garratt, A.N., S. Britsch, and C. Birchmeier. 2000. Neuregulin, a factor with many functions in the life of a schwann cell. Bioessays. 22:987–996.Giovannini, M., E. Robanus-Maandag, M. van der Valk, M. Niwa-Kawakita, V. Abramowski, L. Goutebroze, J.M. Woodruff, A. Berns, and G. Thomas. 2000. Conditional biallelic Nf2 mutation in the mouse promotes manifes-tations of human neurofi bromatosis type 2. Genes Dev. 14:1617–1630.Goodwin, M., E.M. Kovacs, M.A. Thoreson, A.B. Reynolds, and A.S. Yap. 2003. Minimal mutation of the cytoplasmic tail inhibits the ability of E-cadherin to activate Rac but not phosphatidylinositol 3-kinase: direct evidence of a role for cadherin-activated Rac signaling in adhesion and contact forma-tion. J. Biol. Chem. 278:20533–20539.Grazia Lampugnani, M., A. Zanetti, M. Corada, T. Takahashi, G. Balconi, F. Breviario, F. Orsenigo, A. Cattelino, R. Kemler, T.O. Daniel, and E. Dejana. 2003. Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J. Cell Biol. 161:793–804.Gschwind, A., O.M. Fischer, and A. Ullrich. 2004. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer. 4:361–370.Hamaratoglu, F., M. Willecke, M. Kango-Singh, R. Nolo, E. Hyun, C. Tao, H. Jafar-Nejad, and G. Halder. 2006. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell prolif-eration and apoptosis. Nat. Cell Biol. 8:27–36.Hirokawa, Y., A. Tikoo, J. Huynh, T. Utermark, C.O. Hanemann, M. Giovannini, G.H. Xiao, J.R. Testa, J. Wood, and H. Maruta. 2004. A clue to the therapy of neurofi bromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J. 10:20–26.Hoschuetzky, H., H. Aberle, and R. Kemler. 1994. Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J. Cell Biol. 127:1375–1380.Huang, J., S. Wu, J. Barrera, K. Matthews, and D. Pan. 2005. The Hippo signaling pathway coordinately regulates cell proliferation and apop-tosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell. 122:421–434.James, M.F., N. Manchanda, C. Gonzalez-Agosti, J.H. Hartwig, and V. Ramesh. 2001. The neurofi bromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the fi laments through a lateral association. Biochem. J. 356:377–386.Johannessen, L.E., N.M. Pedersen, K.W. Pedersen, I.H. Madshus, and E. Stang. 2006. Activation of the epidermal growth factor (EGF) receptor induces formation of EGF receptor- and Grb2-containing clathrin-coated pits. Mol. Cell. Biol. 26:389–401.Johnson, K.C., J.L. Kissil, J.L. Fry, and T. Jacks. 2002. Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. Oncogene. 21:5990–5997.MERLIN INHIBITS EGFR SIGNALING • CURTO ET AL.903Kissil, J.L., E.W. Wilker, K.C. Johnson, M.S. Eckman, M.B. Yaffe, and T. Jacks. 2003. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol. Cell. 12:841–849.LaJeunesse, D.R., B.M. McCartney, and R.G. Fehon. 2001. A systematic screen for dominant second-site modifi ers of Merlin/NF2 phenotypes reveals an interaction with blistered/DSRF and scribbler. Genetics. 158:667–679.Lallemand, D., M. Curto, I. Saotome, M. Giovannini, and A.I. McClatchey. 2003. NF2 defi ciency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 17:1090–1100.Lazar, C.S., C.M. Cresson, D.A. Lauffenburger, and G.N. Gill. 2004. The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor re-ceptors at the cell surface. Mol. Biol. Cell. 15:5470–5480.Lucero, H.A., and P.W. Robbins. 2004. Lipid rafts-protein association and the regulation of protein activity. Arch. Biochem. Biophys. 426:208–224.Maitra, S., R.M. Kulikauskas, H. Gavilan, and R.G. Fehon. 2006. The tumor suppressors Merlin and expanded function cooperatively to modulate receptor endocytosis and signaling. Curr. Biol. 16:702–709.Manchanda, N., A. Lyubimova, H.Y. Ho, M.F. James, J.F. Gusella, N. Ramesh, S.B. Snapper, and V. Ramesh. 2005. The NF2 tumor suppressor Merlin and the ERM proteins interact with N-WASP and regulate its actin poly-merization function. J. Biol. Chem. 280:12517–12522.McClatchey, A.I. 2003. Merlin and ERM proteins: unappreciated roles in cancer development? Nat. Rev. Cancer. 3:877–883.McClatchey, A.I., and M. Giovannini. 2005. Membrane organization and tumori-genesis–the NF2 tumor suppressor, Merlin. Genes Dev. 19:2265–2277.McClatchey, A.I., I. Saotome, K. Mercer, D. Crowley, J.F. Gusella, R.T. Bronson, and T. Jacks. 1998. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 12:1121–1133.Morrison, H., L.S. Sherman, J. Legg, F. Banine, C. Isacke, C.A. Haipek, D.H. Gutmann, H. Ponta, and P. Herrlich. 2001. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through inter-actions with CD44. Genes Dev. 15:968–980.Murthy, A., C. Gonzalez-Agosti, E. Cordero, D. Pinney, C. Candia, F. Solomon, J. Gusella, and V. Ramesh. 1998. NHE-RF, a regulatory cofactor for Na(+)-H+ exchange, is a common interactor for merlin and ERM (MERM) proteins. J. Biol. Chem. 273:1273–1276.Nguyen, R., D. Reczek, and A. Bretscher. 2001. Hierarchy of merlin and ezrin N- and C-terminal domain interactions in homo- and heterotypic associa-tions and their relationship to binding of scaffolding proteins EBP50 and E3KARP. J. Biol. Chem. 276:7621–7629.Okada, T., M. Lopez-Lago, and F.G. Giancotti. 2005. Merlin/NF-2 mediates con-tact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J. Cell Biol. 171:361–371.Pearson, M.A., D. Reczek, A. Bretscher, and P.A. Karplus. 2000. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell. 101:259–270.Pece, S., and J.S. Gutkind. 2000. Signaling from E-cadherins to the MAPK path-way by the recruitment and activation of epidermal growth factor recep-tors upon cell-cell contact formation. J. Biol. Chem. 275:41227–41233.Postic, C., M. Shiota, K.D. Niswender, T.L. Jetton, Y. Chen, J.M. Moates, K.D. Shelton, J. Lindner, A.D. Cherrington, and M.A. Magnuson. 1999. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specifi c gene knock-outs using Cre recombinase. J. Biol. Chem. 274:305–315.Qian, X., T. Karpova, A.M. Sheppard, J. McNally, and D.R. Lowy. 2004. E-cadherin- mediated adhesion inhibits ligand-dependent activation of diverse re-ceptor tyrosine kinases. EMBO J. 23:1739–1748.Ramesh, V. 2004. Merlin and the ERM proteins in Schwann cells, neurons and growth cones. Nat. Rev. Neurosci. 5:462–470.Reczek, D., M. Berryman, and A. Bretscher. 1997. Identifi cation of EBP50: A PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family. J. Cell Biol. 139:169–179.Roepstorff, K., P. Thomsen, K. Sandvig, and B. van Deurs. 2002. Sequestration of epidermal growth factor receptors in non-caveolar lipid rafts inhibits ligand binding. J. Biol. Chem. 277:18954–18960.Roudabush, F.L., K.L. Pierce, S. Maudsley, K.D. Khan, and L.M. Luttrell. 2000. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J. Biol. Chem. 275:22583–22589.Rouleau, G.A., P. Merel, M. Lutchman, M. Sanson, J. Zucman, C. Marineau, K. Hoang-Xuan, S. Demczuk, C. Desmaze, B. Plougastel, et al. 1993. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fi bromatosis type 2. Nature. 363:515–521.Saotome, I., M. Curto, and A.I. McClatchey. 2004. Ezrin is essential for epithe-lial organization and villus morphogenesis in the developing intestine. Dev. Cell. 6:855–864.Shaw, R.J., A.I. McClatchey, and T. Jacks. 1998. Regulation of the neurofi bro-matosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. J. Biol. Chem. 273:7757–7764.Shaw, R.J., J.G. Paez, M. Curto, A. Yaktine, W.M. Pruitt, I. Saotome, J.P. O'Bryan, V. Gupta, N. Ratner, C.J. Der, et al. 2001. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev. Cell. 1:63–72.Sherr, C.J. 2004. Principles of tumor suppression. Cell. 116:235–246.Silva, E., Y. Tsatskis, L. Gardano, N. Tapon, and H. McNeill. 2006. The tumor-suppressor gene fat controls tissue growth upstream of expanded in the Hippo signaling pathway. Curr. Biol. 16:2081–2089.Sorkin, A., and M. Von Zastrow. 2002. Signal transduction and endocytosis: close encounters of many kinds. Nat. Rev. Mol. Cell Biol. 3:600–614.Stang, E., F.D. Blystad, M. Kazazic, V. Bertelsen, T. Brodahl, C. Raiborg, H. Stenmark, and I.H. Madshus. 2004. Cbl-dependent ubiquitination is re-quired for progression of EGF receptors into clathrin-coated pits. Mol. Biol. Cell. 15:3591–3604.Stickney, J.T., W.C. Bacon, M. Rojas, N. Ratner, and W. Ip. 2004. Activation of the tumor suppressor merlin modulates its interaction with lipid rafts. Cancer Res. 64:2717–2724.Strick-Marchand, H., and M.C. Weiss. 2002. Inducible differentiation and mor-phogenesis of bipotential liver cell lines from wild-type mouse embryos. Hepatology. 36:794–804.Takahashi, K., and K. Suzuki. 1996. Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell-cell adhesion. Exp. Cell Res. 226:214–222.Terawaki, S., R. Maesaki, and T. Hakoshima. 2006. Structural basis for NHERF recognition by ERM proteins. Structure. 14:777–789.Trofatter, J.A., M.M. MacCollin, J.L. Rutter, J.R. Murrell, M.P. Duyao, D.M. Parry, R. Eldridge, N. Kley, A.G. Menon, K. Pulaski, et al. 1993. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofi bromatosis 2 tumor suppressor. Cell. 72:791–800.Weinman, E.J., R.A. Hall, P.A. Friedman, L.Y. Liu-Chen, and S. Shenolikar. 2006. The association of NHERF adaptor proteins with G protein-coupled receptors and receptor tyrosine kinases. Annu. Rev. Physiol. 68:491–505.Wilde, A., E.C. Beattie, L. Lem, D.A. Riethof, S.H. Liu, W.C. Mobley, P. Soriano, and F.M. Brodsky. 1999. EGF receptor signaling stimulates SRC kinase phosphorylation of clathrin, infl uencing clathrin redistribution and EGF uptake. Cell. 96:677–687.Willecke, M., F. Hamaratoglu, M. Kango-Singh, R. Udan, C.L. Chen, C. Tao, X. Zhang, and G. Halder. 2006. The fat cadherin acts through the Hippo tumor-suppressor pathway to regulate tissue size. Curr. Biol. 16:2090–2100.StemCellReportsArticleStemCellFactor-BasedIdentiﬁcationandFunctionalPropertiesofInVitro-SelectedSubpopulationsofMalignantMesotheliomaCellsWalterBlum,1,*La´szlo´Pecze,1EmanuelaFelley-Bosco,2LicunWu,3MarcdePerrot,3andBeatSchwaller11UnitofAnatomy,DepartmentofMedicine,UniversityofFribourg,RouteAlbert-Gockel1,1700Fribourg,Switzerland2LaboratoryofMolecularOncology,Lungen-undThoraxonkologieZentrum,UniversityHospitalZu¨rich,Sternwartstrasse14,8091Zu¨rich,Switzerland3LatnerThoracicSurgeryResearchLaboratories,DivisionofThoracicSurgery,TorontoGeneralHospital,UniversityHealthNetwork,UniversityofToronto,Toronto,ONM5G2C4,Canada*Correspondence:walter-vincent.blum@unifr.chhttp://dx.doi.org/10.1016/j.stemcr.2017.02.005SUMMARYMalignantmesothelioma(MM)isanaggressiveneoplasmcharacterizedbyapoorpatientsurvivalrate,becauseofrapidtumorrecurrencefollowingﬁrst-linetherapy.Cancerstemcells(CSCs)areassumedtoberesponsibleforinitiatingtumorigenesisanddrivingrelapseaftertherapeuticinterventions.CSC-enrichedMMcellsubpopulationswereidentiﬁedbyanOCT4/SOX2reporterapproachandwerecharacterizedby(1)increasedresistancetocisplatin,(2)increasedsensitivitytowardtheFAKinhibitorVS-6063invitro,and(3)ahighertumor-initiatingcapacityinvivoinorthotopicxenograftandallograftmousemodels.OverexpressionofNF2(neuroﬁbromatosis2,merlin),atumorsuppressoroftenmutatedorlostinMM,didnotaffectproliferationandviabilityofCSC-enrichedMMpopulationsbutrobustlydecreasedtheviabilityofreporter-negativecells.Incontrast,downregulationofcalretininstronglydecreasedproliferationandviabilityofbothpopulations.Insummary,wehaveenrichedandcharacterizedasmallMMcellsubpopulationthatbearstheexpectedCSCcharacteristics.INTRODUCTIONMalignantmesothelioma(MM)isahighlyaggressiveneoplasmmostoftenlinkedtoexposuretoasbestosﬁbers,whichinducechronicinﬂammationandperpetualtissuerepairbythesurroundingmesothelialcells.Chronichy-per-proliferationleadstoaseriesofgeneticandepigeneticmodiﬁcationsofthesecellsgraduallydevelopingintoma-lignantcancercellsandtumorformation(Staheletal.,2009).Therapygenerallycomprisesacombinationchemo-therapyconsistingofcisplatin(cis-Pt)andpemetrexed,attimesaccompaniedbyradiotherapyand/ortumorremovalbysurgery(Choetal.,2014).Thelowsuccessrateoftreat-mentsislikelycausedbyasubpopulationoftumorcellscharacterizedbyhighresistancetochemotherapyandahightumor-formingpotentialleadingtorapidrecurrence,theso-calledcancerstemcells(CSCs).Currentlynouni-versalmarkersexistforunambiguouslyidentifyingCSCsinMMorothercancertypes,possiblylinkedtothedy-namicandheterogeneouspropertiesofCSCs(Akrapetal.,2016).VariousassayshavebeendescribedtoenrichCSC-containingtumorcellsubpopulations:ﬂuorescence-activatedcellsorting(FACS)ofputativeCSCs,some-timesalsocalledtumor-initiatingcells(TICs),reliesmostlyonexpressionofcellsurfacemarkers(CD133,CD44,CD24;Klonischetal.,2008;orEpCAM;VisvaderandLin-deman,2008)orondye-exclusionassaysbasedontheelevatedexpressionofABCtransporterfamilymembers,e.g.,ABCG2(Hirschmann-Jaxetal.,2004).Alternatively,increasedaldehydedehydrogenase(ALDH1)activitychar-acterizesasubpopulationofcancercellswithCSCproper-ties(D’AngeloandWicha,2010),alsoinhumanMMcelllines(Shapiroetal.,2014).Thecurrentlymostcomprehen-sivecharacterizationofCSCsubpopulationshasallowedtheidentiﬁcationofahierarchicalorganization,whereCSCsubpopulationsdynamicallychangebetweenvariousdifferentiationstates(clusters)(Akrapetal.,2016).Eachclusterischaracterizedbyaseriesofgenes;CSCsexpressingtypical(normal)pluripotencystemcellmarkergenessuchasSOX2,NANOG,andOCT4(alsonamedPOU5F1)werefoundattheapexofthehierarchy,followedbypopulationsofonetoseveraltypesofprogenitorcellpopulationsexpressinggenessuchasALDH1andABCG2.Thus,CSC-enrichmentmethodsbasedonstemcellmarkerexpressionincludingSOX2andOCT4havebeenparticularlysuccess-fulinselectingtumorcellswith(1)thehightumor-formingpotentialinvivo,(2)theparticulargrowthpropertiesincludingself-renewalandasymmetriccelldivision,(3)theincreasedchemoresistance,and(4)theaggressivenessshowninothercancertypes(Gangemietal.,2009;Tangetal.,2015).TheconceptthatCSCswithinatumormassmightrepresentimportanttargetsfortherapyisnowacceptedfornearlyallcancertypes(Valentetal.,2012).Here,weidentiﬁedandcharacterizedMMcellsubpopu-lationsinvitrobasedontheirincreasedendogenousexpressionofSOX2andOCT4drivingareporter(EGFP)(Hottaetal.,2009;Tangetal.,2015).Wedemonstratethesecellstohavedifferentpropertieswithrespecttochemore-sistance,andthattheproportionofthesecellsappearstobedeterminedintrinsically,alsoinvolvingasymmetriccelldivision.Moreover,overexpressionofthetumorsuppressorNF2causedanalmostcompleteblockofcellStemCellReportsjVol.8j1005–1017jApril11,2017jª2017TheAuthor(s).1005ThisisanopenaccessarticleundertheCCBY-NC-NDlicense(http://creativecommons.org/licenses/by-nc-nd/4.0/).proliferationinnon-enrichedCSCcells,whilehighSOX2/OCT4-expressingcellsselectedbythereporterapproachwerebarelyaffectedbyforcedNF2expression.InjectionoftheEGFP(+)cellsresultedinanincreasedfrequency,number,andsizeoftumorsinvivocomparedwithcellswithlowSOX2/OCT4expression.Theseresultsareindica-tiveofaCSC-enrichedpopulationinMMcelllinesofhu-manandmouseoriginlikelyrelevantfortumorrelapse.RESULTSIdentiﬁcationandInitialCharacterizationofHighSOX2/OCT4-ExpressingHumanCSC-EnrichedMMCellsToidentifyputativeCSCsinMM,wereliedonatoolinitiallydevelopedforstemcellbiology(Hottaetal.,2009).Inthislentivirus-basedapproach,MMcellsofhu-manandmouseoriginwereinfectedwithaconstructthatcontainsSOX2-andOCT4-bindingsitesinthepromoterre-gion,followedbyanexpressioncassettecodingforEGFPandanIRESconnectingtoapuromycin-resistancecassette(Figure1A).Thus,cellsexpressinghighlevelsofSOX2/OCT4canbeidentiﬁedbyEGFPexpressionand,moreover,selected/isolatedbytheirpuromycinresistanceand/orbyFACS.TheoveralllentiviraltransductionefﬁciencyinMMcelllineswasassessedwithaconstitutiveNLS-mCherryconstruct(FiguresS1BandS1C).FACSanalysesre-vealedapproximately85%ofcellstoshowredﬂuorescence;anoverlayofbrightﬁeldandﬂuorescenceimagesfromtransducedZL55andRN5MMcellsandvisualinspectionindicatedthatthetransductionefﬁciencywaslikelyevenhigher,i.e.,intheorderof>90%(FigureS1B).Inthepopu-lationofinfectedZL55cellsnamedZL55-SOcells,weobservedapproximately5%ofEGFP-expressing(EGFP(+))cells(Figure1B).AsimilarpercentageofhighSOX2-andOCT4-expressingEGFP(+)cells(ZL55z4%;FigureS1A3)wasobtainedwiththeSORE6reporterconstructpreviouslyFigure1.AnEGFPReporter-BasedandPu-romycin-SelectedSubpopulationofZL55CellsShowsHigherTranscriptLevelsofCSC-AssociatedGenes(A)SchematicrepresentationofthepL-SIN-EOS-S(4+)-EiPlentiviral(LV)constructwithOCT4(blue)andSOX2(orange)bindingsites.BindingofOCT4andSOX2initiatesexpressionofEGFPandPuroR.(B)AsmallpercentageofEGFP(+)cellsispresentinLV-transducedZL55cells(leftpanel,brightﬁeldimage;rightpanel,ﬂuo-rescenceimage).(C)FACSanalysisrevealsanEGFP(+)sub-populationofaround5%(C2);withthesamegatingonly0.05%ofnon-infectedZL55cellsarecounted(C1).(D)Directlyafterpuromycinselectionstrin-gentFACSanalysisofZL55-SO-P2cellsiden-tiﬁes78.6%ofcellsasEGFP(+).(E)PuroRselectionresultsinavisibly100%positiveEGFP(+)ZL55-SO-P2subpopulation(right);leftimage:brightﬁeldimageofthesamecells.(F)qRT-PCRrevealsa4.5-foldincreaseforSOX2expressioninZL55-SO-P2andZL55-SO-P10cells(selectedwith2or10mg/mLofpuromycin,respectively)comparedwiththenon-selectedZL55-SOcells.OCT4levelsareincreased1.9-foldin-P2andnearly6-foldinthe-P10cells.AsigniﬁcantincreaseintheexpressionofABCG2aswellasCSF1Risdetected.Statisticalcomparisonswereper-formedusingaone-wayANOVA(*p<0.05)fromthreeindependentexperiments;errorbarsrepresentSD.SeealsoFigureS1.1006StemCellReportsjVol.8j1005–1017jApril11,2017usedinbreastcancercells(Tangetal.,2015).Thisper-centagelieswithinasimilarrangetothatobservedfortheZL55sidepopulation(2%SPcells,Freietal.,2011)orALDEFLUOR-positive(+)MM87cells(3.8%;Shapiroetal.,2014).QuantitativeanalysesbyFACSshowed4.86%ofZL55-SOcellstoexpresssufﬁcientlyhighlevelsofSOX2andOCT4todriveEGFPexpression(Figure1C).ZL55-SOcellssubjectedtopuromycin(2mg/mL)selectionfor7daysrevealedthesurvivingcellpopulationtoshowvari-ableEGFPexpressionandwerenamedZL55-SO-P2.InordertoexcludelikelyEGFP-negativeorlowEGFP-expressingcellsinthequantitativeFACSanalyses,basedonthestrin-gentFACSsettings,78.6%ofZL55-SO-P2cellsfulﬁlledthecriteriatobeunmistakablyidentiﬁedasEGFP(+)cells(Fig-ure1D);yet,byeye,essentiallyallcellsappearedtoemitgreenﬂuorescence(Figure1E).Inaddition,wegeneratedZL55-SO-P10cells,wherethepuromycinconcentrationwasaugmentedto10mg/mLaimedatselectingcellswiththehighestlevelsofSOX2andOCT4.Expressionlevels(mRNA)ofSOX2,OCT4,aswellaspreviouslyproposedMMCSCmarkersincludingABCG2andCSF1R,allimpli-catedinmesotheliomachemoresistance,wereconsiderablyincreased(onaverage3-to5-fold)inpuromycin-selectedZL55-SOcells(Figure1F).Thelargestincreasefrom-P2to-P10cellswasobservedforOCT4(Figure1F).ExperimentswerecarriedoutwithFACS-sortedcells,whichweresepa-ratedbasedonlyontheirEGFPﬂuorescence.DetailsforthesortingareprovidedinFigureS2A.TheidenticalapproachwasalsousedtoobtainsortedRN5cells(Fig-ureS2B).WescreenedthesortedcellsforALDH1A1,KLF4,andc-MYC,whichwereallincreasedinZL55-SOhighcells(FiguresS1DandS1E).InthesortedmurineRN5-SOhighcells,besidesSox2andOct4,thestemcellmarkerNanogwasalsosigniﬁcantlyincreased(FigureS1F).AhallmarkforputativeMMandothertumortype-derivedCSCsistheirincreasedresistancetowardchemotherapeuticdrugsincludingcis-Pt,asalsoreportedpreviouslyforovariancan-cer-derivedCSCs(Wiechertetal.,2016).ZL55-SOandZL55-SO-P2cellsweretreatedwithcis-Ptconcentrationsrangingfrom0.625to10mM,andcellsurvivalwasassessed5dayslater(Figure2A,leftpanel).Halfmaximalinhibitoryconcentration(IC50)valueswere0.92mMforZL55-SOand2.13mMforZL55-SO-P2cells,indicatingthattheEGFP(+)cellsdisplayedhigherchemoresistance,i.e.,highersurvivalthanthenon-selectedZL55-SOcells.WhileZL55-SO-P2cellswerealmostcompletelyresistantto1.25mMcis-Ptasshownbynearlyidenticalgrowthcurvesofcis-Pt-exposedanduntreatedcells,thegrowth/survivalofZL55-SOcellswasconsiderablyimpairedundertheseconditions(Fig-ure2C).Ofnote,inZL55-SOcells,thecellssurvivingthecis-PttreatmentweretoalargeextentEGFP(+)cells(Fig-ure2D)presentatabout5%inthenon-selectedZL55-SOcells(Figures1Band1C).Also,thesortedZL55-SOlowandZL55-SOhighcellswereexposedtocis-PtandIC50valuesweredetermined(Figures2Aand2B).Theincreaseinsur-vivalofZL55-SOhighcellscomparedwithZL55-SOlowcellsinthepresenceofcis-Ptwasqualitativelysimilartothatinthepuromycin-selectedZL55-SO-P2versusZL55-SOcells(Figure2A).Withrespecttotheincreasedresistance,theratioofIC50valuesfortheEGFP(+)-sortedcells(2.7-fold)wasslightlyhigherthanforthe-SO-P2versus-SOcells(1.9-fold);thesmallerdifferenceinthepuromycin-selectedcellslikelybeingduetothepresenceofapproximately5%ofEGFP(+)cellsintheparental(unsorted)-SOcellpopula-tion.Sortedcellswerealsoexposedto5-ﬂuorouracyl(5-FU)andtotheFAKinhibitorVS-6063,alsoknownasdefactinib.IC50valuesaresummarizedinFigure2B.Ofnote,nodiffer-encesweredetectedinZL55-SOlowandZL55-SOhighcellswithrespecttotheir5-FUsensitivity.InlinewithpreviousobservationsthatFAKsignalingisincreasedandfunction-allyrelevantinputativeCSCs(Shapiroetal.,2014),ZL55-SOhighcellsweremoresusceptibletowardtheFAKinhibitorthantheZL55-SOlowcells(Figures2Aand2B).SOX2/OCT4-ExpressingCSC-EnrichedMMCellsShowStemCellPropertiesInVitroAnessentialpropertyofstemcellsisasymmetriccelldivision,i.e.,theabilitytogeneratetwodaughtercellswithnon-identicalproperties.WehypothesizedthatinZL55-SO-P2EGFP(+)cellsnotcontinuouslysubjectedtopuromycinselectionorinFACS-sortedZL55-SOhighcells,afractionofcellswouldeventuallyloseEGFPexpression,possiblyresultingfromasymmetriccelldivisionand/oradynamicswitchinCSCdifferentiationstate(MovieS1).While1dayafterpuromycinremovalessentiallyallcellswereEGFP(+),atlatertimepoints(days6,71,and80),ﬁrstindividualEGFP( )cellsandatlaterstagesentirecellclustersofEGFP( )cellswereobserved(Figure3AandMovieS2).Asymmetriccelldivisionsweredocumentedbytime-lapsevideos,wheremitosisofanEGFP(+)cellre-sultedinagreenandanon-greendaughtercell(MovieS1).AdecreaseofEGFP(+)cellsby13%wasobservedatday80(10passages)(Figure3BandMovieS2),andgreencellsdecreasedevenmoreafterlong-termculturinginvitro(datanotshown).Theiradvancementindifferenti-ationfromEGFP(+)toEGFP( )cellswasconﬁrmedbytheirsubsequentincreasedNF2susceptibility(MovieS4).Ofnote,withinthepopulationofEGFP(+)cells,asecondpopulationofcellsappearedwithaweakergreenﬂuores-cenceintensity,closetothegatingboundariesseparatingEGFP(+)andEGFP( )cells(Figure3B).WeconcludethatEGFPexpressionisnotbasedonanall-or-nonemecha-nism,butitexistsratherasacontinuumofcellswithdifferentSOX2/OCT4-basedreportersasshownbythehet-erogeneousEGFPlevelspossiblyresultingfromaswitchinCSCdifferentiationstate.StemCellReportsjVol.8j1005–1017jApril11,20171007SOX2/OCT4-ExpressingCSC-EnrichedMMCellsArePresentinCellLinesDerivedfromAllHumanMMHistotypesandAlsoinMurineRN5MMCellsPatientswithsarcomatoidandbiphasicMMhaveapoorerprognosisthanpatientsdiagnosedwithanepithelioidMM(Bille´etal.,2016).Thus,wesetouttoinvestigatewhetherhighSOX2/OCT4-expressingcellswerepresentincelllinesderivedfromalldifferentMMhistotypesandtodeterminetheproportionofEGFP(+)cells.EGFP(+)cellpopulationsweredetectedinZL55(epithelioid),MSTO-211H,SPC111(biphasic),andmurineRN5(sarcomatoid)cells;theirfrac-tionsrangedfrom4.8%to7.8%(Table1).Thus,inallthreehistotype-derivedMMcelllines,EGFP(+),CSC-enrichedcellpopulationswereidentiﬁed.MurineEGFP(+)RN5cellswereusedinasyngeneicorthotopicinvivomousemodelaimedatdemonstratingthatthedecreaseofEGFP(+)cellsobservedincultureisnotanartifactofinvitrocellcultureconditionsand/orspeciﬁcforacertainMMcellline.SortedRN5-SOhighcellswereusedinaninvivoallograftC57Bl/6Jmousemodel.Intraperitoneal(i.p.)injectionofthesecellsresultedintumornodulesafter8weeks;stainingofﬁxedtumorswithapan-cytokeratin(CK)antibodyallowedidentiﬁcationofthetumorcells,furtherconﬁrmedbydou-blestainingforEGFP(Figure3C).ThetumorcontainedpatchesofcellswithstrongEGFPexpression,butalsore-gionswithweakorabsentexpression,althoughthesecellswereclearlyCKpositive,i.e.,tumorcells.ThisindicatesthatafractionofEGFP(+)tumorcellshadlostSOX2/OCT4-drivenreporterexpressionovertimeinvivo.Furthermore,RN5-SOhigh-sortedcellsweretransducedwithNLS-mCherryandinjected(i.p.)intomice.Tumorswerecollectedafter8weeksandisolatedtumorcellswereculturedinvitroforanalysis.AmongtheNLS-mCherry-labeledRN5MMcells,afractionofEGFP( )cellswasde-tected(markedbyarrows;Figure3D).Inaddition,theseNLS-mCherry-transducedRN5-SOhighcellswereculturedinvitroforanadditional57days.CellswereanalyzedweeklybyFACS;thefractionofEGFP( )cellsincreasedFigure2.HigherResistanceofZL55-SOhighEGFP(+)CellsTowardcis-Ptand5-FUandaLowerOneTowardVS-6063(AandB)IncreasedviabilityofZL55-SO-P2versusZL55-SOcellsexposedtocis-Pt(leftpanel)(A).FromthecurvesderivedfromsortedZL55-SOlowandZL55-SOhighcells(rightthreepanels),IC50valuesforcis-Pt,5-FU,andVS-6063werecalculatedfromthreeindependentexperimentsandareshownin(B).***p<0.001;one-wayANOVA;n.s.,notsigniﬁcant.ZL55-SOhighcellsdisplayhighersusceptibilitytoVS-6063.(C)Real-timegrowthcurvesshowthestrongeffectofcis-Pt(1.25mM)onZL55-SOcellproliferation/survival,whileZL55-SO-P2cellsarealmostcompletelyresistant.Onerepresentativeexperimentfromthreeindependentexperiments.(D)Brightﬁeldandﬂuorescenceimagesshowingtheeffectofcis-PtonZL55-SOcells;thefractionofEGFP(+)cellsisincreasedaftercis-Ptexposure(rightpanels).1008StemCellReportsjVol.8j1005–1017jApril11,2017Figure3.Time-DependentDecreaseinEGFPExpressioninInitially100%EGFP(+)CellsIndicatesGradualLossofStemnessObservedInVitroandInVivo(A)ExampleofEGFP(+)andEGFP( )ZL55-SOcellsinacellculturedishinitiallyplatedwithFACS-sortedZL55-SOhighcells.At80daysinvitromanynon-greenEGFP( )cellsareobserved,oftenarrangedinclusters(markedbyyellowdottedlines)andEGFP(+)(examplesmarkedbyreddottedlines).(B)DecreaseofthefractionofEGFP(+)cellsstartingfromsortedZL55-SOhighcells(initially78.6%EGFP(+)cells)to68.7%afterculturingwithoutpuromycinselectionfor35days(tenpassages).NotetheappearanceofadistinctpopulationofcellswithlowerEGFPﬂuorescence(arrow).(C)TumortissuederivedfromamouseinjectedwithRN5-SOhighcellsfor8weeksinvivo.Inthetumormassidentiﬁedbypan-cytokeratin(CK)immunohistochemistry(redﬂuorescence),clustersofcellswithweak-to-noneEGFPstaining(greenﬂuorescentimage;left)areseen.StainingwithDAPI(blue)allowsbetteridentiﬁcationofindividualcells.Inthemergedimage,thepresenceofclustersofyellowcells(co-localizationofCKandEGFP),butalsoofcellswithoutEGFP(CKonly)demonstrateslossofEGFPexpressionovertimeinvivo.(D)RN5-SOhighcellsadditionallyexpressingNLS-mCherry(redﬂuorescentnuclei)formedtumorsinvivoasdemonstratedafter8weeks.Tumor-derivedcellswerecultivatedinvitroandrevealedthatafractionofNLS-mCherry(+)cellshadlostEGFPexpression(cellsmarkedbyarrows).Inthemergedimagethesecellsappearasredonly.(legendcontinuedonnextpage)StemCellReportsjVol.8j1005–1017jApril11,20171009from0.4%to22.2%after57days,whilethefractionofNLS-mCherry( )cellsonlydecreasedby0.8%inthesametimeperiod(Figure3E).Anoverlayofthegreenandredcellpopulationspresentincellculturesafter57daysinvitrorevealedaleftshiftofthegreencellstowardlowerﬂuorescence(increaseinEGFP( )cells),whileatthesametimetheclusterofredcellsdidnotmove(Figure3E).ThisindicatesaselectivedecreaseofEGFP(+)cellsovertime,i.e.,SOX2/OCT4levelshaddroppedbelowthethresholdtomaintainEGFPexpression.TumorGrowthofZL55-SOhighCellsInVivoStronglyIndicatesCSCPropertiesThegrowthofFACS-sortedZL55-SOlowandZL55-SOhighcellswasinvestigatedinvivoinanorthotopicxeno-graftmousemodel.Non-obesediabetic(NOD)/severecombinedimmunodeﬁciency(SCID)gammamicewereinjectedi.p.with100,000ofeithersortedZL55-SOloworZL55-SOhighcellsandtheformationoftumornoduleswasanalyzed5weeksafterinjection.Allmiceexposedtoeithercellsubpopulationshowedmacroscopictumorformationsonboththeparietalandvisceralpartofthetunicaserosa(Figure4A).Wemeasuredsemi-quanti-tativelytherelativesurfaceareacoveredbytumortis-sue;aclearlylargersurfaceareacoveredbyvisuallydiscernibletumornodulesafterinjectionofZL55-SOhighcellswasobserved(Figure4B).InsomecasesnearlytheentireparietaltunicaserosaofmiceinjectedwithZL55-SOhighcellswascoveredwithtumornodules,buttoalesserextentalsothevisceraltunicaserosaofdifferentorganswascovered(Figure4A).Thesemi-quantitativeanalysesshowedthatthetumor-initiatingcapacityofZL55-SOhighEGFP(+)cellswasclearlyhigherthanthatofZL55-SOlowEGFP( )cells.HistologicalanalysesofselectedZL55-SOhightumornodulesshowedirregularlyformedboundariesbetweenlivertissueandtumormass,indicativeofahighlyinvasivetumor(Figure4C).CharacteristicsofRN5-SOhighTumorCellGrowthInVivoAreDifferentfromtheOneafterInjectionwithRN5-SOlowCellsAlimiteddilutionassaywascarriedout,wheredifferentamountsofFACS-sortedmurineMMcells(RN5-SOhighandRN5-SOlow;5,000,50,000,and500,000cellspermouse)wereinjectedi.p.insyngeneicC57Bl/6Jmice.Atthreetimepoints13,11,and8weekspostinjection,micewiththelargestinitialloadanalyzedaftertheshortestperiodwerekilledandthetumorload/tumorsizewasinvestigatedsemi-quantitatively,ﬁrstatthemacroscopiclevelandtheninmoredetailonhistologicalsections(Fig-ure5).InjectionofEGFP( )RN5-SOlowcellsresultedintheformationofmacroscopicallydiscernabletumorsin1of12mice(8.3%);thetumorlocalizationwasintramuscular(Figure5C).Moretumors(in6of12mice;50%)weredetectedafterinjectionofRN5-SOhighcells;anexampleofanexternallyvisibletumorofRN5-SOhighcellsisshowninFigure5B.HistologicalanalysesrevealedthatRN5-SOhigh-derivedtumorsoftenlocalizedwithinthesub-cutaneousconnectivetissue,inintramuscularregionsoftheabdominalwall,butalsoonthekidneycapsule(Fig-ures5D–5G).Differenttissuesamplescontainingsmalltu-mormassesfrommiceinjectedwitheitherRN5-SOhighandRN5-SOlowcellswerehistologicallyexamined.IntheRN5-SOlowgroup,tumorswereidentiﬁedin4of12(33%)miceandclearlymore(9of12mice;75%)inmiceinjectedwithRN5-SOhighcells(Figure5A).ThetumorincidenceinRN5-SOhigh-injectedmicewashigheratallthreedosesoftumorcellstested(Figure5A).Thecalculatedtumor-initiatingfre-quencyusingtheELDAsoftware(HuandSmyth,2009)forRN5-SOhighcellswasclearlyhigherthanforRN5-SOlowcells(ratioRN5-SOhigh/RN5-SOlow,17.4;p=0.0063).Thus,alsoinvivo,EGFP(+)RN5-SOhighcellsfulﬁllthecriteriaofCSC-enrichedcellsshownbytheirincreasedtu-mor-initiatingfrequency.IncreasedInVitroSelf-RenewalPropertiesofRN5-SOhighandZL55-SOhighCellsComparedwiththeCorresponding-SOlowSubpopulationsOtherimportantCSCcharacteristicsincludeanaugmentedcapacityforself-renewalandalsoforanchorage-indepen-dentgrowthinvitro(Morata-Tarifaetal.,2016).Self-renewalwasassessedinZL55andRN5cellsbyalimitingdilutionassayasdescribedpreviously(Tangetal.,2015;Thiagarajanetal.,2015)usingsorted-SOlowand-SOhighcellsofbothcelltypes.Inbothcelllines,theself-renewalca-pacityofEGFP(+)cellswasclearlyincreased(FiguresS3A(E)Cellsshownin(D)weremaintainedincultureinvitroforanadditional57daysandanalyzedbyFACSforgreen(EGFP)andred(NLS-mCherry)ﬂuorescence.WhilethefractionofNLS-mCherry(+)cellsonlymarginallydecreasedfrom99.8%to99.0%,thefractionofEGFP(+)cellsdecreasedfrom99.6%to77.8%.NotetheleftshiftofthepopulationofEGFP(+)cells:bluecloudatt1;redcloudatt57.SeealsoFigureS2.Table1.PercentageofEGFP(+)CellPopulationsinHumanandMouseMMCellLinesCellLineOrigin/Characterization%GFP(+)CellsZL55human/epithelioid4.8SPC111human/biphasic6.2MSTO-211Hhuman/biphasic6.1RN5murine/sarcomatoid7.81010StemCellReportsjVol.8j1005–1017jApril11,2017andS3B).ExamplesofEGFP( )andEGFP(+)RN5tumorspheresinitiatedfrom10cells/wellandmaintainedincul-turefor10daysareshowninFiguresS3CandS3D,respec-tively;thelargersizeofEGFP(+)tumorsphereswasevident.Inaddition,theanchorage-independentgrowthinsoftagarwasinvestigatedinthesamecelllines.TheaveragecolonysizeofEGFP(+)RN5-SOhighcellsafter2weeks(FigureS3E)wasconsiderablylargerthanthesizeofthecorrespondingEGFP( )RN5-SOlowcolonies(FigureS3F).Assumingasphericalshapeofthecolonies,basedontheareasofthecol-oniesdepictedinFiguresS3EandS3F,theradiusofaspherewascalculated.TheaverageradiuswassigniﬁcantlylargerinRN5-SOhighcellsthanintheRN5-SOlowcells(FigureS3H).ThedifferencesinradiiweresmallerbetweenEGFP( )andEGFP(+)ZL55cellcolonies;however,radiiofZL55-SOhighcellcolonieswerestillsigniﬁcantlylargerthantheonesfromEGFP( )cells(FigureS3G).DecreasedSusceptibilityofEGFP(+)ZL55CellstoAsbestos-InducedAcuteCytotoxicity,butUnalteredCellMobilityInVitroCSCsareknowntoshowhigherresistancetoexposuretocytotoxicagents(Vidaletal.,2013),possiblylinkedtotheirlowerproliferationrates,whileincreasedspreadingoftumorcellstositesdistantfromtheprimarytumorareassociatedwithaugmentedinvasivenessandincreasedmetastaticpotential(Anjomshoaaetal.,2009).ZL55-SO-P2EGFP(+)cellsweresigniﬁcantlymoreresistanttowardcrocidolite-inducedacutecytotoxicity(5mg/cm2ofcrocidolitefor96hr)thanEGFP( )cells(Figure6A).At96hrtheMTTsignalofZL55-SO-P2crocidolite-treatedcellswasonlyslightlylowerthanincontrolZL55-SO-P2cells,indicatinganalmostcompleteprotectionofEGFP(+)cells.Real-timegrowthcurvesofcontrolZL55-SOandZL55-SO-P2cellsdidnotreveallargedifferencesintheproliferationratesofthetwocellpopulations(Figures6Cand6D).TheMTTsignalat120hrpost-platingforEGFP( )ZL55-SOlowcellswasslightlylargerthanforEGFP(+)ZL55-SOhighcells,inlinewithslowergrowthofCSCs(datanotshown).Yetina2Dscratchassay,thewoundclosuretimewasindistinguishable(datanotshown).Amoredetailedanalysisofthemobilityofindivi-dualcellspreferentiallytowardthecell-devoidareashowedafastercellmovementofbothcellgroupsdirectlyfollowingthescratchandlastingforabout2hr,followedbyaconstantdisplacementofapproximately2mm/5minforthenext16hr(FigureS4C).MobilityofZL55-SOcellsgrownatlowconﬂuence,i.e.,allowingfornon-directedmovementwasalsonotdifferentbetweenEGFP(+)andEGFP( )cells(Fig-ureS4C).Inaddition,weusedMSTO-211Hcells,anMMcelllinepronetoformspheroidswhengrownintheabsenceofserum,toanalyzethespheroidformationcapacity(Pasdaretal.,2015).MSTO-211H-SO-P2cellsconsistingofmostlyEGFP(+)cellsshowedqualitativelyalargernumberofspher-oids(datanotshown)thatwerealsobiggerthantheonesfromunsortedMSTO-211H-SOcells(FiguresS4AandS4B).Ofnote,spheroidsproducedfromunsortedMSTO-211H-SOcellscontaininginitially7%ofEGFP(+)cellsweremostlymadeupoftheEGFP(+)cellsubpopulation,sug-gestingthatmostlyEGFP(+)cellsshowthepropensityofformingspheroids(FigureS4A).SimilarSensitivityofEGFP(+)andEGFP( )MMCellstoCalretininDownregulation,butPronouncedDifferenceswithRespecttoEctopicExpressionoftheFunctionalTumorSuppressorNF2andtotheFAKInhibitorVS-6063AlthoughthepreciseroleofthepositiveMMmarkercalre-tinin(CALB2)iscurrentlyunknown,itsdownregulationFigure4.IncreasedTumorGrowthofHumanZL55-SOhighEGFP(+)CellsinNOD/SCIDGammaMice(A)ZL55-SOlowandZL55-SOhighcells(100,000/mouse)werein-jectedi.p.intoNOD/SCIDgammamice.MiceinjectedwithZL55-SOhighcellsshowanincreasednumber/densityoftumornodules,especiallyvisibleonthevisceralpleura(rightimages).(B)Thepercentageoftumornodulescoveringthesurfaceofthevisibleparietalandvisceralperitoneumis9.1%forZL55-SOlowcellsand27.8%forZL55-SOhighcells(***p<0.001;one-wayANOVA).Averageoffourtoﬁveanimalspergroup;errorbarsrepresentSD.(C)Tumormasseswerehistologicallyanalyzed;atumornoduleontheliversurfaceshowshighlyinvasiveedges(arrow).SeealsoFigureS3.StemCellReportsjVol.8j1005–1017jApril11,20171011inZL55cellsbyalentivirus-mediatedshorthairpinRNA(shRNA)approachleadstomassiveapoptosisandnecrosis,moststronglyinepithelioidMM(BlumandSchwaller,2013).Ofnote,calretininproteinlevelsweresimilarinZL55-SOandZL55-SO-P2cells(Figure6G)and,moreimportantly,downregulationwithshCALB2no.5,shCALB2no.7(BlumandSchwaller,2013),andveryefﬁ-cientlywithshCALB2no.84(targetingtheCALB230UTR)affectedthesurvivalofZL55-SOandZL55-SO-P2cellstoasimilarextent(Figure6B).Thus,unlikethesituationwiththeFAKinhibitorVS-4718thatpreferentiallyaffectsALDEFLUOR(+),CSC-enrichedMMcells(Shapiroetal.,2014),CALB2downregulationequallyaffectedprolifera-tionandviabilityofZL55EGFP(+)andEGFP( )cells.Theseresultsunderscorecalretininasaninterestingtargetfortheeliminationofcalretinin-positiveMMcellsirrespectiveoftheirstemness.GenesthataredownregulatedorlostinMMandarethoughttoactasadriverforMMformationincludeNF2(neuroﬁbromatosis2,merlin),CDKN2A,andBAP1(Xuetal.,2014).LossoffunctionalNF2resultingfrommuta-tionsisobservedin40%–50%ofhumanMPM(Bianchietal.,1995)and,moreover,lowNF2-expressingMPMcellsshowahighersensitivitytowardFAKinhibition-inducedgrowtharrest,whileNF2overexpressionresultsinanincreasedresistancetotheFAKinhibitorVS-4718thatpreferentiallyaffectsALDEFLUOR(+)CSC-enrichedcells(Shapiroetal.,2014).Thus,weinvestigatedhowoverex-pressionofhumanwild-typeNF2affectedproliferationand/orsurvivalofEGFP(+)andEGFP( )MMcells.Thepro-liferationofcontrolZL55-SOandZL55-SO-P2wasrathersimilar,aplateauwasreachedbetween70and80hrafterplating(Figures6Cand6D).OverexpressionofNF2(Figures6C–6F)selectivelyaffectedEGFP( )ZL55-SOcells,asshownbyanalmostcompletecellgrowtharrestandcelldeath(Figures6C–6F).NF2-overexpressingEGFP(+)ZL55cellsshowedthetypicalepithelioidmorphology,whileneighboringEGFP( )cellswerecharacterizedbyroundingupandcellprotrusionstypicalfordying(apoptotic/necrotic)cells(Figures6Eand6F;MoviesS3andS4).NF2upregulationonlymarginallyaffectedtheproliferationofEGFP(+)ZL55-SO-P2cells(Figure6D),andthecellFigure5.IncreasedTumor-InitiatingFre-quencyandMorphologicalAspectsofRN5-SOhighEGFP(+)Cell-DerivedTumorsinSyngeneicC57Bl/6JMiceRN5-SOlowandRN5-SOhighcellswereinjectedi.p.inC57Bl/6Jmiceatthreedoses(500,000,50,000,and5,000cells)andkilledafter8,11,and13weeks,respectively.(A)Fractionofmicewithtumorsfoundbymicroscopicanalyses.AtallinjecteddosesofRN5cellsandtimepoints,tumorincidenceishigherwithRN5-SOhighcells.Thetumor-initiatingfrequency(TIF)wascalculatedforbothgroups.(B–F)H&E-stainedsections.(B)TumorofRN5-SOhighcells(500,000cellsat8weeks);tumorcellsarelocatedsubcutaneouslyintheparietalwall.(C)Intramusculartumorintheabdominalwallofthesamemouse.(D)Inthesamegroup(500,000cellsat8weeks),tumorcellgrowthontheliversurface.(E)and(F)Intramusculartumorsinamouse(50,000RN5-SOhighcellsat8weeks).(G)Aparallelsectionoftheonepresentedin(F)showsaGoldnerstainingtobetteremphasizethemuscletissue(red)andtheconnectivetissue(green)inthetumormass.Arrowsin(F)and(G)indicatemuscleﬁbers.SeealsoFigureS3.1012StemCellReportsjVol.8j1005–1017jApril11,2017morphologywasunaltered(Figures6Eand6F).NearlyidenticalresultswereobtainedwithhumanMSTO-211H,SPC111,andZL5cells(FiguresS4E–S4J).Theslowandde-layedincreaseintheproliferationofZL55-SO-NF2cellswastheresultofthelowpercentage(5%)ofEGFP(+)cellspresentintheunselected(-SO)cells,sincenearlyallcellsweregreenat120hr(FigureS4F).AsimilareffectwasalsoseenwithmurineRN5cells.Thesmallermagni-tudeoftheeffectmightbelinkedtothefactthathuman,notmouseNF2,wasoverexpressedinthemousecells.Thus,inlinewithpreviousreportsdemonstratingthatNF2upregulationinMMcellsleadstogrowthinhibitionandapoptosis(Xiaoetal.,2005),NF2overexpressionblockedproliferationonlyin-SOcellsmostlyconsistingofEGFP( )cells,whilebarelyaffectingEGFP(+)cells.Thus,incontrasttotheEGFP( )cells,theCSC-enrichedpopulationderivedfromallMMhistotypeswasratherinsensitivetoNF2overexpression.Ontheotherhand,theFAKinhibitorVS-6063moreefﬁcientlydecreasedcellproliferationinZL55-SO-P2EGFP(+)cellscomparedwithZL55-SOcells(Figures2Aand2B).DISCUSSIONMMareexceptionallyresistanttotherapeuticinter-ventionssuchaschemotherapy,radiotherapy,surgery,andcombinationsthereof.Inmanyinstancestherapyresistanceislinkedtoaparticularmicroenvironment(KlemmandJoyce,2015)createdandmaintainedbythetumortissueand,moreover,bytheheterogeneityofthetu-morcellswithinthetumormass(Bedardetal.,2013).AsmallsubpopulationofcancercellswithstemcellfeaturestermedCSCs,orfunctionallydeﬁnedasTICs,isassumedtoplayacrucialroleinthedevelopmentofcancerandinpromotingitssustainedgrowthandtheinvasiveandFigure6.DecreasedSusceptibilityofEGFP(+)ZL55CellstoAsbestosToxicityandNF2Expression;EqualSensitivityofEGFP(+)andEGFP( )ZL55CellstoCalre-tininDownregulation(A)IncreasedresistanceofZL55-SO-P2cellsexposedto5mg/cm2ofcrocidolitefor96hrdeterminedbyanMTTassaycomparedwithZL55-SOcells(n=3inde-pendentexperiments,one-wayANOVA;***p<0.0005).(B–D)DownregulationofcalretinininZL55-SOandZL55-SO-P2cellsequallydecreasestheviabilityinbothcellpopulationsforthreedifferentshRNAtargetingCALB2(B)(n=3independentexperiments;one-wayANOVA;n.s.,notsigniﬁcant).Overexpressionofmerlin(NF2)inZL55-SO(C)andZL55-SO-P2cells(D)showsstrongproliferation-in-hibitingeffectsonthenon-sortedZL55-SOcells,butalmostnoeffectonZL55-SO-P2cells.Theinsetin(D)showsstrongupregu-lationoffull-lengthNF2(Mr=68kDa)us-ingLV-NF2.AllerrorbarsrepresentSD.(E)Live-cellimagingofZL55-SO3hrafterupregulationofNF2;notethepresenceofEGFP(+)andEGFP( )cellsintheZL55-SOcellpopulation.Themorphologyofgreenandnon-greencellsismostlyepithelioid.(F)Twenty-sevenhourspostinfection,theupregulationofNF2inducedstrongapoptosis/necrosisinnon-greencells(whitearrows)demonstratedbycellshrinkage,blebbing,andcelldebris.EGFP(+)cellsdonotshowstrikingmorphologicalchanges.(G)WesternblotanalysisshowingstrongdownregulationofCR(Mr=31kDa)byshRNACALB2no.5inZL55-SOandZL55-SO-P2cells.Atapproximately35kDa,thenitrocellulosemembranewascutandtheupperpartwasusedforGAPDHdetection(lowerpanel).ControlinfectionwithshRNAGFPhasnoeffectonCRexpression.ForthenormalizationthesignalforGAPDH(Mr38kDa)wasused.SeealsoFigureS4.StemCellReportsjVol.8j1005–1017jApril11,20171013metastaticproperties(Raggietal.,2015).EvidencehasaccumulatedthattheseCSCsarecharacterizedbyhigherlevelsofpluripotencyfactorsincludingSOX2,OCT4,andNANOG.Basedonthis,methodshavebeendevelopedtoisolatethiscellsubpopulationasappliedinourstudy.Otherapproachestoisolate/enrichCSCsexploitspeciﬁcpropertiessuchasenhancedlevelsofdye-exclusiontransporters(ABCG2),increasedaldehydedehydrogenaseactivity(ALDH1),ortheirincreasedpropensitytogeneratespheroids(Pasdaretal.,2015).Whilethelattermethodsmightmodifythesecellstosomeextentbytheselec-tionmethod,theSOX2/OCT4reporterapproachmini-mallyperturbstheendogenousintracellularenvironment(excludingtheputativeeffectsexertedbyEGFP);itallowstheidentiﬁcationandisolationofputativeCSCsbasedontheirendogenouslyelevatedlevelsofSOX2/OCT4.HigherlevelsofSOX2inglioblastomawerelinkedwithanincreasedtumor-initiatingability(Gangemietal.,2009),inovariancarcinomaassociatedwiththestemcellstate,and,inlungcancer,CSCswererequiredforgrowthandmetastaticpotential(Xiangetal.,2011).Moreover,elevatedlevelsofOCT4andotherstemnessmarkersinMMcellsderivedfrommesosphereswereparalleledbyanincreasedtumor-initiatingcapacity(Pasdaretal.,2015).Re-porterapproachesbasedonpluripotencyfactorbindinghavebeensuccessfullyusedfortheenrichmentandidenti-ﬁcationofCSCsinbreastcancer(Tangetal.,2015;Thiagar-ajanetal.,2015)andovariancancer(Wiechertetal.,2016),thelatterusingaNANOG-basedreporter.StrongEGFPexpressioninthelentivirus-mediatedSOX2/OCT4-basedreporterapproachallowedustoisolateandcharacterizeMMcellsinvitroandfurthermoretoinvestigateindetailthepropertiesofthesecellsinvivo.Oneofthemainadvan-tagesofthereporterapproachisthepossibilityofcontinu-ouslymonitoringthesecellsovertime.ThisrevealedthatafractionofinitiallyEGFP(+)cellslosttheirgreenﬂuores-cence,likelyastheresultofadecreaseinSOX2/OCT4levelsinsufﬁcienttodriveEGFPexpression;time-lapsemoviesdemonstratedthislosstooccuroftenwithinonecelldivision.Weattributethistoadynamicshiftinthediffer-entiationstatefromEGFP(+)toEGFP( )cells,thelattercharacterizedbyamorenon-CSCphenotypeasdescribedindetailforbreastcancerCSCs(seeFigure7DinAkrapetal.,2016).Inagreement,thenewlyformedEGFP( )cellswereagainequallysusceptibletotheanti-proliferative/pro-apoptoticactionofelevatedlevelsofNF2asweretheparental-SOEGFP( )cells.ThisprecludesthelossofEGFPbeingtheresultof,e.g.,reportersilencing.ThisconclusionisalsosupportedbytheﬁndingthatthesameMMcellsconstitutivelyexpressingNLS-mCherrydidnotloseredﬂuorescenceovertime.MMareconsideredasanexample,wheretumorigenesisismostlydrivenbylossoftumorsuppressorfunctionsincludinggenessuchasNF2codingformerlin,CDKN2A,CDKN2B,orBAP1(JeanandJaurand,2015).Accord-ingly,NF2ismutatedinapproximately40%ofallhumanMM(Bianchietal.,1995)and/orcompletelyabsentbyallelicloss(Chengetal.,1999).NF2expressionlevelsarestronglycorrelatedwiththesensitivitytoinhibitorsofFAKphosphorylation(Shapiroetal.,2014).TheFAKinhib-itorVS-4718efﬁcientlyinhibitsproliferationofNF2( )MMcells,whileNF2(+)cellsareratherinsensitivetotheinhibitor.Inourstudy,wecomparedthesensitivityofEGFP(+)andEGFP( )MMcellswiththeeffectsofoverexpressionofNF2.InhumanNF2-overexpressingMM-SOcells,prolifer-ationwasalmostcompletelyblocked,whileEGFP(+)CSC-enrichedMMcellpopulationswerebarelyaffectedbyincreasedNF2levels.Thiseffectwascompletelyindepen-dentfromtheNF2statusoftheparentalcells.NF2-nega-tiveZL55cellswereequallyaffected,aswereNF2-positiveMSTO-211Hcells.TheapparentlyweakereffectinMSTO-211H-SOcellsseeninthereal-timegrowthcurves(Fig-ureS4J)isessentiallytheresultoftheinsensitivityofthesmallsubpopulationofEGFP(+)MSTO-211H-SOcellstoNF2overexpression.Adenovirus-mediatedexpressionofNF2waspreviouslyshowntoinhibitproliferationandtocauseaG1cell-cyclearrestinNF2-deﬁcienttumorcells(Xiaoetal.,2005).DetailedanalysesofNF2-overexpressingZL55-SOmostlycomprisingEGFP( )cellsrevealednotonlyaproliferation-inhibitingeffect,butconsiderablecelldeathcausedbyelevatedNF2levels.InhibitionofFAKsignalingbyVS-6063preferentiallyaffectedEGFP(+)ZL55cells,indicatingthatadirectimpairmentofFAKsignalinginCSC-enrichedZL55cellsmightbethemorepromisingstrategythanthelikelyindirecteffectonFAKsignalinginhibitionbyNF2upregulationthatmostlyaffectedtheEGFP( )ZL55cells.SincedownregulationofcalretinindecreasestheviabilityandproliferationofMMcellsinvitro(BlumandSchwaller,2013),weinvestigatedtheeffectsofdecreasingcalretininexpressioninEGFP(+)andEGFP( )cells.Interestingly,shRNACALB2-mediateddownregulationequallyaffectedbothcellpopulationswithrespecttoproliferationandcelldeath.Thus,calretininremainsaninterestingtargettoeradicatebothMMCSCsandnon-CSCs.ThelimiteddilutionassayremainsthegoldstandardfortheidentiﬁcationandcharacterizationofCSC-orTIC-enrichedcellpopulations.Herewehavechosentwoortho-topici.p.modelspresumingthattumorcellsencounteranenvironmentthatismorerelevantwithrespecttohumanMMpathology(alumencoveredbythemesothelium)thaninthemoreoftenusedsubcutaneousmodels(Pasdaretal.,2015;Shapiroetal.,2014).InthexenograftmodelusinghumanZL55cells,formationoftumornodulescoveringtheparietalaswellasthevisceralmesothelium1014StemCellReportsjVol.8j1005–1017jApril11,2017wasclearlyincreasedwheninjectingEGFP(+)cellsincomparisonwithinjection-treatedwithunsortedZL55,comprisinglessthan5%ofEGFP(+)cells.Inthephysiolog-icallymorerelevantallograftmodelusingC57BL/6JmicecharacterizedbytheirhighlycompetentimmunesystemandthepreviouslyestablishedmouseMMcelllineRN5(Blumetal.,2015),thetumor-initiatingcapacityofEGFP(+)RN5cellswasalmost20-foldhigherthanthatofEGFP( )RN5cells.Ofnote,theinitialtumorcellloadtoinducei.p.tumornoduleswithRN5cellswassigniﬁcantlyhigherthanthenumberofmouseMM87cellsthatwerein-jectedsubcutaneously(s.c.)intheNOD/SCIDmousemodel(Shapiroetal.,2014).Tosummarize,bothnormal(C57BL/6J)versuscompromised(NOD/SCID)immunesys-temcells,andorthotopicversuss.c.injectioncells,mightcontributetothehighertumorcell(RN5)loadrequiredforMMformationinvivo.IncomparisonwithCSCsfromtumorsderivedfromothertissues,thenatureofMMCSCswithrespecttoniche,interactionswiththemicroenvironment,andmostimportantlytheimmunesystemandotherproper-tiesinvivoareasyetunderexploited.WeestimatethattheEGFP-basedapproachwillallowalsotovisualizeEGFP(+)cellfateintheintacttumormicroenvironmentinthepleuralorperitonealcavities,e.g.,fordetailedlon-gitudinalstudiesinvivo.Inmostpreviousstudies,e.g.,involvementofSOX2inself-renewal(Arnoldetal.,2011)ortumor-initiatingcapability(Gangemietal.,2009)andtheroleofOCT4indedifferentiationandstemnessofcancercells(Kumaretal.,2012)hasbeeninvestigatedseparately.Finally,weproposethatthesameapproachmightbeappliedforprimary(non-trans-formed)mesothelialcells.Suchstudiesmightshedlightontheroleofnormalmesothelialstemcellsinthepro-cessoftransformationtoMM.TheinsightsintoMMCSCbiologyprovidedhereareexpectedtoberelevantinthesearchforinnovativeapproachestotargetthiscrit-icallyimportantMMcellpopulation.EXPERIMENTALPROCEDURESCellCultureandSelectionofSOX2/OCT4-ExpressingCellsMMcelllineswereculturedasdescribedabove,transducedwithlentiviruscontainingSOX2/OCT4stemnessindicatorconstructs(fordetails,seetheSupplementalExperimentalProcedures)result-ingin‘‘MM-SO’’cellsconsistingofEGFP(+)andEGFP( )subpop-ulations.Treatmentwitheither2or10mg/mLofpuromycinfor10daysledtoanenrichmentofEGFP(+)cells.Insomeexperi-ments,ZL55-SOcellswereexposedto2or10mg/mLofpuromycinfor3weeks,followedbyagrowthperiodof3weeks(10passages)withoutpuromycin.CellswerethenanalyzedbyﬂowcytometryforEGFPexpression.FlowCytometryAnalysisofEGFP(+)CellsTrypsinizedMMcellswereanalyzedbyFACSonaBDAccuriC6(BDBiosciences);detailsaredescribedintheSupplementalExper-imentalProcedures.SortingofEGFP(+)andEGFP( )cellswasperformedonaBDFACSAria(BDBiosciences)cellsorterandselectedcellswereusedforsubsequentcellcultureexperimentsinvitro.DeterminationofthemRNAExpressionofStemnessGeneLevelsbyqRT-PCRTotalRNAextractedfrom80%conﬂuentcellcultures(peqGOLDTriFast)ofpuromycin-selectedorsortedZL55-SOorRN5-SOcellswasusedforqRT-PCRfollowingthemanufacturer’sinstruc-tions(QIAGEN).qRT-PCRprimersequencesarelistedintheSup-plementalExperimentalProcedures.TreatmentofCellswithcis-Pt,5-FU,andVS-6063andDeterminationofIC50ValuesCells(500/wellforcis-Ptand5-FUexperimentsand2,000/wellforVS-6063)wereseededin96-wellplatesandgrownfor24hr.Drugswereaddedatdifferentconcentrations(fordetails,seetheSupplementalExperimentalProcedures)andtheMTTassaywasperformedat48,96,or120hrposttreatment(dependingonthedrug)todetermineIC50values.Additionally,real-timecell-prolifer-ationcurveswereacquiredwiththeIncuCyteLive-CellImagingSystem(EssenBioScience).InVivoLimitingDilutionAssayAnimalexperimentswereperformedwiththepermissionofthelocalanimalcarecommittee(CantonofFribourg,Switzerland)andaccordingtothepresentSwisslawandtheEuropeanCom-munitiesCouncilDirectiveof24November1986(86/609/EEC).MurineRN5-SOlowandRN5-SOhighcellswereresuspendedin200mLPBSandinjectedi.p.inC57Bl/6Jmice(fourmicepergroup,threedifferentconcentrations).Cells(5,000,50,000,and500,000)wereinjectedandgroupskilledinparallelafter13,11,and8weeks,respectively.Photographsweretakentoshowmacroscopictumorappearance.Organsampleswerecollected(diaphragm,spleen,liver,andperitonealwall)forhistologicalanalysis.SortedZL55-SOlowandZL55-SOhighcells(100,000/mouse)wereinjectedintoNOD/SCIDgammamice(fourtoﬁvemicepergroup).WesternBlotAssaysforCalretinin,NF2,andMesothelinProteinswereextractedfromwashedcellpellets(from70%to90%conﬂuentcultures)usingstandardRIPAbuffer(fordetails,seetheSupplementalExperimentalProcedures).Fromtheclearedsupernatant,proteins(50mg)wereseparatedon10%polyacrylamideSDSgelsandtransferredontonitrocellulosemembranes.Afterblocking,membraneswereﬁrstincubatedwithantibodiesagainstcalretinin,mesothelin,orNF2,followedbytheABCdetectionsystemusingthehorseradishperoxi-dasesubstrate(Millipore,LuminataForte);membraneswereimagedonthewesternblotreaderFluorChemESystem(BucherBiotec).StemCellReportsjVol.8j1005–1017jApril11,20171015DownregulationofCalretinininZL55-SOandZL55-SO-P2UsingLentiviral-MediatedCALB2shRNAandUpregulationofNF2Cells(500/wellin96-wellplates)weregrownfor24hrandtrans-ducedwithlentivirusshRNACALB2nos.5and7(BlumandSchwaller,2013)oranovel30UTR-targetedshRNACALB2:50-CCGGTTTAACGCGATCTTCACATTTCTCGAGAAATGTGAAGATCGCGTTAAATTTTTTG-30.MTTassayswereper-formedat120hrpostinfection.ForNF2upregulation,cellsweretransducedwithLV-NF2andgrowthcurvesweredeterminedbytheIncuCytesystem.SUPPLEMENTALINFORMATIONSupplementalInformationincludesSupplementalExperimentalProcedures,fourﬁgures,andfourmoviesandcanbefoundwiththisarticleonlineathttp://dx.doi.org/10.1016/j.stemcr.2017.02.005.ACKNOWLEDGMENTSTheauthorsthankV.Salicio,S.Eichenberger,M.Sanchez,M.Steinauer,andF.Meyenhoferfortheirexcellenttechnicalassis-tance,andT.Henzi,V.Szabolcsi,F.Filice,J.Wo¨rthmu¨ller-Rodri-guez,andV.Serre-Beinier,UniversityofGeneva,forfeedbackonthemanuscript.PL-SIN-EOS-S(4+)-EiPwasagiftfromJ.Ellis(Addgeneplasmidno.21314)andtheSORE6constructswereakindgiftofDr.L.M.Wakeﬁeld.TheprojectwassupportedbytheSwissNationalScienceFoundationSNFgrantnos.130680and139226toB.S.,SanSalvatoreFoundationandSNFSinergiagrantno.147697toE.F.-B.,M.d.P.,andB.S.Received:July18,2016Revised:February6,2017Accepted:February7,2017Published:March9,2017REFERENCESAkrap,N.,Andersson,D.,Bom,E.,Gregersson,P.,Sta˚hlberg,A.,andLandberg,G.(2016).Identiﬁcationofdistinctbreastcancerstemcellpopulationsbasedonsingle-cellanalysesoffunctionallyenrichedstemandprogenitorpools.StemCellRep.6,121–136.Anjomshoaa,A.,Nasri,S.,Humar,B.,McCall,J.L.,Chatterjee,A.,Yoon,H.-S.,McNoe,L.,Black,M.A.,andReeve,A.E.(2009).Slowproliferationasabiologicalfeatureofcolorectalcancermetastasis.Br.J.Cancer101,822–828.Arnold,K.,Sarkar,A.,Yram,M.A.,Polo,J.M.,andBronson,R.(2011).Sox2+adultstemandprogenitorcellsareimportantfortis-sueregenerationandsurvivalofmice.CellStemCell9,317–329.Bedard,P.L.,Hansen,A.R.,Ratain,M.J.,andSiu,L.L.(2013).Tumourheterogeneityintheclinic.Nature501,355–364.Bianchi,A.B.,Mitsunaga,S.I.,Cheng,J.Q.,Klein,W.M.,Jhanwar,S.C.,Seizinger,B.,Kley,N.,Klein-Szanto,A.J.,andTesta,J.R.(1995).Highfrequencyofinactivatingmutationsintheneuroﬁ-bromatosistype2gene(NF2)inprimarymalignantmesotheli-omas.Proc.Natl.Acad.Sci.USA92,10854–10858.Bille´,A.,Krug,L.M.,Woo,K.M.,Rusch,V.W.,andZauderer,M.G.(2016).Contemporaryanalysisofprognosticfactorsinpatientswithunresectablemalignantpleuralmesothelioma.J.Thorac.Oncol.11,249–255.Blum,W.,andSchwaller,B.(2013).Calretininisessentialformeso-theliomacellgrowth/survivalinvitro:apotentialnewtargetformalignantmesotheliomatherapy?Int.J.Cancer133,2077–2088.Blum,W.,Pecze,L.,Felley-Bosco,E.,Worthmu¨ller-Rodriguez,J.,Wu,L.,Vrugt,B.,dePerrot,M.,andSchwaller,B.(2015).Establish-mentofimmortalizedmurinemesothelialcellsandanovelmeso-theliomacellline.InVitroCellDev.Biol.Anim.51,714–721.Cheng,J.Q.,Lee,W.C.,Klein,M.A.,Cheng,G.Z.,Jhanwar,S.C.,andTesta,J.R.(1999).FrequentmutationsofNF2andalleliclossfromchromosomeband22q12inmalignantmesothelioma:evidenceforatwo-hitmechanismofNF2inactivation.GenesChromosomesCancer24,238–242.Cho,B.C.J.,Feld,R.,Leighl,N.,Opitz,I.,Anraku,M.,Tsao,M.-S.,Hwang,D.M.,Hope,A.,anddePerrot,M.(2014).AfeasibilitystudyevaluatingSurgeryforMesotheliomaafterRadiationTher-apy:the‘‘SMART’’approachforresectablemalignantpleuralmeso-thelioma.J.Thorac.Oncol.9,397–402.D’Angelo,R.C.,andWicha,M.S.(2010).Stemcellsinnormaldevelopmentandcancer.Prog.Mol.Biol.TranslSci.95,113–158.Frei,C.,Opitz,I.,Soltermann,A.,Fischer,B.,Moura,U.,Rehrauer,H.,Weder,W.,Stahel,R.,andFelley-Bosco,E.(2011).Pleuralmeso-theliomasidepopulationshaveaprecursorphenotype.Carcino-genesis32,1324–1332.Gangemi,R.M.R.,Griffero,F.,Marubbi,D.,Perera,M.,Capra,M.C.,Malatesta,P.,Ravetti,G.L.,Zona,G.L.,Daga,A.,andCorte,G.(2009).SOX2silencinginglioblastomatumor-initiatingcellscausesstopofproliferationandlossoftumorigenicity.StemCells27,40–48.Hirschmann-Jax,C.,Foster,A.E.,Wulf,G.G.,Nuchtern,J.G.,Jax,T.W.,Gobel,U.,Goodell,M.A.,andBrenner,M.K.(2004).Adistinct‘‘sidepopulation’’ofcellswithhighdrugefﬂuxcapacityinhumantumorcells.Proc.Natl.Acad.Sci.USA101,14228–14233.Hotta,A.,Cheung,A.Y.L.,Farra,N.,Garcha,K.,Chang,W.Y.,Pasceri,P.,Stanford,W.L.,andEllis,J.(2009).EOSlentiviralvectorselectionsystemforhumaninducedpluripotentstemcells.Nat.Protoc.4,1828–1844.Hu,Y.,andSmyth,G.K.(2009).ELDA:extremelimitingdilutionanalysisforcomparingdepletedandenrichedpopulationsinstemcellandotherassays.J.Immunol.Methods347,70–78.Jean,D.,andJaurand,M.-C.(2015).Causesandpathophysi-ologyofmalignantpleuralmesothelioma.LungCancerManag4,219–229.Klemm,F.,andJoyce,J.A.(2015).Microenvironmentalregulationoftherapeuticresponseincancer.TrendsCellBiol.25,198–213.Klonisch,T.,Wiechec,E.,Hombach-Klonisch,S.,Ande,S.R.,Wes-selborg,S.,Schulze-Osthoff,K.,andLos,M.(2008).Cancerstemcellmarkersincommoncancers–therapeuticimplications.TrendsMol.Med.14,450–460.Kumar,S.M.,Liu,S.,Lu,H.,Zhang,H.,Zhang,P.J.,Gimotty,P.A.,Guerra,M.,Guo,W.,andXu,X.(2012).Acquiredcancerstem1016StemCellReportsjVol.8j1005–1017jApril11,2017cellphenotypesthroughOct4-mediateddedifferentiation.Onco-gene31,4898–4911.Morata-Tarifa,C.,Jimenez,G.,Garcia,M.A.,Entrena,J.M.,Grinan-Lison,C.,Aguilera,M.,Picon-Ruiz,M.,andMarchal,J.A.(2016).Lowadherentcancercellsubpopulationsareenrichedintumorigenicandmetastaticepithelial-to-mesenchymaltransi-tion-inducedcancerstem-likecells.ScientiﬁcRep.6,18772.Pasdar,E.A.,Smits,M.,Stapelberg,M.,Bajzikova,M.,Stantic,M.,Goodwin,J.,Yan,B.,Stursa,J.,Kovarova,J.,Sachaphibulkij,K.,etal.(2015).Characterisationofmesothelioma-initiatingcellsandtheirsusceptibilitytoanti-canceragents.PLoSOne10,e0119549.Raggi,C.,Mousa,H.S.,Correnti,M.,Sica,A.,andInvernizzi,P.(2015).Cancerstemcellsandtumor-associatedmacrophages:aroadmapformultitargetingstrategies.Oncogene35,671–682.Shapiro,I.M.,Kolev,V.N.,Vidal,C.M.,Kadariya,Y.,Ring,J.E.,Wright,Q.,Weaver,D.T.,Menges,C.,Padval,M.,McClatchey,A.I.,etal.(2014).MerlindeﬁciencypredictsFAKinhibitorsensi-tivity:asyntheticlethalrelationship.Sci.TranslationalMed.6,237ra68.Stahel,R.A.,Felley-Bosco,E.,Opitz,I.,andWeder,W.(2009).Ma-lignantpleuralmesothelioma.FutureOncol.5,391–402.Tang,B.,Raviv,A.,Esposito,D.,Flanders,K.C.,Daniel,C.,Nghiem,B.T.,Garﬁeld,S.,Lim,L.,Mannan,P.,Robles,A.I.,etal.(2015).Aﬂexiblereportersystemfordirectobservationandisolationofcancerstemcells.StemCellRep.4,155–169.Thiagarajan,P.S.,Hitomi,M.,Hale,J.S.,Alvarado,A.G.,Otvos,B.,Sinyuk,M.,Stoltz,K.,Wiechert,A.,Mulkearns-Hubert,E.,Jarrar,A.M.,etal.(2015).Developmentofaﬂuorescentreportersystemtodelineatecancerstemcellsintriple-negativebreastcancer.StemCells33,2114–2125.Valent,P.,Bonnet,D.,DeMaria,R.,Lapidot,T.,Copland,M.,Melo,J.V.,Chomienne,C.,Ishikawa,F.,Schuringa,J.J.,Stassi,G.,etal.(2012).Perspectives.Nat.Rev.Cancer12,767–775.Vidal,S.J.,Rodriguez-Bravo,V.,Galsky,M.,Cordon-Cardo,C.,andDomingo-Domenech,J.(2013).Targetingcancerstemcellstosuppressacquiredchemotherapyresistance.Oncogene33,4451–4463.Visvader,J.E.,andLindeman,G.J.(2008).Cancerstemcellsinsolidtumours:accumulatingevidenceandunresolvedquestions.Nat.Rev.Cancer8,755–768.Wiechert,A.,Saygin,C.,Thiagarajan,P.S.,Rao,V.S.,Hale,J.S.,Gupta,N.,Hitomi,M.,Nagaraj,A.B.,DiFeo,A.,Lathia,J.D.,andReizes,O.(2016).Cisplatininducesstemnessinovariancancer.Oncotarget7,30511–30522.Xiang,R.,Liao,D.,Cheng,T.,Zhou,H.,Shi,Q.,Chuang,T.S.,Mar-kowitz,D.,Reisfeld,R.A.,andLuo,Y.(2011).DownregulationoftranscriptionfactorSOX2incancerstemcellssuppressesgrowthandmetastasisoflungcancer.Br.J.Cancer104,1410–1417.Xiao,G.-H.,Gallagher,R.,Shetler,J.,Skele,K.,Altomare,D.A.,Pestell,R.G.,Jhanwar,S.,andTesta,J.R.(2005).TheNF2tumorsuppressorgeneproduct,merlin,inhibitscellproliferationandcellcycleprogressionbyrepressingcyclinD1expression.Mol.CellBiol.25,2384–2394.Xu,J.,Kadariya,Y.,Cheung,M.,Pei,J.,Talarchek,J.,Sementino,E.,Tan,Y.,Menges,C.W.,Cai,K.Q.,Litwin,S.,etal.(2014).GermlinemutationofBap1acceleratesdevelopmentofasbestos-inducedmalignantmesothelioma.CancerRes.74,4388–4397.StemCellReportsjVol.8j1005–1017jApril11,20171017   254  Mol. Cells 2017; 40(4): 254-261        Minireview    MicroRNA-296-5p Promotes Invasiveness through Downregulation of Nerve Growth Factor Receptor and Caspase-8  Hong Lee1, Chang Hoon Shin1, Hye Ree Kim1, Kyung Hee Choi1, and Hyeon Ho Kim1,2,*   1Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06351, Korea, 2Research Institute for Future Medicine, Samsung Medical Center, Seoul 06351, Korea *Correspondence: hyeonhkim@skku.edu http://dx.doi.org/10.14348/molcells.2017.2270 www.molcells.org    Glioblastomas (GBM) are very difficult to treat and their ag-gressiveness is one of the main reasons for this as well as for the frequent recurrences. MicroRNAs post-transcriptionally regulate their target genes through interaction between their seed sequence and 3UTR of the target mRNAs. We previous-ly reported that miR-296-3p is regulated by neurofibromatosis 2 (NF2) and enhances the invasiveness of GBM cells via SOCS2/STAT3. In this study, we investigated whether miR-296-5p, which originates from the same precursor miRNA as miR-296-3p, can increase the invasiveness of GBM cells. It was observed that miR-296-5p potentiated the invasion of various GBM cells including LN229, T98G, and U87MG. Through bioinformatics approaches, two genes were identi-fied as miR-296-5p targets: caspase-8 (CASP8) and nerve growth factor receptor (NGFR). From results obtained from Ago2 immunoprecipitation and luciferase assays, we found that miR-296-5p downregulates CASP8 and NGFR through direct interaction between seed sequence of the miRNA and 3UTR of the target mRNA. Knockdown of CASP8 or NGFR also increased the invasive ability of GBM cells, indicating that CASP8 and NGFR are involved in potentiation of invasiveness by miR-296-5p. Consistent with our findings, CASP8 was downregulated in brain metastatic lung cancer cells, which have a high level of miR-296-5p, compared to parental cells, suggesting that miR-296-5p may be generally associated with the acquisition of invasiveness. Collectively, our results implicate  miR-296-5p as a potential cause of invasiveness in cancer and suggest it as a promising therapeutic target for GBM.  Keywords: caspase-8, glioblastoma, invasiveness, miR-296-5p, nerve growth factor receptor   INTRODUCTION  Glioblastoma multiforme (GBM) is the most aggressive and lethal type of brain tumor in adults (Lee et al., 2014; Omuro and DeAngelis, 2013; Thomas et al., 2014). Due to the ex-tremely high invasiveness, approximately 70% of GBM pa-tients suffer from recurrence. Moreover, the invasive ability of GBM cells renders them incurable by current treatment options like surgery, radiotherapy, and chemotherapy. For these reasons, a better understanding of the molecular mechanisms underlying the acquisition of invasiveness will be of help in developing new therapeutic strategies for GBM treatment. MicroRNAs (miRNA) are small non-coding RNAs with ap-proximately 20~23 nucleotides. They are transcribed by RNA polymerase II and then cleaved sequentially by Drosha and Dicer to form miRNA. They are important in post-transcrip-tional gene regulation as they can suppress the expression of their target gene through complementary base pairing Molecules and Cells Received 10 November, 2016; revised 21 November, 2016; accepted 29 November, 2016; published online 8 December, 2016  eISSN: 0219-1032 The Korean Society for Molecular and Cellular Biology. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 UnportedLicense. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/. Potentiation of Invasiveness by miR-296-5p Hong Lee et al.   Mol. Cells 2017; 40(4): 254-261  255   between their seed sequence and 3UTR of the target mRNA. Caspase-8 (CASP8) is a cysteine protease, which triggers apoptotic cell death in response to receptor-mediated extra-cellular stimuli (Lee et al., 2015; Oberst and Green, 2011). CASP8 is known to play a critical role in the processes of extrinsic apoptosis, which is mediated by the activation of death receptors such as those belonging to the tumor ne-crosis receptor (TNF) family (Wilson et al., 2009). Loss of CASP8 in neuroblastomas is associated with increased meta-static potential (Stupack et al., 2006). CASP8 is generally downregulated in metastatic cells in vivo compared to that in parental cells. Nerve growth factor receptor (NGFR), which is also termed as p75NTR, is a glycosylated trans-membrane receptor without a cytoplasmic tyrosine kinase domain. It is known to play important roles in cell survival, migration, and invasion through interaction with several ligands and co-receptors (Barker, 2004; Reichardt, 2006). NGFR functions as a tumor suppressor by negatively regulat-ing cell proliferation and metastatic potential including mi-gratory and invasive abilities. In a previous study, we demonstrated that knockdown of neurofibromatosis 2 (NF2) leads to nuclear localization and the transactivation of YAP by inducing its dephosphorylation (Lee et al., 2016). Nuclear YAP transcriptionally increases the expression of miR-296-3p, which potentiates the invasive-ness of GBM cells via the miR-296-3p/SOCS2/STAT3 axis. During the process of miRNA biogenesis, miR-296-5p is transcribed concomitant with miR-296-3p. In this study, we investigated the effect of miR-296-5p, which is a partner miRNA to miR-296-3p, on the invasiveness of GBM cells. We found that miR-296-5p activates the invasive activity of GBM cells (LN229, T98G, and U87MG) by suppressing the expres-sion of CASP8 and NGFR. In conclusion, our results indicate that both strands of mir-296, miR-296-3p and miR-296-5p, are closely associated with invasiveness and are promising therapeutic targets for GBM.  MATERIALS AND METHODS  Cell culture and transfection Human GBM cell lines (LN229, T98G, and U87MG) were maintained in Dulbecco’s modified Eagle medium (DMEM, Hyclone, GE Healthcare, UK) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution (GIBCO-BRL, Thermo Fisher Scientific, USA). All GBM cells were authenticated through short tandem repeat profiling. For overexpression of miR-296-5p, cells were transfected with control (Con) miRNA or miRNA-296-5p mimic (pre-miR-296-5p, GenePharma, Shanghai, China) using Lipofec-tamine2000 (Invitrogen, Thermo Scientific) according to the manufacturer’s protocol. For knockdown experiments, cells were transfected with control (CTRL) siRNA or indicated siRNAs. SiRNAs for CASP8 (GCUGCUCUUCCGAAUUAAUUU) and NGFR (CGAGCACA UAGACUCCUUU) were synthesized in Bioneer (Korea).  Evaluation of the invasiveness of GBM cells The invasiveness of GBM cells was assessed using a BD Bio-coat™ Matrigel invasion chamber (BD Bioscience, USA). Briefly, equal number of cells in serum-free media was add-ed into the upper and lower chambers. Cellular invasion was triggered by the addition of complete medium containing 10% FBS into the lower chamber. After incubation for 24 h, invaded cells were fixed by methanol and then stained with 0.1% hematoxylin and eosin. Invasiveness was determined by counting the number of invaded cells from more than twelve fields.  Western blot analysis For western blot analysis, cells were lysed in RIPA buffer con-taining a protease and phosphatase inhibitors (Roche, Swit-zerland). Equal amounts of protein were separated by SDS-polyacrylamide gel electrophoresis and transferred onto pol-yvinylidene fluoride membranes (Millipore, USA). The mem-branes were blocked and then incubated with the indicated primary antibody and the appropriate secondary antibody. Bands were visualized using the enhanced chemolumines-cence solution (Amersham, UK). Antibodies used for CASP8 (#9746) and NGFR/p75NTR (sc-6188) were from Cell Signal-ing Technology and Santa Cruz Biotechnology, respectively. GAPDH (ab8245, Abcam) was used as loading control.  RNA isolation and RT-qPCR analysis Total RNA was isolated using TRIzol reagent (Ambion, USA) according to the manufacturer's instructions. After cDNA was synthesized using the SuperScript III First-Strand Synthesis System (Invitrogen, USA), the level of mRNA was quantified by reverse transcription quantitative-PCR (RT-qPCR) (ABI Prism 7600) using Power SYBR Green PCR Master Mix (Applied Biosystems, USA). RT-qPCR was per-formed using the following primers: CASP8, forward: CATCCAGTCACTTTGCCAGA, reverse: GCATCTGTTTCCCC ATGTTT; NGFR, forward: CGACAACCTCATCCCTGTCT, reverse: GCTGTTCCACCTCTTGAAGG. The level of GAPDH mRNA was used for normalization (forward: TGCACCACC AACTGCTTAGC, reverse: GGCATGGACTGTGGTCATGAG). To determine the levels of primary and mature miRNAs, RT-qPCR was performed using primary miR-296-specific pri-mers (forward: TGCCTAATTCAGAGGGTTGG, reverse: CTCC ACTCCTGGCACACAG) and mature miRNA-296-5p-specific TaqMan primer (MIMAT0000690, Applied Biosystems, USA), respectively.  Ago2 immunoprecipitation (IP) To examine whether miR-296-5p directly binds to CASP8 and NGFR mRNA, IP was performed using an Ago2-specific antibody (Sigma-Aldrich, USA). Cytoplasmic lysates were incubated with Ago2 antibody-coated Dynabeads Protein G (10004D, Invitrogen). Beads were washed with PEB buffer more than five times, and RNA in the Ago2-IP materials was then isolated. The enrichment of CASP8 and NGFR mRNA in Ago2-IP was determined by RT-qPCR.  Luciferase reporter assay To investigate whether downregulation of CASP8 and NGFR by miR-296-5p is caused by the direct interaction between the miRNA seed sequence and the 3UTR of their target mRNA, pmirGLO dual-luciferase vectors (E133A, Promega) Potentiation of Invasiveness by miR-296-5p Hong Lee et al.   256  Mol. Cells 2017; 40(4): 254-261   containing the 3UTR of CASP8 and NGFR mRNA were con-structed: pmirGLO-CASP8 3UTR and pmirGLO-NGFR 3UTR, respectively. We prepared two individual vectors containing wild-type or mutated seed region sequences of the miR-296-5p-binding site in the 3UTR of CASP8 and NGFR mRNAs. Cells were transfected with control or pre-miR-296-5p and plated into the 24-well plate. After 24 h, cells were transfected with either wild-type or mutant-type luciferase vector. Effect of the miR-296-5p on luciferase expression was assessed using a Dual-GLO™ Luciferase Assay System (E2940, Promega).   RESULTS  Invasive ability of GBM cells is potentiated by miR-296-5p Previously, we reported that NF2 induces the phosphoryla-tion of YAP and thus inhibits its transactivation by hindering nuclear localization (Lee et al., 2016). It was also found that knockdown of NF2 increases the expression of miR-296-3p, which augments the invasiveness of GBM T98G cells via SOCS2/STAT3 axis. In this report, we further investigated whether miR-296-5p, which is co-expressed with miR-296-3p, induces similar effects on the invasive activity of GBM cells. First, we examined the invasive ability of miR-296-5p-overexpressed GBM cells. LN229, T98G, and U87MG cells were transfected with control miRNA or pre-miR-296-5p and invasive activity was assessed using Transwell invasion assay. Overexpression of miR-296-5p enhanced the inva-siveness of all tested cells. The number of invaded cells was increased by about 4.8-fold (Fig. 1A), 13.2-fold (Fig. 1B), and 2.8-fold (Fig. 1C) in LN229, T98G, and U87MG cells, respectively. Based on the effect of miR-296-5p on their invasiveness, LN229 and T98G cells were chosen for further experiments. From these results, we found that miR-296-5p, similar to its partner miR-296-3p, has the potential to control the invasiveness of GBM cells.   CASP8 and NGFR are targets of miR-296-5p To investigate the molecular mechanism by which miR-296-5p potentiates the invasive ability of GBM cells, we investigated the target genes of miR-296-5p. For this, we used several databases for miRNA target prediction includ-ing TargetScan and miRanda. We identified two putative miR-296-5p target genes: CASP8 and NGFR. Predicted binding sites for miR-296-5p in the 3UTRs of CASP8 and NGFR mRNAs are shown in Fig. 2A and 2B, respectively. Next, we checked the effect of miR-296-5p on the expres-sion of CASP8 and NGFR in LN229 (Fig. 2C and 2D) and T98G (Figs. 2E and 2F) cells. For overexpression, a miR-296-5p-mimic was introduced into these cells. The protein and mRNA expression of CASP8 and NGFR was downregu-lated by miR-296-5p in both cells. Based on these results, CASP8 and NGFR can be considered novel targets of miR-296-5p.   A                             B                            C             D                              E            Fig. 1. miRNA-296-5p enhances the invasiveness of GBM cells. To investigate the effect of miR-296-5p on invasiveness, three GBM cells (LN229 (A), T98G (B), and U87MG(C)) were transfected with control miRNA or pre-miR-296-5p. After 48 h, the invasive activity was determined by counting the number of invaded cells from more than twelve fields. All experiments were performed more than three times and data are represented as mean  S.D. Potentiation of Invasiveness by miR-296-5p Hong Lee et al.   Mol. Cells 2017; 40(4): 254-261  257   Fig. 2. CASP8 and NGFR are targets of miR-296-5p. (A, B) A bioinformatics search using several prediction databases identified CASP8 and NGFR as putative tar-gets of miR-296-5p. Schematics showing miR-296-5p-binding site in the 3UTR of CASP8 (A) and NGFR mRNA (B). (C, D) LN229 cells were transfected with control miRNA or pre-miR-296-5p. After 48 h, whole-cell lysates were prepared and the expression levels of CASP8 and NGFR were determined by Western blot analysis (C). The levels of CASP8 and NGFR mRNA were also assessed by RT-qPCR (D). (E, F) T98G cells were transfected as described above. The protein and mRNA levels of CASP8 and NGFR were examined by Western blot (E) and RT-qPCR analysis (F), respectively. All exper-iments were performed more than three times and data are represented as mean  S.D. A        B        C                  D           E                  F             miR-296-5p directly interacts to the 3’UTR of CASP8 and NGFR mRNA To verify the direct interaction of miR-296-5p and the 3UTR of CASP8 and NGFR mRNAs, an IP assay using Ago2-specific antibody was performed. The LN229 cells were first trans-fected with control miRNA or pre-miR-296-5p; cytoplasmic lysates were then prepared and used for Ago2-IP assay. The level of CASP8 and NGFR mRNA in the IP materials was as-sessed by RT-qPCR analysis. As shown in Fig. 3A, miR-296-5p increased the level of Ago2-bound CASP8 mRNA in both GBM cells. Similarly, the enrichment of NGFR mRNA in Ago2- IP was also increased by miR-296-5p (Fig. 3B). These results suggest that miR-296-5p-containing RISC complex binds to the 3UTR of CASP8 and NGFR mRNA, which is responsible for downregulation of CASP8 and NGFR. Direct interaction between miR-296-5 and target mRNA was fur-ther verified using chimeric luciferase vectors. We manufac-tured two luciferase vectors containing wild-type and mu-tated sequences of the miR-296-5p-binding site from the CASP8 and NGFR mRNAs (Figs. 3C and 3D). In both the luciferase vectors harboring miR-296-5p-binding sequences, miR-296-5p suppressed the luciferase activity. Conversely, disruption of the direct interaction between the seed se-quence of the miRNA and the 3UTR region of its target mRNA by point mutations abolished the miR-296-5p-mediated downregulation of luciferase expression, indicat-ing that this direct interaction is responsible for the down-regulation of CASP8 and NGFR by miR-296-5p.  Downregulation of CASP8 and NGFR is involved in miR-296-5p-mediated invasiveness From the above results, we found that miR-296-5p in-creased the invasiveness of GBM cells and suppressed the expression of CASP8 and NGFR. Next, we investigated whether downregulation of CASP8 and NGFR is necessary for the enhancement of GBM invasion by miR-296-5p. LN229 and T98G cells were transfected with CASP8- or NGFR-specific siRNA and invasive activity was determined by Potentiation of Invasiveness by miR-296-5p Hong Lee et al.   258  Mol. Cells 2017; 40(4): 254-261   Fig. 3. miR-296-5p directly interacts with the3UTR of CASP8 and NGFR mRNAs. (A, B) Toverify whether miR-296-5p-containing RISCcan bind to the 3UTR of CASP8 (A) andNGFR (B) mRNAs, LN229 and T98G cellswere transfected with control miRNA or pre-miR-296-5p. Cytoplasmic lysates of transfect-ed cells were immunoprecipitated with Ago2antibody. The levels of CASP8 and NGFRmRNAs in IP materials were determined byRT-qPCR analysis. (C, D) To verify the directinteraction between seed sequence of miRNAand 3UTR of target mRNA, the luciferasevectors containing wild-type and mutatedsequences of miR-296-5p-binding site wereconstructed [(C), CASP8 mRNA; (D), NGFRmRNA]. To disrupt interaction between miR-NA and target 3UTR, four nucleotides in seedregion were mutated. The expression of lucif-erase was assessed by measuring its activityusing a Dual-GLO™ Luciferase Assay System.All experiments were performed more thanthree times and data are represented asmean  S.D. A                           B          C                           D                      Transwell invasion assay. In both cells, knockdown of CASP8 increased the number of invaded cells (Figs. 4A and 4B). NGFR-silenced cells also showed higher invasiveness as compared to control cells (Figs. 4C and 4D). Based on these results, we concluded that miR-296-5p regulates the inva-sive ability of GBM cells through post-transcriptional regula-tion of CASP8 and NGFR.   miR-296-5p is involved in the acquisition of invasive property In order to generalize our findings, we investigated the role of miR-296-5p in the invasiveness of lung adenocarcinoma cells using previously established brain metastatic PC14PE6/LvBr4 cells, which are generated from lung adeno-carcinoma PC14PE6 cells through repeated intracardiac in-jection (Hwang et al., 2015; 2016). Since PC14PE6 cells barely express NGFR, we could only compare the expression level of CASP8. CASP8 protein and mRNA were found to be highly expressed in parental PC14PE6 cells compared to brain metastatic PC14PE6/LvBr4 cells (Figs. 5A and 5B, re-spectively). As expected, the level of miR-296-5p was higher in the brain metastatic PC14PE6/LvBr4 cells than in the pa-rental PC14PE6 cells (Fig. 5C). Next, we tested whether miR-296-5p suppresses the expression of CASP8 and enhances invasive property in parental PC14PE6 cells. It was found that miR-296-5p decreased the expression level of CASP8 protein (Fig. 5D) and mRNA (Fig. 5E). Along with down-regulation of CASP8, invasiveness was potentiated as well in miR-296-5p-overexpressed PC14PE6 cells (Fig. 5F). Collec-tively, our results demonstrate that miR-296-5p is closely associated with induction of invasiveness in GBM cells through downregulation of CASP8 and NGFR and is a prom-ising therapeutic target for GBM.  DISCUSSION  GBM is a highly prevalent and incurable type of brain cancer, classified as the most aggressive and severe type (Ohgaki and Kleihues, 2007). Many individual genes have been im-plicated in the induction of invasiveness in glioma and shown to be strongly associated with the poor prognosis of patients (Freije et al., 2004; Liang et al., 2005). In this regard, their expression should be tightly controlled in the cancer cells. miRNAs are important in post-transcriptional gene regulation as they can downregulate the expression of tar-get genes through complementary binding of miRNA within RISC to the 3UTR of the target mRNA, which results in mRNA degradation or translational suppression (Winter and Diederichs, 2011). Through comparison of the miRNA ex-pression profiles of GBM samples and normal tissues, several miRNAs have been found to play critical roles in the pro-gression of GBM. As an oncogenic miRNA, miR-21 inhibits  Potentiation of Invasiveness by miR-296-5p Hong Lee et al.   Mol. Cells 2017; 40(4): 254-261  259   Fig. 5. miR-296-5p is involved in the invasiveproperty of brain metastatic lung cancer cells.(A-C) The expression level of CASP8 protein(A) and mRNA (B) in PC14PE6 lung adeno-carcinoma and its brain metastatic derivative(PC14PE6/LvBr4) was determined by West-ern blot and RT-qPCR analysis, respectively.The level of miR-296-5p was assessed by RT-qPCR using miR-296-5p-specific TaqManprimer. All experiments were performedmore than three times and data are repre-sented as mean  S.D. (D-F) ParentalPC14PE6 cells were transfected with controlmiRNA or pre-miR-296-3p. The expressionlevels of CASP8 protein (D) and mRNA (E)were determined by Western blot and RT-qPCR analysis, respectively. The effect ofmiR-296-5p on the invasiveness of PC14PE6cells was assessed by Transwell invasionassay (F). Invaded cells were stained andphotographed under microscope. The inva-sive activity was determined by counting thenumber of invaded cells from more thantwelve fields. All experiments were per-formed more than three times and data arerepresented as mean  S.D. A                                        B          C                                         D          Fig. 4. Knockdown of CASP8 or NGFR increases the invasiveness of GBM cells. (A, C) LN229 cells were transfected with CASP8 (A) or NGFR (C) siRNAs. After 48 h, the level of CASP8 or NGFR was examined by western blot analysis, and invasiveness was assessed by Transwell invasion assay. Invaded cells were photographed under the microscope and counted from more than twelve fields. (B, D) T98G cells were transfected and invasive activity of transfected cells was assessed as described above. All experiments were performed more than three times and data are represented as mean  S.D.     A            B               C          D            E               F          G                 H          Potentiation of Invasiveness by miR-296-5p Hong Lee et al.   260  Mol. Cells 2017; 40(4): 254-261   apoptotic processes, promotes invasive property, and acti-vates several receptor-mediated cellular signaling pathways (Moore and Zhang, 2010). In a previous report, we demonstrated that miR-296-3p is upregulated by NF2 knockdown and dramatically increases the invasiveness of GBM cells (Lee et al., 2016). During miR-NA biogenesis, primary miRNA is transcribed by RNA poly-merase II and sequentially cleaved by a nuclease. Thus, two strands of mature miRNA are produced from one precursor miRNA. In this study, we investigated the effect of miR-296-5p, a partner miRNA of miR-296-3p, on the invasiveness of GBM cells. Similar to results we obtained with miR-296-3p, invasive ability was potentiated by miR-296-5p. By directly binding to the 3UTR of the target mRNA, miR-296-5p sup-pressed the expression of CASP8 and NGFR. Moreover, knockdown of CASP8 or NGFR increased the invasiveness of GBM cells, indicating that these proteins are involved in the potentiation of invasiveness by miR-296-5p. CASP8 is a component of the programmed cell death ma-chinery and is known to be a tumor suppressor. It plays an important role in death receptor-mediated cell death. CASP8 is frequently deleted or silenced mainly through the methyla-tion of its promoter region. Loss of CASP8 is observed in diverse types of cancer including small cell lung carcinoma, retinoblastoma, and medulloblastoma (Hopkins-Donaldson et al., 2003; Pingoud-Meier et al., 2003; Teitz et al., 2001). Interestingly, CASP8 selectively influences the apoptosis of invading cells at the tumor margin rather than in the primary tumor (Stupack et al., 2006). Through interaction with un-ligated integrin, CASP8 can trigger the apoptotic process. It was reported that loss of CASP8 renders cancer cells refrac-tory to integrin-mediated cell death and re-introduction of CASP8 sensitizes neuroblastoma cells to drug-induced apop-tosis. In addition to roles in extrinsic cell death, deficiency of CASP8 confers aggressiveness to neuroblastoma and is closely associated with poor prognosis (Pingoud-Meier et al., 2003; Teitz et al., 2001). It has also been reported that mu-tations in CASP8 promote cellular migration and invasion and confers resistance to death receptor-mediated apoptosis in head and neck cancer (Li et al., 2014). Thus, CASP8 has been identified as a metastasis suppressor.  NGFR is a multifunctional cell surface receptor and be-longs to the TNF receptor family. Interestingly, NGFR plays different roles depending on the cell context. In brain tumor and melanomas, it functions as an oncogene (tumor-promoting) (Marchetti et al., 2004; Menter et al., 1994). In contrast, NGFR impairs tumorigenesis and functions as a tumor suppressor in bladder, stomach, and liver cancers (Jin et al., 2007; Quann et al., 2007; Sachs et al., 2007; Tabas-sum et al., 2003). NGFR is highly expressed in invasive glio-ma cells and contributes to their high invasiveness (Johnston et al., 2007; Wang et al., 2008). Intramembrane proteolysis of NGFR is required for invasion in glioma cells (Wang et al., 2008).  In this study, we observed that miR-296-5p is able to acti-vate the invasive activity of GBM cells (LN229, T98G, and U87MG) through downregulation of CASP8 and NGFR. In accordance with previous reports, it was found that CASP8 and NGFR function as tumor suppressor in GBM. Previously we reported that nuclear localization of YAP is responsible for the transcription of primary miR-296 and thus regulates the biosynthesis of miR-296-3p and -5p as well. Based on our previous and present data, both strands of precursor mir-296 (miR-296-3p and -5p) are main players in the acqui-sition of invasive ability by activating STAT3 pathway and by targeting CASP8 and NGFR, respectively, which suggests that mir-296 is a promising target for GBM treatment   ACKNOWLEDGMENTS This research was supported by a grant from the Mid-career Research Program through the National Research Founda-tion (NRF) funded by the Ministry of Science, ICT, and Future Planning, Republic of Korea (2014R1A2A1A11053130).  REFERENCES  Barker, P.A. (2004). p75NTR is positively promiscuous: novel partners and new insights. Neuron 42, 529-533. Freije, W.A., Castro-Vargas, F.E., Fang, Z., Horvath, S., Cloughesy, T., Liau, L.M., Mischel, P.S., and Nelson, S.F. (2004). Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 64, 6503-6510. Hopkins-Donaldson, S., Ziegler, A., Kurtz, S., Bigosch, C., Kandioler, D., Ludwig, C., Zangemeister-Wittke, U., and Stahel, R. (2003). Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 10, 356-364. Hwang, S.J., Lee, H.W., Kim, H.R., Song, H.J., Lee, D.H., Lee, H., Shin, C.H., Joung, J.G., Kim, D.H., Joo, K.M., et al. (2015). Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1. Oncotarget 6, 20434-20448. Hwang, S.J., Lee, H.W., Kim, H.R., Lee, H., Shin, C.H., Yun, S.I., Lee, D.H., Kim, D.H., Kim, K.K., Joo, K.M., et al. (2016). Ubiquitin-specific protease 4 controls metastatic potential through beta-catenin stabilization in brain metastatic lung adenocarcinoma. Sci. Rep. 6, 21596. Jin, H., Pan, Y., Zhao, L., Zhai, H., Li, X., Sun, L., He, L., Chen, Y., Hong, L., Du, Y., et al. (2007). p75 neurotrophin receptor suppresses the proliferation of human gastric cancer cells. Neoplasia 9, 471-478. Johnston, A.L., Lun, X., Rahn, J.J., Liacini, A., Wang, L., Hamilton, M.G., Parney, I.F., Hempstead, B.L., Robbins, S.M., Forsyth, P.A., et al. (2007). The p75 neurotrophin receptor is a central regulator of glioma invasion. PLoS Biol. 5, e212. Lee, W.S., Kwon, J., Yun, D.H., Lee, Y.N., Woo, E.Y., Park, M.J., Lee, J.S., Han, Y.H., and Bae, I.H. (2014). Specificity protein 1 expression contributes to Bcl-w-induced aggressiveness in glioblastoma multiforme. Mol. Cells 37, 17-23. Lee, H., Park, S., Kang, Y.S., and Park, S. (2015). EphA receptors form a complex with caspase-8 to induce apoptotic cell death. Mol. Cells 38, 349-355. Lee, H., Hwang, S.J., Kim, H.R., Shin, C.H., Choi, K.H., Joung, J.G., and Kim, H.H. (2016). Neurofibromatosis 2 (NF2) controls the invasiveness of glioblastoma through YAP-dependent expression of CYR61/CCN1 and miR-296-3p. Biochim.  Biophys. Acta 1859, 599-611. Li, C., Egloff, A.M., Sen, M., Grandis, J.R., and Johnson, D.E. (2014). Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. Mol. Oncol. 8, 1220-1230. Potentiation of Invasiveness by miR-296-5p Hong Lee et al.   Mol. Cells 2017; 40(4): 254-261  261   Liang, Y., Diehn, M., Watson, N., Bollen, A.W., Aldape, K.D., Nicholas, M.K., Lamborn, K.R., Berger, M.S., Botstein, D., Brown, P.O., et al. (2005). Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc. Natl. Acad. Sci. USA 102, 5814-5819. Marchetti, D., Aucoin, R., Blust, J., Murry, B., and Greiter-Wilke, A. (2004). p75 neurotrophin receptor functions as a survival receptor in brain-metastatic melanoma cells. J. Cell. Biochem. 91, 206-215. Menter, D.G., Herrmann, J.L., Marchetti, D., and Nicolson, G.L. (1994). Involvement of neurotrophins and growth factors in brain metastasis formation. Invasion  Metastasis 14, 372-384. Moore, L.M., and Zhang, W. (2010). Targeting miR-21 in glioma: a small RNA with big potential. Exp. Opin. Ther. Targets 14, 1247-1257. Oberst, A., and Green, D.R. (2011). It cuts both ways: reconciling the dual roles of caspase 8 in cell death and survival. Nat. Rev. Mol. Cell Biol. 12, 757-763. Ohgaki, H., and Kleihues, P. (2007). Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 170, 1445-1453. Omuro, A., and DeAngelis, L.M. (2013). Glioblastoma and other malignant gliomas: a clinical review. Jama 310, 1842-1850. Pingoud-Meier, C., Lang, D., Janss, A.J., Rorke, L.B., Phillips, P.C., Shalaby, T., and Grotzer, M.A. (2003). Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin. Cancer Res. 9, 6401-6409. Quann, E.J., Khwaja, F., and Djakiew, D. (2007). The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of p75 NTR in prostate cancer cells. Cancer Res. 67, 11402-11410. Reichardt, L.F. (2006). Neurotrophin-regulated signalling pathways. Philosophical transactions of the Royal Society of London. Series B, Biol. Sci. 361, 1545-1564. Sachs, B.D., Baillie, G.S., McCall, J.R., Passino, M.A., Schachtrup, C., Wallace, D.A., Dunlop, A.J., MacKenzie, K.F., Klussmann, E., Lynch, M.J., et al. (2007). p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway. J. Cell Biol. 177, 1119-1132. Stupack, D.G., Teitz, T., Potter, M.D., Mikolon, D., Houghton, P.J., Kidd, V.J., Lahti, J.M., and Cheresh, D.A. (2006). Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439, 95-99. Tabassum, A., Khwaja, F., and Djakiew, D. (2003). The p75(NTR) tumor suppressor induces caspase-mediated apoptosis in bladder tumor cells. Int. J. Cancer 105, 47-52. Teitz, T., Lahti, J.M., and Kidd, V.J. (2001). Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death. J. Mol. Med. 79, 428-436. Thomas, A.A., Brennan, C.W., DeAngelis, L.M., and Omuro, A.M. (2014). Emerging therapies for glioblastoma. JAMA Neurol. 71, 1437-1444. Wang, L., Rahn, J.J., Lun, X., Sun, B., Kelly, J.J., Weiss, S., Robbins, S.M., Forsyth, P.A., and Senger, D.L. (2008). Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor. PLoS Biol. 6, e289. Wilson, N.S., Dixit, V., and Ashkenazi, A. (2009). Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat. Immunol. 10, 348-355. Winter, J., and Diederichs, S. (2011). MicroRNA biogenesis and cancer. Method Mol. Biol. 676, 3-22.  Otol Neurotol. Author manuscript; available in PMC 2015 Feb 19.
Published in final edited form as:
Otol Neurotol. 2013 Oct; 34(8): 1519–1527.
doi:  10.1097/MAO.0b013e3182956169
PMCID: PMC4334125
NIHMSID: NIHMS663150
Natural Compounds as Potential Treatments of NF2-Deficient Schwannoma and Meningioma: Cucurbitacin D and Goyazensolide
Samuel A. Spear,1,2,* Sarah S. Burns,1,2 Janet L. Oblinger,1,2 Yulin Ren,4 Li Pan,4 A. Douglas Kinghorn,4 D. Bradley Welling,2 and Long-Sheng Chang1,2,3
Author information ► Copyright and License information ►
The publisher's final edited version of this article is available at Otol Neurotol
See other articles in PMC that cite the published article.
Go to:
Abstract
Hypothesis

Cucurbitacin D and goyazensolide, two plant-derived natural compounds, possess potent growth-inhibitory activity in schwannoma and meningioma cells.

Background

Currently, no FDA-approved drugs are available for neurofibromatosis type 2 (NF2)-associated schwannomas and meningiomas. Selected natural compounds with antineoplastic activity, such as cucurbitacin and goyazensolide, may be developed as potential treatments for these tumors.

Methods

The Nf2-deficient mouse schwannoma Sch10545 and human benign meningioma Ben-Men-1 cells were treated with various concentrations of cucurbitacin D and goyazensolide. The effect on cell proliferation was determined using resazurin assays. Flow cytometry was used to assess the cell cycle profiles. Western blot analysis was performed to investigate the expression of various signal molecules related to the cell cycle and the AKT pathway.

Results

Cucurbitacin D inhibited proliferation of Sch10545 cells (IC50 ~0.75 μM) and Ben-Men-1 cells (IC50 ~0.2 μM). Goyazensolide also reduced cell proliferation of Sch10545 cells (IC50 ~0.9 μM) and Ben-Men-1 cells (IC50 ~1 μM). The G2/M population increased in both Sch10545 and Ben-Men-1 cells treated with cucurbitacin D or goyazensolide around the IC50. Cucurbitacin and goyazensolide substantially reduced the levels of cyclins E and A in treated Sch10545 and Ben-Men-1 cells. Cucurbitacin D also inhibited cyclin B, phospho-AKT and phospho-PRAS40 expression. In addition, goyazensolide reduced the levels of phospho-AKT and NFκB and increased the expression of pro-apoptotic Bim in Sch10545 and Ben-Men-1 cells.

Conclusions

Both cucurbitacin D and goyazensolide effectively inhibit proliferation of NF2-deficient schwannoma and meningioma cells, suggesting that these natural compounds should be further evaluated as potential treatments for NF2-related tumors.

Keywords: Natural compounds, vestibular schwannoma, meningioma, neurofibromatosis type 2 (NF2), cucurbitacin D, goyazensolide
Go to:
INTRODUCTION
Neurofibromatosis type 2 (NF2) is an autosomal-dominant hereditary cancer syndrome characterized by the development of bilateral vestibular schwannomas, meningiomas, spinal schwannomas, and ependymomas1. Bilateral vestibular schwannomas, which arise from Schwann cells that ensheath and myelinate nerve cells of cranial nerve VIII, are the hallmark of NF2. Meningiomas, which derive from the arachnoidal cap cells of the meninges covering the spinal cord and brain, affect 50–60% of NF2 patients1. Clinical symptoms caused by the NF2-associated tumors include hearing loss, tinnitus, vertigo and balance abnormalities, facial paralysis, hydrocephalus, blindness, cranial nerve palsy, seizures, brainstem compression, and other cranial nerve symptoms, such as hoarseness, dysphagia, and aspiration.

Current treatment considerations for NF2-associated tumors include observation, surgery, and radiation therapy. None may be sufficient, however, in patients with high tumor burden, recurrence and involvement of surrounding critical structures. While surgical resection may temporarily alleviate symptoms caused by the tumors or prevent new symptoms from developing, it may cause significant morbidities, including hearing loss, facial paralysis, dizziness, intracranial bleeding, stroke, or even death. Radiation therapy may stop or slow tumor growth or decrease tumor size in some patients, but the risk for malignant transformation and growth acceleration of schwannomas and meningiomas must be considered2. Failure to control growth via stereotactic radiation is higher in NF2-associated tumors than in the more common sporadic vestibular schwannomas. Therefore, new treatment options need to be investigated, particularly in light of recent advances in the understanding of tumor-specific signaling pathways and improved cell culture and mouse models for NF2-associated tumors3.

One area of promise in developing a medical therapy is to identify selected natural compounds with antineoplastic activity and test them in NF2-associated tumors. Natural compounds have been used for thousands of years and are the basis for many current antitumor drugs; for example, taxol (now named paclitaxel), one of the most effective drugs against breast and ovarian cancer, was isolated from the bark of the Pacific yew tree in the early 1970’s and was later partially chemically synthesized for clinical use4. Natural compounds may also inhibit other cellular processes for preventative use4 and could benefit benign and slow-growing tumors that require long-term treatment. Identification of anticancer natural compounds has been promoted by the National Cancer Institute via large-scale anticancer drug discovery and screening programs4.

Cucurbitacin D, a tetracyclic triterpenoid, and goyazensolide, a sesquiterpene lactone, are two unrelated natural compounds first identified in medicinal plants and trees (Figure 1A) and have been shown to have anticancer effects and cytotoxic activities in several types of human cancer5. Cucurbitacins, initially isolated from plants of the family Cucurbitaceae, are known to induce cancer cell death and inhibit the JAK-STAT and MAPK signaling pathways6–7; cucurbitacin D, one of the most potent biologically-active cucurbitacins, has been shown to inhibit proliferation of HT-29 human colon carcinoma cells8. Like cucurbitacins, sesquiterpene lactones comprise a large diverse group of compounds; of which, some possess antitumor effects and can suppress NFκB activity9. Goyazensolide, a sesquiterpene lactone isolated from Piptocoma rufescens, has also been shown to be highly cytotoxic to HT-29 cells10.

Figure 1Figure 1Figure 1
Figure 1
Both Cucurbitacin D and goyazensolide effectively inhibited proliferation of Sch10545 schwannoma and Ben-Men-1 meningioma cells. The molecular structures ...
In this study, we investigated the cell-cycle and antitumor effects of cucurbitacin D and goyazensolide in NF2-deficient meningioma and schwannoma cells. We showed that both of these natural compounds effectively suppressed the growth of schwannoma and meningioma cells, induced cell-cycle arrest at G2/M, and affected the expression of multiple signaling molecules. Our results suggest that these natural compounds should be considered for further evaluation in animal models of NF2-related tumors.

Go to:
MATERIALS AND METHODS
Natural Compound Acquisition

As part of an ongoing multi-institutional program for the discovery of new anticancer agents from plants5, cucurbitacin D was isolated along with several other natural compounds from the fruits and stem bark of Elaeocarpus chinensis (Elaeocarpaceae) collected in Vietnam8. Another compound identified from this drug discovery program was goyazensolide, a sesquiterpene lactone from the plant Piptocoma rufescens (Asteraceae) collected in the Dominican Republic10. These natural compounds were purified and diluted to 10 mM in DMSO for further study.

Cell Culture

An Nf2-deficient mouse schwannoma cell line, Sch10545, was established from a tumor developed in a P0Cre;Nf2flox/flox mouse with conditional Nf2 inactivation in Schwann cells11. Ben-Men-1 is a telomerase-immortalized benign human meningioma cell line established from a grade I meningioma12. Both Sch10545 schwannoma and Ben-Men-1 meningioma cells were grown in Dulbecco-modified Eagle’s (DME) medium supplemented with 10% fetal bovine serum (FBS).

Cell Proliferation Assay

Sch10545 and Ben-Men-1 cells were plated in 96-well plates at a density of 5,000 cells/well and grown at 37°C. The following day, cells were treated with various concentrations of cucurbitacin D and goyazensolide as well as DMSO as a vehicle control at 37°C for 72 hours. Cell proliferation was measured by adding resazurin to treated cells, followed by incubation at 37°C for 1~4 hours13. A microplate reader (Molecular Devices) was used to measure fluorescence emission (excitation at 544 nm and emission at 590 nm), and the results were used to calculate the 50% inhibitory concentration (IC50) according to Lee et al.14

Flow Cytometry

Cells were freshly plated in 10-cm dishes overnight and then treated with increasing concentrations of cucurbitacin D or goyazensolide at 37°C for 24 and 48 hours. Control cells were treated with DMSO. Treated cells were photographed and then harvested by trypsinization, followed by washing with cold phosphate buffered saline (PBS) and centrifugation. The cell pellet was resuspended in 1 ml of PBS and fixed by adding 3 ml of ice-cold ethanol slowly while vortexing. Fixed cells were spun down and stained in propidium iodide (50 μg/ml) and RNase A (100 μg/ml) at 37°C for 1–3 hours in the dark. Stained cells were kept on ice until they were analyzed with a FACS Calibur flow cytometer (BD Biosciences). Data analysis was performed using FlowJo software (Tree Star).

Western Blot Analysis

Subconfluent Sch10545 and Ben-Men-1 cells were treated with various concentrations of cucurbitacin D or goyazensolide at 37°C for 24 and 48 hours. Treated cells were harvested and lysed in RIPA buffer containing proteases and phosphatase inhibitor cocktails (Sigma-Aldrich). The protein concentrations of clear lysates were determined by Bradford Assay. Equal amounts of protein (20 μg each) were electrophoresed in 8% or 10% SDS-polyacrylamide gels, and fractionated proteins were electroblotted onto an Immobilon-P membrane (Millipore). Following protein transfer, the membrane was blocked with 5% non-fat dry milk in TBST (10 mM Tris-buffered saline and 0.05% Tween 20) at room temperature for 1 hour. The primary antibody was applied (1:500–1:2000 dilution) and incubated at 4°C overnight. The membrane was washed with TBST three times, and the secondary antibody (1:5,000 dilution) was added at room temperature for 1 hour. Following washing, the membrane was incubated with the Pierce ECL-2 Western Blotting Reagent for 5 minutes and the chemiluminescence activity was captured by exposure to X-ray films.

Primary antibodies used include: cyclin A, cyclin B1, cyclin D2, cyclin E1, cyclin H, Aurora A and B, PRAS40, BclXL, and BimEL, phospho-PRAS40, S6, phospho-S6, AKT, and phospho-AKT (Cell Signaling Technology), as well as cyclin A, NFκB (p65), CDC2, CDK7, PCNA, p27KIP1, and p57KIP2 (Santa Cruz Biotechnology). Secondary antibodies used were horse-radish peroxidase-conjugated goat anti-mouse or anti-rabbit IgG (Cell Signaling Technology).

Go to:
RESULTS
Cucurbitacin D and goyazensolide efficiently inhibit proliferation of schwannoma and meningioma cells

To search for natural compounds that can inhibit the growth of NF2-deficient schwannoma and meningioma cells, we tested compounds that have already been shown to be highly cytotoxic for one or more cancer cell lines8,10,15 and identified cucurbitacin D and goyazensolide as two compounds that exhibit potent growth inhibitory activities. As shown in Figure 1B, proliferation of Sch10545 schwannoma cells decreased below 50% with the addition of 1.25 μM of goyazensolide, relative to control DMSO-treated cells (IC50 = ~0.9 μM). Likewise, proliferation of Ben-Men-1 meningioma cells fell below 50% in the presence of 1.25 μM of goyazensolide (IC50 = ~1 μM; Figure 1C). Using similar assays, we also determined the IC50 value for cucurbitacin D to be ~0.75 μM and ~0.2 μM in Sch10545 schwannoma and Ben-Men-1 meningioma cells, respectively.

The growth-inhibitory effects of cucurbitacin D and goyazensolide could be directly visualized in drug-treated Sch10545 and Ben-Men-1 cells. Decreased cell density and increased round and presumably dead cells were observed with increasing doses of cucurbitacin D. Also, changes in cell morphology including pleomorphic cells with abnormal nuclear structure resembling multinucleation were noted (Figure 2A), consistent with previous reports of human cancer cell lines exposed to cucurbitacins7. Similar changes in cell density were seen in goyazensolide-treated Sch10545 and Ben-Men-1 cells (Figure 2B). However, the effect of goyazensolide on cell structures was not as prominent as that of cucurbitacin (compare Figure 2B with Figure 2A).

Figure 2Figure 2
Figure 2
Images of Sch10545 and Ben-Men-1 cells treated with cucurbitacin D or goyazensolide
Cucurbitacin D and goyazensolide induced cell cycle arrest at G2/M in both schwannoma and meningioma cells

To examine the effects of cucurbitacin D and goyazensolide on cell cycle progression of Sch10545 and Ben-Men-1 cells, we performed flow cytometry analysis. When Sch10545 cells were treated with cucurbitacin D at concentrations near the IC50 (0.5 or 1.0 μM), the percentage of cells at G2/M increased from 17.6% to 25.4% and 38%, respectively, compared with control DMSO-treated cells (Figure 2). An increase in the G2/M population was also observed in Ben-Men-1 cells treated with the concentrations of cucurbitacin D around the IC50 (0.125 or 0.25 μM) from 14.9% to 34.0% and 39.3%, respectively. Similarly, goyazensolide treatment also led to G2/M arrest in schwannoma and meningioma cells. A dramatic increase in the G2/M population of Sch10545 cells treated with goyazensolide at the concentrations around the IC50 (0.5, 1, and 2 μM) was observed (from 17.6% to 49.3%, 55.45, and 63.9%, respectively in Figure 3). Ben-Men-1 cells treated with goyazensolide at concentrations near the IC50 also showed a substantial increase of cells at G2/M (from 14.9% to 35.8% at 2 μM). These results indicate that cucurbitacin D and goyazensolide induced G2/M arrest in both schwannoma and meningioma cells.

Figure 3Figure 3
Figure 3
Cucurbitacin D and goyazensolide induced cell cycle arrest at G2/M in treated Sch10545 and Ben-Men-1 cells
Both cucurbitacin D and goyazensolide reduced the levels of cyclins E, A, and B in treated cells

To better understand how these two natural compounds caused G2/M arrest in Sch10545 schwannoma and Ben-Men-1 meningioma cells, Western blot analysis for various cell-cycle signaling molecules was conducted. A dose-dependent reduction of the cyclin B1 level was seen in Sch10545 cells treated with increasing concentrations of cucurbitacin D (Figure 4A). We also observed a slight decrease in cyclin E1 expression in cucurbitacin D-treated cells, while little or no change in the levels of cyclins D2 and H was found. Cucurbitacin D also reduced the levels of cyclins E1, A, and B1 in Ben-Men-1 cells. Consistent with G2/M arrest, the expression of PCNA, an S-phase induced protein, was not affected by cucurbitacin treatment in Sch10545 and Ben-Men-1 cells, while a slight decrease in CDC2 expression was noted (Figure 4B). Also, the levels of CDK inhibitors, p27KIP1 and p57KIP2, were not changed by cucurbitacin D treatment. Similarly, goyazensolide inhibited the expression of cyclins D2, E1, and A in Sch10545 cells and decreased the levels of cyclins E1 and A in Ben-Men-1 cells (Figure 5A) while little or no change in the levels of PCNA, cyclin H, and CDK7was found. Taken together, these results suggest that the G2/M arrest induced by cucurbitacin D and goyazensolide is mediated in part through the reduction in the protein levels of multiple cyclins.

Figure 4Figure 4Figure 4
Figure 4
The effect of cucurbitacin D on the expression of various cell-cycle signaling proteins in Sch10545 and Ben-Men-1 cells
Figure 5Figure 5
Figure 5
Expression of various cell-cycle, NFκB (p65), and phospho-AKT proteins in goyazensolide-treated Sch10545 and Ben-Men-1 cells
Consistent with previous reports10,16, goyazensolide reduced the level of the p65 subunit of NFκB in both Sch10545 and Ben-Men-1 cells. Curiously, cucurbitacin D treatment decreased the levels of phospho-AKT and its downstream target phospho-PRAS40 in a dose-dependent manner in Ben-Men-1 cells, while little or no change in the expression of total AKT and PRAS40 was seen (Figure 4C). In addition, we observed decreased phospho-AKT levels in both Sch10545 and Ben-Men-1 cells treated with goyazensolide (Figure 5B). As AKT is a pro-survival serine/threonine kinase, these results suggest that reduction of activated, phosphorylated AKT may result in decreased cell survival in cells treated with these natural compounds. Consistent with decreased cell viability, goyazensolide treatment modestly increased the expression of Bim, a pro-apoptotic factor, in Sch10545 and Ben-Men-1 cells, while the level of the anti-apoptotic BclXL was not affected by the treatment (Figure 5B).

Go to:
DISCUSSION
The natural history of NF2 is unpredictable as NF2-related intracranial tumors may exhibit linear growth, exponential growth, saltatory growth, or periods of quiescence with the most frequent being a saltatory growth pattern17. Surgical resection of tumors or radiation therapy may be reserved for symptom-producing tumors, leaving observation as the only alternative. Therefore, new medical therapies are needed. In this study, we demonstrated the potent growth-inhibitory activity of two natural compounds, cucurbitacin D and goyazensolide, in NF2-deficient schwannoma and meningioma cells.

Natural compounds as anticancer regimens have produced significant results in the past; however, they have not been rigorously evaluated in benign tumors, such as vestibular schwannomas and meningiomas. Caffeic acid phenethyl ester (CAPE)-based extracts and artepillin C-based propolis from bee wax have been shown to suppress the growth of an NF1-deficient malignant peripheral nerve sheath tumor cell line and a human papillomavirus E6/7 oncogene-immortalized vestibular schwannoma cell line, HEI-19318–19; however, the mechanisms by which CAPE and artepillin C suppress tumor growth are not understood. Curcumin found in turmeric, a spice derived from the rhizomes of Curcuma longa of the ginger family, was found to inhibit the growth of HEI-193 cells by down-regulating the phosphorylation of AKT and ERK1/220. Honokiol, a lignan found in Magnolia grandiflora was also shown to exhibit antiproliferative activity in HEI-193 and inhibit ERK phosphorylation21. However, none of these compounds has been tested in other NF2-relevant models and their toxicity profiles are largely unknown.

Triterpenoid natural products from medicinal plants, such as the cucurbitacins, have been shown to exhibit anti-bacterial and anti-inflammatory effects. Extracts from plants in the family Cucurbitaceae have long been used in oriental medicines for their hepatoprotective effects as well as anti-inflammatory and anti-diabetic effects21. Importantly, cucurbitacins induce cancer cell death6. Cucurbitacin B has been shown to induce cell-cycle arrest, apoptosis and autophagy22. Cucurbitacin IIa can cause non-reversible actin aggregation6. Cucurbitacin I can inhibit the growth of NF1-deficient malignant peripheral nerve sheath tumor cells by inducing apoptosis23. Also, cucurbitacin D isolated from Trichosanthes kirilowii, of which the root tuber has been used to reset menstruation and expel retained placenta in China, can inhibit the growth of some symbiotic bacteria of entomopathogenic nematodes24 and induce apoptosis in human hepatocellular carcinoma cells in vitro25. In addition, cucurbitacin D has been shown to suppress proliferation of HT-29 human colon cancer cells8. Consistently, we showed that cucurbitacin D isolated from Elaeocarpus chinensis effectively inhibits the growth of NF2-deficient schwannoma and meningioma cells.

Like cucurbitacins, sesquiterpene lactones, including goyazensolide, exhibit antitumor activity. Initial bioassay screening results showed the majority of the isolated sesquiterpene lactones to be cytotoxic toward HT-29 colon cancer cells10 and to inhibit NFκB activity9. Similarly, we found that goyazensolide isolated from Piptocoma rufescens efficiently inhibits proliferation of NF2-deficient schwannoma and meningioma cells and reduces the expression of the p65 subunit of NFκB.

Consistent with previous reports6,7,25,26, we found that both cucurbitacin and goyazensolide induced cell cycle arrest at G2/M. In the cell cycle, early G1 is characterized by the induced expression of cyclin D from mitogen stimulation, which in turn activates CDK4/6 followed by increased levels of cyclin E and A at late G1. G1-to-S transition is promoted via CDK2, which binds to cyclins E and A. Cyclin B binds and activates CDC2 which is important for progression through G2 and exit from M phase. Thus, it is plausible that the G2/M arrest observed in cucurbitacin D and goyazensolide-treated schwannoma and meningioma cells was in part due to the reduced expression of cyclins E, A, and B, and CDC2.

It has also been reported that cucurbitacin can induce polyploidy, leading to apoptosis7. Consistently, an increase in the population of cells with the DNA content greater than 4N was observed in cucurbitacin D-treated Ben-Men-1 cells. Interestingly, we observed a slight increase in the pro-apoptotic Bim protein in goyazensolide-treated schwannoma and meningioma cells. Experiments are in progress to determine if goyazensolide induces apoptosis in these cells. AKT is important for cell survival and reduction of phospho-AKT levels may lead to decreased cell survival. We observed that goyazensolide inhibited the expression of phospho-AKT and its downstream target phospho-PRAS40 in both schwannoma and meningioma cells. Intriguingly, we also found that cucurbitacin D reduced the phospho-AKT level in Ben-Men-1 meningioma cells. As cucurbitacins have been shown to inhibit the AKT pathway only in a breast cancer cell line7, these results suggest that inhibition of phospho-AKT may be cell-type specific.

In summary, this study demonstrated the potent growth-inhibitory effects of cucurbitacin D and goyazensolide in NF2-deficient schwannoma and meningioma cells. Further in vivo testing of these two natural compounds using relevant animal models is warranted for their development as chemotherapeutic agents for NF2-associated tumors.
correspondencen engl j med 361;18 nejm.org october 29, 20091809than white patients but who have considerable ad-verse effects.2 However, low-dose peginterferon alfa-2b may also lead to a significantly higher rate of treatment discontinuation due to virologic non-response. Whether this result could be extrapolated to low-dose peginterferon alfa-2a therapy remains to be examined. Finally, several factors have been reported to affect early viral kinetic responses and relapse in patients infected with hepatitis C virus (HCV) genotype 1 who are receiving the current standard of care.3 Their roles in the low-dose peginterferon regimen remain unknown.Ching-Sheng Hsu, M.D.Buddhist Tzu Chi General Hospital Taipei, TaiwanJia-Horng Kao, M.D., Ph.D.National Taiwan University College of Medicine Taipei, Taiwan kaojh@ntu.edu.twMcHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginter-1. feron alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93. [Erratum, N Engl J Med 2009;361:1027.]Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a 2. plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47:1260-9.Hsu CS, Liu CH, Liu CJ, et al. Factors affecting early viral 3. load decline of Asian chronic hepatitis C patients receiving pegy-lated interferon plus ribavirin therapy. Antivir Ther 2009;14:45-54.The Authors Reply: Hsu and Kao rightly point out that reported treatment response rates are higher among Asian patients with chronic HCV infection than among other patients. In the Indi-vidualized Dosing Efficacy vs. Flat Dosing to As-sess Optimal Pegylated Interferon Therapy (IDEAL) study, response rates among self-reported Asian patients were also high: 62% (13 of 21 patients) among patients who received peginterferon alfa-2b at a dose of 1.0 μg per kilogram of body weight per week, 70% (7 of 10 patients) among patients who received peginterferon alfa-2b at a dose of 1.5 μg per kilogram per week, and 50% (10 of 20 patients) among patients who received peginter-feron alfa-2a at a dose of 180 μg per week. Re-cently, the response to treatment for HCV infec-tion has been strongly associated with a genetic interleukin-28B variant that resides on chromo-some 19. The “favorable” allele is more prevalent in East Asian populations1; this may, in part, ex-plain the favorable response observed in this pa-tient group. We also agree that a low dose of peginterferon alfa-2b was well tolerated and associated with a similar overall efficacy in our study, but not in all subpopulations. Similar findings have been re-ported with peginterferon alfa-2b monotherapy (at a dose of 135 μg weekly)2 and peginterferon alfa-2a monotherapy (at a dose of 180 μg weekly).3 Janice Albrecht, Ph.D.Schering-Plough Research Institute Kenilworth, NJJohn McHutchison, M.D.Duke University Durham, NC mchut001@mc.duke.eduMark Sulkowski, M.D.Johns Hopkins University Baltimore, MDGe D, Fellay J, Thompson AJ, et al.  Genetic variation in IL28B 1. predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.Pockros PJ, Carithers R, Desmond P, et al.  Efficacy and safety 2. of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, random-ized controlled trial. Am J Gastroenterol 2004;99:1298-305.Lindsay KL, Trepo C, Heintges T, et al.  A randomized, dou-3. ble-blind trial comparing pegylated interferon alfa-2b to inter-feron alfa-2b as initial treatment for chronic hepatitis C. Hepa-tology 2001;34:395-403.Hearing Improvement after Bevacizumab  for Neurofibromatosis Type 2To the Editor: Plotkin et al. (July 23 issue)1 re-port a sustained tumor-volume reduction in 4 of 10 patients and a hearing response in 4 of 10 pa-tients with neurofibromatosis type 2 after beva-cizumab treatment. The authors’ conclusion that tumor shrinkage and hearing improvement are effects of bevacizumab treatment is not convinc-ing, because the study did not involve a control group. Shrinkage of a vestibular schwannoma, especially in cystic tumors in patients with neuro-fibromatosis type 2, can also occur during an ob-servation period without any treatment.2 In addi-tion, some patients who have been assigned to wait-and-scan observation show hearing improve-ment over time without any treatment.3 The non-blinded design of the study might have biased the investigators and patients during the hearing tests. Otherwise, how do Plotkin et al. explain the poor The New England Journal of Medicine Downloaded from nejm.org on June 25, 2017. For personal use only. No other uses without permission.  Copyright © 2009 Massachusetts Medical Society. All rights reserved. The new england journal of medicinen engl j med 361;18 nejm.org october 29, 20091810correlation between tumor-volume shrinkage and hearing improvement? Also, how do they explain the poor correlation between pure-tone thresholds and word-recognition results? Instead of only us-ing subjective acoustic hearing tests, it would have been worthwhile to use objective test methods such as brain-stem auditory evoked response.Orlando Guntinas-Lichius, M.D.Friedrich Schiller University of Jena Jena, Germany orlando.guntinas@med.uni-jena.dePlotkin SR, Stemmer-Rachamimov AO, Barker FG II, et al. 1. Hearing improvement after bevacizumab in patients with neuro-fibromatosis type 2. N Engl J Med 2009;361:358-67.Stangerup SE, Caye-Thomasen P, Tos M, Thomsen J. The 2. natural history of vestibular schwannoma. Otol Neurotol 2006; 27:547-52.Idem.3.  Change in hearing during ‘wait and scan’ management of patients with vestibular schwannoma. J Laryngol Otol 2008; 122:673-81.To the Editor: Plotkin et al. report that vascular endothelial growth factor (VEGF) blockade with bevacizumab improved hearing and decreased the volume of vestibular schwannomas in some pa-tients with neurofibromatosis type 2. Dynamic contrast-enhanced magnetic resonance imaging data indicated that bevacizumab normalized the function of tumor vessels. We wonder whether vascular normalization is the real or unique mechanism of anti-VEGF therapy for vestibular schwannomas. In some clinical trials, vascular normalization might provide benefit by killing tu-mor cells in synergy with chemotherapy; this is accomplished by improving the delivery of cyto-toxic agents to tumors. However, in this study, 10 patients received bevacizumab as monotherapy. Otherwise, VEGF inhibition might have had direct cytotoxic effects on tumor cells that express VEGF receptors and that depend on VEGF for survival.1,2 The authors and other groups have detected VEGF and its receptors in schwannomas, and increased levels of these factors correlate with increased rates of tumor growth.3,4 Therefore, it is not known whether the curative effect is due to the direct kill-ing of tumor cells and increase in apoptosis by bevacizumab or to vascular normalization. Jian-Sheng Diao, M.D. Wen-Sen Xia, M.D. Shu-Zhong Guo, M.D.Fourth Military Medical University Xi’an, ChinaWey JS, Fan F, Gray MJ, et al. Vascular endothelial growth 1. factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 2005;104:427-38.Fan F, Wey JS, McCarty MF, et al. Expression and function of 2. vascular endothelial growth factor receptor-1 on human colorec-tal cancer cells. Oncogene 2005;24:2647-53.Caye-Thomasen P, Baandrup L, Jacobsen GK, Thomsen J, 3. Stangerup SE. Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 2003;113:2129-34.Caye-Thomasen P, Werther K, Nalla A, et al. VEGF and VEGF 4. receptor-1 concentration in vestibular schwannoma homoge-nates correlates to tumor growth rate. Otol Neurotol 2005;26:98-101.The Authors Reply: Guntinas-Lichius raises an important issue about trial design in studies of vestibular schwannomas. Recently, a group of ex-perts endorsed the objective radiographic response rate as the appropriate choice for initial single-group drug trials because the rates of spontaneous tumor shrinkage in untreated vestibular schwan-nomas are low.1 In the study cited by Guntinas-Lichius,2 extremely few tumors decreased in size during the observation period (0.9%), whereas the majority of tumors were either stable (70.2%) or increased in size (28.9%). In our study, 60% of tumors had a radiographic response; this rate far exceeded the rate of spontaneous tumor shrink-age. Moreover, the median annual growth rate of the tumors before bevacizumab therapy was 63%, whereas many of the tumors in the previous study were not growing at baseline. In a companion study3 to the study cited by Guntinas-Lichius, the rate of spontaneous hearing improvement with-out treatment was 2.7%, which is far lower than the reported rate of hearing improvement in our study (57%). Together, these findings provide strong evidence that changes in tumor size and hearing after treatment were related to the effects of bevacizumab.We do not fully understand why word recogni-tion improved more than detection of pure tones. However, we disagree with the assertions that the hearing measurements were subjective and that bias may explain the findings. Standardized methods exist for the determination of pure-tone averages and measurement of word recognition. In hearing loss due to vestibular schwannomas, word recognition typically is affected more than the detection of pure tones.1 Thus, greater im-provement might be expected in word recognition than in the ability to hear pure tones after effec-tive treatment of vestibular schwannomas. Al-though brain-stem auditory evoked response mea-surements would have been worthwhile, we did not include them because we did not have suffi-cient data for comparisons among patients.The New England Journal of Medicine Downloaded from nejm.org on June 25, 2017. For personal use only. No other uses without permission.  Copyright © 2009 Massachusetts Medical Society. All rights reserved. correspondencen engl j med 361;18 nejm.org october 29, 20091811We agree with Diao et al. that inhibiting VEGF in vestibular schwannomas probably affects both the vasculature and tumor cells. Our data do not permit us to estimate the relative contributions of vascular permeability and direct killing of tumor cells to clinical response. However, these two pro-cesses might explain why the effect of bevacizu-mab on tumor size and hearing was not tightly correlated. Scott R. Plotkin, M.D., Ph.D.Massachusetts General Hospital Boston, MA splotkin@partners.orgChris Halpin, Ph.D.Massachusetts Eye and Ear Infirmary Boston, MAEmmanuelle di Tomaso, Ph.D.Novartis Institutes for BioMedical Research Cambridge, MASince publication of the article, Dr. di Tomaso reports being employed by the Novartis Institutes for BioMedical Research. No other potential conflict of interest relevant to this letter was re-ported.Plotkin SR, Halpin C, Blakeley JO, et al. Suggested response 1. criteria for phase II antitumor drug studies for neurofibromato-sis type 2 related vestibular schwannoma. J Neurooncol 2009; 93:61-77.Stangerup SE, Caye-Thomasen P, Tos M, Thomsen J. The 2. natural history of vestibular schwannoma. Otol Neurotol 2006; 27:547-52.Idem.3.  Change in hearing during ‘wait and scan’ management of patients with vestibular schwannoma. J Laryngol Otol 2008; 122:673-81.Death in a Gene-Therapy TrialTo the Editor: Frank et al. (July 9 issue)1 do not discuss the issue of therapeutic misconception2 — namely, the belief by a research subject that the investigational agent is actually therapeutic. Admittedly, there was no concrete evidence for this issue here, but on the basis of the nature and timing of events, the issue was relevant and be-came an important part of the report and recom-mendations of the Recombinant DNA Advisory Committee of the National Institutes of Health.Therapeutic misconception for the subject can be addressed during the consenting procedure.3,4 However, therapeutic misconception is also an issue for investigators for whom conflicting com-mitments can blur the line between research and treatment. Therefore, the protocol itself becomes the main protection for safety in this regard. In addition to recommending screening tests and laboratory requirements before the initiation of therapy, the advisory committee recommended that subjects carry a medical card containing key information about the investigational agent, as well as phone numbers for ready contact with the study’s principal investigator. The protocol should clearly state how to proceed in the event of any unforeseen illness.John A. Zaia, M.D.City of Hope Duarte, CA jzaia@bricoh.eduHoward J. Federoff, M.D., Ph.D.Georgetown University Medical Center Washington, DCDr. Zaia reports being a member, and Dr. Federoff reports being chair, of the Recombinant DNA Advisory Committee, which reviewed this adverse event. No other potential conflict of interest relevant to this letter was reported.Frank KM, Hogarth DK, Miller JL, et al. Investigation of the 1. cause of death in a gene-therapy trial. N Engl J Med 2009;361: 161-9.King NM, Henderson GE, Churchill LR, et al. Consent forms 2. and the therapeutic misconception: the example of gene transfer research. IRB 2005;27:1-8.Kahn J. Informed consent in human gene transfer clinical 3. trials. Hum Gene Ther 2008;19:7-8.National Institutes of Health, Office of Biotechnology Ac-4. tivities. NIH guidance on informed consent for gene transfer research. Bethesda, MD: National Institutes of Health. (Accessed October 8, 2009, at http://oba.od.nih.gov/oba/rac/ic/pdfs/temp_pdf.pdf.)To the Editor: Frank et al. examined the role of a tumor necrosis factor α (TNF-α) antagonist, delivered through an adeno-associated virus, as a precipitating cause of death in a gene-therapy tri-al. When a patient is receiving a TNF-α blocker, education about the risk of opportunistic infec-tion, especially histoplasmosis and tuberculosis, is a requisite. A survey of infectious-disease con-sultants in the United States revealed that histo-plasmosis occurred more often than tuberculosis in patients receiving TNF-α blockers.1 Perhaps because of the regional occurrence of histoplas-mosis in the United States, many physicians may fail to entertain the diagnosis of this infection. Since the presenting clinical features are nonspe-cific and exposure often goes unrecognized, phy-sicians should include histoplasmosis in such evaluations. The role of reactivation of latent in-The New England Journal of Medicine Downloaded from nejm.org on June 25, 2017. For personal use only. No other uses without permission.  Copyright © 2009 Massachusetts Medical Society. All rights reserved. ShivaniAhlawat,MDLauraM.Fayad,MDMuhammadShayanKhan,MDMiriamA.Bredella,MDGordonJ.Harris,PhDD.GarethEvans,MDSaidFarschtschi,MDMichaelA.Jacobs,PhDAvneeshChhabra,MDJohannesM.Salamon,MDRalphWenzel,MDVictorF.Mautner,MDEvaDombi,MDWenliCai,PhDScottR.Plotkin,MD,PhDJaishriO.Blakeley,MDOnbehalfoftheWholeBodyMRICommitteefortheREiNSInternationalCollaborationCorrespondencetoDr.Ahlawat:sahlawa1@jhmi.eduSupplementaldataatNeurology.orgCurrentwhole-bodyMRIapplicationsintheneurofibromatosesNF1,NF2,andschwannomatosisABSTRACTObjectives:TheResponseEvaluationinNeurofibromatosisandSchwannomatosis(REiNS)Inter-nationalCollaborationWhole-BodyMRI(WB-MRI)WorkingGroupreviewedtheexistingliteratureonWB-MRI,anemergingtechnologyforassessingdiseaseinpatientswithneurofibromatosistype1(NF1),neurofibromatosistype2(NF2),andschwannomatosis(SWN),torecommendopti-malimageacquisitionandanalysismethodstoenableWB-MRIasanendpointinNFclinicaltrials.Methods:AsystematicprocesswasusedtoreviewallpublisheddataaboutWB-MRIinNFsyn-dromestoassessdiagnosticaccuracy,feasibilityandreproducibility,anddataaboutspecifictechniquesforassessmentoftumorburden,characterizationofneoplasms,andresponsetotherapy.Results:WB-MRIat1.5Tor3.0Tisfeasibleforimageacquisition.Shorttauinversionrecovery(STIR)sequenceisusedinallinvestigationstodate,suggestingconsensusabouttheutilityofthissequencefordetectionofWBtumorburdeninpeoplewithNF.Thereareinsufficientdatatosupportaconsensusstatementabouttheoptimalimagingplanes(axialvscoronal)or2Dvs3Dapproaches.Functionalimaging,althoughusedinsomeNFstudies,hasnotbeensystematicallyappliedoreval-uated.TherearenocomparativestudiesbetweenregionalvsWB-MRIorevaluationsofWB-MRIreproducibility.Conclusions:WB-MRIisfeasibleforidentifyingtumorsusingboth1.5Tand3.0Tsystems.TheSTIRsequenceisacoresequence.Additionalinvestigationisneededtodefinetheoptimalapproachforvolumetricanalysis,thereproducibilityofWB-MRIinNF,andthediagnosticperfor-manceofWB-MRIvsregionalMRI.Neurology®2016;87(Suppl1):S31–S39GLOSSARYADC5apparentdiffusioncoefficient;DWI5diffusion-weightedimaging;FDG5fluorodeoxyglucose;MPR5multiplanarreformation;NF15neurofibromatosistype1;NF25neurofibromatosistype2;PNST5peripheralnervesheathtumors;REiNS5ResponseEvaluationinNeurofibromatosisandSchwannomatosis;SNR5signaltonoiseratio;STIR5shorttauinversionrecovery;SWN5schwannomatosis;WB-MRI5whole-bodyMRI.Whole-bodyMRI(WB-MRI)allowsimagingofalargevolumeofthebodyinasingleimageacquisitionsession.Ithasbeenextensivelyinvestigatedforthedetectionandstagingofvisceralandosseoustumors1–6andiswell-suitedtotumorsyndromesincludingneurofibromatosistype1(NF1),neurofibromatosistype2(NF2),andschwannomatosis(SWN),7–9asthesepatientsoftenhaveahighburdenoftumorsaswellaslargetumorsthatcrossanatomicplanes(figure).WB-MRIhasbeenusedtoevaluatetumorburdenandtocharacterizeneoplasmsinpatientswithNFsyndromes10–23andisbeingusedinsomeclinicaltrialstoevaluateresponsetotherapy(NCT01207687).AuniformimageacquisitionprotocolandinterpretationmethodwouldenableWB-MRItobeusedasakeyendpointtoassesstumortreatmentresponseinmulticenterFromTheRussellH.MorganDepartmentofRadiologyandRadiologicalScience(S.A.,L.M.F.,M.A.J.),SidneyKimmelComprehensiveCancerCenter(M.A.J.),andDepartmentofNeurology(J.O.B.),JohnsHopkinsUniversity,Baltimore,MD;KhyberMedicalCollege(M.S.K.),Peshawar,Pakistan;DepartmentofRadiology(M.A.B.,G.J.H.,W.C.),MassachusettsGeneralHospitalandHarvardMedicalSchool,Boston;GenomicMedicine(D.G.E.),ManchesterAcademicHealthScienceCentre,TheUniversityofManchester,UK;DepartmentofNeurology(S.F.,V.F.M.),UniversityMedicalCenterHamburg-Eppendorf,Hamburg,Germany;Radiology&OrthopedicSurgery(A.C.),UTSouthwesternMedicalCenter,Dallas,TX;DepartmentofDiagnosticandInterventionalRadiology(J.M.S.),UniversityHospitalHamburg-Eppendorf;RadiologicalPracticeAltona(R.W.),Hamburg,Germany;PediatricOncologyBranch(E.D.),NationalCancerInstitute,Bethesda,MD;andDepartmentofNeurologyandCancerCenter(S.R.P.),MassachusettsGeneralHospital,Boston.REiNSInternationalCollaborationmembersarelistedontheNeurology®WebsiteatNeurology.org.GotoNeurology.orgforfulldisclosures.Fundinginformationanddisclosuresdeemedrelevantbytheauthors,ifany,areprovidedattheendofthearticle.©2016AmericanAcademyofNeurologyS31ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.clinicaltrialsforNF-associatedperipheralnervesheathtumors(PNST).However,thusfar,vari-ableapproacheshavebeenusedforWB-MRIacquisitionandimageanalysisinNF.TheWB-MRIWorkingGroupwasformedaspartoftheResponseEvaluationinNeurofi-bromatosisandSchwannomatosis(REiNS)InternationalCollaborationtogeneratecon-sensusrecommendationsandidentifypriorityareasforfutureresearchregardingWB-MRIasappliedtoNFclinicaltrials.TheworkinggroupreviewedtheexistingliteratureontheuseofWB-MRIinpatientswithNF1,NF2,andSWNtoevaluatedifferencesinimageacquisition(includingmagnetstrengths,imag-ingplanes,and2Dvs3Dapproaches);assessthefeasibility,reproducibility,anddiagnosticaccuracyofWB-MRIinpeoplewithNF;andevaluatethebenefitsoffunctionalMRItechniques,suchasdiffusion-weightedimaging(DWI)withquantitativeapparentdiffusioncoefficient(ADC)mapsandcontrast-enhancedimagingforNF-associatedPNST.WeusedthisinformationtorecommendbestpracticesforWB-MRIforuseinNFclinicaltrialsandtoestablishresearchprioritiesforfuturestudies.METHODSAcomputer-aidedsearchofPubMed/MEDLINEfrominceptiontoMay2015wasconductedtofindrelevantEnglishlanguagepublicationsonWB-MRIandNFsyndromes.Toexpandoursearch,bibliographiesofretrievedarticleswerescreenedforadditionalcitations.Asinglereviewer(S.A.)independentlyscreenedtitles,abstracts,fullarticles,andreferencestodetermineeligibilityforinclusion.StudieswereincludediftheyhadaprospectiveorretrospectivestudydesignwithpatientsofanyagewithNF1,NF2,andSWNusingWB-MRIinwhichatleasttheareafromthenecktothepelviswasimaged.Reviewarticles,meta-analyses,abstracts,casereports,orcaseseriesoflessthan10patients,guidelines,orstudiesperformedinanimalswereexcluded.Inclusionofpatientsbasedonwell-establishedclinicalcriteriafortheNFsyndromeswasadequateforselectionofthepatientpop-ulation,giventhatpathologicconfirmationofeachneoplasmisnotfeasible.7–9Allincludedarticleswereanalyzedfordiagnosis(NF1,NF2,andSWN),indextest(WB-MRI),andreferencetest(clinicalcriteriafordiagnosisoftheNFsyndromes).Thefollowinginfor-mationwasextractedfromarticles:authorname,yearofpublica-tion,numberofparticipants,specifictumorsyndrome,magnetstrength(1.5Tvs3.0T),specificWB-MRItechniques(2Dvs3Dimaging,specificimagingsequences,inclusionoffunctionalMRIsequences,contrastadministration),sex,meanagewithSD,quan-tificationofPNSTsize(2Dvsvolumetric),andtypesoftumors(malignantvsbenignPNST).WB-MRIstudieswerealsoclassifiedbyclinicalindicationinto3categories:tumordetection(includingextentofdisease),tumorcharacterization,orresponsetotherapy.RESULTSTheliteraturesearchyielded25articles.Afterfullreviewofthearticles,14studiesmetallinclu-sioncriteria.10–23Twostudieswereexcludedastheydiscussedextratumoralfindings(i.e.,incidentalfind-ingsonWB-MRIinNFormarrowchangesinpatientswithNFtreatedwithimatinibmesylate22,23).Hence,thefinalanalysisincluded12studies.10–21WB-MRIacquisitionprotocols.Table1summarizestheinformationextractedfromtheinvestigationsthatmetinclusioncriteria.Ofthe12publications,11employed1.5Tmagnetstrength10–12,14–21;only1studyused3.0Tmagnet.13Onestudyperformedat3.0Tacquiredvolumetric3Dimageswithisotropicresolutioninthecoronalplaneandgeneratedmulti-planarreformations(MPR)insagittalandaxialplanewithgooddiagnosticquality.13TheremainderoftheWB-MRIinvestigationsutilized2Dacquisitionsinthecoronalplanealone,orinbothcoronalandaxialplanes.AllinvestigationsincludedashorttauinversionFigureWhole-bodyMRIinneurofibromatosis(A)Apersonwithschwannomatosis.(B)Apersonwithneurofibromatosistype1.Inbothim-ages,therangeoffieldofviewisapparentdependingonthetablelengthandthesizeofthepersonbeingimagedandinbothimagesseveraltumorsdistributedacrossanatomicregionscanbeidentified.In(B),someoftheartifactthatcanoccuraffectinginterpretationisapparent.S32Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.recovery(STIR)sequence.Only1trialperformedfunctionalMRIwithquantitativeDWIandADCmaps.13DWItechniqueincluded3bvaluesandwasperformedwithslicethicknessof5mm.13Threeofthe12studiesusedcontrastmaterialasanadjuncttotraditionalWB-MRIfluid-sensitivesequences.11,13,14Onestudyobtainedpostcontrast3Dvolumetricgradientechoimages13whiletheotherstudyobtained2DspinechoT1-weightedimageswithfatsuppression.14In1study,investigatorsfoundcontrasttobeusefulindistinguishingPNSTfromperineuralcysts.13WB-MRIapplications.Withrespecttoimageinterpreta-tionandanalysis,thefollowingaspectswerespecificallyassessed:tumordetection(evaluationofWBtumorburden,includingtumorsize),tumorcharacterization,andtheassessmentoftreatmentresponse(table2).TherearevariedmethodsofWBtumorburdeneval-uation,withrecentstudiesfavoring3Dtumorvolu-metry,ratherthan1Dor2Dlinearmeasurements(suchasResponseEvaluationCriteriainSolidTumors[RECIST]).Fiveofthe12publishedinvestigationsinthisstudyutilizedMedXsoftware(v3.42;SensorSys-tems,Inc.,Sterling,VA),asemi-automatedmethodforsegmentationandmeasurementwithaheuristics-basedalgorithmforvolumetricanalysis,14,15,17,18,21while5ofthe12publicationsusedacomputerized3D-volumetrymethoddevelopedforWB-MRIusingthedynamicthresholdlevelsetmethod.10–12,16,19TherearelimiteddatawithregardstocharacterizationofneoplasmsasbenignormalignantandnodatatodateTable1ImagingparametersforWB-MRIfromNF-relatedinvestigationsfocusedondetectionorcharacterizationofPNSTPublication(seereferences)Technicalconsiderations:magnetstrength(1.5Tvs3T);sequences(2Dvs3D);planeofacquisition(axial,coronal,sagittal)SpecificsequencesContrastmaterial(1/2)FunctionalDWIandADCmapping(1/2)101.5T;2D;coronalSTIR22111.5T;2DaSTIR:slicethickness5–10mm;matrix256–5123256;T1;slicethickness5–10mm;matrix256–51232561;Gadolinium-DTPA(Magnevist,BayerScheringPharmaAG,Germany)2121.5T;2D;coronalSTIR:TR/TE/IR4,190/111/150;echotrainlength25;FOV50cm;matrix3203240;slicethickness10mm;nointerslicegap22133.0T;3D;coronalPreandpostcontrastVIBE:TR/TE0.88/2/43ms;FOV50cm2;matrix2563256;slicethickness2mm;STIR:TR/TE6,640/84ms;FOV50cm2;matrix2563256;slicethickness2mmwithinterpolation1;0.1mmol/kggadodiamidecontrastagent(Magnevist,BayerScheringPharmaAG,Germany)1;TR/TE4,100/70ms;bvalues50,400,800s/mm2;FOV50cm2;slicethickness5mm141.5T;2D;coronalandaxialSTIR:axial;TR/TE3,690ms/106ms;FOV25.7350.0cm;coronal;TR/TE3,110ms/101ms;FOV48cm2;T1WFSpreandpostcontrast:axial;TR/TE91ms/4.76ms;FOV47.9cm20.1mmol/kgor0.2mmol/kgbodyweightgadolinium-DTPA2151.5T;2DaSTIR:slicethickness10mm;nointerslicegap22161.5T;2D;coronalSTIR:TR/TE/IR4,190/111/150;slicethickness10mm;nointerslicegap;FOV50cm2;echotrainlength25;matrix320324022171.5T;2D;axialSTIR:slicethickness10mm22181.5T;2D;axialSTIR:slicethickness10mm22191.5T;2D;coronalSTIR:TR/TE/IR4,190/111/150;slicethickness10mm;nointerslicegap;FOV50cm2;echotrainlength25;matrix320324022201.5T;2D;coronalandaxialAxial:T1(slicethickness6–12mm);T2FS(slicethickness6–12mm);coronal:T1(slicethickness5–10mm);T2FS(slicethickness5–10mm)22211.5T;2D;coronalandaxialT1SE:slicethickness5–10mm;nointerslicegap;STIR;slicethickness5–10mm;nointerslicegap22Abbreviations:ADC5apparentdiffusioncoefficient;DWI5diffusion-weightedimaging;FOV5fieldofview;IR5inversionrecovery;NF5neurofibro-matosis;PNST5peripheralnervesheathtumors;STIR5shorttauinversionrecovery;TE5echotime;TR5repetitiontime;VIBE5T1-weightedsequences(volumeinterpolatedbreath-holdexamination);WB-MRI5whole-bodyMRI.aAplaneofimagingisnotspecified.Neurology87(Suppl1)August16,2016S33ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.Table2SummaryofWB-MRIinvestigationswithrespecttoimageinterpretationfocusedontumordetection(assessmentofwholebodytumorburden),characterization,andtreatmentresponseReferencePatientpopulation,n,sexcomposition(%male),age,yTumordetection(diseaseburden)Conclusion10245totalPNSTweresegmentedusingcomputerized3D-volumetrymethodsdevelopedforreference19InternaltumorburdenisnotaprimarycontributortoQOLbutitdoescorrelatewithSF-36bodilypainscore1193(31NF1withMPNSTand62NF1withoutMPNST),58%,medianage34(range7–67)PNSTweresegmentedusingcomputerized3D-volumetrymethodsdevelopedforreference19HighernumberofinternalPNsandagreaterwhole-bodyPNvolumeareimportantriskfactorsforthedevelopmentofMPNST1219(NF1),52%,meanage38(range19–58)Tumorvolumerange(0.4–1,182.4mL);PNSTweresegmentedusingcomputerized3D-volumetrymethodsdevelopedforreference19NF1patientswithdeeptumorsandtumorswithinthetrunkaremorelikelytohavemetabolicallyavid(SUVmaxgreaterthan2.5)PNST;increasedPNSTsize,location,andplexiformappearancewereassociatedwithincreasedoddsofhavingametabolicallyactivePNST1311(NF2andSWN)23lesions(median3.5cm,range1.0–10.2cm);2/23,cyst;21/23,PNSTWB-MRIwithvolumetricsequencesisfeasiblefordetectionofPNSTinNF;additionofDWIandcontrastenablespotentialforcharacterizationofcystsvstumors;cystslackenhancementandhavehigherADCvalues1431,42%,meanage30.4614.7(range2–63)PNSTweresegmentedusingcomputerized3D-volumetrymethodsdevelopedforreference19AlthoughPET/CThasahighersensitivityonaperlesionbasisforcharacterizationofPNSTasbenignormalignant,additionofWB-MRImaydecreasetheFPrate15201(71withinternalPNST),44%,medianage28.6(range1.7–63.4)VolumetrywasperformedusingMedXsoftware(v3.42;SensorSystems,Sterling,VA),aheuristics-basedsemi-automatedmethodforsegmentationandmeasurement36Whole-bodyPNSTvolumeatthetimeoftheinitialWB-MRIcorrelatedwiththeabsoluterateofPNSTgrowth;newPNSTareinfrequentinpatientswithNF1withPNSTandunlikelyinpatientswithoutPNST16247Totalof1,286PNST(528plexiformand758circumscribedtumors);PNSTvolume,65,423mLin145/247patients;PNSTweresegmentedusingcomputerized3D-volumetrymethodsdevelopedforreference19PatientswithSWNhadthehighestprevalenceofPNST,butpatientswithNF1hadthehighestmediantumorvolume1738withlargeNF1deletionand114age-andsex-matchedNF1patientswithoutlargedeletionInternalPNSTin22/38(58%)deletionand67/114(59%)nondeletionpatients;volumetrywasperformedusingMedXsoftware(v3.42;SensorSystems),aheuristics-basedsemi-automatedmethodforsegmentationandmeasurement36PatientswithNF1withlargedeletionshavehigherinternalPNSTburden1865(37withPNST),46%,mean10.5(range1.7–17.6)73PNST;meanvolume145.5mL(excludedPNST,3cm);volumetrywasperformedusingMedXsoftware(v3.42;SensorSystems),aheuristics-basedsemi-automatedmethodforsegmentationandmeasurement36PNSTcancauseclinicaldeficitinpediatricpatientswithNF11952(NF1:28,NF2:14,SWN:10),48%,meanage42615(SD)(range24–86)398Nervesheathtumors(185plexiformand213discretetumors)wereidentifiedin29patients;manualandsemi-automated3Dsegmentedvolumetryfor25plexiformand25solitaryPNSTwithhighreliabilityaDTlevelsetsemi-automatedsegmentationisreliablerelativetomanualsegmentation2024NF1,29%,meanandmedianage36(range15–59)4/24,Plexiform;20/24,solitary;nomajorproblemstodifferentiatePNSTfromlymphnodes,vessels,orcystsWB-MRIisfeasibleinNF1fordetectionofPNSTandassessmentoftumorburden2139(13NF1withMPNSTand2age-/sex-matchedNF1withoutMPNST),46%VolumetryusingMEDxsoftwareplatform37WB-MRIenablesdetectionofinternalPNSTburdenAbbreviations:ADC5apparentdiffusioncoefficient;DWI5diffusion-weightedimaging;FP5falsepositive;MPNST5malignantperipheralnervesheathtumor;NF15neurofibromatosistype1;NF25neurofibromatosistype2;PN5peripheralnerve;PNST5peripheralnervesheathtumors;QOL5qualityoflife;SF-365ShortForm–36;SWN5schwannomatosis;WB-MRI5whole-bodyMRI.aSegmentedusingcomputerized3D-volumetrymethodsdevelopedforWB-MRIusing(thedynamicthreshold[DT]levelsetmethod).S34Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.forassessmentoftreatmentresponse,althoughsuchanalysisisongoinginaclinicaltrialassessingWB-MRIovertimeinpeoplewithNF2treatedwithbevacizumab(NCT01207687).Thedatafromtables1and2werecriticallyevalu-atedtogenerateknowledgegapsandfuturedirectionsforWB-MRIinvestigationstoprovidetherequiredmetricsforinclusionofWB-MRIasaprimaryend-pointinclinicaltrialsforNF-associatedPNST.PriorityareasidentifiedincludeWB-MRIreproducibilityforanatomicalmeasures,optimalanalysistechniques,andestablishingtheminimalmeaningfulclinicaldifferenceintumorsize(table3).DISCUSSIONWB-MRIprovidescontinuouscover-ageoflesionsthatcrossanatomicalboundariesandthereforecannotbefullyimagedwithlocalizedMRI,asignificantadvantagewhenevaluatingpatientswithNFsyndromeswheretherearefrequentlylargeinfiltra-tivetumors(figure)ormultifocalPNST,whichmaybemissedwithoutWB-MRIassessment.21Inthissetting,WB-MRIallowsassessmentofdifferentialresponsewithinandacrosstumorsovertime.AnadditionaladvantageisthatWB-MRIcanbecompletedwithatypicalscantimeof45–60minutesonboth1.5Tand3.0Tsystemsandusesthesameprotocolsforpatientsofallages,allowingcontinuityacrossandwithinpatientsenrolledinatherapeutictrial.12,13,18Amajorgoalofthisworkwastoidentifycoreas-pectsofWB-MRIapplicationforassessmentofNF-associatedPNSTtoenableinclusionofWB-MRIasaprimaryendpointfortherapeutictrialsofNF-associatedPNST.Therearenocomparativedataavailablewithrespecttomagnetstrength,imageacquisitionplane(axialvscoronal),2Dor3Dacqui-sition,orthevalueoffunctionalimagingandadmin-istrationofcontrastmaterialavailableacrossallavailableinvestigations.However,aftertheanalysesoftheWB-MRIstudiesinpatientswithNFcon-ductedtodate,severalstatementscanbemade:WB-MRIinNFisfeasiblebothat1.5Tor3.0T;itcanbestandardizedacrossmultiplesitesforanatomictumorassessmentinthesettingofaclinicaltrial;both2Dand3Dacquisitionareoperationalforgeneratingtumordata;STIRisacoresequenceforevaluationoftumorburden;andfunctionalsequencessuchasDWIcanbeconsideredinthesettingofWB-MRI.Outsideofthesestatements,theWB-MRIWorkingGroupofREiNSisnotabletomakespecificrecom-mendationsforacquisitionprotocolsatthistimeduetoalackofdata.Forexample,onlyasinglecaseseriesof4patientscomparedanalysisoftumorburdeninpatientswithNF1whounderwentWB-MRIonboth1.5Tand3.0Twithina6-monthperiod.24Thisstudyshowednodifferenceintumorvolumesbetweenthe2magnetstrengths;however,therearenoothercom-parativeanalysesandthisstudyistoosmalltodrawconclusions.Themajorityofstudiescompletedtodateuse1.5Tasthisismorewidelyavailable.Thewideavailabilityof1.5TmagnetsisanadvantageforapplicationofWB-MRItomulticentertrials.How-ever,3.0TWB-MRIhastheoreticaladvantages,suchasincreasedsignaltonoiseratios(SNR),allowingforimproved3DsequencesaswellasallowingforDWIacquisitioninanacceptableimagingtime.Potentialdisadvantagesof3.0TMRIincludeB1fieldinhomo-geneitiesandsusceptibilityartifacts.2,13Workisongo-ingtooptimizethiswithtechnologicaladvancessuchascontinuoustablemotionandimprovedcoils,whichareexpectedtoshortenacquisitionandincreaseSNR.2,25Withrespecttospecificsequences,theSTIRsequence,withitscombinedT1andT2weighting,hasbeenuniformlyusedintheWB-MRIinvestigationsforPNST.Mostpathologicprocesses,includingtu-mors,areproton-richwithresultantprolongedT1andT2relaxationtimesandincreasedsignalintensityonSTIRimages.Inaddition,fatsuppressionismorerobustandhomogeneousoninversionrecoverysequen-cesthanotherfrequencyselectivesequences.Thesefea-turesmaketheSTIRsequencevaluablefordetectionandmeasurementofPNSTandacoresequenceforassessmentofwholebodytumorburdeninNF.How-ever,detectionofotherpathologiesinthevisceraortheskeletalsystemmayrequireadditionalimaging.Regarding2Dand3Dacquisitions,11ofthe12studiesused2Dimagingsequences,10–12,14–21whileon-ly1study(at3.0T)obtainedimageswith3Dvolu-metricsequences.13Thisallowsustosaythatbotharefeasible,buttherearenodatatosuggestadvantagesofoneovertheother.Thereareimportantdifferencesinspatialresolutionbetween2Dand3Dsequences.For2Dsequencesobtainedat1.5T,thein-planeresolutioncanbe0.3–1.5mmandtheslicethicknesscanrangefrom5to10mmwithnointerslicegap.WB-MRIatTable3Futuredirectionsforwhole-bodyMRI(WB-MRI)investigationsinpatientswithneurofibromatosis(NF)Sensitivity,specificity,andreproducibilityofWB-MRIinNF1.Comparativestudyof3.0Tvs1.5Tfortumordetection2.Comparativestudyfor2Dvs3Dacquisitionfortumordetection3.Comparativestudyofaxialvscoronalimagingacquisitionfortumordetection4.ComparativestudyofregionalvsWB-MRIfortumordetection5.TestretestvariabilityandinterobserverperformanceofWB-MRIinNF6.DeterminationoftheminimallymeaningfulclinicalchangeoftumorsizewithWB-MRIBiologiccharacterizationoftumor1.InvestigatefunctionalMRI(diffusion-weightedimaging/apparentdiffusioncoefficientmapping)vsotherimagingmodalitiessuchasfluorodeoxyglucosePETfortumorcharacterizationandassessmentoftreatmentresponse2.Investigatetheaddedvalueofcontrast-enhancedimagingtoWB-MRIprotocolforcharacterizationandassessmentoftreatmentresponseNeurology87(Suppl1)August16,2016S35ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.thisresolutionmaynotbeadequateforthedetectionorcharacterizationofverysmallneoplasmsandPNSTlocatedintheskinandsubcutaneoustissues.3Dsequencesobtainedat3.0Tcanhaveaninterpolatedspatialresolutionof2mmwithslicethicknessof2mmandnointerslicegap.13Both2Dand3Dsequencescanalsobeperformedwithhigherspatialresolution,butatthecostoflongeracquisitiontime.Apotentialadvan-tageof3DsequencesincludesMPRcapabilitiessuchthata3Disotropicdatasetcanbedisplayedinanyimagingplane.However,3Dacquisitionmaynotbeavailableonallscanners,limitingapplicationinmul-ticenterstudies.Forboth2Dand3Dsequences,thereisalackofconsensusregardinganoptimalimagingplane.AlthoughallWB-MRIinvestigationstodatehaveincludedthecoronalplane,nocomparativestudyhasbeenperformedtodeterminetheidealimagingplane.AnadvantageofcoronalimageacquisitionisthatforanatomicsequencessuchasSTIRorT1-weigtedimaging,thereislessrespiratorymotionduetofasterimageacquisition.Ofnote,thecoronalimageacquisitionmaynotbeoptimalforDWI,par-ticularlyintheneckandthoracicregions,duetocar-diacmotion.ThereisalsoalackofdataregardingtheaddedvalueofIVcontrastmaterial.Useofexogenouscon-trastrequiresvenousaccessandhemodynamicmon-itoringduringtheWB-MRIacquisitionthatmayreducefeasibilityandcarriestheadditionalriskofnephrogenicsystemicfibrosisinthesettingofrenalfailure.Newliteraturealsosuggestsarelationshipbetweenrepetitivegadoliniumexposureandhighsig-nalintensityinthebasalganglia,furtherraisingcon-cernaboutexogenouscontrast.26Therearecurrentlyinsufficientdatatoassessthepotentialdiagnosticben-efitvsriskoftheuseofIVcontrastforPNST.Finally,noinvestigationshavebeenperformedtoassesstheaddedvalueofDWIwithADCmapstostandardsequencesinWB-MRIinpatientswithNF.Thisisfeasibleandthepotentialadvantagesincludetheassessmentoftumorbiologyandpossiblytreatmentresponse,theabilitytodistinguishacystfromaneo-plasm,andthecharacterizationofincidentalfindings.Forexample,specificthresholdADCvaluesenabledistinguishingsofttissuemassesfromcystswithhighspecificity(100%),importantwhenquantifyingtumorburden.13,27Similarly,thereislocalizedMRIexperienceusingDWIandADCmappingforPNSTcharacterizationasbenignormalignantwith100%sensitivity(95%confidenceinterval66.4%–100%)and77%specificity.28Thereisalsolimitedexperi-encecomparingWB-MRIwithwholebody18F-flu-orodeoxyglucose(FDG)PET/CTforcharacterizingPNSTasbenignormalignant.14Although18F-FDGPET/CThadhighersensitivity(100%)comparedwithWB-MRI(66.7%)onaperlesionbasis,WB-MRIhadahigherspecificity(97%forWB-MRIvs74.4%for18F-FDGPET/CT)fordetectingmalig-nancy.14WB-MRIinthisparticularinvestigationusedroutineanatomicsequencesonly,14andthusitremainstobedeterminedwhetheradditionofquan-titativefunctionalMRIsequenceswithADCmeas-urementswouldalterthediagnosticaccuracyfordetectionofmalignancy.AlthoughWB-MRIwithfunctionalsequencesfordetectionandcharacterizationofbenignvsmalignantPNSTshowspromise,currentlythesesequencescanbedifficulttoperformuniformlyacrossmultiplesites.Noinvestigationshavebeenpublishedtodateregard-ingtheassessmentoftreatmentresponseinPNSTinNF,butthereareeffortscurrentlyforanalysisofongoingtherapeuticstudieswithpretreatmentandposttreatmentWB-MRI(NCT01207687).ThisstudywillalsoallowassessmentoftheaddedvalueoffunctionalMRIorcontrast-enhancedsequencesforassessingchangesintumorbiologyindependentofchangesintumorsize.WithrespecttoWB-MRIanalysis,thefieldhasrec-ommendedvolumetricmeasurementsoftumorratherthan2Dmeasures.29–31TumorvolumetryispreferredforquantifyingcomplexPNSTsuchasplexiformneu-rofibromasthatcanbelargeandinfiltrativewhereas2Dorlinearmeasurementismorelikelytomisrepre-sentthetruetumordimensionsbyoverestimatingorunderestimatingPNSTsizeandcanbefraughtwithinterobserverandintraobservervariations.32–34Tumorvolumetry,particularlyininfiltrativeplexiformneo-plasmssuchastheonesidentifiedinpatientswithNFsyndromes,hasbecometheoptimalapproachforassessingtumorburden.Inaddition,thecurrentther-apeutictrialsinNFsyndromesusevolumetricanalysisasaprimaryorsecondaryendpoint(NCT01362803,NCT02101736,NCT02096471).Volumetrictumorburdencanbemeasuredmanually,thoughthisistime-consumingandimpracticalforroutineclinicalevalua-tion.Computer-aidedtumorsegmentationofPNSTcanbeperformedonMRIsequencesthatshowcleardistinctionbetweentumorandsurroundingnormaltissue,suchasSTIRorsimilarfluidsensitivesequen-ces.Inonestudycomparingmanualandsemi-automatedtumorvolumetry,computerizedvolumetryusingadynamicthresholdmethodwassuperiortomanualsegmentationtechniques.19Moreover,com-puterizedvolumetrywasreliableandlesslaborinten-sive,whichmadeitmorerepeatablecomparedtomanualsegmentation.19Itisimportanttonotethatreliabilityandrepeatabilitywerecalculatedusingasmallsamplesize19;however,thistechniquehassubse-quentlybeenappliedinlargerstudiesofapproximately250patients.10–12Amulticenterstudycomparingthe2principalsemi-automatedmethodsforreliabilityandS36Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.interpretationtimecomparedwiththemanualtech-niqueinlesiondetectionandchangeinlesionsizeiscurrentlyunderway.AlthoughthereareseveraladvantagestoWB-MRIforNF,therearealsoimportantlimitations.First,forverytallorlargeindividuals,portionsofthebodymaynotbeadequatelyimaged,includingthedistallegs,shoulders,andarms.Adequateimagingofthedistallowerextremitiesisaparticularconcernfor3.0TscannersandmaylimittheuseofWB-MRIiftherearetumorsofinterestintheseregions.Thiscanbead-dressedbyimagingtheupperandlowerbodysepa-rately;however,thisincreasescostandtime.AnadditionalconcernfortumorassessmentwithWB-MRIisthatthelowerlimitoftumorvolumethatcanbeassessedhasnotbeendescribed,anddepend-ingontheWB-MRItechniqueaswellasthetumordistribution,thecutoffvaluemaybevariable.Select-ingthesamePNSTforcontouringconsistentlyoverconsecutivescansiscrucialfordeterminingsizechangeandcanonlybedoneoncomparablequalityimagesets.Similarly,diagnosticperformanceofWB-MRIfortotaltumorburdenestimatesisdepen-dentonthecorrectrepresentationofthebodyontheMRIandneedstobestandardizedacrosssitesandtimepoints.Importantly,WB-MRIcansufferfromvariedimagedistortionsattheperipheryoftheimag-ingfield,whichmayleadtomeasurementerrors.13Givenspatialresolutionlimitationsanddependingonwhatsequencesareapplied,additionaldedicatedMRIsequencessuchasmagneticresonanceneurog-raphymaybenecessarytoprovideimprovedana-tomicandfunctionalcharacterizationofPNST,35evaluatetumorsinandaroundthespinalcord,iden-tifysmalltumorssuchaspheochromocytomas,ordiagnosevascularanomalies.Finally,itisworthnot-ingthattherearesomelimitationstotheanalysispresentedbasedontheverylimitedliteratureonthistopic.Only14investigationsfulfilledsearchcriteria.Ofthese,severalstudieshadoverlappingpatientdataandWB-MRIprotocolsreportedwithseparateend-points.10,16,19ThisfurtherhighlightstheneedforadditionalresearchonWB-MRIperformanceinNFsyndromes(table3).ChoosingstandardizedimageacquisitionandanalysismethodsisessentialforoptimalmulticentercollaborationapplyingWB-MRIasatoolforassess-ingtumorsinNF.WB-MRImayserveaseitherapri-maryorsecondaryendpointinclinicaldrugtrialsthattargetmultipletumorsrequiringsystemicratherthanlocalizedimaging.ThesystematicprocessdevelopedbytheREiNSWB-MRIWorkingGrouphasenabledamulticenterconversationaboutimagingprotocolsandthedevelopmentoffuturecomparativeprojects.TheseresultswillbeusedbythegrouptoidentifythemostappropriateWB-MRIacquisitionandinterpretationmethodsforindividualswithNFsyn-dromesinfutureclinicaltrialsandprioritizeresearchquestionsabouttheoptimaluseofWB-MRIasanendpointmeasureinNFresearch.AUTHORCONTRIBUTIONSS.Ahlawat:conceptualizationofthestudy,interpretationofthedata,draftingthemanuscript.L.M.Fayad:conceptualizationofthestudy,interpretationofthedata,draftingthemanuscript.S.Khan:analysisofthedata.M.A.Bredella:revisingthemanuscriptforintellectualcontent.G.J.Harris:revisingthemanuscriptforintellectualcontent.D.G.Evans:revisingthemanuscriptforintellectualcontent.S.Farschtschi:analysisofthedata,revisingthemanuscriptforintellectualcontent.M.A.Jacobs:analysisofthedata,revisingthemanuscriptforintellectualcontent.A.Chhabra:revisingthemanuscriptforintellectualcontent.J.M.Salamon:revisingthemanuscriptforintellectualcontent.R.Wenzel:analysisofthedata,revisingthemanuscriptforintellectualcontent.V.F.Mautner:revisingthemanuscriptforintellectualcontent.E.Dombi:conceptualizationofthestudy,interpretationofthedata,revisingthemanuscriptforintellectualcontent.W.Cai:interpretationofthedata,revisingthemanuscriptforintellectualcontent.S.R.Plotkin:conceptualizationofthestudy,interpreta-tionofthedata,revisingthemanuscriptforintellectualcontent.J.O.Blakeley:conceptualizationofthestudy,interpretationofthedata,draftingthemanuscript.ACKNOWLEDGMENTTheauthorsthankRhondaJacksonandMonicaR.Sheridanforadministrativesupport.STUDYFUNDINGNotargetedfundingreported.DISCLOSURES.Ahlawatreportsnodisclosuresrelevanttothemanuscript.L.FayadhasreceivedresearchgrantsfromGeneralElectricRadiologyResearchAca-demicFellowshipprogramandSiemensMedicalSystems.M.KhanandM.Bredellareportnodisclosuresrelevanttothemanuscript.G.HarrisreceivesresearchsupportfromChildren’sTumorFoundationandNIH.HealsoservesonthescientificadvisoryboardofFovia,Inc.G.EvansreceivedsupportfromAstraZenecaandhasservedontheboardofFamilialCancerJournal.S.Farschtschireportsnodisclosuresrelevanttothemanuscript.M.JacobsreceivesfundingfromNIH(P50CA103175,5P30CA006973[IRAT],R01CA190299,U01CA140204)andSiemensMedicalSystems(JHU-2012-MR-86-01).A.ChhabrahasreceivedresearchgrantsfromGeneralElectricRadiologyResearchAcademicFellowshippro-gram,SiemensMedicalSolutions,GatewoodFellowshipAward,andInte-graLifeSciences.HealsoservesasaresearchconsultantwithSiemensCADgroup.HereceivesroyaltiesfromWoltersandJaypeePublishers.J.Salamon,R.Wenzel,V.Mautner,andE.Dombireportnodisclosuresrelevanttothemanuscript.W.CaireceivesresearchsupportfromNCI,AmericanCancerSociety,andChildren’sTumorFoundation.HeservesontheeditorialboardsoftheInternationalJournalofIntelligentInformationProcessing,WorldJournalofRadiology,InternationalJournalofRadiology,andAdvancesinModernOncologyResearch.S.PlotkinreceivesresearchsupportfromtheChildren’sTumorFoundation,NIH,andtheDepartmentofDefenseNeurofibromatosisClinicalTrialsConsortium.J.BlakeleyhasreceivedresearchsupportfromGlaxoSmithKline,Sanofi-Aventis,andLilyPharmaceuticals.ShehasconsultedforAbbvie.GotoNeurology.orgforfulldisclosures.ReceivedNovember19,2015.AcceptedinfinalformMay26,2016.REFERENCES1.Toledano-MassiahS,LucianiA,IttiE,etal.Whole-bodydiffusion-weightedimaginginHodgkinlymphomaanddif-fuselargeB-celllymphoma.Radiographics2015;35:747–764.2.PasoglouV,MichouxN,PeetersF,etal.Whole-body3DT1-weightedMRimaginginpatientswithprostatecancer:Neurology87(Suppl1)August16,2016S37ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.feasibilityandevaluationinscreeningformetastaticdis-ease.Radiology2015;275:155–166.3.FriedmanDN,LisE,SklarCA,etal.Whole-bodymag-neticresonanceimaging(WB-MRI)assurveillanceforsubsequentmalignanciesinsurvivorsofhereditaryretino-blastoma:apilotstudy.PediatrBloodCancer2014;61:1440–1444.4.CilibertoM,MaggiF,TregliaG,etal.Comparisonbetweenwhole-bodyMRIandfluorine-18-fluorodeoxyglucosePETorPET/CTinoncology:asystematicreview.RadiolOncol2013;47:206–218.5.SchlemmerHP,SchäferJ,PfannenbergC,etal.Fastwhole-bodyassessmentofmetastaticdiseaseusinganovelmagneticresonanceimagingsystem:initialexperiences.InvestRadiol2005;40:64–71.6.AttariwalaR,PickerW.WholebodyMRI:improvedlesiondetectionandcharacterizationwithdiffusionweightedtechniques.JMagnResonImaging2013;38:253–268.7.MulvihillJJ,ParryDM,ShermanJL,PikusA,Kaiser-KupferMI,EldridgeR.NIHconference:neurofibroma-tosis1(Recklinghausendisease)andneurofibromatosis2(bilateralacousticneurofibromatosis):anupdate.AnnInternMed1990;113:39–52.8.BaserME,FriedmanJM,WallaceAJ,RamsdenRT,JoeH,EvansDG.Evaluationofclinicaldiagnosticcriteriaforneurofibromatosis2.Neurology2002;59:1759–1765.9.MacCollinM,ChioccaEA,EvansDG,etal.Diagnosticcriteriaforschwannomatosis.Neurology2005;64:1838–1845.10.MerkerVL,BredellaMA,CaiW,etal.Relationshipbetweenwhole-bodytumorburden,clinicalphenotype,andqualityoflifeinpatientswithneurofibromatosis.AmJMedGenetA2014;164A:1431–1437.11.NguyenR,JettK,HarrisGJ,CaiW,FriedmanJM,MautnerVF.Benignwholebodytumorvolumeisariskfactormalignantperipheralnervesheathtumorsinneuro-fibromatosistype1.JNeurooncol2014;116:307–313.12.UrbanT,LimR,MerkerVL,etal.Anatomicandmeta-bolicevaluationofperipheralnervesheathtumorsinpa-tientswithneurofibromatosis1usingwhole-bodyMRIand(18)F-FDGPETfusion.ClinNuclMed2014;39:e301–e307.13.FayadLM,BlakeleyJ,PlotkinS,WidemannB,JacobsMA.WholebodyMRIat3Twithquantitativediffusionweightedimagingandcontrast-enhancedsequen-cesforthecharacterizationofperipherallesionsinpatientswithneurofibromatosistype2andschwannomatosis.ISRNRadiol2013;2013:627932.14.DerlinT,TornquistK,MünsterS,etal.Comparativeeffectivenessof18F-FDGPET/CTversuswhole-bodyMRIfordetectionofmalignantperipheralnervesheathtumorsinneurofibromatosistype1.ClinNuclMed2013;38:e19–e25.15.NguyenR,DombiE,WidemannBC,etal.Growthdynamicsofplexiformneurofibromas:aretrospectivecohortstudyof201patientswithneurofibromatosis1.OrphanetJRareDis2012;7:75.16.PlotkinSR,BredellaMA,CaiW,etal.Quantitativeassessmentofwhole-bodytumorburdeninadultpatientswithneurofibromatosis.PLoSOne2012;7:e35711.17.KluweL,NguyenR,VogtJ,etal.InternaltumorburdeninneurofibromatosistypeIpatientswithlargeNF1dele-tions.GenesChromosomesCancer2012;51:447–451.18.NguyenR,KluweL,FuenstererC,KentschM,FriedrichRE,MautnerVF.Plexiformneurofibromasinchildrenwithneurofibromatosistype1:frequencyandassociatedclin-icaldeficits.JPediatr2011;159:652–655.e2.19.CaiW,KassarjianA,BredellaMA,etal.Tumorburdeninpatientswithneurofibromatosistypes1and2andschwan-nomatosis:determinationonwhole-bodyMRimages.Radiology2009;250:665–673.20.VanMeerbeeckSF,VerstraeteKL,JanssensS,MortierG.WholebodyMRimaginginneurofibromatosistype1.EurJRadiol2009;69:236–242.21.MautnerVF,AsuagborFA,DombiE,etal.Assessmentofbenigntumorburdenbywhole-bodyMRIinpatientswithneurofibromatosis1.NeuroOncol2008;10:593–598.22.JaremkoJL,MacMahonPJ,TorrianiM,etal.Whole-bodyMRIinneurofibromatosis:incidentalfindingsandprevalenceofscoliosis.SkeletalRadiol2012;41:917–923.23.KarmazynB,CohenMD,JenningsSG,RobertsonKA.Mar-rowsignalchangesobservedinfollow-upwhole-bodyMRIstudiesinchildrenandyoungadultswithneurofibromatosistype1treatedwithimatinibmesylate(Gleevec)forplexiformneurofibromas.PediatrRadiol2012;42:1218–1222.24.FarschtschiSC,DombiE,WidemannB,FünstererC,MautnerVF.Comparabilityof1.5Tand3.0TMRI-volumetricsinneurofibromatosistype1.Presentedatthe2013NFConference,Monterey,CA.25.BrauckK,ZengeMO,VogtFM,etal.Feasibilityofwhole-bodyMRwithT2-andT1-weightedreal-timesteady-statefreeprecessionsequencesduringcontinuoustablemovementtodepictmetastases.Radiology2008;246:910–916.26.KandaT,IshiiK,KawaguchiH,KitajimaK,TakenakaD.HighsignalintensityinthedentatenucleusandglobuspallidusonunenhancedT1-weightedMRimages:relation-shipwithincreasingcumulativedoseofagadolinium-basedcontrastmaterial.Radiology2014;270:834–841.27.SubhawongTK,DurandDJ,ThawaitGK,JacobsMA,FayadLM.Characterizationofsofttissuemasses:canquantitativediffusionweightedimagingreliablydistin-guishcystsfromsolidmasses?SkeletalRadiol2013;42:1583–1592.28.DemehriS,BelzbergA,BlakeleyJ,FayadLM.ConventionalandfunctionalMRimagingofperipheralnervesheathtu-mors:initialexperience.AJNR2014;35:1615–1620.29.DombiE,Ardern-HolmesSL,Babovic-VuksanovicD,etal.Recommendationsforimagingtumorresponseinneurofi-bromatosisclinicaltrials.Neurology2013;81(21suppl1):S33–S40.30.WidemannBC,BlakeleyJO,DombiE,etal.ConclusionsandfuturedirectionsfortheReiNSInternationalCollab-oration.Neurology2013;81(21suppl1):S41–S44.31.HarrisGJ,PlotkinSR,MacColllinM,etal.Three-dimen-sionalvolumetricsfortrackingvestibularschwannomagrowthinneurofibromatosistypeII.Neurosurgery2008;62:1314–1319.32.HopperKD,KasalesCJ,VanSlykeMA,SchwartzTA,TenHaveTR,JozefiakJA.AnalysisofinterobserverandintraobservervariabilityinCTtumormeasurements.AJRAmJRoentgenol1996;167:851–854.33.DempseyMF,CondonBR,HadleyDM.Measurementoftumor“size”inrecurrentmalignantglioma:1D,2D,or3D?AJNRAmJNeuroradiol2005;26:770–776.34.ErasmusJJ,GladishGW,BroemelingL,etal.Interobserverandintraobservervariabilityinmeasurementofnon-small-S38Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.cellcarcinomalunglesions:implicationsforassessmentoftumorresponse.JClinOncol2003;21:2574–2582.35.ChhabraA,ThakkarRS,AndresisekG,etal.AnatomicMRimagingandfunctionaldiffusiontensorimagingofperipheralnervetumorsandtumorlikeconditions.AJNRAmJNeuroradiol2013;34:802–807.36.SolomonJ,WarrenK,DombiE,PatronasN,WidemannB:Automateddetectionandvolumemeasurementofplexiformneurofibromasinneurofibromatosis1usingmagneticresonanceimaging.ComputMedImagingGraph2004;28:257–265.37.DombiE,SolomonJ,GillespieAJ,etal.NF1plexiformneurofibromagrowthratebyvolumetricMRI:relationshiptoageandbodyweight.Neurology2007;68:643–647.Neurology87(Suppl1)August16,2016S39ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.DOI 10.1212/WNL.00000000000029292016;87;S31-S39 Neurology(cid:160)Shivani Ahlawat, Laura M. Fayad, Muhammad Shayan Khan, et al. schwannomatosisCurrent whole-body MRI applications in the neurofibromatoses: NF1, NF2, andThis information is current as of August 15, 2016ServicesUpdated Information & http://www.neurology.org/content/87/7_Supplement_1/S31.full.htmlincluding high resolution figures, can be found at:Supplementary Material 002929.DC1http://www.neurology.org/content/suppl/2016/08/15/WNL.0000000000Supplementary material can be found at: References ref-list-1http://www.neurology.org/content/87/7_Supplement_1/S31.full.html##This article cites 36 articles, 5 of which you can access for free at: Citations otherarticleshttp://www.neurology.org/content/87/7_Supplement_1/S31.full.html##This article has been cited by 1 HighWire-hosted articles: Subspecialty Collections http://www.neurology.org//cgi/collection/neurofibromatosisNeurofibromatosisfollowing collection(s): This article, along with others on similar topics, appears in the(cid:160) Permissions & Licensing http://www.neurology.org/misc/about.xhtml#permissionsits entirety can be found online at:Information about reproducing this article in parts (figures,tables) or in(cid:160) Reprints http://www.neurology.org/misc/addir.xhtml#reprintsusInformation about ordering reprints can be found online:rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.1951, it is now a weekly with 48 issues per year. Copyright © 2016 American Academy of Neurology. All ® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology(cid:160)C.OliverHanemann,MD,PhDJaishriO.Blakeley,MDFabioP.Nunes,MD,MMScKentRobertson,MDAnatStemmer-Rachamimov,MDVictorMautner,MDAndreasKurtz,PhDMichaelFerguson,MDBrigitteC.Widemann,MDD.GarethEvans,MDRosalieFerner,MDStevenL.Carroll,MD,PhDBruceKorf,MD,PhDPierreWolkenstein,MDPamelaKnightScottR.Plotkin,MD,PhDFortheREiNSInternationalCollaborationCorrespondencetoDr.Hanemann:Oliver.Hanemann@plymouth.ac.ukSupplementaldataatNeurology.orgCurrentstatusandrecommendationsforbiomarkersandbiobankinginneurofibromatosisABSTRACTObjective:Clinicallyvalidatedbiomarkersforneurofibromatosis1(NF1),neurofibromatosis2(NF2),andschwannomatosis(SWN)havenotbeenidentifiedtodate.Thebiomarkerworkinggroup’sgoalsareto(1)definebiomarkerneedsinNF1,NF2,andSWN;(2)summarizeexistingdataonbiomarkersinNF1,NF2,andSWN;(3)outlinerecommendationsforsamplecollectionandbiomarkerdevelop-ment;and(4)standardizesamplecollectionandmethodologyprotocolswherepossibletopromotecomparisonbetweenstudiesbypublishingstandardoperatingprocedures(SOPs).Methods:ThebiomarkergroupreviewedpublisheddataonbiomarkersinNF1,NF2,andSWNandonbiobankingeffortsoutsidethesediseasesvialiteraturesearch,definedtheneedforbio-markersinNF,anddevelopedrecommendationsinaseriesofconsensusmeetings.Results:WedescribeexistingbiomarkersinNFandreportconsensusrecommendationsforSOPandaminimalclinicaldatasettoaccompanysamplesderivedfrompatientswithNF1,NF2,andSWNindecentralizedbiobanks.Conclusions:TheserecommendationsareintendedtoprovidecliniciansandresearcherswithacommonsetofguidelinestocollectandstorebiospecimensandforestablishmentofbiobanksforNF1,NF2,andSWN.Neurology®2016;87(Suppl1):S40–S48GLOSSARY5-S-CD55-S-cysteinyldopa;ADM5adrenomedullin;MIA5melanomainhibitoryactivity;MPNST5malignantperipheralnervesheathtumors;NF15neurofibromatosis1;NF25neurofibromatosis2;PNF5plexiformneurofibromas;REiNS5ResponseEvaluationinNeurofibromatosisandSchwannomatosis;sAXL5solublegrowthfactorreceptorAxl;SOP5standardoperatingprocedure;SWN5schwannomatosis.Theneurofibromatoses—neurofibromatosis1(NF1),neurofibromatosis2(NF2),andschwan-nomatosis(SWN)—aregeneticallydistinctneurocutaneoussyndromesthatsharemanyfeatures.All3conditionsdemonstratewidevariabilityindiseasemanifestations,andarecharacterizedbyprogressive,lifelong,andpotentiallylife-threateningcomplications.Standardtreatmentislimitedtosurgeryformosttumormanifestations.Giventheunmetneedfornonsurgicaltherapies,therehavebeen.20clinicaltrialsperformedbetween1993and2014forNF1andNF2withvaryingmeasuresofresponse.Fewstudieshavedocumentedevidenceofclinicalefficacyforinvestigationalagents.1Todate,nobiomarker-driventrialshavebeenperformedinNF.TheResponseEvaluationinNeurofibromatosisandSchwannomatosis(REiNS)InternationalCollaborationwascreatedin2011todefineanddevelopthemostinformative,reliable,andmean-ingfulendpointsforclinicaltrialsforNF.TheREiNSgroupiscomposedofseveralworkinggroups.2Thebiomarkerworkinggroup,whichincludesneurologists,oncologists,geneticists,FromPlymouthUniversity(C.O.H.),PeninsulaSchoolsofMedicineandDentistry,TheInstituteofTranslationalandStratifiedMedicine,Plymouth,UK;DepartmentofNeurology(J.O.B.),JohnsHopkinsUniversityMedicalSchool,Baltimore,MD;DepartmentofPediatrics(F.P.N.)andDepartmentofPediatrics,SchoolofMedicine(K.R.,M.F.),IndianaUniversity;TailoredTherapeutics(F.P.N.),EliLillyandCompany,Indianapolis,IN;DepartmentofPathology(A.S.-R.),Neuro-oncology(S.R.P.),MassachusettsGeneralHospital,Boston;NeurologischeKlinik(V.M.),UniklinikEppendorf,Hamburg;Berlin-BrandenburgCenterforRegenerativeTherapies(A.K.),CharitéUniversitätsmedizinBerlin,Germany;SeoulNationalUniversity(A.K.),CollegeofVeterinaryMedicineandResearchInstituteforVeterinaryScience,RepublicofKorea;NCI(B.C.W.),PediatricOncologyBranch,Bethesda,MD;GenomicMedicine(D.G.E.),UniversityofManchester,UK;NationalNeurofibromatosisService(R.F.),DepartmentofNeurology,Guy’sandSt.Thomas’NHSFoundationTrust,LondonUK;DepartmentofPathologyandLaboratoryMedicine(S.L.C.),MedicalUniversityofSouthCarolina,Charleston;andHeflinCenterforGenomicSciences(B.K.),UniversityofAlabamaatBirmingham;Dermatology(P.W.),GHUHenriMondor,Paris,France;Children’sTumorFoundation(P.K.),NewYork.REiNSInternationalCollaborationmembersarelistedontheNeurology®WebsiteatNeurology.org.GotoNeurology.orgforfulldisclosures.Fundinginformationanddisclosuresdeemedrelevantbytheauthors,ifany,areprovidedattheendofthearticle.S40©2016AmericanAcademyofNeurologyª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.pathologists,dermatologists,pediatricians,andbasicscientists,hasthegoalsto(1)definebio-markerneedsinNF1,NF2,andSWN;(2)summarizeexistingdataonbiomarkersinNF1,NF2,andSWN;(3)outlineinitialrecom-mendationsforsamplecollectionandbiomarkerdevelopment;and(4)harmonizesamplecollec-tionandprocessingprotocolswherepossibletoallowfordatacomparisonbetweenstudiesbypublishingstandardoperatingprocedures(SOPs).Thisarticlesummarizestheprogresstowardthesegoals.Thebiomarkergrouphasconcen-tratedonbiomarkersinblood,urine,andtissue.ImagingbiomarkersarediscussedseparatelybytheREiNSimagingworkinggroup.3METHODSThebiomarkergroupfirstperformedaliteraturesearch,andreviewedandsummarizedexistingdataonbiomarkersinNF1,NF2,andSWN.ThegroupthenmetduringaseriesofmeetingsincollaborationwiththeChildren’sTumorFoundation(1)toestablishSOPsforsamplecollectionofNFtissuespecimensthatfacilitatedatacomparisonbetweenstudiesand(2)todevelopaminimalclinicaldatasetthatwouldaccompanyeachsample.Theworkinggroupanticipatesthattheserecommendationswillbeupdatedperiodicallyasnewinformationonbiomarkersbe-comesavailable.DetailedassayprotocolswillbeavailableontheREiNSWebsite(www.reinscollaboration.org).RESULTSBiomarkersareusedforearlydetectionofdiseaseorindiseaseclassification(diagnosticbiomarkers),inpredictingresponseoradverseevents(predictivebio-markers),indefiningoptimaldrugdose(metabolic/phar-macodynamicbiomarkers),orinforecastingprogressionorrecurrence(outcomebiomarkers).4PreviousnaturalhistorystudiesinNF1andNF2haveclearlydemon-stratedahighdegreeofvariabilityindiseasephenotypeandtumorbehaviorintheseconditions.5Thisvariabilityintroducescomplexityintotheidentificationofvalidbio-markersforNFandschwannomatosis.Forexample,abiomarkercouldpotentiallycorrelatewiththepresenceofthegeneticsyndrome(e.g.,NF1,NF2,orschwanno-matosis),ofaspecifictumortype(e.g.,gastrointestinalstromaltumorinNF1),withanontumorphenotypeofNF(e.g.,painseverityinschwannomatosis),withcumu-lativediseaseburden(e.g.,wholebodytumorburden),withdiseaseprogression(e.g.,growthofplexiformneu-rofibromainNF1),orwithmalignanttransformation(e.g.,malignantperipheralnervesheathtumorfromplex-iformneurofibroma).Giventheoverlapinmanyofthesephenotypes,validatingthesebiomarkersforindividualdiseasemanifestationswillrequirecarefulphenotypingofpatients.DiagnosticbiomarkersinNF.Historically,NF1,NF2,andschwannomatosishavebeendiagnosedusingestablishedclinicalcriteria.Advancesinmoleculartechniquesoverthelast2decadeshaveledtotheavailabilityofgeneticdiagnosisfortheseconditions.6,7ThesensitivityofgeneticanalysisfordiagnosisofNFdependsonthefounderstatusandtheclinicalphenotype(segmentalvsgeneral-ized)butrangesfrom30%forsporadicschwannomatosisto.95%forNF1.WhenacausativegeneticalterationintheNF1,NF2,SMARCB1,orLZTR1genesisidenti-fied,itcanbeusedasdiagnosticbiomarkerforrelatedfamilymembers.Inclinicalpractice,thisinformationisusedbyreproductiveendocrinologistsforprenataldiagno-sisorpreimplantationgeneticdiagnosisandbygeneticcounselorsforpresymptomaticdiagnosisoffamilymem-bers.However,additionaldiagnosticbiomarkerswillundoubtedlybeusefultoidentifypatientswithspecificdiseasefeatures,suchasplexiformneurofibromasoropticgliomas.OutcomebiomarkersinNF.Similarly,thereisgreatvariabilityinclinicaloutcomesforpatientswithNF.Forexample,whileopticpathwaygliomaoccursinabout15%ofindividualswithNF1,onlyabout1/3ofthesetumorsaresymptomatic,andlesswillprogressandrequireactivetreatment.8Opticpathwaygliomaswillevenspontaneouslyregresswithouttreatment.ThisvariabilityinoutcomehighlightstheneedtodevelopoutcomebiomarkersforNFdiseasemanifes-tations.Outcomebiomarkersprovideevidenceaboutthepatient’sdiseaseoutcomeindependentofanyspecificintervention.Avalidatedoutcomebiomarkerwouldbevaluabletodeterminethelong-termriskfordermalneurofibromasandmalignantperipheralnervesheathtumorsinpatientswithNF1,forriskofcompletedeafnessinpatientswithNF2,andforriskofseverechronicpaininpatientswithschwannomatosis.PredictivebiomarkersinNF.Overthelastdecade,therehasbeenanexplosionofclinicaltrialsforNF-relatedtumorsandconditions.TheopportunitytostudynovelagentsinNFopensthepossibilityofdevelopingandincorporatingbiomarkerstudiesintoearlyclinicaltrials.Todate,clinicaltrialsrunthroughtheNeurofibromatosisClinicalTrialsConsortiumhaveincludedstudiesofpharmacodynamicbiomarkersandpredictivebiomarkers.AsdrugswithactivityagainstNFbecomeavailable,thesestudieswillprovidevaluableinformationaboutwhichpatientsarelikelytorequiretreatmentinthefutureandwhicharelikelytorespondtotherapy.ExistingdataonbiomarkersinNF1,NF2,andSWN.Duringdevelopment,biomarkerspassthroughaseriesofstages,includingearlyresearchanddevelopment(exploratorybiomarker),demonstrationandvalidation(probablebiomarker),characterizationandqualification(knownbiomarker),andsurrogacy(biomarkercansubsti-tuteforclinicalendpoint).Fortheneurofibromatoses,allNeurology87(Suppl1)August16,2016S41ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.biomarkerspublishedtodateareconsideredexploratory;nonehasbeenvalidatedtoachieveprobablebiomarkerstatus.Thusfar,allpublishedbiomarkerstudieshavebeenperformedinthesettingofNF1(table1);therearenopublisheddataonbiomarkersinNF2orschwan-nomatosis.Theseexploratorystudiesarealllimitedbyavarietyoftechnicalissuessuchaslimitedstatisticalpower,lackofanindependentvalidationset,andlackoflongitudinaldata.DiagnosticbiomarkersinNF1.(cid:129)Melanomainhibitoryactivity(MIA)—Inastudyof42patientswithNF1and22healthycontrols,9MIAserumlevelsweresignificantlyTable1Exploratorybiomarkerstudiespublishedforneurofibromatosis1(NF1)BiomarkerCorrelatewithNFpatients,nControls,nResultReferenceDiagnosticbiomarkersMIANF1status4222GreaterinNF1thaninunaffectedcontrols9TumorloadGreaterinNF1withPNFthaninNF1withoutPNFMPNSTGreaterinpatientswithNF1withhighertumorburdenNodifferencebetweenpatientswithNF1withorwithoutMPNSTMIA5-S-CDNF1status2514MIAgreaterinNF1thaninunaffectedcontrols10PNFstatusNodifferenceinMIAbetweenpatientswithNF1withorwithoutPNFAgeMIAlevelscorrelatewithage5-S-CDgreaterinNF1thaninunaffectedcontrols5-S-CDdoesnotcorrelatewithageADMMPNST3225HigherADMlevelsinNF1withMPNSTthaninNF1withPNF11NodifferencebetweenpatientswithNF1withorwithoutPNFHigherADMlevelsinpatientswithNF16PNFthanincontrolsIL-6,IFN-g,TNF-a,EGFRNF1status10441SerumconcentrationsofIL-6,IFN-g,andTNF-aweresignificantlyhigherinNF1thaninhealthycontrols14MPNSTstatusSerumconcentrationsofEGFRweresignificantlylowerinNF1thaninhealthycontrolsIGFBP-1,RANTESNF1status10441SerumconcentrationsofIGFBP-1andRANTESweresignificantlyhigherinpatientswithNF1withMPNSTthaninthosewithoutMPNST14MPNSTstatusSerumIGFBP-1correlatedwithinternaltumorloadInternaltumorloadFetalantigen1NF113177Statisticallysignificantdifferencebetweenmedianvalues12NotabletodistinguishbetweengroupssAXLNF1diagnosis,presenceofNF17246IncreasedinpatientswithNF1comparedtocontrols13IncreasedinpatientswithNF1withPNFcomparedtothosewithoutRASSF1AmethylationMPNST20MPNTSmethylated,12unmethylatedMPNSTwithRASSF1methylatedhadworseprognosisthanunmethylated,p50.01415miR-204MPNST12NF1,10NF11MPNSTDownregulationofmiR-204downregulatedinMPNST16PredictivebiomarkersFOXM1Survival38MPNSTHighFOXM1proteinexpressionwaspredictorofpoorsurvivalforpatientswithNF1withMPNST17CDK4Survival38MPNSTCDK4copynumbergainbyaCGHwaspredictorofpoorsurvivalforpatientswithNF1withMPNST17Survivin/TK1,TOP2ASurvivalwithMPNST64NF1withMPNSTStratifiesMPNSTintohighandlowrisk20Abbreviations:5-S-CD55-S-cysteinyldopa;aCGH5arraycomparativegenomichybridization;ADM5adrenomedullin;EGFR5epidermalgrowthfactorreceptor;IFN5interferon;IL5interleukin;MIA5melanomainhibitoryactivity;miR5microRNA;MPNST5malignantperipheralnervesheathtumors;PNF5plexiformneurofibromas;sAXL5solublegrowthfactorreceptorAxl;TNF5tumornecrosisfactor.S42Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.greaterinpatientswithNF1(15.2ng/mL)thanincontrols(4.5ng/mL),inpatientswithNF1withplexiformneurofibromas(PNF)thaninthosewithoutPNF,inpatientswithNF1withhighnumbersofcutaneousorsubcutaneousneurofibromasthaninthosewithoutsuchtu-mors,andinpatientswithNF1withgreaterinternaltumorloadthaninthosewithlowinter-naltumorload.Incontrast,serumlevelsofMIAwerenotsignificantlydifferentbetweenpatientswithNF1withandwithoutmalignantperipheralnervesheathtumors(MPNST).MIAasabio-markerforNF1wasalsoinvestigatedbyanothergroup.10Thisgroupaddedtheanal-ysisofthemetabolite5-S-cysteinyldopa(5-S-CD).TheyfoundconcordantresultswithhigherMIAlevelsin25patientswithNF1comparedwith14controls(13.1vs9.3ng/mL)butdidnotfindsignificantlydif-ferentlevelsbetweenpatientswithNF1withorwithoutPNF(15.1vs12.0ng/mL,respectively).Intheirstudy,serum5-S-CDlevelsweresignif-icantlyhigherinpatientswithNF1thanincon-trolsanddidnotcorrelatewithage.Hence,MIAdoesnotappeartobearobustbiomarkerfordistinguishingunaffectedcontrolsfrompatientswithNF1orbetweenpatientswithNF1withorwithoutMPNST.Furtherworkisneededtoexploretheutilityof5-S-CDtodistinguishbetweengroups.(cid:129)Adrenomedullin(ADM)—Inastudyof32patientswithNF1and25controlpatients,11serumADMlevelsweresignificantlygreaterinpatientswithNF1withMPNST(0.24ng/mL,n55)thaninpatientswithNF1withPNF(0.18ng/mL,n517);however,therewassignificantoverlapinADMlevelsbetweenthecohorts.ADMlevelswerealsosignificantlyhigherinpatientswithNF1withorwithoutMPNST(0.18ng/mL,n527)thanincontrols(0.07ng/mL,n525).Nosignif-icantdifferenceswerenotedbetweenpatientswithNF1withorwithoutPNF.AlthoughthedataforADMdataaremorepromisingthanthoseforMIA,thecurrentdatadonotindicatethatADMisareli-ablebiomarkerinNF1andfurtherstudiesarewarranted.(cid:129)Fetalantigen1—Inastudyof13adultpatientswithNF1and177adultcontrols,12themedianfetalantigen1levelsweresignificantlyhigherintheserumofpatientswithNF1(30.6ng/mL)thanincontrolpatients(24.9ng/mL),althoughtherewasconsiderableoverlapbetweenthegroups.12(cid:129)SolublegrowthfactorreceptorAxl(sAXL)—Inastudyof72patientswithNF1and46healthycontrols,serumlevelsofsAXLweresignificantlyincreasedinpatientswithNF1(23ng/mL)comparedwithcontrols(16ng/mL).PatientswithplexiformneurofibromashadsignificantlyhigherlevelsofsAXL(26ng/mL,n536)thanpatientswithNF1withoutplexiformneurofibromas(18ng/mL,n536)althoughtherewasstillsomeoverlapbetweengroups.13(cid:129)Systematicscreenofmultipleserumbio-markers14—Theauthorsevaluated104pa-tientswithNF1and41healthycontrolsandproposed4candidatebiomarkersthatweresta-tisticallysignificantlydifferentinpatientswithNF1vsunaffectedindividuals(interleukin-6,interferon-g,epidermalgrowthfactorreceptor,tumornecrosisfactor–a)and2biomarkercan-didatesthatwerestatisticallysignificantlydif-ferentinpatientswithNF1withandwithoutMPNST(insulin-likegrowthfactorbindingprotein1andRANTES).(cid:129)Danielsenetal.15analyzedthepromotermethyl-ationofRASSF1Ainprimarytumor.Theau-thorsreportedsignificantlydifferentsurvivaldatafor32patientswithmethylatedorunmethy-latedRASSF1Aat5years.(cid:129)MiRNAstudiesinNF1andnon-NF1MPNSTshavebeenperformedusingcelllinesandtissues.ThisstudyidentifiedthedownregulationofmiR-204asanoveldiagnosticbiomarkerandpotentialtherapeutictargetforpatientswithNF1withMPNSTs.16Alltheabove-mentionedstudieswereaimedatidentifyingdiagnosticbiomarkers.Predictiveandpharmacodynamicbiomarkers.(cid:129)Candidategenealterationsintumorspecimens—Usinghigh-resolutionarray-basedcomparativegenomichybridizationin38MPNSTs(23withNF1and15withoutNF1),theauthorsidenti-fiedcandidategenealterationsthatwerethenvalidatedattheDNA,RNA,andproteinlevels.17Candidategenesinregionsofcopynumbergainandassociated(predicted)withpoorsurvivalincludedSOX5,NOL1,MLF2,FOXM1,FKBP1,CDK4,TSPAN31,ERBB2,MYC,andTP53.Inmultivariateanalysis,FOXM1proteinexpressionandCDK4copynumbergainwerethemostsig-nificantindependentgenomicbiomarkersforpoorsurvivalinpatientswithMPNSTs.(cid:129)AurorakinaseA,whichisimportantinmitoticspindleassemblyandnonmitoticrelatedcelldif-ferentiation,isapotentialtherapeutictargetinMPNSTs.RecentstudiesinprimaryMPNSTshavedemonstratedthatpharmacologicaurorakinaseinhibitionresultsinMPNSTcellsNeurology87(Suppl1)August16,2016S43ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.Table2RecommendedminimalclinicaldatasetDemographicsDate:SexmalefemaleBirthmonthyearDiagnosisofNF1,NF2,orschwannomatosisinfancychildhoodadolescenceadulthoodunknownInheritanceparentaffectedparentnotaffectedunknownMosaicismpatientismosaicpatientnotmosaicunknownGermlinemutationnottestedtested1unknowndetermined:(specify___)ClinicalstatusStatusalivedeceasedWHOperformancestatus01234PainnotaproblemoccasionaldisablingTreatmentdirectedattumornospecifictherapychemotherapysurgeryradiationtargetedtherapy(specify)clinicaltrial(specify)NF1‡6Café-au-laitmaculesabsentpresentunknownSkinfoldfrecklingabsentpresentunknownIrisLischnodulesabsentpresentunknownDermalneurofibromasabsentscattereddenseunknownSubcutaneousnodularneurofibromasabsentscattereddenseunknownDiffusedermalneurofibromasabsentscattereddenseunknownSpinalneurofibromasnotimagedabsent1–3levelsalllevels(cervical,thoracic,lumbar,sacral)unknownPlexiformneurofibromaspresentabsentbyMRIabsentclinically,butnoMRIunknownOpticgliomaunknownabsentpresent,asymptomaticpresent,symptomatic,nottreatedpresent,symptomatic,treatedHeartdefectunknownabsentpresent(specify)Vasculardiseaseunknownabsentpresent(specify)PubertyonsetprepubertalprecociousnormallateunknownStature,5thcentile5th–95thcentile.95thcentileunknownPeripheralneuropathyunknownabsentpresentAqueductalstenosisunknownabsentpresentLongbonedysplasiaunknownabsentpresentSphenoiddysplasiaunknownabsentpresentScoliosisunknownabsentpresentIntellectualdisabilityunknownabsentpresentContinuedS44Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.Table2ContinuedNF1LearningdisabilityunknownabsentpresentAttentiondeficitdisorderunknownabsentpresentPheochromocytomaunknownabsentpresentGlomustumorunknownabsentpresentMPNSTunknownabsentpresentGlioma(notopticglioma)unknownabsentpresentGISTunknownabsentpresentLeukemiaunknownabsentpresentBreastcancerunknownabsentpresentOthertumorsunknownabsentpresent(specify_____)NF2VestibularschwannomaMRInotdoneabsentbyMRIunilateralbilateralunknownMeningiomaMRInotdoneabsentbyMRIsinglemultipleunknownGlioma/ependymomaMRInotdoneabsentbyMRIpresentunknownSpinalschwannomaMRInotdoneabsentbyMRIsinglemultipleunknownDermalschwannomaunknownabsentpresentNonvestibularcranialschwannomaMRInotdoneabsentbyMRIpresent(specify)unknownLenticularopacityunknownabsentpresentSchwannomatosisSchwannomas(nonvestibular)onlybyimagingevidence1pathologicallyconfirmed2ormore,atleast1pathologicallyconfirmedunknownNumberofschwannomassinglescattereddenseunknownVestibularschwannomasnotimagedabsentbyimagingunilateralbilateralunknownMeningiomasnotimagedabsentbyimagingsinglemultipleunknownOtherschwannomatosis-relatedtumors(pleasespecify)notinvestigatedabsentpresentunknownAbbreviations:GIST5gastrointestinalstromaltumors;MPNST5malignantperipheralnervesheathtumors;NF15neurofibromatosis1;NF25neurofibromatosis2.Neurology87(Suppl1)August16,2016S45ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.exitingthecellcyclewithcessationofgrowth.18ThecopynumberandexpressionofthegeneproductHMMRwasfoundtobeafunctionalmarkerofresponsivenesstoaurorakinaseinhibition.Avarietyoflesswell-definedandreproducibleprognosticatorsaresummarizedinareviewbyFaridetal.19(cid:129)Recently,geneexpressionanalysisof30MPNSTsandsubsequentimmunohistochemicalstainingof64MPNSTsrevealedacompositesetofsur-vivin(BIRC5),thymidinekinase1(TK1),andtopoisomerase2-a(TOP2A)immunohistochem-icalstaining,whichstratifiesMPNSTintohighandlowrisk20independentofage,sex,tumorsize,grade,NF1status,andsurgicalremission.(cid:129)Blakeleyetal.21havedetectedlowerbloodcircu-latinglevelsofhepatocytegrowthfactorinpatientswithNF2whorespondedtobevacizumab.ThisisthefirstevidencethatabloodbiomarkercouldbeusedpredictivelytostratifypatientswithNF2(n513)withthehighestlikelihoodoftreatmentbenefit.RECOMMENDATIONSFORSAMPLECOLLECTIONANDMETHODOLOGYTheREiNSbiomarkergroupdiscussedpotentialbarrierstobiomarkerresearchforNF.ThesebarriersincludethelowprevalenceofNF1,NF2,andschwannomatosis,whichmakescoordinatedstudiestechnicallydifficultandexpensive;theextremevariabilityoftheseconditionsrequiresexpertclinicalresearcherstoaccuratelyphenotypepatients.Basedonthisdiscussion,thegroupendorsedthefollowinggoalstoadvancethestudyofbiomarkerswithintheNFcommunity:1.Buildaprospectivebiorepositoryofcuratedsam-ples.Theaimwouldbetocollectlongitudinalsamplesfromeachpatienttofacilitatethedevel-opmentofearlydetectionandprognosticmarkers.2.Standardizetissuecollectionatparticipatinginstitu-tions.TheaimwouldbetocollectalltissuesusinganidenticalprotocolthatmeetsstandardssetforthbytheAmericanAssociationforCancerResearch–FoodandDrugAdministration–NationalCancerInstituteCan-cerBiomarkerCollaborative4andwouldbelinkedviaashared,anonymizedregistry(onaWebsite).Par-ticipatingsiteswouldsharecommonconsent,SOPs,qualitycontrol(seesupplementaldataontheNeurology®WebsiteatNeurology.org),minimalclin-icaldataset,anddatabase.3.Annotatesampleswithanagreedminimalclinicaldataset.Thegoalistolinkanonymouslythepheno-typicdatatodeidentifiedsamplesinthebioreposi-tory.AproposedminimalclinicaldatasetdevelopedataconsensusmeetinginOctober2014isshownintable2.Thegroupanticipatesthatmodificationsofthisdatasetmayberequiredinthefuturetooptimizetheutilityofbiomarkerresearch.4.Incorporatethedecentralizedbiorepositoryintoex-istingbiorepositoriesthatareusedfordiagnosticpurposes.Thebiomaterialcouldthusbeusedforbothdiagnosisandresearchandisnotnecessarilyrestrictedtoanupfrontdefinitionoftheamountofsurplustissue.Patientcaretakespreferencewhenallocatingtheamountofsamplesusedforbio-markerinvestigations.5.Provideopenaccesstodepositedbiomarkerstofacilitateresearch.Theaimwouldbetohavesam-plesanddataopentoallqualifiedresearcherswithapprovalofaninstitutionalreviewboard.Abiorepo-sitorycouncilwouldgoverndatabaserequests.6.AnoperationalandanexecutivecommitteewillgovernrequestsandauditimplementationofSOPsandqualitycontrolmeasures.7.Incorporatebiomarkercollectionintoclinicalstudies.Whenfeasible,samplecollectionshouldbeincorpo-ratedintoprospectiveclinicaltrialsandnaturalhis-torystudiestohelpdeveloppharmacodynamicandpredictivebiomarkers.8.Incorporatebiomarkercollectionintoroutineclin-icalvisits.Patientsreceivingroutinecareshouldbeinvitedtoparticipateinprospectivesamplecollec-tionduringroutineclinicvisits.RECOMMENDATIONSFORBIOMARKERSBASEDONEXISTINGDATA1.Validateindividualbiomarkersaswellascocktails/signaturesofbiomarkers.2.ForongoingandplannedNFtrials,studiesofdrugmetabolism/pharmacodynamicbiomarkersshouldbedrug-specific.3.FormalignanttumorssuchasMPNST,exploreandvalidatecDNA,cRNA,andcirculatingtumorcellsasbiomarkers.4.Validateuseofextracellularvesicles(exosomes)basedonencouragingpreliminarydataasbiomarkersofcancer.225.Usingcandidateapproach,focusontheclinicallyrelevantquestions,i.e.,totaltumorload,presenceofplexiformneurofibroma,evidenceofmalignanttransformation,andtakingintoaccountthestatisti-calsignificanceinpublishedstudies.Werecommendvalidatingthefollowingbiomarkercandidatesinpa-tientswithNF1:BIRC5/TK1/TOP2Aimmunohis-tochemistry,ADM,interferon-g,IGFBP-1,andsAXL.6.Complementcandidatebiomarkerapproachwithsys-tematicunbiasedapproach.Encouragewell-poweredstudiesusingsystematicunbiasedapproaches,includ-inggenomics(DNA,RNA,miRNAnext-generationsequencing),metabolomics,andproteomics;thatis,furtherscreeningwithmetabolomics,proteomics,expressionarrays,andmiRNA.S46Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.AUTHORCONTRIBUTIONSC.O.Hanemann:draftingthemanuscript,studyconcept,interpreta-tionofdata,developmentofrecommendationsandSOPs.JaishriBla-keley:studyconcept,reviewofmanuscript,interpretationofdata.FabioNunes:studyconcept,reviewofthemanuscript,developmentofrecommendations,developmentofSOPs.KentRobertson:studyconcept,reviewofmanuscript,developmentofSOPs.AnatStemmer-Rachamimov:studyconcept,reviewofmanuscript,develop-mentofSOPs.VictorMautner:studyconcept,reviewofmanuscript.AndreasKurtz:studyconcept,reviewofmanuscript,developmentofSOPs.MichaelFerguson:studyconcept,reviewofmanuscript,devel-opmentofSOPs.BrigitteC.Widemann:studyconcept,reviewofmanuscript.GarethEvans:studyconcept,reviewofmanuscript.Rosa-lieFerner:reviewofmanuscript,interpretationofdata.StevenL.Car-roll:draftingofmanuscript,developmentofautopsy,surgicalpathology,andbloodbiobankingprotocols.BruceKorf:interpretationofdata,reviewingmanuscript,draftingminimalclinicaldataset.PierreWolkenstein:reviewofmanuscript.PamKnight:studyconcept,reviewofmanuscript.ScottPlotkin:studyconcept,draftingofmanuscript,reviewofmanuscript.ACKNOWLEDGMENTTheauthorsthankChildren’sTumorFoundation(CTF)forsupportandXandraO.Breakefield,MassachusettsGeneralHospital,foradvisingonthemanuscript.STUDYFUNDINGNotargetedfundingreported.DISCLOSUREO.HanemannreceivessupportfromDr.HadwenTrustandBrainTumourResearch.J.BlakeleyhasreceivedresearchsupportfromGlaxoS-mithKline,Sanofi-Aventis,andLilyPharmaceuticals.ShehasconsultedforAbbvie.F.NunesreceivessupportfromEliLillyandCompany.K.RobertsonreceivesresearchsupportfromNovartis,NIH,DepartmentofDefense,andLeukemiaLymphomaSocietyTranslationalResearchPro-gram,andservesonamedicaladvisoryboardforGeneralBioTechnology—CookBiomedical.A.Stemmer-RachamimovreceivessupportfromChild-ren’sTumorFoundation,DanaFarberCancerInstitute,andNIH,andservesontheeditorialboardofJournalofClinicalPathology.V.Mautnerreportsnodisclosuresrelevanttothemanuscript.A.KurtzreceivessupportfromSeoulNationalUniversity,CollegeofVeterinaryMedicine,Novartis,andNolitolib,andservesontheeditorialboardofInternationalJournalofStemCells.M.FergusonservesasanassistantprofessorwithIndianaUniversity.B.WidemannreceivesresearchsupportthroughNCICCRIntramuralResearchProgram.G.EvansreceivedsupportfromAstraZenecaandhasservedontheboardofFamilialCancerJournal.R.FernerreceivesfundsfromtheChildren’sTumorFoundation,EuropeanNeurofibromatosisAssociation,andSpringerPublishingGroup.S.CarrolreceivedfundingfromtheDepartmentofDefense,NIH/NationalCancerInstitute,NIH/NINDS,andChildren’sTumorFoundation.HeservesontheeditorialboardsofJournalofNeuropa-thologyandExperimentalNeurology,Neuro-Oncology,TheAmericanJournalofPathology,andBrainResearchBulletin.B.KorfreceivesfundingfromNIH,DepartmentofDefense,Children’sTumorFoundation,TuberousSclerosisAlliance,andMarchofDimes.HeservesontheboardofNovartis,Accolade,andChildren’sTumorFoundationMedicalAdvisoryCommittee,andadvisesfortheNeurofibromatosisTherapeuticAccelerationProject.HehasservedaseditorforCurrentProtocolsinHumanGeneticsandAnnualReviewsofGeneticsandGenomics.HehasreceivedfundingfromtheAmericanCollegeofMedicalGeneticsandGenomics,AmericanAcademyofPediatrics,CambridgeHealth-TechInstitute,Illumina,andSequenome.HehasreceivedpublishingroyaltiesfromWileyBlackwellandElsevier.P.WolkenstreinservesontheadvisoryboardofAbbvieandPierreFabreDermatologieandconsultsforLaboratoired’UriageandLaboratoireExpansciences.HereceivesresearchsupportfromNovartisandtheFrenchGovernment(PHRC2010).P.Knightreportsnodisclosuresrelevanttothemanuscript.S.PlotkinreceivesresearchsupportfromChildren’sTumorFoundation,NIH,andtheDepartmentofDefenseNeu-rofibromatosisClinicalTrialsConsortium.GotoNeurology.orgforfulldisclosures.ReceivedNovember17,2015.AcceptedinfinalformMarch30,2016.REFERENCES1.PlotkinSR,Stemmer-RachamimovAO,BarkerFG,etal.Hearingimprovementafterbevacizumabinpatientswithneurofibromatosistype2.NEnglJMed2009;361:358–367.2.PlotkinSR,BlakeleyJO,DombiE,etal.Achievingcon-sensusforclinicaltrials:theREiNSInternationalCollab-oration.Neurology2013;81:S1–S5.3.DombiE,Ardern-HolmesSL,Babovic-VuksanovicD,etal.Recommendationsforimagingtumorresponseinneurofibromatosisclinicaltrials.Neurology2013;81:S33–S40.4.KhleifSN,DoroshowJH,HaitWN;AACR-FDA-NCICancerBiomarkersCollaborative.AACR-FDA-NCICancerBiomarkersCollaborativeconsensusreport:advancingtheuseofbiomarkersincancerdrugdevelopment.ClinCancerRes2010;16:3299–3318.5.FernerRE.Neurofibromatosis1andneurofibromatosis2:atwentyfirstcenturyperspective.LancetNeurol2007;6:340–351.6.LloydSK,EvansDG.Neurofibromatosistype2(NF2):diagnosisandmanagement.HandbClinNeurol2013;115:957–967.7.FernerRE,HusonSM,ThomasN,etal.Guidelinesforthediagnosisandmanagementofindividualswithneuro-fibromatosis1.JMedGenet2007;44:81–88.8.ListernickR,FernerRE,LiuGT,GutmannDH.Opticpathwaygliomasinneurofibromatosis-1:controversiesandrecommendations.AnnNeurol2007;61:189–198.9.KolanczykM,MautnerV,KosslerN,etal.MIAisapoten-tialbiomarkerfortumourloadinneurofibromatosistype1.BMCMed2011;9:82.10.YoshidaY,FurumuraM,TahiraM,HorieT,YamamotoO.Serumbiomarkerinneurofibromatosistype1.JDermatolSci2012;67:155–158.11.HummelTR,JessenWJ,MillerSJ,etal.Geneexpressionanalysisidentifiespotentialbiomarkersofneurofibromatosistype1includingadrenomedullin.ClinCancerRes2010;16:5048–5057.12.JensenCH,SchroderHD,TeisnerB,LaursenI,BrandrupF,RasmussenHB.Fetalantigen1,amemberoftheepidermalgrowthfactorsuperfamily,inneurofibro-masandserumfrompatientswithneurofibromatosistype1.BrJDermatol1999;140:1054–1059.13.JohanssonG,PengPC,HuangPY,etal.SolubleAXL:apossiblecirculatingbiomarkerforneurofibromatosistype1relatedtumorburden.PLoSOne2014;9:e115916.14.ParkSJ,SawitzkiB,KluweL,MautnerVF,HoltkampN,KurtzA.Serumbiomarkersforneurofibromatosistype1andearlydetectionofmalignantperipheralnerve-sheathtumors.BMCMed2013;11:109.15.DanielsenSA,LindGE,KolbergM,etal.MethylatedRASSF1Ainmalignantperipheralnervesheathtumorsidentifiesneurofibromatosistype1patientswithinferiorprognosis.NeuroOncol2015;17:63–69.16.GongM,MaJ,LiM,ZhouM,HockJM,YuX.MicroRNA-204criticallyregulatescarcinogenesisinmalignantperipheralnervesheathtumors.NeuroOn-col2012;14:1007–1017.17.YuJ,DeshmukhH,PaytonJE,etal.Array-basedcomparativegenomichybridizationidentifiesCDK4andFOXM1alterationsasindependentpredictorsofsurvivalinmalignantperipheralnervesheathtumor.ClinCancerRes2011;17:1924–1934.Neurology87(Suppl1)August16,2016S47ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.18.MohanP,CastellsagueJ,JiangJ,etal.Genomicimbal-anceofHMMR/RHAMMregulatesthesensitivityandresponseofmalignantperipheralnervesheathtumourcellstoaurorakinaseinhibition.Oncotarget2013;4:80–93.19.FaridM,DemiccoEG,GarciaR,etal.Malignantperipheralnervesheathtumors.Oncologist2014;19:193–201.20.KolbergM,HolandM,LindGE,etal.ProteinexpressionofBIRC5,TK1,andTOP2Ainmalignantperipheralnervesheathtumours:aprognostictestaftersurgicalresec-tion.MolOncol2015;9:1129–1139.21.BlakeleyJO,YeX,DudaDG,etal.Efficacyandbiomarkerstudyofbevacizumabforhearinglossresultingfromneu-rofibromatosistype2-associatedvestibularschwannomas.JClinOncol2016;34:1669–1675.22.KrosJM,MustafaDM,DekkerLJ,SillevisSmittPA,LuiderTM,ZhengPP.Circulatinggliomabiomarkers.NeuroOncol2015;17:343–360.S48Neurology87(Suppl1)August16,2016ª2016AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.DOI 10.1212/WNL.00000000000029322016;87;S40-S48 Neurology(cid:160)C. Oliver Hanemann, Jaishri O. Blakeley, Fabio P. Nunes, et al. neurofibromatosisCurrent status and recommendations for biomarkers and biobanking inThis information is current as of August 15, 2016ServicesUpdated Information & http://www.neurology.org/content/87/7_Supplement_1/S40.full.htmlincluding high resolution figures, can be found at:Supplementary Material 002932.DC2http://www.neurology.org/content/suppl/2016/08/15/WNL.0000000000 002932.DC1http://www.neurology.org/content/suppl/2016/08/15/WNL.0000000000Supplementary material can be found at: References ref-list-1http://www.neurology.org/content/87/7_Supplement_1/S40.full.html##This article cites 22 articles, 9 of which you can access for free at: Subspecialty Collections http://www.neurology.org//cgi/collection/neurofibromatosisNeurofibromatosisfollowing collection(s): This article, along with others on similar topics, appears in the(cid:160) Permissions & Licensing http://www.neurology.org/misc/about.xhtml#permissionsits entirety can be found online at:Information about reproducing this article in parts (figures,tables) or in(cid:160) Reprints http://www.neurology.org/misc/addir.xhtml#reprintsusInformation about ordering reprints can be found online:rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.1951, it is now a weekly with 48 issues per year. Copyright © 2016 American Academy of Neurology. All ® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology(cid:160)The ErbB inhibitors, trastuzumab and erlotinib, inhibit growth ofvestibular schwannoma xenografts in nude mice:a preliminary studyJ. Jason Clark, MS, Matthew Provenzano, MD, Henry R. Diggelmann, BS, Ningyong Xu, BS,Skylar S. Hansen, and Marlan R. Hansen, MDDepartment of Otolaryngology - Head and Neck Surgery, University of Iowa, Iowa City, Iowa52242-1078, United States of AmericaAbstractObjective—To determine the ability of ErbB inhibitors to reduce the growth of vestibularschwannoma (VS) xenografts.Methods—VS xenografts were established in the interscapular fat pad in nude mice for 4 weeks.Initially, a small cohort of animals was treated with the ErbB2 inhibitor, trastuzumab, or saline for2 weeks. Animals also received BrdU injections to label proliferating cells. In a longer-termexperiment, animals were randomized to receive trastuzumab, erlotinib (an ErbB kinase inhibitor),or placebo for 12 weeks. Tumor growth was monitored by magnetic resonance imaging (MRI) overthe treatment period. Cell death was analyzed by terminal dUTP nick end labeling (TUNEL).Results—Tumors could be distinguished with T2 weighted MRI sequences. Trastuzumabsignificantly reduced the proliferation of VS cells compared to control (p<0.01) as determined byBrdU uptake. Control tumors demonstrated slight growth over the 12 week treatment period. Bothtrastuzumab and erlotinib significantly reduced the growth of VS xenografts (p<0.05). Erlotinib, butnot trastuzumab, resulted in a significant increase in the percent of TUNEL-positive VS cells(p<0.01).Conclusions—In this preliminary study, the ErbB inhibitors trastuzumab and erlotinib decreasedgrowth of VS xenografts in nude mice raising the possibility of using ErbB inhibitors in themanagement of patients with schwannomas, particularly those with neurofibromatosis type 2.Keywordsacoustic neuroma; apoptosis; cell proliferation; magnetic resonance imagingINTRODUCTIONVestibular schwannomas (VS) result from mutations in the tumor suppressor gene, merlin orschwannomin, and occur in two forms; sporadic, isolated tumors and bilateral tumors occurringin patients with the genetic disease neurofibromatosis type 2 (NF2) (1-4). Current managementof VSs is limited to observation with serial imaging, stereotactic radiosurgery or radiotherapy(SRS/SRT), and microsurgical removal (5-8). While these therapies are generally well toleratedthey occasionally result in deafness, facial paralysis, spinal fluid leak, continued tumor growth,or even malignant transformation (9-14). VSs arising in patients with NF2 are particularlyCorrespondence: Marlan R. Hansen, MD, 200 Hawkins Dr, 21163 PFP, The University of Iowa, Iowa City, IA 52242-1078, Tel:319-353-7151, Fax: 319-356-4547, E-mail: marlan-hansen@uiowa.edu.NIH Public AccessAuthor ManuscriptOtol Neurotol. Author manuscript; available in PMC 2009 September 1.Published in final edited form as:Otol Neurotol. 2008 September ; 29(6): 846–853. doi:10.1097/MAO.0b013e31817f7398.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscriptdifficult to manage (15). Most patients develop deafness and other cranial and spinalneuropathies and many ultimately succumb to their disease (16). Discovery of alternativetherapies that limit the growth of schwannomas may be of particular benefit to patients withNF2 (4,15,17).Understanding the role of the merlin protein in Schwann cell (SC) homeostasis should helpguide the development of alternative therapies for patients with schwannomas (3,4). Merlinmediates contact inhibition of cell growth and in many cells suppresses the activity ofintracellular signaling cascades implicated in tumor formation including Ras-mitogen activatedprotein kinase/extracellular regulated kinase (ERK) kinase (MEK)-ERK,phosphatidylinositol-3-kinase (PI3K)/Akt, and c-Jun N-terminal kinase (JNK) (18-24).In addition to these intracellular kinases, merlin regulates the subcellular localization andactivity of receptor tyrosine kinases (25) including the epidermal growth factor receptor(EGFR), or ErbB, family of tyrosine kinases (26). Like their SC counterparts, VS cellsuniformly express ErbB2 and ErbB3, with a subset also expressing EGFR, or ErbB1, and ErbB4(27-29). A recent study found increased mRNA expression for ErbB1 and ErbB2 in most VSsand that ErbB1 expression levels correlates with tumor size (30). In normal SCs, merlin isimplicated in the cytoplasmic sequestration of ErbB2 in response to cell-cell contact (26).However, in VS cells ErbB2 constitutively resides in portions of the cell membrane known aslipid rafts and is active (28,29). This lipid raft localization of ErbB2 in VS cells mirrors themovement of ErbB2 into lipid rafts in proliferating, denervated SCs following axotomy (31).Thus, ErbB receptors represent a potential target for therapies to limit VS growth (27-30,32).Given their involvement in a number of different tumors, several ErbB inhibitors have beendeveloped and are used clinically (33).Here we tested the efficacy of two ErbB inhibitors on VS growth in a xenograft model of humanVSs using nude mice. We report that trastuzumab, a humanized anti-ErbB2 monoclonalantibody, and erlotinib, an inhibitor of ErbB1 and ErbB2 kinase activity (34), both reduce thegrowth of VS xenografts as measured by magnetic resonance imaging (MRI) over a 3-monthinterval. Erlotinib, but not trastuzumab, resulted in increased VS cell death in these xenografts.Thus, ErbB inhibitors serve as potential novel therapies for the treatment of schwannomas.MATERIALS AND METHODSVestibular Schwannoma XenograftsXenografts were developed in male athymic Ncr Nu/Nu mice (National Cancer Institute, NIH,Bethesda, MD) from VS specimens derived from four separate patients. All patients providedwritten, informed consent for use of tumor harvested at time of surgery. The institutional reviewboard at the University of Iowa approved the study protocol and the University of IowaInstitutional Animal Care and Use Committee approved all animal protocols. Mice werehoused in a barrier room and watered and fed rodent chow freely.Acutely resected VS specimens were transported to the laboratory in ice cold Hank’s BalancedSalt Solution (Invitrogen, Calsbad, CA), cut into approximately 10 mm3 fragments, and placedinto the interscapular fat pad in nude mice anesthetized with ketamine (100 mg/kg, Hospira,Lake Forest, IL) and xylazine (10 mg/kg Phoenix Scientific, St. Joseph, MO). The grafts wereallowed to develop for 4 weeks prior to initiating any treatment.Measurement of tumor volumeTumor volume was determined by magnetic resonance imaging (MRI). Mice were removedfrom the barrier facility and imaged in a small animal MRI (Varian Unity/INOVA 4.7 Teslascanner, Varian Inc., Palo Alto, CA). T2- weighted images were acquired in the axial andClark et al.Page 2Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscriptsagittal planes by placing an anesthetized mouse inside a 37.5 mm diameter transmit/receivevolume coil. Slice thickness was 0.5 mm in each plane. To calculate the tumor volume, thesurface area of the tumor on each sequential image was determined using the measurementtool on Image J software (NIH, Bethesda, MD) by drawing a region of interest encompassingthe tumor. The reviewer was blinded to the experimental group. The measurements wererepeated three times in both the axial and sagittal planes and the average tumor surface areawas multiplied by the slice thickness (0.5 mm) to calculate the slice volume. Slice volumeswere halved for the initial and final slices of each imaging series. Slice volumes were thensummed for total tumor volume. We also calculated total tumor volumes using the entirevolume of the initial and final slices for each series. This did not affect the overall results ofthe experiments. To calculate the relative tumor growth, the initial tumor volume (Vi) wassubstracted from the final tumor volume (Vf) and the difference was divided by Vi ([Vf-Vi]/Vi) to account for differences in initial xenograft volumes. There was no significant differencein the relative tumor growth rates of the trastuzumab control and erlotinib control animals andthe data from these animals were pooled.Treatment with ErbB inhibitorsA total of 19 mice bearing human VS xenografts derived from 4 separate patients were analyzedin this study. Table 1 presents the distribution of VS specimens used for these studies. In apreliminary experiment, 4 mice were implanted with VSs derived from two patients and wererandomly divided into two groups four weeks after tumor implantation. Two mice receivedtrastuzumab (25 mg/kg in 0.25 ml normal saline i.p., Genentech, South San Francisco, CA)three times per week for two weeks while two animals received saline injections. During thefinal week of treatment, all mice were injected with BrdU (50 mg/kg i.p., Sigma-Aldrich, St.Louis, MO) daily to label dividing cells. After the two-week treatment interval, the xenograftswere harvested and fixed in 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO).For the longer-term experiment, the xenografts were derived from 2 additional VSs and initialimages with MRI were obtained four weeks after tumor implantation. Following the initialMRI, the mice were returned to a quarantine room where they were randomly divided intothree groups of 5 animals each (15 total). One group received trastuzumab (25 mg/kg i.p.) threetimes per week. This is similar to trastuzumab doses shown to inhibit growth of xenograftsderived from human carcinomas that overexpress ErbB2 (35,36). The second group was gavagefed erlotinib (50 mg/kg, Genentech, South San Francisco, CA), five days a week. This is similarto erlotinib doses shown to reduce growth of xenografts derived from non-small cell lung cancerand malignant nerve sheath tumors (37,38). Erlotinib was suspended in a solution of 0.5%methyl cellulose (MP Biomedicals, Solon, OH) and 0.4% Tween-80 (Fischer Scientific,Pittsburgh, PA). The final group of mice served as controls. In this group, three animals weregavage fed erlotinib vehicle and two animals received saline injections for trastuzumab control.Treatment continued for 12 weeks. Following completion of the treatment, the mice were onceagain imaged to determine final tumor volume and the xenografts were harvested and fixed in4% paraformaldehyde.Immunofluorescence and TUNEL stainingFollowing fixation, the xenografts were washed in phosphate buffered saline (PBS) andcryoprotected in 30% sucrose. The samples were then embedded in optimum cuttingtemperature (OCT) compound (Thermo Fischer Scientific, Waltham, MA) and cryosectionedat 10-15 μm. Frozen sections from the preliminary group of animals were treated with 2N HClfor 30 min, permeabilized with 0.8% Triton-X100 in PBS for 20 min, and then blocked withblocking buffer (5% goat serum, 2% bovine serum albumin, and 0.8% Triton-X100) for 30min. Next, the samples were incubated in mouse monoclonal anti-BrdU (1:800, Sigma-Aldrich,St. Louis, MO) and rabbit anti-S100 (1:800, Sigma-Aldrich, St. Louis, MO) diluted in blockingClark et al.Page 3Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscriptbuffer for 2h at 37°C. Following several washes in PBS, secondary antibodies (anti-mouseAlexa Fluor 568 and anti-rabbit Alexa Fluor 488, 1:800 each, Invitrogen, Carlsbad, CA) dilutedin PBS were applied for 1 h at room temperature. Nuclei were then labeled with Hoechst 3342(10 μg/ml, Invitrogen, Carlsbad, CA) for 10 min and the slides were mounted and coverslipped.Frozen sections from the longer-term groups of animals were labeled with anti-S100 antibodyas above. Following immunostaining, terminal dUTP nick end labeling (TUNEL) wasperformed as previously described (39) and the nuclei were labeled with Hoechst 3342. Digitalimages were captured on a Leica DMIRE2 epifluorescence microscope (Bannockburn, IL)equipped with a CCD camera and Leica FW4000 software.Determination of cell proliferation and cell deathCell proliferation was determined by assaying BrdU uptake in xenograft frozen sections aspreviously described (31). The number of BrdU-positive S100-positive cells was determinedfrom digital images from five randomly selected 30x microscopic fields (331±108 VS cellnuclei/30x field, mean±SD) for each of 3 frozen sections/xenograft (fifteen 30x microscopicfields/xenograft). The average percent of BrdU-positive VS cells was determined for eachxenograft. The investigator was blinded to treatment conditions.Cell death was determined using TUNEL to identify apoptotic VS cells as previously described(39). The number of TUNEL-positive S100-positive nuclei was determined from five randomlyselected 30x microscopic fields for each of 3 frozen sections/xenograft and the average percentof TUNEL-positive cells was determined for each xenograft. The investigator was blinded totreatment conditions.Statistical AnalysisDifferences in cell proliferation and cell death were analyzed by Student’s two-tailed t-testusing Excel software (Microsoft, Redmond, WA). Differences in relative tumor growth wereanalyzed by one-way analysis of variance (ANOVA) followed by a post-hoc Kruskal-Wallistest using SigmaStat (Systat Incorporated, Richmond, CA).ReagentsTrastuzumab was a generous gift from Genentech (South San Francisco, CA). Erlotinib,ketamine, and xylazine were obtained from the University of Iowa Hospitals and Clinicspharmacy. All other reagents were from Sigma-Aldrich (St. Louis, MO) unless otherwisespecified.RESULTSTumor imaging and cell proliferationTo test the ability of ErbB inhibitors to limit VS growth, we used a xenograft model bytransplanting fragments of freshly excised VSs into the interscapular subcutaneous fat of nudemice. Initially, we performed a proof of principle experiment to verify that cells in thexenografts remained viable and were capable of dividing. We also tested the efficacy oftrastuzumab to reduce VS cell proliferation in these xenografts since it has already been shownto reduce VS cell proliferation in vitro (29). Xenografts were allowed to establish for 4 weeksin 4 nude mice. Figure 1 shows representative MRI imaging of xenografts 4 weeks aftertransplantation. Figure 1 also shows a frozen section immunolabeled with the Schwann cellmarker anti-S100 antibody and Hoechst (nuclear stain). This section was taken from the edgeof the graft to illustrate the specificity of S100 immunolabeling for viable tumor cells comparedwith the cells comprising the tumor capsule that fail to label with anti-S100 antibody.Clark et al.Page 4Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptAfter 4 weeks, the animals were randomly assigned to receive trastuzumab (25 mg/kg threetimes/week for 2 weeks) (2 animals) or saline injections (2 control animals). All animals werealso injected with BrdU daily for the final 7 days prior to sacrifice to allow identification ofdividing cells. Cell proliferation was determined by counting the number of BrdU-positive,S100-positive VS cell nuclei from frozen sections (Fig. 2). The results represent the averagepercent of BrdU-positive VS cells for each animal. There was a statistically significantreduction in the percent of BrdU-positive VS cells in xenografts from trastuzumab treatedanimals (0.040%±0.029% mean±SD) compared to those from control animals (0.201%±0.026%, mean±SD) (p<0.028, Student’s two-tailed t-test) in the 2 week trial.Tumor response to ErbB inhibitorsHaving demonstrated that the xenografts remained viable 4 weeks after implantation and thatwe could image them with MRI, we performed a second experiment with a separate group of15 animals to determine if ErbB inhibition could reduce the growth of the xenografts. InitialMRIs were taken 4 weeks after implantation (Fig. 1). The animals were then randomized toreceive trastuzumab, erlotinib, or placebo (the carrier compounds for the pharmaceuticalagents) for 12 weeks. Following treatment the animals were re-imaged and the xenograftsharvested to evaluate for cell death. One tumor in the erlotinib treated group did not appear onthe final MRI.Relative tumor growth was determined by comparing the difference in tumor volumes betweenthe initial and final MRI images normalized to the initial tumor volume. Control animalsdemonstrated a slight increase in relative tumor volume (0.23±0.15, mean±SE) whiletrastuzumab (-0.32±0.09, mean±SE) and erlotinib (-0.50±0.16, mean±SE) resulted in reductionin tumor volume (Fig. 3). The difference in tumor growth was statistically significant betweencontrol and trastuzumab (p=0.025, one way ANOVA followed by Kruskal-Wallis) anderlotinib (p=0.017) treated animals, but was not significantly different between either treatmentgroup (p=0.375).In Figure 3, control animals (n=5) receiving saline injections (n=2) or erlotinib vehicle bygavage (n=3) were pooled since there was no known biological effect of either placebo andthere was no statistical difference (p=0.65) in relative tumor growth for animals receiving saline(0.13±0.3, mean±SE) or erlotinib vehicle (0.32±0.28, mean±SE). If we analyze the data withoutpooling the control animals, the mean relative tumor growth in animals receiving erlotinib isstatistically less than animals receiving ertoltinib vehicle (p=0.01, Student’s two-tailed t-test).Similarly, the mean relative tumor growth in animals receiving trastuzumab trended less thananimals receiving saline injections (p=0.09, Student’s two-tailed t-test).Erlotinib induces cell death in VS xenograftsTreatment with ErbB inhibitors caused a reduction in the final tumor volume compared withthe initial volume raising the possibility that the inhibitors may cause death of the VS cells. Toexamine this possibility we stained frozen sections of the xenografts with TUNEL which labelsapoptotic nuclei. There was no significant difference in the percentage of TUNEL positivecells between xenografts from animals receiving trastuzumab injections (0.24% ± 0.04%, mean± SE) compared with saline injected animals (0.29% ± 0.09%, mean ± SE). However, tumorsections harvested from animals treated with erlotinib demonstrated a significant increase inthe percentage of TUNEL positive cells compared to the placebo controls (p<0.01, Student’stwo-tailed t-test). This control group demonstrated 0.36% ± 0.06% (mean ± SE) TUNELpositive VS cells compared with 0.76% ±0.14% (mean ± SE) for the erlotinib treated group.Clark et al.Page 5Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptDISCUSSIONIn this preliminary study involving a small cohort of animals we demonstrate that ErbBinhibitors reduce the growth of VS xenografts. These encouraging results need to be replicatedwith tumors derived from a larger group of patients and in other models of VS disease.Nevertheless, they identify a systemic therapy capable of reducing VS growth in vivo and areparticularly relevant to patients with NF2 who often suffer multiple cranial and spinalneuropathies due to schwannoma growth.In this study we did not screen the tumors for merlin mutations and thus it is not possible todetermine if the effects seen here are mutation specific (40-43). Likewise, the expression ofErbB receptors was not determined in these tumors as the entire xenograft specimen wasconsumed in cell proliferation and death analyses. However, several studies confirm that VSsuniversally express both ErbB2 and ErbB3, similar to their Schwann cell counterparts(27-30,32). Significantly, ErbB2 is activated in VSs and drives cell proliferation.(27-29,32)The extent of ErbB1 and ErbB4 expression in VSs is less clear yet a recent study suggests thatErbB1 expression correlates with tumor size (30).Models of vestibular schwannomas and NF2 diseaseRepresentative models to evaluate therapeutic agents for VSs and NF2 are lacking. Severalinvestigators have developed VS xenograft models (44-47). In general, these tumors grow veryslowly, mimicking their behavior in patients (7,48). Similarly, in our study, control tumorsdemonstrated slight growth over a three-month interval. Thus, sophisticated and sensitiveimaging modalities are required to detect small differences in tumor growth (44). Here we usedT2 weighted MRI sequences which were able to clearly delineate tumor volumes.Transgenic animals represent an alternative model of NF2 disease. Heterozygous mice carryinggermline mutations in merlin (Nf2-/Nf2+) develop osteosarcomas and liver tumors but fail todevelop schwannomas (49,50). Mice carrying biallelic targeted deletion of merlin exon 2 inSCs develop SC hyperplasia and peripheral nerve schwannomas that can be imaged with MRI,representing a potential model to evaluate therapies aimed at reducing schwannoma formationor growth (51-53). However, these mice do not appear to develop VSs. Cell cultures allow forhigher through put screening and complement animal models. Of particular relevance to theresults of these experiments, trastuzumab reduces cell proliferation in primary VS culturesderived from human patients (29).In addition to tumor imaging, we also analyzed the proliferative capacity of VS cells in thesexenografts. Consistent with their slow growth rates, we found that only 0.2% of VS cellsincorporated BrdU in control animals treated with daily doses of BrdU for 7 days. Bycomparison, approximately 0.5% of denervated eighth nerve SCs in rats incorporate BrdU after4 systemic doses (Provenzano, et. al., unpublished data) suggesting that the proliferative rateof VS cells is somewhat comparable to that of denervated SCs. This low proliferative rate isconsistent with the slow tumor growth observed on MRI and with the clinical behavior of mostVSs in humans.Potential therapies for NF2Understanding the cellular and molecular events contributing to schwannoma formation andgrowth will help guide the development of novel therapies. Recent studies have identified manyof the signaling molecules that are regulated by merlin and are implicated in tumor formation.In particular, several intracellular kinases are inhibited by merlin including ERK, Akt, JNK,PAK (18-24) Since dysregulated activity of these kinases contributes to neoplasia, severalinhibitory reagents have been developed and represent potential therapies for VSs (54).Clark et al.Page 6Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptIn addition to intracellular kinases, activation of ErbB2, a receptor tyrosine kinase essential forSC development, proliferation, and survival, appears to contribute to Schwann cell neoplasia,including VSs (27-29,32,55-58). The contribution of ErbB family members to neoplasia ingeneral is well established and many molecules that inhibit ErbB family members are usedclinically in the management of breast, head and neck, lung, central nervous system, and othermalignancies (59). In general, these ErbB inhibitors display fewer side effects than cytotoxicagents and may be more suitable for long-term therapy as would likely be required in NF2patients (33).The purpose of this preliminary study was to validate the xenograft model of VS and the generalability of ErbB inhibitors to reduce tumor growth. It was not designed to evaluate the relativeefficacy of different ErbB inhibitors, which will require a much larger sample of animals todetermine dose response relationships. However, the observation that both ErbB inhibitorsreduced tumor growth provides encouragement that targeting these molecules may ultimatelyprove effective.ConclusionsIn summary, we have shown that trastuzumab and erlotinib reduced the growth of VSxenografts. Although the growth of tumors was very slow, we were able to detect smalldifferences in tumor growth using MRI and complement the imaging studies with assays ofcell proliferation and death. These results raise the possibility of using ErbB inhibitors assystemic therapy to limit schwannoma growth in patients with NF2 or those unsuitable forcurrent therapies.AcknowledgementsWe thank Dan Thedens for assistance with MRI. Trastuzumab was a generous gift from Genentech (South SanFrancisco, CA)Support for this study was provided by NIDCD KO8 DC006211. Genentech (South San Francisco, CA) provided thetrastuzumab used in this study.References1. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515–21. [PubMed: 8379998]2. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidatefor the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791–800. [PubMed: 8453669]3. Neff BA, Welling DB, Arkhmametyeva E, et al. The molecular biology of vestibular schwannomas:dissecting the pathogenic process at the molecular level. Otol Neurotol 2006;27:197–208. [PubMed:16436990]4. Welling DB, Packer MD, Chang LS. Molecular studies of vestibular schwannomas: a review. CurrOpin Otolaryngol Head Neck Surg 2007;15:341–6. [PubMed: 17823551]5. National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma.The Consensus Development Panel. Arch Neurol December 11-13;1994 51:201–7. [PubMed:8304846]19916. Smouha EE, Yoo M, Mohr K, et al. Conservative management of acoustic neuroma: a meta-analysisand proposed treatment algorithm. Laryngoscope 2005;115:450–4. [PubMed: 15744156]7. Battaglia A, Mastrodimos B, Cueva R. Comparison of growth patterns of acoustic neuromas with andwithout radiosurgery. Otol Neurotol 2006;27:705–12. [PubMed: 16868519]8. Wackym PA. Stereotactic radiosurgery, microsurgery, and expectant management of acousticneuroma: basis for informed consent. Otolaryngol Clin North Am 2005;38:653–70. [PubMed:16005724]Clark et al.Page 7Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscript9. Evans DG, Birch JM, Ramsden RT, et al. Malignant transformation and new primary tumours aftertherapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J MedGenet 2006;43:289–94. [PubMed: 16155191]10. Bari ME, Forster DM, Kemeny AA, et al. Malignancy in a vestibular schwannoma. Report of a casewith central neurofibromatosis, treated by both stereotactic radiosurgery and surgical excision, witha review of the literature. Br J Neurosurg 2002;16:284–9. [PubMed: 12201399]11. Wilkinson JS, Reid H, Armstrong GR. Malignant transformation of a recurrent vestibularschwannoma. J Clin Pathol 2004;57:109–10. [PubMed: 14693854]12. Lanman TH, Brackmann DE, Hitselberger WE, et al. Report of 190 consecutive cases of large acoustictumors (vestibular schwannoma) removed via the translabyrinthine approach. J Neurosurg1999;90:617–23. [PubMed: 10193604]13. Meyer TA, Canty PA, Wilkinson EP, et al. Small acoustic neuromas: surgical outcomes versusobservation or radiation. Otol Neurotol 2006;27:380–92. [PubMed: 16639278]14. Slattery WH 3rd, Fisher LM, Iqbal Z, et al. Vestibular schwannoma growth rates in neurofibromatosistype 2 natural history consortium subjects. Otol Neurotol 2004;25:811–7. [PubMed: 15354016]15. Baser ME, DG RE, Gutmann DH. Neurofibromatosis 2. Curr Opin Neurol 2003;16:27–33. [PubMed:12544854]16. Otsuka G, Saito K, Nagatani T, et al. Age at symptom onset and long-term survival in patients withneurofibromatosis Type 2. J Neurosurg 2003;99:480–3. [PubMed: 12959433]17. Hanemann CO, Evans DG. News on the genetics, epidemiology, medical care and translationalresearch of Schwannomas. J Neurol 2006;253:1533–41. [PubMed: 17219030]18. Lim JY, Kim H, Kim YH, et al. Merlin suppresses the SRE-dependent transcription by inhibiting theactivation of Ras-ERK pathway. Biochem Biophys Res Commun 2003;302:238–45. [PubMed:12604337]19. Jung JR, Kim H, Jeun SS, et al. The Phosphorylation status of merlin is important for regulating theRas-ERK pathway. Mol Cells 2005;20:196–200. [PubMed: 16267393]20. Lim JY, Kim H, Jeun SS, et al. Merlin inhibits growth hormone-regulated Raf-ERKs pathways bybinding to Grb2 protein. Biochem Biophys Res Commun 2006;340:1151–7. [PubMed: 16405865]21. Morrison H, Sperka T, Manent J, et al. Merlin/neurofibromatosis type 2 suppresses growth byinhibiting the activation of Ras and Rac. Cancer Res 2007;67:520–7. [PubMed: 17234759]22. Rong R, Tang X, Gutmann DH, et al. Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibitsphosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A2004;101:18200–5. [PubMed: 15598747]23. Chadee DN, Xu D, Hung G, et al. Mixed-lineage kinase 3 regulates B-Raf through maintenance ofthe B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc Natl Acad SciU S A 2006;103:4463–8. [PubMed: 16537381]24. Kaempchen K, Mielke K, Utermark T, et al. Upregulation of the Rac1/JNK signaling pathway inprimary human schwannoma cells. Hum Mol Genet 2003;12:1211–21. [PubMed: 12761036]25. Fraenzer JT, Pan H, Minimo L Jr, et al. Overexpression of the NF2 gene inhibits schwannoma cellproliferation through promoting PDGFR degradation. Int J Oncol 2003;23:1493–500. [PubMed:14612918]26. Fernandez-Valle C, Tang Y, Ricard J, et al. Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet 2002;31:354–62. [PubMed:12118253]27. Hansen MR, Linthicum FH Jr. Expression of neuregulin and activation of erbB receptors in vestibularschwannomas: possible autocrine loop stimulation. Otol Neurotol 2004;25:155–9. [PubMed:15021776]28. Stonecypher MS, Chaudhury AR, Byer SJ, et al. Neuregulin growth factors and their ErbB receptorsform a potential signaling network for schwannoma tumorigenesis. J Neuropathol Exp Neurol2006;65:162–75. [PubMed: 16462207]29. Hansen MR, Roehm PC, Chatterjee P, et al. Constitutive neuregulin-1/ErbB signaling contributes tohuman vestibular schwannoma proliferation. Glia 2006;53:593–600. [PubMed: 16432850]30. Doherty JK, Ongkeko W, Crawley B, et al. ErbB and Nrg: Potential Molecular Targets for VestibularSchwannoma Pharmacotherapy. Otol Neurotol 2008;29:50–7. [PubMed: 18199957]Clark et al.Page 8Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscript31. Brown KD, Hansen MR. Lipid raft localization of erbB2 in vestibular schwannoma and Schwanncells. Otol Neurotol 2008;29:79–85. [PubMed: 18199961]32. Wickremesekera A, Hovens CM, Kaye AH. Expression of ErbB-1 and 2 in vestibular schwannomas.J Clin Neurosci 2007;14:1199–206. [PubMed: 17964790]33. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys2004;59:21–6. [PubMed: 15142631]34. Schaefer G, Shao L, Totpal K, et al. Erlotinib directly inhibits HER2 kinase activation and downstreamsignaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res2007;67:1228–38. [PubMed: 17283159]35. Wang CX, Koay DC, Edwards A, et al. In vitro and in vivo effects of combination of Trastuzumab(Herceptin) and Tamoxifen in breast cancer. Breast Cancer Res Treat 2005;92:251–63. [PubMed:16155796]36. Kimura K, Sawada T, Komatsu M, et al. Antitumor effect of trastuzumab for pancreatic cancer withhigh HER-2 expression and enhancement of effect by combined therapy with gemcitabine. ClinCancer Res 2006;12:4925–32. [PubMed: 16914581]37. Friess T, Scheuer W, Hasmann M. Erlotinib antitumor activity in non-small cell lung cancer modelsis independent of HER1 and HER2 overexpression. Anticancer Res 2006;26:3505–12. [PubMed:17094474]38. Mahller YY, Vaikunth SS, Currier MA, et al. Oncolytic HSV and erlotinib inhibit tumor growth andangiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther2007;15:279–86. [PubMed: 17235305]39. Provenzano MJ, Xu N, Ver Meer MR, et al. p75NTR and Sortilin Increase After Facial Nerve Injury.Laryngoscope 2008;118:87–93. [PubMed: 18090258]40. Stemmer-Rachamimov AO, Xu L, Gonzalez-Agosti C, et al. Universal absence of merlin, but notother ERM family members, in schwannomas. Am J Pathol 1997;151:1649–54. [PubMed: 9403715]41. Zucman-Rossi J, Legoix P, Der Sarkissian H, et al. NF2 gene in neurofibromatosis type 2 patients.Hum Mol Genet 1998;7:2095–101. [PubMed: 9817927]42. Mautner VF, Baser ME, Kluwe L. Phenotypic variability in two families with novel splice-site andframeshift NF2 mutations. Hum Genet 1996;98:203–6. [PubMed: 8698343]43. Bruder CE, Hirvela C, Tapia-Paez I, et al. High resolution deletion analysis of constitutional DNAfrom neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet 2001;10:271–82. [PubMed: 11159946]44. Chang LS, Jacob A, Lorenz M, et al. Growth of benign and malignant schwannoma xenografts insevere combined immunodeficiency mice. Laryngoscope 2006;116:2018–26. [PubMed: 17075413]45. Charabi S, Rygaard J, Klinken L, et al. Subcutaneous growth of human acoustic schwannomas inathymic nude mice. Acta Otolaryngol 1994;114:399–405. [PubMed: 7526595]46. Lee JK, Kim TS, Chiocca EA, et al. Growth of human schwannomas in the subrenal capsule of thenude mouse. Neurosurgery 1990;26:598–605. [PubMed: 2330081]47. Lee JK, Sobel RA, Chiocca EA, et al. Growth of human acoustic neuromas, neurofibromas andschwannomas in the subrenal capsule and sciatic nerve of the nude mouse. J Neurooncol1992;14:101–12. [PubMed: 1432035]48. Roehm PC, Gantz BJ. Management of Acoustic Neuromas in Patients 65 Years or Older. OtolNeurotol. 200749. McClatchey AI, Saotome I, Mercer K, et al. Mice heterozygous for a mutation at the Nf2 tumorsuppressor locus develop a range of highly metastatic tumors. Genes Dev 1998;12:1121–33.[PubMed: 9553042]50. Gutmann DH, Giovannini M. Mouse models of neurofibromatosis 1 and 2. Neoplasia 2002;4:279–90. [PubMed: 12082543]51. Giovannini M, Robanus-Maandag E, van der Valk M, et al. Conditional biallelic Nf2 mutation in themouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 2000;14:1617–30.[PubMed: 10887156]52. Messerli SM, Tang Y, Giovannini M, et al. Detection of spontaneous schwannomas by MRI in atransgenic murine model of neurofibromatosis type 2. Neoplasia 2002;4:501–9. [PubMed: 12407444]Clark et al.Page 9Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscript53. Messerli SM, Prabhakar S, Tang Y, et al. Treatment of schwannomas with an oncolytic recombinantherpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther 2006;17:20–30. [PubMed: 16409122]54. Hirokawa Y, Tikoo A, Huynh J, et al. A clue to the therapy of neurofibromatosis type 2: NF2/merlinis a PAK1 inhibitor. Cancer J 2004;10:20–6. [PubMed: 15000491]55. Adlkofer K, Lai C. Role of neuregulins in glial cell development. Glia 2000;29:104–11. [PubMed:10625327]56. Stonecypher MS, Byer SJ, Grizzle WE, et al. Activation of the neuregulin-1/ErbB signaling pathwaypromotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheathtumors. Oncogene. 200557. Huijbregts RP, Roth KA, Schmidt RE, et al. Hypertrophic neuropathies and malignant peripheralnerve sheath tumors in transgenic mice overexpressing glial growth factor beta3 in myelinatingSchwann cells. J Neurosci 2003;23:7269–80. [PubMed: 12917360]58. Frohnert PW, Stonecypher MS, Carroll SL. Constitutive activation of the neuregulin-1/ErbB receptorsignaling pathway is essential for the proliferation of a neoplastic Schwann cell line. Glia2003;43:104–18. [PubMed: 12838503]59. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-targetHER3. Br J Cancer 2007;97:453–7. [PubMed: 17667926]Clark et al.Page 10Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptFigure 1.Human vestibular schwannoma xenograft in nude mice. A and B. MRI of xenografts in sagittal(A) and axial (B) planes demonstrating survival of xenografts one month after implantation.Arrows indicate xenografts. C. Immunofluorescent labeling of xenograft frozen section withanti-S100 antibody followed by Alexa 568 (red) secondary antibody. Nuclei are labeled withHoechst. This section is taken near the capsule, or edge, of the specimen demonstrating theS100 labeling of viable tumor cells and the lack of S100 labeling in the capsule cells.Clark et al.Page 11Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptFigure 2.Trastuzumab inhibits cell proliferation in vestibular schwannoma (VS) xenografts. A and B.Nude mice bearing VS xenografts were treated with saline (A, control) or trastuzumab (B) for2 weeks. The animals received daily injections of BrdU to allow identification of proliferatingcells. Representative images of xenograft frozen sections immunolabeled with anti-BrdU andanti-S100 antibodies with Alexa 568 (red, BrdU-positive) and Alexa 488 (green, S100-positive) conjugated secondary antibodies respectively are shown. Nuclei were labeled withHoechst (blue). Arrows indicate TUNEL-positive nuclei. Scale bar=50 μm. C. The averagenumber of BrdU-positive, S100-positive nuclei was determined for each condition from 5random selected fields from 3-4 sections/xenograft from 2 separate animals for each group.Clark et al.Page 12Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptTrastuzumab significantly reduced BrdU uptake in these xenografts (p<0.01, Student’s two-tailed t-test). Error bars represent standard error. n=total number of VS cells scored for eachcondition. N=total number of xenografts analyzed for each condition.Clark et al.Page 13Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptFigure 3.Trastuzumab and Erlotinib reduce the growth of VS xenografts. A. The change in relativetumor volume was determined by subtracting the initial tumor volume (Vi) from the final tumorvolume (Vf) and dividing the difference by the initial tumor volume according to the formula:(Vf-Vi)/Vi and is plotted for the 12 week interval for each xenograft. Dashed lines in controlgroup represent animals receiving saline while solid lines represent animals receiving erlotinibvehicle. B. The average relative growth of the xenografts for each condition is plotted..Differences among the means for the treatment groups were determined by one-way ANOVAfollowed by a Kruskal-Wallis test. Error bars represent standard error. Both trastuzumabClark et al.Page 14Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscript(p=0.025) and erlotinib (p=0.017) reduced the growth of the VS xenografts compared withcontrols.Clark et al.Page 15Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptFigure 4.Erlotinib but not trastuzumab induces cell death in vestibular schwannoma (VS) xenografts.A and B. Representative images of xenograft frozen sections from control (A) and erlotinibtreated (B) animals immunolabeled with anti- S100 antibody and Alexa 488 (green, S100-positive) conjugated secondary antibody. Apoptotic cells were determined by TUNEL stainingusing biotin labeled dUTP and detected with Alexa 568 labeled streptavidin (red, TUNEL-positive). Nuclei were labeled with Hoechst (blue). Arrows indicate TUNEL-positive nuclei.Scale bar=50 μm. C and D. The average number of TUNEL-positive, S100-positive nuclei wasdetermined for each condition from 5 random selected fields from 3-4 sections/xenograft from3 separate animals for each group. Erlotinb significantly increased the percent of TUNEL-Clark et al.Page 16Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscriptpositive VS cells in these xenografts (p=0.03, Student’s two-tailed t-test) (C) compared withcontrol animals while trastuzumab did not (p=0.61) (D). Error bars in C and D representstandard error. n=total number of VS cells scored for each condition. N=total number ofxenografts analyzed for each condition.Clark et al.Page 17Otol Neurotol. Author manuscript; available in PMC 2009 September 1.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptMerlin Is a Potent Inhibitor of Glioma GrowthYing-Ka Ingar Lau1, Lucas B. Murray1, Sean S. Houshmandi2, Yin Xu1, David H.Gutmann2, and Qin Yu11Department of Oncological Sciences, Mount Sinai School of Medicine, New York, New York2Department of Neurology, Washington University School of Medicine, St. Louis, MissouriAbstractNeurofibromatosis 2 (NF2) is an inherited cancer syndrome in which affected individuals developnervous system tumors, including schwannomas, meningiomas, and ependymomas. The NF2 proteinmerlin (or schwannomin) is a member of the Band 4.1 superfamily of proteins, which serve as linkersbetween transmembrane proteins and the actin cytoskeleton. In addition to mutational inactivationof the NF2 gene in NF2-associated tumors, mutations and loss of merlin expression have also beenreported in other types of cancers. In the present study, we show that merlin expression is dramaticallyreduced in human malignant gliomas and that reexpression of functional merlin dramatically inhibitsboth subcutaneous and intracranial growth of human glioma cells in mice. We further show thatmerlin reexpression inhibits glioma cell proliferation and promotes apoptosis in vivo. Usingmicroarray analysis, we identify altered expression of specific molecules that play key roles in cellproliferation, survival, and motility. These merlin-induced changes of gene expression wereconfirmed by real-time quantitative PCR, Western blotting, and functional assays. These resultsindicate that reexpression of merlin correlates with activation of mammalian sterile 20-like 1/2–largetumor suppressor 2 signaling pathway and inhibition of canonical and noncanonical Wnt signals.Collectively, our results show that merlin is a potent inhibitor of high-grade human glioma.IntroductionThe most common brain tumor in adults is high-grade glial neoplasm, termed malignant glioma(1). Despite advances in neurosurgery, radiotherapy, and chemotherapy, the prognosis ofmalignant glioma remains dismal, with an estimated median survival of <1 year (2). With theemergence of biologically target-based therapies, it is important to identify new therapeutictargets and to develop novel targeted treatments to battle this deadly disease. Insights into thepathogenesis of gliomas are likely to arise from the study of inherited cancer syndromes, inwhich affected individuals are prone to the development of glial malignancies. One of thesedisorders is neurofibromatosis type 2 (NF2). Patients with NF2 develop schwannomas,meningiomas, and ependymomas, an uncommon type of glioma (3).The NF2 gene shares sequence similarity with the members of Band 4.1 superfamily (4,5). Inparticular, the NF2 protein, merlin (or schwannomin), most closely resembles proteins of theezrin-radixin-moesin (ERM) subfamily. Similar to the ERM proteins, merlin serves as a linker©2008 American Association for Cancer Research.Requests for reprints: Qin Yu, 16-20A-Icahn, 1425 Madison Ave, Department of Oncological Sciences, Mount Sinai School ofMedicine, New York, NY 10029. Phone: 212-659-8218; Fax: 212-987-2240; qin.yu@mssm.edu.Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).Disclosure of Potential Conflicts of InterestThe authors have no conflicts of financial interest to declare.NIH Public AccessAuthor ManuscriptCancer Res. Author manuscript; available in PMC 2009 November 17.Published in final edited form as:Cancer Res. 2008 July 15; 68(14): 5733–5742. doi:10.1158/0008-5472.CAN-08-0190.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscriptbetween transmembrane proteins and the actin cytoskeleton and regulates cytoskeletonremodeling and cell motility (6–8). Unlike ERM proteins, merlin functions as a negative growthregulator or tumor suppressor. In this regard, mutational inactivation of the NF2 gene issufficient to result in the development of NF2-associated nervous system tumors. Moreover,NF2 mutations have also been reported in other tumor types, including melanoma andmesothelioma (9), suggesting that merlin plays an important role, not only in NF2-associatedtumors but also in sporadic cancers.Merlin has a conserved trilobe NH2 terminal FERM (the band four-point-one/ezrin/radixin/moesin) domain, a central α-helical region, and an extended COOH terminal tail (4,5). Merlinis capable of forming head-to-tail intramolecular and intermolecular association, and the head-to-tail closed conformation is required for the tumor suppressor activity (10,11).Phosphorylation of Ser518 at the COOH terminus results in an open conformation, whichinactivates the tumor suppressor activity of merlin.Whereas numerous studies have examined the role of merlin in schwannomas andmeningiomas, comparatively little is known about the function of merlin in glial cell tumors.In the present study, we show, for the first time, that merlin expression is dramatically reducedin high-grade human malignant gliomas. Furthermore, reexpression of merlin inhibits thegrowth of human glioma cells in vitro and in vivo, whereas NF2 knockdown promotes gliomagrowth in vivo. Lastly, using microarray analyses and subsequent validation and functionalassays, we show that merlin positively regulates the large tumor suppressor 2 (Lats2) signalingpathway and down-regulates canonical and noncanonical Wnt signaling. The demonstrationthat merlin is a critical negative regulator of glioma growth coupled with the identification ofnovel downstream effectors will provide new targets for the development of future brain tumortreatments.Materials and MethodsPatient samplesThe glioma tissue microarray was assembled at the M. D. Anderson Cancer Center, andadditional tumor samples were obtained from the Washington University/Siteman CancerCenter Tumor Tissue Repository, as previously described (12). Human tissues were used inaccordance with approved Human Studies Protocols.Cell lines and reagentsHuman glioma cells, M089J, U138MG, DBRG05MG, LN229, M059K, Hs683, LN18, LN229,and A172 cells were obtained from American Type Culture Collection (ATCC); SNB19,U373MG, SF763, U251, SF268, SF539, U343MG, SF188, SF295, SF797, SNB75, SF126,SF210, U118MG, and U87MG and rat glioma cell 9L were obtained from University ofCalifornia-San Francisco and National Cancer Institute (NCI). Normal human astrocytes (NHAcells) were obtained from ALLCELLS, Inc. Cells were maintained following the providers’and manufacturers’ instructions. Anti-v5 epitope (Invitrogen), anti-merlin (Santa Cruz), anti–mammalian sterile 20-like 1/2 (MST1/2; Bethyl Laboratories), anti-Lats2 (BethylLaboratories), anti–Yes-associated protein (YAP; Abnova), anti–cellular inhibitor of apoptosis1/2 (cIAP1/2; Santa Cruz), anti-actin (Sigma), anti–phosphorylated MST1/2 (Cell Signaling),anti–phosphorylated Lats2 (Abnova), and anti–phosphorylated YAP (Cell Signaling) wereused in the experiments. 5-Bromo-2’-deoxy-uridine (BrdUrd) cell proliferation kit (Roche),Apoptag kit (Chemicon), and RhoA pull-down kit (Cytoskeleton, Inc.) were also used.Lau et al.Page 2Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptReverse transcriptase-PCR, mutagenesis, and expression and knockdown constructionsFull-length merlin isoform I was obtained as described (13), and the merlin mutants weregenerated using the QuikChange mutagenesis kits (Stratagene). Wild-type merlin and themerlin mutants together with their COOH terminal v5-epitope tags were cloned into theretroviral expression vector pQCXIP (BD Bioscience; ref. 13). Retroviruses were generatedusing these expression constructs and pVSVG/ GP2 293 cells following the manufacturer’sinstructions (BD Bioscience). All expression constructs were verified by DNA sequencing.To knockdown merlin expression, several shRNAmir constructs against human merlin and anontargeting shRNAmir control construct were obtained from Open Biosystems. Lentivirusescarrying these short hairpin RNAs (shRNA) were generated following the manufacturer’sinstructions.Lentivirus and retrovirus transductionU87MG and U251 human glioma cells were first transduced with retroviruses carryingluciferase and a hygromycin-resistant gene and then transduced with retroviruses carrying theempty retroviral expression vector, wild-type merlin, or merlin mutants. RNA knockdown wasaccomplished using lentiviruses carrying shRNAs against merlin and a nontargeting controlshRNA following the manufacturer’s instructions. Infected cells were selected for theirresistance to hygromycin and puromycin. Anti-v5 monoclonal antibody (mAb; Invitrogen) wasused to detect exogenous merlin, whereas anti-merlin antibodies (Santa Cruz) were used forendogenous merlin.Expression profiling and real-time quantitative PCRTo compare gene expression profiles, we used human U133v2 gene chips (Affymetrix) andthe probes derived from three independently transduced and pooled puromycin-resistantU87MG cells that reexpress merlin (U87MGmerlin) or were transduced with empty retroviruses(U87MGwt) following standard protocols at the University of Pennsylvania MicroarrayFacility. Probe intensity data were imported to ArrayAssist Lite version 3.4 (Stratagene), andexpression values for the probe sets were calculated using GCRMA. Affymetrix Absent,Marginal, and Present (A, M, P) scoring designations were also included. The data were thenimported back to GeneSpringGX version 7.3.1 (Agilent) and filtered based on P in at least twoof six samples. Finally, SAM version 2.2.1 (Stanford University) was applied using a two-classunpaired analysis, and differentially expressed genes were identified using a fold change cutoffof > 1.5 and a false discovery rate of <5%.For patient sample analysis, cDNAs were prepared from 1µg total RNA. Real-time quantitativePCR (qPCR) was performed and analyzed as previously described (12). In addition, total RNAsfrom U87MGmerlin and U87MGwt cells were isolated using RNeasy columns (Qiagen). cDNAswere generated using SuperScript First-Strand Synthesis System for reverse transcription–PCR(Invitrogen). Primers for real-time qPCR were designed according to the Primer Bank Program(Massachusetts General Hospital3). qPCR was performed by using SYBR Green PCR MasterMix (Roche) and the Chromo4 real-time PCR Machine (Bio-Rad). The cycling variables usedwere 95°C for 8 min followed by 40 cycles of 95°C (15 s), 60°C (30s), and 72°C (30 s) and amelting curve analysis. Relative quantification of the targets were normalized with anendogenous housekeeping gene (TATA-box binding protein), and data analyses wereperformed using a comparative (ΔΔCt) method using manufacturer’s software and accordingto manufacturer’s instructions.3http://pga.mgh.harvard.edu/primerbank/index.htmlLau et al.Page 3Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptWestern blot analysis and immunocytochemistryCells and tumor samples were extracted with 4 × SDS Laemmli sample buffer without the dye,and protein concentrations were determined using Bio-Rad Dc Protein Assay Reagents. Forthe immunocytochemical analyses, glioma cells were cultured in 35-mm dishes for 24 h andfixed in 3.7% paraformaldehyde. Fixed cells were then washed with PBS and blocked with 2%bovine serum albumin. Antibodies against v5-epitope or merlin were used to detect theappropriate antigens.Soft agar colony formation assaysTo perform anchorage-independent growth assays, six-well plates were first covered with alayer of 0.6% agar made in 10% fetal bovine serum (FBS) DMEM and the pooled populationof transduced U87MG cells (1 × 105 per well) in 0.3% agar (in DMEM) were seeded on topof the 0.6% agar layer and incubated in a humidified chamber for 3 wk. The six-well plateswere inspected, and 30 randomly selected fields were photographed under a 2.5× microscopiclens and a 10× optical lens (25× magnification). Colonies were then counted, and the meannumber of colonies per field was calculated. All experiments were done in triplicate.Transwell tumor cell invasion assayTumor cell invasion assays were performed using Transwell chambers with 8-µm pores(Costar) that were coated with a layer of Matrigel (Collaborative Biomedical). DMEMcontaining 10% FBS was added to the lower chambers of the Transwells. Transduced U87MGcells (2 × 105 per well) were seeded on the top of the Transwell in triplicate and incubated for24 h. The bottom filters were fixed and stained at the end of the experiments. Cells in the topchambers were removed by wiping with cotton swabs, and the stained cells that had migratedthrough the Matrigel were counted under a microscope. Thirty randomly selected 100×microscopic fields were counted.Apoptosis induced by chemotherapeutic drug and irradiationTransduced U87MG cells were cultured with different concentrations of 5-fluorouracil (5-FU)(0, 5, or 50 µmol/L; Sigma) and incubated at 37°C for 24 h. After the incubation period, thefloating and adherent cells were harvested for apoptosis detection (n = 6).4 × 106 transduced U87MG cells were irradiated by γ-radiation at a dose rate of 2.78 Gy/minand divided into sets that received 0, 5, 10, or 20 Gy of total irradiation. Irradiated cells werereplated into culture dishes and incubated at 37°C for 2 d before harvest (n = 6).Detection of apoptosisCollected cells were lysed, diluted to 104 cells/mL in lysis buffer, and assayed for apoptosisusing the Cell Death Detection ELISA kit (Roche), according to the manufacturer’sinstructions.Luciferase reporter assayTo measure canonical Wnt signaling in U87MGwt and U87MGmerlinS518D, U87MGmerlin, andU87MGmerlinS518A cells, we used the β-catenin–responsive luciferase reporter construct(TopFlash, Addgene), which contains T-cell factor/lymphocyte enhancer factor (TCF/LEF)binding sites and a negative control construct, FopFlash, which contains mutated TCF/LEFbinding sites. These reporters were transfected transiently into these transduced glioma cellsin triplicate. The luciferase activity in these transfected cells were measured 24 hposttransfection following the manufacturer’s instructions (Promega) using a ModulusMicroplate Luminometer/Fluorometer (Turner Biosystems).Lau et al.Page 4Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptSubcutaneous and intracranial tumor growth experimentsPooled populations of transduced U87MG and U251 glioma cells were used for subcutaneoustumor growth experiments. Briefly, 1 × 106 glioma cells were injected into eachimmunocompromised B6.129S7-Rag1tmMom (Rag1, Jackson Laboratories) mouse. Six micewere used for each type of the infected glioma cell lines. After solid tumors became visible(10–15 d after the injection), the longest and shortest diameters of the solid tumors weremeasured using a digital caliper every third day for 5 to 7 wk. Tumor volumes were calculatedusing the following formula: tumor volume = 1 / 2 × (shortest diameter)2 × longest diameter(mm3). At the end of the experiments, tumors were fixed and sectioned for the histologic andimmunologic analyses.Transduced U87MG and U251 cells were also used for the intracranial tumor growthexperiments. U87MG (2 × 105cells in 10 µL HBSS/Rag1 mouse)/U251 cells (1 × 105cells in10 µL HBSS/Rag1 mouse) were stereotactically injected at the bregma 2 mm to the right ofthe sagittal suture and 3 mm below the surface of the skull. After injection, mice were closelymonitored and the duration of their survival was recorded. Mice that showed signs of morbiditywere euthanized and considered as if they had died on that day, and the number of survivingmice was recorded. The survival rates were calculated as follows: survival rate (%) = (numberof mice still alive / total number of experimental mice) × 100%. At the end of the experiments,the mouse brains were removed, fixed, and sectioned for histologic analysis. Mice that werefree of symptoms 60 d after intracranial injection were euthanized and examined.Bioluminescence imaging analysis of the intracranial gliomasTo monitor the growth of intracranial gliomas in living animal, we used bioluminescenceimaging approach. We infected U87MG and U251 cells with a retroviral-based luciferaseexpression vector that also contains an internal ribosome entry site (IRES) and the hygromycinresistance gene. Hygromycin-resistant U87MG and U251 cells express a high level ofluciferase (data not shown). These cells were then infected with retroviruses carrying the emptyretroviral expression vector containing puromycin-resistant gene alone (U87MG/U251-Lucwt) or containing wild-type merlin (U87MG/U251-Lucmerlin), merlinS518A (U87MG/U251-LucmerlinS518A), or merlinS518D (U87MG/U251-LucmerlinS518D). These double drug-resistant cells expressed high levels of luciferase and/or wt merlin/merlin mutant and were usedfor intracranial injection into Rag-1 mice. At 4, 10, and 16 d after the injections,bioluminescence images of the intracranial tumors were acquired by using IVIS-200 imagingsystem (Xenogen) at In vivo Molecular Imaging Shared Facility (Mount Sinai School ofMedicine).Histology and immunohistochemistryTo determine the tumor cell proliferation rate in vivo, BrdUrd was injected i.p. into mice 4 hbefore euthanasia. Gliomas were removed, fixed, sectioned, and stained with H&E as described(13). In addition, the sections were reacted with anti-BrdUrd antibodies to detect proliferatingcells or with the Apoptag kit to detect apoptotic cells in situ (14).StatisticsOther than the survival experiments, Student’s t test was used to analyze statistical differencesbetween the control and experimental groups. For the mouse survival experiments, log-rankstatistical analysis (SigmaStat) was used to calculate the statistical differences between controland experimental groups. Differences were considered statistically significant at p < 0.05.Lau et al.Page 5Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptResultsReduced NF2 expression in human gliomasAccording to WHO classification, astrocytic tumors are classified and graded from 1 to 4 asfollows: pilocytic astrocytoma (grade 1), diffuse astrocytoma (grade 2), anaplastic astrocytoma(grade 3), and glioblastoma multiforme (GBM; grade 4). We assessed the level of merlinexpression in 23 human GBM tissues by Western blot and real-time qPCR analyses. Proteinlysates from these 23 GBM samples were analyzed by Western blot using anti-merlin antibody(Santa Cruz; C-18), and merlin expression levels were determined by scanning densitometry(Gel-Pro). We observed more than a 2-fold reduction of merlin expression in 14 of 23 GBMtumors relative to normal brain (61%; Fig. 1A) and more than a 4-fold reduction in six tumors(26%; Fig. 1A). Real-time qPCR analysis of merlin RNA from the same 23 samples, as wellas two normal brain (NB) and NHA samples, showed that, compared with NB and NHA cells,there is a >2-fold reduction of merlin RNA expression in 15 of 23 GBM tumors (65%; Fig.1B) and more than a 4-fold reduction in 6 of these 23 samples (26%; Fig. 1B). The remainingtumors showed <2-fold decreases in merlin expression. Together, we found a 93% concordancebetween loss of merlin RNA and protein expression in these GBM tumors. In addition, usinga glioma tissue microarray stained with NF2 (C-18) antibody, we observed that merlinexpression was absent in 27.4% of the GBM tumors (Fig. 1C). Interestingly, we did not observeany reduction in merlin expression in anaplastic astrocytoma (WHO grade 3 tumors),suggesting that loss of merlin is associated with grade 4 glioma (GBM).Establishment of human glioma cells that overexpress merlin and merlin mutantsTo assess the potential role of merlin in glioma growth, we first analyzed the level of merlinexpression in a variety of human glioma cell lines. In general, human glioma cell lines, suchas U87MG, U251, SF763, and SF767 that are capable of forming subcutaneous and/orintracranial tumors in immunodeficient Rag-1 mice, expressed lower levels of merlin and/ora phosphorylated/inactive form of merlin (lanes 12 and 20, the upper band of the double bands).In contrast, NHAs and the nontumorigenic or low tumorigenic human glioma cell lines, suchas M089J, Hs683, LN18, SNB19, SF295, and SF210, expressed higher levels of merlin (Fig.2A).U87MG and U251 cells which express very low or intermediate levels of endogenous merlin,respectively, were infected with retroviruses containing the empty retroviral expression vector(U87MG/U251wt), wild-type merlin (U87MG/U251merlin), merlin S518A mutant (U87MG/U251merlinS518A), or merlinS518D mutant (U87MG/U251merlinS518D). The S518A mutationresults in a non-phosphorylatable form of merlin that is constitutively active, whereasmerlinS518D mimics a phosphorylated and inactive form of merlin (10,11,15). The retroviralexpression vectors used also contain an IRES positioned between the cDNA inserts and thepuromycin resistance gene, so that all the puromycin-resistant cells should express merlin orthe merlin mutants. After selection of the infected cells with puromycin, the pooled drug-resistant cells were found to express high levels of merlin or the merlin mutants (Fig. 2B andSupplementary Fig. S1; data not shown). Glioma cells expressing exogenous merlin andmerlinS518A, but not merlin S518D, displayed an altered morphology that is characterized byextended cellular processes and a reduced transformation phenotype (Fig. 2C; data not shown).Merlin reexpression inhibits anchorage-independent growth and invasiveness of gliomacells and sensitizes glioma cells to chemotherapy and irradiationTo determine how merlin affects the cellular behavior of glioma cells, we first investigated theeffect of merlin on anchorage-independent growth of U87MG cells by assessing the ability ofthese transduced glioma cells to form colonies in soft agar. We found that U87MGwt andU87MGmerlinS518D cells readily formed large colonies in soft agar and that merlin andLau et al.Page 6Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptmerlinS518A reexpression dramatically reduced the number and size of the colonies (Fig. 3A),suggesting that active, but not inactive, merlin inhibits anchorage-independent growth. Thisresult is consistent with our previous findings (13). We then determined the effect of merlinon glioma cell invasion. Similarly, active, but not inactive, merlin inhibits invasiveness of theseglioma cells (Fig. 3B).Glioblastomas are often chemoresistant and radioresistant as a result of constitutive activationand/or induced activation of several distinct signaling pathways, including thephosphatidylinositol 3-kinase (PI3K) signaling pathway (16,17). We examined the ability ofmerlin to sensitize glioma cells to 5-FU and irradiation. We found that reexpression of merlinsensitized U87MG cells to 5-FU and irradiation (Fig. 3C and D). Whereas the exact mechanismunderlying the slightly reduced apoptosis rate of U87MGwt cells treated with 20Gy of irradationrelative to those treated with 5 or 10Gy is not known, high dose radiation may actually inducea higher level of activation of antiapoptotic signals in U87MGwt cells, which counteracts theapoptotic effect of high-dose radiation (16,17). Regardless, reexpression of merlin consistentlysensitizes the response of the U87 cells to radiation.Merlin inhibits U87MG and U251glioma cell subcutaneous growth by reducing proliferationand promoting apoptosis in vivoTransduced U87MG and U251 cells were used for subcutaneous tumor growth experiments toassess the effect of merlin and merlin mutants on tumor growth in vivo. We found that wild-type merlin and merlinS518A, but not merlinS518D, dramatically inhibited subcutaneousgrowth of glioma cells (Fig. 4A–C). To determine the cellular mechanism underlying this effect,we analyzed proliferation and apoptosis of the transduced U87MG cells in vivo. We observedthat reexpression of merlin and merlinS518A, but not merlinS518D, inhibited tumor cellproliferation (BrdUrd incorporation) and promoted apoptosis (terminaldeoxynucleotidyltransferase–mediated dUTP nick end labeling staining) of tumor cells invivo (Fig. 4D).Merlin inhibits the intracranial growth of U87MG and U251 glioma cells, whereas knockdownof merlin promotes U251 glioma intracranial growthTo monitor intracranial tumor growth, we infected luciferase-expressing U87MG and U251cells with the retroviruses carrying the empty retroviral expression vector containingpuromycin-resistant gene alone (U87MG/U251-Lucwt), wild-type merlin (U87MG/U251-Lucmerlin), merlinS518A (U87MG/U251-LucmerlinS518A), or merlinS518D (U87MG/U251-LucmerlinS518D). Transduced U87MG cells were injected intracranially into Rag-1 mice, andtumor growth was studied using the IVIS-200 imaging system (Xenogen; Fig. 5A). As seenwith the subcutaneous explants, wild-type merlin and merlinS518A, but not merlinS518D,expression in either U87MG (Fig. 5B) or U251 (Fig. 5D) significantly increased the survivalof the experimental mice. Importantly, a large fraction of these mice only had nonsymptomaticsmall tumors 40 days after intracranial injection. In contrast, the mean survival of the mice thatreceived U87MG/U251-Lucwt and U87MG/U251-LucmerlinS518D cells was <3 to 4 weeks (Fig.5B and D).Unlike U87MG cells, which express very low levels of endogenous merlin (Fig. 2A, lane 6,arrow), U251 cells express intermediate levels of endogenous merlin (Fig. 2A, lane 13,arrow). Accordingly, U87MG cells grow more aggressively than U251 cells in vivo (Fig. 4and Fig 5). To determine whether knockdown expression of endogenous merlin in U251 gliomacells promotes tumor growth, we screened a set of shRNAmir constructs against human merlin.A nontargeting shRNA construct was used as a negative control. The lentiviruses carryingthese shRNA constructs were used to infect U251-Luc cells. We found that two of the threeshRNAmir constructs (mer-shRNA#1 and mer-shRNA#3, Open Biosystems) reduced merlinLau et al.Page 7Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscriptexpression by ~70%, whereas the nontargeting control construct had no effect on merlinexpression (Fig. 5C). We then assessed tumorigenicity of the pooled U251-Lucwt, U251-Lucmer-shRNA#1, U251-Lucmer-shRNA#3, and U251-LuccontrolshRNA cells by injecting thesecells intracranially into Rag1 mice. Consistent with our reexpression studies, knockdown ofmerlin expression in U251 cells increased intracranial glioma growth and reduced overallsurvival of these mice (Fig. 5D).Transcript profiling of U87MGmerlin cells suggests that merlin is a master regulator of severalimportant signaling pathwaysTo identify potential downstream targets of merlin glioma growth inhibition, we comparedgene expression profiles from three independently transduced and pooled puromycin-resistantU87MGmerlin and U87MGwt cells. We identified 362 genes whose expression increased and364 genes whose expression decreased in U87MGmerlin cells compared with U87MGwt cells(data not shown). These genes were then imported to David Functional AnnotationBioinformatics Microarray Analysis software4 (NIAID/NIH) to enrich for functionally relatedgene groups affected by merlin expression. After classification of these transcripts intofunctional pathways, we found that merlin reexpression results in increased expression oftranscripts that activate the Lats2 signaling pathway, as well as increased expression ofmolecules that inhibit canonical Wnt and RhoA signaling and decreased expression oftranscripts that activate canonical Wnt and RhoA signaling (Supplementary Table S1).Merlin activates Lats2 signaling pathway and inhibits canonical and noncanonical WntsignalingTo validate the microarray results, we performed quantitative real-time qPCR using cDNAsfrom U87MGmerlin and U87MGwt cells. The qPCR results confirmed the increased expressionof inhibitors of canonical Wnt signaling (DKK-1 and DKK-3) and decreased expression of anactivator of canonical Wnt signaling (FZD1; Fig. 6A). In addition, we found that merlinreexpression reduced the expression of activators of RhoA signaling (ARHGEF3 and VAV3)and increased the expression of proteins that inhibit RhoA signaling (DLC1, ARHGAP29, andRRAD; Fig. 6A). Lastly, merlin reexpression resulted in increased expression of themammalian homologues of proteins in the Drosophila Hippo (Hpo)–Warts (Wts)–Yorkie(Yki) pathway (FAT3, MST1, MST2, Lats1, and Lats2; Fig. 6A). Taken together, these resultssuggest that merlin activates Lats2 signaling and inhibits canonical and noncanonical Wntsignaling.We next assessed these merlin-induced changes of the expression at the protein or functionallevel. Because canonical Wnt signaling regulates gene expression by modulating the levels ofβ-catenin expression, a coactivator of the TCF/LEF transcription factors, we performedreporter assays using a β-catenin–responsive luciferase reporter construct, TopFlash(Addgene). FopFlash, which contains mutated TCF/LEF binding sites, was used as a negativecontrol. We found that β-catenin transcriptional activity is inhibited by wild-type merlin andmerlinS518A, but not by merlinS518D (Fig. 6B). We then assessed RhoA activity inU87MGwt and U87MGmerlin cells using a commercially available RhoA activity assay(Cytoskeleton, Inc.). We found that RhoA activity was reduced after wild-type merlinreexpression (data not shown).We then used Western blotting to determine the activity and expression of several componentsof the Lats2 signaling cascade. Activation was assessed using phosphorylated-specificantibodies. We found that merlin reexpression resulted in increased phosphorylation of4http://david.abcc.ncifcrf.gov/home.jspLau et al.Page 8Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptMST1/2, Lats2, and YAP (Fig. 6D), whereas the levels of cIAP1/2 expression were reduced(Fig. 6D). These results show that merlin activates MST-Lats signaling in human glioma cells.DiscussionThe NF2 gene is a critical tumor suppressor for several distinct cell types in the nervous system,including Schwann and leptomeningeal cells, such that Nf2 inactivation in Schwann cellprecursors and leptomeningeal cells is sufficient for schwannoma and meningioma formationin mice, respectively. Because glial cell tumors (e.g., ependymomas) arise in patients withNF2, we postulated that merlin might also function as a negative growth regulator for glial celltumors. In this study, we show for the first time that merlin expression at both the RNA andprotein levels is decreased in sporadic glioblastoma tumors and malignant glioma cell lines.Moreover, we show that increased expression of merlin suppresses glioma cell growth invitro and glioma tumor growth in vivo and that merlin knockdown promotes glioma tumorgrowth in vivo. Collectively, these findings suggest that merlin might be an important growthregulator in high-grade glioma and expand the role of the NF2 gene in the pathogenesis ofcentral nervous system tumors. NF2 loss in GBM tumors is unlikely to result from mutationalinactivation, in light of previous studies examining gliomas for NF2 gene mutations (18).Moreover, we did not find reduced merlin expression in low-grade gliomas5 or in WHO grade3 gliomas, suggesting that reduced NF2 expression might be a hallmark of grade 4 glioma.In addition to its function as a potent negative growth regulator, we show that merlin alsosensitizes glioma cells to 5-FU chemotherapy and irradiation. We show that merlinreexpression increased the response of U87MG cells to 5-FU. High-grade gliomas are oftenchemoresistant and radioresistant as a result of constitutive activation and/or induced activationof several distinct signaling pathways, including the PI3K signaling pathways (16,17).Irradiation activates PI3K pathway in human gliomas (16,17). In light of published reports inother tumor types (19,20), it is interesting to note that merlin reexpression results in decreasedexpression of two members of the cIAP family, cIAP1 and cIAP2. cIAP1 and cIAP2 have beenshown to directly bind to and inhibit caspase activity (21), which underlies the prosurvivaleffect of IAP proteins. Studies have shown that both cIAP1 and cIAP2 are up-regulated inGBM tumors compared with normal brain tissue (data derived from ref. 22), suggesting apossible mechanism underlying the relative resistance of GBM tumors to chemotherapy andradiation.In our studies, U87MGwt cells treated with 20 Gy of irradiation showed reduced apoptosisrelative to U87MG cells treated with 5 or 10Gy. Whereas these findings seem contradictory,high-dose radiation may actually induce a higher level of activation of antiapoptotic signals inU87MGwt cells, which counteracts the apoptotic effect of high-dose radiation (16,17).Regardless, reexpression of merlin consistently sensitizes the response of U87MG cells toradiation.Numerous studies have focused on defining the mechanism underlying merlin tumorsuppressor activity and identified several distinct growth regulatory pathways. One of thesepathways includes the Rac1 signaling pathway. Merlin overexpression inhibits Rac1-mediatedanchorage-independent growth (23) and inhibits the activity of the p21-activated kinase 1(11). Related to this mechanism, a recent study showed that a GTP-binding protein (termedthe NF2-associated GTP-binding protein) interacts with merlin and may regulate theantiproliferative activity of merlin by interfering with small GTPase protein signaling (24). Inaddition, other investigators have shown that merlin may regulate mitogen-activated proteinkinase, Akt, and c-Jun NH2 kinase signaling (15,25).5S.S. Houshmandi and D.H. Gutmann, unpublished results.Lau et al.Page 9Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptThese prior investigations have examined merlin in nonbrain tissues and tumors. To gaininsights into the potential mechanism(s) responsible for merlin-negative regulation of braintumor (GBM) growth, we performed RNA expression profiling. Our study revealed that merlinreexpression resulted in activation of the Lats signaling pathway and inhibition of canonicalWnt and non-canonical Wnt/RhoA signaling. These findings suggest that merlin may serve tointegrate several signaling pathways important for cell growth, apoptosis, and motility inglioma cells.In Drosophila, merlin (mer) inactivating mutations result in reduced apoptosis and increasedcell proliferation, which led to the discovery that mer functions upstream of the Hpo-Wts-Ykipathway (26–29). In flies, FAT, a large protocadherin, functions upstream of merlin. Merlinactivates Hpo kinase, which in turn phosphorylates and activates Wts kinase. Wtsphosphorylates and inactivates Yki and blocks its proproliferation and antiapoptotic activity(26–31). Yki, a transcriptional coactivator, regulates the expression of a common set ofdownstream target genes, including wingless (wg), DIAP, and cyclin E (26–31).The mammalian homologues of Hpo, Wts, Yki, DIAP, and wg are MST kinase 1/2 2 (32),Lats1/2 (33,34), YAP (35), cIAP1/2, and the Wnt family proteins. MST1 and MST2 canphosphorylate and activate Lats1 and Lats2 (36). Like MST1/2 genes, Lats1/2 genes encodeserine/threonine kinases and display antitumor activity (37–39). Lats1 and Lats2 are down-regulated in human astrocytomas through hypermethylation of their promoters (40). On thecontrary, YAP is amplified in human cancers and displays oncogenic activity (35,41). As atranscriptional coactivator, YAP promotes cell proliferation and inhibits apoptosis by up-regulating expression of cyclin E and cIAP1/2, respectively (28). Although it is unknownwhether the entire FAT-Hpo-Wts-Yki signaling pathway is conserved in mammalian cells, likeYki, YAP rescues the pupal lethality caused by overexpression of hpo or wts in Drosophila(28). Similarly, human homologues of hpo and wts rescue their corresponding Drosophilamutants (42,43). In the current study, we show that merlin modulates the activity and/orexpression MST1/2, Lats2, and YAP, suggesting that this pathway is conserved in glioma cellsand is regulated by merlin. Our results also suggest that merlin inhibition of glioma cellproliferation and promotion of apoptosis may reflect the increased activation of MST1/2 andLats1/2, which inhibits YAP activity, leading to reduced expression of cIAP1/2 and cyclin E(not shown).Wnt signals play essential roles in regulating cell differentiation, proliferation, apoptosis, andmotility (44). Wnts activate the canonical pathway by binding to the FZD receptors and thelow-density lipoprotein receptor–related proteins (LRP-5 and LRP-6), which in turn activ ateβ-catenin. β-Catenin interacts with members of the TCF/LEF family of transcription factors toinduce expression of the Wnt-responsive genes (45). Antagonists of the Wnt signaling pathwayinclude the members of the secreted frizzled-related protein family and the members of theDickkopf family (46). Work in Drosophila implicated Wingless (Wg) as a downstream effectorof merlin (29). Studies have shown that FDZ9 and WNT pathway are up-regulated inastrocytomas (47,48) and that DKK-1 sensitizes U87MG cells to apoptosis after alkylationagent induced DNA damage (49). Our finding that merlin reexpression in human glioma cellsdecreased FDZ1 expression, increased DKK1 and DKK3 expression, and reduced canonicalWnt activity is consistent with these observations.Collectively, we show that merlin is a potent negative growth regulator in WHO grade 4gliomas and that merlin reexpression results in decreased glioma cell growth in vitro and invivo. We further showed that merlin induce apoptosis of glioma cells potentiated bychemotherapy and radiation. Analysis of the signaling pathways revealed that merlin regulatesthe MST/LATS/YAP/cIAP pathway, a critical modulator of apoptosis, and reduces canonicalWnt and RhoA signaling, important regulators of cell proliferation and/or motility. These novelLau et al.Page 10Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscriptfindings provide new insights into the pathogenesis of human high-grade gliomas and suggestnew therapeutic strategies for these aggressive and typically fatal brain tumors.Supplementary MaterialRefer to Web version on PubMed Central for supplementary material.AcknowledgmentsGrant support: Department of Defense-U.S. Army Medical Research grants W81XWH-05-1-0191 (Q. Yu) andDAMD-17-04-0266 (D.H. Gutmann) and NIH NRSA fellowship grant 1F32CA128335-01A1 (S.S. Houshmandi).We thank Dr. Gregory Fuller (M. D. Anderson Cancer Center) for providing the glioma tissue microarray, Dr. YuZhou at the Molecular Imaging Shared Facility (Mount Sinai School of Medicine) for performing bioluminescenceimaging analysis, Dr. John Tobias at the Bioinformatics Core of University of Pennsylvania for performing microarrayanalysis, and Dr. Stuart Aaronson and Dr. Ivan Stamenkovic for their stimulating discussions and support.References1. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter.Genes Dev 2001;15:1311–1333. [PubMed: 11390353]2. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignantbrain tumors stratified by patient age and tumor histological type: an analysis based on surveillance,epidemiology, and end results (SEER) data, 1973–1991. J Neurosurg 1998;88:1–10. [PubMed:9420066]3. Gutmann DH, Giordano MJ, Fishback AS, Guha A. Loss of merlin expression in sporadicmeningiomas, ependymomas and schwannomas. Neurology 1997;49:267–270. [PubMed: 9222206]4. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515–521. [PubMed: 8379998]5. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidatefor the neurofibromatosis 2 tumor suppressor. Cell 1993;72:1–20.6. Bretscher A, Chambers D, Nguyen R, Reczek D. ERM-Merlin and EBP50 protein families in plasmamembrane organization and function. Annu Rev Cell Dev Biol 2000;16:113–143. [PubMed:11031232]7. Gautreau A, Louvard D, Arpin M. ERM proteins and NF2 tumor suppressor: the Yin and Yang ofcortical actin organization and cell growth signaling. Curr Opin Cell Biol 2002;14:104–109. [PubMed:11792551]8. McClatchey AI. Merlin and ERM proteins: unappreciated roles in cancer development? Nat Rev Cancer2003;3:877–883. [PubMed: 14668818]9. Bianchi AB, Hara T, Ramesh V, et al. Mutations in transcript isoforms of the neurofibromatosis 2 genein multiple human tumour types. Nat Genet 1994;6:185–192. [PubMed: 8162073]10. Sherman L, Xu H-M, Geist RT, et al. Interdomain binding mediates tumor growth suppression bythe NF2 gene product. Oncogene 1997;15:2505–2509. [PubMed: 9395247]11. Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. Merlin, the product of the Nf2tumor suppressor gene, is an inhibitor of the p21 activated kinase, Pak1. Mol Cell 2003;12:841–849.[PubMed: 14580336]12. Houshmandi SS, Surace EI, Zhang HB, Fuller GN, Gutmann DH. Tumor suppressor in lung cancer-1(TSLC1) functions as a glioma tumor suppressor. Neurology 2006;67:1863–1866. [PubMed:17130425]13. Bai Y, Liu YJ, Wang H, Xu Y, Stamenkovic I, Yu Q. Inhibition of the hyaluronan-CD44 interactionby merlin contributes to the tumor-suppressor activity of merlin. Oncogene 2007;26:836–850.[PubMed: 16953231]14. Liu YJ, Xu Y, Yu Q. Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- andantimetastatic activity, respectively. Oncogene 2006;25:2452–2467. [PubMed: 16314835]Lau et al.Page 11Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscript15. Tang X, Jang SW, Wang X, et al. Akt phosphorylation regulates the tumour-suppressor merlin throughubiquitination and degradation. Nat Cell Biol 2007;9:1199–1207. [PubMed: 17891137]16. Park CM, Park MJ, Kwak HJ, et al. Ionizing radiation enhances matrix metalloproteinase-2 secretionand invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt andphosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 2006;66:8511–8519. [PubMed:16951163]17. Kao GD, Jiang Z, Fernandes AM, Gupta AK, Maity A. Inhibition of phosphatidylinositol-3-OHkinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J BiolChem 2007;282:21206–21212. [PubMed: 17513297]18. Alonso ME, Bello MJ, Arjona D, et al. Analysis of the NF2 gene in oligodendrogliomas andependymomas. Cancer Genet Cytogenet 2002;134:1–5. [PubMed: 11996787]19. Liu X, Shi Y, Giranda VL, Luo Y. Inhibition of the phosphatidylinositol 3-kinase/Akt pathwaysensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis. Mol Cancer Ther2006;5:494–501. [PubMed: 16546963]20. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, et al. Cisplatin activates Akt in small cell lungcancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 2005;117:755–763.[PubMed: 15981204]21. Aggarwal BB, Bhardwaj U, Takada Y. Regulation of TRAIL-induced apoptosis by ectopic expressionof antiapoptotic factors. Vitam Horm 2004;67:453–483. [PubMed: 15110190]22. Bredel M, Bredel C, Juric D, et al. Functional network analysis reveals extended gliomagenesispathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 2005;65:8679–8689. [PubMed: 16204036]23. Shaw RJ, Paez JG, Curto M, et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependentsignaling. Dev Cell 2001;1:63–72. [PubMed: 11703924]24. Lee H, Kim D, Dan HC, et al. Identification and characterization of putative tumor suppressor NGB,a GTP-binding protein that interacts with the neurofibromatosis 2 protein. Mol Cell Biol2007;27:2103–2119. [PubMed: 17210637]25. Chadee DN, Xu D, Hung G, et al. Mixed-lineage kinase 3 regulates B-Raf through maintenance ofthe B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc Natl Acad SciU S A 2006;103:4463–4468. [PubMed: 16537381]26. Hamaratoglu F, Willecke M, Kango-Singh M, et al. The tumour-suppressor genes NF2/Merlin andExpanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol2006;8:27–36. [PubMed: 16341207]27. McCartney BM, Kulikauskas RM, LaJeunesse DR, Fehon RG. The neurofibromatosis-2 homologue,Merlin, and the tumor suppressor expanded function together in Drosophila to regulate cellproliferation and differentiation. Development 2000;127:1315–1324. [PubMed: 10683183]28. Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulatescell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell2005;122:421–434. [PubMed: 16096061]29. Pellock BJ, Buff E, White K, Hariharan IK. The Drosophila tumor suppressors expanded and merlindifferentially regulate cell cycle exit, apoptosis, and wingless signaling. Dev Biol 2007;304:102–115. [PubMed: 17258190]30. Cho E, Feng Y, Rauskolb C, Maitra S, Fehon R, Irvine KD. Delineation of a Fat tumor suppressorpathway. Nat Genet 2006;38:1142–1150. [PubMed: 16980976]31. Maitra S, Kulikauskas RM, Gavilan H, Fehon RG. The tumor suppressors merlin and expandedfunction cooperatively to modulate receptor endocytosis and signaling. Curr Biol 2006;16:702–709.[PubMed: 16581517]32. Creasy CL, Chernoff J. Cloning and characterization of a member of the MST subfamily of Ste20-like kinases. Gene 1995;167:303–306. [PubMed: 8566796]33. Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, Oren M. A positive feedback loop betweenthe p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev 2006;20:2687–2700.[PubMed: 17015431]Lau et al.Page 12Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscript34. Takahashi Y, Miyoshi Y, Takahata C, et al. Downregulation of LATS1 and LATS2 mRNA expressionby promoter hypermethylation and its association with biologically aggressive phenotype in humanbreast cancers. Clin Cancer Res 2005;11:1380–1385. [PubMed: 15746036]35. Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties of YAP, a candidate oncogeneon the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006;103:12405–12410. [PubMed:16894141]36. Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA, Sillje HH. The Ste20-like kinaseMst2 activates the human large tumor suppressor kinase Lats1. Oncogene 2005;24:2076–2086.[PubMed: 15688006]37. Li Y, Pei J, Xia H, Ke H, Wang H, Tao W. Lats2, a putative tumor suppressor, inhibits G1/S transition.Oncogene 2003;22:4398–4405. [PubMed: 12853976]38. St John MA, Tao W, Fei X, et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovariantumours and pituitary dysfunction. Nat Genet 1999;21:182–186. [PubMed: 9988269]39. McPherson JP, Tamblyn L, Elia A, et al. Lats2/Kpm is required for embryonic development,proliferation control and genomic integrity. EMBO J 2004;23:3677–3688. [PubMed: 15343267]40. Jiang Z, Li X, Hu J, et al. Promoter hypermethylationmediated down-regulation of LATS1 and LATS2in human astrocytoma. Neurosci Res 2006;56:450–458. [PubMed: 17049657]41. Zender L, Spector MS, Xue W, et al. Identification and validation of oncogenes in liver cancer usingan integrative oncogenomic approach. Cell 2006;125:1253–1267. [PubMed: 16814713]42. Wu S, Huang J, Dong J, Pan D. hippo encodes a Ste-20 family protein kinase that restricts cellproliferation and promotes apoptosis in conjunction with salvador and warts. Cell 2003;114:445–446. [PubMed: 12941273]43. Tao W, Zhang S, Turenchalk GS, et al. Human homologue of the Drosophila melanogaster latstumour suppressor modulates CDC2 activity. Nat Genet 1999;21:177–181. [PubMed: 9988268]44. Vlad A, Röhrs S, Klein-Hitpass L, Müller O. The first five years of the Wnt targetome. Cell Signal.2007 Nov 17;[Epub ahead of print]45. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and β-catenin signaling: diseases and therapies.Nat Rev Genet 2004;5:691–701. [PubMed: 15372092]46. Kawano Y, Kypta R. Secreted antagonists of the Wnt signaling pathway. J Cell Sci 2003;116:2627–2634. [PubMed: 12775774]47. Zhang Z, Schittenhelm J, Guo K, et al. Up-regulation of frizzled 9 in astrocytomas. Neuropathol ApplNeurobiol 2006;32:615–624. [PubMed: 17083476]48. Jozwiak J, Kotulska K, Grajkowska W, et al. Upregulation of the WNT pathway in tuberous sclerosis-associated subependymal giant cell astrocytomas. Brain Dev 2007;29:273–280. [PubMed:17071037]49. Shou J, Ali-Osman F, Multani AS, Pathak S, Fedi P, Srivenugopal KS. Human Dkk-1, a gene encodinga Wnt antagonist, responds to DNA damage and its over-expression sensitizes brain tumor cells toapoptosis following alkylation damage of DNA. Oncogene 2002;21:878–889. [PubMed: 11840333]Lau et al.Page 13Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptFigure 1.Expression of merlin is down-regulated in human GBM samples. A, merlin expression in NB(lane 1, top) and human gliomas (lanes 2–24, top) was determined by Western blotting usinganti-merlin antibody (C-18, Santa Cruz). Tubulin was included as an internal control for equalprotein loading (bottom). B, merlin mRNA expression was examined by real-time qPCR usinghuman merlin primers in the same GBM samples used in the Western blotting as well as NBand NHA samples. C, merlin immunohistochemistry was performed on normal brain andgliomas representing WHO malignancy grades 3 and 4. Representative immunohistochemistryimages are shown (top). Whereas no loss of merlin expression was observed in normal brainand anaplastic astrocytomas (WHO III), >27% of glioblastomas (WHO IV) exhibited loss ofmerlin expression (bottom).Lau et al.Page 14Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptFigure 2.Establishment of glioma cells expressing merlin and merlin mutants. A, expression ofendogenous merlin in a panel of human/rat glioma cells was determined by Western blottingusing anti-merlin antibody (C-18, Santa Cruz), including M089J, U138MG, DBRG05MG,LN229, M059K, U87MG (lane 6, A), Hs683, LN18, and A172 cells (A, top, lanes 1–9; ATCC),SNB19, U373MG, SF763, U251( lane 13), 9L (rat, lane 14), SF268, SF539, U343MG, SF188,SF295, SF797, SNB75, SF126, SF210, U118MG, LN229, U87MG, and NHAs (ALLCELLS,Inc.; A, bottom, lanes 10–27, UCSF and NCI collections). Total protein (50 µg) was loaded ineach lane. The WHO grades 1 and 3 glioma cells are indicated. All the other glioma cells arederived from grade 4 GBM tumors. B, U87MG/U251merlin, U87MG/U251merlinS518A, andLau et al.Page 15Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptU87MG/U251merlinS518D cells express a similar level of v5-epitope tagged exogenous merlinand the merlin mutants as determined by Western blot using anti-v5 mAb (Invitrogen). Lanes1–6, the proteins derived from the transduced U87MG cells; lanes 7–12, the proteins derivedform the transduced U251cells. Total protein (20 µg) was loaded in each lane. C, transducedU87MG cells (2 × 105 per dish) were seeded in 35-mm cell culture dishes and grown for 24 hbefore taking photographs. U87MGmerlin and U87MGmerlinS518A cells display an alteredmorphology when compared with U87MGwt and U87MGmerlinS518D cells. Bar, 120 µm.Lau et al.Page 16Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptFigure 3.Increased expression of merlin alters U87MG cell growth (anchorage independent), motility,and response to chemotherapy and radiation. A, reexpression of merlin and merlinS518A, butnot merlinS518D, inhibited anchorage-independent growth of U87MG cells. Three weeks afterseeding the cells in soft agar, 30 randomly selected microscopic fields were counted.Columns, mean; bars, SD. Bar, 480 µm. B, reexpression of merlin and merlinS518A, but notmerlinS518D, inhibited U87MG cells invasion through Matrigel. Quantitation is shown in thegraph to the right of the photomicrographs. Thirty randomly selected microscopic fields werecounted. Scale bar, 200 µm. Reexpression of merlin promoted drug-induced (C) and radiation-induced (D) apoptosis of U87MGwt cells.Lau et al.Page 17Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptFigure 4.Merlin reexpression potently inhibits U87MG and U251subcutaneous tumor growth. A,Photographs of U87MGwt, U87MGmerlinS518A, U87MGmerlin, and U87MGmerlinS518Dsubcutaneous tumors. B and C, growth rates of the subcutaneous tumors derived from thetransduced U87MG and U251cells were determined as described in Materials and Methodsand expressed as the mean of tumor volume (mm3) ± SD. The P values demonstratingsignificant inhibition are included. D, morphology, proliferation, and apoptosis of explantedglioma tumors. Tumor sections were stained with H&E to determine histologic morphology.In vivo proliferation was detected using an anti-BrdUrd antibody (Roche). Apoptosis in situwas detected using the Apoptag kit (Chemicon). Tumor sections are derived from U87MGwt,U87MGmerlin, U87MGmerlinS518A, and U87MGmerlinS518D. Bar, 100 µm.Lau et al.Page 18Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptFigure 5.Merlin inhibits U87MG and U251glioma intracranial growth, whereas merlin knockdownpromotes U251glioma intracranial growth. A, bioluminescence imaging analysis of mice 4,10, and 16 d after the intracranial injection of U87MG-Lucwt (top) and U87MG-Lucmerlin(bottom). The images were obtained 4 min after injection of D-luciferin using the same intensityscaling. B and D, survival rates of mice after the intracranial injections of transduced U87MG(B) and U251( D) cells. The P values demonstrating significant effects on survival are included.C, knockdown of merlin expression in U251cells. Western blot was performed using the anti-merlin antibody (C-18, Santa Cruz) on lysates from U251-Lucwt, U251-Lucmer-shRNA#1, U251-Lucmer-shRNA#2, U251-Lucmer-shRNA#3, and U251-LuccontrolshRNA cells.Lau et al.Page 19Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptFigure 6.Merlin activates Lats2 signaling and inhibits canonical Wnt and RhoA signaling in gliomacells. A, real-time qPCR validation of the microarray results. B, luciferase activity wasmeasured in U87MGwt, U87MGmerlin, U87MGmerlinS518D, and U87MGmerlinS518A cells 24 hafter transfection of cells with TopFlash (top) or FopFlash (bottom). C and D, Western blotswere performed on lysates from U87MGwt (lanes 1 and 2) and U87MGmerlin (lanes 3 and 4)cells using the antibodies (as detailed in the figure) against MST1/2 (C, Bethyl Laboratories),Lats2 (C, Bethyl Laboratories), YAP (D, Abnova), cIAP1/2 (D, Santa Cruz), and actin (C andD, Sigma) and the antibodies against phosphorylated MST1/2 (C, Cell Signaling),phosphorylated Lats2 (C, Abnova), and phosphorylated YAP (D, Cell Signaling).Lau et al.Page 20Cancer Res. Author manuscript; available in PMC 2009 November 17.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptVestibular Schwannoma Quantitative Polymerase ChainReaction Expression of Estrogen and Progesterone ReceptorsAndrew K. Patel, MD, Thomas H. Alexander, MD, MS, Ali Andalibi, PhD, Allen F. Ryan, PhD,and Joni K. Doherty, MD, PhDDepartment of Surgery (A.K.P., T.H.A., A.F.R., J.K.D.), Division of Otolaryngology, Head andNeck Surgery, University of California, San Diego School of Medicine and Veterans AffairsMedical Center, La Jolla, California, U.S.A.; House Ear Institute (A.A.), Los Angeles, California,U.S.A.; and National Cancer Institute (A.A.), Washington, District of Columbia, U.S.AAbstractObjectives/Hypothesis—Determine the role of estrogen receptor (ER) and progesteronereceptor (PR) expression in sporadic and neurofibromatosis 2 (NF2)-related vestibularschwannomas (VS). Growth and proliferation signaling in human VS tumorigenesis may play akey role in molecular therapeutic targeting. VS carry mutations of the NF2 gene encoding thetumor suppressor, merlin, which interacts with ErbB2 in Schwann cells, implicating ErbBreceptors in VS tumorigenesis. ErbB receptor family members are overexpressed or constitutivelyactivated in many human tumors, and are effective therapeutic targets in some human cancers. VSoccur more frequently in women and are larger, more vascular, and demonstrate increased growthrates during pregnancy. ER and PR may play a role in ErbB pathway activation and VSprogression.Study Design—Quantitative real-time polymerase chain reaction (qRT-PCR) for ER and PRmessenger RNA was performed using greater auricular and vestibular nerve controls (n = 8),sporadic VS (n = 23), and NF2-related VS (n = 16) tissues.Methods—The qRT-PCR data were normalized with standardization to a single constitutivelyexpressed control gene, human cyclophylin.Results—Reverse transcription of messenger RNA from control and tumor specimens followedby RT Q-PCR demonstrated differences in ER and PR gene expression between sporadic andNF2-related VS.Conclusions—ER and PR expression in VS might have implications for development of a VS-specific drug delivery system using antihormone and ErbB pathway small molecule inhibitors, dueto crosstalk between these receptors. These signals may be critical for re-establishing ErbB-mediated cell density dependent growth inhibition.KeywordsVestibular schwannoma; neurofibromatosis 2; estrogen receptor; progesterone receptor; acoustic-neuroma; pregnancy; ErbB receptor family© 2008 The American Laryngological, Rhinological and Otological Society, Inc.Send correspondence to: Joni K. Doherty, MD, PhD, 200 W. Arbor Drive, Mail Code 8895, San Diego, CA 92103.jkdoherty@ucsd.edu.Presented at the 2008 Western Section Meeting of the Triological Society, Rancho Mirage, California, U.S.A., January 31–February 2,2008.NIH Public AccessAuthor ManuscriptLaryngoscope. Author manuscript; available in PMC 2013 February 12.Published in final edited form as:Laryngoscope. 2008 August ; 118(8): 1458–1463. doi:10.1097/MLG.0b013e318177e20b.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptINTRODUCTIONMuch has been written about the variable natural history of vestibular schwannomas (VS),in which continuous growth, stagnation or rarely, even shrinkage may occur.1 Additionally,resumption of growth after a period of quiescence can occur. VS, also known as acousticneuromas, are benign neurilemmomas caused by aberrant proliferation of Schwann cells inthe vestibular division of the vestibulocochlear nerve (VIIIth cranial nerve). VS commonlycause tinnitus, hearing loss, disequilibrium, facial hypesthesias, and in rare casescatastrophic brainstem compression, stroke, or death. They account for ~8% of allintracranial neoplasms and comprise ~80% of tumors in the cerebellopontine angle.2 Thereported incidence rate of VS varies worldwide from 1 to 20 cases per million inhabitantsper year in earlier studies rising to a sporadic VS incidence of 1 in 80,000 in more recentreports.3The presentation of VS is usually unilateral, sporadic, and nonfamilial, though in less than5% of cases tumors are bilateral and caused by an autosomal dominant disorder known astype 2 neurofibromatosis (NF2) due to mutations in the NF2 gene that encodes the putativetumor suppressor, merlin (also called schwannomin). Most cases of VS are diagnosed inpersons in the fourth to sixth decade of life, while patients with NF2 become symptomaticroughly 20 years earlier in life. Additionally, VS can infrequently arise in association withschwannomatosis, resulting from mosaicism with respect to somatic mutations in the NF2gene that occurs during embryogenesis.4 To date, VS are presumed to arise due to amutation of NF2 and subsequent loss of heterozygosity at 22q12. Thus, functional merlinexpression is lost. The pathogenic mechanisms that follow loss of merlin expression andcontribute to the diverse patterns of VS growth are unknown.Similar to other neoplasms, it must be assumed that initiation and maintenance of VS growthis related to a dysregulation of the balance between cell proliferation and cell death, and thatproliferation of tumor cells might be promoted by mitogens that physiologically regulateSchwann cell proliferation during development or in peripheral nerve regeneration afterSchwann cell trauma.5 Schwann cells, the myelinating glial cells in the peripheral nervoussystem, synthesize progesterone in response to a diffusible neuronal signal. Progesteronethen plays a role in the formation of myelin sheaths, in addition to Schwann cells expressingan intracellular receptor for progesterone, which then functions as an autocrine signalingmolecule.6 Similarly, VS were recently shown to both produce the glial growth factorneuregulin and demonstrate activated neuregulin receptors, suggesting that VS produce andrespond to neuregulin in an autocrine fashion.7Other intriguing evidence for a hormonal influence on tumor growth emerges from studiesin which preservation of preoperative hearing after VS resection was less likely forpremenopausal women than for men or post-menopausal women.8 It has long beenspeculated that pregnancy stimulates the growth of VS. Several published reports in theliterature describe the infrequent presentation of pregnant patients with VS.9 VS arestatistically more frequent in women, and larger, more vascular tumors are twice as commonin women.10 Since nausea, vomiting, headaches and vertigo are common complaints bothduring pregnancy and in the presence of brain tumors, though intracranial lesions are rare, itis possible that they may be under-diagnosed or even missed in the pregnant patient untilneurological deficits appear. Although only 25 cases of pregnant patients with VS have beendescribed in the literature, the signs and symptoms of these tumors are generallydemonstrated to dramatically worsen during the last 3 to 4 months of pregnancy.11Prior publications have demonstrated that some VS contain estrogen receptors (ER), and ithas been theorized that estrogen may be the factor related to the acceleration of symptomsPatel et al.Page 2Laryngoscope. Author manuscript; available in PMC 2013 February 12.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscriptduring pregnancy. Additionally, one author previously recommended termination ofpregnancy to avoid the accelerated growth phase of tumors in NF.12 Dr. Harvey Cushing in1917 was the first to report the acceleration of growth of VS during pregnancy.13 Kachharaet al.14 articulated the two leading hypotheses regarding the mechanisms underlying thegrowth of VS during pregnancy: one theory based on the rapid expansion or engorgement ofthe vascular bed based on the increased blood volume during pregnancy, and the secondbased on a direct hormonal effect of tumor growth mediated by the progesterone receptor(PR) and ER, which are also known to mediate the growth of meningioma cells.Investigations of the expression of estrogen and progesterone began in VS in the 1980second with significant variation in the methods employed and somewhat confusing results.Several reports in the literature have suggested a possible link between tumor behavior andexpression levels of hormone receptors.10 The first attempt to detect ER was reported in1981 by Kasantikul and detected ERs in all eight samples tested. Subsequently, eight studiesusing the radioimmunoassay method to detect radioactive bound hormone to receptors in thetumor tissue demonstrated ER present only in a minority of samples (10 –25%) of four ofthese studies.15–18 The other four studies reported no evidence of ER in theirspecimens.19 –22 Subsequently, two studies using the sucrose gradient method ofmeasurement of ER in VS tissue demonstrated four of eight specimens positive for ER, andzero of two specimens positive for ER.23 Two studies employing monoclonal antibodymethods to detect ER found no evidence of ERs in all 28 samples.21,24 A subsequent studyof messenger RNA (mRNA) levels of ER and PR detected PR mRNA in 33% of specimensbut no ER expression in any specimens.25 Allen et al.26 more recently reported a series ofeight pregnant patients with VS in 1974 and attributed increased symptoms to hormonalstimulation of tumor growth or hormonally induced intratumoral vascular dilation. In thelargest study to date, Cafer et al.27 evaluated 59 formalin-fixed, paraffin-embedded samplesfor estrogen and PR as well as for Ki-67 proliferative marker, and found that all sampleswere positive for PR and negative for ER by immunohistochemistry. Based on informationfrom these numerous diverging studies, it was inferred that preoperative hormonal treatmentwas of unclear benefit in the treatment of VS, but interest in the possible inhibitory effect ofantiprogesterone treatment was renewed.28,29RTq-PCR has evolved as a valuable alternative to techniques such as Southern blot andfluorescence in situ hybridization for the molecular detection of alterations in gene copynumber. The technique uses complimentary DNA (cDNA) generated from mRNA, whichrepresents the expressed genes in that tissue. The advantages of this method include the lackof postPCR manipulation (thereby significantly reducing contamination risk and hands-ontime), the short time interval necessary, and the requirement for only minimal amounts ofinput cDNA, and the large dynamic range of accurate quantification. Constitutivelyexpressed reference genes are selected to normalize the data to eliminate nonspecificvariation, such as variation in cDNA input amounts between samples.No prior studies have investigated differences in expression of estrogen and PRs betweensporadic and NF2-related VS. In this study, 39 patients with sporadic VS (n =23) and NF2tumors (n =16) underwent evaluation by qPCR of expression of ER and PR compared toexpression of a constitutively active housekeeping gene, human cyclophyllin, as in internalcontrol. Expression levels of these receptor proteins were then analyzed with respect to age,gender, NF2 status, and tumor size.PATIENTS AND METHODSTo quantify endogenous expression levels of ER and PR in VS tumors, quantitative reversetranscriptase PCR (Q-PCR) was used using cDNA previously isolated from VS tissuePatel et al.Page 3Laryngoscope. Author manuscript; available in PMC 2013 February 12.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscriptgraciously provided by the House Ear Institute (IRB approval No. 97–157). Tumors orcontrol nerve tissue obtained via this protocol are immediately snap frozen in liquid nitrogenand transferred to the laboratory and stored at −70°C. The diagnosis was verified byconventional histopathologic examination of a part of the tumor. Subsequently, total RNAwas extracted from VS and control nerve samples using the Trizol reagent (GibcoInvitrogen, Carlsbad, CA) per the manufacturer’s instructions. mRNA was selected byrunning total RNA over oligo-dT columns (Invitrogen, Carlsbad, CA), and mRNA (5 μg per50 μL sample) was reverse transcribed using the Gene AMP kit (Perkin-Elmer; Waltham,MA) in a DNA Engine Peltier Thermal cycler (PTC-200; MJ Research, Watertown, MA) at42°C for 1 minute, followed by 72°C for 2 hours, then held at 4°C until ready for use in Q-PCR.In each Q-PCR reaction, Taqman Universal PCR Master Mix (2× buffer containingpolymerase; Applied Biosystems, Foster City, CA) was used in a 15 μL reaction including 2μL of cDNA (reverse-transcribed mRNA [0.2 μg]) and 20× solution of primers andfluorophor-labeled probe (Taqman Gene Expression Assays; Applied Biosystems, FosterCity, CA) for both the transcript encoding the receptor of interest (i.e., human ER alpha orhuman PR) and an internal control (human cyclophyllin, a mitochondrial structure protein)(Table I). All expression assays were designed to span exon boundaries, to eliminate the riskof contamination from DNA or unprocessed RNA.Analysis of 39 VS specimens was completed, including 23 sporadic and 16 NF2-related VS.As controls for normal Schwann cell expression levels of ER and PR, Q-PCR analysis wasperformed using three independent sciatic nerve (SN) and four independent greater auricularnerve (GAN) specimens. Additionally, four vestibular nerve samples obtained fromMénière’s patients undergoing vestibular nerve sectioning at the University of Iowa as agenerous gift from Dr. Marlan Hansen were analyzed.An ABI Prism 7,000 Sequence Detection System was used for all reactions with thefollowing cycling parameters: 50°C for 2 minutes, 95°C for 10 minutes, then 50 cycles of(95°C for 10 second, 60°C for 1 minute) for amplification and simultaneous detection.Reactions were all performed in duplicate, and an internal control of human cyclophyllinwas amplified within the same sample well using a different fluorophor reporter fordetection (VIC; Applied Biosystems, Inc., Foster City, CA). When the gene of interest wasundetected, the reactions were repeated with 60 cycles. Results were analyzed using aMicrosoft Excel program designed for Q-PCR quantitation based on internal control mRNAlevels, to control for differences in mRNA integrity between samples. Additionally, thisprogram calculates mRNA transcript levels as fold-induction of baseline tissue (SN andGAN, designated arbitrarily as “one-fold”) to provide comparative data.Statistical AnalysisER and PR expression levels were considered to be upregulated if they were at least 10-foldgreater than controls. Clinical information and Q-PCR data were combined and analyzedstatistically using the Fisher’s Exact test (for age, size of tumor in centimeter as measured inlargest dimension, NF2 status, and expression data), the Mann-Whitney U test (for NF2 vs.sporadic data), and the Spearman R for correlations. A two-tailed t test was used to compareQ-PCR expression data means for NF2 and sporadic VS.RESULTSA total of 12 of 23 (52%) sporadic VS samples upregulate ER, and 16 of 23 (69.6%)sporadic VS samples upregulate PR (Fig. 1A). A total of 4 of 16 (25%) NF2-related VSupregulated ER and 5 of 16 (31.3%) upregulated PR (Fig. 1B). Most NF2-related VS did notPatel et al.Page 4Laryngoscope. Author manuscript; available in PMC 2013 February 12.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscriptupregulate ER mRNA, and downregulated PR mRNA in a statistically significant manner(Fig. 2). The variability in ER mRNA expression was not statistically significant in sporadicVS versus NF2-related VS (Figs. 3A and B). Sporadic VS upregulate ER mRNA above 10-fold, and upregulate levels of PR mRNA over 100-fold.Results of Q-PCR analyses indicate that the four control GAN samples expressed higherlevels of ER and PR mRNA when compared with SN or VS (data not shown).To explore the clinical relevance of ER and PR expression, mRNA expression levels werecorrelated with clinical parameters, including patient age at presentation, tumor size, andNF2 status. The average age at presentation for NF2-related tumors was 24.5 years of age,and the mean patient age in sporadic VS was 51.6 years of age. The male to female ratio inNF2-related VS was 1:0.875, and the male to female ratio in sporadic VS was 1:2. Theaverage NF2-related VS tumor size was 2.21 cm which was similar to the average sporadicVS average tumor size of 2.17 cm.Using logistic regression with all the variables (age, gender, tumor size, ER, PR), the onlyclinical parameter that was significantly associated with NF2-related VS was younger age (P< .0148).DISCUSSIONOur results suggest that ER and PR may be potential therapeutic targets in sporadic VSbecause they were upregulated in most VS. Interestingly, PR mRNA was downregulated inNF2-related VS, which was not been reported in the literature. ER mRNA upregulationoccurred in sporadic VS, whereas PR mRNA downregulation was specific to NF2-relatedVS. Our data support the previously published suggestion that sporadic VS are twice ascommon in women than men.10It has been previously established that VS tumor cells express PR, and that conflictingreports exist regarding the expression of ER in these cells. Many of the prior studiesinvestigating ER and PR expression in VS tumors used predominantlyimmunohistochemistry. Because immunohistochemistry is nonquantitative and is notoriousfor difficulties with antigen retrieval, we felt that the question of ER and PR expression inthese tumors merited further investigation. Our results indicate that PR is downregulated inNF2-related VS, and that PR is significantly upregulated in sporadic VS. Furthermore, thelack of adequate numbers of NF2 tumors in the previous studies may explain their resultsand conclusions.The differences between NF2-related and sporadic VS are particularly interesting andsuggest possible differences in mechanisms of tumor growth. Although expression of ERand PR may play a role in the pathogenesis of sporadic VS, PR downregulation in NF2-related VS may suggest a less differentiated state. The molecular differences betweensporadic and NF2-related VS may partially explain the growth characteristics seenclinically, specifically that NF2-related VS grow at a faster rate on average and NF2-relatedVS tend to be more invasive.30 ER and PR are overexpressed or constitutively activated inseveral types of human tumors and are effective therapeutic targets in some humancancers.23,31 Tamoxifen, an orally active selective ER modulator, is used clinically in thetreatment of early and advanced ER positive breast cancer and is also Food and DrugAdministration approved for prevention of breast cancer in women at high risk ofdeveloping the disease. Selective PR modulators are defined as a new class of PR ligands,which exhibit both progesterone agonistic and antagonistic activities in vivo and are underinvestigation for the treatment of endometriosis. ER and PR independently act astranscriptional regulators. Activation of ER by ligand binding or phosphorylation is requiredPatel et al.Page 5Laryngoscope. Author manuscript; available in PMC 2013 February 12.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscriptfor its activity. There is abundant evidence that ER enhances growth factor receptorsignaling independent of ligand binding. Growth factor signaling is thought to be onemechanism by which breast cancer cells become resistant to tamoxifen. Dual therapy withHerceptin (an ErbB2 inhibitor) and tamoxifen in breast cancer has decreased the occurrenceof tumor resistance. Based on the results of this study, targeting ER and PR may havetherapeutic effect in sporadic VS, but not in NF2-related VS.CONCLUSIONAs the diagnostic studies for detecting VS have become significantly more sensitive inrecent years, patients are obtaining a diagnosis with only minor symptoms. Due to highvariability in the growth rate of these tumors between patients, understanding themechanism of growth in VS tumors would be very useful for optimal management. Thehormonal status of these tumors was investigated because of the possible induction ofvascular endothelium or proliferation of Schwann cells by the estrogenic stimulation, andthe historically suggested increase in VS growth during pregnancy.The nervous system is a target for sex steroid hormones, which have significant actions onthe growth, maturation, differentiation and functioning of glial cells. The effects of thesesteroid hormones are mediated by specific high-affinity intracellular receptors, whichfunction as activated transcription factors after hormone binding. In particular, a significantincrease in myelin-specific proteins such as myelin basic protein and cyclic nucleotidephosphodiesterase was observed when oligodendrocytes, the myelinating glial cells of thecentral nervous system, were cultured in the presence of progesterone.32In this study, a relatively limited number of tumors were investigated, and a larger seriesshould be examined for further confirmation of the results. Further quantification of theresults by other confirmatory methods such as enzyme-linked immunosorbent assay shouldbe performed. If such studies support the present findings, several possible clinicalperspectives appear. Noninvasive ER and PR imaging and thereby indication of tumorgrowth would provide an equivalent perspective. Patients with fast-growing tumors maybenefit from a blockage of the ER and/or PR.Inherited cancer syndromes, like NF2, represent the ultimate mutagenesis screen for criticalgrowth regulators (tumor suppressor genes). The fact that individuals with these cancerpredisposition syndromes predictably develop specific tumors points to the unique roles ofeach of the implicated genes in growth regulation. Targeted therapies are rationally designedto interfere with specific molecular events that are important in tumor growth, progression,or survival. Clinical studies are focusing on how to best incorporate targeted therapy intocurrent treatment regimens and other studies are exploring whether different strategies forinhibiting these targets will offer greater benefit.It is clear that optimal use of targeted therapy will depend on understanding how agentsacting on ER and PR in VS tumors work mechanistically, and recognizing that theiractivities may differ across patient populations, VS tumor types, and disease stages,especially NF2. Current therapies under discussion for initiating clinical trials to treat NF2include ErbB family inhibitors, kinase inhibitors, PAK inhibitors, PI3 K/Akt inhibitors, FAKinhibitors, Raf inhibitors, MTOR inhibitors, and angiogenesis inhibitors. Since crosstalkoccurs between ER and ErbB2 signaling pathways, dual therapy, targeting these tworeceptor types, might prove more effective in the long term.We are currently investigating the role of ER and PR in VS growth in an in vitro model.Further studies are necessary to determine whether hormone receptors play a significant rolein VS tumorigenesis or progression.Patel et al.Page 6Laryngoscope. Author manuscript; available in PMC 2013 February 12.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptAcknowledgmentsSupported by the American Otological Society Clinician Scientist Award to the senior author (J.K.D.), and by theT32 NIH training grant awarded to the Division of Otolaryngology—Head and Neck Surgery support for the firstauthor (A.K.P).The authors thank Ramina Amino for providing assistance with technical aspects of the project and in datatabulation. Special appreciation goes to Michael David, PhD, for his assistance with quantitative real-timepolymerase chain reaction techniques and for his advice and encouragement.BIBLIOGRAPHY1. Rosenberg SI. Natural history of acoustic neuromas. Laryngoscope. 2000; 110:497–508. [PubMed:10763994]2. Lanser MJ, Sussman SA, Frazer K. Epidemiology, pathogenesis, and genetics of acoustic tumors.Otolaryngol Clin North Am. 1992; 25:499–520. [PubMed: 1625863]3. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibularschwannoma and neurofibromatosis 2 in North West of England over a 10-year period: higherincidence than previously thought. Otol Neurotol. 2005; 26:93–97. [PubMed: 15699726]4. MacCollin M, Chiocca E, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, et al.Diagnostic criteria for schwannomatosis. Neurology. 2005; 64:138–145.5. Beatty CW, Scheithauer BW, Katzmann JA, Roche PC, Kjeldahl KS, Ebersold MJ. Acousticschwannoma and pregnancy: a DNA flow cytometric, steroid hormone receptor, and proliferationmarker study. Laryngoscope. 1995; 105:693–700. [PubMed: 7603272]6. Schumacher M, Guennoun R, Mercier G, Desarnaud F, Lacor P, Benavides J, Ferzaz B, et al.Progesterone synthesis and myelin formation in peripheral nerves. Brain Res Brain Res Rev. 2001;37:343–359. [PubMed: 11744099]7. Hansen MR, Linthichum FH Jr. Expression of neuregulin and activation of erbB receptors investibular schwannoma: possible autocrine loop stimulation. Otol Neurotol. 2004; 25:155–159.[PubMed: 15021776]8. Schaller B, Probst R, Gratzl O, Rem JA, Hauser R, Tolnay M. Different aspects of hearingpreservation in surgery of vestibular schwannoma in women and men. Acta Neurochir. 1996;138:1275–1281. [PubMed: 8980729]9. Magliulo G, Ronzoni R, Petti R, Marcotullio D, Marini M. Acoustic neuroma in the pregnantpatient. Eur Arch Otorhinolaryngol. 1995; 252:123–124. [PubMed: 7598873]10. Kasantikul V, Netsky MG, Glasscock ME III, Hays JW. Acoustic neurilemmomas:clinicoanatomical study of 103 patients. J Neurosurg. 1980; 52:28–35. [PubMed: 7350277]11. Beni-Adani L, Pomeranz S, Flores I, Shoshan Y, Ginosar Y, Ben-Shachar I. Huge acousticneurinomas presenting in the late stage of pregnancy. Acta Obstet Gynecol Scand. 2001; 80:179–184. [PubMed: 11167216]12. Ansari AH, Nagamani M. Pregnancy and neurofibromatosis (vonRecklinghausen’s disease). ObstetGynecol. 1976; 47:25–29.13. Cushing, H. Tumors of the Nervus Acusticus and the Syndrome of the Cerebellopontine Angle.Philadelphia: WB Saunders; 1917.14. Kachhara R, Chandrika Devi CG, Nair S, Bhattacharya RN, Radhakrishnan VV. Acousticneurinomas during pregnancy: report of two cases and review of literature. Acta Neurochir. 2001;143:587–591. [PubMed: 11534675]15. Fujimoto M, Yoshino E, Hirakawa K, Fujimoto J, Tamaya T. Estrogen receptors in brain tumors.Clin Neuropharmacol. 1984; 7:357–362. [PubMed: 6509447]16. Curley JW, Ramsden RT, Howell A, Healy K, Lye RH. Oestrogen and progesterone receptors inacoustic neuroma. J Laryngol Otol. 1990; 104:865– 867. [PubMed: 1702456]17. Markwalder TM, Waelti E, Markwalder RV. Estrogen and progestin receptors in acoustic andspinal neurilemmomas. Clinicopathologic correlations. Surg Neurol. 1986; 26:142–148. [PubMed:3726740]Patel et al.Page 7Laryngoscope. Author manuscript; available in PMC 2013 February 12.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscript18. Klinken L, Thomsen J, Rasmussen BB, Wiet RJ, Tos M. Estrogen and progesterone receptors inacoustic neuromas. Arch Otolaryngol Head Neck Surg. 1990; 116:202–204. [PubMed: 2297415]19. Kornblum JA, Bay JW, Gupta MK. Steroid receptors in human brain and spinal tumors.Neurosurgery. 1988; 23:185–188. [PubMed: 3185877]20. Whittle IR, Hawkins RA, Miller JD. Sex hormone receptors in intracranial tumours and normalbrain. Eur J Surg Oncol. 1987; 13:303–307. [PubMed: 3622783]21. Kasantikul V, Brown WJ. Estrogen receptors in acoustic neurilemmomas. Surg Neurol. 1981;15:105–109. [PubMed: 7245001]22. Doherty JK, Ongkeko O, Crawley B, Andalibi A, Ryan AF. ErbB and Nrg: Potential moleculartargets for vestibular schwannoma pharmacotherapy. Otol Neurotol. 2008; 29:50–57. [PubMed:18199957]23. Vaquero J, Marcos ML, Martinez R, Bravo G. Estrogen—and progesterone-receptor proteins inintracranial tumors. Surg Neurol. 1983; 19:11–13. [PubMed: 6828987]24. Welling DB, Packer MD, Chang LS. Molecular studies of vestibular schwannomas: a review. CurrOpin Otolaryngol Head Neck Surg. 2007; 15:341–346. [PubMed: 17823551]25. Filipo R, Petrangeli E, Monini S, Ortolani F, Gulino A, Barbara M, Frati L. Expression of steroidreceptors in acoustic neuroma. Clin Otolaryngol Allied Sci. 1995; 20:413–417. [PubMed:8582072]26. Allen J, Eldridge R, Koerber T. Acoustic neuroma in the last months of pregnancy. Am J ObstetGynecol. 1974; 119:516–520. [PubMed: 4842596]27. Cafer S, Bayramoglu I, Uzum N, Yilmaz M, Memis L, Uygur K. Expression and clinicalsignificance of Ki-67, oestrogen and progesterone receptors in acoustic neuroma. J Laryngol Otol.2008; 122:125–127. [PubMed: 17666143]28. Martinez R, Marcos ML, Figueras A, Vaquero J. Estrogen and progesterone receptors inintracranial tumors. Clin Neuropharmacol. 1984; 7:338–342. [PubMed: 6509443]29. Martuza RL, MacLaughlin DT, Ojemann RG. Specific estradiol binding in schwannomas,meningiomas, and neurofibromas. Neurosurgery. 1981; 9:665– 671. [PubMed: 7198726]30. Abaza MM, Makariou E, Armstrong M, Lalwani A. Growth rate characteristics of acousticneuromas associated with neurofibromatosis type 2. Laryngoscope. 1996; 106:694–698. [PubMed:8656953]31. Lee KS, Nagashima T, Cho KG, Mampalam TJ, Pitts LH, Hoshino T. The proliferative activity ofneurilemmomas. Surg Neurol. 1989; 32:427– 433. [PubMed: 2700052]32. Jung-Testas I, Baulieu EE. Steroid hormone receptors and steroid action in rat glial cells of thecentral and peripheral nervous system. J Steroid Biochem Mol Biol. 1998; 65:243–251. [PubMed:9699879]Patel et al.Page 8Laryngoscope. Author manuscript; available in PMC 2013 February 12.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptFig. 1.(A) Estrogen and Progesterone Receptor expression in Sporadic vestibular schwannoma(VS) tumors. (B). Estrogen and Progesterone Receptor expression in neurofibromatosis 2(NF2)-related VS tumors. Bar graphs showing results from quantitative reverse transcriptasePCR (Q-PCR) analysis of vestibular nerve and primary VS tissue removed at surgery frompatients with unilateral sporadic VS (Figure 1A; n = 23, average size 2.17 cm) and fromNF2 patients (Figure 1B; n = 17; average VS size 2.21 cm), compared with pooled sciaticnerve (SN) and greater auricular nerve (GAN) (designated SN here) as baseline (expressionin pooled SN and GAN samples was arbitrarily assigned as a ‘1’ and is not shown in thisfigure. There were no differences between GAN or SN samples nor when GAN and SNPatel et al.Page 9Laryngoscope. Author manuscript; available in PMC 2013 February 12.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscriptsamples were compared independently. Results are shown with as relative expression levelfor each targeted transcript (mRNA) on a log10 fold-induction scale. In many cases,amplification was not detected with the maximum amount of cycles in the PCR reaction (60cycles); therefore, a value of 0.00001 was assigned based on lowest level of transcriptmeasurable at 0.0001. For each sample, an internal control, human cyclophyllin, wasamplified to verify complimentary DNA (cDNA) integrity and the reaction efficacy.Upgoing bars indicate increased expression and downgoing bars indicate decreasedexpression compared with control tissue.Patel et al.Page 10Laryngoscope. Author manuscript; available in PMC 2013 February 12.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptFig. 2.ER and PR mRNA median fold-induction in NF2-related and sporadic VS. Meidanexpression was calculated due to a high degree of variability in the expression levels. NF2-related VS are shown in light blue and sporadic VS in red.Patel et al.Page 11Laryngoscope. Author manuscript; available in PMC 2013 February 12.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptFig. 3.(A) Median ER mRNA fold induction for sporadic and NF2-related VS. Though overallspread of ER expression in sporadic VS appeared less variable, this did not reach statisticalsignificance. (B) Median PR mRNA fold induction for sporadic and NF2-related VS. PRmNRA expression was significantly less in NF2-related VS compared with sporadic VS.Patel et al.Page 12Laryngoscope. Author manuscript; available in PMC 2013 February 12.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author ManuscriptPatel et al.Page 13TABLE IGene Expression Assays Used in Quantitative Reverse Transcription PCR Experiments.TransciptTaqMan Gene ExpressionAssay No.Amplicon Length (nt)Reporter Sequence (FAM Labeled)Chromosomal LocationER (alpha)Hs01046818_m167GATGAAAGGTGGGATACGAAAAGAC6q25.1PRHs00172183_m1118AATCATTGCCAGGTTTTCGAAACTT11q22–q23PCR = polymerase chain reaction; ER = estrogen receptor; PR = progesterone receptor.Laryngoscope. Author manuscript; available in PMC 2013 February 12.Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2Scott R. Plotkin, M.D., Ph.D., Anat O. Stemmer-Rachamimov, M.D., Fred G. Barker II, M.D., Chris Halpin, Ph.D., Timothy P. Padera, Ph.D., Alex Tyrrell, Ph.D., A. Gregory Sorensen, M.D., Rakesh K. Jain, Ph.D., and Emmanuelle di Tomaso, Ph.D.Departments of Neurology (S.R.P.), Pathology (A.O.S.-R.), and Radiation Oncology (T.P.P., A.T., R.K.J., E.T.); the Cancer Center (S.R.P.); the Neurosurgical Service (F.G.B.); and the A.A. Martinos Center for Biomedical Imaging (A.G.S.) — all at Massachusetts General Hospital; and the Department of Audiology, Massachusetts Eye and Ear Infirmary (C.H.) — all in BostonAbstractBACKGROUND—Profound hearing loss is a serious complication of neurofibromatosis type 2, a genetic condition associated with bilateral vestibular schwannomas, benign tumors that arise from the eighth cranial nerve. There is no medical treatment for such tumors.METHODS—We determined the expression pattern of vascular endothelial growth factor (VEGF) and three of its receptors, VEGFR-2, neuropilin-1, and neuropilin-2, in paraffin-embedded samples from 21 vestibular schwannomas associated with neurofibromatosis type 2 and from 22 sporadic schwannomas. Ten consecutive patients with neurofibromatosis type 2 and progressive vestibular schwannomas who were not candidates for standard treatment were treated with bevacizumab, an anti-VEGF monoclonal antibody. An imaging response was defined as a decrease of at least 20% in tumor volume, as compared with baseline. A hearing response was defined as a significant increase in the word-recognition score, as compared with baseline.RESULTS—VEGF was expressed in 100% of vestibular schwannomas and VEGFR-2 in 32% of tumor vessels on immunohistochemical analysis. Before treatment, the median annual volumetric growth rate for 10 index tumors was 62%. After bevacizumab treatment in the 10 patients, tumors shrank in 9 patients, and 6 patients had an imaging response, which was maintained in 4 patients during 11 to 16 months of follow-up. The median best response to treatment was a volumetric reduction of 26%. Three patients were not eligible for a hearing response; of the remaining seven patients, four had a hearing response, two had stable hearing, and one had progressive hearing loss. There were 21 adverse events of grade 1 or 2.CONCLUSIONS—VEGF blockade with bevacizumab improved hearing in some, but not all, patients with neurofibromatosis type 2 and was associated with a reduction in the volume of most growing vestibular schwannomas.Address reprint requests to Dr. Plotkin at Yawkey 9E, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114, or at splotkin@partners.org. No other potential conflict of interest relevant to this article was reported.HHS Public AccessAuthor manuscriptN Engl J Med. Author manuscript; available in PMC 2016 March 31.Published in final edited form as:N Engl J Med. 2009 July 23; 361(4): 358–367. doi:10.1056/NEJMoa0902579.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptNeurofibromatosis type 2 is a dominantly inherited genetic condition with a birth prevalence of 1 in 25,000.1 Bilateral vestibular schwannomas (also known as acoustic neuromas), which are benign tumors composed of neoplastic Schwann cells that arise from eighth cranial nerve, are the hallmark of neurofibromatosis 2. These tumors cause progressive hearing loss in most patients with neurofibromatosis type 2, who commonly lose all functional hearing during early adulthood or middle age. Standard therapy for growing sporadic, unilateral vestibular schwannomas includes surgical removal or radiation therapy. Both treatments usually achieve tumor control, but at the frequent cost of hearing loss in the affected ear.2,3Treatment options are limited for patients with neurofibromatosis type 2 and a growing vestibular schwannoma ipsilateral to the only ear with hearing. Results of surgery and radiation therapy for vestibular schwannomas associated with neurofibromatosis type 2 are worse than for sporadic tumors, because rates of tumor control are reduced and iatrogenic hearing loss is more frequent.4–6 Although the morbidity of active treatment can be prohibitively high, the consequences of unchecked tumor growth (including progressive brain-stem compression) are also severe. Currently, no medical treatments for tumors associated with neurofibromatosis type 2 are available, and a safe and effective treatment for these patients is needed.Vascular endothelial growth factor (VEGF) is a critical mediator of tumor angiogenesis and vessel permeability.7–9 VEGF and its receptor VEGFR-1 have been detected in schwannomas, and increased levels of these factors correlate with increased rates of tumor growth.10–14 Although schwannomas are not considered vascular tumors, the non–VEGF-related, antiangiogenic compound AGM-1470 inhibits angiogenesis and reduces the growth of nerve-sheath tumors in mouse models.15 The VEGF-neutralizing antibody bevacizumab has been approved by the Food and Drug Administration for use in the treatment of cancers, but no studies have been performed in patients with neurofibromatosis type 2 or vestibular schwannomas.Here we describe a retrospective study of 10 consecutive patients with neurofibromatosis type 2 and growing vestibular schwannomas who were treated with bevacizumab. We chose this agent on the basis of tumor immunohistochemical analyses suggesting a potential pathophysiological role for the VEGF pathway in vestibular schwannomas. We provide radiologic and audiologic evidence that bevacizumab treatment offered durable clinical benefit to some patients, including a reduction in tumor volume and an improvement in chronic hearing loss.METHODSIMMUNOHISTOCHEMICAL ANALYSESParaffin-embedded tissue sections from 21 schwannomas associated with neurofibromatosis type 2, 22 sporadic schwannomas, and 9 normal spinal-nerve roots were immunostained with the following antibodies: CD31, VEGF, VEGFR-2, platelet-derived growth factor receptor α (PDGFR-α), PDGFR-β, neuropilin-1, neuropilin-2, semaphorin 3A, and semaphorin 3F. Semiquantitative analysis was performed by two authors, who scored the intensity of tumor-cell and blood-vessel staining on a scale of 0 (no staining) to 3 (strong Plotkin et al.Page 2N Engl J Med. Author manuscript; available in PMC 2016 March 31.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptstaining). A customized software analysis tool was used to determine the number of vessels, perimeter, the minor axis of best fitted ellipse (representative of vessel diameter), and the total surface covered by vascular spaces. The same method was used, with the substitution of either VEGFR-2 or neuropilin-2 labeling, to determine the proportion of vessels expressing these VEGF receptors (for details, see the Supplementary Appendix, available with the full text of this article at NEJM.org).SELECTION OF PATIENTSWe offered bevacizumab on a compassionate-use basis to patients who fulfilled the clinical diagnostic criteria for neurofibromatosis type 2,16 had evidence of progressive vestibular schwannomas, and were considered poor candidates for surgery and radiation therapy or declined these treatments. Consecutive patients who met these criteria and had received at least one bevacizumab dose as of August 1, 2008, were included in the analysis.CLINICAL EVALUATIONSThe intervals for clinical evaluations were determined before treatment of the first patient. Baseline magnetic resonance imaging (MRI) and audiology were performed within 1 month before starting treatment. Clinical evaluation, which included a physical examination, complete blood count, blood chemical analysis, and urinalysis, was performed every 2 to 4 weeks during treatment. Tumor response was monitored with the use of serial MRI scanning at clinical visits at months 1, 3, and 6 and every 3 months thereafter. Tumor volumetric analysis was performed as described previously.17 To investigate whether tumor shrinkage might be related, in part, to a decrease in intratumoral vasogenic edema, we subsequently determined the mean apparent diffusion coefficient (a measure of the magnitude of diffusion of water molecules within tissue and a marker of edema on imaging with MRI18) within vestibular schwannomas at baseline. Dynamic contrast-enhanced MRI (DCE-MRI) was performed in Patient 6 to evaluate changes in blood flow and vascular permeability after treatment.18 Hearing response was monitored with the use of serial audiologic evaluations, including determination of pure-tone thresholds and word-recognition scores (for details, see the Supplementary Appendix).19,20 Data regarding toxic effects were collected monthly during routine clinic visits, and adverse events were scored according to the Common Terminology Criteria for Adverse Events, version 3.0.DEFINITIONS OF IMAGING AND HEARING RESPONSESWe established definitions of imaging and hearing responses after noting a clinical benefit in the first patient. An imaging response was defined as a decrease of at least 20% in tumor volume, as compared with the pretreatment baseline.21 Volumetric changes of 15% or 20% have been used to define response and progression in early-phase trials involving patients with plexiform neurofibromas associated with neurofibromatosis type 1.22,23A hearing response was defined as a significant increase in the word-recognition score, as compared with the baseline score.24 Patients were eligible for a hearing response if their pretreatment word-recognition score allowed for hearing improvement above the upper limit of the critical-difference threshold (i.e., a word-recognition score of 94% or less). Patients with surgically disrupted auditory nerves were not eligible for a hearing response. We used Plotkin et al.Page 3N Engl J Med. Author manuscript; available in PMC 2016 March 31.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptpublished guidelines25 to determine significant differences between word-recognition scores to compare each patient’s scores after treatment with baseline values.STUDY OVERSIGHTThe institutional review board at Massachusetts General Hospital approved the retrospective chart review and tumor-specimen collections. All patients provided written informed consent for treatment. The authors vouch for the completeness and veracity of the data and data analyses. Bevacizumab was provided as part of clinical care; Genentech, the maker of bevacizumab, had no role in the study.STATISTICAL ANALYSISFor analyses of morphologic features, microvascular density, and measures of diameter and perimeter, we used Bartlett’s test for the equality of multiple variances to analyze between-group differences in variance. Analysis-of-variance estimate models were then built and appropriate post hoc testing was performed on the basis of Bartlett’s test results. For measures with equal variances, Tukey’s test was used. For measures with unequal variances, the Games–Howell test was used. A P value of less than 0.05 was considered to indicate statistical significance.RESULTSIMMUNOHISTOCHEMICAL ANALYSESIn normal peripheral nerves, the ligands VEGF, semaphorin 3A, semaphorin 3F, and the receptors VEGFR-2 and neuropilin-1 were consistently expressed in both Schwann cells and vascular endothelial cells; neuropilin-2 was seen in all Schwann cells but in less than 5% of blood vessels (Fig. 1A, and Fig. 1 in the Supplementary Appendix). In the schwannomas, tumor cells had expression patterns of VEGF, neuropilin-1, and neuropilin-2 that were similar to those in normal nerve. In contrast, VEGFR-2 was expressed in about half of all schwannomas, and semaphorin 3A and semaphorin 3F were expressed in only 20% of schwannomas and at reduced intensity (Fig. 1A and 1B, and Fig. 2 in the Supplementary Appendix).VEGFR-2 was found in 32% of vessels in tumors associated with neurofibromatosis type 2 and in sporadic tumors. In contrast, all vessels expressed neuropilin-1 (similar to normal nerve), and about 10% of vessels expressed neuropilin-2 (Fig. 1C). Most tumor cells showed little or no expression of PDGFR-α or PDGFR-β. More than 50% of tumor specimens expressed both PDGFR-α and PDGFR-β on the vascular endothelium, consistent with an angiogenic phenotype (Fig. 3 in the Supplementary Appendix).Morphometric analysis revealed that schwannomas associated with neurofibromatosis type 2 showed a greater microvascular density (22 vessels per square millimeter) and a larger vessel diameter (mean, 14.2 μm), and perimeter (mean, 91 μm) than normal nerve (with 18 vessels per square millimeter and a mean vessel diameter of 7.9 μm and perimeter of 47 μm) (Fig. 1D).Plotkin et al.Page 4N Engl J Med. Author manuscript; available in PMC 2016 March 31.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptPATIENTSThe baseline characteristics of the 10 patients in the study are shown in Table 1. All patients were poor candidates for standard treatment, since eight were at high risk for complete hearing loss and one for bilateral lower cranial-nerve palsies, and one patient had declined surgery or radiation. Patients 1 through 5 had been treated previously with erlotinib chemotherapy26 but stopped treatment because of either toxic effects (Patient 1) or tumor growth (Patients 2 through 5).TREATMENTSix men and four women with a median age of 25 years (range, 16 to 53) received intravenous bevacizumab at a dose of 5 mg per kilogram of body weight every 2 weeks. The median annual growth rate in tumor volume before treatment was 62% (range, 9 to 121). The median duration of treatment was 12 months (range, 3 to 19), and six patients were followed for at least 1 year. Six patients continued to be treated with bevacizumab at the end of the study. Patient 1 stopped treatment after 19 months because of slow growth of a vestibular schwannoma, which caused brainstem compression; the tumor was subsequently resected. Patient 5 discontinued bevacizumab temporarily as she awaited surgical removal of a nonvestibular schwannoma. Patient 7 stopped bevacizumab after 3 months because of progressive growth of a spinal meningioma; he died of complications after surgery to resect the tumor 5 months later. Patient 8 stopped treatment after 8 months because of progressive growth of a vestibular schwannoma and hearing loss.IMAGING RESPONSEOf the 10 tumors, 9 shrank after bevacizumab treatment, and 6 had an imaging response (Table 1, and Fig. 4 in the Supplementary Appendix). The median best response to treatment was 26% shrinkage (range, 44% shrinkage to 32% growth). Of six tumors that had an objective imaging response, the response was maintained in four tumors at the last imaging follow-up 11 to 16 months after the initiation of treatment. Three tumors remained stable (i.e., ranging from a 19% reduction to a 19% increase in volumetric growth, as compared with baseline) during bevacizumab treatment, and one patient had an increase in tumor volume of 32%.A strong correlation was observed between the mean apparent diffusion coefficient at baseline within tumors and the percent decrease in volume at 3 months (Pearson’s r correlation, −0.87; r2 = 0.75; P = 0.001) (Fig. 2A). In the single patient with complete DCE-MRI data (Patient 6), a measure of blood flow and vascular permeability decreased by 68%, tumor blood volume decreased by 77%, tumor blood flow decreased by 51%, mean transit time decreased by 9%, and the average vessel size decreased by 70% at 3 months (Fig. 2B). Twelve months after the initiation of treatment, measures of blood flow and vascular permeability continued to fall. Although the amount of gadolinium enhancement decreased over time, the enhancement pattern within vestibular schwannomas did not change noticeably during treatment (Fig. 2C).Plotkin et al.Page 5N Engl J Med. Author manuscript; available in PMC 2016 March 31.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptHEARING RESPONSESeven patients were considered eligible for a hearing response. Of the other three patients, two had normal hearing ipsilateral to index vestibular schwannomas at baseline (and thus could not improve), and one had undergone surgical resection of both auditory nerves. A hearing response was observed in four of seven eligible patients (57%) (Fig. 5 in the Supplementary Appendix). The hearing benefit of bevacizumab was large for Patient 2, whose word-recognition score increased from 8% to 98%, and for Patient 3, whose word-recognition score increased from 34% to 76%. Both Patient 2 and Patient 3 regained useful hearing, and they were able to resume school and work, respectively. Patient 4, whose word-recognition score increased from 0% to 40%, reported better speech-reading (lip-reading), and Patient 5, whose word-recognition score increased from 76% to 94%, also reported improvement in face-to-face conversation. Patients with a hearing response showed progressive improvement in word recognition, which began about 8 weeks after the initiation of treatment and continued to improve for as long as 16 months (Fig. 5 in the Supplementary Appendix). Among the four patients who had a hearing response, the result was durable for 11 to 16 months.Of the three patients who did not have a hearing response, Patient 1 had had no word recognition for at least 8 months before treatment, Patient 8 had a decline in word recognition (44% to 16%) after starting treatment despite initial tumor shrinkage, and Patient 10 had stable hearing despite a sustained reduction in tumor volume. Although Patient 1 did not have a hearing or an imaging response, he had clinical improvement that may have been related to treatment. Before treatment, he was receiving hospice care because of intractable headache and vomiting associated with critical brain-stem compression. Within 4 weeks after starting therapy, his headaches and vomiting resolved, and he returned to high school. He remained clinically improved for 19 months of treatment but then required resection of his vestibular schwannoma for tumor growth. Four of five patients reported subjective improvement in baseline tinnitus, and one noted no change.ADVERSE EFFECTSA total of 21 grade 1 or 2 adverse events were reported, including increased levels of aspartate aminotransferase (4 events) and alanine aminotransferase (3 events), proteinuria (3 events), hypertension (2 events), delayed wound healing (2 events), hyperkalemia (2 events), hyperbilirubinemia (2 events), uterine bleeding (1 event), hypocalcemia (1 event), hypophosphatemia (1 event), and hypomagnesemia (1 event). Two patients had infected vascular access ports requiring removal. In this small sample of patients, no patients had thromboembolic events, hemorrhage, congestive heart failure, gastrointestinal perforation, or reversible posterior leukoencephalopathy. No patient discontinued treatment because of adverse events, and no grade 3 or 4 adverse events were reported.DISCUSSIONOur study showed that bevacizumab treatment was followed by clinically meaningful hearing improvement, tumor-volume reduction, or both in some, but not all, patients with neurofibromatosis type 2 who were at risk for complete hearing loss or brain-stem Plotkin et al.Page 6N Engl J Med. Author manuscript; available in PMC 2016 March 31.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptcompression from growing vestibular schwannomas. Our findings confirm that VEGF is produced by schwannoma tumor cells10–14 and suggests that this growth factor may participate in tumor growth and hearing loss associated with vestibular schwannomas. The imaging findings indicate that the mean apparent diffusion coefficient at baseline might be a potential marker for volumetric response to anti-VEGF therapy. The DCE-MRI data, though limited, further suggest that bevacizumab normalizes the function of tumor vessels and potentially restores a more normal blood–nerve barrier.These findings have implications for patients with neurofibromatosis type 2 and for the study of vestibular schwannoma biology. First, the reduced expression of VEGFR-2 on tumor vessels suggested that interfering with the function of VEGF receptors might be less effective than targeting VEGF directly, which prompted our choice of bevacizumab for treatment. Our data suggest that the current understanding of VEGF-mediated angiogenesis — that VEGF is secreted by tumor cells and then binds to and activates VEGFR-2 on endothelial cells — may be more complex in schwannomas, in which vessels express different VEGF receptors. Further work is needed to understand the role of the semaphorin–neuropilin axis in these tumors.Second, VEGF inhibition can lead to modest but relevant decreases in the volume of vestibular schwannomas. This effect is notable, given the lack of sensitivity of benign nervous-system tumors to standard cytotoxic chemotherapy. Third, in some patients, VEGF inhibition can lead to a relatively rapid (<12 weeks) improvement in hearing, as reflected by word-recognition scores, with sustained improvement for up to 16 months. Observational studies have shown that word-recognition scores deteriorate over time in patients with vestibular schwannomas and that significant improvement is not expected.27 We posit that improvement is due to a reduction in intraneural edema, as well as tumor shrinkage. This assertion is supported by the time course of hearing improvement, the correlation between the mean apparent diffusion coefficient and tumor shrinkage, and the changes in intratumoral vascular permeability, as seen on DCE-MRI. This mechanism is consistent with the vascular-normalization hypothesis28 and previous studies of anti-VEGF therapy in malignant brain tumors.18,29To date, four of our six patients with an imaging response and all four patients with a hearing response have continued to respond to therapy for 11 to 16 months. This suggests that response to anti-VEGF therapy can be durable for progressive vestibular schwannomas associated with neurofibromatosis type 2. In contrast, the median time to progression for recurrent glioblastoma treated with antiangiogenic therapy is about 16 weeks.18,30 Patients with benign tumors who benefit from anti-VEGF therapy present unique clinical challenges: they may have prolonged survival during which unanticipated delayed toxic effects could become manifest, and the implications of stopping therapy are unknown, with the potential for rebound tumor growth when monoclonal treatment is stopped.18Although the need for an effective medical therapy for patients with neurofibromatosis type 2 is clear, the risk of toxic effects deserves careful consideration. In our preliminary experience, toxic effects were limited to grade 1 or 2 adverse events during follow-up of up to 16 months, which is not long in comparison with the expected survival of these young Plotkin et al.Page 7N Engl J Med. Author manuscript; available in PMC 2016 March 31.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptpatients. The absence of many common toxic effects of bevacizumab in our patients may have reflected their relative youth, the lack of other medical conditions, and the small number of patients who were treated.Our results show an interesting biologic effect of bevacizumab treatment on vestibular schwannomas associated with neurofibromatosis type 2. However, we treated only patients with neurofibromatosis type 2 who were at imminent risk for severe neurologic consequences and not those with less advanced symptoms or patients with sporadic vestibular schwannomas. Additional research will be necessary to determine the optimal drug regimen, duration, and adverse-effect profile for long-term anti-VEGF therapy for vestibular schwannomas associated with neurofibromatosis type 2.Supplementary MaterialRefer to Web version on PubMed Central for supplementary material.AcknowledgmentsSupported by the Harvard Medical School Center for Neurofibromatosis and Allied Disorders; Neurofibromatosis, Inc., New England; the Children’s Tumor Foundation; a grant (NF050202, to Dr. Plotkin) from the Neurofibromatosis Research Program of the Department of Defense; a Claflin Award (to Dr. di Tomaso); grants (P01NS024279, to Dr. Stemmer-Rachamimov; and P01CA80124, to Dr. Jain) from the National Institutes of Health; and grants from the Federal Share/National Cancer Institute Proton Beam Program (to Drs. di Tomaso and Jain).Dr. Plotkin reports receiving consulting fees from Novartis and grant support from Pfizer; Dr. Sorensen, receiving grant support from AstraZeneca, Exelixis, Schering-Plough, Genentech, Novartis, Takeda/Millennium, and Siemens Medical Solutions and consulting fees from AstraZeneca, Bayer Healthcare, Genentech, Mitsubishi Pharma, Novartis, and Takeda/Millennium; and Dr. Jain, receiving consulting fees from AstraZeneca, Dyax, Enlight, and Millennium and lecture fees from Roche Pharmaceuticals and Pfizer, having an equity interest in Enlight and SynDevRx, and receiving grant support from AstraZeneca and Dyax.We thank Marybeth Singh for her clinical care and Drs. Meiyun Wang, Poe-jou Chen, and Dominique Jennings for their work in analyzing the imaging data.References1. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. 2005; 26:93–7. [PubMed: 15699726] 2. Samii M, Gerganov V, Samii A. Improved preservation of hearing and facial nerve function in vestibular schwannoma surgery via the retrosigmoid approach in a series of 200 patients. J Neurosurg. 2006; 105:527–35. [PubMed: 17044553] 3. Flickinger JC, Kondziolka D, Niranjan A, Lunsford LD. Results of acoustic neuroma radiosurgery: an analysis of 5 years’ experience using current methods. J Neurosurg. 2001; 94:1–6. [PubMed: 11147876] 4. Brackmann DE, Fayad JN, Slattery WH III, et al. Early proactive management of vestibular schwannomas in neurofibromatosis type 2. Neurosurgery. 2001; 49:274–80. [PubMed: 11504103] 5. Combs SE, Volk S, Schulz-Ertner D, Huber PE, Thilmann C, Debus J. Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys. 2005; 63:75–81. [PubMed: 16111574] 6. Samii M, Matthies C, Tatagiba M. Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery. 1997; 40:696–705. [PubMed: 9092842] Plotkin et al.Page 8N Engl J Med. Author manuscript; available in PMC 2016 March 31.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285:1182–6. [PubMed: 4938153] 8. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407:249–57. [PubMed: 11001068] 9. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis. 2008; 11:109–19. [PubMed: 18293091] 10. Brieger J, Bedavanija A, Lehr HA, Maurer J, Mann WJ. Expression of angiogenic growth factors in acoustic neurinoma. Acta Otolaryngol. 2003; 123:1040–5. [PubMed: 14710905] 11. Cayé-Thomasen P, Baandrup L, Jacobsen GK, Thomsen J, Stangerup SE. Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope. 2003; 113:2129–34. [PubMed: 14660915] 12. Cayé-Thomasen P, Werther K, Nalla A, et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol. 2005; 26:98–101. [PubMed: 15699727] 13. Saito K, Kato M, Susaki N, Nagatani T, Nagasaka T, Yoshida J. Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Neuropathol. 2003; 22:30–4. [PubMed: 12617191] 14. Uesaka T, Shono T, Suzuki SO, et al. Expression of VEGF and its receptor genes in intracranial schwannomas. J Neurooncol. 2007; 83:259–66. [PubMed: 17570036] 15. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza RL. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery. 1994; 34:869–75. [PubMed: 8052385] 16. Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R. NIH conference: neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis): an update. Ann Intern Med. 1990; 113:39–52. [PubMed: 2112353] 17. Harris GJ, Plotkin SR, MacCollin M, et al. Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery. 2008; 62:1314–9. [PubMed: 18824998] 18. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007; 11:83–95. [PubMed: 17222792] 19. Monsell EM. New and revised reporting guidelines from the Committee on Hearing and Equilibrium, American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc. Otolaryngol Head Neck Surg. 1995; 113:176–8. [PubMed: 7675474] 20. Hirsh IJ, Davis H, Silverman SR, Reynolds EG, Eldert E, Benson RW. Development of materials for speech audiometry. J Speech Hear Disord. 1952; 17:321–37. [PubMed: 13053556] 21. Plotkin SR, Halpin C, Blakely JO, et al. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol. 2009; 93:61–77. [PubMed: 19430883] 22. Babovic-Vuksanovic D, Ballman K, Michels V, et al. Phase II trial of pirfenidone in adults with neurofibromatosis type 1. Neurology. 2006; 67:1860–2. [PubMed: 17035676] 23. Babovic-Vuksanovic D, Widemann BC, Dombi E, et al. Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr Neurol. 2007; 36:293–300. [PubMed: 17509460] 24. Thornton AR, Raffin MJ. Speech-discrimination scores modeled as a binomial variable. J Speech Hear Res. 1978; 21:507–18. [PubMed: 713519] 25. Halpin C, Rauch SD. Using audiometric thresholds and word recognition in a treatment study. Otol Neurotol. 2006; 27:110–6. [PubMed: 16371857] 26. Plotkin SR, Singh MA, O’Donnell CC, Harris GJ, McClatchey AI, Halpin C. Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol. 2008; 5:487–91. [PubMed: 18560388] 27. Caye-Thomasen P, Dethloff T, Hansen S, Stangerup SE, Thomsen J. Hearing in patients with intracanalicular vestibular schwannomas. Audiol Neurootol. 2007; 12:1–12. [PubMed: 17033159] 28. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307:58–62. [PubMed: 15637262] Plotkin et al.Page 9N Engl J Med. Author manuscript; available in PMC 2016 March 31.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript29. Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009; 27:2542–52. [PubMed: 19332720] 30. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000; 18:708–15. [PubMed: 10673511] Plotkin et al.Page 10N Engl J Med. Author manuscript; available in PMC 2016 March 31.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 1. Angiogenic Profile of Vestibular SchwannomasPanel A shows immunohistochemical analysis of members of the vascular endothelial growth factor (VEGF) pathway in normal peripheral nerve and schwannoma. In normal nerve, staining for VEGF highlights Schwann cells (arrows), and staining for VEGF receptor 2 (VEGFR-2) highlights vessels (arrowheads). Staining for neuropilin-2 (NRP-2) and semaphorin 3F (SEMA-3F) highlights Schwann cells in normal nerve. In schwannomas, VEGF staining highlights tumor cells (arrowhead) and blood vessels (arrow); VEGFR-2 staining highlights some vessels (arrowheads), whereas others remain unstained (arrows). Plotkin et al.Page 11N Engl J Med. Author manuscript; available in PMC 2016 March 31.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptTumor cells stain diffusely for NRP-2 but not for SEMA-3F. In all panels, brown staining shows positivity for the given antigen, and blue labels the nuclei, with the letter A denoting axon, the letter M myelin, and the letter S Schwann cell. Panel B shows the percentage of samples with expression of more than 1 on a scale of 0 (no staining) to 3 (strong staining) for the known members of the VEGF pathway (ligands and receptors). SEMA-3F and SEMA-3A are expressed in all nerve roots (3 intensity). In samples from patients with neurofibromatosis type 2 (NF2), 58% of the tumors have completely negative staining for SEMA-3F, and 22% are negative for SEMA-3A. In samples from patients with sporadic tumors, 44% of tumors are negative for SEMA-3F, and 33% are negative for SEMA-3A. Since none of the samples were scored as 2 or 3, no bar is shown for SEMA-3A. Panel C shows the quantification of the number of vessels per square millimeter expressing VEGFR-2 and NRP-2 in vestibular schwannomas associated with neurofibromatosis type 2 and sporadic vestibular schwannomas. CD31 was used to count the total number of vessels per square millimeter. There were no significant differences between tumors associated with neurofibromatosis type 2 and sporadic tumors. Panel D shows statistical analysis of the morphometric measures. Diameter, perimeter, and microvascular density were all significantly smaller for the 470 vessels analyzed in normal peripheral nerve roots than in either schwannomas associated with neurofibromatosis type 2 (1215 vessels from 20 patients) or sporadic schwannomas (2104 vessels from 17 patients). The perimeters (or surface area, data not shown) were significantly larger in tumors associated with neurofibromatosis type 2 than in sporadic tumors.Plotkin et al.Page 12N Engl J Med. Author manuscript; available in PMC 2016 March 31.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 2. Changes in Magnetic Resonance Imaging (MRI) Measures during Treatment with BevacizumabPanel A shows the correlation between mean apparent diffusion coefficients (ADCs) at baseline and subsequent changes in tumor volume for the 10 patients after 3 months of treatment with bevacizumab. Panel B shows dynamic contrast-enhanced MRIs of Patient 6, with measures of blood flow and vascular permeability indicating the permeability of vestibular schwannomas (with the most permeable areas shown in white and the least permeable areas in dark red). At baseline, permeability is high for both tumors but decreases progressively during 12 months of treatment, as shown by the values beneath the images. Plotkin et al.Page 13N Engl J Med. Author manuscript; available in PMC 2016 March 31.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptPanel C shows representative cranial T1-weighted MRI scans of Patient 2 after the administration of contrast material at baseline (left) and after 9 months of treatment (right). T2-weighted scans are also shown at the same time points. The overall decrease in tumor volume (30%) can be seen by comparing the tumor outline at baseline (yellow line) with the outline after 3 months of treatment with bevacizumab (red line). The enhancement pattern in vestibular schwannomas did not change noticeably during treatment with bevacizumab.Plotkin et al.Page 14N Engl J Med. Author manuscript; available in PMC 2016 March 31.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptPlotkin et al.Page 15Table 1Baseline Characteristics of the Patients and Outcomes after Treatment with Bevacizumab.PatientNo.AgeSexInheritancePreviousChemotherapyIndicationfor TreatmentBaselineTumor SizeBaselineAnnualGrowth RateTreatmentDurationMaximumChangein TumorVolumeImaging Response*HearingResponse†yrcm3%mo%116MFamilialErlotinibBrain-stem compression24.911819    −5Stable diseaseStable hearing222FFounderErlotinibHearing loss10.4  7517‡−30Imaging responseHearing response323MFounderErlotinibHearing loss19.512115‡−28Imaging responseHearing response426FFounderErlotinibHearing loss  2.2  2615‡−14Progressive diseaseHearing response518FFounderErlotinibHearing loss28.9  6512  −44Imaging responseHearing response653MFounderNoneHearing loss  2.5  5812‡−32Imaging responseNot eligible732MFamilialNoneBrain-stem compression38.7  53  3−24Imaging responseNot eligible844FFounderNoneHearing loss  2.2    9  8−27Progressive diseaseProgressive hearing loss932MFounderNoneHearing loss  2.5  1410‡+32Progressive diseaseNot eligible1018MFounderNoneHearing loss22.6  78  8‡−17Stable diseaseStable hearing*An imaging response was defined as a decrease in tumor volume of at least 20% on MRI, as compared with baseline. Progressive disease was defined as an increase in tumor volume of at least 20%, as compared with baseline. Stable disease was defined as a change in tumor volume ranging from a reduction of 19% to an increase of 19%, as compared with baseline.†A hearing response was defined as an increase in the word-recognition score above the critical-difference threshold, as compared with baseline. Progressive hearing loss was defined as a decrease in the word-recognition score below the critical-difference threshold, as compared with baseline. Stable hearing was defined as a change in the word-recognition score within the critical-difference threshold.‡This patient was still receiving bevacizumab at the end of the study period.N Engl J Med. Author manuscript; available in PMC 2016 March 31.High-resolution interrogation of functional elements in the noncoding genomeNeville E. Sanjana1,2,*,†,‡, Jason Wright1,2,*, Kaijie Zheng1,2, Ophir Shalem1,2, Pierre Fontanillas1, Julia Joung1,2, Christine Cheng1,3, Aviv Regev1,3, and Feng Zhang1,2,†1Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA2McGovern Institute for Brain Research, Department of Brain and Cognitive Sciences, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA3Howard Hughes Medical Institute, David H. Koch Institute of Integrative Cancer Biology, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USAAbstractThe noncoding genome affects gene regulation and disease, yet we lack tools for rapid identification and manipulation of noncoding elements. We develop a CRISPR screen employing ~18,000 sgRNAs targeting >700 kb surrounding the genes NF1, NF2, and CUL3, which are involved in BRAF inhibitor resistance in melanoma. We find that noncoding locations that modulate drug resistance also harbor predictive hallmarks of noncoding function. With a subset of regions at the CUL3 locus, we demonstrate that engineered mutations alter transcription factor occupancy and long-range and local epigenetic environments, implicating these sites in gene regulation and chemotherapeutic resistance. Though our expansion of the potential of pooled CRISPR screens we provide tools for genomic discovery and for elucidating biologically relevant mechanisms of gene regulation.Pooled CRISPR mutagenesis identifies functional elements in the noncoding genome.More than 98% of the human genome does not code for proteins, however, unlike the coding genome there exists no overarching framework to translate noncoding genomic sequence into functional elements (1, 2). Evidence from genome-wide association studies (GWAS) suggests many noncoding regions are critical for human health (3, 4). The significance of these associations, however, has been difficult to assess, in part because we lack the tools to determine which variants alter functional elements. Molecular hallmarks, such as epigenetic †Correspondence should be addressed to: nsanjana@nygenome.org (N.S.) and zhang@broadinstitute.org (F.Z.).*These authors contributed equally to this work.‡Present address: New York Genome Center, New York, NY 10013, Department of Biology, New York University, New York, NY 10012.Supplementary MaterialsMaterials and MethodsSupplementary TextFigures S1 to S13Tables S1 to S7References (26–42)HHS Public AccessAuthor manuscriptScience. Author manuscript; available in PMC 2017 March 30.Published in final edited form as:Science. 2016 September 30; 353(6307): 1545–1549. doi:10.1126/science.aaf7613.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptstate, chromatin accessibility, transcription factor binding, and evolutionary conservation, correlate with putative functional elements in the noncoding genome and can predict regulatory function (2, 5). However, these predictions largely bypass regions lacking hallmarks, and it is difficult to ascertain what hallmarks play a correlative or truly causal role in function or phenotype (6, 7). Efforts to determine causality have employed preselected DNA fragments with expression serving as a proxy for function (8) but these methods lack the local chromatin context and broader regulatory interactions. Thus there is a need for systematic approaches to sift through noncoding variants and determine if and how they affect phenotypes within a native biological context.For this purpose, we designed a high-throughput method using pooled CRISPR (Clustered regularly-interspaced short palindromic repeat)-Cas9 single guide RNA (sgRNA) libraries to screen noncoding genomic loci to identify functional regions related to phenotype and gene regulation. Previous applications of CRISPR screens within the noncoding genome have focused on specific functional elements (e.g. miRNAs, transcription factor binding sites) or required fluorescent reporters (9–12). Here, we comprehensively assay a total of 715 kb of sequence surrounding three different genes by performing unbiased mutagenesis to identify functional elements relevant to cancer drug resistance.Vemurafenib inhibits BRAF proteins carrying the V600E mutation, found in 50–70% of melanomas (13). Resistance to vemurafenib arises within months in almost all melanoma patients (14) and surviving tumor cells display increased malignancy that rapidly leads to lethality (15). A genome-scale CRISPR screen found that loss-of-function mutations in NF1, NF2, and CUL3 result in vemurafenib resistance (16). To explore if mutations in the noncoding regions around these three genes could similarly impact drug resistance, we designed three sgRNA libraries tiling across 100 kb regions 5´ and 3´ of each gene’s major isoforms (Fig. 1A). For each library, we synthesized the sgRNAs as a pool (6,682 for NF1, 6,934 for NF2, and 4,699 for CUL3; 18,315 sgRNAs total) and cloned them into a lentiviral vector (fig. S1). We transduced A375 human melanoma cells, which carry the BRAF mutation, with the sgRNA libraries at a low multiplicity of infection and cultured them in 2uM vemurafenib or control (DMSO) for 14 days. Using deep sequencing, we counted the representation of sgRNAs in the library in both conditions (Fig. 1B–D) and identified vemurafenib-enriched sgRNAs as those enriched >4 standard deviations from the control distribution (fig. S2).Overall, most sgRNAs were depleted after treatment with vemurafenib, which is expected since vemurafenib targets the oncogene addiction that drives A375 growth (Fig. 1E). However, in all three libraries, we found a small group of sgRNAs that were enriched after vemurafenib treatment (log2 ratio of Vemu/Control > 0), with the CUL3 library having the largest percentage of enriched sgRNAs. As we also included a small number of sgRNAs targeting the coding region of each gene, most sgRNAs targeting coding regions (70 – 80%) were enriched, as expected (fig. S3A). However, amongst the sgRNAs targeting noncoding regions, approximately 4-fold more sgRNAs were enriched in the CUL3 library than in the NF1 or NF2 libraries (7.2% in CUL3, 1.7% in NF1, and 2.1% in NF2), suggesting the presence of more gene regulatory elements in the noncoding regions flanking the gene (fig. S3A). To determine if this increase in putative gene regulatory elements in the 200 kb region Sanjana et al.Page 2Science. Author manuscript; available in PMC 2017 March 30.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptsurrounding CUL3 is also reflected in human gene expression and genotyping data, we queried the Genotype-Tissue Expression (GTEx) database (7,051 tissue samples from 449 donors). Indeed, we found that CUL3 had the largest number of cis-expression quantitative trait loci (eQTL) (n = 161 eQTLs, mean effect size = −0.21), and the region targeted by the sgRNA library overlaps with a large number of these eQTLs (fig. S3B) (17). We thus chose to focus our downstream analysis and validation efforts on CUL3.We visualized the enriched sgRNAs in a genome browser-style view (Figs. 1F, S4A, B). We found that a higher percentage of sgRNAs targeting gene-proximal elements were enriched compared to other noncoding regions (Fig. 1G) and greater enrichment for sgRNAs targeting noncoding elements on the 5´ side of the gene than for those on the 3´ side (fig. S4C).To test if regions targeted by enriched sgRNAs from the screen physically interact with the CUL3 promoter via chromatin looping (18), we created three independent chromosome conformation capture (3C) libraries (Fig. 2A) (19). We quantified the interaction frequency for each site across the ~200 kb region (43) and found that regions on the 5´ side of CUL3 tend to interact more strongly with the promoter. Regions with higher 3C interaction contain, on average, more vemurafenib-enriched sgRNAs (Fig. 2B).Since chromatin accessibility can identify regulatory regions (20, 21), we performed Assay of Transposase-Accessible Chromatin sequencing (ATAC-seq) in A375 melanoma, MCF7 breast adenocarcinoma and U87 glioblastoma cells (Fig. 2C). Overall, we found higher sgRNA enrichment near A375-specific ATAC peaks than near those from other cell types, which was replicated with DNAseI hypersensitivity data (Figs. 2D–E, S5). These regions suggest the presence of cell type-specific enhancers (22, 23). Even though the accessible peaks overlap with enriched sgRNA sites, the chromatin accessibility data by itself only predicts a small fraction of the total number of enriched sgRNA sites (table S1).Since evolutionary conservation varies widely across the noncoding genome, we sought to test whether regions exhibiting higher levels of conservation harbor more enriched sgRNAs. We examined phastCons conservation scores among primates, placental mammals, and vertebrates over the CUL3 locus (Fig. 2F) (24). Overall, enriched sgRNAs are ~1.8-fold more likely to be found near peaks of primate conservation and are ~1.7-fold less likely to be found near conservation peaks among mammals and vertebrates (Figs. 2G, S5). In contrast, the genomic sites of sgRNAs targeting coding regions of CUL3 do not demonstrate differential conservation (phastCons probability ~ 0.95 in primates, mammals and vertebrates). This observation supports recent findings that enhancers evolve rapidly in a lineage- or species-specific manner and conserved enhancers between mammals tend to be rare (25).To confirm that mutations in these specific noncoding regions were mediated by CUL3 and lead to altered drug resistance, we transduced cells with individual sgRNAs having at least one other enriched sgRNA within 500 bp (Fig. 3A). We validated that the sgRNA created mutations at the intended target sites (fig. S6) and found that 24 out of the 25 sgRNAs resulted in decreased CUL3 expression relative to non-targeting sgRNAs (Fig. 3B). As expected, there is a negative correlation between CUL3 gene expression and vemurafenib Sanjana et al.Page 3Science. Author manuscript; available in PMC 2017 March 30.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscriptresistance (r = −0.54, p = 0.005) (Fig. 3C) and increased vemurafenib resistance can be reversed by restoring CUL3 expression (fig. S7).Next, we surveyed changes in post-translational histone modifications at each target site (fig. S8A) (43). With target sites near the promoter, we found a 56% average decrease of H3K4me3 after editing (p = 7×10−4, n = 9 sites) (Fig. 3D), consistent with the reduced gene expression. At distal sites, we found a 41% average decrease in H3K27ac (p = 0.02, n = 7 sites) after editing and no significant change in H3K4me2 (p = 0.82, n = 7 sites) (Fig. 3D), although a subset of H3K4me2 levels decreased after editing (fig. S8B). We also found that mutagenesis of a ~22 kb distal histone acetyl-transferase (p300) binding site that has a strong 3C promoter interaction results in a 75% decline of promoter H3K27ac and a 50% decrease in CUL3 expression (fig. S9, 43).By examining regions targeted by enriched sgRNAs, we found individual loci containing the canonical transcription factor binding motifs for Yin Yang 1 (YY1), Zinc Finger Protein 263 (ZNF263), CCCTC-binding factor (CTCF) and activation protein 1 (AP-1) complex which were disrupted after editing (Figs. 4A–D, S10). We found that mutations within these binding sites abrogate transcription factor recruitment leading to loss of CUL3 expression (Figs. 4E–H). For example, specific sgRNAs that target near a YY1 ChIP peak (Fig. 4B) disrupt the YY1 motif (fig. S11) and vemurafenib treatment selects for mutations that are more deleterious to the binding site (fig. S12). Although both sgRNAs targeting near the site decrease YY1 binding, the sgRNA whose cut site overlaps the motif more efficiently disrupts YY1 binding (67% vs. 26%) (Fig. 4E). In addition, mutagenesis by either sgRNA significantly decreases CUL3 expression. Similarly, 2 sgRNAs in the first intron of CUL3 spaced 30 bp apart overlap a ZNF263 ChIP-seq peak (Fig. 4B). Both result in a significant decrease in ZNF263 occupancy and in CUL3 expression (Fig. 4F).Although we observed a bias in the presence of regulatory elements 5´ of the transcription start site, we did find several enriched sgRNAs downstream of CUL3 (Fig. 4C, D) (43). One sgRNA cuts inside the core motif of CTCF (Fig. 4C). After editing, CTCF occupancy is decreased by 45% with a concurrent 30% decrease in CUL3 expression (Fig. 4G). For AP-1, a heterodimer of FOS and JUN, editing at either of two nearby sites decreases FOS and JUN binding compared with control cells and decreases CUL3 expression by ~25% (Fig. 4H). Overall, as in the pooled screen, transcription factor binding sites located on the 3´ side exhibit weaker effects on gene expression than those located on the 5´ side.Thus we show how a Cas9-mediated systematic dissection of noncoding loci can identify functional elements involved in gene regulation and cancer drug resistance. In combination with other genome-wide assays, we demonstrate high-throughput identification of regions where changes in chromatin context and transcription factor binding are causally linked to loss of gene expression and a disease-relevant phenotype. This approach is generalizable, and we anticipate that the extension of pooled CRISPR screens into the noncoding genome will provide further insights and methods for unbiased interrogation of the genome.Sanjana et al.Page 4Science. Author manuscript; available in PMC 2017 March 30.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptSupplementary MaterialRefer to Web version on PubMed Central for supplementary material.AcknowledgmentsWe would like to thank R. Macrae, D. Scott and the entire Zhang laboratory. N.S. is supported by the NIH through a NHGRI Pathway to Independence Award (R00-HG008171) and a postdoctoral fellowship from the Simons Center for the Social Brain at MIT. J.W. is supported by the NIH through a Ruth L. Kirschstein National Research Service Award (F32-DK096822). O.S. is a Klarman Fellow of the Broad-Israel Partnership. F.Z. is a New York Stem Cell Foundation-Robertson Investigator and is supported by the NIH through NIMH (5DP1-MH100706 and 1R01-MH110049), NSF, the New York Stem Cell, Simons, Paul G. Allen Family, and Vallee Foundations; and James and Patricia Poitras, Robert Metcalfe, and David Cheng. A.R. is on the SAB for Syros Pharmaceuticals and Thermo Fisher and a consultant for Driver group. N.S., J.W., O.S., and F.Z. are listed as inventors on a related patent application. Plasmids are available from Addgene subject to a material transfer agreement. Deep sequencing data are available at Sequence Read Archive under BioProject accession number PRJNA324504 and software tools are available on GitHub (https://github.com/nsanjana/BashRegion).References1. Visel A, Rubin EM, Pennacchio LA. Genomic views of distant-acting enhancers. Nature. 2009; 461:199–205. [PubMed: 19741700] 2. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489:57–74. [PubMed: 22955616] 3. Hindorff LA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009; 106:9362–9367. [PubMed: 19474294] 4. Maurano MT, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science. 2012; 337:1190–1195. [PubMed: 22955828] 5. Roadmap Epigenomics Consortium. et al. Integrative analysis of 111 reference human epigenomes. Nature. 2015; 518:317–330. [PubMed: 25693563] 6. Kwasnieski JC, Fiore C, Chaudhari HG, Cohen BA. High-throughput functional testing of ENCODE segmentation predictions. Genome Res. 2014; 24:1595–1602. [PubMed: 25035418] 7. Mundade R, Ozer HG, Wei H, Prabhu L, Lu T. Role of ChIP-seq in the discovery of transcription factor binding sites, differential gene regulation mechanism, epigenetic marks and beyond. Cell Cycle. 2014; 13:2847–2852. [PubMed: 25486472] 8. Melnikov A, et al. Systematic dissection and optimization of inducible enhancers in human cells using a massively parallel reporter assay. Nat Biotechnol. 2012; 30:271–277. [PubMed: 22371084] 9. Chen S, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015; 160:1246–1260. [PubMed: 25748654] 10. Canver MC, et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature. 2015; 527:192–197. [PubMed: 26375006] 11. Korkmaz G, et al. Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9. Nat Biotechnol. 2016; 34:192–198. [PubMed: 26751173] 12. Rajagopal N, et al. High-throughput mapping of regulatory DNA. Nat Biotechnol. 2016; 34:167–174. [PubMed: 26807528] 13. Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell. 2015; 161:1681–1696. [PubMed: 26091043] 14. Sosman JA, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366:707–714. [PubMed: 22356324] 15. Zubrilov I, et al. Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells. Cancer Lett. 2015; 361:86–96. [PubMed: 25725450] 16. Shalem O, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014; 343:84–87. [PubMed: 24336571] Sanjana et al.Page 5Science. Author manuscript; available in PMC 2017 March 30.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript17. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015; 348:648–660. [PubMed: 25954001] 18. Lieberman-Aiden E, et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science. 2009; 326:289–293. [PubMed: 19815776] 19. Dekker J, Rippe K, Dekker M, Kleckner N. Capturing chromosome conformation. Science. 2002; 295:1306–1311. [PubMed: 11847345] 20. Crawford GE, et al. Identifying gene regulatory elements by genome-wide recovery of DNase hypersensitive sites. Proc Natl Acad Sci U S A. 2004; 101:992–997. [PubMed: 14732688] 21. Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods. 2013; 10:1213–1218. [PubMed: 24097267] 22. Heintzman ND, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007; 39:311–318. [PubMed: 17277777] 23. Sheffield NC, et al. Patterns of regulatory activity across diverse human cell types predict tissue identity, transcription factor binding, and long-range interactions. Genome Res. 2013; 23:777–788. [PubMed: 23482648] 24. Felsenstein J, Churchill GA. A Hidden Markov Model approach to variation among sites in rate of evolution. Mol Biol Evol. 1996; 13:93–104. [PubMed: 8583911] 25. Villar D, et al. Enhancer evolution across 20 mammalian species. Cell. 2015; 160:554–566. [PubMed: 25635462] 26. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014; 11:783–784. [PubMed: 25075903] 27. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009; 10:R25. [PubMed: 19261174] 28. Miele A, Gheldof N, Tabuchi TM, Dostie J, Dekker J. Mapping chromatin interactions by chromosome conformation capture. Curr Protoc Mol Biol. 2006 Chapter 21, Unit 21.11. 29. Van der Auwera GA, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013; 11:11.10.1–11.10.33.30. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010; 26:841–842. [PubMed: 20110278] 31. Joung J, et al. Protocol: Genome-scale CRISPR-Cas9 Knockout and Transcriptional Activation Screening. 2016; doi: 10.1101/05962632. Mathelier A, et al. JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2016; 44:D110–5. [PubMed: 26531826] 33. Tan G, Lenhard B. TFBSTools: an R/Bioconductor package for transcription factor binding site analysis. Bioinformatics. 2016; doi: 10.1093/bioinformatics/btw02434. Wasserman WW, Sandelin A. Applied bioinformatics for the identification of regulatory elements. Nat Rev Genet. 2004; 5:276–287. [PubMed: 15131651] 35. Bhandaru M, et al. A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma. BMC Cancer. 2014; 14:398. [PubMed: 24893747] 36. Lai F, et al. Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death Dis. 2013; 4:e655. [PubMed: 23744355] 37. Bushmeyer S, Park K, Atchison ML. Characterization of functional domains within the multifunctional transcription factor, YY1. J Biol Chem. 1995; 270:30213–30220. [PubMed: 8530432] 38. Zhang Q, Stovall DB, Inoue K, Sui G. The oncogenic role of Yin Yang 1. Crit Rev Oncog. 2011; 16:163–197. [PubMed: 22248053] 39. Katainen R, et al. CTCF/cohesin-binding sites are frequently mutated in cancer. Nat Genet. 2015; 47:818–821. [PubMed: 26053496] 40. Sanborn AL, et al. Chromatin extrusion explains key features of loop and domain formation in wild-type and engineered genomes. Proc Natl Acad Sci U S A. 2015; 112:E6456–65. [PubMed: 26499245] Sanjana et al.Page 6Science. Author manuscript; available in PMC 2017 March 30.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript41. Ding X, et al. Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis. Sci Signal. 2013; 6 ra28.1–13–S0–15. 42. Alipanahi B, Delong A, Weirauch MT, Frey BJ. Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning. Nat Biotechnol. 2015; 33:831–838. [PubMed: 26213851] 43. Materials, methods and supplementary text are available as supplementary materials on Science Online.Sanjana et al.Page 7Science. Author manuscript; available in PMC 2017 March 30.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 1. CRISPR mutagenesis of noncoding regions flanking three genes involved in BRAF inhibitor resistanceA) Design of sgRNA libraries targeting 100 kb 5` and 100 kb 3` of a gene. The sgRNAs are array synthesized and cloned into a lentiviral vector. BRAF mutant cells are transduced with the pooled lentivirus and treated with vemurafenib (Vemu) or DMSO (Control). A deep sequencing readout identifies sgRNAs enriched after treatment with vemurafenib.Scatterplot of normalized read counts (average of the 2 infection replicates) for B: NF1, C: NF2, D: CUL3 sgRNAs at Day 0 (x axis) and Day 14 (y axis) Read counts from control (gray) and vemurafenib-treated cells (red) are shown relative to 4 standard deviations of the control cell distribution (dotted line) with the percentage of enriched sgRNAs in vemurafenib (>4 s.d.).E) Distribution of log2 ratio of the normalized read count for each sgRNA in vemurafenib to its normalized read count in control (minimum of the 2 infection replicates).F) All CUL3 sgRNAs plotted by hg19 coordinates and the percent expression of the two most highly expressed CUL3 isoforms (Primary, Alt.). For vemurafenib-enriched sgRNAs, the log2 enrichment over control (minimum value of 2 replicate screens) is plotted (red); non-enriched sgRNAs are indicated in blue.G) Percent of enriched sgRNAs by genomic category.Sanjana et al.Page 8Science. Author manuscript; available in PMC 2017 March 30.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 2. Characteristics of functional noncoding elements at the CUL3 locusA) Plot of 3C interaction frequencies with the CUL3 promoter in A375 cells. Data points represent independent libraries generated with BglII, EcoRI, and HindIII restriction enzymes. The grey curve shows a smoothed estimate of interaction frequency.B) Average enrichment of sgRNAs (log2 ratio of vemurafenib/DMSO reads) near 3C sites with specified minimum interaction frequency with the CUL3 promoter (43).C) An example of enriched sgRNAs (red) that overlap with a melanoma-specific region of open chromatin. ATAC-seq in A375 melanoma (orange), MCF-7 breast cancer (purple) and U-87 glioblastoma (blue) and Melanoma DNAse I hypersensitivity sequencing (green, ENCODE/Colo-829). Loci investigated relative to CUL3 is shown at top (yellow). Scale bar: 500 bp.D) Fold enrichment of enriched sgRNAs near ATAC-seq open chromatin peaks in melanoma, breast cancer and glioblastoma cell lines.E) Fold enrichment of enriched sgRNAs near DNAse I HS-seq open chromatin peaks in melanoma, breast cancer and glioblastoma cell lines.F) An example of enriched sgRNAs (red) that coincide with regions that show greater primate-specific conservation than placental mammal and vertebrate conservation. Loci investigated relative to CUL3 is shown at top (yellow). Scale bar: 200 bp.Sanjana et al.Page 9Science. Author manuscript; available in PMC 2017 March 30.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptG) Fold enrichment of enriched sgRNAs near phastCons peaks in primates, placental mammals and vertebrates.Sanjana et al.Page 10Science. Author manuscript; available in PMC 2017 March 30.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 3. Noncoding mutations impact CUL3 expression and histone modificationsA) Criteria selecting 25 sgRNAs targeting noncoding regions for validation.B) CUL3 RNA expression (normalized to non-targeting sgRNAs) after transduction with lentivirus expressing non-targeting (triangles), noncoding region-targeting (colored circles) and coding region-targeting (squares) sgRNAs.C) Relationship between CUL3 expression and cell survival after vemurafenib. Linear fit is to noncoding sgRNAs only (rnoncoding = −0.54, p = 0.005) and does not include coding region-targeting or non-targeting sgRNAs.D) Percent change in average H3K4me3 chromatin immunoprecipitation (ChIP) for all validation sgRNAs within 1 kb of the transcription start site (TSS) of CUL3 (left). Percent change in average H3K27ac and average H3K4me2 ChIP for all validation sgRNAs >1 kb from the TSS of CUL3 (right).Sanjana et al.Page 11Science. Author manuscript; available in PMC 2017 March 30.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptFigure 4. Cas9 mutagenesis disrupts predicted transcription factors and DNA binding proteins at target sites of vemurafenib-enriched sgRNAsA–D) sgRNA target locations in relation to predicted binding sites.E–H) Change in transcription factor/DNA binding protein occupancy around cleavage site and change in CUL3 expression. Both measurements are normalized to cells transduced with non-targeting sgRNAs.Sanjana et al.Page 12Science. Author manuscript; available in PMC 2017 March 30.Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor ManuscriptResearchPaperGlobalProteomeandPhospho-proteomeAnalysisofMerlin-deﬁcientMeningiomaandSchwannomaIdentiﬁesPDLIM2asaNovelTherapeuticTargetKayleighBassiria,1,SaraFerlugaa,1,VikramSharmab,NeloferSyedc,ClaireL.Adamsa,EdwinLasonderb,COliverHanemanna,⁎aInstituteofTranslationalandStratiﬁedMedicine,PlymouthUniversityPeninsulaSchoolsofMedicineandDentistry,JohnBullBuilding,PlymouthSciencePark,ResearchWay,Derriford,PlymouthPL68BU,UKbSchoolofBiomedicalandHealthcareSciences,PlymouthUniversity,DrakesCircus,PlymouthPL48AA,UKcJohnFulcherNeuro-oncologyLaboratory,DivisionofBrainSciences,FacultyofMedicine,ImperialCollegeLondon,LondonW68RP,UKabstractarticleinfoArticlehistory:Received10October2016Receivedinrevisedform13January2017Accepted13January2017Availableonline18January2017LossormutationofthetumoursuppressorMerlinpredisposesindividualstodevelopmultiplenervoussystemtumours,includingschwannomasandmeningiomas,sporadicallyoraspartoftheautosomaldominantinheritedconditionNeuroﬁbromatosis2(NF2).Thesetumoursdisplaylargelylowgradefeaturesbuttheirpresencecanleadtosigniﬁcantmorbidity.Surgeryandradiotherapyremaintheonlytreatmentoptionsdespiteyearsofre-search,thereforeaneffectivetherapeuticisrequired.Unbiasedomicsstudieshavebecomepivotalintheidentiﬁcationofdifferentiallyexpressedgenesandproteinsthatmayactasdrugtargetsorbiomarkers.Hereweanalysedtheproteomeandphospho-proteomeofthesege-neticallydeﬁnedtumoursusingprimaryhumantumourcellstoidentifyupregulated/activatedproteinsand/orpathways.Weidentiﬁedover2000proteinsincomparativeexperimentsbetweenMerlin-deﬁcientschwannomaandmeningiomacomparedtohumanSchwannandmeningealcellsrespectively.UsingfunctionalenrichmentanalysiswehighlightedseveraldysregulatedpathwaysandGeneOntologyterms.Weidentiﬁedseveralproteinsandphospho-proteinsthataremorehighlyexpressedintumourscomparedtocontrols.AmongproteinsjointlydysregulatedinbothtumourswefocusedinparticularonPDZandLIMdomainprotein2(PDLIM2)andvalidateditsoverexpressioninseveraltumoursamples,whilenotdetectingitinnormalcells.WeshowedthatshRNAme-diatedknockdownofPDLIM2inbothprimarymeningiomaandschwannomaleadstosigniﬁcantreductionsincellularproliferation.Toourknowledge,thisistheﬁrstcomprehensiveassessmentoftheNF2-relatedmeningiomaandschwannomaproteomeandphospho-proteome.Takentogether,ourdatahighlightseveralcommonlyderegulatedfactors,andindicatethatPDLIM2mayrepresentanovel,commontargetformeningiomaandschwannoma.©2017TheAuthors.PublishedbyElsevierB.V.ThisisanopenaccessarticleundertheCCBY-NC-NDlicense(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:MeningiomaSchwannomaNF2MerlinProteomePhospho-proteome1.IntroductionNeuroﬁbromin2(Merlin,NF2)isatumoursuppressorproteinexpressedduringembryonicdevelopmentandthereafter(Gronholmetal.,2005).Inadults,signiﬁcantlevelsofexpressionarefoundinSchwannandmeningealcells,nerveandlens(Claudioetal.,1997;Sakudaetal.,1996;SchererandGutmann,1996).Mutationsintheencodinggene(NF2)leadtoformationofschwannomasandmeningiomas,andlessoftenofependymomasandretinalastrocytichamartomas(Hanemann,2008;Martinetal.,2010;Rouleauetal.,1993).ThesetumoursoriginatesporadicallyoraspartofthegeneticconditionNeuroﬁbromatosistype2(NF2)(Hanemann,2008).Theyarelargelyunresponsivetoclassicche-motherapeuticagents,leavingsurgeryandradiotherapyastheonlyre-mainingtreatmentoptionswhichcanleavethepatientwithmildtoseveremorbidity(Hanemann,2008).Additionally,NF2patientsoftende-velopmultipletumourssimultaneously(Hanemann,2008),strengthen-ingtheneedforeffectivesystemictherapeuticoptions.LossofMerlinhasalsobeenrelatedtoavarietyofothercancers,includingglioblasto-mas,malignantmesotheliomasandthyroidcarcinomas,highlightingitsroleastumoursuppressor(Garcia-Renduelesetal.,2015;Guerreroetal.,2015;Leeetal.,2016;Morrowetal.,2016;Sheikhetal.,2004).MerlinsharesstructuralsimilaritywiththeEzrin/Radixin/Moesin(ERM)familyofproteinsthatlinkthecytoskeletonwithcomponentsofthecellmembrane(Bretscheretal.,2000;McClatchey,2003;McClatcheyandGiovannini,2005).AlthoughMerlinlackstheC-EBioMedicine16(2017)76–86⁎Correspondingauthorat:JohnBullBuilding,PlymouthSciencePark,ResearchWay,Derriford,PlymouthPL68BU,UK.E-mailaddress:oliver.hanemann@plymouth.ac.uk(C.O.Hanemann).1Theseauthorsequallycontributedtothemanuscript.http://dx.doi.org/10.1016/j.ebiom.2017.01.0202352-3964/©2017TheAuthors.PublishedbyElsevierB.V.ThisisanopenaccessarticleundertheCCBY-NC-NDlicense(http://creativecommons.org/licenses/by-nc-nd/4.0/).ContentslistsavailableatScienceDirectEBioMedicinejournalhomepage:www.ebiomedicine.comterminalactin-bindingdomainpresentintheothermembersoftheERMfamily,itcanlocalizetothecorticalcytoskeletonandinteractdi-rectlywiththeactin-bindingproteinα-catenin(Gladdenetal.,2010).Atsitesofcell-cellcontactMerlinactsastumoursuppressorcontrollingcadherin-mediatedcontact-dependentinhibitionofproliferationandadherensjunctionformation(Flaizetal.,2008;Lallemandetal.,2003).Severalreceptortyrosinekinases(RTKs)havebeenfoundtobeMerlin-dependent(Curtoetal.,2007;Lallemandetal.,2009).Ourgroupandothersshowedoverexpressionandreduceddegradationoftheplatelet-derivedgrowthfactorreceptorβ(PDGFRβ)inschwannomacomparedtonormalSchwanncellswhich,togetherwiththelossofMerlin,leadstoincreasedcellularproliferationandaberrantactivationoftheMAPKandPI3Ksignallingpathways(Ammounetal.,2008;Fraenzeretal.,2003).RTKsarefoundtobelinkedtoMerlinandthusthecytoskeletonviathePDZdomain–containingadapterNHERF-1(Na+/H+exchangerregulatoryfactor)(Maudsleyetal.,2000;Weinmanetal.,2000).MerlinlossfurthercontributestotumorigenesisviatheactivationofanumberofotherpathwaysincludingtheHippo,RasandWnt/β-catenin(Lietal.,2014;Mohleretal.,1999;Zhaoetal.,2010,2011).Merlinactivityisalsointhenucleus,whereitbindstotheE3ubiquitinligaseCRL4(DCAF1)suppressingitsactivity.DepletionofDCAF1inMerlin-deﬁcientschwannomacellswassufﬁcienttoblockproliferation(Cooperetal.,2011).Unbiasedgenomicstudieshavebeenperformedaimingtoidentifynoveldifferentially-expressedgenesinschwannomasandmeningio-mas(Fevre-Montangeetal.,2009;Hanemannetal.,2006;Torres-Martinetal.,2013a,b,2014;Wangetal.,2012)aswellasnoveldrivermutations,exclusiveofNF2(Clarketal.,2013).Massspectrometry(MS)isapowerful,high-throughputtechniquetoidentifythousandsofproteinsaberrantlyexpressedandregulated.RecentlySharmaandcolleaguesperformedcomparativeproteomicanalysisondifferentgradesofmeningiomastoinvestigatealterationsinthemeningiomatissueandinthehumanserumofmeningiomapa-tientscomparedtonormalbraintissue.Theyidentiﬁedseveralderegulatedproteinsincludingtransgelin-2andcaveolinintissue,plusapoliopoproteinsAandEinserum(Sharmaetal.,2014,2015).Hereweanalysedbylabelfreequantitativeproteomicsboththepro-teomeandphospho-proteomeofmeningiomaandschwannomaprimarytumourcells.Byanalysingproteomesandphospho-proteomestogether,weidentifyoverexpressedproteinsintumourcellsandregulatorysignal-lingpathwaysthatmaybe‘switchedoff’withtherapeuticintervention.WealsocomparedproteinabundancesinprimaryMerlin-deﬁcienthumanmeningiomacellsagainsthumanmeningealcells,andprimaryhumanschwannomacellsagainstprimaryhumanSchwanncells.Weidentiﬁednumerousnovelupregulatedanddownregulatedproteinsandphospho-proteins,performedGeneOntology(GO)mappingandfunctionalenrichmentanalysesforGOandpathwayterms.Weidenti-ﬁedproteinscommontobothMerlin-deﬁcienttumourtypes.SeveraloftheupregulatedproteinscontainedeitheraPDZ/LIMdomain,orboth.Theseproteinshavebeenshowntohaveawiderangeofbiologicalfunctionsincludingrolesincellsignalling(TeVelthuisetal.,2007).WefoundPDZandLIMdomainprotein2(PDLIM2/mystique/SLIM)com-monlyupregulatedinbothtumourtypescomparedtothenormalcon-trols.PreviousexperimentsonPDLIM2suggestedaroleincytoskeletalorganizationasitwasco-immunoprecipitatedtogetherwithalpha-actinin-1,alpha-actinin-4,ﬁlaminA,andmyosinheavypolypeptide9inratcornealepithelialcells(Loughranetal.,2005a;Torradoetal.,2004).PDLIM2wasalsoidentiﬁedatthenuclearlevelexertingtumoursuppressivefunctionsbyterminatingNF-κBactivationduringinﬂam-mation(Tanakaetal.,2007)andinbreastcancer(Quetal.,2010).PDLIM2overexpressionwasfoundinmetastaticcancercells(Loughranetal.,2005b)andandrogen-independentprostatecancercelllines(Kangetal.,2016).Usingourprimaryhumanculturesweper-formedPDLIM2silencinginprimaryhumanschwannomasandmenin-giomasandobservedastatisticallysigniﬁcantreductionincellproliferationinbothtumourtypes.Toourknowledge,thisworkistheﬁrstproteomicstudyaimingtodeciphercommonderegulatedelementsintheproteomeandphospho-proteomeofMerlin-deﬁcientschwannomasandmeningiomas.2.MaterialsandMethods2.1.ClinicalSamplesMeningiomaandschwannomaspecimenswerecollectedafterpa-tientsconsentedtothestudyandgivenauniqueMOTidentiﬁcationnumber.ThisstudywasgrantedfullnationalethicsapprovalbytheSouthWestresearchethicscommittee(RECNo:14/SW/0119;IRASpro-jectID:153,351)andlocalresearchanddevelopmentapproval(Plym-outhHospitalsNHSTrust:R&DNo:14/P/056andNorthBristolNHSTrust:R&DNo:3458).NormalhumanSchwanncellswerecollectedafterethicalapprovalundertheRECnumberREC6/Q2103/123.ThebraintumourmaterialwasobtainedfromtheImperialbraintumourbankandthissub-collectioniscoveredbyImperialCollegeTissuebankethics.AllmeningiomasamplesusedinthisstudyweregradeI.2.2.CellCultureHumanmeningealcells(HMC)wereobtainedfromSciencell™andmaintainedinthemanufacturer'srecommendedmediaat5%CO2.HumanprimarySchwann/schwannomacellsweremaintainedasde-scribedpreviously(Rosenbaum2000).Ben-Men-1cellsandprimarymeningiomacellswereroutinelygrowninDMEM,10%FBSand100U/mlPenicillin/Streptomycin,andwerekeptat5%CO2/37°C.2.3.Phospho-proteinPuriﬁcationPhospho-proteinswereisolatedfromcelllysatesusingthecommer-ciallyavailablephospho-proteinpuriﬁcationkitfromQiagen®.Themanufacturersreportedanenrichmentofover80%withlessthan5%phosphorylationintheﬂow-throughfraction.SimilarlyMeimounetal.reportedanenrichmentof88%usingthiskit(Meimounetal.,2007).Theprotocolwascarriedoutaccordingtothemanufacturer'sin-structionsusing2.5mgofstartingmaterial.ProteinconcentrationsweredeterminedbytheBCAproteinassayaccordingtothemanufacturer'sinstructions.2.4.In-gelDigestionCellswerelysedinthebufferprovidedwiththephospho-proteinpuriﬁcationkit.50μgofproteinandcorrespondingisolatedphospho-proteinwereseparatedviaSDS-PAGE.Gelswerestainedwithcolloidalcoomassiebluestain(LifeTechnologies)for3hatroomtemperature(RT).DestainingwasperformedusingMSgradewater(Fisher)over-nightatRT.Individuallaneswerecutintosmall1mm×1mmpiecesbeforein-geldigestionasdescribedpreviously(Lasonderetal.,2002).Theprotocolwasperformedasfollowperslice:equilibrationin200μlof50mMammoniumbicarbonate(ABC)for5minat37°C,destainingin200μlof50%acetonitrile(ACN)/50%H2Ofor5minat37°Cthen200μlof100%ACNfor5minat37°C.Thesestepswereperformedintriplicate.200μlofreductionbuffer(10mMdithiothreitolinABC)wasaddedtothegelslicesandincubatedfor20minat56°C.Sliceswerethenshrunkusing100%ACNfor5minatRTandalkylatedusing200μlofalkylationbuffer(23.35mg2-choloroacetamide,5ml50mMABC)for20minatRTinthedark.Thegelpieceswereincubatedwithdigestionbuffer(12.5ng/μltrypsininABC)overnightat37°C.Digestedpeptideswereextractedbytheadditionof2%Triﬂuoroaceticacid(TFA)tothedigestionbufferincubatedfor20minonashakerat37°C.Peptidesolutionsweretransferredtofreshtubes,and100μlofbufferB(80%ACN,0.5%aceticacid,1%TFA)wasaddedtothegelpiecesandincubatedforafurther20minonashakerat37°C.ThebufferBsolutionwasthencombinedwiththesolutionfromtheﬁrstpeptideextraction,and77K.Bassirietal./EBioMedicine16(2017)76–86sampleswereconcentratedinaDNAcentrifuge(LabconcoCentriVap®)untillessthan40μlofsamplewasleft.SampleswerethendissolvedinbufferA(0.5%aceticacid,1%TFA)priortoMSanalysis.2.5.PeptidePuriﬁcationWithStageTipsStagetipswereassembledbyplacinghighperformanceC18extrac-tiondisksintopipettetipsasdescribed(Rappsilberetal.,2003).50μlofmethanolwasaddedtothepreparedstagetipsandcentrifugeduntilthewholevolumepassedthrough.ThiswasrepeatedwithbufferB(80%acetonitrile,0.5%aceticacid)andthentwicewithbufferA(0.5%aceticacid).Sampleswereaddedtostagetipsandcentrifuged(1min;10,000×gatRT).50μlofbufferAwasthenaddedandcentrifugeduntilallthevolumehadpassedthrough.Peptideswereelutedbyaddi-tionof20μlofbufferBandcentrifugation.Thesampleswereconcen-tratedusingaspeedvacbeforeresuspensioninbufferAtogiveaﬁnalvolumeofapproximately25μl(Rappsilberetal.,2003).2.6.LiquidChromatographyTandemMassSpectrometryMSwascarriedoutusinganUltimate3000UPLCsystem(ThermoFisher,Germany)connectedtoanOrbitrapVelosPromassspectrometer(ThermoFisher,Bremen,Germany).Thepreparedpeptideswereloadedontoa2cmAcclaim™PepMap™100Nano-TrapColumn(ThermoFisher,Germany)andseparatedbya25cmAcclaim™PepMap™100NanoLCcolumn(ThermoFisher,Germany)packedwithC18beadsof3μmandrunninga120mingradientof95%bufferA/5%bufferB(bufferAcontains0.5%aceticacidandbufferBcontains0.5%aceticacidin100%acetonitrile)to65%bufferA/35%bufferBandaﬂowrateof300nl/min.Elutedpeptideswereelectrosprayedintothemassspectrometeratasprayvoltageof2.5kV.TheOrbitrapinstrumentperformsdataacquisi-tioninadatadependentmodetoswitchbetweenMSandMS2.TheOrbitrapcellwitharesolutionof60,000acquiresafull-scanMSspec-trumofintactpeptides(m/z350–1500)withanautomatedgaincontrolaccumulationtargetvalueof1000,0000ions.Inthelineariontrapthetenmostabundantionsareisolatedandfragmentedbyapplyingcolli-sioninduceddissociationusinganaccumulationtargetvalueof10,000,acapillarytemperatureof275°C,andnormalizedcollisionener-gyof30%.Adynamicexclusionofionspreviouslysequencedwithin45swasapplied.Anysinglychargedionsandunassignedchargedstateswereexcludedfromsequencingandaminimumof10,000countswasrequiredforMS2selection.Dynamicexclusionisawidelyusedtoolinmassspectrometrydataacquisitionsoftwareenablingmoreproteinstobeidentiﬁedandincreaseproteomecoverage(Zhangetal.,2009).2.7.ProteinIdentiﬁcationAndromedasearchengineintegratedinMaxQuantversion1.3.05programmewasusedtoidentifytheproteinsintheUniprotdatabase(www.uniprot.org/downloads,November2015)andsupplementedwithsequencesoffrequentlyobservedcontaminants.Amasstoleranceof6ppmfortheparentalpeptideand0.5Daforfragmentationspectraandatrypsinspeciﬁcityallowingupto2mis-cleavedsitesweresetastheAndromedasearchparameters.Fixedmodiﬁcationsofcarboxyamidomethylationofcysteinesandvariablemodiﬁcationsofoxidationofmethionine,deamidationofglutamineandasparaginewereset.Aminimalpeptidelengthof7aminoacidswasset.MaxQuantperformedaninternalmasscalibrationofmeasuredionsandpeptidevalidationbythetargetdecoyapproachasdescribed.Proteinsandpep-tideswithabetterthan1%falsediscoveryrate(FDR)wereacceptediftheyhadbeenidentiﬁedbyatleast2peptidesinoneofthesamples.Sharedpeptidesequences(razorpeptides)weremappedtoproteinsbytheprincipleofmaximumparsimonyinMaxQuant.Proteinswerequantiﬁedbynormalizedsummedpeptideintensitiescomputedaslabelfreequantiﬁcation(LFQ)valuesinMaxQuant1.3.05￼(Coxetal.,2014)LFQdatawasgeneratedintriplicateforallsamples.LFQdatawasgeneratedintriplicateforallsamples.2.8.QuantiﬁcationAnalysisLFQdatageneratedbyMaxquantwereprocessedusingMicrosoftExcelandspeciallydevelopedproteomicssoftware,Perseus(Tyanovaetal.,2016).LFQvaluesforproteinsandphospho-proteinswereLog2transformedandfoldchange(FC)wascalculatedbasedontheequa-tion:AverageLog2LFQtumour-AverageLog2LFQcontrol.Entrieswith0forLFQwerekeptandincludedinthefoldchangecalculations.A2samplet-testwasperformedgeneratingp-valuesforeachidentiﬁedprotein/phospho-protein.Theproteinswithap-valueb0.05werecon-sidereddifferentiallyexpressedandincludedinfurtheranalysis.Signif-icantlychangedphospho-proteinswerecomparedagainstrespectiveproteinchangestoidentifythosethatarerelativelyhighlyupregulatedi.e.displayingalargesigniﬁcantchangeinphosphorylationandasmall-erincreaseoradecreaseinproteinabundance.2.9.FunctionalEnrichmentAnalysisFunctionalenrichmentanalysiswasperformedusingBenjamini-Hochbergmultiplecorrectiontestingintegratedintothedatabaseforannotation,visualizationandintegrateddiscovery(DAVID)software(Huangdaetal.,2009)forGeneOntology(GO)annotationsandforKEGGpathwaysannotations.FunctionalenrichmentanalysiscomparescoverageofGOandpathwaytermsfromsigniﬁcantlydifferentiallyexpressedproteinswithcoverageofthesetermsinadeﬁnedcontrolbackground–inthiscasetheentirehumanproteome.Thisallowspath-ways,biologicalprocesses,molecularfunctionsandproteinsofparticu-larcellularcomponentstobeidentiﬁedthatareproportionallyoverrepresentedintheexperimentaldatasetthantheyareintheback-grounddatasetandcalculatedasfoldenrichment.WeacceptedenrichedGOandpathwaytermswithpadjustedb0.05andFoldEnrichmentN2.Therepresentativestepsinvolvedintargetidentiﬁcationarepre-sentedinFig.S1.2.10.WesternBlottingCellswerelysedinRIPAbufferconsistingof(150mMNaCl,1%Tri-ton-X,0.5%Sodiumdeoxycholate,0.1%SDSand50mMTrispH8.0)be-foreproteinconcentrationwasdeterminedusingacolorimetricBCAproteinassay(Pierce),andimmunoblottingproceededasdescribedpreviously(Kaempchenetal.,2003).SamplesintendedforMSmea-surementwereseparatedusing4–15%gradientpre-castgels(Bio-rad).Theantibodiesusedinthestudyincluded:Merlin(1:1000),pMerlin(1:500),HDAC1(1:1000)andPDLIM2(1:500)fromCellSig-nalingTechnology;PDLIM2(1:500)fromSantaCruzBiotechnologyandGAPDH(1:50.000)fromMillipore.2.11.ImmunoﬂuorescenceMicroscopyForimmunoﬂuorescence,cellsweregrownO/Nonglassslides.ThefollowingdayslideswerewashedtwicewithPBSandﬁxedwith4%Paraformaldehyde(PFA)/PBSfor10min.SlideswerethenwashedtwicewithPBSandcellswerepermeabilizedwith0.2%TritonX-100/PBSfor5minatRT.SlideswerewashedthreetimeswithPBSandblockedfor1hin10%BSA/PBSatRT.Primaryantibodiesweredilutedin5%BSA/PBSandincubatedO/Nat4°C.SlideswerethenwashedthriceinPBSfor5mineachandincubatedwithsecondaryantibodies(1:200,AlexaFluor®,LifeTechnologies),nuclearcounter-stained(DAPI,4μg/ml)andmountedwithProLongDiamondantifademountant(LifeTechnologies).ConfocalmicroscopywasperformedusingaLeicaDMI6000Bmicroscope.78K.Bassirietal./EBioMedicine16(2017)76–862.12.shRNAMediatedGeneSilencingCulturedcellswereseededat80%conﬂuencybeforetransfectionwithlentiviralparticles(10μl/6well,2μllabtek)directedtowardsPDLIM2(Sigma)inthepresenceof5μg/mlpolybrene(SantaCruzbio-technology).Lentiviruswasappliedfor24h,atwhichpointmediumwasremovedandreplacedwithnormalmediumforafurther24h.Pu-romycinwasthenappliedtocellsataconcentrationof5μg/mlforcellselection.Selectiontookplaceover4–5days,atwhichpointcellswerelysedforWesternblotanalysis,orﬁxedandstainedforKi-67expres-sion.FivedifferentshRNAclonesweretested(sequenceclone1:CCGGCTCGGAAGTCTTCAAGATGCTCTCGAGAGCATCTTGAAGACTTCCG-AGTTTTTTG;sequenceclone2:CCGGGCTCTTACATGAGCTAAGTTTCTCGAGAAACTTAGCTCATGTAAGAGCTTTTTTG;sequenceclone3:CCGGGAGGACATACACTGAGAGTCACTCGAGTGACTCTCAGTGTATGTCC-TCTTTTTTG;sequenceclone4:CCGGCCACTGCCTTTGATCAACCTTCTCGAGAAGGTTGATCAAAGGCAGTGGTTTTTTG;sequenceclone5:CCGGGAGCTGTACTGTGAGAAGCATCTCGAGATGCTTCTCACAGTACAGCTCTTTTTTG),clonedintotheplasmidpLKO.1-puro.Clone5wasthemostsuccessfulinknockingdownPDLIM2.2.13.λ-PhosphataseTreatmentandCytoplasmic-nuclearExtractionCellswerelysedinRIPAbuffercontainingproteaseinhibitorsbutnotphosphataseinhibitors.Proteindephosphorylationwasachievedbytreating20μgofproteinlysatewithλ-phosphatase(NewEnglandBiolabs)followingtheinstructionsofthesupplier.Thereactionwasallowedtoproceedfor2hat30°C.Nontreatedsamplewasincubatedinthesamebufferandforthesameamountoftimeat30°Cbutwaterwasaddedinplaceofλ-phosphatase.ToascertainthecellularlocationofPDLIM2,acytoplasmicandnu-clearextractionassay(ThermoScientiﬁc)wasperformed.Primaryad-herentmeningiomacellswereharvestedwithtrypsinandcentrifugedat500gfor5min.ThecellpelletwasthenwashedonceinPBS,trans-ferredtoamicrocentrifugetubeandcentrifugedfor3minat500g.IcecoldCERIreagent(CytoplasmicExtractionReagent,providedwiththekit)wasaddedtothepellet,vortexedvigorouslyfor15sandincubatedonicefor10min.IcecoldCERIIwasthenaddedtothetubeandvortexedfor5sonthehighestsettingbeforeincubationonicefor1min.Thetubewasthencentrifugedfor5minat16,000gandthesu-pernatantimmediatelytransferredtoapre-chilledtube(thecytoplas-micfraction).IcecoldNER(NuclearExtractionReagent,providedwithkit)wasaddedtotheremainingpelletandvortexedfor15s.Afterincu-bationonicefor40minwithrigorousvortexingevery10min,thetubewascentrifugedatmaximumspeedfor10min.Thesupernatant(nucle-arfraction)wastransferredtoacleantubeandbothextractswerestoredat−80°CuntilanalysisbyWesternblot.Theexperimentwasre-peatedintriplicateonthreedifferentmeningiomacellpopulations.TotalHDAC1andGAPDHwereincludedasreferenceproteinsforthenuclearandcytoplasmicfractionsrespectively.3.Results3.1.DifferentialProteinandPhospho-proteinExpressioninSchwannomavs.SchwannCellsThreeprimaryMerlin-deﬁcientschwannoma-derivedcellpopula-tionswereanalysedvs.humanprimarySchwanncells.MerlinstatuswasconﬁrmedbyWesternblotpriortoMSanalysis(Fig.1A).Theglobalproteomeandtheisolatedphospho-proteomeweremeasuredinparal-leltoallowanindirectcomparisonbetweenproteomeandphospho-proteomedata,andalsotoidentifybothphosphorylatedandnon-phos-phorylatedpotentialtargets.Over1559proteins(TableS1a)(peptidesinTableS1c)andover2455phospho-proteins(TableS1b)(peptidesinTableS1d)wereidentiﬁedinprimaryschwannomavs.Schwanncellswitha32%overlap(Fig.S5a).Only16proteinsintheproteomedatasetwerefoundtobesigniﬁcantlyupregulatedwithaLog2FCN1,while93proteinsweredownregulatedwithaLog2FCb−1.AlistofthesigniﬁcantdifferentiallyexpressedproteinsissummarizedinTableS2.Thetopthreeupregulatedincludethefructose-bisphosphatealdolaseC(ALDOC),theproteasomesubunitbetatype-5(PSMB5)andtransgelin(TAGLN),thelatteridentiﬁedalsoinpreviousstudies(Sharmaetal.,2015).Allupregulatedproteinsweregroupedbasedonproteinclassandarerepresentedbyapiechart(Fig.1B).Thelargestproportionofupregulatedproteinswerecytoskeletal(50%).Interest-ingly,11ofthe16upregulatedproteinsinteractwithoneanother,asidentiﬁedbystring.db(Fig.S3).Inthephospho-proteomedataset,122weresigniﬁcantlyupregulatedwithalogfold-changeover1and101phospho-proteinsweresigniﬁcantlydownregulatedwithaLog2FCb−1(TableS3).Amongthemostupregulatedphospho-pro-teinswastheYorkiehomolog(YAP),previouslyshowntobeactiveinschwannoma(Lietal.,2014)aswellasmembersassociatedtotheRaspathway(Ammounetal.,2008;Morrisonetal.,2007).Inordertoidentifyindividualproteinsaberrantlyregulatedthatmaybeinvolvedinproteinsignallingandpathwayactivation,weanalysedthephospho-proteomedatasetwithrespecttowholepath-waysand/orbiologicalprocessesthataresigniﬁcantlyrepresentedusingDAVID(Huangdaetal.,2009).Theupregulatedphospho-proteinsweremappedtoseveralpathways(Fig.1C).Amongthestatisticallyenrichedpathways(Benjamini-HochbergAdjustedpb0.05)represent-edbytheupregulatedproteinswerefocaladhesion(18%,Foldenrich-ment(FE)5),theMAPKpathway(16%,FE3)andregulationoftheactincytoskeleton(12%,FE3),pathwaysthathavepreviouslybeenshowntobeactivatedinschwannoma(Ammounetal.,2014;Schulzeetal.,2002).Amongtheotherderegulatedpathwaysidentiﬁedwereendocytosis(12%,FE3),vascularsmoothmusclecontraction(12%,FE6),neurotrophinsignalling(9%,FE4),glycolysis/gluconeogenesis(7%,FE6).Wealsoperformedfunctionalenrichmentanalysisontheupreg-ulatedphospho-proteindatasettoidentifythemostsigniﬁcantGOterms(Fig.1D).RASproteinsignaltransductionwasidentiﬁedasthemostenrichedbiologicalprocessinlinewiththeroleoftheRaspathwayinschwannoma(Ammounetal.,2008;Morrisonetal.,2007).ThemostenrichedGOtermoverallcorrespondingtoupregulatedphospho-pro-teinsis‘AP-2adaptorcomplex’,linkedtoclathrin-mediatedendocyto-sis.Amongthedownregulatedphospho-proteins,therewassigniﬁcantenrichmentoflysosomalproteins(Fig.S3).TheseareARSA,AGA,CTSD,GUSB,PSAPandSMPD1.CTSD,orCathepsinD,inparticularisassociatedwithcaspase-3inductionofcelldeathanditsdownregula-tionmayberelatedtoschwannomacellsurvival(Pranjoletal.,2015).Inordertoidentifyproteinsthatwerehighlyactivatedwewantedtoidentifythosethatdisplayedarelativelysmallchangeinproteinabun-dancerelativetophospho-proteinexpression.ThesimplestwayofperformingthisanalysiswastoplotbothdatasetsagainsteachotherasLog2FC,allowingforfastvisualidentiﬁcationofthehighlyupregulat-edphospho-proteins(Fig.1E).Foldchangesofsigniﬁcantlychangedphospho-proteins(p-valueb0.05)areplottedontheyaxis,againsttheirrespectiveproteinfoldchanges(irrespectiveofp-value).Themostrelevantdifferenceswerefoundonthetoppartofthegraph;amongthemwefoundseveralcytoskeletal-relatedproteinslikePDLIM2,PDLIM5andPDLIM7,theregulatorofcellpolarityRho-associ-atedproteinkinase1(ROCK1),Filamin-BandVinculin.Numerouswerealsoinvolvedinvesiculartransportlikethealpha-solubleNSFat-tachmentprotein(NAPA),theChargedMultivascularBodyProtein2B(CHMP2B)andtheVacuolarProteinSorting-associated29(VPS29).3.2.DifferentialProteinandPhospho-proteinExpressioninMeningiomavs.MeningealCellsThreeprimaryhumanmeningioma-derivedcellpopulations(MN)andthemeningiomacelllineBenMen-1(Puttmannetal.,2005),wereanalysedagainstHumanMeningealCells(HMC)asnormal79K.Bassirietal./EBioMedicine16(2017)76–86control.AllsampleswereanalysedforMerlinstatusbyWesternblotpriorMS(Fig.2A).InthecomparisonbetweengradeImeningiomaprimarycellsvs.HMC,2582proteinswereidentiﬁed(TableS4a)(peptidesinTableS4c),andafterphospho-proteinenrichment,weidentiﬁed2505phospho-proteins(TableS4b)(peptidesinTableS4d)witha6%overlap(Fig.S5b).186proteinswereupregulated(Log2FCN1)and494weredownregulated(Log2FCb−1)(TableS5).Oftheidentiﬁedphosphopro-teins,478weresigniﬁcantlychangedbetweenthetwocelltypes;35proteinswereupregulated(Log2FCN1)and443weredownregulated(Log2FCb−1)(TableS6).Duetotherelativelylownumberofsigniﬁ-cantlychangedphosphoproteins(35),itwasnotfeasibletodetectsta-tisticallysigniﬁcantenrichedGOandpathwaytermsbyfunctionalenrichmentanalysisinDAVID.WealsotestedthebenignmeningiomacelllineandcomparedBenMen-1cellsvs.HMC,grownandprocessedintriplicateseparatelyandsawa39%overlapbetweenidentiﬁedpro-teinsandphosphoproteins(Fig.S5c).Inthisanalysis3129proteinswereidentiﬁed(TableS7a)(peptidesinTableS7c),176weresigniﬁ-cantlyupregulated(Log2FCN1),and232weresigniﬁcantlydownregu-lated(Log2FCb−1)(TableS8).Amongthemostupregulatedwefoundthetumournecrosisfactorreceptorsuperfamilymember10D(TNFRSF10D),andfewintegrins(ITGB3,ITGA8,ITGA4,ITGA1).Theup-regulatedproteinsweregroupedbasedonproteinclassasbefore;alargenumberofthemwerenucleicacidbinding(29%),cytoskeletal(17%)orreceptorproteins(14%)(Fig.2B).GOenrichmentanalysisofupregulatedproteinsintheproteomedatasetidentiﬁedtermsrelatinglargelytoECMinteraction,collagenandintegrinmediatedsignalling(Fig.S4).Afterphospho-enrichmentweidentiﬁed2770proteins(TableS7b)(peptidesinTableS7d)andatotalof240phospho-proteinswerefoundsigniﬁcantlyupregulated,whilst195weresigniﬁcantlydownreg-ulated(pb0.05,Log2FCN1/b−1,TableS9).Theupregulatedphospho-proteinsweresubmittedforfunctionalenrichmentanalysisusingDAVID.Thetopenrichedpathwayswerespliceosome(25%),ribosome(13%)andcellcycle(13%)(Fig.2C).Proteasomeisrepresentedby11%,meaningaquitesigniﬁcantaberrationintheproteindegradationmachinery,aswellasantigenprocessing(11%),suggestingapossibleimpairedimmuneresponse.Therewasalsosigniﬁcantrepresentationofphospho-proteinsinvolvedinnon-homologousendjoining(NHEJ)(6%)andnucleotideexcisionrepair(10%).Thedatathereforealsoindi-catestheremaybealterationsinDNArepairmechanisms.GOenrich-mentanalysisidentiﬁedsigniﬁcantenrichmentofproteasomeactivatorcomplex(~80fold)andproteasomeactivatoractivity(~60fold),aswellaspositiveregulationofubiquitin-proteinligaseactivity,inlinewithfunctionalenrichmentanalysis(Fig.2D).Signiﬁcantlychangedphospho-proteinswereplottedinagraphagainsttheirrespectivetotalproteinabundances(Fig.2E).Amongthemostinterestingphospho-proteinsidentiﬁedweretransgelin-2(TAGLN2),previouslyfoundoverexpressedinmeningioma(Sharmaetal.,2015);calcyclinbindingprotein(CACYBP),thatcanFig.1.Functionalcomparativeanalysisofschwannomavs.normalSchwanncells.(A)WesternblotshowingMerlinexpressioninnormalhumanSchwanncellsandlossofMerlinexpressioninschwannomas.(B)Piechart,createdusingPANTHER.db,showingtheupregulatedproteinsgroupedbasedonproteinclass.About50%ofthetotalupregulatedproteinsinschwannomaswerecytoskeletal.(C)Piechartshowingtheupregulatedphospho-proteinssubmittedforfunctionalenrichmentanalysisusingDAVID,theﬁgurehighlightsanumberofactivatedpathwaysinschwannomacellsbutnotinnormalSchwanncells.FocaladhesionandMAPKsignallingwerethemostenriched(18%and16%respectively).(D)MostsigniﬁcantlyenrichedGOtermsintheproteinclasses‘molecularfunction’(green),‘cellularcomponent’(blue)and‘biologicalprocess’(red).Ascellularcomponent,theAP-2adaptorcomplexwasfoundhighlyenriched(about80%)aswellasclathrin-mediatedendocytosis(nearly70%and50%)(E)Signiﬁcantlychangedphospho-proteinsinschwannomacellsvs.phospho-proteinsinnormalSchwanncellsplottedagainsttheirrespectiveproteinandphospho-proteinamounts.DatawereplottedasaLog2FCLFQtumour/normal.80K.Bassirietal./EBioMedicine16(2017)76–86actaseitheranoncogeneoratumoursuppressordependingonthetypeofcancer(Topolska-Wosetal.,2016);Deltex3likeE3ubiquitinligase(DTX3L),abletomodulateDNAdamageresponsesrenderingcancercellsresistanttocertainchemotherapydrugs(Thangetal.,2015).Interestingly,therewereseveralphospho-proteinsidentiﬁedasdownregulatedthatarerelatedtoorganizationofthecytoskele-tonlikeJunctionPlakoglobin(JUP),withaLog2FC=−20.663.Pro-teinabundancewasmostlyunalteredindicatingthatdecreasedphosphorylationofJUPintumourcellsisperhapsgrowthpermis-sive.JUP,alsoknownasγ-cateninisstructurallyandfunctionallyre-latedtoβ-catenin.Phosphorylatedβ-cateninwasalsofoundtobedownregulatedinBen-Men-1cells.3.3.SchwannomaandMeningiomaCommonPhospho-proteinsTheamountofcrossoverbetweendifferentiallyexpressedphospho-proteinsinschwannomavs.SchwanncellsandintheBenMen-1vs.HMCdatasetswasasexpectedhigherthanwiththeprimarymeningio-macellsvs.HMCdataset.Intheanalysisbetweensigniﬁcantlychangedphospho-proteinsinBenMen-1cellscomparedwiththoseinprimaryschwannomacells,11werefoundcommonlyupregulatedand4down-regulated(Table1).Thusweusedthismoreinformativedatasetforcomparisonandsubsequentlyveriﬁedexpressioninprimarymeningio-matumours.AmongthecommonlyupregulatedandactivatedproteinsinbothtumoursweconsistentlyﬁndPDLIM2andFilamin-Bagain.Inaddition,weidentiﬁedtheEpidermalgrowthfactorreceptorkinaseSubstrate8-Likeprotein2(EPS8L2),thatwasfoundnothighlyexpressedinthebrainandlinksgrowthfactorstimulationtocytoskele-talreorganizationandtheRas/Racpathway(Offenhauseretal.,2004),andtheSignalTransducerandActivatorofTranscription1alpha/beta(STAT1).Thesubunitbetatype8andtype7oftheproteasomewerealsofoundcommonlyup-anddownregulatedrespectively,againindi-catingproteasomedysregulation.Wedecidedtoperforminitialvalida-tionstudiesonPDLIM2.Thiscandidatewasprioritisedforthefollowingreasons:1.clearabnormalitiesinthecytoskeletonofthesetumourcells(Flaizetal.,2007;Jamesetal.,2008);2.weidentiﬁedseveralupregulat-edproteinscontainingeitheraPDZ/LIMdomainorboth;3.PDLIM2actsbothasanadaptorproteinatthecytoskeletallevel(Torradoetal.,2004)andanE3ubiquitinligaseintothenucleus(Tanakaetal.,2007);previ-ousstudiesidentiﬁedCRL4(DCAF1),anE3ubiquitinligaseimportantinschwannomaformationandrelatedtoMerlin(LiandGiancotti,2010;Lietal.,2010),indicatingthatpossiblytheregulationofE3ubiquitinli-gasesispivotalinthepathogenesisofMerlin-deﬁcienttumours;4)PDLIM2wasalsoidentiﬁedinprimarymeningiomawithalog2FCof2.6comparedwithHMC.3.4.PDLIM2IsOverexpressedinBothSchwannomasandMeningiomasWeanalysedsixschwannomascomparedwithnormalhumanSchwanncellsbyWesternblot.TheproteinwasfoundoverexpressedinfouroutofthesixschwannomascomparedtothenormalSchwanncellexamined(Schwann-0615)(Fig.3A).AsimilaranalysiswasFig.2.Functionalcomparativeanalysisofmeningiomacellsvs.normalHMC.(A)WesternblotshowingMerlinexpressioninnormalHMCandnoMerlinexpressioninmeningiomatumour-derivedcells.(B)Piechartrepresentingtheupregulatedproteins,groupedbasedonproteinclass(PANTHER.db).Thetopthreeupregulatedproteinclassesinmeningiomawererelatedtonucleicacidbinding(29%),thecytoskeleton(17%)andmembranereceptors(14%).(C)Piechartpresentationoftheupregulatedphospho-proteinssubmittedforfunctionalenrichmentanalysisusingDAVID,theﬁgurehighlightsanumberofactivatedpathwaysinmeningiomacellsbutnotinnormalmeningealcells.(D)MostsigniﬁcantlyenrichedGOtermsintheproteinclasses‘molecularfunction’(green),‘cellularcomponent’(blue)and‘biologicalprocess’(red).Amongthemtheproteasomewasfoundthemostenrichedcellularcomponent(about80%)andbiologicalprocess(nearly60%).(E)Signiﬁcantlychangedphospho-proteinsinBenMen-1cellsvs.phospho-proteinsinnormalHMCplottedagainsttheirrespectiveproteinandphospho-proteinamounts.DatawereplottedasaLog2FCLFQtumour/normal.81K.Bassirietal./EBioMedicine16(2017)76–86performedonmeningiomas;wevalidatedPDLIM2overexpressioninBenMen-1cellsandinsixtumour-derivedprimarycellscomparedtonormalHMC(Fig.3B).WealsotestedthelevelofPDLIM2expressionintumourlysatescomparedtonormalmeninges(Fig.3C).InallcasesPDLIM2wasfoundoverexpressedcomparedtonormalcellsortissue.3.5.PDLIM2KnockdownHighlyDecreasesCellularProliferationofMeningi-omaandSchwannomaCellsToinvestigatethefunctionalrelevanceofPDLIM2expressioninschwannomaandmeningiomawesilencedPDLIM2inthreeprimaryschwannomasandthreeprimarymeningiomasusingshRNAlentiviralparticles.PDLIM2expressionwassigniﬁcantlyknockeddowninschwannomascellsasconﬁrmedbyWesternblot(Fig.3D);thisledtoasigniﬁcantreductioninki-67positivecells(pb0.001),reﬂectingasubstantialreductioninproliferationinresponsetotheknockdown(Fig.3F).Thesamewasrepeatedonmeningiomacellsandagainweobservedareductionofproteinexpressionaftersilencing(Fig.3E)leadingtoasigniﬁcantdecreaseincellularproliferationasmeasuredbyaki-67pro-liferationassay(Fig.3G).AltogetherthesedatastronglysuggestthatPDLIM2isinvolvedincellularproliferationinbothschwannomasandmeningiomas.3.6.PDLIM2CanBePhosphoprylatedandLocalisesIntotheNucleusofSchwannomaandMeningiomaCellsQuantitativeproteomicanalysisshowedastatisticallysigniﬁcantin-creaseofPDLIM2inBenMen-1cellscomparedtoHMCafterphospho-proteinenrichment(Fig.4A),suggestingapossiblephosphorylatedstateoftheprotein.Unfortunatelytherearenospeciﬁcphospho-anti-bodiescommerciallyavailableforpPDLIM2,soweperformedaninvitrodephosphorylationassayusinglambdaphosphatase.TheshiftofthePDLIM2immunoreactivebandafterWesternblotanalysisindeedconﬁrmedthephosphorylationonPDLIM2(Fig.4B).PDLIM2waspreviouslyreportedtoactasacytoplasmicprotein(Torradoetal.,2004)andalsoasanuclearprotein(Tanakaetal.,2007),exhibitingdifferentfunctions.TostudythelocalizationofPDLIM2inourcellularmodelsweperformedcytoplasmicandnuclearproteinextractionandexaminedbyWesternblot.PDLIM2wasfoundtolocalizelargelyintothenucleus(Fig.4C)suggestingapossiblefunc-tionasE3ubiquitinligaseaspreviouslyreported(Tanakaetal.,2007).WealsoperformedimmunoﬂuorescentstainingtofurtherdeterminePDLIM2localizationandidentiﬁeditbothinthecytoplasmandthenu-cleusofBenMen-1andprimarymeningiomacells(Fig.4DandE).4.DiscussionTheaimofthisstudywastodeciphertheproteomeandphospho-proteomeofMerlin-deﬁcientschwannomasandmeningiomasrelativetonormalcontrols.Priortothisstudy,therewasonlyonecomparativeanalysisbetweenmeningiomaandschwannomaatthegenomiclevelreportedintheliterature(Torres-Martinetal.,2013b,2014).Weﬁrstanalysedproteomeandphospho-proteomeofschwannomaandmeningiomaseparately,andcomparedthemtotheirnormalcon-trolsinordertoidentifyproteinsandphospho-proteinssigniﬁcantlydifferentiallyexpressedinthetwotumourtypes.Then,wemergedthetwosetsofcandidatesidentifyingthecommondysregulatedpro-teinsbecauseinNF2patientsthesetumoursfrequentlyoccurtogetherandneedtreatment.Ourproteomicanalysiswashighlyinformativeandrevealedmanyproteinsofpotentialinterestineachdataset.However,despitethevastamountofinformationprovidedbythisstudytherearealsosomelimitationsthathavetobeconsidered.Firstly,thisresearchapproachprovidesageneraloverviewaboutdysregulatedproteinsandpath-ways;however,itisimpossibletodetectthewholeproteomeasnon-abundantproteinscannotreachthelevelofdetection.Secondly,phosphoproteomicstudiesrequirealargeamountofstartingmaterialpriorphospho-enrichment;schwannomaandespeciallyhumanprima-rymeningiomacellsgrowatslowrateforalimitednumberofpassages(b7)makingextremelydifﬁculttoobtaintherequiredamountofpro-teins.Likeeveryenrichmenttechnique,therearepossiblefalse-posi-tivesinthedatasetandadditionalvalidationexperimentsareneeded.Theslowproliferationrateofourprimarycellslikelyexplainthere-duceddatasetobtainedfromtheanalysisofprimarymeningiomaswhichwereculturedwithouttheadditionofexternalgrowthfactorstoavoidartiﬁcialmanipulationoftheproteinsignalling.Whileproteomeofwholetumourbiopsiescomparedtonormalme-ningeswouldprovideinformationaboutenvironmentalsignals,herewedecidedtoconductthestudyonprimarytumourcellsandanestablishedmeningiomacellline,onwhichitwaspossibletoperformsubsequentfunctionalvalidation.Usingpuretumourcellpopulationsinsteadoftissuealsomakesthecomparisonbetweentumoursmoremeaningfulasdifferenttissuewouldvaryinthetumourmicroenvironment.Inschwannomas,byfunctionalenrichmentanalysis,weidentiﬁedseveralfactorsrelatedtothecytoskeletonanditsregulation,inlinewiththepivotalroleofMerlinascytoskeletalregulator(Gladdenetal.,2010;Johnsonetal.,2002;Lallemandetal.,2003;McClatcheyandGiovannini,2005).MAPKsignallingwasalsofoundenriched,inagree-mentwithpreviousstudies(Ammounetal.,2008;Fraenzeretal.,2003).Endocytosis,possiblyclathrin-mediated,waslistedamongtheupregulatedpathwaysandcellularcomponentsinschwannoma,aswellastheAP-2adaptorcomplexrequiredtointernalizecargoinclathrin-mediatedendocytosis(McMahonandBoucrot,2011).ThisisinkeepingwithpreviousdatainﬂiesthatshowedMerlinisimportantforcontrollingmembraneproteinturnoverinpartbyregulatingendo-cytosis(Maitraetal.,2006).Whentheproteomeandphospho-prote-omewerecomparedinordertoidentifyhighlyactivatedproteins,weidentiﬁedseveralcytoskeletalproteinslikePDLIM2,FilaminB,VinculinandthekinaseROCK1,akeyregulatoroftheactincytoskeletonandcellpolarity,andpreviouslyassociatedwiththeERMfamily(Hebertetal.,2008).Again,werecognizedproteinsrelatedtoendocytosisandvesicletransportlikePACSIN3,NAPA,CHMP2BandVPS29.Asopposedtoschwannomas,otherdrivermutationshavebeeniden-tiﬁedinmeningioma,butthosearemutuallyexclusiveofMerlin(Clarketal.,2013).Inordertokeepthegeneticbackgroundconsistentwithschwannoma,weanalysedonlyMerlin-deﬁcientWHOgradeITable1Phospho-proteinscommonlyandsigniﬁcantlyup-ordownregulatedinBenMen-1andprimaryschwannomacells(pb0.05).GenesymbolProteinnameLog2FCmeningiomaLog2FCschwannomaCORO1CCoronin-1C2.601.45CTPSCTPsynthase11.233.70CUTAProteinCutA1.441.50EPS8L2Epidermalgrowthfactorreceptorkinasesubstrate8-likeprotein23.3624.27FLNBFilamin-B1.2224.49HSPA1AHeatshock70kDaprotein1A/1B1.213.23PDE1CCalcium/calmodulin-dependent3,5-cyclicnucleotidephosphodiesterase1C3.161.36PDLIM2PDZandLIMdomainprotein23.9424.53PSMB8Proteasomesubunitbetatype-81.401.29STAT1Signaltransducerandactivatoroftranscription1-alpha/beta4.5726.24TCEB2TranscriptionelongationfactorBpolypeptide21.011.02MAP1AMicrotubule-associatedprotein1A−19.89−1.00PACSIN2ProteinkinaseCandcaseinkinasesubstrateinneuronsprotein2−2.11−1.19PSMB7Proteasomesubunitbetatype-7−1.17−1.32UFL1E3UFM1-proteinligase1−1.14−1.4382K.Bassirietal./EBioMedicine16(2017)76–86meningiomas.Comparativefunctionalenrichmentanalysisintheme-ningiomadatasetsidentiﬁedpathwaysthatmightbeofparticularimpor-tance;amongthemwefoundproteasomeactivationtobearecurringthemethroughout,highlightingitasanimportanttargetinmeningioma.A2014studylookingattheproteasomeinhibitorbortezomibshowedthatitwaseffectiveinsensitizingmeningiomacellstoTRAIL-inducedap-optosis(Koschnyetal.,2014).Further,theproteasomeinhibitorMG132wasalsofoundtoincreaselevelsofN-cadherininschwannomacells,whichinturndecreasedproliferation(Zhouetal.,2011).Ourdataandpreviousreportsthussuggestproteasomeinhibitionasapotentialther-apy,eitheraloneorincombinationwithdrugstargetingotherrelevantpathways.ThephosphorylatedproteinwiththelargestfoldchangeinprimarymeningiomacellswasTGM2,ortransglutaminase2.Theex-pressionofthisproteinhasbeenpreviouslystudiedinmeningiomaandwasfoundtobehighlyupregulatedandsuggestedasatherapeutictarget.TheauthorsalsoshowedthatlossoftheNF2genewasassociatedwithhighexpressionofTGM2(Huangetal.,2014).WealsofoundTAGLN2asupregulatedinmeningiomacells,inkeepingwithpreviousproteomicstudiesonmeningioma(Sharmaetal.,2015).Itissimilarinitsfunctiontotransgelin(TAGLN),whichweidentiﬁedashighlyexpressedinschwannoma.Thetransgelinsareafamilyofproteinsabletoinﬂuenceadiverserangeofcellularprocesses,includingproliferation,migrationandapoptosis(Dvorakovaetal.,2014).ThestudybySharmaetal.usedasimilarproteomicapproachtoidentifypotentialtherapeutictargetsusingmeningiomatissue(comparedtonormalbrain)asopposedtocells.Therewere12proteinssigniﬁcantlyupregulatedandcommontobothdatasetsincludingtheLIMdomaincontainingproteinFHL1,drebrin,ﬁbronectinandtranslationallycontrolledtumourprotein(TCTP),alllinkedwithstructuralregulation.WealsoidentiﬁedpossiblealterationsinDNArepairmechanisms,consistentlywithpreviousresultsshowingchromosomeinstabilityanddefectsinthemitoticapparatusinmeningioma(vanTilborgetal.,2005),inparticularintheNF2-mutated(Goutagnyetal.,2010).StudiesbyYangetal.(2012)showedthatthetumoursuppressorCHEK2onchromosome22qisoftendeletedtogetherwithMerlin,thusimpairingDNArepairmechanismsandincreasingchromosomalinstabilityinme-ningiomas(Yangetal.,2012).BenMen-1cells,whichhaveaknownNF2mutation,havebeenusedasaWHOgradeImeningiomacelllinemodelandcomparedtoHMC,bearinginmindpossiblemodiﬁcationsduetoimmortalization(Puttmannetal.,2005),howeverhelpingthestudybybeinganhomo-geneouspopulationofcells.ThecomparisonbetweenBenMen-1andFig.3.PDLIM2overexpressedinschwannomasandmeningiomasislinkedtoincreasedproliferationoftumourcells.(A)WesternblotanalysisofPDLIM2expressioninprimaryschwannomacellscomparedtoprimaryhumanSchwanncell.(B–C)WesternblotanalysisofPDLIM2expressioninBenMen-1andprimarymeningiomacellscomparedtoHMC(B),andmeningiomatumourspecimenscomparedtonormalhumanmeninges(C).(D)PDLIM2shRNA-mediatedknockdowninthreeprimaryschwannomas,conﬁrmedbytheabsenceofimmunoreactivebandinWesternblotanalysiscomparedtothesh-scramblecontrol.Thesamplesanalysedwere;(1)NF1:NF1115(Fig.3A),Merlin-positiveandpMerlin-positive,NF0116;(2)NF2:NF0116,Merlin-positiveandpMerlinfaintband(datanotshown);(3)NF3:NF0216,Merlin-negativeandpMerlin-negative(datanotshown).(E)PDLIM2shRNA-mediatedknockdowninthreeprimarymeningiomacells,conﬁrmedbythereductionofintensityoftheimmunoreactivebanddetectedbyWesternblotanalysiscomparedtothesh-Scramblecontrol.Thesamplesanalysedwere;(1)MN1:MN026,Merlin-negativeandpMerlin-negative(datanotshown),(2)MN2:MN028,and(3)MN3:MN031,bothMerlin-negativeandpMerlin-negative(Fig.3B).(F)Ki-67immunoﬂuorescentstaining(green)ofthethreeschwannomacellpopulationsafterPDLIM2shRNAknockdowncomparedtosh-Scramblecontrol.Ontheleftsidethehistogramshowingthehighlystatisticallysigniﬁcant(***,pb0.001)reducedproliferationinPDLIM2knockdowncells.(G)Ki-67immunoﬂuorescentstaining(green)ofthethreeprimarymeningiomacellsafterPDLIM2shRNAknockdowncomparedtosh-Scramblecontrol.Ontheleftsidethehistogramshowingthestatisticallysigniﬁcant(*,pb0.05)reducedproliferationinPDLIM2knockdowncells.NucleiarestainedwithDAPI(Blue).Micrographsaretakenat20×magniﬁcation.SC-Scramble;KD-knockdown.83K.Bassirietal./EBioMedicine16(2017)76–86schwannomadatasetscomparedwithcontrolsrevealedseveralcom-monupregulatedproteins.Amongthemweidentiﬁedtheepidermalgrowthfactorreceptorkinasesubstrate8-likeprotein2(EPS8L2),partoftheEPSfamilyofproteinsrelatedtoactincytoskeletonreorganizationundergrowthfactorsstimulation(Offenhauseretal.,2004);thecyto-skeletalproteinFilamin-B(FLNB);andthesignaltransducerandactiva-toroftranscription1-alpha/beta(STAT1),partoftheJAK/STAT1activatedinresponsetointerferonandpreviouslyfoundexpressedinmeningiomas(Magrassietal.,1999),currentlyundervalidation.HerewedecidedtofurtheranalysePDLIM2forseveralreasons;weidentiﬁedseveralPDZ/LIMdomainsproteinsthroughoutthestudy,in-dicatingapossiblyimportantroleofthisfamilyofproteinsinMerlin-deﬁcienttumours.PDLIM2wasﬁrstdescribedin2004asanadaptorproteinlinkingotherproteinstothecytoskeleton(Torradoetal.,2004),soitsdysregulationinMerlin-deﬁcienttumoursappearedhighlyplausible.Since,ithasbeenfoundtohaveanumberofdifferentrolesandhasbeenparticularlywellstudiedinbreastcancerwhereithasbeenidentiﬁedasadriveroftumourprogressionandinvasion(Deevietal.,2014;Loughranetal.,2005a).In2007,fortheﬁrsttimePDLIM2wasshowntopossessnuclearubiquitinE3ligaseactivitynegativelyregulatingNF-kappaBbytargetingthep65subunitduringinﬂamma-tion(Tanakaetal.,2007).PreviousstudiesalreadyidentiﬁedanotherE3ubiquitinligase,CRL4(DCAF1),involvedintheformationofMerlin-deﬁcienttumours(Cooperetal.,2011;Lietal.,2010).Finally,thedys-regulatedubiquitinligaseactivity,togetherwiththedysregulatedproteasomalactivityfoundinmeningiomasinourstudy,cansuggestnoveltherapeuticstrategies.WeﬁrstconﬁrmedPDLIM2overexpressioninprimarymeningiomaandschwannomasamplesandshowedthatitisnotexpressedinHMCornormalmeningealtissueandminimallyexpressedintheSchwanncellexamined.PDLIM2wassigniﬁcantlyknockeddowninthreeprima-rymeningiomaandthreeprimaryschwannomacellpopulations.Thisledtosigniﬁcantreductionsincellproliferationinbothcelltypes.TheseresultsareinlinewithapreviousstudywhichshowedhowPDLIM2suppressionleadstodecreasedproliferationinandrogen-inde-pendentprostatecancercelllines(Kangetal.,2016).Ontheotherhand,otherstudieshaveidentiﬁedPDLIM2asanimportanttumoursuppres-sor(Sunetal.,2015;Zhaoetal.,2016).Interestinglyenough,PDLIM5,thatwefoundhighlyoverexpressedintheschwannomaphospho-pro-teome,wasfoundoverexpressedingastriccancercellsanditssiRNA-Fig.4.PDLIM2actsasphosphoproteinandlocalisesintothenucleus.(A)HistogramshowingPDLIM2MSquantiﬁcationasLog2LFQvalueinBenMen-1(BM)cellsvs.HMCafterphosphoenrichment.PhosphorylatedPDLIM2wasstatisticallysigniﬁcantlyenrichedinBenMen-1cells(**,pb0.012)comparedtoHMC.(B)WesternblotanalysisconﬁrmingthephosphorylatedstatusofPDLIM2inBenMen-1cells.Lambdaphosphatasetreatment(λ-Ph)inducedindeedashiftinPDLIM2immunoreactivebandcomparedtonon-treated(NT)control.(C)RepresentativeWesternblotshowingPDLIM2localizationafternuclearandcytoplasmicproteinfractionation.TotalHDAC1andGAPDHareshownasreferenceproteinforthenuclearandcytoplasmicfractionrespectively.(D)Confocalmicroscopy(Z-stacks)ofPDLIM2(red)inBenMen-1cellsandinprimarymeningiomacells(MN028,MN033,MN036)(E).NucleiwerestainedwithDAPI(blue).84K.Bassirietal./EBioMedicine16(2017)76–86mediatedsilencingsigniﬁcantlyreducedcellularproliferation(Lietal.,2015),highlightingapossiblecommonroleforthisfamilyasregulatorsofcellproliferation.OurresultsshowedthatPDLIM2canbephosphorylated.RecentlyoneproteomicstudyidentiﬁedspeciﬁcphosphoserinesitesonPDLIM2(Bianetal.,2014);however,nophosphospeciﬁcantibodiesareavailableandtheresultneedsfurthervalidation.Uponsubcellularfractionation,PDLIM2wasfoundtolocalizeintothenucleus,possiblyexploitingE3ubiquitinligaseactivity(Tanakaetal.,2007).ICCanalysisshoweditlocalisedtoboththenucleusandthecytoplasm.ItmaybethatPDLIM2associateswiththecytoskeletonandisthusrenderedinsolubleduringsubcellularfractionation,asisthecasewithsomecytoskeletalproteinse.g.intermediateﬁlaments,explainingwhyonlynuclearPDLIM2wasdetectableviaWesternblot.OuroverallresultsindicatethatPDLIM2hasbothnuclearandcytoplas-micfunctionsinmeningiomacells.Additionalstudieswillbeperformedtoverifywhethertheproteinactsonp65eveninMerlin-negativeme-ningiomasandschwannomas,andtheroleofthephosphorylationonPDLIM2activity.Inconclusion,weperformedacomprehensiveanalysisofproteomeandphosphoproteomeexpressioninMerlin-deﬁcientschwannomasandmeningiomas,foundseveraldysregulatedproteins/pathwaysineachdatasetandunderlyingknownandnovelcandidatesinvolvedinthepathogenesisofbothtumours.Additionally,wevalidatedtheover-expressionofPDLIM2whichwasfoundinvolvedintheproliferationofbothmeningiomaandschwannomacells,conﬁrmingthatPDLIM2war-rantsfurtherinvestigationasapotentialcommontargetinMerlin-deﬁ-cientmeningiomasandschwannomas.Supplementarydatatothisarticlecanbefoundonlineathttp://dx.doi.org/10.1016/j.ebiom.2017.01.020.FundingSourcesThisstudywassupportedbygrantsfromDHT(Dr.HadwenTrust);BrainTumourResearchandtheBiochemicalSociety(EricReidFundforMethodology).AcknowledgementWethankDr.DavidHiltonforprovidingtumourspecimens,thesur-geonsfromPlymouthandBristolhospitalsandDr.EmanuelaErcolanoforhelpingwithprimarycellcultures.ReferencesAmmoun,S.,Flaiz,C.,Ristic,N.,Schuldt,J.,Hanemann,C.O.,2008.Dissectingandtargetingthegrowthfactor-dependentandgrowthfactor-independentextracellularsignal-regulatedkinasepathwayinhumanschwannoma.CancerRes.68,5236–5245.Ammoun,S.,Provenzano,L.,Zhou,L.,Barczyk,M.,Evans,K.,Hilton,D.A.,Haﬁzi,S.,Hanemann,C.O.,2014.Axl/Gas6/NFkappaBsignallinginschwannomapathologicalproliferation,adhesionandsurvival.Oncogene33,336–346.Bian,Y.,Song,C.,Cheng,K.,Dong,M.,Wang,F.,Huang,J.,Sun,D.,Wang,L.,Ye,M.,Zou,H.,2014.AnenzymeassistedRP-RPLCapproachforin-depthanalysisofhumanliverphosphoproteome.J.Proteome96,253–262.Bretscher,A.,Chambers,D.,Nguyen,R.,Reczek,D.,2000.ERM-MerlinandEBP50proteinfamiliesinplasmamembraneorganizationandfunction.Annu.Rev.CellDev.Biol.16,113–143.Clark,V.E.,Erson-Omay,E.Z.,Serin,A.,Yin,J.,Cotney,J.,Ozduman,K.,Avşar,T.,Li,J.,Murray,P.B.,Henegariu,O.,Yilmaz,S.,Günel,J.M.,Carrión-Grant,G.,Yilmaz,B.,Grady,C.,Tanrikulu,B.,Bakircioğlu,M.,Kaymakçalan,H.,Caglayan,A.O.,Sencar,L.,Ceyhun,E.,Atik,A.F.,Bayri,Y.,Bai,H.,Kolb,L.E.,Hebert,R.M.,Omay,S.B.,Mishra-Gorur,K.,Choi,M.,Overton,J.D.,Holland,E.C.,Mane,S.,State,M.W.,Bilgüvar,K.,Baehring,J.M.,Gutin,P.H.,Piepmeier,J.M.,Vortmeyer,A.,Brennan,C.W.,Pamir,M.N.,Kiliç,T.,Lifton,R.P.,Noonan,J.P.,Yasuno,K.,Günel,M.,2013.Genomicanalysisofnon-NF2meningiomasrevealsmutationsinTRAF7,KLF4,AKT1,andSMO.Science339,1077–1080.Claudio,J.O.,Veneziale,R.W.,Menko,A.S.,Rouleau,G.A.,1997.ExpressionofschwannomininlensandSchwanncells.Neuroreport8,2025–2030.Cooper,J.,Li,W.,You,L.,Schiavon,G.,Pepe-Caprio,A.,Zhou,L.,Ishii,R.,Giovannini,M.,Hanemann,C.O.,Long,S.B.,Erdjument-Bromage,H.,Zhou,P.,Tempst,P.,Giancotti,F.G.,2011.Merlin/NF2functionsupstreamofthenuclearE3ubiquitinligaseCRL4DCAF1tosuppressoncogenicgeneexpression.Sci.Signal.4(pt6).Cox,J.,Hein,M.Y.,Luber,C.A.,Paron,I.,Nagaraj,N.,Mann,M.,2014.Accurateproteome-widelabel-freequantiﬁcationbydelayednormalizationandmaximalpeptideratioextraction,termedMaxLFQ.Mol.Cell.Proteomics13,2513–2526.Curto,M.,Cole,B.K.,Lallemand,D.,Liu,C.H.,McClatchey,A.I.,2007.Contact-dependentin-hibitionofEGFRsignalingbyNf2/Merlin.J.CellBiol.177,893–903.Deevi,R.K.,Cox,O.T.,O'Connor,R.,2014.EssentialfunctionforPDLIM2incellpolarizationinthree-dimensionalculturesbyfeedbackregulationofthebeta1-integrin-RhoAsig-nalingaxis.Neoplasia16,422–431.Dvorakova,M.,Nenutil,R.,Bouchal,P.,2014.Transgelins,cytoskeletalproteinsimplicatedindifferentaspectsofcancerdevelopment.ExpertRev.Proteomics11,149–165.Fevre-Montange,M.,Champier,J.,Durand,A.,Wierinckx,A.,Honnorat,J.,Guyotat,J.,Jouvet,A.,2009.Microarraygeneexpressionproﬁlinginmeningiomas:differentialexpressionaccordingtogradeorhistopathologicalsubtype.Int.J.Oncol.35,1395–1407.Flaiz,C.,Kaempchen,K.,Matthies,C.,Hanemann,C.O.,2007.Actin-richprotrusionsandnonlocalizedGTPaseactivationinMerlin-deﬁcientschwannomas.J.Neuropathol.Exp.Neurol.66,608–616.Flaiz,C.,Utermark,T.,Parkinson,D.B.,Poetsch,A.,Hanemann,C.O.,2008.Impairedinter-cellularadhesionandimmatureadherensjunctionsinmerlin-deﬁcienthumanpri-maryschwannomacells.Glia56,506–515.Fraenzer,J.T.,Pan,H.,MinimoJr.,L.,Smith,G.M.,Knauer,D.,Hung,G.,2003.Overexpres-sionoftheNF2geneinhibitsschwannomacellproliferationthroughpromotingPDGFRdegradation.Int.J.Oncol.23,1493–1500.Garcia-Rendueles,M.E.,Ricarte-Filho,J.C.,Untch,B.R.,Landa,I.,Knauf,J.A.,Voza,F.,Smith,V.E.,Ganly,I.,Taylor,B.S.,Persaud,Y.,Oler,G.,Fang,Y.,Jhanwar,S.C.,Viale,A.,Heguy,A.,Huberman,K.H.,Giancotti,F.,Ghossein,R.,Fagin,J.A.,2015.NF2losspromotesoncogenicRAS-inducedthyroidcancersviaYAP-dependenttransactivationofRASproteinsandsensitizesthemtoMEKinhibition.CancerDiscov.5,1178–1193.Gladden,A.B.,Hebert,A.M.,Schneeberger,E.E.,McClatchey,A.I.,2010.TheNF2tumorsup-pressor,Merlin,regulatesepidermaldevelopmentthroughtheestablishmentofajunctionalpolaritycomplex.Dev.Cell19,727–739.Goutagny,S.,Yang,H.W.,Zucman-Rossi,J.,Chan,J.,Dreyfuss,J.M.,Park,P.J.,Black,P.M.,Giovannini,M.,Carroll,R.S.,Kalamarides,M.,2010.Genomicproﬁlingrevealsalterna-tivegeneticpathwaysofmeningiomamalignantprogressiondependentontheun-derlyingNF2status.Clin.CancerRes.16,4155–4164.Gronholm,M.,Teesalu,T.,Tyynela,J.,Piltti,K.,Bohling,T.,Wartiovaara,K.,Vaheri,A.,Carpen,O.,2005.CharacterizationoftheNF2proteinmerlinandtheERMproteinezrininhuman,rat,andmousecentralnervoussystem.Mol.Cell.Neurosci.28,683–693.Guerrero,P.A.,Yin,W.,Camacho,L.,Marchetti,D.,2015.OncogenicroleofMerlin/NF2inglioblastoma.Oncogene34,2621–2630.Hanemann,C.O.,2008.Magicbuttreatable?Tumoursduetolossofmerlin.Brain131,606–615.Hanemann,C.O.,Bartelt-Kirbach,B.,Diebold,R.,Kampchen,K.,Langmesser,S.,Utermark,T.,2006.DifferentialgeneexpressionbetweenhumanschwannomaandcontrolSchwanncells.Neuropathol.Appl.Neurobiol.32,605–614.Hebert,M.,Potin,S.,Sebbagh,M.,Bertoglio,J.,Breard,J.,Hamelin,J.,2008.Rho-ROCK-de-pendentezrin-radixin-moesinphosphorylationregulatesFas-mediatedapoptosisinJurkatcells.J.Immunol.181,5963–5973.Huangda,W.,Sherman,B.T.,Lempicki,R.A.,2009.SystematicandintegrativeanalysisoflargegenelistsusingDAVIDbioinformaticsresources.Nat.Protoc.4,44–57.Huang,Y.C.,Wei,K.C.,Chang,C.N.,Chen,P.Y.,Hsu,P.W.,Chen,C.P.,Lu,C.S.,Wang,H.L.,Gutmann,D.H.,Yeh,T.H.,2014.Transglutaminase2expressionisincreasedasafunc-tionofmalignancygradeandnegativelyregulatescellgrowthinmeningioma.PLoSOne9,e108228.James,M.F.,Lelke,J.M.,Maccollin,M.,Plotkin,S.R.,Stemmer-Rachamimov,A.O.,Ramesh,V.,Gusella,J.F.,2008.ModelingNF2withhumanarachnoidalandmeningiomacellculturesystems:NF2silencingreﬂectsthebenigncharacteroftumorgrowth.Neurobiol.Dis.29,278–292.Johnson,K.C.,Kissil,J.L.,Fry,J.L.,Jacks,T.,2002.CellulartransformationbyaFERMdomainmutantoftheNf2tumorsuppressorgene.Oncogene21,5990–5997.Kaempchen,K.,Mielke,K.,Utermark,T.,Langmesser,S.,Hanemann,C.O.,2003.Upregula-tionoftheRac1/JNKsignalingpathwayinprimaryhumanschwannomacells.Hum.Mol.Genet.12,1211–1221.Kang,M.,Lee,K.H.,Lee,H.S.,Park,Y.H.,Jeong,C.W.,Ku,J.H.,Kim,H.H.,Kwak,C.,2016.PDLIM2suppressionefﬁcientlyreducestumorgrowthandinvasivenessofhumancastration-resistantprostatecancer-likecells.Prostate76,273–285.Koschny,R.,Boehm,C.,Sprick,M.R.,Haas,T.L.,Holland,H.,Xu,L.X.,Krupp,W.,Mueller,W.C.,Bauer,M.,Koschny,T.,Keller,M.,Sinn,P.,Meixensberger,J.,Walczak,H.,Ganten,T.M.,2014.BortezomibsensitizesprimarymeningiomacellstoTRAIL-in-ducedapoptosisbyenhancingformationofthedeath-inducingsignalingcomplex.J.Neuropathol.Exp.Neurol.73,1034–1046.Lallemand,D.,Curto,M.,Saotome,I.,Giovannini,M.,McClatchey,A.I.,2003.NF2deﬁciencypromotestumorigenesisandmetastasisbydestabilizingadherensjunctions.GenesDev.17,1090–1100.Lallemand,D.,Manent,J.,Couvelard,A.,Watilliaux,A.,Siena,M.,Chareyre,F.,Lampin,A.,Niwa-Kawakita,M.,Kalamarides,M.,Giovannini,M.,2009.Merlinregulatestrans-membranereceptoraccumulationandsignalingattheplasmamembraneinprimarymouseSchwanncellsandinhumanschwannomas.Oncogene28,854–865.Lasonder,E.,Ishihama,Y.,Andersen,J.S.,Vermunt,A.M.,Pain,A.,Sauerwein,R.W.,Eling,W.M.,Hall,N.,Waters,A.P.,Stunnenberg,H.G.,Mann,M.,2002.AnalysisofthePlas-modiumfalciparumproteomebyhigh-accuracymassspectrometry.Nature419,537–542.Lee,H.,Hwang,S.J.,Kim,H.R.,Shin,C.H.,Choi,K.H.,Joung,J.G.,Kim,H.H.,2016.Neuroﬁ-bromatosis2(NF2)controlstheinvasivenessofglioblastomathroughYAP-85K.Bassirietal./EBioMedicine16(2017)76–86dependentexpressionofCYR61/CCN1andmiR-296-3p.Biochim.Biophys.Acta1859,599–611.Li,W.,Giancotti,F.G.,2010.Merlin'stumorsuppressionlinkedtoinhibitionoftheE3ubiquitinligaseCRL4(DCAF1).CellCycle9,4433–4436.Li,W.,You,L.,Cooper,J.,Schiavon,G.,Pepe-Caprio,A.,Zhou,L.,Ishii,R.,Giovannini,M.,Hanemann,C.O.,Long,S.B.,Erdjument-Bromage,H.,Zhou,P.,Tempst,P.,Giancotti,F.G.,2010.Merlin/NF2suppressestumorigenesisbyinhibitingtheE3ubiquitinligaseCRL4(DCAF1)inthenucleus.Cell140,477–490.Li,W.,Cooper,J.,Zhou,L.,Yang,C.,Erdjument-Bromage,H.,Zagzag,D.,Snuderl,M.,Ladanyi,M.,Hanemann,C.O.,Zhou,P.,Karajannis,M.A.,Giancotti,F.G.,2014.Mer-lin/NF2loss-driventumorigenesislinkedtoCRL4(DCAF1)-mediatedinhibitionofthehippopathwaykinasesLats1and2inthenucleus.CancerCell26,48–60.Li,Y.,Gao,Y.,Xu,Y.,Sun,X.,Song,X.,Ma,H.,Yang,M.,2015.si-RNA-mediatedknockdownofPDLIM5suppressesgastriccancercellproliferationinvitro.Chem.Biol.DrugDes.85,447–453.Loughran,G.,Healy,N.C.,Kiely,P.A.,Huigsloot,M.,Kedersha,N.L.,O'Connor,R.,2005a.Mystiqueisanewinsulin-likegrowthfactor-I-regulatedPDZ-LIMdomainproteinthatpromotescellattachmentandmigrationandsuppressesAnchorage-indepen-dentgrowth.Mol.Biol.Cell16,1811–1822.Loughran,G.,Huigsloot,M.,Kiely,P.A.,Smith,L.M.,Floyd,S.,Ayllon,V.,O'Connor,R.,2005b.GeneexpressionproﬁlesincellstransformedbyoverexpressionoftheIGF-Ireceptor.Oncogene24,6185–6193.Magrassi,L.,De-Fraja,C.,Conti,L.,Butti,G.,Infuso,L.,Govoni,S.,Cattaneo,E.,1999.Expres-sionoftheJAKandSTATsuperfamiliesinhumanmeningiomas.J.Neurosurg.91,440–446.Maitra,S.,Kulikauskas,R.M.,Gavilan,H.,Fehon,R.G.,2006.ThetumorsuppressorsMerlinandexpandedfunctioncooperativelytomodulatereceptorendocytosisandsignal-ing.Curr.Biol.16,702–709.Martin,K.,Rossi,V.,Ferrucci,S.,Pian,D.,2010.Retinalastrocytichamartoma.Optometry81,221–233.Maudsley,S.,Zamah,A.M.,Rahman,N.,Blitzer,J.T.,Luttrell,L.M.,Lefkowitz,R.J.,Hall,R.A.,2000.Platelet-derivedgrowthfactorreceptorassociationwithNa(+)/H(+)ex-changerregulatoryfactorpotentiatesreceptoractivity.Mol.Cell.Biol.20,8352–8363.McClatchey,A.I.,2003.MerlinandERMproteins:unappreciatedrolesincancerdevelop-ment?Nat.Rev.Cancer3,877–883.McClatchey,A.I.,Giovannini,M.,2005.Membraneorganizationandtumorigenesis–theNF2tumorsuppressor,Merlin.GenesDev.19,2265–2277.McMahon,H.T.,Boucrot,E.,2011.Molecularmechanismandphysiologicalfunctionsofclathrin-mediatedendocytosis.Nat.Rev.Mol.CellBiol.12,517–533.Meimoun,P.,Ambard-Bretteville,F.,Colas-desFrancs-Small,C.,Valot,B.,Vidal,J.,2007.Analysisofplantphosphoproteins.Anal.Biochem.371,238–246.Mohler,P.J.,Kreda,S.M.,Boucher,R.C.,Sudol,M.,Stutts,M.J.,Milgram,S.L.,1999.Yes-as-sociatedprotein65localizesp62(c-Yes)totheapicalcompartmentofairwayepithe-liabyassociationwithEBP50.J.CellBiol.147,879–890.Morrison,H.,Sperka,T.,Manent,J.,Giovannini,M.,Ponta,H.,Herrlich,P.,2007.Merlin/neuroﬁbromatosistype2suppressesgrowthbyinhibitingtheactivationofRasandRac.CancerRes.67,520–527.Morrow,K.A.,Das,S.,Meng,E.,Menezes,M.E.,Bailey,S.K.,Metge,B.J.,Buchsbaum,D.J.,Samant,R.S.,Shevde,L.A.,2016.LossoftumorsuppressorMerlinresultsinaberrantactivationofWnt/beta-cateninsignalingincancer.Oncotarget7,17991–18005.Offenhauser,N.,Borgonovo,A.,Disanza,A.,Romano,P.,Ponzanelli,I.,Iannolo,G.,DiFiore,P.P.,Scita,G.,2004.Theeps8familyofproteinslinksgrowthfactorstimulationtoactinreorganizationgeneratingfunctionalredundancyintheRas/Racpathway.Mol.Biol.Cell15,91–98.Pranjol,M.Z.,Gutowski,N.,Hannemann,M.,Whatmore,J.,2015.ThepotentialroleoftheproteasescathepsinDandcathepsinLintheprogressionandmetastasisofepithelialovariancancer.Biomolecules5,3260–3279.Puttmann,S.,Senner,V.,Braune,S.,Hillmann,B.,Exeler,R.,Rickert,C.H.,Paulus,W.,2005.EstablishmentofabenignmeningiomacelllinebyhTERT-mediatedimmortalization.Lab.Investig.85,1163–1171.Qu,Z.,Fu,J.,Yan,P.,Hu,J.,Cheng,S.Y.,Xiao,G.,2010.EpigeneticrepressionofPDZ-LIMdo-main-containingprotein2:implicationsforthebiologyandtreatmentofbreastcan-cer.J.Biol.Chem.285,11786–11792.Rappsilber,J.,Ishihama,Y.,Mann,M.,2003.Stopandgoextractiontipsformatrix-assistedlaserdesorption/ionization,nanoelectrospray,andLC/MSsamplepretreatmentinproteomics.Anal.Chem.75,663–670.Rouleau,G.A.,Merel,P.,Lutchman,M.,Rouleau,G.A.,Merel,P.,Lutchman,M.,Sanson,M.,Zucman,J.,Marineau,C.,Hoang-Xuan,K.,Demczuk,S.,Desmaze,C.,Plougastel,B.,etal.,1993.Alterationinanewgeneencodingaputativemembrane-organizingproteincausesneuro-ﬁbromatosistype2.Nature363,515–521.Sakuda,K.,Kohda,Y.,Matsumoto,T.,Park,C.,Seto,A.,Tohma,Y.,Hasegawa,M.,Kida,S.,Nitta,H.,Yamashima,T.,Yamashita,J.,1996.ExpressionofNF2geneproductmerlininarachnoidvilliandmeningiomas.NoshuyoByori13,145–148.Scherer,S.S.,Gutmann,D.H.,1996.Expressionoftheneuroﬁbromatosis2tumorsuppres-sorgeneproduct,Merlin,inSchwanncells.J.Neurosci.Res.46,595–605.Schulze,K.M.,Hanemann,C.O.,Muller,H.W.,Hanenberg,H.,2002.Transductionofwild-typemerlinintohumanschwannomacellsdecreasesschwannomacellgrowthandinducesapoptosis.Hum.Mol.Genet.11,69–76.Sharma,S.,Ray,S.,Moiyadi,A.,Sridhar,E.,Srivastava,S.,2014.Quantitativeproteomicanalysisofmeningiomasfortheidentiﬁcationofsurrogateproteinmarkers.Sci.Rep.4,7140.Sharma,S.,Ray,S.,Mukherjee,S.,Moiyadi,A.,Sridhar,E.,Srivastava,S.,2015.Multi-prongedquantitativeproteomicanalysesindicatemodulationofvarioussignaltrans-ductionpathwaysinhumanmeningiomas.Proteomics15,394–407.Sheikh,H.A.,Tometsko,M.,Niehouse,L.,Aldeeb,D.,Swalsky,P.,Finkelstein,S.,Barnes,E.L.,Hunt,J.L.,2004.Moleculargenotypingofmedullarythyroidcarcinomacanpredicttumorrecurrence.Am.J.Surg.Pathol.28,101–106.Sun,F.,Xiao,Y.,Qu,Z.,2015.OncovirusKaposisarcomaherpesvirus(KSHV)repressestumorsuppressorPDLIM2topersistentlyactivatenuclearfactorkappaB(NF-kappaB)andSTAT3transcriptionfactorsfortumorigenesisandtumormaintenance.J.Biol.Chem.290,7362–7368.Tanaka,T.,Grusby,M.J.,Kaisho,T.,2007.PDLIM2-mediatedterminationoftranscriptionfactorNF-kappaBactivationbyintranuclearsequestrationanddegradationofthep65subunit.Nat.Immunol.8,584–591.TeVelthuis,A.J.,Isogai,T.,Gerrits,L.,Bagowski,C.P.,2007.Insightsintothemolecularevo-lutionofthePDZ/LIMfamilyandidentiﬁcationofanovelconservedproteinmotif.PLoSOne2,e189.Thang,N.D.,Yajima,I.,Kumasaka,M.Y.,Iida,M.,Suzuki,T.,Kato,M.,2015.Deltex-3-like(DTX3L)stimulatesmetastasisofmelanomathroughFAK/PI3K/AKTbutnotMEK/ERKpathway.Oncotarget6,14290–14299.Topolska-Wos,A.M.,Chazin,W.J.,Filipek,A.,2016.CacyBP/SIP—structureandvarietyoffunctions.Biochim.Biophys.Acta1860,79–85.Torrado,M.,Senatorov,V.V.,Trivedi,R.,Fariss,R.N.,Tomarev,S.I.,2004.Pdlim2,anovelPDZ-LIMdomainprotein,interactswithalpha-actininsandﬁlaminA.Invest.Ophthalmol.Vis.Sci.45,3955–3963.Torres-Martin,M.,Lassaletta,L.,deCampos,J.M.,Isla,A.,Gavilan,J.,Pinto,G.R.,Burbano,R.R.,Latif,F.,Melendez,B.,Castresana,J.S.,Rey,J.A.,2013a.Globalproﬁlinginvestib-ularschwannomasshowscriticalderegulationofmicroRNAsandupregulationinthoseincludedinchromosomalregion14q32.PLoSOne8,e65868.Torres-Martin,M.,Lassaletta,L.,San-Roman-Montero,J.,DeCampos,J.M.,Isla,A.,Gavilan,J.,Melendez,B.,Pinto,G.R.,Burbano,R.R.,Castresana,J.S.,Rey,J.A.,2013b.MicroarrayanalysisofgeneexpressioninvestibularschwannomasrevealsSPP1/METsignalingpathwayandandrogenreceptorderegulation.Int.J.Oncol.42,848–862.Torres-Martin,M.,Lassaletta,L.,Isla,A.,DeCampos,J.M.,Pinto,G.R.,Burbano,R.R.,Castresana,J.S.,Melendez,B.,Rey,J.A.,2014.GlobalexpressionproﬁleinlowgrademeningiomasandschwannomasshowsupregulationofPDGFD,CDH1andSLIT2comparedtotheirhealthytissue.Oncol.Rep.32,2327–2334.Tyanova,S.,Temu,T.,Sinitcyn,P.,Carlson,A.,Hein,M.Y.,Geiger,T.,Mann,M.,Cox,J.,2016.ThePerseuscomputationalplatformforcomprehensiveanalysisof(prote)omicsdata.Nat.Methods.vanTilborg,A.A.,AlAllak,B.,Velthuizen,S.C.,deVries,A.,Kros,J.M.,Avezaat,C.J.,deKlein,A.,Beverloo,H.B.,Zwarthoff,E.C.,2005.Chromosomalinstabilityinmeningiomas.J.Neuropathol.Exp.Neurol.64,312–322.Wang,X.,Gong,Y.,Wang,D.,Xie,Q.,Zheng,M.,Zhou,Y.,Li,Q.,Yang,Z.,Tang,H.,Li,Y.,Hu,R.,Chen,X.,Mao,Y.,2012.Analysisofgeneexpressionproﬁlinginmeningioma:deregulatedsignalingpathwaysassociatedwithmeningiomaandEGFL6overexpres-sioninbenignmeningiomatissueandserum.PLoSOne7,e52707.Weinman,E.J.,Steplock,D.,Donowitz,M.,Shenolikar,S.,2000.NHERFassociationswithsodium-hydrogenexchangerisoform3(NHE3)andezrinareessentialforcAMP-me-diatedphosphorylationandinhibitionofNHE3.Biochemistry39,6123–6129.Yang,H.W.,Kim,T.M.,Song,S.S.,Shrinath,N.,Park,R.,Kalamarides,M.,Park,P.J.,Black,P.M.,Carroll,R.S.,Johnson,M.D.,2012.AlternativesplicingofCHEK2andcodeletionwithNF2promotechromosomalinstabilityinmeningioma.Neoplasia14,20–28.Zhang,Y.,Wen,Z.,Washburn,M.P.,Florens,L.,2009.Effectofdynamicexclusiondurationonspectralcountbasedquantitativeproteomics.Anal.Chem.81,6317–6326.Zhao,B.,Li,L.,Lei,Q.,Guan,K.L.,2010.TheHippo-YAPpathwayinorgansizecontrolandtumorigenesis:anupdatedversion.GenesDev.24,862–874.Zhao,L.,Yu,C.,Zhou,S.,Lau,W.B.,Lau,B.,Luo,Z.,Lin,Q.,Yang,H.,Xuan,Y.,Yi,T.,Zhao,X.,Wei,Y.,2016.EpigeneticrepressionofPDZ-LIMdomain-containingprotein2pro-motesovariancancerviaNOS2-derivednitricoxidesignaling.Oncotarget7,1408–1420.Zhou,L.,Ercolano,E.,Ammoun,S.,Schmid,M.C.,Barczyk,M.A.,Hanemann,C.O.,2011.Merlin-deﬁcienthumantumorsshowlossofcontactinhibitionandactivationofWnt/beta-cateninsignalinglinkedtothePDGFR/SrcandRac/PAKpathways.Neopla-sia13,1101–1112.86K.Bassirietal./EBioMedicine16(2017)76–86Neurofibromatosis Remedies
May 01, 2017


Treatment of neurofibromatosis often varies; however, natural supplements and dietary changes are often the most effective, safest treatments available. Avoiding inflammatory and toxin-laden foods including milk, meat, caffeine and sugar is crucial for successfully treating the condition. Additionally, supplements including aloe vera and others help remove toxins from the body and eliminate tumors effectively.
What is Neurofibromatosis?
A genetic disorder, neurofibromatosis is a condition that targets the nervous system. Characterized by dark skin patches and tumors on the nerves, the condition ranges in severity. While the exact symptoms of the condition depend on the type, common symptoms include skin changes, bone deformities, hearing loss, ringing in the ears, poor balance and intense pain.

Natural Remedies for Tumors in the Nervous System
Treating tumors of the nervous system can be achieved by raising the alkalinity of the body as well as removing toxins. Natural supplements are effective treatment options and include such compounds as bee propolis, aloe vera and other supplements. Boosting the immune system by eating a balanced diet and staying active is another important component of a treatment regimen for neurofibromatosis.

Bee Propolis
Bee propolis is a natural compound crated by bees that has been found effective in treating neurofibromatosis. The compound contains a variety of anti-carcinogenic compounds that block and reverse the development of tumors. The compound is also rich in nutrients that boost the body’s immune system.

Aloe Vera
Aloe vera is another natural compound that is found within the aloe plant. The gel from within the aloe leaves is rich with immune boosting nutrients. Additionally, aloe attacks abnormal cells eliminating them from the body while leaving healthy cells intact.

Supplements
Regular dietary supplements are also effective for treating tumors. Vitamin C, E and B help reduce the size of and eliminate tumors. Colloidal silver is another anti-toxin compound that can treat tumors.

Neurofibromatosis is a genetic disorder that affects the nervous system and typically manifests as growths on the nerve cells. Natural treatments used consistently can eliminate tumors as well as the other symptoms of the condition and prevent the need for more invasive treatments.
1535www.eymj.orgINTRODUCTIONThe treatment options for small to medium sized vestibular schwannomas include observation, radiotherapy, and sur-gery.1 Recent refinement of surgical techniques has made it possible to prioritize hearing preservation after tumor resec-tion.2 Moreover, hearing after tumor removal can be restored in patients with bilateral vestibular schwannomas or those with a schwannoma in the only-hearing ear.3 The standard treatment for unilateral hearing loss after uni-lateral vestibular schwannoma resection has been bone con-ducting or bone anchoring hearing aids (BCHA or BAHA), though cochlear implantation (CI) has emerged as an alterna-tive method of acoustic rehabilitation, provided that the co-chlear nerve remains intact.4 Studies of electrical promontory stimulation in patients after vestibular schwannoma resection have demonstrated favorable results.5,6 Since the indications for CI have recently expanded, CI has been suggested by many as an appropriate adjunctive treat-ment to vestibular schwannoma resection.7-9 Patients with bi-lateral vestibular schwannomas or with a schwannoma in the only-hearing ear are candidates for CI. In addition, patients with good hearing in the contralateral side are also candidates for the quality of life. Early cochlear degeneration can limit hearing rehabilitation via CI, particularly if there is significant delay after schwannoma resection, despite of sparing the co-chlear nerve.4We describe herein two cases of hearing rehabilitation via CI implemented at the time of vestibular schwannoma resection.CASE REPORTCase 1A 72-year-old woman presented with moderate to severe bi-lateral hearing impairment. She had used conventional hear-ing aids in the left ear for eight years, but presented for evalua-tion of deteriorating hearing secondary to worsening otorrhea. Otoscopic examination revealed a small perforation and dis-Simultaneous Translabyrinthine Tumor Removal and Cochlear Implantation in Vestibular  Schwannoma PatientsJin Won Kim, Ji Hyuk Han, Jin Woong Kim, and In Seok MoonDepartment of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea.Refinement of surgical techniques has allowed hearing preservation after tumor resection to be prioritized. Moreover, restoration of hearing after tumor removal can be attempted in patients with bilateral vestibular schwannomas or those with a schwannoma in the only-hearing ear. Cochlear implantation (CI) has emerged as a proper method of acoustic rehabilitation, provided that the cochlear nerve remains intact. Studies of electrical promontory stimulation in patients after vestibular schwannoma resection have demonstrated favorable results. We describe herein two cases of hearing rehabilitation via CI implemented at the time of vestibu-lar schwannoma resection. Tumors were totally removed, and cochlear implant electrodes were successfully inserted in both cases. Also, post operative CI-aided hearing showed improved results.Key Words:  Vestibular schwannoma, cochlear implantation, translabyrinthine approachCase ReportpISSN: 0513-5796 · eISSN: 1976-2437Received: July 1, 2015   Revised: October 13, 2015Accepted: October 13, 2015Corresponding author: Dr. In Seok Moon, Department of Otorhinolaryngology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.Tel: 82-2-2228-3606, Fax: 82-2-393-0580, E-mail: ismoonmd@yuhs.ac•The authors have no financial conflicts of interest.© Copyright: Yonsei University College of Medicine 2016This is an Open Access article distributed under the terms of the Creative Com-mons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and repro-duction in any medium, provided the original work is properly cited.Yonsei Med J 2016 Nov;57(6):1535-1539http://dx.doi.org/10.3349/ymj.2016.57.6.15351536Simultaneous CI in VS’shttp://dx.doi.org/10.3349/ymj.2016.57.6.1535Fig. 1. (A) Preoperative pure tone audiogram revealed moderate sensorineural hearing loss on the right and severe mixed hearing loss on the left. (B) Postoperative aided hearing threshold. Right ear was aided by hearing aid, and left ear was aided by CI. (C) The right side was aided by hearing aid and the left side by cochlear implant. Low signal on T2 and high signal enhanced T1 (D) indicate that the tumor (arrow) is a schwannoma. (E) The tumor (ar-row) was totally removed via a translabyrinthine approach. The cochlear nerve was anatomically preserved during the operation. (F) Cochlear implanta-tion was performed simultaneously. The internal device electrode was inserted through a posterior tympanotomy site (arrow). To prevent cerebrospinal fluid leakage, the tympanotomy site was plugged with a small piece of temporalis muscle after implantation.-100102030405060708090100110-100102030405060708090100110125           250        500       1000       2000        4000         8000125           250        500       1000       2000        4000         8000Frequencies (Hz)Frequencies (Hz)Hearing threshold (dBHL)Hearing threshold (dBHL)ABCEDF1537Jin Won Kim, et al.http://dx.doi.org/10.3349/ymj.2016.57.6.1535charge at the left tympanic membrane. A pure tone audiogram revealed right sensorineural and left mixed hearing loss (Fig. 1A). Speech discrimination scores were 72% in the right ear at the most comfortable listening (MCL) level, and immeasur-able in the left ear. Temporal magnetic resonance imaging (MRI) scan was thus obtained, revealing an 8 mm intracanalicular schwannoma on the left (Fig. 1C and D). Due to the patient’s age and small tumor size, our initial management was conservative, consisting of observation and infection control. However, as the patient desired improvement of hearing in her left ear, we opted for tumor resection with si-multaneous CI. Six months pre-operatively, we performed a tympanomastoidectomy on the left ear, which resulted in con-trolled infection and a well-tympanized eardrum. The bone conduction of the left ear was reserved, and the air-bone gap of left ear was reduced. Subsequently, we resected the tumor via a translabyrinthine approach with concurrent CI (SONATATI100, MedEL, Innsbruck, Austria) via facial recess approach (Fig. 1E and F). We were able to preserve the cochlear nerve, as well as achieve total tumor resection.Two years post-operatively, pure tone audiometry demon-strated a threshold of 38.8 dB in the CI augmented left ear and 30.0 dB in the hearing aid augmented right ear (Fig. 1B). The re-sults of the Korean Hearing in Noise test (K-HINT), which mea-Table 1. Outcomes of the Korean Hearing in Noise Test (K-HINT) of Case 1Signal to noise ratio (SNR, dB)N/FN/RN/LN/CPreoperative unaided7.89.42.56.9Hearing aid (HA) only6.39.23.66.3Cochlear implant (CI) only5.68.95.26.4Bimodal (CI+HA)3.87.54.54.9N/F, noise from front; N/R, noise from right; N/L, noise from left; N/C, noise from composite.Fig. 2. (A) Preoperative pure tone audiogram revealed bilateral sensorineural hearing loss. The right side showed moderate and the left side showed pro-found hearing loss. (B) Postoperative bimodal aided hearing threshold. Right side was aided by hearing aid and left side was aided by CI. (C) Low signal on T2 image and high signal on gadolinium-enhanced T1 (D) indicate that the tumor (arrow) has a high possibility of schwannoma. -100102030405060708090100110-100102030405060708090100110125          250       500      1000     2000       4000       8000125           250        500       1000       2000        4000         8000Frequencies (Hz)Frequencies (Hz)Hearing threshold (dBHL)Hearing threshold (dBHL)ABCD1538Simultaneous CI in VS’shttp://dx.doi.org/10.3349/ymj.2016.57.6.1535sures the binaural hearing performance in a noisy environ-ment, are described in Table 1. A 1 dB decrease in the signal to noise ratio (SNR) corresponds to a 9% improvement in binau-ral hearing.10,11 On average, patients who received CI showed a 19.8% improvement in binaural hearing under front noise; in bimodal mode, a 36% improvement was shown under front noise, and 27% improvement under composite noise. Case 2A 58-year-old man who had undergone canal wall down tym-panomastoidectomy in his right ear presented with bilateral hearing impairment. He complained of chronic hearing loss in the right ear, as well as abrupt hearing loss in the left. A pure tone audiogram revealed bilateral mixed hearing loss with an average air conduction threshold of 43 dB in the right ear and 72 dB in the left (Fig. 2A). Speech discrimination scores were 92% in the right ear at 86 dB MCL and 88% in the left ear at 102 dB MCL. A year later, a follow-up pure tone audiogram showed complete hearing loss (scale out) in the left ear, along with an unmeasurable speech discrimination score. A left internal au-ditory canal intracanalicular mass lesion was noted on the pre-operative brain MRI scan, with diameter of 6 mm and width of 13 mm (Fig. 2C and D).We proposed two surgical approaches: mass excision via translabyrinthine approach, followed by either BAHA or CI. This patient and his family opted for the latter option. We con-ducted canal wall down mastoidectomy, subtotal petrosecto-my and EAC closure for infection control, and the tumor was totally resected via translabyrinthine approach, with success-ful electrode insertion via round window approach (CONCER-TO08363, MedEL, Austria) (Fig. 2E-H). At three month follow-up, CI-aided pure tone audiogram revealed an average sound field threshold of 48.8 dB in the left ear (Fig. 2B). Notably, his tinnitus was also markedly reduced.DISCUSSIONIn considering surgical resection of small or medium sized vestibular schwannomas, priority should be given to the pres-ervation or restoration of hearing. BCHA or BAHA have been standard treatments for post-surgical unilateral hearing impair-ment, but are limited in their capacity to improve hearing in the affected ear. Reports from several centers on CI and laby-rinthectomy or vestibular schwannoma resection show a favor-able prognosis for concurrent or post-operative CI.7,9,12-14 In fact, the prognosis was similar to that of unilaterally deaf pa-tients treated with CI. Fig. 2. (E) The tumor (T) was separated and dissected from CN VIII (white arrow). (F) After tumor removal via a translabyrinthine approach, a well-pre-served cochleo-vestibular nerve (arrow) and intact facial nerve (white arrowhead) were noted. (G) After repair of the dura with abdominal fat, the round window of the cochlea (arrowhead) was identified. (H) Cochlear implantation was performed simultaneously. The internal device electrode (arrow) was inserted through the round window.GHCOLOREF1539Jin Won Kim, et al.http://dx.doi.org/10.3349/ymj.2016.57.6.1535Candidacy criteria for CI with tumor resection include total tumor removal, preservation of the cochlear nerve anatomy and function, and surgeon experience. Anatomical preserva-tion of cochlear nerve cannot assure its functional preservation, therefore, intraoperative monitoring can be useful. However, in the present case, we couldn’t monitor for several reasons.MRI can be used post-operatively to evaluate remnant tu-mor tissue prior to CI implementation, if performed years af-ter resection. In such cases, however, cochlear ossification and cochlear nerve atrophy can present complications. In our cases, complete tumor resection was not necessary for MRI evalua-tion, therefore, an enhanced CT was used instead for follow-up. Arriaga and Marks10 were the first to report on concurrent CI and schwannoma resection with favorable outcomes. Suc-cessful hearing restoration with CI depends on survival of the spiral ganglion nerve fibers, as well as the patency of the co-chlea. The rapid and significant improvement in speech recog-nition with CI suggests that, despite the presence of tumor in the cochlear nerve and potential intra-operative injuries, the number of surviving spiral ganglion axons is sufficient for CI rehabilitation. There are thus far no reports comparing out-comes between concurrent and staged procedures. Neverthe-less, since calcification of inner ear structures can occur as a post-operative complication, earlier implementation of CI op-eration should be sought for hearing restoration and improve-ment of quality of life.REFERENCES1. Lustig LR, Yeagle J, Niparko JK, Minor LB. Cochlear implantation in patients with bilateral Ménière’s syndrome. Otol Neurotol 2003; 24:397-403.2. Cohen NL, Lewis WS, Ransohoff J. Hearing preservation in cerebel-lopontine angle tumor surgery: the NYU experience 1974-1991. Am J Otol 1993;14:423-33.3. Arístegui M, Denia A. Simultaneous cochlear implantation and translabyrinthine removal of vestibular schwannoma in an only hearing ear: report of two cases (neurofibromatosis type 2 and uni-lateral vestibular schwannoma). Otol Neurotol 2005;26:205-10.4. Zanetti D, Campovecchi CB, Pasini S, Nassif N. Simultaneous trans-labyrinthine removal of acoustic neuroma and cochlear implan-tation. Auris Nasus Larynx 2008;35:562-8.5. Lambert PR, Ruth RA, Halpin CF. Promontory electrical stimula-tion in labyrinthectomized ears. Arch Otolaryngol Head Neck Surg 1990;116:197-201.6. Kartush JM, Linstrom CJ, Graham MD, Kulick KC, Bouchard KR. Promontory stimulation following labyrinthectomy: implications for cochlear implantation. Laryngoscope 1990;100:5-9.7. Hoffman RA, Kohan D, Cohen NL. Cochlear implants in the man-agement of bilateral acoustic neuromas. Am J Otol 1992;13:525-8.8. Shin YJ, Fraysse B, Sterkers O, Bouccara D, Rey A, Lazorthes Y. Hearing restoration in posterior fossa tumors. Am J Otol 1998;19: 649-53.9. Tono T, Ushisako Y, Morimitsu T. Cochlear implantation in an in-tralabyrinthine acoustic neuroma patient after resection of an in-tracanalicular tumor. Adv Otorhinolaryngol 1997;52:155-7.10. Lim HW, Hong SM, Choi SW, Jung JW, Shin J, Chae SW. Availability of Korean hearing in noise test (KHINT) in children. Korean J Oto-rhinolaryngol-Head Neck Surg 2011;54:462-6.11. Moon SK, Mun HA, Jung HK, Soli SD, Lee JH, Park K. Development of sentences for Korean hearing in noise test (KHINT). Korean J Otolaryngol-Head Neck Surg 2005;48:724-8.12. Arriaga MA, Marks S. Simultaneous cochlear implantation and acoustic neuroma resection: imaging considerations, technique, and functional outcome. Otolaryngol Head Neck Surg 1995;112: 325-8.13. Kveton JF, Abbott C, April M, Drumheller G, Cohen N, Poe DS. Co-chlear implantation after transmastoid labyrinthectomy. Laryngo-scope 1989;99(6 Pt 1):610-3.14. Zwolan TA, Shepard NT, Niparko JK. Labyrinthectomy with co-chlear implantation. Am J Otol 1993;14:220-3.AberrantepithelialmorphologyandpersistentepidermalgrowthfactorreceptorsignalinginamousemodelofrenalcarcinomaZacharyS.MorrisandAndreaI.McClatchey1MassachusettsGeneralHospitalCenterforCancerResearchandDepartmentofPathology,HarvardMedicalSchool,Charlestown,MA02129EditedbyRobertA.Weinberg,WhiteheadInstituteforBiomedicalResearch,Cambridge,MA,andapprovedApril24,2009(receivedforreviewFebruary24,2009)Theepidermalgrowthfactorreceptor(EGFR)hasfrequentlybeenimplicatedinhyperproliferativediseasesofrenaltubuleepithelia.WehaveshownthattheNF2tumorsuppressorMerlininhibitsEGFRinternalizationandsignalinginacellcontact–dependentmanner.Interestingly,despitethepaucityofrecurringmutationsinhumanrenalcellcarcinoma(RCC),homozygousmutationoftheNF2geneisfoundin⬇2%ofRCCpatientsamplesintheSangerCOSMICdata-base.ToexaminetherolesofMerlinandEGFRinkidneytumorigen-esis,wegeneratedmicewithatargeteddeletionofNf2intheproximalconvolutedepitheliumusingaVillin-Cretransgene.Allofthesemicedevelopedintratubularneoplasiaby3months,whichprogressedtoinvasivecarcinomaby6–10months.Kidneysfromthesemicedemonstratedmarkedhyperproliferationandaconcom-itantincreaseinlabel-retainingputativeprogenitorcells.Earlylumen-ﬁllinglesionsinthismodelexhibitedhyperactivationofEGFRsignal-ing,alteredsolubilityofadherensjunctionscomponents,andlossofepithelialpolarity.RenalcorticalepithelialcellsderivedfromeitherearlyorlatelesionsweredependentonEGFforinvitroproliferationandwerearrestedbypharmacologicinhibitionofEGFRorre-expres-sionofNf2.Thesecellsformedmalignanttumorsupons.c.injectionintoimmunocompromisedmicebeforeinvitropassage.TreatmentofVil-Cre;Nf2lox/loxmicewiththeEGFRinhibitorerlotinibhaltedtheproliferationoftumorcells.ThesestudiesgiveaddedcredencetotheroleofEGFRsignalingandperhapsNf2deﬁciencyinRCCanddescribearareandvaluablemousemodelforexploringthemolecularbasisofthisdisease.EGFR兩kidney兩Merlin兩Nf2兩renalcellcarcinomaRenalcellcarcinomas(RCC)arisefromrenaltubuleepithelialcellsandaccountfor85%ofkidneytumors(1).MostcasesofRCCaresporadic(⬎97%),yethereditarysyndromes,suchasVonHippel-Lindau,hereditarypapillaryrenalcarcinoma,Birt-Hogg-Dube´,hereditaryleiomyomatosisandrenalcellcancer,andtuber-oussclerosiscomplex,contributetodiseaseincidence(2).Somaticmutationsinthegenesassociatedwiththesesyndromes—VHL,c-Met,BHD,FH,TSC-1,andTSC-2,respectively—havebeenidentifiedinsporadicRCC(3,4).Studiesofthecellularconse-quencesofspecificgeneticmutationsassociatedwithhereditaryRCCshavespawnedmuchofourcurrentunderstandingoftumor-igenesisfromrenaltubuleepithelia.Yetthesewell-studiedgeneticeventsdonotaccountforthetotalityofsporadictumorigenesisinRCC,suggestingthatadditionalcausativemutationsremainun-identified(5).StudiesofRCCpathogenesishavebeenlimitedbythepaucityofgeneticallydefinedanimalmodels.Surprisingly,micewithgeneticdisruptionsofVHL,c-Met,orFHdonotdevelopkidneytumors(6–8).Todate,onlymutationofBHD,TSC-1,TSC-2,ortheAPCtumorsuppressoryieldstumorsreminiscentofRCCingeneticallyengineeredanimals(9–14).YetmutationofthesegenesisrareinsporadicRCC,andtheseanimalmodelsprovideanincompletepictureofthediversemolecularmechanismsimplicatedinthisdisease.Moreover,noneofthesemodelsisidealforstudyingrenaltumorigenesis,owingtohighneonatalmortality(BHD,APC),longlatencyoftumordevelopment(TSC-1),orlackoftissue-specifictargeting(TSC-1,TSC-2)(9–14).AdditionalandimprovedanimalmodelsofRCCareneededtoadvancebasicandpreclinicalstudiesofrenalepithelialneoplasia.ThepaucityofrecurrentgeneticalterationsthathavebeenidentifiedinRCCisstriking.AccordingtotheSangerCatalogofSomaticMutationsinCancer(COSMIC)database(15),only3genesaremutatedatafrequencygreaterthan4%inRCCpatientsamples(VHL,42%;CDKN2A,12%;andKIT,8%).Thefactthathomozygousmutationoftheneurofibromatosistype2(NF2)tumorsuppressorgenewasidentifiedin⬇2%(2of126)oftheRCCsamplesinthisdatabaseisthereforepotentiallysignificant,espe-ciallyinlightoftheassociationsbetweenaberrantepidermalgrowthfactorreceptor(EGFR)signalingandbothRCCandNf2(16–20).WerecentlydemonstratedthattheNf2tumorsuppressorMerlinisacriticalregulatorofEGFR(17,21).InavarietyofcellularcontextsMerlincoordinatestheinhibitionofEGFRsig-nalingwiththeestablishmentofstableadherensjunctions(AJs)(22),therebymediatingcontact-dependentinhibitionofprolifera-tion.ItiswelldocumentedthatEGFRanditsligands,EGFandTGF-␣,arefrequentlyoverexpressedinmanyformsofRCC(16,18,19,23,24),andactivationofEGFRhasbeenimplicatedinVHL-associatedRCC(20,25,26).EGFligandsareessentialfortheproliferationofmanyhumanRCCcelllines,andinhibitorsofEGFRantagonizeRCCcelldivisioninvitroandinvivo(18,27–29).ClinicaltrialshavedemonstratedsomeefficacyoftheEGFR/ErbB2dualkinaseinhibitorlapatinibforadvanced-stageRCC(30).However,atpresentthereisnoanimalmodelofEGFR-drivenRCC;suchamodelwouldbevaluableforidentifyingpredictorsand/ormodifiersofclinicalresponsetoEGFR-targetedtherapies.InlightofthecontributionofEGFRtokidneytumorigenesis,thedemonstratedroleforMerlin/Nf2inregulatingEGFR,andpre-liminaryevidenceimplicatingmutationofNf2insomeRCCpatientsamples,wehypothesizedthatNf2mutationwouldcontributetotumorigenesisfromrenaltubuleepithelialcellsinamousemodel.WefoundthattargetedinactivationofNf2inmouseproximalconvolutedtubules(PCT),thesiteoforiginformosthumanRCC,ledtomultifocaltumordevelopmentfeaturinglumen-fillingneo-plasiathatprogressedtoinvasivecarcinoma.Thesetumorsex-pressedmarkerscharacteristicofhumanRCCanddisplayedab-errantEGFRsignalingandproliferation.Infact,pharmacologicinhibitionofEGFRcompletelyhaltedtheproliferationofNf2-deficientrenaltumorcellsinvivo.Authorcontributions:Z.S.M.andA.I.M.designedresearch;Z.S.M.performedresearch;Z.S.M.andA.I.M.contributednewreagents/analytictools;Z.S.M.andA.I.M.analyzeddata;andZ.S.M.andA.I.M.wrotethepaper.Theauthorsdeclarenoconﬂictofinterest.ThisarticleisaPNASDirectSubmission.1Towhomcorrespondenceshouldbeaddressed.E-mail:mcclatch@helix.mgh.harvard.edu.Thisarticlecontainssupportinginformationonlineatwww.pnas.org/cgi/content/full/0902031106/DCSupplemental.www.pnas.org兾cgi兾doi兾10.1073兾pnas.0902031106PNAS兩June16,2009兩vol.106兩no.24兩9767–9772GENETICSResultsTodeterminewhetherthelossofNf2cancontributetotumorigenesisinthekidney,wecrossedNf2lox/loxmicewithVillin(Vil)-Cremice.OnthebasisofthereportedexpressionofVil-Cre,weexpectedthatthesemicewouldexhibitconstitutivelossofNf2intherenaltubuleepitheliaofthePCT(31).WeconfirmedthisbycrossingVil-Cre;Nf2lox/loxmicewithmicecarryingaGtRosa26lox/stop/lox␤-galactosidasereportertrans-gene(R26LSL-LacZ).Bothchemicaldetectionof␤-galactosidaseactivityinwhole-mountandparaffinsectionaswellasimmunohistochemicallabelingusinga␤-galactosidase–specificantibodyrevealedCreactivityinthecorticalrenaltubuleepitheliaofVil-Cre;Nf2lox/loxmicebutnotinNf2lox/loxcontrols[supportinginformation(SI)Fig.S1AandB].CostainingwiththePCT-specificLotustetragonolobusagglutinin(32)confirmedexclusivetargetingofthePCTepithelia(Fig.S1B).Immu-noblottingofdissectedrenalcortexlysatesrevealedamarkedreductioninMerlinlevels,confirmingthatwehadachievedtargetedinactivationofNf2(Fig.S1C).AllVil-Cre;Nf2lox/loxmicewereruntedfrombirthandoccasionallydiedintheperinatalperiodbetweenembryonicday17andpostnatalday3.Vil-Cre;Nf2lox/loxmicethatsurviveduntilweaning(⬇10%ofallpups)livedto⬇10monthsofage.Allofthesemicedevelopedlumen-fillingintratubularneoplasiaby3months(Fig.1A).Lesionswereapparentasearlyas15daysofageandmostcommonlyinitiatedinthecorticomedullaryjunctionasprojectionsofatypicalepithelialcellsintothePCTlumen(Fig.1A).By6monthsthesizeandnumberoftumorswasgreatlyincreased,displacinglargeareasofnormalrenaltissueandpenetratingtubulebasementmembraneasinvasivecarcinomas.HeterozygousVil-Cre;Nf2lox/⫹mice,ontheotherhand,wereindistinguishablefromNf2lox/loxcontrols(notshown).RenaltumorsinVil-Cre;Nf2lox/loxmicestainedpositiveforvimentin(Fig.1B).Immunoblottingofkidneycortexlysateindicatedthattheselesionswerealsogalectin-3positive(Fig.1C).Vimentinandgalectin-3areestablishedmarkersofclearcellRCCinhumans(33).ToascertainwhetherrenaltubuletumorsthatdevelopinVil-Cre;Nf2lox/loxmicederivefromadevelopmentallyand/orregionallyspecificcellpopulation,wedeletedNf2intheadultkidneyusingtheIFN-␣–inducibleMx1-Cretransgene.TheMx1promoterdrivesCre-recombinaseactivityinepithelialcellsofthecollectingductandthethickascendingloopofHenleinthenephronbutnotinthePCT(34).Mx1-Cre;Nf2lox/loxmicealsodevelopedlumen-fillingrenaltubuleneoplasiawithin6monthsofMx1-Creinduction(Fig.1A).Consistentwiththedistallocationoftheselesionsinthenephron,kidneysofMx1-Cre;Nf2lox/loxmicedisplayeddilationofupstreamtubulesupontumordevelopment,likelyduetoblockedurinaryflow.ThiswasunderstandablynotprominentinVil-Cre;Nf2lox/loxmice,whichdevelopedmoreproximaltumorsinthePCT.Never-theless,thedevelopmentofmorphologicallysimilarlesionsinVil-Cre;Nf2lox/loxandMx1-Cre;Nf2lox/loxmicesuggeststhatMerlinisanessentialregulatorofproliferationacrosstherenaltubuleepitheliumandfurthersupportsthenotionthatsomaticlossofNf2maycontributetosporadicrenaltumorigenesisinhumans.Veryfewcellsareproliferatinginthenormaladultmousekidney.Incontrast,renaltubulecarcinomasinVil-Cre;Nf2lox/loxmicewerehyperproliferative,displayingagreaterthan7-foldincreaseinKi67-andphosphorylatedhistone3(PH3)-positivenucleiandinthenumberofnucleilabeledbyBrdUduringashort3-hpremortemlabeling(Fig.2AandB;datanotshown).Inaddition,Vil-Cre;Nf2lox/loxkidneysexhibitedamarkedin-creaseinthenumberofBrdUlabel-retainingputativepro-genitorcells(35–37)duringa1-weekpulse/2-weekchaseexperiment(Fig.2CandD).Notably,thisincreaseinprolif-erationwasaccompaniedbyadramaticincreaseinphospho-tyrosinelevelswithinbothearlyandlatelesions(Fig.3A).Immunoblottingdemonstratedstrongandprogressiveactiva-tionofEGFR,itsprincipledimerizationpartnerErbB2,anditsdownstreamtargetsAkt,MAPK,andSTAT-3(Fig.3B).ImmunohistochemistryconfirmedthattheactivationofthesetargetswasrestrictedtoNf2-deficienttumors(Fig.3C).Im-portantly,wedidnotdetectsignificantdifferencesintheexpressionofEGFligandsinNf2lox/loxandVil-Cre;Nf2lox/loxkidneys(Fig.S2A).WepreviouslyfoundthatMerliniscriticalfortheestablishmentofstableAJsinseveraltypesofculturedcells(22).Intriguingly,althoughequivalentlevelsofcoreAJcomponentswerepresentinrenalcorticallysatesderivedfromNf2lox/loxandVil-Cre;Nf2lox/loxkidneys,wenotedastrikingdifferenceintheirdetergentsolubilityintheabsenceofMerlin(Fig.4A).Bothp120-and␤-cateninexhibitedgreatlyenhanceddetergentsolubilityinVil-Cre;Nf2lox/loxkidneys.ThiscouldbeconsistentwithafailuretostabilizetheseABCFig.1.TargetedlossofNf2inrenaltubuleepitheliagivesrisetovimentin-andgalectin-3–positivetumorsthatprogresstoinvasivecarcinoma.(A)AllVil-Cre;Nf2lox/loxmicedevelopedsmallintratubularneo-plasticgrowthsofatypicalepithelialcellsby30daysofage.Thesegrewtolargetumorswithin3monthsandprogressedtoinvasivecarcinomasby6months.Renaltumorsinthesemiceconsistentlygrewintothetubulelumen,ofteninitiatingwithapolypoidmorphology(LowerLeft).TheVil-Cre;Nf2lox/loxkidneyphenotypeisrecapitulatedininducibleMx1-Cre;Nf2lox/loxmice,whichtargetCre-recombinaseexpressiontothecol-lectingduct(Right).(B)TumorsinVil-Cre;Nf2lox/loxkid-neysstainpositivebyimmunohistochemistryforvi-mentin.InNf2lox/loxcontrolkidneysvimentinisseenonlyinglomeruli,arterioles,andinterstitialﬁbro-blasts.(C)RenalcortexlysatesfromVil-Cre;Nf2lox/loxmicedisplayincreasedexpressionofgalectin-3byim-munoblot.Together,vimentinandgalectin-3arehis-tologicmarkersforclearcellRCCinhumans(33).ForAandB,thesectionsshownarerepresentativeof3mice⫻2slidespermouse⫻3sectionsperslide⫻2kidneyspersection⫻⬇10lesionsperkidney⫽⬇360lesionsexamined.N⫽normaltubules,G⫽glomeruli.*Lesion/tumor.9768兩www.pnas.org兾cgi兾doi兾10.1073兾pnas.0902031106MorrisandMcClatcheyproteinsattheinsoluble,cytoskeleton-associatedAJcomplexintheabsenceofMerlin.Indeed,immunohistochemicalstainingdemon-stratedthat␤-cateninwasnotstronglylocalizedtocell–cellcontactsinNf2-deficientlesions(Fig.4B).Interestingly,giventhepurportednecessityofAJsinestablishingapico-basolateralpolarity(38–40),wealsofoundthatcellswithinVil-Cre;Nf2lox/loxneoplastictissuesfailedtoproperlylocalizetheapicalmarkersezrinandNa/Hexchangerregulatoryfactor(NHERF)-1andtheapicaltightjunc-tionmarkerZO-1(Fig.4C,Fig.S2B).Notably,increasedEGFRsignalingwasnotseparatedtemporallyfromalteredlocalizationofjunctionalproteinsandpolaritymarkers,andtheseeffectsofNf2deficiencywereapparentintheearliestdetectablelesionsin2-week-oldVil-Cre;Nf2lox/loxmice(notshown).TofurtherinvestigatethecellularandmoleculareffectsofNf2deficiencyinrenaltubuleepithelialcells,wederivedprimaryepithelialcellculturesfromtherenalcortexofNf2lox/lox,Vil-Cre;Nf2lox/lox,andIFN-inducedMx1-Cre;Nf2lox/loxmice.OnlycellsfromVil-Cre;Nf2lox/loxandMx1-Cre;Nf2lox/loxcortexgrewtoconflu-enceandsurvivedpassaging(Fig.S3A).LikeotherNf2-/-cells,Nf2-deficientkidneyepithelialcellsfailedtoundergocontact-dependentinhibitionofproliferation,aphenotypethatwasre-versedbyviralre-expressionofNf2(Fig.S3B–D).Notably,wealsofoundthatNf2-deficientrenalepithelialcellsrequiredEGFforgrowthincultureandwerestronglyandreversiblygrowthsup-pressedbytreatmentwiththeEGFRtyrosinekinaseinhibitorerlotinib(Fig.S3CandD).Remarkably,Nf2-deficientrenalABDCFig.2.Vil-Cre;Nf2lox/loxkidneysdisplayheightenedepithelialcellproliferationandanincreasednumberoflabel-retainingputativeprogenitorcells.(A)Three-month-oldVil-Cre;Nf2lox/loxkidneysdisplayedin-creasedproliferationofcellsmostlylocalizedtolu-men-ﬁllingneoplasticgrowths,asmeasuredbynuclearstainingofKi67(immunohistochemistry)andPH3(green,immunoﬂuorescence).Renalepithelialcellsaredisplayedinredonimmunoﬂuorescenceim-ages.(B)Quantiﬁcationper100cellsrevealeda⬇7-foldincreaseinKi67-positivenucleiintheVil-Cre;Nf2lox/loxrenalcortexrelativetocontrols.(CandD)BrdUpulse–chaseexperiments(1-weekpulse,2-weekchase),previouslyreportedtoidentifyputativeprogen-itorcells(57),demonstrateda⬇5-foldincreaseinthenumberoflabel-retainingcellsintheVil-Cre;Nf2lox/loxrenalcortexrelativetocontrols.Thesectionsshownarerepresentativeofmultiplemice,sections,andlesionsasdeﬁnedinthelegendtoFig.1.ABCFig.3.TumorsinVil-Cre;Nf2lox/loxkidneysarefociofactivatedEGFRsignaling.(A)Immunoﬂuorescentde-tectionusingthepY100antibody(green)revealedamarkedincreaseinphosphotyrosinesignalinginearly(Right)andlate(Middle)lesionsinVil-Cre;Nf2lox/loxkidneys.Renalepithelialcellsaredisplayedinred.(B)ImmunoblotdemonstratedactivationofEGFR,itspre-ferreddimerizationpartnerErbB2,anditsdown-streameffectorsinrenalcortexlysatesfrom3-and6-month-oldVil-Cre;Nf2lox/loxmice.(C)Immunohisto-chemicaldetectionofphosphorylatedAkt,MAPK,andSTAT-3inparafﬁnsectionsof3-month-oldkidneysdemonstratedthathyperactivationoftheseEGFRef-fectorswasconﬁnedtoneoplasticlesionsinVil-Cre;Nf2lox/loxmice.Thesectionsshownarerepresenta-tiveofmultiplemice,sectionsandlesionsasdeﬁnedinthelegendtoFig.1.MorrisandMcClatcheyPNAS兩June16,2009兩vol.106兩no.24兩9769GENETICSepithelialcellswerecapableofformingmalignants.c.tumorsinnudemicewithoutinvitropassage(Fig.S3EandF).Thesetumorsdisplayedanintriguingmixedhistology,withsomeareasseemingtoregenerateatubulararchitecturethatwascompromisedbylumenfilling.Collectively,thesedatasuggestedthataberrantEGFRsignalingmayunderliethetumorigenicconsequencesofNf2deficiencyinthekidneyepitheliuminvivo.Totestthishypothesis,wetreated12–16-weekoldVil-Cre;Nf2lox/loxmicewitherlotinibbyi.p.injection,twicedailyfor10days.Erlotinibtreatmentcompletelyhaltedtheover-proliferationofrenaltumorcellswithinthesemice,restoringwild-typelevelsofKi67-andPH3-positivenuclei(Fig.5A).Thiswasassociatedwithdecreasedactivationofclassicdownstreamsignal-ingeffectors,suchasAkt,MAPK,andSTAT-3;notably,erlotinibalsoreducedtheactivationofnonclassicEGFReffectors,suchascaveolin-1(Fig.5BandC).Consistentwiththecytostaticeffectsobservedinvitro(Fig.S3CandD),erlotinibtreatmentdidnotinduceapoptosisornecrosisinrenaltumorsfromVil-Cre;Nf2lox/loxmice(notshown).DiscussionInthisworkwepresentageneticallyengineeredmousemodelofrenalepithelialcelltumorigenesis.TheVil-Cre;Nf2lox/loxmousejoinsashortlistofgeneticallydefinedmodelsofRCCandisthefirsttorecapitulatetheactivationofEGFRsignalingthatisoftenreportedinhumanRCC.TargetedlossoftheNf2tumorsuppressorinrenaltubuleepithelialcellsgivesrisetotumordevelopmentwith100%penetrance.LesionswithintheNf2-deficientrenaltubuleepitheliadevelopviaareproducibleprogressionfromlumen-fillingintratubularneoplasiathatdevelopsoverthecourseof3to4monthstoinvasivecarcinomaby6–10months.ThesetumorsdisplayhistologicfeaturesandexpressmarkersthatarediagnosticofhumanclearcellRCC.TreatmentofthesemicewiththeEGFRtyrosinekinaseinhibitorerlotinibdemonstratedthatEGFRsig-nalingwasnecessaryfortheover-proliferationobservedinthesetumors.Nf2-deficientepithelialcellsderivedfromearlyorlatelesionsinthesekidneysdonotundergocontact-dependentinhibi-tionofproliferationbutareantagonizedbypharmacologicinhibi-tionofEGFRsignaling.Thesecellscanbepassagedrepeatedlyinculturebut,remarkably,arecapableofgeneratingmalignanttu-morsupons.c.injectionintoimmunocompromisedmicebeforeinvitropassage.Thismousemodelandcellsderivedfromitmaythereforeproveusefulforexamininginvivomechanismsofresis-tanceorsensitivitytoEGFR-targetedtherapeuticsinthekidney.TherobustactivationofdownstreamEGFRsignalingpathwaysinABCFig.4.TumorcellsinVil-Cre;Nf2lox/loxkidneysexhibitincreasedsolubilityofAJcomponentsandalossofpolarity.(A)Rigorous1%SDSsolubilizationdemon-stratedequivalentexpressionofAJcomponents.Agentler0.1%SDSsolubilizationrevealedstarkdiffer-encesinthesolubilityoftheAJcomponents,p120-and␤-catenin,betweenVil-Cre;Nf2lox/loxandNf2lox/loxkid-neylysates.(B)Immunohistochemicalstainingdemon-stratedthatthischangeinsolubilitycorrelatedwithalossof␤-cateninlocalizationtocell–cellcontactsinneoplasticcellsof3-month-oldVil-Cre;Nf2lox/loxmice.(C)HistologicexaminationoftheapicalmarkersNHERF-1(green,immunoﬂuorescence)andezrin(im-munohistochemistry)showedalossofcellpolarityinearlyintratubulegrowthsarisinginVil-Cre;Nf2lox/loxkidneys.Renalepithelialcellsaredisplayedinredonimmunoﬂuorescenceimages.Thesectionsshownarerepresentativeofmultiplemice,sections,andlesionsasdeﬁnedinthelegendtoFig.1.BDCAFig.5.ErlotinibtreatmentofVil-Cre;Nf2lox/loxmicerestoreswild-typelevelsofproliferationtoNf2-deﬁcientrenaltubuleepithelia.(AandB)Twelve-to16-week-oldVil-Cre;Nf2lox/loxmiceweretreatedbyi.p.injectionof100mg/kgerlotinibtwicedailyfor10days.Erlotinibtreatmentrestoredwild-typelevelsofprolif-erationinVil-Cre;Nf2lox/loxmice,asassayedbyquanti-ﬁcationofKi67(immunohistochemistry)andPH3(green,immunoﬂuorescence)positivenucleiper100cells.Statisticalsigniﬁcancewasdeterminedbyone-tailed,independentsamples,parametricttest,P⫽0.00085.(C)Renaltumorsinerlotinib-treatedmiceexhibiteddecreasedactivationofEGFRsignalingef-fectorsbyimmunohistochemistry.Thesectionsshownarerepresentativeofmultiplemice,sections,andle-sionsasdeﬁnedinthelegendtoFig.2.(D)Immunoblotof0.1%SDSrenalcortexlysatesconﬁrmeddecreasedactivationofEGFR,itsdimerizationpartnerErbB2,anditsdownstreameffectorsinerlotinibtreatedVil-Cre;Nf2lox/loxmiceascomparedwithuntreatedcon-trols.Interestingly,targetingEGFRsignalingalsoseemedtonormalizethesolubilityof␤-catenin.9770兩www.pnas.org兾cgi兾doi兾10.1073兾pnas.0902031106MorrisandMcClatcheythismodelwillprovideanexcellentmetricforexploringandquantifyingthemoleculareffectsofsuchinterventions.TheVil-Cre;Nf2lox/loxmousegivesaddedcredencetotheroleoftheEGFRpathwayinRCCandprovidesanexcellenttoolforinvestigatingthemolecularmechanismsthatcontributetoEGFR-dependenttumorigenesisinthekidney.WepreviouslyreportedthatpersistentEGFRsignalingdrivesthelossofcontact-dependentinhibitionofproliferationexhibitedbyprimaryculturedNf2-deficientcellsofseveraldifferenttypes(17,21).Herewedemon-strateacausalroleforaberrantEGFRsignalinginNf2-associatedtumorigenesisinvivo.Inculturedcells,MerlinantagonizesEGFRsignalinginacontact-dependentmannerbycoordinatingtheestablishmentofstableAJswithinhibitionofEGFRinternaliza-tion,therebylimitingaccessofEGFRtoitsdownstreameffectors(17,22).InadditiontothecanonicalEGFReffectors,wefoundthatNf2-deficientkidneylysatesexhibitmarkedlyelevatedlevelsofphosphorylatedcaveolin-1(Fig.5C),whichisdownstreamofEGFRactivationandpermissivetocaveolae-mediatedendocytosis,1of2majorroutesofEGFRinternalization(41–43).ThissupportsthenotionthatMerlincanalsoregulateEGFRendocytosisinvivo.HerewealsopresentevidencethatMerlinstabilizesAJsinvivoasitdoesincellculture(22).Thus,incontrasttomembrane-boundE-cadherin,bothp120-and␤-cateninfailtolocalizetoabiochem-icallyinsolublesubcellularcompartmentintheabsenceofMerlin(Fig.4A).ThiscouldreflectafailuretolinkE-cadherintetramerstotheinsolublecytoskeletonandtherebyformmatureAJs.AlthoughclinicaltrialsthatexaminedtheefficacyofEGFRinhibitorsinRCCwerelargelydisappointing,thedualEGFR/ErbB2kinaseinhibitorlapatinibhasshownefficacyagainstthera-py-resistantRCCtumorsthatover-expressEGFR(30).Notably,EGFRiscapableofsignalingfromheterodimericEGFR–ErbB2complexesintherenalepitheliumand,althoughrare,co-overexpressionofthese2proteinsisassociatedwithpooroutcomeinRCC(44,45).WefoundmarkedlyincreasedphosphorylationofbothEGFRandErbB2intheVil-Cre;Nf2lox/loxrenalcortex,sug-gestingthatMerlinantagonizesactivationofErbB2,perhapsviaregulationofEGFR–ErbB2heterodimers.PerhapsretrospectiveanalyseswillrevealNF2deficiencyorderegulationasapredictorofpatientresponsetolapatinibinRCC.Interestingly,in3-dimen-sionalmammaryepithelialcultures,aberrantErbB2activitydriveslossofpolarityandlumenfilling(46),bothofwhichareprominentfeaturesoftheearlylesionsthatdevelopintheNf2-deficientkidney.TogetherwiththeknownroleofAJsintheestablishmentofapico-basolateralcellpolarity(38,39),theseobservationsmaysuggestabroaderroleforMerlinincoordinatingErbBsignalingwiththeestablishmentofcellpolarityinvivo.Notably,wealsoobserveEGFR-dependenthyperactivationofAktintherenalcortexofVil-Cre;Nf2lox/loxmice.AktsignalingcanbeproximallyregulatedbyPI3-kinase,mammaliantargetofrapamycin,andphosphataseandtensinhomolog(PTEN)—eachofwhichcontrib-utestoRCCwhendisrupted(47–50).ThismousemodelmayfurthersupporttheimportanceofAktsignalinginRCCandbeusefulinstudyingthetumorigeniceffectsofthispathway.PreliminarydatafrompatientsamplesintheSangerCOSMICdatabasesuggestthatNF2maybedisruptedinsomecasesofsporadicRCC(15).Ourfindingswarrantamorerigorousinvesti-gationofthispossibilityacrossalargesetofsporadicRCCtumors.TheabsenceofaclearincreaseinkidneytumorsusceptibilityinNF2patientscouldreflectthefactthatNF2israreandcompro-miseslifeexpectancyinmostpatientsbeforetheaverageageofonsetofRCC.Alternatively,additionalcooperatingmutationsmaybenecessaryforNF2-drivenRCCinhumans,wheresomaticinactivationofNF2likelyoccursinindividualcellsinanotherwisewild-typeorheterozygous-mutantepithelium.Infact,thismodelmaybevaluableinidentifyingsuchcooperatingmutations.AlthoughwetargetedlossofNf2inrenalepitheliathroughoutentireregionsofthenephron,wecommonlyobservedpolypoidtumorformation,ofteninitiallysurroundedbynormal-lookingepithelialcells(Fig.1).ThepervasiveexpressionandactivityofaRosa26-driven␤-galactosidasereporteracrosstheepitheliumtar-getedbybothVillin-andMx1-CretransgenesarguesagainstthepossibilitythatthisreflectsselectiveexcisionofNf2inafewcellsoftherenalepithelialmonolayer.Similarly,therapidonsetandmultiplicityofearlylesionssuggeststhatcooperatingeventsarenotrequiredfortheinitiationoftumorigenesisinthismodel.Alterna-tively,theobservationofpolypoidtumorssurroundedbyapparentlynormalNf2-deficientepithelialcellsmaysuggestthataspecificcelloforiginispreferentiallyaffectedbylossofNf2.MountingevidencefromtargetedinactivationofNf2inothertissuessuggeststhattissueprogenitorcellsareparticularlysensitivetolossofMerlin(M.Curto,S.Benhamouche,A.Gladden,andA.I.M.,unpublisheddata).Infact,Nf2deficiencyresultsinadramaticincreaseinthenumberoflabel-retainingputativeprogenitorcellsinthekidney,andpolypoidtumorsintheNf2-deficientrenalepitheliuminitiateatthecorticomedullaryjunction,aregionthoughttoharbortheprogenitorcellnicheintheadultkidney(35–37).ItistemptingtospeculatethatakidneyprogenitorcellisparticularlysensitivetolossofMerlin-mediated,contact-dependentinhibitionofproliferationinvivoandthatthisisthecelloforiginofRCCinthismodelandperhapsinsomecasesofhumanRCC.MaterialsandMethodsSIMaterialsandMethodsprovidesfurtherdetails.AnimalsandAnimalProcedures.HomozygousNf2lox/loxmicewerekindlyprovidedbyM.Giovannini(51)andcrossedwithtransgenicmiceexpressingtheCrerecombinaseundertheVillinpromoter(Vil-Cre)kindlyprovidedbyS.Robine(31)ortheIFN-␣–inducibleMx1promoter(Mx1-Cre)[Tg(Mx1-Cre)1Cgn/J;JacksonLaboratory](52).TomonitorCre-mediatedexcision,micewerecrossedtoR26LSL-LacZ[B6;129-Gt(ROSA)26Sortm1Sho/J;JacksonLabora-tory]reportermice(53).Immunocompromised5-week-oldfemalenu/numicewereobtainedfromtheMassachusettsGeneralHospital(MGH)Cox7facility.Erlotinib(ChemieTek)wassolubilizedat10mg/mLina6%wt/volaqueoussolutionofCaptisol(CyDexPharmaceuticals).FourVil-Cre;Nf2lox/loxand4Nf2lox/loxcontrolmiceweretreatedbyi.p.injectionoferlotinibat100mg/kgbodyweightonceevery12hfor10days.TwoVil-Cre;Nf2lox/loxand2Nf2lox/loxcontrolmiceweretreatedonthesameschedulewithvehiclealone,withnodetectableeffect.Wechosetotreatmiceatanage(12–16weeks)whenallhaddevelopedasigniﬁcanttumorburdenbutnotumorshadacquiredinvasivecharacteristics.Atthisearlystage,tumorswerealsonotvascularized,andneitherapoptosisnornecrosiswasdetectable.AllanimalprocedureswereperformedaccordingtofederalandinstitutionalguidelinesandapprovedbytheMGHSubcommitteeonResearchAnimalCare.HistologyandImmunohistochemistry.Sectionswereincubatedovernightat4°Cwiththefollowingprimaryantibodies:BDBiosciences(␤-catenin,1:500,#610154),CellSignaling(anti-pAkt,1:50,#4060;Anti-pMAPK,1:200,#4370;andAnti-pSTAT3,1:50,#9145),Neomarkers(anti-Ezrin,1:200,#3C12;andanti-Vimentin,1:400,V9),andNovocastra(anti-Ki67,1:200).BrdU-labeledcellsweredetectedusingakit(Zymed)accordingtothemanufacturer’sinstructions.HRP-conjugatedsecondaryantibodies(usedforEzrin,Vimentin,andKi67)weredetectedusingtheDABperoxidasesubstratekit(VectorLaboratories).Biotin-ylatedsecondaryantibodies(for␤-catenin,pAkt,pMAPK,andpSTAT3)weredetectedusingtheABCimmunoperoxidasekit(VectorLaboratories).Immunofluorescence.Parafﬁnsectionswereincubatedovernightat4°Cwiththefollowingprimaryantibodies:CellSignaling(PH3,1:200,#9701;andP-Y100,1:1,000,#9411),Abcam(NHERF-1,1:200,#3452),andZymed(anti-ZO-1,1:60).PrimaryantibodiesweredetectedusingAlexaFluor488secondaryantibodies(Invitrogen),andslideswerecostainedwithDAPIandmounted(Vectashield;VectorLaboratories).Renalepithelialcellswerevisualizedbyautoﬂuorescenceat594nminparafﬁnsections.Cryosectionswereincubatedat37°C(30min)withbiotinylatedLotustetragonolobusagglutinin(1:80fromstocksolution;VectorLaboratories).Sectionsweresubsequentlyincubatedovernightat4°Cwithanti-␤-galactosidase(1:500,Cappel#55976).FITC–streptavidinandAlexaFluor594secondaryantibodieswereusedfordetec-tion,andslideswerecostainedwithDAPI.Imageswereacquiredasz-stacksonanOlympus1⫻81spinningdiskconfocalmicroscopewithaHamamatsuEMCCDdigitalcameraandprocessedusingSlidebookimagingsoftware(Olym-pus)andPhotoshopCS4(AdobeSystems).MorrisandMcClatcheyPNAS兩June16,2009兩vol.106兩no.24兩9771GENETICSImmunoblotting.Proteinsweredetectedusingthefollowingprimaryantibodies:CellSignaling(pEGFR,#2235;pSTAT-3,#9145;STAT-3,#4904;pAkt,#4060;Akt,#4685;pMAPK,#4370;MAPK,#4696;pErbB2,#2243;andTGF-␣,#3175,allat1:1,000),SantaCruzBiotechnology(NF2,#sc-331,1:2,000;ErbB2,#sc-284;andEGFR,#sc-03,bothat1:1,000;andHB-EGF,#sc-21593,1:200),BDBiosciences(E-cadherin,#610182;p120catenin,#610134;andCaveolin-1,#610407,allat1:2,000;␤-catenin,#610154,1:500;andpCaveolin,#611339,1:1,000),Sigma(actin,AC40,1:4,000;and␤-tubulin,#SAP-4G5,1:500),Abcam(Galectin-3,#A3A12,1:1,000),andNeomarkers(amphiregulin,AB-1,1:200).HRP-conjugatedsecondaryantimouseandantirabbitantibodieswerefromAmersham.PrimaryCultures.PrimaryculturesofrenalepithelialcellsweregeneratedbydissectionofPBS-ﬂushedkidneysusingmodiﬁedprotocols(54,55).Whereindi-cated,cellsweretreatedwith1␮MerlotiniborDMSOovernight.Mousewild-typeNf2cDNAwasclonedintoapuromycin-selectableretroviralpBabevectorfromapreviouslydescribedplasmid(22).Cellswereinfected,selected,andpassagedoncebeforeexperiments.Toevaluatecontact-inhibitionofcell-cycleprogression,conﬂuentcellsweretrypsinized,washedinPBS,ﬁxedovernightat⫺20°Cin70%ethanol,stainedfor30minwithpropidiumiodide(10␮g/mLinPBS),andanalyzedbyFACStoevaluateDNAcontent.Forxenograftexperiments,immunocompromisedmicewereinjecteds.c.with1⫻106prepassagecells(isolated,plated,andgrowntoconﬂuence)thathadbeentrypsinized,washedinPBSwith0.1%soytrypsininhibitor,andresuspendedinPBS.ACKNOWLEDGMENTS.WethankMarcoGiovanniniandSylvieRobineforNf2lox/loxandVillin-Cremice,respectively;OthonIliopoulos,JordanKreidberg,andMarcelloCurtoforadviceanddiscussion;RodBronson,SabinaSignoretti,andChin-LeeWuforpathologyconsultation;andAndrewGladdenandBrettMorrisforassistancewithFACSandimmunohistochemistry,respectively.ThisworkwassupportedbyNationalInstitutesofHealth(NIH)/NationalCancerInstituteGrantCA113733(toA.I.M.);NIH/NationalInstituteofGeneralMed-icalSciencesGrantT32GM07306(toZ.S.M.);andDepartmentofDefenseGrantW81XWH-05–1-0189(toA.I.M.).1.CohenHT,McGovernFJ(2005)Renal-cellcarcinoma.NEnglJMed353:2477–2490.2.ValladaresAyerbesM,etal.(2008)Originofrenalcellcarcinomas.ClinTranslOncol10:697–712.3.IliopoulosO(2006)Molecularbiologyofrenalcellcancerandtheidentiﬁcationoftherapeutictargets.JClinOncol24:5593–5600.4.MotzerRJ,BanderNH,NanusDM(1996)Renal-cellcarcinoma.NEnglJMed335:865–875.5.TakahashiM,KahnoskiR,GrossD,NicolD,TehBT(2002)Familialadultrenalneoplasia.JMedGenet39:1–5.6.KleymenovaE,etal.(2004)SusceptibilitytovascularneoplasmsbutnoincreasedsusceptibilitytorenalcarcinogenesisinVhlknockoutmice.Carcinogenesis25:309–315.7.GraveelC,etal.(2004)ActivatingMetmutationsproduceuniquetumorproﬁlesinmicewithselectiveduplicationofthemutantallele.ProcNatlAcadSciUSA101:17198–17203.8.PollardPJ,etal.(2007)Targetedinactivationoffh1causesproliferativerenalcystdevelopmentandactivationofthehypoxiapathway.CancerCell11:311–319.9.KobayashiT,etal.(2001)Agerm-lineTsc1mutationcausestumordevelopmentandembryoniclethalitythataresimilar,butnotidenticalto,thosecausedbyTsc2mutationinmice.ProcNatlAcadSciUSA98:8762–8767.10.KobayashiT,etal.(1999)Renalcarcinogenesis,hepatichemangiomatosis,andembry-oniclethalitycausedbyagerm-lineTsc2mutationinmice.CancerRes59:1206–1211.11.BabaM,etal.(2008)Kidney-targetedBirt-Hogg-Dubegeneinactivationinamousemodel:Erk1/2andAkt-mTORactivation,cellhyperproliferation,andpolycystickid-neys.JNatlCancerInst100:140–154.12.ChenJ,etal.(2008)DeﬁciencyofFLCNinmousekidneyledtodevelopmentofpolycystickidneysandrenalneoplasia.PLoSONE3:e3581.13.QianCN,etal.(2005)Cysticrenalneoplasiafollowingconditionalinactivationofapcinmouserenaltubularepithelium.JBiolChem280:3938–3945.14.SansomOJ,GrifﬁthsDF,ReedKR,WintonDJ,ClarkeAR(2005)Apcdeﬁciencypredis-posestorenalcarcinomainthemouse.Oncogene24:8205–8210.15.ForbesSA,etal.(2008)TheCatalogueofSomaticMutationsinCancer(COSMIC).CurrProtocHumGenetChapter10:Unit10.11.16.UhlmanDL,etal.(1995)Epidermalgrowthfactorreceptorandtransforminggrowthfactoralphaexpressioninpapillaryandnonpapillaryrenalcellcarcinoma:Correlationwithmetastaticbehaviorandprognosis.ClinCancerRes1:913–920.17.CurtoM,ColeBK,LallemandD,LiuCH,McClatcheyAI(2007)Contact-dependentinhibitionofEGFRsignalingbyNf2/Merlin.JCellBiol177:893–903.18.MochH,etal.(1997)Epidermalgrowthfactorreceptorexpressionisassociatedwithrapidtumorcellproliferationinrenalcellcarcinoma.HumPathol28:1255–1259.19.MerseburgerAS,etal.(2005)Membranousexpressionandprognosticimplicationsofepidermalgrowthfactorreceptorproteininhumanrenalcellcancer.AnticancerRes25:1901–1907.20.SmithK,etal.(2005)Silencingofepidermalgrowthfactorreceptorsuppresseshy-poxia-induciblefactor-2-drivenVHL-/-renalcancer.CancerRes65:5221–5230.21.ColeBK,CurtoM,ChanAW,McClatcheyAI(2008)Localizationtothecorticalcytoskel-etonisnecessaryforNf2/merlin-dependentepidermalgrowthfactorreceptorsilenc-ing.MolCellBiol28:1274–1284.22.LallemandD,CurtoM,SaotomeI,GiovanniniM,McClatcheyAI(2003)NF2deﬁciencypromotestumorigenesisandmetastasisbydestabilizingadherensjunctions.GenesDev17:1090–1100.23.AnanthS,etal.(1999)Transforminggrowthfactorbeta1isatargetforthevonHippel-Lindautumorsuppressorandacriticalgrowthfactorforclearcellrenalcarci-noma.CancerRes59:2210–2216.24.FranovicA,etal.(2007)Translationalup-regulationoftheEGFRbytumorhypoxiaprovidesanonmutationalexplanationforitsoverexpressioninhumancancer.ProcNatlAcadSciUSA104:13092–13097.25.dePaulsenN,etal.(2001)Roleoftransforminggrowthfactor-alphainvonHippel-Lindau(VHL)(-/-)clearcellrenalcarcinomacellproliferation:ApossiblemechanismcouplingVHLtumorsuppressorinactivationandtumorigenesis.ProcNatlAcadSciUSA98:1387–1392.26.GunaratnamL,etal.(2003)Hypoxiainduciblefactoractivatesthetransforminggrowthfactor-alpha/epidermalgrowthfactorreceptorgrowthstimulatorypathwayinVHL(-/-)renalcellcarcinomacells.JBiolChem278:44966–44974.27.PrewettM,etal.(1998)Mouse-humanchimericanti-epidermalgrowthfactorreceptorantibodyC225inhibitsthegrowthofhumanrenalcellcarcinomaxenograftsinnudemice.ClinCancerRes4:2957–2966.28.RowinskyEK,etal.(2004)Safety,pharmacokinetics,andactivityofABX-EGF,afullyhumananti-epidermalgrowthfactorreceptormonoclonalantibodyinpatientswithmetastaticrenalcellcancer.JClinOncol22:3003–3015.29.FoonKA,etal.(2004)PreclinicalandclinicalevaluationsofABX-EGF,afullyhumananti-epidermalgrowthfactorreceptorantibody.IntJRadiatOncolBiolPhys58:984–990.30.RavaudA,etal.(2008)Lapatinibversushormonetherapyinpatientswithadvancedrenalcellcarcinoma:ArandomizedphaseIIIclinicaltrial.JClinOncol26:2285–2291.31.elMarjouF,etal.(2004)Tissue-speciﬁcandinducibleCre-mediatedrecombinationinthegutepithelium.Genesis39:186–193.32.FaraggianaT,MalchiodiF,PradoA,ChurgJ(1982)Lectin-peroxidaseconjugatereactivityinnormalhumankidney.JHistochemCytochem30:451–458.33.YoungAN,etal.(2001)Expressionproﬁlingofrenalepithelialneoplasms:Amethodfortumorclassiﬁcationanddiscoveryofdiagnosticmolecularmarkers.AmJPathol158:1639–1651.34.SchneiderA,ZhangY,GuanY,DavisLS,BreyerMD(2003)Differential,induciblegenetargetinginrenalepithelia,vascularendothelium,andvisceraofMx1Cremice.AmJPhysiolRenalPhysiol284:F411–F417.35.SakakimaM,FujigakiY,YamamotoT,HishidaA(2008)AdistinctpopulationoftubularcellsinthedistalS3segmentcontributestoS3segmentregenerationinratsfollowingacuterenalfailureinducedbyuranylacetate.NephronExpNephrol109:e57–e70.36.KimK,LeeKM,HanDJ,YuE,ChoYM(2008)Adultstemcell-liketubularcellsresideinthecorticomedullaryjunctionofthekidney.IntJClinExpPathol1:232–241.37.MaeshimaA(2007)Label-retainingcellsinthekidney:Originofregeneratingcellsafterrenalischemia.ClinExpNephrol11:269–274.38.CaplanMJ,Seo-MayerP,ZhangL(2008)Epithelialjunctionsandpolarity:Complexesandkinases.CurrOpinNephrolHypertens17:506–512.39.CapaldoCT,MacaraIG(2007)DepletionofE-cadherindisruptsestablishmentbutnotmaintenanceofcelljunctionsinMadin-Darbycaninekidneyepithelialcells.MolBiolCell18:189–200.40.SuzukiA,OhnoS(2006)ThePAR-aPKCsystem:Lessonsinpolarity.JCellSci119(Pt6):979–987.41.SigismundS,etal.(2005)Clathrin-independentendocytosisofubiquitinatedcargos.ProcNatlAcadSciUSA102:2760–2765.42.KimYN,WiepzGJ,GuadarramaAG,BerticsPJ(2000)Epidermalgrowthfactor-stimulatedtyrosinephosphorylationofcaveolin-1.Enhancedcaveolin-1tyrosinephos-phorylationfollowingaberrantepidermalgrowthfactorreceptorstatus.JBiolChem275:7481–7491.43.SverdlovM,ShajahanAN,MinshallRD(2007)Tyrosinephosphorylation-dependenceofcaveolae-mediatedendocytosis.JCellMolMed11:1239–1250.44.WilsonSJ,etal.(2006)InhibitionofHER-2(neu/ErbB2)restoresnormalfunctionandstructuretopolycystickidneydisease(PKD)epithelia.BiochimBiophysActa1762:647–655.45.LatifZ,WattersAD,BartlettJM,UnderwoodMA,AitchisonM(2002)Geneampliﬁca-tionandoverexpressionofHER2inrenalcellcarcinoma.BJUInt89:5–9.46.MuthuswamySK,LiD,LelievreS,BissellMJ,BruggeJS(2001)ErbB2,butnotErbB1,reinitiatesproliferationandinducesluminalrepopulationinepithelialacini.NatCellBiol3:785–792.47.HagerM,etal.(2008)IncreasedactivatedAktexpressioninrenalcellcarcinomasandprognosis.JCellMolMed,inpress.48.MerseburgerAS,etal.(2008)ActivationofPI3Kisassociatedwithreducedsurvivalinrenalcellcarcinoma.UrolInt80:372–377.49.PantuckAJ,etal.(2007)PrognosticrelevanceofthemTORpathwayinrenalcellcarcinoma:Implicationsformolecularpatientselectionfortargetedtherapy.Cancer109:2257–2267.50.BrennerW,etal.(2002)LossoftumorsuppressorproteinPTENduringrenalcarcino-genesis.IntJCancer99:53–57.51.GiovanniniM,etal.(2000)ConditionalbiallelicNf2mutationinthemousepromotesmanifestationsofhumanneuroﬁbromatosistype2.GenesDev14:1617–1630.52.KuhnR,SchwenkF,AguetM,RajewskyK(1995)Induciblegenetargetinginmice.Science269:1427–1429.53.MaoX,FujiwaraY,OrkinSH(1999)ImprovedreporterstrainformonitoringCrerecombinase-mediatedDNAexcisionsinmice.ProcNatlAcadSciUSA96:5037–5042.54.TaubM(2005)Primarykidneyproximaltubulecells.MethodsMolBiol290:231–247.55.ChungSD,AlaviN,LivingstonD,HillerS,TaubM(1982)Characterizationofprimaryrabbitkidneyculturesthatexpressproximaltubulefunctionsinahormonallydeﬁnedmedium.JCellBiol95:118–126.56.RobineS,JaisserF,LouvardD(1997)Epithelialcellgrowthanddifferentiation.IV.Controlledspatiotemporalexpressionoftransgenes:Newtoolstostudynormalandpathologicalstates.AmJPhysiol273(4Pt1):G759–762.57.MaeshimaA,YamashitaS,NojimaY(2003)Identiﬁcationofrenalprogenitor-liketubularcellsthatparticipateintheregenerationprocessesofthekidney.JAmSocNephrol14:3138–3146.9772兩www.pnas.org兾cgi兾doi兾10.1073兾pnas.0902031106MorrisandMcClatchey